PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Inukai, N; Yamaguchi, Y; Kuraoka, I; Yamada, T; Kamijo, S; Kato, J; Tanaka, K; Handa, H				Inukai, N; Yamaguchi, Y; Kuraoka, I; Yamada, T; Kamijo, S; Kato, J; Tanaka, K; Handa, H			A novel hydrogen peroxide-induced phosphorylation and ubiquitination pathway leading to RNA polymerase II proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; COUPLED DNA-REPAIR; HIPPEL-LINDAU PROTEIN; COCKAYNE-SYNDROME; TRANSCRIPTION ELONGATION; LARGE SUBUNIT; IN-VITRO; DAMAGE; KINASES; COMPLEX	DNA damage-induced ubiquitination of the largest subunit of RNA polymerase II, Rpb1, has been implicated in transcription-coupled repair for years. The studies so far, however, have been limited to the use of bulky helix-distorting DNA damages caused by UV light and cisplatin, which are corrected by the nucleotide excision repair pathway. Non-bulky, non-helix-distorting damages are caused at high frequency by reactive oxygen species in cells and corrected by the base excision repair pathway. Contrary to a classic view, we recently found that the second type of DNA lesions also causes RNA polymerase II stalling in vitro. In this paper, we show that hydrogen peroxide (H2O2) causes significant ubiquitination and proteasomal degradation of Rpb1 by mechanisms that are distinct from those employed after UV irradiation. UV irradiation and H2O2 treatment cause characteristic changes in protein kinases phosphorylating the carboxyl-terminal domain at Ser-2 and -5. The H2O2-induced ubiquitination is likely dependent on unusual Ser-5 phosphorylation by ERK1/2. Moreover, the H2O2-induced ubiquitination occurs on transcriptionally engaged polymerases without the help of Cockayne syndrome A and B proteins and von Hippel-Lindau tumor suppressor proteins, which are all required for the UV-induced ubiquitination. These results suggest that stalled polymerases are recognized and ubiquitinated differentially depending on the types of DNA lesions. Our findings may have general implications in the basic mechanism of transcription-coupled nucleotide excision repair and base excision repair.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Agcy, PRESTO, Yokohama, Kanagawa 2268501, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Osaka University	Handa, H (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	hhanda@bio.titech.ac.jp	Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X; Kuraoka, Isao/0000-0001-6391-3411				BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Hasegawa J, 2003, J BIOCHEM, V133, P133, DOI 10.1093/jb/mvg013; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; MARKOWITZ RB, 1995, BIOCHEM BIOPH RES CO, V207, P1051, DOI 10.1006/bbrc.1995.1291; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang LY, 2003, INT J ONCOL, V22, P683; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	35	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8190	8195		10.1074/jbc.M311412200	http://dx.doi.org/10.1074/jbc.M311412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662762	hybrid			2022-12-25	WOS:000189103300100
J	Iwamoto, T; Kita, S; Uehara, A; Imanaga, I; Matsuda, T; Baba, A; Katsuragi, T				Iwamoto, T; Kita, S; Uehara, A; Imanaga, I; Matsuda, T; Baba, A; Katsuragi, T			Molecular determinants of Na+/Ca2+ exchange (NCX1) inhibition by SEA0400	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; CARDIAC NA+-CA2+ EXCHANGER; REVERSE MODE; DEPENDENT REGULATION; SELECTIVE INHIBITOR; DYNAMIC PROPERTIES; CA2+ OVERLOAD; ISOFORMS NCX1; STEADY-STATE; KB-R7943	SEA0400 is a potent and selective Na+/Ca2+ exchanger (NCX) inhibitor. We evaluated the inhibitory effects of SEA0400 on Na-i(+)-dependent Ca-45(2+) uptake and whole-cell Na+/Ca2(+) exchange currents in NCX-transfected fibroblasts. SEA0400 preferentially inhibited Ca-45(2+) uptake by NCX1 compared with inhibitions by NCX2, NCX3, and NCKX2. SEA0400 also selectively blocked outward exchange currents from NCX1 transfectants. We searched for regions that may form the SEA0400 receptor in the NCX1 molecule by NCX1/NCX3 chimeric analysis. The results suggest that the first intracellular loop and the fifth transmembrane segment are mostly responsible for the differential drug responses between NCX1 and NCX3. Further site-directed mutagenesis revealed that multiple mutations at Phe-213 markedly reduced sensitivity to SEA0400 without affecting that to KB-R7943. We also found that Gly-833-to-Cys mutation (within the alpha-2 repeat) greatly reduced the inhibition by SEA0400, but unexpectedly the NCX1 chimera with an alpha-2 repeat from NCKX2 possessed normal drug sensitivity. In addition, exchangers with mutated exchanger inhibitory peptide regions, which display either undetectable or accelerated Na+-dependent inactivation, had a markedly reduced sensitivity or hypersensitivity to SEA0400, respectively. To verify the efficacy of the NCX inhibitor, we examined the renoprotective effect of SEA0400 in a hypoxic injury model using porcine renal tubular cells. SEA0400 protected against hypoxia/reoxygenation-induced cell damage in tubular cells expressing wild-type NCX1 but not in cells expressing SEA0400-insensitive mutants. These results suggest that Phe-213, Gly-833, and residues that eliminate Na+-dependent inactivation are critical determinants for the inhibition by SEA0400, and their mutants are very useful for checking the pharmacological importance of NCX inhibition by SEA0400.	Fukuoka Univ, Sch Med, Dept Pharmacol, Jonan Ku, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Dept Physiol, Jonan Ku, Fukuoka 8140180, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Neuropharmacol Lab, Suita, Osaka 5650871, Japan	Fukuoka University; Fukuoka University; National Cerebral & Cardiovascular Center - Japan; Osaka University; Osaka University	Iwamoto, T (corresponding author), Fukuoka Univ, Sch Med, Dept Pharmacol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.	tiwamoto@cis.fukuoka-u.ac.jp						Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Choptiany P, 2003, BIOPHYS J, V84, p518A; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Elias CL, 2001, AM J PHYSIOL-HEART C, V281, pH1334, DOI 10.1152/ajpheart.2001.281.3.H1334; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hilgemann DW, 1996, ANN NY ACAD SCI, V779, P136, DOI 10.1111/j.1749-6632.1996.tb44783.x; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Iwamoto T, 1999, J BIOL CHEM, V274, P23094, DOI 10.1074/jbc.274.33.23094; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Iwamoto T, 2003, BIOPHYS J, V84, p189A; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Iwamoto T, 2001, MOL PHARMACOL, V59, P524, DOI 10.1124/mol.59.3.524; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kimura J, 1999, BRIT J PHARMACOL, V128, P969, DOI 10.1038/sj.bjp.0702869; Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Magee WP, 2003, AM J PHYSIOL-HEART C, V284, pH903, DOI 10.1152/ajpheart.00784.2002; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; MATSUOKA S, 1994, J PHYSIOL-LONDON, V476, P443, DOI 10.1113/jphysiol.1994.sp020146; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nakamura Aki, 1998, Folia Pharmacologica Japonica, V111, P105, DOI 10.1254/fpj.111.105; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Ogata M, 2003, EUR J PHARMACOL, V478, P187, DOI 10.1016/j.ejphar.2003.08.082; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pilitsis JG, 2001, BRAIN RES, V916, P192, DOI 10.1016/S0006-8993(01)02896-7; Pintado AJ, 2000, BRIT J PHARMACOL, V130, P1893, DOI 10.1038/sj.bjp.0703519; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reuter H, 2002, CIRC RES, V91, P90, DOI 10.1161/01.RES.0000027529.37429.38; Satoh H, 2000, CIRCULATION, V101, P1441, DOI 10.1161/01.CIR.101.12.1441; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Seki S, 2002, CIRC J, V66, P390, DOI 10.1253/circj.66.390; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Sobolevsky AI, 1999, NEUROPHARMACOLOGY, V38, P1235, DOI 10.1016/S0028-3908(99)00040-4; Takahashi K, 2003, EUR J PHARMACOL, V458, P155, DOI 10.1016/S0014-2999(02)02732-2; Tanaka H, 2002, BRIT J PHARMACOL, V135, P1096, DOI 10.1038/sj.bjp.0704574; TANI M, 1990, ANNU REV PHYSIOL, V52, P543; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Watano T, 1996, BRIT J PHARMACOL, V119, P555, DOI 10.1111/j.1476-5381.1996.tb15708.x; Watano T, 1999, BRIT J PHARMACOL, V127, P1846, DOI 10.1038/sj.bjp.0702740; Yamashita J, 2003, J PHARMACOL EXP THER, V304, P284, DOI 10.1124/jpet.102.039024; Yamashita J, 2001, J PHARMACOL EXP THER, V296, P412	57	103	113	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7544	7553		10.1074/jbc.M310491200	http://dx.doi.org/10.1074/jbc.M310491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660663	hybrid			2022-12-25	WOS:000189103300023
J	Curtis, AM; Seo, SB; Westgate, EJ; Rudic, RD; Smyth, EM; Chakravarti, D; FitzGerald, GA; McNamara, P				Curtis, AM; Seo, SB; Westgate, EJ; Rudic, RD; Smyth, EM; Chakravarti, D; FitzGerald, GA; McNamara, P			Histone acetyltransferase-dependent chromatin remodeling and the vascular clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CIRCADIAN CLOCK; ADENOVIRAL ONCOPROTEIN E1A; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION FACTORS; ACETYLATION; MECHANISM; CBP/P300; COACTIVATOR; PROTEIN; CELLS	Rhythmic gene expression is central to the circadian control of physiology in mammals. Transcriptional activation of Per and Cry genes by heterodimeric bHLH-PAS proteins is a key event in the feedback loop that drives rhythmicity; however, the mechanism is not clearly understood. Here we show the transcriptional coactivators and histone acetyltransferases, p300/CBP, PCAF, and ACTR associate with the bHLH-PAS proteins, CLOCK and NPAS2, to regulate positively clock gene expression. Furthermore, Cry2 mediated repression of NPAS2:BMAL1 is overcome by overexpression of p300 in transactivation assays. Accordingly, p300 exhibits a circadian time-dependent association with NPAS2 in the vasculature, which precedes peak expression of target genes. In addition, a rhythm in core histone H3 acetylation on the mPer1 promoter in vivo correlates with the cyclical expression of their mRNAs. Temporal coactivator recruitment and HAT-dependent chromatin remodeling on the promoter of clock controlled genes in the vasculature permits the mammalian clock to orchestrate circadian gene expression.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Seoul Natl Univ, Coll Dent, Seoul, South Korea; Phenomix Corp, La Jolla, CA 92037 USA	University of Pennsylvania; University of Pennsylvania; Seoul National University (SNU)	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.uperm.edu	FitzGerald, Garret A/A-4222-2010; Rudic, Dan/B-3432-2016	Rudic, Dan/0000-0001-9122-3127; Curtis, Annie/0000-0002-9601-9624; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250, P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62250, HL-54500] Funding Source: Medline; NIDDK NIH HHS [DK 57079] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Glass CK, 2000, GENE DEV, V14, P121; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Kramer A, 2001, SCIENCE, V294, P2511, DOI 10.1126/science.1067716; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REICK M, 2001, SCIENCE, V5, P5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108	44	167	184	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7091	7097		10.1074/jbc.M311973200	http://dx.doi.org/10.1074/jbc.M311973200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645221	hybrid			2022-12-25	WOS:000188969200107
J	Forsyth, CM; Lemongello, D; LaCount, DJ; Friesen, PD; Fisher, AJ				Forsyth, CM; Lemongello, D; LaCount, DJ; Friesen, PD; Fisher, AJ			Crystal structure of an invertebrate caspase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH PROTEASE; 3-DIMENSIONAL STRUCTURE; COMBINATORIAL APPROACH; DROSOPHILA CASPASE; BACULOVIRUS P35; GRANZYME-B; ACTIVATION; INHIBITION; APOPTOSIS; ENZYME	Caspases play an essential role in the execution of apoptosis. These cysteine proteases are highly conserved among metazoans and are translated as inactive zymogens, which are activated by proteolytic cleavages to generate the large and small subunits and remove the N-terminal prodomain. The 2.3 Angstrom resolution crystal structure of active Sf-caspase-1, the principal effector caspase of the insect Spodoptera frugiperda, is presented here. The structure represents the first nonhuman caspase to be resolved. The structure of the cleaved and active protease was determined with the tetrapeptide inhibitor N-acetyl-Asp-Glu-Val-Asp-chloromethylketone covalently bonded to the active site cysteine. As expected, the overall fold of Sf-caspase-1 is exceedingly similar to that of the five active caspases from humans solved to date. The overall structure and active site arrangement of Sf-caspase-1 is most comparable with that of the human effector caspases, with which it shares highest sequence homology. The most prominent structural difference with Sf-caspase-1 is the position of the N-terminal region of the large subunit. Unlike the N terminus of human caspases, the N terminus of Sf-caspase-1 originates from the active site side where it interacts with active site loop L2 and then extends to the backside of the heterodimer. This unusual structural arrangement raises the possibility that the N-terminal prodomain plays a regulatory role during effector caspase activation or enzyme activity in insects.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fisher, AJ (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.	fisher@chem.ucdavis.edu		Fisher, Andrew/0000-0003-3488-6594	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040482, R56AI040482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056774] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40482] Funding Source: Medline; NIGMS NIH HHS [GM56774] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayascas JR, 2002, CELL DEATH DIFFER, V9, P1078, DOI 10.1038/sj.cdd.4401075; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chereau D, 2003, BIOCHEMISTRY-US, V42, P4151, DOI 10.1021/bi020593l; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; dela Cruz WP, 2001, J BIOL CHEM, V276, P32933, DOI 10.1074/jbc.M103930200; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meergans T, 2000, BIOCHEM J, V349, P135, DOI 10.1042/0264-6021:3490135; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rossmann M. G., 1972, MOL REPLACEMENT METH; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zoog SJ, 2002, EMBO J, V21, P5130	61	14	14	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7001	7008		10.1074/jbc.M312472200	http://dx.doi.org/10.1074/jbc.M312472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645217	hybrid			2022-12-25	WOS:000188969200096
J	Heathfield, TF; Onnerfjord, P; Dahlberg, L; Heinegard, D				Heathfield, TF; Onnerfjord, P; Dahlberg, L; Heinegard, D			Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOARTHRITIC ARTICULAR-CARTILAGE; ARTHRITIC SYNOVIAL-FLUID; COLLAGEN TYPE-I; EXTRACELLULAR-MATRIX; CONNECTIVE TISSUES; REPEAT PROTEINS; BINDING SITES; PROTEOGLYCAN; DECORIN; IDENTIFICATION	Integrity of cartilage fails in joint disease. The current work aimed to identify candidate active proteinases in joint diseases using an in vitro model for cartilage degradation induced by interleukin-1. A critical event in the process of cartilage destruction in joint disease is the failure of the collagen fiber network to maintain integrity. Proteins binding to the surface of the fibers are likely early points of failure. Fibromodulin, a member of the leucine-rich repeat protein family, is one predominant protein in cartilage and is known for its roles in the formation of collagen fibrils and sustained interaction with these formed fibers. Cleavage removes the tyrosine sulfate-rich region in the N terminus of fibromodulin. Whereas fibromodulin bound to collagen in tissue was digested, purified fibromodulin was not cleaved. In contrast an N-terminal 10-kDa fragment, Gln(19)-Lys(98), of the protein generated by Lys-C digestion contains the cleavage site and was a substrate cleaved by the enzyme in medium from stimulated cultures. In solution, digestion of this substrate with matrix metalloproteinase (MMP)-2, -9, -8, and -13 demonstrated that only NMP-13 was capable to efficiently cleave it. The cleavage product obtained after MMP-13 digestion was identical to that observed in cleaved fibromodulin from cartilage explant cultures stimulated with interleukin-1. NMP-13 treatment of fresh articular cartilage also produced the fragment under study. The elucidation of the enzyme responsible for such cleavage may lead to treatment modalities involving its selective inhibition for patients suffering from arthritis. The known structure of the fragments permits the generation of neo-epitope antibodies to the cleavage site, which can be used to detect ongoing cartilage degradation in patients with arthritic disease, an important adjunct in monitoring disease progression, active disease, and efficacy of treatment.	Lund Univ, BMC, Sect Connect Tissue Biol, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Lund Univ, Malmo Univ Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden	Lund University; Lund University; Skane University Hospital	Heinegard, D (corresponding author), Lund Univ, BMC, Sect Connect Tissue Biol, Dept Cell & Mol Biol, Plan C12, SE-22184 Lund, Sweden.	dick.heinegard@medkem.lu.se	Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937				ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BAYLISS MT, 1978, BIOCHEM J, V169, P123, DOI 10.1042/bj1690123; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; Billinghurst RC, 2000, ARTHRITIS RHEUM, V43, P664, DOI 10.1002/1529-0131(200003)43:3<664::AID-ANR24>3.0.CO;2-D; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; Flannelly J, 2002, OSTEOARTHR CARTILAGE, V10, P722, DOI 10.1053/joca.2002.0818; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Ganu V, 1998, ARTHRITIS RHEUM, V41, P2143, DOI 10.1002/1529-0131(199812)41:12<2143::AID-ART9>3.0.CO;2-P; Gill MR, 2002, OSTEOARTHR CARTILAGE, V10, P751, DOI 10.1053/joca.2002.0527; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LIU J, 1994, J BIOL CHEM, V269, P28366; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; Roughley PJ, 1996, OSTEOARTHR CARTILAGE, V4, P153, DOI 10.1016/S1063-4584(96)80011-2; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SAXNE T, 1988, COLLAGEN REL RES, V8, P233; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	53	81	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6286	6295		10.1074/jbc.M307765200	http://dx.doi.org/10.1074/jbc.M307765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660626	hybrid			2022-12-25	WOS:000188969200013
J	Marx, PF; Havik, SR; Marquart, JA; Bouma, BN; Meijers, JCM				Marx, PF; Havik, SR; Marquart, JA; Bouma, BN; Meijers, JCM			Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROCARBOXYPEPTIDASE-B; PROTEOLYTIC CLEAVAGE; THERMAL-STABILITY; INTRINSIC PATHWAY; TAFI LEVELS; FACTOR-XI; COAGULATION; PLASMINOGEN; CARBOXYPEPTIDASE; THROMBOMODULIN	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is a carboxypeptidase B that can down-regulate fibrinolysis. TAFIa is a labile enzyme that can be inactivated by conformational instability or proteolysis. TAFI is similar to 40% identical to pancreatic carboxypeptidase B (CPB). In contrast to TAFIa, pancreatic CPB is a stable protease. We hypothesized that regions or residues that are not conserved in TAFIa compared with pancreatic CPB play a role in the conformational instability of TAFIa and that replacement of these non-conserved residues with residues of pancreatic CPB would lead to a TAFIa molecule with an increased stability. Therefore, we have expressed, purified, and characterized two TAFI-CPB chimeras: TAFI-CPB-(293-333) and TAFI-CPB-(293-401). TAFI-CPB-(293-333) could be activated by thrombin-thrombomodulin, but not as efficiently as wild-type TAFI. After activation, this mutant was unstable and was hardly able to prolong clot lysis of TAFI-deficient plasma. Binding of TAFI-CPB-(293-333) to both plasminogen and fibrinogen was normal compared with wild-type TAFI. TAFI-CPB-(293-401) could be activated by thrombin-thrombomodulin, although at a lower rate compared with wild-type TAFI. The activated mutant displayed a markedly prolonged half-life of 1.5 h. Plasmin could both activate and inactivate this chimera. Interestingly, this chimera did not bind to plasminogen or fibrinogen. TAFI-CPB-(293-401) could prolong the clot lysis time in TAFI-deficient plasma, although not as efficiently as wild-type TAFI. In conclusion, by replacing a region in TAFI with the corresponding region in pancreatic CPB, we were able to generate a TAFIa form with a highly stable activity.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Scripps Research Institute; Utrecht University; Utrecht University Medical Center	Marx, PF (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, G1-113,POB 22660, NL-1100 DD Amsterdam, Netherlands.	P.F.Marx@amc.uva.nl	Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; Bouma BN, 1998, THROMB HAEMOSTASIS, V80, P24; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Brouwers GJ, 2001, BLOOD, V98, P1992, DOI 10.1182/blood.V98.6.1992; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4082, DOI 10.1021/bi00230a038; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1991, J BIOL CHEM, V266, P21833; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2000, THROMB HAEMOSTASIS, V83, P297; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; MEIJERS JCM, 1992, BLOOD, V79, P1435; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Mosnier LO, 2003, BLOOD, V101, P4844, DOI 10.1182/blood-2002-09-2944; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Pereira PJB, 2002, J MOL BIOL, V321, P537, DOI 10.1016/S0022-2836(02)00648-4; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Reijerkerk A, 2003, MOL CANCER RES, V1, P561; Schatteman KA, 1999, CLIN CHEM, V45, P807; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; WALKER JB, 2003, J THROMB HAEMOSTA S1, V1; WANG W, 1994, J BIOL CHEM, V269, P15937	25	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6620	6628		10.1074/jbc.M307337200	http://dx.doi.org/10.1074/jbc.M307337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660622	hybrid			2022-12-25	WOS:000188969200051
J	Coombs, GH; Westrop, GD; Suchan, P; Puzova, G; Hirt, RP; Embley, TM; Mottram, JC; Muller, S				Coombs, GH; Westrop, GD; Suchan, P; Puzova, G; Hirt, RP; Embley, TM; Mottram, JC; Muller, S			The amitochondriate eukaryote Trichomonas vaginalis contains a divergent thioredoxin-linked peroxiredoxin antioxidant system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORIZONTAL GENE-TRANSFER; ESCHERICHIA-COLI; PHYSIOLOGICAL FUNCTIONS; HYDROGEN-PEROXIDE; REDUCTASE; METRONIDAZOLE; PURIFICATION; RESISTANCE; GLUTATHIONE; EVOLUTION	Trichomonas is an amitochondriate parasitic protozoon specialized for an anaerobic lifestyle. Nevertheless, it is exposed to oxygen and is able to cope with the resultant oxidative stress. In the absence of glutathione, cysteine has been thought to be the major antioxidant. We now report that the parasite contains thioredoxin reductase, which functions together with thioredoxin and thioredoxin peroxidase to detoxify potentially damaging oxidants. Thioredoxin reductase and thioredoxin also reduce cystine and so may play a role in maintaining the cellular cysteine levels. The importance of the thioredoxin system as one of the major antioxidant defense mechanisms in Trichomonas was confirmed by showing that the parasite responds to environmental changes resulting in increased oxidative stress by upregulating thioredoxin and thioredoxin peroxidases levels. Sequence data indicate that the thioredoxin reductase of Trichomonas differs fundamentally in structure from that of its human host and thus may represent a useful drug target. The protein is generally similar to thioredoxin reductases present in other lower eukaryotes, all of which probably originated through horizontal gene transfer from a prokaryote. The phylogenetic signal in thioredoxin peroxidase is weak, but evidence from trees suggests that this gene has been subject to repeated horizontal gene transfers from different prokaryotes to different eukaryotes. The data are thus consistent with the complexity hypothesis that predicts that the evolution of simple pathways such as the thioredoxin cascade are likely to be affected by horizontal gene transfer between species.	Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Nat Hist Museum, Dept Zool, London SW7 5BD, England; Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Glasgow; Natural History Museum London; University of Glasgow; University of Dundee	Coombs, GH (corresponding author), Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.coombs@bio.gla.ac.uk	Hirt, Robert/R-5429-2017	Hirt, Robert/0000-0002-3760-9958; Embley, Thomas Martin/0000-0002-1484-340X; Mottram, Jeremy/0000-0001-5574-3766; Westrop, Gareth/0000-0002-8011-6219				Andersson JO, 2003, CURR BIOL, V13, P94, DOI 10.1016/S0960-9822(03)00003-4; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BROWN DM, 1995, MOL BIOCHEM PARASIT, V72, P47, DOI 10.1016/0166-6851(95)00065-9; Bruchhaus I, 1998, BIOCHEM J, V330, P1217, DOI 10.1042/bj3301217; Bruchhaus I, 1997, BIOCHEM J, V326, P785, DOI 10.1042/bj3260785; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; ELLIS JE, 1994, MICROBIOL-SGM, V140, P2489, DOI 10.1099/13500872-140-9-2489; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Hirt RP, 2002, TRENDS PARASITOL, V18, P302, DOI 10.1016/S1471-4922(02)02293-6; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Land KM, 1999, DRUG RESIST UPDATE, V2, P289, DOI 10.1054/drup.1999.0104; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; LINSTEAD DJ, 1988, MOL BIOCHEM PARASIT, V27, P125, DOI 10.1016/0166-6851(88)90032-1; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Maidak BL, 1996, NUCLEIC ACIDS RES, V24, P82, DOI 10.1093/nar/24.1.82; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Marzluf GA, 1997, ANNU REV MICROBIOL, V51, P73, DOI 10.1146/annurev.micro.51.1.73; McKie AE, 1998, J BIOL CHEM, V273, P5549, DOI 10.1074/jbc.273.10.5549; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nixon JEJ, 2002, EUKARYOT CELL, V1, P181, DOI 10.1128/EC.1.2.181-190.2002; PageSharp M, 1996, MICROBIOL-UK, V142, P207, DOI 10.1099/13500872-142-1-207; PAGET TA, 1990, MOL BIOCHEM PARASIT, V41, P65, DOI 10.1016/0166-6851(90)90097-6; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300; Poole LB, 2000, BIOCHEMISTRY-US, V39, P6602, DOI 10.1021/bi000405w; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; Rasoloson D, 2002, MICROBIOL-SGM, V148, P2467, DOI 10.1099/00221287-148-8-2467; Rasoloson D, 2001, PARASITOLOGY, V123, P45, DOI 10.1017/S0031182001008022; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Richards TA, 2003, PROTIST, V154, P17, DOI 10.1078/143446103764928468; Roger AJ, 1999, AM NAT, V154, pS146, DOI 10.1086/303290; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Selkirk ME, 1998, INT J PARASITOL, V28, P1315, DOI 10.1016/S0020-7519(98)00107-6; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Sobel JD, 1999, NEW ENGL J MED, V341, P292, DOI 10.1056/NEJM199907223410417; Sogin ML, 1997, CURR OPIN GENET DEV, V7, P792, DOI 10.1016/S0959-437X(97)80042-1; Sorvillo F, 2001, EMERG INFECT DIS, V7, P927, DOI 10.3201/eid0706.010603; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001; van der Giezen M, 2002, EMBO J, V21, P572, DOI 10.1093/emboj/21.4.572; Vanacova S, 2003, INT J PARASITOL, V33, P235, DOI 10.1016/S0020-7519(02)00267-9; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; WILLIAMS CH, 1967, J BIOL CHEM, V242, P5226; World Health Organization (WHO), 2001, WHOCDSCSREDC200110	61	59	63	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5249	5256		10.1074/jbc.M304359200	http://dx.doi.org/10.1074/jbc.M304359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630923	hybrid			2022-12-25	WOS:000188776500027
J	Haggie, PM; Stanton, BA; Verkman, AS				Haggie, PM; Stanton, BA; Verkman, AS			Increased diffusional mobility of CFTR at the plasma membrane after deletion of its C-terminal PDZ binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMAIN INTERACTION CONTROLS; PROTEIN-KINASE-A; BETA(2)-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION; INTERACTING DOMAIN; LATERAL MOBILITY; EZRIN; CELLS; ORGANIZATION	The cystic fibrosis transmembrane conductance regulator ( CFTR) protein is a cAMP- regulated Cl (-) channel expressed at the apical plasma membrane. It has been proposed that the C- terminal PDZ binding motif of CFTR is required for its apical membrane targeting and that PDZ- domain interactions may tether CFTR to the actin cytoskeleton via soluble proteins including EBP50/ NHERF1 and ezrin. We measured the diffusional mobility of human CFTR in the plasma membrane of Madin-Darby canine kidney cells by photobleaching of green fluorescent protein ( GFP)- CFTR chimeras. After bleaching by a focused laser beam, GFP- CFTR fluorescence in the bleached membrane region recovered to similar to 90% of its initial level, indicating that nearly all of the CFTR was mobile. The GFP- CFTR diffusion coefficient ( D) was 0.99 +/- 0.09 x 10(-10) cm(2)/ s at 37degreesC, similar to that of other membrane proteins. GFP- CFTR diffusion was not altered by protein kinase A or C activators but was blocked by paraformaldehyde and filipin. CFTR mutants lacking functional PDZ- binding domains ( GFP-CFTRDelta TRL and GFP- CFTR- Delta TRA) were also mobile with D significantly increased by similar to 60% compared with GFP- CFTR. However, GFP- CFTR, GFP- CFTR- Delta TRL, and GFP- CFTR- Delta TRA had similar mobilities ( D similar to 12 x 10(-10) cm(2)/ s) at the endoplasmic reticulum in brefeldin A- treated cells. Agents that modulate the actin cytoskeleton ( cytochalasin D and jasplakinolide) altered the plasma membrane mobility of CFTR but not CFTR-Delta TRL. EBP50 ( NHERF1), a PDZ domain- containing protein that interacts with the C terminus of CFTR, diffused freely in the cytoplasm with a diffusion coefficient of 0.9 +/- 0.1 x 10(-7) cm(2)/ s. EBP50 diffusion increased by similar to 2- fold after deletion of its ezrin- binding domain. These results indicate that wild- type CFTR is not tethered statically at the plasma membrane but that its diffusion is dependent on PDZ- domain interactions and an intact actin skeleton. PDZ- domain interactions of CFTR are thus dynamic and occur on a time scale of seconds or faster.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Dartmouth Coll Sch Med, Hanover, NH 03755 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK45881, DK35124, DK34533] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK034533, R37DK035124, R01DK045881] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Coscoy S, 2002, P NATL ACAD SCI USA, V99, P12813, DOI 10.1073/pnas.192084599; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Haggie PM, 2002, J BIOL CHEM, V277, P16419, DOI 10.1074/jbc.M112361200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; Milewski MI, 2001, J CELL SCI, V114, P719; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Okabe S, 1999, NAT NEUROSCI, V2, P804, DOI 10.1038/12175; Ostedgaard LS, 2003, P NATL ACAD SCI USA, V100, P1937, DOI 10.1073/pnas.2627982100; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Verkman AS, 2003, METHOD ENZYMOL, V360, P635; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	51	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5494	5500		10.1074/jbc.M312445200	http://dx.doi.org/10.1074/jbc.M312445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660592	hybrid			2022-12-25	WOS:000188776500057
J	Heinrich, R; Livne, E; Ben-Izhak, O; Aronheim, A				Heinrich, R; Livne, E; Ben-Izhak, O; Aronheim, A			The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP-1 TRANSCRIPTION FACTOR; REPRESSOR; JDP2; DIFFERENTIATION; IDENTIFICATION; DOMAIN; PROLIFERATION; EXPRESSION; ACTIVATION; PROMOTER	The c-Jun dimerization protein, JDP2, is a member of the AP-1 (activating protein-1) family of the basic leucine zipper transcription factors. JDP2 can bind 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element and cAMP-responsive element DNA response elements, resulting in the inhibition of transcription. Although the role of AP-1 in cell proliferation and malignant transformation is well established, the role of JDP2 in this process is of subject to debate. On the one hand, JDP2 was shown to inhibit cyclin D transcription and promote differentiation of skeletal muscle and osteoclast cells. On the other hand, JDP2 was shown to partially transform chicken embryo fibroblast and was identified in a screen for oncogenes able to collaborate with the loss of p27(kip) cyclin-dependent inhibitor to induce lymphomas. Using cell transformation assays in NIH3T3 cells and injection of prostate cancer cell lines overexpressing JDP2 into severe combined immuno-deficient ( SCID) mice, we show for the first time the potential role of JDP2 in inhibition of cell transformation and tumor suppression. The mechanism of tumor suppressor action of JDP2 can be partially explained by the generation of inhibitory AP-1 complexes via the increase of JunB, JunD, and Fra2 expression and decrease of c-Jun expression.	Technion Israel Inst Technol, Fac Med, B Rappaport Inst Med Sci, Dept Mol Genet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, B Rappaport Inst Med Sci, Dept Anat, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Dept Pathol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology	Aronheim, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Mol Genet, 7 Efron St, IL-31096 Haifa, Israel.	Aronheim@tx.technion.ac.il		Aronheim, Ami/0000-0002-8575-4092				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Blazek E, 2003, ONCOGENE, V22, P2151, DOI 10.1038/sj.onc.1206312; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Katz S, 2002, BIOCHEM J, V368, P939, DOI 10.1042/BJ20021127; Katz S, 2001, FEBS LETT, V506, P196, DOI 10.1016/S0014-5793(01)02907-6; Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Nagler RM, 2002, CANCER LETT, V186, P137, DOI 10.1016/S0304-3835(02)00265-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ostrovsky O, 2002, J BIOL CHEM, V277, P40043, DOI 10.1074/jbc.M205494200; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheerin A, 2002, CANCER LETT, V177, P83, DOI 10.1016/S0304-3835(01)00751-0; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	27	60	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5708	5715		10.1074/jbc.M307608200	http://dx.doi.org/10.1074/jbc.M307608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14627710	hybrid			2022-12-25	WOS:000188776500083
J	Sakata, Y; Arima, K; Takai, T; Sakurai, W; Masumoto, K; Yuyama, N; Suminami, Y; Kishi, F; Yamashita, T; Kato, T; Ogawa, H; Fujimoto, K; Matsuo, Y; Sugita, Y; Izuhara, K				Sakata, Y; Arima, K; Takai, T; Sakurai, W; Masumoto, K; Yuyama, N; Suminami, Y; Kishi, F; Yamashita, T; Kato, T; Ogawa, H; Fujimoto, K; Matsuo, Y; Sugita, Y; Izuhara, K			The squamous cell carcinoma antigen 2 inhibits the cysteine proteinase activity of a major mite allergen, der p 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DER-P-I; CROSS-CLASS INHIBITION; PROTEASE ACTIVITY; PROTEOLYTIC ACTIVITY; EPITHELIAL-CELLS; ATOPIC ASTHMA; CATHEPSIN-L; GRANZYME-B; SERPIN; CLEAVAGE	The squamous cell carcinoma antigens 1 (SCCA1) and SCCA2 belong to the ovalbumin-serpin family. Although SCCA1 and SCCA2 are closely homologous, these two molecules have distinct properties; SCCA1 inhibits cysteine proteinases such as cathepsin K, L, and S, whereas SCCA2 inhibits serine proteinases such as cathepsin G and human mast cell chymase. Although several intrinsic target proteinases for SCCA1 and SCCA2 have been found, the biological roles of SCCA1 and SCCA2 remain unknown. A mite allergen, Der p 1, is one of the most immunodominant allergens and also acts as a cysteine proteinase probably involved in the pathogenesis of allergic diseases. We have recently shown that both SCCA1 and SCCA2 are induced by two related Th2-type cytokines, IL-4 and IL-13, in bronchial epithelial cells and that SCCA expression is augmented in bronchial asthma patients. In this study, we explored the possibility that SCCA proteins target Der p 1, and it turned out that SCCA2, but not SCCA1, inhibited the catalytic activities of Der p 1. We furthermore analyzed the inhibitory mechanism of SCCA2 on Der p 1. SCCA2 contributed the suicide substrate-like mechanism without formation of a covalent complex, causing irreversible impairment of the catalytic activity of Der p 1, as SCCA1 does on papain. In addition, resistance to cleavage by Der p 1 also contributed to the inhibitory mechanism of SCCA2. These results suggest that SCCA2 acts as a cross-class serpin targeting an extrinsic cysteine proteinase derived from house dust mites and that it may have a protective role against biological reactions caused by mites.	Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga 8498501, Japan; Saga Med Sch, Dept Internal Med, Div Gastroenterol, Saga 8498501, Japan; Saga Med Sch, Ctr Comprehens Community Med, Div Med Res, Saga 8498501, Japan; Juntendo Univ, Atopy Allergy Res Ctr, Tokyo 1138421, Japan; RIKEN Genom Sci Ctr, Prot Res Grp, Computat Proteom Team, Yokohama, Kanagawa 2300045, Japan; Genox Res Inc, Tokyo 1128088, Japan; Onoda Municipal Hosp, Onoda 7560094, Japan; Kagoshima Univ, Sch Dent, Dept Microbiol & Immunol, Kagoshima 8908544, Japan; Mitsubishi Kagaku BCL, Tokyo 1748555, Japan	Saga University; Saga University; Saga University; Juntendo University; RIKEN; Kagoshima University; Mitsubishi Kagaku Bio-Clinical Laboratories	Izuhara, K (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga 8498501, Japan.	kizuhara@med.saga-u.ac.jp	Arima, Kazuhiko/I-8962-2014; Takai, Toshiro/K-5690-2013	Arima, Kazuhiko/0000-0002-0607-8787; Takai, Toshiro/0000-0001-8363-0355				Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Finkelman FD, 2001, J ALLERGY CLIN IMMUN, V107, P772, DOI 10.1067/mai.2001.114989; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Izuhara Kenji, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P505; John RJ, 2000, CLIN EXP ALLERGY, V30, P784, DOI 10.1046/j.1365-2222.2000.00840.x; KATO H, 1977, CANCER, V40, P1621, DOI 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I; King C, 1998, J IMMUNOL, V161, P3645; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Luke C, 2000, BIOCHEMISTRY-US, V39, P7081, DOI 10.1021/bi000050g; Masumoto K, 2003, J BIOL CHEM, V278, P45296, DOI 10.1074/jbc.M307741200; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Schulz O, 1998, J CLIN PATHOL-MOL PA, V51, P222, DOI 10.1136/mp.51.4.222; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; SHARMA S, 2001, AM J RESP CRIT CARE, V163, pA862; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; TAKEDA A, 1995, FEBS LETT, V359, P78, DOI 10.1016/0014-5793(94)01456-B; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x; Ye S, 2001, CURR OPIN STRUC BIOL, V11, P740, DOI 10.1016/S0959-440X(01)00275-5; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972	41	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5081	5087		10.1074/jbc.M311585200	http://dx.doi.org/10.1074/jbc.M311585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630915	hybrid			2022-12-25	WOS:000188776500007
J	Peirce, SK; Chen, WY				Peirce, SK; Chen, WY			Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice	ONCOGENE			English	Article						prolactin antagonist; bax; bcl-2; cytochrome c; breast cancer; apoptosis	MAMMARY-GLAND; APOPTOSIS; GROWTH; FAMILY; PROMOTER	To gain insight into the molecular mechanisms involved in human prolactin receptor antagonist (hPRL-G129R)induced apoptosis, we used real-time reverse transcription - polymerase chain reaction to measure bax and bcl-2 gene expression in 11 human breast cancer cell lines following treatment with hPRL and hPRL-G129R. We also measured bax and bcl-2 gene expression in the mammary glands of transgenic mice expressing hPRL or hPRL-G129R. A time-course study of hPRL and antagonist treatment in T-47D cells indicated changing bax/bcl-2 mRNA ratios beginning at 24 h. We found that bax/bcl-2 mRNA ratios were significantly elevated in seven of the 11 hPRL-G129R-treated cell lines, as well as in the hPRL-G129R transgenic mice. To confirm these results, Bax and Bcl-2 proteins were analysed by Western blot methods in mammary gland tissue homogenates of transgenic mice. Bax/Bcl-2 ratios were highest in the 6-month group of hPRL-G129R transgenics, and lowest in the 6-month group of hPRL transgenics. We expanded our findings by examining the release of a downstream Bax-induced protein, cytochrome c, a hallmark protein of apoptosis, in transgenic mice. Again, cytochrome c levels were highest in the 6-month hPRL-G129R transgenic group. Thus, hPRL-G129R-induced breast cancer cell and/or mammary gland apoptosis is mediated, at least in part, through the regulation of Bax and Bcl-2 gene expression.	Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Clemson Univ, Dept Biol Sci, Clemson, SC 29630 USA; Clemson Univ, Dept Biochem & Genet, Clemson, SC 29630 USA	Greenville Health System; Clemson University; Clemson University	Chen, WY (corresponding author), Greenville Hosp Syst, Oncol Res Inst, 900 W Faris Rd, Greenville, SC 29605 USA.	wchen@ghs.org			NCI NIH HHS [CA87093] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; Binart N, 2000, ADV EXP MED BIOL, V480, P85; Binder C, 1996, ANN ONCOL, V7, P129; BLACKWELL RE, 1999, HORMONAL CONTROL NOR, P3; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Corbacho AM, 2002, J ENDOCRINOL, V173, P219, DOI 10.1677/joe.0.1730219; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; GINSBURG E, 1995, CANCER RES, V55, P2591; Green DR, 1999, CANC DRUG DISC DEV, V5, P157; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Kuo CB, 2002, CELL TISSUE RES, V309, P429, DOI 10.1007/s00441-002-0598-8; Marti A, 1997, EUR J CELL BIOL, V73, P158; NAGASAWA H, 1985, EXP CLIN ENDOCRINOL, V86, P357, DOI 10.1055/s-0029-1210509; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Schorr K, 1999, CANCER RES, V59, P2541; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	31	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1248	1255		10.1038/sj.onc.1207245	http://dx.doi.org/10.1038/sj.onc.1207245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647416				2022-12-25	WOS:000188892200009
J	Buttiglieri, S; Deregibus, MC; Bravo, S; Cassoni, P; Chiarle, R; Bussolati, B; Camussi, G				Buttiglieri, S; Deregibus, MC; Bravo, S; Cassoni, P; Chiarle, R; Bussolati, B; Camussi, G			Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; GROWTH-FACTOR; TAT PROTEIN; EXPRESSION; SURVIVAL; TRANSFORMATION; INFECTION; ORIGIN	In this study, we found that Kaposi's sarcoma cells but not human microvascular endothelial cells expressed PAX2, a gene coding for a transcription factor involved both in organogenesis and tumorigenesis. Moreover, Pax2 was frequently expressed, on spindle-shaped cells, in Kaposi's sarcoma lesions. We cloned PAX2 from Kaposi's sarcoma cells and obtained antisense and sense DNA. Transfection of Kaposi's sarcoma cells with antisense DNA, which suppressed Pax2 protein expression, reduced cell growth and survival and enhanced the sensitivity of Kaposi's sarcoma cells to apoptosis induced by serum deprivation or vincristine treatment. In addition, antisense transfection inhibited the cell motility, the invasion of Matrigel, and the spindle shape morphology, which are characteristics of Kaposi's sarcoma cells. Moreover, the alpha(v)beta(3) integrin, known to be involved in tumor invasion, was down-regulated. To evaluate the possible role of Pax2 expression in the endothelial origin of Kaposi's sarcoma cells, human microvascular endothelial cells were transfected with sense DNA. Endothelial cells transfected with sense PAX2 acquired spindle shape morphology, showed enhanced motility and Matrigel invasion, and displayed an enhanced expression of alpha(v)beta(3) integrin. In conclusion, the expression of Pax2 by Kaposi's sarcoma cells correlated with an enhanced resistance against apoptotic signals and with the proinvasive phenotype. Moreover, PAX2-transfected endothelial cells acquired a phenotype resembling that of Kaposi's lesional cells, suggesting a role of this embryonic gene in tumorigenesis.	Univ Turin, Dipartimento Med Interna, Cattedra Nefrol, I-10126 Turin, Italy; Univ Turin, Ctr Ric Med Sperimentale, I-10126 Turin, Italy; Univ Turin, Dipartimento Sci Biomed & Oncol, I-10126 Turin, Italy	University of Turin; University of Turin; University of Turin	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Cassoni, Paola/I-8544-2018; Camussi, Giovanni/J-7624-2016; buttiglieri, stefano/L-3005-2013; Bussolati, Benedetta/AAA-9058-2022	Camussi, Giovanni/0000-0003-2795-232X; Bussolati, Benedetta/0000-0002-3663-5134; CHIARLE, Roberto/0000-0003-1564-8531				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; ALBINI A, 1987, CANCER RES, V47, P3239; BECKSTEAD JH, 1985, AM J PATHOL, V119, P294; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Bussolati B, 2002, INT J CANCER, V100, P654, DOI 10.1002/ijc.10545; CANTALUPPI V, 2001, AIDS, V10, P965; Cassoni P, 2002, CANCER RES, V62, P2406; Conaldi PG, 1997, J INFECT DIS, V175, P693, DOI 10.1093/infdis/175.3.693; CORBEIL J, 1991, J IMMUNOL, V146, P2972; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; GNARRA JR, 1995, CANCER RES, V55, P4092; Halder G, 1998, DEVELOPMENT, V125, P2181; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; Jussila L, 1998, CANCER RES, V58, P1599; Kaaya EE, 1996, HISTOPATHOLOGY, V29, P337, DOI 10.1111/j.1365-2559.1996.tb01417.x; Lee FC, 1996, HEMATOL ONCOL CLIN N, V10, P1051, DOI 10.1016/S0889-8588(05)70384-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Mitsuyasu RT, 2000, CURR OPIN ONCOL, V12, P174, DOI 10.1097/00001622-200003000-00013; Mori S, 1996, CANCER RES, V56, P1874; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; MURATOVSKA A, 2003, ONCOGENE, V11, P6045; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SCULLY PA, 1988, AM J PATHOL, V130, P244; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Torban E, 2000, AM J PATHOL, V157, P833, DOI 10.1016/S0002-9440(10)64597-X; UCCINI S, 1994, J PATHOL, V173, P23, DOI 10.1002/path.1711730105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0	39	39	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4136	4143		10.1074/jbc.M306824200	http://dx.doi.org/10.1074/jbc.M306824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627715	hybrid			2022-12-25	WOS:000188554300028
J	Wu, HY; Tomizawa, K; Oda, Y; Wei, FY; Lu, YF; Matsushita, M; Li, ST; Moriwaki, A; Matsui, H				Wu, HY; Tomizawa, K; Oda, Y; Wei, FY; Lu, YF; Matsushita, M; Li, ST; Moriwaki, A; Matsui, H			Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALPASTATIN PEPTIDE; KAINIC ACID; CELL-DEATH; ACTIVATION; PHOSPHATASE; CALMODULIN; RELEASE; DEPHOSPHORYLATION; NEUROTOXICITY; MECHANISMS	Calcineurin and calpain, a Ca2+/calmodulin-dependent protein phosphatase and a Ca2+-dependent cysteine protease, respectively, mediate neuronal cell death through independent cascades. Here, we report that during neuroexcitotoxicity, calcineurin A (CnA) is directly cleaved by calpain in vitro and in vivo, resulting in the enzyme being converted to an active form. Mass spectrometry identified three cleavage sites in CnA, two of which were constitutively active forms. Overexpression of the cleaved CnA induced caspase activity and neuronal cell death. Calpain inhibitors and membrane-permeable calpastatin peptides not only blocked the cleavage of CnA, but also protected against excitotoxic neuronal cell death in vitro and in vivo. These results indicate that CnA is a crucial target for calpain, and the calpain-mediated activation of CnA triggers excitotoxic neurodegeneration. This study established a molecular link between calpain and calcineurin, thereby demonstrating a new mechanism for proteolytical regulation of calcineurin by calpain in response to certain pathological states.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008558, Japan; Eisai & Co Ltd, Lab Seeds Finding Technol, Tsukuba, Ibaraki 3002635, Japan; Japan Sci & Technol Corp, New Technoventure Oriented R&D, Prot Therapy, Okayama 7008558, Japan	Okayama University; Eisai Co Ltd; Japan Science & Technology Agency (JST)	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata, Okayama 7008558, Japan.	tomikt@md.okayama-u.ac.jp	Wei, Fan-Yan/AAD-8461-2021; Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Wei, Fan-Yan/0000-0002-4843-724X; Li, Sheng Tian/0000-0002-2836-3802				Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Betts R, 2003, J BIOL CHEM, V278, P7800, DOI 10.1074/jbc.M208350200; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; HUBBARD MJ, 1989, EUR J BIOCHEM, V185, P411, DOI 10.1111/j.1432-1033.1989.tb15130.x; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P9870, DOI 10.1073/pnas.152336999; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kurz JE, 2001, J NEUROCHEM, V78, P304, DOI 10.1046/j.1471-4159.2001.00426.x; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; MAKI M, 1989, J BIOL CHEM, V264, P18866; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MATSUI H, 1987, BRAIN RES, V402, P193, DOI 10.1016/0006-8993(87)91067-5; Matsushita M, 2001, J NEUROSCI, V21, P6000, DOI 10.1523/JNEUROSCI.21-16-06000.2001; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MOIA LJMP, 1994, BRAIN RES, V648, P337, DOI 10.1016/0006-8993(94)91138-X; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Mukerjee N, 2001, BIOCHEM BIOPH RES CO, V285, P1192, DOI 10.1006/bbrc.2001.5278; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; OLNEY JW, 1978, NATURE, V271, P557, DOI 10.1038/271557a0; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Springer JE, 2000, J NEUROSCI, V20, P7246; Takenobu T, 2002, MOL CANCER THER, V1, P1043; TALLANT EA, 1988, BIOCHEMISTRY-US, V27, P2205, DOI 10.1021/bi00406a059; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wu HY, 2003, NEUROSCI RES, V47, P131, DOI 10.1016/S0168-0102(03)00195-0; Yang Seun-Ah, 2002, Methods Mol Biol, V172, P317; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	48	197	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4929	4940		10.1074/jbc.M309767200	http://dx.doi.org/10.1074/jbc.M309767200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627704	Green Submitted, hybrid			2022-12-25	WOS:000188554300119
J	Stoner, M; Wormke, M; Saville, B; Samudio, I; Qin, CH; Abdelrahim, M; Safe, S				Stoner, M; Wormke, M; Saville, B; Samudio, I; Qin, CH; Abdelrahim, M; Safe, S			Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins	ONCOGENE			English	Article						estrogen; VEGF; transactivation; ER alpha/Sp1; ER alpha/Sp3	PERMEABILITY FACTOR EXPRESSION; NECROSIS-FACTOR-ALPHA; CATHEPSIN-D GENE; TRANSCRIPTIONAL ACTIVATION; FACTOR VEGF; PROGESTERONE-RECEPTOR; HORMONAL-REGULATION; RESPONSIVE ELEMENT; GLIOMA-CELLS; TUMOR-GROWTH	Vascular endothelial growth factor (VEGF) is expressed in multiple hormone-dependent cancer cells/tumors. Treatment of ZR-75 breast cancer cells with 17beta-estradiol (E2) induced a greater than fourfold increase of VEGF mRNA levels. ZR-75 breast cancer cells were transfected with pVEGF1, a construct containing a -2018 to +50 VEGF prom oter insert, and E2 induced reporter gene (luciferase) activity. Deletion and mutation analysis of the VEGF gene promoter identified a GC-rich region (-66 to -47) which was required for E2-induced transactivation of pVEGF5, a construct containing the minimal promoter (-66 to +54) that exhibited E2-responsiveness. Interactions of nuclear proteins from ZR-75 cells with the proximal GC-rich region of the VEGF gene promoter were investigated by electrophoretic mobility shift and chromatin immunoprecipitation assays. The results demonstrate that both Sp1 and Sp3 proteins bound the GC-rich motif (-66 to +47), and estrogen receptor alpha (ERalpha) interactions were confirmed by chromatin immunoprecipitation. Moreover, E2-dependent activation of constructs containing proximal and distal GC/GT-rich regions of the VEGF promoter was inhibited in ZR-75 cells transfected with small inhibitory RNAs for Sp1 and Sp3. These results were consistent with a mechanism of hormone activation of VEGF through ERalpha/Sp1 and ERalpha/Sp3 interactions with GC-rich motifs.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, R01ES004176] Funding Source: NIH RePORTER; NCI NIH HHS [CA076636] Funding Source: Medline; NIEHS NIH HHS [ES04176, ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bogin L, 2002, CANCER RES, V62, P1948; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brekken RA, 2000, CANCER RES, V60, P5117; BROWN LF, 1993, AM J PATHOL, V143, P1255; Buteau-Lozano H, 2002, CANCER RES, V62, P4977; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; Classen-Linke I, 2000, STEROIDS, V65, P763, DOI 10.1016/S0039-128X(00)00180-X; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harborth J, 2001, J CELL SCI, V114, P4557; Hyder SM, 1997, CANCER LETT, V120, P165, DOI 10.1016/S0304-3835(97)00306-6; Hyder SM, 1998, CANCER RES, V58, P392; Hyder SM, 1996, CANCER RES, V56, P3954; Hyder SM, 2000, CANCER RES, V60, P3183; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KLOTZ DM, 1995, BIOCHEM BIOPH RES CO, V210, P609, DOI 10.1006/bbrc.1995.1702; Laitinen M, 1997, ENDOCRINOLOGY, V138, P4748, DOI 10.1210/en.138.11.4748; Linderholm BK, 2001, CANCER RES, V61, P2256; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; Nakamura J, 1996, ENDOCRINOLOGY, V137, P5589, DOI 10.1210/en.137.12.5589; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Scheidegger KJ, 2000, J BIOL CHEM, V275, P38921, DOI 10.1074/jbc.M004691200; Schlaeppi JM, 1999, CANCER METAST REV, V18, P473, DOI 10.1023/A:1006358220123; Shi Q, 2001, CANCER RES, V61, P4143; Simmen RCM, 1999, ENDOCRINOLOGY, V140, P2517, DOI 10.1210/en.140.6.2517; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshiji H, 1997, CANCER RES, V57, P3924; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	63	114	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1052	1063		10.1038/sj.onc.1207201	http://dx.doi.org/10.1038/sj.onc.1207201			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647449				2022-12-25	WOS:000188749900004
J	Hashikawa, T; Hooker, SW; Maj, JG; Knott-Craig, CJ; Takedachi, M; Murakami, S; Thompson, LF				Hashikawa, T; Hooker, SW; Maj, JG; Knott-Craig, CJ; Takedachi, M; Murakami, S; Thompson, LF			Regulation of adenosine receptor engagement by ecto-adenosine deaminase	FASEB JOURNAL			English	Article						CD26; cAMP; CD73	T-CELL-ACTIVATION; DIPEPTIDYL PEPTIDASE-IV; SURFACE EXPRESSION; HUMAN CD26; BINDING; LYMPHOCYTES; DEFICIENCY; CD73; PROTEIN; ASSOCIATION	Adenosine deaminase (ADA) can localize to the cell surface through its interaction with CD26. Using CD26-transfected cells, we demonstrate that cell surface ADA (ecto-ADA) can regulate adenosine receptor engagement by degrading extracellular adenosine (Ado) to inosine. This ability was dependent upon CD26 expression, the extent of CD26 saturation with ecto-ADA, and the kinetics of the cAMP response. Thus, the cAMP response was markedly decreased when CD26-transfected cells were incubated with an exogenous source of ADA to increase ecto-ADA expression. The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2'-deoxycoformycin. This inhibited the ability of ecto-ADA to degrade Ado and increased the cAMP response. Although CD26 expression on human thymocytes was low compared with that of CD26-transfected cells, it was saturated with ecto-ADA. When thymocytes incubated at high densities (to mimic the situation in tissues) were exposed to exogenous adenosine, the cAMP response was dramatically decreased by ecto-ADA. We conclude that ecto-ADA has the potential to regulate adenosine receptor-mediated cAMP responses in vivo in tissues with CD26(+) cells and sufficient cell death caused by apoptosis or inflammation to provide a source of ADA to bind to CD26.	Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, Oklahoma City, OK 73104 USA; Osaka Univ, Grad Sch Dent, Dept Periodontol, Suita, Osaka 5650871, Japan; Oklahoma Univ Hlth Sci Ctr, Dept Surg, Oklahoma City, OK USA	Oklahoma Medical Research Foundation; Osaka University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Thompson, LF (corresponding author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Linda-Thompson@omrf.ouhsc.edu	Takedachi, Masahide/GVS-6539-2022		NIH [AI18220, HD36044, AI45864]; Japan Society for the Promotion of Science [15659498]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Michael Hershfield for human recombinant ADA and helpful discussions and Kerry Humphrey for manuscript preparation. This work was supported by NIH grants AI18220, HD36044, and AI45864 and grant No.15659498 from the Japan Society for the Promotion of Science. L.F.T. holds the Putnam City Schools Chair in Cancer Research.	ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; AGARWAL RP, 1977, BIOCHEM PHARMACOL, V26, P359, DOI 10.1016/0006-2952(77)90192-7; BOSS GR, 1981, CLIN IMMUNOL IMMUNOP, V19, P1, DOI 10.1016/0090-1229(81)90042-8; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CHECHIK BE, 1981, J IMMUNOL, V126, P1003; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; DANG NH, 1990, J IMMUNOL, V144, P4092; Dong RP, 1997, J IMMUNOL, V159, P6070; Dong RP, 1996, J IMMUNOL, V156, P1349; FOX RI, 1981, J IMMUNOL, V126, P2062; GIBLETT ER, 1972, LANCET, V2, P1067; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hegen M, 1997, IMMUNOLOGY, V90, P257, DOI 10.1046/j.1365-2567.1997.00053.x; Herrera C, 2001, MOL PHARMACOL, V59, P127, DOI 10.1124/mol.59.1.127; IwakiEgawa S, 1997, CELL IMMUNOL, V178, P180, DOI 10.1006/cimm.1997.1123; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; MA DDF, 1982, J IMMUNOL, V129, P1430; MARTIN M, 1993, CLIN EXP IMMUNOL, V93, P286; MARTIN M, 1995, J IMMUNOL, V155, P4630; Matsuoka I, 2002, MOL PHARMACOL, V61, P606, DOI 10.1124/mol.61.3.606; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Ramkumar V, 1988, Prog Drug Res, V32, P195; RESTA R, 1994, J IMMUNOL, V153, P1046; Resta R, 1997, J CLIN INVEST, V99, P676, DOI 10.1172/JCI119211; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; Saura CK, 1998, J BIOL CHEM, V273, P17610, DOI 10.1074/jbc.273.28.17610; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; STILES GL, 1992, J BIOL CHEM, V267, P6451; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; VANDERWEYDEN MB, 1976, J BIOL CHEM, V251, P5448; Yamashita Y, 1998, EUR J IMMUNOL, V28, P2981, DOI 10.1002/(SICI)1521-4141(199810)28:10<2981::AID-IMMU2981>3.0.CO;2-D; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	40	50	51	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					131	133		10.1096/fj.03-0011fje	http://dx.doi.org/10.1096/fj.03-0011fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630704				2022-12-25	WOS:000188829300050
J	Kammanadiminti, SJ; Mann, BJ; Dutil, L; Chadee, K				Kammanadiminti, SJ; Mann, BJ; Dutil, L; Chadee, K			Regulation of Toll-like receptor-2 expression by the Gal-lectin of Entamoeba histolytica	FASEB JOURNAL			English	Article						galactose lectin; TLR-2; macrophage		The Gal/GalNAc lectin (Gal-lectin) of Entamoeba histolytica is a surface molecule involved in parasite adherence to host cells and is the most promising subunit vaccine candidate against amoebiasis. As macrophages are the major effector cells in host defense against amoebas, we studied the molecular mechanisms by which Gal-lectin activates macrophage. Microarray analysis showed that Gal-lectin up-regulated mRNAs of several cytokines and receptor genes involved in proinflammatory responses. The mechanism whereby the Gal-lectin regulates Toll-like receptor 2 (TLR-2) expression in macrophages was studied. Native Gal-lectin increased TLR-2 mRNA expression in a dose- and time-dependent fashion; peak response occurred with 1 mu g/ml after 2 h stimulation. By immunoflourescence, enhanced surface expression of TLR-2 was observed after 12 h. With the use of nonoverlapping anti-Gal-lectin monoclonal antibodies that map to the carbohydrate recognition domain, amino acid 596-1082 was identified as the TLR-2 stimulating region. The Gal-lectin increased TLR-2 gene transcription, and the half-life of the mRNA transcripts was 1.4 h. Inhibition of nuclear factor (NF)-kappa B suppressed TLR-2 mRNA induction by the Gal-lectin. Moreover, cells pretreated with an inhibitor of p38 kinase (SB 208530) inhibited Gal-lectin induced TLR-2 mRNA expression by 40%. We conclude that the Gal-lectin activates NF-kappaB and MAP kinase-signaling pathways in macrophages culminating in the induction of several genes including TLR-2 and hypothesize that this could have a significant impact on macrophage activation and contribute to amoebic pathogenesis.	McGill Univ, Inst Parasitol, Ste Anne De Bellevue, PQ, Canada; Univ Virginia, Charlottesville, VA USA	McGill University; University of Virginia	Chadee, K (corresponding author), McGill Univ, Inst Parasitol, Macdonald Campus,21,111 Lakeshore Rd, Ste Anne De Bellevue, PQ, Canada.	kris.chadee@mcgill.ca			Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Fonds pour la Formation de Chercheurs et l' Aide a la recherche du Quebec; McGill University Graduate Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Fonds pour la Formation de Chercheurs et l' Aide a la recherche du Quebec; McGill University Graduate Fellowship	This study was supported in part by grants from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada. Research at the Institute of Parasitology was partially funded by the Fonds pour la Formation de Chercheurs et l' Aide a la recherche du Quebec. S. Kammanadiminti was the recipient of a McGill University Graduate Fellowship.	Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell D, 2000, EUR J IMMUNOL, V30, P423, DOI 10.1002/1521-4141(200002)30:2&lt;423::AID-IMMU423&gt;3.0.CO;2-0; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; CHADEE K, 1984, AM J PATHOL, V117, P71; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; Dhiman N, 2001, VACCINE, V20, P22, DOI 10.1016/S0264-410X(01)00319-X; Dodson JM, 1999, J INFECT DIS, V179, P460, DOI 10.1086/314610; Eskra L, 2003, INFECT IMMUN, V71, P1125, DOI 10.1128/IAI.71.3.1125-1133.2003; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Hamilton JA, 1998, INT J BIOCHEM CELL B, V30, P271, DOI 10.1016/S1357-2725(97)00111-8; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; Hecker M, 1996, BRIT J PHARMACOL, V118, P2178, DOI 10.1111/j.1476-5381.1996.tb15660.x; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KYRIAKIS JM, 2000, SCI STKE; Lockhart BP, 1998, BRIT J PHARMACOL, V123, P879, DOI 10.1038/sj.bjp.0701664; MANN BJ, 1993, INFECT IMMUN, V61, P1772, DOI 10.1128/IAI.61.5.1772-1778.1993; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; MCCOY JJ, 1994, INFECT IMMUN, V62, P3045, DOI 10.1128/IAI.62.8.3045-3050.1994; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Neurath MF, 1997, IMMUNOBIOLOGY, V198, P91, DOI 10.1016/S0171-2985(97)80030-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366; Park SJ, 2002, CELL BIOL TOXICOL, V18, P121, DOI 10.1023/A:1015384201785; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1990, J IMMUNOL, V144, P4803; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SEGUIN R, 1995, IMMUNOLOGY, V86, P49; Seguin R, 1995, P NATL ACAD SCI USA, V92, P12175, DOI 10.1073/pnas.92.26.12175; Seguin R, 1997, INFECT IMMUN, V65, P2522; Seydel KB, 1998, GASTROENTEROLOGY, V115, P1446, DOI 10.1016/S0016-5085(98)70023-X; Shimizu H, 2002, GASTROENTEROLOGY, V123, P1265, DOI 10.1053/gast.2002.36006; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Stanley SL, 2001, J INFECT DIS, V184, P504, DOI 10.1086/322046; Tengku-Muhammad TS, 1999, CYTOKINE, V11, P463, DOI 10.1006/cyto.1998.0460; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Wang TY, 2001, J IMMUNOL, V167, P6924, DOI 10.4049/jimmunol.167.12.6924; WHO (World Health Organization), 1998, WORLD HLTH REP 1998	47	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					155	157		10.1096/fj.03-0578fje	http://dx.doi.org/10.1096/fj.03-0578fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630697				2022-12-25	WOS:000188829300059
J	Aebersold, DM; Landt, O; Berthou, S; Gruber, G; Beer, KT; Greiner, RH; Zimmer, Y				Aebersold, DM; Landt, O; Berthou, S; Gruber, G; Beer, KT; Greiner, RH; Zimmer, Y			Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx	ONCOGENE			English	Article						Met receptor; activating mutation; radiotherapy; head and neck cancer	GROWTH-FACTOR RECEPTOR; SOMATIC MUTATIONS; FACTOR PROTECTS; SCATTER FACTOR; C-MET; RADIATION; DNA; CARCINOMAS; ONCOGENE; KINASE	Aberrant signalling through the hepatocyte growth factor/scatter factor receptor Met has been implicated in various aspects of the development of human cancer including the promotion of tumour invasion, angiogenesis and metastasis. Moreover, experimental data indicate that activation of the Met receptor may be involved in cellular resistance towards antineoplastic treatments such as chemotherapy and ionizing radiation. We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. To screen archival tissue for the presence of a low-abundance point mutation, we developed a sensitive screening method using real-time polymerase chain reaction along with peptide nucleic acid-based DNA clamping and melting curve analysis. By this approach, Met Y1253D was detected in tumours of 15 out of 138 patients (10.9%). Both univariate and multivariate survival analysis revealed Met Y1253D to be significantly associated with impaired local tumour control. Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; MOLBIOL, TIB, Berlin, Germany; Inselspital, Dept Radiat Oncol, Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern	Zimmer, Y (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35-D-809, CH-3010 Bern, Switzerland.		Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834				Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Bowers DC, 2000, CANCER RES, V60, P4277; CHIARA F, 2003, J BIOL CHEM, V12, P12; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Lindel K, 2001, CANCER-AM CANCER SOC, V92, P805, DOI 10.1002/1097-0142(20010815)92:4<805::AID-CNCR1386>3.0.CO;2-9; Lorenzato A, 2002, CANCER RES, V62, P7025; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Park WS, 1999, CANCER RES, V59, P307; Pietras RJ, 1999, CANCER RES, V59, P1347; Raben David, 2002, Expert Rev Anticancer Ther, V2, P461, DOI 10.1586/14737140.2.4.461; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Sun XY, 2002, NAT BIOTECHNOL, V20, P186, DOI 10.1038/nbt0202-186; To CTT, 1998, ONCOL REP, V5, P1013; Turner BC, 1997, CANCER RES, V57, P3079	19	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8519	8523		10.1038/sj.onc.1206968	http://dx.doi.org/10.1038/sj.onc.1206968			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627992				2022-12-25	WOS:000186650300015
J	Brill, J; Klocke, R; Paul, D; Boison, D; Gouder, N; Klugbauer, N; Hofmann, F; Becker, CM; Becker, K				Brill, J; Klocke, R; Paul, D; Boison, D; Gouder, N; Klugbauer, N; Hofmann, F; Becker, CM; Becker, K			entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; CALCIUM-CHANNEL SUBUNIT; DE-NOVO MUTATION; EPISODIC ATAXIA; GABAPENTIN-BINDING; RECEPTOR SUBUNIT; NMDA RECEPTOR; NEUROLOGICAL MUTATION; MISSENSE MUTATION; GLYCINE RECEPTOR	entla (ent) is a novel recessive phenotype of mice. The underlying mutation was mapped to chromosome 9 (60.1 centimorgans) and identified as an allele of the Cacna2d2 gene encoding the alpha2delta-2 subunit of voltage-gated calcium channels. The Cacna2d2(entla) allele harbors a 38-kb duplication comprising the 117 nucleotides of exon 3. The predicted duplication of 39 amino acid residues near the subunit's N terminus results in the expression of a full-length, membrane-associated protein. Western blot data were consistent with correct cleavage of the alpha2delta-2(entla) precursor into alpha2(entla) and delta2 proteins but indicated loss of the disulfide linkage between the two proteins. ent/ent mice develop ataxia by postnatal day 13-15, followed by paroxysmal dyskinesia a few days later. Two distinct types of cortical and hippocampal epileptic activity at 2 and 4 Hz were recorded, indicative of absence epilepsy. Homozygotes display reduced size and weight, increased mortality before weaning, and female infertility. No overt neuroanatomical abnormalities were detected. Ca2+ current densities recorded from acutely dissociated Purkinje cells of homozygous entla animals were reduced by 50% compared with wild type. Ligand binding assays using the antiepileptic drug [H-3]gabapentin, a specific ligand of the alpha2delta-1 and alpha2delta-2 subunits, revealed a >60% reduced maximum binding to cerebellar membranes of ent/ent compared with unaffected littermates. entla is allelic to ducky and ducky(2J), representing the third murine Cacna2d2 allele identified and so far the only one encoding an untruncated protein that is incorporated into membranes.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Univ Hamburg, Inst Expt & Klin Pharmakol, Zentrum Expt Med, D-20246 Hamburg, Germany; Univ Zurich, Inst Pharmakol & Toxikol, CH-8057 Zurich, Switzerland; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of Erlangen Nuremberg; University of Hamburg; University of Zurich; Technical University of Munich	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781				Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Bazil CW, 2002, NEUROLOGIST, V8, P71, DOI 10.1097/00127893-200203000-00002; Brodbeck J, 2002, J BIOL CHEM, V277, P7684, DOI 10.1074/jbc.M109404200; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Doyle J, 1997, MAMM GENOME, V8, P113, DOI 10.1007/s003359900369; Ducros A, 1999, AM J HUM GENET, V64, P89, DOI 10.1086/302192; Eichler EE, 2001, TRENDS GENET, V17, P661, DOI 10.1016/S0168-9525(01)02492-1; Escayg A, 2000, AM J HUM GENET, V66, P1531, DOI 10.1086/302909; Felix R, 2002, CELL MOL NEUROBIOL, V22, P103, DOI 10.1023/A:1019807719343; Friend KL, 1999, HUM GENET, V105, P261, DOI 10.1007/s004390051099; Gong HC, 2001, J MEMBRANE BIOL, V184, P35, DOI 10.1007/s00232-001-0072-7; Guida S, 2001, AM J HUM GENET, V68, P759, DOI 10.1086/318804; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jouvenceau A, 2002, NEUROPHARMACOLOGY, V42, P444, DOI 10.1016/S0028-3908(01)00202-7; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; Lorenzon NM, 1998, J NEUROSCI, V18, P4482; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Marais E, 2001, MOL PHARMACOL, V59, P1243, DOI 10.1124/mol.59.5.1243; McCormick DA, 2002, INT REV NEUROBIOL, V49, P99; MEIER H, 1968, ACTA NEUROPATHOL, V11, P15, DOI 10.1007/BF00692792; MEIER H, 1970, EXP MED SURG, V28, P256; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; ORTIZ JG, 1990, NEUROSCI LETT, V114, P231, DOI 10.1016/0304-3940(90)90077-M; Perucca E, 2001, EPILEPSIA, V42, P31, DOI 10.1046/j.1528-1157.2001.042suppl.3031.x; PFEIFFER F, 1981, BRAIN RES, V226, P273, DOI 10.1016/0006-8993(81)91099-4; REHM H, 1988, TRENDS PHARMACOL SCI, V9, P316, DOI 10.1016/0165-6147(88)90099-5; Seeber S, 2000, J NEUROCHEM, V75, P2472, DOI 10.1046/j.1471-4159.2000.0752472.x; SNELL GEORGE D., 1955, JOUR HEREDITY, V46, P27; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; Stefani A, 1998, NEUROPHARMACOLOGY, V37, P83, DOI 10.1016/S0028-3908(97)00189-5; Vahedi K, 2000, NEUROLOGY, V55, P1040, DOI 10.1212/WNL.55.7.1040; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Yue Q, 1998, AM J MED GENET, V77, P298, DOI 10.1002/(SICI)1096-8628(19980526)77:4<298::AID-AJMG9>3.0.CO;2-J; Zhang Y, 2002, J NEUROSCI, V22, P6362; Zwingman TA, 2001, J NEUROSCI, V21, P1169	47	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7322	7330		10.1074/jbc.M308778200	http://dx.doi.org/10.1074/jbc.M308778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660671	hybrid			2022-12-25	WOS:000188969200134
J	Han, SU; Kim, HT; Seong, DH; Kim, YS; Park, YS; Bang, YJ; Yang, HK; Kim, SJ				Han, SU; Kim, HT; Seong, DH; Kim, YS; Park, YS; Bang, YJ; Yang, HK; Kim, SJ			Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer	ONCOGENE			English	Article						TGF-b; Smad3; gastric cancer; tumorigenicity; gene expression	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; II RECEPTOR GENE; TGF-BETA; E-CADHERIN; CARCINOMA-CELLS; MICROSATELLITE INSTABILITY; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; COLON	Loss of the tumor suppressive effect of transforming growth factor-beta (TGF-beta) has been commonly found at later stages in carcinogenic progression. Although the genes encoding TGF-beta receptors and Smads have been found genetically altered in certain human cancers, no mutation in Smad3 has been observed. Therefore, suppression of Smad3 expression may mediate key oncogenic properties of TGF-beta. First, we observed that 37.5% of human gastric cancer tissues showed low to undetectable levels of Smad3 and that in nine human gastric cancer cell lines examined, two showed deficient Smad3 expression. Introduction of Smad3 into human gastric cancer cells that did not express Smad3, restored TGF-beta responsiveness: induction of p21 and p15 gene expression, and growth inhibition in response to TGF-beta. Furthermore, these Smad3-expressing cells showed markedly decreased and delayed tumorigenicity in vivo. These findings suggest that Smad3 expression may have a critical role in tumor suppression in the early stages of gastric carcinogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Gen Surg, Seoul 110744, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hanyang University; Seoul National University (SNU); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Room B1106, Bethesda, MD 20892 USA.	kims@mail.nih.gov	Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chang J, 1997, CANCER RES, V57, P2856; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 2001, CANCER RES, V61, P256; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada H, 1999, CANCER RES, V59, P3783; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Keller G., 2002, Pathologica (Genoa), V94, P229, DOI 10.1007/s102420200037; KIESER A, 1994, ONCOGENE, V9, P963; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Powell SM, 1997, CANCER RES, V57, P4221; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1999, ANN ONCOL, V10, P56, DOI 10.1023/A:1008336703450; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shattuck TM, 2002, J CLIN ENDOCR METAB, V87, P3911, DOI 10.1210/jc.87.8.3911; Shitara Y, 1999, JPN J CLIN ONCOL, V29, P3, DOI 10.1093/jjco/29.1.3; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	64	104	111	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1333	1341		10.1038/sj.onc.1207259	http://dx.doi.org/10.1038/sj.onc.1207259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647420				2022-12-25	WOS:000189035800001
J	Gorbatyuk, VY; Tsai, CK; Chang, CF; Huang, TH				Gorbatyuk, VY; Tsai, CK; Chang, CF; Huang, TH			Effect of N-terminal and Met(23) mutations on the structure and dynamics of onconase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL-FREE APPROACH; SEQUENCE-SPECIFIC RIBONUCLEASE; MAGNETIC-RESONANCE RELAXATION; AMINO-ACID-SEQUENCE; CYTOTOXIC RIBONUCLEASE; P-30 PROTEIN; COUPLING-CONSTANTS; BACKBONE DYNAMICS; CHEMICAL-SHIFT; OOCYTES	Onconase (rONC), otherwise known as ranpirnase or P-30 protein, which was initially purified from extracts of Rana pipiens oocytes and early embryos, exhibits anticancer activity both in vitro and in vivo and is in phase III clinical trials for tumor therapy. We have determined the solution NMR structure of a recombinant onconase with Met(-1), Gln(1), and Leu(23) residues (M-1, Q1, M23L)rONC. The 20 best solution structures had a backbone root mean square deviation of 0.41 +/- 0.09 degrees with respect to the average structure. The energy-minimized average NMR structure had a backbone root mean square deviation of 0.72 Angstrom from the x-ray crystallographic structure of native onconase; however, the orientation of the N-terminal residue in the two structures was very different. Comparison of the N-15 HSQC spectrum of (M-1, Q1, M23L) rONC with that of a mutant E1S-rONC, which is identical to the nONC except with the N-terminal pyroglutamyl residue replaced by Ser, showed that N-terminal and residue 23 mutations induced structural changes in regions beyond the mutation sites. Model-free analysis of the backbone amide N-15-T-1, N-15-T-2, and N-15-H-1 NOE relaxation data for (M-1, Q1, M23L) rONC and E1S-rONC revealed that the E1S-rONC molecule showed very little flexibility, whereas (M-1, Q1, M23L) rONC exhibited substantial flexibility, which may account for the previously observed reduced stability and increased protease susceptibility. The alpha(1) helix and beta-sheets of (M-1, Q1, M23L) rONC displayed bending motions. These data provided strong evidence for the presence of an N-terminal hydrogen bond network in E1S-rONC, but not in (M-1, Q1, M23L) rONC.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Taiwan Normal Univ, Dept Phys, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Taiwan Normal University	Huang, TH (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmthh@ibms.sinica.edu.tw		Chang, Chi-Fon/0000-0002-2961-0748				ARDELT W, 1991, J BIOL CHEM, V266, P245; BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CF, 1998, J MOL BIOL, V283, P231, DOI 10.1006/jmbi.1998.2082; Chen CP, 1996, J BIOMOL NMR, V8, P331, DOI 10.1007/BF00410331; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; Gorbatyuk VY, 1999, J BIOMOL NMR, V15, P343, DOI 10.1023/A:1008312325225; Hsu CH, 2003, J MOL BIOL, V326, P1189, DOI 10.1016/S0022-2836(02)01472-9; Huang YT, 2001, J MOL BIOL, V307, P1075, DOI 10.1006/jmbi.2001.4539; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JE, 2003, BIOCHEMISTRY-US, V42, P11443, DOI 10.1021/bi035147s; Leu YJ, 2003, J BIOL CHEM, V278, P7300, DOI 10.1074/jbc.M206701200; LIAO YD, 1992, NUCLEIC ACIDS RES, V20, P1371, DOI 10.1093/nar/20.6.1371; Liao YD, 2003, NUCLEIC ACIDS RES, V31, P5247, DOI 10.1093/nar/gkg746; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; Merlino A, 2003, PROTEINS, V53, P101, DOI 10.1002/prot.10466; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; Newton DL, 1998, BIOCHEMISTRY-US, V37, P5173, DOI 10.1021/bi972147h; NEWTON DL, 1994, J NEUROSCI, V14, P538; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x; Notomista E, 1999, FEBS LETT, V463, P211, DOI 10.1016/S0014-5793(99)01623-3; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; ZHU GA, 1992, J MAGN RESON, V98, P192, DOI 10.1016/0022-2364(92)90124-P	50	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5772	5780		10.1074/jbc.M311233200	http://dx.doi.org/10.1074/jbc.M311233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645226	hybrid			2022-12-25	WOS:000188776500091
J	Keenan, SM; Lents, NH; Baldassare, JJ				Keenan, SM; Lents, NH; Baldassare, JJ			Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G(1)-S phase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; GENE-PRODUCT; S-PHASE; HISTONE DEACETYLASE; ECTOPIC EXPRESSION; DEPENDENT KINASES; ALPHA-THROMBIN; BREAST-CANCER; GROWTH-FACTOR	The activation of CDK2-cyclin E in late G(1) phase has been shown to play a critical role in retinoblastoma protein (pRb) inactivation and G(1)-S phase progression of the cell cycle. The phosphatidylinositol 3-OH-kinase inhibitor LY294002 has been shown to block cyclin D1 accumulation, CDK4 activity and, thus, G(1) progression in alpha-thrombin-stimulated IIC9 cells (Chinese hamster embryonic fibroblasts). Our previous results show that expression of cyclin E rescues S phase progression in alpha-thrombin-stimulated IIC9 cells treated with LY294002, arguing that cyclin E renders CDK4 activity dispensable for G(1) progression. In this work we investigate the ability of alpha-thrombin-induced CDK2-cyclin E activity to inactivate pRb in the absence of prior CDK4-cyclin D1 activity. We report that in the absence of CDK4-cyclin D1 activity, CDK2-cyclin E phosphorylates pRb in vivo on at least one residue and abolishes pRb binding to E2F response elements. We also find that expression of cyclin E rescues E2F activation and cyclin A expression in cyclin D kinase-inhibited, alpha-thrombin-stimulated cells. Furthermore, the rescue of E2F activity, cyclin A expression, and DNA synthesis by expression of E can be blocked by the expression of either CDK2(D145N) or Rb-DeltaCDK, a constitutively active mutant of pRb. However, restoring four known cyclin E-CDK2 phosphorylation sites to Rb-DeltaCDK renders it susceptible to inactivation in late G(1), as assayed by E2F activation, cyclin A expression, and S phase progression. These data indicate that CDK2-cyclin E, without prior CDK4-cyclin D activity, can phosphorylate and inactivate pRb, activate E2F, and induce DNA synthesis.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.	baldasjj@slu.edu						Adams PD, 1999, MOL CELL BIOL, V19, P1068; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Courjal F, 1996, INT J CANCER, V69, P247; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dhillon NK, 2002, ONCOGENE, V21, P4626, DOI 10.1038/sj.onc.1205576; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harwell RM, 2000, CANCER RES, V60, P481; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; KATO J, 1993, GENE DEV, V7, P331; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; NEVINS JR, 1992, SCIENCE, V258, P424; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Span PN, 2003, ONCOGENE, V22, P4898, DOI 10.1038/sj.onc.1206818; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338	83	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5387	5396		10.1074/jbc.M310383200	http://dx.doi.org/10.1074/jbc.M310383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645251	hybrid			2022-12-25	WOS:000188776500044
J	Leontieva, OV; Black, JD				Leontieva, OV; Black, JD			Identification of two distinct pathways of protein kinase C alpha down-regulation in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE; PHOSPHATASE 2A; BRYOSTATIN 1; PHOSPHORYLATION; DEPHOSPHORYLATION; INHIBITION; ACTIVATION; ISOZYMES; PKC; DEGRADATION	Signal transduction pathways are controlled by desensitization mechanisms, which can affect receptors and/or downstream signal transducers. It has long been recognized that members of the protein kinase C (PKC) family of signal transduction molecules undergo down-regulation in response to activation. Previous reports have indicated that key steps in PKCalpha desensitization include caveolar internalization, priming site dephosphorylation, ubiquitination of the dephosphorylated protein, and degradation by the proteasome. In the current study, comparative analysis of PKCalpha processing induced by the PKC agonists phorbol 12-myristate 13-acetate and bryostatin 1 in IEC-18 rat intestinal epithelial cells demonstrates that: (a) at least two pathways of PKCalpha down-regulation can co-exist within cells, and (b) a single PKC agonist can activate both pathways at the same time. Using a combined biochemical and morphological approach, we identify a novel pathway of PKCalpha desensitization that involves ubiquitination of mature, fully phosphorylated activated enzyme at the plasma membrane and subsequent down-regulation by the proteasome. The phosphatase inhibitors okadaic acid and calyculin A accelerated PKCalpha down-regulation and inhibitors of vesicular trafficking did not prevent degradation of the protein, indicating that neither internalization nor priming site dephosphorylation are requisite intermediate steps in this ubiquitin/proteasome dependent pathway of PKCalpha down-regulation. Instead, caveolar trafficking and dephosphorylation are involved in a second, proteasome-independent mechanism of PKCalpha desensitization in this system. Our findings highlight subcellular distribution and phosphorylation state as critical determinants of PKCalpha desensitization pathways.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org			NCI NIH HHS [CA 16056] Funding Source: Medline; NIDDK NIH HHS [DK 54909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BORNER C, 1989, J BIOL CHEM, V264, P13902; CHEN J, 1994, J BIOL CHEM, V269, P7957; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HUWILER A, 1994, BIOCHEM PHARMACOL, V48, P689, DOI 10.1016/0006-2952(94)90046-9; JALAVA A, 1993, BIOCHEM BIOPH RES CO, V191, P472, DOI 10.1006/bbrc.1993.1242; Junoy B, 2002, ENDOCRINOLOGY, V143, P1386, DOI 10.1210/en.143.4.1386; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mochly-Rosen D, 1998, FASEB J, V12, P35; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; Prevostel C, 2000, J CELL SCI, V113, P2575; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Srivastava J, 2002, BIOCHEM J, V368, P349, DOI 10.1042/BJ20020737; Srivastava J, 2002, FEBS LETT, V516, P265, DOI 10.1016/S0014-5793(02)02500-0; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; XIE HY, 1994, J BIOL CHEM, V269, P1981	39	90	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5788	5801		10.1074/jbc.M308375200	http://dx.doi.org/10.1074/jbc.M308375200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638691	hybrid			2022-12-25	WOS:000188776500093
J	Major, MB; Jones, DA				Major, MB; Jones, DA			Identification of a gadd45 beta 3 ' enhancer that mediates SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NF-KAPPA-B; TGF-BETA; DIRECT BINDING; DNA-DAMAGE; CELLS; GENE; EXPRESSION; PROMOTER; MYD118	GADD45beta regulates cell growth, differentiation, and cell death following cellular exposure to diverse stimuli, including DNA damage and transforming growth factor-beta (TGFbeta). We examined how cells transduce the TGFbeta signal from the cell surface to the gadd45beta genomic locus and describe how GADD45beta contributes to TGFbeta biology. Following an alignment of gadd45beta genomic sequences from multiple organisms, we discovered a novel TGFbeta-responsive enhancer encompassing the third intron of the gadd45beta gene. Using three different experimental approaches, we found that SMAD3 and SMAD4, but not SMAD2, mediate transcription from this enhancer. Three lines of evidence support our conclusions. First, overexpression of SMAD3 and SMAD4 activated the transcriptional activity from this enhancer. Second, silencing of SMAD protein levels using short interfering RNAs revealed that TGFbeta-induced activation of the endogenous gadd45beta gene required SMAD3 and SMAD4 but not SMAD2. In contrast, we found that the regulation of plasminogen activator inhibitor type I depended upon all three SMAD proteins. Last, SMAD3 and SMAD4 reconstitution in SMAD-deficient cancer cells restored TGFbeta induction of gadd45beta. Finally, we assessed the function of GADD45beta within the TGFbeta response and found that GADD45beta-deficient cells arrested in G(2) following TGFbeta treatment. These data support a role for SMAD3 and SMAD4 in activating gadd45beta through its third intron to facilitate G2 progression following TGFbeta treatment.	Univ Utah, Huntsman Canc Inst, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Med Chem, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu		Major, Michael/0000-0002-6753-8513	NCI NIH HHS [CA42104] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Bray N, 2003, NUCLEIC ACIDS RES, V31, P3525, DOI 10.1093/nar/gkg623; Bray N, 2003, GENOME RES, V13, P97, DOI 10.1101/gr.789803; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kovalsky O, 2001, J BIOL CHEM, V276, P39330, DOI 10.1074/jbc.M105115200; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miller GS, 1997, COMPUT APPL BIOSCI, V13, P81; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Xu GX, 2002, BIOCHEM BIOPH RES CO, V294, P1079, DOI 10.1016/S0006-291X(02)00605-8; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	37	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5278	5287		10.1074/jbc.M311517200	http://dx.doi.org/10.1074/jbc.M311517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630914	hybrid			2022-12-25	WOS:000188776500031
J	Cao, Q; Mak, KM; Ren, CL; Lieber, CS				Cao, Q; Mak, KM; Ren, CL; Lieber, CS			Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells - Respective roles of the JAK/STAT and JAK-mediated H2O2-dependent MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; MESSENGER-RNA; SERUM LEPTIN; P38 MAPK; EXPRESSION; RECEPTOR; FIBROSIS; PROLIFERATION	Leptin is recognized as a profibrogenic hormone in the liver, but the mechanisms involved have not been clarified. The tissue inhibitor of metalloproteinase (TIMP)-1, which acts through inhibition of collagen degradation, is synthesized by activated hepatic stellate cells (HSC) in response to fibrogenic substances. The capacity of leptin to induce TIMP-1 and its signaling molecules were investigated in a human HSC cell line, LX-2. Leptin stimulated TIMP-1 protein, mRNA, and promoter activity. JAK1 and -2, as well as STAT3 and -5, were activated. After leptin, there was increased expression of tyrosine 1141-phosphorylated leptin receptor, which may contribute to STAT3 activation. AG 490, a JAK inhibitor, blocked JAK phosphorylation with concomitant inhibition of STAT activation, TIMP-1 mRNA expression, and promoter activity. Leptin also induced an oxidative stress, which was inhibited by AG 490, indicating a JAK mediation process. ERK1/2 MAPK and p38 were activated, which was prevented by catalase, indicating an H2O2-dependent mechanism. Catalase treatment resulted in total suppression of TIMP-1 mRNA expression and promoter activity. SB203580, a p38 inhibitor, prevented p38 activation and reduced TIMP-1 message half-life with down-regulation of TIMP-1 mRNA. These changes were reproduced by overexpression of the dominant negative p38alpha and p38beta mutants. PD098059, an ERK1/2 inhibitor, opposed ERK1/2 activation and TIMP-1 promoter activity, leading to TIMP-1 mRNA down-regulation. Thus, leptin has a direct action on liver fibrogenesis by stimulating TIMP-1 production in activated HSC. This process appears to be mediated by the JAK/STAT pathway via the leptin receptor long form and the H2O2-dependent p38 and ERK1/2 pathways via activated JAK.	Bronx Vet Affairs Med Ctr, Alcohol & Nutr Res Ctr, Bronx, NY 10468 USA; Mt Sinai Sch Med, Bronx, NY 10468 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Icahn School of Medicine at Mount Sinai	Lieber, CS (corresponding author), Bronx Vet Affairs Med Ctr, Alcohol & Nutr Res Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.	liebercs@aol.com			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012867, R01AA011115] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA11115, R01 AA012867] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; BUNGO M, 1995, NUCLEIC ACIDS RES, V23, P5041; Burysek L, 2002, J BIOL CHEM, V277, P33509, DOI 10.1074/jbc.M201941200; Cao Q, 2002, J LAB CLIN MED, V139, P202, DOI 10.1067/mlc.2002.121853; Cao Q, 2002, AM J PHYSIOL-GASTR L, V283, pG1051, DOI 10.1152/ajpgi.00128.2002; Cao Q, 2002, BIOCHEM BIOPH RES CO, V294, P849, DOI 10.1016/S0006-291X(02)00586-7; Cassiman D, 2002, J HEPATOL, V36, P200, DOI 10.1016/S0168-8278(01)00260-4; Chen XM, 2002, KIDNEY INT, V61, P1377, DOI 10.1046/j.1523-1755.2002.00283.x; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Crespo J, 2002, DIGEST DIS SCI, V47, P1604, DOI 10.1023/A:1015835606718; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Friedman JM, 1998, NUTR REV, V56, pS38; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Henriksen JH, 1999, HEPATOLOGY, V29, P1818, DOI 10.1002/hep.510290601; Honda H, 2002, HEPATOLOGY, V36, P12, DOI 10.1053/jhep.2002.33684; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ikejima K, 2002, GASTROENTEROLOGY, V122, P1399, DOI 10.1053/gast.2002.32995; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Leclercq IA, 2002, J HEPATOL, V37, P206, DOI 10.1016/S0168-8278(02)00102-2; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; LI JJ, 1994, HEPATOLOGY, V19, P1418, DOI 10.1002/hep.1840190616; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; MAK KM, 1988, HEPATOLOGY, V8, P1027, DOI 10.1002/hep.1840080508; McCullough AJ, 1998, GASTROENTEROLOGY, V115, P947, DOI 10.1016/S0016-5085(98)70267-7; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Murakami T, 1997, BIOCHEM BIOPH RES CO, V231, P26, DOI 10.1006/bbrc.1996.6030; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Potter JJ, 2003, J HEPATOL, V38, P281, DOI 10.1016/S0168-8278(02)00414-2; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Saxena NK, 2003, J CELL BIOCHEM, V89, P311, DOI 10.1002/jcb.10494; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; SCHMITTGRAFF A, 1991, AM J PATHOL, V138, P1233; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Sohara N, 2002, J HEPATOL, V36, P191, DOI 10.1016/S0168-8278(01)00265-3; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Takekoshi K, 2001, ENDOCRINOLOGY, V142, P290, DOI 10.1210/en.142.1.290; Tanabe K, 1997, BIOCHEM BIOPH RES CO, V241, P765, DOI 10.1006/bbrc.1997.7894; Tang M, 2002, BIOCHEM BIOPH RES CO, V297, P906, DOI 10.1016/S0006-291X(02)02300-8; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Ueki N, 1998, BBA-MOL CELL RES, V1403, P28, DOI 10.1016/S0167-4889(98)00015-9; Uygun A, 2000, AM J GASTROENTEROL, V95, P3584; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van den Brink Gijs R., 2000, Molecular Cell Biology Research Communications, V4, P144, DOI 10.1006/mcbr.2001.0270; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; Yang CQ, 2003, GASTROENTEROLOGY, V124, P147, DOI 10.1053/gast.2003.50012; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348	64	135	156	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4292	4304		10.1074/jbc.M308351200	http://dx.doi.org/10.1074/jbc.M308351200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625304	hybrid			2022-12-25	WOS:000188554300047
J	Rozanov, DV; Hahn-Dantona, E; Strickland, DK; Strongin, AY				Rozanov, DV; Hahn-Dantona, E; Strickland, DK; Strongin, AY			The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BREAST-CARCINOMA CELLS; INTEGRIN ALPHA(V) SUBUNIT; ALPHA-2-MACROGLOBULIN RECEPTOR; GELATINASE-A; TUMOR-CELLS; MATRIX-METALLOPROTEINASE-9 MMP-9; CELLULAR INTERNALIZATION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX	We demonstrate that the presentation of LRP and the subsequent uptake of its ligands by malignant cells are both strongly regulated by MT1-MMP. Because LRP is essential for the clearance of multiple ligands, these findings have important implications for many pathophysiological processes including the pericellular proteolysis in neoplastic cells as well as the fate of the soluble matrix-degrading proteases such as MMP-2. MT1-MMP is a key protease in cell invasion and a physiological activator of MMP-2. Cellular LRP consists of a non-covalently associated 515-kDa extracellular alpha-chain (LRP-515) and an 85-kDa membrane-spanning beta-chain, and plays a dual role as a multifunctional endocytic receptor and a signaling molecule. Through the capture and uptake of several soluble proteases, LRP is involved in the regulation of matrix proteolysis. LRP-515 associates with the MT1-MMP catalytic domain and is highly susceptible to MT1-MMP proteolysis in vitro. Similar to MT1-MMP, the metalloproteinases MT2-MMP, MT3-MMP and MT4-MMP also degrade LRP. The N-terminal and C-terminal parts of the LRP-515 subunit are resistant and susceptible, respectively, to MT1-MMP proteolysis. In cells co-expressing LRP and MT1-MMP, the proteolytically competent protease decreases the levels of cellular LRP and releases its N-terminal portion in the extracellular milieu while the catalytically inert protease co-precipitates with LRP. These events implicate MT1-MMP, not only in the activation of MMP-2, but also in the mechanisms that control the subsequent fate of MMP-2 in cells and tissues.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	Sanford Burnham Prebys Medical Discovery Institute; American Red Cross	Strongin, AY (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 1998, CANCER RES, V58, P3743; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Hussain MM, 2001, FRONT BIOSCI, V6, pD417, DOI 10.2741/Hussain1; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Makarova A, 2003, J BIOL CHEM, V278, P50250, DOI 10.1074/jbc.M309150200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Patel M, 2003, J BIOL CHEM, V278, P44799, DOI 10.1074/jbc.M308982200; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Rochette MJ, 2002, MOL NEUROBIOL, V26, P81, DOI 10.1385/MN:26:1:081; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	52	113	116	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4260	4268		10.1074/jbc.M311569200	http://dx.doi.org/10.1074/jbc.M311569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645246	hybrid			2022-12-25	WOS:000188554300043
J	Simons, CT; Staes, A; Rommelaere, H; Ampe, C; Lewis, SA; Cowan, NJ				Simons, CT; Staes, A; Rommelaere, H; Ampe, C; Lewis, SA; Cowan, NJ			Selective contribution of eukaryotic prefoldin subunits to actin and tubulin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; CYTOPLASMIC CHAPERONIN; NONNATIVE POLYPEPTIDE; FOLDING MACHINE; RNA-POLYMERASE; NASCENT CHAIN; PROTEIN; COMPLEX; EXPRESSION; MTGIMC	Eukaryotic prefoldin (PFD) is a heterohexameric chaperone with a jellyfish-like structure whose function is to deliver nonnative target proteins, principally actins and tubulins, to the eukaryotic cytosolic chaperonin for facilitated folding. Here we demonstrate that functional PFD can spontaneously assemble from its six constituent individual subunits (PFD1-PFD6), each expressed as a recombinant protein. Using engineered forms of PFD assembled in vitro, we show that the tips of the PFD tentacles are required to form binary complexes with authentic target proteins. We show that PFD uses the distal ends of different but overlapping sets of subunits to form stable binary complexes with different target proteins, namely actin and alpha- and beta-tubulin. We also present data that suggest a model for the order of these six subunits within the hexamer. Our data are consistent with the hypothesis that PFD, like the eukaryotic cytosolic chaperonin, has co-evolved specifically to facilitate the folding of its target proteins.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; State Univ Ghent VIB, B-9000 Ghent, Belgium; Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium	New York University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Cowan, NJ (corresponding author), NYU, Med Ctr, Dept Biochem, 55 1st ave, New York, NY 10016 USA.	Nicholas.Cowan@nyu.med.edu	Ampe, Christophe/B-5534-2012	Staes, An/0000-0001-8767-8508	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059121] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59121] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; Ellis RJ, 2001, CURR BIOL, V11, pR1038, DOI 10.1016/S0960-9822(01)00620-0; Erbse A, 2003, NAT STRUCT BIOL, V10, P84, DOI 10.1038/nsb0203-84; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horovitz A, 2001, J STRUCT BIOL, V135, P104, DOI 10.1006/jsbi.2001.4377; Houry WA, 2001, CURR PROTEIN PEPT SC, V2, P227, DOI 10.2174/1389203013381134; Hynes GM, 2000, J BIOL CHEM, V275, P18985, DOI 10.1074/jbc.M910297199; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2001, J STRUCT BIOL, V135, P205, DOI 10.1006/jsbi.2001.4359; Martin J, 2000, CURR PROTEIN PEPT SC, V1, P309, DOI 10.2174/1389203003381342; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Rommelaere H, 2001, J BIOL CHEM, V276, P41023, DOI 10.1074/jbc.M106591200; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Saibil HR, 2002, ADV PROTEIN CHEM, V59, P45; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116	38	48	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4196	4203		10.1074/jbc.M306053200	http://dx.doi.org/10.1074/jbc.M306053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14634002	hybrid			2022-12-25	WOS:000188554300036
J	Woo, JH; Lim, JH; Kim, YH; Suh, SI; Min, DS; Chang, JS; Lee, YH; Park, JW; Kwon, TK				Woo, JH; Lim, JH; Kim, YH; Suh, SI; Min, DS; Chang, JS; Lee, YH; Park, JW; Kwon, TK			Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction	ONCOGENE			English	Article						resveratrol; matrix metalloproteinase-9; NF-kappa B; PMA; PKC; JNK	ACTIVATED PROTEIN-KINASE; IV COLLAGENASE GENE; MECHANISM; METALLOPROTEINASES; PHOSPHORYLATION; SURFACE; ERK	Proteolytic degradation of the extracellular matrix and tumor metastasis correlate with the expression of endopeptidases known as matrix metalloproteinases (MMPs). The expression of MMPs is regulated by cytokines and signal transduction pathways, including those activated by phorbol myristate acetate (PMA). We found that resveratrol, a phytoalexin present in grapes, significantly inhibits the PMA-induced increase in MMP-9 expression and activity. These effects of resveratrol are dose dependent and correlate with the suppression of MMP-9 mRNA expression levels. PMA caused about a 23-fold increase in MMP-9 promoter activity, which was suppressed by resveratrol. Transient transfection utilizing MMP-9 constructs, in which specific transcriptional factors were mutagenized, indicated that the effects of PMA and resveratrol were mediated via an activator protein-1 and nuclear factor-kappaB response element. Resveratrol inhibited PMA-mediated activation of c-Jun N-terminal kinase (JNK) and protein kinase C (PKC)-delta activation. Therefore, we conclude that the MMP-9 inhibition activity of resveratrol and its inhibition of JNK and PKC-delta may have a therapeutic potential, given that a novel means of controlling growth and invasiveness of tumors.	Keimyung Univ, Sch Med, Dept Immunol, Taegu, South Korea; Keimyung Univ, Sch Med, Dept Microbiol, Taegu 700712, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Daejin Univ, Dept Life Sci, Pochon Gun, Kyeonggido, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Taegu, South Korea	Keimyung University; Keimyung University; Catholic University of Korea; Daejin University; Yeungnam University	Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, 194 DongSan Dong, Taegu, South Korea.	kwontk@dsmc.or.kr						Baek WK, 2002, GENE, V295, P117, DOI 10.1016/S0378-1119(02)00827-2; Banerjee S, 2002, CANCER RES, V62, P4945; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Godichaud S, 2000, HEPATOLOGY, V31, P922, DOI 10.1053/he.2000.5848; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; JANG M, 1999, CANC CHEMOTHER PHA S, V43, pS42; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OHagan RC, 1996, ONCOGENE, V13, P1323; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; Simon C, 1998, CANCER RES, V58, P1135; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Waas ET, 2002, BRIT J CANCER, V86, P1876, DOI 10.1038/sj.bjc.6600366; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; ZUCKER S, 1993, CANCER RES, V53, P140	30	181	187	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1845	1853		10.1038/sj.onc.1207307	http://dx.doi.org/10.1038/sj.onc.1207307			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14661062				2022-12-25	WOS:000220129500006
J	Nukaga, M; Kumar, S; Nukaga, K; Pratt, RF; Knox, JR				Nukaga, M; Kumar, S; Nukaga, K; Pratt, RF; Knox, JR			Hydrolysis of third-generation cephalosporins by class C beta-lactamases - Structures of a transition state analog of cefotaxime in wild-type and extended spectrum enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROBACTER-CLOACAE P99; MOLECULAR EVOLUTION; SUBSTRATE; INHIBITION; RESISTANCE; MECHANISM; PROTEIN; CEPHALOTHIN; SPECIFICITY; MUTATIONS	Bacterial resistance to the third-generation cephalosporins is an issue of great concern in current antibiotic therapeutics. An important source of this resistance is from production of extended-spectrum (ES) beta-lactamases by bacteria. The Enterobacter cloacae GC1 enzyme is an example of a class C ES beta-lactamase. Unlike wild-type (WT) forms, such as the E. cloacae P99 and Citrobacter freundii enzymes, the ES GC1 beta-lactamase is able to rapidly hydrolyze third-generation cephalosporins such as cefotaxime and ceftazidime. To understand the basis for this ES activity, m-nitrophenyl 2-(2-aminothiazol-4- yl)-2-[(Z)-methoxyimino] acetylaminomethyl phosphonate has been synthesized and characterized. This phosphonate was designed to generate a transition state analog for turnover of cefotaxime. The crystal structures of complexes of the phosphonate with both ES GC1 and WT C. freundii GN346 beta-lactamases have been determined to high resolution (1.4 - 1.5 Angstrom). The serine-bound analog of the tetrahedral transition state for deacylation exhibits a very different binding geometry in each enzyme. In the WT beta-lactamase the cefotaxime-like side chain is crowded against the Omega loop and must protrude from the binding site with its methyloxime branch exposed. In the ES enzyme, a mutated Omega loop adopts an alternate conformation allowing the side chain to be much more buried. During the binding and turnover of the cefotaxime substrate by this ES enzyme, it is proposed that ligand-protein contacts and intra-ligand contacts are considerably relieved relative to WT, facilitating positioning and activation of the hydrolytic water molecule. The ES beta-lactamase is thus able to efficiently inactivate third-generation cephalosporins.	Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	Wesleyan University; University of Connecticut	Pratt, RF (corresponding author), Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA.	rpratt@wesleyan.edu; james.knox@uconn.edu		Pathak, Sanjai/0000-0003-1799-9730	NCRR NIH HHS [RR-01646] Funding Source: Medline; NIAID NIH HHS [AI-17986] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017986, R56AI017986] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barlow M, 2003, GENETICS, V164, P23; Barnaud G, 2001, FEMS MICROBIOL LETT, V195, P185, DOI 10.1111/j.1574-6968.2001.tb10519.x; Beadle BM, 2002, STRUCTURE, V10, P413, DOI 10.1016/S0969-2126(02)00725-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crichlow GV, 2001, BIOCHEMISTRY-US, V40, P6233, DOI 10.1021/bi010131s; Crichlow GV, 1999, BIOCHEMISTRY-US, V38, P10256, DOI 10.1021/bi9908787; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; KOTRA LP, 2001, BACTERIAL RESISTANCE, P123; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LOBKOVSKY E, 1994, BIOCHEMISTRY-US, V33, P6762, DOI 10.1021/bi00188a004; Matagne A, 1999, NAT PROD REP, V16, P1, DOI 10.1039/a705983c; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morosini MI, 1998, FEMS MICROBIOL LETT, V165, P85, DOI 10.1111/j.1574-6968.1998.tb13131.x; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; Nukaga M, 2003, BIOCHEMISTRY-US, V42, P13152, DOI 10.1021/bi034986b; NUKAGA M, 1994, ANTIMICROB AGENTS CH, V38, P1374, DOI 10.1128/AAC.38.6.1374; Nukaga M, 1998, BIOCHEMISTRY-US, V37, P10461, DOI 10.1021/bi980184i; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Powers RA, 1999, PROTEIN SCI, V8, P2330; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; RAHIL J, 1992, BIOCHEMISTRY-US, V31, P5869, DOI 10.1021/bi00140a024; RAHIL J, 1991, J CHEM SOC PERK T 2, P947, DOI 10.1039/p29910000947; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Siemers NO, 1996, BIOCHEMISTRY-US, V35, P2104, DOI 10.1021/bi9514166; Trepanier S, 1999, ANTIMICROB AGENTS CH, V43, P543, DOI 10.1128/AAC.43.3.543; TSUKAMOTO K, 1992, EUR J BIOCHEM, V207, P1123, DOI 10.1111/j.1432-1033.1992.tb17150.x; Vakulenko SB, 2002, ANTIMICROB AGENTS CH, V46, P1966, DOI 10.1128/AAC.46.6.1966-1970.2002; Xu Y, 1996, BIOCHEMISTRY-US, V35, P3595, DOI 10.1021/bi952106q	34	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9344	9352		10.1074/jbc.M312356200	http://dx.doi.org/10.1074/jbc.M312356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660590	hybrid			2022-12-25	WOS:000189265900098
J	Liu, YQ; Moibi, JA; Leahy, JL				Liu, YQ; Moibi, JA; Leahy, JL			Chronic high glucose lowers pyruvate dehydrogenase activity in islets through enhanced production of long chain acyl-CoA - Prevention of impaired glucose oxidation by enhanced pyruvate recycling through the malate-pyruvate shuttle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; STIMULATED INSULIN-SECRETION; GLYCEROL PHOSPHATE DEHYDROGENASE; CARBOXYLASE GENE-EXPRESSION; FATTY-ACID; LINE INS-1; RAT ISLETS; PHOSPHOFRUCTOKINASE ACTIVITY; REGULATED ANAPLEROSIS; CULTURED ISLETS	In islet beta-cells, the high expression of pyruvate carboxylase and the functional importance of the downstream anaplerosis pathways result in a unique characteristic whereby high glucose and fatty acids both increase production of a key fatty acid metabolite, long chain acyl-CoA, for signaling and enzyme regulation in beta-cells. We showed previously in islets that pyruvate dehydrogenase (PDH) activity is lowered by excess fatty acids (the so-called Randle effect). We have now investigated PDH activity and pyruvate metabolism in islets after 48-h culture at 16.7 mmol/liter glucose. Active PDH V-max was lowered 65% by 48 h of high glucose, and this effect was markedly attenuated by co-culture with triacsin C, which inhibits acyl-CoA synthase. Despite the large reduction in PDH activity, glucose oxidation was twice normal. The reason was continued metabolism of pyruvate through pyruvate carboxylase (V-max, 83% of control) and diversion of flux through the pyruvate-malate shuttle. The result was a 3-fold increase of the pyruvate concentration that overcame the lowered PDH activity by mass action as shown by glucose oxidation measured with [6-C-14] glucose being twice normal. In addition, glucose-induced insulin secretion was 3-fold increased after 48 h of high glucose, and this effect was totally blocked by co-culture with triacsin C. These results show that a unique feature of islet beta-cells is not only fatty acids but also excess glucose that impairs PDH activity. Also, a specialized trait of beta-cells is a long chain acyl-CoA-mediated defense mechanism that prevents a reduction in glucose oxidation and consequently in insulin secretion.	Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Burlington, VT 05405 USA	University of Vermont	Leahy, JL (corresponding author), Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Given C331, Burlington, VT 05405 USA.	jleahy@zoo.uvm.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056818, R01DK056818] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR/DE17702] Funding Source: Medline; NIDDK NIH HHS [DK56818] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; BRUN T, 1993, J BIOL CHEM, V268, P18905; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; CHEN C, 1994, J CLIN INVEST, V94, P399, DOI 10.1172/JCI117335; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; HARTMAN EJ, 1989, PROSTAGLANDINS, V37, P655, DOI 10.1016/0090-6980(89)90103-2; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; Patane G, 2002, DIABETES, V51, P2749, DOI 10.2337/diabetes.51.9.2749; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RANDLE PJ, 1994, DIABETOLOGIA, V37, P155; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; Shrago E, 2000, J NUTR, V130, p290S, DOI 10.1093/jn/130.2.290S; SPEARS G, 1971, BIOCHEM J, V125, P1149, DOI 10.1042/bj1251149; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Yajima H, 2000, DIABETES, V49, P712, DOI 10.2337/diabetes.49.5.712; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394	48	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7470	7475		10.1074/jbc.M307921200	http://dx.doi.org/10.1074/jbc.M307921200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660628	hybrid			2022-12-25	WOS:000189103300014
J	Politi, K; Kljuic, A; Szabolcs, M; Fisher, P; Ludwig, T; Efstratiadis, A				Politi, K; Kljuic, A; Szabolcs, M; Fisher, P; Ludwig, T; Efstratiadis, A			'Designer' tumors in mice	ONCOGENE			English	Article						breast cancer; sarcoma; animal models of cancer; gene expression profiling	MIDDLE-T-ONCOGENE; AMINO-TERMINAL DOMAIN; TRANSGENIC MICE; MESSENGER-RNA; SINGLE-COPY; K-RAS; EXPRESSION; VIRUS; ACTIN; MOUSE	We have developed and tested successfully a general method based on Cre-mediated recombination that can be used for ubiquitous or tissue-specific expression of protein products, including tumor-inducing oncoproteins. Depending on the specificity of a chosen promoter driving cre expression, tumors develop by design in bitransgenic mouse progeny derived by crossing Cre-producing mice with partners carrying a dormant oncogenic transgene (targeted into the 3' noncoding region of the cytoplasmic beta-actin locus) that becomes functional after excision of a 'floxed' DNA segment. To provide proof-of-principle, we have used as models transgenes encoding the polyomavirus middle T antigen (PVMT) and the T antigens of the SV40 early region (SVER). Cre-dependent activation of widespread SVER expression resulted in hyperplasias or invasive tumors affecting particular visceral smooth muscles, whereas Cre-dependent, mammary gland-specific expression of PVMT-induced adenocarcinomas, according to plan. Unexpectedly, we also encountered spontaneous (Cre-independent) oncogene expression occurring as a rare event, which simulates the initiation of sporadic tumors and leads to PVMT-induced hemangiomas and mammary carcinomas or SVER-induced disseminated sarcomas, thus, revealing particular tissue susceptibilities to the actions of these oncoproteins.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Efstratiadis, A (corresponding author), Columbia Univ, Dept Genet & Dev, Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.	arg@cancercenter.columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NATIONAL CANCER INSTITUTE [P01CA075553, T32CA009503, P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75553, P01 CA97403, T32 CA09503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1992, PROG CLIN BIOL RES, V376, P1; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; Berns A, 2001, NATURE, V410, P1043, DOI 10.1038/35074238; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DARBY I, 1990, LAB INVEST, V63, P21; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; Dorer DR, 1997, TRANSGENIC RES, V6, P3, DOI 10.1023/A:1018460413680; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; Eyden B, 2001, ULTRASTRUCT PATHOL, V25, P39, DOI 10.1080/019131201300004672; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hollies CR, 2001, EUR J HUM GENET, V9, P143, DOI 10.1038/sj.ejhg.5200590; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; POLITI K, 2004, IN PRESS AM J PATHOL, V164; Ratineau C, 2000, GASTROENTEROLOGY, V119, P1305, DOI 10.1053/gast.2000.19278; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Wallace H, 2000, NUCLEIC ACIDS RES, V28, P1455, DOI 10.1093/nar/28.6.1455; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WILLIAMS RL, 1988, CELL, V52, P121; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x	34	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1558	1565		10.1038/sj.onc.1207275	http://dx.doi.org/10.1038/sj.onc.1207275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14661057				2022-12-25	WOS:000189219500009
J	Ge, SJ; Pachter, JS				Ge, SJ; Pachter, JS			Caveolin-1 knockdown by small interfering RNA suppresses responses to the chemokine monocyte chemoattractant protein-1 by human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE PHOSPHORYLATION; AUTOIMMUNE ENCEPHALOMYELITIS; MEDIATED ENDOCYTOSIS; KINASE ACTIVATION; BETA-CHEMOKINES; MESSENGER-RNA; CELL BIOLOGY; IN-VITRO; EXPRESSION	Astrocytes regulate the integrity of the blood-brain barrier and influence inflammatory processes in the central nervous system. The pro-inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1), which is both released by and stimulates astrocytes, is thought to play a crucial role in both these activities. Because astrocytes have been shown to possess caveolae, vesicular structures that participate in intracellular transport and signal transduction events, we reasoned that expression of the major structural protein of these organelles, caveolin-1, might feature critically in the cellular responses to MCP-1. To test this hypothesis, caveolin-1 level was "knocked down" in human astrocyte cultures by using a small interfering RNA approach. This method resulted in efficient (>90% loss) and specific knockdown of caveolin-1 expression while sparring glial fibrillary acidic protein as well as several other proteins involved in endocytosis. Astrocytes suffering caveolin-1 loss showed diminished ability to down-modulate and internalize the MCP-1 receptor (CCR2) in response to exposure to this chemokine and also demonstrated significantly reduced capacity to undergo chemotaxis and calcium flux when MCP-1-stimulated. The results highlight a potentially prominent role for caveolae and/or caveolin-1 in mediating astrocyte responses to MCP-1, a feature that might significantly dictate the progression of inflammatory events at the blood-brain barrier.	Univ Connecticut, Ctr Hlth, Dept Pharmacol, Blood Brain Barrier Lab, Farmington, CT 06030 USA	University of Connecticut	Pachter, JS (corresponding author), Univ Connecticut, Ctr Hlth, Dept Pharmacol, Blood Brain Barrier Lab, 263 Farmington Ave, Farmington, CT 06030 USA.	pachter@nsol.uchc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054718] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH54718] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andjelkovic AV, 1999, GLIA, V28, P225, DOI 10.1002/(SICI)1098-1136(199912)28:3<225::AID-GLIA6>3.0.CO;2-6; Andjelkovic AV, 2002, J NEUROSCI RES, V70, P219, DOI 10.1002/jnr.10372; Andjelkovic AV, 2000, J LEUKOCYTE BIOL, V68, P545; ANDJELKOVIC AV, 2002, UNIVERSES DELICATE B, P301; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Berman JW, 1996, J IMMUNOL, V156, P3017; Biber K, 2002, CURR OPIN PHARMACOL, V2, P63, DOI 10.1016/S1471-4892(01)00122-9; BJORKSTEN B, 1976, INFECT IMMUN, V14, P315; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Carnevale KA, 2003, J BIOL CHEM, V278, P25317, DOI 10.1074/jbc.M304182200; Cheeran MCJ, 2001, J NEUROVIROL, V7, P135; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Croitoru-Lamoury J, 2003, GLIA, V41, P354, DOI 10.1002/glia.10181; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dzenko KA, 2001, J NEUROSCI, V21, P9214, DOI 10.1523/JNEUROSCI.21-23-09214.2001; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Heesen M, 1996, J NEUROSCI RES, V45, P382; Huang DR, 2002, J NEUROSCI, V22, P10633; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Jee Y, 2002, J NEUROIMMUNOL, V128, P49, DOI 10.1016/S0165-5728(02)00147-9; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Katayama T, 2002, NEUROSCI LETT, V328, P277, DOI 10.1016/S0304-3940(02)00550-5; KENSWORTHY A, 2002, TRENDS BIOCHEM SCI, V27, P435; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Li CY, 2003, ANESTH ANALG, V97, P205, DOI 10.1213/01.ANE.0000066013.34263.54; Luo Y, 2003, GLIA, V43, P119, DOI 10.1002/glia.10231; Mack M, 2000, METH MOL B, V138, P191; Maggi D, 2002, BIOCHEM BIOPH RES CO, V295, P1085, DOI 10.1016/S0006-291X(02)00809-4; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Megias L, 2000, INT J DEV BIOL, V44, P209; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pearson H, 2002, NATURE, V415, P8, DOI 10.1038/415008a; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Razani B, 2001, J BIOL CHEM, V276, P38121; Rezaie P, 2002, GLIA, V37, P64, DOI 10.1002/glia.1128; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Sauder C, 2000, J VIROL, V74, P9267, DOI 10.1128/JVI.74.19.9267-9280.2000; Sharafeldin A, 2000, J NEUROIMMUNOL, V103, P165, DOI 10.1016/S0165-5728(99)00238-6; Smits HA, 2002, J NEUROIMMUNOL, V127, P160, DOI 10.1016/S0165-5728(02)00112-1; Solari R, 1997, J BIOL CHEM, V272, P9617; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; VAN DV, 1999, AM J PATHOL, V154, P45; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X; Zuurman MW, 2003, GLIA, V41, P327, DOI 10.1002/glia.10156	66	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6688	6695		10.1074/jbc.M311769200	http://dx.doi.org/10.1074/jbc.M311769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660607	hybrid			2022-12-25	WOS:000188969200060
J	Goldoni, S; Owens, RT; McQuillan, DJ; Shriver, Z; Sasisekharan, R; Birk, DE; Campbell, S; Iozzo, RV				Goldoni, S; Owens, RT; McQuillan, DJ; Shriver, Z; Sasisekharan, R; Birk, DE; Campbell, S; Iozzo, RV			Biologically active decorin is a monomer in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; COLLAGEN FIBRILLOGENESIS INVITRO; GROWTH-FACTOR; ENDOTHELIAL-CELLS; SELF-ASSOCIATION; DOWN-REGULATION; EXPRESSION; PROTEIN; SUPPRESSION; MIGRATION	It has been reported that decorin and its protein core can have molecular masses nearly double the size of those previously published, suggesting a dimeric structure. In this study we tested whether biologically active decorin and its glycoprotein core would form dimers in solution. We used homo- and hetero-bifunctional chemical cross-linking reagents, BS3 and sulfo-SMPB, respectively, as well as glutaraldehyde and found no preferential dimer formation, whether chemical cross-linking was performed in the presence or absence of live cells. Under the same experimental conditions, we easily detected dimers of epidermal growth factor receptor and basic fibroblast growth factor, two glycoproteins known to dimerize. Only at very high cross-linker to decorin molar ratios (2000:1) were trimers and multimers observed, but performing the chemical cross-linking in the presence of a reducing agent abolished these. The elution of decorin protein core in Superose 6 gel chromatography gave masses compatible with monomeric proteins, both before and after denaturation with 2.5 m guanidine HCl. Matrix-assisted laser desorption ionization gave a mass of 44,077 Da for decorin protein core, without any evidence of dimers or oligomers. Extensive oligomerization of the decorin protein core was observed only after dialysis against water and freeze-drying. These oligomers were considered artifacts because they were independent of chemical cross-linking and were resistant to heat denaturation and disulfide-bond reduction. Oligomeric preparations showed markedly reduced biological activity in both phosphorylation and collagen fibrillogenesis assays. Thus, biologically active decorin is a monomer in solution and, as such, is a monovalent ligand for various extracellular matrix proteins, growth factors, and cell surface receptors.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Massachusetts Institute of Technology (MIT); Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Pranić, Shelly Melissa/E-1974-2017; Birk, David/I-4072-2012; Iozzo, Renato/AAS-1980-2020	Pranić, Shelly Melissa/0000-0001-5524-1723; Birk, David/0000-0002-4865-9088; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NEI NIH HHS [R01 EY05129] Funding Source: Medline; NIAMS NIH HHS [R01 AR44745, R01 AR42826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044745, R01AR042826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRK DE, 1981, BIOCHIM BIOPHYS ACTA, V670, P362, DOI 10.1016/0005-2795(81)90108-2; BIRK DE, 1984, ARCH BIOCHEM BIOPHYS, V235, P178, DOI 10.1016/0003-9861(84)90266-2; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Funderburgh JL, 1998, INVEST OPHTH VIS SCI, V39, P1957; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; GUO BP, 1995, INFECT IMMUN, V63, P3467, DOI 10.1128/IAI.63.9.3467-3472.1995; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Huttenlocher A, 1996, MATRIX BIOL, V15, P239, DOI 10.1016/S0945-053X(96)90115-8; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; LIU J, 1994, J BIOL CHEM, V269, P28366; Neame P. J., 2000, PROTEOGLYCANS STRUCT, P201; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TOOLE BP, 1969, NATURE, V222, P872, DOI 10.1038/222872a0; TOOLE BP, 1968, BIOCHEM J, V109, P857, DOI 10.1042/bj1090857; Troup S, 2003, CLIN CANCER RES, V9, P207; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Xu GX, 2002, BIOL REPROD, V67, P681, DOI 10.1095/biolreprod67.2.681; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	46	95	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6606	6612		10.1074/jbc.M310342200	http://dx.doi.org/10.1074/jbc.M310342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660661	hybrid			2022-12-25	WOS:000188969200049
J	Muller, C; Calkhoven, CF; Sha, XJ; Leutz, A				Muller, C; Calkhoven, CF; Sha, XJ; Leutz, A			The CCAAT enhancer-binding protein alpha (C/EBP alpha) requires a SWI/SNF complex for proliferation arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; ACUTE MYELOID-LEUKEMIA; SWI-SNF COMPLEX; GROWTH ARREST; RETINOBLASTOMA PROTEIN; IN-VIVO; EXPRESSION; DIFFERENTIATION; BRG1; TRANSCRIPTION	The transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha) is a tumor suppressor in myeloid cells and inhibits proliferation in all cell types examined. C/EBPalpha interacts with the SWI/SNF chromatin-remodeling complex during the regulation of differentiation-specific genes. Here we show that C/EBPalpha fails to suppress proliferation in SWI/SNF defective cell lines after knock-down of SWI/SNF core components or after deletion of the SWI/SNF interaction domain in C/EBPalpha, respectively. Reconstitution of SWI/SNF function restores C/EBPalpha-dependent proliferation arrest. Our results show that the anti-proliferation activity of C/EBPalpha critically depends on components of the SWI/SNF core complex and suggest that the functional interaction between SWI/SNF and C/EBPalpha is a prerequisite for proliferation arrest.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Leutz, A (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	aleutz@mdc-berlin.de	Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X; Calkhoven, Cornelis/0000-0001-6318-7210				BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCOTT LM, 1992, BLOOD, V80, P1725; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Snaddon J, 2003, GENE CHROMOSOME CANC, V37, P72, DOI 10.1002/gcc.10185; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	60	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7353	7358		10.1074/jbc.M312709200	http://dx.doi.org/10.1074/jbc.M312709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660596	hybrid			2022-12-25	WOS:000188969200138
J	Wu, WI; Voelker, DR				Wu, WI; Voelker, DR			Reconstitution of phosphatidylserine transport from chemically defined donor membranes to phosphatidylserine decarboxylase 2 implicates specific lipid domains in the process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 4-KINASE; TRANSFER PROTEIN; PHOSPHOLIPASE-D; NULL ALLELE; YEAST; PHOSPHATIDYLETHANOLAMINE	Phosphatidylserine (PtdSer) is transported from its site of synthesis in the endoplasmic retiuculum to the locus of PtdSer decarboxylase 2 (Psd2p) in the Golgi/vacuole and decarboxylated to form phosphatidylethanolamine. Recent biochemical and genetic evidence has implicated the C2 domain of Psd2p and a membrane-ound form of the phosphatidylinositol binding/transfer protein, PstB2p, as essential for this transport process. We devised a reconstituted system in which chemically defined donor membranes function to transfer PtdSer to the biological acceptor membranes containing Psd2p. The transfer of PtdSer is poor when the donor membranes have a high degree of curvature but markedly enhanced when the membranes are relatively planar (greater than or equal to400-nm diameter). PtdSer transfer is also dependent upon both the bulk and the surface concentrations of the lipid, with pure PtdSer vesicles acting as the most efficient donors at all concentrations. The lipid transfer from donor membranes containing either 100% PtdSer or 50% PtdSer at a fixed concentration (e.g. 250 muM PtdSer) differs by a factor of 20. Surface dilution of PtdSer by choline, ethanolamine, glycerol, and inositol phospholipids markedly inhibits PtdSer transfer, whereas phosphatidic acid (PtdOH) stimulates the transfer. Most importantly, the transfer of PtdSer from liposomes to Psd2p fails to occur in acceptor membranes from strains lacking PstB2p or the C2 domain of Psd2p. These data support a model for PtdSer transport from planar domains highly enriched in PtdSer or in PtdSer plus PtdOH.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org			NIGMS NIH HHS [R01 GM032453, 2 R37 GM 32453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; GNAMUSCH E, 1992, BIOCHIM BIOPHYS ACTA, V1111, P120, DOI 10.1016/0005-2736(92)90281-P; Kitamura H, 2002, J BIOL CHEM, V277, P33720, DOI 10.1074/jbc.M205672200; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; NICHOLS JW, 1985, BIOCHEMISTRY-US, V24, P6390, DOI 10.1021/bi00344a011; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Schumacher MM, 2002, J BIOL CHEM, V277, P51033, DOI 10.1074/jbc.M205301200; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SLEIGHT RG, 1983, J BIOL CHEM, V258, P9050; Sweeney DA, 2002, J BIOL CHEM, V277, P3030, DOI 10.1074/jbc.M104639200; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; Wu WI, 2002, SEMIN CELL DEV BIOL, V13, P185, DOI 10.1016/S1084-9521(02)00047-2; Wu WI, 2001, J BIOL CHEM, V276, P7114, DOI 10.1074/jbc.M010278200; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	37	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6635	6642		10.1074/jbc.M311570200	http://dx.doi.org/10.1074/jbc.M311570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660568	hybrid			2022-12-25	WOS:000188969200053
J	Xun, LY; Webster, CM				Xun, LY; Webster, CM			A monooxygenase catalyzes sequential dechlorinations of 2,4,6-trichlorophenol by oxidative and hydrolytic reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-CEPACIA AC1100; SPHINGOBIUM-CHLOROPHENOLICUM; IRREVERSIBLE INHIBITION; GLUTATHIONE CONJUGATE; ESCHERICHIA-COLI; BACTERIUM BNC1; PENTACHLOROPHENOL; PURIFICATION; DEGRADATION; SOIL	Ralstonia eutropha JMP134 2,4,6-trichlorophenol (2,4,6-TCP) 4-monooxygenase catalyzes sequential dechlorinations of 2,4,6-TCP to 6-chlorohydroxyquinol. Although 2,6-dichlorohydroxyquinol is a logical metabolic intermediate, the enzyme hardly uses it as a substrate, implying it may not be a true intermediate. Evidence is provided to support the proposition that the monooxygenase oxidized 2,4,6-TCP to 2,6-dichloroquinone that remained with the enzyme and got hydrolyzed to 2-chlorohydroxyquinone, which was chemically reduced by ascorbate and NADH to 6-chlorohydroxyquinol. When the monooxygenase oxidized 2,6-dichlorophenol, the product was 2,6-dichloroquinol, which was not further converted to 6-chlorohydroxyquinol, implying that the enzyme only converts 2,6-dichloroquinone to 6-chlorohydroxyquinol. Stoichiometric analysis indicated the consumption of one O-2 molecule per 2,4,6-TCP converted to 6-chlorohydroxyquinol, ruling out the possibility of two oxidative reactions. Experiments with O-18-labeling gave direct evidence for the incorporation of oxygen from both O-2 and H2O into the produced 6-chlorohydroxyquinol. A monooxygenase that catalyzes hydroxylation by both oxidative and hydrolytic reactions has not been reported to date. The ability of the enzyme to perform two types of reactions is not due to the presence of a second functional domain but rather is due to catalytic promiscuity, as a homologous monooxygenase converts 2,4,6-TCP to only 2,6-dichloroquinol. Employing both conventional catalysis and catalytic promiscuity of a single enzyme in two consecutive steps of a metabolic pathway has been unknown previously.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Xun, LY (corresponding author), Washington State Univ, Sch Mol Biosci, Abelson Hall 301, Pullman, WA 99164 USA.	xun@mail.wsu.edu						Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BIRCHMORE RJ, 1979, PHYTOPATHOLOGY, V69, P1022; Bock C, 1996, APPL MICROBIOL BIOT, V45, P257, DOI 10.1007/s002530050680; Bohuslavek J, 2001, APPL ENVIRON MICROB, V67, P688, DOI 10.1128/AEM.67.2.688-695.2001; Cai M, 2002, J BACTERIOL, V184, P4672, DOI 10.1128/JB.184.17.4672-4680.2002; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; CRAWFORD RL, 1985, ENZYME MICROB TECH, V7, P617, DOI 10.1016/0141-0229(85)90031-6; Dai MH, 2003, J BACTERIOL, V185, P302, DOI 10.1128/JB.185.1.302-310.2003; FIRESTONE D, 1978, ECOL B STOCKHOLM, V27, P39; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003; Haigler BE, 1996, J BACTERIOL, V178, P6019, DOI 10.1128/jb.178.20.6019-6024.1996; Hoekstra EJ, 1999, ENVIRON SCI TECHNOL, V33, P2543, DOI 10.1021/es9900104; HUSAIN M, 1980, J BIOL CHEM, V255, P4189; Kadiyala V, 1998, APPL ENVIRON MICROB, V64, P2479; Kaiser J, 2000, SCIENCE, V288, P1941; KARNS JS, 1983, APPL ENVIRON MICROB, V46, P1182, DOI 10.1128/AEM.46.5.1182-1186.1983; KITUNEN VH, 1987, ENVIRON SCI TECHNOL, V21, P96, DOI 10.1021/es00155a012; Liu Y, 2001, APPL ENVIRON MICROB, V67, P696, DOI 10.1128/AEM.67.2.696-701.2001; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; MIDDAUGH DP, 1994, ARCH ENVIRON CON TOX, V26, P309; Miethling R, 1996, APPL ENVIRON MICROB, V62, P4361, DOI 10.1128/AEM.62.12.4361-4366.1996; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; PLOEMEN JHTM, 1991, BIOCHEM PHARMACOL, V41, P1665, DOI 10.1016/0006-2952(91)90167-4; Seffernick JL, 2001, BIOCHEMISTRY-US, V40, P12747, DOI 10.1021/bi011293r; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; Ward BA, 2003, J PHARMACOL EXP THER, V306, P287, DOI 10.1124/jpet.103.049601; Witschel M, 1997, J BACTERIOL, V179, P6937, DOI 10.1128/jb.179.22.6937-6943.1997; World Health Organization-International Agency for Research on Cancer, 1986, IARC MONOGR, V41, P319; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000; XUN LY, 1992, J BACTERIOL, V174, P2898, DOI 10.1128/JB.174.9.2898-2902.1992; XUN LY, 1995, APPL ENVIRON MICROB, V61, P3499, DOI 10.1128/AEM.61.9.3499-3502.1995; Zaborina O, 1998, J BACTERIOL, V180, P4667, DOI 10.1128/JB.180.17.4667-4675.1998	35	77	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6696	6700		10.1074/jbc.M312072200	http://dx.doi.org/10.1074/jbc.M312072200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662756	hybrid			2022-12-25	WOS:000188969200061
J	Yamasaki, M; Masgrau, R; Morgan, AJ; Churchill, GC; Patel, S; Ashcroft, SJH; Galione, A				Yamasaki, M; Masgrau, R; Morgan, AJ; Churchill, GC; Patel, S; Ashcroft, SJH; Galione, A			Organelle selection determines agonist-specific Ca2+ signals in pancreatic acinar and beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; CALCIUM; NAADP; RELEASE; GLUCOSE; STORES; PATHWAYS	How different extracellular stimuli can evoke different spatiotemporal Ca2+ signals is uncertain. We have elucidated a novel paradigm whereby different agonists use different Ca2+-storing organelles ("organelle seleetion") to evoke unique responses. Some agonists select the endoplasmic reticulum (ER), and others select lysosome-related (acidic) organelles, evoking spatial Ca2+ responses that mirror the organellar distribution. In pancreatic acinar cells, acetylcholine and bombesin exclusively select the ER Ca2+ store, whereas cholecystokinin additionally recruits a lysosome-related organelle. Similarly, in a pancreatic beta cell line MIN6, acetylcholine selects only the ER, whereas glucose mobilizes Ca2+ from a lysosome-related organelle. We also show that the key to organelle selection is the agonist-specific coupling messenger(s) such that the ER is selected by recruitment of inositol 1,4,5-trisphosphate (or cADP-ribose), whereas lysosome-related organelles are selected by NAADP.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; UCL, Dept Physiol, London WC1E 6BT, England; Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England	University of Oxford; University of London; University College London; University of Oxford	Masgrau, R (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	roser.masgrau-juanola@pharmacology.oxford.ac.uk	Masgrau, Roser/D-3047-2011; Galione, Antony/E-5884-2011; Patel, Sandip/O-9591-2015	Masgrau, Roser/0000-0002-6722-5939; Galione, Antony/0000-0002-4132-7646; Patel, Sandip/0000-0001-7247-2013				Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; Arredouani A, 2002, AM J PHYSIOL-ENDOC M, V282, pE982, DOI 10.1152/ajpendo.00347.2001; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Burdakov D, 2000, CURR BIOL, V10, P993, DOI 10.1016/S0960-9822(00)00649-7; Burdakov D, 2001, CELL CALCIUM, V29, P211, DOI 10.1054/ceca.2000.0188; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Christensen KA, 2002, J CELL SCI, V115, P599; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; DAWSON CM, 1984, Q J EXP PHYSIOL CMS, V69, P819, DOI 10.1113/expphysiol.1984.sp002871; Fogarty KE, 2000, J BIOL CHEM, V275, P22487, DOI 10.1074/jbc.M909402199; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Gerasimenko OV, 2002, CELL CALCIUM, V32, P261, DOI 10.1016/S0143416002001938; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; JADOT M, 1984, BIOCHEM J, V219, P965, DOI 10.1042/bj2190965; Krause E, 2002, J BIOL CHEM, V277, P11696, DOI 10.1074/jbc.M107794200; Larbaud D, 2001, CLIN SCI, V101, P551, DOI 10.1042/CS20010042; Lee HC, 2003, CURR BIOL, V13, pR186, DOI 10.1016/S0960-9822(03)00120-9; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Martin F, 1997, BIOCHEM BIOPH RES CO, V235, P465, DOI 10.1006/bbrc.1997.6804; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; Renstrom E, 2002, J BIOL CHEM, V277, P26717, DOI 10.1074/jbc.C200314200; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; Titievsky AV, 1996, PFLUG ARCH EUR J PHY, V432, P938, DOI 10.1007/s004240050218; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5	42	170	174	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7234	7240		10.1074/jbc.M311088200	http://dx.doi.org/10.1074/jbc.M311088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660554	hybrid			2022-12-25	WOS:000188969200124
J	Yoneda, K; Furukawa, T; Zheng, Y; Momoi, T; Izawa, I; Inagaki, M; Manabe, M; Inagaki, N				Yoneda, K; Furukawa, T; Zheng, Y; Momoi, T; Izawa, I; Inagaki, M; Manabe, M; Inagaki, N			An autocrine/paracrine loop linking keratin 14 aggregates to tumor necrosis factor alpha-mediated cytotoxicity in a keratinocyte model of epidermolysis bullosa simplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; INTERLEUKIN-1-BETA-CONVERTING ENZYME; INTERMEDIATE-FILAMENTS; CYSTEINE PROTEASES; SIGNALING PATHWAY; CELL-DEATH; APOPTOSIS; RECEPTOR; DISEASE	Epidermolysis bullosa simplex (EBS) is a blistering cutaneous disease featuring protein aggregates. Here we investigate the molecular mechanisms linking protein aggregates to cell death in a cellular model of EBS in which HaCaT keratinocytes are transfected with plasmids expressing various mutant forms of keratin 14 (K14). In HaCaT cells, mutant K14 was found to form ubiquitinated protein aggregates that suppressed 20 S proteasome function instead of being degraded by 20 S proteasome. Keratinocytes with mutant K14-induced phosphorylation of the stress-activated kinase c-Jun, as well as up-regulation of unfolding protein Bip, indicates induction of endoplasmic reticulum stress. HaCaT cells were susceptible to apoptosis by activation of caspases-3, and -8, but not caspase-9 or -12. Tumor necrosis factor-alpha (TNFalpha) in the culture medium was increased in keratinocytes with mutant K14 compared with wild K14, and the addition of neutralizing anti-TNFalpha antibody to the culture medium rescued keratinocytes from cell death. Thus, TNFalpha release and the subsequent activation of the TNFalpha receptor by an autocrine/paracrine pathway links protein aggregates to cell death in this keratinocyte EBS cellular model. Furthermore, mutation in K14 reduced its affinity to TNFalpha receptor-associated death domain (TRADD), suggesting that the susceptibility of keratinocytes to caspase-8-mediated apoptosis is increased in mutated K14 because of impairment of the cytoprotective mechanism mediated by K14-TRADD interaction.	Akita Univ, Sch Med, Dept Dermatol, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Natl Inst Neurosci, NCNP, Div Dev Differentiat, Tokyo 1878502, Japan; Aichi Canc Ctr, Res Inst, Div Biochem, Aichi 4648681, Japan; Japan Sci & Technol Corp, CREST, Akita 0108543, Japan	Akita University; Akita University; National Center for Neurology & Psychiatry - Japan; Aichi Cancer Center; Japan Science & Technology Agency (JST)	Yoneda, K (corresponding author), Akita Univ, Sch Med, Dept Dermatol, 1-1-1 Hondo, Akita 0108543, Japan.	kyoneda@doc.med.akita-u.ac.jp	Inagaki, Masaki/B-9920-2016; furukawa, tetsushi/ABD-3178-2020	Inagaki, Nobuya/0000-0001-8261-2593				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Arin MJ, 2001, TRENDS MOL MED, V7, P422, DOI 10.1016/S1471-4914(01)02095-0; Ban N, 2002, DIABETES, V51, P1409, DOI 10.2337/diabetes.51.5.1409; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Beaulieu JM, 2003, J NEUROCHEM, V85, P248, DOI 10.1046/j.1471-4159.2003.01653.x; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; CEICHANOVER A, 1994, CELL, V79, P13; Chan YM, 1996, J INVEST DERMATOL, V106, P327, DOI 10.1111/1523-1747.ep12342985; COCKAYNE EA, 1938, BRIT J DERMATOL, V55, P358; Corden L D, 1996, Exp Dermatol, V5, P297, DOI 10.1111/j.1600-0625.1996.tb00133.x; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Furukawa T, 2001, J MOL BIOL, V313, P775, DOI 10.1006/jmbi.2001.5053; Gamady A, 2003, J CELL BIOCHEM, V89, P440, DOI 10.1002/jcb.10508; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Koizumi H, 2001, ARCH DERMATOL RES, V293, P325, DOI 10.1007/s004030100237; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; LIN AN, 1993, ANNU REV MED, V44, P189, DOI 10.1146/annurev.med.44.1.189; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; Mattson MP, 1998, J NEUROCHEM, V70, P1; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; PETERS JM, 1998, UBIQUITIN BIOL CELL; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Vidair CA, 1996, INT J HYPERTHER, V12, P681, DOI 10.3109/02656739609027676; Walczak H, 2001, TRENDS BIOCHEM SCI, V26, P452, DOI 10.1016/S0968-0004(01)01895-3; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Yamada H, 2001, J BIOL CHEM, V276, P19052, DOI 10.1074/jbc.M100615200; Yarosh D, 2000, PHOTODERMATOL PHOTO, V16, P263, DOI 10.1034/j.1600-0781.2000.160606.x; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONEDA K, 1990, J INVEST DERMATOL, V94, P724, DOI 10.1111/1523-1747.ep12876298; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; Zheng YJ, 2002, J BIOL CHEM, V277, P32268, DOI 10.1074/jbc.M202105200	61	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7296	7303		10.1074/jbc.M307242200	http://dx.doi.org/10.1074/jbc.M307242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660619	hybrid			2022-12-25	WOS:000188969200131
J	Go, YM; Gipp, JJ; Mulcahy, RT; Jones, DP				Go, YM; Gipp, JJ; Mulcahy, RT; Jones, DP			H2O2-dependent activation of GCLC-ARE4 reporter occurs by mitogen-activated protein kinase pathways without oxidation of cellular glutathione or thioredoxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAPHTHOFLAVONE-INDUCED EXPRESSION; EPIDERMAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; HEAVY SUBUNIT GENE; HYDROGEN-PEROXIDE; C-JUN; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS	The gp91(phox) homologue Nox1 produces H2O2, which induces cell growth, transformation, and tumorigenicity. However, it has not been clear whether H2O2 effects are mediated indirectly via a generally oxidizing cellular environment or whether H2O2 more directly targets specific signaling pathways. Here, we investigated signaling by H2O2 induced by Nox1 overexpression using a luciferase reporter regulated by the antioxidant response element ARE4. Surprisingly, Nox1-derived H2O2 activated the reporter gene 15-fold with no effect on the redox state of the major thiol antioxidant substances, glutathione and thioredoxin. H2O2 signaling to ARE4 was mediated by activation of both the c-Jun N-terminal kinase and ERK1/2 pathways modulated by Ras. Thus, "redox signaling" resulting in kinase signaling pathways is distinct from "oxidative stress," and is mediated by discrete, localized redox circuitry.	Emory Univ, Rollins Res Ctr 4131, Dept Med, Sch Med,Div Cardiol, Atlanta, GA 30322 USA; Emory Univ, Ctr Clin & Mol Nutr, Atlanta, GA 30322 USA; Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53792 USA	Emory University; Emory University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jones, DP (corresponding author), Emory Univ, Rollins Res Ctr 4131, Dept Med, Sch Med,Div Cardiol, Atlanta, GA 30322 USA.	dpjones@emory.edu			NIEHS NIH HHS [ES011195] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011195] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; De Keulenaer GW, 2000, ARTERIOSCL THROM VAS, V20, P385, DOI 10.1161/01.ATV.20.2.385; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Griendling KK, 1997, CIRCULATION, V96, P3264; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Wallace DC, 1998, NAT GENET, V19, P105, DOI 10.1038/448; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Watson WH, 2003, FEBS LETT, V543, P144, DOI 10.1016/S0014-5793(03)00430-7; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; Yoshizumi Masanori, 2001, Journal of Medical Investigation, V48, P11	50	76	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5837	5845		10.1074/jbc.M307547200	http://dx.doi.org/10.1074/jbc.M307547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638694	hybrid			2022-12-25	WOS:000188776500098
J	Han, GS; Johnston, CN; Carman, GM				Han, GS; Johnston, CN; Carman, GM			Vacuole membrane topography of the DPP1-encoded diacylglycerol pyrophosphate phosphatase catalytic site from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID PRODUCTION; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; LIPID-COMPOSITION; REGULATED GENES; PHOSPHOLIPASE-D; SEQUENCE MOTIF; YEAST VACUOLE; ACTIVE-SITE; PROTEIN	The Saccharomyces cerevisiae DPP1-encoded diacylglycerol pyrophosphate phosphatase is a vacuole membrane-associated enzyme that catalyzes the removal of the beta-phosphate from diacylglycerol pyrophosphate to form phosphatidate, and it then removes the phosphate from phosphatidate to form diacylglycerol. The enzyme has six putative transmembrane domains and a hydrophilic region that contains a phosphatase motif required for its catalytic activity. In this work, we examined the topography of diacylglycerol-pyrophosphate phosphatase catalytic site within the transverse plane of the vacuole membrane. Results of protease protection analysis using endoproteinase Lys-C and labeling of cysteine residues using sulfhydryl reagents were consistent with a model where the catalytic site of diacylglycerol-pyrophosphate phosphatase was oriented to the cytosolic face of the vacuole membrane. In addition, diacylglycerol-pyrophosphate phosphatase activity was found with intact vacuoles. The phospholipids diacylglycerol pyrophosphate (0.6 mol %) and phosphatidate (1.4 mol %) were found in the vacuole membrane, and their levels decreased to an undetectable level and by 79%, respectively, when cells were depleted for zinc. The reduced levels of diacylglycerol pyrophosphate and phosphatidate correlated with the induced expression of diacylglycerol-pyrophosphate phosphatase. This work suggested that diacylglycerol pyrophosphate phosphatase functions to regulate the levels of diacylglycerol pyrophosphate and phosphatidate on the cytosolic face of the vacuole membrane.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; AMES BN, 1960, J BIOL CHEM, V235, P769; Balboa MA, 1999, J BIOL CHEM, V274, P522, DOI 10.1074/jbc.274.1.522; BALLAS LM, 1981, BIOCHIM BIOPHYS ACTA, V665, P586, DOI 10.1016/0005-2760(81)90274-5; Bangham AD, 1982, TECHNIQUES LIFE SCI, P1; Barila D, 1996, J BIOL CHEM, V271, P29928, DOI 10.1074/jbc.271.47.29928; BELL RM, 1981, J LIPID RES, V22, P391; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CULBERTSON MR, 1975, GENETICS, V80, P23; den Hartog M, 2001, PLANT J, V25, P55, DOI 10.1046/j.1365-313x.2001.00931.x; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Harlow E., 1988, ANTIBODIES LAB MANUA; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; JONES EW, 1997, MOL CELLULAR BIOL YE, P363; Kates M., 1986, TECHNIQUES LIPIDOLOG, P186; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; LIN YP, 1989, J BIOL CHEM, V264, P8641; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Oshiro J, 2003, BBA-MOL CELL BIOL L, V1635, P1, DOI 10.1016/j.bbalip.2003.10.002; Oshiro J, 2003, J BIOL CHEM, V278, P31495, DOI 10.1074/jbc.M305452200; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Pierrugues O, 2001, J BIOL CHEM, V276, P20300, DOI 10.1074/jbc.M009726200; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; Rogers PD, 2003, ANTIMICROB AGENTS CH, V47, P1220, DOI 10.1128/AAC.47.4.1220-1227.2003; Sciorra VA, 2002, BBA-MOL CELL BIOL L, V1582, P45, DOI 10.1016/S1388-1981(02)00136-1; Simon MF, 2002, J BIOL CHEM, V277, P23131, DOI 10.1074/jbc.M201530200; Smyth SS, 2003, J BIOL CHEM, V278, P43214, DOI 10.1074/jbc.M306709200; Stack JH, 1993, CURR OPIN CELL BIOL, V5, P641, DOI 10.1016/0955-0674(93)90134-C; Stukey J, 1997, PROTEIN SCI, V6, P469; Tanyi JL, 2003, CANCER RES, V63, P1073; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Toke DA, 1999, BIOCHEMISTRY-US, V38, P14606, DOI 10.1021/bi991472x; UCHIDA E, 1988, METHOD ENZYMOL, V157, P544; van der Luit AH, 2000, PLANT PHYSIOL, V123, P1507, DOI 10.1104/pp.123.4.1507; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WALSH JP, 1986, J BIOL CHEM, V261, P6239; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yuan DS, 2000, GENETICS, V156, P45; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	71	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5338	5345		10.1074/jbc.M311779200	http://dx.doi.org/10.1074/jbc.M311779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630917	hybrid			2022-12-25	WOS:000188776500038
J	Li, ZQ; Yasuda, Y; Li, WJ; Bogyo, M; Katz, N; Gordon, RE; Fields, GB; Bromme, D				Li, ZQ; Yasuda, Y; Li, WJ; Bogyo, M; Katz, N; Gordon, RE; Fields, GB; Bromme, D			Regulation of collagenase activities of human cathepsins by glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE TYPE-I; COLLAGENOLYTIC CATHEPSIN; MATRIX METALLOPROTEINASES; FUNCTIONAL EXPRESSION; CYSTEINE PROTEINASES; MOLECULAR-CLONING; PROTEASE; CARTILAGE; INHIBITORS; ATHEROSCLEROSIS	Cathepsin K, a lysosomal papain- like cysteine protease, forms collagenolytically highly active complexes with chondroitin sulfate and represents the most potent mammalian collagenase. Here we demonstrate that complex formation with glycosaminoglycans ( GAGs) is unique for cathepsin K among human papain- like cysteine proteases and that different GAGs compete for the binding to cathepsin K. GAGs predominantly expressed in bone and cartilage, such as chondroitin and keratan sulfates, enhance the collagenolytic activity of cathepsin K, whereas dermatan, heparan sulfate, and heparin selectively inhibit this activity. Moreover, GAGs potently inhibit the collagenase activity of other cysteine proteases such as cathepsins L and S at 37 degrees C. Along this line MMP1- generated collagen fragments in the presence of GAGs are stable against further degradation at 28 degrees C by all cathepsins but cathepsin K, whereas thermal destabilization at 37 degrees C renders the fragments accessible to all cathepsins. These results suggest a novel mechanism for the regulation of matrix protein degradation by GAGs. It further implies that cathepsin K represents the only lysosomal collagenolytic activity under physiologically relevant conditions.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; Stanford Univ, Stanford, CA 94305 USA; Florida Atlantic Univ, Boca Raton, FL 33431 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Stanford University; State University System of Florida; Florida Atlantic University	Bromme, D (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave & 100th St, New York, NY 10029 USA.	dieter.bromme@mssm.edu		Bogyo, Matthew/0000-0003-3753-4412	NCI NIH HHS [CA77402, CA98799] Funding Source: Medline; NIAMS NIH HHS [AR 48669, AR46182] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077402, R01CA098799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182, R01AR048669] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Benjamin IJ, 2001, J INVEST MED, V49, P381, DOI 10.2310/6650.2001.33783; Bilato C, 1996, AGING CLIN EXP RES, V8, P221; Bromme D, 1996, PROTEIN SCI, V5, P789; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; Buttle DJ, 1994, IMMUNOPHARMACOLOGY J, P225; Davies JA, 2001, BIOCHEM SOC T, V29, P166, DOI 10.1042/BST0290166; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; ETHERINGTON DJ, 1977, ACTA BIOL MED GER, V36, P1555; EVANS P, 1978, EUR J BIOCHEM, V83, P87, DOI 10.1111/j.1432-1033.1978.tb12071.x; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Everts V, 2003, CALCIFIED TISSUE INT, V73, P380, DOI 10.1007/s00223-002-2092-4; EVERTS V, 1985, COLLAGEN REL RES, V5, P315; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; FIRSCHEIN HE, 1966, ANAL BIOCHEM, V14, P296, DOI 10.1016/0003-2697(66)90140-0; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Hou WS, 2003, BIOL CHEM, V384, P891, DOI 10.1515/BC.2003.100; Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114; Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002-9440(10)63068-4; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; KomsaPenkova R, 1996, BBA-PROTEIN STRUCT M, V1297, P171, DOI 10.1016/S0167-4838(96)00092-1; Konttinen YT, 2002, ARTHRITIS RHEUM, V46, P953, DOI 10.1002/art.10185; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; Ortega N, 2003, ANN NY ACAD SCI, V995, P109, DOI 10.1111/j.1749-6632.2003.tb03214.x; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sames K, 1994, EXS, V70, P243; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; YAMAMOTO H, 1992, RES COMMUN CHEM PATH, V76, P95; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569	50	177	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5470	5479		10.1074/jbc.M310349200	http://dx.doi.org/10.1074/jbc.M310349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645229	hybrid			2022-12-25	WOS:000188776500054
J	Tahara, T; Sun, JY; Nakanishi, K; Yamamoto, M; Mori, H; Saito, T; Fujita, H; Igarashi, K; Taketani, S				Tahara, T; Sun, JY; Nakanishi, K; Yamamoto, M; Mori, H; Saito, T; Fujita, H; Igarashi, K; Taketani, S			Heme positively regulates the expression of beta-globin at the locus control region via the transcriptional factor Bach1 in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; GENE-EXPRESSION; MESSENGER-RNA; MOLECULAR CHARACTERIZATION; TRANSLATIONAL REGULATION; SMALL MAF; DIFFERENTIATION; BINDING; NF-E2; HEMOGLOBIN	The transcription factor Bach1 heterodimerizes with small Maf proteins to repress Maf recognition element ( MARE)- dependent gene expression. The repressor activity of Bach1 is inhibited by the direct binding of heme. To investigate the involvement of Bach1 in the heme- dependent regulation of the expression of the beta- globin gene, mouse erythroleukemia ( MEL) cells were cultured with succinylacetone ( SA), a specific inhibitor of heme biosynthesis, and the level of beta- globin mRNA was examined. A marked decrease of beta- globin mRNA in SA- treated cells was observed, and this decrease was reversed by the addition of hemin. An iron chelator, desferrioxamine, also lowered the level of beta- globin mRNA. The heme- dependent expression of beta- globin is a transcriptional event since the expression of the human beta- globin gene promoter- reporter gene containing the microlocus control region ( mu LCR) was inhibited when human erythroleukemia K562 cells and MEL cells were cultured with SA. Hemin treatment restored the decrease in promoter activity caused by SA. The control of the mu LCR- beta- globin promoter reporter gene by heme was dependent on DNase I- hypersensitive site 2 ( HS2), which contains MARE. The MARE binding activity of Bach1 in K562 and MEL cells increased upon SA treatment, and the increase was diminished by the treatment with hemin. Transient expression of Bach1 suppressed the mu LCR activity, and this repressor activity was cancelled by treatment with hemin. The expression of a mutated Bach1 lacking heme- binding sites led to a loss in the heme responsiveness of the mu LCR. Furthermore, chromatin immunoprecipitation experiments revealed that Bach1 bound to the MARE of HS2 increased by the treatment of MEL cells with SA, and this was cancelled by hemin. We propose that heme positively regulates the beta- globin gene expression by blocking the interaction of Bach1 with the MARE in the LCR.	Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med Chem, Hiroshima 7348551, Japan; Hokkaido Univ, Sch Med, Dept Environm Biol, Sapporo, Hokkaido 0608638, Japan	Kyoto Institute of Technology; Hiroshima University; Hokkaido University	Taketani, S (corresponding author), Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan.	taketani@ipc.kit.ac.jp	Tahara, Tsuyoshi/E-4024-2010; Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475; Mori, Hajime/0000-0001-9219-6140				BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BATTISTINI A, 1991, J BIOL CHEM, V266, P528; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Blank V, 1997, GENOMICS, V44, P147, DOI 10.1006/geno.1997.4847; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; Courey AJ, 2001, GENE DEV, V15, P2786; Crosby JS, 2000, BLOOD, V96, P3241; Ellis J, 1997, NUCLEIC ACIDS RES, V25, P1296, DOI 10.1093/nar/25.6.1296; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FIBACH E, 1995, BLOOD, V85, P2967, DOI 10.1182/blood.V85.10.2967.bloodjournal85102967; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FUJITA H, 1991, J BIOL CHEM, V266, P17494; FUKUDA Y, 1994, BLOOD, V83, P1662; FUKUDA Y, 1993, BRIT J HAEMATOL, V85, P670, DOI 10.1111/j.1365-2141.1993.tb03207.x; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MEGURO K, 1995, BLOOD, V86, P940; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Sassa S, 1996, INT J HEMATOL, V63, P167; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6417; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; STAMATOYANNOPOU.G, 1993, MOL BASIS HUMAN DIS, P106; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki T, 2000, BIOCHEM PHARMACOL, V60, P275, DOI 10.1016/S0006-2952(00)00324-5; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	40	103	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5480	5487		10.1074/jbc.M302733200	http://dx.doi.org/10.1074/jbc.M302733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660636	hybrid			2022-12-25	WOS:000188776500055
J	Takada, Y; Aggarwal, BB				Takada, Y; Aggarwal, BB			Flavopiridol inhibits NF-kappa B activation induced by various carcinogens and inflammatory agents through inhibition of I kappa B alpha kinase and p65 phosphorylation - Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; TRANSCRIPTIONAL REPRESSION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FACTOR REQUIRES; DOWN-REGULATION; LEUKEMIA CELLS; TNF-ALPHA	Flavopiridol, a synthetic flavone closely related to a compound originally isolated from the stem bark of the native Indian plant Dysoxylum binectariferum, has been found to inhibit cyclin-dependent kinases, induce apoptosis, suppress inflammation, and modulate the immune response. Because several genes in which expression is altered by flavopiridol are regulated by NF-kappaB, we propose that this flavone must affect the activation of NF-kappaB. For this report, we investigated the effect of flavopiridol on NF-kappaB activation by various carcinogens and inflammatory agents. Flavopiridol suppressed tumor necrosis factor (TNF)-activation of NF-kappaB in a dose- and time-dependent manner in several cell types, with optimum inhibition occurring upon treatment of cells with 100 nM flavopiridol for 6 h. This effect was mediated through inhibition of IkappaBalpha kinase, phosphorylation, ubiquitination, and degradation of IkappaBalpha (an inhibitor of NF-kappaB), and suppression of phosphorylation, acylation, and nuclear translocation of the p65 subunit of NF-kappaB. Besides TNF, flavopiridol also suppressed NF-kappaB activated by a carcinogen (cigarette smoke condensate), tumor promoters (phorbol myristate acetate and okadaic acid), and an inflammatory agent (H2O2). TNF-induced NF-kappaB-dependent reporter gene transcription was also suppressed by this flavone. NF-kappaB reporter activity induced by TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kinase, and IkappaBalpha kinase, were all blocked by flavopiridol but not that activated by p65. Furthermore, flavopiridol suppressed TNF-induced activation of Akt. Flavopiridol also inhibited the expression of the TNF-induced NFkappaB-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9. Overall, our results indicated that flavopiridol inhibits activation of NF-kappaB and NF-kappaB-regulated gene expression, which may explain the ability of flavopiridol to suppress inflammation, modulate the immune response, and regulate cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	高, 雨莉/HGU-8187-2022; Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Arguello F, 1998, BLOOD, V91, P2482; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bible KC, 1996, CANCER RES, V56, P4856; Bible KC, 1997, CANCER RES, V57, P3375; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Carlson B, 1999, CANCER RES, V59, P4634; Carlson BA, 1996, CANCER RES, V56, P2973; Cartee L, 2003, MOL CANCER THER, V2, P83; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang S, 2000, CANCER RES, V60, P5334; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karp JE, 2003, CLIN CANCER RES, V9, P307; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kim DM, 2003, CANCER RES, V63, P621; Kitada S, 2000, BLOOD, V96, P393; Konig A, 1997, BLOOD, V90, P4307; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Melillo G, 1999, CANCER RES, V59, P5433; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Nahta R, 2002, CANCER RES, V62, P2267; NAIK RG, 1988, TETRAHEDRON, V44, P2081, DOI 10.1016/S0040-4020(01)90352-7; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rapella A, 2002, INT J CANCER, V99, P658, DOI 10.1002/ijc.10392; SCHWARTZ GK, 1998, P AN M AM SOC CLIN, V17, P188; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wittmann S, 2003, CANCER RES, V63, P93; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; Wu KM, 2002, MOL CANCER THER, V1, P695; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	60	154	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4750	4759		10.1074/jbc.M304546200	http://dx.doi.org/10.1074/jbc.M304546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14630924	hybrid			2022-12-25	WOS:000188554300100
J	Yokoyama, M; Yagyu, H; Hu, YY; Seo, T; Hirata, K; Homma, S; Goldberg, IJ				Yokoyama, M; Yagyu, H; Hu, YY; Seo, T; Hirata, K; Homma, S; Goldberg, IJ			Apolipoprotein B production reduces lipotoxic cardiomyopathy - Studies in heart-specific lipoprotein lipase transgenic mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-DEFICIENT MICE; TRIGLYCERIDE ACCUMULATION; DIABETES-MELLITUS; OVEREXPRESSION; EXPRESSION; SECRETION; OBESITY; ATHEROGENESIS; DYSFUNCTION; INCREASES	Lipid accumulation is associated with cardiac dysfunction in diabetes and obesity. Transgenic mice expressing non-transferable lipoprotein lipase (LpL) with a glycosylated phosphatidyl-inositol (GPI) anchor in cardiomyocytes have dilated cardiomyopathy. However, the mechanisms responsible for lipid accumulation and cardiomyopathy are not clear. Hearts from 3-month-old mice expressing GPI-anchored human LpL (hLpL(GPI)) mice had increased fatty acid oxidation and heart failure genes and decreased glucose transporter genes. 6-month-old mice had increased mRNA expression and activation of the apoptosis marker caspase-3. Moreover, hLpLGPI hearts had significant cytochrome c release from mitochondria to cytosol. Low density lipoprotein uptake was greater in hLpLGPI hearts, and this was associated with more intracellular apolipoprotein B (apoB). To test whether lipid accumulation in the hLpLGPI heart is reduced by cardiac expression of apoB, hLpLGPI mice were bred with transgenic human apoB (HuB)-expressing mice. Hearts of HuB/hLpL(GPI) mice had less triglyceride (38%) and free fatty acids (19%), secreted more apoB, and expressed less atrial natriuretic factor (ANT) and brain natriuretic peptide (BNP) and more glucose transporter 4 (GLUT4). The increased mortality of the mice was abrogated by the transgenic expression of apoB. Therefore, we hypothesize that cardiac apoB expression improves cardiomyopathy by increasing lipid resecretion from the heart.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Goldberg, IJ (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	ijg3@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095, R01HL073029] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45095, HL73029] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Finck BN, 2003, P NATL ACAD SCI USA, V100, P1226, DOI 10.1073/pnas.0336724100; Finck BN, 2002, J CLIN INVEST, V109, P121, DOI 10.1172/JCI200214080; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Kako Y, 2002, J LIPID RES, V43, P872; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Listenberger LL, 2002, TRENDS CARDIOVAS MED, V12, P134, DOI 10.1016/S1050-1738(02)00152-4; Napoli C, 2002, CIRCULATION, V105, P1360, DOI 10.1161/01.CIR.0000013090.96919.FA; Nielsen LB, 2002, J BIOL CHEM, V277, P27014, DOI 10.1074/jbc.M203458200; Nohammer C, 2003, LAB INVEST, V83, P259, DOI 10.1097/01.LAB.0000053916.61772.CA; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Nuotio IP, 1997, ARTERIOSCL THROM VAS, V17, P820, DOI 10.1161/01.ATV.17.5.820; Pierpont MEM, 2000, AM HEART J, V139, pS96, DOI 10.1067/mhj.2000.103921; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; Yagyu H, 2003, J CLIN INVEST, V111, P419, DOI [10.1172/JCI200316751, 10.1172/JCI16751]; Yagyu H, 2002, J BIOL CHEM, V277, P10037, DOI 10.1074/jbc.M109966200; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	26	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4204	4211		10.1074/jbc.M311995200	http://dx.doi.org/10.1074/jbc.M311995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14634011	hybrid			2022-12-25	WOS:000188554300037
J	Andoh, T; Kuraishi, Y				Andoh, T; Kuraishi, Y			Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I	FASEB JOURNAL			English	Article						IgG; Fc gamma RI; substance P; calcium channel	ITCH-ASSOCIATED RESPONSE; SUBSTANCE-P RELEASE; MOUSE MAST-CELLS; IFN-GAMMA; CONDUCTION-VELOCITY; HERPES-ZOSTER; IGG; MICE; HISTAMINE; CAPSAICIN	Immunoglobulin G (IgG) binds specific antigens, and IgG-antigen complexes primarily activate immune cells and the complement system. These immune reactions are known to affect neural functions through the production and release of mediators such as cytokines. The high affinity IgG receptor FcgammaRI, but not the low affinity receptors Fc gamma RII and Fc gamma RIII, was expressed on the mouse dorsal root ganglion (DRG) neurons, especially small- or medium-sized neurons. IgG bound to DRG neurons and made a complex with antigen there. Ragweed pollen bound to nerve fibers in the skin of sensitized mouse in situ. The formation of IgG-ragweed pollen complex increased the concentration of Ca2+ ions in the DRG neurons. This increase was inhibited by a Ca2+ chelator, L- and N-type voltage-dependent Ca2+ channel blockers, and anti-FcgammaRI antibody. IgG-antigen complex released substance P from DRG neurons, which was inhibited by L- and N-type Ca2+ channel blockers. Thus, IgG and antigen combine on primary sensory neurons to directly activate them, which may be a novel type of immune-neuron linkage.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan	University of Toyama	Kuraishi, Y (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Appl Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.	kuraisiy@ms.toyama-mpu.ac.jp						Andoh T, 1998, J PHARMACOL EXP THER, V286, P1140; CARPENTER SE, 1981, BRIT J PHARMACOL, V73, P755, DOI 10.1111/j.1476-5381.1981.tb16812.x; Chen YL, 1998, INT ARCH ALLERGY IMM, V116, P269, DOI 10.1159/000023955; DISCLAFANI A, 1983, CUTIS, V31, P523; FERGUSON AC, 1984, J ALLERGY CLIN IMMUN, V74, P678, DOI 10.1016/0091-6749(84)90229-X; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; HANDWERKER HO, 1991, J NEUROPHYSIOL, V66, P307, DOI 10.1152/jn.1991.66.1.307; Harding LM, 1999, PROG NEURO-PSYCHOPH, V23, P1103, DOI 10.1016/S0278-5846(99)00049-4; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; HAYWARD A, 1991, J INFECT DIS, V163, P873, DOI 10.1093/infdis/163.4.873; HILL PB, 1995, VET IMMUNOL IMMUNOP, V44, P105, DOI 10.1016/0165-2427(94)05298-7; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; JONAKAIT GM, 1991, ANN NY ACAD SCI, V632, P19, DOI 10.1111/j.1749-6632.1991.tb33090.x; Kumazawa T, 1996, PROG BRAIN RES, V113, P3, DOI 10.1016/S0079-6123(08)61078-X; KURAISHI Y, 1995, EUR J PHARMACOL, V275, P229, DOI 10.1016/0014-2999(94)00780-B; KURAISHI Y, 1985, BRAIN RES, V325, P294, DOI 10.1016/0006-8993(85)90326-9; LEE KH, 1986, J COMP NEUROL, V243, P335, DOI 10.1002/cne.902430305; MAGGI CA, 1990, NEUROSCI LETT, V114, P203, DOI 10.1016/0304-3940(90)90072-H; Morioka N, 2002, J NEUROCHEM, V80, P989, DOI 10.1046/j.0022-3042.2002.00722.x; Ohtsuka E, 2003, J PHARMACOL SCI, V91, P263, DOI 10.1254/jphs.91.263; Ohtsuka E, 2001, JPN J PHARMACOL, V86, P97, DOI 10.1254/jjp.86.97; OVARY Z, 1971, J IMMUNOL, V107, P1795; PETRONI KC, 1988, J IMMUNOL, V140, P3467; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Takahashi T, 2001, INT ARCH ALLERGY IMM, V125, P228, DOI 10.1159/000053820; TIGELAAR RE, 1971, J IMMUNOL, V106, P661; Uciechowski P, 1998, EUR J IMMUNOL, V28, P2928, DOI 10.1002/(SICI)1521-4141(199809)28:09<2928::AID-IMMU2928>3.0.CO;2-8; UEDA M, 1994, NEUROSCI RES, V20, P231, DOI 10.1016/0168-0102(94)90092-2; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315	29	73	78	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					182	184		10.1096/fj.02-1169fje	http://dx.doi.org/10.1096/fj.02-1169fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630707				2022-12-25	WOS:000188829300067
J	Aglipay, JA; Lee, SW; Okada, S; Fujiuchi, N; Ohtsuka, T; Kwak, JC; Wang, Y; Johnstone, RW; Deng, CX; Qin, J; Ouchi, T				Aglipay, JA; Lee, SW; Okada, S; Fujiuchi, N; Ohtsuka, T; Kwak, JC; Wang, Y; Johnstone, RW; Deng, CX; Qin, J; Ouchi, T			A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway	ONCOGENE			English	Article						BRCA1; IFI16; p53; apoptosis	CELL-CYCLE; BRCA1; PHOSPHORYLATION; CANCER; TRANSCRIPTION; BREAST; DOMAIN; P53; CHECKPOINT; MUTATION	We identified IFI16 as a BRCA1-associated protein involved in p53-mediated apoptosis. IFI16 contains the Pyrin/PAAD/DAPIN domain, commonly found in cell death-associated proteins. BRCA1 (aa 502-802) interacted with the IFI16 Pyrin domain (aa 1-130). We found that IFI16 was localized in the nucleoplasm and nucleoli. Clear nucleolar IFI16 localization was not observed in HCC1937 BRCA1 mutant cells, but reintroduction of wild-type BRCA1 restored IFI16 nuclear relocalization following IR (ionizing radiation). Coexpression of IFI16 and BRCA1 enhanced DNA damage-induced apoptosis in mouse embryonic fibroblasts from BRCA1 mutant mice expressing wild-type p53, although mutant IFI16 deficient in binding to BRCA1 did not induce apoptosis. Furthermore, tetracycline-induced IFI16 collaborated in inducing apoptosis when adenovirus p53 was expressed in DNA-damaged p53-deficient EJ cells. These results indicate a BRCA1-IFI16 role in p53-mediated transmission of DNA damage signals and apoptosis.	NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic, Australia; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	Icahn School of Medicine at Mount Sinai; New York University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine; Peter Maccallum Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu	deng, chuxia/N-6713-2016; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NCI NIH HHS [CA80058, CA84199, CA78356, CA90631, CA79892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084199, R01CA090631, R01CA079892, R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KAELIN WG, 1994, CELL, V644, P521; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Tomlinson GE, 1998, CANCER RES, V58, P3237; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; Wang Y, 2000, GENE DEV, V14, P927; Xu B, 2002, CANCER RES, V62, P4588; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	35	105	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8931	8938		10.1038/sj.onc.1207057	http://dx.doi.org/10.1038/sj.onc.1207057			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654789				2022-12-25	WOS:000186982200014
J	McBride', K; Charron, F; Lefebvre, C; Nemer, M				McBride', K; Charron, F; Lefebvre, C; Nemer, M			Interaction with GATA transcription factors provides a mechanism for cell-specific effects of c-Fos	ONCOGENE			English	Article						c-Fos; GATA factors; AP-1; transcription	GENE-EXPRESSION; COOPERATIVE INTERACTION; CARDIAC TRANSCRIPTION; LEUKEMIA GENE; DOCKING SITES; MICE LACKING; JUN; ACTIVATION; PROTEINS; RECEPTOR	c-Fos is a multifunctional transcription factor that is involved in cellular proliferation, differentiation and apoptosis. c-Fos is rapidly induced by a variety of hormones, growth factors and other extracellular stimuli, resulting in cell-specific responses. One potential mechanism underlying the cell-specific effects of c-Fos may be its ability to regulate gene expression through interaction with tissue-restricted transcription factors. We report here that c-Fos interacts with the cell-specific GATA proteins to potentiate their ability to transactivate target promoters, via GATA-binding sites. c-Fos is recruited to GATA proteins through direct interaction with their N-terminal activation domain. Neither the leucine zipper nor the DNA-binding domain of c-Fos is required for physical interaction with GATA proteins. Instead, a C-terminal domain located between amino acids 235 and 296, which is conserved in FosB but not in the nontransforming Fos family members, FosB/SF or Fra-1, is essential for c-Fos-GATA interaction. These data suggest that c-Fos may act as an inducible cofactor for cell-specific transcription factors and unravel a novel mechanism for transcriptional regulation by c-Fos, independent of the well-studied AP-1 pathway. The results also raise the possibility that dysregulated interaction with cell-specific transcription factors may be an important component in cellular transformation by nuclear oncogenes.	Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University	Nemer, M (corresponding author), Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.		Charron, Frederic/O-8017-2019	Charron, Frederic/0000-0003-3483-8672				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Ciapponi L, 2001, GENE DEV, V15, P1540, DOI 10.1101/gad.886301; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Gottgens B, 2002, GENOME RES, V12, P749, DOI 10.1101/gr.45502; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kataoka K, 1996, ONCOGENE, V12, P53; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McBride K, 2001, CAN J PHYSIOL PHARM, V79, P673, DOI 10.1139/cjpp-79-8-673; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Nemer G, 1999, MAMM GENOME, V10, P993, DOI 10.1007/s003359901146; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PANDEY KN, 1986, BIOCHEM BIOPH RES CO, V138, P399, DOI 10.1016/0006-291X(86)90295-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wenzel A, 2002, J NEUROCHEM, V80, P1089, DOI 10.1046/j.0022-3042.2002.00807.x; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	20	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8403	8412		10.1038/sj.onc.1206877	http://dx.doi.org/10.1038/sj.onc.1206877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627981				2022-12-25	WOS:000186650300004
J	Chu, JL; Bresnick, EH				Chu, JL; Bresnick, EH			Evidence that C promoter-binding factor 1 binding is required for Notch-1-mediated repression of activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; NEOPLASTIC TRANSFORMATION; INTRACELLULAR DOMAIN; GENE-EXPRESSION; ANKYRIN REPEAT; NOTCH; LIGAND; SUPPRESSOR	Cell fate determination in invertebrate and vertebrate systems is regulated by the Notch signaling pathway. Four mammalian Notch genes, Notch 1-4, encode differentially expressed transmembrane receptors. The canonical Notch pathway involves proteolytic liberation of the Notch-1 intracellular domain (NIC-1), which activates CSL ((C) under bar BF1, (S) under baru(H), and (L) under bar ag-1)-mediated transactivation. We showed previously that NIC-1 also represses activator protein-1 (AP-1)-mediated transactivation. The N-terminal RAM (RBP-Jkappa associated molecule) domain of NIC-1 was required for both activation and repression. To investigate the mechanism of AP-1 repression, we tested whether distinct sequences within the RAM domain mediate activation versus repression. We analyzed the capacity of RAM domain mutants to bind endogenous CBF1, to activate CSL-mediated transactivation, and to repress AP-1. A mutant lacking 20 amino acids of the RAM domain (Delta1759-1778) resembled the RAM domain deletion mutant in being defective in all activities. Analysis of 14 deletion and alanine substitution mutants revealed a correlation between CBF1 binding, CSL-mediated transactivation, and AP-1 repression. Stably transfected K562 cells could only tolerate very low level expression of wild-type NIC-1 and NIC-1 mutants retaining activation/repression activities. By contrast, transcriptionally compromised NIC-1 mutants accumulated at high levels. These results support a model in which the binding of NIC-1 to CBF1 is required for AP-1 repression and reveal a powerful cell-sensing mechanism that suppresses the levels of transcriptionally competent NIC-1.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 383 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; Cornell M, 1999, GENETICS, V152, P567; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Johansen LM, 2003, J VIROL, V77, P6029, DOI 10.1128/JVI.77.10.6029-6040.2003; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Krebs LT, 2000, GENE DEV, V14, P1343; Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074-7613(03)00117-1; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lam LT, 1998, J BIOL CHEM, V273, P24223, DOI 10.1074/jbc.273.37.24223; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Mazaleyrat SL, 2003, DEV BIOL, V255, P363, DOI 10.1016/S0012-1606(02)00086-6; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 2000, DEVELOPMENT, V127, P4937; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shutter JR, 2000, GENE DEV, V14, P1313; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; Wolfer A, 2002, IMMUNITY, V16, P869, DOI 10.1016/S1074-7613(02)00330-8; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	55	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12337	12345		10.1074/jbc.M311510200	http://dx.doi.org/10.1074/jbc.M311510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14645224	hybrid			2022-12-25	WOS:000220334900041
J	Roh, JH; Smith, WE; Kaplan, S				Roh, JH; Smith, WE; Kaplan, S			Effects of oxygen and light intensity on transcriptome expression in Rhodobacter sphaeroides 2.4.1 - Redox active gene expression profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; COPROPORPHYRINOGEN-III OXIDASE; HISTIDINE KINASE PRRB; PUC OPERON EXPRESSION; CAROTENOID BIOSYNTHESIS; PHOTOSYNTHETIC GROWTH; PHOTOSYSTEM FORMATION; RHODOPSEUDOMONAS-SPHAEROIDES; POSTTRANSCRIPTIONAL CONTROL; SEQUENCE-ANALYSIS	The roles of oxygen and light on the regulation of photosynthesis gene expression in Rhodobacter sphaeroides 2.4.1 have been well studied over the past 50 years. More recently, the effects of oxygen and light on gene regulation have been shown to involve the interacting redox chains present in R. sphaeroides under diverse growth conditions, and many of the redox carriers comprising these chains have been well studied. However, the expression patterns of those genes encoding these redox carriers, under aerobic and anaerobic photosynthetic growth, have been less well studied. Here, we provide a transcriptional analysis of many of the genes comprising the photosynthesis lifestyle, including genes corresponding to many of the known regulatory elements controlling the response of this organism to oxygen and light. The observed patterns of gene expression are evaluated and discussed in light of our knowledge of the physiology of R. sphaeroides under aerobic and photosynthetic growth conditions. Finally, this analysis has enabled to us go beyond the traditional patterns of gene expression associated with the photosynthesis lifestyle and to consider, for the first time, the full complement of genes responding to oxygen, and variations in light intensity when growing photosynthetically. The data provided here should be considered as a first step in enabling one to model electron flow in R. sphaeroides 2.4.1.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kaplan, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, 6431 Fannin St, Houston, TX 77030 USA.	samuel.kaplan@uth.tmc.edu			NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addlesee HA, 2000, J BACTERIOL, V182, P3175, DOI 10.1128/JB.182.11.3175-3182.2000; BOWYER JR, 1985, J BIOL CHEM, V260, P3295; Braatsch S, 2002, MOL MICROBIOL, V45, P827, DOI 10.1046/j.1365-2958.2002.03058.x; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BUGGY JJ, 1994, J BACTERIOL, V176, P6936, DOI 10.1128/JB.176.22.6936-6943.1994; CAO J, 1992, J BIOL CHEM, V267, P24273; CHORY J, 1983, J BACTERIOL, V153, P465, DOI 10.1128/JB.153.1.465-474.1983; Choudhary M, 2000, NUCLEIC ACIDS RES, V28, P862, DOI 10.1093/nar/28.4.862; COOMBER SA, 1992, MOL MICROBIOL, V6, P3159, DOI 10.1111/j.1365-2958.1992.tb01772.x; Daldal F, 2001, J BACTERIOL, V183, P2013, DOI 10.1128/JB.183.6.2013-2024.2001; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DONOHUE TJ, 1986, J BACTERIOL, V168, P953, DOI 10.1128/jb.168.2.953-961.1986; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; Eraso JM, 1996, J BACTERIOL, V178, P7037, DOI 10.1128/jb.178.24.7037-7046.1996; Eraso JM, 2000, BIOCHEMISTRY-US, V39, P2052, DOI 10.1021/bi9923858; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; Ermolenko DN, 2002, CELL MOL LIFE SCI, V59, P1902, DOI 10.1007/PL00012513; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; Gibson JL, 2002, J BACTERIOL, V184, P6654, DOI 10.1128/JB.184.23.6654-6664.2002; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; Gomelsky L, 2003, MICROBIOL-SGM, V149, P377, DOI 10.1099/mic.0.25972-0; GOMELSKY M, 1995, MICROBIOL-UK, V141, P1805, DOI 10.1099/13500872-141-8-1805; GOMELSKY M, 1995, J BACTERIOL, V177, P4609, DOI 10.1128/jb.177.16.4609-4618.1995; Gomelsky M, 1998, J BIOL CHEM, V273, P35319, DOI 10.1074/jbc.273.52.35319; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; Gomelsky M, 2000, J BACTERIOL, V182, P2253, DOI 10.1128/JB.182.8.2253-2261.2000; Gualerzi CO, 2003, J MOL BIOL, V331, P527, DOI 10.1016/S0022-2836(03)00732-0; HALLENBECK PL, 1990, J BACTERIOL, V172, P1749, DOI 10.1128/jb.172.4.1749-1761.1990; Horne IM, 1998, MICROBIOL-UK, V144, P2255, DOI 10.1099/00221287-144-8-2255; Hunter C N, 1982, Prog Clin Biol Res, V102 Pt B, P257; HUNTER CN, 1987, BIOCHEM J, V247, P489, DOI 10.1042/bj2470489; JENNEY FE, 1993, EMBO J, V12, P1283, DOI 10.1002/j.1460-2075.1993.tb05773.x; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KAPLAN S, 1982, PHOTOSYNTHETIC ENERG, P67; KILEY PJ, 1988, MICROBIOL REV, V52, P50, DOI 10.1128/MMBR.52.1.50-69.1988; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LEE JK, 1989, J BIOL CHEM, V264, P19354; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; LEE JK, 1993, J BIOL CHEM, V268, P24491; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LIN ECC, 1996, REGULATION GENE EXPR; MACGREGOR BJ, 1991, J BACTERIOL, V173, P3949, DOI 10.1128/jb.173.13.3949-3957.1991; Mackenzie C, 2001, PHOTOSYNTH RES, V70, P19, DOI 10.1023/A:1013831823701; Masuda S, 2002, CELL, V110, P613, DOI 10.1016/S0092-8674(02)00876-0; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; Mouncey NJ, 1998, J BACTERIOL, V180, P2228, DOI 10.1128/JB.180.8.2228-2231.1998; Mouncey NJ, 2000, FEMS MICROBIOL LETT, V192, P205, DOI 10.1111/j.1574-6968.2000.tb09383.x; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; NEIDLE EL, 1993, J BACTERIOL, V175, P2292, DOI 10.1128/JB.175.8.2292-2303.1993; OGara JP, 1997, J BACTERIOL, V179, P1951, DOI 10.1128/jb.179.6.1951-1961.1997; Oh JI, 1999, BIOCHEMISTRY-US, V38, P2688, DOI 10.1021/bi9825100; Oh JI, 2003, MICROBIOL-SGM, V149, P949, DOI 10.1099/mic.0.26010-0; Oh JI, 2001, J BACTERIOL, V183, P6807, DOI 10.1128/JB.183.23.6807-6814.2001; Oh JI, 2001, MOL MICROBIOL, V39, P1116, DOI 10.1046/j.1365-2958.2001.02299.x; Oh JI, 2000, J BACTERIOL, V182, P3081, DOI 10.1128/JB.182.11.3081-3087.2000; Oh JI, 2000, EMBO J, V19, P4237, DOI 10.1093/emboj/19.16.4237; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Porter SL, 2002, MOL MICROBIOL, V46, P1081, DOI 10.1046/j.1365-2958.2002.03218.x; Roh JH, 2002, J BACTERIOL, V184, P5330, DOI 10.1128/JB.184.19.5330-5338.2002; Romagnoli S, 2002, J BACTERIOL, V184, P5590, DOI 10.1128/JB.184.20.5590-5598.2002; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Sabaty M, 1996, J BACTERIOL, V178, P35, DOI 10.1128/jb.178.1.35-45.1996; SCHILKE BA, 1992, J MOL BIOL, V226, P101, DOI 10.1016/0022-2836(92)90127-6; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; SHAPLEIGH JP, 1992, J BACTERIOL, V174, P2338, DOI 10.1128/JB.174.7.2338-2343.1992; Shimada H, 1996, PLANT CELL PHYSIOL, V37, P515, DOI 10.1093/oxfordjournals.pcp.a028974; TAI SP, 1985, J BACTERIOL, V164, P181, DOI 10.1128/JB.164.1.181-186.1985; Toledo-Cuevas M, 1998, BBA-BIOENERGETICS, V1365, P421, DOI 10.1016/S0005-2728(98)00095-4; WARD MJ, 1995, MOL MICROBIOL, V17, P357, DOI 10.1111/j.1365-2958.1995.mmi_17020357.x; Wartmann T, 2001, CURR GENET, V40, P172, DOI 10.1007/s002940100254; Weber Michael H. W., 2003, Science Progress, V86, P9, DOI 10.3184/003685003783238707; Yakunin AF, 2001, CAN J MICROBIOL, V47, P206, DOI 10.1139/cjm-47-3-206; Yeliseev AA, 1996, J BACTERIOL, V178, P5877, DOI 10.1128/jb.178.20.5877-5883.1996; YELISEEV AA, 1995, J BIOL CHEM, V270, P21167, DOI 10.1074/jbc.270.36.21167; Yeliseev AA, 1999, J BIOL CHEM, V274, P21234, DOI 10.1074/jbc.274.30.21234; Yeliseev AA, 2000, J BIOL CHEM, V275, P5657, DOI 10.1074/jbc.275.8.5657; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; Zeilstra-Ryalls J, 1998, J BACTERIOL, V180, P2801, DOI 10.1128/JB.180.11.2801-2809.1998; Zeilstra-Ryalls JH, 1998, J BACTERIOL, V180, P1496, DOI 10.1128/JB.180.6.1496-1503.1998; ZEILSTRARYALLS JH, 1995, J BACTERIOL, V177, P6422, DOI 10.1128/jb.177.22.6422-6431.1995; Zeng XH, 2003, J BACTERIOL, V185, P6171, DOI 10.1128/JB.185.20.6171-6184.2003; Zeng XH, 2001, J BACTERIOL, V183, P6355, DOI 10.1128/JB.183.21.6355-6364.2001; ZHU YS, 1986, P NATL ACAD SCI USA, V83, P7613, DOI 10.1073/pnas.83.20.7613; ZHU YS, 1986, J BACTERIOL, V168, P1180, DOI 10.1128/jb.168.3.1180-1188.1986	87	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9146	9155		10.1074/jbc.M311608200	http://dx.doi.org/10.1074/jbc.M311608200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14662761	hybrid			2022-12-25	WOS:000189265900076
J	Basha, E; Lee, GJ; Breci, LA; Hausrath, AC; Buan, NR; Giese, KC; Vierling, E				Basha, E; Lee, GJ; Breci, LA; Hausrath, AC; Buan, NR; Giese, KC; Vierling, E			The identity of proteins associated with a small heat shock protein during heat stress in vivo indicates that these chaperones protect a wide range of cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; BACTERIAL INCLUSION-BODIES; SYNECHOCYSTIS PCC 6803; ESCHERICHIA-COLI; DENATURED PROTEINS; RIBOSOMAL-PROTEIN; BINDING PROTEIN; RNA; AGGREGATION; EXPRESSION	The small heat shock proteins (sHSPs) are a ubiquitous class of ATP-independent chaperones believed to prevent irreversible protein aggregation and to facilitate subsequent protein renaturation in cooperation with ATP-dependent chaperones. Although sHSP chaperone activity has been studied extensively in vitro, understanding the mechanism of sHSP function requires identification of proteins that are sHSP substrates in vivo. We have used both immunoprecipitation and affinity chromatography to recover 42 proteins that specifically interact with Synechocystis Hsp16.6 in vivo during heat treatment. These proteins can all be released from Hsp16.6 by the ATP-dependent activity of DnaK and cochaperones and are heat-labile. Thirteen of the putative substrate proteins were identified by mass spectrometry and reveal the potential for sHSPs to protect cellular functions as diverse as transcription, translation, cell signaling, and secondary metabolism. One of the putative substrates, serine esterase, was purified and tested directly for interaction with purified Hsp16.6. Hsp16.6 effectively formed soluble complexes with serine esterase in a heat-dependent fashion, thereby preventing formation of insoluble serine esterase aggregates. These data offer critical insights into the characteristics of native sHSP substrates and extend and provide in vivo support for the chaperone model of sHSP function.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@u.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018966, R01GM042762, F32GM016748] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM42762, F32-GM18966, F32-GM16748] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PN, 1991, CELL, V66, P141, DOI 10.1016/0092-8674(91)90146-P; Anderson P, 2002, J CELL SCI, V115, P3227; BECK SC, 1994, J BIOL CHEM, V269, P21803; Boelens WC, 2001, BBA-PROTEIN STRUCT M, V1544, P311, DOI 10.1016/S0167-4838(00)00243-0; Carrio MM, 2001, FEBS LETT, V489, P29, DOI 10.1016/S0014-5793(01)02073-7; Carrio MM, 2002, J BIOTECHNOL, V96, P3, DOI 10.1016/S0168-1656(02)00032-9; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Cuesta R, 2000, GENE DEV, V14, P1460; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Djabali K, 1997, J CELL SCI, V110, P2759; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FEN Y, 2001, J BIOL CHEM, V276, P31651; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Hallberg EM, 1996, CELL STRESS CHAPERON, V1, P70, DOI 10.1379/1466-1268(1996)001<0070:TTISC>2.3.CO;2; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Horvath I, 1998, P NATL ACAD SCI USA, V95, P3513, DOI 10.1073/pnas.95.7.3513; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; JINN TL, 1995, PLANT PHYSIOL, V108, P693, DOI 10.1104/pp.108.2.693; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; KAMPINGA HH, 1995, EXP CELL RES, V219, P536, DOI 10.1006/excr.1995.1262; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1998, METHOD ENZYMOL, V290, P350, DOI 10.1016/S0076-6879(98)90031-3; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lee SY, 1998, CURR MICROBIOL, V37, P403, DOI 10.1007/s002849900400; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; NEUMANN D, 1987, EUR J CELL BIOL, V43, P71; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Perng MD, 1999, J CELL SCI, V112, P2099; Persson BC, 1997, NUCLEIC ACIDS RES, V25, P4093, DOI 10.1093/nar/25.20.4093; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; Pfennig PL, 2001, MOL GENET GENOMICS, V266, P313, DOI 10.1007/s004380100559; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; Sugita C, 2000, MOL GEN GENET, V263, P655, DOI 10.1007/s004380051214; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Theriault JR, 1999, FEBS LETT, V452, P170, DOI 10.1016/S0014-5793(99)00634-1; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; van Thor JJ, 1998, PLANT MOL BIOL, V36, P353, DOI 10.1023/A:1005935819038; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	63	127	137	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7566	7575		10.1074/jbc.M310684200	http://dx.doi.org/10.1074/jbc.M310684200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662763	hybrid, Green Published			2022-12-25	WOS:000189103300025
J	Juszczak, LJ				Juszczak, LJ			Comparative vibrational spectroscopy of intracellular tau and extracellular collagen I reveals parallels of gelation and fibrillar structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; UV RESONANCE RAMAN; PROTEIN SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; EXCITATION PROFILES; CIRCULAR-DICHROISM; N-METHYLACETAMIDE; INFRARED-SPECTRA; ULTRAVIOLET; DEPENDENCE	The N-terminal tau 2-19 peptide undergoes gelation, syneresis, and aggregation over a period of years. These changes may be approximated on a shorter time scale by agitation and partial dehydration. The anomalously enhanced (229 nm) ultraviolet resonance Raman (UVRR) imide II band reveals a common structural feature for gels of nondehydrated tau 2-19 and collagen I and insoluble paired helical filaments (PHFs) and collagen I of weak hydrogen bonding at proline carbonyls. Anomalous UVRR enhancement of amide bands at 229 nm results from gel structure, as demonstrated by increased amide absorption at the red edge for tau 2-19 gel and implies the involvement of water in gel structure. In aged, dehydrated tau 2-19 gel, proline carbonyls lose their bonds to water and tyrosine becomes deprotonated, as demonstrated by UVRR spectroscopy. The Fourier transform infrared (FTIR) amide I band shows that antiparallel beta-sheet structure increases with syneresis in the tau 2-19 hydrogel. The comparison of FTIR results for PHFs with collagen I gel and polyproline demonstrates that the secondary structure of PHFs is polyproline II. One implication of this assignment is that the fibrillation of hydrophilic tau is thermodynamically driven by the entropy gained as hydrogen-bonded water is freed, as for collagen I. The FTIR results also show that peptide domains culled from a longer protein do not necessarily fold into identical secondary structures. A pathological, sequential mechanism of gelation, syneresis, and fibrillation for tau in AD is suggested and is supported by the observation of amorphous neurofibrillary tangle development and fibrillation in vivo.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Juszczak, LJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	juzak@aecom.yu.edu						Asher SA, 2001, J AM CHEM SOC, V123, P11775, DOI 10.1021/ja0039738; ASHER SA, 1986, J AM CHEM SOC, V108, P3186, DOI 10.1021/ja00272a005; Austin J. C., 1993, BIOMOLECULAR SPECT A, P55; Bhatnagar RS, 1996, CIRCULAR DICHROISM C, P183; BORNSTEIN P, 1974, ANNU REV BIOCHEM, V43, P567, DOI 10.1146/annurev.bi.43.070174.003031; BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984; Braak H, 1996, ACTA NEUROL SCAND, V93, P3; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brandt R, 2001, CELL TISSUE RES, V305, P255, DOI 10.1007/s004410000334; BUNKER C, 1990, SOL GEL SCI, P357; CAMPENOT RB, 1985, DEV BRAIN RES, V20, P149, DOI 10.1016/0165-3806(85)90099-9; CANTOR C, 1980, BIOPHYSICAL CHEM, V1, P95; Chan WC, 2000, FMOC SOLID PHASE PEP; Chi ZH, 1998, BIOCHEMISTRY-US, V37, P2854, DOI 10.1021/bi971160z; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; Cleary E., 1996, EXTRACELLULAR MATRIX, V1, P77; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CRICK FHC, 1950, EXP CELL RES, V1, P37, DOI 10.1016/0014-4827(50)90048-6; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; Danowski BA, 1998, CELL MOTIL CYTOSKEL, V40, P1; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; DiTella MC, 1996, J CELL SCI, V109, P467; DUDIK JM, 1985, J CHEM PHYS, V82, P1732, DOI 10.1063/1.448405; Farrell HM, 2002, J PROTEIN CHEM, V21, P307, DOI 10.1023/A:1019992900455; FERRY JD, 1948, ADV PROTEIN CHEM, V4, P1, DOI 10.1016/S0065-3233(08)60004-2; Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; Forgacs G, 2003, BIOPHYS J, V84, P1272, DOI 10.1016/S0006-3495(03)74942-X; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goux WJ, 2002, BIOCHEMISTRY-US, V41, P13798, DOI 10.1021/bi016079h; GUNDERSEN RW, 1988, J NEUROSCI RES, V21, P298, DOI 10.1002/jnr.490210222; HARADA L, 1986, SPECTROSCOPY BIOL SY, P113; HILDEBRANDT PG, 1988, BIOCHEMISTRY-US, V27, P5426, DOI 10.1021/bi00415a007; Hoffmann R, 1997, J PEPT RES, V50, P132; Holtz JSW, 2000, BIOPOLYMERS, V57, P55, DOI 10.1002/(SICI)1097-0282(2000)57:2<55::AID-BIP2>3.0.CO;2-B; INGBER DE, 1993, J CELL SCI, V104, P613; Iwaura R, 2002, CHEM MATER, V14, P3047, DOI 10.1021/cm020263n; JENNESS DD, 1976, BIOPOLYMERS, V15, P513, DOI 10.1002/bip.1976.360150308; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; Juszczak LJ, 1997, BIOCHEMISTRY-US, V36, P2227, DOI 10.1021/bi9622130; Juszczak LJ, 2002, BIOCHEMISTRY-US, V41, P376, DOI 10.1021/bi011212r; Juszczak LJ, 1998, J RAMAN SPECTROSC, V29, P963, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<963::AID-JRS332>3.0.CO;2-4; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Kiyonaka S, 2003, CHEM-EUR J, V9, P976, DOI 10.1002/chem.200390120; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Kucharz E. J., 1992, COLLAGENS BIOCH PATH; LAMOUREUX P, 1990, J CELL BIOL, V110, P71, DOI 10.1083/jcb.110.1.71; LAMOUREUX P, 1989, NATURE, V340, P156, DOI 10.1038/340159a0; Lockwood NA, 2002, BIOMACROMOLECULES, V3, P1225, DOI 10.1021/bm025573d; LORD RC, 1977, APPL SPECTROSC, V31, P187, DOI 10.1366/000370277774463706; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Mirkin NG, 2002, J PHYS CHEM A, V106, P3391, DOI 10.1021/jp012324v; MOONEY DJ, 1995, J CELL SCI, V108, P2311; MOONEY DJ, 1994, MOL BIOL CELL, V5, P1281, DOI 10.1091/mbc.5.12.1281; Ostrovskii D, 1999, MACROMOLECULES, V32, P5552, DOI 10.1021/ma9904969; Perez M, 1996, J NEUROCHEM, V67, P1183; PORTER KR, 1984, J CELL BIOL, V99, pS3, DOI 10.1083/jcb.99.1.3s; RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1; Ramirez G, 1999, BRAZ J MED BIOL RES, V32, P611, DOI 10.1590/S0100-879X1999000500015; Sadqi M, 2002, BIOCHEMISTRY-US, V41, P7150, DOI 10.1021/bi025777e; Schneider JP, 2002, J AM CHEM SOC, V124, P15030, DOI 10.1021/ja027993g; Shi ZS, 2002, P NATL ACAD SCI USA, V99, P9190, DOI 10.1073/pnas.112193999; SIMS JR, 1992, J CELL SCI, V103, P1215; Sokolov L, 1998, J PHYS CHEM B, V102, P8314, DOI 10.1021/jp982099q; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SU C, 1990, J RAMAN SPECTROSC, V21, P435, DOI 10.1002/jrs.1250210709; SUGAWARA Y, 1984, J MOL SPECTROSC, V108, P206, DOI 10.1016/0022-2852(84)90179-6; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1971, BIOPOLYMERS, V10, P1597, DOI 10.1002/bip.360100913; TAKEUCHI H, 1992, J AM CHEM SOC, V114, P5321, DOI 10.1021/ja00039a049; TAKEUCHI H, 1988, SPECTROCHIM ACTA A, V44, P749, DOI 10.1016/0584-8539(88)80138-7; TAKEUCHI H, 1990, J RAMAN SPECTROSC, V21, P509, DOI 10.1002/jrs.1250210807; TIFFANY ML, 1968, BIOPOLYMERS, V6, P1379, DOI 10.1002/bip.1968.360060911; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Tseng Y, 2002, J BIOL CHEM, V277, P18143, DOI 10.1074/jbc.M110868200; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VEIS A, 1996, EXTRACELLULAR MATRIX, P41; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wang DJ, 1998, BIOCHEMISTRY-US, V37, P9940, DOI 10.1021/bi980295h; WANG Y, 1991, J AM CHEM SOC, V113, P6368, DOI 10.1021/ja00017a003; WESTERMARK G, 1999, AMYLOID PRIONS OTHER; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884	89	30	31	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7395	7404		10.1074/jbc.M309971200	http://dx.doi.org/10.1074/jbc.M309971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660656	hybrid			2022-12-25	WOS:000189103300005
J	Mancini, F; Gentiletti, F; D'Angelo, M; Giglio, S; Nanni, S; D'Angelo, C; Farsetti, A; Citro, G; Sacchi, A; Pontecorvi, A; Moretti, F				Mancini, F; Gentiletti, F; D'Angelo, M; Giglio, S; Nanni, S; D'Angelo, C; Farsetti, A; Citro, G; Sacchi, A; Pontecorvi, A; Moretti, F			MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH ARREST; EMBRYONIC LETHALITY; CELLULAR-RESPONSE; UV-IRRADIATION; EXPRESSION; PROTEIN; CELLS; DEGRADATION; ACTIVATION; MICE	Rescue of embryonic lethality in MDM4(-/-) mice through concomitant loss of p53 has revealed a functional partnership between the two proteins. Biochemical studies have suggested that MDM4 may act as a negative regulator of p53 levels and activity. On the other hand, MDM4 overexpression has been reported to stabilize p53 levels and to counteract MDM2-degradative activity. We have investigated the functional role of MDM4 overexpression on cell behavior. In both established and primary cells cultured under stress conditions, overexpression of MDM4 significantly increased p53-dependent cell death, in correlation with enhanced induction of the endogenous p53 protein levels. This phenomenon was associated with induced p53 transcriptional activity and increased levels of the proapoptotic protein, Bax. Further, p53 stabilization was accompanied by decreased association of the protein to its negative regulator, MDM2. These findings reveal a novel role for MDM4 by demonstrating that in non-tumor cells under stress conditions it may act as a positive regulator of p53 activity, mainly by controlling p53 levels. They also indicate a major distinction between the biological consequences of MDM4 and MDM2 overexpression.	Regina Elena Inst Canc Res, Lab Mol Oncogenesis, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Lab Expt Chemotherapy, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Anim House Serv, I-00158 Rome, Italy; Catholic Univ, Inst Med Pathol, I-00100 Rome, Italy; CNR, Neurobiol & Mol Med Inst, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR)	Moretti, F (corresponding author), Regina Elena Inst Canc Res, Lab Mol Oncogenesis, Via Messi Oro 156, I-00158 Rome, Italy.	moretti@ifo.it	Carmen, D'Angelo/J-2639-2017; mancini, francesca/K-6062-2016; Moretti, Fabiola/I-5647-2013; Mancini, Francesca/AAZ-1672-2021; Farsetti, Antonella/I-8710-2018	mancini, francesca/0000-0002-2459-8815; Moretti, Fabiola/0000-0002-2691-1254; Mancini, Francesca/0000-0002-2459-8815; Farsetti, Antonella/0000-0002-8603-7925				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Candi E, 2002, J INVEST DERMATOL, V119, P670, DOI 10.1046/j.1523-1747.2002.01853.x; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finch RA, 2002, CANCER RES, V62, P3221; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Freedman DA, 1999, CANCER RES, V59, P1; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; LUNA RMD, 1995, NATURE, V378, P203; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Prives C, 1999, J PATHOL, V187, P112; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Wadhwa R, 1999, CELL RES, V9, P261, DOI 10.1038/sj.cr.7290025; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Yap DBS, 2000, J BIOL CHEM, V275, P37296, DOI 10.1074/jbc.M004359200; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516	68	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8169	8180		10.1074/jbc.M311793200	http://dx.doi.org/10.1074/jbc.M311793200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660608	hybrid			2022-12-25	WOS:000189103300098
J	Schmidt, M; Gerlach, F; Avivi, A; Laufs, T; Wystub, S; Simpson, JC; Nevo, E; Saaler-Reinhardt, S; Reuss, S; Hankeln, T; Burmester, T				Schmidt, M; Gerlach, F; Avivi, A; Laufs, T; Wystub, S; Simpson, JC; Nevo, E; Saaler-Reinhardt, S; Reuss, S; Hankeln, T; Burmester, T			Cytoglobin is a respiratory protein in connective tissue and neurons, which is up-regulated by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STELLATE CELL ACTIVATION; PROLYL 4-HYDROXYLASE; MESSENGER-RNA; NITRIC-OXIDE; OXYGEN; NEUROGLOBIN; GLOBIN; HEMOGLOBINS; EXPRESSION; TRANSPORT	Cytoglobin is a recently discovered vertebrate globin distantly related to myoglobin, and its function is unknown. Here we present the first detailed analysis of the distribution and expression of cytoglobin. Northern and Western blotting experiments show the presence of cytoglobin mRNA and protein in a broad range of tissues. Quantitative PCR demonstrates an up-regulation of cytoglobin mRNA levels in rat heart and liver under hypoxic conditions (22 and 44 h of 9% oxygen). Immunofluorescence studies with three antibodies directed against different epitopes of the protein consistently show cytoglobin in connective tissue fibroblasts as well as in hepatic stellate cells. Cytoglobin is also present in chondroblasts and osteoblasts and shows a decreased level of expression upon differentiation to chondrocytes and osteocytes. Cytoglobin is located in the cytoplasm of these cell types. Evidence against an exclusively nuclear localization of cytoglobin, as recently proposed, is also provided by transfection assays with green fluorescent protein fusion constructs, which demonstrates the absence of an active nuclear import. The differential expression of cytoglobin argues against a general respiratory function of this molecule, but rather indicates a connective tissue-specific function. We hypothesize that cytoglobin may be involved in collagen synthesis. Cytoglobin expression was also observed in some neuronal subpopulations of the central and the peripheral nervous systems. Surprisingly, cytoglobin is localized in both the cytoplasm and nucleus of neurons, indicating a possible additional role of this protein in neuronal tissues.	Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Anat, D-55099 Mainz, Germany; Univ Haifa, Inst Evolut, IL-31095 Haifa, Israel; European Mol Biol Lab, D-69117 Heidelberg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Haifa; European Molecular Biology Laboratory (EMBL)	Burmester, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Zool, Mullerweg 6, D-55099 Mainz, Germany.	burmeste@uni-mainz.de	Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863; Reuss, Stefan/0000-0003-1064-5067; Simpson, Jeremy/0000-0002-7956-7805				Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Asahina K, 2002, BBA-GENE STRUCT EXPR, V1577, P471, DOI 10.1016/S0167-4781(02)00477-3; Baroni GS, 1998, HEPATOLOGY, V27, P720; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; de Sanctis D, 2003, ACTA CRYSTALLOGR D, V59, P1285, DOI 10.1107/S0907444903009867; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; FALANGA V, 1993, J CELL PHYSIOL, V157, P408, DOI 10.1002/jcp.1041570225; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hardison R, 1998, J EXP BIOL, V201, P1099; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Horino Y, 2002, LIFE SCI, V71, P3031, DOI 10.1016/S0024-3205(02)02142-2; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kundu S, 2003, BIOPHYS J, V84, P3931, DOI 10.1016/S0006-3495(03)75121-2; LEONE AM, 1991, J BIOL CHEM, V266, P23790; Maher JJ, 1999, ALCOHOL CLIN EXP RES, V23, P917, DOI 10.1097/00000374-199905000-00022; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Merx Marc W., 2001, FASEB Journal, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Nieto N, 2002, J BIOL CHEM, V277, P9853, DOI 10.1074/jbc.M110506200; OSTADAL B, 1995, PHYSIOL RES, V44, P45; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; PIHLAJANIEMI T, 1991, J HEPATOL, V13, pS2, DOI 10.1016/0168-8278(91)90002-S; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; ROGERS AW, 1983, CELLS TISSUES INTRO; Sawai H, 2003, BIOCHEMISTRY-US, V42, P5133, DOI 10.1021/bi027067e; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; Spagnoli FM, 1998, J CELL BIOL, V143, P1101, DOI 10.1083/jcb.143.4.1101; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; YEN EHK, 1979, BIOCHEM J, V178, P605, DOI 10.1042/bj1780605	41	183	204	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8063	8069		10.1074/jbc.M310540200	http://dx.doi.org/10.1074/jbc.M310540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660570	hybrid			2022-12-25	WOS:000189103300085
J	Franz, CM; Ridley, AJ				Franz, CM; Ridley, AJ			p120 catenin associates with microtubules - Inverse relationship between microtubule binding and Rho GTPase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; CELL-CELL ADHESION; CADHERIN CYTOPLASMIC DOMAIN; MEMBRANE-PROXIMAL REGION; EPITHELIAL-CELLS; DELTA-CATENIN; ACTIN CYTOSKELETON; FAMILY GTPASES; PROTEIN; P120(CTN)	p120 catenin (p120ctn), an armadillo protein and component of the cadherin adhesion complex, has been found recently to induce a dendritic morphology by regulating Rho family GTPases. We have identified specific serines within the Arm repeat domain that, when mutated to alanine, promote p120ctn association with interphase microtubules, leading to microtubule reorganization and stabilization. The mutant p120ctn also localized to the mitotic spindle and centrosomes. In contrast to wild-type p120ctn, the microtubule-associated p120ctn mutant did not activate Rac1 and did not induce a dendritic morphology. In addition, we show that a basic motif within the p120ctn Arm repeat domain known to be required for the inhibition of RhoA is also required for binding to microtubules. We therefore propose that binding of p120ctn to microtubules is inversely related to its ability to regulate Rho GTPases.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk		Ridley, Anne/0000-0001-8186-5708; Franz, Clemens/0000-0003-0104-4841				Albertinazzi C, 1999, J CELL SCI, V112, P3821; Allan V, 2001, NAT CELL BIOL, V3, pE226, DOI 10.1038/ncb1001-e226; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chauvet N, 2003, MOL CELL NEUROSCI, V22, P467, DOI 10.1016/S1044-7431(03)00030-7; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; DOWNING JR, 1991, ONCOGENE, V6, P607; FALCONER MM, 1989, CELL MOTIL CYTOSKEL, V12, P169, DOI 10.1002/cm.970120306; FERREIRA A, 1989, DEV BRAIN RES, V49, P205, DOI 10.1016/0165-3806(89)90022-9; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grosheva I, 2001, J CELL SCI, V114, P695; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kim K, 2002, EXP CELL RES, V275, P171, DOI 10.1006/excr.2002.5503; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; LEE G, 1992, J CELL SCI, V102, P227; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Lu Q, 2002, J NEUROSCI RES, V67, P618, DOI 10.1002/jnr.10151; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Ratcliffe MJ, 1997, J BIOL CHEM, V272, P31894, DOI 10.1074/jbc.272.50.31894; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Shea TB, 1999, BRAIN RES BULL, V48, P255, DOI 10.1016/S0361-9230(98)00019-7; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Thompson AJ, 2003, ANAL CHEM, V75, P3232, DOI 10.1021/ac034134h; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; WEBSTER DR, 1989, J CELL SCI, V92, P57; WEBSTER DR, 1987, J CELL BIOL, V105, P265, DOI 10.1083/jcb.105.1.265; Winkler AA, 1998, YEAST, V14, P37, DOI 10.1002/(SICI)1097-0061(19980115)14:1<37::AID-YEA198>3.3.CO;2-U; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	58	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6588	6594		10.1074/jbc.M312812200	http://dx.doi.org/10.1074/jbc.M312812200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660598	hybrid			2022-12-25	WOS:000188969200047
J	Kloeker, S; Major, MB; Calderwood, DA; Ginsberg, MH; Jones, DA; Beckerle, MC				Kloeker, S; Major, MB; Calderwood, DA; Ginsberg, MH; Jones, DA; Beckerle, MC			The kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE FORMATION; EPITHELIAL-CELL PLASTICITY; MESENCHYMAL TRANSDIFFERENTIATION; ACTIN CYTOSKELETON; FOCAL ADHESIONS; SWISS-MODEL; FERM DOMAIN; EXPRESSION; BINDING	Transforming growth factor-beta1 (TGF-beta1) contributes to tumor invasion and cancer progression by increasing the motility of tumor cells. To identify genes involved in TGF-beta-mediated cell migration, the transcriptional profiles of human mammary epithelial cells (HMEC) treated with TGF-beta were compared with untreated cells by cDNA microarray analysis. One gene up-regulated by TGF-beta was recently named kindlerin (Jobard, F., Bouadjar, B., Caux, F., Hadj-Rabia, S., Has, C., Matsuda, F., Weissenbach, J., Lathrop, M., Prud'homme, J. F., and Fischer, J. (2003) Hum. Mol. Genet. 12, 925-935). This gene is significantly overexpressed in some cancers (Weinstein, E. J., Bourner, M., Head, R., Zakeri, H., Bauer, C., and Mazzarella, R. (2003) Biochim. Biophys. Acta 1637, 207-216), and mutations in this gene lead to Kindler syndrome, an autosomal-recessive genodermatosis. TGF-beta stimulation of HMEC resulted in a marked induction of kindlerin RNA, and Western blotting demonstrated a corresponding increase in protein abundance. Kindlerin displays a putative FERM (four point one ezrin radixin moesin) domain that is closely related to the sequences in talin that interact with integrin beta subunit cytoplasmic domains. The critical residues in the talin FERM domain that mediate integrin binding show a high degree of conservation in kindlerin. Furthermore, kindlerin is recruited into a molecular complex with the beta(1A) and beta(3) integrin cytoplasmic domains. Consistent with these biochemical findings, kindlerin is present at focal adhesions, sites of integrin-rich, membrane-substratum adhesion. Additionally, kindlerin is required for normal cell spreading. Taken together, these data suggest a role for kindlerin in mediating cell processes that depend on integrins.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Dept Biol, Salt Lake City, UT 84112 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Scripps Research Institute	Beckerle, MC (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	mary.beekerle@hci.utah.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142; Major, Michael/0000-0002-6753-8513	NCI NIH HHS [CA42014, T32 CA93247] Funding Source: Medline; NHLBI NIH HHS [HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM050877, GM50877] Funding Source: Medline; PHS HHS [F32 20457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014, T32CA093247] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akimov SS, 2001, J CELL SCI, V114, P2989; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Bellone G, 2001, EUR J CANCER, V37, P224, DOI 10.1016/S0959-8049(00)00391-9; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boland S, 1996, J CELL SCI, V109, P2207; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V; Claisse D, 1999, J CELL SCI, V112, P1405; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Ellenrieder V, 2001, CANCER RES, V61, P4222; FORMAN AB, 1989, PEDIATR DERMATOL, V6, P91, DOI 10.1111/j.1525-1470.1989.tb01004.x; Furuyama A, 1999, EUR J CELL BIOL, V78, P867, DOI 10.1016/S0171-9335(99)80088-0; GARBI C, 1990, EUR J CELL BIOL, V53, P281; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GATES RE, 1993, BIOCHEM J, V289, P221, DOI 10.1042/bj2890221; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; GERWIN BI, 1990, AM J PHYSIOL, V259, pL262, DOI 10.1152/ajplung.1990.259.4.L262; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haber RM, 1996, ARCH DERMATOL, V132, P1487, DOI 10.1001/archderm.132.12.1487; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HORIBA K, 1994, VIRCHOWS ARCH, V425, P425; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jobard F, 2003, HUM MOL GENET, V12, P925, DOI 10.1093/hmg/ddg097; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; KINDLER T, 1954, BRIT J DERMATOL, V66, P104, DOI 10.1111/j.1365-2133.1954.tb12598.x; Koivisto L, 1999, CELL ADHES COMMUN, V7, P245, DOI 10.3109/15419069909010806; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Miller GS, 1997, COMPUT APPL BIOSCI, V13, P81; Nguyen NM, 2002, AM J PHYSIOL-LUNG C, V282, pL1004, DOI 10.1152/ajplung.00379.2001; Niessen CM, 1996, J CELL SCI, V109, P1695; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pulkkinen L, 1997, HUM MOL GENET, V6, P669, DOI 10.1093/hmg/6.5.669; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; RAHILLY MA, 1991, J PATHOL, V165, P163, DOI 10.1002/path.1711650212; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shimizu H, 1997, ARCH DERMATOL, V133, P1111, DOI 10.1001/archderm.133.9.1111; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; STAMPFER MR, 1993, J CELL PHYSIOL, V155, P210, DOI 10.1002/jcp.1041550127; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Weinstein EJ, 2003, BBA-MOL BASIS DIS, V1637, P207, DOI 10.1016/S0925-4439(03)00035-8; Yi JY, 2002, EUR J CELL BIOL, V81, P457, DOI 10.1078/0171-9335-00265; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	67	130	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6824	6833		10.1074/jbc.M307978200	http://dx.doi.org/10.1074/jbc.M307978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14634021	hybrid			2022-12-25	WOS:000188969200076
J	Tyurina, YY; Serinkan, FB; Tyurin, VA; Kini, V; Yalowich, JC; Schroit, AJ; Fadeel, B; Kagan, VE				Tyurina, YY; Serinkan, FB; Tyurin, VA; Kini, V; Yalowich, JC; Schroit, AJ; Fadeel, B; Kagan, VE			Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DOSE ETOPOSIDE; FREE-RADICALS; HL-60 CELLS; HYDROGEN-PEROXIDE; STRESS; PHAGOCYTOSIS; RECOGNITION; EXPOSURE; MITOCHONDRIA; METABOLISM	Apoptosis is associated with the externalization of phosphatidylserine (PS) in the plasma membrane and subsequent recognition of PS by specific macrophage receptors. Selective oxidation of PS precedes its externalization/ recognition and is essential for the PS-dependent engulfment of apoptotic cells. Because etoposide is a potent and selective lipid antioxidant that does not block thiol oxidation, we hypothesized that it may affect PS externalization/ recognition without affecting other features of the apoptotic program. We demonstrate herein that etoposide induced apoptosis in HL-60 cells without the concomitant peroxidation of PS and other phospholipids. HL-60 cells also failed to externalize PS in response to etoposide treatment. In contrast, oxidant (H2O2)-induced apoptosis was accompanied by PS externalization and oxidation of different phospholipids, including PS. Etoposide potentiated H2O2-induced apoptosis but completely blocked H2O2-induced PS oxidation. Etoposide also inhibited PS externalization as well as phagocytosis of apoptotic cells by J774A.1 macrophages. Integration of exogenous PS or a mixture of PS with oxidized PS in etoposide-treated HL-60 cells reconstituted the recognition of these cells by macrophages. The current data demonstrate that lipid antioxidants, capable of preventing PS peroxidation, can block PS externalization and phagocytosis of apoptotic cells by macrophages and hence dissociate PS-dependent signaling from the final common pathway for apoptosis.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Canc Res Inst, Pittsburgh, PA 15260 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Karolinska Inst, Div Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Karolinska Institutet	Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA.	kagan@pitt.edu		Tyurin, Vladimir/0000-0002-3474-1697; Yalowich, Jack/0000-0001-5414-573X; Tyurina, Yulia/0000-0003-0287-2091	NCI NIH HHS [CA90787] Funding Source: Medline; NHLBI NIH HHS [HL70755] Funding Source: Medline; NIGMS NIH HHS [GM64610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090787] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson HA, 2002, CELL DEATH DIFFER, V9, P616, DOI 10.1038/sj.cdd.4401013; Arroyo A, 2002, J BIOL CHEM, V277, P49965, DOI 10.1074/jbc.M204513200; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Fadeel B, 2003, REDOX REP, V8, P143, DOI 10.1179/135100003225001511; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Ferraro-Peyret C, 2002, J IMMUNOL, V169, P4805, DOI 10.4049/jimmunol.169.9.4805; FLEMING RA, 1989, CLIN PHARMACY, V8, P274; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frey T, 1997, CYTOMETRY, V28, P253, DOI 10.1002/(SICI)1097-0320(19970701)28:3<253::AID-CYTO10>3.0.CO;2-O; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; GRECO FA, 1991, CANCER, V67, P303; HAIM N, 1987, CANCER RES, V47, P5835; Hainsworth JD, 1999, DRUGS, V58, P51, DOI 10.2165/00003495-199958003-00008; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HANDE KR, 1992, SEMIN ONCOL, V19, P3; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 2001, CANCER RES, V61, P7777; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; Kagan VE, 1999, MOL PHARMACOL, V56, P494, DOI 10.1124/mol.56.3.494; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5; KALYANARAMAN B, 1989, BIOCHEMISTRY-US, V28, P4839, DOI 10.1021/bi00437a048; Kanfer EJ, 1998, BRIT J CANCER, V78, P928, DOI 10.1038/bjc.1998.603; Kawagishi C, 2001, BBA-MOL CELL RES, V1541, P221, DOI 10.1016/S0167-4889(01)00158-6; Le Deley MC, 2003, J CLIN ONCOL, V21, P1074, DOI 10.1200/JCO.2003.04.100; MANS DRA, 1992, BIOCHEM PHARMACOL, V43, P1761, DOI 10.1016/0006-2952(92)90708-Q; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Myzak MC, 2002, REDOX REP, V7, P47, DOI 10.1179/135100002125000181; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; Packer L, 2002, SKIN PHARMACOL APPL, V15, P282, DOI 10.1159/000064531; Persson HL, 2001, REDOX REP, V6, P327, DOI 10.1179/135100001101536472; Pham NA, 2001, EXP CELL RES, V264, P345, DOI 10.1006/excr.2000.5148; Pucci G, 1998, BRIT J HAEMATOL, V100, P612; Puskas F, 2002, ANTIOXID REDOX SIGN, V4, P357, DOI 10.1089/15230860260196164; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Ramirez CD, 2002, APOPTOSIS, V7, P59, DOI 10.1023/A:1013564928999; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Savill J, 1997, BRIT MED BULL, V53, P491; Schroeder PE, 2003, CANCER CHEMOTH PHARM, V52, P167, DOI 10.1007/s00280-003-0619-7; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; Shvedova AA, 2000, J INVEST DERMATOL, V114, P354, DOI 10.1046/j.1523-1747.2000.00865.x; Shvedova AA, 2002, J INVEST DERMATOL, V118, P1008, DOI 10.1046/j.1523-1747.2002.01759.x; Tyurina YY, 2002, METHOD ENZYMOL, V352, P159; Tyurina YY, 2000, TOXICOLOGY, V148, P93, DOI 10.1016/S0300-483X(00)00199-2; USUI N, 1990, FREE RADICAL RES COM, V10, P287, DOI 10.3109/10715769009149897; Uthaisang W, 2003, FEBS LETT, V545, P110, DOI 10.1016/S0014-5793(03)00508-8; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017	61	65	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6056	6064		10.1074/jbc.M309929200	http://dx.doi.org/10.1074/jbc.M309929200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630936	hybrid			2022-12-25	WOS:000188776500121
J	Zoccarato, F; Cavallini, L; Alexandre, A				Zoccarato, F; Cavallini, L; Alexandre, A			Respiration-dependent removal of exogenous H2O2 in brain mitochondria - Inhibition by Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE PRODUCTION; ELECTRON-TRANSPORT CHAIN; HEART-MITOCHONDRIA; PARKINSONS-DISEASE; SUPEROXIDE ANIONS; RAT-HEART; GENERATION; GLUTATHIONE; CALCIUM; UBISEMIQUINONE	In brain mitochondria, state 4 respiration supported by the NAD-linked substrates glutamate/malate in the presence of EGTA promotes a high rate of exogenous H2O2 removal. Omitting EGTA decreases the H2O2 removal rate by almost 80%. The decrease depends on the influx of contaminating Ca2+, being prevented by the Ca2+ uniporter inhibitor ruthenium red. Arsenite is also an inhibitor (maximal effect similar to40%, IC50, 12 muM). The H2O2 removal rate (EGTA present) is decreased by 20% during state 3 respiration and by 60-70% in fully uncoupled conditions. H2O2 removal in mitochondria is largely dependent on glutathione peroxidase and glutathione reductase. Both enzyme activities, as studied in disrupted mitochondria, are inhibited by Ca2+. Glutathione reductase is decreased by 70% with an IC50 of about 0.9 muM, and glutathione peroxidase is decreased by 38% with a similar IC50. The highest Ca2+ effect with glutathione reductase is observed in the presence of low concentrations of H2O2. With succinate as substrate, the removal is 50% less than with glutamate/malate. This appears to depend on succinate-supported production of H2O2 by reverse electron flow at NADH dehydrogenase competing with exogenous H2O2 for removal. Succinate-dependent H2O2 is inhibited by rotenone, decreased DeltaPsi, as described previously, and by ruthenium red and glutamate/malate. These agents also increase the measured rate of exogenous H2O2 removal with succinate. Succinate-dependent H2O2 generation is also inhibited by contaminating Ca2+. Therefore, Ca2+ acts as an inhibitor of both H2O2 removal and the succinate-supported H2O2 production. It is concluded that mitochondria function as intracellular Ca2+-modulated peroxide sinks.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Consiglio Nazl Ric, Unit Study Biomembranes, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Zoccarato, F (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	franco.zoccarato@unipd.it						AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Jenner P, 2001, TRENDS NEUROSCI, V24, P245, DOI 10.1016/S0166-2236(00)01789-6; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Rhee S.G., 2000, SCI STKE; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; SANDRI G, 1990, BIOCHIM BIOPHYS ACTA, V1035, P300, DOI 10.1016/0304-4165(90)90092-B; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Staniek K, 2000, BBA-BIOENERGETICS, V1460, P268, DOI 10.1016/S0005-2728(00)00152-3; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; XIA Y, 1985, J NUTR, V115, P733, DOI 10.1093/jn/115.6.733; ZOCCARATO F, 1988, BIOCHEM BIOPH RES CO, V154, P727, DOI 10.1016/0006-291X(88)90200-8; ZOCCARATO F, 1989, EUR J BIOCHEM, V180, P473, DOI 10.1111/j.1432-1033.1989.tb14670.x	36	108	110	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4166	4174		10.1074/jbc.M308143200	http://dx.doi.org/10.1074/jbc.M308143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14634020	hybrid			2022-12-25	WOS:000188554300032
J	Sugihara, E; Kanai, M; Matsui, A; Onodera, M; Schwab, M; Miwa, M				Sugihara, E; Kanai, M; Matsui, A; Onodera, M; Schwab, M; Miwa, M			Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells	ONCOGENE			English	Article						MYCN; centrosome; micronuclei; DNA damage	GENETIC INSTABILITY; N-MYC; AMPLIFICATION; CYCLE; P53; OVERDUPLICATION; ABNORMALITIES; DUPLICATION; DEFECTS; ABSENCE	Centrosomes play important roles in cell polarity, regulation of cell cycle and chromosomal stability. Centrosome abnormality is frequently found in many cancers and contributes to chromosomal instability (including aneuploidy, tetraploidy, and/or micronuclei) in daughter cells through the assembly of multipolar or monopolar spindles during mitosis. It has recently been reported that loss of tumor suppressor genes or overexpression of oncogenes causes centrosome hyperamplification. Amplification and overexpression of the MYCN oncogene is found in a subgroup of neuroblastomas. In this study, we examined whether overexpression of MYCN causes centrosome hyperamplification in neuroblastoma cells. We show that ectopic expression of MYCN alone in a neuroblastoma cell line did not cause centrosome hyperamplification. However, centrosome hyperamplification and micronuclei formation were seen in these cells after DNA damage. These findings suggest that overexpression of MYCN abrogates the regulation of the centrosome cycle after DNA damage.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem & Mol Oncol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 305, Japan; Deutsch Krebsforschungszentrum, Dept Tumour Genet B030, D-69120 Heidelberg, Germany; Univ Tsukuba, Inst Clin Med, Dept Hematol, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; University of Tsukuba; Helmholtz Association; German Cancer Research Center (DKFZ); University of Tsukuba	Miwa, M (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem & Mol Oncol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	m-miwa@md.tsukuba.ac.jp	Sugihara, Eiji/J-8058-2013	Sugihara, Eiji/0000-0002-3233-1045				BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lutz W, 1996, ONCOGENE, V13, P803; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Pihan GA, 1998, CANCER RES, V58, P3974; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Sato N, 1999, CLIN CANCER RES, V5, P963; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Suzuki A, 2002, J NEUROCHEM, V82, P953, DOI 10.1046/j.1471-4159.2002.01048.x; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	33	15	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1005	1009		10.1038/sj.onc.1207216	http://dx.doi.org/10.1038/sj.onc.1207216			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647433				2022-12-25	WOS:000188486600017
J	Smith, SL; Watson, SG; Ratschiller, D; Gugger, M; Betticher, DC; Heighway, J				Smith, SL; Watson, SG; Ratschiller, D; Gugger, M; Betticher, DC; Heighway, J			Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions	ONCOGENE			English	Article						serpin; maspin; immunohistochemistry; lung cancer; preneoplastic	CELL CARCINOMA ANTIGEN; TUMOR-SUPPRESSOR; BREAST-CANCER; OVEREXPRESSION; INHIBITION; P53; METASTASIS; EPITHELIA; HEADPIN	Maspin, SCCA1/2 and hurpin were identified by cDNA microarray analyses as dramatically differentially expressed transcripts in primary non-small cell lung cancer (NSCLC). These sequences are located within a 10-gene serpin cluster on 18q21.3. Using comparative RT-PCR, we have investigated the expression of each of these serpins, including their flanking loci, in an independent NSCLC series. Whereas six of the genes (maspin, SCCA1, SCCA2, hurpin, megsin and pAI-2) were commonly differentially expressed in primary lesions, each significantly more often in squamous cell tumours, maspin was identified as the most frequently over-represented sequence in both squamous cell carcinoma and adenocarcinoma. Using a well-characterized monoclonal antibody, we have shown strong maspin expression in tumour protein extracts, detected multiple isoforms of the 42 kDa protein and shown that maspin is localized specifically to the tumour cells within neoplastic lesions. In contrast, most cells in non-neoplastic lung tissue appear not to express the gene, with the exception of the multipotent basal epithelial cells that line the bronchial airway. These reserve cells generally show strong predominantly nuclear localization of maspin. Strong nuclear expression of maspin within primary tumour cells is correlated with increased survival (P = 0.05) and a longer remission duration (P = 0.02) in resectable-staged patients. However, within the airways of cancer patients and somewhat in contrast to this observation, such expression was more frequently detected in the superficial cells of preneoplastic over non-neoplastic epithelia (P < 0.0001), consistent with a role for the protein in early neoplasia.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, Liverpool L3 9TA, Merseyside, England; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland	University of Liverpool; University of Bern	Heighway, J (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, 200 London Rd, Liverpool L3 9TA, Merseyside, England.	heighwayj@roycastle.liv.ac.uk	Betticher, Daniel C/G-5849-2013					Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Betticher DC, 1997, BRIT J CANCER, V75, P1761, DOI 10.1038/bjc.1997.300; Biliran H, 2001, CANCER RES, V61, P8676; Borner MM, 1999, BRIT J CANCER, V79, P952, DOI 10.1038/sj.bjc.6690152; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; Champelovier P, 2001, EUR UROL, V39, P343, DOI 10.1159/000052465; Duggan C, 1997, BRIT J CANCER, V76, P622, DOI 10.1038/bjc.1997.435; Fujita T, 1999, INT J ONCOL, V15, P927; HAMADA K, 2001, BIOCHIM BIOPHYS ACTA, V19, P124; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; Heighway Jim, 2003, Methods Mol Med, V75, P291; Jayakumar A, 2003, ARCH BIOCHEM BIOPHYS, V409, P367, DOI 10.1016/S0003-9861(02)00635-5; Kato H., 1992, SEROLOGICAL CANC MAR, P437; Kishimoto H, 2001, INT J ONCOL, V18, P297; Maass N, 2001, J PATHOL, V195, P321; Maass N, 2001, CLIN BIOCHEM, V34, P303, DOI 10.1016/S0009-9120(01)00220-X; Miyata T, 2002, J CLIN INVEST, V109, P585, DOI 10.1172/JCI200214336; Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; Murakami A, 2000, TUMOR BIOL, V21, P224, DOI 10.1159/000030128; Nakashima T, 2000, BBA-GENE STRUCT EXPR, V1492, P441, DOI 10.1016/S0167-4781(00)00100-7; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Pierson CR, 2002, PROSTATE, V53, P255, DOI 10.1002/pros.10107; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ratschiller D, 2003, J CLIN ONCOL, V21, P2085, DOI 10.1200/JCO.2003.03.103; Reis JS, 2002, J PATHOL, V197, P272, DOI 10.1002/path.1104; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shi HY, 2001, CANCER RES, V61, P6945; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Stenman J, 2001, INT J CANCER, V95, P39, DOI 10.1002/1097-0215(20010120)95:1<39::AID-IJC1007>3.0.CO;2-N; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; Travis WD, 1999, HISTOLOGICAL TYPING; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; Yasumatsu R, 2001, HEAD NECK-J SCI SPEC, V23, P962, DOI 10.1002/hed.1139; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	60	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8677	8687		10.1038/sj.onc.1207127	http://dx.doi.org/10.1038/sj.onc.1207127			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647462				2022-12-25	WOS:000186844900005
J	Galang, CK; Muller, WJ; Foos, G; Oshima, RG; Hauser, CA				Galang, CK; Muller, WJ; Foos, G; Oshima, RG; Hauser, CA			Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; HUMAN BREAST-CANCER; PEA3 SUBFAMILY; MOUSE MODEL; ACTIVATE; PROTEIN; EPITHELIUM; INVASION; DOMAIN; RAS	Interfering with Ets transcription factor function reverses multiple aspects of the transformed phenotype of mouse or human tumor cells. However, the unknown number of individual Ets factors expressed in any cellular context and the similar DNA binding specificities of Ets family members complicates the identification of those that mediate transformation. By utilizing quantitative PCR assays for 25 mouse Ets factors, we analyzed the expression of essentially the entire Ets family in normal mammary tissue, mammary-related cell lines, and mammary tumors. In normal mammary tissue, 24 Ets factors were expressed. Even clonal derived cell lines expressed 14-20 Ets members. The most abundant Ets factor mRNAs measured in normal mammary tissue were Elk4, Elf1, and Ets2. Subtractive analysis of mammary tissue identified which Ets factors were predominantly expressed in the myeloid/lymphoid or epithelial cell compartments. Comparison of Ets factor expression in normal mammary tissue and mammary tumors identified significantly elevated expression of Pse/ PDEF, Ese2/Elf5, Ese3/Ehf, TEL/Etv6, and Elf2/NERF in mammary tumors and confirmed previously reported alterations in expression of Ese1/Elf3 and the PEA3 subfamily. Expression of 13 Ets target genes, implicated in various aspects of tumor progression, was also analyzed. Altered expression of particular Ets target genes was significantly correlated with particular Ets factors (e. g. maspin and Ese2), suggesting specific in vivo regulatory roles. Together, this comprehensive analysis revealed unexpectedly diverse Ets family gene expression, characterized novel Ets factor changes in mammary tumors, and implicated specific Ets factors in the regulation of multiple genes involved in mammary tumor progression.	Burnham Inst, La Jolla Canc Res Ctr, Oncodev Biol Program, La Jolla, CA 92037 USA; McGill Univ, Mol Oncol Labs, Montreal, PQ H3A 1A5, Canada	Sanford Burnham Prebys Medical Discovery Institute; McGill University	Hauser, CA (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chauser@burnham.org			NCI NIH HHS [CA30199, CA63130, CA74547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA063130, R01CA074547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen JH, 1996, ONCOGENE, V13, P1667; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Curry J, 2002, BIOTECHNIQUES, V32, P768, DOI 10.2144/02324st02; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Nigris F, 2001, CANCER RES, V61, P2267; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Deprez RHL, 2002, ANAL BIOCHEM, V307, P63, DOI 10.1016/S0003-2697(02)00021-0; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; Feldman RJ, 2003, CANCER RES, V63, P4626; Feroze-Merzoug F, 2002, BIOTECHNIQUES, V32, P776, DOI 10.2144/02324st03; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Foos G, 2000, ONCOGENE, V19, P5507, DOI 10.1038/sj.onc.1203946; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graven KK, 1999, BBA-GENE STRUCT EXPR, V1447, P208, DOI 10.1016/S0167-4781(99)00118-9; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hever A, 2003, EXP CELL RES, V290, P132, DOI 10.1016/S0014-4827(03)00315-X; Hogan B, 1994, MANIPULATING MOUSE E; Kleinbaum LA, 1999, BIOCHEM BIOPH RES CO, V264, P119, DOI 10.1006/bbrc.1999.1493; LALLI E, 1992, ANAL BIOCHEM, V207, P298, DOI 10.1016/0003-2697(92)90015-Y; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lopez RG, 2003, J BIOL CHEM, V278, P41316, DOI 10.1074/jbc.M306435200; LU S, 2003, BIOCHIM BIOPHYS ACTA, V1574, P152; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Mitas M, 2002, BRIT J CANCER, V86, P899, DOI 10.1038/sj.bjc.6600190; Netzer S, 2002, TRANSGENIC RES, V11, P123, DOI 10.1023/A:1015248525364; Neznanov N, 1999, CANCER RES, V59, P4242; Nozawa M, 2000, CANCER RES, V60, P1348; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; Rozen S, 2000, Methods Mol Biol, V132, P365; Sapi E, 1998, CANCER RES, V58, P1027; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Singh S, 2002, CURR DRUG TARGETS, V3, P359, DOI 10.2174/1389450023347489; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Xuan ZY, 2002, GENOME RES, V12, P1142, DOI 10.1101/gr.220102; Young LJT, 2000, METHODS MAMMARY GLAN, P67; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198	73	107	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11281	11292		10.1074/jbc.M311887200	http://dx.doi.org/10.1074/jbc.M311887200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14662758	hybrid			2022-12-25	WOS:000220157600056
J	Hirotsu, S; Chu, GC; Unno, M; Lee, DS; Yoshida, T; Park, SY; Shiro, Y; Ikeda-Saito, M				Hirotsu, S; Chu, GC; Unno, M; Lee, DS; Yoshida, T; Park, SY; Shiro, Y; Ikeda-Saito, M			The crystal structures of the ferric and ferrous forms of the heme complex of HmuO, a heme oxygenase of Corynebacterium diphtheriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; GRAM-NEGATIVE BACTERIA; OXIDATIVE CLEAVAGE; ACTIVE-SITE; DEGRADATION; MECHANISM; PRODUCT; SYSTEM; LIGAND; GENE	Crystal structures of the ferric and ferrous heme complexes of HmuO, a 24-kDa heme oxygenase of Corynebacterium diphtheriae, have been refined to 1.4 and 1.5 Angstrom resolution, respectively. The HmuO structures show that the heme group is closely sandwiched between the proximal and distal helices. The imidazole group of His-20 is the proximal heme ligand, which closely eclipses the beta- and delta-meso axis of the porphyrin ring. A long range hydrogen bonding network is present, connecting the iron-bound water ligand to the solvent water molecule. This enables proton transfer from the solvent to the catalytic site, where the oxygen activation occurs. In comparison to the ferric complex, the proximal and distal helices move closer to the heme plane in the ferrous complex. Together with the kinked distal helix, this movement leaves only the alpha-meso carbon atom accessible to the iron-bound dioxygen. The heme pocket architecture is responsible for stabilization of the ferric hydroperoxo-active intermediate by preventing premature heterolytic O-O bond cleavage. This allows the enzyme to oxygenate selectively at the alpha-meso carbon in HmuO catalysis.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan; RIKEN Harima inst, Inst Phys & Chem Res, Sayo, Hyogo 6795143, Japan	Tohoku University; Case Western Reserve University; Yamagata University; RIKEN	Ikeda-Saito, M (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.	mis2@tagen.tohoku.ac.jp	Shiro, Yoshitsugu Y/J-3757-2014; Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Shiro, Yoshitsugu Y/0000-0003-0695-8327; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057272] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57272] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chu GC, 1999, J STRUCT BIOL, V126, P171, DOI 10.1006/jsbi.1999.4122; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Chu GC, 2000, J BIOL CHEM, V275, P17494, DOI 10.1074/jbc.M000830200; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Friedman J, 2003, J BIOL CHEM, V278, P34654, DOI 10.1074/jbc.M302985200; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; Li YM, 2003, J BIOL CHEM, V278, P6651, DOI 10.1074/jbc.M211249200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHEIDT WR, 1986, J AM CHEM SOC, V108, P1163, DOI 10.1021/ja00266a008; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SMULEVICH G, 1990, BIOCHEMISTRY-US, V29, P7174, DOI 10.1021/bi00483a004; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Suematsu M, 2000, HEPATOLOGY, V31, P3, DOI 10.1002/hep.510310102; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; Wilks A, 2000, J BIOL CHEM, V275, P11686, DOI 10.1074/jbc.275.16.11686; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; Yasutake Y, 2001, ACTA CRYSTALLOGR D, V57, P1682, DOI 10.1107/S0907444901012823; Zhang XH, 2003, BIOCHEMISTRY-US, V42, P7418, DOI 10.1021/bi027173g; Zhou H, 2000, J AM CHEM SOC, V122, P8311, DOI 10.1021/ja0002868; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	56	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11937	11947		10.1074/jbc.M311631200	http://dx.doi.org/10.1074/jbc.M311631200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14645223	hybrid			2022-12-25	WOS:000220157600131
J	McCarthy, JK; Uzelac, A; Davis, DF; Eveleigh, DE				McCarthy, JK; Uzelac, A; Davis, DF; Eveleigh, DE			Improved catalytic efficiency and active site modification of 1,4-beta-D-glucan glucohydrolase A from Thermotoga neapolitana by directed evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE BETA-GLUCOSIDASE; CRYSTAL-STRUCTURE; AGLYCONE SPECIFICITY; TRICHODERMA-REESEI; IN-VITRO; MECHANISM; SEQUENCE; PURIFICATION; CELLULASES; INSIGHTS	Thermotoga neapolitana 1,4-beta-D-glucan glucohydrolase A preferentially hydrolyzes cello-oligomers, such as cellotetraose, releasing single glucose moieties from the reducing end of the cello-oligosaccharide chain. Using directed evolution techniques of error-prone PCR and mutant library screening, a variant glucan glucohydrolase has been isolated that hydrolyzes the disaccharide, cellobiose, at a 31% greater rate than its wild type (WT) predecessor. The mutant library, expressed in Escherichia coli, was screened at 85degreesC for increased hydrolysis of cellobiose, a native substrate rather than a chromogenic analog, using a continuous, thermostable coupled enzyme assay. The V-max for the mutant was 108 +/- 3 units mg(-1), whereas that of the WT was 75 +/- 2 units mg(-1). The K-m for both proteins was nearly the same. The k(cat) for the new enzyme increased by 31% and its catalytic efficiency (k(cat)/K-m) for cellobiose also rose by 31% as compared with the parent. The nucleotide sequence of two positive clones and two null clones identified 11 single base shifts. The nucleotide transition in the most active clone caused an isoleucine to threonine amino acid substitution at position 170. Structural models for I170T and WT proteins were derived by sequence homology with Protein Data Bank code 1BGA from Paenibacillus polymyxa. Analysis of the WT and I170T model structures indicated that the substitution in the mutant enzyme repositioned the conserved catalytic residue Asn-163 and reconfigured entry to the active site.	Rutgers State Univ, Cook Coll, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Eveleigh, DE (corresponding author), Rutgers State Univ, Cook Coll, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA.	eveleigh@aesop.rutgers.edu	Uzelac, Aleksandra/GQI-2085-2022	Uzelac, Aleksandra/0000-0002-1424-0123				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andre G, 2003, PROTEIN ENG, V16, P125, DOI 10.1093/proeng/gzg017; Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; Bok JD, 1998, APPL ENVIRON MICROB, V64, P4774; Brown NP, 1998, BIOINFORMATICS, V14, P380, DOI 10.1093/bioinformatics/14.4.380; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; CONN EE, 1992, ACS SYM SER, V533, P15; Czjzek M, 2001, BIOCHEM J, V354, P37, DOI 10.1042/0264-6021:3540037; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DESAI UJ, 1995, BIOTECHNIQUES, V19, P780; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hrmova M, 1997, CARBOHYD RES, V305, P209, DOI 10.1016/S0008-6215(97)00257-7; Hrmova M, 1998, J BIOL CHEM, V273, P11134, DOI 10.1074/jbc.273.18.11134; HUBER R, 1992, PROKARYOTES HDB BIOL, V4, P3809; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; Joshi MD, 2000, J MOL BIOL, V299, P255, DOI 10.1006/jmbi.2000.3722; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leung DW, 1989, TECHNIQUE, V1, P11; McCarthy JK, 2003, ANAL BIOCHEM, V318, P196, DOI 10.1016/S0003-2697(03)00243-4; MONTENECOURT BS, 1977, APPL ENVIRON MICROB, V34, P777, DOI 10.1128/AEM.34.6.777-782.1977; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Nagano N, 2001, PROTEIN ENG, V14, P845, DOI 10.1093/protein/14.11.845; NEIDLEMAN SL, 2000, ACS SYM SER, V776, P14; Nesbo CL, 2002, J BACTERIOL, V184, P4475, DOI 10.1128/JB.184.16.4475-4488.2002; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Rignall TR, 2002, APPL BIOCHEM BIOTECH, V98, P383, DOI 10.1385/ABAB:98-100:1-9:383; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; Shafikhani S, 1997, BIOTECHNIQUES, V23, P304, DOI 10.2144/97232rr01; Sheehan JS, 2001, AGRO FOOD IND HI TEC, V12, P54; Spiridonov NA, 2001, CURR MICROBIOL, V42, P295, DOI 10.1007/s002840010220; Srisodsuk M, 1997, J BIOTECHNOL, V57, P49, DOI 10.1016/S0168-1656(97)00088-6; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Sunna A, 1997, EXTREMOPHILES, V1, P2, DOI 10.1007/s007920050009; TOLLEY SP, 1993, J MOL BIOL, V229, P791, DOI 10.1006/jmbi.1993.1082; TULL D, 1991, J BIOL CHEM, V266, P15621; VANTILBEURGH H, 1988, METHOD ENZYMOL, V160, P45; Verdoucq L, 2003, J BIOL CHEM, V278, P25055, DOI 10.1074/jbc.M301978200; Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183; WOOD TM, 1988, METHOD ENZYMOL, V160, P87; Yernool DA, 2000, J BACTERIOL, V182, P5172, DOI 10.1128/JB.182.18.5172-5179.2000; Zhao HM, 2002, CURR OPIN BIOTECH, V13, P104, DOI 10.1016/S0958-1669(02)00291-4; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3; Zverlov VV, 1997, MICROBIOL-SGM, V143, P3537, DOI 10.1099/00221287-143-11-3537	57	34	38	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11495	11502		10.1074/jbc.M305642200	http://dx.doi.org/10.1074/jbc.M305642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14660638	hybrid			2022-12-25	WOS:000220157600081
J	Pons, V; Peres, C; Teulie, JM; Nauze, M; Mus, M; Rolland, C; Collet, X; Perret, B; Gassama-Diagne, A; Hullin-Matsuda, F				Pons, V; Peres, C; Teulie, JM; Nauze, M; Mus, M; Rolland, C; Collet, X; Perret, B; Gassama-Diagne, A; Hullin-Matsuda, F			Enterophilin-1 interacts with focal adhesion kinase and decreases beta 1 integrins in intestinal Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FAMILIAL MEDITERRANEAN FEVER; MAP KINASE; ENTEROCYTIC DIFFERENTIATION; FIBRONECTIN RECEPTOR; MATRIX INTERACTIONS; CYCLE PROGRESSION; SORTING NEXINS; EGF RECEPTOR; INTEGRIN	Intestinal cell growth and differentiation are tightly regulated by growth factors and extracellular matrix components along the crypt-villus axis. We previously described enterophilin-1 (Ent-1) as a new intestinal protein associated with growth arrest and enterocyte differentiation. Ent-1 interacted with sorting nexin 1 and decreased cell surface epidermal growth factor receptor. Because beta(1) integrins are mostly found in vivo in the proliferative crypt cells, we investigated the role of Ent-1 in the fate of beta(1) integrin subunits. In undifferentiated intestinal Caco-2 cells, overexpression of Ent-1 induces a marked decrease of alpha(5)beta(1) integrin pools, whereas alpha(2)beta(1) integrin is weakly affected. Conversely, overexpression of sorting nexin 1 has no effect on integrin levels despite its ability to interact with Ent-1. Interestingly, we identified focal adhesion kinase as a new Ent-1 partner using yeast two-hybrid screening and coprecipitation experiments. Furthermore by confocal microscopy, we observed that Ent-1 and beta(1) integrins partly co-localize on vesicular structures, suggesting a role for Ent-1 in integrin trafficking. Because focal adhesion kinase is able to bind both Ent-1 and beta(1) integrins, the kinase might act as a molecular bridge between the two proteins. Altogether, these results support a role of Ent-1 in regulating beta(1) integrin expression that could favor intestinal differentiation.	Hop Purpan, Dept Lipoprot & Mediateurs Lipid, Inst Federat Rech Claude de Preval, IFR30,INSERM,U563, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Hullin-Matsuda, F (corresponding author), RIKEN Frontier Res Syst, Suprabiomol Syst Res Grp, Sphingolipid Funct Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hullin-matsuda@riken.jp	Peres, Carlos A./B-1276-2013; Collet, Xavier/M-6938-2017; Hullin-Matsuda, Françoise/N-3880-2017; Peres, Carlos Augusto/N-8275-2019; Peres, Carlos A./ABE-8361-2020	Peres, Carlos A./0000-0002-1588-8765; Hullin-Matsuda, Françoise/0000-0002-6042-2841; Peres, Carlos A./0000-0002-1588-8765; PONS, Veronique/0000-0001-5821-8481; Bertrand, PERRET/0000-0001-7568-445X				Aksentijevich I, 1997, CELL, V90, P797; Aplin AE, 1998, PHARMACOL REV, V50, P197; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Bernot A, 1997, NAT GENET, V17, P25; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Buda A, 2003, GUT, V52, P729, DOI 10.1136/gut.52.5.729; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; Gassama-Diagne A, 2001, J BIOL CHEM, V276, P18352, DOI 10.1074/jbc.M009784200; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kuwada SK, 1999, GROWTH FACTORS, V17, P139, DOI 10.3109/08977199909103522; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY P, 1994, FEBS LETT, V338, P272, DOI 10.1016/0014-5793(94)80282-3; Levy P, 1998, J CELL PHYSIOL, V177, P618, DOI 10.1002/(SICI)1097-4652(199812)177:4<618::AID-JCP12>3.0.CO;2-R; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Loeffler M, 1997, J THEOR BIOL, V186, P41, DOI 10.1006/jtbi.1996.0340; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Martel V, 2000, J CELL SCI, V113, P1951; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Owens DM, 2001, CANCER RES, V61, P5248; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; PERREAULT N, 1995, ANAT REC, V242, P242, DOI 10.1002/ar.1092420214; PINTO M, 1983, BIOL CELL, V47, P323; Pons V, 2003, J BIOL CHEM, V278, P21155, DOI 10.1074/jbc.M211008200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stutzmann J, 2000, MICROSC RES TECHNIQ, V51, P179, DOI 10.1002/1097-0029(20001015)51:2<179::AID-JEMT9>3.0.CO;2-4; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Yu X, 2000, J CELL SCI, V113, P2139; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	52	3	4	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9270	9277		10.1074/jbc.M309764200	http://dx.doi.org/10.1074/jbc.M309764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14630935	hybrid			2022-12-25	WOS:000189265900089
J	Feramisco, JD; Goldstein, JL; Brown, MS				Feramisco, JD; Goldstein, JL; Brown, MS			Membrane topology of human Insig-1, a protein regulator of lipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; STEROL-SENSING DOMAIN; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; SREBP; SCAP; ER; PATHWAY; CELLS	Insig-1 is an intrinsic protein of the endoplasmic reticulum (ER) that regulates the proteolytic processing of membrane-bound sterol regulatory element-binding proteins (SREBPs), transcription factors that activate the synthesis of cholesterol and fatty acids in mammalian cells. When cellular levels of sterols rise, Insig-1 binds to the membranous sterol-sensing domain of SREBP cleavage-activating protein ( SCAP), retaining the SCAP/SREBP complex in the ER and preventing it from moving to the Golgi for proteolytic processing. Under conditions of sterol excess, Insig-1 also binds to the ER enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, facilitating its ubiquitination and proteasomal degradation. Here, we use protease protection, glycosylation site mapping, and cysteine derivitization to define the topology of the 277-amino acid human Insig-1. The data indicate that short segments at the N and C termini of Insig-1 face the cytosol. Most of the protein is buried within the membrane, forming six transmembrane segments separated by five short luminal and cytosolic loops that range from similar to5 to 16 amino acids. The membranous nature of Insig-1 is consistent with its sterol-dependent binding to hydrophobic sterol-sensing domains in SCAP and HMG CoA reductase.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	joe.goldstein@utsouthwestern.edu; mike.brown@utsouthwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Espenshade PJ, 2002, P NATL ACAD SCI USA, V99, P11694, DOI 10.1073/pnas.182412799; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; KOCH GLE, 1988, J CELL SCI, V90, P485; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISCUM L, 1985, J BIOL CHEM, V260, P522; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rutledge EA, 1998, J BIOL CHEM, V273, P12169, DOI 10.1074/jbc.273.20.12169; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	30	73	78	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8487	8496		10.1074/jbc.M312623200	http://dx.doi.org/10.1074/jbc.M312623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660594	hybrid			2022-12-25	WOS:000189103300132
J	Krishnamurthy, PK; Johnson, GVW				Krishnamurthy, PK; Johnson, GVW			Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME-17 FRONTOTEMPORAL DEMENTIA; PROTEIN PHOSPHATASE 2A; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEUROBLASTOMA-CELLS; PRESENILE-DEMENTIA; FILAMENT FORMATION; GENE-EXPRESSION; P301L TAU; MUTATIONS	Frontotemporal dementia and Parkinsonism linked to chromosome 17 ( FTDP-17) is an autosomal dominant neurodegenerative disorder caused by mutations in the gene that encodes for tau, a microtubule- binding protein. Neuropathologically the disease is characterized by extensive neuronal loss in the frontal and temporal lobes and the filamentous accumulation of hyperphosphorylated tau. The R406W missense mutation was originally described in an American and a Dutch family. Although R406W tau is hyperphosphorylated in FTDP-17 cases, R406W tau expressed in cell model systems has not shown increased phosphorylation. The purpose of this study was to establish a neuronal model system in which the phosphorylation of R406W tau is increased and thus more representative of the in vivo situation. To accomplish this goal immortalized mouse cortical cells that express low levels of endogenous tau were stably transfected with human wild type or R406W tau. In this neuronal model R406W tau was more highly phosphorylated at numerous epitopes and showed decreased microtubule binding compared with wild type tau, an effect that could be reversed by dephosphorylation. In addition the expression of R406W tau in the cortical cells resulted in increased cell death as compared with wild type tau-expressing cells when the cells were exposed to an apoptotic stressor. These results indicate that in an appropriate cellular context R406W tau is hyperphosphorylated, which leads to decreased microtubule binding. Furthermore, expression of R406W tau sensitized cells to apoptotic stress, which may contribute to the neuronal cell loss that occurs in this FTDP-17 tauopathy.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave,S SC 1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS35060] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035060] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen B, 2002, J NEUROSCI, V22, P9340; Arawaka S, 1999, NEUROREPORT, V10, P993, DOI 10.1097/00001756-199904060-00018; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bongarzone E. R., 1996, Methods (Orlando), V10, P489, DOI 10.1006/meth.1996.0126; Bongarzone ER, 1998, J NEUROSCI RES, V54, P309, DOI 10.1002/(SICI)1097-4547(19981101)54:3<309::AID-JNR2>3.0.CO;2-5; CACERES A, 1991, J NEUROSCI, V11, P1515; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Fath T, 2002, J NEUROSCI, V22, P9733; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Furukawa K, 2000, NEUROREPORT, V11, P57, DOI 10.1097/00001756-200001170-00011; Goedert M, 2000, J NEUROCHEM, V75, P2155, DOI 10.1046/j.1471-4159.2000.0752155.x; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Ho L, 2001, NEUROSCI LETT, V310, P1, DOI 10.1016/S0304-3940(01)02044-4; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Johnson GVW, 2002, J ALZHEIMERS DIS, V4, P375, DOI 10.3233/JAD-2002-4505; JOHNSON GV, 1996, J ALZHEIMERS DIS, V1, P329; Johnson GVW, 1997, J NEUROCHEM, V68, P430; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; Krishnamurthy PK, 2000, J NEUROSCI RES, V61, P515, DOI 10.1002/1097-4547(20000901)61:5<515::AID-JNR6>3.0.CO;2-#; LEE G, 1992, J CELL SCI, V102, P227; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mack TGA, 2001, NEUROSCIENCE, V108, P701, DOI 10.1016/S0306-4522(01)00434-1; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Rosso SM, 2000, ANN NY ACAD SCI, V920, P115; Sahara N, 2000, J NEUROSCI RES, V60, P380, DOI 10.1002/(SICI)1097-4547(20000501)60:3<380::AID-JNR13>3.0.CO;2-5; Saito Y, 2002, NEUROLOGY, V58, P811, DOI 10.1212/WNL.58.5.811; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stoothoff WH, 2001, J NEUROSCI RES, V65, P573, DOI 10.1002/jnr.1187; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I	61	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7893	7900		10.1074/jbc.M311203200	http://dx.doi.org/10.1074/jbc.M311203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660557	hybrid			2022-12-25	WOS:000189103300066
J	Reiland, J; Sanderson, RD; Waguespack, M; Barker, SA; Long, R; Carson, DD; Marchetti, D				Reiland, J; Sanderson, RD; Waguespack, M; Barker, SA; Long, R; Carson, DD; Marchetti, D			Heparanase degrades syndecan-1 and perlecan heparan sulfate - Functional implications for tumor cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MAMMALIAN HEPARANASE; SOLUBLE SYNDECAN-1; NEUROTROPHIN STIMULATION; SURFACE PROTEOGLYCAN; MATRIX PROTEOGLYCANS; METASTATIC MELANOMA; CORE PROTEIN; IN-VIVO; DEGRADATION	Heparanase (HPSE-1) is involved in the degradation of both cell-surface and extracellular matrix (ECM) heparan sulfate (HS) in normal and neoplastic tissues. Degradation of heparan sulfate proteoglycans (HSPG) in mammalian cells is dependent upon the enzymatic activity of HPSE-1, an endo-beta-D-glucuronidase, which cleaves HS using a specific endoglycosidic hydrolysis rather than an eliminase type of action. Elevated HPSE-1 levels are associated with metastatic cancers, directly implicating HPSE-1 in tumor progression. The mechanism of HPSE-1 action to promote tumor progression may involve multiple substrates because HS is present on both cell-surface and ECM proteoglycans. However, the specific targets of HPSE-1 action are not known. Of particular interest is the relationship between HPSE-1 and HSPG, known for their involvement in tumor progression. Syndecan-1, an HSPG, is ubiquitously expressed at the cell surface, and its role in cancer progression may depend upon its degradation. Conversely, another HSPG, perlecan, is an important component of basement membranes and ECM, which can promote invasive behavior. Down-regulation of perlecan expression suppresses the invasive behavior of neoplastic cells in vitro and inhibits tumor growth and angiogenesis in vivo. In this work we demonstrate the following. 1) HPSE-1 cleaves HS present on the cell surface of metastatic melanoma cells. 2) HPSE-1 specifically degrades HS chains of purified syndecan-1 or perlecan HS. 3) Syndecan-1 does not directly inhibit HPSE-1 enzymatic activity. 4) The presence of exogenous syndecan-1 inhibits HPSE-1-mediated invasive behavior of melanoma cells by in vitro chemoinvasion assays. 5) Inhibition of HPSE-1-induced invasion requires syndecan-1 HS chains. These results demonstrate that cell-surface syndecan-1 and ECM perlecan are degradative targets of HPSE-1, and syndecan-1 regulates HPSE-1 biological activity. This suggest that expression of syndecan-1 on the melanoma cell surface and its degradation by HPSE-1 are important determinants in the control of tumor cell invasion and metastasis.	Louisiana State Univ, Dept Comparat Biomed Sci, SVM, Baton Rouge, LA 70803 USA; Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Anat, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Neurobiol, Little Rock, AR 72205 USA; Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	Louisiana State University System; Louisiana State University; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Delaware	Marchetti, D (corresponding author), Louisiana State Univ, Dept Comparat Biomed Sci, SVM, Rm 2522,Skip Bertman Dr, Baton Rouge, LA 70803 USA.	dmarchetti@vetmed.lsu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA068494, R01CA086832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013542] Funding Source: NIH RePORTER; NCI NIH HHS [5R0-1 CA86832, CA68494] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline; NIDCR NIH HHS [DE13542] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Bame KJ, 1997, J BIOL CHEM, V272, P2245; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; Dhodapkar MV, 1997, BRIT J HAEMATOL, V99, P368, DOI 10.1046/j.1365-2141.1997.3893203.x; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; Engbring JA, 2002, CANCER RES, V62, P3549; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1996, BIOCHEM J, V315, P589, DOI 10.1042/bj3150589; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Ho GY, 1997, J BIOL CHEM, V272, P16838, DOI 10.1074/jbc.272.27.16838; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Keiser N, 2001, NAT MED, V7, P123, DOI 10.1038/83263; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Knox S, 2001, PROTEOMICS, V1, P1534, DOI 10.1002/1615-9861(200111)1:12<1534::AID-PROT1534>3.0.CO;2-A; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Kovalszky I, 1998, MOL CELL BIOCHEM, V183, P11, DOI 10.1023/A:1006898920637; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Ma YQ, 2000, J IMMUNOL, V165, P558, DOI 10.4049/jimmunol.165.1.558; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 2001, ADV ENZYME REGUL, V41, P343, DOI 10.1016/S0065-2571(00)00016-9; Marchetti D, 1997, J CELL PHYSIOL, V172, P334, DOI 10.1002/(SICI)1097-4652(199709)172:3<334::AID-JCP7>3.0.CO;2-P; Marchetti D, 2000, CANCER RES, V60, P4767; Myler HA, 2002, J BIOCHEM, V131, P913, DOI 10.1093/oxfordjournals.jbchem.a003182; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; TANG JP, 1987, J BIOL CHEM, V262, P12832; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Yang Y, 2003, J BIOL CHEM, V278, P12888, DOI 10.1074/jbc.M209440200; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610	64	118	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8047	8055		10.1074/jbc.M304872200	http://dx.doi.org/10.1074/jbc.M304872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14630925	hybrid			2022-12-25	WOS:000189103300083
J	Carreira, A; Menendez, M; Reguera, J; Almendral, JM; Mateu, MG				Carreira, A; Menendez, M; Reguera, J; Almendral, JM; Mateu, MG			In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINUTE VIRUS; CANINE PARVOVIRUS; FUNCTIONAL IMPLICATIONS; PORCINE PARVOVIRUS; ANTIGENIC SITE; B-CELL; PROTEIN; PARTICLES; POLIOVIRUS; MICE	We have analyzed the in vitro disassembly of the capsid of the minute virus of mice, and the stability of capsid chimeras carrying heterologous epitope insertions. Upon heating in a physiological buffer, empty capsids formed by 60 copies of protein VP2 underwent first a reversible conformational change with a small enthalpy change detected by fluorescence. This change was associated with, but not limited to, externalization of the VP2 N terminus. Irreversible capsid dissociation as detected by changes in fluorescence, hemagglutination activity, and electrophoretic mobility occurred at much higher temperatures. Differential scanning calorimetry in the same conditions indicated that the dissociation/denaturation transition involved a high enthalpy change and proceeded through one or more intermediates. In contrast, in the presence of 1.5 m guanidinium chloride, heat-induced disassembly fitted a two-state irreversible process. Both thermally and chemically induced dissociation/denaturation yielded a form that had lost a part of the tertiary structure, but still retained the native secondary structure. Data from chemical dissociation indicates this form may correspond to a molten globule-like monomeric state of the capsid protein. All five antigenic peptide insertions attempted in exposed loops, despite being perhaps among the least disruptive, led to defects in folding/assembly of the capsid and, in most cases, to reduced capsid stability against thermal dissociation. The results with one of the simplest viral capsids reveal a complex pathway for disassembly, and a reduction in capsid assembly and stability upon insertion of peptides, even within the most exposed capsid loops.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Mateu, MG (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mgarcia@cbm.uam.es	Vidaechea, Juan J Reguera/G-7451-2012; Reguera, Juan/A-7551-2017; Mateu, Mauricio/ABF-2146-2021; Menendez, Margarita/M-1795-2014; Almendral, Jose M/I-2510-2015	Reguera, Juan/0000-0003-4977-7948; Mateu, Mauricio/0000-0002-2915-1529; Menendez, Margarita/0000-0002-3267-4443; Almendral, Jose M/0000-0003-3457-0389; Carreira, Aura/0000-0001-5489-4343				AGBANDJE M, 1993, PROTEINS, V16, P155, DOI 10.1002/prot.340160204; Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3; BASAK S, 1992, VIROLOGY, V186, P368, DOI 10.1016/0042-6822(92)90002-7; BROWN CS, 1994, VIROLOGY, V198, P477, DOI 10.1006/viro.1994.1059; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CARRASCOSA AL, 1994, BIOTECHNIQUES, V16, P1078; Casal JI, 1999, BIOTECHNOL APPL BIOC, V29, P141; Casal JI, 1999, METHODS, V19, P174, DOI 10.1006/meth.1999.0843; Chiu W., 1997, STRUCTURAL BIOL VIRU; Chow M., 1997, STRUCTURAL BIOL VIRU, P157; Cotmore SF, 1999, VIROLOGY, V254, P169, DOI 10.1006/viro.1998.9520; DIANA GD, 1997, STRUCTURAL BIOL VIRU, P432; Dokland T, 2000, STRUCTURE, V8, pR157, DOI 10.1016/S0969-2126(00)00181-7; Douar AM, 2003, VIROLOGY, V309, P203, DOI 10.1016/S0042-6822(03)00186-7; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; Greber Urs F., 1994, Trends in Microbiology, V2, P52, DOI 10.1016/0966-842X(94)90126-0; HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234; Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123; Hurtado A, 1996, J VIROL, V70, P5422, DOI 10.1128/JVI.70.8.5422-5429.1996; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Johnson J. E., 1999, ENCY VIROLOGY, P1946; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; JURNAK FA, 1984, BIOL MACROMOLECULES; Kruger DH, 1999, BIOL CHEM, V380, P275, DOI 10.1515/BC.1999.037; Ladurner AG, 1997, J MOL BIOL, V273, P330, DOI 10.1006/jmbi.1997.1304; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; Liljas Lars, 1999, Current Opinion in Structural Biology, V9, P129, DOI 10.1016/S0959-440X(99)80017-7; LlamasSaiz AL, 1997, ACTA CRYSTALLOGR D, V53, P93, DOI 10.1107/S0907444996010566; Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000; Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1128/JVI.76.14.7049-7059.2002; Lomonossoff GP, 1996, CURR OPIN STRUC BIOL, V6, P176, DOI 10.1016/S0959-440X(96)80072-8; Lopez-Bueno A, 2003, J VIROL, V77, P2701, DOI 10.1128/JVI.77.4.2701-2708.2003; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Mach H, 1995, Methods Mol Biol, V40, P91; Mateo R, 2003, J BIOL CHEM, V278, P41019, DOI 10.1074/jbc.M304990200; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; MINOR PD, 1983, NATURE, V301, P674, DOI 10.1038/301674a0; MIYAMURA K, 1994, P NATL ACAD SCI USA, V91, P8507, DOI 10.1073/pnas.91.18.8507; MOYNIHAN CT, 1974, J PHYS CHEM-US, V78, P2673, DOI 10.1021/j100619a008; MURRAY MG, 1988, P NATL ACAD SCI USA, V85, P3203, DOI 10.1073/pnas.85.9.3203; MUZYCZKA N, 2001, FIELDS VIROLOGY, P2361; Prevelige PE, 1998, TRENDS BIOTECHNOL, V16, P61, DOI 10.1016/S0167-7799(97)01154-2; RAMIREZ JC, 1995, VIROLOGY, V206, P57, DOI 10.1016/S0042-6822(95)80019-0; Regan L, 1999, CURR OPIN STRUC BIOL, V9, P494, DOI 10.1016/S0959-440X(99)80070-0; Ros C, 2002, J VIROL, V76, P12634, DOI 10.1128/JVI.76.24.12634-12645.2002; ROSE CSP, 1991, TRENDS BIOTECHNOL, V9, P415, DOI 10.1016/0167-7799(91)90142-5; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1997, STRUCTURAL BIOL VIRU, P105; Rueda P, 1999, VACCINE, V18, P325, DOI 10.1016/S0264-410X(99)00202-9; Rueda P, 1999, VIROLOGY, V263, P89, DOI 10.1006/viro.1999.9911; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sedlik C, 1997, P NATL ACAD SCI USA, V94, P7503, DOI 10.1073/pnas.94.14.7503; SEDLIK C, 1995, J GEN VIROL, V76, P2361, DOI 10.1099/0022-1317-76-9-2361; Simpson AA, 2002, J MOL BIOL, V315, P1189, DOI 10.1006/jmbi.2001.5319; Smyth MS, 2002, J CLIN PATHOL-MOL PA, V55, P214, DOI 10.1136/mp.55.4.214; Steven AC, 1997, FASEB J, V11, P733, DOI 10.1096/fasebj.11.10.9271358; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WU H, 1993, J MOL BIOL, V233, P231, DOI 10.1006/jmbi.1993.1502; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; Yuan W, 2001, VIROLOGY, V279, P546, DOI 10.1006/viro.2000.0734	66	56	56	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6517	6525		10.1074/jbc.M307662200	http://dx.doi.org/10.1074/jbc.M307662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660623	hybrid			2022-12-25	WOS:000188969200038
J	Goh, CH; Jung, KH; Roberts, SK; McAinsh, MR; Hetherington, AM; Park, Y; Suh, K; An, GH; Nam, HG				Goh, CH; Jung, KH; Roberts, SK; McAinsh, MR; Hetherington, AM; Park, Y; Suh, K; An, GH; Nam, HG			Mitochondria provide the main source of cytosolic ATP for activation of outward-rectifying K+ channels in mesophyll protoplast of chlorophyll-deficient mutant rice (OsCHLH) seedlings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUARD-CELL PROTOPLASTS; MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; BLUE-LIGHT; OXIDATIVE-PHOSPHORYLATION; LEAF PROTOPLASTS; VICIA-FABA; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; ELECTRON-TRANSPORT	The role of mitochondria in providing intracellular ATP that controls the activity of plasma membrane outward-rectifying K+ channels was evaluated. The Os-CHLH rice mutant, which lacks chlorophyll in the thylakoids, was isolated by T-DNA gene trapping (Jung, K.-H., Hur, J., Ryu, C.-H., Choi, Y., Chung, Y.-Y., Miyao, A., Hirochika, H., and An, G. (2003) Plant Cell Physiol. 44, 463-472). The OsCHLH mutant is unable to fix CO2 and exhibits reduced growth. Wild type and mutant plants exhibit similar rates of respiratory O-2 uptake in the dark, whereas the rate of photosynthetic O-2 evolution by the mutant was negligible during illumination. During dark respiration the wild type and mutant exhibited similar levels of cytoplasmic ATP. In the mutant oligomycin treatment (an inhibitor of mitochondrial F1F0-ATPase) drastically reduced ATP production. The fact that this was reversed by the addition of glucose suggested that the mutant produced ATP exclusively from mitochondria but not from chloroplasts. In whole cell patch clamp experiments, the activity of outward-rectifying K+ channels of rice mesophyll cells showed ATP-dependent currents, which were 1.5-fold greater in wild type than in mutant cells. Channels in both wild type and mutant cells were deactivated by the removal of cytosolic ATP, whereas in the presence of ATP the channels remained active. We conclude that mesophyll cells in the OsCHLH rice mutant derive ATP from mitochondrial respiration, and that this is critical for the normal function of plasma membrane outward-rectifying K+ channels.	Pohang Univ Sci & Technol, Dept Life Sci, Bionanotechnol Ctr, Kyungbuk 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Kyungbuk 790784, South Korea; Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Daegu Univ, Div Life Sci, Taegu 712714, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Lancaster University; Chungnam National University; Daegu University	Goh, CH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Bionanotechnol Ctr, Kyungbuk 790784, South Korea.	gohunse@postech.ac.kr	Jung, Ki Hong/L-5570-2019; Park, Youn-Il/S-2997-2019	Jung, Ki Hong/0000-0003-0427-5901; Park, Youn-Il/0000-0003-2912-2821; McAinsh, Martin Robert/0000-0003-4294-6470; roberts, stephen/0000-0003-1740-5330; Hetherington, Alistair/0000-0001-6060-9203	Biotechnology and Biological Sciences Research Council [P18229] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASSMANN SM, 1985, NATURE, V318, P285, DOI 10.1038/318285a0; Bei QX, 1998, PLANT J, V13, P857, DOI 10.1046/j.1365-313X.1998.00084.x; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bricker TM, 2002, BBA-BIOENERGETICS, V1556, P92, DOI 10.1016/S0005-2728(02)00367-5; Briskin DP, 1996, PLANT PHYSIOL, V111, P1199, DOI 10.1104/pp.111.4.1199; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Choi SM, 2002, PLANTA, V216, P315, DOI 10.1007/s00425-002-0852-z; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DAVIES JM, 1995, J MEMBRANE BIOL, V145, P75; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; Dutilleul C, 2003, PLANT CELL, V15, P1212, DOI 10.1105/tpc.009464; GARDESTROM P, 1995, J BIOENERG BIOMEMBR, V27, P415, DOI 10.1007/BF02110004; GARDESTROM P, 1987, FEBS LETT, V212, P114, DOI 10.1016/0014-5793(87)81567-3; Goh CH, 1996, PLANT PHYSIOL, V111, P433, DOI 10.1104/pp.111.2.433; Goh CH, 2002, PLANT J, V32, P623, DOI 10.1046/j.1365-313X.2002.01451.x; Goh CH, 1999, PLANT CELL ENVIRON, V22, P1057, DOI 10.1046/j.1365-3040.1999.00475.x; GOH CH, 1995, PLANT PHYSIOL, V109, P187, DOI 10.1104/pp.109.1.187; Harada A, 2002, PLANTA, V214, P863, DOI 10.1007/s00425-001-0689-x; Haupt-Herting S, 2001, PLANT PHYSIOL, V126, P388, DOI 10.1104/pp.126.1.388; Homann U, 2002, P NATL ACAD SCI USA, V99, P10215, DOI 10.1073/pnas.152324399; Jensen PE, 1996, MOL GEN GENET, V250, P383; Jeong WJ, 2002, PLANT PHYSIOL, V129, P112, DOI 10.1104/pp.000588; Jung KH, 2003, PLANT CELL PHYSIOL, V44, P463, DOI 10.1093/pcp/pcg064; Keunecke M, 2000, PLANTA, V210, P792, DOI 10.1007/s004250050681; KISHONY R, 2003, J BIOL; Knopp A, 2001, CARDIOVASC RES, V52, P236, DOI 10.1016/S0008-6363(01)00395-9; KOURIE J, 1992, PLANT PHYSIOL, V98, P1087, DOI 10.1104/pp.98.3.1087; KROMER S, 1993, PLANT PHYSIOL, V102, P947, DOI 10.1104/pp.102.3.947; KROMER S, 1995, ANNU REV PLANT PHYS, V46, P45, DOI 10.1146/annurev.pp.46.060195.000401; LAMBERS H, 1997, OXIDATION MITOCHONDR, P200; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Leonhardt N, 1997, P NATL ACAD SCI USA, V94, P14156, DOI 10.1073/pnas.94.25.14156; LI WW, 1993, P NATL ACAD SCI USA, V90, P262, DOI 10.1073/pnas.90.1.262; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; Maathuis FJM, 1997, PLANT PHYSIOL, V114, P1141, DOI 10.1104/pp.114.4.1141; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Moran N, 1996, PLANT PHYSIOL, V111, P1281, DOI 10.1104/pp.111.4.1281; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NORMA A, 1983, NATURE, V305, P147; Padmasree K, 2002, CRIT REV BIOCHEM MOL, V37, P71, DOI 10.1080/10409230290771465; PARNIK T, 1995, J EXP BOT, V46, P1439, DOI 10.1093/jxb/46.special_issue.1439; Pastore D, 1996, BIOCHEM MOL BIOL INT, V39, P149; Pineros MA, 2003, PLANT PHYSIOL, V131, P583, DOI 10.1104/pp.011932; Priebe L, 1996, J PHYSIOL-LONDON, V492, P405, DOI 10.1113/jphysiol.1996.sp021317; RAGHAVENDRA AS, 1994, PLANT SCI, V97, P1, DOI 10.1016/0168-9452(94)90101-5; REY P, 1989, PLANT PHYSIOL, V89, P762, DOI 10.1104/pp.89.3.762; Romano LA, 1998, PLANT CELL PHYSIOL, V39, P1133, DOI 10.1093/oxfordjournals.pcp.a029314; RORSMAN P, 1990, POTASSIUM CHANNELS S, P96; Rosenberg C, 1999, BIOCHEMISTRY-US, V38, P15994, DOI 10.1021/bi991326r; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; SPALDING EP, 1992, PLANT PHYSIOL, V99, P96, DOI 10.1104/pp.99.1.96; SPALDING EP, 1992, PLANTA, V188, P199, DOI 10.1007/BF00216814; Spalding EP, 2000, PLANT CELL ENVIRON, V23, P665, DOI 10.1046/j.1365-3040.2000.00594.x; SPALDING EP, 1993, PLANT CELL, V5, P477, DOI 10.2307/3869727; Stahlberg R, 1999, PLANTA, V208, P188, DOI 10.1007/s004250050549; Stahlberg R, 2000, PLANTA, V212, P1, DOI 10.1007/s004250000365; Stiles KA, 2002, J EXP BOT, V53, P1651, DOI 10.1093/jxb/erf015; STITT M, 1982, PLANT PHYSIOL, V70, P971, DOI 10.1104/pp.70.4.971; Taylor AR, 2001, PLANT PHYSIOL, V125, P329, DOI 10.1104/pp.125.1.329; Thomine S, 1995, PLANT CELL, V7, P2091, DOI 10.1105/tpc.7.12.2091; Trapp S, 1998, J GEN PHYSIOL, V112, P325, DOI 10.1085/jgp.112.3.325; VALERIO M, 1993, EUR J BIOCHEM, V216, P565, DOI 10.1111/j.1432-1033.1993.tb18175.x; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VANSELOW KH, 1989, J MEMBRANE BIOL, V110, P175, DOI 10.1007/BF01869472; VANVOLKENBURGH E, 1990, PLANTA, V182, P72, DOI 10.1007/BF00239986; VEKSHIN NL, 1991, BIOCHEM INT, V25, P603; Walker D, 1987, USE OXYGEN ELECTRODE; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; Xie ZX, 1999, PLANT PHYSIOL, V120, P217, DOI 10.1104/pp.120.1.217; ZIMMERMANN S, 1994, PLANT J, V6, P707, DOI 10.1046/j.1365-313X.1994.6050707.x	74	22	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6874	6882		10.1074/jbc.M309071200	http://dx.doi.org/10.1074/jbc.M309071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660680	hybrid			2022-12-25	WOS:000188969200082
J	Inaba, K; Takahashi, YH; Ito, K				Inaba, K; Takahashi, YH; Ito, K			DsbB elicits a red-shift of bound ubiquinone during the catalysis of DsbA oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BOND-FORMATION; MEMBRANE-PROTEIN DSBB; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; ELECTRON-TRANSPORT; CYSTEINE RESIDUES; FORMATION PATHWAY; FORMATION INVIVO; IN-VIVO; IDENTIFICATION	DsbB is an Escherichia coli plasma membrane protein that reoxidizes the Cys(30)-Pro-His-Cys(33) active site of DsbA, the primary dithiol oxidant in the periplasm. Here we describe a novel activity of DsbB to induce an electronic transition of the bound ubiquinone molecule. This transition was characterized by a striking emergence of an absorbance peak at 500 nm giving rise to a visible pink color. The ubiquinone red-shift was observed stably for the DsbA(C33S)-DsbB complex as well as transiently by stopped flow rapid scanning spectroscopy during the reaction between wild-type DsbA and DsbB. Mutation and reconstitution experiments established that the unpaired Cys at position 44 of DsbB is primarily responsible for the chromogenic transition of ubiquinone, and this property correlates with the functional arrangement of amino acid residues in the neighborhood Of Cys(44). We propose that the Cys(44)-induced anomaly in ubiquinone represents its activated state, which drives the DsbB-mediated electron transfer.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Japan Sci & Technol Corp, PRESTO, Kyoto 6068507, Japan; Japan Sci & Technol Corp, CREST, Kyoto 6068507, Japan	Kyoto University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp		Inaba, Kenji/0000-0001-8229-0467				AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 2001, MOL MICROBIOL, V39, P158, DOI 10.1046/j.1365-2958.2001.02229.x; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Regeimbal J, 2003, P NATL ACAD SCI USA, V100, P13779, DOI 10.1073/pnas.1935988100; Regeimbal J, 2002, J BIOL CHEM, V277, P32706, DOI 10.1074/jbc.M205433200; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025	30	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6761	6768		10.1074/jbc.M310765200	http://dx.doi.org/10.1074/jbc.M310765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14634016	hybrid			2022-12-25	WOS:000188969200069
J	Ishii, H; Sen, RJ; Pazin, MJ				Ishii, H; Sen, RJ; Pazin, MJ			Combinatorial control of DNase I-hypersensitive site formation and erasure by immunoglobulin heavy chain enhancer-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ATTACHMENT REGIONS; HELIX-LOOP-HELIX; TISSUE-SPECIFIC TRANSCRIPTION; TRANSGENIC MICE; V(D)J RECOMBINATION; GENE ENHANCER; CHROMATIN TEMPLATES; INTRONIC ENHANCER; FACTOR PU.1; B-LINEAGE	DNase I-hypersensitive sites in cellular chromatin are usually believed to be nucleosome-free regions generated by transcription factor binding. Using a cell-free system we show that hypersensitivity does not simply correlate with the number of DNA-bound proteins. Specifically, the leucine zipper containing basic helix-loop-helix protein TFE3 was sufficient to induce a DNase I-hypersensitive site at the immunoglobulin heavy chain mu enhancer in vitro. TFE3 enhanced binding of an ETS protein PU.1 to the enhancer. However, PU.1 binding erased the DNase I-hypersensitive site without abolishing TFE3 binding. Furthermore, TFE3 binding enhanced transcription in the presence and absence of a hypersensitive site, whereas endonuclease accessibility correlated strictly with DNase I hypersensitivity. We infer that chromatin constraints for transcription and nuclease sensitivity can differ.	Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Grad Program Biophys & Struct Biol, Waltham, MA 02454 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Harvard University; Brandeis University; Brandeis University; Brandeis University	Pazin, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.	michael.pazin@cbrc2.mgh.harvard.edu		Pazin, Michael/0000-0002-7561-3640; Ishii, Haruhiko/0000-0002-1593-096X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038925, R01GM038925, R01GM061011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000524, Z01AG000524, Z01AG000383, ZIAAG000383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38925, GM61011] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Angelin-Duclos C, 1998, MOL CELL BIOL, V18, P6253, DOI 10.1128/MCB.18.11.6253; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bulger M., 1994, METH MOL G, V5, P241; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; FERNEX C, 1995, MOL CELL BIOL, V15, P3217; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; FORD AM, 1988, EMBO J, V7, P2393, DOI 10.1002/j.1460-2075.1988.tb03084.x; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Miller JA, 2003, MOL CELL BIOL, V23, P1623, DOI 10.1128/MCB.23.5.1623-1632.2003; MILLS FC, 1983, NATURE, V306, P809, DOI 10.1038/306809a0; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; OLTZ EM, 1993, MOL CELL BIOL, V13, P6223, DOI 10.1128/MCB.13.10.6223; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Pazin MJ, 1998, CHROMATIN PRACTICAL, P173; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; Rieske P, 2001, J BIOL CHEM, V276, P8460, DOI 10.1074/jbc.M007482200; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; Sikes ML, 2002, P NATL ACAD SCI USA, V99, P12309, DOI 10.1073/pnas.182166699; Tian G, 1999, MOL CELL BIOL, V19, P2946; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Whitehurst CE, 2000, IMMUNITY, V13, P703, DOI 10.1016/S1074-7613(00)00069-8; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	61	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7331	7338		10.1074/jbc.M308973200	http://dx.doi.org/10.1074/jbc.M308973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660676	hybrid			2022-12-25	WOS:000188969200135
J	O'Sullivan, A; Chang, HC; Yu, Q; Kaplan, MH				O'Sullivan, A; Chang, HC; Yu, Q; Kaplan, MH			STAT4 is required for interleukin-12-induced chromatin remodeling of the CD25 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN GENE; ACTIVATED PROTEIN-KINASE; IFN-GAMMA PROMOTER; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; HISTONE ACETYLATION; SIGNAL TRANSDUCER; NATURAL-KILLER; BINDING-SITES; FACTOR-I	Signal transducer and activator of transcription 4 (STAT4) is a critical mediator of interleukin-12 (IL-12)stimulated inflammatory immune responses. Despite extensive analysis of the immune responses of STAT4-deficient mice, there is still very little understood about STAT4-dependent gene induction. IL-12 stimulated increases in IL-2 receptor a chain gene (CD25) mRNA levels and surface expression require STAT4. In this report, we utilize chromatin immunoprecipitation assays to analyze IL-12-stimulated and STAT4-dependent changes in chromatin remodeling of the CD25 gene. Gene activation requires binding of STAT4 to the PRRIII upstream regulatory element, the recruitment of the CREB-binding protein (CBP), and chromatin remodeling including increased acetylation and decreased methylation of histones within the CD25 promoter. Evidence suggests that STAT4 also facilitates binding of other factors to the CD25 promoter including c-Jun. Thus, these results provide a model for STAT4-dependent gene induction and a mechanism for cytokine-induced expression of the CD25 gene.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Kaplan, MH (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, 950 W Walnut St,Rm 302, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu			NIAID NIH HHS [AI45515] Funding Source: Medline; NIDDK NIH HHS [T32DK007519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045515, R56AI045515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Barbulescu K, 1998, J IMMUNOL, V160, P3642; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chang HC, 2003, J BIOL CHEM, V278, P32471, DOI 10.1074/jbc.M302776200; Coccia EM, 1999, J BIOL CHEM, V274, P6698, DOI 10.1074/jbc.274.10.6698; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Galon J, 1999, J IMMUNOL, V162, P7256; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guler ML, 1997, J IMMUNOL, V159, P1767; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; John S, 1999, MOL CELL BIOL, V19, P1910; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kato T, 1997, CELL IMMUNOL, V176, P50, DOI 10.1006/cimm.1996.1072; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lawless VA, 2000, J IMMUNOL, V165, P6803, DOI 10.4049/jimmunol.165.12.6803; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Morris AC, 2002, MOL CELL BIOL, V22, P4781, DOI 10.1128/MCB.22.13.4781-4791.2002; Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875; Nakahira M, 2001, J IMMUNOL, V167, P1306, DOI 10.4049/jimmunol.167.3.1306; Nakahira M, 2002, J IMMUNOL, V168, P1146, DOI 10.4049/jimmunol.168.3.1146; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nguyen T, 2000, EUR J IMMUNOL, V30, P1445, DOI 10.1002/(SICI)1521-4141(200005)30:5<1445::AID-IMMU1445>3.0.CO;2-M; Nishikomori R, 2002, J IMMUNOL, V169, P4388, DOI 10.4049/jimmunol.169.8.4388; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PIERCE JW, 1995, J IMMUNOL, V155, P1972; Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502; Schuh K, 1998, J EXP MED, V188, P1369, DOI 10.1084/jem.188.7.1369; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tsytsykova AV, 2002, MOL CELL BIOL, V22, P2620, DOI 10.1128/MCB.22.8.2620-2631.2002; Valenzuela J, 2002, J IMMUNOL, V169, P6842, DOI 10.4049/jimmunol.169.12.6842; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YANAGIDA T, 1994, J IMMUNOL, V152, P4919; Yeh JH, 2001, MOL CELL BIOL, V21, P4515, DOI 10.1128/MCB.21.14.4515-4527.2001; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	58	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7339	7345		10.1074/jbc.M309979200	http://dx.doi.org/10.1074/jbc.M309979200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660657	hybrid			2022-12-25	WOS:000188969200136
J	Osman, A; Niles, EG; LoVerde, PT				Osman, A; Niles, EG; LoVerde, PT			Expression of functional Schistosoma mansoni Smad4 - Role in Erk-mediated transforming growth factor beta (TGF-beta) down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNAL; TUMOR-SUPPRESSOR SMAD4; MAD-RELATED PROTEIN; CRYSTAL-STRUCTURE; TYROSINE KINASE; DNA-BINDING; RECEPTOR; FAMILY; RAS; ACTIVATION	Members of the transforming growth factor (TGF)-beta superfamily play pivotal roles in cell migration, differentiation, adhesion, pattern formation, and apoptosis. The family of Smad proteins acts as intracellular signal transducers of TGF-beta and related peptides. Smad4, a common mediator Smad (co-Smad), performs a central role in transmitting signals from TGF-beta, BMP, and activins. Schistosoma mansoni receptor-regulated Smad1 and SmSmad2 were previously identified and shown to act in TGF-beta signaling. Herein, we report the identification and characterization of a Smad4 homologue from S. mansoni and provide details about its role in mediation and down-regulation of TGF-beta signaling in schistosomes. In order to identify the schistosome co-Smad, we designed degenerate primers based on the sequence of the conserved MH1/MH2 domains of Smad4 proteins, which were used in PCR to amplify a 137-bp PCR product. A S. mansoni adult worm pair cDNA library was screened resulting in the isolation of a cl)NA clone that encodes a 738 amino acid protein (SmSmad4). SmSmad4 was shown to interact with schistosome R-Smads (SmSmad1 and SmSmad2) in vivo and in vitro. The interaction with SmSmad2 was dependent on the receptor-mediated phosphorylation of SmSmad2. In addition, several potential phosphorylation sites for Erk1/2 kinases were identified in the SmSmad4 linker region and shown to be phosphorylated in vitro by an active mutant of mammalian Erk2. Furthermore, Erk-mediated phosphorylation of SmSmad4 decreased its interaction with the receptor- activated form of SmSmad2, in vitro. SmSmad4 was shown to complement a human Smad4 deficiency through the restoration of TGF-beta-responsiveness in MDA-MB-468 breast cancer cells.	SUNY Buffalo, Sch Med, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	LoVerde, PT (corresponding author), SUNY Buffalo, Sch Med, Dept Microbiol & Immunol, Buffalo, NY 14214 USA.	loverde@buffalo.edu			NIAID NIH HHS [AI46762] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046762] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Beall MJ, 2000, MOL BIOCHEM PARASIT, V111, P131, DOI 10.1016/S0166-6851(00)00307-8; Beall MJ, 2001, J BIOL CHEM, V276, P31613, DOI 10.1074/jbc.M104685200; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Davies SJ, 1998, J BIOL CHEM, V273, P11234, DOI 10.1074/jbc.273.18.11234; Davies SJ, 2003, INT J PARASITOL, V33, P1277, DOI 10.1016/S0020-7519(03)00161-9; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANDSEN F, 1979, J HELMINTHOL, V53, P321, DOI 10.1017/S0022149X00006179; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inoue H, 1998, MOL BIOL CELL, V9, P2145, DOI 10.1091/mbc.9.8.2145; James P, 1996, GENETICS, V144, P1425; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; LoVerde PT, 2002, J PARASITOL, V88, P3, DOI 10.1645/0022-3395(2002)088[0003:PASASA]2.0.CO;2; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Osman A, 2001, J BIOL CHEM, V276, P10072, DOI 10.1074/jbc.M005933200; Osman A, 1999, MOL BIOCHEM PARASIT, V100, P27, DOI 10.1016/S0166-6851(99)00029-8; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Ramachandran H, 1996, MOL BIOCHEM PARASIT, V83, P1, DOI 10.1016/S0166-6851(96)02731-4; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Salzet M, 2000, PARASITOL TODAY, V16, P536, DOI 10.1016/S0169-4758(00)01787-7; Schussler P, 1997, PARASITOLOGY, V115, P629, DOI 10.1017/S003118209700173X; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Smithers S. R., 1982, Immunology of parasitic infections.  2nd edition., P527; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; Vicogne J, 2003, MOL BIOCHEM PARASIT, V126, P51, DOI 10.1016/S0166-6851(02)00249-9; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; WEBSTER PJ, 1992, MOL BIOCHEM PARASIT, V51, P169, DOI 10.1016/0166-6851(92)90214-5; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	64	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6474	6486		10.1074/jbc.M310949200	http://dx.doi.org/10.1074/jbc.M310949200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14630909	hybrid			2022-12-25	WOS:000188969200033
J	Roitelman, J; Masson, D; Avner, R; Ammon-Zufferey, C; Perez, A; Guyon-Gellin, Y; Bentzen, CL; Niesor, EJ				Roitelman, J; Masson, D; Avner, R; Ammon-Zufferey, C; Perez, A; Guyon-Gellin, Y; Bentzen, CL; Niesor, EJ			Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; HMG-COA REDUCTASE; UBIQUITIN-PROTEASOME PATHWAY; STEROL-SENSING DOMAIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; CHOLESTEROL ACYLTRANSFERASE	Apomine, a novel 1,1-bisphosphonate ester, has been shown to lower plasma cholesterol concentration in several species. Here we show that Apomine reduced the levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the rate-limiting enzyme in the mevalonate pathway, both in rat liver and in cultured cells. Apomine resembles sterols such as 25-hydroxycholesterol in its ability to potently accelerate the rate of HMGR degradation by the ubiquitin-proteasome pathway, a process that depends on the transmembrane domain of the enzyme. The similarity between Apomine and sterols in promoting rapid HMGR degradation extends to its acute requirements for ongoing protein synthesis and mevalonate-derived non-sterol product(s) as a co-regulator. Yet, at suboptimal concentrations, sterols potentiated the effect of Apomine in stimulating HMGR degradation, indicating that these agents act via distinct modes. Furthermore, unlike sterols, Apomine inhibited the activity of acyl-CoA:cholesterol acyltransferase in intact cells but not in cell-free extracts. Apomine stimulated the cleavage of the precursor of sterol-regulatory element-binding protein-2 and increased the activity of low density lipoprotein receptor pathway. This Apomine-enhanced activation of sterol-regulatory element-binding protein-2 was prevented by sterols or mevalonate. Taken together, our results provide a molecular mechanism for the hypocholesterolemic activity of Apomine.	Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel; Ilex Oncol Res Sarl, CH-1290 Versoix, Switzerland	Chaim Sheba Medical Center	Niesor, EJ (corresponding author), F Hoffmann La Roche & Co Ltd, Div Pharmaceut, Bldg 69-201,Grenzacherstr 124, CH-4070 Basel, Switzerland.	eric_j.niesor@roche.com						BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; Berkhout TA, 1996, J BIOL CHEM, V271, P14376, DOI 10.1074/jbc.271.24.14376; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Engfelt WH, 1997, J BIOL CHEM, V272, P24579, DOI 10.1074/jbc.272.39.24579; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Jackson B, 2000, ARZNEIMITTEL-FORSCH, V50, pE380; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; LISCUM L, 1985, J BIOL CHEM, V260, P522; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NGUYEN L, 1991, Patent No. 5043330; Niesor EJ, 2001, CURR PHARM DESIGN, V7, P231, DOI 10.2174/1381612013398185; NIESOR EJ, 1999, DRUGS FUTURE, V4, P431; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Ravid T, 1999, J BIOL CHEM, V274, P29341, DOI 10.1074/jbc.274.41.29341; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROSS AC, 1984, J BIOL CHEM, V259, P815; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Xu LW, 2003, ARCH BIOCHEM BIOPHYS, V414, P232, DOI 10.1016/S0003-9861(03)00168-1; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	59	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6465	6473		10.1074/jbc.M308094200	http://dx.doi.org/10.1074/jbc.M308094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14627708	hybrid			2022-12-25	WOS:000188969200032
J	Wang, Y; Coulombe, R; Cameron, DR; Thauvette, L; Massariol, MJ; Amon, LM; Fink, D; Titolo, S; Welchner, E; Yoakim, C; Archambault, J; White, PW				Wang, Y; Coulombe, R; Cameron, DR; Thauvette, L; Massariol, MJ; Amon, LM; Fink, D; Titolo, S; Welchner, E; Yoakim, C; Archambault, J; White, PW			Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PAPILLOMAVIRUS; DNA-REPLICATION; FUNCTIONAL INTERACTION; ACTIVATION DOMAIN; COMPLEX-FORMATION; ESCHERICHIA-COLI; HIV-1 PROTEASE; AMINO-ACIDS; E1; TRANSCRIPTION	Interaction between the E2 protein and E1 helicase of human papillomaviruses (HPVs) is essential for the initiation of viral DNA replication. We recently described a series of small molecules that bind to the N-terminal transactivation domain (TAD) of HPV type 11 E2 and inhibits its interaction with E1 in vitro and in cellular assays. Here we report the crystal structures of both the HPV11 TAD and of a complex between this domain and an inhibitor, at 2.5- and 2.4-Angstrom resolution, respectively. The HPV11 TAD structure is very similar to that of the analogous domain of HPV16. Inhibitor binding caused no significant alteration of the protein backbone, but movements of several amino acid side chains at the binding site, in particular those of Tyr-19, His-32, Leu-94, and Glu-100, resulted in the formation of a deep hydrophobic pocket that accommodates the indandione moiety of the inhibitor. Mutational analysis provides functional evidence for specific interactions between Tyr-19 and E1 and between His-32 and the inhibitor. A second inhibitor molecule is also present at the binding pocket. Although evidence is presented that this second molecule makes only weak interactions with the protein and is likely an artifact of crystallization, its presence defines additional regions of the binding pocket that could be exploited to design more potent inhibitors.	Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Dept Chem, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA	Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim	White, PW (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Biol Sci, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	pwhite@lav.boehringer-ingelheim.com		Archambault, Jacques/0000-0001-8107-3428; Cameron, Dale/0000-0001-6274-2913				Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Brokaw JL, 1996, J VIROL, V70, P23, DOI 10.1128/JVI.70.1.23-29.1996; Cooper CS, 1998, VIROLOGY, V241, P312, DOI 10.1006/viro.1997.8941; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; GEHLHAAR DK, 1995, CHEM BIOL, V2, P317, DOI 10.1016/1074-5521(95)90050-0; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Jeffery JA, 2002, ANAL BIOCHEM, V304, P55, DOI 10.1006/abio.2002.5632; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1995, METHOD ENZYMOL, V259, P427; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Liang J, 1998, PROTEINS, V33, P1; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j; Muzammil S, 2003, BIOCHEMISTRY-US, V42, P631, DOI 10.1021/bi027019u; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Piirsoo M, 1996, EMBO J, V15, P1; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SHAH KV, 1996, FIELDS VIROLOGY, P2077; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; Tsai CJ, 1997, PROTEIN SCI, V6, P53; White PW, 2003, J BIOL CHEM, V278, P26765, DOI 10.1074/jbc.M303608200; White PW, 2001, J BIOL CHEM, V276, P22426, DOI 10.1074/jbc.M101932200; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; Yoakim C, 2003, BIOORG MED CHEM LETT, V13, P2539, DOI 10.1016/S0960-894X(03)00510-9; Yoakim C, 2003, HELV CHIM ACTA, V86, P3427, DOI 10.1002/hlca.200390287; YPHANTIS DA, 1956, J PHYS CHEM-US, V60, P623	49	73	77	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6976	6985		10.1074/jbc.M311376200	http://dx.doi.org/10.1074/jbc.M311376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14634007	hybrid			2022-12-25	WOS:000188969200093
J	Weng, YP; Lin, YP; Hsu, CI; Lin, JY				Weng, YP; Lin, YP; Hsu, CI; Lin, JY			Functional domains of a pore-forming cardiotoxic protein, volvatoxin A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-DEPENDENT CYTOLYSIN; SITE-DIRECTED MUTAGENESIS; BACILLUS-THURINGIENSIS; ALPHA-HEMOLYSIN; MEMBRANE ASSOCIATION; SECONDARY STRUCTURE; BINDING; TOXINS; HELIX; MECHANISM	Volvatoxin A2 (VVA2), a novel pore-forming cardiotoxic protein was isolated from the mushroom Volvariella volvacea. We identified an N-terminal fragment (NTF) (1-127 residues) of VVA2 as a domain for oligomerization by limited tryptic digestion. On preincubation of NTF with VVA2, NTF was found to inhibit VVA2 hemolytic activity by inducing VVA2 oligomerization in the solution in the same manner as liposomes. By site-directed mutagenesis, the amphipathic a-helix B of NTF or VVA2 was shown to be indispensable for its biological functions. Interestingly, at a molar ratio of recombinant NTF (reNTF)/VVA2 as low as 0.01, reNTF was able to inhibit VVA2 hemolytic activity and induce VVA2 oligomerization. This indicates that reNTF can trigger VVA2 oligomerization by a seeding effect. Furthermore, the recombinant C-terminal fragment (128-199 residues) was found to be a functional domain that mediates the membrane binding of VVA2. We found a fragment localized at the C-terminal half of VVA2 containing beta6, -7, and -8, which is protected from protease digestion because of its insertion of a membrane. We also identified a putative heparin binding site (HBS) located in the VVA2 C terminus (166-194 residues), which was conserved among 10 kinds of snake venom cardiotoxins. VVA2 or the reHBS fragment was shown to interact with sulfated glycoaminoglycans by affinity column chromatography. The finding of a higher number of glycoaminoglycans in the membrane of cardiac myocytes suggested that they could be the specific membrane target for VVA2. Taken together, these findings indicate that VVA2 contains two functional domains, NTF and CTF. The NTF domain is responsible for VVA2 oligomerization and the CTF domain for membrane binding and insertion. Our results support a model whereby the formation of VVA2 oligomeric pre-pore complexes precedes their membrane insertion.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10081, Taiwan	National Taiwan University	Lin, JY (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, F9,1,Sect 1,Jen Ai Rd, Taipei 10081, Taiwan.	jylin@ha.mc.ntu.edu.tw	Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Du JP, 1999, BIOCHEM J, V338, P185, DOI 10.1042/0264-6021:3380185; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Erb EM, 2000, ANAL BIOCHEM, V280, P29, DOI 10.1006/abio.1999.4469; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FASSOLD E, 1976, J MOL CELL CARDIOL, V8, P501, DOI 10.1016/0022-2828(76)90052-3; GATINEAU E, 1990, BIOCHEMISTRY-US, V29, P6480, DOI 10.1021/bi00479a021; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; LIN JY, 1973, NATURE, V246, P524, DOI 10.1038/246524a0; Lin WH, 1997, J BIOL CHEM, V272, P20044, DOI 10.1074/jbc.272.32.20044; Liu CL, 2000, J BIOL CHEM, V275, P1897, DOI 10.1074/jbc.275.3.1897; Martin GA, 2001, BIOTECHNIQUES, V31, P948, DOI 10.2144/01314pf01; McInerney TL, 1998, J VIROL, V72, P1523, DOI 10.1128/JVI.72.2.1523-1533.1998; Menestrina G, 2001, TOXICON, V39, P1661, DOI 10.1016/S0041-0101(01)00153-2; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Patel HV, 1997, J BIOL CHEM, V272, P1484, DOI 10.1074/jbc.272.32.20185; Promdonkoy B, 2000, BIOCHEM J, V350, P275, DOI 10.1042/0264-6021:3500275; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; Sangha N, 1999, J BIOL CHEM, V274, P9193, DOI 10.1074/jbc.274.14.9193; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shimada Y, 1999, J BIOL CHEM, V274, P18536, DOI 10.1074/jbc.274.26.18536; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Vyas AA, 1997, J BIOL CHEM, V272, P9661, DOI 10.1074/jbc.272.15.9661; Wang W, 1998, J BIOL CHEM, V273, P27438, DOI 10.1074/jbc.273.42.27438; WENG YP, 2000, P TAIW SOC BIOCH MOL, P49; YAMANAKA H, 1987, J GEN MICROBIOL, V133, P2859	43	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6805	6814		10.1074/jbc.M308675200	http://dx.doi.org/10.1074/jbc.M308675200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645370	hybrid			2022-12-25	WOS:000188969200074
J	Bundgaard, JR; Birkedal, H; Rehfeld, JF				Bundgaard, JR; Birkedal, H; Rehfeld, JF			Progastrin is directed to the regulated secretory pathway by synergistically acting basic and acidic motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CARBOXYPEPTIDASE-E; SORTING RECEPTOR; CHROMOGRANIN-A; MUTATIONAL ANALYSIS; ENDOCRINE-CELLS; CLEAVAGE SITE; GRANULES; PROTEIN; BINDING	Bioactivation of prohormones occurs in the granules of the regulated secretory pathway of endocrine cells, which release hormones in response to external stimulation. How secretory granules are formed and how the cargo is selected is still unclear, but it has been shown for several prohormones and processing enzymes that domains within the prohormone structure can act as " sorting signals" for this pathway. The domains mediate interactions with other proteins or with the membrane or facilitate aggregation of the ( pro) peptides. We have now searched for domains in progastrin that are active in sorting the prohormone into secretory granules. Truncation studies showed that the N- terminal 30 residues of progastrin are dispensable, whereas the last 49 residues are sufficient for correct biosynthesis of bioactive gastrin. Thus, further N- terminal truncation abolished gastrin expression. C- terminal truncation of 8 residues resulted in an increase in basal secretion as did point mutations in the dibasic processing sites of progastrin. These mutants, however, still responded to secretagogues, suggesting a residual sorting capacity to the regulated pathway. Amino acid substitutions in an acidic, polyglutamate motif within gastrin- 17, the main bioactive, cellular gastrin form, did not alter secretion per se, but when these residues were substituted in C-terminally truncated mutants, double mutants increased in basal secretion and did not respond to secretagogue stimulation. This implies that the mutants are constitutively secreted. Our data suggest that the dibasic processing sites constitute the most important sorting domain of progastrin, and these sites act in synergy with the acidic domain.	Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Bundgaard, JR (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	jrb@rh.dk						Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Bernard N, 2003, J NEUROCHEM, V85, P1592, DOI 10.1046/j.1471-4159.2003.01823.x; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; Brakch N, 2002, J NEUROCHEM, V81, P1166, DOI 10.1046/j.1471-4159.2002.00919.x; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bundgaard Jens R, 2002, Methods Mol Biol, V194, P291; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Bundgaard JR, 1996, DNA CELL BIOL, V15, P147, DOI 10.1089/dna.1996.15.147; Canaff L, 1996, P NATL ACAD SCI USA, V93, P9483, DOI 10.1073/pnas.93.18.9483; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 2001, MOL CELL ENDOCRINOL, V177, P87, DOI 10.1016/S0303-7207(01)00437-3; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; Dhanvantari S, 2002, BIOCHEMISTRY-US, V41, P52, DOI 10.1021/bi015698n; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; Feliciangeli S, 2001, J BIOL CHEM, V276, P6140, DOI 10.1074/jbc.M009613200; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Gorr SU, 2001, MOL CELL ENDOCRINOL, V172, P1, DOI 10.1016/S0303-7207(00)00342-7; GORR SU, 1989, AM J PHYSIOL, V257, P247; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KRANE IM, 1988, J BIOL CHEM, V263, P13317; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Pannequin J, 2002, J BIOL CHEM, V277, P48602, DOI 10.1074/jbc.M208440200; REHFELD JF, 1978, J BIOL CHEM, V253, P4016; REHFELD JF, 1994, EUR J BIOCHEM, V223, P765, DOI 10.1111/j.1432-1033.1994.tb19051.x; Rehfeld JF, 2002, FEBS LETT, V510, P89, DOI 10.1016/S0014-5793(01)03234-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHIELDS PP, 1990, J BIOL CHEM, V265, P10905; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Thiele C, 1997, CURR BIOL, V7, P496; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Yoo SH, 1998, FEBS LETT, V427, P55, DOI 10.1016/S0014-5793(98)00393-7; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5488	5493		10.1074/jbc.M310547200	http://dx.doi.org/10.1074/jbc.M310547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660571	hybrid			2022-12-25	WOS:000188776500056
J	Chen, NH; Rickey, J; Berfield, JL; Reith, MEA				Chen, NH; Rickey, J; Berfield, JL; Reith, MEA			Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE TRANSPORTERS; CROSS-LINKING; INHIBITION; EXPRESSION; CLONING; SITE; ACCESSIBILITY; CYSTEINE; ALTERS	present study elucidated the role of aspartate 345, a residue conserved in the third intracellular loop of all Na+/Cl-- dependent neurotransmitter transporters, in conformational changes of the dopamine ( DA) transporter. Asparagine substitution ( D345N) resulted in near normal transporter expression on the cell surface but caused extremely low V-max and K-m values for DA uptake, converted the inhibitory effect of Zn2+ on DA uptake to a stimulatory one, and eliminated reverse transport. The cocaine- like inhibitor 2 beta- carbomethoxy-3beta ( 4- fluorophenyl) tropane or the selective DA transporter inhibitor GBR12935 bound to D345N with a normal affinity and still inhibited DA uptake potently. However, the mutation reduced the binding capacity of the surface transporter for these two inhibitors by 90% or more. Moreover, the binding activity of D345N can be significantly improved by Zn2+ but not by Na+. These results are consistent with a defect in reorientation of the substrate- binding site to the extracellular side, leading to a loss of the outward- facing conformational state where external DA binds to initiate uptake and the inhibitors bind to initiate uptake inhibition. Alanine or glutamate substitution produced a similar phenotype, suggesting that both the negative charge and the residue volume at position 345 are vital. Furthermore, in intact cells, cocaine potentiated the reaction of the membrane- impermeant sulfhydryl reagent methanethiosulfonate ethyltrimethylammonium with the extracellularly located endogenous cysteines of D345N but not those of wild type, and this potentiation was blocked upon K+ substitution for Na+. Thus, cocaine binding to D345N likely induces a different and Na+- dependent conformational change, which may contribute to its Na+ -dependent uptake inhibitory activity.	NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA	New York University; University of Illinois System; University of Illinois Peoria	Chen, NH (corresponding author), NYU, Sch Med, Dept Psychiat, 550 1st Ave,HN 604, New York, NY 10016 USA.	nianhang.chen@med.nyu.edu	Reith, Maarten E./AAD-2303-2019	Reith, Maarten E./0000-0002-1900-842X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008379] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08379] Funding Source: Medline; PHS HHS [13261] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Bonisch H, 1998, METHOD ENZYMOL, V296, P259; BURNETTE WB, 1996, ANAL CHEM, V269, P12290; Carroll F. Ivy, 2002, P381; CHEN N, 2003, IN PRESS PFLUEGERS A; Chen NH, 2003, J NEUROCHEM, V86, P678, DOI 10.1046/j.1471-4159.2003.01889.x; Chen NH, 2002, J NEUROCHEM, V81, P1383, DOI 10.1046/j.1471-4159.2002.00941.x; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Chen NH, 2000, MOL BRAIN RES, V75, P208, DOI 10.1016/S0169-328X(99)00288-0; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; Chen Nian-Hang, 2002, P53; Deken Scott L., 2002, P193; Eshleman AJ, 1999, J PHARMACOL EXP THER, V289, P877; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1992, MOL PHARMACOL, V42, P383; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KRUPKA RM, 1983, INT REV CYTOL, V84, P303, DOI 10.1016/S0074-7696(08)61021-9; Kula NS, 1999, EUR J PHARMACOL, V385, P291, DOI 10.1016/S0014-2999(99)00695-0; LITTLE KY, 1995, J PHARMACOL EXP THER, V274, P1473; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Povlock SL, 1997, J NEUROCHEM, V69, P1093; REITH MEA, 1993, J NEUROCHEM, V61, P167, DOI 10.1111/j.1471-4159.1993.tb03552.x; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; RICHFIELD EK, 1991, BRAIN RES, V540, P1, DOI 10.1016/0006-8993(91)90486-F; ROSS SB, 1976, MECH NEUROANAL EXTRA, P49; Scholze P, 2002, J BIOL CHEM, V277, P21505, DOI 10.1074/jbc.M112265200; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200	36	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5508	5519		10.1074/jbc.M306294200	http://dx.doi.org/10.1074/jbc.M306294200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660644	hybrid			2022-12-25	WOS:000188776500059
J	Grimard, V; Li, CH; Ramjeesingh, M; Bear, CE; Goormaghtigh, E; Ruysschaert, JM				Grimard, V; Li, CH; Ramjeesingh, M; Bear, CE; Goormaghtigh, E; Ruysschaert, JM			Phosphorylation-induced conformational changes of cystic fibrosis transmembrane conductance regulator monitored by attenuated total reflection-fourier transform IR spectroscopy and fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN STRUCTURE; CFTR CHLORIDE CHANNEL; R-DOMAIN; INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; ESCHERICHIA-COLI; MULTIDRUG TRANSPORTER; MASS-SPECTROMETRY; ORIENTATION; EXCHANGE	Cystic fibrosis transmembrane conductance regulator ( CFTR) is a member of the ABC protein superfamily. Phosphorylation of a regulatory domain of this protein is a prerequisite for activity. We analyzed the effect of protein kinase A ( PKA) phosphorylation on the structure of purified and reconstituted CFTR protein. H-1/H-2 exchange monitored by attenuated total reflection Fourier transform IR spectroscopy demonstrates that CFTR is highly accessible to aqueous medium. Phosphorylation of the regulatory ( R) domain by PKA further increases this accessibility. More specifically, fluorescence quenching of cytosolic tryptophan residues revealed that the accessibility of the cytoplasmic part of the protein is modified by phosphorylation. Moreover, the combination of polarized IR spectroscopy with H-1/H-2 exchange suggested an increase of the accessibility of the transmembrane domains of CFTR. This suggests that CFTR phosphorylation can induce a large conformational change that could correspond either to a displacement of the R domain or to long range conformational changes transmitted from the phosphorylation sites to the nucleotide binding domains and the transmembrane segments. Such structural changes may provide better access for the solutes to the nucleotide binding domains and the ion binding site.	Free Univ Brussels, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium; Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Ruysschaert, JM (corresponding author), Free Univ Brussels, Ctr Struct Biol & Bioinformat, Campus Plaine CP206-2, B-1050 Brussels, Belgium.	jmruysss@ulb.ac.be		Goormaghtigh, Erik/0000-0002-2071-2262				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; Baldursson O, 2001, J BIOL CHEM, V276, P1904, DOI 10.1074/jbc.M006934200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; DEMPSEY CE, 1992, BIOCHEMISTRY-US, V31, P11973, DOI 10.1021/bi00163a003; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; Goormaghtigh E, 1996, APPL SPECTROSC, V50, P1519, DOI 10.1366/0003702963904610; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; Grimard V, 2001, BIOCHEMISTRY-US, V40, P11876, DOI 10.1021/bi010017+; HOWELL LD, 2003, IN PRESS BIOCH J; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; King SA, 2000, BIOCHEMISTRY-US, V39, P9868, DOI 10.1021/bi992807d; Kogan I, 2003, EMBO J, V22, P1981, DOI 10.1093/emboj/cdg194; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1997, J GEN PHYSIOL, V110, P355, DOI 10.1085/jgp.110.4.355; Linsdell P, 1998, AM J PHYSIOL-CELL PH, V275, pC323, DOI 10.1152/ajpcell.1998.275.1.C323; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Manciu L, 2000, BIOCHEMISTRY-US, V39, P13026, DOI 10.1021/bi001043v; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Neville DCA, 1997, PROTEIN SCI, V6, P2436; Ostedgaard LS, 2000, P NATL ACAD SCI USA, V97, P5657, DOI 10.1073/pnas.100588797; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; Ramjeesingh M, 1999, Methods Enzymol, V294, P227; Raussens V, 2003, ANAL BIOCHEM, V319, P114, DOI 10.1016/S0003-2697(03)00285-9; Reddy MM, 2003, NATURE, V423, P756, DOI 10.1038/nature01694; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIORDAN JR, 1989, SCIENCE, V245, P1066; Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912; Vigano C, 2002, FEBS LETT, V530, P197, DOI 10.1016/S0014-5793(02)03485-3; Wang WL, 2002, AM J PHYSIOL-CELL PH, V282, pC1170, DOI 10.1152/ajpcell.00337.2001; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	51	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5528	5536		10.1074/jbc.M311014200	http://dx.doi.org/10.1074/jbc.M311014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660584	hybrid			2022-12-25	WOS:000188776500061
J	Kollewe, C; Mackensen, AC; Neumann, D; Knop, J; Cao, P; Li, SU; Wesche, H; Martin, MU				Kollewe, C; Mackensen, AC; Neumann, D; Knop, J; Cao, P; Li, SU; Wesche, H; Martin, MU			Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-6 TRAF6; CUTTING EDGE; MICE LACKING; IL-1; IRAK; PROTEIN; ACTIVATION; MEMBER; MYD88	The interleukin-1 receptor-associated kinase 1 (IRAK-1) is an important adapter in the signaling complex of the Toll/interleukin-1 (IL-1) receptor family. Formation of the signaling IL-1 receptor complex results in the activation and hyperphosphorylation of IRAK-1, which leads to a pronounced shift of its apparent molecular mass in gel electrophoresis. Presently, the individual residues phosphorylated in IRAK-1 and the consequences for IRAK-1 function are unknown. We define sequential phosphorylation steps in IRAK-1, which are, in vitro, autophosphorylation. First, IRAK-1 is phosphorylated at Thr(209). By fluorescence energy transfer experiments, we demonstrate that Thr209 phosphorylation results in a conformational change of the kinase domain, permitting further phosphorylations to take place. Substitution of Thr209 by alanine results in a kinase-inactive IRAK-1. Second, Thr(387) in the activation loop is phosphorylated, leading to full enzymatic activity. Third, IRAK-1 autophosphorylates several times in the proline-, serine-, and threonine-rich ProST region between the N-terminal death domain and kinase domain. Hyperphosphorylation of this region leads to dissociation of IRAK-1 from the upstream adapters MyD88 and Tollip but leaves its interaction with the downstream adapter TRAF6 unaffected. This identifies IRAK-1 as a novel type of adapter protein, which employs its own kinase activity to introduce negative charges adjacent to the protein interaction domain, which anchors IRAK-1 at the active receptor complex. Thus, IRAK-1 regulates its own availability as an adapter molecule by sequential autophosphorylation.	Hannover Med Sch, Dept Pharmacol, D-30623 Hannover, Germany; Hannover Med Sch, Dept Biochem, D-30623 Hannover, Germany; Tularik Inc, San Francisco, CA 94080 USA	Hannover Medical School; Hannover Medical School	Kollewe, C (corresponding author), Univ Giessen, Immunol FB 08, Winchesterstr 2, D-35394 Giessen, Germany.	Christian.Kollewe@bio.uni-giessen.de	Neumann, Detlef/F-6182-2011	Neumann, Detlef/0000-0003-0145-7507				Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao P, 2000, RAPID COMMUN MASS SP, V14, P1600, DOI 10.1002/1097-0231(20000915)14:17<1600::AID-RCM68>3.0.CO;2-V; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hu J, 2002, J IMMUNOL, V168, P3910, DOI 10.4049/jimmunol.168.8.3910; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kanakaraj P, 1999, J EXP MED, V189, P1129, DOI 10.1084/jem.189.7.1129; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Ross K, 2002, J BIOL CHEM, V277, P37414, DOI 10.1074/jbc.M205160200; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takatsuna H, 2003, J BIOL CHEM, V278, P12144, DOI 10.1074/jbc.M300720200; Thomas JA, 1999, J IMMUNOL, V163, P978; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	40	175	194	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5227	5236		10.1074/jbc.M309251200	http://dx.doi.org/10.1074/jbc.M309251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625308	hybrid			2022-12-25	WOS:000188776500024
J	Murthy, KGK; Deb, A; Goonesekera, S; Szabo, C; Salzman, AL				Murthy, KGK; Deb, A; Goonesekera, S; Szabo, C; Salzman, AL			Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE FLAGELLIN; TOLL-LIKE RECEPTOR-5; INTESTINAL EPITHELIAL-CELLS; BACTERIAL FLAGELLIN; PROINFLAMMATORY RESPONSE; DENDRITIC CELLS; IMMUNE-RESPONSE; EXPRESSION; PROTEIN; BINDING	The bacterial surface protein flagellin is widely distributed and well conserved among distant bacterial species. We and other investigators have reported recently that purified flagellin from Salmonella dublin or recombinant flagellin of Salmonella muenchen origin binds to the eukaryotic toll receptor TLR5 and activates the nuclear translocation of NF-kappaB and mitogen-activated protein kinase, resulting in the release of a host of pro-inflammatory mediators in vitro and in vivo. The amino acid sequence alignment of flagellins from various Gram-negative bacteria shows that the C and N-termini are well conserved. It is possible that sequences within the N and C termini or both may regulate the pro-inflammatory activity of flagellin. Here we set out to map more precisely the regions in both termini that are required for TLR5 activation and pro-inflammatory signaling. Systematic deletion of amino acids from either terminus progressively reduced eukaryotic pro-inflammatory activation. However, deletion of amino acids 95 108 (motif N) in the N terminus and 441-449 (motif C) in the C terminus abolished pro-inflammatory activity completely. Site-directed mutagenesis analysis provided further evidence for the importance of motifs N and C. We also present evidence for the functional role of motifs N and C with the TLR5 receptor using a reporter assay system. Taken together, our results demonstrate that the pro-inflammatory activity of flagellin results from the interaction of motif N with the TLR5 receptor on the cell surface.	Inotek Pharmaceut Corp, Beverly, MA 01915 USA	Inotek Pharmaceuticals	Salzman, AL (corresponding author), Inotek Pharmaceut Corp, 100 Cummings Ctr,Ste 419E, Beverly, MA 01915 USA.	alsalzman@aol.com	Szabo, Csaba/D-1882-2013; Szabo, Csaba/ABG-2644-2021		NIAID NIH HHS [R43AI48249] Funding Source: Medline; NIGMS NIH HHS [R01GM60699] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI048249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060699] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldridge P, 2002, CURR OPIN MICROBIOL, V5, P160, DOI 10.1016/S1369-5274(02)00302-8; Ciacci-Wooline F, 1999, INFECT IMMUN, V67, P5176, DOI 10.1128/IAI.67.10.5176-5185.1999; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Donnelly MA, 2002, J BIOL CHEM, V277, P40456, DOI 10.1074/jbc.M206851200; DWYER JM, 1972, INT ARCH ALLER A IMM, V43, P434, DOI 10.1159/000230860; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Jacchieri SG, 2003, J BACTERIOL, V185, P4243, DOI 10.1128/JB.185.14.4243-4247.2003; Liaudet L, 2003, SHOCK, V19, P131, DOI 10.1097/00024382-200302000-00008; Liaudet L, 2002, INFECT IMMUN, V70, P192, DOI 10.1128/IAI.70.1.192-198.2002; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Mizel SB, 2003, J BIOL CHEM, V278, P23624, DOI 10.1074/jbc.M303481200; Mizel SB, 2003, J IMMUNOL, V170, P6217, DOI 10.4049/jimmunol.170.12.6217; Mizel SB, 2002, J BIOL CHEM, V277, P22414, DOI 10.1074/jbc.M201762200; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Reed KA, 2002, J BIOL CHEM, V277, P13346, DOI 10.1074/jbc.M200149200; Salzman AL, 1996, AM J PHYSIOL-GASTR L, V270, pG565, DOI 10.1152/ajpgi.1996.270.4.G565; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zhou X, 2003, INFECT IMMUN, V71, P2120, DOI 10.1128/IAI.71.4.2120-2129.2003	30	92	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5667	5675		10.1074/jbc.M307759200	http://dx.doi.org/10.1074/jbc.M307759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634022	hybrid			2022-12-25	WOS:000188776500078
J	Sundararaj, KP; Wood, RE; Ponnusamy, S; Salas, AM; Szulc, Z; Bielawska, A; Obeid, LM; Hannun, YA; Ogretmen, B				Sundararaj, KP; Wood, RE; Ponnusamy, S; Salas, AM; Szulc, Z; Bielawska, A; Obeid, LM; Hannun, YA; Ogretmen, B			Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE FIBROBLASTS; LUNG ADENOCARCINOMA CELLS; CANCER CELLS; PROTEIN; END; RNA; SEQUENCE; POT1; GENE; EXPRESSION	Ceramide has been demonstrated as one of the upstream regulators of telomerase activity. However, the role for ceramide in the control of telomere length remains unknown. It is shown here that treatment of the A549 human lung adenocarcinoma cells with C-6-ceramide results in rapid shortening of telomere length. During the examination of ceramide-regulated telomere-binding proteins, nuclear glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified to associate with both single- and double-stranded telomeric DNA with high specificity in vitro. The association of nuclear GAPDH with telomeres in interphase nuclei was also demonstrated by co-fluorescence in situ hybridization and chromatin immunoprecipitation analysis. Further data demonstrated that the nuclear localization of GAPDH is regulated by ceramide in a cell cycle-dependent manner parallel with the inhibition of its telomere binding activity in response to ceramide. In addition, the results revealed that nuclear GAPDH is distinct from its cytoplasmic isoform and that telomere binding function of nuclear GAPDH is strikingly higher than the cytoplasmic isoform. More importantly, the functional role for nuclear GAPDH in the maintenance and/or protection of telomeric DNA was identified by partial inhibition of the expression of GAPDH using small interfering RNA, which resulted in rapid shortening of telomeres. In contrast, overexpression of nuclear GAPDH resulted in the protection of telomeric DNA in response to exogenous ceramide as well as in response to anticancer drugs, which have been shown to induce endogenous ceramide levels. Therefore, these results demonstrate a novel function for nuclear GAPDH in the maintenance and/or protection of telomeres and also show that mechanisms of the rapid degradation of telomeres in response to ceramide involve the inhibition of the telomere binding activity of nuclear GAPDH.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,BSB-518E, Charleston, SC 29425 USA.	ogretmen@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [R01CA088932, P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [CA88932, P01 CA097132] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; Epner DE, 1996, PROSTATE, V28, P372; Flamigni F, 1997, BIOCHEM J, V324, P783, DOI 10.1042/bj3240783; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Kellner U, 2000, PATHOL RES PRACT, V196, P801, DOI 10.1016/S0344-0338(00)80079-5; Kiyozuka Y, 2000, ANTICANCER RES, V20, P203; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; Kruk PA, 1997, BIOCHEM BIOPH RES CO, V233, P717, DOI 10.1006/bbrc.1997.6549; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lowe DA, 2000, J GERONTOL A-BIOL, V55, pB160, DOI 10.1093/gerona/55.3.B160; Mazzola JL, 2002, MOL BRAIN RES, V100, P95, DOI 10.1016/S0169-328X(02)00160-2; Mazzola JL, 2001, J NEUROCHEM, V76, P442, DOI 10.1046/j.1471-4159.2001.00033.x; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Riha K, 2003, P NATL ACAD SCI USA, V100, P611, DOI 10.1073/pnas.0236128100; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sprott KM, 2002, BIOCHEM J, V365, P181, DOI 10.1042/BJ20020215; Tatton WG, 2000, ADV RES NEURODEGENER, V8, P77; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	49	100	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6152	6162		10.1074/jbc.M310549200	http://dx.doi.org/10.1074/jbc.M310549200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630908	hybrid			2022-12-25	WOS:000188776500131
J	Koh, EY; Chen, T; Daley, GQ				Koh, EY; Chen, T; Daley, GQ			Genetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation	ONCOGENE			English	Article						expression cloning; cytokine signaling; tyrosine kinase; myeloproliferative disease	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; HOMEOBOX GENE; PROTEIN-KINASE; MYELODYSPLASTIC SYNDROMES; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; TRANSFORMING GENE; MYELOID-LEUKEMIA	Molecular evidence suggests a multistep process in the development of acute leukemia. Since inappropriate activation of cytokine signaling cascades is a recurring theme in human leukemia, we performed expression screens to identify genes that transform cytokine-dependent cells. Using retroviral cDNA libraries derived from peripheral blood mononuclear cells of patients with myeloproliferative disorders, we isolated numerous genes that genetically complement cytokine requirements for proliferation of BaF/3 and TF-1 cells. The majority of recovered genes represent members of the kinase family, including several previously linked to leukemogenesis. Our unbiased screen highlights the central role of kinase activation in hematopoietic cell proliferation and identifies a number of potential leukemic oncoproteins.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; Harvard Univ, Sch Med,Childrens Hosp, Dept Biol Chem & Mol Pharmacol, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Daley, GQ (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991, T32CA009541] Funding Source: NIH RePORTER; NCI NIH HHS [CA09541, CA76418, CA86991] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, GM07753-22] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ALLEN JD, 1995, J IMMUNOL, V154, P1531; ALLEN JD, 1993, BLOOD, V81, P3242; AOKI M, 1993, J BIOL CHEM, V268, P22723; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BAKER DA, 1994, LEUKEMIA, V8, P141; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108; Bourette RP, 1992, GROWTH FACTORS, V7, P315, DOI 10.3109/08977199209046414; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHAN AML, 1993, ONCOGENE, V8, P1329; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Deguchi K, 2002, LEUKEMIA, V16, P740, DOI 10.1038/sj.leu.2402500; DEGUCHI Y, 1992, J BIOL CHEM, V267, P8222; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hariharan I K, 1988, Oncogene Res, V3, P387; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; KOH EY, 2001, CHRONIC MYELOID LEUK, P56; Kulkarni S, 2000, CANCER RES, V60, P3592; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; MCARTHUR GA, 1994, BLOOD, V83, P972; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tabrizi M, 1998, LEUKEMIA, V12, P200, DOI 10.1038/sj.leu.2400949; TOBAL K, 1990, LEUKEMIA, V4, P486; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yates KE, 1996, STEM CELLS, V14, P117, DOI 10.1002/stem.140117	61	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1214	1220		10.1038/sj.onc.1207209	http://dx.doi.org/10.1038/sj.onc.1207209			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647454				2022-12-25	WOS:000188892200005
J	Ismail, IH; Martensson, S; Moshinsky, D; Rice, A; Tang, C; Howlett, A; McMahon, G; Hammarsten, O				Ismail, IH; Martensson, S; Moshinsky, D; Rice, A; Tang, C; Howlett, A; McMahon, G; Hammarsten, O			SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization	ONCOGENE			English	Article						radiotherapy; DNA-PK; radio sensitizer; ATM	SEVERE COMBINED IMMUNODEFICIENCY; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; MAMMALIAN DNA; HISTONE H2AX; PHOSPHORYLATION; WORTMANNIN	Loss of the DNA-dependent protein kinase (DNA-PK) results in increased sensitivity to ionizing radiation due to inefficient repair of DNA double-strand breaks. Overexpression of DNA-PK in tumor cells conversely results in resistance to ionizing radiation. It is therefore possible that inhibition of DNA-PK will enhance the preferential killing of tumor cells by radiotherapy. Available inhibitors of DNA-PK, like wortmannin, are cytotoxic and stop the cell cycle because they inhibit phoshatidylinositol-3-kinases at 100-fold lower concentrations required to inhibit DNA-PK. In an effort to develop a specific DNA-PK inhibitor, we have characterized SU11752, from a three-substituted indolin-2-ones library. SU11752 and wortmannin were equally potent inhibitors of DNA-PK. In contrast, inhibition of the phoshatidylinositol-3-kinase p110gamma required 500-fold higher concentration of SU11752. Thus, SU11752 was a more selective inhibitor of DNA-PK than wortmannin. Inhibition kinetics and a direct assay for ATP binding showed that SU11752 inhibited DNA-PK by competing with ATP. SU11752 inhibited DNA double-strand break repair in cells and gave rise to a five-fold sensitization to ionizing radiation. At concentrations of SU11752 that inhibited DNA repair, cell cycle progression was still normal and ATM kinase activity was not inhibited. We conclude that SU11752 defines a new class of drugs that may serve as a starting point for the development of specific DNA-PK inhibitors.	Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden; SUGEN Inc, San Francisco, CA 94080 USA	Sahlgrenska University Hospital; University of Gothenburg; Pfizer	Hammarsten, O (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.	ola.hammarsten@clinchem.gu.se	Hammarsten, Ola/A-2791-2012	Ismail, Ismail Hassan/0000-0002-5526-6063				Ahn JY, 2000, CANCER RES, V60, P5934; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; Christodoulopoulos G, 1998, CANCER RES, V58, P1789; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dibiase SJ, 2000, CANCER RES, V60, P1245; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Elmroth K, 2000, INT J RADIAT BIOL, V76, P1501, DOI 10.1080/09553000050176261; Elmroth K, 2003, DNA REPAIR, V2, P363, DOI 10.1016/S1568-7864(02)00235-5; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frit P, 1999, MOL PHARMACOL, V56, P141, DOI 10.1124/mol.56.1.141; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Martensson S, 2002, J BIOL CHEM, V277, P3020, DOI 10.1074/jbc.M106711200; Martensson S, 2003, RADIAT RES, V160, P291, DOI 10.1667/0033-7587(2003)160[0291:AOTDPK]2.0.CO;2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; NIAS AHW, 1998, INTRO RADIOBIOLOGY, P116; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Puglianiello A, 2000, J ENDOCRINOL, V165, P123, DOI 10.1677/joe.0.1650123; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; RUBIN P, 1993, CLIN ONCOLOGY MULTID, P71; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shen HX, 1997, ONCOL RES, V9, P295; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shin EK, 1997, J IMMUNOL, V158, P3565; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stenerlow B, 2003, RADIAT RES, V159, P502, DOI 10.1667/0033-7587(2003)159[0502:MOPDDS]2.0.CO;2; Stockley M, 2001, BIOORG MED CHEM LETT, V11, P2837, DOI 10.1016/S0960-894X(01)00537-6; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TAKE Y, 1995, BIOCHEM BIOPH RES CO, V215, P41, DOI 10.1006/bbrc.1995.2431; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Tounekti O, 2001, BRIT J CANCER, V84, P1272, DOI 10.1054/bjoc.2001.1786; Vaganay-Juery S, 2000, BRIT J CANCER, V83, P514, DOI 10.1054/bjoc.2000.1258; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, CANCER RES, V61, P270; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Williams CJ, 2001, MOL CELL BIOL, V21, P400, DOI 10.1128/MCB.21.2.400-413.2001; XU W, 2002, NAT CELL BIOL, V2, P339; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	67	72	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					873	882		10.1038/sj.onc.1207303	http://dx.doi.org/10.1038/sj.onc.1207303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661061				2022-12-25	WOS:000188486600002
J	Lee, M; Daniels, MJ; Venkitararnan, AR				Lee, M; Daniels, MJ; Venkitararnan, AR			Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression	ONCOGENE			English	Article						BRCA2; polo; DNA repair; mitosis	CANCER SUSCEPTIBILITY GENE; HUMAN BREAST-CANCER; CELL-CYCLE; PROGNOSTIC-SIGNIFICANCE; PROTEIN-KINASE; RAD51 PROTEIN; EXPRESSION; RECOMBINATION; ACTIVATION; PROPHASE	The breast cancer susceptibility protein, BRCA2, preserves chromosomal stability through roles in the repair of DNA double-strand breaks, and possibly, cell division. Post-translational modifications that may coordinate these functions remain poorly characterized. Here, we report that BRCA2 is a substrate for the mitotic Polo-like kinase, Plk1. BRCA2 undergoes phosphorylation in cells synchronously passing through the G2/M phases of cell cycle, when Plk1 expression and activity are maximal. Depletion of Plk1 by RNA interference suppresses BRCA2 modification. BRCA2 and Plk1 interact with one another in cell lysates, through a conserved region in BRCA2, which spans the eight BRC repeat motifs essential for its function in DNA repair. Within this. region, residues positioned between BRC repeats - but not the repeat motifs themselves - are phosphorylated by Plk1. Interestingly, Plk1-mediated modification of BRCA2 during the G2/M phases is inhibited by treatment with the radiomimetic agent, adriamycin. Thus, our findings define a regulatory circuit for BRCA2 phosphorylation by Plk1 that is responsive to DNA damage as well as mitotic progression.	Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England	University of Cambridge; University of Cambridge	Venkitararnan, AR (corresponding author), Univ Cambridge, CR UK Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Lee, MiYoung/G-3748-2014	Daniels, Matthew/0000-0002-9250-6214				Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2000, PHILOS T R SOC B, V355, P191, DOI 10.1098/rstb.2000.0558; Weitzer S, 2002, DEV CELL, V2, P381, DOI 10.1016/S1534-5807(02)00155-7; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu KJ, 2003, J BIOL CHEM, V278, P15652, DOI 10.1074/jbc.M211297200; Yu VPCC, 2000, GENE DEV, V14, P1400	41	67	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					865	872		10.1038/sj.onc.1207223	http://dx.doi.org/10.1038/sj.onc.1207223			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647413				2022-12-25	WOS:000188486600001
J	Mackenzie, GG; Carrasquedo, F; Delfino, JM; Keen, CL; Fraga, CG; Oteiza, PI				Mackenzie, GG; Carrasquedo, F; Delfino, JM; Keen, CL; Fraga, CG; Oteiza, PI			Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappa B activation at multiple steps in Jurkat T cells	FASEB JOURNAL			English	Article						(-)-epicatechin; (+)-catechin; dimeric procyanidin; immune response; IL-2	GENE-EXPRESSION; ANTIOXIDANT ACTIVITY; COCOA PROCYANIDINS; HUMAN PLASMA; KINASE-BETA; TRANSCRIPTION; POLYPHENOLS; CHOCOLATE; INTERLEUKIN-2; ALPHA	The capacity of the flavan-3-ols [(-)-epicatechin (EC) and (+)-catechin (CT)] and a B dimeric procyanidin (DP-B) to modulate phorbol 12-myristate 13-acetate (PMA)-induced NF-kappa B activation in Jurkat T cells was investigated. The classic PMA-triggered increase in cell oxidants was prevented when cells were preincubated for 24 h with EC, CT, or DP-B (1.7-17.2 mu M). PMA induced the phosphorylation of IKK beta and the subsequent degradation Of I kappa B alpha: These events were inhibited in cells pretreated with the flavonoids. PMA induced a 4.6-fold increase in NF-kappa B nuclear binding activity in control cells. Pretreatment with EC, CT, or DP-B decreased PMA-induced NF-kappa B binding activity and the transactivation of the NF-kappa B-driven gene IL-2. EC, CT, and DP-B inhibited, in vitro, NF-kappa B binding to its DNA consensus sequence, but they had no effect on the binding activity of CREB or OCT-1. Thus, EC, CT, or DP-B can influence the immune response by modulating NF-kappa B activation. This modulation can occur at early (regulation of oxidant levels, IKK activation) as well as late (binding of NF-kappa B to DNA) stages of the NF-kappa B activation cascade. A model is presented for possible interactions between DP-B and NF-kappa B proteins, which could lead to the inhibition of NF-kappa B binding to kappa B sites.	Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; Univ Buenos Aires, Fac Farm & Bioquim, Consejo Nacl Invest Cient & Tecn, Programa Rad Libres, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Biol, Inst Quim & Fisicoquim Biol, RA-1113 Buenos Aires, DF, Argentina	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires	Oteiza, PI (corresponding author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.	poteiza@ucdavis.edu	Fraga, Cesar/Q-8161-2019; Mackenzie, Gerardo G/AAW-5114-2020		University of Buenos Aires, Argentina [B054, BO42]; Mars, Inc., Hackettstown, NJ; National Institutes of Health, Bethesda, MD [DK35747]	University of Buenos Aires, Argentina(University of Buenos Aires); Mars, Inc., Hackettstown, NJ; National Institutes of Health, Bethesda, MD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants (B054 and BO42) from the University of Buenos Aires, Argentina; Mars, Inc., Hackettstown, NJ; the National Institutes of Health (DK35747), Bethesda, MD. G. G. Mackenzie is a fellow from the University of Buenos Aires, Argentina.	Adamson GE, 1999, J AGR FOOD CHEM, V47, P4184, DOI 10.1021/jf990317m; Arighi CN, 1998, BIOCHEMISTRY-US, V37, P16802, DOI 10.1021/bi981827x; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Hammerstone JF, 2000, J NUTR, V130, p2086S, DOI 10.1093/jn/130.8.2086S; Han SH, 1998, J PHARMACOL EXP THER, V287, P1105; Heiss C, 2003, JAMA-J AM MED ASSOC, V290, P1030, DOI 10.1001/jama.290.8.1030; Holt RR, 2002, AM J CLIN NUTR, V76, P798, DOI 10.1093/ajcn/76.4.798; Holt RR, 2002, JAMA-J AM MED ASSOC, V287, P2212, DOI 10.1001/jama.287.17.2212; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kondo K, 1996, LANCET, V348, P1514, DOI 10.1016/S0140-6736(05)65927-2; Kris-Etherton PM, 2002, CURR OPIN LIPIDOL, V13, P41, DOI 10.1097/00041433-200202000-00007; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lotito SB, 2000, BIOCHEM BIOPH RES CO, V276, P945, DOI 10.1006/bbrc.2000.3571; Lotito SB, 1998, FREE RADICAL BIO MED, V24, P435, DOI 10.1016/S0891-5849(97)00276-1; Mackenzie GG, 2002, J BIOL CHEM, V277, P34610, DOI 10.1074/jbc.M203616200; Mao T, 2000, J MED FOOD, V3, P107, DOI DOI 10.1089/; Mao TK, 1999, INT J IMMUNOTHER, V15, P23; Mao TK, 2000, LIFE SCI, V66, P1377, DOI 10.1016/S0024-3205(00)00449-5; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Moran LK, 2001, CURR MED CHEM, V8, P763, DOI 10.2174/0929867013372904; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park YC, 2000, FEBS LETT, V465, P93, DOI 10.1016/S0014-5793(99)01735-4; Rein D, 2000, J NUTR, V130, p2109S, DOI 10.1093/jn/130.8.2109S; Ren H, 2002, J IMMUNOL, V168, P3721, DOI 10.4049/jimmunol.168.8.3721; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Saliou C, 2001, METHOD ENZYMOL, V335, P380; Sanbongi C, 1997, CELL IMMUNOL, V177, P129, DOI 10.1006/cimm.1997.1109; Santos-Buelga C, 2000, J SCI FOOD AGR, V80, P1094, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;1094::AID-JSFA569&gt;3.0.CO;2-1, 10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.3.CO;2-T]; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Singh R, 2002, ARTHRITIS RHEUM, V46, P2079, DOI 10.1002/art.10443; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Taubert D, 2003, JAMA-J AM MED ASSOC, V290, P1029, DOI 10.1001/jama.290.8.1029; Waterhouse AL, 1996, LANCET, V348, P834, DOI 10.1016/S0140-6736(05)65262-2; Weisburger JH, 2001, EXP BIOL MED, V226, P891, DOI 10.1177/153537020122601003; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; Zhao W, 1999, TOXICOL APPL PHARM, V154, P153, DOI 10.1006/taap.1998.8545	54	155	165	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					167	169		10.1096/fj.03-0402fje	http://dx.doi.org/10.1096/fj.03-0402fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630700				2022-12-25	WOS:000188829300063
J	Weber, AA; Neuhaus, T; Skach, RA; Hescheler, J; Ahn, HY; Schror, K; Ko, Y; Sachinidis, A				Weber, AA; Neuhaus, T; Skach, RA; Hescheler, J; Ahn, HY; Schror, K; Ko, Y; Sachinidis, A			Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis	FASEB JOURNAL			English	Article						catechins; smooth muscle; endothelial cells; PDGF isoforms; receptor tyrosine kinases	SMOOTH-MUSCLE-CELLS; (-)-EPIGALLOCATECHIN GALLATE; TRANSDUCTION PATHWAY; GREEN TEA; TYROSINE-PHOSPHORYLATION; HUMAN GLIOBLASTOMA; FACTOR RECEPTORS; BETA-RECEPTOR; CANCER; RAT		Univ Clin Dusseldorf, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany; Univ Bonn, Med Policlin, Bonn, Germany; Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Chungbuk Natl Univ, Coll Med, Dept Pharmacol, Cheongju, South Korea	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Bonn; University of Cologne; Chungbuk National University	Sachinidis, A (corresponding author), Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany.	A.Sachinidis@unikoeln.de	Sachinidis, Agapios/AAM-7988-2020; Weber, Artur-Aron/GOH-2864-2022; Sachinidis, Agapios/AAD-4178-2020		Deutsche Forschungsgemeinschaft [Sa 568/5-3, DFG KOR-113/157/0-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by a grant from the Deutsche Forschungsgemeinschaft (Sa 568/5-3) and DFG KOR-113/157/0-1. We thank Claudia Seul for excellent technical assistance.	Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chen QX, 1998, BIOCHEM MOL BIOL INT, V45, P465; George D, 2001, SEMIN ONCOL, V28, P27, DOI 10.1053/sonc.2001.29185; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; Kitano K, 1997, BIOPHYS CHEM, V65, P157, DOI 10.1016/S0301-4622(96)02254-5; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; Sachinidis A, 1996, EUR J CELL BIOL, V71, P79; Sachinidis A, 2002, FASEB J, V16, P893, DOI 10.1096/fj.01-0799fje; Sachinidis A, 1999, BRIT J PHARMACOL, V128, P1761, DOI 10.1038/sj.bjp.0702969; Sachinidis A, 1997, HYPERTENSION, V29, P326, DOI 10.1161/01.HYP.29.1.326; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; Sazuka M, 1996, BIOSCI BIOTECH BIOCH, V60, P1317, DOI 10.1271/bbb.60.1317; Sazuka M, 1998, BIOSCI BIOTECH BIOCH, V62, P1031, DOI 10.1271/bbb.62.1031; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; WANG ZY, 1988, DRUG METAB DISPOS, V16, P98; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49	27	70	72	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					128	130		10.1096/fj.03-0007fje	http://dx.doi.org/10.1096/fj.03-0007fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630705				2022-12-25	WOS:000188829300049
J	Lefevre, G; Calipel, A; Mouriaux, F; Hecquet, C; Malecaze, F; Mascarelli, F				Lefevre, G; Calipel, A; Mouriaux, F; Hecquet, C; Malecaze, F; Mascarelli, F			Opposite long-term regulation of c-Myc and p27(Kip1)through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells	ONCOGENE			English	Article						choroidal melanoma; proliferation; Raf-1; antisense strategy	ACTIVATED PROTEIN-KINASE; UVEAL MELANOMA; UP-REGULATION; IN-VITRO; APOPTOSIS; GROWTH; CYCLE; INHIBITION; EXPRESSION; MUTATIONS	Although there is no current evidence for ras gene mutation in choroidal melanoma, there is an increasing body of evidence indicating that deregulated intracellular signalling pathways are involved in choroidal melanoma pathogenesis. The various components of the linear Raf/MEK/ERK signalling pathway have been implicated in various tumours. We therefore investigated the role of Raf-1 and the MEK/ERK module in the proliferation of human normal choroidal melanocytes (NCM) and cells from the ocular choroidal melanoma (OCM-1) cell line. OCM-1 cells proliferated four times faster than NCM. High basal activation of the MEK/ERK module was observed in unstimulated OCM-1 cells, whereas rapid and persistent activation was detected after serum stimulation, throughout the 24-h period of culture. In contrast, the activation of MEK/ERK was barely detectable in unstimulated NCM and occurred late (6 h) after the stimulation of cell proliferation. Inhibition of Raf-1 and MEK1/2 activation by pharmacological approaches and of the production of Raf-1 and ERK1/2 by antisense oligonucleotide approaches demonstrated that Raf-1 and the MEK/ERK module controlled proliferation in OCM-1 cells, but not in NCM. OCM-1 cells produced very low levels of p27(Kip1), whereas NCM produced constant, high levels of p27(Kip1). The inhibition of Raf-1 or MEK1/2 induced a large increase in p27(Kip1) in OCM-1 cells, associated with an arrest of cell proliferation. Levels of c-Myc production were high and constant in OCM-1 cells and low in NCM, in contrast to what was observed for p27(Kip1). The inhibition of both Raf-1 and MEK1/2 induced a decrease in c-Myc production and downregulated c-Myc activity by preventing c-Myc phosphorylation in OCM-1 cells. We conclude that Raf-1 and the MEK/ERK module control the production of both p27(Kip1) and c-Myc, and the activation of c-Myc for OCM-1 cell proliferation.	Inst Biomed Cordeliers, IFR58, INSERM, U450, F-75006 Paris, France; CHRU, Hop Purpan, Serv Ophtalmol, F-31000 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Toulouse	Mascarelli, F (corresponding author), Inst Biomed Cordeliers, IFR58, INSERM, U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mouriaux, Frederic/T-1440-2019; Mascarelli, Frederic/L-8916-2018					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barry OP, 2001, J BIOL CHEM, V276, P15537, DOI 10.1074/jbc.M010847200; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; KANMITCHELL J, 1989, INVEST OPHTH VIS SCI, V30, P829; Kimura A, 1999, CANCER RES, V59, P5133; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouriaux F, 1998, INVEST OPHTH VIS SCI, V39, P876; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Pyrhonen S, 1998, EUR J CANCER, V34, pS27; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev	34	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8813	8822		10.1038/sj.onc.1207099	http://dx.doi.org/10.1038/sj.onc.1207099			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654778				2022-12-25	WOS:000186982200002
J	de Lange, P; Ragni, M; Silvestri, E; Moreno, M; Schiavo, L; Lombardi, A; Farina, P; Feola, A; Goglia, F; Lanni, A				de Lange, P; Ragni, M; Silvestri, E; Moreno, M; Schiavo, L; Lombardi, A; Farina, P; Feola, A; Goglia, F; Lanni, A			Combined cDNA array/RT-PCR analysis of gene expression profile in rat gastrocnemius muscle: relation to its adaptive function in energy metabolism during fasting	FASEB JOURNAL			English	Article						differentiation; energy expenditure; protein degradation; muscle fibers; uncoupling protein 3	PROLIFERATOR-ACTIVATED RECEPTORS; UBIQUITIN-PROTEASOME PATHWAY; SKELETAL-MUSCLE; UNCOUPLING PROTEIN-3; MESSENGER-RNA; FATTY-ACIDS; SUBSTRATE METABOLISM; UP-REGULATION; UCP3; KINASE	We evaluated the effects of fasting on the gene expression profile in rat gastrocnemius muscle using a combined cDNA array and RT-PCR approach. Of the 1176 distinct rat genes analyzed on the cDNA array, 114 were up-regulated more than twofold in response to fasting, including all 17 genes related to lipid metabolism present on the membranes and all 10 analyzed components of the proteasome machinery. Only 7 genes were down-regulated more than twofold. On the basis of our analysis of genes on the cDNA array plus the data from our RT-PCR assays, the metabolic adaptations shown by rat gastrocnemius muscle during fasting are reflected by i) increased transcription both of myosin heavy chain (NMC) Ib (associated with type I fibers) and of at least three factors involved in the shift toward type I fibers [p27kip1, muscle LIM protein (MLP), cystein rich protein-2], of which one (MLP) has been shown to enhance the activity of MyoD, which would explain the known increase in the expression of skeletal muscle uncoupling protein-3 (UCP3); ii) increased lipoprotein lipase (LPL) expression, known to trigger UCP3 transcription, which tends, together with the first point, to underline the suggested role of UCP3 in mitochondrial lipid handling (the variations under the first point and this one have not been observed in mice, indicating a species-specific regulation of these mechanisms); iii) reduced expression of the muscle-specific coenzyme Q (CoQ)7 gene, which is necessary for mitochondrial CoQ synthesis, together with an increased expression of mitochondrial adenylate kinase 3, which inactivates the resident key enzyme for CoQ synthesis, 3-hydroxy-3-methylglutaryl CoA reductase (HMGR), the mRNA level for which fell during fasting; and iv) increased transcription of components of the proteasomal pathways involved in protein degradation/turnover.	Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Naples Federico II, Dipartimento Fisiol Gen & Ambientale, I-80134 Naples, Italy	Universita della Campania Vanvitelli; University of Sannio; University of Naples Federico II	Lanni, A (corresponding author), Univ Naples 2, Dipartimento Sci Vita, Via Vivaldi 43, I-81100 Caserta, Italy.	pieter.delange@unina2.it; antonia.lanni@unina2.it	de Lange, Pieter/GXA-3052-2022; Schiavo, Luigi/K-5202-2016; Ragni, Maurizio/AAB-1527-2020; Schiavo, Luigi/AAO-7168-2021	Schiavo, Luigi/0000-0003-3639-6847; Ragni, Maurizio/0000-0001-6548-741X; GOGLIA, Fernando/0000-0003-0468-9645; Silvestri, Elena/0000-0002-0592-9033; MORENO, Maria/0000-0002-6218-5501				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Attaix D, 1998, ADV MOL CEL, V27, P235, DOI 10.1016/S1569-2558(08)60463-4; BARGOSSI AM, 1994, MOL ASPECTS MED, V15, P187, DOI 10.1016/0098-2997(94)90028-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Bukovsky Antonin, 2001, BMC Clin Pathol, V1, P4, DOI 10.1186/1472-6890-1-4; Busquets S, 1998, FEBS LETT, V440, P348, DOI 10.1016/S0014-5793(98)01485-9; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Fang CH, 2000, ENDOCRINOLOGY, V141, P2743, DOI 10.1210/en.141.8.2743; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; GROS G, 1988, ANNU REV PHYSIOL, V50, P669, DOI 10.1146/annurev.ph.50.030188.003321; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Jaschinski F, 1998, AM J PHYSIOL-CELL PH, V274, pC365, DOI 10.1152/ajpcell.1998.274.2.C365; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Khassaf M, 2001, J APPL PHYSIOL, V90, P1031, DOI 10.1152/jappl.2001.90.3.1031; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kratky D, 2001, BIOCHEM J, V355, P647, DOI 10.1042/bj3550647; LAEMMLI UK, 1970, NATURE, V193, P1058; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Moreno M, 2003, FASEB J, V17, P1112, DOI 10.1096/fj.02-0839fje; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Pierrat B, 2000, EUR J BIOCHEM, V267, P2680, DOI 10.1046/j.1432-1327.2000.01285.x; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Richter E.A., 1996, COMPR PHYSIOL, P912, DOI [10.1002/cphy.cp120120, DOI 10.1002/CPHY.CP120120]; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; Samec S, 2002, PFLUG ARCH EUR J PHY, V445, P80, DOI 10.1007/s00424-002-0879-9; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Solanes G, 2000, FASEB J, V14, P2141; Son C, 2001, ENDOCRINOLOGY, V142, P4189, DOI 10.1210/en.142.10.4189; Tu N, 2000, LIFE SCI, V67, P2267, DOI 10.1016/S0024-3205(00)00802-X; Turunen M, 2002, FREE RADICAL RES, V36, P437, DOI 10.1080/10715760290021298; Van der Lee KAJM, 2001, J LIPID RES, V42, P1752; Wang L, 1998, SHOCK, V10, P298, DOI 10.1097/00024382-199810000-00011; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WILLIS RA, 1990, P NATL ACAD SCI USA, V87, P8928, DOI 10.1073/pnas.87.22.8928; Willmann R, 2001, AM J PHYSIOL-CELL PH, V280, pC273, DOI 10.1152/ajpcell.2001.280.2.C273; Wing SS, 1996, BIOCHEM J, V319, P455, DOI 10.1042/bj3190455; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	60	50	52	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					350	+		10.1096/fj.03-0342fje	http://dx.doi.org/10.1096/fj.03-0342fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656997				2022-12-25	WOS:000188067500020
J	Namazi, MR				Namazi, MR			Pyridoxal 5 '-phosphateas a novel weapon against autoimmunity and transplant rejection	FASEB JOURNAL			English	Article						autoimmunity; HIV; pyridoxal 5 '-phosphate; transplant rejection; treatment; CD4	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MONOCLONAL-ANTIBODY THERAPY; POSSIBLE INVOLVEMENT; CD4; ACTIVATION; RECEPTOR; PROLIFERATION; MOLECULE	Activation of CD4 T cells by antigen-presenting cells is required for the full expression of most autoimmune diseases and allogeneic transplant rejection. The extracellular part of CD4 molecule is composed of four domains, D1-D4. CD4 binds to MHC class II via its D1 and D2 domains. Pyridoxal 5'-phosphate (PLP) binds very tightly to the D1 domain of CD4 and therefore could interfere with proper CD4-MHC II interaction. Nonincorporation of CD4 into the activation complex can result in T cell apoptosis and anergy to autoantigen (s). Occupancy of D1 by PLP may prevent the proper protein-protein interactions of the CD4 molecule itself, which are important in T cell activation. PLP may also interfere with the dimerization of CD4 molecules, which occurs during T cell activation, or with the interaction of this dimer with other molecules on the T cell surface, such as CD45, thereby further rendering T cells anergic or driven to apoptosis. Therefore, PLP may have utility in the treatment of autoimmunity and transplant rejection. Furthermore, as the interaction of the HIV gp120 and CD4 occurs via D1, PLP is supposed to have anti-HIV effect as well. PLP may prove of special utility in the treatment of patients affected with both autoimmunity and HIV, for whom the routine immunosuppressives are contraindicated.	Shiraz Univ Med Sci, Dept Dermatol, Shiraz, Iran	Shiraz University of Medical Science	Namazi, MR (corresponding author), POB 71955-687, Shiraz, Iran.	namazi_mr@yahoo.com	namazi, mohammad reza/E-3197-2018	namazi, mohammad reza/0000-0002-7409-7437				BENJAMIN RJ, 1986, NATURE, V320, P449, DOI 10.1038/320449a0; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; Breedveld FC, 1998, RHEUM DIS CLIN N AM, V24, P567, DOI 10.1016/S0889-857X(05)70026-0; Cobbold S P, 1990, Semin Immunol, V2, P377; CUSH JJ, 1991, CLIN ORTHOP RELAT R, V265, P9; DESILVA DR, 1991, J IMMUNOL, V147, P3261; KLEIN J, 1999, IMMUNOLOGY, P195; KORCHAK HM, 1990, P NATL ACAD SCI USA, V77, P2721; KOTZIN BL, 2001, CLIN IMMUNOLOGY PRIN, V1; Marini JC, 1996, J IMMUNOL, V157, P3706; MITTLER RS, 1991, J IMMUNOL, V147, P3434; PARNES JR, 1989, ADV IMMUNOL, V44, P265; RANGES GE, 1985, J EXP MED, V162, P1105, DOI 10.1084/jem.162.3.1105; SAKANE T, 1989, CLIN EXP IMMUNOL, V75, P269; SALHANY JM, 1993, J BIOL CHEM, V268, P7643; Schulze-Koops H, 2000, CURR DIRECT AUTOIMMU, V2, P24; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; ZERBIB AC, 1994, J EXP MED, V179, P1973, DOI 10.1084/jem.179.6.1973	18	4	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2184	2186		10.1096/fj.03-0465hyp	http://dx.doi.org/10.1096/fj.03-0465hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656979				2022-12-25	WOS:000188067500038
J	Schechner, JS; Crane, SK; Wang, FY; Szeglin, AM; Tellides, G; Lorber, MI; Bothwell, ALM; Pober, JS				Schechner, JS; Crane, SK; Wang, FY; Szeglin, AM; Tellides, G; Lorber, MI; Bothwell, ALM; Pober, JS			Engraftment of a vascularized human skin equivalent	FASEB JOURNAL			English	Article						transplantation; HUVEC; vascularization	ENDOTHELIAL GROWTH-FACTOR; CULTURED KERATINOCYTES; FULL-THICKNESS; VENOUS ULCERS; ATHYMIC MICE; IN-VITRO; ANGIOGENESIS; SUBSTITUTES; GRAFTS; TISSUE	Clinical performance of currently available human skin equivalents is limited by failure to develop perfusion. To address this problem we have developed a method of endothelial cell transplantation that promotes vascularization of human skin equivalents in vivo. Enhancement of vascularization by Bcl-2 overexpression was demonstrated by seeding human acellular dermis grafts with human umbilical vein endothelial cells (HUVEC) transduced with the survival gene Bcl-2 or an EGFP control transgene, and subcutaneous implantation in immunodeficient mice (n=18). After 1 month the grafts with Bcl-2-transduced cells contained a significantly greater density of perfused HUVEC-lined microvessels (55.0/mm(3)) than controls (25.4/mm(3), P= 0.026). Vascularized skin equivalents were then constructed by sequentially seeding the apical and basal surfaces of acellular dermis with cultured human keratinocytes and Bcl-2-transduced HUVEC, respectively. Two weeks after orthotopic implantation onto mice, 75% of grafts (n=16) displayed both a differentiated human epidermis and perfusion through HUVEC-lined microvessels. These vessels, which showed evidence of progressive maturation, accelerated the rate of graft vascularization. Successful transplantation of such vascularized human skin equivalents should enhance clinical utility, especially in recipients with impaired angiogenesis.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Interdepartmental Program Vasc Biol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Schechner, JS (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059, New Haven, CT 06520 USA.	jeffrey.schechner@yale.edu			NHLBI NIH HHS [HL51014] Funding Source: Medline; NIAMS NIH HHS [AR02134, P30 AR4192] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002134] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balasubramani M, 2001, BURNS, V27, P534, DOI 10.1016/S0305-4179(01)00018-3; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; Brem H, 2000, ARCH SURG-CHICAGO, V135, P627, DOI 10.1001/archsurg.135.6.627; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; DEMARCHEZ M, 1992, TRANSPLANTATION, V54, P317, DOI 10.1097/00007890-199208000-00023; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; EAGLSTEIN WH, 1995, DERMATOL SURG, V21, P839, DOI 10.1111/j.1524-4725.1995.tb00709.x; Erdag G, 2002, TRANSPLANTATION, V73, P519, DOI 10.1097/00007890-200202270-00005; Falabella AF, 2000, ARCH DERMATOL, V136, P1225, DOI 10.1001/archderm.136.10.1225; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; KREJCI NC, 1991, J INVEST DERMATOL, V97, P843, DOI 10.1111/1523-1747.ep12491522; LANGDON RC, 1988, J INVEST DERMATOL, V91, P478, DOI 10.1111/1523-1747.ep12476623; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Medalie DA, 1997, TRANSPLANTATION, V64, P454, DOI 10.1097/00007890-199708150-00015; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Phillips T, 2002, ARCH DERMATOL, V138, P1079, DOI 10.1001/archderm.138.8.1079; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Sheridan RL, 2001, BURNS, V27, P421, DOI 10.1016/S0305-4179(00)00156-X; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; Supp Dorothy M., 2002, Journal of Burn Care & Rehabilitation, V23, P10, DOI 10.1097/00004630-200201000-00004; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005	32	66	72	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2250	2256		10.1096/fj.03-0257com	http://dx.doi.org/10.1096/fj.03-0257com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656987				2022-12-25	WOS:000188067500046
J	Beigneux, AP; Kosinski, C; Gavino, B; Horton, JD; Skarnes, WC; Young, SG				Beigneux, AP; Kosinski, C; Gavino, B; Horton, JD; Skarnes, WC; Young, SG			ATP-citrate lyase deficiency in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; INSERTIONAL MUTATIONS; SEQUENCE-ANALYSIS; SYNTHESIS INVIVO; RAT; CHOLESTEROL; ACETYLCHOLINE; LIVER; BRAIN; MICE	ATP-citrate lyase (Acly) is one of two cytosolic enzymes that synthesize acetyl-coenzyme A (CoA). Because acetyl-CoA is an essential building block for cholesterol and triglycerides, Acly has been considered a therapeutic target for hyperlipidemias and obesity. To define the phenotype of Acly-deficient mice, we created Acly knockout mice in which a beta-galactosidase marker is expressed from Acly regulatory sequences. We also sought to define the cell type-specific expression patterns of Acly to further elucidate the in vivo roles of the enzyme. Homozygous Acly knockout mice died early in development. Heterozygous mice were healthy, fertile, and normolipidemic on both chow and high fat diets, despite expressing half-normal amounts of Acly mRNA and protein. Fibroblasts and hepatocytes from heterozygous Acly mice contained half-normal amounts of Acly mRNA and protein, but this did not perturb triglyceride and cholesterol synthesis or the expression of lipid biosynthetic genes regulated by sterol regulatory element-binding proteins. The expression of acetyl-CoA synthetase 1, another cytosolic enzyme for producing acetylCoA, was not up-regulated. As judged by beta-galactosidase staining, Acly was expressed ubiquitously but was expressed particularly highly in tissues with high levels of lipogenesis, such as in the livers of mice fed a high-carbohydrate diet. beta-Galactosidase staining was intense in the developing brain, in keeping with the high levels of de novo lipogenesis of the tissue. In the adult brain, beta-galactosidase staining was in general much lower, consistent with reduced levels of lipogenesis; however, beta-galactosidase expression remained very high in cholinergic neurons, likely reflecting the importance of Acly in generating acetyl-CoA for acetylcholine synthesis. The Acly knockout allele is useful for identifying cell types with a high demand for acetyl-CoA synthesis.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Beigneux, AP (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	abeigneux@gladstone.ucsf.edu		Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [U01 HL066600, U01 HL066590, R01 HL094732, R01 HL094732-01S1, U01 HL066621, HL66621, HL66600, HL66590, R01 HL094732-01, R01 HL094732-02, R01 HL094732-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066600, U01HL066621, U01HL066590, R01HL094732] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNUM TE, 1969, ENZYME HDB; Beigneux A, 2002, J BIOL CHEM, V277, P38358, DOI 10.1074/jbc.M205183200; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; BRAY GA, 1976, CLIN ENDOCRINOL META, V5, P455, DOI 10.1016/S0300-595X(76)80031-X; Carroll PT, 1997, BRAIN RES, V753, P47, DOI 10.1016/S0006-8993(96)01485-0; CHEE H, 1977, J NUTR, V107, P112, DOI 10.1093/jn/107.1.112; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; DIETSCHY JM, 1983, J LIPID RES, V24, P469; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; ENDEMANN G, 1980, J BIOL CHEM, V255, P1091; FOSTER DW, 1968, J BIOL CHEM, V243, P1926; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; GREENWOOD MRC, 1981, AM J PHYSIOL, V240, pE72, DOI 10.1152/ajpendo.1981.240.1.E72; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; KNOWLES SE, 1974, BIOCHEM J, V142, P401, DOI 10.1042/bj1420401; Leonhardt M, 2001, PHYSIOL BEHAV, V74, P191, DOI 10.1016/S0031-9384(01)00547-9; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Melnick JZ, 1996, J CLIN INVEST, V98, P2381, DOI 10.1172/JCI119051; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; Pearce NJ, 1998, BIOCHEM J, V334, P113, DOI 10.1042/bj3340113; RICNY J, 1980, BIOCHEM J, V188, P683, DOI 10.1042/bj1880683; RICNY J, 1982, J NEUROCHEM, V39, P668; SAXTY BA, 1991, EUR J BIOCHEM, V202, P889, DOI 10.1111/j.1432-1033.1991.tb16448.x; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SPADY DK, 1983, J LIPID RES, V24, P303; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; Szutowicz A, 1999, J NEUROSCI RES, V57, P131, DOI 10.1002/(SICI)1097-4547(19990701)57:1<131::AID-JNR14>3.0.CO;2-M; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099	35	94	98	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9557	9564		10.1074/jbc.M310512200	http://dx.doi.org/10.1074/jbc.M310512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14662765	hybrid, Green Accepted			2022-12-25	WOS:000189265900123
J	Grace, ML; Chandrasekharan, MB; Hall, TC; Crowe, AJ				Grace, ML; Chandrasekharan, MB; Hall, TC; Crowe, AJ			Sequence and spacing of TATA box elements are critical for accurate initiation from the beta-phaseolin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CORE PROMOTER; BINDING-PROTEIN; HISTONE ACETYLATION; CHROMATIN-STRUCTURE; DNA-SEQUENCES; MINOR-GROOVE; START SITE; IN-VITRO; GENE	The beta-phaseolin (phas) gene, which encodes one of the major seed storage proteins of P. vulgaris, is tightly regulated at the transcription level resulting in strict tissue-specific and spatial expression during embryonic development. The phas proximal promoter contains a complex arrangement of core promoter elements including three TATA boxes as well as several putative initiator elements. To delineate the respective contributions of the core promoter elements to transcription initiation we have performed site-directed mutagenesis of the phas promoter. In vivo expression studies were performed on transgenic Arabidopsis harboring phas promoter mutants driving expression of the beta-glucuronidase (gus) reporter gene. Quantitative assessment of GUS activity in seeds bearing the promoter mutants indicated that both sequence and spacing of the TATA elements influenced the efficiency of transcription. Substitution, insertion or deletion mutations had no effect on histochemical staining patterns indicating that strict spacing requirements are not essential for correct spatial expression of phas during embryogenesis. Further evaluation of the phas promoter by in vitro transcription analysis revealed the presence of multiple TATA-dependent transcription initiation start sites. The distance between TATA elements and transcription start sites was maintained in insertion and deletion mutants through the creation of novel initiation sites, indicating that positioning of the TATA elements rather than DNA sequence was the primary determinant of start site location. We conclude that, while dispensable for proper spatial distribution, the complex architecture of the phas promoter is required to ensure high levels of accurate phas transcription initiation in the developing embryo.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	University of Washington; University of Washington Seattle; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Crowe, AJ (corresponding author), Univ Washington, Dept Biol, POB 351800, Seattle, WA 98195 USA.	acrowe@u.washington.edu	Chandrasekharan, Mahesh/AAF-4793-2020	Chandrasekharan, Mahesh/0000-0002-9956-8354				APSIT V, 1993, NUCLEIC ACIDS RES, V21, P1494, DOI 10.1093/nar/21.6.1494; Bechtold N, 1998, METH MOL B, V82, P259; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; Burke TW, 1998, COLD SPRING HARB SYM, V63, P75, DOI 10.1101/sqb.1998.63.75; BUSTOS MM, 1991, EMBO J, V10, P1469, DOI 10.1002/j.1460-2075.1991.tb07667.x; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Chandrasekharan MB, 2003, PLANT J, V33, P853, DOI 10.1046/j.1365-313X.2003.01678.x; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Doyle MC, 2001, MOL CELLS, V12, P197; Duan ZJ, 2002, P NATL ACAD SCI USA, V99, P5509, DOI 10.1073/pnas.072084499; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kadonaga JT, 2002, EXP MOL MED, V34, P259, DOI 10.1038/emm.2002.36; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Li GF, 2001, PLANT MOL BIOL, V46, P121, DOI 10.1023/A:1010693703421; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MUKUMOTO F, 1993, PLANT MOL BIOL, V23, P995, DOI 10.1007/BF00021814; Nakamura M, 2002, PLANT J, V29, P1, DOI 10.1046/j.0960-7412.2001.01188.x; Nap J. P., 1993, Plant Molecular Biology Reporter, V11, P156, DOI 10.1007/BF02670473; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shen CH, 2002, MOL CELL BIOL, V22, P6406, DOI 10.1128/MCB.22.18.6406-6416.2002; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SLIGHTOM JL, 1985, NUCLEIC ACIDS RES, V13, P6483, DOI 10.1093/nar/13.18.6483; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, PREPARATION NUCL CYT, V2; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; Yamada M, 2001, BIOCHEM BIOPH RES CO, V281, P53, DOI 10.1006/bbrc.2001.4308; ZHU Q, 1995, PLANT CELL, V7, P1681, DOI 10.1105/tpc.7.10.1681	47	59	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8102	8110		10.1074/jbc.M309376200	http://dx.doi.org/10.1074/jbc.M309376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660650	hybrid			2022-12-25	WOS:000189103300090
J	Chuang, SS; Helvig, C; Taimi, M; Ramshaw, HA; Collop, AH; Amad, M; White, JA; Petkovich, M; Jones, G; Korczak, B				Chuang, SS; Helvig, C; Taimi, M; Ramshaw, HA; Collop, AH; Amad, M; White, JA; Petkovich, M; Jones, G; Korczak, B			CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MOLECULAR-CLONING; LINOLEIC ACIDS; METABOLITES; PATHWAYS; RECEPTOR; CYCLOOXYGENASE; IDENTIFICATION; OXYGENATION; EXPRESSION	Long chain fatty acids have recently emerged as critical signaling molecules in neuronal, cardiovascular, and renal processes, yet little is presently known about the precise mechanisms controlling their tissue distribution and bioactivation. We have identified a novel cytochrome P450, CYP2U1, which may play an important role in modulating the arachidonic acid signaling pathway. Northern blot and real-time PCR analysis demonstrated that CYP2U1 transcripts were most abundant in the thymus and the brain (cerebellum), indicating a specific physiological role for CYP2U1 in these tissues. Recombinant human CYP2U1 protein, expressed in baculovirus-infected So insect cells, was found to metabolize arachidonic acid exclusively to two region-specific products as determined by liquid chromatography-mass spectrometry. These metabolites were identified as 19- and 20-hydroxy-modified arachidonic acids by liquid chromatography-tandem mass spectrometry analysis. In addition to omega/omega-1 hydroxylation of arachidonic acid, CYP2U1 protein also catalyzed the hydroxylation of structurally related long chain fatty acid (docosahexaenoic acid) but not fatty acids such as lauric acid or linoleic acid. This is the first report of the cloning and functional expression of a new human member of P450 family 2, CYP2U1, which metabolizes long chain fatty acids. Based on the ability of CYP2U1 to generate bioactive eicosanoid derivatives, we postulate that CYP2U1 plays an important physiological role in fatty acid signaling processes in both cerebellum and thymus.	Cytochroma Inc, Markham, ON L3R 8E4, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Korczak, B (corresponding author), Cytochroma Inc, 330 Cochrane Dr, Markham, ON L3R 8E4, Canada.	bozena@cytochroma.com						AOYAMA T, 1990, J LIPID RES, V31, P1477; Bazan NG, 2002, PROG BRAIN RES, V135, P175; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; Bylund J, 1998, ANAL BIOCHEM, V265, P55, DOI 10.1006/abio.1998.2897; Bylund J, 1998, J PHARMACOL EXP THER, V284, P51; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2002, CELL MOL LIFE SCI, V59, P780, DOI 10.1007/s00018-002-8466-y; Capdevila JH, 2000, J LIPID RES, V41, P163; Cheng JB, 2003, J BIOL CHEM, V278, P38084, DOI 10.1074/jbc.M307028200; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; ESCALANTE B, 1990, J CARDIOVASC PHARM, V16, P438, DOI 10.1097/00005344-199009000-00013; Fang X, 1999, HYPERTENSION, V34, P1242, DOI 10.1161/01.HYP.34.6.1242; Fang X, 2001, J BIOL CHEM, V276, P14867, DOI 10.1074/jbc.M011761200; Fleming I, 2001, CIRC RES, V89, P753, DOI 10.1161/hh2101.099268; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Glenn HL, 2003, CELL MOTIL CYTOSKEL, V55, P265, DOI 10.1002/cm.10128; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Imig JD, 2000, AM J PHYSIOL-RENAL, V279, pF965, DOI 10.1152/ajprenal.2000.279.6.F965; Kehl F, 2002, AM J PHYSIOL-HEART C, V282, pH1556, DOI 10.1152/ajpheart.00924.2001; Koike K, 1997, BIOCHEM BIOPH RES CO, V232, P643, DOI 10.1006/bbrc.1997.6342; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; McMurray DN, 2000, J INFECT DIS, V182, pS103, DOI 10.1086/315909; Moreno C, 2001, AM J HYPERTENS, V14, p90S, DOI 10.1016/S0895-7061(01)02075-1; Nie DT, 2001, CANCER METAST REV, V20, P195, DOI 10.1023/A:1015579209850; Oleksiak MF, 2000, J BIOL CHEM, V275, P2312, DOI 10.1074/jbc.275.4.2312; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; Parnes Steven M, 2002, Expert Opin Pharmacother, V3, P33, DOI 10.1517/14656566.3.1.33; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; SAWAMURA A, 1993, BIOCHIM BIOPHYS ACTA, V1168, P30; Seeds MC, 1999, CLIN REV ALLERG IMMU, V17, P5, DOI 10.1007/BF02737594; Stockton RA, 2001, MOL BIOL CELL, V12, P1937, DOI 10.1091/mbc.12.7.1937; Werck-Reichhart D, 2000, GENOME BIOL, V6, P1, DOI [10.1186/GB-2000-1-6-REVIEWS3003, DOI 10.1186/GB-2000-1-6-REVIEWS3003]; Wu S, 1996, J BIOL CHEM, V271, P3460; Yamane M, 1995, NEUROSCI LETT, V200, P203, DOI 10.1016/0304-3940(95)12132-N; YAQOOB P, 1994, IMMUNOLOGY, V82, P603; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zheng YM, 1998, BIOCHEMISTRY-US, V37, P12847, DOI 10.1021/bi981280m; Ziboh VA, 2002, ARCH PHARM RES, V25, P747, DOI 10.1007/BF02976988	43	127	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6305	6314		10.1074/jbc.M311830200	http://dx.doi.org/10.1074/jbc.M311830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660610	hybrid			2022-12-25	WOS:000188969200015
J	Lin, PJ; Straight, DL; Stafford, DW				Lin, PJ; Straight, DL; Stafford, DW			Binding of the factor IX gamma-carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPEPTIDE REGION; ENZYME-ACTIVITY; FACTOR-X; PROTEINS; OSTEOCALCIN; PROTHROMBIN; MECHANISM; COAGULATION; RECOGNITION; ACTIVATION	Propeptides of the vitamin K-dependent proteins bind to an exosite on gamma-glutamyl carboxylase; while they are bound, multiple glutamic acids in the gamma-carboxyglutamic acid (Gla) domain are carboxylated. The role of the propeptides has been studied extensively; however, the role of the Gla domain in substrate binding is less well understood. We used kinetic and fluorescence techniques to investigate the interactions of the carboxylase with a substrate containing the propeptide and Gla domain of factor IX (FIXproGla41). In addition, we characterized the effect of the Gla domain and carboxylation on propeptide and substrate binding. For the propeptide of factor IX (proFIX18), FIXproGla41, and carboxylated FIXproGla41, the K-d values were 50, 2.5, and 19.7 nm and the k(off) values were 273 X 10(-5), 9 x 10(-5), and 37 x 10(-5) s(-1), respectively. The k(off) of proFIX18 is reduced 3-fold by FLEEL and 9-fold by the Gla domain (residues 1-46) of FIX. The pre-steady state rate constants for carboxylation of FIXproGla41 was 0.02 s-1 in enzyme excess and 0.016 s(-1) in substrate excess. The steady state rate in substrate excess is 4.5 x 10(-4) s(-1). These results demonstrate the following. 1) The pre-steady state carboxylation rate constant of FIXproGla41 is significantly slower than that of FLEEL. 2) The Gla domain plays an allosteric role in substrate-enzyme interactions. 3) Carboxylation reduces the allosteric effect. 4) The similarity between the steady state carboxylation rate constant and product dissociation rate constant suggests that product release is rate-limiting. 5) The increased dissociation rate after carboxylation contributes to the release of product.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	dws@email.unc.edu			NHLBI NIH HHS [HL06350, HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Binkley NC, 2000, AM J CLIN NUTR, V72, P1523; Binkley NC, 2002, AM J CLIN NUTR, V76, P1055, DOI 10.1093/ajcn/76.5.1055; Bovill E G, 1987, Adv Exp Med Biol, V214, P17; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; ESMON CT, 1975, J BIOL CHEM, V250, P4744; Furie BC, 1997, J BIOL CHEM, V272, P28258, DOI 10.1074/jbc.272.45.28258; Gillis S, 1997, PROTEIN SCI, V6, P185; Hallgren KW, 2002, BIOCHEMISTRY-US, V41, P15045, DOI 10.1021/bi026016e; Houben RJTJ, 2002, BIOCHEM J, V364, P323, DOI 10.1042/bj3640323; Houben RJTJ, 1999, BIOCHEM J, V341, P265, DOI 10.1042/0264-6021:3410265; KATAYAMA K, 1979, P NATL ACAD SCI USA, V76, P4990, DOI 10.1073/pnas.76.10.4990; Kelleher RL, 1999, ANAL CHEM, V71, P4250, DOI 10.1021/ac990684x; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Lin PJ, 2002, J BIOL CHEM, V277, P28584, DOI 10.1074/jbc.M202292200; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; Oldenburg J, 1997, BRIT J HAEMATOL, V98, P240, DOI 10.1046/j.1365-2141.1997.2213036.x; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; Stenina O, 2001, BIOCHEMISTRY-US, V40, P10301, DOI 10.1021/bi0107039; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	32	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6560	6566		10.1074/jbc.M312239200	http://dx.doi.org/10.1074/jbc.M312239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660587	hybrid, Green Published			2022-12-25	WOS:000188969200044
J	Miedlich, SU; Gama, L; Seuwen, K; Wolf, RM; Breitwieser, GE				Miedlich, SU; Gama, L; Seuwen, K; Wolf, RM; Breitwieser, GE			Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; PROTEIN-COUPLED RECEPTORS; CALCIMIMETIC COMPOUND; CRYSTAL-STRUCTURE; ACTIVATION; ANTAGONISTS; RHODOPSIN; COOPERATIVITY; RECOGNITION; PREDICTION	A homology model for the human calcium sensing receptor (hCaR) transmembrane domain utilizing bovine rhodopsin (bRho) structural information was derived and tested by docking the allosteric antagonist, NPS 2143, followed by mutagenesis of predicted contact sites. Mutation of residues Phe-668 (helix II), Arg-680, or Phe-684 (helix III) to Ala (or Val or Leu) and Glu-837 (helix VII) to Ile (or Gln) reduced the inhibitory effects of NPS 2143 on [Ca2+](i) responses. The calcimimetic NPS R-568 increases the potency of Ca2+ in functional assays of Call. Mutations at Phe-668, Phe-684, or Glu-837 attenuated the effects of this compound, but mutations at Arg-680 had no effect. In all cases, mutant Calls responded normally to Ca2+ or phenylalanine, which act at distinct site(s). Discrimination by the Arg-680 mutant is consistent with the structural differences between NPS 2143, which contains an alkyl bridge hydroxyl group, and NPS R-568, which does not. The homology model of the Call transmembrane domain robustly accounts for binding of both an allosteric antagonist and agonist, which share a common site, and provides a basis for the development of more specific and/or potent allosteric modulators of Call. These studies suggest that the bRho backbone can be used as a starting point for homology modeling of even distantly related G protein-coupled receptors and provide a rational framework for investigation of the contributions of the transmembrane domain to Call function.	Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Syracuse University; Novartis	Breitwieser, GE (corresponding author), Syracuse Univ, Dept Biol, 122 Lyman Hall,108 Coll Pl, Syracuse, NY 13244 USA.	gebreitw@syr.edu		Gama, Lucio/0000-0001-9511-012X; Breitwieser, Gerda/0000-0001-9081-0362	NIGMS NIH HHS [GM58578] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bikker JA, 1998, J MED CHEM, V41, P2911, DOI 10.1021/jm970767a; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Breitwieser GE, 2001, AM J PHYSIOL-CELL PH, V280, pC1412, DOI 10.1152/ajpcell.2001.280.6.C1412; BROWN EM, 1991, J BONE MINER RES, V6, P1217; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Burley SK, 2002, ANNU REV GENOM HUM G, V3, P243, DOI 10.1146/annurev.genom.3.022502.103227; Cohen A, 2002, CURR OPIN PHARMACOL, V2, P734, DOI 10.1016/S1471-4892(02)00210-2; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Doggrell SA, 2002, DRUG FUTURE, V27, P140, DOI 10.1358/dof.2002.027.02.656406; Dunbrack RL, 1999, PROTEINS, P81; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P775; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Litschig S, 1999, MOL PHARMACOL, V55, P453; Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Miedlich S, 2002, J BIOL CHEM, V277, P49691, DOI 10.1074/jbc.M205578200; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Spooren WPJM, 2001, TRENDS PHARMACOL SCI, V22, P331, DOI 10.1016/S0165-6147(00)01694-1; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200	47	136	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7254	7263		10.1074/jbc.M307191200	http://dx.doi.org/10.1074/jbc.M307191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660633	hybrid			2022-12-25	WOS:000188969200127
J	Akunda, JK; Lao, HC; Lee, CA; Sessoms, AR; Slade, RM; Langenbach, R				Akunda, JK; Lao, HC; Lee, CA; Sessoms, AR; Slade, RM; Langenbach, R			Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or-2 induces mouse keratinocyte differentiation in vitro and in vivo	FASEB JOURNAL			English	Article						knockout; celecoxib; SC-560; terminal differentiation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; H SYNTHASE ISOENZYMES; COLON-CANCER CELLS; EPIDERMAL DIFFERENTIATION; GROWTH-INHIBITION; TUMOR-GROWTH; APOPTOSIS; SKIN; EXPRESSION; MICE	Previously we demonstrated that genetic deficiency of the cyclooxygenases (COX-1 or COX-2) altered keratinocyte differentiation in mouse skin [Tiano et. al. (2002) Cancer Res. 62, 3395-3401]. In this study, we show that topical application of SC-560 (a COX-1 selective inhibitor) or celecoxib (COX-2 selective) to TPA-treated wild-type skin caused fivefold increases in the number of basal keratinocytes expressing the early differentiation marker keratin 1 (K1). In contrast to skin, COX-2 not COX-1 was the major isoform expressed in cultured primary keratinocytes. COX-1 was predominantly expressed in detached, differentiated cells, whereas COX-2 was found in the attached, proliferating cells. High Ca++ medium induced K1 and COX-1 in wild-type keratinocytes but did not change COX-2 expression. As observed in skin, COX-1(-/-) and COX-2(-/-) primary keratinocytes expressed fivefold more K1 than wild-type cells. K1 levels in cultured wild-type keratinocytes were also increased by treatment with celecoxib and indomethacin. However, unlike its in vivo effect, SC-560, possibly due to low COX-1 expression in cultured mouse keratinocytes, did not increase K1 levels. Furthermore, no increases in apoptotic cell numbers were observed in COX-deficient keratinocytes or COX-inhibitor treated wild-type cells. Thus, a major effect of COX inhibitors and COX-deficiency is the induction of keratinocyte differentiation.	NIEHS, NIH, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; Myriad Pharmaceut Inc, Salt Lake City, UT USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Myriad Genetics, Inc	Langenbach, R (corresponding author), NIEHS, MD C4-09,POB 12233, Res Triangle Pk, NC 27709 USA.	langenb1@niehs.nih.gov					The authors wish to thank Carl Bortner (NIEHS) for help with the FACS analysis, Kevin Trouba (NIEHS) for helping with human keratinocyte cultures, Robert Smart (North Carolina State University), Thomas Eling, Carol Trempus, and Thomas Gray (All at NIEHS) for the critical review of this manuscript.	Bol DK, 2002, CANCER RES, V62, P2516; Chulada PC, 2000, CANCER RES, V60, P4705; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Elder DJE, 2000, INT J CANCER, V86, P553, DOI 10.1002/(SICI)1097-0215(20000515)86:4<553::AID-IJC18>3.3.CO;2-0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; Kitamura T, 2002, CARCINOGENESIS, V23, P1463, DOI 10.1093/carcin/23.9.1463; Kundu N, 2002, CANCER RES, V62, P2343; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Leong J, 1996, EXP CELL RES, V224, P79, DOI 10.1006/excr.1996.0113; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Masferrer JL, 2000, CANCER RES, V60, P1306; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Muller-Decker K, 1999, INT J CANCER, V82, P648, DOI 10.1002/(SICI)1097-0215(19990827)82:5<648::AID-IJC6>3.0.CO;2-D; Muller-Decker K, 1998, EXP CELL RES, V242, P84, DOI 10.1006/excr.1998.4068; Muller-Decker K, 1998, MOL CARCINOGEN, V23, P36, DOI 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F; Neufang G, 2001, P NATL ACAD SCI USA, V98, P7629, DOI 10.1073/pnas.121574098; Nishimura G, 1999, JPN J CANCER RES, V90, P1152, DOI 10.1111/j.1349-7006.1999.tb00690.x; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; SCHOLZ K, 1995, BIOCHEM J, V309, P263, DOI 10.1042/bj3090263; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Tiano HF, 2002, CANCER RES, V62, P3395; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Waskewich C, 2002, CANCER RES, V62, P2029; Williams CS, 2000, CANCER RES, V60, P6045; Yamazaki R, 2002, FEBS LETT, V531, P278, DOI 10.1016/S0014-5793(02)03535-4; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	40	18	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					185	187		10.1096/fj.02-1192fje	http://dx.doi.org/10.1096/fj.02-1192fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630706				2022-12-25	WOS:000188829300068
J	Barone, F; Aguanno, S; D'Alessio, A; D'Agostino, A				Barone, F; Aguanno, S; D'Alessio, A; D'Agostino, A			Sertoli cell modulates MAA-induced apoptosis of germ cells throughout voltage-operated calcium channels	FASEB JOURNAL			English	Article						apoptosis; Sertoli cells; calcium channels; seminiferous tubule	METHOXYACETIC-ACID; SEMINIFEROUS EPITHELIUM; SPERMATOCYTE TOXICITY; FLOW-CYTOMETRY; ADULT-RAT; CLUSTERIN; TESTIS; MICE; DEGENERATION; BLOCKERS	Spontaneous cell death by apoptosis-occurring during normal spermatogenesis in mammals-is a prominent event, which results in the loss of up to 75% of the potential number of mature spermatozoa. In the rat testis, the most conspicuous dying cells are pachytene spermatocytes, which are also the primary target of the apoptosis experimentally induced by methoxyacetic acid (MAA). In this paper, we have used clusterin expression as an indicator of germ cell apoptosis in rat seminiferous tubules treated with MAA in the presence or in the absence of voltage-operated calcium channels (VOCCs) inhibitors. We performed both a qualitative analysis of clusterin expression by immunofluorescence experiments and a quantitative analysis of apoptosis by in situ end labeling of apoptotic germ cells followed by flow cytometry. The results obtained demonstrate that Sertoli cells, the somatic component of the seminiferous epithelium, which control male germ cell differentiation, also modulate MAA-induced apoptosis of germ cells throughout voltage-operated calcium channels.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; ENEA, Casaccia Res Ctr, Biotechnol Unit, I-00060 Rome, Italy	Sapienza University Rome; Italian National Agency New Technical Energy & Sustainable Economics Development	D'Agostino, A (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via A Scarpa 14, I-00161 Rome, Italy.	angela.dagostino@uniroma1.it		Aguanno, Salvatore/0000-0002-0352-4948				Bailey RW, 2002, BIOL REPROD, V66, P1042, DOI 10.1095/biolreprod66.4.1042; BARTKE A, 1995, ENDOCRINOLOGY, V136, P3, DOI 10.1210/en.136.1.3; BlancoRodriguez J, 1996, CELL PROLIFERAT, V29, P13, DOI 10.1046/j.1365-2184.1996.d01-5.x; Cano-Abad MF, 2002, ANN NY ACAD SCI, V971, P171, DOI 10.1111/j.1749-6632.2002.tb04459.x; Clark AM, 1997, BIOL REPROD, V57, P837, DOI 10.1095/biolreprod57.4.837; DAGOSTINO A, 1992, BIOL REPROD, V46, P414, DOI 10.1095/biolreprod46.3.414; DEROOIJ DG, 1987, ANAT REC, V217, P124, DOI 10.1002/ar.1092170203; FLICKINGER C, 1967, ANAT RECORD, V158, P207, DOI 10.1002/ar.1091580210; Fragale A, 2000, MOL CELL ENDOCRINOL, V162, P25, DOI 10.1016/S0303-7207(00)00213-6; French LE, 1996, BIOL REPROD, V55, P1213, DOI 10.1095/biolreprod55.6.1213; Galdieri M, 1981, J ANDROL, V5, P249; GHANAYEM BI, 1990, EXP MOL PATHOL, V52, P279, DOI 10.1016/0014-4800(90)90069-P; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; HARDIN BD, 1983, TOXICOLOGY, V27, P91, DOI 10.1016/0300-483X(83)90014-8; Ho R, 2001, J ALZHEIMERS DIS, V3, P479, DOI 10.3233/JAD-2001-3507; HSDB, 2000, HSDB TOXNET HAZ SUBS; JEONGWU L, 1997, ENDOCRINOLOGY, V138, P2081; Krishnamurthy H, 1998, J ANDROL, V19, P710; KU WW, 1995, TOXICOL APPL PHARM, V134, P100, DOI 10.1006/taap.1995.1173; KU WW, 1994, TOXICOL IN VITRO, V8, P1191, DOI 10.1016/0887-2333(94)90109-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LH, 1997, TOXICOL APPL PHARM, V144, P105, DOI 10.1006/taap.1997.8129; LI LH, 1996, J ANDROL, V17, P153; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; McHattie S, 1999, J COMP PATHOL, V121, P159, DOI 10.1053/jcpa.1999.0313; Otori Y, 2003, BRAIN RES, V961, P213, DOI 10.1016/S0006-8993(02)03951-3; Read DS, 2002, EXP EYE RES, V75, P415, DOI 10.1006/exer.2002.2034; Richburg JH, 2000, ENDOCRINOLOGY, V141, P787, DOI 10.1210/en.141.2.787; RUSSELL LD, 1978, ANAT REC, V190, P99, DOI 10.1002/ar.1091900109; SHERI AH, 2001, BIOL REPROD, V65, P1771; Taranta A, 2000, MATRIX BIOL, V19, P11, DOI 10.1016/S0945-053X(99)00054-2; Taranta A, 1997, MOL CELL ENDOCRINOL, V126, P117, DOI 10.1016/S0303-7207(96)03973-1; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5	33	10	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					353	+		10.1096/fj.03-0347fje	http://dx.doi.org/10.1096/fj.03-0347fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656996				2022-12-25	WOS:000188067500029
J	Tullo, A; Mastropasqua, G; Bourdon, JC; Centonze, P; Gostissa, M; Costanzo, A; Levrero, M; Del Sal, G; Saccone, C; Sbisa, E				Tullo, A; Mastropasqua, G; Bourdon, JC; Centonze, P; Gostissa, M; Costanzo, A; Levrero, M; Del Sal, G; Saccone, C; Sbisa, E			Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target	ONCOGENE			English	Article						p73; p53; adenosine deaminase; p53 family; purine metabolism	CANCER CELL-LINE; P53 HOMOLOG; FUNCTIONAL IMPLICATIONS; GENE-EXPRESSION; BINDING-SITE; P63; APOPTOSIS; FAMILY; IDENTIFICATION; ACTIVATION	The discovery of the p73 and p63 genes, homologous to p53 tumor suppressor has uncovered a family of transcription factors and widened the scenario of cell cycle control and apoptosis. We have identified a putative p53-responsive element in the human adenosine deaminase (ADA) gene, an important enzyme involved in nucleotide metabolism, the deficit of which causes the inhibition of DNA synthesis and repair. Here, we demonstrate that the ectopic expression of p73 isoforms leads to the ADA gene upregulation, showing for the first time a correlation between p73 and ADA. W e found that p73 promotes ADA gene expression following a dNTP unbalance generated by ADA enzyme deficiency and 2' deoxyadenosine accumulation. The abrogation of p73 transcriptional activity by the specific dominant-negative p73DD abolishes ADA induction. By contrast, the ADA gene does not appear to be a functional p53 target in the physiological conditions we tested. On the whole, our results contribute to the emerging picture that p73 could play a different role from p53 in normal growth and development by inducing alternative target genes, which are not shared by p53.	CNR, Sez Bari Bioinformat & Genom, Ist Tecnol Biomed, I-70126 Bari, Italy; Univ Bari, Dipartimento Biochim & Biol Mol, I-70125 Bari, Italy; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Consorzio Interuniv Biotecnol, Lab Nazl, Trieste, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00161 Rome, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); Universita degli Studi di Bari Aldo Moro; University of Dundee; Sapienza University Rome; University of Rome Tor Vergata; University of Trieste	Tullo, A (corresponding author), CNR, Sez Bari Bioinformat & Genom, Ist Tecnol Biomed, Via Amendola 165-A, I-70126 Bari, Italy.		MASTROPASQUA, Mauro/AAK-8813-2020; JC, Bourdon/A-4439-2008; Sbisa', Elisabetta/AAW-9727-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Tullo, Apollonia/AAX-1079-2020; Levrero, Massimo/G-5680-2016	MASTROPASQUA, Mauro/0000-0002-8306-0839; JC, Bourdon/0000-0003-4623-9386; Costanzo, Antonio/0000-0001-9697-2557; Tullo, Apollonia/0000-0002-5081-4745; DEL SAL, GIANNINO/0000-0003-2185-6003; Levrero, Massimo/0000-0002-4978-0875				ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bemi V, 1998, INT J CANCER, V75, P713, DOI 10.1002/(SICI)1097-0215(19980302)75:5<713::AID-IJC9>3.0.CO;2-1; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; CAMICI M, 1995, INT J CANCER, V62, P176, DOI 10.1002/ijc.2910620212; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; D'Erchia A. M., 2003, Current Genomics, V4, P13, DOI 10.2174/1389202033350173; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; GIBLETT ER, 1972, LANCET, V2, P1067; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HE YP, 1993, J NUTR, V123, P1017; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIZAKI H, 1988, J IMMUNOL, V141, P1652; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moriwaki Y, 1999, HISTOL HISTOPATHOL, V14, P1321, DOI 10.14670/HH-14.1321; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Saccone C, 2002, GENE, V300, P195, DOI 10.1016/S0378-1119(02)01036-3; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sciacchitano S, 2002, MOL ENDOCRINOL, V16, P1577, DOI 10.1210/me.16.7.1577; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Vikhanskaya F, 2001, CANCER RES, V61, P935; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6; Zhou HJ, 2001, J MOL BIOL, V306, P227, DOI 10.1006/jmbi.2000.4370	51	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8738	8748		10.1038/sj.onc.1206967	http://dx.doi.org/10.1038/sj.onc.1206967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647469				2022-12-25	WOS:000186844900012
J	Aki, T; Yamaguchi, K; Fujimiya, T; Mizukami, Y				Aki, T; Yamaguchi, K; Fujimiya, T; Mizukami, Y			Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2	ONCOGENE			English	Article						phosphoinositide 3-kinase; autophagy; glucose deprivation; cell death	PROTEIN-DEGRADATION; 3T3-L1 ADIPOCYTES; DISEASE; KINASE; HEPATOCYTES; MECHANISMS; MORPHOLOGY; APOPTOSIS; TRANSPORT; VACUOLES	We investigated cell death during glucose deprivation in rat cardiomyocyte-derived H9c2 cells. Electron microscopic analysis revealed accumulation of autophagic vacuoles during glucose deprivation. The addition of 3-methyladenine or LY294002, which are known to inhibit autophagosome formation, reduced cell death while Z-VAD-FMK, a caspase inhibitor, slightly affected cell death. Thus, cell death during glucose deprivation is not type I programmed cell death (apoptotic cell death) but type 11 programmed cell death (autophagic cell death). Moreover, we found that both insulin-like growth factor-I and the adenovirus-mediated overexpression of wild-type class I PI 3-kinase accelerated cell death as well as accumulation of autophagic vacuoles during glucose deprivation while dominant-negative PI 3-kinase reduced these phenomena. The results indicate that IGF-I/PI 3-kinase accelerates the accumulation of autophagic vacuoles and subsequent autophagic cell death during glucose deprivation, revealing the opposing role of IGF-I/PI 3-kinase in two distinct types of programmed cell death (apoptotic and autophagic cell death).	Yamaguchi Univ, Ctr Gene Res, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Inst Lab Anim, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Legal Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University	Aki, T (corresponding author), Yamaguchi Univ, Ctr Gene Res, 1-1-1 Minamikoguchi, Ube, Yamaguchi 7558505, Japan.			Mizukami, Yoichi/0000-0002-3290-0754				Aki T, 2001, BIOCHEM J, V358, P481, DOI 10.1042/0264-6021:3580481; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Izuishi K, 2000, CANCER RES, V60, P6201; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KEGAL BK, 2000, J NEUROSCI, V20, P7268; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Munafo DB, 2001, J CELL SCI, V114, P3619; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	31	109	117	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8529	8535		10.1038/sj.onc.1207197	http://dx.doi.org/10.1038/sj.onc.1207197			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627994				2022-12-25	WOS:000186650300017
J	Das, S; El-Deiry, WS; Somasundaram, K				Das, S; El-Deiry, WS; Somasundaram, K			Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73 beta	ONCOGENE			English	Article						p53; p73; human papilloma virus; cervical cancer; E6; gene therapy	HUMAN-PAPILLOMAVIRUS; DNA-BINDING; GENE; APOPTOSIS; DEGRADATION; SUPPRESSION; CARCINOMA; PROMOTES; PROTEIN; ARREST	Tumor suppressor p53 functions are downregulated in most cervical cancers, because the product of human papilloma virus (HPV) oncogene E6 binds to and inactivates p53 by promoting its degradation. p73, a p53 homologue, is similar to p53 in structure and function but yet not degraded by HPV E6 gene product. In this study, we have developed a replication-deficient recombinant adenovirus, which expresses p73beta (Ad-p73). Infection of human cancer cells with Ad-p73 results in several fold increase of p73beta levels as well as its known target genes like p21(WAF1/CIP1). Ad-p73-infected cells showed reduced cellular DNA synthesis, arrest in G1 phase of cell cycle and induction of apoptosis. Ad-p73 inhibited the growth of cancer cells of different types. More importantly, Ad-p73 inhibited the growth of cell tines carrying HPV E6 gene, which was introduced by stable integration, more efficiently in comparison to an Ad-p53. Furthermore, Ad-p73 also inhibited the growth of HeLa cells, a cell line derived from cervical cancer, very efficiently. The ability of Ad-p73 to inhibit the growth of HPV E6-expressing cells and HeLa cells correlated with the stable expression of functional p73 in the presence of E6. These results suggest that Ad-p73 could be used as a potential gene therapy agent against cervical cancer.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Indian Institute of Science (IISC) - Bangalore; Howard Hughes Medical Institute; University of Pennsylvania	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Das, Sanjeev/0000-0002-3594-1033				BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hamada K, 1996, CANCER RES, V56, P3047; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huh WK, 2001, GYNECOL ONCOL, V83, P370, DOI 10.1006/gyno.2001.6403; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNGU O, 1995, OBSTET GYNECOL, V85, P337, DOI 10.1016/0029-7844(94)00399-X; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prabhu NS, 1998, INT J ONCOL, V13, P5; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; ROSE PG, 2000, COMBINED MODALITY TR; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Yatabe N, 2002, CANCER GENE THER, V9, P624, DOI 10.1038/sj.cgt.7700479; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	32	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8394	8402		10.1038/sj.onc.1206908	http://dx.doi.org/10.1038/sj.onc.1206908			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627980				2022-12-25	WOS:000186650300003
J	Mao, JH; Wu, D; Perez-Losada, J; Nagase, H; DelRosario, R; Balmain, A				Mao, JH; Wu, D; Perez-Losada, J; Nagase, H; DelRosario, R; Balmain, A			Genetic interactions between Pten and p53 in radiation-induced lymphoma development	ONCOGENE			English	Article						Pten; p53; loss of heterozygosity; intragenic deletion; radiation induced lymphoma	TUMOR-SUPPRESSOR GENE; MUTATIONS; TRANSCRIPTION; INACTIVATION; IRRADIATION; LOCUS; MDM2; FORM	Genetic analysis of radiation-induced lymphomas from p53 heterozygous or null mice has revealed a high frequency of genetic alterations on mouse chromosome 19. Detailed microsatellite analysis of chromosome 19 deletions identified three independent regions of loss of heterozygosity, one of which was refined to a 0.3 Mb interval that contained the Pten tumor suppressor gene. More than 50% of radiation-induced tumors from p53+/- and p53-/- mice showed heterozygous loss of one Pten allele. In most cases, the remaining allele was wild type and expressed, suggesting that Pten is a haploinsufficient tumor suppressor gene for mouse lymphoma development. This conclusion was supported by the detection of specific intragenic deletions in Pten in tumors that retained one wild-type allele. Pten heterozygous mice were just as sensitive as p53+/- mice to induction of tumors by radiation, and surprisingly, the double p53+/-Pten+/- mice were equivalent to p53 null mice in radiation sensitivity. Despite the fact that Pten appears to be a haploinsufficient tumor suppressor gene, most tumors from both the single and double heterozygous mice had lost the remaining wild-type allele. The mechanism of loss in all cases involved the complete chromosome, suggesting that it is driven by other tumor suppressor genes on this chromosome. This sensitized screen therefore identified complementary roles for Pten and p53 pathways in suppression of tumor development induced by radiation exposure.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; Roswell Park Cancer Institute	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022; Pérez-Losada, Jesús/A-5883-2019	Mao, Jian-Hua/0000-0001-9320-6021; Pérez-Losada, Jesús/0000-0003-2400-624X	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Butler MP, 1999, GENE CHROMOSOME CANC, V24, P322, DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Gronbaek K, 1998, BLOOD, V91, P4388; Herranz M, 2000, LEUKEMIA, V14, P1325, DOI 10.1038/sj.leu.2401813; Izumoto S, 2001, J NEURO-ONCOL, V53, P21, DOI 10.1023/A:1011839920176; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Shin KH, 2002, INT J ONCOL, V21, P997; Sjoling A, 2003, GENE CHROMOSOME CANC, V36, P70, DOI 10.1002/gcc.10143; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774	32	39	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8379	8385		10.1038/sj.onc.1207083	http://dx.doi.org/10.1038/sj.onc.1207083			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627978				2022-12-25	WOS:000186650300001
J	Yang, C; Boucher, F; Tremblay, A; Michaud, JL				Yang, C; Boucher, F; Tremblay, A; Michaud, JL			Regulatory interaction between arylhydrocarbon receptor and SIM1, two basic helix-loop-helix PAS proteins involved in the control of food intake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR FAMILY; DIOXIN-RESPONSIVE ENHANCER; TISSUE-SPECIFIC EXPRESSION; CENTRAL-NERVOUS-SYSTEM; LIGANDED AH RECEPTOR; NUCLEAR TRANSLOCATOR; MESSENGER-RNA; CDNA CLONING; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD	The basic helix-loop-helix PAS (bHLH-PAS) transcription factors SIM1 and arylhydrocarbon receptor (AHR) are involved in the control of feeding behavior. Sim1 haploinsufficiency causes hyperphagia in mice and humans, most likely by perturbing the hypothalamus function. The administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD), a ligand of AHR, causes severe anorexia, which also appears to be of central origin. Both SIM1 and AHR require heterodimerization either with ARNT or ARNT2 to function. Here, we characterize the promoter for Sim1 and show that a consensus AHR-ARNT/2 binding site positively regulates its activity in the context of transfection experiments in Neuro-2A cells. A gel shift assay indicated that AHR-ARNT/2 can bind its putative site in the Sim1 promoter. Overexpression of Arnt, Arnt2, or Ahr increased the activity of a reporter construct containing the Sim1 promoter by 1.8-, 1.5-, and 2.2-fold, respectively, but failed to do so when the AHRARNT/2 binding site was mutated. Similarly, TCDD increased the activity of the reporter construct by 1.8- fold but not that of its mutated version. Finally, we found that TCDD increased Sim1 expression in Neuro-2A cells and in mouse kidney and hypothalamus by 4-, 3-, and 2-fold, respectively. We conclude that Sim1 expression is regulated by AHR-ARNT/2. This result raises the possibility that Sim1 mediates the effect of TCDD on feeding and points to a complex network of regulatory interactions between bHLH-PAS proteins.	Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada	Universite de Montreal	Michaud, JL (corresponding author), Hop St Justine, Ctr Rech, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	jmichaud@justine.umontreal.ca						Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Buckhaults P, 2001, CANCER RES, V61, P6996; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Cheng SB, 2002, BRAIN RES, V931, P176, DOI 10.1016/S0006-8993(02)02257-6; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Falahatpisheh MH, 2003, ONCOGENE, V22, P2160, DOI 10.1038/sj.onc.1206238; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Holder JL, 2000, HUM MOL GENET, V9, P101; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; Huang P, 2000, TOXICOL APPL PHARM, V169, P159, DOI 10.1006/taap.2000.9064; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V275, P493, DOI 10.1006/bbrc.2000.3248; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Jeon MS, 2000, J IMMUNOL, V165, P6975, DOI 10.4049/jimmunol.165.12.6975; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; KELLING CK, 1985, FUND APPL TOXICOL, V5, P700, DOI 10.1016/0272-0590(85)90194-0; Laiosa MD, 2002, TOXICOL SCI, V69, P117, DOI 10.1093/toxsci/69.1.117; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maemura K, 2000, J BIOL CHEM, V275, P36847, DOI 10.1074/jbc.C000629200; Michaud JL, 2000, MECH DEVELOP, V90, P253, DOI 10.1016/S0925-4773(99)00328-7; Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264; Michaud JL, 2001, HUM MOL GENET, V10, P1465, DOI 10.1093/hmg/10.14.1465; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Moriguchi T, 2003, P NATL ACAD SCI USA, V100, P5652, DOI 10.1073/pnas.1037886100; Okano T, 2001, NEUROSCI LETT, V300, P111, DOI 10.1016/S0304-3940(01)01581-6; Petersen SL, 2000, J COMP NEUROL, V427, P428, DOI 10.1002/1096-9861(20001120)427:3<428::AID-CNE9>3.0.CO;2-P; POHJANVIRTA R, 1989, TOXICOLOGY, V58, P167, DOI 10.1016/0300-483X(89)90006-1; POHJANVIRTA R, 1994, PHARMACOL BIOCHEM BE, V47, P273, DOI 10.1016/0091-3057(94)90010-8; POHJANVIRTA R, 1994, PHARMACOL REV, V46, P483; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Shridhar S, 2001, TOXICOL SCI, V63, P181, DOI 10.1093/toxsci/63.2.181; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; UNKILA M, 1995, INT J BIOCHEM CELL B, V27, P443, DOI 10.1016/1357-2725(95)00023-I; Wang F, 2001, MOL CELL ENDOCRINOL, V172, P91, DOI 10.1016/S0303-7207(00)00379-8; Wei YD, 2000, ARCH BIOCHEM BIOPHYS, V383, P99, DOI 10.1006/abbi.2000.2037; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wolting CD, 1998, MAMM GENOME, V9, P463, DOI 10.1007/s003359900797; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200	53	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9306	9312		10.1074/jbc.M307927200	http://dx.doi.org/10.1074/jbc.M307927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660629	hybrid			2022-12-25	WOS:000189265900093
J	Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T				Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T			Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation	ONCOGENE			English	Article						Cbl family; v-Src; transformation; ubiquitination	MEDIATED TYROSINE PHOSPHORYLATION; D-ASPARTATE RECEPTOR; DOWN-REGULATION; NEGATIVE REGULATOR; LIGASE ACTIVITY; KINASE; ACTIVATION; ZAP-70; CELLS; PROLIFERATION	The Cbl family proteins Cbl, Cbl- b, and Cbl-c/Cbl-3 are thought to regulate signaling through protein-tyrosine kinases, positively as scaffold proteins and negatively as ubiquitin ligases. However, the precise signaling pathways and target proteins for each Cbl family member are not well understood. Here we show that Src is a preferential target of Cbl- c for degradation. Although exogenous expression of all Cbl family proteins suppressed the anchorage-independent growth of v-Src-transformed NIH3T3 cells, only Cbl- c caused reversion of the refractile morphology. The level of v-Src protein was reduced by Cbl- c, possibly through a lysosome-dependent pathway. The TKB domain and RING finger of Cbl- c were important for its antioncogenic activity. Wild-type Cbl- c promoted ubiquitination of Src in 293T cells, whereas a RING finger mutant did not. Cbl- c bound specifically to Src phosphorylated at Tyr419. Furthermore, Cbl- c together with UbcH5 induced ubiquitination of Src in vitro. Importantly, the Tyr419 nonphosphorylated form of Src was not ubiquitinated by Cbl- c. Therefore, activated Src may be a direct target of Cbl- c in vivo. Our results suggest that Cbl and Cbl- b suppress v-Src-induced transformation through mechanisms distinct from that of Cbl- c.	Univ Tokyo, Inst Med Sci, Div Oncol, Dept Canc Biol,Minato Ku, Tokyo 1088639, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Dept Canc Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp		Kim, Minsoo/0000-0001-8536-8653				Astarie-Dequeker C, 2002, J CELL SCI, V115, P81; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; ODAJIMA J, 2000, J BIOL CHEM, V11, P11; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	33	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1645	1655		10.1038/sj.onc.1207298	http://dx.doi.org/10.1038/sj.onc.1207298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14661060				2022-12-25	WOS:000220029300001
J	Bergt, C; Fu, XY; Huq, NP; Kao, J; Heinecke, JW				Bergt, C; Fu, XY; Huq, NP; Kao, J; Heinecke, JW			Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE-CHLORIDE; HUMAN ATHEROSCLEROTIC LESIONS; HUMAN NEUTROPHILS EMPLOY; AMINO-ACIDS; GENERATED HYPOCHLORITE; MYELOPEROXIDASE SYSTEM; MODIFIED PROTEINS; TYROSYL RESIDUES; HUMAN PHAGOCYTES; LIPID-FREE	Oxidized lipoproteins may play an important role in the pathogenesis of atherosclerosis. Elevated levels of 3-chlorotyrosine, a specific end product of the reaction between hypochlorous acid (HOCl) and tyrosine residues of proteins, have been detected in atherosclerotic tissue. Thus, HOCl generated by the phagocyte enzyme myeloperoxidase represents one pathway for protein oxidation in humans. One important target of the myeloperoxidase pathway may be high density lipoprotein (HDL), which mobilizes cholesterol from artery wall cells. To determine whether activated phagocytes preferentially chlorinate specific sites in HDL, we used tandem mass spectrometry (MS/MS) to analyze apolipoprotein A-I that had been oxidized by HOCl. The major site of chlorination was a single tyrosine residue located in one of the protein's YXXK motifs ( where X represents a nonreactive amino acid). To investigate the mechanism of chlorination, we exposed synthetic peptides to HOCl. The peptides encompassed the amino acid sequences YKXXY, YXXKY, or YXXXY. MS/MS analysis demonstrated that chlorination of tyrosine in the peptides that contained lysine was regioselective and occurred in high yield if the substrate was KXXY or YXXK. NMR and MS analyses revealed that the N-epsilon amino group of lysine was initially chlorinated, which suggests that chloramine formation is the first step in tyrosine chlorination. Molecular modeling of the YXXK motif in apolipoprotein A-I demonstrated that these tyrosine and lysine residues are adjacent on the same face of an amphipathic alpha-helix. Our observations suggest that HOCl selectively targets tyrosine residues that are suitably juxtaposed to primary amino groups in proteins. This mechanism might enable phagocytes to efficiently damage proteins when they destroy microbial proteins during infection or damage host tissue during inflammation.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL)	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu		Huq Saifee, Nabiha/0000-0003-1646-9201	NHLBI NIH HHS [HL64344] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Aratani Y, 1999, INFECT IMMUN, V67, P1828; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491; Chapman ALP, 2000, ARCH BIOCHEM BIOPHYS, V377, P95, DOI 10.1006/abbi.2000.1744; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Frank PG, 2000, J LIPID RES, V41, P853; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hawkins CL, 1999, BIOCHEM J, V340, P539, DOI 10.1042/0264-6021:3400539; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Nightingale ZD, 2000, FREE RADICAL BIO MED, V29, P425, DOI 10.1016/S0891-5849(00)00262-8; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; Raftery MJ, 2001, J BIOL CHEM, V276, P33393, DOI 10.1074/jbc.M101566200; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rosen H, 2002, J BIOL CHEM, V277, P30463, DOI 10.1074/jbc.M202331200; Schoneich C, 2002, CHEM RES TOXICOL, V15, P717, DOI 10.1021/tx025504k; SCOTT JW, 1974, J AM OIL CHEM SOC, V51, P200, DOI 10.1007/BF02632894; SEGREST JP, 1992, J LIPID RES, V33, P141; SELVARAJ RJ, 1974, INFECT IMMUN, V9, P255, DOI 10.1128/IAI.9.2.255-260.1974; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WILEY WC, 1955, REV SCI INSTRUM, V26, P1150, DOI 10.1063/1.1715212; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Yang CY, 2001, J LIPID RES, V42, P1891; ZGLICZYNSKI JM, 1968, EUR J BIOCHEM, V4, P540, DOI 10.1111/j.1432-1033.1968.tb00246.x	65	110	120	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7856	7866		10.1074/jbc.M309046200	http://dx.doi.org/10.1074/jbc.M309046200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660678	hybrid			2022-12-25	WOS:000189103300062
J	Sekiguchi, T; Todaka, Y; Wang, YG; Hirose, E; Nakashima, N; Nishimoto, T				Sekiguchi, T; Todaka, Y; Wang, YG; Hirose, E; Nakashima, N; Nishimoto, T			A novel human nucleolar protein, Nop132, binds to the G proteins, RRAG A/C/D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; RAN; RCC1; GTPASE; EXCHANGE; GTR1P; PROGRESSION; MECHANISMS; INHIBITOR	RRAG A (Rag A)/Gtr1p is a member of the Ras-like small G protein family that genetically interacts with RCC1, a guanine nucleotide exchange factor for RanGTPase. RRAG A/Gtr1p forms a heterodimer with other G proteins, RRAG C and RRAG D/Gtr2p, in a nucleotide-independent manner. To further elucidate the function of RRAG A/Gtr1p, we isolated a protein that interacts with RRAG A. This protein is a novel nucleolar protein, Nop132. Nop132 is associated with the GTP form, but not the GDP form, of RRAG A, suggesting that RRAG A might regulate Nop132 function. Nop132 is also associated with RRAG C and RRAG D. The Nop132 amino acid sequence is similar to the Saccharomyces cerevisiae nucleolar Nop8p, which is associated with Gtr1p, Gtr2p, and Nip7p. Nop132 also interacts with human Nip7 and is colocalized with RRAG A, RRAG C, and Nip7. RNA interference knockdown of Nop132 inhibited cell growth of HeLa cells.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sekiguchi, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	sekigu@molbiol.med.kyushu-u.ac.jp	Nakashima, Nobutaka/G-3777-2016	Nakashima, Nobutaka/0000-0002-5836-9148				Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BUN YM, 1992, MOL CELL BIOL, V12, P2958; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Exton JH, 1998, J BIOL CHEM, V273, P19923, DOI 10.1074/jbc.273.32.19923; Heald R, 2000, TRENDS CELL BIOL, V10, P1, DOI 10.1016/S0962-8924(99)01691-8; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Hirose E, 1998, J CELL SCI, V111, P11; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Isaac C, 2001, J CELL SCI, V114, P4253; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Li HN, 2003, J CELL BIOL, V160, P635, DOI 10.1083/jcb.200211004; Li YG, 1997, J VIROL, V71, P1576, DOI 10.1128/JVI.71.2.1576-1582.1997; Lukashok SA, 2000, J VIROL, V74, P4705, DOI 10.1128/JVI.74.10.4705-4709.2000; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Nakashima N, 1999, GENETICS, V152, P853; Nakashima N, 1996, J CELL SCI, V109, P2311; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishimoto T, 2000, BIOL CHEM, V381, P397, DOI 10.1515/BC.2000.052; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; Sazer S, 2000, J CELL SCI, V113, P1111; SCHURMANN A, 1995, J BIOL CHEM, V270, P28982, DOI 10.1074/jbc.270.48.28982; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Zanchin NIT, 1999, MOL CELL BIOL, V19, P1518	34	25	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8343	8350		10.1074/jbc.M305935200	http://dx.doi.org/10.1074/jbc.M305935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660641	hybrid			2022-12-25	WOS:000189103300116
J	Ho, RH; Leake, BF; Robertson, RL; Lee, W; Kim, RB				Ho, RH; Leake, BF; Robertson, RL; Lee, W; Kim, RB			Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; ANION UPTAKE SYSTEMS; SALT EXPORT PUMP; EXPRESSION CLONING; RAT HEPATOCYTES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; HUMAN LIVER; SODIUM; TRANSPORTER	The key transporter responsible for hepatic uptake of bile acids from portal circulation is Na+-taurocholate cotransporting polypeptide (NTCP, SLC10A1). This transporter is thought to be critical for the maintenance of enterohepatic recirculation of bile acids and hepatocyte function. Therefore, functionally relevant polymorphisms in this transporter would be predicted to have an important impact on bile acid homeostasis/liver function. However, little is known regarding genetic heterogeneity in NTCP. In this study, we demonstrate the presence of multiple single nucleotide polymorphisms in NTCP in populations of European, African, Chinese, and Hispanic Americans. Specifically four nonsynonymous single nucleotide polymorphisms associated with a significant loss of transport function were identified. Cell surface biotinylation experiments indicated that the altered transport activity of T668C (Ile(223) --> Thr), a variant seen only in African Americans, was due at least in part to decreased plasma membrane expression. Similar expression patterns were observed when the variant alleles were expressed in HepG2 cells, and plasma membrane expression was assessed using immunofluorescence confocal microscopy. Interestingly the C800T (Ser(267) --> Phe) variant, seen only in Chinese Americans, exhibited a near complete loss of function for bile acid uptake yet fully normal transport function for the nonbile acid substrate estrone sulfate, suggesting this position may be part of a region in the transporter critical and specific for bile acid substrate recognition. Accordingly, our study indicates functionally important polymorphisms in NTCP exist and that the likelihood of being carriers of such polymorphisms is dependent on ethnicity.	Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Master Sci Clin Invest Program, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Kim, RB (corresponding author), Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Dept Med, 572 Robinson Res Bldg,23rd Ave & Pierce Ave, Nashville, TN 37232 USA.	richard.kim@vanderbilt.edu	Lee, Wooin/K-7789-2012; Kim, Richard/D-6971-2011	Lee, Wooin/0000-0001-7805-869X; Kim, Richard/0000-0001-8148-1632	NATIONAL CANCER INSTITUTE [K12CA090625, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304, U01GM061374, R01GM054724, R55GM054724] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, K12-CA90625] Funding Source: Medline; NHLBI NIH HHS [U01 HL65962] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK58404] Funding Source: Medline; NIGMS NIH HHS [GM54724, U01GM61374, GM31304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Cattori V, 1999, BBA-GENE STRUCT EXPR, V1445, P154, DOI 10.1016/S0167-4781(99)00029-9; CONNOLLY CS, 1995, J AM ACAD DERMATOL, V33, P801, DOI 10.1016/0190-9622(95)91818-3; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; Dawson Paul A., 1995, Current Opinion in Lipidology, V6, P109, DOI 10.1097/00041433-199504000-00009; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Hagenbuch B, 1996, BIOCHEM J, V316, P901, DOI 10.1042/bj3160901; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Hallen S, 1999, BIOCHEMISTRY-US, V38, P11379, DOI 10.1021/bi990554i; Hofmann A.F., 1998, GASTROINTESTINAL LIV, P937; Jansen PLM, 1999, GASTROENTEROLOGY, V117, P1370, DOI 10.1016/S0016-5085(99)70287-8; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Kim RB, 1999, J PHARMACOL EXP THER, V291, P1204; Koop I, 1996, GUT, V39, P661, DOI 10.1136/gut.39.5.661; Kouzuki H, 1998, J PHARMACOL EXP THER, V286, P1043; Kramer W, 1999, J LIPID RES, V40, P1604; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Muller M, 1998, J HEPATOL, V28, P344, DOI 10.1016/0168-8278(88)80024-2; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Riepl R L, 1996, Eur J Med Res, V1, P499; Saito S, 2002, J HUM GENET, V47, P576, DOI 10.1007/s100380200088; SCHARSCHMIDT BF, 1981, P NATL ACAD SCI-BIOL, V78, P986, DOI 10.1073/pnas.78.2.986; Shneider BL, 1997, HEPATOLOGY, V25, P1176, DOI 10.1002/hep.510250521; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tirona RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/jbc.M103792200; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; Weinman SA, 1997, YALE J BIOL MED, V70, P331; WONG MH, 1994, J BIOL CHEM, V269, P1340; YAMAZAKI M, 1993, AM J PHYSIOL, V264, pG693, DOI 10.1152/ajpgi.1993.264.4.G693	34	141	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7213	7222		10.1074/jbc.M305782200	http://dx.doi.org/10.1074/jbc.M305782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660639	hybrid			2022-12-25	WOS:000188969200121
J	Sauer, U; Canonaco, F; Heri, S; Perrenoud, A; Fischer, E				Sauer, U; Canonaco, F; Heri, S; Perrenoud, A; Fischer, E			The soluble and membrane-bound transhydrogenases UdhA and PntAB have divergent functions in NADPH metabolism of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE; CENTRAL CARBON METABOLISM; SACCHAROMYCES-CEREVISIAE; FLUX ANALYSIS; CORYNEBACTERIUM-GLUTAMICUM; NETWORK ANALYSIS; GLUCOSE; GROWTH; MODEL; RESPONSES	Pentose phosphate pathway and isocitrate dehydrogenase are generally considered to be the major sources of the anabolic reductant NADPH. As one of very few microbes, Escherichia coli contains two transhydrogenase isoforms with unknown physiological function that could potentially transfer electrons directly from NADH to NADP(+) and vice versa. Using defined mutants and metabolic flux analysis, we identified the proton-translocating transhydrogenase PntAB as a major source of NADPH in E. coli. During standard aerobic batch growth on glucose, 35-45% of the NADPH that is required for biosynthesis was produced via PntAB, whereas pentose phosphate pathway and isocitrate dehydrogenase contributed 35-45% and 20-25%, respectively. The energy-independent transhydrogenase UdhA, in contrast, was essential for growth under metabolic conditions with excess NADPH formation, i.e. growth on acetate or in a phosphoglucose isomerase mutant that catabolized glucose through the pentose phosphate pathway. Thus, both isoforms have divergent physiological functions: energy-dependent reduction of NADP(+) with NADH by PntAB and reoxidation of NADPH by UdhA. Expression appeared to be modulated by the redox state of cellular metabolism, because genetic and environmental manipulations that increased or decreased NADPH formation down-regulated pntA or udhA transcription, respectively. The two transhydrogenase isoforms provide E. coli primary metabolism with an extraordinary flexibility to cope with varying catabolic and anabolic demands, which raises two general questions: why do only a few bacteria contain both isoforms, and how do other organisms manage NADPH metabolism?	ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Sauer, U (corresponding author), ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland.	sauer@biotech.biol.ethz.ch	Sauer, Uwe/Y-3556-2019; Fischer, Eliane/M-2590-2013	Fischer, Eliane/0000-0002-3399-3737				Bizouarn T, 2002, BBA-BIOENERGETICS, V1555, P122, DOI 10.1016/S0005-2728(02)00266-9; BOLES E, 1993, EUR J BIOCHEM, V217, P469, DOI 10.1111/j.1432-1033.1993.tb18266.x; Boonstra B, 1999, J BACTERIOL, V181, P1030, DOI 10.1128/JB.181.3.1030-1034.1999; Canonaco F, 2001, FEMS MICROBIOL LETT, V204, P247, DOI 10.1111/j.1574-6968.2001.tb10892.x; Chassagnole C, 2002, BIOTECHNOL BIOENG, V79, P53, DOI 10.1002/bit.10288; Christiansen T, 2002, METAB ENG, V4, P159, DOI 10.1006/mben.2001.0219; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; CSONKA LN, 1977, J BIOL CHEM, V252, P3382; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P144, DOI 10.1002/bit.1154; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Emmerling M, 1999, METAB ENG, V1, P117, DOI 10.1006/mben.1998.0109; Fiaux J, 2003, EUKARYOT CELL, V2, P170, DOI 10.1128/EC.2.1.170-180.2003; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2004, ANAL BIOCHEM, V325, P308, DOI 10.1016/j.ab.2003.10.036; Fischer E, 2003, J BIOL CHEM, V278, P46446, DOI 10.1074/jbc.M307968200; Flores S, 2002, METAB ENG, V4, P124, DOI 10.1006/mben.2001.0209; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; FRAENKEL DG, 1968, J BIOL CHEM, V243, P6451; FRAENKEL DG, 1967, J BACTERIOL, V93, P1571, DOI 10.1128/JB.93.5.1571-1578.1967; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; GEROLIMATOS B, 1978, J BACTERIOL, V134, P394, DOI 10.1128/JB.134.2.394-400.1978; Gottschalk G., 1986, BACTERIAL METABOLISM; HANSON RL, 1980, J BACTERIOL, V141, P401, DOI 10.1128/JB.141.1.401-404.1980; Harold F. M., 1986, VITAL FORCE STUDY BI; HOEK JB, 1988, BIOCHEM J, V254, P1; Holden C, 2002, SCIENCE, V297, P1459; Jackson JB, 1998, BBA-BIOENERGETICS, V1365, P79; LIANG A, 1980, FEBS LETT, V109, P185, DOI 10.1016/0014-5793(80)81082-9; Marx A, 2003, J BIOTECHNOL, V104, P185, DOI 10.1016/S0168-1656(03)00153-6; Marx A, 1999, METAB ENG, V1, P35, DOI 10.1006/mben.1998.0106; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; Nissen TL, 2001, YEAST, V18, P19, DOI 10.1002/1097-0061(200101)18:1<19::AID-YEA650>3.3.CO;2-X; Ouzounis CA, 2000, GENOME RES, V10, P568, DOI 10.1101/gr.10.4.568; Papin JA, 2003, TRENDS BIOCHEM SCI, V28, P250, DOI 10.1016/S0968-0004(03)00064-1; Park SM, 1997, BIOTECHNOL BIOENG, V55, P864, DOI 10.1002/(SICI)1097-0290(19970920)55:6<864::AID-BIT5>3.0.CO;2-E; Pramanik J, 1997, BIOTECHNOL BIOENG, V56, P398, DOI 10.1002/(SICI)1097-0290(19971120)56:4<398::AID-BIT6>3.0.CO;2-J; RUSSELL JB, 1995, MICROBIOL REV, V59, P48, DOI 10.1128/MMBR.59.1.48-62.1995; Sambrook J, 2001, MOL CLONING LAB MANU; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; Schmidt K, 1998, BIOTECHNOL BIOENG, V58, P254, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<254::AID-BIT19>3.0.CO;2-C; Schmidt K, 1999, J BIOTECHNOL, V71, P175, DOI 10.1016/S0168-1656(99)00021-8; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; VOORDOUW G, 1983, EUR J BIOCHEM, V131, P527, DOI 10.1111/j.1432-1033.1983.tb07293.x; WIDMER F, 1977, BIOCHEM BIOPH RES CO, V76, P1287, DOI 10.1016/0006-291X(77)90995-0; Wiechert W, 2001, METAB ENG, V3, P195, DOI 10.1006/mben.2001.0187; Wittmann C, 2002, APPL ENVIRON MICROB, V68, P5843, DOI 10.1128/AEM.68.12.5843-5859.2002; Yang C, 2003, BIOTECHNOL BIOENG, V84, P129, DOI 10.1002/bit.10692; Zamboni N, 2003, FEMS MICROBIOL LETT, V226, P121, DOI 10.1016/S0378-1097(03)00614-1; Zhao J, 2003, J BIOTECHNOL, V101, P101, DOI 10.1016/S0168-1656(02)00316-4	54	399	452	3	96	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6613	6619		10.1074/jbc.M311657200	http://dx.doi.org/10.1074/jbc.M311657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660605	hybrid			2022-12-25	WOS:000188969200050
J	Perez-Garcia, MJ; Cena, V; de Pablo, Y; Llovera, M; Comella, JX; Soler, RM				Perez-Garcia, MJ; Cena, V; de Pablo, Y; Llovera, M; Comella, JX; Soler, RM			Glial cell line-derived neurotrophic factor increases intracellular calcium concentration - Role of calcium/calmodulin in the activation of the phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; RET RECEPTOR; NEURONAL SURVIVAL; MOTONEURON SURVIVAL; CYTOSOLIC CA2+; GDNF FAMILY; AKT KINASE; CALMODULIN; NERVE; DEATH	Moderate increases of intracellular Ca2+ concentration ([Ca2+](i)), induced by either the activation of tropomyosin receptor kinase (Trk) receptors for neurotrophins or by neuronal activity, regulate different intracellular pathways and neuronal survival. In the present report we demonstrate that glial cell line-derived neurotrophic factor (GDNF) treatment also induces [Ca2+](i) elevation by mobilizing this cation from internal stores. The effects of [Ca2+](i) increase after membrane depolarization are mainly mediated by calmodulin (CaM). However, the way in which CaM exerts its effects after tyrosine kinase receptor activation remains poorly characterized. It has been reported that phosphatidylinositol 3-kinase (PI 3-kinase) and its downstream target protein kinase B (PKB) play a central role in cell survival induced by neurotrophic factors; in fact, GDNF promotes neuronal survival through the activation of the PI 3-kinase/PKB pathway. We show that CaM antagonists inhibit PI 3-kinase and PKB activation as well as motoneuron survival induced by GDNF. We also demonstrate that endogenous Ca2+/CaM associates with the 85-kDa regulatory subunit of PI 3-kinase (p85). We conclude that changes of [Ca2+](i), induced by GDNF, promote neuronal survival through a mechanism that involves a direct regulation of PI 3-kinase activation by CaM thus suggesting a central role for Ca2+ and CaM in the signaling cascade for neuronal survival mediated by neurotrophic factors.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Grp Neurobiol Mol, Lleida 25198, Spain; Univ Castilla La Mancha, Ctr Reg Invest Biomed, Albacete 02071, Spain	Universitat de Lleida; Universidad de Castilla-La Mancha	Soler, RM (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Grp Neurobiol Mol, 44 Rovira Roure, Lleida 25198, Spain.	rosa.soler@cmb.udl.es	de Pablo, Yolanda/AAD-1642-2019; Llovera, Marta/AAE-4230-2021; Comella, Joan X/D-7333-2012; Cena, Valentin/L-1751-2017; Comella, Joan/GQA-4279-2022; Soler, Rosa M/A-7361-2010; Tatche, Rosa M Soler/AAJ-6721-2021; Llovera, Marta/B-5585-2009	de Pablo, Yolanda/0000-0001-5208-2114; Comella, Joan X/0000-0002-6218-0786; Cena, Valentin/0000-0001-8928-3681; Soler, Rosa M/0000-0003-0528-3102; Tatche, Rosa M Soler/0000-0003-0528-3102; Llovera, Marta/0000-0001-8399-6867				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Arce V, 1998, J NEUROSCI, V18, P1440; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng AW, 2003, J BIOL CHEM, V278, P7591, DOI 10.1074/jbc.M207232200; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; COMELLA JX, 1994, J NEUROSCI, V14, P2674; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DeBernardi MA, 1996, J BIOL CHEM, V271, P6092, DOI 10.1074/jbc.271.11.6092; Dolcet X, 1999, J NEUROCHEM, V73, P521, DOI 10.1046/j.1471-4159.1999.0730521.x; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Egea J, 2001, J CELL BIOL, V154, P585, DOI 10.1083/jcb.200101023; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Fischer R, 1998, FEBS LETT, V425, P175, DOI 10.1016/S0014-5793(98)00225-7; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; Martin-Caraballo M, 2002, J NEUROSCI, V22, P10201; MUNSHI R, 1993, MOL PHARMACOL, V44, P1185; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Silva AJ, 2003, J NEUROBIOL, V54, P224, DOI 10.1002/neu.10169; Soler RM, 1999, J NEUROSCI, V19, P9160; Soler RM, 1998, J NEUROSCI, V18, P1230; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Wright DE, 1996, CELL TISSUE RES, V286, P209, DOI 10.1007/s004410050689	46	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6132	6142		10.1074/jbc.M308367200	http://dx.doi.org/10.1074/jbc.M308367200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630929	hybrid, Green Published			2022-12-25	WOS:000188776500129
J	Tsygankova, OM; Feshchenko, E; Klein, PS; Meinkoth, JL				Tsygankova, OM; Feshchenko, E; Klein, PS; Meinkoth, JL			Thyroid-stimulating hormone/cAMP and glycogen synthase kinase 3 beta elicit opposing effects on Rap1GAP stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SCLEROSIS GENE-2 PRODUCT; P70 S6 KINASE; CYCLIC-AMP; BETA-CATENIN; CELL-CYCLE; PROTEASOME INHIBITORS; 3-KINASE/AKT PATHWAY; SIGNALING PATHWAYS; DEPENDENT KINASE	Beyond regulating Rap activity, little is known regarding the regulation and function of the Rap GTPase-activating protein Rap1GAP. Tuberin and E6TP1 protein levels are tightly regulated through ubiquitin-mediated proteolysis. A role for these RapGAPs, along with SPA- 1, as tumor suppressors has been demonstrated. Whether Rap1GAP performs a similar role was investigated. We now report that Rap1GAP protein levels are dynamically regulated in thyroid- stimulating hormone ( TSH)- dependent thyroid cells. Upon TSH withdrawal, Rap1GAP undergoes a net increase in phosphorylation followed by proteasome- mediated degradation. Sequence analysis identified two putative destruction boxes in the Rap1GAP C- terminal domain. Glycogen synthase kinase 3 beta ( GSK3beta) phosphorylated Rap1GAP immunoprecipitated from thyroid cells, and GSK3beta inhibitors prevented phosphorylation and degradation of endogenous Rap1GAP. Co- expression of GSK3beta and Rap1GAP in human embryonic kidney 293 cells stimulated proteasome- dependent Rap1GAP turnover. Mutational analysis established a role for serine 525 in the regulation of Rap1GAP stability. Overexpression of Rap1GAP in thyroid cells impaired TSH/ cAMP-stimulated p70S6 kinase activity and cell proliferation. These data are the first to show that Rap1GAP protein levels are tightly regulated and are the first to support a role for Rap1GAP as a tumor suppressor.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Hematol Oncol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 164 John Morgan,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Gao QS, 1999, MOL CELL BIOL, V19, P733; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Hengstschlager M, 2001, MUTAT RES-REV MUTAT, V488, P233, DOI 10.1016/S1383-5742(01)00058-8; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; JANOUEIXLEROSEY I, 1994, BIOCHEM BIOPH RES CO, V202, P967, DOI 10.1006/bbrc.1994.2024; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; Meng JW, 2002, J BIOL CHEM, V277, P43417, DOI 10.1074/jbc.M204074200; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NICE EC, 1992, J BIOL CHEM, V267, P1546; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; PIERCE SB, 1995, DEVELOPMENT, V121, P755; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Riedel C, 2001, J BIOL CHEM, V276, P21458, DOI 10.1074/jbc.M100561200; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7	59	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5501	5507		10.1074/jbc.M305824200	http://dx.doi.org/10.1074/jbc.M305824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660640	hybrid			2022-12-25	WOS:000188776500058
J	Zhou, XL; Thorgeirsson, SS; Popescu, NC				Zhou, XL; Thorgeirsson, SS; Popescu, NC			Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells	ONCOGENE			English	Article						DLC-1 function; cell growth inhibition; cell migration inhibition; apoptosis reduction of tumorigenicity	CHROMOSOME 8P DELETION; RHO GTPASES; IN-VIVO; METASTASIS; PROTEINS; LINES; DISEASE; DOMAIN; START; DEATH	The gene deleted in liver cancer-1 (DLC-1) is located on human chromosome 8p21-22, a region thought to harbor tumor suppressor genes on the basis of its frequent deletion or loss of heterozygosity in a variety of human cancers, including hepatocellular carcinoma (HCC). Deletion or altered expression of DLC-1 is common in HCC. In the current study, the subcellular localization of Dlc-1 protein was determined by immunostaining with antibody to DLC-1 and the possible tumor growth suppressor activity of DLC-1 was investigated by examining the effects of of DLC-1 cDNA transfection in two human HCC cell lines lacking expression of the endogenous gene. The results show that Dlc-1protein is localized in the cell cytoplasm, and the restoration of DLC-1 expression in HCC cells resulted in caspase-3-mediated apoptosis, inhibition of cell growth and invasiveness in vitro as well as in reduction of the ability of the cells to form tumors in athymic nude mice. These observations thus support the notion that Dlc-1 protein is involved in hepatocarcinogenesis and has oncosuppressive activity in HCC.	NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bldg 37,Room 4128,37 Convent Dr,MSC 4264, Bethesda, MD 20892 USA.	popescun@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010038, Z01BC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Euer N, 2002, ANTICANCER RES, V22, P733; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kahng YS, 2003, J GASTROEN HEPATOL, V18, P430, DOI 10.1046/j.1440-1746.2003.02997.x; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Keck CL, 1999, CANCER GENET CYTOGEN, V111, P37, DOI 10.1016/S0165-4608(98)00210-6; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Ng IOL, 2000, CANCER RES, V60, P6581; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	27	123	139	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1308	1313		10.1038/sj.onc.1207246	http://dx.doi.org/10.1038/sj.onc.1207246			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647417				2022-12-25	WOS:000188892200016
J	Felberg, J; Lefebvre, DC; Lam, M; Wang, YN; Ng, DHW; Birkenhead, D; Cross, JL; Johnson, P				Felberg, J; Lefebvre, DC; Lam, M; Wang, YN; Ng, DHW; Birkenhead, D; Cross, JL; Johnson, P			Subdomain X of the kinase domain of Lck binds CD45 and facilitates dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL ANTIGEN RECEPTOR; NEGATIVE REGULATORY SITE; CRYSTAL-STRUCTURE; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; CYTOPLASMIC DOMAIN; SH2 DOMAIN; C-SRC	CD45 is a transmembrane, two-domain protein-tyrosine phosphatase expressed exclusively in nucleated hematopoietic cells. The Src family kinase, Lck, is a major CD45 substrate in T cells and CD45 dephosphorylation of Lck is important for both T cell development and activation. However, how the substrate specificity of phosphatases such as CD45 is achieved is not well understood. Analysis of the interaction between the cytoplasmic domain of CD45 and its substrate, Lck, revealed that the active, membrane-proximal phosphatase domain of CD45 (CD45-D1) bound to the phosphorylated Lck kinase domain, the SH2 domain, and the unique N-terminal region of Lck. The second, inactive phosphatase domain (CD45-D2) bound only to the kinase domain of Lck. CD45-D2 was unable to bind phosphotyrosine, and its interaction with the kinase domain of Lck was independent of tyrosine phosphorylation. The binding of CD45-D2 was localized to subdomain X (SD10) of Lck. CD45-D2 bound similarly to Src family kinases but bound Csk to a lesser extent and did not bind significantly to the less related kinase, Erk1. CD45 dephosphorylated Lck and Src at similar rates but dephosphorylated Csk and Erk1 at lower rates. Replacement of Erk1 SD10 with that of Lck resulted in the binding of CD45-D2 and the conversion of Erk1 to a more efficient CD45 substrate. This demonstrates a role for CD45-D2 in binding substrate and identifies the SD10 region in Lck as a novel site involved in substrate recognition.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	pauline@interchange.ubc.ca	Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BOUGERET C, 1993, ONCOGENE, V8, P1241; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURG DL, 1994, J BIOL CHEM, V269, P28136; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; COOKE M P, 1989, New Biologist, V1, P66; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; Doro U, 1996, MOL CELL BIOL, V16, P4996; Felberg J, 2000, BIOCHEM BIOPH RES CO, V271, P292, DOI 10.1006/bbrc.2000.2623; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HARDIE DG, 1995, PROTEIN KINASE FACTS, P43; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Hayami-Noumi K, 2000, FEBS LETT, V468, P68, DOI 10.1016/S0014-5793(00)01200-X; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JOHNSON P, 2000, MOD ASP IMMUNOBIOL, V1, P156; Joukov V, 1997, BIOCHEM J, V322, P927, DOI 10.1042/bj3220927; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; Lefebvre DC, 2003, BBA-PROTEINS PROTEOM, V1650, P40, DOI 10.1016/S1570-9639(03)00190-0; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; Ng DHW, 1997, BIOCHEM J, V327, P867; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERI KG, 1993, ONCOGENE, V8, P2765; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Veillette A, 1999, J BIOL CHEM, V274, P14392, DOI 10.1074/jbc.274.20.14392; Wang Y, 1999, J BIOL CHEM, V274, P7454, DOI 10.1074/jbc.274.11.7454; Weil R, 1996, CURR TOP MICROBIOL, V205, P63; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	68	15	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3455	3462		10.1074/jbc.M309537200	http://dx.doi.org/10.1074/jbc.M309537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14625311	hybrid			2022-12-25	WOS:000188379600041
J	Theoleyre, O; Deguillien, M; Moriniere, M; Starck, J; Moreau-Gachelin, F; Morle, F; Baklouti, F				Theoleyre, O; Deguillien, M; Moriniere, M; Starck, J; Moreau-Gachelin, F; Morle, F; Baklouti, F			Spi-l/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythroleukemia cells	ONCOGENE			English	Article						alternative splicing; erythroleukemia; Spi-l/PU.1; Fli-1; protein 4.1R; erythroid differentiation	INSERTION DELETION MUTATIONS; ACTIN-BINDING DOMAIN; TRANSCRIPTION FACTOR; PU.1 TRANSCRIPTION; MOLECULAR ANALYSIS; TERNARY COMPLEX; DIFFERENTIATION; PROTEIN-4.1; SPI-1/PU.1; SPECTRIN	The inclusion of exon 16 in mature protein 4.1R mRNA arises from a stage-specific splicing event that occurs during late erythroid development. We have shown that mouse erythroleukemia (MEL) cells reproduce this erythroid-specific splicing event upon induction of differentiation. We here found that this splicing event is regulated specifically in erythroleukemic cells that have the potential to differentiate and produce hemoglobin, regardless of the nature of the differentiation inducer. Knowing that dysregulated expression of spi-1/pu.1 and fli-1 oncogenes is involved in MEL cell differentiation arrest, we looked at their effect on exon 16 erythroid splicing. We found that exon 16 inclusion requires Spi-1/ PU.1 shutdown in MEL cells, and that enforced expression of Spi-1/PU.1 inhibits exon selection, regardless of the presence or absence of a chemical inducer. By contrast, endogenous overexpression or enforced expression of Fli-1 has no effect on exon selection. We further showed that Spi-1/PU.1 acts similarly on the endogenous and on a transfected exon 16, suggesting a promoter-independent effect of Spi-1/PU.1 on splicing regulation. This study provides the first evidence that Spi-1/PU.1 displays the unique property, not shared with Fli-1, to inhibit erythroid-specific pre-mRNA splicing in erythroleukemia cell context.	Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Inst Curie, INSERM, U528, Lab Transduct Signal & Oncogenese, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Baklouti, F (corresponding author), Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 16 Rue R Dubois, F-69622 Villeurbanne, France.	baklouti@univ-lyon1.fr	BAKLOUTI, Faouzi/E-7670-2013	BAKLOUTI, Faouzi/0000-0002-2830-292X				Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bolduc L, 2001, J BIOL CHEM, V276, P17597, DOI 10.1074/jbc.M011769200; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CONBOY J, 1990, J CLIN INVEST, V86, P524, DOI 10.1172/JCI114739; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DELGADO MD, 1994, ONCOGENE, V9, P1723; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HANSPAL M, 1992, BLOOD, V80, P530; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; HORNE WC, 1993, BLOOD, V82, P2558; LORENZO F, 1994, J CLIN INVEST, V94, P1651, DOI 10.1172/JCI117508; Maillet P, 1999, HUM MUTAT, V14, P145, DOI 10.1002/(SICI)1098-1004(1999)14:2<145::AID-HUMU6>3.0.CO;2-L; MARCHESI SL, 1990, J CLIN INVEST, V86, P516, DOI 10.1172/JCI114738; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; Starck J, 1999, MOL CELL BIOL, V19, P121; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	32	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					920	927		10.1038/sj.onc.1207206	http://dx.doi.org/10.1038/sj.onc.1207206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647452				2022-12-25	WOS:000188486600007
J	Wichert, A; Stege, A; Midorikawa, Y; Holm, PS; Lage, H				Wichert, A; Stege, A; Midorikawa, Y; Holm, PS; Lage, H			Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells	ONCOGENE			English	Article						drug resistance; mitoxantrone; glypicans; ribozymes; gastric carcinoma	HEPARAN-SULFATE PROTEOGLYCANS; DEVELOPMENTALLY-REGULATED TRANSCRIPT; BEHMEL OVERGROWTH SYNDROME; DNA TOPOISOMERASE-II; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; MELANOMA-CELLS; IN-VITRO; EXPRESSION	Elevated expression of the heparan sulphate proteoglycan glypican-3 (GPC3) was found on mRNA and protein levels in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV, which was established by in vitro selection against mitoxantrone. In order to elucidate a putative role of GPC3 in the drug-resistant phenotype, the mitoxantrone-resistant cell line EPG85-257RNOV was transfected with an expression vector construct carrying an anti-GPC3 hammerhead ribozyme. It could be demonstrated that in anti-GPC3 ribozyme-transfected cell clones, the GPC3-specific mRNA and corresponding protein expression levels were decreased to levels that are similar to those observed in nonresistant, parental cells. The anti-GPC3 ribozyme-containing clones reduced the mitoxantrone resistance level up to 21% of the original resistance and the crossresistance against etoposide to 33% of the original value. This reversal of drug resistance was accompanied by an increased cellular mitoxantrone accumulation in the anti-GPC3 ribozyme-expressing cells. In conclusion, it was verified that GPC3 is involved in the cellular protection against mitoxantrone in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV.	Humboldt Univ, Inst Pathol, Charite, D-10117 Berlin, Germany; Univ Tokyo, Genome Sci Div, Meguro Ku, Tokyo 1538944, Japan	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Tokyo	Lage, H (corresponding author), Humboldt Univ, Inst Pathol, Charite, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	hermann.lage@charite.de		Stege, Alexandra/0000-0001-9659-1930				AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIETEL M, 1990, CANCER RES, V50, P6100; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Hsu HC, 1997, CANCER RES, V57, P5179; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; HYAFIL F, 1993, CANCER RES, V53, P4595; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kellner U, 1997, INT J CANCER, V71, P817, DOI 10.1002/(SICI)1097-0215(19970529)71:5<817::AID-IJC20>3.0.CO;2-3; Kowalski P, 2002, CANCER GENE THER, V9, P579, DOI 10.1038/sj.cgt.7700471; Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6; Lage H, 2000, BRIT J CANCER, V82, P488, DOI 10.1054/bjoc.1999.0947; Lage H, 1997, GENE, V188, P151, DOI 10.1016/S0378-1119(96)00689-0; Lage H, 1998, INT J CLIN PHARM TH, V36, P58; Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y; Lage H, 2001, FEBS LETT, V503, P179, DOI 10.1016/S0014-5793(01)02722-3; Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3; Lage H, 2000, Lancet Oncol, V1, P169, DOI 10.1016/S1470-2045(00)00032-2; Lin HC, 1999, CANCER RES, V59, P807; Midorikawa Y, 2003, INT J CANCER, V103, P455, DOI 10.1002/ijc.10856; Mulder M, 1998, HAEMOSTASIS, V28, P174; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Saikali Z, 2000, INT J CANCER, V89, P418; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; WALKER PR, 1991, CANCER RES, V51, P1078; Wells MJ, 1998, J BIOL CHEM, V273, P23440, DOI 10.1074/jbc.273.36.23440; Wichert A, 1999, CANCER GENE THER, V6, P263, DOI 10.1038/sj.cgt.7700045; Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925	47	30	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					945	955		10.1038/sj.onc.1207237	http://dx.doi.org/10.1038/sj.onc.1207237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661052				2022-12-25	WOS:000188486600010
J	Zou, MX; Butcher, DT; Sadikovic, B; Groves, TC; Yee, SP; Rodenhiser, DI				Zou, MX; Butcher, DT; Sadikovic, B; Groves, TC; Yee, SP; Rodenhiser, DI			Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region	ONCOGENE			English	Article						neurofibromatosis; promoter; transcription; methylation	DNA METHYLATION; TRANSCRIPTION FACTOR; GENE; BINDING; ACTIVATION; PROTEIN; CANCER; FAMILY; CREB; SP1	An essential requirement to understand how genes contribute to genetic disease is the thorough knowledge of the transcriptional regulation of gene expression. Here, we have characterized transcription factor binding sites within the type 1 neurofibromatosis (NF1) proximal regulatory region, and addressed the molecular mechanisms that regulate NF1 transcription. Overlapping regions of the NF1 proximal promoter have been cloned and characterized for use in luciferase reporter assays. These assays have identified a 500 bp region displaying activities up to 80-fold higher than control reporter levels. Mutations at putative CRE and SP1-binding sites immediately 5' to the transcription start site have dramatic effects that lead to a 70-90% decrease in reporter activity in all cell lines tested. Gelshift assays confirm binding of CREB and SP1/KLF family members to their putative recognition sequences, and provide the first evidence identifying functional sites likely involved in regulating NF1 transcription. These assays have also revealed a putative repressor region within the NF1 promoter region corresponding to CCCTC-rich sequences between the transcription and translation start sites. This work provides new information concerning the transcriptional regulation of the NF1 gene, and is the most thorough attempt to date to map functionally relevant regions within the NF1 proximal promoter region.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Room A4-134,Victoria Res Tower,790 Commissioners, London, ON N6A 4L6, Canada.	drodenhi@uwo.ca						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; HOFMAN KJ, 1994, J PEDIATR-US, V124, pS1, DOI 10.1016/S0022-3476(05)83163-4; Horan MP, 2000, HUM GENET, V107, P33, DOI 10.1007/s004390050007; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kim HA, 2001, J NEUROSCI, V21, P1110; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Luijten M, 2000, EUR J HUM GENET, V8, P939, DOI 10.1038/sj.ejhg.5200565; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MANCINIDINARDO DN, 2001, ONCOGENE, V20, P5331; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; RUBENSTEIN A, 1990, NEUROFIBROMATOSIS HD; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; ZOLLER M, 1995, ACTA DERM-VENEREOL, V75, P136	30	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					330	339		10.1038/sj.onc.1207053	http://dx.doi.org/10.1038/sj.onc.1207053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647436				2022-12-25	WOS:000188098300002
J	Schwab, JM; Beiter, T; Linder, JU; Laufer, S; Schulz, JE; Meyermann, R; Schluesener, HJ				Schwab, JM; Beiter, T; Linder, JU; Laufer, S; Schulz, JE; Meyermann, R; Schluesener, HJ			COX-3 - a virtual pain target in humans?	FASEB JOURNAL			English	Editorial Material									Univ Tubingen, Inst Brain Res, Sch Med, D-72076 Tubingen, Germany; Univ Tubingen, Inst Pharm, D-72064 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schwab, JM (corresponding author), Univ Tubingen, Inst Brain Res, Sch Med, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de		Schwab, Jan/0000-0001-6784-4919; Beiter, Thomas/0000-0001-7299-7303; Laufer, Stefan/0000-0001-6952-1486				Bazan NG, 2002, NATURE, V420, P135, DOI 10.1038/420135a; Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Senior K, 2002, LANCET NEUROL, V1, P399, DOI 10.1016/S1474-4422(02)00207-7; Smith A, 2002, NAT REV DRUG DISCOV, V1, P839, DOI 10.1038/nrd951; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099	7	39	40	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2174	2175		10.1096/fj.03-0595lte	http://dx.doi.org/10.1096/fj.03-0595lte			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656977				2022-12-25	WOS:000188067500036
J	Sung, S; Yao, YM; Uryu, K; Yang, HX; Lee, VMY; Trojanowski, JQ; Pratico, D				Sung, S; Yao, YM; Uryu, K; Yang, HX; Lee, VMY; Trojanowski, JQ; Pratico, D			Early Vitamin E supplementation in young but not aged mice reduces A beta levels and amyloid deposition in a transgenic model of Alzheimer's disease	FASEB JOURNAL			English	Article						oxidative stress; transgenic mouse models; amyloid beta; anti-oxidants	LIPID-PEROXIDATION; OXIDATIVE STRESS; IN-VIVO; INCREASED 8,12-ISO-IPF(2-ALPHA)-VI; COGNITIVE IMPAIRMENT; DOWNS-SYNDROME; MOUSE MODEL; DAMAGE	Increased brain oxidative stress is a key feature of Alzheimer's disease (AD) and manifests predominantly as lipid peroxidation. However, clinical evidence that antioxidants can affect the clinical course of the disease is limited. In the present study, we investigated the effect of the antioxidant Vitamin E on the AD-like phenotype when given to a transgenic mouse model (Tg2576) of the disease before or after the amyloid plaques are deposited. One group of Tg2576 received Vitamin E starting at 5 months of age until they were 13 months old, the second group started at 14 months of age until they were 20 months old. Brain levels of 8,12-iso-iPF(2alpha)-VI, a specific marker of lipid peroxidation, were significantly reduced in both groups of mice receiving Vitamin E compared with placebo. Tg2576 administered with Vitamin E at a younger age showed a significant reduction in Abeta levels and amyloid deposition. By contrast, mice receiving the diet supplemented with Vitamin E at a later age did not show any significant difference in either marker when compared with placebo. These results support the hypothesis that oxidative stress is an important early event in AD pathogenesis, and antioxidant therapy may be beneficial only if given at this stage of the disease process.	Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Pratico, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, BRB 2-3,Room 812,421 Curie Blvd, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020					Cyrus T, 2001, CIRCULATION, V104, P1940, DOI 10.1161/hc4101.097114; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Odetti P, 1998, BIOCHEM BIOPH RES CO, V243, P849, DOI 10.1006/bbrc.1998.8186; Pappolla MA, 1998, AM J PATHOL, V152, P871; Parks E, 2000, ANTIOXID REDOX SIGN, V2, P405, DOI 10.1089/15230860050192189; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Pratico D, 2000, ANN NEUROL, V48, P795, DOI 10.1002/1531-8249(200011)48:5<795::AID-ANA15>3.0.CO;2-#; Pratico D, 2001, Ital Heart J, V2, P878; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2002, BIOCHEM PHARMACOL, V63, P563, DOI 10.1016/S0006-2952(01)00919-4; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; PRATICO D, 2002, FASEB J, DOI DOI 10.1096/FJ02-0012FJE; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002	22	243	257	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					323	+		10.1096/fj.03-0961fje	http://dx.doi.org/10.1096/fj.03-0961fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656990				2022-12-25	WOS:000188067500021
J	Fromigue, O; Louis, K; Dayem, M; Milanini, J; Pages, G; Tartare-Deckert, S; Ponzio, G; Hofman, P; Barbry, P; Auberger, P; Mari, B				Fromigue, O; Louis, K; Dayem, M; Milanini, J; Pages, G; Tartare-Deckert, S; Ponzio, G; Hofman, P; Barbry, P; Auberger, P; Mari, B			Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival	ONCOGENE			English	Article						tumor-stroma; fibroblast; coculture; cDNA arrays; desmoplasia; stromelysin-3	EPITHELIAL-MESENCHYMAL INTERACTIONS; HUMAN BREAST CARCINOMAS; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; TUMOR PROGRESSION; STROMAL CELLS; OVER-EXPRESSION; RETINOIC ACID; ID PROTEINS; HUMAN COLON	Increasing evidence supports a major role for the microenvironment in carcinoma formation and progression. The influence of the stroma is partly mediated by signalling between epithelial tumor cells and neighboring fibroblasts. However, the molecular mechanisms underlying these interactions are largely unknown. To mimic the initial steps of invasive carcinoma in which tumor cells come in contact with normal stromal cells, we used a coculture model of non-small-cell lung cancer tumor cells and normal pulmonary fibroblasts. Using DNA filter arrays, we first analysed the overall modification of gene expression profile after a 24 h period of coculture. Next, we focused our interest on the transcriptome of the purified fibroblastic fraction of coculture using both DNA filter arrays and a laboratory-made DNA microarray. These experiments allowed the identification of a set of modulated genes coding for growth and survival factors, angiogenic factors, proteases and protease inhibitors, transmembrane receptors, kinases and transcription regulators that can potentially affect the regulation of matrix degradation, angiogenesis, invasion, cell growth and survival. This study represents to our knowledge the first attempt to dissect early global gene transcription occurring in a tumor-stroma coculture model and should help to understand better some of the molecular mechanisms involved in heterotypic signalling between epithelial tumor cells and fibroblasts.	Fac Med Pasteur, INSERM U526, F-06107 Nice 2, France; Fac Med Pasteur, INSERM EPI0215, F-06107 Nice 2, France; Fac Med Pasteur, INSERM U385, F-06107 Nice 2, France; Ctr Antoine Lacassagne, CNRS, UNSA UMR 6543, F-06054 Nice, France; IPMC, CNRS, UNSA UMR 6097, Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Mari, B (corresponding author), Fac Med Pasteur, INSERM U526, Ave Valombrose,IFR 50, F-06107 Nice 2, France.	bmari@unice.fr	Ponzio, Gilles/Q-1256-2016; Hofman, Paul/P-7654-2018; Fromigue, Olivia/B-8225-2013; TARTARE-DECKERT, Sophie/P-6057-2015; Mari, Bernard P/F-8960-2013; AUBERGER, Patrick/G-1491-2013; Pages, Gilles/N-7135-2017; Mari, Bernard/Q-5832-2019; Barbry, Pascal/O-5021-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022	Ponzio, Gilles/0000-0003-2741-0248; Hofman, Paul/0000-0003-0431-9353; Fromigue, Olivia/0000-0002-3050-6155; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard/0000-0002-0422-9182; Barbry, Pascal/0000-0001-9632-6483; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Milanini, Julie/0000-0002-5861-2830				Ahmed W, 1998, CONNECT TISSUE RES, V37, P263, DOI 10.3109/03008209809002444; ANDERSON IC, 1995, CANCER RES, V55, P4120; Anderson IC, 2000, CANCER RES, V60, P269; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Birckbichler PJ, 2000, CANCER-AM CANCER SOC, V89, P412, DOI 10.1002/1097-0142(20000715)89:2<412::AID-CNCR29>3.0.CO;2-O; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Christensen L, 1996, INT J CANCER, V66, P441; Cursio R, 2001, FASEB J, V15, P93, DOI 10.1096/fj.01-0279fje; Dayem MA, 2003, COMP FUNCT GENOM, V4, P47, DOI 10.1002/cfg.239; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GIOANNI J, 1988, EUR J CANCER CLIN ON, V24, P1445, DOI 10.1016/0277-5379(88)90335-5; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; He C, 2001, J CANCER RES CLIN, V127, P180, DOI 10.1007/s004320000192; Heppner KJ, 1996, AM J PATHOL, V149, P273; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kleeff J, 1998, INT J CANCER, V77, P860, DOI 10.1002/(SICI)1097-0215(19980911)77:6<860::AID-IJC11>3.0.CO;2-5; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lee HY, 2002, CANCER RES, V62, P3530; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Linder C, 1997, BREAST CANCER RES TR, V42, P207, DOI 10.1023/A:1005769622570; LINGE C, 1989, EXP CELL RES, V185, P519, DOI 10.1016/0014-4827(89)90320-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Mascaux C, 2002, ANTICANCER RES, V22, P1273; Matrisian LM, 2001, CANCER RES, V61, P3844; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ohtani H, 1998, PATHOL INT, V48, P1, DOI 10.1111/j.1440-1827.1998.tb03820.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Porte H, 1998, CLIN CANCER RES, V4, P1375; Rabbani SA, 1998, IN VIVO, V12, P135; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; ROUYER N, 1994, INVAS METAST, V14, P269; Sampson MT, 2002, BIOCHEM SOC T, V30, P201, DOI 10.1042/bst0300201; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SESLAR SP, 1993, CANCER RES, V53, P1233; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umeda T, 1997, J PATHOL, V183, P388; Vitolo D, 2001, J PATHOL, V195, P197, DOI 10.1002/path.938; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Wojtukiewicz MZ, 1999, THROMB HAEMOSTASIS, V82, P1659; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Wu-Wong J Ruth, 2002, Curr Opin Investig Drugs, V3, P1234; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	77	40	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8487	8497		10.1038/sj.onc.1206918	http://dx.doi.org/10.1038/sj.onc.1206918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627989				2022-12-25	WOS:000186650300012
J	Crack, J; Green, J; Thomson, AJ				Crack, J; Green, J; Thomson, AJ			Mechanism of oxygen sensing by the bacterial transcription factor fumarate-nitrate reduction (FNR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; IRON-SULFUR CENTER; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; CRYSTAL-STRUCTURE; REGULATOR FNR; PROTEIN; CLUSTER; DNA; 4FE-4S	The facultative anaerobe Escherichia coli adopts different metabolic modes in response to the availability of oxygen. The global transcriptional regulator FNR (fumarate-nitrate reduction) monitors the availability of oxygen in the environment. Binding as a homodimer to palindromic sequences of DNA, FNR carries a sensory domain, remote from the DNA binding helix-turn-helix motif, which responds to oxygen. The sensing mechanism involves the transformation of a [4Fe-4S](2+) cluster into a [2Fe-2S] form in vitro on reaction with oxygen. Evidence is presented to show that this process proceeds by at least two steps, the first, an oxidative one, being the formation, on reaction with O-2, of a [3Fe-4S](1+) cluster as an intermediate accompanied by the production of hydrogen peroxide. This is followed by a slower, non-redox, pseudo-first order step in which the [3Fe-4S](1+) form converts to a [2Fe-2S](2+) cluster. This must be accompanied by a substantial protein conformational change since the four cysteine ligands that bind the two forms of the FeS clusters have different spatial disposition. Hydrogen peroxide is also an oxidant of the [4Fe-4S](2+), causing a similar cluster transformation to a [2Fe-2S] form. Either the hydrogen peroxide formed on reaction with oxygen can be recycled by intracellular catalase or it can be used to oxidize further Fe-S clusters. In both cases, the efficacy of oxygen sensing by FNR will be increased.	Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of East Anglia; University of Sheffield	Thomson, AJ (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England.	a.thomson@uea.ac.uk		Crack, Jason C./0000-0002-4979-1910				AEBI H, 1984, METHOD ENZYMOL, V105, P121; AGARWAL A, 1995, P NATL ACAD SCI USA, V92, P9440, DOI 10.1073/pnas.92.21.9440; Becker S, 1996, J BACTERIOL, V178, P4515, DOI 10.1128/jb.178.15.4515-4521.1996; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; Bes MT, 1999, STRUCT FOLD DES, V7, P1201, DOI 10.1016/S0969-2126(00)80054-4; Busby Stephen, 1996, P255; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Green J, 1996, MOL MICROBIOL, V19, P125, DOI 10.1046/j.1365-2958.1996.353884.x; GREEN J, 1991, P ROY SOC B-BIOL SCI, V244, P137, DOI 10.1098/rspb.1991.0062; Guest JR, 1995, PHILOS T R SOC B, V350, P189, DOI 10.1098/rstb.1995.0152; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Miller J. H., 1972, EXPT MOL GENETICS, P431; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Tilley GJ, 2001, BIOCHEM J, V360, P717, DOI 10.1042/0264-6021:3600717; Unden G, 1997, MOL MICROBIOL, V25, P205, DOI 10.1046/j.1365-2958.1997.4731841.x; Vogel A. I., 1989, VOGELS TXB PRACTICAL, P395; Wu GH, 2000, J BIOL CHEM, V275, P4679, DOI 10.1074/jbc.275.7.4679; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	37	104	104	2	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9278	9286		10.1074/jbc.M309878200	http://dx.doi.org/10.1074/jbc.M309878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14645253	hybrid			2022-12-25	WOS:000189265900090
J	Johnson, AA; Sayer, JM; Yagi, H; Kalena, GP; Amin, R; Jerina, DM; Pommier, Y				Johnson, AA; Sayer, JM; Yagi, H; Kalena, GP; Amin, R; Jerina, DM; Pommier, Y			Position-specific suppression and enhancement of HIV-1 integrase reactions by minor groove benzo[a]pyrene diol epoxide deoxyguanine adducts - Implications for molecular interactions between integrase and DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; TOPOISOMERASE-I; CLEAVAGE SITE; PROTEIN; SEQUENCE; COMPLEXES; BINDING; POLYAMIDES; DOMAINS; VITRO	The viral protein HIV-1 integrase is required for insertion of the viral genome into human chromosomes and for viral replication. Integration proceeds in two consecutive integrase-mediated reactions: 3'-processing and strand transfer. To investigate the DNA minor groove interactions of integrase relative to known sites of integrase action, we synthesized oligodeoxynucleotides containing single covalent adducts of known absolute configuration derived from trans-opening of benzo[ a] pyrene 7,8-diol9,10-epoxide by the exocyclic 2-amino group of deoxyguanosine at specific positions in a duplex sequence corresponding to the terminus of the viral U5 DNA. Because the orientations of the hydrocarbon in the minor groove are known from NMR solution structures of duplex oligonucleotides containing these deoxyguanosine adducts, a detailed analysis of the relationship between the position of minor groove ligands and integrase interactions is possible. Adducts placed in the DNA minor groove two or three nucleotides from the 3'-processing site inhibited both 3'-processing and strand transfer. Inosine substitution showed that the guanine 2-amino group is required for efficient 3'-processing at one of these positions and for efficient strand transfer at the other. Mapping of the integration sites on both strands of the DNA substrates indicated that the adducts both inhibit strand transfer specifically at the minor groove bound sites and enhance integration at sites up to six nucleotides away from the adducts. These experiments demonstrate the importance of position-specific minor groove contacts for both the integrase-mediated 3'-processing and strand transfer reactions.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bldg 37,Room 5068, Bethesda, MD 20892 USA.	pommier@nih.gov			NATIONAL CANCER INSTITUTE [ZIABC007333, Z01BC007333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUSHMAN FD, 1992, P NATL ACAD SCI USA, V89, P3458, DOI 10.1073/pnas.89.8.3458; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; KHAN QA, 2003, P NATL ACAD SCI US; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Kroth H, 2000, J ORG CHEM, V65, P5558, DOI 10.1021/jo000522x; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Moravek Z, 2002, NUCLEIC ACIDS RES, V30, P1182, DOI 10.1093/nar/30.5.1182; Neamati N, 1998, MOL PHARMACOL, V54, P280, DOI 10.1124/mol.54.2.280; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Podtelezhnikov AA, 2003, BIOPOLYMERS, V68, P110, DOI 10.1002/bip.10217; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang T, 2001, J BIOL CHEM, V276, P14710, DOI 10.1074/jbc.M007754200; Yan SX, 2003, BIOPHYS J, V84, P2137, DOI 10.1016/S0006-3495(03)75020-6; Yang F, 2003, BIOCHEMISTRY-US, V42, P6249, DOI 10.1021/bi034177s; YOSHINAGA T, 1995, J VIROL, V69, P3233, DOI 10.1128/JVI.69.5.3233-3236.1995	31	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7947	7955		10.1074/jbc.M311263200	http://dx.doi.org/10.1074/jbc.M311263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14627697	hybrid			2022-12-25	WOS:000189103300072
J	Heath, C; Cross, NCP				Heath, C; Cross, NCP			Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-1; MYELOPROLIFERATIVE DISORDER FUSES; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; FUSION PROTEINS; CELLS; GENE; APOPTOSIS; LEUKEMIA; FGFR1	The 8p11 myeloproliferative syndrome is an aggressive disorder caused by FGFR1 fusion proteins resulting from a subset of acquired translocations that target chromosome band 8p11. These chimeric proteins have constitutive FGFR1 tyrosine kinase activity and are believed to deregulate hemopoietic development in a manner analogous to BCR-ABL in chronic myeloid leukemia. Here we have studied the role of STAT proteins in transformation mediated by the most common of these fusions, ZNF198-FGFR1. We found that STATs 1, 3, and 5 were activated constitutively in ZNF198-FGFR1-transformed Ba/F3 cells and that STATs 2, 4, and 6 were also tyrosine-phosphorylated. Induction of dominant negative STAT mutants showed that activation of STAT5, but not STATs 1 or 3, was essential for the anti-apoptotic effect of ZNF198-FGFR1 and that STAT5 activation is essential for the elevated levels of BclXL in transformed cells. STAT5 activation was also shown to be required for continued cell cycle progression of BaF3/ZNF198-FGFR1 cells in conditions of cytokine deprivation and for up-regulation of the DNA repair protein Rad51. These findings suggest a critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.	Hammersmith Hosp, Imperial Coll, Fac Med, Dept Haematol, London W12 ONN, England; Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England; Univ Southampton, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England	Imperial College London; University of Southampton	Cross, NCP (corresponding author), Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England.	ncpc@soton.ac.uk	Cross, Nicholas/B-4817-2009	Cross, Nicholas/0000-0001-5481-2555				Baumann H, 2003, J BIOL CHEM, V278, P16198, DOI 10.1074/jbc.M300018200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 1996, ONCOGENE, V13, P247; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; Smedley Damian, 1999, Neoplasia (New York), V1, P349, DOI 10.1038/sj.neo.7900035; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84	35	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6666	6673		10.1074/jbc.M308743200	http://dx.doi.org/10.1074/jbc.M308743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660670	hybrid			2022-12-25	WOS:000188969200057
J	Hiromasa, Y; Fujisawa, T; Aso, Y; Roche, TE				Hiromasa, Y; Fujisawa, T; Aso, Y; Roche, TE			Organization of the cores of the mammalian pyruvate dehydrogenase complex formed by E2 and E2 plus the E3-binding protein and their capacities to bind the E1 and E3 components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACETYLASE COMPONENT; ACETYLTRANSFERASE COMPONENT; CRYOELECTRON MICROSCOPY; NUCLEOTIDE-SEQUENCE; RECONSTITUTION; EXPRESSION; DOMAINS; KINASE; ACETYLATION; CLEAVAGE	The subunits of the dihydrolipoyl acetyltransferase (E2) component of mammalian pyruvate dehydrogenase complex can form a 60-mer via association of the C-terminal I domain of E2 at the vertices of a dodecahedron. Exterior to this inner core structure, E2 has a pyruvate dehydrogenase component (El)-binding domain followed by two lipoyl domains, all connected by mobile linker regions. The assembled core structure of mammalian pyruvate dehydrogenase complex also includes the dihydrolipoyl dehydrogenase (E3)-binding protein (E3BP) that binds the I domain of E2 by its C-terminal I' domain. E3BP similarly has linker regions connecting an E3-binding domain and a lipoyl domain. The composition of E2.E3BP was thought to be 60 E2 plus similar to12 E3BP. We have prepared homogenous human components. E2 and E2.E3BP have s(20,w) values of 36 S and 31.8 S, respectively. Equilibrium sedimentation and small angle x-ray scattering studies indicate that E2.E3BP has lower total mass than E2, and small angle x-ray scattering showed that E3 binds to E2.E3BP outside the central dodecahedron. In the presence of saturating levels of E1, E2 bound similar to60 E1 and maximally sedimented 64.4 +/- 1.5 S faster than E2, whereas E1-saturated E2.E3BP maximally sedimented 49.5 +/- 1.4 S faster than E2.E3BP. Based on the impact on sedimentation rates by bound E1, we estimate fewer E1 (similar to12) were bound by E2.E3BP than by E2. The findings of a smaller E2.E3BP mass and a lower capacity to bind El support the smaller E3BP substituting for E2 subunits rather than adding to the 60-mer. We describe a substitution model in which 12 I' domains of E3BP replace 12 1 domains of E2 by forming 6 dimer edges that are symmetrically located in the dodecahedron structure. Twelve E3 dimers were bound per E2(48).E3BP(12) mass, which is consistent with this model.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; RIKEN, Harima Inst, Lab Struct Biochem, Hyogo 3410198, Japan; Kyushu Univ, Lab Prot Chem & Engn, Fukuoka 8128581, Japan	Kansas State University; RIKEN; Kyushu University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, Willard Hall, Manhattan, KS 66506 USA.	bchter@ksu.edu	Fujisawa, Tetsuro/AAA-5202-2019		NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ET, 1962, ULTRACENTRIFUGAL ANA, P119; AMEMIYA Y, 1995, REV SCI INSTRUM, V66, P2290, DOI 10.1063/1.1145667; BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BEHAL RH, 1994, J BIOL CHEM, V269, P31372; BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BLEILE DM, 1981, J BIOL CHEM, V256, P514; CHATELIER RC, 1987, BIOPOLYMERS, V26, P507, DOI 10.1002/bip.360260405; COLE N, 1992, BIOCHIM BIOPHYS ACTA, V1121, P23, DOI 10.1016/0167-4838(92)90332-8; Correia JJ, 2000, METHOD ENZYMOL, V321, P81; DEMARCUCCI O, 1985, EUR J BIOCHEM, V149, P641, DOI 10.1111/j.1432-1033.1985.tb08972.x; Fujisawa T, 1999, J SYNCHROTRON RADIAT, V6, P1106, DOI 10.1107/S0909049599010250; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GRAY RA, 1995, A1815A BECKM APPL IN, P1; Guinier A., 1955, SMALL ANGLE SCATTERI; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Hiromasa Y, 2003, J BIOL CHEM, V278, P33681, DOI 10.1074/jbc.M212733200; HODGSON JA, 1986, EUR J BIOCHEM, V158, P595, DOI 10.1111/j.1432-1033.1986.tb09796.x; Izard T, 1999, P NATL ACAD SCI USA, V96, P1240, DOI 10.1073/pnas.96.4.1240; JILKA JM, 1986, J BIOL CHEM, V261, P1858; KIM HJ, 1991, J BIOL CHEM, V266, P9367; Kong YF, 2003, J MOL BIOL, V330, P129, DOI 10.1016/S0022-2836(03)00555-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1996, A1821A BECKM APPL IN, P1; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P11249, DOI 10.1021/bi00111a009; LI L, 1992, ARCH BIOCHEM BIOPHYS, V296, P497, DOI 10.1016/0003-9861(92)90603-T; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; McCartney RG, 1997, BIOCHEMISTRY-US, V36, P6819, DOI 10.1021/bi9630016; MINTON AP, 1995, BIOPHYS CHEM, V57, P65, DOI 10.1016/0301-4622(95)00046-Z; NEAGLE J, 1989, FEBS LETT, V253, P11, DOI 10.1016/0014-5793(89)80919-6; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; REED LJ, 1990, J BIOL CHEM, V265, P8971; Roche T. E., 1996, CHANNELING INTERMEDI, P115; ROCHE TE, 1993, BIOCHEMISTRY-US, V32, P5629, DOI 10.1021/bi00072a019; Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SCHACHMAN HK, 1992, ANAL ULTRACENTRIFUGA, P3; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TECUNG L, 1995, J BIOL CHEM, V270, P15545; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698; Zhou ZH, 2001, J BIOL CHEM, V276, P21704, DOI 10.1074/jbc.M101765200	60	79	91	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6921	6933		10.1074/jbc.M308172200	http://dx.doi.org/10.1074/jbc.M308172200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638692	hybrid			2022-12-25	WOS:000188969200087
J	Whittington, DA; Grubb, JH; Waheed, A; Shah, GN; Sly, WS; Christianson, DW				Whittington, DA; Grubb, JH; Waheed, A; Shah, GN; Sly, WS; Christianson, DW			Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV - Implications for selective inhibition of membrane-associated isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CDNA CLONING; GXXXG MOTIF; PH SHIFTS; WILD-TYPE; MN/CA IX; IV; PURIFICATION; MECHANISM; SUBSTRATE	Carbonic anhydrase (CA) XIV is the most recently identified mammalian carbonic anhydrase isozyme, and its presence has been demonstrated in a number of tissues. Full-length CA XIV is a transmembrane protein composed of an extracellular catalytic domain, a single transmembrane helix, and a short intracellular polypeptide segment. The amino acid sequence identity of human CA XIV relative to the other membrane-associated isozymes (CA IV, CA IX, and CA XII) is 34-46%. We report here the expression and purification of both the full-length enzyme and a truncated, secretory form of murine CA XIV. Both forms of this isozyme are highly active, and both show an abrogation of activity in the presence of 0.2% SDS, in contrast to the behavior of murine CA IV. We also report the crystal structure of the extracellular domain of murine CA XIV at 2.8 Angstrom resolution and of an enzyme-acetazolamide complex at 2.9 Angstrom resolution. The structure shows a monomeric glycoprotein with a topology similar to that of other mammalian CA isozymes. Based on the x-ray crystallographic results, we compare and contrast known structures of membrane-associated CA isozymes to rationalize the structural elements responsible for the SDS resistance of CA IV and to discuss prospects for the design of selective inhibitors of membrane-associated CA isozymes.	St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA	Saint Louis University; University of Pennsylvania	Sly, WS (corresponding author), St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	slyws@slu.edu; chris@xtal.chem.upenn.edu	Wahhed, Abdul/AAA-3099-2020		NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM45614] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045614, R01GM045614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN JCT, 1992, P NATL ACAD SCI USA, V89, P7786, DOI 10.1073/pnas.89.16.7786; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; Fokine A, 2002, ACTA CRYSTALLOGR D, V58, P1387, DOI 10.1107/S0907444902010284; Fujikawa-Adachi K, 1999, GENOMICS, V61, P74, DOI 10.1006/geno.1999.5938; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HAKANSSON K, 1994, ACTA CRYSTALLOGR D, V50, P101, DOI 10.1107/S0907444993009667; Hewett-Emmett D, 2000, EXS, V90, P29; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; JEWELL DA, 1991, BIOCHEMISTRY-US, V30, P1484, DOI 10.1021/bi00220a006; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karhumaa P, 2000, MOL HUM REPROD, V6, P68, DOI 10.1093/molehr/6.1.68; Kaunisto K, 2002, KIDNEY INT, V61, P2111, DOI 10.1046/j.1523-1755.2002.00371.x; Kim CY, 2002, J MED CHEM, V45, P888, DOI 10.1021/jm010163d; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAREN TH, 1960, J PHARMACOL EXP THER, V130, P26; McKiernan JM, 1997, CANCER RES, V57, P2362; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; Mori K, 1999, J BIOL CHEM, V274, P15701, DOI 10.1074/jbc.274.22.15701; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 2000, EXS, V90, P79; Parkkila S, 2001, P NATL ACAD SCI USA, V98, P1918, DOI 10.1073/pnas.98.4.1918; Parkkila Seppo, 2002, BMC Gastroenterol, V2, P13, DOI 10.1186/1471-230X-2-13; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Ponstingl H, 2000, PROTEINS, V41, P47; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; Stams T, 1996, P NATL ACAD SCI USA, V93, P13589, DOI 10.1073/pnas.93.24.13589; Stams T, 1998, PROTEIN SCI, V7, P556, DOI 10.1002/pro.5560070303; Sugrue MF, 2000, PROG RETIN EYE RES, V19, P87, DOI 10.1016/S1350-9462(99)00006-3; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025; Tamai S, 1996, P NATL ACAD SCI USA, V93, P13647, DOI 10.1073/pnas.93.24.13647; Tashian RE, 2000, EXS, V90, P105; Tong CK, 2000, GLIA, V31, P125, DOI 10.1002/1098-1136(200008)31:2<125::AID-GLIA40>3.0.CO;2-7; Torcynski R. M., 1996, US Pat., Patent No. 5589579; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Ulmasov B, 2000, P NATL ACAD SCI USA, V97, P14212, DOI 10.1073/pnas.97.26.14212; WALZ W, 1989, CAN J PHYSIOL PHARM, V67, P577, DOI 10.1139/y89-092; Whittington DA, 2001, P NATL ACAD SCI USA, V98, P9545, DOI 10.1073/pnas.161301298; XUE YF, 1993, PROTEINS, V17, P93, DOI 10.1002/prot.340170112; XUE YF, 1993, PROTEINS, V15, P80, DOI 10.1002/prot.340150110; ZHU XL, 1990, J BIOL CHEM, V265, P8795	51	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7223	7228		10.1074/jbc.M310809200	http://dx.doi.org/10.1074/jbc.M310809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660577	hybrid			2022-12-25	WOS:000188969200122
J	Yamada, T; Sato, K; Komachi, M; Malchinkhuu, E; Tobo, M; Kimura, T; Kuwabara, A; Yanagita, Y; Ikeya, T; Tanahashi, Y; Ogawa, T; Ohwada, S; Morishita, Y; Ohta, H; Im, DS; Tamoto, K; Tomura, H; Okajima, F				Yamada, T; Sato, K; Komachi, M; Malchinkhuu, E; Tobo, M; Kimura, T; Kuwabara, A; Yanagita, Y; Ikeya, T; Tanahashi, Y; Ogawa, T; Ohwada, S; Morishita, Y; Ohta, H; Im, DS; Tamoto, K; Tomura, H; Okajima, F			Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; LOW-DENSITY-LIPOPROTEIN; OVARIAN-CANCER; SPHINGOSINE 1-PHOSPHATE; QUANTITATIVE-ANALYSIS; LYSOPHOSPHOLIPASE-D; SIGNALING PATHWAYS; ACTIVATION; INVASION	Cytokines and growth factors in malignant ascites are thought to modulate a variety of cellular activities of cancer cells and normal host cells. The motility of cancer cells is an especially important activity for invasion and metastasis. Here, we examined the components in ascites, which are responsible for cell motility, from patients and cancer cell-injected mice. Ascites remarkably stimulated the migration of pancreatic cancer cells. This response was inhibited or abolished by pertussis toxin, monoglyceride lipase, an enzyme hydrolyzing lysophosphatidic acid (LPA), and Ki16425 and VPC12249, antagonists for LPA receptors (LPA(1) and LPA(3)), but not by an LPA(3)-selective antagonist. These agents also inhibited the response to LPA but not to the epidermal growth factor. In malignant ascites, LPA is present at a high level, which can explain the migration activity, and the fractionation study of ascites by lipid extraction and subsequent thin-layer chromatography indicated LPA as an active component. A significant level of LPA(1) receptor mRNA is expressed in pancreatic cancer cells with high migration activity to ascites but not in cells with low migration activity. Small interfering RNA against LPA(1) receptors specifically inhibited the receptor mRNA expression and abolished the migration response to ascites. These results suggest that LPA is a critical component of ascites for the motility of pancreatic cancer cells and LPA(1), receptors may mediate this activity. LPA receptor antagonists including Ki16425 are potential therapeutic drugs against the migration and invasion of cancer cells.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Grad Sch Med, Dept Lab Med, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Dept Surg 2, Maebashi, Gumma 3718511, Japan; Maebashi Red Cross Hosp, Maebashi, Gumma 3710014, Japan; Kirin Brewery Co Ltd, Res Lab, Takasaki, Gumma 3701295, Japan; Pusan Natl Univ, Coll Pharm, Pharmacol Lab, Pusan 609735, South Korea; Hlth Sci Univ Hokkaido, Dept Microbiol, Ishikari, Hokkaido 06102, Japan	Gunma University; Gunma University; Gunma University; Maebashi Red Cross Hospital; Kirin Brewery Company Limited; Pusan National University; Health Sciences University of Hokkaido	Okajima, F (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	fokajima@showa.gunma-u.ac.jp	Malchinkhuu, Enkhzol/AAH-4600-2019	IM, DONG-SOON/0000-0001-8054-8946; Sato, Koichi/0000-0001-7694-4014; Malchinkhuu, Enkhzol/0000-0003-0744-079X				Aihara Y, 2001, STROKE, V32, P212, DOI 10.1161/01.STR.32.1.212; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fishman DA, 2001, CANCER RES, V61, P3194; Goetzl EJ, 1999, CANCER RES, V59, P5370; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KAYAHARA M, 1992, CANCER, V70, P2061, DOI 10.1002/1097-0142(19921015)70:8<2061::AID-CNCR2820700808>3.0.CO;2-V; Keleg S, 2003, MOL CANCER, V2, P1; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Liu CD, 2002, J SURG RES, V102, P31, DOI 10.1006/jsre.2001.6307; Maschberger P, 2000, J BIOL CHEM, V275, P19159, DOI 10.1074/jbc.M910257199; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; PLANTE M, 1994, CANCER, V73, P1882, DOI 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Sawada K, 2002, CANCER RES, V62, P6015; Shida D, 2003, CANCER RES, V63, P1706; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Tanyi JL, 2003, CANCER RES, V63, P1073; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamada T, 1998, INT J CANCER, V76, P141, DOI 10.1002/(SICI)1097-0215(19980330)76:1<141::AID-IJC22>3.0.CO;2-E; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317	46	152	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6595	6605		10.1074/jbc.M308133200	http://dx.doi.org/10.1074/jbc.M308133200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660630	hybrid			2022-12-25	WOS:000188969200048
J	Davies, ML; Roberts, GT; Spiller, DG; Wakeman, JA				Davies, ML; Roberts, GT; Spiller, DG; Wakeman, JA			Density-dependent location and interactions of truncated APC and beta-catenin	ONCOGENE			English	Article						adenomatous polyposis coli; beta-catenin; cell density; E-cadherin; tumour progression	TUMOR-SUPPRESSOR; E-CADHERIN; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; CYCLIN D1; TARGET; IDENTIFICATION; MUTATIONS; GENES; TRANSACTIVATION	Adenomatous polyposis coli (APC) is a multifunctional tumour suppressor protein, central to development and the mature organism. It is mutated in most cases of colorectal cancer, rendering it ineffective in mediating beta-catenin degradation. We show that localization of full-length APC in colon carcinoma and noncancer cell lines is independent of cell density. However, the location of truncated APC is a function of cell density and in high-density cells truncated APC is predominantly not nuclear. Although the distribution of truncated APC and beta-catenin is closely linked in subconfluent SW480 cells, at high cell density they are not colocalized. We postulated that in this cell line this could be due to an increase in beta-catenin bound to E-cadherin with formation of adherens junctions at high cell density. However, while in coimmunoprecipitation assays we observe an increase in binding between beta-catenin and E-cadherin and a corresponding decrease in binding between beta-catenin and APC at high cell density, we did not observe a strict colocalization of beta-catenin and E-cadherin at the membrane of all cells.	Univ Wales Bangor, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Bangor University; University of Liverpool	Wakeman, JA (corresponding author), Univ Wales Bangor, Sch Biol Sci, Deiniol Rd, Bangor LL57 2UW, Gwynedd, Wales.	j.a.wakeman@bangor.ac.uk	Spiller, David G/I-3645-2012	Spiller, David Geoffrey/0000-0003-2502-6787; Wakeman, Jane/0000-0002-7561-634X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Allan V, 2001, NAT CELL BIOL, V3, pE226, DOI 10.1038/ncb1001-e226; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, EMBO REP, V1, P519; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orsulic S, 1999, J CELL SCI, V112, P1237; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	37	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1412	1419		10.1038/sj.onc.1207266	http://dx.doi.org/10.1038/sj.onc.1207266			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647421				2022-12-25	WOS:000189035800008
J	Cordeiro, Y; Lima, LMTR; Gomes, MPB; Foguel, D; Silva, JL				Cordeiro, Y; Lima, LMTR; Gomes, MPB; Foguel, D; Silva, JL			Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,4 '-dianilino-1,1 '-binaphthyl-5,5 '-sulfonate (bis-ANS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; CONGO RED; CONFORMATIONAL TRANSITIONS; POTENT INHIBITION; DISSOCIATION; PRESSURE; DISEASE; TRANSTHYRETIN; THERAPEUTICS; ACCUMULATION	The prion protein (PrP) is the major agent implicated in the diseases known as transmissible spongiform encephalopathies. The onset of transmissible spongiform encephalopathy is related to a change in conformation of the PrPC, which loses most of its alpha-helical content, becoming a beta-sheet-rich protein, known as PrPSc. Here we have used two Syrian hamster prion domains (PrP 109-141 and PrP 109-149) and the murine recombinant PrP (rPrP 23 231) to investigate the effects of anilino-naphtalene compounds on prion oligomerization and aggregation. Aggregation in the presence of bis-ANS (4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate), ANS (1-anilinonaphthalene-8-sulfonate), and AmNS (1-amino-5-naphtalenesulfonate) was monitored. Bis-ANS was the most effective inhibitor of prion peptide aggregation. Bis-ANS binds strongly to rPrP 23-231 leading to a substantial increase in beta-sheet content and to limited oligomerization. More strikingly, the binding of bis-ANS to full-length rPrP is diminished by the addition of nanomolar concentrations of oligonucleotides, demonstrating that they compete for the same binding site. Thus, bis-ANS displays properties similar to those of nucleic acids, causing oligomerization and conversion to beta-sheet (Cordeiro, Y., Machado, F., Juliano, L., Juliano, M. A., Brentani, R. R., Foguel, D., and Silva, J. L. (2001) J. Biol. Chem. 276, 49400-49409). This dual effect of bis-ANS on prion protein makes this compound highly important to sequester crucial conformations of the protein, which may be useful to the understanding of the disease and to serve as a lead for the development of new therapeutic strategies.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Medicamentos, Fac Farm, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil.	jerson@bioqmed.ufrj.br	SILVA, JERSON Lima/GRF-1442-2022; Cordeiro, Yraima/J-7619-2012; Silva, Jerson/J-8984-2014; Lima, Luis Mauricio/AAL-2098-2021; Gomes, Mariana/A-6618-2013	SILVA, JERSON Lima/0000-0001-9523-9441; Cordeiro, Yraima/0000-0003-4278-212X; Silva, Jerson/0000-0001-9523-9441; Foguel, Debora/0000-0001-7312-7115; TR Lima, Luis Mauricio/0000-0001-6020-0504				Adjou KT, 2003, J GEN VIROL, V84, P2595, DOI 10.1099/vir.0.19073-0; Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Bonafe CFS, 2000, BIOCHEM BIOPH RES CO, V275, P955, DOI 10.1006/bbrc.2000.3402; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; Caughey B, 2003, NATURE, V425, P673, DOI 10.1038/425673a; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; Ferrao-Gonzales AD, 2003, J MOL BIOL, V328, P963, DOI 10.1016/S0022-2836(03)00368-1; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; Follette P, 2003, SCIENCE, V299, P191, DOI 10.1126/science.299.5604.191; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; HOROWITZ P, 1984, J BIOL CHEM, V259, P4647; Kocisko DA, 2003, J VIROL, V77, P10288, DOI 10.1128/JVI.77.19.10288-10294.2003; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; Priola SA, 1999, CURR OPIN MICROBIOL, V2, P563, DOI 10.1016/S1369-5274(99)00020-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rudyk H, 2000, J GEN VIROL, V81, P1155, DOI 10.1099/0022-1317-81-4-1155; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; Smoot AL, 2001, BIOCHEMISTRY-US, V40, P4484, DOI 10.1021/bi001822b; Srisailam S, 2002, J AM CHEM SOC, V124, P1884, DOI 10.1021/ja012070r; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	40	55	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5346	5352		10.1074/jbc.M312262200	http://dx.doi.org/10.1074/jbc.M312262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634010	hybrid			2022-12-25	WOS:000188776500039
J	Hinrichs, JWJ; Klappe, K; Hummel, I; Kok, JW				Hinrichs, JWJ; Klappe, K; Hummel, I; Kok, JW			ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CHOLESTEROL TRANSPORT; P-GLYCOPROTEIN; ABC TRANSPORTERS; PLASMA-MEMBRANE; LIPID FLUIDITY; UP-REGULATION; MICRODOMAINS; EFFLUX; LOCALIZATION; PROTEINS	In this study we show that P-glycoprotein in multi-drug-resistant 2780AD human ovarian carcinoma cells and multidrug resistance-associated protein 1 in multi-drug-resistant HT29(col) human colon carcinoma cells are predominantly located in Lubrol-based detergent-insoluble glycosphingolipid-enriched membrane domains. This localization is independent of caveolae, since 2780AD cells do not express caveolin-1. Although HT29(col) cells do express caveolin-1, the ATP-binding cassette transporter and caveolin-1 were dissociated on the basis of differential solubility in Triton X-100 and absence of microscopical colocalization. While both the multidrug resistance-associated protein 1 and caveolin-1 are located in Lubrol-based membrane domains, they occupy different regions of these domains.	Univ Groningen, Dept Membrane Cell Biol, Inst Drug Explorat, NL-9713 AV Groningen, Netherlands	University of Groningen	Kok, JW (corresponding author), Univ Groningen, Dept Membrane Cell Biol, Inst Drug Explorat, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.w.kok@med.rug.nl						Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Demeule M, 2000, FEBS LETT, V466, P219, DOI 10.1016/S0014-5793(00)01087-5; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; DUDEJA PK, 1995, ARCH BIOCHEM BIOPHYS, V319, P309, DOI 10.1006/abbi.1995.1298; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 1997, J LIPID RES, V38, P1503; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liscovitch M, 2000, TRENDS BIOCHEM SCI, V25, P530, DOI 10.1016/S0968-0004(00)01668-6; Luker GD, 2000, BIOCHEMISTRY-US, V39, P7651, DOI 10.1021/bi9928593; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SINICROPE FA, 1992, J BIOL CHEM, V267, P24995; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; VELDMAN RJ, 2002, FASEB J; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4	29	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5734	5738		10.1074/jbc.M306857200	http://dx.doi.org/10.1074/jbc.M306857200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14627714	hybrid			2022-12-25	WOS:000188776500086
J	Kostyukova, AS; Hitchcock-DeGregori, SE				Kostyukova, AS; Hitchcock-DeGregori, SE			Effect of the structure of the N terminus of tropomyosin on tropomodulin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ALPHA-TROPOMYOSIN; COILED-COIL; SKELETAL-MUSCLE; POINTED-END; ADP-ACTIN; BINDING; FILAMENTS; DYNAMICS; PROTEIN	Tropomodulins (Tmod) bind to the N terminus of tropomyosin and cap the pointed end of actin filaments. Tropomyosin alone also inhibits the rate of actin depolymerization at the pointed end of filaments. Here we have defined 1) the structural requirements of the N terminus of tropomyosin important for regulating the pointed end alone and with erythrocyte Tmod (Tmod1), and 2) the Tmod1 subdomains required for binding to tropomyosin and for regulating the pointed end. Changes in pyrene-actin fluorescence during polymerization and depolymerization were measured with actin filaments blocked at the barbed end with gelsolin. Three tropomyosin isoforms differently influence pointed end dynamics. Recombinant TM5a, a short non-muscle alpha-tropomyosin, inhibited depolymerization. Recombinant (unacetylated) TM2 and N-acetylated striated muscle TM (stTM), long alpha-tropomyosin isoforms with the same N-terminal sequence, different from TM5a, also inhibited depolymerization but were less effective than TM5a. All blocked the pointed end with Tmod1 in the order of effectiveness TM5a > stTM > TM2, showing the importance of the N-terminal sequence and modification. Tmod1-(1-344), lacking the C-terminal 15 residues, did not nucleate polymerization but blocked the pointed end with all three tropomyosin isoforms as does a shorter fragment, Tmod1-(1-92), lacking the C-terminal "capping" domain though higher concentrations were required. An even shorter fragment, Tmod1-(1-48), bound tropomyosin but did not influence actin filament elongation. Tropomyosin-Tmod may function to locally regulate cytoskeletal dynamics in cells by stabilizing actin filaments.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Kostyukova, AS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA.	kostyuas@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BROSCHAT KO, 1989, BIOCHEMISTRY-US, V28, P8501, DOI 10.1021/bi00447a035; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DesMarais V, 2002, J CELL SCI, V115, P4649, DOI 10.1242/jcs.00147; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FASMAN GD, 1989, PRACTICAL HDB BIOCH, P84; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Fowler VM, 1997, SOC GEN PHY, V52, P79; FOWLER VM, 2003, J BIOL CHEM, V14, P14; FUJIME S, 1971, J MOL BIOL, V62, P251, DOI 10.1016/0022-2836(71)90144-6; Geeves Michael A, 2002, Results Probl Cell Differ, V36, P111; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Greenfield NJ, 1998, BIOCHEMISTRY-US, V37, P7834, DOI 10.1021/bi973167m; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; Greenfield NJ, 2001, J MOL BIOL, V312, P833, DOI 10.1006/jmbi.2001.4982; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HITCHCOCKDEGREGORI SE, 1985, BIOCHEMISTRY-US, V24, P3305, DOI 10.1021/bi00334a035; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Kostyukova A, 2000, EUR J BIOCHEM, V267, P6470, DOI 10.1046/j.1432-1327.2000.01738.x; Kostyukova AS, 2001, BIOPHYS J, V81, P345, DOI 10.1016/S0006-3495(01)75704-9; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer Sherwin S, 2002, Results Probl Cell Differ, V36, P107; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Moraczewska J, 1999, BIOCHEMISTRY-US, V38, P15885, DOI 10.1021/bi991816j; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; Nyakern-Meazza M, 2002, J BIOL CHEM, V277, P28774, DOI 10.1074/jbc.M203360200; OHTSUKI I, 1982, ADV BIOPHYS, V15, P93, DOI 10.1016/0065-227X(82)90006-5; Ono S, 2002, J CELL BIOL, V156, P1065, DOI 10.1083/jcb.200110013; Percival JM, 2000, CELL MOTIL CYTOSKEL, V47, P189, DOI 10.1002/1097-0169(200011)47:3<189::AID-CM3>3.0.CO;2-C; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1986, J CELL BIOCHEM, V31, P87, DOI 10.1002/jcb.240310202; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUNG LA, 1994, BIOCHEM BIOPH RES CO, V201, P627, DOI 10.1006/bbrc.1994.1747; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; Vera C, 2000, ARCH BIOCHEM BIOPHYS, V378, P16, DOI 10.1006/abbi.2000.1802; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973	60	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5066	5071		10.1074/jbc.M311186200	http://dx.doi.org/10.1074/jbc.M311186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660556	hybrid			2022-12-25	WOS:000188776500005
J	Boldt, JL; Pinilla, C; Segall, AM				Boldt, JL; Pinilla, C; Segall, AM			Reversible inhibitors of lambda integrase-mediated recombination efficiently trap Holliday junction intermediates and form the basis of a novel assay for junction resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-LAMBDA; TOPOISOMERASE-I; TYROSINE RECOMBINASES; DNA; MECHANISM; SYNAPSIS; PROTEIN; MUTATIONS; RESIDUES	The bacteriophage lambda integrase catalyzes four site-specific recombination pathways with distinct protein and DNA requirements and nucleoprotein intermediates. Some of these intermediates are very transient and difficult to obtain in significant amounts, due to the high efficiency and processivity of integrase, the lack of requirements for external energy factors or metal ions, and the highly reversible nature of each of the intermediates. We have previously used mixture-based combinatorial libraries to identify hexapeptides that trap 40-60% of recombination substrates at the Holliday junction stage of the reaction. These inhibitors discriminate between the four pathways, blocking one of them (bent-L recombination) more severely than the others and blocking the excision pathway least. We presume that these differences reflect specific conformational differences of the nucleoprotein intermediates in each pathway. We have now identified new inhibitors of the excision pathway. One of these, WRWYCR, is over 50-fold more potent at inhibiting excision than the previously identified peptides. This peptide stably traps Holliday junction complexes in all recombination pathways mediated by integrase as well as Cre. This finding and other data presented indicate that the peptide's target is a common feature shared by the Holliday junction complexes assembled by tyrosine recombinases. We have taken advantage of reversible inhibition by the active peptides to develop a new assay for Holliday junction resolution. This assay is particularly useful for determining junction resolution rates in cases where complexes directly assembled on junction substrates undergo little or no catalysis.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA; San Diego State Univ, Ctr Microbial Sci, San Diego, CA 92182 USA	California State University System; San Diego State University; Torrey Pines Institute for Molecular Studies, California; California State University System; San Diego State University	Segall, AM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	asegall@sunstroke.sdsu.edu		Segall, Anca/0000-0002-8454-5248	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052847] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI058253] Funding Source: Medline; NIGMS NIH HHS [R01-GM52847] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1988, J MOL BIOL, V202, P59, DOI 10.1016/0022-2836(88)90518-9; AZARO MA, 2002, MOBILE DNA, V2, P117; Bankhead T, 2000, J BIOL CHEM, V275, P36949, DOI 10.1074/jbc.M004679200; Bankhead TM, 2003, J BACTERIOL, V185, P2653, DOI 10.1128/JB.185.8.2653-2666.2003; Bolla ML, 2003, ORG LETT, V5, P109, DOI 10.1021/ol020204f; Cassell G, 2000, J MOL BIOL, V299, P1193, DOI 10.1006/jmbi.2000.3828; Cassell GD, 2003, J MOL BIOL, V327, P413, DOI 10.1016/S0022-2836(03)00058-5; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; DEMASSY B, 1989, EMBO J, V8, P1591, DOI 10.1002/j.1460-2075.1989.tb03543.x; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; KIKUCHI A, 1985, J MOL BIOL, V183, P129, DOI 10.1016/0022-2836(85)90207-4; Klemm M, 2000, J MOL BIOL, V299, P1203, DOI 10.1006/jmbi.2000.3829; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; Maniatis T., 1989, MOL CLONING LAB MAN; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NASH HA, 1987, P NATL ACAD SCI USA, V84, P4049, DOI 10.1073/pnas.84.12.4049; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; Pinilla C, 1998, J MOL BIOL, V283, P1013, DOI 10.1006/jmbi.1998.2137; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; SEGALL AM, 1993, EMBO J, V12, P4567, DOI 10.1002/j.1460-2075.1993.tb06145.x; Segall AM, 1998, J BIOL CHEM, V273, P24258, DOI 10.1074/jbc.273.37.24258; Segall AM, 1996, GENES CELLS, V1, P453, DOI 10.1046/j.1365-2443.1996.d01-254.x; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Zhang HL, 1996, J BIOL CHEM, V271, P9039, DOI 10.1074/jbc.271.15.9039	37	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3472	3483		10.1074/jbc.M309361200	http://dx.doi.org/10.1074/jbc.M309361200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14625310	hybrid			2022-12-25	WOS:000188379600043
J	Wang, F; Thirumurugan, K; Stafford, WF; Hammer, JA; Knight, PJ; Sellers, JR				Wang, F; Thirumurugan, K; Stafford, WF; Hammer, JA; Knight, PJ; Sellers, JR			Regulated conformation of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; BOUNDARY ANALYSIS; SCALLOP MYOSIN; ACTIN; BINDING; CONTRACTION; MICROSCOPY; MECHANISM; MOTILITY; CALCIUM	We have found that myosin V, an important actin-based vesicle transporter, has a folded conformation that is coupled to inhibition of its enzymatic activity in the absence of cargo and Ca2+. In the absence of Ca2+ where the actin-activated MgATPase activity is low, purified brain myosin V sediments in the analytical ultracentrifuge at 14 S as opposed to 11 S in the presence of Ca2+ where the activity is high. At high ionic strength it sediments at 10 S independent of Ca2+, and its regulation is poor. These data are consistent with myosin V having a compact, inactive conformation in the absence of Ca2+ and an extended conformation in the presence of Ca2+ or high ionic strength. Electron microscopy reveals that in the absence of Ca2+ the heads and tail are both folded to give a triangular shape, very different from the extended appearance of myosin V at high ionic strength. A recombinant myosin V heavy meromyosin fragment that is missing the distal portion of the tail domain is not regulated by calcium and has only a small change in sedimentation coefficient, which is in the opposite direction to that seen with intact myosin V. Electron microscopy shows that its heads are extended even in the absence of calcium. These data suggest that interaction between the motor and cargo binding domains may be a general mechanism for shutting down motor protein activity and thereby regulating the active movement of vesicles in cells.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Boston Biomed Res Inst, Watertown, MA 02472 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Leeds; University of Leeds; Boston Biomedical Research Institute	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.	sellersj@nhlbi.nih.gov	Stafford, Walter/ABC-6553-2020; Thirumurugan, Kavitha/B-3282-2010	Thirumurugan, Kavitha/0000-0002-4673-4099; Hammer, John/0000-0002-2496-5179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000514, ZIAHL000514] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cameron LC, 1998, ARCH BIOCHEM BIOPHYS, V355, P35, DOI 10.1006/abbi.1998.0700; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Evans LL, 1997, J CELL SCI, V110, P439; Evans LL, 1998, J CELL SCI, V111, P2055; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Liu J, 2003, J MOL BIOL, V329, P963, DOI 10.1016/S0022-2836(03)00516-3; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Regnier M, 1998, BIOPHYS J, V74, P3044, DOI 10.1016/S0006-3495(98)78012-9; Rudolf R, 2003, J CELL SCI, V116, P1339, DOI 10.1242/jcs.00317; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; SELLERS JR, 1985, CURR TOP CELL REGUL, V27, P51; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stafford W. F., 2003, CURRENT PROTOCOLS PR; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STAFFORD WF, 2003, IN PRESS BIOPHYS CHE; Tauhata SBF, 2001, J BIOL CHEM, V276, P39812, DOI 10.1074/jbc.M102583200; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; VALE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6775, DOI 10.1073/pnas.81.21.6775; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	37	126	126	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2333	2336		10.1074/jbc.C300488200	http://dx.doi.org/10.1074/jbc.C300488200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14634000	hybrid			2022-12-25	WOS:000188211300002
J	Oshima, K; Shimamura, M; Mizuno, S; Tamai, K; Doi, K; Morishita, R; Nakamura, T; Kubo, T; Kaneda, Y				Oshima, K; Shimamura, M; Mizuno, S; Tamai, K; Doi, K; Morishita, R; Nakamura, T; Kubo, T; Kaneda, Y			Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats	FASEB JOURNAL			English	Article						hair cell; spiral ganglion; cochlear implants; gene therapy	HEPATOCYTE GROWTH-FACTOR; ESSENTIAL TRANSCRIPTION FACTOR; CISPLATIN-INDUCED DAMAGE; SPIRAL GANGLION NEURONS; FACTOR-SCATTER FACTOR; AUDITORY NEURONS; TRANSGENE EXPRESSION; NEUROTROPHIC FACTOR; SUBARACHNOID SPACE; NUCLEAR-PROTEIN	Hearing impairment, which is the most prevalent sensory deficit of human beings, needs a breakthrough in therapeutic technologies. One technology is the usage of a vector system to reach the inner ear, and another is by a therapeutic molecule. Here we developed a novel gene therapy strategy by combining hepatocyte growth factor (HGF) with hemagglutinating virus of Japan envelope (HVJ-E) vector. When HVJ-E containing human HGF gene was injected intrathecally into the cerebrospinal fluid via cisterna magna of rats, the vector reached the inner ear region, and human HGF gene expression was detected in the spiral ganglion cells (SGCs) of the inner ear. Expression of endogenous rat HGF and its receptor, c-Met, was also induced in SGCs by human HGF. Kanamycin treatment results in hearing impairment by inducing degeneration of hair cells (HCs) and apoptosis of SGCs in rats. By HGF gene transfer before kanamycin treatment, both loss of HCs and apoptosis of SGCs were prevented. Furthermore, hearing function, evaluated by auditory brainstem response, was maintained at a normal level. When HGF gene transfer was performed 2 wk after kanamycin treatment, hearing impairment was significantly recovered. These results indicate a novel and effective therapeutic strategy against sensorineural hearing impairment.	Osaka Univ, Div Gene Therapy Sci, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Otolaryngol & Sensory Organ Surg, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Div Biochem, Grad Sch Med, Dept Oncol,Biomed Res Ctr B7, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kaneda, Y (corresponding author), Osaka Univ, Div Gene Therapy Sci, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneday@gts.med.osaka-u.ac.jp			grants from the Ministry of Health, Labor and Welfare of Japan	grants from the Ministry of Health, Labor and Welfare of Japan	We thank Yoshinaga Saeki, Masayuki Endoh, Seiji Yamamoto, Yo C.Y., and members of our laboratory for helpful comments and discussions. This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan.	Aoki M, 2000, GENE THER, V7, P417, DOI 10.1038/sj.gt.3301104; BICHLER E, 1983, ARCH OTO-RHINO-LARYN, V237, P201, DOI 10.1007/BF00453725; Bowers WJ, 2002, MOL THER, V6, P12, DOI 10.1006/mthe.2002.0627; Chen XW, 2001, MOL THER, V3, P958, DOI 10.1006/mthe.2001.0334; DOI K, 1999, OTOL JPN, V9, P85; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; Forge A, 2000, AUDIOL NEURO-OTOL, V5, P3, DOI 10.1159/000013861; Gabaizadeh R, 1997, ACTA OTO-LARYNGOL, V117, P232, DOI 10.3109/00016489709117778; Gao WQ, 1998, MOL NEUROBIOL, V17, P17, DOI 10.1007/BF02802022; Hashimoto N, 2001, MOL BRAIN RES, V97, P83, DOI 10.1016/S0169-328X(01)00284-4; Hashimoto N, 2001, NEUROREPORT, V12, P1403, DOI 10.1097/00001756-200105250-00022; Hayashi K, 2001, GENE THER, V8, P1167, DOI 10.1038/sj.gt.3301498; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; Incesulu A, 1998, ANN OTO RHINOL LARYN, V107, P906, DOI 10.1177/000348949810701102; Jero J, 2001, HUM GENE THER, V12, P539, DOI 10.1089/104303401300042465; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; Kaneda Y, 1999, MOL MED TODAY, V5, P298, DOI 10.1016/S1357-4310(99)01482-3; Kaneda Y, 2002, MOL THER, V6, P219, DOI 10.1006/mthe.2002.0647; KATO K, 1991, J BIOL CHEM, V266, P3361; Kawamoto K, 2001, MOL THER, V4, P575, DOI 10.1006/mthe.2001.0490; Kho ST, 2000, MOL THER, V2, P368, DOI 10.1006/mthe.2000.0129; Lalwani AK, 1997, HEARING RES, V114, P139, DOI 10.1016/S0378-5955(97)00151-2; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; MILLS JH, 1982, ENVIRON HEALTH PERSP, V44, P119, DOI 10.2307/3429484; Miyazawa T, 1998, J CEREBR BLOOD F MET, V18, P345, DOI 10.1097/00004647-199804000-00001; Morishita R, 2002, CIRC J, V66, P1077, DOI 10.1253/circj.66.1077; Nakagami H, 2002, DIABETES, V51, P2604, DOI 10.2337/diabetes.51.8.2604; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V300, P464, DOI 10.1016/S0006-291X(02)02807-3; SPOENDLIN H, 1975, ACTA OTO-LARYNGOL, V79, P266, DOI 10.3109/00016487509124683; Staecker H, 1996, NEUROREPORT, V7, P889, DOI 10.1097/00001756-199603220-00011; Stover T, 1999, HEARING RES, V136, P124, DOI 10.1016/S0378-5955(99)00115-X; Stover T, 2000, GENE THER, V7, P377, DOI 10.1038/sj.gt.3301108; Sun W, 2002, J NEUROSCI, V22, P6537; Sun W, 2002, MOL BRAIN RES, V103, P36, DOI 10.1016/S0169-328X(02)00168-7; Sun W, 1999, BRAIN RES, V851, P46, DOI 10.1016/S0006-8993(99)02097-1; Taniyama Y, 2002, HYPERTENSION, V40, P47, DOI 10.1161/01.HYP.0000020755.56955.BF; Tomita N, 1996, BIOCHEM BIOPH RES CO, V224, P43, DOI 10.1006/bbrc.1996.0982; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; Tsujie M, 2001, J AM SOC NEPHROL, V12, P949, DOI 10.1681/ASN.V125949; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Wu WJ, 2001, HEARING RES, V158, P165, DOI 10.1016/S0378-5955(01)00303-3; Yagi M, 2000, JARO-J ASSOC RES OTO, V1, P315, DOI 10.1007/s101620010011; Yamada K, 1996, AM J PHYSIOL-REG I, V271, pR1212, DOI 10.1152/ajpregu.1996.271.5.R1212; Yamasoba T, 1999, HUM GENE THER, V10, P769, DOI 10.1089/10430349950018526; Yang XM, 1998, J NEUROSCI, V18, P8369; Yoshimura S, 2002, HYPERTENSION, V39, P1028, DOI 10.1161/01.HYP.0000017553.67732.E1	52	41	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					212	214		10.1096/fj.03-0567fje	http://dx.doi.org/10.1096/fj.03-0567fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630698				2022-12-25	WOS:000188829300077
J	Schiller, M; Verrecchia, F; Mauviel, A				Schiller, M; Verrecchia, F; Mauviel, A			Cyclic adenosine 3 ',5 '-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism	ONCOGENE			English	Article						cAMP; CREB; gene regulation; PAI-1; PKA; SMAD signaling; TGF-beta	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; TGF-BETA; GENE-EXPRESSION; ANTISENSE OLIGONUCLEOTIDE; DERMAL FIBROBLASTS; PROSTAGLANDIN E-2; FACTOR CREB; C-JUN; COACTIVATOR	Transforming growth factor-beta (TGF-beta) plays complex roles in carcinogenesis, as it may exert both tumor suppressor and pro-oncogenic activities depending on the stage of the tumor. SMAD proteins transduce signals from the TGF-beta receptors to regulate the transcription of specific target genes. Crosstalks with other signaling pathways may contribute to the speci. city of TGF-beta effects. In this report, we have investigated the effects of cyclic adenosine 3',5'-monophosphate (cAMP), a key second messenger in the cellular response to various hormones, on SMAD-dependent signaling in human HaCaT keratinocytes. Using either an artificial SMAD3/4-dependent reporter construct or the natural TGF-beta target, plasminogen activator inhibitor-1, we show that membrane-permeable dibutyryl cAMP, and other intracellular cAMP-elevating agents such as the phosphodiesterase inhibitor isobutyl-methylxanthine, the adenylate cyclase activator forskolin, or exogenous prostaglandin E-2 (PGE(2)), interfere with TGF-beta-induced SMAD-specific gene transactivation. Inhibition of protein kinase A (PKA), the main downstream effector of cAMP, with H-89, suppressed cAMP-dependent repression of SMAD-driven gene expression. Inversely, coexpression of either an active PKA catalytic subunit or that of the cAMP response element (CRE)-binding protein (CREB) blocked SMAD-driven gene transactivation. cAMP-elevating agents did not inhibit nuclear translocation and DNA binding of SMAD3/4complexes, but abolished the interactions of SMAD3 with the transcription coactivators CREB-binding protein (CBP) and p300 in a PKA-dependent manner. These results suggest that suppression of TGF-beta/SMAD signaling and resulting gene transactivation by cAMP-inducing agents occurs via PKA-dependent, CREB-mediated, disruption of SMAD-CBP/p300 complexes.	Univ Paris 07, Hop St Louis, Inst Rech Peau, INSERM,U532, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mauviel, A (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U532, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	mauviel@chu-stlouis.fr	Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bianco C, 2000, CLIN CANCER RES, V6, P4343; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corley DA, 2003, GASTROENTEROLOGY, V124, P47, DOI 10.1053/gast.2003.50008; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson TW, 2002, CANCER EPIDEM BIOMAR, V11, P1586; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rodeck U, 1999, CANCER RES, V59, P547; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Tortora G, 1997, P NATL ACAD SCI USA, V94, P12586, DOI 10.1073/pnas.94.23.12586; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	44	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8881	8890		10.1038/sj.onc.1206871	http://dx.doi.org/10.1038/sj.onc.1206871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654784				2022-12-25	WOS:000186982200009
J	Shikata, Y; Birukov, KG; Birukova, AA; Verin, A; Garcia, JGN				Shikata, Y; Birukov, KG; Birukova, AA; Verin, A; Garcia, JGN			Involvement of site-specific FAK phosphorylation in sphingosine-1 phosphate- and thrombin-induced focal adhesion remodeling: role of Src and GIT	FASEB JOURNAL			English	Article						human pulmonary artery endothelium; barrier function; cytoskeleton	PROTEIN-KINASE-C; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; QUANTITATIVE MEASUREMENT; LYSOPHOSPHATIDIC ACID; BARRIER DYSFUNCTION; MOLECULAR-CLONING; BINDING-SITE; LIM DOMAINS; IN-VITRO	Sphingosine-1 phosphate (S1P) and thrombin are agents with profound but divergent effects on vascular endothelial cell (EC) barrier properties. We have previously reported that S1P-induced focal adhesion (FA) remodeling involves interactions between focal adhesion kinase (FAK), paxillin, and G-protein-coupled receptor kinase-interacting proteins GIT1 and GIT2 and suggested a critical involvement of focal adhesions in the EC barrier regulation. In this study, we examined redistribution of FA proteins (FAK, paxillin, GIT1, and GIT2) and site-specific FAK tyrosine phosphorylation in human pulmonary artery endothelial cells stimulated with thrombin. In contrast to S1P, which we have shown to induce peripheral translocation of FA proteins associated with cortical actin ring formation, thrombin caused the redistribution of FA proteins to the ends of the newly formed massive stress fibers. S1P and thrombin induced distinct patterns of FAK site-specific phosphorylation with the FAK Y-576 phosphorylation site targeted by SIP challenge and phosphorylation of three FAK sites (Y-397, Y-576, and Y-925) in response to thrombin stimulation. Pharmacological inhibition of Src with Src-specific inhibitor PP2 abolished S1P-induced translocation of FA proteins, cortical actin ring formation, and FAK [Y576] phosphorylation. However, PP2 failed to alter thrombin-induced morphological changes and exhibited only partial inhibition of FAK site-specific tyrosine phosphorylation. These observations highlight the differential mechanisms of focal adhesion protein complex remodeling and FAK activation by S1P and thrombin and link differential FA remodeling to EC barrier regulation.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	Johns Hopkins University	Garcia, JGN (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle,JHAAC,4B-77, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Garcia, Joe GN/E-8862-2010; Birukov, Konstantin/FJB-5755-2022		NHLBI NIH HHS [HL 69340, HL 58064, HL 50533] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050533, P01HL058064, R01HL069340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; GARCIA JGN, 1992, BLOOD, V79, P2056; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1992, AM J RESP CELL MOL, V6, P315, DOI 10.1165/ajrcmb/6.3.315; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GIMBRONE MA, 1969, NATURE, V221, P33; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LO SK, 1988, AM J PHYSIOL, V254, pHMLO; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; MCDNAGH PF, 1986, AM J PHYSIOL, V251, pH581; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; Ren XD, 2000, J CELL SCI, V113, P3673; ROY AJ, 1972, P SOC EXP BIOL MED, V139, P137; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHEPRO D, 1984, THROMB RES, V35, P421, DOI 10.1016/0049-3848(84)90234-2; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Shikata Y, 1999, BIOCHEM BIOPH RES CO, V257, P234, DOI 10.1006/bbrc.1999.0441; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WENG ZG, 1993, J BIOL CHEM, V268, P14956; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; WOOD CK, 1994, J CELL SCI, V107, P709; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	49	107	109	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2240	2249		10.1096/fj.03-0198com	http://dx.doi.org/10.1096/fj.03-0198com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656986				2022-12-25	WOS:000188067500045
J	Catto, JWF; Azzouzi, AR; Amira, N; Rehman, I; Feeley, KM; Cross, SS; Fromont, G; Sibony, M; Hamdy, FC; Cussenot, O; Meuth, M				Catto, JWF; Azzouzi, AR; Amira, N; Rehman, I; Feeley, KM; Cross, SS; Fromont, G; Sibony, M; Hamdy, FC; Cussenot, O; Meuth, M			Distinct patterns of microsatellite instability are seen in tumours of the urinary tract	ONCOGENE			English	Article						microsatellite instability; HNPCC; bladder cancer; upper urinary tract cancer	TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; TETRANUCLEOTIDE REPEATS; COLORECTAL-CANCER; YOUNG-PATIENTS; HMLH1; PHENOTYPES; EXPRESSION; MUTATIONS; COLON	To date, two forms of microsatellite instability (MSI) have been described in human cancer. MSI typical of hereditary nonpolyposis colon cancer (HNPCC), is due to deficient DNA mismatch repair (MMR) and is defined with mono- and dinucleotide repeat microsatellites. A second variety of instability is best seen at selective tetranucleotide repeats (EMAST; elevated microsatellite alterations at select tetranucleotides). While MSI occurs infrequently in bladder cancers, EMAST is common. Sporadic tumours with the largest proportion showing MSI are those found most frequently in HNPCC kindreds. While bladder cancer is not frequently seen in HNPCC, upper urinary tract tumours (UTTs) are. Having previously found a low frequency of MSI in bladder cancer, we sought to determine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower urinary tracts. Microsatellite analysis was performed at 10 mono- and dinucleotide and eight tetranucleotide loci, in 89 bladder and 71 UTT TCC. Contrasting patterns of instability were seen in urinary tumours. In bladder cancer, MSI was rare and EMAST was common. The presence of EMAST was not related to tumour grade, stage, subsequent outcome or immunohistochemical expression of the MMR proteins. In UTT, while MSI occurred frequently, EMAST was seen less frequently than in bladder cancer. When TCC of the upper and lower urinary tracts are compared, MSI-H is more frequent in UTT and EMAST more frequent in bladder cancer. Our findings show that, as for colorectal cancer, the pattern of MSI varies with location in the urinary tract. In addition, we have confirmed that MSI and EMAST are discrete forms of MSI, and that the presence of EMAST does not affect tumour phenotype.	Univ Sheffield, Inst Canc Studies, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Acad Urol Unit, Sheffield S10 2TN, S Yorkshire, England; Fac Med, Dept Urol, CeRePP EA3104, Paris, France; Royal Hallamshire Hosp, Dept Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Pathol Unit, Sheffield S10 2TN, S Yorkshire, England; Inst Mutualiste Montsouris, Serv Anatomopathol, Paris, France; Hop Tenon, Serv Anatomopathol, F-75970 Paris, France	University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Catto, JWF (corresponding author), Royal Hallamshire Hosp, Acad Urol Unit, I Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.		fromont, gaelle/N-8708-2016	catto, james/0000-0003-2787-8828; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754; cussenot, olivier/0000-0002-9912-0533				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahrendt SA, 2000, CANCER RES, V60, P2488; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Boland CR, 1998, CANCER RES, V58, P5248; Bonnal C, 2000, UROLOGY, V55, P287, DOI 10.1016/S0090-4295(99)00399-4; Catto JWF, 2003, INT J CANCER, V105, P484, DOI 10.1002/ijc.11109; Christensen M, 1998, INT J CANCER, V79, P396, DOI 10.1002/(SICI)1097-0215(19980821)79:4<396::AID-IJC15>3.0.CO;2-3; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Dietmaier W, 1997, CANCER RES, V57, P4749; Furihata M, 2000, INT J ONCOL, V16, P491; Furihata M, 2001, J UROLOGY, V165, P1760, DOI 10.1016/S0022-5347(05)66409-9; Gleeson CM, 1996, CANCER RES, V56, P259; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Hartmann A, 2002, CANCER RES, V62, P6796; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; Li MM, 1996, AM J PATHOL, V149, P229; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Ottini L, 1997, CANCER RES, V57, P4523; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Slebos RJC, 2002, CANCER RES, V62, P6052; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Xu LH, 2001, INT J CANCER, V91, P200, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1031>3.0.CO;2-0	28	106	107	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8699	8706		10.1038/sj.onc.1206964	http://dx.doi.org/10.1038/sj.onc.1206964			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647464	Bronze			2022-12-25	WOS:000186844900007
J	Denkert, C; Furstenberg, A; Daniel, PT; Koch, I; Kobel, M; Weichert, W; Siegert, A; Hauptmann, S				Denkert, C; Furstenberg, A; Daniel, PT; Koch, I; Kobel, M; Weichert, W; Siegert, A; Hauptmann, S			Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference	ONCOGENE			English	Article						cyclooxygenase; ovarian carcinoma; NS-398; RNA interference	COLON-CANCER CELLS; CULTURED-MAMMALIAN-CELLS; CYCLOOXYGENASE-2 EXPRESSION; CHEMOTHERAPY RESISTANCE; PROGNOSTIC-SIGNIFICANCE; GROWTH-INHIBITION; BREAST-CANCER; UP-REGULATION; COX-2; APOPTOSIS	Cyclooxygenases, particularly COX-2, play an important role in tumor development and progression. We have previously shown that COX-2 expression is an independent prognostic factor in human ovarian carcinoma. In this study, we investigated the effects of the inhibition of COX isoforms by the NSAID NS-398 as well as by COX-isoform-specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1 and an induction of high levels of COX-2 and PGE(2) after stimulation with interleukin-1beta. In contrast, SKOV-3 cells were negative for both COX isoforms. In OVCAR-3 cells, PGE(2) production was inhibited by NS-398 in concentrations of 1 muM and by a COX-2-specific silencing RNA ( siRNA), while a COX-1-specific siRNA did not have an effect. This suggests that COX-2 is the major source of PGE(2) in this cell line. To dissociate COX-2-specific and non-COX-2-specific effects on cell proliferation, a proliferation assay was performed after incubation of cells with NS-398 and COX siRNAs. NS-398 induced an inhibition of cell proliferation at concentrations of 50-500 muM, which are above the concentrations needed for the inhibition of PGE(2) production. This inhibitory effect was present in the COX-positive cell line OVCAR-3 as well as in the COX-negative cell line SKOV-3 and could not be reverted by addition of exogenous PGE(2). Neither COX-1- nor COX-2-specific siRNAs had an effect on cell proliferation of OVCAR-3 cells. Cell cycle analysis showed an increased accumulation of cells in the G0/G1 phase after treatment with NS-398, but not with COX siRNAs. These experiments suggest that NS-398 reduced cell proliferation in ovarian carcinoma cells by induction of G0/G1 cell cycle arrest independent of COX-2 inhibition. Our study shows that specific inhibition of COX isoforms by RNAi could be used to dissociate effects of NSAIDs. Furthermore, our results suggest that cell cycle arrest is one of the primary mechanisms responsible for the antiproliferative effects of NS-398 on ovarian carcinoma cells.	Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Halle Wittenberg, Inst Pathol, Halle Saale, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Martin Luther University Halle Wittenberg	Denkert, C (corresponding author), Humboldt Univ, Charite Hosp, Inst Pathol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.		Köbel, Martin/A-7373-2011; Denkert, Carsten/AHE-2675-2022	Denkert, Carsten/0000-0002-2249-0982; Kobel, Martin/0000-0002-6615-2037				Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973; Ferrandina G, 2002, ANN ONCOL, V13, P1205, DOI 10.1093/annonc/mdf207; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; Goldberg Y, 1996, ONCOGENE, V12, P893; HAMILTON TC, 1983, CANCER RES, V43, P5379; Harborth J, 2001, J CELL SCI, V114, P4557; Huang M, 1998, CANCER RES, V58, P1208; Hung WC, 2000, MOL PHARMACOL, V58, P1398, DOI 10.1124/mol.58.6.1398; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ristimaki A, 2002, CANCER RES, V62, P632; Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202; Shono T, 2001, CANCER RES, V61, P4375; THOMPSON HJ, 1995, J NATL CANCER I, V87, P1259; THUN MJ, 1994, CANCER METAST REV, V13, P269, DOI 10.1007/BF00666097; Toyoshima T, 2002, BRIT J CANCER, V86, P1150, DOI 10.1038/sj/bcj/6600183; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yip-Schneider MT, 2001, J PHARMACOL EXP THER, V298, P976; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C	31	85	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8653	8661		10.1038/sj.onc.1206920	http://dx.doi.org/10.1038/sj.onc.1206920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647459				2022-12-25	WOS:000186844900002
J	Mawji, IA; Robb, GB; Tai, SC; Marsden, PA				Mawji, IA; Robb, GB; Tai, SC; Marsden, PA			Role of the 3 '-untranslated region of human endothelin-1 in vascular endothelial cells - Contribution to transcript lability and the cellular heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; GATA-BINDING PROTEIN; AU-RICH ELEMENTS; GENE-EXPRESSION; SELECTIVE DEGRADATION; INDUCTION; SEQUENCE; APOPTOSIS; TURNOVER	Endothelin-1 (ET-1) is a potent vasoconstrictor peptide expressed in the vascular endothelium. Stringent control over ET-1 expression is achieved through a highly regulated promoter and rapid mRNA turnover. Since little is known about mechanisms governing ET-1 post-transcriptional regulation, and changes in ET-1 mRNA stability are implicated in disease processes, we characterized these pathways using a variety of functional approaches. We expressed human ET-1 and luciferase transcripts with or without a wild type ET-1 3'-untranslated region (3'-UTR) and found that the 3'-UTR had potent mRNA destabilizing activity. Deletion analysis localized this activity to two domains of the 3'-UTR we have termed destabilizing elements 1 and 2 (DE1 and DE2). Mutational studies revealed that DE1 functions as an AU-rich element (ARE) dependent on a 100-nucleotide region. This activity was further localized to a 10-nucleotide region at position 978 - 987 of the 3'-UTR. Depletion of AUF1 by RNA interference up-regulated ET-1 in endothelial cells suggesting AUF1-dependent regulation. Since AUF1 functions through the ubiquitin-proteasome pathway, we disrupted this pathway with heat shock and proteasome inhibitor in endothelial cells and observed stabilization of endogenous ET-1 mRNA. Chimeric transcripts bearing wild type ET-1 3'-UTRs were also stabilized in response to proteasome inhibition whereas DE1 mutants failed to respond. Taken together, these findings suggest a complex model of ARE-mediated mRNA turnover dependent on two 3'-UTR domains, DE1 and DE2. Furthermore, DE1 functions as an ARE directing mRNA half-life through the proteasome. Finally, this data provides evidence for a novel pathway of ET-1 mRNA stabilization by heat shock.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Marsden, Philip A/B-1441-2012	Robb, Gregory Brett/0000-0002-2382-2256				BERBERIAN PA, 1990, AM J PATHOL, V136, P71; Bitzan MM, 1998, J CLIN INVEST, V101, P372, DOI 10.1172/JCI522; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; Douthwaite JA, 2003, BIOCHEM PHARMACOL, V66, P589, DOI 10.1016/S0006-2952(03)00336-8; Gan LM, 2000, CARDIOVASC RES, V48, P168, DOI 10.1016/S0008-6363(00)00174-7; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; HORIE M, 1991, J CARDIOVASC PHARM, V17, pS222, DOI 10.1097/00005344-199100177-00064; INOUE A, 1989, J BIOL CHEM, V264, P14954; IWASAKI S, 1995, J BIOL CHEM, V270, P6997, DOI 10.1074/jbc.270.12.6997; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; KETIS NV, 1988, CANCER RES, V48, P2101; Knapp M, 1998, FEBS LETT, V434, P108, DOI 10.1016/S0014-5793(98)00961-2; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; LEE ME, 1991, J BIOL CHEM, V266, P16188; Lee SD, 2000, PULM PHARMACOL THER, V13, P257, DOI 10.1006/pupt.2000.0252; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; Mawji IA, 2003, MICROSC RES TECHNIQ, V60, P46, DOI 10.1002/jemt.10242; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Moffat GJ, 1997, BIOCHEM J, V324, P91, DOI 10.1042/bj3240091; Moraes KCM, 2003, BIOL CHEM, V384, P25, DOI 10.1515/BC.2003.004; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Ochoa TJ, 2003, CURR OPIN INFECT DIS, V16, P259, DOI 10.1097/00001432-200306000-00013; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101; RAJAGOPALAN LE, 1995, BLOOD, V86, P2551; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; SCHEPER W, 1995, MOL CELL BIOL, V15, P235, DOI 10.1128/MCB.15.1.235; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Sonna LA, 2002, J APPL PHYSIOL, V92, P1725, DOI 10.1152/japplphysiol.01143.2001; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wong HR, 1996, AM J RESP CELL MOL, V15, P745, DOI 10.1165/ajrcmb.15.6.8969269; Wu-Wong JR, 1997, BIOCHEM J, V328, P733, DOI 10.1042/bj3280733; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhu WM, 1996, ARTERIOSCL THROM VAS, V16, P1104, DOI 10.1161/01.ATV.16.9.1104	71	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8655	8667		10.1074/jbc.M312190200	http://dx.doi.org/10.1074/jbc.M312190200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660616	hybrid			2022-12-25	WOS:000189265900018
J	Tan, BCM; Lee, SC				Tan, BCM; Lee, SC			Nek9, a novel FACT-associated protein, modulates interphase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTORS; DNA-POLYMERASE ALPHA; KINASE AURORA-A; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; POB3; COMPLEX; SPT16; INTERACTS; SSRP1	The heterodimeric Spt16-Pob3/DUF/FACT complex is a class of chromatin structure modulators with important roles in replication and transcription. Although regarded as a transcription elongator for chromatin template, little is known about the mode of action and involvement in other molecular processes of the mammalian FACT. Here we report the identification of a novel interacting and functional partner of FACT, Nek9. Nek9 forms a stable, similar to600-kDa complex with FACT in the interphase nuclei. Its active form is characterized by phosphorylation-dependent electrophoretic mobility shift and phosphorylation at a conserved residue within the activation loop (Thr(210)). When complexed with FACT, Nek9 exhibits markedly elevated phosphorylation on Thr(210). Cell cycle analysis on the Nek9(dsRNAi) cells directly implicated Nek9 in maintaining proper G(1) and S progression, a role temporally correlated to the formation of a phospho-Nek9-FACT complex. Collectively, these observations provide evidence that Nek9, potentially as an active enzymatic partner of FACT, mediates certain FACT-associated cellular processes, which are ultimately essential for interphase progression.	Natl Taiwan Univ, Coll Med, Sch Med, Inst Mol Med, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei 10018, Taiwan; Acad Sinica, Inst Biol Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Sch Med, Inst Mol Med, 7 Chung Shan S Rd, Taipei 10018, Taiwan.	slee@ccms.ntu.edu.tw		Tan, Bertrand/0000-0002-2218-7115				Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Evans DRH, 1998, GENETICS, V150, P1393; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2002, GENETICS, V162, P1557; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; John S, 2000, GENE DEV, V14, P1196; Kang SW, 2000, GENES CELLS, V5, P251, DOI 10.1046/j.1365-2443.2000.00323.x; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Schlesinger MB, 2000, GENETICS, V155, P1593; Seo H, 2003, BIOCHEM BIOPH RES CO, V303, P8, DOI 10.1016/S0006-291X(03)00307-3; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553	26	40	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9321	9330		10.1074/jbc.M311477200	http://dx.doi.org/10.1074/jbc.M311477200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660563	hybrid			2022-12-25	WOS:000189265900095
J	Cok, SJ; Acton, SJ; Sexton, AE; Morrison, AR				Cok, SJ; Acton, SJ; Sexton, AE; Morrison, AR			Identification of RNA-binding proteins in RAW 264.7 cells that recognize a lipopolysaccharide-responsive element in the 3-untranslated region of the murine cyclooxygenase-2 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH-ELEMENT; TNF-ALPHA; TYROSINE PHOSPHORYLATION; 3'-UNTRANSLATED REGION; GENOMIC ORGANIZATION; STABILITY; EXPRESSION; HUR; TRISTETRAPROLIN; MACROPHAGES	RAW 264.7 cells rapidly induce cyclooxygenase-2 (COX-2) in response to lipopolysaccharide treatment. Part of the increased COX-2 expression occurred through post-transcriptional mechanisms mediated through specific regions of the 3'-untranslated region (UTR) of the message. The proximal region of the 3'-UTR of COX-2 contains a highly conserved AU-rich element that was able to confer lipopolysaccharide regulation of a chimeric reporter-gene. Electrophoretic mobility shift assays demonstrated that the RNA-binding proteins TIAR, AUF1, HuR, and TIA-1 all form an RNA-protein complex with the first 60 nucleotides of the 3'-UTR of COX-2. Biotinylated RNA probes were used to isolate additional proteins that bind the 3'-UTR of COX-2. We identified several RNA-binding proteins including TIAR, AUF1, CBF-A, RBM3, heterogeneous nuclear ribonucleoprotein (hnRNP) A3, and hnRNP A2/B1. We identified four alternatively spliced isoforms of AUF1 which migrated at multiple isoelectric points. Likewise, we identified alternatively spliced isoforms of CBF-A, hnRNP A3, and hnRNP A2/B1. Western analysis of two-dimensional gels identified multiple isoforms of TIA-1, TIAR, and AUF1 at pI values that spanned nearly 3 pH units. Thus, through a combination of alternative splicing and post-translational modification cells are able to increase greatly the repertoire of protein species expressed at a given time or in response to extracellular stimuli.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Morrison, AR (corresponding author), Washington Univ, Sch Med, Dept Med, 4940 Parkview Pl,Wohl Clin,Rm 8843, St Louis, MO 63110 USA.	Morrison@pcg.wustl.edu			NIDDK NIH HHS [DK 59932] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baghdoyan S, 2000, BLOOD, V95, P3750; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; Danno S, 2000, AM J PATHOL, V156, P1685, DOI 10.1016/S0002-9440(10)65039-0; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Ma ASW, 2002, J BIOL CHEM, V277, P18010, DOI 10.1074/jbc.M200050200; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; PYPE S, 1994, J BIOL CHEM, V269, P31457; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Tebo J, 2003, J BIOL CHEM, V278, P12085, DOI 10.1074/jbc.M212992200; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	38	90	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8196	8205		10.1074/jbc.M308475200	http://dx.doi.org/10.1074/jbc.M308475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662769	hybrid			2022-12-25	WOS:000189103300101
J	Novi, F; Scarselli, M; Corsini, GU; Maggio, R				Novi, F; Scarselli, M; Corsini, GU; Maggio, R			The paired activation of the two components of the muscarinic M-3 receptor dimer is required for induction of ERK1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ARRESTIN; DOPAMINE; OLIGOMERIZATION; IDENTIFICATION	Muscarinic M-3 receptors stimulate ERK1/2, the mitogen-activated protein kinase pathway. A mutant of the muscarinic M-3 receptor in which most of the third intracellular (i3) loop had been deleted (M-3-short) completely lost the ability to stimulate the ERK1/2 phosphorylation in COS-7 cells. This loss was evident despite the fact that the receptor was able to couple efficiently to the phospholipase C second messenger pathway. In co-transfected cells, M-3-short greatly reduced the ability of M-3 to activate ERK1/2. In another set of experiments we tested the ability of a mutant M-3/M-2(16aa) receptor, in which the first 16 amino acids of the i3 loop of the M-3 receptor were replaced with the corresponding segment of the muscarinic M-2 receptor to stimulate ERK1/2 phosphorylation. This mutant is not coupled to Galpha(q), but it is weakly coupled to Galpha(i). Despite its coupling modification this receptor was able to stimulate ERK1/2 phosphorylation. Again, M-3-short greatly reduced the ability of M-3/M-2(16aa) to activate ERK1/2 in co-transfected cells. Similar results were obtained in stable-transfected Chinese hamster ovary (CHO) cells lines. In CHO M-3 cells carbachol induced a biphasic increase of ERK1/2 phosphorylation; a first increase at doses as low as 0.1 muM and a second increase starting from 10 muM. In CHO M-3-short and in double-transfected CHO M-3/M-3-short cells we observed only the lower doses increase of ERK1/2 phosphorylation; no further increase was observed up to 1 mM carbachol. This suggests that in double-transfected CHO cells M-3-short prevents the effect of the higher doses of carbachol on the M-3 receptor. In a final experiment we tested the ability of co-transfected chimeric alpha(2)/M-3 and M-3/alpha(2) receptors to activate the ERK1/2 pathway. When given alone, carbachol and, to a lesser extent, clonidine, stimulated the coupling of the co-transfected chimeric receptors to the phospholipase C second messenger pathway, but they were unable to stimulate ERK1/2 phosphorylation. On the contrary, a strong stimulation of ERK1/2 phosphorylation was observed when the two agonists were given together despite the fact that the overall increase in phosphatidylinositol hydrolysis was not dissimilar from that observed in cells treated with carbachol alone. Our data suggest that the activation of the ERK1/2 pathway requires the coincident activation of the two components of a receptor dimer.	Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy	University of Pisa	Maggio, R (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 55, I-56100 Pisa, Italy.	r.maggio@drugs.med.unipi.it	maggio, Roberto/Q-2032-2015	Scarselli, Marco/0000-0001-5087-3182; Maggio, Roberto/0000-0003-4436-2356				AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Budd DC, 2001, J BIOL CHEM, V276, P4581, DOI 10.1074/jbc.M008827200; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Shiina T, 2001, LIFE SCI, V68, P2251, DOI 10.1016/S0024-3205(01)01013-X; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WESS J, 1990, MOL PHARMACOL, V38, P517; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	29	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7476	7486		10.1074/jbc.M306818200	http://dx.doi.org/10.1074/jbc.M306818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660647	hybrid			2022-12-25	WOS:000189103300015
J	Gerard, A; Favre, C; Garcon, F; Nemorin, JG; Duplay, P; Pastor, S; Collette, Y; Olive, D; Nunes, JA				Gerard, A; Favre, C; Garcon, F; Nemorin, JG; Duplay, P; Pastor, S; Collette, Y; Olive, D; Nunes, JA			Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase	ONCOGENE			English	Article						Dok adaptor proteins; Tec tyrosine kinase; signal transduction; tumor suppressors; T cells	CHRONIC MYELOGENOUS LEUKEMIA; CELL ANTIGEN RECEPTOR; T-CELLS; P62(DOK); FAMILY; PHOSPHORYLATION; RECRUITMENT; ABL	The Dok adaptor family of proteins binding to RasGAP, consisting of Dok-1 and Dok-2, are critical regulators in cell proliferation. These molecules are partners and/or substrates of different protein tyrosine kinases considered as oncoproteins. Here, we show that Dok-1 and Dok-2 are the major tyrosine-phosphorylated proteins associated to Tec, a protein tyrosine kinase expressed in T cells. Furthermore, we evaluate the effect of Dok-1 or Dok-2 on Tec-mediated signalling pathways in T cells. Here, we provide evidence that Dok-1 and Dok-2 proteins are involved in a negative feedback regulation of Tec via a downregulation of its tyrosine phosphorylation and downstream signalling pathways including the Ras pathway. Either Dok-1 or Dok-2 therefore represents a mean of potent retrograde control for protein tyrosine kinase signalling, and then possibly of tumor development.	Univ Mediterranee, Inst Canc & Immunol Marseille, INSERM, U119, F-13009 Marseille, France; Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, Laval, PQ, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Quebec; Institut national de la recherche scientifique (INRS)	Nunes, JA (corresponding author), Univ Mediterranee, Inst Canc & Immunol Marseille, INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	nunes@marseille.inserm.fr	COLLETTE, Yves/F-2270-2013; NUNES, Jacques A/F-4952-2013	COLLETTE, Yves/0000-0001-5359-7099; NUNES, Jacques A/0000-0003-4865-0400				Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Gugasyan R, 2002, J CELL BIOL, V158, P115, DOI 10.1083/jcb.200112066; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Master Z, 2003, J BIOL CHEM, V278, P30170, DOI 10.1074/jbc.M301339200; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; van Dijk TB, 2000, BLOOD, V96, P3406; Yamanashi Y, 2000, GENE DEV, V14, P11; Yang WC, 2000, INT IMMUNOL, V12, P1547, DOI 10.1093/intimm/12.11.1547; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	23	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1594	1598		10.1038/sj.onc.1207283	http://dx.doi.org/10.1038/sj.onc.1207283			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647425				2022-12-25	WOS:000189219500013
J	Boue-Grabot, E; Emerit, MB; Toulme, E; Seguela, P; Garret, M				Boue-Grabot, E; Emerit, MB; Toulme, E; Seguela, P; Garret, M			Cross-talk and co-trafficking between rho 1/GABA receptors and ATP-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GABA(C) RECEPTOR; RHO-SUBUNITS; IMMUNOCYTOCHEMICAL LOCALIZATION; P2X RECEPTORS; ION CHANNELS; RAT; NEURONS; EXPRESSION; SYNAPSES	gamma-Aminobutyric-acid (GABA) and ATP ionotropic receptors represent two structurally and functionally different classes of neurotransmitter-gated channels involved in fast synaptic transmission. We demonstrate here that, when the inhibitory rho1/GABA and the excitatory P2X(2) receptor channels are co-expressed in Xenopus oocytes, activation of one channel reduces the currents mediated by the other one. This reciprocal inhibitory cross-talk is a receptor-mediated phenomenon independent of agonist cross-modulation, membrane potential, direction of ionic flux, or channel densities. Functional interaction is disrupted when the cytoplasmic C-terminal domain of P2X(2) is deleted or in competition experiments with minigenes coding for the C-terminal domain of P2X(2) or the main intracellular loop of rho1 subunits. We also show a physical interaction between P2X(2) and rho1 receptors expressed in oocytes and the co-clustering of these receptors in transfected hippocampal neurons. Co-expression with P2X(2) induces retargeting and recruitment of mainly intracellular rho1/ GABA receptors to surface clusters. Therefore, molecular and functional cross-talk between inhibitory and excitatory ligand-gated channels may regulate synaptic strength both by activity-dependent current occlusion and synaptic receptors co-trafficking.	Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France; Hop La Pitie Salpetriere, INSERM, U288, F-75013 Paris, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; McGill University	Boue-Grabot, E (corresponding author), Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France.	eric.boue-grabot@umr5543.u-bordeaux2.fr	Boué-Grabot, Eric/AAQ-2061-2020	Boué-Grabot, Eric/0000-0003-2187-9037				Barajas-Lopez C, 1998, J PHYSIOL-LONDON, V513, P671, DOI 10.1111/j.1469-7793.1998.671ba.x; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Bormann J, 2000, TRENDS PHARMACOL SCI, V21, P16, DOI 10.1016/S0165-6147(99)01413-3; Boue-Grabot E, 2000, ENDOCRINOLOGY, V141, P1627, DOI 10.1210/en.141.5.1627; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; Boue-Grabot E, 1998, J NEUROCHEM, V70, P899; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1998, MOL BRAIN RES, V59, P269, DOI 10.1016/S0169-328X(98)00159-4; Cheng Q, 2001, J NEUROPHYSIOL, V86, P2605, DOI 10.1152/jn.2001.86.5.2605; Dutton JL, 2000, NEUROPHARMACOLOGY, V39, P2054, DOI 10.1016/S0028-3908(00)00058-7; Enz R, 1996, J NEUROSCI, V16, P4479; Gendreau S, 2003, J CHROMATOGR B, V786, P311, DOI 10.1016/S1570-0232(02)00743-2; Giustetto M, 1998, J COMP NEUROL, V395, P231, DOI 10.1002/(SICI)1096-9861(19980601)395:2<231::AID-CNE7>3.0.CO;2-3; Goslin K., 1998, CULTURING NERVE CELL, P339; Hanley JG, 1999, NATURE, V397, P66, DOI 10.1038/16258; Jo YH, 2002, J NEUROSCI, V22, P4794, DOI 10.1523/JNEUROSCI.22-12-04794.2002; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Knuesel I, 1999, EUR J NEUROSCI, V11, P4457, DOI 10.1046/j.1460-9568.1999.00887.x; Koulen P, 1997, J COMP NEUROL, V380, P520, DOI 10.1002/(SICI)1096-9861(19970421)380:4<520::AID-CNE8>3.0.CO;2-3; Koulen P, 1998, EUR J NEUROSCI, V10, P115, DOI 10.1046/j.1460-9568.1998.00005.x; Le KT, 1999, J BIOL CHEM, V274, P15415, DOI 10.1074/jbc.274.22.15415; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Li GH, 2000, J BIOL CHEM, V275, P29107, DOI 10.1074/jbc.M910277199; Li Y, 2003, J BIOL CHEM, V278, P38637, DOI 10.1074/jbc.M303735200; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pan ZH, 2000, EUR J NEUROSCI, V12, P3137, DOI 10.1046/j.1460-9568.2000.00198.x; Qian HH, 1999, P ROY SOC B-BIOL SCI, V266, P2419, DOI 10.1098/rspb.1999.0941; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Searl TJ, 1998, J PHYSIOL-LONDON, V510, P783, DOI 10.1111/j.1469-7793.1998.783bj.x; Sokolova E, 2001, J NEUROSCI, V21, P4958, DOI 10.1523/JNEUROSCI.21-14-04958.2001; Stojilkovic SS, 2000, BIOCHEM CELL BIOL, V78, P393, DOI 10.1139/bcb-78-3-393; Vulchanova L, 1997, NEUROPHARMACOLOGY, V36, P1229, DOI 10.1016/S0028-3908(97)00126-3; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wegelius K, 1998, EUR J NEUROSCI, V10, P350, DOI 10.1046/j.1460-9568.1998.00023.x; WHEELERSCHILLIN.TH, 2002, BRAIN RES MOL BRAIN, V76, P415; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; Zheng W, 2003, J BIOL CHEM, V278, P48321, DOI 10.1074/jbc.M307930200; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	48	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6967	6975		10.1074/jbc.M307772200	http://dx.doi.org/10.1074/jbc.M307772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660627	hybrid			2022-12-25	WOS:000188969200092
J	Brunson, LE; Dixon, C; Kozubowski, L; Mathias, N				Brunson, LE; Dixon, C; Kozubowski, L; Mathias, N			The amino-terminal portion of the F-box protein Met30p mediates its nuclear import and assimilation into an SCF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; YEAST; DEGRADATION; PROTEOLYSIS; CDC4P; MET4; DESTRUCTION; INHIBITOR	SCF complexes are a conserved family of ubiquitin ligases composed of a common core of components and a variable component called an F-box protein that defines substrate specificity. The F-box motif links the F-box protein to the core components via its interaction with Skp1p. In yeast, the SCFMet30p complex contains the Met30p F-box protein and regulates Met4p, a transcription factor that mediates sulfur fixation and methionine biosynthesis. Although a nuclear protein, Met30p lacks a definable nuclear localization sequence. Here we show that the entire amino-terminal half of Met30p is required for its proper nuclear localization. Mutations in the F-box, but not mutations in Skp1p, affect Met30p nuclear localization, indicating that the F-box motif plays an important role in Met30p trafficking independent of its interaction with Skp1p binding. Met30p mutants that poorly localize to the nucleus display increased nuclear to cytoplasmic exchange, indicating that the amino terminus mediates nuclear retention in addition to nuclear import. The Met30p F-box motif, residues 180-225, is necessary and sufficient to bind Skp1p; however, mutations upstream of the Met30p F-box inhibit Skp1p binding. We propose that additional factors bind the amino-terminal region of Met30p and mediate its nuclear localization and assimilation into an SCF complex.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Mathias, N (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	pmathi@lsuhsc.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dixon C, 2003, EUKARYOT CELL, V2, P123, DOI 10.1128/EC.2.1.123-133.2003; Elbe R, 1992, BIOTECHNIQUES, V13, P18; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; James P, 1996, GENETICS, V144, P1425; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rose MD., 1990, METHODS YEAST GENETI; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	32	7	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6674	6682		10.1074/jbc.M308875200	http://dx.doi.org/10.1074/jbc.M308875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660673	hybrid			2022-12-25	WOS:000188969200058
J	Demozay, D; Rocchi, S; Mas, JC; Grillo, S; Pirola, L; Chavey, C; Van Obberghen, E				Demozay, D; Rocchi, S; Mas, JC; Grillo, S; Pirola, L; Chavey, C; Van Obberghen, E			Fatty aldehyde dehydrogenase - Potential role in oxidative stress protection and regulation of its gene expression by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE EXPRESSION; PROTEIN-KINASE B/AKT; PHOSPHATIDYLINOSITOL 3-KINASE; LIPID-PEROXIDATION; SIGNALING PATHWAY; LEPTIN RECEPTOR; SKELETAL-MUSCLE; IN-VIVO; BINDING; ACTIVATION	Phosphatidylinositol 3-kinase signaling regulates the expression of several genes involved in lipid and glucose homeostasis; deregulation of these genes may contribute to insulin resistance and progression toward type 2 diabetes. By employing RNA arbitrarily primed-PCR to search for novel phosphatidylinositol 3-kinase-regulated genes in response to insulin in isolated rat adipocytes, we identified fatty aldehyde dehydrogenase (FALDH), a key component of the detoxification pathway of aldehydes arising from lipid peroxidation events. Among these latter events are oxidative stresses associated with insulin resistance and diabetes. Upon insulin injection, FALDH mRNA expression increased in rat liver and white adipose tissue and was impaired in two models of insulin-resistant mice, db/db and high fat diet mice. FALDH mRNA levels were 4-fold decreased in streptozotocin-treated rats, suggesting that FALDH deregulation occurs both in hyperinsulinemic insulin-resistant state and hypoinsulinemic type 1 diabetes models. Moreover, insulin treatment increases FALDH activity in hepatocytes, and expression of FALDH was augmented during adipocyte differentiation. Considering the detoxifying role of FALDH, its deregulation in insulin-resistant and type 1 diabetic models may contribute to the lipid-derived oxidative stress. To assess the role of FALDH in the detoxification of oxidized lipid species, we evaluated the production of reactive oxygen species in normal versus FALDH-overexpressing adipocytes. Ectopic expression of FALDH significantly decreased reactive oxygen species production in cells treated by 4-hydroxynonenal, the major lipid peroxidation product, suggesting that FALDH protects against oxidative stress associated with lipid peroxidation. Taken together, our observations illustrate the importance of FALDH in insulin action and its deregulation in states associated with altered insulin signaling.	INSERM, U145, Fac Med, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Rocchi, S (corresponding author), INSERM, U145, Fac Med, IFR 50,Ave Valombrose, F-06107 Nice 2, France.	srocchi@unice.fr	Rocchi, Stephane/O-4152-2016; Pirola, Luciano/I-5250-2018	Rocchi, Stephane/0000-0002-0943-1304; Pirola, Luciano/0000-0001-6539-5435; Chavey, Carine/0000-0002-5267-5638				Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Andreelli F, 1999, DIABETOLOGIA, V42, P358, DOI 10.1007/s001250051163; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Brown MS, 1998, NUTR REV, V56, pS1; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; FEHLMANN M, 1979, J BIOL CHEM, V254, P431; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; HAUGUELDEMOUZON S, 1993, ENDOCRINOLOGY, V132, P67, DOI 10.1210/en.132.1.67; JUNOD A, 1969, J CLIN INVEST, V48, P2129, DOI 10.1172/JCI106180; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Laville M, 1996, J CLIN INVEST, V98, P43, DOI 10.1172/JCI118775; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Maziere C, 2003, FREE RADICAL BIO MED, V34, P629, DOI 10.1016/S0891-5849(02)01329-1; MITCHELL DY, 1989, ARCH BIOCHEM BIOPHYS, V269, P11, DOI 10.1016/0003-9861(89)90081-7; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MORIN O, 1982, MOL CELL ENDOCRINOL, V25, P339, DOI 10.1016/0303-7207(82)90089-2; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Rizzo WB, 2001, CHEM-BIOL INTERACT, V130, P297, DOI 10.1016/S0009-2797(00)00273-8; Roques M, 1999, J BIOL CHEM, V274, P34005, DOI 10.1074/jbc.274.48.34005; Rosen P, 2001, DIABETES-METAB RES, V17, P189, DOI 10.1002/dmrr.196; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Townsend AJ, 2001, CHEM-BIOL INTERACT, V130, P261, DOI 10.1016/S0009-2797(00)00270-2; Traverso N, 2002, FREE RADICAL BIO MED, V32, P350, DOI 10.1016/S0891-5849(01)00811-5; Traverso N, 1999, FREE RADICAL BIO MED, V26, P538, DOI 10.1016/S0891-5849(98)00238-X; Valverde AM, 1999, BIOCHEM J, V337, P397, DOI 10.1042/0264-6021:3370397; Van Obberghen E, 2001, EUR J CLIN INVEST, V31, P966, DOI 10.1046/j.1365-2362.2001.00896.x; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X; Yang YS, 2003, ACTA BIOCHIM POL, V50, P319; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x	51	69	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6261	6270		10.1074/jbc.M312062200	http://dx.doi.org/10.1074/jbc.M312062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638678	hybrid			2022-12-25	WOS:000188969200010
J	Noel, AJ; Wende, W; Pingoud, A				Noel, AJ; Wende, W; Pingoud, A			DNA recognition by the homing endonuclease PI-SceI involves a divalent metal ion cofactor-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CRYSTAL-STRUCTURE; AFFINITY CLEAVAGE; RESTRICTION; BINDING; IDENTIFICATION; KINETICS; COMPLEX; SITE	PI-SceI, a homing endonuclease of the IAGLIDADG family, consists of two domains involved in DNA cleavage and protein splicing, respectively. Both domains cooperate in binding the recognition sequence. Comparison of the structures of PI-SceI in the absence and presence of substrate reveals major conformational changes in both the protein and DNA. Notably, in the protein-splicing domain the loop comprising residues 53-70 and adopts a "closed" conformation, thus enabling it to interact with the DNA. We have studied the dynamics of DNA binding and subsequent loop movement by fluorescence techniques. Six amino acids in loop53-70 were individually replaced by cysteine and modified by fluorescein. The interaction of the modified PI-SceI variants with the substrate, unlabeled or labeled with tetramethylrhodamine, was analyzed in equilibrium and stopped-flow experiments. A kinetic scheme was established describing the interaction between PI-SceI and DNA. It is noteworthy that the apparent hinge-flap motion of loop53-70 is only observed in the presence of a divalent metal ion cofactor. Substitution of the major Mg2+-binding ligands in PI-SceI, Asp-218 and Asp-326, by Asn or "nicking" PI-SceI with trypsin at Arg-277, which interferes with formation of an active enzyme-substrate complex, both prevent the conformational change of loop53-70. Deletion of the loop inactivates the enzyme. We conclude that loop53-70 is an important structural element that couples DNA recognition by the splicing domain with DNA cleavage by the catalytic domain and as such "communicates" with the Mg2+ binding sites at the catalytic centers.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen	Pingoud, A (corresponding author), Univ Giessen, Inst Biochem, D-35392 Giessen, Germany.	Alfred.M.Pingoud@chemie.bio.uni-giessen.de	Wende, Wolfgang/F-6127-2014	Wende, Wolfgang/0000-0001-6577-9535				ALVES J, 1989, BIOCHEMISTRY-US, V28, P7879, DOI 10.1021/bi00445a050; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BREMER MCD, 1992, NUCLEIC ACIDS RES, V20, P5484, DOI 10.1093/nar/20.20.5484; Chevalier B, 2003, J MOL BIOL, V329, P253, DOI 10.1016/S0022-2836(03)00447-9; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; Christ F, 2000, J MOL BIOL, V300, P867; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Conlan LH, 2002, BIOCHEMISTRY-US, V41, P14848, DOI 10.1021/bi026403o; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Erskine SG, 1997, BIOCHEMISTRY-US, V36, P7567, DOI 10.1021/bi970155s; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; Grindl W, 1998, NUCLEIC ACIDS RES, V26, P1857, DOI 10.1093/nar/26.8.1857; HENSLEY P, 1990, J BIOL CHEM, V265, P15300; Hu DL, 1999, BIOCHEMISTRY-US, V38, P12621, DOI 10.1021/bi991192h; Hu DL, 2000, J BIOL CHEM, V275, P2705, DOI 10.1074/jbc.275.4.2705; JENJACOBSON L, 1986, CELL, V45, P619, DOI 10.1016/0092-8674(86)90294-1; Jurica MS, 1999, CELL MOL LIFE SCI, V55, P1304, DOI 10.1007/s000180050372; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Marras SAE, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf121; Moure CM, 2002, NAT STRUCT BIOL, V9, P764, DOI 10.1038/nsb840; Perona JJ, 1997, J MOL BIOL, V273, P207, DOI 10.1006/jmbi.1997.1315; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud V, 1998, BIOCHEMISTRY-US, V37, P8233, DOI 10.1021/bi980013d; Pingoud V, 1999, J BIOL CHEM, V274, P10235, DOI 10.1074/jbc.274.15.10235; Posey KL, 2002, BIOCHEMISTRY-US, V41, P2184, DOI 10.1021/bi015944v; Schottler S, 2000, BIOCHEMISTRY-US, V39, P15895, DOI 10.1021/bi001775n; Silva GH, 1999, J MOL BIOL, V286, P1123, DOI 10.1006/jmbi.1998.2519; STEUER S, 2003, IN PRESS CHEMBIOCHEM; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; Wende W., 2000, Molekulyarnaya Biologiya (Moscow), V34, P1054; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	36	7	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6794	6804		10.1074/jbc.M311372200	http://dx.doi.org/10.1074/jbc.M311372200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14634013	hybrid			2022-12-25	WOS:000188969200073
J	Jones, MR; Ravid, K				Jones, MR; Ravid, K			Vascular smooth muscle polyploidization as a biomarker for aging and its impact on differential gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL HYPERTROPHY; RAT; METHYLATION; HYPERPLOIDY; HEPATOCYTES; DEFICIENCY; ACTIVATION; PROTEIN; ARREST; NUCLEI	Polyploidy is characterized by a greater than diploid content of DNA in a cell. Previous measurements of ploidy level in different organs of humans and rodents, including the aorta, indicated an increase in old versus young. We hypothesized that aortic vascular smooth muscle polyploidy is a biomarker for aging and that the augmented DNA dosage affects selective gene-specific transcript expression. Our results demonstrate that tetraploidy increases exponentially over the life span of the animal, serving as an indicator of age. Approximately 60% of the vascular smooth muscle cells in the thoracic aorta of 36-month-old Brown Norway rats are tetraploid compared with 8% in their 3-month-old counterparts. Microarray analysis and reverse transcriptase-PCR was performed with mRNA isolated from sorted diploid (2N) and tetraploid (4N) vascular smooth muscle cells from old rats to identify differentially expressed transcripts. For the majority of detectable transcripts, an increase in DNA content led to a proportional increase in mRNA. A select group of transcripts, however, were reduced in tetraploid compared with diploid cells. These mRNAs correspond to guanine deaminase, to the matrix proteins rat glypican 3 (OCI-5) and decorin, as well as to the inflammation-associated transcripts, insulin-like growth factor-binding protein 6, macrophage inflammatory protein 2 precursor, macrophage galactose N-acetylgalactoseamine-specific lectin, and complement component C4. Our study is the first to describe aortic ploidy level as a biomarker for aging and to indicate that changes associated with increased DNA content per cell may selectively suppress the expression of specific genes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Ravid, K (corresponding author), Boston Univ, Sch Med, Dept Biochem, K225, Boston, MA 02118 USA.	ravid@biochem.bumc.bu.edu		Jones, Matthew/0000-0003-4647-2962; Ravid, Katya/0000-0002-9918-3024	NATIONAL INSTITUTE ON AGING [R03AG022623] Funding Source: NIH RePORTER; NIA NIH HHS [AG022623] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Assadnia S, 1999, CIRC RES, V84, P1252, DOI 10.1161/01.RES.84.11.1252; BARRETT TB, 1983, P NATL ACAD SCI-BIOL, V80, P882, DOI 10.1073/pnas.80.3.882; BOHN RC, 1976, J NEUROBIOL, V7, P255, DOI 10.1002/neu.480070308; Borrego F, 2002, MOL IMMUNOL, V38, P637, DOI 10.1016/S0161-5890(01)00107-9; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRODSKY VY, 1994, VIRCHOWS ARCH, V424, P429; CAPDEVILLE M, 1989, BLOOD VESSELS, V26, P197; DAMAS J, 1980, EXPERIENTIA, V36, P586, DOI 10.1007/BF01965817; Denton CP, 2003, J BIOL CHEM, V278, P25109, DOI 10.1074/jbc.M300636200; DEVLIN AM, 1995, J HYPERTENS, V13, P211; Dozmorov I, 2002, J GERONTOL A-BIOL, V57, pB99, DOI 10.1093/gerona/57.3.B99; Driscoll KE, 2000, TOXICOL LETT, V112, P177, DOI 10.1016/S0378-4274(99)00282-9; ENESCO HE, 1991, MECH AGEING DEV, V59, P69, DOI 10.1016/0047-6374(91)90074-A; Fattori R, 2003, LANCET, V361, P247, DOI 10.1016/S0140-6736(03)12275-1; Fischer MB, 1996, J IMMUNOL, V157, P549; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Hixon ML, 2000, J BIOL CHEM, V275, P40434, DOI 10.1074/jbc.M005059200; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jiang CH, 2001, P NATL ACAD SCI USA, V98, P1930, DOI 10.1073/pnas.98.4.1930; Lee HS, 2001, P NATL ACAD SCI USA, V98, P6753, DOI 10.1073/pnas.121064698; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Matturri L, 1997, Cardiologia, V42, P833; Matturri L, 2001, ATHEROSCLEROSIS, V154, P755, DOI 10.1016/S0021-9150(00)00488-3; Miller RA, 2000, J GERONTOL A-BIOL, V55, pB117, DOI 10.1093/gerona/55.3.B117; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52; Mizuno Y, 2002, BIOCHEM BIOPH RES CO, V290, P1499, DOI 10.1006/bbrc.2002.6370; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; Onami TM, 2002, MOL CELL BIOL, V22, P5173, DOI 10.1128/MCB.22.14.5173-5181.2002; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; SCHWARZE PE, 1984, CARCINOGENESIS, V5, P1267, DOI 10.1093/carcin/5.10.1267; SIGAL SH, 1995, DIFFERENTIATION, V59, P35, DOI 10.1046/j.1432-0436.1995.5910035.x; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Sprott RL, 1997, EXP GERONTOL, V32, P205, DOI 10.1016/S0531-5565(96)00065-4; TATE EH, 1983, CYTOMETRY, V4, P211, DOI 10.1002/cyto.990040304; Tung WS, 2001, J VASC SURG, V34, P143, DOI 10.1067/mva.2001.113310; WEINDRUCH R, 1991, J GERONTOL, V46, pB87, DOI 10.1093/geronj/46.3.B87; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X	47	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5306	5313		10.1074/jbc.M308406200	http://dx.doi.org/10.1074/jbc.M308406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634004	hybrid			2022-12-25	WOS:000188776500034
J	Meng, XB; Yuan, Y; Maestas, A; Shen, ZY				Meng, XB; Yuan, Y; Maestas, A; Shen, ZY			Recovery from DNA damage-induced G(2) arrest requires actin-binding protein filamin-A/actin-binding protein 280	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CHK1; CELL-CYCLE ARREST; MITOTIC CATASTROPHE; MORPHOGENESIS CHECKPOINT; TUMOR-CELLS; ATAXIA-TELANGIECTASIA; ANDROGEN RECEPTOR; FISSION YEAST; PHOSPHORYLATION; APOPTOSIS	Filamin-A (filamin-1) is an actin-binding protein involved in the organization of actin networks. Our previous study shows that filamin-A interacts with BRCA2, and lack of filamin-A expression results in increased cellular sensitivity to several DNA damaging agents in melanoma cells (Yuan, Y., and Shen, Z. (2001) J. Biol. Chem. 276, 48318-48324), suggesting a role of filamin-A in DNA damage response. In this report, we demonstrated that deficiency of filamin-A results in an 8-h delay in the recovery from G(2) arrest in response to ionizing radiation. However, filamin-A deficiency does not affect the initial activation of the G(2)/M checkpoint. We also found that filamin-A deficiency results in sustained activation of Chk1 and Chk2 after irradiation. This in turn causes a delay in the dephosphorylation of phospho-Cdc2, which is inhibitory to the G(2)/M transition. In addition, filamin-A-deficient M2 cells undergo mitotic catastrophe-related nuclear fragmentation after they are released from the G(2) arrest. Together, these data suggest a functional role of filamin-A in the recovery from G(2) arrest and subsequent mitotic cell death after DNA damage.	1 Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico	Shen, ZY (corresponding author), 1 Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, MSC08 4660, Albuquerque, NM 87131 USA.	zshen@salud.unm.edu		meng, xiangbing/0000-0002-9612-6438; Shen, Zhiyuan/0000-0003-2834-0309	NIEHS NIH HHS [R01 ES08353] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Berry L D, 1996, Prog Cell Cycle Res, V2, P99; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; Ianzini F, 1997, INT J RADIAT BIOL, V72, P409, DOI 10.1080/095530097143185; Ianzini F, 1999, INT J RADIAT BIOL, V75, P717, DOI 10.1080/095530099140050; Jackson JR, 2000, CANCER RES, V60, P566; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu JH, 2000, J CELL SCI, V113, P1223; Liu QH, 2000, GENE DEV, V14, P1448; Lock RB, 1996, CANCER RES, V56, P4006; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Nakahata K, 2002, INT J HYPERTHER, V18, P332, DOI 10.1080/02656730210129736; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OConnor PM, 1997, CANCER SURV, V29, P151; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ross GM, 1999, ENDOCR-RELAT CANCER, V6, P41, DOI 10.1677/erc.0.0060041; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yu Q, 2002, CANCER RES, V62, P5743; Yuan Y, 2001, J BIOL CHEM, V276, P48318, DOI 10.1074/jbc.M102557200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6098	6105		10.1074/jbc.M306794200	http://dx.doi.org/10.1074/jbc.M306794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660646	hybrid			2022-12-25	WOS:000188776500125
J	Roher, AE; Kokjohn, TA; Esh, C; Weiss, N; Childress, J; Kalback, W; Luehrs, DC; Lopez, J; Brune, D; Kuo, YM; Farlow, M; Murrell, J; Vidal, R; Ghetti, B				Roher, AE; Kokjohn, TA; Esh, C; Weiss, N; Childress, J; Kalback, W; Luehrs, DC; Lopez, J; Brune, D; Kuo, YM; Farlow, M; Murrell, J; Vidal, R; Ghetti, B			The human amyloid-beta precursor protein(770) mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; TRANSGENIC MICE; CHEMICAL-CHARACTERIZATION; CLEAVAGE; DEPOSITION; PATHOLOGY; DISTINCT	One of the familial forms of Alzheimer's disease (AD) encodes the amyloid-beta precursor protein (AbetaPP) substitution mutation V717F. This mutation is relevant to AD research, since it has been utilized to generate transgenic mice models to study AD pathology and therapeutic interventions. Amyloid beta (Abeta) peptides were obtained from the cerebral tissue of three familial AD subjects carrying the AbetaPP V717F mutation. A combination of ultracentrifugation, size-exclusion, and reverse-phase high performance liquid chromatography, tryptic and cyanogen bromide hydrolysis, amino acid analysis, and matrix-assisted laser desorption ionization and surface-enhanced laser desorption ionization mass spectrometry was used to characterize the familial AD mutant Abeta peptides. The AbetaPP V717F mutation, located 4-6 residues beyond the wild-type AbetaPP gamma-secretase cleavage site, yielded longer Abeta peptides with C termini between residues 43 and 54. In the cerebral cortex these peptides aggregated into thin water- and SDS-insoluble amyloid bundles that condensed into flocculent spherical plaques. In the leptomeningeal arteries the amyloid was deposited in moderate amounts and was primarily composed of the shorter and more soluble Abeta species ending at residues 40, 42, and 44. The single V717F mutation in AbetaPP results in distinctive and drastic changes in the length and tertiary structure of Abeta peptides, which appear to be responsible for the earlier clinical manifestations of dementia and death of these patients.	Sun Hlth Res Inst, Longtine Ctr Mol Biol & Genet, Sun City, AZ 85351 USA; Midwestern Univ, Dept Microbiol, Glendale, AZ 85308 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Natl Cheng Kung Univ, Dept Cell Biol & Anat, Tainan 701, Taiwan; Indiana Alzheimer Dis Ctr, Indianapolis, IN 46202 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; Midwestern University; Arizona State University; Arizona State University-Tempe; National Cheng Kung University	Roher, AE (corresponding author), Sun Hlth Res Inst, Longtine Ctr Mol Biol & Genet, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA.	alex.roher@sunhealth.org	Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482	NIA NIH HHS [AG-10133, AG-17490, AG-19795, U24 AG021886] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133, U24AG021886, P01AG017490, R01AG019795] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; FARLOW M, 1994, NEUROLOGY, V44, P105, DOI 10.1212/WNL.44.1.105; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GHETTI B, 1992, BRAIN RES, V571, P133, DOI 10.1016/0006-8993(92)90519-F; GOWING E, 1994, J BIOL CHEM, V269, P10987; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Higaki J, 1996, J BIOL CHEM, V271, P31885, DOI 10.1074/jbc.271.50.31885; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; Kuo YM, 1997, BIOCHEM BIOPH RES CO, V237, P188, DOI 10.1006/bbrc.1997.7083; Kuo YM, 2000, AM J PATHOL, V156, P797, DOI 10.1016/S0002-9440(10)64947-4; Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Masliah E, 1996, J NEUROSCI, V16, P5795; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Mirra S. S., 2002, GREENFIELDS NEUROPAT, V2, P195; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shimizu T, 2000, ARCH BIOCHEM BIOPHYS, V381, P225, DOI 10.1006/abbi.2000.1955; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7	31	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5829	5836		10.1074/jbc.M311380200	http://dx.doi.org/10.1074/jbc.M311380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645225	hybrid			2022-12-25	WOS:000188776500097
J	Srinivasan, P; Abraham, EG; Ghosh, AK; Valenzuela, J; Ribeiro, JMC; Dimopoulos, G; Kafatos, FC; Adams, JH; Fujioka, H; Jacobs-Lorena, M				Srinivasan, P; Abraham, EG; Ghosh, AK; Valenzuela, J; Ribeiro, JMC; Dimopoulos, G; Kafatos, FC; Adams, JH; Fujioka, H; Jacobs-Lorena, M			Analysis of the Plasmodium and Anopheles transcriptomes during oocyst differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-BINDING-PROTEIN; CIRCUMSPOROZOITE PROTEIN; MALARIA PARASITE; GENOME SEQUENCE; MOSQUITO; FALCIPARUM; SPOROZOITE; GAMBIAE; IDENTIFICATION; EXPRESSION	Understanding the life cycle of the malaria parasite in its mosquito vector is essential for developing new strategies to combat this disease. Subtractive hybridization cDNA libraries were constructed that are enriched for Plasmodium berghei and Anopheles stephensi genes expressed during oocyst differentiation on the midgut. Sequencing of 1485 random clones led to the identification of 1137 unique expressed sequence tags. Of the 608 expressed sequence tags with data base hits, 320 ( 53%) had significant matches to the non- redundant protein data base, whereas 288 ( 47%) with matches only to genomic data bases represent novel Plasmodium and Anopheles genes. Transcription of six novel parasite genes and two previously identified asexual stage genes was up- regulated during oocyst differentiation. In addition, the mRNA for an Anopheles fibrinogen domain gene was induced on day 2 after an infectious blood meal, at the time of ookinete to oocyst differentiation. The subcellular distribution of MAEBL, a sporozoite surface protein, is developmentally regulated from presumed storage organelles in day 15 oocysts to uniform distribution on the surface in day 22 oocysts. This redistribution may reflect a sporozoite maturation program in preparation for salivary gland invasion. Furthermore, apical membrane antigen 1, another parasite surface molecule, is translationally regulated late in sporozoite development, suggesting a role during infection of the vertebrate host. The present results and those of an accompanying report ( Abraham, E. G., Islam, S., Srinivasan, P., Ghosh, A. K., Valenzuela, J., Ribeiro, J. M., Kafatos, F. C., Dimopoulos, G., & Jacobs- Lorena, M. ( 2003) J. Biol. Chem. 279, 5573 - 5580) provide the foundation for studies seeking to understand at the molecular level Plasmodium development and its interactions with the mosquito.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; NIAID, Med Entomol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); European Molecular Biology Laboratory (EMBL); University of Notre Dame	Jacobs-Lorena, M (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.	mlorena@jhsph.edu	Adams, John/G-1800-2015; Adams, John H./ABB-8458-2020	Adams, John/0000-0003-3707-7979; Adams, John H./0000-0003-3707-7979; Ribeiro, Jose/0000-0002-9107-0818; Dimopoulos, George/0000-0001-6755-8111	NIAID NIH HHS [R01 AI031478, R01 AI033656] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031478, R01AI033656, Z01AI000810] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; Al-Olayan EM, 2002, SCIENCE, V295, P677, DOI 10.1126/science.1067159; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; Breman JG, 2001, AM J TROP MED HYG, V64, P1; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Claudianos C, 2002, MOL MICROBIOL, V45, P1473, DOI 10.1046/j.1365-2958.2002.03118.x; deCastro FA, 1996, MOL BIOCHEM PARASIT, V80, P77, DOI 10.1016/0166-6851(96)02670-9; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Ghai M, 2002, MOL BIOCHEM PARASIT, V123, P35, DOI 10.1016/S0166-6851(02)00123-8; Ghosh A, 2000, PARASITOL TODAY, V16, P196, DOI 10.1016/S0169-4758(99)01626-9; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Kappe SHI, 1997, MOL BIOCHEM PARASIT, V89, P137, DOI 10.1016/S0166-6851(97)00113-8; Kappe SHI, 1998, P NATL ACAD SCI USA, V95, P1230, DOI 10.1073/pnas.95.3.1230; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; Kariu T, 2002, J EXP MED, V195, P1317, DOI 10.1084/jem.20011876; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000; Noe AR, 2000, MOL BIOCHEM PARASIT, V108, P169, DOI 10.1016/S0166-6851(00)00198-5; Rahlfs S, 2002, CELL MOL LIFE SCI, V59, P1024, DOI 10.1007/s00018-002-8484-9; Sinden Robert E., 1998, P25; Stowers AW, 2002, INFECT IMMUN, V70, P6961, DOI 10.1128/IAI.70.12.6961-6967.2002; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; Tsang JSH, 1999, J BACTERIOL, V181, P6003, DOI 10.1128/JB.181.19.6003-6009.1999; WARBURG A, 1992, EXP PARASITOL, V75, P303, DOI 10.1016/0014-4894(92)90215-V; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061	31	60	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5581	5587		10.1074/jbc.M307587200	http://dx.doi.org/10.1074/jbc.M307587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14627711	Green Accepted, hybrid			2022-12-25	WOS:000188776500067
J	Vega, A; Salas, A; Gamborino, E; Sobrido, MJ; Macaulay, V; Carracedo, A				Vega, A; Salas, A; Gamborino, E; Sobrido, MJ; Macaulay, V; Carracedo, A			MtDNA mutations in tumors of the central nervous system reflect the neutral evolution of mtDNA in populations	ONCOGENE			English	Article						mtDNA; CNS tumors; neutral evolution; instability; hotspots	MITOCHONDRIAL-DNA MUTATIONS; MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; CONTROL REGION; CANCER; CARCINOMA; GENOME; HETEROPLASMY; FREQUENCY; SEQUENCES	Mitochondrial DNA ( mtDNA) instability has been observed in different types of cancer, including colorectal, breast, and gastric cancer. The relationship between the occurrence of such alteration and the nuclear microsatellite instability (nMI) status of the neoplastic cells remains controversial. In an attempt to clarify this issue, we sequenced the first and second mtDNA hypervariable regions, and typed the mitochondrial ( CA)(n) dinucleotide polymorphism in 69 patients with primary tumors of the central nervous system (CNS), previously screened for nMI. Tumor samples showed 27 D-loop sequence changes (39.1%) compared to the corresponding blood samples. Microsatellite homoplasmic allele mutations were detected in four cases (5.8%). We did not find significant associations of the mtDNA instability status with clinicopathological parameters including sex, age, tumor size, and duration of clinical course. Neither did we find any association between mtDNA and nuclear instabilities, indicating that, at least in CNS tumors, they respond to different DNA repair mechanisms. We have also compiled the mtDNA instabilities previously reported by other authors for several types of tumors, comparing them to mtDNA polymorphisms in human populations. Most of the tumor-associated changes are common human polymorphisms and mutational hotspots. To explain the molecular behavior of mtDNA instability in tumors, we propose a model also common to other biological situations.	Univ Santiago de Compostela, Fac Med, Unidad Genet Forense, Galica, Spain; Univ Santiago de Compostela, Hosp Clin Univ, Unidad Mol Med, Galica, Spain; Univ Santiago de Compostela, Hosp Clin Univ, Serv Cirugia, Galica, Spain; Hosp San Rafael, La Coruna, Galica, Spain; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Univ Glasgow, Dept Stat, Glasgow, Lanark, Scotland	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; University of Oxford; University of Glasgow	Salas, A (corresponding author), Univ Santiago de Compostela, Fac Med, Unidad Genet Forense, Galica, Spain.	apimlase@usc.es	Salas, Antonio/E-3977-2012; Carracedo, Angel/D-4257-2012	Salas, Antonio/0000-0002-2336-702X; Carracedo, Angel/0000-0003-1085-8986				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; BANDELT HJ, 1995, GENETICS, V141, P743; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Bandelt HJ, 2002, AM J HUM GENET, V71, P1150, DOI 10.1086/344397; Bodenteich Angelika, 1992, Human Molecular Genetics, V1, P140, DOI 10.1093/hmg/1.2.140-a; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Forster L, 2002, P NATL ACAD SCI USA, V99, P13950, DOI 10.1073/pnas.202400499; GALL K, 1993, INT J EXP PATHOL, V74, P333; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; Kirches E, 1999, GENE CHROMOSOME CANC, V26, P80, DOI 10.1002/(SICI)1098-2264(199909)26:1<80::AID-GCC11>3.0.CO;2-4; Maca-Meyer N, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-13; Malyarchuk BA, 2002, HUM GENET, V111, P46, DOI 10.1007/s00439-002-0740-4; Maximo V, 2000, GASTROENTEROLOGY, V119, P1808, DOI 10.1016/S0016-5085(00)70044-8; Meyer S, 1999, GENETICS, V152, P1103; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Richards M, 2001, AM J HUM GENET, V68, P1315, DOI 10.1086/320615; RISINGER JI, 1993, CANCER RES, V53, P5100; Salas A, 2002, AM J HUM GENET, V71, P1082, DOI 10.1086/344348; Salas A, 2001, INT J LEGAL MED, V114, P186, DOI 10.1007/s004140000164; Sobrido MJ, 2000, J NEUROL NEUROSUR PS, V69, P369, DOI 10.1136/jnnp.69.3.369; Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TULLY G, 2003, UNPUB FORENSIC SCI I; Vega A, 2001, CANCER, V92, P2920, DOI 10.1002/1097-0142(20011201)92:11<2920::AID-CNCR10110>3.3.CO;2-J; YEE CJ, 1994, CANCER RES, V54, P1641	37	38	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1314	1320		10.1038/sj.onc.1207214	http://dx.doi.org/10.1038/sj.onc.1207214			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647457				2022-12-25	WOS:000188892200017
J	Walters, DK; Jelinek, DF				Walters, DK; Jelinek, DF			A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells	ONCOGENE			English	Article						Jak1; Tyk2; ErbB3; interferon-alpha; multiple myeloma	TYROSINE KINASE; BREAST-CANCER; MULTIPLE-MYELOMA; RECEPTOR; EXPRESSION; LEUKEMIA; OVEREXPRESSION; INTERLEUKIN-6; ACTIVATION; RESPONSES	Receptor crosstalk is an emerging and recurrent theme in cytokine and growth factor signaling; however, insight into the mechanism(s) underlying these interactions remains limited. Recently, we reported that crosstalk occurs between ErbB3 and the interferon alpha (IFN-alpha) signaling complex in the myeloma cell line KAS-6/1 and that this crosstalk contributes to the regulation of cell proliferation. In this study, we examined the mechanism underlying the transactivation of ErbB3 in the IFN-alpha growth-responsive KAS-6/1 cells. The examination of IFN-alpha receptor 1 and 2 (IFNAR1 and IFNAR2) levels revealed that the KAS-6/1 cell line overexpresses IFNAR1 relative to other myeloma cell lines that are growth arrested by IFN-alpha. Subsequent investigation of Tyk2, which is constitutively associated with IFNAR1, demonstrated that Tyk2 activation is uniquely sustained in the KAS-6/1 cell line following IFN-alpha stimulation. Interestingly, silencing of Tyk2 expression via siRNA resulted in attenuation of ErbB3 transactivation. However, inhibit ion of Jak1 expression also decreased IFN-alpha-induced tyrosine phosphorylation of ErbB3. Finally, siRNA downregulation of Tyk2 and Jak1 was found to decrease IFN-alpha-stimulated proliferation. These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Jelinek, DF (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	jelinek.diane@mayo.edu			NCI NIH HHS [CA62228, CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062228, R55CA062228, P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arora T, 1999, J IMMUNOL, V162, P3289; BLADE J, 1991, BRIT J HAEMATOL, V79, P523, DOI 10.1111/j.1365-2141.1991.tb08068.x; BOUNDY V, 2002, NEOPLASMA, V49, P349; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; BUHRING HJ, 1995, BLOOD, V86, P1916, DOI 10.1182/blood.V86.5.1916.bloodjournal8651916; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DiGiovanna MP, 2002, CANCER RES, V62, P6667; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Dumont JE, 2001, CELL SIGNAL, V13, P457, DOI 10.1016/S0898-6568(01)00168-1; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JELINEK DF, 2003, HEMATOL J, V4, pS37; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Kuhn DJ, 2003, J CELL BIOCHEM, V89, P824, DOI 10.1002/jcb.10557; Long IS, 2003, MOL CANCER RES, V1, P393; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; SAWAMURA M, 1992, BRIT J HAEMATOL, V82, P631, DOI 10.1111/j.1365-2141.1992.tb06484.x; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Walters DK, 2003, ONCOGENE, V22, P3598, DOI 10.1038/sj.onc.1206512; Walters DK, 2002, ANTISENSE NUCLEIC A, V12, P411, DOI 10.1089/108729002321082483; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	30	6	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1197	1205		10.1038/sj.onc.1207203	http://dx.doi.org/10.1038/sj.onc.1207203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647450				2022-12-25	WOS:000188892200003
J	Dawson, TR; Sansam, CL; Emeson, RB				Dawson, TR; Sansam, CL; Emeson, RB			Structure and sequence determinants required for the RNA editing of ADAR2 substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; ADENOSINE DEAMINASES; GLUR-B; UNWINDING ACTIVITY; PREFRONTAL CORTEX; IN-VITRO; RECEPTOR; BINDING; SITE; PURIFICATION	ADAR2 is a double-stranded RNA-specific adenosine deaminase involved in the editing of mammalian RNAs by the site-specific conversion of adenosine to inosine. We have demonstrated previously that ADAR2 can modify its own pre-mRNA, leading to the creation of a proximal 3'-splice junction containing a non-canonical adenosine-inosine (A-I) dinucleotide. Alternative splicing to this proximal acceptor shifts the reading frame of the mature mRNA transcript, resulting in the loss of functional ADAR2 expression. Both evolutionary sequence conservation and mutational analysis support the existence of an extended RNA duplex within the ADAR2 pre-mRNA formed by base-pairing interactions between regions similar to1.3-kilobases apart in intron 4 and exon 5. Characterization of ADAR2 pre-mRNA transcripts isolated from adult rat brain identified 16 editing sites within this duplex region, and sites preferentially modified by ADAR1 and ADAR2 have been defined using both tissue culture and in vitro editing systems. Statistical analysis of nucleotide sequences surrounding edited and non-edited adenosine residues have identified a nucleotide sequence bias correlating with ADAR2 site preference and editing efficiency. Among a mixed population of ADAR substrates, ADAR2 preferentially favors its own transcript, yet mutation of a poor substrate to conform to the defined nucleotide bias increases the ability of that substrate to be modified by ADAR2. These data suggest that both sequence and structural elements are required to define adenosine moieties targeted for specific ADAR2-mediated deamination.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Emeson, RB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 465 21st Ave S,8160 Med Res Bldg 3, Nashville, TN 37232 USA.	ron.emeson@vanderbilt.edu	Dawson, Toni/P-8599-2016	Sansam, Christopher/0000-0002-0545-2693; Emeson, Ronald/0000-0002-4585-1648	NINDS NIH HHS [NS33323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033323] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKBARIAN S, 1995, BRAIN RES, V699, P297, DOI 10.1016/0006-8993(95)00922-D; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; Beghini A, 2000, HUM MOL GENET, V9, P2297, DOI 10.1093/oxfordjournals.hmg.a018921; Bratt E, 2003, RNA, V9, P309, DOI 10.1261/rna.2750803; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; EMESON RB, 2000, RNA EDITING, P109; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; Gurevich I, 2002, NEURON, V34, P349, DOI 10.1016/S0896-6273(02)00660-8; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Holz B, 1999, J BIOL CHEM, V274, P15066, DOI 10.1074/jbc.274.21.15066; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hough RF, 1997, RNA, V3, P356; Kallman AM, 2003, NUCLEIC ACIDS RES, V31, P4874, DOI 10.1093/nar/gkg681; Klaue Y, 2003, RNA, V9, P839, DOI 10.1261/rna.2167603; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lehmann KA, 2000, BIOCHEMISTRY-US, V39, P12875, DOI 10.1021/bi001383g; Lehmann KA, 1999, J MOL BIOL, V291, P1, DOI 10.1006/jmbi.1999.2914; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 1999, P NATL ACAD SCI USA, V96, P6048, DOI 10.1073/pnas.96.11.6048; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; Niswender CM, 2001, NEUROPSYCHOPHARMACOL, V24, P478, DOI 10.1016/S0893-133X(00)00223-2; O'Connell MA, 1998, METHODS, V15, P51, DOI 10.1006/meth.1998.0605; OConnell MA, 1997, J BIOL CHEM, V272, P473; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Schaub M, 2002, BIOCHIMIE, V84, P791, DOI 10.1016/S0300-9084(02)01446-3; Slavov D, 2002, GENE, V299, P83, DOI 10.1016/S0378-1119(02)01016-8; Sodhi MS, 2001, MOL PSYCHIATR, V6, P373, DOI 10.1038/sj.mp.4000920; Stephens OM, 2000, BIOCHEMISTRY-US, V39, P12243, DOI 10.1021/bi0011577; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354; Yi-Brunozzi HY, 2001, J BIOL CHEM, V276, P37827; Yi-Brunozzi HY, 1999, NUCLEIC ACIDS RES, V27, P2912, DOI 10.1093/nar/27.14.2912; Zuker M, 1994, Methods Mol Biol, V25, P267; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	63	82	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4941	4951		10.1074/jbc.M310068200	http://dx.doi.org/10.1074/jbc.M310068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14660658	hybrid, Green Submitted			2022-12-25	WOS:000188554300120
J	Tanaka, M; Kim, YM; Lee, G; Junn, E; Iwatsubo, T; Mouradian, MM				Tanaka, M; Kim, YM; Lee, G; Junn, E; Iwatsubo, T; Mouradian, MM			Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; SPORADIC PARKINSONS-DISEASE; INCLUSION-BODY FORMATION; CORTICAL LEWY BODIES; NEURODEGENERATIVE DISORDERS; RETROGRADE TRANSPORT; DROSOPHILA MODEL; TRANSGENIC MICE; WILD-TYPE; DEGRADATION	Lewy bodies (LBs), which are the hallmark pathologic features of Parkinson's disease and of dementia with LBs, have several morphologic and molecular similarities to aggresomes. Whether such cytoplasmic inclusions contribute to neuronal death or protect cells from the toxic effects of misfolded proteins remains controversial. In this report, the role of aggresomes in cell viability was addressed in the context of over-expressing alpha-synuclein and its interacting partner synphilin-1 using engineered 293T cells. Inhibition of proteasome activity elicited the formation of juxtanuclear aggregates with characteristics of aggresomes including immunoreactivity for vimentin, gamma-tubulin, ubiquitin, proteasome subunit, and hsp70. As expected from the properties of aggresomes, the microtubule disrupting agents, vinblastin and nocodazole, markedly prevented the formation of these inclusions. Similar to LBs, the phosphorylated form of alpha-synuclein co-localized in these synphilin-1-containing aggresomes. Although the caspase inhibitor z-VAD-fmk significantly reduced the number of apoptotic cells, it had no impact on the percentage of aggresome-positive cells. Finally, quantitative analysis revealed aggresomes in 60% of non-apoptotic cells but only in 10% of apoptotic cells. Additionally, alpha-synuclein-induced apoptosis was not coupled with increased prevalence of aggresome-bearing cells. Taken together, these observations indicate a disconnection between aggresome formation and apoptosis, and support a protective role for these inclusions from the toxicity associated with the combined over-expression of alpha-synuclein and synphilin-1.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, Piscataway, NJ 08854 USA; NINDS, Genet Pharmacol Unit, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Tokyo	Mouradian, MM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, 683 Hoes Lane,Room 180, Piscataway, NJ 08854 USA.	Mouradian@umdnj.edu		Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FORNO LS, 1993, NEURODEGENERATION, V2, P19; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Hurtig HI, 2000, NEUROLOGY, V54, P1916, DOI 10.1212/WNL.54.10.1916; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kim M, 1999, J NEUROSCI, V19, P964; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lee G, 2002, J NEUROCHEM, V83, P346, DOI 10.1046/j.1471-4159.2002.01136.x; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsumine H, 1998, J NEUROL, V245, pP10, DOI 10.1007/PL00007741; Mattila PM, 2000, ACTA NEUROPATHOL, V100, P285, DOI 10.1007/s004019900168; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Neystat M, 2002, NEUROSCI LETT, V325, P119, DOI 10.1016/S0304-3940(02)00253-7; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ribeiro CS, 2002, J BIOL CHEM, V277, P23927, DOI 10.1074/jbc.M201115200; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451; Wigley WC, 1999, J CELL BIOL, V145, P481; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	63	319	330	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4625	4631		10.1074/jbc.M310994200	http://dx.doi.org/10.1074/jbc.M310994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627698	hybrid			2022-12-25	WOS:000188554300084
J	Bahar, A; Bicknell, JE; Simpson, DJ; Clayton, RN; Farrell, WE				Bahar, A; Bicknell, JE; Simpson, DJ; Clayton, RN; Farrell, WE			Loss of expression of the growth inhibitory gene GADD45 gamma, in human pituitary adenomas, is associated with CpG island methylation	ONCOGENE			English	Article						GADD45 gamma; CpG island methylation; pituitary adenomas	DNA METHYLATION; MAMMALIAN-CELLS; BREAST-CANCER; P16 GENE; TUMORS; HYPERMETHYLATION; INACTIVATION; TUMORIGENESIS; PATHOGENESIS; DELETION	Inappropriate expression of cell-cycle regulatory genes and/or their protein products are a frequent finding in pituitary tumours; however, genetic changes associated with or responsible for their dysregulation are in general uncommon. In a search for novel genes, and employing eDNA-representational difference analysis, the gene encoding GADD45gamma was recently isolated and identified as being under-represented in pituitary adenomas. GADD45gamma is a member of a family of genes that are induced by DNA damage and function in the negative regulation of cell growth. In this study, we further confirm this initial report that the majority of pituitary adenomas (22 of 33; 67%) do not express GADD45gamma as determined by RT-PCR analysis. Loss of expression was not associated with either loss of heterozygosity or mutations within the coding region of this gene. In marked contrast, epigenetic change, namely methylation of the GADD45gamma genes CpG island, was a frequent finding (19 of 33 adenoma; 58%) and was significantly associated with tumours in which GADD45gamma transcript was not expressed (18 of 22; 82%; P = 0.002). In common with the primary tumours, methylation-associated gene silencing of the GADD45gamma gene was also found in the pituitary tumour cell line AtT20. The treatment of AtT20 cells with the demethylating agent, 5-Aza-2'-deoxycytidine, induced the re-expression of this gene. These findings show that silencing of the GADD45gamma gene in pituitary tumours is primarily associated with methylation of the genes CpG island. Methylation has functional importance since reversal of this epigenetic change in a pituitary-derived cell line is associated with reexpression. Silencing of GADD45gamma, a negative regulator of cell growth, is most likely responsible for conferring a selective growth advantage during tumour evolution and outgrowth.	Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Farrell, WE (corresponding author), Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England.	w.e.farrell@keele.ac.uk						Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Davis JRE, 2001, REPRODUCTION, V121, P363, DOI 10.1530/rep.0.1210363; Esteller M, 2001, CANCER RES, V61, P3225; Farrell WE, 2000, FRONT NEUROENDOCRIN, V21, P174, DOI 10.1006/frne.1999.0195; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hibberts NA, 1999, CLIN CANCER RES, V5, P2133; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Jaffrain-Rea ML, 1999, CLIN ENDOCRINOL, V51, P317; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Korabiowska M, 1999, IN VIVO, V13, P483; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ruebel KH, 2001, ENDOCR PATHOL, V12, P281, DOI 10.1385/EP:12:3:281; Seemann N, 2001, J PATHOL, V193, P491, DOI 10.1002/path.833; Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328; Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195; Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149; Simpson DJ, 2000, CANCER RES, V60, P1211; SIMPSON DJ, 1999, CANCER RES, V59, P2703; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TERADA T, 1995, ENDOCR PATHOL, V6, P301, DOI 10.1007/BF02738730; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wan YS, 2000, INT J MOL MED, V6, P683; Woloschak M, 1997, MOL CARCINOGEN, V19, P221, DOI 10.1002/(SICI)1098-2744(199708)19:4<221::AID-MC1>3.0.CO;2-F; Yan PS, 2000, CLIN CANCER RES, V6, P1432; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761	38	73	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					936	944		10.1038/sj.onc.1207193	http://dx.doi.org/10.1038/sj.onc.1207193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647444				2022-12-25	WOS:000188486600009
J	Germani, A; Prabel, A; Mourah, S; Podgorniak, MP; Di Carlo, A; Ehrlich, R; Gisselbrecht, S; Varin-Blank, N; Calvo, F; Bruzzoni-Giovanelli, H				Germani, A; Prabel, A; Mourah, S; Podgorniak, MP; Di Carlo, A; Ehrlich, R; Gisselbrecht, S; Varin-Blank, N; Calvo, F; Bruzzoni-Giovanelli, H			SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway	ONCOGENE			English	Article						SIAH-1; CtIP; p21(Waf-1/Cip-1); protein degradation; transcription; ubiquitin; E3 ligase	TRANSCRIPTIONAL REPRESSOR; CHROMOSOME ALIGNMENT; TUMOR SUPPRESSION; BINDING-PROTEIN; DNA-DAMAGE; BRCA1; CTBP; COREPRESSOR; MECHANISM; XKID	SIAH-1 and SIAH-2 are the human members of an evolutionary highly conserved E3 ligase family. SIAH-1 is a p53 and p21(Waf-1/Cip-1) induced gene during apoptosis and tumor suppression. In stable-transfected clones of MCF-7 cells, SIAH-1 overexpression was associated with apoptosis, mitotic alterations and p21(Waf-1/Cip-1) induction of expression. Using a two-hybrid screening, we identified here the transcriptional corepressor CtBP-interacting protein (CtIP) as a SIAH-1-interacting protein. CtIP has been proposed as a regulator of p21(Waf-1/Cip-1) gene transcription through a protein complex involving BRCA1. We demonstrate that SIAH-1 associates with CtIP both in vitro and in vivo. This interaction led to CtIP degradation by the ubiquitin-proteasome pathway. As expected, SIAH-1 induced p21(Waf-1/Cip-1) transcription in Jurkat-T cell. Surprisingly, a SIAH protein deleted of its RING finger, SIAH-1DeltaN, which is able to interact with CtIP but does not promote its degradation, also induced transcription from the p21(Waf-1) promoter in a similar extent as did SIAH-1. Our results suggest that p21(Waf-1/Cip-1) induction by SIAH-1 could not be mediated by CtIP degradation.	Hop St Louis, INSERM, EMI 0334, Inst Genet Mol,Lab Pharmacol Expt & Clin, F-75010 Paris, France; Ctr Cardiol Fdn I Monzino, IRCCS, Lab Vasc Biol & Gene Therapy, I-20138 Milan, Italy; Univ Paris 05, Hop Cochin, Inst Cochin, Dept Hematol,CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Fac Ciencias, Secc Bioquim, Montevideo, Uruguay	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; IRCCS Centro Cardiologico Monzino; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad de la Republica, Uruguay	Bruzzoni-Giovanelli, H (corresponding author), Hop St Louis, INSERM, EMI 0334, Inst Genet Mol,Lab Pharmacol Expt & Clin, 27 Rue Juliette Dodu, F-75010 Paris, France.		Di Carlo, Anna/AAY-4368-2021; Varin-Blank, Nadine/G-4396-2013	Di Carlo, Anna/0000-0002-6037-6160; calvo, fabien/0000-0002-0298-7633; VARIN-BLANK, Nadine/0000-0003-2769-018X				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Koipally J, 2002, J BIOL CHEM, V277, P23143, DOI 10.1074/jbc.M202079200; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	26	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8845	8851		10.1038/sj.onc.1206994	http://dx.doi.org/10.1038/sj.onc.1206994			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654780				2022-12-25	WOS:000186982200005
J	Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Ramos, MA; Nunez, MD; Campos, J; Lacal, JC				Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Ramos, MA; Nunez, MD; Campos, J; Lacal, JC			Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells	ONCOGENE			English	Article						choline kinase inhibitors; new therapies; signal transduction; specificity; apoptosis	NIH 3T3 FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTORS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPID-METABOLISM; ANTITUMOR STRATEGY; DRUG DISCOVERY; RAS ONCOGENE; ACTIVATION; STIMULATION	Cancer treatment is in the need of selective drugs that can interfere specifically with signalling pathways affected during the carcinogenic process. Identification of new potential molecular targets is the key event in the design of new anticancer strategies. Once identified, attempts for the generation of specific molecules to regulate their function can be achieved. The relevance of deregulation of choline kinase (ChoK, E.C. 2.7.1.32) in oncogene-driven cell transformation has been previously demonstrated. Here we provide strong evidence that MN58b, a selective inhibitor of ChoK, is rather specific to this enzyme, with no effect on a variety of oncogene-activated signalling pathways involved in the regulation of cell proliferation. MN58b does not affect MAPKs, PI3K, and other enzymes involved in the regulation of phospholipid metabolism such as phospholipases C, D, and A2, CTP:phosphocholine cytidylyltransferase, or diacylglycerol choline-phosphotransferase. Consistent with this specificity, ectopic expression of ChoK resulted in resistance to its inhibitor. Finally, nontransformed cells were able to resume cell proliferation after removal of the drug, while transformed cells were irreversibly affected. These results indicate that inhibition of ChoK is a rather specific strategy for the cytotoxic treatment of transformed cells.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain; Fac Farm, Dept Quim Organ, E-18071 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Arturo Duperier 4, E-28029 Madrid, Spain.		del Carmen Nuñez-Carretero, M/L-7150-2014; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/AAL-2235-2020; Rosa, Joaquín/L-8436-2014; Lacal, Juan Carlos/N-9064-2015	Rosa, Joaquín/0000-0002-9035-8123; Lacal, Juan Carlos/0000-0002-1908-2777				Aboagye EO, 1999, CANCER RES, V59, P80; ANSELL GB, 1974, J NEUROCHEM, V22, P1153, DOI 10.1111/j.1471-4159.1974.tb04352.x; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Bhakoo KK, 1996, CANCER RES, V56, P4630; CANNON JG, 1994, MED RES REV, V14, P505, DOI 10.1002/med.2610140503; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; Chung TW, 2000, CELL SIGNAL, V12, P279, DOI 10.1016/S0898-6568(00)00065-6; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; De molina AR, 2001, INT J ONCOL, V19, P5; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; Finney RE, 2000, CANCER RES, V60, P5204; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Friend SH, 1998, NEW ENGL J MED, V338, P125, DOI 10.1056/NEJM199801083380211; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; KO KWS, 1986, J BIOL CHEM, V261, P7846; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; OIKAWA T, 1991, P NATL ACAD SCI USA, V88, P3057, DOI 10.1073/pnas.88.8.3057; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RATMANT JC, 1995, ARCH BIOCHEM BIOPHYS, V323, P313; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Ting YLT, 1996, ANTICANCER RES, V16, P1381; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; YANG W, 1990, J BIOL CHEM, V265, P13553; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	48	75	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8803	8812		10.1038/sj.onc.1207062	http://dx.doi.org/10.1038/sj.onc.1207062			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654777				2022-12-25	WOS:000186982200001
J	Rassool, FV; North, PS; Mufti, GJ; Hickson, ID				Rassool, FV; North, PS; Mufti, GJ; Hickson, ID			Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells	ONCOGENE			English	Article						Bloom's syndrome; DNA damage; double-strand break repair; timing of replication	SYNDROME GENE-PRODUCT; DEFENDING GENOME INTEGRITY; SISTER-CHROMATID EXCHANGES; WERNERS-SYNDROME GENES; RECQ FAMILY HELICASES; STRAND BREAK REPAIR; COMMON FRAGILE SITE; SYNDROME PROTEIN; S-PHASE; TOPOISOMERASE-III	Bloom's syndrome (BS) is an autosomal recessive disorder associated with an elevated incidence of cancers. The gene mutated in BS, BLM, encodes a RecQ helicase family member. BS cells exhibit genomic instability, including excessive homologous recombination and chromosomal aberrations. W e reported previously that BS cells also demonstrate increased error-prone nonhomologous end-joining, which could contribute to genomic instability in these cells. Here, we show that BS cells display an abnormality in the timing of replication of both early-replicating genes and late-replicating loci such as chromosomal fragile sites. This delayed replication is associated with a constitutively increased frequency of sites of DNA damage and repair, as determined by the presence of DNA repair factors such as RAD51 and Ku86. In addition, another RecQ family helicase, WRN, also localizes to these repair sites. The presence of these repair sites correlates with the temporal appearance of cyclin B1 expression, indicative of the cells having progressed beyond mid-S phase in the cell division cycle. Critically, these defects in BS cells are the direct result of loss of BLM function, because BS cells phenotypically 'reverted' following transfection with the BLM cDNA no longer show such defects. Thus, our data indicate that constitutive DNA damage is coupled to delayed DNA replication in BS cells.	Guys Kings & Thomas Sch Med, Rayne Inst, Leukaemia Sci Labs, Dept Haematol Med, London SE5 9NU, England; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Labs, Oxford OX3 9DS, England	University of London; King's College London; Cancer Research UK; University of Oxford	Rassool, FV (corresponding author), Guys Kings & Thomas Sch Med, Rayne Inst, Leukaemia Sci Labs, Dept Haematol Med, 123 Coldharbour Lane, London SE5 9NU, England.	feyruz.rassool@kcl.ac.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Cooper MP, 2000, GENE DEV, V14, P907; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, J CELL SCI, V113, P2641; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Glover TW, 1998, RECENT RES CANCER, V154, P185; GLOVER TW, 1987, AM J HUM GENET, V41, P882; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Langland G, 2002, CANCER RES, V62, P2766; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P39800; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; LONN U, 1990, CANCER RES, V50, P3141; Moens PB, 2000, J CELL SCI, V113, P663; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2001, CELL MOL LIFE SCI, V58, P894, DOI 10.1007/PL00000909; Wu L, 2000, COLD SPRING HARB SYM, V65, P573, DOI 10.1101/sqb.2000.65.573; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YUNIS JJ, 1987, ONCOGENE, V1, P59	45	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8749	8757		10.1038/sj.onc.1206970	http://dx.doi.org/10.1038/sj.onc.1206970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647470	Bronze			2022-12-25	WOS:000186844900013
J	Hideshima, T; Chauhan, D; Hayashi, T; Akiyama, M; Mitsiades, N; Mitsiades, C; Podar, K; Munshi, NC; Richardson, PG; Anderson, KC				Hideshima, T; Chauhan, D; Hayashi, T; Akiyama, M; Mitsiades, N; Mitsiades, C; Podar, K; Munshi, NC; Richardson, PG; Anderson, KC			Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; proteasome inhibitor; IL-6; gp130; caspase	ACTIVATED PROTEIN-KINASE; MARROW STROMAL CELLS; DEXAMETHASONE-INDUCED APOPTOSIS; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; THERAPEUTIC APPLICATIONS; MOLECULAR-MECHANISMS; DRUG-RESISTANCE; UP-REGULATION; PLASMA-CELLS	Proteasome inhibitor PS-341 is one of the most promising novel agents against multiple myeloma (MM). We have previously shown that PS-341 inhibits IL-6 triggered phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 (also known as p42/44 mitogen-activated protein kinases) in MM cells. In this study, we further examined whether clinically achievable concentrations of PS-341 could inhibit IL-6 triggered signaling cascades in MM. We found that PS-341 inhibited not only ERK, but also signal transducers and activators of transcription (STAT) 3 as well as Akt phosphorylation. Since gp130 (CD130) dimerizes and is phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be involved in PS-341-induced blockade of signaling cascades mediating MM cell growth, survival, and drug resistance in the bone marrow (BM) microenvironment. In this study, we first demonstrate that PS-341 induces downregulation of gp130 in a time- and dose-dependent manner in vitro, prior to MM cell death. Conversely, downregulation of gp130 is completely abrogated by the pan-caspase inhibitor Z-VAD-FMK, suggesting that downregulation of gp130 is mediated via caspase activation. Z-VAD-FMK also abrogates the inhibitory effect of PS-341 on IL-6-triggered signaling cascades. Importantly, we demonstrate that phosphorylation of ERK, STAT3, and Akt in MM.1S cells induced by either exogenous IL-6 or by binding of MM cells to BM stromal cells is abrogated by PS-341. These studies, therefore, define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Mayer 557,44 Binney St, Boston, MA 02115 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA 50947] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, MOL CANCER THER, V1, P539; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; Kurth I, 1999, J IMMUNOL, V162, P1480; LeBlanc R, 2002, CANCER RES, V62, P4996; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; Ogata A, 1997, J IMMUNOL, V159, P2212; Ogawa M, 2000, CANCER RES, V60, P4262; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Richardson PG, 2001, BLOOD, V98, p774A; Semenov I, 2002, LEUKEMIA RES, V26, P271, DOI 10.1016/S0145-2126(01)00103-5; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733	44	140	155	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8386	8393		10.1038/sj.onc.1207170	http://dx.doi.org/10.1038/sj.onc.1207170			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627979				2022-12-25	WOS:000186650300002
J	Jin, SQ; Mazzacurati, L; Zhu, XC; Tong, T; Song, YM; Shao, SJ; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM				Jin, SQ; Mazzacurati, L; Zhu, XC; Tong, T; Song, YM; Shao, SJ; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM			Gadd45a contributes to p53 stabilization in response to DNA damage	ONCOGENE			English	Article						p53; Gadd45a; DNA damage	CELL-CYCLE CHECKPOINT; P53-REGULATED PROTEIN GADD45; TUMOR-SUPPRESSOR P53; INDUCED PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; KINASE-ACTIVITY; ACTIVATES P53; MDM2; ARREST; INHIBITION	p53 is an important molecule in cellular response to DNA damage. After genotoxic stress, p53 protein stabilizes transiently and accumulates in the nucleus, where it functions as a transcription factor and upregulates multiple downstream-targeted genes, including p21(Waf1/Cip1), Gadd45a and Bax. However, regulation of p53 stabilization is complex and may mainly involve post-translational modification of p53, such as phosphorylation and acetylation. Using mouse embryonic fibroblasts (MEFs) derived from Gadd45a knockouts, we found that disruption of Gadd45a greatly abolished p53 protein stabilization following UVB treatment. Phosphorylation of p53 at Ser-15 was substantially reduced in Gadd45a-/- MEFs. In addition, p53 induction by UVB was shown to be greatly abrogated in the presence of p38 kinase inhibitor, but not c-Jun N-terminal kinase (JNK) and extracellular-signal regulated kinase (ERK), suggesting that p38 protein kinase is involved in the regulation of p53 induction. Along with the findings presented above, inducible expression of Gadd45a enhanced p53 accumulation after cell exposure to UVB. Taken together, the current study demonstrates that Gadd45a, a conventional downstream gene of p53, may play a role as an upstream effector in p53 stabilization following DNA damage, and thus has defined a positive feedback signal in the activation of the p53 pathway.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College	Zhan, QM (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, UPCI Res Pavil,Suite G5,5117 Ctr Ave, Pittsburgh, PA 15213 USA.			mazzacurati, lucia/0000-0002-8336-8032; song, yongmei/0000-0002-7789-0158	NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-83874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang XH, 2001, TRIBOL LETT, V11, P15, DOI 10.1023/A:1016677321278; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	48	76	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8536	8540		10.1038/sj.onc.1206907	http://dx.doi.org/10.1038/sj.onc.1206907			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627995				2022-12-25	WOS:000186650300018
J	Stockel, J; Oelmuller, R				Stockel, J; Oelmuller, R			A novel protein for photosystem I biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SYNECHOCYSTIS SP; LUPINUS-LUTEUS COTYLEDONS; SYNECHOCOCCUS SP PCC-7002; SP PCC 6803; ARABIDOPSIS-THALIANA; CHLAMYDOMONAS-REINHARDTII; ESCHERICHIA-COLI; SUBCELLULAR-LOCALIZATION; PHOTOAUTOTROPHIC GROWTH; STRUCTURAL ORGANIZATION	Hcf101-1 is a high-chlorophyll-fluorescence (hcf) Arabidopsis mutant that lacks photosystem I ( 1). Photosystem I subunits are synthesized in the mutant but do not assemble into a stable complex. hcf101 was isolated by map-based cloning and encodes an MRP-like protein with a nucleotide-binding domain. The protein is localized in the chloroplast stroma. In green tissue, the Hcf101 level is stimulated by light, and the protein is not detectable in roots. Two independent knock-out lines, hcf101-2 and hcf101-3, are also impaired in Hcf101 accumulation, although to different extents. Like hcf101-1, hcf101-2 and hcf01-3 are hcf mutants with impaired photosystem I. Our results indicate that Hcf101 is a novel component required for photosystem I biosynthesis.	Univ Jena, Inst Allgemeine Bot & Pflanzenphysiol, D-07747 Jena, Germany	Friedrich Schiller University of Jena	Oelmuller, R (corresponding author), Univ Jena, Inst Allgemeine Bot & Pflanzenphysiol, Dornburger Str 159, D-07747 Jena, Germany.	b7oera@uni-jena.de						Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Barth C, 2002, PLANTA, V216, P273, DOI 10.1007/s00425-002-0843-0; Bartsevich VV, 1997, J BIOL CHEM, V272, P6382, DOI 10.1074/jbc.272.10.6382; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; CHITNIS PR, 2001, ANNU REV PLANT PHYS, V52, P627; Colletti KS, 2000, CURR BIOL, V10, P507, DOI 10.1016/S0960-9822(00)00466-8; Cordell SC, 2001, FEBS LETT, V492, P160, DOI 10.1016/S0014-5793(01)02216-5; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Diener A, 2000, TRENDS PLANT SCI, V5, P10, DOI 10.1016/S1360-1385(99)01512-5; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fischer N, 1999, BIOCHEMISTRY-US, V38, P5546, DOI 10.1021/bi982821a; Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Hihara Y, 1998, PLANT PHYSIOL, V117, P1205, DOI 10.1104/pp.117.4.1205; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hu ZL, 2003, J BACTERIOL, V185, P196, DOI 10.1128/JB.185.1.196-203.2003; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Kusnetsov V, 1998, MOL GEN GENET, V259, P21, DOI 10.1007/PL00008626; KUSNETSOV VV, 1994, PLANTA, V194, P318, DOI 10.1007/BF00197531; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; Lutkenhaus J, 2003, MOL MICROBIOL, V48, P295, DOI 10.1046/j.1365-2958.2003.03427.x; MACHOLD O, 1979, CARLSBERG RES COMMUN, V44, P235, DOI 10.1007/BF02906158; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Meurer J, 2002, PLANT CELL, V14, P3255, DOI 10.1105/tpc.006809; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; PALOMARES R, 1993, EUR J BIOCHEM, V217, P345, DOI 10.1111/j.1432-1033.1993.tb18252.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Reardon EM, 1995, PLANT MOL BIOL REP, V13, P320, DOI 10.1007/BF02669185; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Ruf S, 1997, J CELL BIOL, V139, P95, DOI 10.1083/jcb.139.1.95; Schaffner AR, 1996, PLANT MOL BIOL REP, V14, P11, DOI 10.1007/BF02671897; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Schneider A, 1998, J BIOL CHEM, V273, P21608, DOI 10.1074/jbc.273.34.21608; Schwabe TME, 2000, INDIAN J BIOCHEM BIO, V37, P351; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Theodoulou FL, 2000, BBA-BIOMEMBRANES, V1465, P79, DOI [10.1016/S0005-2736(00)00132-2, 10.1199/tab.0153]; Vassiliev IR, 1999, J BIOL CHEM, V274, P9993, DOI 10.1074/jbc.274.15.9993; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wilde A, 2001, BIOCHEM J, V357, P211, DOI 10.1042/0264-6021:3570211; WILDE A, 1995, PLANT CELL, V7, P649, DOI 10.1105/tpc.7.5.649; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; Zak E, 1999, EUR J BIOCHEM, V261, P311, DOI 10.1046/j.1432-1327.1999.00281.x; Zak E, 2000, PLANT PHYSIOL, V123, P215, DOI 10.1104/pp.123.1.215; Zhou TQ, 2001, J BIOL CHEM, V276, P30414, DOI 10.1074/jbc.M103671200	74	65	74	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10243	10251		10.1074/jbc.M309246200	http://dx.doi.org/10.1074/jbc.M309246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14645254	hybrid			2022-12-25	WOS:000220050400072
J	Kim, W; Kook, S; Kim, DJ; Teodorof, C; Song, WK				Kim, W; Kook, S; Kim, DJ; Teodorof, C; Song, WK			The 31-kDa caspase-generated cleavage product of p130(cas) functions as a transcriptional repressor of E2A in apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; LOOP-HELIX PROTEINS; DNA-BINDING; EXTRACELLULAR-MATRIX; DOCKING PROTEIN; GROWTH ARREST; ID PROTEINS; DEPENDENT CLEAVAGE; ENDOTHELIAL-CELLS; CARCINOMA CELLS	In response to integrin receptor binding to the extracellular matrix, the multidomain docking protein p130(cas) (Crk-associated substrate) activates various signaling cascades modulating such cellular processes as proliferation, migration, and apoptosis. During apoptosis, caspase-mediated cleavage of p130(cas) generated a C-terminal 31-kDa fragment (31-kDa) and promoted morphological changes characteristic of apoptosis, including loss of focal adhesions, cell rounding, and nuclear condensation and fragmentation. By contrast, a p130(cas) D748E mutant, which was unable to produce 31-kDa, attenuated the disassembly of focal adhesions at the bottom of the cell. 31-kDa contains a helix-loop-helix (HLH) domain that shows greater sequence homology with Id proteins than with basic HLH proteins, which enabled heterodimerization with E2A. Once coupled to E2A, 31-kDa was translocated to the cell nucleus, where it inhibited E2A-mediated p21(Waf1/Cip1) transcription. Moreover, overexpression of 31-kDa led to cell death that could be inhibited by treatment with the caspase inhibitor ZVAD-fluoromethyl ketone or by ectopic expression of E2A or p21(Waf1/Cip1). These data suggest that during etoposide-induced apoptosis, 31-kDa promotes caspase-mediated cell death by inhibiting E2A-mediated activation of p21(Waf1/Cip1) transcription.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Gwangju Institute of Science & Technology (GIST); Vanderbilt University	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	wksong@kjist.ac.kr						Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Herblot S, 2002, MOL CELL BIOL, V22, P886, DOI 10.1128/MCB.22.3.886-900.2002; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Kee BL, 2002, EMBO J, V21, P103, DOI 10.1093/emboj/21.1.103; Kim DH, 2003, BIOCHEM BIOPH RES CO, V300, P141, DOI 10.1016/S0006-291X(02)02786-9; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Shim SR, 2001, BIOCHEM BIOPH RES CO, V286, P601, DOI 10.1006/bbrc.2001.5441; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tian H, 2000, CANCER RES, V60, P679; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	56	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8333	8342		10.1074/jbc.M312026200	http://dx.doi.org/10.1074/jbc.M312026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660614	hybrid			2022-12-25	WOS:000189103300115
J	Kappler, U; Aguey-Zinsou, KF; Hanson, GR; Bernhardt, PV; McEwan, AG				Kappler, U; Aguey-Zinsou, KF; Hanson, GR; Bernhardt, PV; McEwan, AG			Cytochrome c(551) from Starkeya novella - Characterization, spectroscopic properties, and phylogeny of a diheme protein of the SoxAX family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC SULFUR-COMPOUNDS; PARACOCCUS-PANTOTROPHUS; THIOSULFATE OXIDATION; THIOBACILLUS-NOVELLUS; SULFITE DEHYDROGENASE; OXIDIZING SYSTEM; STRUCTURAL BASIS; SIGNAL PEPTIDES; GENE-CLUSTER; IDENTIFICATION	Cytochromes from the SoxAX family have a major role in thiosulfate oxidation via the thiosulfate-oxidizing multi-enzyme system (TOMES). Previously characterized SoxAX proteins from Rhodovulum sulficlophilum and Paracoccus pantotrophus contain three heme c groups, two of which are located on the SoxA subunit. In contrast, the SoxAX protein purified from Starkeya novella was found to contain only two heme groups. Mass spectrometry showed that a disulfide bond replaced the second heme group found in the diheme SoxA subunits. Apparent molecular masses of 27,229 +/- 10.3 Da and 20,258.6 +/- 1 Da were determined for SoxA and SoxX with an overall mass of 49.7 kDa, indicating a heterodimeric structure. Optical redox potentiometry found that the two heme cofactors are reduced at similar potentials (versus NHE) that are as follows: + 133 mV (pH 6.0); + 104 mV (pH 7.0); +49 (pH 7.9) and +10 mV (pH 8.7). EPR spectroscopy revealed that both ferric heme groups are in the low spin state, and the spectra were consistent with one heme having a His/Cys axial ligation and the other having a His/Met axial ligation. The His/Cys ligated heme is present in different conformational states and gives rise to three distinct signals. Amino acid sequencing was used to unambiguously assign the protein to the encoding genes, soxAX, which are part of a complete sox gene cluster found in S. novella. Phylogenetic analysis of soxA- and soxX-related gene sequences indicates a parallel development of SoxA and SoxY, with the diheme and monoheme SoxA sequences located on clearly separated branches of a phylogenetic tree.	Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Dept Chem, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Magnet Resonance, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Kappler, U (corresponding author), Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia.	u.kappler@uq.edu.au	Bernhardt, Paul V/J-8008-2013; Kappler, Ulrike/A-9483-2013; Aguey-Zinsou, Kondo-Francois/D-7162-2012; /C-3940-2008	Bernhardt, Paul V/0000-0001-6839-1763; Kappler, Ulrike/0000-0002-2642-1319; /0000-0003-0306-4360; McEwan, Alastair/0000-0002-2419-1003				Aguey-Zinsou KF, 2003, J AM CHEM SOC, V125, P530, DOI 10.1021/ja028293e; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Appia-Ayme C, 2002, BIOCHEM BIOPH RES CO, V296, P737, DOI 10.1016/S0006-291X(02)00936-1; Appia-Ayme C, 2001, J BACTERIOL, V183, P6107, DOI 10.1128/JB.183.20.6107-6118.2001; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bamford VA, 2002, EMBO J, V21, P5599, DOI 10.1093/emboj/cdf566; Bardischewsky F, 2001, FEMS MICROBIOL LETT, V202, P215, DOI 10.1016/S0378-1097(01)00318-4; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BOHAN TL, 1977, J MAGN RESON, V26, P109, DOI 10.1016/0022-2364(77)90240-2; Cheesman MR, 2001, BIOCHEMISTRY-US, V40, P10562, DOI 10.1021/bi0100081; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dutton P L, 1978, Methods Enzymol, V54, P411; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Friedrich CG, 1998, ADV MICROB PHYSIOL, V39, P235; Friedrich CG, 2001, APPL ENVIRON MICROB, V67, P2873, DOI 10.1128/AEM.67.7.2873-2882.2001; Friedrich CG, 2000, J BACTERIOL, V182, P4677, DOI 10.1128/JB.182.17.4677-4687.2000; Griffin M., 1999, Molecular Physics Reports, V26, P60; Hanson GR, 2003, PROG T CHEM, V10, P197; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Kappler U, 2001, ARCH MICROBIOL, V175, P102, DOI 10.1007/s002030000241; Kelly DP, 1997, ANTON LEEUW INT J G, V71, P95, DOI 10.1023/A:1000135707181; Kelly DP, 2000, INT J SYST EVOL MICR, V50, P1797, DOI 10.1099/00207713-50-5-1797; Klarskov K, 1998, BIOCHEMISTRY-US, V37, P10555, DOI 10.1021/bi9806706; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITCH FA, 1984, BIOCHEMISTRY-US, V23, P1831, DOI 10.1021/bi00303a039; McEwan AG, 2002, FEBS LETT, V518, P10, DOI 10.1016/S0014-5793(02)02532-2; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; OH JK, 1977, J GEN MICROBIOL, V99, P413, DOI 10.1099/00221287-99-2-413; OH JK, 1977, J GEN MICROBIOL, V99, P397, DOI 10.1099/00221287-99-2-397; Petri R, 2001, FEMS MICROBIOL LETT, V197, P171, DOI 10.1111/j.1574-6968.2001.tb10600.x; Pettigrew, 1990, CYTOCHROME C EVOLUTI; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Quentmeier A, 2001, FEBS LETT, V503, P168, DOI 10.1016/S0014-5793(01)02727-2; Quentmeier A, 2000, ARCH MICROBIOL, V173, P117, DOI 10.1007/s002039900118; Rother D, 2002, BBA-PROTEINS PROTEOM, V1598, P65, DOI 10.1016/S0167-4838(02)00332-1; Rother D, 2001, J BACTERIOL, V183, P4499, DOI 10.1128/JB.183.15.4499-4508.2001; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; Starkey RL, 1935, SOIL SCI, V39, P197, DOI 10.1097/00010694-193503000-00004; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Verte F, 2002, BIOCHEMISTRY-US, V41, P2932, DOI 10.1021/bi011404m; Westermeier R, 2002, PROTEOMICS PRACTICE; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; Wodara C, 1997, J BACTERIOL, V179, P5014, DOI 10.1128/jb.179.16.5014-5023.1997; WODARA C, 1994, J BACTERIOL, V176, P6188, DOI 10.1128/jb.176.20.6188-6191.1994	54	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6252	6260		10.1074/jbc.M310644200	http://dx.doi.org/10.1074/jbc.M310644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645228	hybrid			2022-12-25	WOS:000188969200009
J	Lee, G; Tanaka, M; Park, K; Lee, SS; Kim, YM; Junn, E; Lee, SH; Mouradian, MM				Lee, G; Tanaka, M; Park, K; Lee, SS; Kim, YM; Junn, E; Lee, SH; Mouradian, MM			Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ABNORMAL PHOSPHORYLATION; LEWY BODIES; PROTEIN; SYNPHILIN-1; TAU; AGGREGATION; MUTATION; BRAIN	alpha-Synuclein is a phosphoprotein that accumulates as a major component of Lewy bodies in the brains of patients with Parkinson disease. Synphilin-1, which is also present in Lewy bodies, binds with alpha-synuclein and forms cytoplasmic inclusions in transfected cells. Yet the molecular determinants of this protein-protein interaction are unknown. Here we report that casein kinase II (CKII) phosphorylates synphilin-1 and that the beta subunit of this enzyme complex binds to synphilin-1. Additionally, both CKII alpha and beta subunits are present within cytoplasmic inclusions in cells that overexpress synphilin-1. Notably, the interaction between synphilin-1 and alpha-synuclein is markedly dependent on phosphorylation. Inhibition of CKII activity by 5,6-dichlorol-beta-D-ribofuranosylbenzimidazole blocks the binding between these two proteins and significantly reduces the percentage of cells that contain eosinophilic cytoplasmic inclusions. Mutation of the major CKII phosphorylation site in alpha-synuclein (S129A) has no significant impact on the binding between alpha-synuclein and synphilin-1 or on the formation of synphilin-1/alpha-synuclein-positive inclusions. These data suggest that the CKII-mediated phosphorylation of synphilin-1 rather than that of alpha-synuclein is critical in modulating their tendency to aggregate into inclusions. These observations collectively indicate that a ubiquitous post-translational modification such as phosphorylation can regulate inclusion body formation in the context of alpha-synuclein and synphilin-1 interaction.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, Piscataway, NJ 08854 USA; NINDS, Genet Pharmacol Unit, NIH, Bethesda, MD 20824 USA; Ajou Univ, Sch Med, Med Genet Lab, Suwon 442721, South Korea	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Ajou University	Mouradian, MM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, 683 Hoes Lane,Rm 180, Piscataway, NJ 08854 USA.	mouradian@umdnj.edu		Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Baba M, 1998, AM J PATHOL, V152, P879; BAUM L, 1992, BRAIN RES, V573, P126, DOI 10.1016/0006-8993(92)90121-O; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GIRAULT JA, 1990, J NEUROCHEM, V55, P1772, DOI 10.1111/j.1471-4159.1990.tb04968.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; IIMOTO DS, 1990, BRAIN RES, V507, P273, DOI 10.1016/0006-8993(90)90282-G; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee G, 2002, J NEUROCHEM, V83, P346, DOI 10.1046/j.1471-4159.2002.01136.x; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MARTIN ME, 1990, INT J DEV NEUROSCI, V8, P47; MASLIAH E, 1992, AM J PATHOL, V140, P263; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; NAKAJO S, 1986, BIOCHEM INT, V13, P701; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451	41	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6834	6839		10.1074/jbc.M312760200	http://dx.doi.org/10.1074/jbc.M312760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645218	hybrid			2022-12-25	WOS:000188969200077
J	Vainauskas, S; Menon, AK				Vainauskas, S; Menon, AK			A conserved proline in the last transmembrane segment of Gaa1 is required for glycosylphosphatidylinositol (GPI) recognition by GPI transamidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ANCHOR ATTACHMENT; MEMBRANE-PROTEINS; PIG-T; COMPLEX; BIOSYNTHESIS; MECHANISM; SUBUNITS; HELICES; FORM	Glycosylphosphatidylinositol (GPI)-anchored proteins are synthesized as precursor proteins that are processed in the endoplasmic reticulum by GPI transamidase (GPIT). Human GPIT is a multisubunit membrane-bound protein complex consisting of Gaa1, Gpi8, phosphatidylinositol glycan (PIG)-S, PIG-T, and PIG-U. The enzyme recognizes a C-terminal signal sequence in the proprotein and replaces it with a preformed GPI lipid. The nature of the functional interaction of the GPIT subunits with each other and with the proprotein and GPI substrates is largely unknown. We recently analyzed the GPIT subunit Gaa1, a polytopic protein with seven transmembrane (TM) spans, to identify sequence determinants in the protein that are required for its interaction with other subunits and for function (Vainauskas, S., Maeda, Y., Kurniawan, H., Kinoshita, T., and Menon, A. K. (2002) J. Biol Chem. 277, 30535-30542). We showed that elimination of the C-terminal TM segment of Gaa1 allows the protein to interact with Gpi8, PIG-S, and PIG-T but renders the resulting GPIT complex nonfunctional. We now show that GPIT complexes containing C-terminally truncated Gaa1 possess a full complement of subunits and are able to interact with a proprotein substrate but cannot co-immunoprecipitate GPI. We go on to show that mutation of a conserved proline residue centrally located within the C-terminal TM span of Gaa1 is sufficient to abrogate the ability of the resulting GPIT complex to co-immunoprecipitate GPI. We suggest that the putative dynamic hinge created by the proline residue provides a structural basis for the interaction of GPI with GPIT.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Vainauskas, S (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	saulius@biochem.wisc.edu		Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Chen R, 2003, J CELL BIOCHEM, V88, P1025, DOI 10.1002/jcb.10439; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hiroi Y, 1998, FEBS LETT, V421, P252, DOI 10.1016/S0014-5793(97)01576-7; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Karaoglu D, 2001, BIOCHEMISTRY-US, V40, P12193, DOI 10.1021/bi0111911; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Nagamune K, 2003, P NATL ACAD SCI USA, V100, P10682, DOI 10.1073/pnas.1833260100; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2003, J BIOL CHEM, V278, P13959, DOI 10.1074/jbc.M300586200; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Reiersen H, 2001, TRENDS BIOCHEM SCI, V26, P679, DOI 10.1016/S0968-0004(01)01957-0; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; Tieleman DP, 2001, PROTEINS, V44, P63, DOI 10.1002/prot.1073; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; VIDUGIRIENE J, 1995, METHOD ENZYMOL, V250, P513; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	28	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6540	6545		10.1074/jbc.M312191200	http://dx.doi.org/10.1074/jbc.M312191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660601	hybrid			2022-12-25	WOS:000188969200041
J	Cartoni, A; Menna, P; Salvatorelli, E; Braghiroli, D; Giampietro, R; Animati, F; Urbani, A; Del Boccio, P; Minotti, G				Cartoni, A; Menna, P; Salvatorelli, E; Braghiroli, D; Giampietro, R; Animati, F; Urbani, A; Del Boccio, P; Minotti, G			Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids - Novel function for ferrylmyoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; MOLECULAR-MECHANISM; DOXORUBICIN; METMYOGLOBIN; ADRIAMYCIN; MYOGLOBIN; METABOLISM; IRON; INHIBITION; PACLITAXEL	We show that the pseudoperoxidase activity of ferrylmyoglobin (Mb(IV)) promotes oxidative degradation of doxorubicin (DOX), an anticancer anthracycline known to induce severe cardiotoxicity. Mb(IV), formed in vitro by reacting horse heart Mb(III) with H2O2, caused disappearance of the spectrum of DOX at 477 nm and appearance of UV-absorbing chromophores that indicated opening and degradation of its tetracyclic ring. Electron spray ionization mass spectrometry analyses of DOX/Mb(IV) ultrafiltrates showed that DOX degradation resulted in formation of 3-methoxyphthalic acid, the product of oxidative modifications of its methoxy-substituted ring D. Other methoxy-substituted anthracyclines similarly released 3-methoxyphthalic acid after oxidation by Mb(IV), whereas demethoxy analogs released simple phthalic acid. Kinetic and stoichiometric analyses of reactions between DOX and Mb(III)/H2O2 or hemin/H2O2 showed that the porphyrin radical of Mb(IV)-compound I and the iron-oxo moiety of Mb(IV)-compound II were sequentially involved in oxidizing DOX; however, oxidation by compound I formed more 3-methoxyphthalic acid than oxidation by compound II. Sizeable amounts of 3-methoxyphthalic acid were formed in the heart of mice treated with DOX, in human myocardial biopsies exposed to DOX in vitro, and in human cardiac cytosol that oxidized DOX after activation of its endogenous myoglobin by H2O2. Importantly, H9c2 cardiomyocytes were damaged by low concentrations of DOX but could tolerate concentrations of 3-methoxyphthalic acid higher than those measured in murine or human myocardium. These results unravel a novel function for Mb(IV) in the oxidative degradation of anthracyclines to phthalic acids and suggest that this may serve a salvage pathway against cardiotoxicity.	Univ G dAnnunzio, Sch Med, Ctr Studi Invecchiamento, I-66013 Chieti, Italy; Menarini Ric, Dept Chem, I-00040 Rome, Italy; Univ G dAnnunzio, Sch Pharm, I-66013 Chieti, Italy	G d'Annunzio University of Chieti-Pescara; Menarini Group; G d'Annunzio University of Chieti-Pescara	Minotti, G (corresponding author), Univ G dAnnunzio, Sch Med, Ctr Studi Invecchiamento, Rm 412,Via Vestini, I-66013 Chieti, Italy.	gminotti@unich.it	Braghiroli, Daniela/D-3528-2015; Urbani, Andrea/B-2953-2012; DEL BOCCIO, PIERO/AAC-7392-2022	Braghiroli, Daniela/0000-0002-0232-0193; DEL BOCCIO, PIERO/0000-0003-1653-2194; Minotti, Giorgio/0000-0002-5678-6175; MENNA, Pierantonio/0000-0002-7755-818X; Salvatorelli, Emanuela/0000-0001-9805-4100				AKMAN SA, 1990, CANCER RES, V50, P1397; ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96; ALEXANDER J, 1980, J ORG CHEM, V45, P20, DOI 10.1021/jo01289a004; ARCAMONE F, 1984, CANCER CHEMOTH PHARM, V12, P157; ARCAMONE F, 1972, INT S ADR, P10; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; Baron CP, 2000, FREE RADICAL BIO MED, V28, P549, DOI 10.1016/S0891-5849(99)00240-3; BLOOM J, 1992, J ANAL TOXICOL, V16, P223, DOI 10.1093/jat/16.4.223; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Galaris D, 1997, FREE RADICAL BIO MED, V22, P657, DOI 10.1016/S0891-5849(96)00382-6; Gianni L, 1997, J CLIN ONCOL, V15, P1906, DOI 10.1200/JCO.1997.15.5.1906; Gille L, 1997, FREE RADICAL BIO MED, V23, P775, DOI 10.1016/S0891-5849(97)00025-7; Giulivi C, 1998, FREE RADICAL BIO MED, V24, P269, DOI 10.1016/S0891-5849(97)00226-8; Gunther MR, 1999, FREE RADICAL BIO MED, V26, P1388, DOI 10.1016/S0891-5849(98)00338-4; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790; Menna P, 2002, CHEM RES TOXICOL, V15, P1179, DOI 10.1021/tx020055+; Minotti G, 2001, CLIN CANCER RES, V7, P1511; Minotti G, 2001, CANCER RES, V61, P8422; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; Miura T, 2000, BIOCHEM PHARMACOL, V60, P95, DOI 10.1016/S0006-2952(00)00303-8; MORDENTE A, 1994, J BIOL CHEM, V269, P27394; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ramu A, 2000, CANCER CHEMOTH PHARM, V46, P449, DOI 10.1007/s002800000174; RAO SI, 1994, J BIOL CHEM, V269, P7210; Reszka KJ, 2002, FREE RADICAL BIO MED, V33, pS443; Reszka KJ, 2003, FREE RADICAL BIO MED, V35, P78, DOI 10.1016/S0891-5849(03)00238-7; Reszka KJ, 2001, BIOCHEMISTRY-US, V40, P15349, DOI 10.1021/bi011869c; SANTAVY F, 1970, COLLECT CZECH CHEM C, V35, P2418, DOI 10.1135/cccc19702418; SCHMIDT HWH, 1989, BIOCHEMISTRY-US, V28, P1776, DOI 10.1021/bi00430a053; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Swaanenburg JCJM, 2001, AM J CLIN PATHOL, V115, P770; Taatjes DJ, 1997, J MED CHEM, V40, P1276, DOI 10.1021/jm960835d; TAYLOR D, 1978, BIOCHEM PHARMACOL, V27, P2079, DOI 10.1016/0006-2952(78)90073-4; TROST LC, 1994, BIOCHEM BIOPH RES CO, V204, P30, DOI 10.1006/bbrc.1994.2421; VanderZee J, 1996, FREE RADICAL BIO MED, V20, P199, DOI 10.1016/0891-5849(95)02031-4; Wentzel BB, 2000, TETRAHEDRON, V56, P7797, DOI 10.1016/S0040-4020(00)00679-7; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018	41	26	26	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5088	5099		10.1074/jbc.M306568200	http://dx.doi.org/10.1074/jbc.M306568200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634026	hybrid			2022-12-25	WOS:000188776500008
J	Gagnon, E; Bergeron, MJ; Brunet, GM; Daigle, ND; Simard, CF; Isenring, P				Gagnon, E; Bergeron, MJ; Brunet, GM; Daigle, ND; Simard, CF; Isenring, P			Molecular mechanisms of Cl- transport by the renal Na+-K+-Cl- cotransporter - Identification of an intracellular locus that may form part of a high affinity Cl--binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-2CL(-) COTRANSPORTER; BUMETANIDE BINDING; CHLORIDE COTRANSPORTER; FUNCTIONAL EXPRESSION; ION-TRANSPORT; CLONING; RABBIT; KIDNEY; FAMILY; NKCC1	The 2(nd) transmembrane domain ( tm) of the secretory Na+-K+-Cl- cotransporter ( NKCC1) and of the kidney-specific isoform ( NKCC2) has been shown to play an important role in cation transport. For NKCC2, by way of illustration, alternative splicing of exon 4, a 96- bp sequence from which tm2 is derived, leads to the formation of the NKCC2A and F variants that both exhibit unique affinities for cations. Of interest, the NKCC2 variants also exhibit substantial differences in Cl- affinity as well as in the residue composition of the first intracellular connecting segment ( cs1a), which immediately follows tm2 and which too is derived from exon 4. In this study, we have prepared chimeras of the shark NKCC2A and F ( saA and saF) to determine whether cs1a could play a role in Cl (-) transport; here, tm2 or cs1a in saF was replaced by the corresponding domain from saA ( generating saA/ F or saF/ A, respectively). Functional analyses of these chimeras have shown that cs1a- specific residues account for most of the A- F difference in Cl (-) affinity. For example, Km(Cl-) s were similar to 8 mM for saF/ A and saA, and similar to 70 mM for saA/ F and saF. Intriguingly, variant residues in cs1a also affected cation transport; here, Km(Na+) s for the chimeras and for saA were all similar to 20 mM, and Km(Rb+) all similar to 2 mM. Regarding tm2, our studies have confirmed its importance in cation transport and have also identified novel properties for this domain. Taken together, our results demonstrate for the first time that an intracellular loop in NKCC contributes to the transport process perhaps by forming a flexible structure that positions itself between membrane spanning domains.	Univ Laval, Fac Med, Dept Med, Nephrol Res Grp, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), Hotel Dieu Quebec Res Ctr, 10 Rue McMahon Rm 3852, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						Benjamin BA, 1997, AM J PHYSIOL-RENAL, V273, pF473, DOI 10.1152/ajprenal.1997.273.3.F473; Bergeron MJ, 2003, AM J PHYSIOL-RENAL, V285, pF68, DOI 10.1152/ajprenal.00032.2003; BROWN CDA, 1985, J MEMBRANE BIOL, V87, P131, DOI 10.1007/BF01870659; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FORBUSH B, 1995, INT SOC NEPHR AM PHY; Gagnon E, 2003, AM J PHYSIOL-CELL PH, V284, pC365, DOI 10.1152/ajpcell.00262.2002; Gagnon E, 2002, AM J PHYSIOL-RENAL, V283, pF1046, DOI 10.1152/ajprenal.00107.2002; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HAAS M, 1987, KIDNEY INT, V32, pS134; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Labro AJ, 2003, J BIOL CHEM, V278, P50724, DOI 10.1074/jbc.M306097200; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC299, DOI 10.1152/ajpcell.1998.274.2.C299; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; MIYAMOTO H, 1986, J MEMBRANE BIOL, V92, P135, DOI 10.1007/BF01870703; MOORE ML, 1995, BIOCHEM J, V309, P637, DOI 10.1042/bj3090637; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Mount DB, 1998, J EXP BIOL, V201, P2091; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931	40	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5648	5654		10.1074/jbc.M311218200	http://dx.doi.org/10.1074/jbc.M311218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645215	hybrid			2022-12-25	WOS:000188776500075
J	Ploplis, VA; Balsara, R; Sandoval-Cooper, MJ; Yin, ZJ; Batten, J; Modi, N; Gadoua, D; Donahue, D; Martin, JA; Castellino, FJ				Ploplis, VA; Balsara, R; Sandoval-Cooper, MJ; Yin, ZJ; Batten, J; Modi, N; Gadoua, D; Donahue, D; Martin, JA; Castellino, FJ			Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DEFICIENT MICE; GROWTH-FACTOR; VASCULAR ENDOTHELIUM; TRANSCRIPTION; UROKINASE; VIVO; ANGIOGENESIS; STIMULATION; MECHANISMS; MIGRATION	A number of studies have identified a role for plasminogen activator inhibitor-1 (PAI-1) in regulating angiogenesis, although results from these investigations have been controversial. Among key cellular components of an angiogenic vessel are endothelial cells (ECs), which are known to express several components of the fibrinolytic system, including PAI-1. Thus, alterations in expression of this protein may have direct effects on cell functions involved in vascular development. In this study, ECs were isolated from sections of murine arterial trees from wild-type and PAI-1-deficient mice, and low passage (passages 3-4) homogeneous subpopulations of these cells were obtained by immunomagnetic absorption to antibodies against CD105/CD106. The homogeneity of these cells was further assessed by immunohistochemistry and quantitative real-time reverse transcription-PCR analysis of a number of EC markers. Comparative analyses of EC proliferation (one event associated with angiogenesis) in wild-type and PAI-1-deficient ECs demonstrated enhanced rates of cell growth for PAI-1-deficient cells relative to wild-type cells. Additional studies demonstrated similar levels of both vascular endothelial growth factor (VEGF) mRNA and protein and enhanced levels of VEGF receptor-1 (Flt-1) mRNA in PAI-1-deficient cells relative to wild-type cells. Immunohistochemical analyses indicated that phosphorylation of Akt was also enhanced in PAI-1-deficient cells, implicating VEGF-induced cell signaling alterations in PAI-1-deficient cells, the result of which may contribute to alterations in cell proliferation.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	Ploplis, VA (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 251 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013423, R01HL013423, R01HL063682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13423, HL-63682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Bisgaard HC, 1998, LAB INVEST, V78, P237; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brodsky S, 2001, AM J PHYSIOL-HEART C, V281, pH1784, DOI 10.1152/ajpheart.2001.281.4.H1784; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28; Fu L, 2001, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V18, P110; Gutierrez LS, 2000, CANCER RES, V60, P5839; Jih Yng-Jyh, 2001, Angiogenesis, V4, P313, DOI 10.1023/A:1016080321956; Kliche S, 2001, IUBMB LIFE, V52, P61, DOI 10.1080/15216540252774784; Kreisel D, 2001, J IMMUNOL METHODS, V254, P31, DOI 10.1016/S0022-1759(01)00371-4; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Mars WM, 1996, CANCER RES, V56, P2837; Nor J E, 1999, Angiogenesis, V3, P101, DOI 10.1023/A:1009053411094; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; Ploplis VA, 2001, AM J PATHOL, V158, P107, DOI 10.1016/S0002-9440(10)63949-1; Sandberg T, 1998, BIOL REPROD, V59, P759, DOI 10.1095/biolreprod59.4.759; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; Takahashi M, 2003, HEPATOL RES, V26, P232, DOI 10.1016/S1386-6346(03)00112-8	31	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6143	6151		10.1074/jbc.M307297200	http://dx.doi.org/10.1074/jbc.M307297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625301	hybrid			2022-12-25	WOS:000188776500130
J	Rydziel, S; Delany, AM; Canalis, E				Rydziel, S; Delany, AM; Canalis, E			AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; FAR UPSTREAM ELEMENT; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; URIDINE BINDING-FACTOR; 3'-UNTRANSLATED REGION; PARATHYROID-HORMONE; C-MYC; INTERSTITIAL COLLAGENASE; POSTTRANSCRIPTIONAL MECHANISMS; MOLECULAR-CLONING	Collagenase 3 degrades collagen fibrils and is necessary for bone resorption. Cortisol increases collagenase 3 mRNA in osteoblasts by stabilizing collagenase 3 transcripts. To understand mechanisms involved, we used RNA electrophoretic mobility shift assay and RNA turnover studies. Cortisol increased the binding of Ob cell cytosolic extracts to AU-rich sequences in the collagenase 3 3'-untranslated region (UTR). No cortisol-dependent protein complexes were formed with the coding region or the 5'-UTR. Functional assays, using transient transfections of CMV-driven c-fos collagenase 3'-UTR chimeric constructs, demonstrated that the 3'-UTR of collagenase 3 stabilizes c-fos mRNA in transcriptionally arrested Ob cells, cortisol prolongs the transcript half-life, and mutations of AU-rich sequences destabilize c-fos transcripts precluding the cortisol effect. Purification of osteoblast cytosolic extracts by ultracentrifugation, ion exchange, and RNA affinity chromatography, and polyacrylamide gel electrophoresis followed by mass spectroscopy identified specific proteins. RNA gel mobility supershift assays demonstrated that vinculin and far upstream element (FUSE)-binding protein 2 interacted with collagenase 3 3'-UTR sequences, and RNA interference demonstrated these proteins altered collagenase mRNA stability. In conclusion, AU-rich sequences of the 3'-UTR of collagenase 3 and vinculin and FUSE-binding protein 2 regulate collagenase mRNA stability in osteoblasts.	St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	Saint Francis Hospital & Medical Center; University of Connecticut	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	ecanalis@stfranciscare.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45227] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441; Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CURRAN T, 1987, ONCOGENE, V2, P79; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Gramolini AO, 2001, J CELL BIOL, V154, P1173, DOI 10.1083/jcb.200101108; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; Hel Z, 1996, MOL CELL BIOL, V16, P5579; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; Horton R. M., 1993, PCR PROTOCOLS, P251; HUANG LY, 1993, J BIOL CHEM, V268, P25769; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756-3282(02)00687-7; Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756-3282(01)00422-7; Poon M, 1999, MOL CELL BIOL, V19, P6471; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; RIFAS L, 1994, ENDOCRINOLOGY, V134, P213, DOI 10.1210/en.134.1.213; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Sokal R. R, 1981, BIOMETRY; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; Wang XJ, 1998, NEUROSCI LETT, V252, P191, DOI 10.1016/S0304-3940(98)00598-9; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	63	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5397	5404		10.1074/jbc.M311984200	http://dx.doi.org/10.1074/jbc.M311984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645243	hybrid			2022-12-25	WOS:000188776500045
J	Lim, ACB; Tiu, SY; Li, Q; Qi, RZ				Lim, ACB; Tiu, SY; Li, Q; Qi, RZ			Direct regulation of microtubule dynamics by protein kinase CK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NEUROBLASTOMA-CELLS; COLD STABILITY; BETA-SUBUNIT; PHOSPHORYLATION; TUBULIN; DOUBLECORTIN; DISRUPTION; DEPLETION; ENZYME	Microtubule dynamics is essential for many vital cellular processes such as morphogenesis and motility. Protein kinase CK2 is a ubiquitous protein kinase that is involved in diverse cellular functions. CK2 holoenzyme is composed of two catalytic alpha or alpha' subunits and two regulatory beta subunits. We show that the alpha subunit of CK2 binds directly to both microtubules and tubulin heterodimers. CK2 holoenzyme but neither of its individual subunits exhibited a potent effect of inducing microtubule assembly and bundling. Moreover, the polymerized microtubules were strongly stabilized by CK2 against cold-induced depolymerization. Interestingly, the kinase activity of CK2 is not required for its microtubule-assembling and stabilizing function because a kinase-inactive mutant of CK2 displayed the same microtubule-assembling activity as the wild-type protein. Knockdown of CK2alpha/alpha' in cultured cells by RNA interference dramatically destabilized their microtubule networks, and the destabilized microtubules were readily destructed by colchicine at a very low concentration. Further, over-expression of chicken CK2alpha or its kinase-inactive mutant in the endogenous CK2alpha/alpha'-depleted cells fully restored the microtubule resistance to the low dose of colchicine. Taken together, CK2 is a microtubule-associated protein that confers microtubule stability in a phosphorylation-independent manner.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 117609, Singapore	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Qi, RZ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	qirz@ust.hk		Qi, Robert Zhong/0000-0001-5596-8172				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BAAS PW, 1994, J CELL SCI, V107, P135; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Denarier E, 1998, P NATL ACAD SCI USA, V95, P6055, DOI 10.1073/pnas.95.11.6055; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DIAZNIDO J, 1992, 2 MESSENGERS PHOSPHO, V14, P39; Faust M, 1999, FEBS LETT, V462, P51, DOI 10.1016/S0014-5793(99)01492-1; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GASKIN F, 1982, METHOD ENZYMOL, V85, P433; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Tang BL, 2001, J BIOL CHEM, V276, P40008, DOI 10.1074/jbc.M106189200; ULLOA L, 1994, CELL MOL NEUROBIOL, V14, P407, DOI 10.1007/BF02088827; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; WEBB BC, 1980, BIOCHEMISTRY-US, V19, P1993, DOI 10.1021/bi00550a041; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X	38	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4433	4439		10.1074/jbc.M310563200	http://dx.doi.org/10.1074/jbc.M310563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14634006	hybrid			2022-12-25	WOS:000188554300062
J	Cho, NH; Hong, KP; Hong, SH; Kang, S; Chung, KY; Cho, SH				Cho, NH; Hong, KP; Hong, SH; Kang, S; Chung, KY; Cho, SH			MMP expression profiling in recurred stage IB lung cancer	ONCOGENE			English	Article						recurred stage IB lung cancer; MMP-10; MMP-12; c-DNA array; real-time RT-PCR	MATRIX METALLOPROTEINASES; CARCINOMAS; GENES; METASTASIS; INHIBITORS; OVEREXPRESSION; STROMELYSIN-2; COLLAGENASE; GELATINASE; TUMORS	We aimed to clarify the prime role of recurrence in stage I lung cancer. To determine the expression profiles, quantitative RT - PCR and real-time PCR were performed subsequently to evaluate the validity of meaningful molecules identified by 0.12K c-DNA array experiment surveys. In all, 10 lung cancer patients presenting with recurrence of stage IB were selected and compared with 10 stage IB lung cancer patients without recurrence since biopsied 3 years previously. On c-DNA microarray data analysis using pairs of recurred and the corresponding nonrecurred patients, the following genes were found to be upregulated in the recurred cases: matrix metalloproteinase (MMP)-10 in five cases, MMP-12 in two cases, MMP-11, MMP-14, MMP-15, fos, cyclin E2, E2F3, TGF-alpha in each one case. The most frequently upregulated genes in recurred lung cancers were MMP-10 (stromelysin-2) and MMP-12 ( macrophage elastase). On transcriptional assay by quantitative RT - PCR and real-time RT - PCR analysis to validate those molecules, both transcripts of MMP-10 and MMP-12 were significantly more upregulated in recurred stage IB lung cancer than in the non-recurred stage IB lung cancer ( P = 0.004). Transcript levels were identical to c-DNA array data. The protein levels of these entities were also evaluated by immunohistochemistry of archival slides. By immunohistochemistry, MMP-10 monoclonal antibody showed more intense immunoreactivity in the recurred stage IB lung cancer than in the nonrecurred stage IB lung cancer ( P = 0.0313). Our approach revealed that MMP-10 plays an important role in the recurrence in stage IB lung cancer, irrespective of the histologic type.	Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Thorac Surg, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, SH (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, Shinchon Dong 134, Seoul, South Korea.	shjo@yumc.yonsei.ac.kr		KANG, SUKI/0000-0002-9957-3479; jo, namhun/0000-0002-0045-6441				Bolon I, 1997, AM J PATHOL, V150, P1619; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Cai M, 2002, CLIN CANCER RES, V8, P1152; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; MARTINI N, 1977, J THORAC CARDIOV SUR, V74, P499; MARTINI N, 1995, J THORAC CARDIOV SUR, V109, P120, DOI 10.1016/S0022-5223(95)70427-2; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 2001, J PATHOL, V195, P135, DOI 10.1002/1096-9896(200109)195:2<135::AID-PATH939>3.0.CO;2-G; NAGAKAWA H, 1994, JPN J CANCER RES, V85, P934; NAGASE H, 1998, STROMELYSINS 1 2, P43; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; OHORI NP, 1992, AM J SURG PATHOL, V16, P675, DOI 10.1097/00000478-199207000-00006; Passlick B, 2000, CLIN CANCER RES, V6, P3944; Rechardt O, 2000, J INVEST DERMATOL, V115, P778, DOI 10.1046/j.1523-1747.2000.00135.x; SHAPIRO SD, 1998, MATRIX METALLOPROTEI, P185; SOINI Y, 1993, AM J PATHOL, V142, P1622; SREENATH T, 1992, CANCER RES, V52, P4942; Thomas P, 2000, J PATHOL, V190, P150; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434	27	48	53	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					845	851		10.1038/sj.onc.1207140	http://dx.doi.org/10.1038/sj.onc.1207140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647437				2022-12-25	WOS:000188304900024
J	Nekhotiaeva, N; Elmquist, A; Rajarao, GK; Hallbrink, M; Langel, U; Good, L				Nekhotiaeva, N; Elmquist, A; Rajarao, GK; Hallbrink, M; Langel, U; Good, L			Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides	FASEB JOURNAL			English	Article						bacteria; fungi; cell-permeable peptide; drug delivery	MEMBRANES; PERMEABILITY; ANTIBIOTICS; MECHANISM; BUFORIN; ANALOGS	Antimicrobial drug action is limited by both microbial and host cell membranes. Microbes stringently exclude the entry of most drugs, and mammalian membranes limit drug distribution and access to intracellular pathogens. Recently, cell-penetrating peptides (CPPs) have been developed as carriers to improve mammalian cell uptake. Given that CPP's are cationic and often amphipathic, similar to membrane active antimicrobial peptides, it may be possible to use CPP activity to improve drug delivery to microbes. Here, two CPPs, TP10 and pVEC, were found to enter a range of bacteria and fungi. The uptake route involves rapid surface accumulation within minutes followed by cell entry. TP10 inhibited Candida albicans and Staphylococcus aureus growth, and pVEC inhibited Mycobacterium smegmatis growth at low micromolar doses, below the levels that harmed human HeLa cells. Therefore, although TP10 and pVEC entered all cell types tested, they preferentially damage microbes, and this effect was sufficient to clear HeLa cell cultures from noninvasive S. aureus infection. Also, conversion of the cytotoxicity indicator dye SYTOX Green showed that TP10 causes rapid and lethal permeabilization of S. aureus and pVEC permeabilizes M. smegmatis, but not HeLa cells. Therefore, TP10 and pVEC can enter both mammalian and microbial cells and preferentially permeabilize and kill microbes.	Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Stockholm Univ, Dept Neurochem & Neurotoxicol, SE-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Good, L (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Berzelius Vag 35, S-17177 Stockholm, Sweden.	liam.good@cgb.ki.se		Good, Liam/0000-0002-2798-8640; Langel, Ulo/0000-0001-6107-0844				Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dathe M, 2002, BBA-BIOMEMBRANES, V1558, P171, DOI 10.1016/S0005-2736(01)00429-1; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Efron L, 2002, J BIOL CHEM, V277, P24067, DOI 10.1074/jbc.M202089200; Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316; Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200; Good L, 2001, NAT BIOTECHNOL, V19, P360, DOI 10.1038/86753; Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Levitt David G, 2003, BMC Clin Pharmacol, V3, P3, DOI 10.1186/1472-6904-3-3; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lorian V., 2005, ANTIBIOTICS LAB MED; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Pokorny A, 2002, BIOCHEMISTRY-US, V41, P11044, DOI 10.1021/bi020244r; Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje; RICHARD JP, 2002, J BIOL CHEM, P585; Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9; Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jbc.M208762200; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242	21	109	114	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					394	+		10.1096/fj.03-0449fje	http://dx.doi.org/10.1096/fj.03-0449fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656995				2022-12-25	WOS:000188067500030
J	Wellman, TL; Jenkins, J; Penar, PL; Tranmer, B; Zahr, R; Lounsbury, KM				Wellman, TL; Jenkins, J; Penar, PL; Tranmer, B; Zahr, R; Lounsbury, KM			Nitric oxide and reactive oxygen species exert opposing effects on the stability of hypoxia inducible factor-1 alpha (HIF-1 alpha) in explants of human pial arteries	FASEB JOURNAL			English	Article						angiogenesis; oxidant stress; cerebral ischemia; VEGF transcription	ENDOTHELIAL GROWTH-FACTOR; MITOCHONDRIAL RESPIRATORY-CHAIN; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; FACTOR-I; FACTOR 1-ALPHA; CARBON-MONOXIDE; PROTEIN-KINASE; RAT-BRAIN; ACTIVATION	Hypoxia induces angiogenesis, partly through stabilization of hypoxia-inducible factor-1alpha (HIF-1alpha), leading to transcription of pro-angiogenic factors. Here we examined the regulation of HIF-1alpha. by hypoxia and nitric oxide (NO) in explants of human cerebrovascular smooth muscle cells. Cells were treated with NO donors under normoxic or hypoxic (2% O-2) conditions, followed by analysis of HIF-1alpha. protein levels. Treatment with the NO donor sodium nitroprusside reduced levels of HIF-1alpha, whereas NO donors, NOC-18 and S-nitrosoglutathione, increased HIF-1alpha levels. SIN-1, which releases both NO and superoxide (O-2(.-)), reduced HIF-1alpha levels, suggesting that inhibitory NO donors may elicit effects through peroxynitrite (ONOO.-). O-2(.-) generation by xanthine/xanthine oxidase also reduced HIF-1alpha levels, confirming an inhibitory role for reactive oxygen species (ROS). Furthermore, superoxide dismutase increased HIF-1alpha levels, and the NO scavenger carboxy-PTIO reversed HIF-1alpha stabilization by NO donors. Effects on HIF-1alpha levels correlated with vascular endothelial growth factor transcription but did not affect HIF-1alpha transcription, as measured by RT-PCR and luciferase-reporter assays. The results indicate that HIF-1alpha is stabilized by agents that produce NO and reduce ROS but destabilized by agents that increase ROS, including O-2(.-) and ONOO.-. Thus we propose that the effect of NO on HIF-1alpha signaling is critically dependent on the form of NO and the physiological environment of the responding cell.	Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA; Univ Vermont, Dept Surg, Div Neurol Surg, Burlington, VT 05405 USA; Univ Vermont, Totman Ctr Cerebrovasc Res, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	Lounsbury, KM (corresponding author), Univ Vermont, Dept Pharmacol, Given Bldg,89 Beaumont Ave, Burlington, VT 05405 USA.	Karen.Lounsbury@uvm.edu						Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Christensen T, 1994, Neurobiol Dis, V1, P131, DOI 10.1006/nbdi.1994.0016; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GEBREMEDHIN D, 1994, PFLUG ARCH EUR J PHY, V428, P621, DOI 10.1007/BF00374586; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kimura H, 2002, BIOCHEM BIOPH RES CO, V296, P976, DOI 10.1016/S0006-291X(02)02029-6; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Lounsbury KM, 2000, FREE RADICAL BIO MED, V28, P1362, DOI 10.1016/S0891-5849(00)00222-7; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; Osipenko ON, 2000, CIRC RES, V86, P534, DOI 10.1161/01.RES.86.5.534; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PEARCE WJ, 1995, PHARMACOL THERAPEUT, V65, P75, DOI 10.1016/0163-7258(94)00058-B; PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x; Richard DE, 2000, J BIOL CHEM, V275, P26765; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Stevenson AS, 2001, EXP CELL RES, V263, P118, DOI 10.1006/excr.2000.5107; Sumbayev VV, 2003, FEBS LETT, V535, P106, DOI 10.1016/S0014-5793(02)03887-5; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wolff C B, 2000, High Alt Med Biol, V1, P33, DOI 10.1089/152702900320667; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang RL, 2003, CIRC RES, V92, P308, DOI 10.1161/01.RES.0000056757.93432.8C	50	67	71	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					379	+		10.1096/fj.03-0143fje	http://dx.doi.org/10.1096/fj.03-0143fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657004				2022-12-25	WOS:000188067500026
J	Berken, A; Abel, J; Unfried, K				Berken, A; Abel, J; Unfried, K			beta 1-integrin mediates asbestos-induced phosphorylation of AKT and ERK1/2 in a rat pleural mesothelial cell line	ONCOGENE			English	Article						asbestos; integrin; mesothelioma; ERK1/2; AKT; FAK	SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED CARCINOGENESIS; CROCIDOLITE ASBESTOS; INTEGRINS; FIBRONECTIN; ACTIVATION; PATHWAYS; ADHESION; FAK	Integrin-mediated signalling has been implicated in asbestos-induced carcinogenesis. In studies here, we examined signal transduction events associated with integrin-directed cell reactions triggered by crocidolite asbestos in the pleural mesothelial cell line 4/4 RM-4. Crocidolite fibres induced a significant time- and dose-dependent activation of the extracellular-signal-regulated kinases ERK1 and ERK2. ERK activation was specifically inhibited by integrin-blocking agents, that are integrin-binding peptides containing the sequence arginine-glycine-aspartic acid (RGD), and monoclonal antibodies against the integrin B1-chain. Integrin-dependent activation of ERK1/2 in response to asbestos appeared to be independent of focal adhesion kinase pp125(FAK) (FAK) since FAK autophosphorylation remained unaffected in crocidolite-exposed mesothelial cells. Instead, we observed striking similarities in the kinetics of asbestos-induced ERK1/2 responses and phosphorylation of protein kinase B (AKT) at serine 473, a possible target residue for integrin-linked kinase. As with ERK activation, asbestos-induced AKT stimulation was significantly blocked by both the RGD-peptide and the B1-integrin antibodies. These studies are the first to establish that in mesothelial cells ERK1/2 and AKT are simultaneously phosphorylated upon asbestos exposure in a B1-integrin-dependent manner.	Univ Dusseldorf, Inst Umweltmed Forsch, Dept Toxicol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Unfried, K (corresponding author), Univ Dusseldorf, Inst Umweltmed Forsch, Dept Toxicol, Hennekamp 50, D-40225 Dusseldorf, Germany.	Klaus.Unfried@uni-duesseldorf.de						Albrecht C, 2002, TOXICOL APPL PHARM, V184, P37, DOI 10.1006/taap.2002.9500; Aplin AE, 1998, PHARMACOL REV, V50, P197; ARONSON JF, 1981, AM J RESP CELL MOL B, V15, P141; BOYLAN AM, 1995, J CLIN INVEST, V96, P1987, DOI 10.1172/JCI118246; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1998, BIOCHEM J, V335, P1; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KUWAHARA M, 1994, AM J RESP CELL MOL, V10, P167, DOI 10.1165/ajrcmb.10.2.8110473; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu WH, 2000, AM J RESP CELL MOL, V23, P371, DOI 10.1165/ajrcmb.23.3.4094; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sandhu H, 2000, INHAL TOXICOL, V12, P337, DOI 10.1080/08958378.2000.11463243; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Unfried K, 2000, INHAL TOXICOL, V12, P149, DOI 10.1080/08958378.2000.11463208; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684	30	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8524	8528		10.1038/sj.onc.1207195	http://dx.doi.org/10.1038/sj.onc.1207195			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627993				2022-12-25	WOS:000186650300016
J	Gemignani, F; Moreno, V; Landi, S; Moullan, N; Chabrier, A; Gutierrez-Enriquez, S; Hall, J; Guino, E; Peinado, MA; Capella, G; Canzian, F				Gemignani, F; Moreno, V; Landi, S; Moullan, N; Chabrier, A; Gutierrez-Enriquez, S; Hall, J; Guino, E; Peinado, MA; Capella, G; Canzian, F			A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA	ONCOGENE			English	Article						TP53; colorectal cancer; polymorphism; mRNA levels	BREAST-CANCER; COMMON POLYMORPHISMS; OVARIAN-CANCER; P53 GENE; SEQUENCE; INFORMATION; PREDICTION; MUTATIONS; VARIANTS	We undertook a case-control study to examine the possible associations of the TP53 variants Arg>Pro at codon 72 and p53PIN3, a 16 bp insertion/duplication in intron 3, with the risk of colorectal cancer (CRC). The p53PIN3 A2 allele (16 bp duplication) was associated with an increased risk (OR 1.55, 95% CI 1.10-2.18, P = 0.012), of the same order of magnitude as that observed in previous studies for other types of cancer. The Pro72 allele was weakly associated with CRC (OR = 1.34, 95% CI 0.98-1.84, P = 0.066). The possible functional role of p53PIN3 was investigated by examining the TP53 mRNA transcripts in 15 lymphoblastoid cell lines with different genotypes. The possibility that the insertion/deletion could lead to alternatively spliced mRNAs was excluded. However, we found reduced levels of TP53 mRNA associated with the A2 allele. In conclusion, the epidemiological study suggests a role for p53PIN3 in tumorigenesis, supported by the in vitro characterization of this variant.	Int Agcy Res Canc, Genome Anal Grp, F-69372 Lyon, France; Univ Pisa, Dipartimento Sci Uomo & Ambiente, I-56100 Pisa, Italy; Inst Catala Oncol, Barcelona, Spain; Inst Recerca Oncol, Barcelona, Spain	World Health Organization; International Agency for Research on Cancer (IARC); University of Pisa; Catalan Institute of Oncology	Canzian, F (corresponding author), Int Agcy Res Canc, Genome Anal Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	canzian@iarc.fr	Canzian, Federico/I-2804-2014; Peinado, Miguel A./A-5591-2008; Moreno, Victor/A-1697-2010; Capella, Gabriel/I-1879-2015; hall, janet/G-1372-2013; Gutierrez, Sara/GXE-9832-2022	Peinado, Miguel A./0000-0002-4090-793X; Moreno, Victor/0000-0002-2818-5487; Capella, Gabriel/0000-0002-4669-7320; hall, janet/0000-0002-4397-6295; Landi, Stefano/0000-0001-8364-6357; GEMIGNANI, Federica/0000-0003-1297-0701; Guino, Elisabet/0000-0003-0093-2652; Gutierrez-Enriquez, Sara/0000-0002-1711-6101; Canzian, Federico/0000-0002-4261-4583				BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Cox DG, 2001, BIOINFORMATICS, V17, P738, DOI 10.1093/bioinformatics/17.8.738; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Landi S, 2003, CANCER RES, V63, P3560; LAZAR V, 1993, ONCOGENE, V8, P1703; Powell BL, 2002, CARCINOGENESIS, V23, P311, DOI 10.1093/carcin/23.2.311; Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO;2-O; RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tonisson N, 2002, P NATL ACAD SCI USA, V99, P5503, DOI 10.1073/pnas.082100599; Wang-Gohrke S, 2002, PHARMACOGENETICS, V12, P269, DOI 10.1097/00008571-200204000-00012; Wang-Gohrke S, 1999, BRIT J CANCER, V81, P179, DOI 10.1038/sj.bjc.6690669; Weston A, 1997, CANCER EPIDEM BIOMAR, V6, P105; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681	16	171	182	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1954	1956		10.1038/sj.onc.1207305	http://dx.doi.org/10.1038/sj.onc.1207305			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647431				2022-12-25	WOS:000220129500018
J	Lee, DK; Lanca, AJ; Cheng, R; Nguyen, T; Ji, XD; Gobeil, F; Chemtob, S; George, SR; O'Dowd, BF				Lee, DK; Lanca, AJ; Cheng, R; Nguyen, T; Ji, XD; Gobeil, F; Chemtob, S; George, SR; O'Dowd, BF			Agonist-independent nuclear localization of the apelin, angiotensin AT(1), and bradykinin B-2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROSTAGLANDIN E-2 RECEPTORS; PROTEIN-COUPLED RECEPTOR; ENDOGENOUS LIGAND APELIN; HUMAN APJ RECEPTOR; ORPHAN RECEPTOR; MESSENGER-RNA; TISSUE DISTRIBUTION; RAT-BRAIN; TRANSLOCATION	Signaling of the apelin, angiotensin, and bradykinin peptides is mediated by G protein-coupled receptors related through structure and similarities of physiological function. We report nuclear expression as a characteristic of these receptors, including a nuclear localization for the apelin receptor in brain and cerebellum-derived D283 Med cells and the AT(1) and bradykinin B-2 receptors in HEK-293T cells. Immunocytochemical analyses revealed the apelin receptor with localization in neuronal nuclei in cerebellum and hypothalamus, exhibiting expression in neuronal cytoplasm or in both nuclei and cytoplasm. Confocal microscopy of HEK-293T cells revealed the majority of transfected cells displayed constitutive nuclear localization of AT(1) and B-2 receptors, whereas apelin receptors did not show nuclear localization in these cells. The majority of apelin receptor-transfected cerebellum D283 Med cells showed receptor nuclear expression. Immunoblot analyses of subcellular-fractionated D283 Med cells demonstrated endogenous apelin receptor species in nuclear fractions. In addition, an identified nuclear localization signal motif in the third intracellular loop of the apelin receptor was disrupted by a substituted glutamine in place of lysine. This apelin receptor (K242Q) did not exhibit nuclear localization in D283 Med cells. These results demonstrate the following: (i) the apelin receptor exhibits nuclear localization in human brain; (ii) distinct cell-dependent mechanisms for the nuclear transport of apelin, AT(1), and B-2 receptors; and (iii) the disruption of a nuclear localization signal sequence disrupts the nuclear translocation of the apelin receptor. This discovery of apelin, AT(1), and B-2 receptors with agonist-independent nuclear translocation suggests major unanticipated roles for these receptors in cell signaling and function.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Menatl Hlth, Toronto, ON M5S 2S1, Canada; Hop St Justine, Dept Pediat Ophthalmol & Pharmacol, Montreal, PQ M3T 1C5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Universite de Montreal; McGill University	O'Dowd, BF (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,Rm 4352,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	brian.odowd@utoronto.ca	George, Susan R/P-9669-2018; George, Susan/W-7494-2019					AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Bachvarov DR, 2001, J PHARMACOL EXP THER, V297, P19; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; Brailoiu GC, 2002, NEUROSCI LETT, V327, P193, DOI 10.1016/S0304-3940(02)00411-1; Chen R, 2000, AM J PHYSIOL-RENAL, V279, pF440, DOI 10.1152/ajprenal.2000.279.3.F440; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe W, 2000, J NEUROVIROL, V6, pS61; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; De Falco M, 2002, IN VIVO, V16, P333; De Mota N, 2000, NEUROENDOCRINOLOGY, V72, P400, DOI 10.1159/000054609; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; EGGENA P, 1993, HYPERTENSION, V22, P496, DOI 10.1161/01.HYP.22.4.496; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fatima S, 2003, J CELL SCI, V116, P353, DOI 10.1242/jcs.00242; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; Katugampola SD, 2001, BRIT J PHARMACOL, V132, P1255, DOI 10.1038/sj.bjp.0703939; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Lanca AJ, 1999, NEUROSCIENCE, V91, P1331, DOI 10.1016/S0306-4522(98)00709-X; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; Miserey-Lenkei S, 2001, MOL ENDOCRINOL, V15, P294, DOI 10.1210/me.15.2.294; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Puffer BA, 2000, VIROLOGY, V276, P435, DOI 10.1006/viro.2000.0557; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; Reaux A, 2002, NEUROSCIENCE, V113, P653, DOI 10.1016/S0306-4522(02)00192-6; ROTH BL, 1981, J BIOL CHEM, V256, P117; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; Yamamoto S, 1998, MICROSC RES TECHNIQ, V40, P479, DOI 10.1002/(SICI)1097-0029(19980301)40:6<479::AID-JEMT8>3.0.CO;2-K	52	160	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7901	7908		10.1074/jbc.M306377200	http://dx.doi.org/10.1074/jbc.M306377200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14645236	hybrid			2022-12-25	WOS:000189103300067
J	Lara-Pezzi, E; Pezzi, N; Prieto, I; Barthelemy, I; Carreiro, C; Martinez, A; Maldonado-Rodriguez, A; Lopez-Cabrera, M; Barbero, JL				Lara-Pezzi, E; Pezzi, N; Prieto, I; Barthelemy, I; Carreiro, C; Martinez, A; Maldonado-Rodriguez, A; Lopez-Cabrera, M; Barbero, JL			Evidence of a transcriptional co-activator function of cohesin STAG/SA/Scc3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; NUCLEAR RECEPTOR; SUBUNIT SCC1; COMPLEX; EXPRESSION; SEPARATION; RAD21; HETEROCHROMATIN; CHROMOSOMES	Cohesins hold sister chromatids together from DNA replication until they are segregated. Although cohesins Smc1, Smc3, and Scc1/Rad21 are involved in chromatid cohesion and other cellular processes, little is known about the other mitotic cohesin subunit, Scc3/STAG. Here we describe STAG/Scc3, which may act as a transcriptional co-activator. STAG2 is able to enhance the activity of the tumor necrosis factor alpha, the CD69, and the human immunodeficiency virus long terminal repeat promoters in a NF-kappaB-dependent manner. In addition, STAG2 interacts with the viral transactivator Tat and enhances the Tat-mediated activation of the human immunodeficiency virus long terminal repeat promoter. Moreover, STAG2 co-activates a multimeric NF-kappaB reporter construct and enhances the activity of the transactivation domain of p65/RelA in a Gal4 system. This function is dependent on one of the LXXLL co-activation motives present in this cohesin and is substantiated by the interaction of STAG2 with the p65 subunit of NF-kappaB. These results describe a novel activity for cohesins, suggesting a role for STAG/ Scc3 in transcriptional regulation.	Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Madrid 28049, Spain; Hosp Princesa, Unidad Biol Mol, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital de La Princesa	Barbero, JL (corresponding author), Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Campus Cantoblanco, Madrid 28049, Spain.	jlbarbero@cnb.uam.es	Lara-Pezzi, Enrique/E-2350-2015; Barbero, Jose Luis/J-9833-2014; Cabrera, Manuel López/AAA-5463-2019	Lara-Pezzi, Enrique/0000-0002-2743-1033; Lopez Cabrera, Manuel/0000-0002-0976-9719; BARBERO, JOSE LUIS/0000-0002-1226-0323				Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Carretero M, 2002, VIROLOGY, V299, P288, DOI 10.1006/viro.2002.1526; Castellanos MD, 2002, EUR J IMMUNOL, V32, P3108; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Ghiselli G, 2000, J BIOL CHEM, V275, P20235, DOI 10.1074/jbc.C000213200; Glass CK, 2000, GENE DEV, V14, P121; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horak CE, 2002, GENE DEV, V16, P3017, DOI 10.1101/gad.1039602; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Prieto I, 2002, EMBO REP, V3, P543, DOI 10.1093/embo-reports/kvf108; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Vass S, 2003, CURR BIOL, V13, P208, DOI 10.1016/S0960-9822(03)00047-2; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	34	40	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6553	6559		10.1074/jbc.M307663200	http://dx.doi.org/10.1074/jbc.M307663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660624	hybrid			2022-12-25	WOS:000188969200043
J	Zhang, YC; Berger, SA				Zhang, YC; Berger, SA			Increased calcium influx and ribosomal content correlate with resistance to endoplasmic reticulum stress-induced cell death in mutant leukemia cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELLS; CA2+ STORES; ENTRY; ACTIVATION; APOPTOSIS; DEPLETION; GRP78; INHIBITION; MECHANISM; ECONAZOLE	Cell clones were derived by treatment of HL-60 cells with stepwise increasing concentrations of econazole (EC), an imidazole antifungal that blocks Ca2+ influx and induces endoplasmic reticulum (ER) stress-related cell death in multiple mammalian cell types. Clones exhibit 20- to more than 300-fold greater resistance to Ec. Unexpectedly, they also display stable cross-resistance to tunicamycin, thapsigargin, dithiothreitol, and cycloheximide but not doxorubicin, etoposide, or Fas ligand. Phenotypic analysis indicates that the cells display increased store-operated calcium influx and resistance to ER Ca2+ store depletion by Ec. E2R2, the most resistant clone, was observed to maintain protein synthesis levels after treatment with Ec or thapsigargin. Expression of GRP78, an ER-based chaperone, was induced by these ER stress treatments but to equal degrees in HL-60 and E2R2 cells. By using microarray analysis, at least 15 ribosomal protein genes were found to be overexpressed in E2R2 compared with HL-60 cells. We also found that ribosomal protein content was increased by 30% in E2R2 as well as other clones. The resistance phenotype was partially reversed by the ribosome-inactivating protein saporin. Therefore, increased store-operated calcium influx, resistance to ER Ca2+ store depletion, and overexpression of ribosomal proteins define a novel phenotype of ER stress-associated multidrug resistance.	Univ Hlth Network, Arthrit & Immune Disorder Res Ctr, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Berger, SA (corresponding author), Univ Hlth Network, Arthrit & Immune Disorder Res Ctr, 620 Univ Ave,Ste 700, Toronto, ON M5G 2M9, Canada.	Berger@uhnres.utoronto.ca						Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; BUCKLEY NE, 1995, BBA-LIPID LIPID MET, V1256, P275, DOI 10.1016/0005-2760(95)00030-G; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ESTACION M, 1993, CELL CALCIUM, V14, P439, DOI 10.1016/0143-4160(93)90003-O; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gamberucci A, 1998, BIOCHEM BIOPH RES CO, V248, P75, DOI 10.1006/bbrc.1998.8810; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jan CR, 1999, BBA-MOL CELL RES, V1448, P533, DOI 10.1016/S0167-4889(98)00159-1; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOHN EC, 1992, CANCER RES, V52, P3208; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MADJAR JJ, 1977, MOL BIOL REP, V3, P289, DOI 10.1007/BF00368299; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miyake H, 2000, J CELL BIOCHEM, V77, P396, DOI 10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Soboloff J, 2002, J BIOL CHEM, V277, P13812, DOI 10.1074/jbc.M112129200; Soboloff J, 2002, EXP HEMATOL, V30, P1219, DOI 10.1016/S0301-472X(02)00893-7; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Zhang YC, 2002, BREAST CANCER RES TR, V72, P265, DOI 10.1023/A:1014965726663; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	36	21	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6507	6516		10.1074/jbc.M306117200	http://dx.doi.org/10.1074/jbc.M306117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660643	hybrid			2022-12-25	WOS:000188969200037
J	Fanelli, M; Fantozzi, A; De Luca, P; Caprodossi, S; Matsuzawa, S; Lazar, MA; Pelicci, PG; Minucci, S				Fanelli, M; Fantozzi, A; De Luca, P; Caprodossi, S; Matsuzawa, S; Lazar, MA; Pelicci, PG; Minucci, S			The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIAH UBIQUITIN LIGASE; ALPHA FUSION PROTEIN; PML-RAR-ALPHA; RETINOIC ACID; PML/RAR-ALPHA; TRANSCRIPTIONAL REPRESSION; PREMATURE SENESCENCE; HISTONE DEACETYLASE; ONCOGENIC RAS; PATHWAY	Mammalian homologues of Drosophila Seven in Absentia (SIAHs) target for proteasome-mediated degradation several factors involved in cell growth and tumorigenesis. Here we show that SIAH-1/2 binds and targets for proteasome-mediated degradation the putative tumor suppressor and tripartite motif (TRIM) family member PML, leading to the loss of its transcriptional co-activating properties and a reduction in the number of endogenous PML nuclear bodies. Association with PML requires the substrate-binding domain (SBD) of SIAH-1/2 through an interacting surface apparently distinct from those predicted by the structural studies, or shown experimentally to mediate binding to SIAH-associated factors. Within PML, the coiled-coil domain is required for Siah- and proteasome-mediated degradation, and deletions of regions critical for the integrity of this region impair the ability of Siah to trigger PML-RAR degradation. Fusion of the coiled-coil domain to heterologous proteins resulted in the capacity of mSiah-2 to target their degradation. All of the TRIM proteins tested were degraded upon mSiah-2 overexpression. Finally, we show that the fusion protein PML-RAR (that retains the coiled-coil domain), which causes acute promyelocytic leukemias, is also a potential substrate of mSiah-2. As a result of mSiah-2 overexpression and subsequent degradation of the fusion protein, the arrest in hematopoietic differentiation because of expression of PML-RAR is partially rescued. These results identify PML and other TRIMs as new factors post-translationally regulated by SIAH and involve the coiled-coil region of PML and of other SIAH substrates as a novel structural determinant for targeted degradation.	Univ Urbino Carlo Bo, Ctr Biotecnol, Fac Sci, MM FF NN, I-61032 Fano, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, Fac Biol Sci, I-20132 Milan, Italy; Burnham Inst, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Med Genet & Biochem, Philadelphia, PA 19104 USA	University of Urbino; IRCCS European Institute of Oncology (IEO); University of Milan; Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania	Fanelli, M (corresponding author), Univ Urbino Carlo Bo, Ctr Biotecnol, Fac Sci, MM FF NN, Via Campanella 1, I-61032 Fano, Italy.	mirco.fanelli@uniurb.it	Fanelli, Mirco/F-2665-2011; Lazar, Mitchell A/AAF-3738-2019; Minucci, Saverio/J-9669-2012; De Luca, Pasquale/AAL-5673-2021; Pelicci, Pier Giuseppe/AAL-6572-2020	Fanelli, Mirco/0000-0002-9649-8661; De Luca, Pasquale/0000-0003-4289-6784; 				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Antolini F, 2003, PROTEIN EXPRES PURIF, V29, P94, DOI 10.1016/S1046-5928(03)00004-4; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Frew IJ, 2002, MOL CELL BIOL, V22, P8155, DOI 10.1128/MCB.22.23.8155-8164.2002; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1998, CANCER RES, V58, P14; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Li SH, 2002, MOL CELL BIOL, V22, P6854, DOI 10.1128/MCB.22.19.6854-6865.2002; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nervi C, 1998, BLOOD, V92, P2244; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yoshida H, 1996, CANCER RES, V56, P2945; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	46	50	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5374	5379		10.1074/jbc.M306407200	http://dx.doi.org/10.1074/jbc.M306407200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645235	hybrid			2022-12-25	WOS:000188776500042
J	Niida, S; Kawahara, M; Ishizuka, Y; Ikeda, Y; Kondo, T; Hibi, T; Suzuki, Y; Ikeda, K; Taniguchi, N				Niida, S; Kawahara, M; Ishizuka, Y; Ikeda, Y; Kondo, T; Hibi, T; Suzuki, Y; Ikeda, K; Taniguchi, N			gamma-glutamyltranspeptidase stimulates receptor activator of nuclear factor-kappa B ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED IMMUNOSORBENT-ASSAY; RESISTANT ACID-PHOSPHATASE; OSTEOCLAST DIFFERENTIATION; TRANSFERASE TRANSPEPTIDASE; DEFICIENT MICE; CELLS; GENE; GLUTAMYLTRANSFERASE; HEPATOMA; TUMORS	A novel bone-resorbing factor was cloned using an expression cloning technique, which involved a Xenopus oocyte expression system and an assay for osteoclast formation. A candidate clone was isolated from a BW5147 mouse T-lymphoma cell cDNA library. Sequencing analysis identified the factor as gamma-glutamyltranspeptidase (GGT), which is an enzyme involved in glutathione metabolism. The addition of purified GGT protein to mouse bone marrow culture effectively induced formation of osteoclasts. An antibody against GGT inhibited osteoclast formation but not the enzymatic activity. We also demonstrated that an inactive form of GGT, the enzymatic activity of which had been blocked by chemical modification with a specific inhibitor, acivicin, supported osteoclast formation. These results indicate that GGT acts on osteoclast formation independent of its own enzymatic activity. Furthermore, both native GGT and inactive GGT stimulated the expression of the receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA and protein from bone marrow stromal cells. This report is the first demonstration of a novel biological activity of GGT protein in a manner independent of its enzymatic activity.	Natl Inst Longev Sci, Dept Geriatr Sci, Aichi 4748522, Japan; Hiroshima Univ, Fac Dent, Dept Orthodont, Hiroshima 7348553, Japan; Appl Cell Biotechnol Ltd, Tsukuba, Ibaraki 3050028, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Sumitomo Pharmaceut Res Ctr, Osaka 5540022, Japan	Hiroshima University; Osaka University	Niida, S (corresponding author), Natl Inst Longev Sci, Dept Geriatr Sci, Aichi 4748522, Japan.	niida@nils.go.jp	Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016; Hibi, Terumasa/I-3407-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Hibi, Terumasa/0000-0001-9373-9602				ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; BAROUKI R, 1983, HEPATOLOGY, V3, P323; COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18; HANIGAN MH, 1994, CANCER RES, V54, P286; Hanigan MH, 1999, HUM PATHOL, V30, P300, DOI 10.1016/S0046-8177(99)90009-6; Heathcote J, 1999, Curr Gastroenterol Rep, V1, P455, DOI 10.1007/s11894-999-0001-y; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Ishizuka Y, 1999, BBA-MOL CELL RES, V1450, P92, DOI 10.1016/S0167-4889(99)00039-7; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levasseur R, 2003, ENDOCRINOLOGY, V144, P2761, DOI 10.1210/en.2002-0071; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; Lieberman MW, 1996, P NATL ACAD SCI USA, V93, P7923, DOI 10.1073/pnas.93.15.7923; MIESTER A, 1981, METHOD ENZYMOL, V77, P237; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756-3282(96)00211-6; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; ROOS E, 1985, CANCER RES, V45, P6238; Santolaria F, 2000, ALCOHOL, V22, P147, DOI 10.1016/S0741-8329(00)00115-4; Shi ZZ, 1995, GENE, V167, P233, DOI 10.1016/0378-1119(95)00618-4; SMITH TK, 1995, P NATL ACAD SCI USA, V92, P2360, DOI 10.1073/pnas.92.6.2360; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1997, METHOD ENZYMOL, V282, P223; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; TANIGUCHI N, 1985, CANCER RES, V45, P5835; Taniguchi N, 1998, ADV ENZYMOL RAMB, V72, P239; TANIGUCHI N, 1983, ANN NY ACAD SCI, V417, P203, DOI 10.1111/j.1749-6632.1983.tb32864.x; TANIGUCHI N, 1985, J NATL CANCER I, V75, P841, DOI 10.1093/jnci/75.5.841; TESCHKE R, 1983, GUT, V24, P625, DOI 10.1136/gut.24.7.625; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang JA, 2002, J BONE MINER RES, V17, P1256, DOI 10.1359/jbmr.2002.17.7.1256	40	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5752	5756		10.1074/jbc.M311905200	http://dx.doi.org/10.1074/jbc.M311905200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634009	hybrid			2022-12-25	WOS:000188776500088
J	Guidi, CJ; Veal, TM; Jones, SN; Imbalzano, AN				Guidi, CJ; Veal, TM; Jones, SN; Imbalzano, AN			Transcriptional compensation for loss of an allele of the Ini1 tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; CENTRAL-NERVOUS-SYSTEM; CELL-CYCLE ARREST; RHABDOID TUMORS; SWI-SNF; NUCLEOSOMAL DNA; SWI/SNF COMPLEX; MICE; GENE; HSNF5/INI1	The gene encoding INI1, a component of the mammalian SWI/SNF ATP-dependent chromatin remodeling enzymes, has been classified as a tumor suppressor in humans. Gene-targeting experiments confirmed that Ini1 also functions as a tumor suppressor in mice. Although Ini1-null mice are embryonic lethal, 15-30% of mice heterozygous for Ini1 presented with poorly differentiated tumors with variable rhabdoid features. All tumors examined showed loss of heterozygosity at the Ini1 locus. We report here that cells and tissues heterozygous for the Ini1 tumor suppressor express levels of Ini1 protein and message roughly equivalent to the levels observed in wild type counterparts. Compensation of Ini1 is mediated by an increase in the rate of transcription from the Ini1 promoter. Moreover, when Ini1 is expressed exogenously, transcription from the endogenous promoter is reduced, suggesting that Ini1 levels are tightly regulated. This is the first report describing transcriptional compensation for haploinsufficiency of a tumor suppressor gene.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Imbalzano, AN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	anthony.imbalzano@umassmed.edu						Aalfs JD, 2001, J BIOL CHEM, V276, P34270, DOI 10.1074/jbc.M104163200; Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Becker PB, 2002, EMBO J, V21, P4749, DOI 10.1093/emboj/cdf486; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; Biegel JA, 1999, CANCER RES, V59, P74; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Grand F, 1999, CANCER RES, V59, P3870; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Narlikar GJ, 2001, MOL CELL, V8, P1219, DOI 10.1016/S1097-2765(01)00412-9; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Razani B, 2001, J BIOL CHEM, V276, P38121; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Trieu M, 2003, DEVELOPMENT, V130, P111, DOI 10.1242/dev.00194; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	45	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4180	4185		10.1074/jbc.M312043200	http://dx.doi.org/10.1074/jbc.M312043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14630919	hybrid			2022-12-25	WOS:000188554300034
J	Li, HW; Kim, JH; Koh, SS; Stallcup, MR				Li, HW; Kim, JH; Koh, SS; Stallcup, MR			Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation - Cross-talk between androgen receptor and Wnt signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; PROSTATE-CANCER; NUCLEAR RECEPTORS; PROTEIN METHYLTRANSFERASE; METHYLATION; COMPLEX; ACETYLTRANSFERASE; DOMAINS; CARM1; COREGULATORS	The p160 coactivators, such as GRIP1, bind nuclear receptors and help to mediate transcriptional activation. beta-Catenin binds to and serves as a coactivator for the nuclear receptor, androgen receptor (AR), and the Lymphoid Enhancer Factor/T Cell Factor family member, Lef1. Here we report that GRIP1 and beta-catenin can bind strongly to each other through the AD2 domain of GRIP1. Furthermore, GRIP1 and beta-catenin can synergistically enhance the activity of both AR and Lef1, and both coactivators are recruited specifically to AR-driven and Lef1-driven promoters. However, the mechanism of beta-catenin-GRIP1 coactivator function and synergy is different with AR and Lef1. While beta-catenin can bind directly to both AR and Lef1, GRIP1 can only bind directly to AR; the ability of GRIP1 to associate with and function as a coactivator for Lef1 is entirely dependent on the presence of beta-catenin. Thus, whereas GRIP1 coactivator function involves direct binding to nuclear receptors and most other classes of DNA-binding transcriptional activator proteins, the coactivator function of GRIP1 with Lef1 follows a novel paradigm where GRIP1 is recruited indirectly to Lef1 through their mutual association with beta-catenin. The beta-catenin-GRIP1 interaction represents another potential point of crosstalk between the AR and Wnt signaling pathways.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [DK43093] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glass CK, 2000, GENE DEV, V14, P121; Gregory CW, 2001, CANCER RES, V61, P4315; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Ma H, 2003, METHOD ENZYMOL, V364, P284; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Ross RK, 1998, CANCER RES, V58, P4497; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Truica CI, 2000, CANCER RES, V60, P4709; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	45	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4212	4220		10.1074/jbc.M311374200	http://dx.doi.org/10.1074/jbc.M311374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638683				2022-12-25	WOS:000188554300038
J	Ree, AH; Bratland, A; Nome, RV; Stokke, T; Fodstad, O				Ree, AH; Bratland, A; Nome, RV; Stokke, T; Fodstad, O			Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1	ONCOGENE			English	Article						BRCA1; polo-like kinase 1; cell cycle control; DNA damage; breast cancer	POLO-LIKE-KINASE; DOWN-REGULATION; CHECKPOINT; EXPRESSION; ATM; PROTEIN; PHOSPHORYLATION; PHOSPHATASE; REGULATORS; LINKAGE	DNA damage activates the G(2) cell cycle checkpoint to allow time for DNA repair before mitotic entry. The mechanism involves inhibition of the enzymatic activity for polo-like kinase 1 (Plk1), rendering Cdc25C with a basal phosphatase activity that is insufficient for converting Cdc2 to the fully active G(2)/M transition kinase. We found that cell cycle arrest at the G(2)/M boundary after ionizing radiation (IR) of breast carcinoma cells may involve repression of the gene for Plk1, PLK, mediated by the tumor-suppressor protein BRCA1. The p53-defective MT-1 cell line had an apparent accumulation of G(2)/M phase cells 12 h after irradiation. This response was preceded by a transient downregulation of PLK mRNA expression with a barely detectable level 6 h after exposure to IR but recovered after 12 h. A significantly lower fraction of irradiated BRCA1(-/-) HCC1937 cells arrested in the G(2)/M phase after 12 h, and the transient response of PLK mRNA was also considerably impaired. After reconstitution of wild-type BRCA1 in the HCC1937 cells however, downregulation of PLK mRNA as well as Plk1 protein expression after IR was restored. Moreover, the suppression of PLK mRNA expression 6 h after irradiation was completely abolished by the specific CHEK1 kinase inhibitor UCN-01, further indicating that the effector mechanism of DNA damage on PLK signals through BRCA1 and its downstream CHEK1. Our observations provide new information about the diversity of regulatory mechanisms governed by BRCA1 in DNA damage checkpoint control.	Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Biophys, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Ree, AH (corresponding author), Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway.			Ree, Anne H./0000-0002-8264-3223				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; Deng CX, 2000, BIOESSAYS, V22, P728; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; Engebraaten O, 1999, INT J CANCER, V82, P219, DOI 10.1002/(SICI)1097-0215(19990719)82:2<219::AID-IJC12>3.0.CO;2-#; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Tomlinson GE, 1998, CANCER RES, V58, P3237; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837	28	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8952	8955		10.1038/sj.onc.1207000	http://dx.doi.org/10.1038/sj.onc.1207000			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654792				2022-12-25	WOS:000186982200017
J	Wu, YZ; Zhang, XP; Zehner, ZE				Wu, YZ; Zhang, XP; Zehner, ZE			c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1	ONCOGENE			English	Article						c-Jun; coactivator; Sp1; vimentin; dominantnegative TAM67	CANCER CELL-LINES; NF-KAPPA-B; BREAST-CANCER; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; TUMOR-CELLS; PROMOTER; OVEREXPRESSION; PHENOTYPE; MECHANISMS	Vimentin exhibits a complex pattern of developmental- and tissue-specific expression. Since it is aberrantly expressed in metastatic tumors, which have progressed through the epithelial-mesenchymal transition, it has been cited as a marker for tumor progression. Previous studies have indicated that the transcription factor activator protein (AP1) is important in tumor progression. The stable transformation of the MCF7 cell line with the oncogene c-Jun resulted in a cell line (MCF7Jun), which displayed a change in morphology, enhanced migratory and invasive properties, and metastatic behavior. Of the 21 genes whose expression levels were altered in the MCF7Jun cell line, the greatest change in expression occurred for the vimentin gene. Previously, tandem AP1 sites in the promoter were reported to be important for the serum and TPA inducibility of the vimentin gene. However, we find that the AP1 elements only contribute in part to c-Jun activation. Moreover, this activation can be duplicated in COS-1 or S2 cells by expression of c-Jun or TAM67, and is dependent only on the leucine-zipper region of c-Jun. Transient transfection analyses, electrophoretic mobility shift assays, DNA precipitation assays, and coimmunoprecipitation studies suggest that c-Jun is able to synergize with the activator protein Sp1 in binding to GC-box1 to enhance vimentin gene expression.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.				NHLBI NIH HHS [HL-45422] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakovic M, 2000, J LIPID RES, V41, P583; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen JH, 1996, ONCOGENE, V13, P1667; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILLES C, 1996, BREAST J, V2, P83; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schneider I, 1972, J EMBRYOL EXP MORPH, V27, P363; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1989, CANCER RES, V49, P4258; STOVER DM, 1994, CANCER RES, V54, P3092; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZHANG X, 2003, NUCLEIC ACIDS RES, V31, P1	33	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8891	8901		10.1038/sj.onc.1206898	http://dx.doi.org/10.1038/sj.onc.1206898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654785				2022-12-25	WOS:000186982200010
J	Poliakov, E; Brennan, ML; Macpherson, J; Zhang, RL; Sha, W; Narine, IA; Salomon, RG; Hazen, SL				Poliakov, E; Brennan, ML; Macpherson, J; Zhang, RL; Sha, W; Narine, IA; Salomon, RG; Hazen, SL			Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo	FASEB JOURNAL			English	Article						isoprostane; myeloperoxidase; isolevuglandin; oxidant stress	LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; GAMMA-KETOALDEHYDES ISOLEVUGLANDINS; SCAVENGER RECEPTOR CD36; LIPID-PEROXIDATION; PROTEIN ADDUCTS; OXIDIZED PHOSPHOLIPIDS; 8-EPI-PROSTAGLANDIN F2-ALPHA; STRUCTURAL IDENTIFICATION; CARDIOVASCULAR-DISEASE	Isolevuglandins (isoLGs) are a family of reactive gamma-ketoaldehydes generated by free radical oxidation of arachidonate-containing lipids through the isoprostane pathway. Elevated plasma levels of isoLG protein adducts are observed in subjects with atherosclerosis compared with age/gender-matched controls. However, mechanisms for the generation of isoLGs in vivo are not established. Here we show that free radical-induced peroxidation promoted by the myeloperoxidase (MPO)/H2O2 system of leukocytes serves as one mechanism for the generation of isoLGs in vivo. Using a Candida sepsis model of inflammation, we demonstrate 3.5- and 2.7-fold increases in iso[4]LGE(2) and isoLGE(2) adducts of plasma proteins after pathogen exposure in wild-type mice. Plasma levels of F-2 isoprostanes were not significantly increased after pathogen challenge in this model. MPO knockout mice demonstrated significant reductions (34%, P=0.003) in plasma levels of iso[4]LGE(2) protein adducts after pathogen challenge compared with wild-type mice. Mass spectrometry and immunochemical methods demonstrate MPO-dependent formation of iso[4]LGE(2) and isoLGE(2) phospholipids and their corresponding isoLG protein adducts in model systems. The present studies thus identify MPO as one pathway for generation of isoLGs in vivo. They also suggest that long-lived protein isoLG adducts may serve as an alternative integrated sensor of oxidant stress in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Salomon, Robert G/C-3463-2008; Hazen, Stanley L/ABD-5845-2021	Salomon, Robert/0000-0001-9456-3557	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL61878, HL70621, HL62526] Funding Source: Medline; NIGMS NIH HHS [GM21249] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL070621, R01HL062526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aratani Y, 1999, INFECT IMMUN, V67, P1828; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Carr AC, 2000, ARTERIOSCL THROM VAS, V20, P1716, DOI 10.1161/01.ATV.20.7.1716; Chiabrando C, 1999, J BIOL CHEM, V274, P1313, DOI 10.1074/jbc.274.3.1313; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DIFRANCO E, 1995, CHEM RES TOXICOL, V8, P61, DOI 10.1021/tx00043a008; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HALLIWELL B, 1987, FEBS LETT, V213, P9, DOI 10.1016/0014-5793(87)81455-2; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hoppe G, 1997, BBA-LIPID LIPID MET, V1344, P1, DOI 10.1016/S0005-2760(96)00160-9; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; JIROUSEK MR, 1990, PROSTAGLANDINS, V40, P187, DOI 10.1016/0090-6980(90)90083-8; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Meagher EA, 2000, FREE RADICAL BIO MED, V28, P1745, DOI 10.1016/S0891-5849(00)00232-X; Mezzetti A, 2000, CARDIOVASC RES, V47, P475, DOI 10.1016/S0008-6363(00)00118-8; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MURTHI KK, 1990, PROSTAGLANDINS, V39, P611, DOI 10.1016/0090-6980(90)90022-N; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; Noguchi N, 2000, J BIOCHEM-TOKYO, V127, P971, DOI 10.1093/oxfordjournals.jbchem.a022713; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratico D, 1999, ATHEROSCLEROSIS, V147, P1, DOI 10.1016/S0021-9150(99)00257-9; Roberts LJ, 1999, FASEB J, V13, P1157, DOI 10.1096/fasebj.13.10.1157; Roberts LJ, 1996, J BIOL CHEM, V271, P20617, DOI 10.1074/jbc.271.34.20617; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Salomon RG, 1997, CHEM RES TOXICOL, V10, P536, DOI 10.1021/tx960157y; Salomon RG, 2000, BBA-MOL CELL BIOL L, V1485, P225, DOI 10.1016/S1388-1981(00)00038-X; Salomon RG, 1999, J BIOL CHEM, V274, P20271, DOI 10.1074/jbc.274.29.20271; Salomon RG, 2000, TRENDS CARDIOVAS MED, V10, P53, DOI 10.1016/S1050-1738(00)00040-2; SALOMON RG, 1987, PROSTAGLANDINS, V34, P643, DOI 10.1016/0090-6980(87)90289-9; Salomon RG, 2000, CHEM RES TOXICOL, V13, P557, DOI 10.1021/tx000007u; Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; SCHMIDLEY JW, 1992, PROSTAG LEUKOTR ESS, V47, P105, DOI 10.1016/0952-3278(92)90145-9; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; SPECTOR IM, 1974, NATURE, V249, P66, DOI 10.1038/249066a0; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang RL, 2002, BLOOD, V99, P1802, DOI 10.1182/blood.V99.5.1802.h8001802_1802_1810	70	41	44	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2209	2220		10.1096/fj.03-0086com	http://dx.doi.org/10.1096/fj.03-0086com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656983				2022-12-25	WOS:000188067500042
J	Del Bufalo, D; Trisciuoglio, D; Scarsella, M; Zangemeister-Wittke, U; Zupi, G				Del Bufalo, D; Trisciuoglio, D; Scarsella, M; Zangemeister-Wittke, U; Zupi, G			Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity	ONCOGENE			English	Article						bcl-2; antisense oligonucleotides; vascular endothelial growth factor; angiogenesis; melanoma	GROWTH-FACTOR EXPRESSION; PROTEIN-KINASE-A; BCL-2 OVEREXPRESSION; CARCINOMA-CELLS; IN-VIVO; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; TYROSINE KINASE; FACTOR RECEPTOR; TUMOR-GROWTH	We have recently reported that bcl-2 overexpression and hypoxia synergistically interact to modulate vascular endothelial growth factor (VEGF) and in vivo angiogenesis in tumour cells through VEGF mRNA stabilization and hypoxia-inducible factor 1-mediated transcriptional activity. Bcl-2 antisense treatment has shown promising clinical results in patients with malignant melanoma. In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. The antiangiogenic effect was determined in in vitro and in vivo angiogenesis assays. In particular, a reduction of hypoxia-induced VEGF secretion was observed after 4625 treatment, and the conditioned medium (CM) of bcl-2 overexpressing clones treated with 4625 and exposed to hypoxic conditions resulted in decreased endothelial cell proliferation when compared to CM of untreated control cells. In addition, we found that CM of 4625 antisense-treated bcl-2 transfectants inhibited in vivo vessel formation in matrigel plugs implanted subcutaneously in C57/B16 mice. Our findings confirm that bcl-2 plays a crucial role in melanoma angiogenesis and demonstrate for the first time that downregulation of bcl-2 by antisense treatment has potential to inhibit angiogenesis independent of its effect on cell survival. The use of 4625 in cancer therapy is suggested as an approach to facilitate simultaneously tumour cell apoptosis and inhibit tumour angiogenesis.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Zurich; University Zurich Hospital	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi dOro 156, I-00158 Rome, Italy.	zupi@ifo.it	Del Bufalo, Donatella/AAC-1594-2021; trisciuoglio, daniela/AAL-4002-2021; trisciuoglio, Daniela/H-2131-2016; Del Bufalo, Donatella/K-8673-2016	Del Bufalo, Donatella/0000-0002-3148-6096; trisciuoglio, Daniela/0000-0002-7007-7914; Del Bufalo, Donatella/0000-0002-3148-6096; Scarsella, Marco/0000-0002-3386-9664				Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; Del Bufalo D, 2002, EUR J CANCER, V38, P2455, DOI 10.1016/S0959-8049(02)00391-X; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Del Bufalo D, 2001, J CELL BIOCHEM, V83, P473, DOI 10.1002/jcb.1245; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; FOLKMAN J, 1986, CANCER RES, V46, P467; Fong TAT, 1999, CANCER RES, V59, P99; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Koty PP, 2002, MOL CELL BIOCHEM, V234, P125, DOI 10.1023/A:1015932615769; McCarthy M, 2001, LANCET, V357, P1593, DOI 10.1016/S0140-6736(00)04782-6; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam NH, 2003, CURR DRUG TARGETS, V4, P159, DOI 10.2174/1389450033346966; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Nor JE, 2001, CANCER RES, V61, P2183; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Olie RA, 2002, BBA-GENE STRUCT EXPR, V1576, P101, DOI 10.1016/S0167-4781(02)00300-7; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Presta LG, 1997, CANCER RES, V57, P4593; Rak J, 2002, CANCER RES, V62, P1931; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Wang JH, 2002, CANCER-AM CANCER SOC, V94, P2745, DOI 10.1002/cncr.10520; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547	46	45	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8441	8447		10.1038/sj.onc.1206999	http://dx.doi.org/10.1038/sj.onc.1206999			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627985				2022-12-25	WOS:000186650300008
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Samara, R; Espinoza, LA; Hassa, PO; Hottiger, MO; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Samara, R; Espinoza, LA; Hassa, PO; Hottiger, MO; Smulson, ME			PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase	ONCOGENE			English	Article						PARP-1; E2F-1; DNA replication; promoter activity; gene expression; cell cycle; coactivator	POLY(ADP-RIBOSE) POLYMERASE BINDS; DEPENDENT TRANSCRIPTION; RIBOSE POLYMERASE; GENE-EXPRESSION; DISTINCT ROLES; CYCLIN-A; PROTEIN; P53; CDNA; IDENTIFICATION	The transcription factor E2F-1 is implicated in the activation of S-phase genes as well as, induction of apoptosis, and is regulated by interactions with Rb and by cell cycle-dependent alterations in E2F-1 abundance. We. earlier demonstrated a pivotal role for poly(ADP-ribose) polymerase-1 (PARP-1) in the regulation of E2F-1 expression and promoter activity during S-phase re-entry when quiescent cells re-enter the cell cycle. We now investigate the putative mechanism(s) by which PARP-1 may upregulate E2F-1 promoter activity during S-phase re-entry. DNase-1 footprint assays with purified PARP-1 showed that PARP-1 did not directly bind the E2F-1 promoter in a sequence-specific manner. In contrast to p53, a positive acceptor in poly(ADP-ribosyl)ation reactions, E2F-1 was not poly(ADP-ribosyl)ated by wild-type PARP-1 in vitro, indicating that PARP-1 does not exert a dual effect on F2F-1 transcriptional activation. Protein-binding reactions and coimmunoprecipitation experiments with purified PARP-1 and E2F-1, however, revealed that PARP-1 binds to E2F-1 in vitro. More significantly, physical association of PARP-1 and E2F-1 in vivo also occurred in wild-type fibroblasts 5h after re-entry into S phase, coincident with the increase in E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes cyclin A and c-Myc. Mapping of the interaction domains revealed that full-length PARP-1 as well as PARP-1 mutants lacking either the catalytic active site or the DNA-binding domain equally bind E2F-1, whereas a PARP-1 mutant lacking the automodification domain does not, suggesting that the protein interaction site is located in this central domain. Finally, get shift analysis with end-blocked E2F-1 promoter sequence probes verified that the binding of PARP-1 to E2F-1 enhances binding to the E2F-1 promoter, indicating that PARP-1 acts as a positive cofactor of E2F-1-mediated transcription.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20057 USA; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Georgetown University; University of Zurich	Simbulan-Rosenthal, CM (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20057 USA.	simbulac@georgetown.edu	Rosenthal, Dean S/J-2360-2014; Hottiger, Michael O./J-7747-2013; Simbulan-Rosenthal, Cynthia M./W-8429-2019	Hottiger, Michael O./0000-0002-7323-2270; Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA25344, P01 CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; De Capoa A, 1999, FASEB J, V13, P89; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim H, 1997, BIOCHEM J, V322, P469, DOI 10.1042/bj3220469; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Rosenthal DS, 1997, NUCLEIC ACIDS RES, V25, P1437, DOI 10.1093/nar/25.7.1437; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 1998, CANCER RES, V58, P3495; TANG A, 1989, ONCOGENE, V4, P401; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wesierska-Gadek J, 2003, J CELL BIOCHEM, V89, P220, DOI 10.1002/jcb.10521; Yamane K, 2001, ONCOGENE, V20, P2859, DOI 10.1038/sj.onc.1204408; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	65	81	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8460	8471		10.1038/sj.onc.1206897	http://dx.doi.org/10.1038/sj.onc.1206897			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627987				2022-12-25	WOS:000186650300010
J	Ishino, T; Pasut, G; Scibek, J; Chaiken, I				Ishino, T; Pasut, G; Scibek, J; Chaiken, I			Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; GM-CSF; CHAIN; IDENTIFICATION; MUTAGENESIS; AFFINITY; IL-5; EXPRESSION; RESIDUES; DYNAMICS	Human interleukin 5 receptor alpha (IL5Ralpha) comprises three fibronectin type III domains (D1, D2, and D3) in the extracellular region. Previous results have indicated that residues in the D1D2 domains are crucial for high affinity interaction with human interleukin 5 (IL5). Yet, it is the D2D3 domains that have sequence homology with the classic cytokine recognition motif that is generally assumed to be the minimum cytokine-recognizing unit. In the present study, we used kinetic interaction analysis of alanine-scanning mutational variants of IL5Ralpha to define the residues involved in IL5 recognition. Soluble forms of IL5Ralpha variants were expressed in S2 cells, selectively captured via their C-terminal V5 tag by anti-V5 tag antibody immobilized onto the sensor chip and examined for IL5 interaction by using a sandwich surface plasmon resonance biosensor method. Marked effects on the interaction kinetics were observed not only in D1 (Asp(55), Asp(56), and Glu(58)) and D2 (Lys(186) and Arg(188)) domains, but also in the D3 (Arg(297)) domain. Modeling of the tertiary structure of IL5Ralpha indicated that these binding residues fell into two clusters. The first cluster consists of D1 domain residues that form a negatively charged patch, whereas the second cluster consists of residues that form a positively charged patch at the interface of D2 and D3 domains. These results suggest that the IL5 . IL5Ralpha system adopts a unique binding topology, in which the cytokine is recognized by a D2D3 tandem domain combined with a D1 domain, to form an extended cytokine recognition interface.	Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, Aj Drexel Inst Basic & Appl Prot Sci, Philadelphia, PA 19102 USA; Univ Padua, Dept Pharmaceut Sci, I-35121 Padua, Italy	Drexel University; Drexel University; University of Padua	Chaiken, I (corresponding author), Drexel Univ, Coll Med, Dept Biochem, 11102 New Coll Bldg,MS 497,245 N 15th St, Philadelphia, PA 19102 USA.	imc23@drexel.edu	Pasut, Gianfranco/I-5944-2012	Pasut, Gianfranco/0000-0002-8754-0899	NIAID NIH HHS [AI40462] Funding Source: Medline; NIGMS NIH HHS [GM55648] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055648] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHAIKEN MI, 1999, INTERLEUKIN 5 MOL DR, P167; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; Czabotar PE, 2000, CYTOKINE, V12, P867, DOI 10.1006/cyto.1999.0663; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; DEVOS R, 1994, EUR J BIOCHEM, V225, P635, DOI 10.1111/j.1432-1033.1994.00635.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Dowd CS, 2002, BIOCHEMISTRY-US, V41, P7038, DOI 10.1021/bi012168i; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Foster PS, 2002, TRENDS MOL MED, V8, P162, DOI 10.1016/S1471-4914(02)02302-X; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Karlen S, 1998, Int Rev Immunol, V16, P227, DOI 10.3109/08830189809042996; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MCKINNON M, 1999, INTERLEUKIN 5 MOL DR, P299; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; Plugariu CG, 2000, BIOCHEMISTRY-US, V39, P14939, DOI 10.1021/bi001467p; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scibek JJ, 2002, ANAL BIOCHEM, V307, P258, DOI 10.1016/S0003-2697(02)00043-X; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Tello Diana, 1994, Journal of Molecular Recognition, V7, P57, DOI 10.1002/jmr.300070108; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walter MR, 2002, BIOTECHNIQUES, P46; Wu SJ, 1999, J BIOL CHEM, V274, P20479, DOI 10.1074/jbc.274.29.20479	43	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9547	9556		10.1074/jbc.M309327200	http://dx.doi.org/10.1074/jbc.M309327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14662768	hybrid			2022-12-25	WOS:000189265900122
J	Bohm, M; Raghunath, M; Sunderkotter, C; Schiller, M; Stander, S; Brzoska, T; Cauvet, T; Schioth, HB; Schwarz, T; Luger, TA				Bohm, M; Raghunath, M; Sunderkotter, C; Schiller, M; Stander, S; Brzoska, T; Cauvet, T; Schioth, HB; Schwarz, T; Luger, TA			Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN DERMAL FIBROBLASTS; NF-KAPPA-B; MELANOCORTIN-1 RECEPTOR; HUMAN SKIN; IN-VITRO; FIBROSIS; EXPRESSION; CELLS; SCLERODERMA	Suppression of collagen synthesis is a major therapeutic goal in the treatment of fibrotic disorders. We show here that alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide well known for its pigment-inducing capacity, modulates collagen synthesis and deposition. alpha-MSH in vitro suppresses the synthesis of collagen types I, III, and V and down-regulates the secretion of procollagen type I C-terminal peptide (PICP) in human dermal fibroblasts treated with the fibrogenic cytokine transforming growth factor-beta(1), (TGF-beta(1)). alpha-MSH did not interfere with TGF-beta(1) signaling, because TGF-beta(1)-induced expression of collagen mRNA was not affected, implying a posttranscriptional mechanism. Human dermal fibroblasts in vitro express a high affinity binding site for MSH, which was identified by reverse transcription PCR and immunofluoreseence analysis as the melanocortin-1 receptor (MC-1R). Immunohistochemical studies on normal adult human skin confirmed MC-1R expression in distinct dermal fibroblastic cells. The MC-1R on fibroblasts appears to be functionally relevant because a-MSH increased the amount of intracellular cAMP, and coincubation with a synthetic peptide corresponding to the human Agouti signaling protein abrogated the inhibition of TGF-beta(1)-induced PICP secretion by a-MSH. To assess the in vivo relevance of these findings, a mouse model was used in which dermal fibrosis was induced by repetitive intracutaneous injections with TGF-beta(1). The inductive activity of TGF-beta(1) on collagen deposition and the number of dermal cells immunoreactive for vimentin and a-smooth muscle actin was significantly suppressed by injection of a-MSH. Melanocortins such as alpha-MSH may therefore represent a novel class of modulators with potential usefulness for the treatment of fibrotic disorders.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Univ Munster, Dept Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Haematol & Med Oncol, D-48149 Munster, Germany; Uppsala Univ, Dept Neurosci, S-75124 Uppsala, Sweden	University of Munster; University of Munster; University of Munster; University of Munster; Uppsala University	Bohm, M (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.	bohmm@uni-muenster.de	Schioth, Helgi/AAQ-7239-2020; Raghunath, Michael/E-6483-2010; Raghunath, Michael/M-2727-2019	Raghunath, Michael/0000-0002-2138-6614; Stander, Sonja/0000-0003-3612-7786; Sunderkotter, Cord/0000-0002-2929-145X				Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; BATEMAN JF, 1990, BIOCHEM J, V267, P573, DOI 10.1042/bj2670573; Berk JL, 2000, J APPL PHYSIOL, V89, P1425, DOI 10.1152/jappl.2000.89.4.1425; Bhardwaj R, 1997, J IMMUNOL, V158, P3378; Bohm M, 2002, J INVEST DERMATOL, V118, P533, DOI 10.1046/j.0022-202x.2001.01704.x; Bohm M, 2000, HORM RES, V54, P287, DOI 10.1159/000053273; Bohm M, 1999, ANN NY ACAD SCI, V885, P277; Bohm M, 1999, EXP DERMATOL, V8, P453, DOI 10.1111/j.1600-0625.1999.tb00303.x; Bohm M, 1999, ANN NY ACAD SCI, V885, P372; CANNON JG, 1986, J IMMUNOL, V137, P2232; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; GLINSKI W, 1994, BRIT J DERMATOL, V131, P260; Hartmeyer M, 1997, J IMMUNOL, V159, P1930; HaskellLuevano C, 1997, J MED CHEM, V40, P2133, DOI 10.1021/jm960840h; Hill C, 2001, J ENDOCRINOL, V170, P647, DOI 10.1677/joe.0.1700647; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; KHALIL N, 1991, CIBA F SYMP, V157, P194; KISS M, 1995, BIOL CHEM H-S, V376, P425, DOI 10.1515/bchm3.1995.376.7.425; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Manna SK, 1998, J IMMUNOL, V161, P2873; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCormick LL, 1999, J IMMUNOL, V163, P5693; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Ng YY, 1998, KIDNEY INT, V54, P864, DOI 10.1046/j.1523-1755.1998.00076.x; Pedagogos E, 1997, AM J KIDNEY DIS, V29, P912, DOI 10.1016/S0272-6386(97)90466-2; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RAGHUNATH M, 1994, PEDIATR RES, V36, P441, DOI 10.1203/00006450-199410000-00005; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Schiller M, 2001, J INVEST DERMATOL, V117, P227, DOI 10.1046/j.0022-202x.2001.01412.x; SCHIOTH HB, 1995, EUR J PHARM-MOLEC PH, V288, P311, DOI 10.1016/0922-4106(95)90043-8; Shihab FS, 1996, SEMIN NEPHROL, V16, P536; Shinozaki M, 1997, BIOCHEM BIOPH RES CO, V237, P292, DOI 10.1006/bbrc.1997.7134; SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; THODY AJ, 1983, PEPTIDES, V4, P813, DOI 10.1016/0196-9781(83)90072-4; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; VARGA JM, 1976, P NATL ACAD SCI USA, V73, P559, DOI 10.1073/pnas.73.2.559; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Yamamoto T, 1999, CLIN IMMUNOL, V92, P6, DOI 10.1006/clim.1999.4720; Yokozeki M, 1997, EXP CELL RES, V231, P328, DOI 10.1006/excr.1997.3473	49	85	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6959	6966		10.1074/jbc.M312549200	http://dx.doi.org/10.1074/jbc.M312549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645373	hybrid			2022-12-25	WOS:000188969200091
J	Dhanasekaran, S; Chandra, NR; Sagar, BKC; Rangarajan, PN; Padmanaban, G				Dhanasekaran, S; Chandra, NR; Sagar, BKC; Rangarajan, PN; Padmanaban, G			delta-aminolevulinic acid dehydratase from Plasmodium falciparum - Indigenous versus imported	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN SYNTHASE; PSEUDOMONAS-AERUGINOSA; MALARIAL PARASITE; ESCHERICHIA-COLI; PISUM-SATIVUM; IDENTIFICATION; BIOSYNTHESIS; PURIFICATION; ALIGNMENT	The heme biosynthetic pathway of the malaria parasite is a drug target and the import of host delta-aminolevulinate dehydratase (ALAD), the second enzyme of the pathway, from the red cell cytoplasm by the intra erythrocytic malaria parasite has been demonstrated earlier in this laboratory. In this study, ALAD encoded by the Plasmodium falciparum genome (PfALAD) has been cloned, the protein overexpressed in Escherichia coli, and then characterized. The mature recombinant enzyme (rPfALAD) is enzymatically active and behaves as an octamer with a subunit M-r of 46,000. The enzyme has an alkaline pH optimum of 8.0 to 9.0. rPfALAD does not require any metal ion for activity, although it is stimulated by 20-30% upon addition of Mg2+. The enzyme is inhibited by Zn2+ and succinylacetone. The presence of PfALAD in P. falciparum can be demonstrated by Western blot analysis and immunoelectron microscopy. The enzyme has been localized to the apicoplast of the malaria parasite. Homology modeling studies reveal that PfALAD is very similar to the enzyme species from Pseudomonas aeruginosa, but manifests features that are unique and different from plant ALADs as well as from those of the bacterium. It is concluded that PfALAD, while resembling plant ALADs in terms of its alkaline pH optimum and apicoplast localization, differs in its Mg2+ independence for catalytic activity or octamer stabilization. Expression levels of PfALAD in P. falciparum, based on Western blot analysis, immunoelectron microscopy, and EDTA-resistant enzyme activity assay reveals that it may account for about 10% of the total ALAD activity in the parasite, the rest being accounted for by the host enzyme imported by the parasite. It is proposed that the role of PfALAD may be confined to heme synthesis in the apicoplast that may not account for the total de novo heme biosynthesis in the parasite.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Bioinformat Ctr, Bangalore 560012, Karnataka, India; Indian Inst Sci, Interact Graph Facil, Bangalore 560012, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; National Institute of Mental Health & Neurosciences - India	Padmanaban, G (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	geepee@biochem.iisc.ernet.in	Rangarajan, Pundi/A-7365-2009	Rangarajan, Pundi/0000-0002-6536-9891; Chandra, Nagasuma/0000-0002-9939-8439				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BEVAN DR, 1980, J BIOL CHEM, V255, P2030; BOESE QF, 1991, J BIOL CHEM, V266, P17060; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; Bonday ZQ, 2000, NAT MED, V6, P898, DOI 10.1038/78659; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P57, DOI 10.1093/protein/4.1.57; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P49, DOI 10.1093/protein/4.1.49; Erskine PT, 1999, BIOCHEMISTRY-US, V38, P4266, DOI 10.1021/bi982137w; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13976, DOI 10.1021/bi9906470; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; Frere F, 2002, J MOL BIOL, V320, P237, DOI 10.1016/S0022-2836(02)00472-2; He CY, 2001, J BIOL CHEM, V276, P28436, DOI 10.1074/jbc.M102000200; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jaffe EK, 2003, J BIOL INORG CHEM, V8, P176, DOI 10.1007/s00775-002-0403-x; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; JAFFE EK, 1995, J BIOENERG BIOMEMBR, V27, P169, DOI 10.1007/BF02110032; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; Sato S, 2000, INT J PARASITOL, V30, P427, DOI 10.1016/S0020-7519(99)00185-X; Sato S, 2002, CURR GENET, V40, P391, DOI 10.1007/s00294-002-0273-3; Senior NM, 1996, BIOCHEM J, V320, P401; SIRAWARAPORN W, 1985, GENETIC ENG TECHNIQU, P407; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; Varadharajan S, 2002, BIOCHEM J, V367, P321, DOI 10.1042/BJ20020834; Wilson CM, 1996, MOL BIOCHEM PARASIT, V75, P271, DOI 10.1016/0166-6851(95)02531-6; Zimmermann JL, 1999, BIOCHEMISTRY-US, V38, P15343, DOI 10.1021/bi9910732	38	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6934	6942		10.1074/jbc.M311409200	http://dx.doi.org/10.1074/jbc.M311409200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638682	hybrid			2022-12-25	WOS:000188969200088
J	Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P				Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P			Identification of porcine coaglulation factor VIII domains responsible for high level expression via enhanced secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIII; CLOTTING FACTOR-VIII; FACTOR-V; MAMMALIAN-CELLS; SCANNING MUTAGENESIS; INHIBITORY EPITOPE; MAJOR DETERMINANT; CODING REGION; HEMOPHILIA-A; PROTEIN	Blood coagulation factor VIII has a domain structure designated A1-A2-B-ap-A3-C1-C2. Human factor VIII is present at low concentration in normal plasma and, comparably, is produced at low levels in vitro and in vivo using transgenic expression techniques. Heterologous expression of B domain-deleted porcine factor VIII in mammalian cell culture is significantly greater than B domain-deleted human or murine factor VIII. Novel hybrid human/porcine factor VIII molecules were constructed to identify porcine factor VIII domains that confer high level expression. Hybrid human/porcine factor VIII constructs containing the porcine factor VIII A1 and ap-A3 domains expressed at levels comparable with recombinant porcine factor VIII. A hybrid construct containing only the porcine A1 domain expressed at intermediate levels between human and porcine factor VIII, whereas a hybrid construct containing the porcine ap-A3 domain expressed at levels comparable with human factor VIII. Additionally, hybrid murine/porcine factor VIII constructs containing the porcine factor VIII A1 and ap-A3 domain sequences expressed at levels significantly higher than recombinant murine factor VIII. Therefore, the porcine Al and ap-A3 domains are necessary and sufficient for the high level expression associated with porcine factor VIII. Metabolic radiolabeling experiments demonstrated that high level expression was attributable to enhanced secretory efficiency.	Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Lollar, P (corresponding author), Emory Univ, Winship Canc Inst, 1639 Pierce Dr,Rm 1003 Woodruff Mem Bldg, Atlanta, GA 30322 USA.	jlollar@emory.edu	Doering, Christopher/W-2064-2019		PHS HHS [R01-L40921] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barrow RT, 2001, BLOOD, V97, P169, DOI 10.1182/blood.V97.1.169; Barrow RT, 2000, BLOOD, V95, P564, DOI 10.1182/blood.V95.2.564; Bohn RL, 1998, THROMB HAEMOSTASIS, V79, P932; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; Doering CB, 2002, J BIOL CHEM, V277, P38345, DOI 10.1074/jbc.M206959200; Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; Fang XD, 2001, THROMB RES, V102, P177, DOI 10.1016/S0049-3848(01)00229-8; Garber K, 2000, NAT BIOTECHNOL, V18, P1133, DOI 10.1038/81098; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; Healey JF, 1996, BLOOD, V88, P4209; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAUFMAN RJ, 1997, BLOOD COAGUL FIBRIN, V8, P3; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; Lubin IM, 1997, J BIOL CHEM, V272, P30191, DOI 10.1074/jbc.272.48.30191; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; Qian JJ, 1999, THROMB HAEMOSTASIS, V81, P240, DOI 10.1055/s-0037-1614450; Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; Tagliavacca L, 2000, BIOCHEMISTRY-US, V39, P1973, DOI 10.1021/bi991896r; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	41	50	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6546	6552		10.1074/jbc.M312451200	http://dx.doi.org/10.1074/jbc.M312451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660593	hybrid			2022-12-25	WOS:000188969200042
J	Sekiya, T; Adachi, S; Kohu, K; Yamada, T; Higuchi, O; Furukawa, Y; Nakamura, Y; Nakamura, T; Tashiro, K; Kuhara, S; Ohwada, S; Akiyama, T				Sekiya, T; Adachi, S; Kohu, K; Yamada, T; Higuchi, O; Furukawa, Y; Nakamura, Y; Nakamura, T; Tashiro, K; Kuhara, S; Ohwada, S; Akiyama, T			Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS-POLYPOSIS-COLI; APC GENE-PRODUCT; SUPPRESSOR PROTEIN; HEPATOCELLULAR CARCINOMAS; IN-VIVO; CANCER; AXIN; EXPRESSION; ICAT; ASSOCIATION	The Wnt signaling pathway is activated in most human colorectal tumors. Mutational inactivation in the tumor suppressor adenomatous polyposis coli (APC), as well as activation of beta-catenin, causes the accumulation of beta-catenin, which in turn associates with the T cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors and activates transcription of their target genes. Here we show that beta-catenin activates transcription of the BMP and activin membrane-bound inhibitor (BAMBI)/NMA gene. The expression level of BAMBI was found to be aberrantly elevated in most colorectal and hepatocellular carcinomas relative to the corresponding non-cancerous tissues. Expression of BAMBI in colorectal tumor cell lines was repressed by a dominant-negative mutant of TCF-4 or by an inhibitor of beta-catenin-TCF interaction, suggesting that beta-catenin is responsible for the aberrant expression of BAMBI in colorectal tumor cells. Furthermore, overexpression of BAMBI inhibited the response of tumor cells to transforming growth factor-beta signaling. These results suggest that beta-catenin interferes with transforming growth factor-beta-mediated growth arrest by inducing the expression of BAMBI, and this may contribute to colorectal and hepatocellular tumorigenesis.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Gunma Univ, Sch Med, Dept Surg 2, Maebashi, Gumma 371, Japan; Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Lab Mol Gene Tech,Higashi Ku, Fukuoka 8128581, Japan	University of Tokyo; University of Tokyo; Gunma University; Kyushu University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp	Adachi, Shungo/L-6348-2018	Adachi, Shungo/0000-0001-5232-411X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NAKAMURA Y, 1995, J CANCER RES CLIN, V121, P529, DOI 10.1007/BF01197765; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sekiya T, 2002, CANCER RES, V62, P3322; Shtutman Michael, 2002, Cancer Research, V62, P5947; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Tago K, 2000, GENE DEV, V14, P1741; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Tsang M, 2000, GENESIS, V28, P47, DOI 10.1002/1526-968X(200010)28:2<47::AID-GENE20>3.0.CO;2-S; Xu LF, 2000, GENE DEV, V14, P585; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	54	121	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6840	6846		10.1074/jbc.M310876200	http://dx.doi.org/10.1074/jbc.M310876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660579	hybrid			2022-12-25	WOS:000188969200078
J	Yu, KF; Huang, FT; Lieber, AR				Yu, KF; Huang, FT; Lieber, AR			DNA substrate length and surrounding sequence affect the activation-induced deaminase activity at cytidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; SOMATIC HYPERMUTATION; AID; TRANSCRIPTION; EXCISION; REGIONS; GENES; MECHANISM	Activation-induced deaminase (AID) is required for both immunoglobulin class switch recombination and somatic hypermutation. AID is known to deaminate cytidines in single-stranded DNA, but the relationship of this step to the class switch or somatic hypermutation processes is not entirely clear. We have studied the activity of a recombinant form of the mouse AID protein that was purified from a baculovirus expression system. We find that the length of the single-stranded DNA target is critical to the action of AID at the Cs positioned anywhere along the length of the DNA. The DNA sequence surrounding a given C influences AID deamination efficiency. AID preferentially deaminates Cs in the WRC motif, and additionally has a small but consistent preference for purine at the position after the WRC, thereby favoring WRCr (the lowercase r corresponds to the smaller impact on activity).	Univ So Calif, Norris Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lieber, AR (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA.	lieber@usc.edu	Hsiao, Wei-Hung/B-9931-2013	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056984] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056984] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Fugmann SD, 2003, NAT IMMUNOL, V4, P429, DOI 10.1038/ni0503-429; Kitao H, 2000, INT IMMUNOL, V12, P959, DOI 10.1093/intimm/12.7.959; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Michael N, 2002, IMMUNITY, V16, P123, DOI 10.1016/S1074-7613(02)00261-3; Milstein C, 1998, P NATL ACAD SCI USA, V95, P8791, DOI 10.1073/pnas.95.15.8791; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; REABAN ME, 1994, J BIOL CHEM, V269, P21850; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Shapiro GS, 2002, J IMMUNOL, V168, P2302, DOI 10.4049/jimmunol.168.5.2302; Shinkura R, 2003, NAT IMMUNOL, V4, P435, DOI 10.1038/ni918; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; TA VT, 2003, NAT IMMUNOL, V4, P945; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919	32	148	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6496	6500		10.1074/jbc.M311616200	http://dx.doi.org/10.1074/jbc.M311616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645244	hybrid			2022-12-25	WOS:000188969200035
J	Costa, FF; Verbisck, NV; Salim, ACM; Ierardi, DF; Pires, LC; Sasahara, RM; Sogayar, MC; Zanata, SM; Mackay, A; O'Hare, M; Soares, F; Simpson, AJG; Camargo, AA				Costa, FF; Verbisck, NV; Salim, ACM; Ierardi, DF; Pires, LC; Sasahara, RM; Sogayar, MC; Zanata, SM; Mackay, A; O'Hare, M; Soares, F; Simpson, AJG; Camargo, AA			Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors	ONCOGENE			English	Article						ADAM23; methylation; cell adhesion; downregulation; breast tumor	DNA METHYLATION; CELL-ADHESION; CPG ISLAND; METALLOPROTEASE DOMAIN; MEMBRANE-PROTEINS; SUPPRESSOR GENES; DISINTEGRIN-LIKE; CANCER; EXPRESSION; FAMILY	Altered cell adhesion is causally involved in tumor progression, and the identification of novel adhesion molecules altered in tumors is crucial for our understanding of tumor biology and for the development of new prognostic and therapeutic strategies. Here, we provide evidence for the epigenetic downregulation in breast tumors of the A Desintegrin And Metalloprotease domain 23 gene ( ADAM 23), a member of a new family of surface molecules with roles in cell - cell adhesion and/or cell matrix interactions. W e examined the mRNA expression and methylation status of the 50 upstream region of the ADAM23 gene in different breast tumor cell lines as well as in primary breast tumors. We found ADAM23 50 hypermethylation in eight out of 12 (66.7%) tumor cell lines and in nine out of 13 (69.2%) primary tumors. Promoter hypermethylation was strongly associated with reductions in both mRNA and protein expression, with a threshold of 40 - 60% of modified CpG dinucleotides being required for the complete silencing of ADAM23 mRNA expression. Treatment of MCF-7 and SKBR-3 cell lines with 5'-Aza-2'-deoxycytidine led to a reactivation of ADAM23 mRNA expression and a marked decrease in the methylation level. It is worth noting that primary breast tumors with a more advanced grade showed a higher degree of methylation, suggesting that the adhesion molecule ADAM23 may be downregulated during the progression of breast cancer.	Ludwig Inst Canc Res, Lab Mol Biol & Genom, BR-01509010 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; Univ Fed Parana, Neurobiol Lab, BR-80060000 Curitiba, Parana, Brazil; Univ Coll, Ludwig Inst Canc Res, Breast Canc Lab, London, England; Hosp ACCamargo, Dept Patol, Sao Paulo, Brazil	Ludwig Institute for Cancer Research; Universidade de Sao Paulo; Universidade Federal do Parana; Ludwig Institute for Cancer Research; University of London; University College London; A.C.Camargo Cancer Center	Camargo, AA (corresponding author), Ludwig Inst Canc Res, Lab Mol Biol & Genom, Rua Prof Antonio Prudente 109,4th Floor, BR-01509010 Sao Paulo, Brazil.	anamaria@compbio.ludwig.org.br	Zanata, Silvio/AAC-9670-2021; Camargo, Anamaria A/E-9388-2012; Verbisck, Newton Valerio/I-1356-2012; Simpson, Amelia/HGB-1823-2022; Sogayar, Mari C/B-3980-2017	Zanata, Silvio/0000-0003-2818-6954; Camargo, Anamaria A/0000-0002-6076-9597; Verbisck, Newton Valerio/0000-0001-9817-7223; Sogayar, Mari C/0000-0003-4805-4609; Soares, Fernando Augusto/0000-0003-1647-7842; Soares, Fernando/0000-0002-1212-9093				Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1; Moss ML, 2001, DRUG DISCOV TODAY, V6, P417, DOI 10.1016/S1359-6446(01)01738-X; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Radice D, 2003, PHARMACOECONOMICS, V21, P383, DOI 10.2165/00019053-200321060-00003; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sagane K, 1998, BIOCHEM J, V334, P93, DOI 10.1042/bj3340093; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714	36	51	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1481	1488		10.1038/sj.onc.1207263	http://dx.doi.org/10.1038/sj.onc.1207263			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14661055	Bronze			2022-12-25	WOS:000189035800016
J	Roman-Roman, S; Shi, DL; Stiot, V; Hay, E; Vayssiere, B; Garcia, T; Baron, R; Rawadi, G				Roman-Roman, S; Shi, DL; Stiot, V; Hay, E; Vayssiere, B; Garcia, T; Baron, R; Rawadi, G			Murine Frizzled-1 behaves as an antagonist of the canonical Wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; RECEPTOR-RELATED PROTEIN-5; GROWTH-FACTOR-BETA; WNT; PATHWAY; CELLS; DIFFERENTIATION; EXPRESSION; XENOPUS; LINEAGE	Activation of the Wnt signaling cascade provides key signals during development and in disease. Wnt signals are transduced by seven-transmembrane Frizzleds (Fzs) and the single transmembrane low density lipoprotein receptor-related proteins 5 or 6. In the course of the analysis of genes regulated by bone morphogenetic protein 2 in mesenchymal cells we found a significant induction of murine Frizzled-1 (mFz1) gene expression. Unexpectedly overexpression of mFz1 dramatically repressed the induction of alkaline phosphatase mediated by either bone morphogenetic protein 2 or Wnt3a in these cells. Moreover mFz1 overexpression significantly repressed both beta-catenin translocation into the nucleus and T cell factor signaling mediated by Wnt3a. Importantly microinjection of mFz1 transcript in Xenopus embryo inhibited the ability of Wnt1 to induce the expression of the Wnt/beta-catenin target gene Siamois in animal cap assay and secondary axis formation in whole embryo. By using chimeric constructs in which N- and C-terminal segments of mFz1 were replaced by the corresponding parts of Xfz3 we demonstrated that the antagonistic activity resides in the cysteine-rich domain of the N- terminal part. The antagonist activity of mFz1 could be prevented by overexpression of Galpha(q)-(305-359), which specifically uncouples G(q)-coupled receptors, suggesting that Galpha(q) signaling contributes to the inhibition of Wnt/beta-catenin pathway by mFz1. This is the first time that a Frizzled receptor has been reported to antagonize Wnt/beta-catenin.	ProSkelia Pharmaceut, F-93230 Romainville, France; CNRS, UMR 7622, Grp Biol Expt, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Rawadi, G (corresponding author), ProSkelia Pharmaceut, 102 Route Noisy, F-93230 Romainville, France.	georges.rawadi@proskelia.com	Roman-Roman, Sergio/K-9993-2014; Shi, De-Li/AAG-1807-2021	Roman-Roman, Sergio/0000-0001-6459-2613; Rawadi, Georges/0000-0003-4735-2188; Hay, Eric/0000-0002-0131-9983				Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.0.CO;2-U; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Carnac G, 1996, DEVELOPMENT, V122, P3055; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; INGRAM RT, 1994, DIFFERENTIATION, V55, P153, DOI 10.1046/j.1432-0436.1994.5520153.x; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sato A, 1999, DEVELOPMENT, V126, P4421; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shibamoto S, 1998, GENES CELLS, V3, P659; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; Staal A, 1996, ENDOCRINOLOGY, V137, P2001, DOI 10.1210/en.137.5.2001; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Theilhaber J, 2002, GENOME RES, V12, P165, DOI 10.1101/gr.182601; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	48	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5725	5733		10.1074/jbc.M309233200	http://dx.doi.org/10.1074/jbc.M309233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14627707	hybrid			2022-12-25	WOS:000188776500085
J	Tantin, D; Tussie-Luna, MI; Roy, AL; Sharp, PA				Tantin, D; Tussie-Luna, MI; Roy, AL; Sharp, PA			Regulation of immunoglobulin promoter activity by TFII-I class transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC COACTIVATOR; RNA-POLYMERASE-II; BINDING PROTEIN; SEQUENCE ELEMENTS; ENHANCER-BINDING; IMMUNE-RESPONSE; MICE LACKING; DNA-BINDING; GENE; IDENTIFICATION	The restriction of immunoglobulin variable region promoter activity to B lymphocytes is a well known paradigm of promoter specificity. Recently, a cis- element, located downstream of the transcription initiation site of murine heavy chain variable promoters, was shown to be critical for B cell activity and specificity. Here we show that mutation of this element, termed DICE ( Downstream Immunoglobulin Control Element), reduces in vivo activity in B cells. Gel mobility shift assays show that DICE forms B cell- specific complexes that were also sensitive to DICE mutation. DICE mutation strongly reduces the ability of a distal immunoglobulin heavy chain intronic enhancer to stimulate transcription. We also identify a DICE- interacting factor: a TFII- I- related protein known as BEN ( also termed Mus-TRD1 and WBSCR11). Dominant- negative and RNA(i)- mediated knockdown experiments indicate that BEN can both positively and negatively regulate IgH promoter activity, depending on the cell line.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; McGovern Inst, Cambridge, MA 02139 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Tufts University	Sharp, PA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Rm E17-529, Cambridge, MA 02139 USA.	sharppa@mit.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NIAID NIH HHS [AI 45150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045150, R56AI045150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; Bayarsaihan D, 2002, GENOMICS, V79, P137, DOI 10.1006/geno.2001.6674; Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Casellas R, 2002, CELL, V110, P575, DOI 10.1016/S0092-8674(02)00911-X; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUNDERSON SI, 1988, J BIOL CHEM, V263, P17603; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; Handa H, 1999, PRACT APPROACH SER, V204, P283; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Henderson AJ, 1995, CRIT REV EUKAR GENE, V5, P255, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.30; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MERCOLA M, 1983, SCIENCE, V221, P663, DOI 10.1126/science.6306772; MURPHY JT, 1982, CELL, V29, P265, DOI 10.1016/0092-8674(82)90111-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; Pelletier MR, 1997, NUCLEIC ACIDS RES, V25, P3995, DOI 10.1093/nar/25.20.3995; Polly P, 2003, J BIOL CHEM, V278, P36603, DOI 10.1074/jbc.M212814200; Ring C, 2002, GENE DEV, V16, P820, DOI 10.1101/gad.963802; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Tantin D, 2002, MOL CELL BIOL, V22, P1460, DOI 10.1128/MCB.22.5.1460-1473.2002; Tay ESE, 2003, BIOCHEM J, V374, P359, DOI 10.1042/BJ20030189; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tussie-Luna MI, 2002, J BIOL CHEM, V277, P43185, DOI 10.1074/jbc.M207635200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; Vullhorst D, 2003, J BIOL CHEM, V278, P8370, DOI 10.1074/jbc.M209361200; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	67	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5460	5469		10.1074/jbc.M311177200	http://dx.doi.org/10.1074/jbc.M311177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645227	hybrid			2022-12-25	WOS:000188776500053
J	Wittmann, T; Bokoch, GM; Waterman-Storer, CM				Wittmann, T; Bokoch, GM; Waterman-Storer, CM			Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; EPIDERMAL GROWTH-FACTOR; ONCOPROTEIN 18; IN-VIVO; P21-ACTIVATED KINASES; DYNAMIC INSTABILITY; CELL MOTILITY; RHO-GTPASES; SERINE 16; PHOSPHORYLATION	In the leading edge of migrating cells, a subset of microtubules exhibits net growth in a Rac1- and p21-activated kinase-dependent manner. Here, we explore the possibility of whether phosphorylation and inactivation of the microtubule-destabilizing protein Op18/stathmin could be a mechanism regulating microtubule dynamics downstream of Rac1 and p21-activated kinases. We find that, in vitro, Pak1 phosphorylates Op18/stathmin specifically at serine 16 and inactivates its catastrophe promoting activity in biochemical and time lapse microscopy microtubule assembly assays. Furthermore, phosphorylation of either serine 16 or 63 is sufficient to inhibit Op18/stathmin in vitro. In cells, the microtubule-destabilizing effect of an excess of Op18/stathmin can be partially overcome by expression of constitutively active Rac1(Q61L), which is dependent on Pak activity, suggesting that the microtubule cytoskeleton can be regulated through inactivation of Op18/stathmin downstream of Rac1 and Pak in vivo. However, in vivo, Pak1 activity alone is not sufficient to phosphorylate Op18, indicating that additional pathways downstream of Rac1 are required for Op18 regulation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wittmann, T (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	twittman@scripps.edu; waterman@scripps.edu	Wittmann, Torsten/F-9833-2013	Wittmann, Torsten/0000-0001-9134-691X; Waterman, Clare/0000-0001-6142-6775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39434, GM68104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 2002, BIOESSAYS, V24, P305, DOI 10.1002/bies.10084; BELL CW, 1982, METHOD CELL BIOL, V24, P373; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; BRATTSAND G, 1993, LEUKEMIA, V7, P569; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Gavet O, 1998, J CELL SCI, V111, P3333; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Gupton SL, 2002, CURR BIOL, V12, P1891, DOI 10.1016/S0960-9822(02)01276-9; HOELSCHER SR, 1994, ENDOCRINOLOGY, V135, P662, DOI 10.1210/en.135.2.662; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; JI H, 1993, J BIOL CHEM, V268, P13396; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; le Gouvello S, 1998, J IMMUNOL, V161, P1113; MELANDER HG, 1998, J CELL BIOL, V140, P131; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Segerman B, 2003, J CELL SCI, V116, P197, DOI 10.1242/jcs.00205; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wittmann T, 2001, J CELL SCI, V114, P3795; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHAI Y, 1994, J CELL SCI, V107, P881; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	54	187	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6196	6203		10.1074/jbc.M307261200	http://dx.doi.org/10.1074/jbc.M307261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645234	hybrid			2022-12-25	WOS:000188776500136
J	Brunelle, JK; Santore, MT; Budinger, GRS; Tang, YM; Barrett, TA; Zong, WX; Kandel, E; Keith, B; Simon, MC; Thompson, CB; Hay, N; Chandel, NS				Brunelle, JK; Santore, MT; Budinger, GRS; Tang, YM; Barrett, TA; Zong, WX; Kandel, E; Keith, B; Simon, MC; Thompson, CB; Hay, N; Chandel, NS			c-Myc sensitization to oxygen deprivation-induced cell death is dependent on Bax/Bak, but is independent of p53 and hypoxia-inducible factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER CELLS; BCL-2 FAMILY MEMBERS; CYTOCHROME-C; INDUCED APOPTOSIS; MEDIATED APOPTOSIS; CYCLE ARREST; BAX; MITOCHONDRIA; EXPRESSION; PROTEIN	Deregulated expression of c-Myc can sensitize cells to a variety of death stimuli, including loss of growth factors and oxygen. In this study, we examined whether rodent fibroblasts that conditionally express c-Myc undergo a similar mechanism of cell death in response to serum or oxygen deprivation. Our results demonstrate that murine embryonic fibroblasts from bax(-/-)bak(-/-) mice that conditionally express c-Myc did not die in response to either oxygen or serum deprivation. Fibroblasts from p53(-/-) mice that conditionally express c-Myc died in response to oxygen (but not serum) deprivation. The inability of p53 to regulate oxygen deprivation-induced cell death was due to the lack of induction of p53 target genes Puma, Noxa, and Pten. In contrast, serum deprivation transcriptionally induced Puma and Pten in cells that conditionally express c-Myc. The failure of p53 to regulate oxygen deprivation-induced cell death led us to hypothesize whether hypoxia-inducible factor (HIF) might be a critical regulator of cell death during oxygen deprivation. Fibroblasts from HIF-1beta(-/-) cells that conditionally express c-Myc were not able to transcriptionally activate HIF during oxygen deprivation. These cells died in response to oxygen deprivation. Thus, oxygen deprivation-induced cell death in fibroblasts with deregulated expression of c-Myc is independent of p53 or HIF-1 status, but is dependent on the Bcl-2 family member Bax or Bak to initiate mitochondrial dependent cell death.	Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Penn, Abramson Family Canc Res Inst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	Northwestern University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Chandel, NS (corresponding author), Northwestern Univ, Sch Med, Dept Med, Tarry Bldg 14-707,303 E Chicago Ave, Chicago, IL 60611 USA.	nav@northwestern.edu	Simon, Celeste/AAG-3941-2021	Barrett, Terrence/0000-0001-6428-3271	NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09560] Funding Source: Medline; NHLBI NIH HHS [P01HL071643-01A4] Funding Source: Medline; NIDDK NIH HHS [DK54778] Funding Source: Medline; NIGMS NIH HHS [GM60472-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	65	48	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4305	4312		10.1074/jbc.M312241200	http://dx.doi.org/10.1074/jbc.M312241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627695	hybrid			2022-12-25	WOS:000188554300048
J	Kugler, G; Weiss, RG; Flucher, BE; Grabner, M				Kugler, G; Weiss, RG; Flucher, BE; Grabner, M			Structural requirements of the dihydropyridine receptor alpha(1S) II-III loop for skeletal-type excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM TRANSIENTS; RYANODINE RECEPTOR; CHARGE MOVEMENTS; MUSCLE; REGIONS; INVOLVEMENT; RESIDUES; CHANNELS; SUBUNIT; ABSENCE	Residues Leu(720)-Leu(764) within the II-III loop of the skeletal muscle dihydropyridine receptor (DHPR) alpha(1S) subunit represent a critical domain for the orthograde excitation-contraction coupling as well as for retrograde DHPR L-current-enhancing coupling with the ryanodine receptor (RyR1). To better understand the molecular mechanism underlying this bidirectional DHPR-RyR1 signaling interaction, we analyzed the critical domain to the single amino acid level. To this end, constructs based on the highly dissimilar housefly DHPR II-III loop in an otherwise skeletal DHPR as an interaction-inert sequence background were expressed in dysgenic (alpha(1S)-null) myotubes for simultaneous recordings of depolarization-induced intracellular Ca2+ transients (orthograde coupling) and whole-cell Ca2+ currents (retrograde coupling). In the minimal skeletal II-III loop sequence (Asp(734)-Asp(748)) required for full bidirectional coupling, eight amino acids heterologous between skeletal and cardiac DHPR were exchanged for the corresponding cardiac residues. Four of these skeletal-specific residues (Ala(739), Phe(741), Pro(742), and Asp(744)) turned out to be essential for orthograde and two of them (Ala(739) and Phe(741)) for retrograde coupling, indicating that orthograde coupling does not necessarily correlate with retrograde signaling. Secondary structure predictions of the critical domain show that an alpha-helical (cardiac sequence-type) conformation of a cluster of negatively charged residues (Asp(744)-Glu(751) of alpha(1S)) corresponds with significantly reduced Ca2+ transients. Conversely, a predicted random coil structure (skeletal sequence-type) seems to be prerequisite for the restoration of skeletal-type excitation-contraction coupling. Thus, not only the primary but also the secondary structure of the critical domain is an essential determinant of the tissue-specific mode of EC coupling.	Univ Innsbruck, Dept Biochem Pharmacol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Physiol, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Grabner, M (corresponding author), Univ Innsbruck, Dept Biochem Pharmacol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.	manfred.grabner@uibk.ac.at	Tuluc, Petronel/C-2527-2011	Flucher, Bernhard/0000-0002-5255-4705				ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; Ahern CA, 2003, BIOPHYS J, V84, P942, DOI 10.1016/S0006-3495(03)74911-X; Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Coffin J. M., 1997, RETROVIRUSES, P1; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; Haarmann CS, 2003, BIOCHEM J, V372, P305, DOI 10.1042/BJ20021763; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Powell JA, 1996, J CELL BIOL, V134, P375, DOI 10.1083/jcb.134.2.375; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098	35	67	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4721	4728		10.1074/jbc.M307538200	http://dx.doi.org/10.1074/jbc.M307538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627713	hybrid			2022-12-25	WOS:000188554300096
J	Kuang, CZ; Chen, Y				Kuang, CZ; Chen, Y			Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction	ONCOGENE			English	Article						TGF-beta; Smad4; mutations; cancer	GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; STRUCTURAL BASIS; L3 LOOP; PROTEINS; GENE; SUPPRESSOR; PROMOTER; RECEPTOR; SIGNAL	Smad4 is a critical component in transforming growth factor beta (TGF-beta) signaling and frequently mutated in pancreatic and colorectal cancers. Smad4 has two important functional domains, MH1 and MH2, that are involved in different biological processes. The MH1 domain comprises a DNA binding domain and the MH2 domain is mainly implicated in transcriptional activation and homo- and heteromeric complex formation among Smad proteins. In the present study, a total of nine Smad4 mutations at both MH1 and MH2 domains were analysed and all of them had a reduced activity to stimulate transcription of a TGF-beta-responsive reporter gene. All four MH1 mutations had a markedly reduced ability to bind a consensus Smad binding element by an in vitro assay using GST fusion proteins. Among the MH2 mutations, R497H, K507Q, and R515G mutations of Smad4 gave rise to a reduced DNA binding capacity. The R497H mutation had a slightly reduced interaction with Smad2 upon activation of TGF-beta receptor. However, the K507Q and R515G mutations greatly lost their ability to associate with Smad2. Using a GST pull-down assay, it was found that the Smad4 MH2 domain bearing R497H and R515G mutations had an enhanced interaction with the MH1 region of the Smad4 protein, indicating that an increased intramolecular interaction by these mutations may alleviate the DNA binding activity at the MH1 domain. Consistent with these observations, the MH2 domain with R497H mutation had an enhanced ability to inhibit TGF-beta receptor-mediated transcription. In addition, the full-length R497H mutation was able to antagonize TGF-beta signaling in a dominant-negative manner. Therefore, these studies revealed novel mechanisms by which the Smad4 mutations utilize to abrogate their functions in transducing the signaling of TGF-beta, which plays an important role in various stages of cancer formation.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Chinese Academy of Sciences	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB130, Indianapolis, IN 46202 USA.	ychen3@iupui.edu			NIDDK NIH HHS [R01 DK55991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055991] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li W, 2001, BIOCHEM BIOPH RES CO, V286, P1163, DOI 10.1006/bbrc.2001.5529; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212	29	19	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1021	1029		10.1038/sj.onc.1207219	http://dx.doi.org/10.1038/sj.onc.1207219			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647410				2022-12-25	WOS:000188749900001
J	Dong, L; Xu, CW				Dong, L; Xu, CW			Carbohydrates induce mono-ubiquitination of H2B in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H2B; SACCHAROMYCES-CEREVISIAE; METHYLATION; RAD6; H3; MONOUBIQUITINATION; EXPRESSION; COMPONENT; SEQUENCE; COMPASS	Histone modifications have emerged to be a major regulatory mechanism for gene expression ( 1 - 4). However, it is not clear how histone modifications are physiologically regulated. Here, we show that mono-ubiquitinated H2B at lysine 123 (uH2B) in the yeast ( Saccharomyces cerevisiae) is present in exponential phase and absent in stationary phase. A wide array of carbohydrates or sugars, including glucose, fructose, mannose, and sucrose, are capable of inducing uH2B in stationary phase yeast. In contrast, non-metabolic glucose analogs are defective in inducing uH2B. Furthermore, uH2B induction is inhibited by iodoacetate, an inhibitor of glyceraldehyde-3- phosphate dehydrogenase in glycolysis. Moreover, uH2B induction is markedly impaired in yeast mutants, in which glycolytic genes are deleted. These data indicate that glycolysis is required for the carbohydrate-induced mono-ubiquitination of H2B at lysine 123. Therefore, our study reveals a novel paradigm of metabolic regulation of histone modifications.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Xu, CW (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.	xuc@mskcc.org						Alberts B, 2002, MOL BIOL CELL; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; GUELMAN R, 2002, BONE, V30, P23; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; HUNT LT, 1977, BIOCHEM BIOPH RES CO, V74, P650, DOI 10.1016/0006-291X(77)90352-7; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Klein CJL, 1998, MICROBIOL-SGM, V144, P13, DOI 10.1099/00221287-144-1-13; Michal G, 1999, BIOCH PATHWAYS ATLAS; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; OLSON MOJ, 1976, J BIOL CHEM, V251, P5901; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; van Holde KE., 1989, SPRINGER SERIES MOL; WEBB J, 1966, ENZYME METABOLIC INH, V3; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	31	23	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1577	1580		10.1074/jbc.C300505200	http://dx.doi.org/10.1074/jbc.C300505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14660635	hybrid			2022-12-25	WOS:000188005700002
J	Nubel, T; Dippold, W; Kleinert, H; Kaina, B; Fritz, G				Nubel, T; Dippold, W; Kleinert, H; Kaina, B; Fritz, G			Lovastatin inhibits Rho-regulated expression of E-selectin by TNF-alpha and attenuates tumor cell adhesion	FASEB JOURNAL			English	Article						statins; Rho GTPases; invasiveness	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITORS; HUMAN ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; LEUKOCYTE ADHESION; P21RAS ISOPRENYLATION; CYTOKINE INDUCTION; ACTIN CYTOSKELETON; CYCLE PROGRESSION	E-selectin mediated cell-cell adhesion plays an important role in inflammatory processes and extravasation of tumor cells. Tumor necrosis factor-alpha (TNF-) induces E-selectin gene and protein expression in primary human endothelial cells (HUVEC) and in an endothelial cell line (EA.hy-926). As shown by ELISA and FACS analyses, HMG-CoA reductase inhibitors (e.g., lovastatin) impair the TNF-alpha stimulated increase in E-selectin protein expression. Similar results were obtained for E-selectin mRNA expression and promoter activity, indicating that the effect of lovastatin is based on inhibition of gene expression. The effective inhibitory concentration of lovastatin was in a physiologically relevant range (IC50<0.1 mu M). Lovastatin-mediated block of TNF-alpha induced E-selectin expression is due to inhibition of protein geranylgeranylation rather than farnesylation. Down-regulation of Rho signaling by coexpression of dominant-negative Rho mutants (i.e RhoA, RhoB and Rac) impaired TNF-alpha driven E-selectin gene expression, indicating Rho signaling to be essential for transcriptional activation of the E-selectin gene. Inhibition of E-selectin expression by lovastatin gives rise to a significant reduction in TNF-alpha stimulated adhesion of colon carcinoma cells to HUVEC. Furthermore, low concentration of lovastatin (i.e., <= 1 mu M) attenuated TNF-alpha induced tumor cell invasion in vitro. The data support the view that statins might be clinically useful in protection against E-selectin mediated metastasis.	Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany; St Vincenz & Elisabeth Hosp, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pharmacol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Fritz, G (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany.	fritz@mail.uni-mainz.de	Kleinert, Hartmut/M-2988-2018	Kleinert, Hartmut/0000-0003-2202-3548	Deutsche Forschungsgemeinschaft [Fr 1241/3-1, SFB 519]; Wilhelm Sander-Stiftung [AZ: 1999.014.2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm Sander-Stiftung	This work was supported by the Deutsche Forschungsgemeinschaft (Fr 1241/3-1 and SFB 519) and the Wilhelm Sander-Stiftung (AZ: 1999.014.2). We would like to thank W. Roos for critical reading of the manuscript.	Barkalow FJ, 1996, BLOOD, V88, P4585, DOI 10.1182/blood.V88.12.4585.bloodjournal88124585; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; Brodt P., 1996, Clinical and Experimental Metastasis, V14, P74; Chung HK, 2002, EXP MOL MED, V34, P451, DOI 10.1038/emm.2002.63; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DUNHAM AJ, 1995, ANAL CHEM, V67, P220, DOI 10.1021/ac00097a033; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Forstermann U, 1998, FASEB J, V12, P773; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; Gnad R, 2000, MOL PHARMACOL, V58, P1389, DOI 10.1124/mol.58.6.1389; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; Hallahan DE, 1998, CANCER RES, V58, P5484; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Koch G, 1997, J PHARMACOL EXP THER, V283, P901; Kong LP, 1996, CLIN EXP METASTAS, V14, P335, DOI 10.1007/BF00123392; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kusama T, 2001, CANCER RES, V61, P4885; Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Matar P, 1999, CLIN EXP METASTAS, V17, P19; Meroni PL, 2001, ARTHRITIS RHEUM-US, V44, P2870, DOI 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; MILLER AC, 1995, INT J CANCER, V60, P249; Min W, 1997, J IMMUNOL, V159, P3508; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; Mueck AO, 2001, EXP CLIN ENDOCR DIAB, V109, P181, DOI 10.1055/s-2001-14843; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; Raab M, 2002, CLIN CHIM ACTA, V321, P11; Rasmussen LM, 2001, BIOCHEM J, V360, P363, DOI 10.1042/0264-6021:3600363; Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schmidt A, 2002, ATHEROSCLEROSIS, V164, P57, DOI 10.1016/S0021-9150(02)00053-9; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Seeger H, 2001, Climacteric, V4, P209, DOI 10.1080/713605099; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Wang IK, 2000, ONCOLOGY-BASEL, V59, P245, DOI 10.1159/000012168; WELLER A, 1992, J BIOL CHEM, V267, P15176; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Wittig BM, 1996, EUR J CANCER, V32A, P1215, DOI 10.1016/0959-8049(96)00086-X; WITTIG BM, 1995, GASTROENTEROLOGY SUP, V108; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yamada N, 1997, BRIT J CANCER, V76, P582, DOI 10.1038/bjc.1997.429; Yudoh K, 1997, CLIN EXP METASTAS, V15, P557, DOI 10.1023/A:1018487213157	61	106	108	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					140	142		10.1096/fj.03-0261fje	http://dx.doi.org/10.1096/fj.03-0261fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630701				2022-12-25	WOS:000188829300053
J	Pession, A; Martino, V; Tonelli, R; Beltramini, C; Locatelli, F; Biserni, G; Franzoni, M; Freccero, F; Montemurro, L; Pattacini, L; Paolucci, G				Pession, A; Martino, V; Tonelli, R; Beltramini, C; Locatelli, F; Biserni, G; Franzoni, M; Freccero, F; Montemurro, L; Pattacini, L; Paolucci, G			MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells	ONCOGENE			English	Article						MLL-AF9; cell growth; differentiation; expression; THP-1	FUSION GENE; HEMATOLOGICAL MALIGNANCIES; M-CSF; LEUKEMIA; MLL; LINE; PROTEIN; LEUKEMOGENESIS; MICE; ESTABLISHMENT	The MLL-AF9 oncogene - one of the most frequent MLL/HRX/ALL-1 rearrangements found in infantile and therapy-related leukaemias - originates from t(9;11) (p22;q23) and is mainly associated with monocytic acute myeloid leukaemia (AML-M5; FAB-classification). Here, we investigated the MLL-AF9 function by means of an antisense phosphorothioate-oligodeoxyribonucleotide (MLL-AF9-PS-ODNas) using the THP-1 AML-M5 cell line carrying t(9;11). Having confirmed that MLL-AF9-PS-ODNas induces strong inhibition of THP-1 cell growth, but only a moderate increase in apoptosis, we found that MLL-AF9-PS-ODNas did not induce morphofunctional terminal differentiation or restore M-CSF-, G-CSF- or GM-CSF-induced differentiation. Moreover, THP-1 cells showed the same phenotype with/without MLL-AF9-PS-ODNas. In THP-1 cells differentiated to mature macrophage-like cells by PMA/TPA or ATRA, MLL-AF9 expression was downregulated. Thus, in the monocytic lineage, MLL-AF9 may be expressed only in early phases and can induce deregulated amplification in both nonmalignant and malignant cells, maintaining the monocytic phenotype without blocking final maturation. Our findings suggest that: (1) as well as directly promoting cell growth, MLL-AF9 may also indirectly determine phenotype; (2) other leukaemogenic mutations associated with MLL-AF9-related leukaemias should be searched for mainly in processes of resistance to apoptosis (where MLL-AF9 may play only a limited role) and differentiation blockage (where MLL-AF9 may play no role).	Univ Bologna, Policlin S Orsola Malpighi, Dept Paediat, I-40138 Bologna, Italy; Univ Pavia, Policlin San Matteo, IRCCS, I-27100 Pavia, Italy; Univ Bologna, Policlin S Orsola Malpighi, Inst Haematol & Med Oncol LA Seragnoli, I-40138 Bologna, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Fondazione San Matteo; University of Pavia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Pession, A (corresponding author), Policlin S Orsola Malpighi, Dipartimento Sci Pediat Med & Chirurg, Unita Terapia Cellulare, Via Massarenti 11, I-40138 Bologna, Italy.		Pession, Andrea/O-3200-2013	Pession, Andrea/0000-0002-0379-9562				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; BRACH MA, 1990, VIRCHOWS ARCH B, V59, P54, DOI 10.1007/BF02899387; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Ennas MG, 1997, CANCER RES, V57, P2035; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Giles RV, 1998, NUCLEIC ACIDS RES, V26, P1567, DOI 10.1093/nar/26.7.1567; IIDA S, 1993, ONCOGENE, V8, P3085; Ikeda T, 1998, BIOCHEM BIOPH RES CO, V253, P265, DOI 10.1006/bbrc.1998.9702; Ikeda T, 1998, BLOOD, V91, P4543, DOI 10.1182/blood.V91.12.4543.412k27_4543_4553; Joh T, 1999, ONCOGENE, V18, P1125, DOI 10.1038/sj.onc.1202400; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Joh T, 1996, ONCOGENE, V13, P1945; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kawagoe H, 2001, LEUKEMIA, V15, P1743, DOI 10.1038/sj.leu.2402262; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; MATIKAINEN S, 1994, INT J CANCER, V57, P98, DOI 10.1002/ijc.2910570118; Niitsu N, 2001, ONCOGENE, V20, P375, DOI 10.1038/sj.onc.1204081; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Swansbury GJ, 1998, LEUKEMIA, V12, P792, DOI 10.1038/sj.leu.2401014; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	32	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8671	8676		10.1038/sj.onc.1207125	http://dx.doi.org/10.1038/sj.onc.1207125			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647461				2022-12-25	WOS:000186844900004
J	Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Oikawa, T				Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Oikawa, T			Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression	ONCOGENE			English	Article						PU.1; MeCP2; Ets; co-repressor; transcriptional repression	DNA-BINDING PROTEIN; HISTONE DEACETYLASE; ERYTHROLEUKEMIA-CELLS; ACTIVATION DOMAIN; METHYLATED DNA; NUCLEAR-FACTOR; ACETYLATION; DIFFERENTIATION; HDAC1; SPI-1/PU.1	PU.1, a member of the Ets family of transcription factors, is implicated in hematopoietic cell differentiation through its interactions with other transcriptional factors and cofactors. To identify a novel protein(s) binding to PU.1, we carried out affinity purification using a column of Glutathione-Sepharose beads bound to GST-PU.1 fusion protein and isolated several individual proteins using murine erythroleukemia (MEL) cell extracts. Sequence analysis of these proteins revealed that one was MeCP2 a methyl CpG binding protein. GST-pull-down assay and immunoprecipitation assay showed that PU.1 bound directly to MeCP2 via its Ets domain and MeCP2 bound to PU.1 via either its amino terminal domain or transrepression domain. MeCP2 repressed transcriptional activity of PU.1 on a reporter construct with trimerized PU.1 binding sites. This downregulation was recovered in the presence of histone deacetylase inhibitor, trichostatin A (TSA). MeCP2 was integrated in PU.1-mSin3A-HDAC complex but not in PU.1-CBP complex. Chromatin immunoprecipitation (ChIP) assays showed that PU.1 and MeCP2 were collocated at the PU.1 binding site on the reporter construct and the PU.1 binding site of the intervening sequence 2 (IVS2) region in the intron of the beta-globin gene, which has been proposed to regulate expression of the gene, in undifferentiated MEL cells. The complex disappeared from the region during the course of erythroid differentiation of MEL cells. Our results suggest that MeCP2 acts as a corepressor of PU.1 probably due to facilitating complex formation with mSin3A and HDACs.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan		Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; TENEN DG, 1997, BLOOD, V90, P498; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	42	67	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8688	8698		10.1038/sj.onc.1207182	http://dx.doi.org/10.1038/sj.onc.1207182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647463				2022-12-25	WOS:000186844900006
J	Gallego, MI; Bierie, B; Hennighausen, L				Gallego, MI; Bierie, B; Hennighausen, L			Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways	ONCOGENE			English	Article						breast cancer; transgenic mice; HGF; scatter factor; c-Met	HEPATOCYTE GROWTH-FACTOR; MET TYROSINE KINASE; NEGATIVE BREAST-CANCER; FACTOR SCATTER FACTOR; C-MET; BETA-CATENIN; GLAND DEVELOPMENT; FACTOR/SCATTER FACTOR; RECEPTOR MET; COLORECTAL-CANCER	Overexpression of hepatocyte growth factor (HGF), also called scatter factor (SIT), and its receptor c-Met are associated with poor prognosis for cancer patients. In particular, breast cancer cells can produce HGF that acts in a paracrine as well as in an autocrine manner. Therefore, HGF and c-Met are putative targets for cancer therapy. To explore HGF/c-Met signaling in breast cancer, we have generated transgenic mice expressing HGF specifically in mammary epithelium under the transcriptional control of the whey acidic protein (WAP) gene promoter. WAP-HGF transgenic females developed hyperplastic ductal trees and multifocal invasive tumors after several pregnancies, some of which progressed to lung metastases. Tumors produced HGF and displayed phosphorylated c-Met, which correlated with increased Akt as well as c-myc activation. A high growth rate, as demonstrated by Ki67 nuclear antigen staining, and a lack of progesterone receptor were characteristic of the tumors. Immunohistochemical analysis revealed areas of osteopontin (Opn) expression in WAP-HGF tumors and lung metastases in agreement with a previously reported role for Opn in invasive growth. We suggest that these mice may serve as a new breast cancer model for the evaluation of the effects of unscheduled HGF expression in breast cancer.	Fdn Marcelino Botin, Ctr Invest Energet Medioambientales & Tecnol, Project Breast Canc, Madrid 28042, Spain; NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gallego, MI (corresponding author), CIEMAT, Av Complutense 22,Edificio 7, E-28040 Madrid, Spain.			Gallego, Marta I./0000-0003-0143-2553; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulmann S, 2002, BREAST CANCER RES TR, V74, P25, DOI 10.1023/A:1016061327812; Bieche I, 1999, INT J CANCER, V82, P908, DOI 10.1002/(SICI)1097-0215(19990909)82:6<908::AID-IJC22>3.0.CO;2-N; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Boon EMJ, 2002, CANCER RES, V62, P5126; Bowers DC, 2000, CANCER RES, V60, P4277; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Greenberg R, 2003, BREAST CANCER RES, V5, pR71, DOI 10.1186/bcr588; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hogan B, 1994, MANIPULATING MOUSE E; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kamalati T, 1999, J MAMMARY GLAND BIOL, V4, P69, DOI 10.1023/A:1018756620265; Kang JY, 2003, CANCER RES, V63, P1101; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Medico E, 2001, CANCER RES, V61, P5861; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Monga SPS, 2002, CANCER RES, V62, P2064; Nakopoulou L, 2000, HISTOPATHOLOGY, V36, P313; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Oates AJ, 1996, ONCOGENE, V13, P97; Ocal IT, 2003, CANCER-AM CANCER SOC, V97, P1841, DOI 10.1002/cncr.11335; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Rudland PS, 2002, CANCER RES, V62, P3417; Schlotter CM, 2003, BREAST CANCER RES, V5, pR30, DOI 10.1186/bcr568; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tuck AB, 1996, AM J PATHOL, V148, P225; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Walter KA, 2002, MOL CELL BIOL, V22, P2703, DOI 10.1128/MCB.22.8.2703-2715.2002; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yant J, 1998, EXP CELL RES, V241, P476, DOI 10.1006/excr.1998.4028; Yoshida S, 2003, J INVEST DERMATOL, V120, P335, DOI 10.1046/j.1523-1747.2003.12039.x; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	62	83	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8498	8508		10.1038/sj.onc.1207063	http://dx.doi.org/10.1038/sj.onc.1207063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627990				2022-12-25	WOS:000186650300013
J	de Marval, PLM; Macias, E; Conti, CJ; Rodriguez-Puebla, ML				de Marval, PLM; Macias, E; Conti, CJ; Rodriguez-Puebla, ML			Enhanced malignant tumorigenesis in Cdk4 transgenic mice	ONCOGENE			English	Article						CDK4; carcinogenesis; skin; cell-cycle; cyclin; papillomas	SKIN TUMOR-DEVELOPMENT; CYCLIN-DEPENDENT KINASES; SENCAR MOUSE SKIN; CELL-CYCLE; GERMLINE MUTATIONS; PREMALIGNANT PROGRESSION; HOMOZYGOUS DELETION; IN-VIVO; EXPRESSION; OVEREXPRESSION	In a previous study, we reported that overexpression of cyclin-dependent kinase-4 (CDK4) in mouse epidermis results in epidermal hyperplasia, hypertrophy and severe dermal fibrosis. In this study, we have investigated the susceptibility to skin tumor formation by forced expression of CDK4. Skin tumors from transgenic mice showed a dramatic increase in the rate of malignant progression to squamous cell carcinomas (SCC) in an initiation-promotion protocol. Histopathological analysis of papillomas from transgenic mice showed an elevated number of premalignant lesions characterized by dysplasia and marked atypia. Interestingly, transgenic mice also developed tumors in initiated but not promoted skin, demonstrating that CDK4 replaced the action of tumor promoters. These results suggest that expression of cyclin D1 upon ras activation synergizes with CDK4 overexpression. However, cyclin D1 transgenic mice and double transgenic mice for cyclin D1 and CDK4 did not show increased malignant progression in comparison to CDK4 transgenic mice. Biochemical analysis of tumors showed that CDK4 sequesters the CDK2 inhibitors p27(Kip1) and p21(Cip1), suggesting that indirect activation of CDK2 plays an important role in tumor development. These results indicate that, contrary to the general assumption, the catalytic subunit, CDK4, has higher oncogenic activity than cyclin D1, revealing a potential use of CDK4 as therapeutic target.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA	University of North Carolina; North Carolina State University; University of Texas System; UTMD Anderson Cancer Center	Rodriguez-Puebla, ML (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	marcelo_rodriguez-puebla@ncsu.edu			NATIONAL CANCER INSTITUTE [P01CA057596, R01CA042157, P30CA016672, R01CA090864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90864, P30 CA016672, R01 CA042157, CA 57596, CA 16672, R01 CA090864, CA 42157, R01 CA090864-02] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDAZ M, 1989, EXPT CLIN ASPECTS; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; CONTI C, 1992, CANC B, V54, P62; de Marval PLM, 2001, AM J PATHOL, V159, P369, DOI 10.1016/S0002-9440(10)61703-8; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Lam PYP, 2000, BRIT J NEUROSURG, V14, P28; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; NEVINS JR, 1992, SCIENCE, V258, P424; Nikitakis NG, 2002, EXP MOL PATHOL, V73, P198, DOI 10.1006/exmp.2002.2465; OHTA M, 1994, CANCER RES, V54, P5269; Parry D, 1999, MOL CELL BIOL, V19, P1775; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLAGA T J, 1989, P1; SONODA Y, 1995, ONCOGENE, V11, P2145; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TOLFGARD R, 1985, CARCINOGENESIS, V6, P655; Tos APD, 2000, J PATHOL, V190, P531; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; YUSPA SH, 1990, ENVIRON HEALTH PERSP, V88, P193; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	61	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1863	1873		10.1038/sj.onc.1207309	http://dx.doi.org/10.1038/sj.onc.1207309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647432	Green Accepted			2022-12-25	WOS:000220129500008
J	Piccinni, SA; Bolcato-Bellemin, AL; Klein, A; Yang, VW; Kedinger, M; Simon-Assmann, P; Lefebvre, O				Piccinni, SA; Bolcato-Bellemin, AL; Klein, A; Yang, VW; Kedinger, M; Simon-Assmann, P; Lefebvre, O			Kruppel-like factors regulate the Lama1 gene encoding the laminin alpha 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; GLUCOCORTICOID-RECEPTOR; TRANSGENIC MICE; RETINOIC ACID; IN-VITRO; PROMOTER; GUT; GROWTH	Laminin-1 (alpha1beta1gamma1), a basement membrane ( BM) constituent, has been associated with differentiation processes and also with malignant progression. In the intestinal tissue, the alpha1 chain is expressed and secreted in the subepithelial BM during the developmental period; in the adult rodent tissue, it is restricted to the BM of the dividing cells. To understand how laminin alpha1 chain expression is regulated, we cloned and characterized a 2-kb promoter region of the Lama1 mouse gene. Analysis of the promoter was conducted in the Caco2-TC7 intestinal epithelial cells by transient transfection of serially deleted and site-directed mutated promoter constructs, by electrophoretic mobility shift assays, and expression of selected transcription factors. We determined that a proximal region, which includes an Sp1-binding GC box and a Kruppel-like element, was important for the promoter activity. This region is conserved between the human and mouse genes. Interestingly, two Kruppel-like factors KLF4 and KLF5 exhibit opposing effects on the Lama1 promoter activity that are decreased and increased, respectively, in the intestinal epithelial cells. These data corroborate the complementary expression of KLF4 and KLF5 along the intestinal crypt-villus axis and the parallel expression of KLF5 and laminin alpha1 chain in the crypt region. Finally, we showed that glucocorticoids stimulate the promoter activity. This study is the first characterization of the Lama1 promoter; we identified regulatory elements that may account for the expression pattern of the endogenous protein in the mouse intestine.	Univ Strasbourg, INSERM, U381, F-67200 Strasbourg, France; Emory Univ, Sch Med, Div Digest Dis, Atlanta, GA 30322 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Emory University	Lefebvre, O (corresponding author), Univ Strasbourg, INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.	olivier.lefebvre@INSERM.u-strasbg.fr	Lefebvre, Olivier/S-6436-2019; Lefebvre, Olivier/I-2388-2016	Lefebvre, Olivier/0000-0001-9130-9174; Lefebvre, Olivier/0000-0001-9130-9174	NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230, R01 DK052230-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Brembeck FH, 2001, GASTROENTEROLOGY, V120, P1720, DOI 10.1053/gast.2001.24846; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CHANTRET I, 1994, J CELL SCI, V107, P213; CHAO KM, 1992, COMPUT APPL BIOSCI, V8, P481; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; De Arcangelis A, 2001, INT J CANCER, V94, P44, DOI 10.1002/ijc.1444; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Ekblom P, 2003, MATRIX BIOL, V22, P35, DOI 10.1016/S0945-053X(03)00015-5; Fritsch C, 1999, EXP CELL RES, V248, P391, DOI 10.1006/excr.1999.4414; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Gustafsson E, 2000, EXP CELL RES, V261, P52, DOI 10.1006/excr.2000.5042; HARTL L, 1988, EUR J BIOCHEM, V173, P629, DOI 10.1111/j.1432-1033.1988.tb14045.x; Henning Susan J., 1994, P571; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Hlubek F, 2001, CANCER RES, V61, P8089; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; Kedinger M., 2000, DEV GASTROINTESTINAL, P83; Kuratomi Y, 1999, EXP CELL RES, V249, P386, DOI 10.1006/excr.1999.4497; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li TWH, 1999, AM J PHYSIOL-GASTR L, V276, pG1425, DOI 10.1152/ajpgi.1999.276.6.G1425; Lietard J, 1997, AM J PATHOL, V151, P1663; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Maatta A, 2000, J BIOL CHEM, V275, P19857, DOI 10.1074/jbc.M001028200; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; Nieto N, 2003, J BIOL CHEM, V278, P15360, DOI 10.1074/jbc.M206790200; Olsen J, 2003, BIOCHEM J, V371, P211, DOI 10.1042/BJ20021454; ONeill BC, 1997, AM J PHYSIOL-RENAL, V273, pF411, DOI 10.1152/ajprenal.1997.273.3.F411; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Plateroti M, 1997, J CELL SCI, V110, P1227; Ramos RA, 1999, FASEB J, V13, P169, DOI 10.1096/fasebj.13.1.169; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sasaki T, 2002, EXP CELL RES, V275, P185, DOI 10.1006/excr.2002.5499; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sharif KA, 2001, MECH DEVELOP, V103, P13, DOI 10.1016/S0925-4773(01)00326-4; SHIE JL, 2000, AM J PHYSIOL, V5, pG806; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shim C, 1996, MOL REPROD DEV, V44, P44, DOI 10.1002/(SICI)1098-2795(199605)44:1&lt;44::AID-MRD5&gt;3.0.CO;2-T; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SIMO P, 1991, DEVELOPMENT, V112, P477; SIMO P, 1992, J CELL SCI, V101, P161; SIMO P, 1992, GASTROENTEROLOGY, V102, P1835, DOI 10.1016/0016-5085(92)90303-G; Simon-Assmann P, 2003, FALK SYMP, V132, P223; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TOPLEY P, 1993, BRIT J CANCER, V67, P953, DOI 10.1038/bjc.1993.176; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Virolle T, 2002, NUCLEIC ACIDS RES, V30, P1789, DOI 10.1093/nar/30.8.1789; WEWER UM, 1987, DEV BIOL, V121, P397, DOI 10.1016/0012-1606(87)90176-X; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189	61	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9103	9114		10.1074/jbc.M305804200	http://dx.doi.org/10.1074/jbc.M305804200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14634001	hybrid, Green Accepted			2022-12-25	WOS:000189265900072
J	Shim, JS; Kim, DH; Kwon, HJ				Shim, JS; Kim, DH; Kwon, HJ			Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells	ONCOGENE			English	Article						histone deacetylase; transcriptional repression; plakoglobin; oncogene	BETA-CATENIN; TUMOR-SUPPRESSOR; GAMMA-CATENIN; EXPRESSION; INHIBITORS; DROSOPHILA; PROTEIN; AGENTS; CANCER; CARCINOGENESIS	Histone deacetylase ( HDAC) plays a key role in gene expression, by suppressing the transcription of a number of target genes. Identification of such genes is important for deciphering the functional role of HDAC. Here, using cancer gene-focused DNA microarray analysis, we identified plakoglobin as a new target gene of HDAC. Functional inhibition of HDAC by its specific inhibitors induced the expression of plakoglobin by eight-fold in human fibrosarcoma HT1080 cells. However, the expression of beta-catenin, which is closely related to plakoglobin, was not altered, implying the specific function of HDAC in plakoglobin expression. Using antiacetyl-H4 antibody, chromatin immunoprecipitation analysis revealed that the distal region ( - 945 similar to - 646) of the promoter of plakoglobin is responsible for the HDAC-mediated repression of the gene. Moreover, the induced expression of plakoglobin by the inhibition of HDAC activated the Tcf/ Lef-dependent luciferase reporter gene, a well-known downstream effector of the Wnt signaling pathway. Furthermore, transient transfection of plakoglobin also activated Tcf/ Lef reporter gene expression. Taken together, our results demonstrate that plakoglobin is a new target gene governed by HDAC, and that it acts as an oncogene in HT1080 cells.	Sejong Univ, Dept Biosci & Biotechnol, Inst Biosci, Seoul 143747, South Korea	Sejong University	Kwon, HJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, Inst Biosci, 98 Kunja Dong, Seoul 143747, South Korea.	kwonhj@sejong.ac.kr	Shim, Joong Sup/G-8383-2011; 권, 호정/AAS-3642-2021; Shim, Joong Sup/O-2848-2016	Shim, Joong Sup/0000-0003-0167-7307; Shim, Joong Sup/0000-0003-0167-7307				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim JH, 2002, JPN J CANCER RES, V93, P1378, DOI 10.1111/j.1349-7006.2002.tb01247.x; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kolligs FT, 2000, GENE DEV, V14, P1319; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ogden SK, 2001, J BIOL CHEM, V276, P42057, DOI 10.1074/jbc.C100381200; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Richon VM, 2002, CLIN CANCER RES, V8, P662; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VanLint C, 1996, GENE EXPRESSION, V5, P245; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963	30	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1704	1711		10.1038/sj.onc.1207289	http://dx.doi.org/10.1038/sj.onc.1207289			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14661058				2022-12-25	WOS:000220029300006
J	Carlson, BA; Novoselov, SV; Kumaraswamy, E; Lee, BJ; Anver, MR; Gladyshev, VN; Hatfield, DL				Carlson, BA; Novoselov, SV; Kumaraswamy, E; Lee, BJ; Anver, MR; Gladyshev, VN; Hatfield, DL			Specific excision of the selenocysteine tRNA([Ser]Sec) (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; TRANSFER-RNA; SELENIUM; MICE; DISRUPTION; PATTERNS; PROTEIN; PLASMA	Selenium is essential in mammalian embryonic development. However, in adults, selenoprotein levels in several organs including liver can be substantially reduced by selenium deficiency without any apparent change in phenotype. To address the role of selenoproteins in liver function, mice homozygous for a floxed allele encoding the selenocysteine (Sec) tRNA([Ser]Sec) gene were crossed with transgenic mice carrying the Cre recombinase under the control of the albumin promoter that expresses the recombinase specifically in liver. Recombination was nearly complete in mice 3 weeks of age, whereas liver selenoprotein synthesis was virtually absent, which correlated with the loss of Sec tRNA([Ser] Sec) and activities of major selenoproteins. Total liver selenium was dramatically decreased, whereas levels of low molecular weight selenocompounds were little affected. Plasma selenoprotein P levels were reduced by about 75%, suggesting that selenoprotein P is primarily exported from the liver. Glutathione S-transferase levels were elevated in the selenoprotein-deficient liver, suggesting a compensatory activation of this detoxification program. Mice appeared normal until about 24 h before death. Most animals died between 1 and 3 months of age. Death appeared to be due to severe hepatocellular degeneration and necrosis with concomitant necrosis of peritoneal and retroperitoneal fat. These studies revealed an essential role of selenoproteins in liver function.	NCI, Sect Mol Biol Selenium, Basic Res Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Seoul Natl Univ, Sch Biol Sci, Mol Genet Lab, Seoul 151742, South Korea; NCI, Pathol Histotechnol Lab, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Lincoln; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Hatfield, DL (corresponding author), NCI, Sect Mol Biol Selenium, Basic Res Lab, Ctr Canc Res,NIH, Bldg 37,Rm 6016,9000 Rockville Pike, Bethesda, MD 20892 USA.	hatfield@dc37a.nci.nih.gov	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Novoselov, Sergey/0000-0003-0104-6492; Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL CANCER INSTITUTE [Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM065204, R01GM065204, R01GM061603] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NIGMS NIH HHS [GM065204, GM061603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; BOUWENS L, 1992, ENZYME, V46, P155, DOI 10.1159/000468782; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Burk RF, 2001, BIOFACTORS, V14, P107, DOI 10.1002/biof.5520140115; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Esworthy RS, 2001, AM J PHYSIOL-GASTR L, V281, pG848, DOI 10.1152/ajpgi.2001.281.3.G848; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Gladyshev VN, 1999, P NATL ACAD SCI USA, V96, P835, DOI 10.1073/pnas.96.3.835; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; HAMES BD, 1995, PRACTICAL APPROACH S; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; Hatfield D. L., 2001, SELENIUM ITS MOL BIO; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; KATO T, 1992, AM J PHYSIOL, V262, pG854, DOI 10.1152/ajpgi.1992.262.5.G854; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; LEI XG, 1995, J NUTR, V125, P1438; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; Schneider MJ, 2001, MOL ENDOCRINOL, V15, P2137, DOI 10.1210/me.15.12.2137; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Watanabe Y, 2003, J CELL BIOCHEM, V89, P244, DOI 10.1002/jcb.10501; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6	30	142	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8011	8017		10.1074/jbc.M310470200	http://dx.doi.org/10.1074/jbc.M310470200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660662	hybrid, Green Submitted			2022-12-25	WOS:000189103300079
J	Melino, G; Bernassola, F; Ranalli, M; Yee, K; Zong, WX; Corazzari, M; Knight, RA; Green, DR; Thompson, C; Vousden, KH				Melino, G; Bernassola, F; Ranalli, M; Yee, K; Zong, WX; Corazzari, M; Knight, RA; Green, DR; Thompson, C; Vousden, KH			p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; BCL-X-L; CELL-SURVIVAL; P53; GENE; DEATH; DELTA-NP73; PROTEIN; CYTOSOL; TARGET	p73, an important developmental gene, shares a high sequence homology with p53 and induces both G(1) cell cycle arrest and apoptosis. However, the molecular mechanisms through which p73 induces apoptosis are unclear. We found that p73-induced apoptosis is mediated by PUMA (p53 up-regulated modulator of apoptosis) induction, which, in turn, causes Bax mitochondrial translocation and cytochrome c release. Overexpression of p73 isoforms promotes cell death and bax promoter transactivation in a time-dependent manner. However, the kinetics of apoptosis do not correlate with the increase of Bax protein levels. Instead, p73-induced mitochondrial translocation of Bax is kinetically compatible with the induction of cell death. p73 is localized in the nucleus and remains nuclear during the induction of cell death, indicating that the effect of p73 on Bax translocation is indirect. The ability of p73 to directly trans-activate PUMA and the direct effect of PUMA on Bax conformation and mitochondrial relocalization suggest a molecular link between p73 and the mitochondrial apoptotic pathway. Our data therefore indicate that PUMA-mediated Bax mitochondrial translocation, rather than its direct transactivation, correlates with cell death. Finally, human DeltaNp73, an isoform lacking the amino-terminal transactivation domain, inhibits TAp73-induced as well as p53-induced apoptosis. The DeltaNp73 isoforms seem therefore to act as dominant negatives, repressing the PUMA/Bax system and, thus, finely tuning p73-induced apoptosis. Our findings demonstrate that p73 elicits apoptosis via the mitochondrial pathway using PUMA and Bax as mediators.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Ist Ricovero & Cura Carattere Sci, Inst Dermopat Immacolata,Biochem Lab, I-00133 Rome, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cyst Fibrosis, London SW3 6LR, England; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92037 USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Leicester; Beatson Institute; University of Pennsylvania; Pennsylvania Medicine; Imperial College London; La Jolla Institute for Immunology	Melino, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IRCCS,IDI, D26-F153,Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it	Green, Douglas R/N-8083-2018; Corazzari, Marco/B-4631-2019; Corazzari, Marco/J-5825-2019; Corazzari, Marco/K-6422-2016	Green, Douglas R/0000-0002-7332-1417; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968	Telethon [E.0872] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zarotti M., 1995, BIOCHIM BIOPHYS ACTA, V1241, P139; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	44	296	309	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8076	8083		10.1074/jbc.M307469200	http://dx.doi.org/10.1074/jbc.M307469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14634023	hybrid			2022-12-25	WOS:000189103300087
J	Chen, LY; Zuraw, BL; Ye, RD; Pan, ZXK				Chen, LY; Zuraw, BL; Ye, RD; Pan, ZXK			A Rho exchange factor mediates fMet-Leu-Phe-induced NF-kappa B activation in human peripheral blood monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BINDING PROTEIN-RHO; DBL ONCOGENE PRODUCT; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-8 EXPRESSION; FAMILY GTPASES; CELLS; HOMOLOGY	We reported previously that fMLP stimulates NF-kappaB activation, and this function of fMLP requires small GTPase RhoA in human peripheral blood monocytes (Huang, S., Chen, L.-Y., Zuraw, B. L., Ye, R. D., and Pan, Z. K. (2001) J. Biol. Chem. 276, 40977-40981). Here we present evidence that RhoA associates specifically with the guanine nucleotide exchange factor Lbc in human peripheral blood monocytes stimulated with fMLP and that Lbc specifically catalyzes the guanine nucleotide exchange activity of RhoA in human peripheral blood monocytes. Cotransfection of the monocytic THP1 cells with Ibc with a kappaB promoter reporter plasmid results in a marked increase in NF-kappaB-mediated reporter gene expression. Finally, Lbc-enhanced NF-kappaB activation is inhibited by a RhoA inhibitor, C3 transferase from Clostridium botulinum. A dominant-negative form of RhoA (T19N) also inhibited Lbc-enhanced reporter gene expression in a kappaB-dependent manner. These results indicate that guanine nucleotide exchange factor Lbc is a novel signal transducer for RhoA-mediated NF-kappaB activation in human peripheral blood monocytes stimulated with bacterial products.	Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Scripps Research Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pan, ZXK (corresponding author), Med Coll Ohio, Dept Microbiol & Immunol, 3035 Arlington Ave, Toledo, OH 43614 USA.	zkpan@mco.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Zuraw, Bruce/0000-0003-0640-6768	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI043524, T32AI007469, R01AI043524] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI43524, T32 AI 07469] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JM, 1992, ONCOGENE, V7, P611; Arbour N, 1996, CYTOKINE, V8, P468, DOI 10.1006/cyto.1996.0063; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Cochrane CG, 1990, CELLULAR MOL MECHANI, P83; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hippenstiel S, 2000, BLOOD, V95, P3044; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARI B, 1994, J BIOL CHEM, V269, P8517; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKSOZ D, 1994, ONCOGENE, V9, P621; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	36	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7208	7212		10.1074/jbc.M309542200	http://dx.doi.org/10.1074/jbc.M309542200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660653	hybrid			2022-12-25	WOS:000188969200120
J	Kolfschoten, MV; Dirven, RJ; Vos, HL; Tans, G; Rosing, J; Bertina, RM				Kolfschoten, MV; Dirven, RJ; Vos, HL; Tans, G; Rosing, J; Bertina, RM			Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; PEPTIDE-BOND CLEAVAGES; BLOOD-COAGULATION; FACTOR-XA; THROMBOTIC DISEASE; FACTOR VA(R506Q); HONG-KONG; MUTATION; RESISTANCE; CAMBRIDGE	Activated protein C (APC) exerts its anticoagulant activity via proteolytic degradation of the heavy chains of activated factor VIII (FVIIIa) and activated factor V (FVa). So far, three APC cleavage sites have been identified in the heavy chain of FVa: Arg-306, Arg-506, and Arg-679. To obtain more insight in the structural and functional implications of each individual cleavage, recombinant factor V (rFV) mutants were constructed in which two or three of the APC cleavage sites were mutated. After expression in COS-1 cells, rFV mutants were purified, activated with thrombin, and inactivated by APC. During this study we observed that activated rFV-GQA (rFVa-GQA), in which the arginines at positions 306, 506, and 679 were replaced by glycine, glutamine, and alanine, respectively, was still inactivated by APC. Further analysis showed that the inactivation of rFVa-GQA by APC was phospholipid-dependent and sensitive to an inhibitory monoclonal antibody against protein C. Inactivation proceeded via a rapid phase (k(x1) = 5.4 x 10(4) M-1 s(-1)) and a slow phase (k(x2) = 3.2 x 10(3) M-1 s(-1)). Analysis of the inactivation curves showed that the rapid phase yielded a reaction intermediate that retained similar to 80% of the original FVa activity, whereas the slow cleavage resulted in formation of a completely inactive reaction product. Inactivation of rFVa-GQA was accelerated by protein S, most likely via stimulation of the slow phase. Immunoblot analysis using a monoclonal antibody recognizing an epitope between Arg-306 and Arg-506 indicated that during the rapid phase of inactivation a fragment of 80 kDa was generated that resulted from cleavage at a residue very close to Arg-506. The slow phase was associated with the formation of fragments resulting from cleavage at a residue 1.5-2 kDa carboxyl-terminal to Arg-306. Our observations may explain the unexpectedly mild APC resistance associated with mutations at Arg-306 (FV HongKong and FV Cambridge) in the heavy chain of FV.	Leiden Univ, Med Ctr, Dept Hematol, Ctr Hemostasis & Thrombosis Res, NL-2300 RC Leiden, Netherlands; Univ maastricht, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University	Kolfschoten, MV (corresponding author), Leiden Univ, Med Ctr, Dept Hematol, Ctr Hemostasis & Thrombosis Res, C2-R,POB 9600, NL-2300 RC Leiden, Netherlands.	mneut@lumc.nl	Bertina, Rogier/AGQ-5246-2022	Dirven, Richard/0000-0001-9626-9925				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Chan WP, 1998, BLOOD, V91, P1135, DOI 10.1182/blood.V91.4.1135; Chen F, 1999, THROMB HAEMOSTASIS, P105; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Franco RF, 1998, BRIT J HAEMATOL, V103, P888; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P312; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; Guasch JF, 1998, BRIT J HAEMATOL, V101, P32, DOI 10.1046/j.1365-2141.1998.00664.x; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; Hockin MF, 1997, ARTERIOSCL THROM VAS, V17, P2765, DOI 10.1161/01.ATV.17.11.2765; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kolfschoten MV, 2002, BLOOD COAGUL FIBRIN, V13, P207, DOI 10.1097/00001721-200204000-00006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Norstrom E, 2002, BLOOD, V100, P524, DOI 10.1182/blood-2002-02-0343; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; OWREN PA, 1947, LANCET, V252, P446; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; SALA N, 1984, BLOOD, V63, P671; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; van der Neut Kolfschoten M, 2003, THROMB HAEMOSTASIS, V89, P429; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140	43	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6567	6575		10.1074/jbc.M308574200	http://dx.doi.org/10.1074/jbc.M308574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660667	hybrid			2022-12-25	WOS:000188969200045
J	Schafer, T; Zentgraf, H; Zehe, C; Brugger, B; Bernhagen, J; Nickel, W				Schafer, T; Zentgraf, H; Zehe, C; Brugger, B; Bernhagen, J; Nickel, W			Unconventional secretion of fibroblast growth factor 2 is mediated by direct translocation across the plasma membrane of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION INHIBITORY FACTOR; BINDING CASSETTE TRANSPORTER; RETICULUM-GOLGI-COMPLEX; COPI-COATED VESICLES; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; SIGNAL SEQUENCE; INTERCELLULAR TRAFFICKING; STRUCTURAL PROTEIN; INNER MEMBRANES	Fibroblast growth factor 2 (FGF-2) is a pro-angiogenic mediator that is secreted by both normal and neoplastic cells. Intriguingly, FGF-2 has been shown to be exported by an endoplasmic reticulum/Golgi-independent pathway; however, the molecular machinery mediating this process has remained elusive. Here we introduce a novel in vitro system that functionally reconstitutes FGF-2 secretion. Based on affinity-purified plasma membrane inside-out vesicles, we demonstrate post-translational membrane translocation of FGF-2 as shown by protease protection experiments. This process is blocked at low temperature but apparently does not appear to be driven by ATP hydrolysis. FGF-2 membrane translocation occurs in a unidirectional fashion requiring both integral and peripheral membrane proteins. These findings provide direct evidence that FGF-2 secretion is based on its direct translocation across the plasma membrane of mammalian cells. When galectin-1 and macrophage migration inhibitory factor, other proteins exported by unconventional means, were analyzed for translocation into plasma membrane inside-out vesicles, galectin-1 was found to be transported as efficiently as FGF-2. By contrast, migration inhibitory factor failed to traverse the membrane of inside-out vesicles. These findings establish the existence of multiple distinct secretory routes that are operational in the absence of a functional endoplasmic reticulum/Golgi system.	Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Hosp RWTH Aachen, Inst Biochem, Unit Biochem & Mol Cell Biol, D-52074 Aachen, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); RWTH Aachen University; RWTH Aachen University Hospital	Nickel, W (corresponding author), Univ Heidelberg, Biochem Ctr, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	walter.nickel@urz.uni-heidelberg.de						Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; AURON PE, 1987, J IMMUNOL, V138, P1447; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Dahl JP, 2000, BIOCHEMISTRY-US, V39, P14877, DOI 10.1021/bi001073y; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; Keppler D, 1998, METHOD ENZYMOL, V292, P607; KETTLUN AM, 1994, INT J BIOCHEM, V26, P437, DOI 10.1016/0020-711X(94)90065-5; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Lecellier CH, 2002, J VIROL, V76, P3388, DOI 10.1128/JVI.76.7.3388-3394.2002; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; Mandinova A, 2003, J CELL SCI, V116, P2687, DOI 10.1242/jcs.00471; McKean PG, 2001, CELL MICROBIOL, V3, P511, DOI 10.1046/j.1462-5822.2001.00135.x; Mehul B, 1997, J CELL SCI, V110, P1169; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nickel W, 2002, J CELL SCI, V115, P3235; Nickel W, 1998, J CELL SCI, V111, P3081; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pencer J, 2001, BIOPHYS J, V81, P2716, DOI 10.1016/S0006-3495(01)75914-0; Prudovsky I, 2002, J CELL BIOL, V158, P201, DOI 10.1083/jcb.200203084; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Swope MD, 1999, REV PHYSIOL BIOCH P, V139, P1, DOI 10.1007/BFb0033647; Trotman LC, 2003, TRAFFIC, V4, P390, DOI 10.1034/j.1600-0854.2003.00094.x; Trudel C, 2000, J CELL PHYSIOL, V185, P260, DOI 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; Zhou XQ, 2002, BIOCHEM BIOPH RES CO, V291, P598, DOI 10.1006/bbrc.2002.6473	64	105	106	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6244	6251		10.1074/jbc.M310500200	http://dx.doi.org/10.1074/jbc.M310500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645213	hybrid			2022-12-25	WOS:000188969200008
J	Yu, CR; Rahmani, M; Almenara, J; Sausville, EA; Dent, P; Grant, S				Yu, CR; Rahmani, M; Almenara, J; Sausville, EA; Dent, P; Grant, S			Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process	ONCOGENE			English	Article						leukemia; apoptosis; adaphostin; ROS; ERK; Akt	ACTIVATED PROTEIN-KINASE; CHRONIC MYELOGENOUS LEUKEMIA; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; IN-VIVO; GROWTH-FACTOR; MAP KINASES; PATHWAY; JNK; PHOSPHORYLATION	Effects of the tyrphostin tyrosine kinase inhibitor adaphostin (NSC 680410) have been examined in human leukemia cells ( Jurkat, U937) in relation to mitochondrial events, apoptosis, and perturbations in signaling and cell cycle regulatory events. Exposure of cells to adaphostin concentrations greater than or equal to0.75 muM for intervals greater than or equal to6 h resulted in a pronounced release of cytochrome c and AIF, activation of caspase-9, -8, and -3, and apoptosis. These events were accompanied by the caspase-independent downregulation of Raf-1, inactivation of MEK1/2, ERK, Akt, p70S6K, dephosphorylation of GSK-3, and activation of c-Jun-N-terminal kinase (JNK) and p38 MAPK. Adaphostin also induced cleavage and dephosphorylation of pRb on CDK2- and CDK4-specific sites, as well as the caspase-dependent downregulation of cyclin D-1. Inducible expression of a constitutively active MEK1 construct markedly diminished adaphostin-induced cytochrome c and AIF release, JNK activation, and apoptosis in Jurkat cells. Ectopic expression of Raf-1 or constitutively activated ( myristolated) Akt also significantly attenuated adaphostin-induced apoptosis, but protection was less than that conferred by enforced activation of MEK. Lastly, antioxidants (e.g., L-N-acetylcysteine; L-NAC) opposed adaphostin-mediated mitochondrial dysfunction, Raf-1/ MEK/ERK downregulation, JNK activation, and apoptosis. However, in contrast to L-NAC, enforced activation of MEK failed to block adaphostin-mediated ROS generation. Together, these findings demonstrate that the tyrphostin adaphostin induces multiple perturbations in signal transduction pathways in human leukemia cells, particularly inactivation of the cytoprotective Raf-1/ MEK/ERK and Akt cascades, that culminate in mitochondrial injury, caspase activation, and apoptosis. They also suggest that adaphostin-related oxidative stress acts upstream of perturbations in these signaling pathways to trigger the cell death process.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; NCI, Dev Therapeut Program, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93738, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arguello F, 1998, BLOOD, V91, P2482; Avramis IA, 2002, CANCER CHEMOTH PHARM, V50, P479, DOI 10.1007/s00280-002-0507-6; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Carlson B, 1999, CANCER RES, V59, P4634; CHANDRA J, 2003, BLOOD; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wolf C, 2001, FEBS LETT, V488, P154, DOI 10.1016/S0014-5793(00)02403-0; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CR, 2003, CANCER RES, V63, P1822; Yu CR, 2003, CANCER RES, V63, P2118; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143	45	61	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1364	1376		10.1038/sj.onc.1207248	http://dx.doi.org/10.1038/sj.onc.1207248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647418				2022-12-25	WOS:000189035800004
J	Boguslawski, G; McGlynn, PW; Harvey, KA; Kovala, AT				Boguslawski, G; McGlynn, PW; Harvey, KA; Kovala, AT			SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATASES PTP-SL; MAP KINASE; CELL-MIGRATION; B-RAF; SPHINGOSINE 1-PHOSPHATE; DIFFERENTIAL REGULATION; COUPLED RECEPTORS; SMOOTH-MUSCLE; CYCLIC-AMP	SU1498, an inhibitor of vascular endothelial growth factor receptor 2, has been used successfully to study the physiological manifestations of receptor functions. Here we report that in addition to its anti-receptor activity, SU1498 stimulates accumulation of phosphorylated ERKs in human umbilical vein endothelial cells and in human aortic endothelial cells in a manner that is dependent on the functioning of the upstream components of the MAPK pathway, B-Raf, and MEK kinases. The enhanced accumulation of phospho-ERKs is observed only in cells that have been stimulated with sphingosine 1-phosphate or protein growth factors; SU1498 by itself is ineffective. We show that the inhibitor acts by blocking the kinase activity of phospho-ERK both in a direct assay and in immunoprecipitates from cells treated with the compound. The data reveal a novel and unique way in which MAPK signaling pathway may be blocked in human endothelial cells.	Indiana Univ, Sch Med, Methodist Res Inst, Clarian Hlth Patners, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Kovala, AT (corresponding author), Indiana Univ, Sch Med, Methodist Res Inst, Clarian Hlth Patners, Indianapolis, IN 46202 USA.	tkovala@clarian.org		Kovala, A. Thomas/0000-0002-2908-5613				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BEITZ JG, 1991, P NATL ACAD SCI USA, V88, P2021, DOI 10.1073/pnas.88.5.2021; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boguslawski G, 2000, BIOCHEM BIOPH RES CO, V272, P603, DOI 10.1006/bbrc.2000.2822; Boguslawski G, 2002, EXP CELL RES, V274, P264, DOI 10.1006/excr.2002.5472; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Calleja V, 1997, ENDOCRINOLOGY, V138, P1111, DOI 10.1210/en.138.3.1111; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Cottom J, 2003, J BIOL CHEM, V278, P7167, DOI 10.1074/jbc.M203901200; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goetze S, 2002, HYPERTENSION, V40, P748, DOI 10.1161/01.HYP.0000035522.63647.D3; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; McGovern SL, 2003, J MED CHEM, V46, P1478, DOI 10.1021/jm020427b; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Munoz JJ, 2003, BIOCHEM J, V372, P193, DOI 10.1042/BJ20021941; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Renner O, 2003, MOL BRAIN RES, V113, P44, DOI 10.1016/S0169-328X(03)00085-8; REUTERDAHL C, 1993, J CLIN INVEST, V91, P2065, DOI 10.1172/JCI116429; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sano H, 2002, AM J PATHOL, V161, P135, DOI 10.1016/S0002-9440(10)64165-X; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Strawn LM, 1996, CANCER RES, V56, P3540; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tarrega C, 2002, J BIOL CHEM, V277, P2629, DOI 10.1074/jbc.M108874200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang DG, 1999, CANCER RES, V59, P1464; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wojta J, 1999, LAB INVEST, V79, P427; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	66	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5716	5724		10.1074/jbc.M308625200	http://dx.doi.org/10.1074/jbc.M308625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625306	hybrid			2022-12-25	WOS:000188776500084
J	Sharma, S; Sathyanarayana, BK; Bird, JG; Hoskins, JR; Lee, B; Wickner, S				Sharma, S; Sathyanarayana, BK; Bird, JG; Hoskins, JR; Lee, B; Wickner, S			Plasmid P1 RepA is homologous to the F plasmid RepE class of initiators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REPLICATION INITIATOR; DNA-REPLICATION; CLPA CHAPERONE; COPY NUMBER; HOST-RANGE; ORIGIN; BINDING; MUTANTS	DNA replication of plasmid P1 requires a plasmid-encoded origin DNA-binding protein, RepA. RepA is an inactive dimer and is converted by molecular chaperones into an active monomer that binds RepA binding sites. Although the sequence of RepA is not homologous to that of F plasmid RepE, we found by using fold-recognition programs that RepA shares structural homology with RepE and built a model based on the RepE crystal structure. We constructed mutants in the two predicted DNA binding domains to test the model. As expected, the mutants were defective in P1 DNA binding. The model predicted that RepA binds the first half of the binding site through interactions with the C-terminal DNA binding domain and the second half through interactions with the N-terminal domain. The experiments supported the prediction. The model was further supported by the observation that mutants defective in dimerization map to the predicted subunit interface region, based on the crystal structure of pPS10 RepA, a RepE family member. These results suggest P1 RepA is structurally homologous to plasmid initiators, including those of F, R6K, pSC101, pCU1, pPS10, pFA3, pGSH500, Rts1, RepHI1B, RepFIB, and RSF1010.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr,MSC37-4264, Bethesda, MD 20892 USA.	suewick@helix.nih.gov		Bird, Jeremy/0000-0003-2690-8474	NATIONAL CANCER INSTITUTE [Z01BC008710, ZIABC008710, Z01BC008759] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1989, J BACTERIOL, V171, P43, DOI 10.1128/jb.171.1.43-52.1989; BAUMSTARK BR, 1984, MOL GEN GENET, V194, P513, DOI 10.1007/BF00425567; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; Chattoraj DK, 1997, PROG NUCLEIC ACID RE, V57, P145, DOI 10.1016/S0079-6603(08)60280-9; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; Diaz-Lopez T, 2003, J BIOL CHEM, V278, P18606, DOI 10.1074/jbc.M212024200; Filutowicz M, 1998, GENE, V223, P195, DOI 10.1016/S0378-1119(98)00367-9; Fischer D, 2000, Pac Symp Biocomput, P119; FROEHLICH BJ, 1988, PLASMID, V19, P121, DOI 10.1016/0147-619X(88)90051-0; Giraldo R, 2003, NAT STRUCT BIOL, V10, P565, DOI 10.1038/nsb937; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; INGMER H, 1995, J MOL BIOL, V250, P309, DOI 10.1006/jmbi.1995.0378; ISHIAI M, 1992, J BACTERIOL, V174, P5597, DOI 10.1128/JB.174.17.5597-5603.1992; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; Jung J, 2000, PROTEIN ENG, V13, P535, DOI 10.1093/protein/13.8.535; KAWASAKI Y, 1991, J BACTERIOL, V173, P1064, DOI 10.1128/jb.173.3.1064-1072.1991; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Maestro B, 2003, J BACTERIOL, V185, P1367, DOI 10.1128/JB.185.4.1367-1375.2003; MANEN D, 1992, P NATL ACAD SCI USA, V89, P8923, DOI 10.1073/pnas.89.19.8923; Matsunaga F, 1997, J MOL BIOL, V274, P27, DOI 10.1006/jmbi.1997.1373; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; PAPP PP, 1994, NUCLEIC ACIDS RES, V22, P152, DOI 10.1093/nar/22.2.152; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SCOTT JR, 1982, J BACTERIOL, V150, P1329, DOI 10.1128/JB.150.3.1329-1339.1982; Sharma R, 2001, EMBO J, V20, P4577, DOI 10.1093/emboj/20.16.4577; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; TILLY K, 1990, New Biologist, V2, P812; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; Urh M, 1998, J MOL BIOL, V283, P619, DOI 10.1006/jmbi.1998.2120; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690	45	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6027	6034		10.1074/jbc.M310917200	http://dx.doi.org/10.1074/jbc.M310917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634015	hybrid			2022-12-25	WOS:000188776500118
J	Viviano, BL; Paine-Saunders, S; Gasiunas, N; Gallagher, J; Saunders, S				Viviano, BL; Paine-Saunders, S; Gasiunas, N; Gallagher, J; Saunders, S			Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist noggin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS CELLULAR-RESPONSES; STRUCTURAL FEATURES; MITOGENIC ACTIVITY; SPEMANN ORGANIZER; XENOPUS EMBRYOS; SONIC HEDGEHOG; PROTEOGLYCANS; SURFACE; WNT; OLIGOSACCHARIDES	We have reported previously that Noggin is a heparin-binding protein and associates with the cell surface through heparan sulfate proteoglycans, where it remains functional for the binding of bone morphogenetic proteins ( BMPs). Here we report that the binding of Noggin to the cell surface is highly selective for heparan sulfate and that specific structural features are required for the interaction. Noggin binds most efficiently to heparin sequences composed of 10 or more monosaccharides; N-, 6- O-, and 2- O- sulfates contribute to this interaction. In addition, we have shown that the developmentally regulated endosulfatase Qsulf1 selectively removes sulfate groups from the 6- O position of sugars within the most highly sulfated S domains of heparan sulfate, whereas 6- O- sulfates in the NA/ NS domains are not substrates for the enzyme. The activity of Qsulf1 in cells in culture results in the release of Noggin from the cell surface and a restoration of BMP responsiveness to the cells. This shows that Noggin binds to the S domains of heparan sulfate and provides evidence that, in addition to modulating Wnt signaling in vivo by the release of heparan sulfate bound Wnt, Qsulf1 also modulates BMP signaling by the release of surface- bound Noggin.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Paterson Inst Canc Res, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Paterson Institute for Cancer Research	Saunders, S (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	saunders_s@kids.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD039952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056063] Funding Source: NIH RePORTER; NICHD NIH HHS [HD39952] Funding Source: Medline; NIDDK NIH HHS [DK56063] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Dale L, 1999, SEMIN CELL DEV BIOL, V10, P319, DOI 10.1006/scdb.1999.0308; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Dosch R, 1997, DEVELOPMENT, V124, P2325; Friedl A, 1997, AM J PATHOL, V150, P1443; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hirsinger E, 1997, DEVELOPMENT, V124, P4605; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rubin JB, 2002, DEVELOPMENT, V129, P2223; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; Tonegawa A, 1998, DEV BIOL, V202, P172, DOI 10.1006/dbio.1998.8895; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	32	158	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5604	5611		10.1074/jbc.M310691200	http://dx.doi.org/10.1074/jbc.M310691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645250	hybrid			2022-12-25	WOS:000188776500070
J	Nishikawa, H; Ooka, S; Sato, K; Arima, K; Okamoto, J; Klevit, RE; Fukuda, M; Ohta, T				Nishikawa, H; Ooka, S; Sato, K; Arima, K; Okamoto, J; Klevit, RE; Fukuda, M; Ohta, T			Mass spectrometric and mutational analyses reveal lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN CHAIN; DNA-REPAIR; BRCA1/BARD1 HETERODIMER; REGULATORY COMPLEX; 26S PROTEASOMES; RING DOMAIN; BRCA1; PROTEIN; CANCER; DEGRADATION	The breast and ovarian cancer suppressor BRCA1 acquires significant ubiquitin ligase activity when bound to BARD1 as a RING heterodimer. Although the activity may well be important for the role of BRCA1 as a tumor suppressor, the biochemical consequence of the activity is not yet known. Here we report that BRCA1-BARD1 catalyzes Lys-6-linked polyubiquitin chain formation. K6R mutation of ubiquitin dramatically reduces the polyubiquitin products mediated by BRCA1-BARD1 in vitro. BRCA1-BARD1 preferentially utilizes ubiquitin with a single Lys residue at Lys-6 or Lys-29 to mediate autoubiquitination of BRCA1 in vivo. Furthermore, mass spectrometry analysis identified the Lys-6-linked branched ubiquitin fragment from the polyubiquitin chain produced by BRCA1-BARD1 using wild type ubiquitin. The BRCA1-BARD1-mediated Lys-6-linked polyubiquitin chains are deubiquitinated by 26 S proteasome in vitro, whereas autoubiquitinated CUL1 through Lys-48-linked polyubiquitin chains is degraded. Proteasome inhibitors do not alter the steady state level of the autoubiquitinated BRCA1 in vivo. Hence, the results indicate that BRCA1-BARD1 mediates novel polyubiquitin chains that may be distinctly edited by 26 S proteasome from conventional Lys-48-linked polyubiquitin chains.	St Marianna Univ, Sch Med, Inst Med Sci, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan; St Marianna Univ, Sch Med, Inst Med Sci, Div Immunoregulat, Kawasaki, Kanagawa 2168511, Japan; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Saint Marianna University; Saint Marianna University; University of Washington; University of Washington Seattle	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Inst Med Sci, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.	to@marianna-u.ac.jp	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; Ohta, Tomohiko/0000-0002-9700-7342				Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	35	180	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3916	3924		10.1074/jbc.M308540200	http://dx.doi.org/10.1074/jbc.M308540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638690	hybrid			2022-12-25	WOS:000188554300004
J	Yoshida, K; Furuya, S; Osuka, S; Mitoma, J; Shinoda, Y; Watanabe, M; Azuma, N; Tanaka, H; Hashikawa, T; Itohara, S; Hirabayashi, Y				Yoshida, K; Furuya, S; Osuka, S; Mitoma, J; Shinoda, Y; Watanabe, M; Azuma, N; Tanaka, H; Hashikawa, T; Itohara, S; Hirabayashi, Y			Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SERINE; HIPPOCAMPAL-NEURONS; METABOLISM; CELLS; BIOSYNTHESIS; EXPRESSION; TISSUES; LINEAGE; MUTANTS; GLIA	D-3-Phosphoglycerate dehydrogenase (Phgdh; EC 1.1.1.95) is the first committed enzyme of L-serine biosynthesis in the phosphorylated pathway. To determine the physiological importance of Phgdh-dependent L-serine biosynthesis in vivo, we generated Phgdh-deficient mice using targeted gene disruption in embryonic stem cells. The absence of Phgdh led to a drastic reduction of L-serine metabolites such as phosphatidyl-L-serine and sphingolipids. Phgdh null embryos have small bodies with abnormalities in selected tissues and died after days post-coitum 13.5. Striking abnormalities were evident in the central nervous system in which the Phgdh null mutation culminated in hypoplasia of the telencephalon, diencephalon, and mesencephalon; in particular, the olfactory bulbs, ganglionic eminence, and cerebellum appeared as indistinct structures. These observations demonstrate that the Phgdh-dependent phosphorylated pathway is essential for normal embryonic development, especially for brain morphogenesis.	RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Behab Genet, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan; Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 0608638, Japan; Utsunomiya Univ, Fac Agr, Dept Appl Biochem, Utsunomiya, Tochigi 3218505, Japan; Tokyo Univ Agr & Technol, United Grad Sch Agr Sci, Fuchu, Tokyo 1838509, Japan	RIKEN; RIKEN; RIKEN; Sanford Burnham Prebys Medical Discovery Institute; Hokkaido University; Utsunomiya University; Tokyo University of Agriculture & Technology	Furuya, S (corresponding author), RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 3510198, Japan.	furuyash@postman.riken.go.jp; hirabaya@postman.riken.go.jp	Watanabe, Masahiko/S-3614-2019; WATANABE, Masahiko/A-4055-2012; Itohara, Shigeyoshi/I-8769-2012	Watanabe, Masahiko/0000-0001-5037-7138; WATANABE, Masahiko/0000-0001-5037-7138; Itohara, Shigeyoshi/0000-0002-2410-9989; Hirabayashi, Yoshio/0000-0002-5774-7354; Furuya, Shigeki/0000-0001-9020-3597				Achouri Y, 1997, BIOCHEM J, V323, P365, DOI 10.1042/bj3230365; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen YP, 1998, J EXP ZOOL, V282, P691; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; Furuya S, 2000, P NATL ACAD SCI USA, V97, P11528, DOI 10.1073/pnas.200364497; Furuya S, 2003, ARCH HISTOL CYTOL, V66, P109, DOI 10.1679/aohc.66.109; FURUYA S, 1994, J BIOL CHEM, V269, P32418; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; ICHIHARA A, 1957, J BIOL CHEM, V224, P331; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Mitoma J, 1998, J BIOL CHEM, V273, P19363, DOI 10.1074/jbc.273.31.19363; Mitoma J, 1998, NEUROSCI RES, V30, P195, DOI 10.1016/S0168-0102(97)00113-2; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Narkewicz MR, 1996, PEDIATR RES, V39, P1085, DOI 10.1203/00006450-199606000-00025; Nishijima M, 1997, TRENDS CELL BIOL, V7, P324, DOI 10.1016/S0962-8924(97)01084-2; ROWSELL EV, 1969, BIOCHEM J, V115, P1071, DOI 10.1042/bj1151071; Shibata T, 1997, J NEUROSCI, V17, P9212; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; SNELL K, 1987, BIOCHEM J, V245, P609, DOI 10.1042/bj2450609; WALSH DA, 1966, J BIOL CHEM, V241, P4068; WHITE FV, 1986, J NEUROCHEM, V46, P1200, DOI 10.1111/j.1471-4159.1986.tb00638.x; Yamasaki M, 2001, J NEUROSCI, V21, P7691, DOI 10.1523/JNEUROSCI.21-19-07691.2001; Yanagawa Y, 1999, TRANSGENIC RES, V8, P215, DOI 10.1023/A:1008914020843	25	102	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3573	3577		10.1074/jbc.C300507200	http://dx.doi.org/10.1074/jbc.C300507200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14645240	hybrid			2022-12-25	WOS:000188379600054
J	Bos, R; van Diest, PJ; van der Groep, P; Greijer, AE; Hermsen, MA; Heijnen, I; Meijer, GA; Baak, JPA; Pinedo, HM; van der Wall, E; Shvarts, A				Bos, R; van Diest, PJ; van der Groep, P; Greijer, AE; Hermsen, MA; Heijnen, I; Meijer, GA; Baak, JPA; Pinedo, HM; van der Wall, E; Shvarts, A			Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D-1 and hypoxia-inducible factor-1 alpha (HIF-1 alpha)	ONCOGENE			English	Article						BCL-6; HIF-1 alpha; cyclin D-1; oncogenes; breast cancer	D1; DIFFERENTIATION; OVEREXPRESSION	B-cell lymphoma gene (BCL-6) upregulation contributes to immortalization of mouse embryo fibroblast and primary B cells via upregulation of cyclin D-1. As cyclin D-1 overexpression is a common phenomenon in different cancers, BCL-6 protein overexpression may not be restricted to lymphomas. In this study, expression of BCL-6 was investigated by immunohistochemistry on paraffin-embedded specimens from 150 breast cancer patients and 10 specimens of normal breast tissue. The results showed BCL-6 overexpression (greater than or equal to10% of cells) in 24/150 (16%) breast cancer patients, whereas in normal breast low expression (<1%) of BCL-6 was observed. In linear regression analysis BCL-6 expression was associated with cyclin D-1 (r = 0.197, P = 0.016). Further, in chi(2) analyses, BCL-6-positivity was associated with overexpression of p53 (P = 0.016), and hypoxia-inducible factor-1 alpha (P < 0.001). Involvement of BCL-6 in breast carcinogenesis is further underscored by comparative genomic hybridization analysis that showed gains at the BCL-6 locus (3q27) in 14/86 (16%) breast cancer tissues. The cases with amplification in BCL-6 showed an increased (25%) incidence of BCL-6 protein overexpression. Thus, this study is the first to show that BCL-6 oncogene activation plays a role in cancers other than lymphomas.	Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; SiR Hosp, Dept Pathol, Stavanger, Norway	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Shvarts, A (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	a.shvarts@vumc.nl	Bos, Reinhard/AAS-1726-2020	Meijer, Gerrit/0000-0003-0330-3130; Bos, Reinhard/0000-0003-1094-5596				Bindra RS, 2002, CANCER RES, V62, P3014; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; de Jong JS, 1999, J CLIN PATHOL-MOL PA, V52, P78, DOI 10.1136/mp.52.2.78; Dunphy CH, 2001, LEUKEMIA LYMPHOMA, V41, P585, DOI 10.3109/10428190109060349; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Hermsen MAJA, 1998, J PATHOL, V186, P356; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ree HJ, 2003, HUM PATHOL, V34, P610, DOI 10.1016/S0046-8177(03)00086-8; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; vanDiest PJ, 1997, AM J PATHOL, V150, P705; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Ye BH, 2000, CANCER INVEST, V18, P356, DOI 10.3109/07357900009012179; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zhong H, 1999, CANCER RES, V59, P5830	19	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8948	8951		10.1038/sj.onc.1206995	http://dx.doi.org/10.1038/sj.onc.1206995			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654791				2022-12-25	WOS:000186982200016
J	Brummer, T; Naegele, H; Reth, M; Misawa, Y				Brummer, T; Naegele, H; Reth, M; Misawa, Y			Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf	ONCOGENE			English	Article						B-Raf; feedback phosphorylation; ERK; B-cell antigen receptor; DT40; MEK-inhibitor UO126	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; CELL ANTIGEN RECEPTOR; COMPLETE CODING SEQUENCE; NERVE GROWTH-FACTOR; JUN NH2-TERMINAL KINASE; NEGATIVE REGULATION; POSITIVE FEEDBACK; TYROSINE KINASES; STRUCTURAL BASIS	The extracellular signal-regulated kinase (ERK) pathway plays an important role during the development and activation of B lymphocytes. We have recently shown that B-Raf is a dominant ERK activator in B-cell antigen receptor signalling. We now show that B-Raf is hyperphosphorylated upon BCR engagement and undergoes a prominent electrophoretic mobility shift. This shift correlates with ERK activation and is prevented by the MEK inhibitor U0126. Syk-deficient DT40 B cells display neither dual ERK phosphorylation nor a mobility shift of B-Raf upon BCR engagement. The inducible expression of a constitutively active B-Raf in this mutant line restores dual ERK phosphorylation and the mobility shift of endogenous B-Raf, indicating that these two events are connected to each other. By site-directed mutagenesis studies, we demonstrate that the shift is due to an ERK2-mediated feedback phosphorylation of serine/threonine residues within an evolutionary conserved SPKTP motif at the C-terminus of B-Raf. Replacement of these residues by negatively charged amino acids causes a constitutive mobility shift and a reduction of PC12 cell differentiation. We discuss a model in which ERK-mediated phosphorylation of the SPKTP motif is involved in negative feedback regulation of B-Raf.	Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; Max Planck Society	Misawa, Y (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ym8n@virginia.edu	Brummer, Tilman/B-6218-2016; Brummer, Tilman/AAA-9428-2020	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Gold MR, 2000, CURR TOP MICROBIOL, V245, P77; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KOENEN M, 1988, ONCOGENE, V2, P179; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEE RM, 1992, J BIOL CHEM, V267, P1088; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shirakata Y, 1999, J IMMUNOL, V163, P6589; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UEKI K, 1994, J BIOL CHEM, V269, P15756; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Xu R, 1999, J IMMUNOL, V163, P1110; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; ZHUO S, 1993, J BIOL CHEM, V268, P17754; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322	67	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8823	8834		10.1038/sj.onc.1207185	http://dx.doi.org/10.1038/sj.onc.1207185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654779				2022-12-25	WOS:000186982200003
J	Petrosillo, G; Ruggiero, FM; Paradies, G				Petrosillo, G; Ruggiero, FM; Paradies, G			Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria	FASEB JOURNAL			English	Article						ROS; cytochrome c release; mitochondrial dysfunction	ELECTRON-TRANSPORT CHAIN; LIVER-MITOCHONDRIA; RESPIRATORY-CHAIN; PEROXIDATION; APOPTOSIS; MEMBRANE; PERMEABILIZATION; DISSOCIATION; METABOLISM; BINDING	Several lines of evidence indicate that mitochondria-mediated reactive oxygen species (ROS) generation is a major source of oxidative stress in the cell. Release of cytochrome c from mitochondria is a central event in apoptosis induction and appears to be mediated by ROS. Dissociation of cytochrome c from the IMM, where it is bound to cardiolipin, represents a necessary first step for cytochrome c release. In the present study, the role of ROS and cardiolipin in the release of cytochrome c from rat liver mitochondria was investigated. ROS were produced by mitochondria oxidizing succinate in the nonphosphorylating state. Cytochrome c was quantitated by a new, very sensitive and rapid reverse-phase HPLC method. We found that succinate-supported ROS production resulted in a release of cytochrome c from mitochondria and a parallel loss of cardiolipin content. These effects were directly and significantly correlated and also abolished by ADP, which prevents succinate-mediated ROS production. The ROS-induced cytochrome c release was independent from MPT and appears to involve VDAC. It is suggested that mitochondrial-induced ROS production promotes cytochrome c release from mitochondria by a two-steps process, consisting of the dissociation of this protein from cardiolipin, followed by permeabilization of the outer membrane, probably by interaction with VDAC. The data may help clarify the molecular mechanism underlying the release of cytochrome c from the mitochondria to the cytosol and the role of ROS and cardiolipin in this release.	Univ Bari, Dept Biochem & Mol Biol, Bari, Italy; Univ Bari, CNR, Inst Biomembranes & Bioenerget, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Bari, Italy.	g.paradies@biologia.uniba.it		PETROSILLO, GIUSEPPE/0000-0001-8035-8368				Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Buege J A, 1978, Methods Enzymol, V52, P302; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; DUTTON PL, 1975, BIOCHIM BIOPHYS ACTA, V387, P536, DOI 10.1016/0005-2728(75)90092-4; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; Nishimura G, 2001, FEBS LETT, V505, P399, DOI 10.1016/S0014-5793(01)02859-9; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Picklo MJ, 1999, ANAL BIOCHEM, V276, P166, DOI 10.1006/abio.1999.4349; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Subramanian M, 1998, BIOCHEMISTRY-US, V37, P1394, DOI 10.1021/bi9716581; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	45	490	515	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2202	2208		10.1096/fj.03-0012com	http://dx.doi.org/10.1096/fj.03-0012com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656982				2022-12-25	WOS:000188067500041
J	Arnott, CH; Scott, KA; Moore, RJ; Robinson, SC; Thompson, RG; Balkwill, FR				Arnott, CH; Scott, KA; Moore, RJ; Robinson, SC; Thompson, RG; Balkwill, FR			Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development	ONCOGENE			English	Article						TNFR1; TNFR2; keratinocyte; GM-CSF; MMP-9; c-jun	NECROSIS-FACTOR RECEPTOR; DEFICIENT LIVER-REGENERATION; FACTOR-KAPPA-B; MOUSE SKIN; C-JUN; TRANSGENIC MICE; CARCINOGENESIS; CELLS; LIGAND; P55	Keratinocyte-derived TNF-alpha acts as an endogenous tumour promoter and can also regulate AP-1 activity in mouse epidermis. To gain further insight into TNF-alpha signalling during skin tumour formation, mice deficient in TNFR1 (TNFR1(-/-) mice) or TNFR2 (TNFR2(-/-) mice) were subjected to chemical carcinogenesis. Tumour multiplicity was significantly reduced in TNFR1(-/-) and TNFR2(-/-) mice compared to wild-type (wt) mice, suggesting that both receptors have protumour activity. However, TNFR1(-/-) mice were markedly more resistant to tumour development than TNFR2(-/-) mice indicating that TNFR1 is the major mediator of TNF-alpha-induced tumour formation. TNFR1 and TNFR2 were both expressed in wt epidermis during tumour promotion and by primary keratinocytes in vitro. TPA-induced c-Jun expression was transient in TNFR1(-/-) and TNFR2(-/-) compared to wt epidermis and this was reflected by reduced induction of the AP-1-responsive genes granulocyte/macrophage-colony stimulating factor, matrix metalloproteinase-9 and matrix metalloproteinase-3. The se genes were differentially regulated in TNFR1(-/-) compared to TNFR2(-/-) epidermis, suggesting that the TNF-alpha receptors act independently via different AP-1 complexes to transduce TNF-alpha signals during tumour promotion. In addition, TNFR2 cooperated with TNFR1 to optimise TNFR1-mediated TNF-alpha bioactivity on keratinocytes in vitro. Our data provide further insight into TNF-alpha signalling in malignancy and provide some rationale for the use of TNF-alpha antagonists in the treatment of cancer.	Barts & London Queen Marys Sch Med & Dent, John Vane Sci Ctr, Canc Res UK Translat Oncol Lab, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Scott, KA (corresponding author), Barts & London Queen Marys Sch Med & Dent, John Vane Sci Ctr, Canc Res UK Translat Oncol Lab, Charterhouse Sq, London EC1M 6BQ, England.	kate.scott@cancer.org.uk		Balkwill, Frances/0000-0002-5587-9759				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnott CH, 2002, ONCOGENE, V21, P4728, DOI 10.1038/sj.onc.1205588; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; Hulboy DL, 2001, MOL CELL BIOL, V21, P5478, DOI 10.1128/MCB.21.16.5478-5487.2001; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kitakata H, 2002, CANCER RES, V62, P6682; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Littlejohn AF, 2003, BIOCHEM PHARMACOL, V65, P91, DOI 10.1016/S0006-2952(02)01443-0; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mann A, 2001, CANCER RES, V61, P2311; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Papathoma AS, 2001, MOL CARCINOGEN, V31, P74, DOI 10.1002/mc.1042; Peschon JJ, 1998, J IMMUNOL, V160, P943; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Rutberg SE, 1996, ONCOGENE, V13, P167; Scott KA, 2003, MOL CANCER THER, V2, P445; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Suganuma M, 1999, CANCER RES, V59, P4516; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yamada Y, 1998, AM J PATHOL, V152, P1577; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhong SP, 2001, CANCER RES, V61, P4084; Zhuang LH, 1999, J IMMUNOL, V162, P1440	43	152	157	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1902	1910		10.1038/sj.onc.1207317	http://dx.doi.org/10.1038/sj.onc.1207317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14661063				2022-12-25	WOS:000220129500012
J	Gao, GH; Prutzman, KC; King, ML; Scheswohl, DM; DeRose, EF; London, RE; Schaller, MD; Campbell, SL				Gao, GH; Prutzman, KC; King, ML; Scheswohl, DM; DeRose, EF; London, RE; Schaller, MD; Campbell, SL			NMR solution structure of the focal adhesion targeting domain of focal adhesion kinase in complex with a paxillin LD peptide - Evidence for a two-site binding model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; DIFFERENTIAL REGULATION; BIOLOGICAL RESPONSES; DIPOLAR COUPLINGS; HIGH-SENSITIVITY; TERMINAL DOMAIN; C-13	Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is regulated by integrins. Upon activation, FAK generates signals that modulate crucial cell functions, including cell proliferation, migration, and survival. The C-terminal focal adhesion targeting ( FAT) sequence mediates localization of FAK to discrete regions in the cell called focal adhesions. Several binding partners for the FAT domain of FAK have been identified, including paxillin. We have determined the solution structure of the avian FAT domain in complex with a peptide mimicking the LD2 motif of paxillin by NMR spectroscopy. The FAT domain retains a similar fold to that found in the unliganded form when complexed to the paxillin-derived LD2 peptide, an antiparallel four-helix bundle. However, noticeable conformational changes were observed upon the LD2 peptide binding, especially the position of helix 4. Multiple lines of evidence, including the results obtained from isothermal titration calorimetry, intermolecular nuclear Overhauser effects, mutagenesis, and protection from paramagnetic line broadening, support the existence of two distinct paxillin-binding sites on the opposite faces of the FAT domain. The structure of the FAT domain-LD2 complex was modeled using the program HADDOCK based on our solution structure of the LD2-bound FAT domain and mutagenesis data. Our model of the FAT domain-LD2 complex provides insight into the molecular basis of FAK-paxillin binding interactions, which will aid in understanding the role of paxillin in FAK targeting and signaling.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Comprehens Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Campbell, SL (corresponding author), Univ N Carolina, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	campbesl@med.unc.edu	London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463; campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050110, ZIAES050111, Z01ES050111, Z01ES050110] Funding Source: NIH RePORTER; NCI NIH HHS [CA90901] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIDCR NIH HHS [DE13079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Arumugam S, 1998, BIOCHEMISTRY-US, V37, P9650, DOI 10.1021/bi980128h; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Boetzel R, 2000, PROTEIN SCI, V9, P1709, DOI 10.1110/ps.9.9.1709; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hauck CR, 2001, CANCER RES, V61, P7079; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Hecker TP, 2003, FRONT BIOSCI-LANDMRK, V8, pS705, DOI 10.2741/1115; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hubbard SJ, 1993, NACCESS COMPUTER PRO; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones G, 2001, CANCER RES, V61, P4978; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Leyton J, 2001, CANCER LETT, V162, P87, DOI 10.1016/S0304-3835(00)00639-X; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li XW, 2001, J CELL SCI, V114, P2665; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; LYONS BA, 1993, BIOCHEMISTRY-US, V32, P7839, DOI 10.1021/bi00082a001; Matsuo H, 1996, J MAGN RESON SER B, V113, P91, DOI 10.1006/jmrb.1996.0161; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; NILGES M, 1997, FOLD DES, V2, P53; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schneider GB, 2002, CANCER, V95, P2508, DOI 10.1002/cncr.10992; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; TURNER CE, 1994, J CELL SCI, V107, P1583; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Yang DW, 1999, J BIOMOL NMR, V14, P333, DOI 10.1023/A:1008314803561; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	77	62	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8441	8451		10.1074/jbc.M309808200	http://dx.doi.org/10.1074/jbc.M309808200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662767	hybrid			2022-12-25	WOS:000189103300127
J	McCarron, JG; MacMillan, D; Bradley, KN; Chalmers, S; Muir, TC				McCarron, JG; MacMillan, D; Bradley, KN; Chalmers, S; Muir, TC			Origin and mechanisms of Ca2+ waves in smooth muscle as revealed by localized photolysis of caged inositol 1,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; LUMINAL CA2+; RYANODINE RECEPTORS; SIGNAL-TRANSDUCTION; CALCIUM-RELEASE; GATED CHANNELS; CYTOSOLIC CA2+; TRISPHOSPHATE; INHIBITION; OSCILLATIONS	The cytosolic Ca2+ concentration ([Ca2+](c)) controls diverse cellular events via various Ca2+ signaling patterns; the latter are influenced by the method of cell activation. Here, in single-voltage clamped smooth muscle cells, sarcolemma depolarization generated uniform increases in [Ca2+](c) throughout the cell entirely by Ca2+ influx. On the other hand, the Ca2+ signal produced by InsP(3)-generating agonists was a propagated wave. Using localized uncaged InsP(3), the forward movement of the Ca2+ wave arose from Ca2+-induced Ca2+ release at the InsP(3) receptor (InsP(3)R) without ryanodine receptor involvement. The decline in [Ca2+](c) ( the back of the wave) occurred from a functional compartmentalization of the store, which rendered the site of InsP(3)-mediated Ca2+ release, and only this site, refractory to the phosphoinositide. The functional compartmentalization arose by a localized feedback deactivation of InsP(3) receptors produced by an increased [Ca2+](c) rather than a reduced luminal [Ca2+] or an increased cytoplasmic [InsP(3)]. The deactivation of the InsP(3) receptor was delayed in onset, compared with the time of the rise in [Ca2+](c), persisted (>30 s) even when [Ca2+](c) had regained resting levels, and was not prevented by kinase or phosphatase inhibitors. Thus different forms of cell activation generate distinct Ca2+ signaling patterns in smooth muscle. Sarcolemma Ca2+ entry increases [Ca2+](c) uniformly; agonists activate InsP(3)R and produce Ca2+ waves. Waves progress by Ca2+-induced Ca2+ release at InsP(3)R, and persistent Ca2+-dependent inhibition of InsP(3)R accounts for the decline in [Ca2+](c) at the back of the wave.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	McCarron, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.	J.McCarron@bio.gla.ac.uk	Chalmers, Susan/C-1392-2009	Chalmers, Susan/0000-0002-8073-7576				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Ashby MC, 2002, J CELL BIOL, V158, P283, DOI 10.1083/jcb.200112025; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; Boittin FX, 1999, AM J PHYSIOL-CELL PH, V277, pC139, DOI 10.1152/ajpcell.1999.277.1.C139; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; Bradley KN, 2002, J PHYSIOL-LONDON, V538, P465, DOI 10.1113/jphysiol.2001.013039; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dreja K, 2001, BRIT J PHARMACOL, V132, P1957, DOI 10.1038/sj.bjp.0703986; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Flynn ERM, 2001, J BIOL CHEM, V276, P36411, DOI 10.1074/jbc.M104308200; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gordienko DV, 2002, J PHYSIOL-LONDON, V542, P743, DOI 10.1113/jphysiol.2001.015966; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Heppner TJ, 2002, AM J PHYSIOL-HEART C, V283, pH2169, DOI 10.1152/ajpheart.00603.2002; IINO M, 1994, MOL CELL ENDOCRINOL, V98, P141, DOI 10.1016/0303-7207(94)90132-5; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IINO M, 1994, EMBO J, V13, P5026, DOI 10.1002/j.1460-2075.1994.tb06831.x; ILYIN V, 1994, J PHYSIOL-LONDON, V477, P503, DOI 10.1113/jphysiol.1994.sp020211; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Lansley AB, 1999, BIOPHYS J, V77, P629, DOI 10.1016/S0006-3495(99)76919-5; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Lukyanenko V, 1999, J PHYSIOL-LONDON, V518, P173, DOI 10.1111/j.1469-7793.1999.0173r.x; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; McCarron JG, 2002, J CELL SCI, V115, P2207; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; McCarron JG, 2000, J PHYSIOL-LONDON, V525, P113, DOI 10.1111/j.1469-7793.2000.00113.x; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; NUNN DL, 1992, MOL PHARMACOL, V41, P115; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Sanders KM, 2001, J APPL PHYSIOL, V91, P1438, DOI 10.1152/jappl.2001.91.3.1438; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TAKEI K, 1992, J NEUROSCI, V12, P489; TOESCU EC, 1995, AM J PHYSIOL-GASTR L, V269, pG173, DOI 10.1152/ajpgi.1995.269.2.G173; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Wier WG, 2004, REV PHYSIOL BIOCH P, V150, P91, DOI 10.1007/s10254-003-0019-8; ZHOLOS AV, 1994, J PHYSIOL-LONDON, V481, P97, DOI 10.1113/jphysiol.1994.sp020421	58	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8417	8427		10.1074/jbc.M311797200	http://dx.doi.org/10.1074/jbc.M311797200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660609	hybrid			2022-12-25	WOS:000189103300125
J	Arimura, T; Hayashi, T; Terada, H; Lee, SY; Zhou, Q; Takahashi, M; Ueda, K; Nouchi, T; Hohda, S; Shibutani, M; Hirose, M; Chen, J; Park, JE; Yasunami, M; Hayashi, H; Kimura, A				Arimura, T; Hayashi, T; Terada, H; Lee, SY; Zhou, Q; Takahashi, M; Ueda, K; Nouchi, T; Hohda, S; Shibutani, M; Hirose, M; Chen, J; Park, JE; Yasunami, M; Hayashi, H; Kimura, A			A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN; HEART-FAILURE; GENE; PDZ; TRANSLOCATION; EPSILON; MUSCLE; IDENTIFICATION; PHOSPHOLAMBAN; LOCALIZATION	Dilated cardiomyopathy is characterized by ventricular dilation with systolic dysfunction of cardiac muscle. Recent genetic studies have revealed that mutations in genes for cytoskeleton proteins distributed in the Z-disc and/or intercalated discs of the cardiac muscle are major predictors of cardiomyopathy. However, as mutations in these genes can account for only a part of the patient population, there should be another disease-causing gene(s) for cardiomyopathy. Cypher/ZASP appears to be an ideal candidate for the cardiomyopathy causative gene, because Cypher/ZASP encodes a Z-disc associated protein, and recent studies have demonstrated that Cypher/ZASP knock-out mice develop cardiomyopathy. In this study, we searched for sequence variations in Cypher/ZASP in 96 unrelated Japanese patients with dilated cardiomyopathy. A D626N mutation located within the third LIM domain was identified in a familial case but not found in the unrelated controls. A family study of the patient showed that all affected siblings tested had the same mutation. Clinical information of the affected family members suggested that the mutation was associated with late onset cardiomyopathy. To reveal the biochemical changes due to the mutation, we performed a yeast two-hybrid assay and a pull-down assay. It was demonstrated by both assays that the D626N mutation of Cypher/ZASP increased the affinity of the LIM domain for protein kinase C, suggesting a novel biochemical mechanism of the pathogenesis of dilated cardiomyopathy.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pathogenesis, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Lab Genome Divers, Sch Biomed Sci, Tokyo 1010062, Japan; Natl Inst Hlth Sci, Div Pathol, Tokyo 1588501, Japan; Hamamatsu Univ Sch Med, Dept Internal Med 3, Hamamatsu, Shizuoka 4313192, Japan; Samsung Med Ctr, Div Cardiol, Seoul 135230, South Korea; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Institute of Health Sciences - Japan; Hamamatsu University School of Medicine; Sungkyunkwan University (SKKU); Samsung Medical Center; University of California System; University of California San Diego; University of California System; University of California San Diego	Kimura, A (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pathogenesis, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan.	akitis@mri.tmd.ac.jp	Shibutani, Makoto/AGK-2801-2022; Chen, Ju/E-5579-2011; Arimura, Takuro/AAA-2745-2022; Shibutani, Makoto/C-2510-2013; Kimura, Akinori/I-5989-2018	Shibutani, Makoto/0000-0003-3417-9697; Arimura, Takuro/0000-0002-0929-3140; Kimura, Akinori/0000-0002-4933-2132	NHLBI NIH HHS [R01 HL066100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Huang CQ, 2003, J BIOL CHEM, V278, P7360, DOI 10.1074/jbc.M211875200; Itoh-Satoh M, 2002, BIOCHEM BIOPH RES CO, V291, P385, DOI 10.1006/bbrc.2002.6448; Jalili T, 1999, AM J PHYSIOL-HEART C, V277, pH2298, DOI 10.1152/ajpheart.1999.277.6.H2298; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kurokawa M, 1998, NAT PROD LETT, V12, P35, DOI 10.1080/10575639808048868; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Robia SL, 2001, BIOPHYS J, V80, P2140, DOI 10.1016/S0006-3495(01)76187-5; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; STEINBERG SF, 1995, J MOL CELL CARDIOL, V27, P141, DOI 10.1016/S0022-2828(08)80014-4; Towbin J A, 2000, Curr Cardiol Rep, V2, P475, DOI 10.1007/s11886-000-0063-9; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; WU RY, 1994, J BIOL CHEM, V269, P25085; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	37	113	120	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6746	6752		10.1074/jbc.M311849200	http://dx.doi.org/10.1074/jbc.M311849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660611	hybrid			2022-12-25	WOS:000188969200067
J	Qi, XM; Borowicz, S; Pramanik, R; Schultz, RM; Han, JH; Chen, G				Qi, XM; Borowicz, S; Pramanik, R; Schultz, RM; Han, JH; Chen, G			Estrogen receptor inhibits c-Jun-dependent stress-induced cell death by binding and modifying c-Jun activity in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE PATHWAY; AP-1 ACTIVITY; ACTIVATION; APOPTOSIS; DNA; P38; EXPRESSION; TAMOXIFEN; ALPHA	c-Jun, a major component of the AP-1 transcription factor, is either pro- or anti-apoptotic with cellular determinants unknown. Nuclear estrogen receptor (ER), on the other hand, regulates gene expression through both estrogen response elements and AP-1. Here we show that stress stimulates c-Jun phosphorylation and AP-1 activity in both ER+ and ER- human breast cancer cells and only induces cell death in ER- cells, indicating a determinant role of ER in c-Jun/AP-1 activity. The inhibitory effect of ER in stress-induced cell death is confirmed by ER transfection into ER- cells. Furthermore, inhibition of c-Jun activation by a dominant negative c-Jun blocks AP-1 activity in ER+ cells and attenuates stress-induced cell death but not AP-1 activity in ER- cells, suggesting that the c-Jun/AP-1 activity has distinct properties depending on ER status. ER was shown to inhibit stress-induced cell death through its physical interaction with c-Jun. This is because ER binds c-Jun in breast cancer cells, stress treatment further increases the ER-bound phosphorylated c-Jun, and the c-Jun binding-deficient ER mutant fails to protect stress-induced cell death. Together, our studies reveal a novel function of ER in stress response by modification of c-Jun activity.	Loyola Univ, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Dept Cell Biol Neurobiol & Anat, Div Biochem, Maywood, IL 60153 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Loyola University Chicago; Loyola University Chicago; Scripps Research Institute	Chen, G (corresponding author), Loyola Univ, Dept Radiat Oncol, 114B Bldg 1,B303 Hines,2160 S 1st Ave, Maywood, IL 60153 USA.	gehen1@lumc.edu	Han, J/G-4671-2010		NCI NIH HHS [CA91576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BROWN PH, 1993, ONCOGENE, V8, P877; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell I, 2000, CANCER GENE THER, V7, P1270, DOI 10.1038/sj.cgt.7700226; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; CHEN G, 1994, BIOCHEM PHARMACOL, V47, P1079, DOI 10.1016/0006-2952(94)90420-0; Clarke R, 2001, PHARMACOL REV, V53, P25; CLARKE R, 1992, CRIT REV ONCOL HEMAT, V12, P1, DOI 10.1016/1040-8428(92)90062-U; Dixit M, 1997, J NATL CANCER I, V89, P365, DOI 10.1093/jnci/89.5.365; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fan MY, 2001, CANCER RES, V61, P4450; GALANG CK, 1994, ONCOGENE, V9, P2913; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Helczynska K, 2003, CANCER RES, V63, P1441; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; INCE BA, 1993, J BIOL CHEM, V268, P14026; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Kato K, 2002, J BIOL CHEM, V277, P11217, DOI 10.1074/jbc.M107391200; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu X, 1997, J BIOL CHEM, V272, P11690, DOI 10.1074/jbc.272.18.11690; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Reuther-Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175-8183.2002; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479; Zhao BH, 1997, MOL CARCINOGEN, V19, P180, DOI 10.1002/(SICI)1098-2744(199707)19:3<180::AID-MC6>3.3.CO;2-O	60	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6769	6777		10.1074/jbc.M311492200	http://dx.doi.org/10.1074/jbc.M311492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638681	hybrid			2022-12-25	WOS:000188969200070
J	Hur, EM; Park, YS; Lee, BD; Jang, IH; Kim, HS; Kim, TD; Suh, PG; Ryu, SH; Kim, KT				Hur, EM; Park, YS; Lee, BD; Jang, IH; Kim, HS; Kim, TD; Suh, PG; Ryu, SH; Kim, KT			Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src - Implications for a role of lipid microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; ADRENAL CHROMAFFIN CELLS; SMOOTH-MUSCLE-CELLS; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; ACTION-POTENTIALS; ERK ACTIVATION; CALCIUM-ENTRY; CELLULAR SRC	Communication between receptor tyrosine kinase (RTK)- and G protein-coupled receptor (GPCR)- mediated signaling systems has received increasing attention in recent years. Here, we report that activation of G protein-coupled bradykinin B-2 receptor induces an up-regulation of cellular responses mediated by epidermal growth factor receptor (EGFR) and provide essential mechanistic characteristics of this sensitization process. EGF, which failed to evoke detectable amount of calcium increase and neurotransmitter release when administrated alone in primary cultures of rat adrenal chromaffin cells and PC12 cells, became capable of inducing these responses specifically after bradykinin pretreatment. Both EGFR and non-receptor tyrosine kinase p60(Src), whose kinase activities were required in the sensitization, were found to be enriched in cholesterolrich lipid rafts. Bradykinin caused activation of p60(Src) and Src-dependent phosphorylation of the EGFR on Tyr-845 in lipid rafts, as well as recruitment of phospholipase C (PLC) gamma1 to the rafts. Depletion of cholesterol by methyl-beta-cyclodextrin disrupted the raft localization of EGFR and Src, as well as bradykinin-induced translocation of PLCgamma1. Furthermore, sensitization, which was impaired by cholesterol depletion, was restored by repletion of cholesterol. Therefore, we suggest that lipid rafts are essential participants in the regulation of receptor-mediated signal transduction and cross-talk via organizing signaling complexes in membrane microdomains.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Kim, KT (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, San 31, Pohang 790784, South Korea.	ktk@postech.ac.kr	Park, Yongsoo/G-9285-2014; Suh, Pann-Ghill/F-3610-2010; Hur, Eun Mi/AAU-4906-2021	Park, Yongsoo/0000-0001-8336-8051; Jang, Il Ho/0000-0002-0820-3035; Kim, Tae-Don/0000-0002-5910-4264; KIM, KYONG-TAI/0000-0001-7292-2627; Ryu, Sung Ho/0000-0003-0913-3048				AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BRANDT BL, 1976, J PHYSIOL-LONDON, V263, P417, DOI 10.1113/jphysiol.1976.sp011638; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Engisch KL, 1997, J NEUROSCI, V17, P9010; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giovannucci DR, 1997, J PHYSIOL-LONDON, V498, P735, DOI 10.1113/jphysiol.1997.sp021898; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Hur EM, 2001, AM J PHYSIOL-CELL PH, V280, pC1121, DOI 10.1152/ajpcell.2001.280.5.C1121; Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2; Johenning FW, 2002, NEURON, V34, P173, DOI 10.1016/S0896-6273(02)00665-7; Kaiser RA, 2002, CIRC RES, V91, P292, DOI 10.1161/01.RES.0000030711.21521.AC; Khiroug L, 1998, J NEUROSCI, V18, P2458; Kim KT, 2000, J NEUROSCI, V20, part. no.; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; OLSEN R, 1988, J BIOL CHEM, V263, P18030; PANDIELLA A, 1989, J BIOL CHEM, V264, P3122; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; Schlesinger TK, 1999, BIOCHEM J, V344, P519, DOI 10.1042/0264-6021:3440519; Seward EP, 1996, J NEUROSCI, V16, P553; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; SUH PG, 1988, J BIOL CHEM, V263, P14497; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	58	68	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5852	5860		10.1074/jbc.M311687200	http://dx.doi.org/10.1074/jbc.M311687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630916	hybrid			2022-12-25	WOS:000188776500100
J	Runzler, D; Huber, C; Moll, D; Kohler, G; S ra, M				Runzler, D; Huber, C; Moll, D; Kohler, G; S ra, M			Biophysical characterization of the entire bacterial surface layer protein SbsB and its two distinct functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL POLYMER; BACILLUS-STEAROTHERMOPHILUS PV72/P2; CIRCULAR-DICHROISM SPECTRA; S-LAYERS; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; FLUORESCENCE ANISOTROPY; AEROMONAS-HYDROPHILA; SEQUENCE-ANALYSIS; BINDING	The crystalline bacterial cell surface layer (S-layer) protein SbsB of Geobacillus stearothermophilus PV72/p2 was dissected into an N-terminal part defined by the three consecutive S-layer homologous motifs and the remaining large C-terminal part. Both parts of the mature protein were produced as separate recombinant proteins (rSbsB(1-178) and rSbsB(177-889)) and compared with the full-length form rSbsB(1-889) (rSbsB). Evidence for functional and structural integrity of the two truncated forms was provided by optical spectroscopic methods and electron microscopy. In particular, binding of the secondary cell wall polymer revealed a high affinity dissociation constant of 3 nM and could be assigned solely to the soluble rSbsB(1-178), whereas rSbsB(177-889) self-assembled into the same lattice as the full-length protein. Furthermore, thermal as well as guanidinium hydrochloride induced equilibrium unfolding profiles monitored by intrinsic fluorescence, and circular dichroism spectroscopy allowed characterization of rSbsB(1-178) as an alpha-helical protein with a single cooperative unfolding transition yielding a DeltaG value of 26.5 kJ mol(-1). The C-terminal rSbsB(177-889) could be characterized as a beta-sheet protein with typical multidomain unfolding, which is partially less stable as stand-alone protein. In general, the truncated forms showed identical properties compared with the full-length rSbsB with respect to structure and function. Consequently, rSbsB is characterized by its two functionally and structurally separated parts, the specific secondary cell wall polymer binding rSbsB(1-178) and the larger rSbsB(177-889) responsible for formation of the crystalline array.	Univ Vienna, Inst Theoret Chem & Struct Biol, A-1030 Vienna, Austria; Austrian Soc Aerosp Med, A-1090 Vienna, Austria; Univ Nat Resources & Appl Life Sci, BOKU, Ctr Ultrastruct Res, A-1180 Vienna, Austria; Univ Nat Resources & Appl Life Sci, BOKU, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Biomol Therapeut GmbH, A-1235 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna	Runzler, D (corresponding author), Univ Vienna, Inst Theoret Chem & Struct Biol, Campus Vienna Bioctr 6-1, A-1030 Vienna, Austria.	dominik.ruenzler@univie.ac.at	Moll, Wulf-Dieter/H-5448-2019; Rünzler, Dominik/G-9393-2014	Moll, Wulf-Dieter/0000-0001-9891-4991; Rünzler, Dominik/0000-0002-6020-3411; Huber-Gries, Carina/0000-0002-1305-5233				Beveridge TJ, 1997, FEMS MICROBIOL REV, V20, P99, DOI 10.1016/S0168-6445(97)00043-0; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BOWDITCH RD, 1989, J BACTERIOL, V171, P4178, DOI 10.1128/JB.171.8.4178-4188.1989; Breitwieser A, 1998, ALLERGY, V53, P786; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DOOLEY JSG, 1988, J BACTERIOL, V170, P2631, DOI 10.1128/jb.170.6.2631-2638.1988; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Engelhardt H, 1998, J STRUCT BIOL, V124, P276, DOI 10.1006/jsbi.1998.4070; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Ilk N, 1999, J BACTERIOL, V181, P7643, DOI 10.1128/JB.181.24.7643-7646.1999; Jarosch M, 2001, MICROBIOL-SGM, V147, P1353, DOI 10.1099/00221287-147-5-1353; Joseph C, 2001, BIOCHEMISTRY-US, V40, P4957, DOI 10.1021/bi002739r; Kuen B, 1997, J BACTERIOL, V179, P1664, DOI 10.1128/jb.179.5.1664-1670.1997; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lemaire M, 1998, MICROBIOL-UK, V144, P211, DOI 10.1099/00221287-144-1-211; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; LUPAS A, 1994, J BACTERIOL, V176, P1224, DOI 10.1128/jb.176.5.1224-1233.1994; Mader C, 2000, BBA-BIOMEMBRANES, V1463, P142, DOI 10.1016/S0005-2736(99)00190-X; MATUSCHEK M, 1994, J BACTERIOL, V176, P3295, DOI 10.1128/jb.176.11.3295-3302.1994; Mesnage S, 1997, MOL MICROBIOL, V23, P1147, DOI 10.1046/j.1365-2958.1997.2941659.x; Mesnage S, 1999, MOL MICROBIOL, V31, P927, DOI 10.1046/j.1365-2958.1999.01232.x; Mesnage S, 2000, EMBO J, V19, P4473, DOI 10.1093/emboj/19.17.4473; Meyer JD, 1998, INT J BIOL MACROMOL, V23, P27, DOI 10.1016/S0141-8130(98)00009-9; Moll D, 2002, P NATL ACAD SCI USA, V99, P14646, DOI 10.1073/pnas.232299399; Olabarria G, 1996, J BACTERIOL, V178, P4765, DOI 10.1128/jb.178.16.4765-4772.1996; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; Pace C N, 1986, Methods Enzymol, V131, P266; Pfuhl M, 1997, J MOL BIOL, V265, P242, DOI 10.1006/jmbi.1996.0725; Pum D, 2000, NANOTECHNOLOGY, V11, P100, DOI 10.1088/0957-4484/11/2/310; Ries W, 1997, J BACTERIOL, V179, P3892, DOI 10.1128/jb.179.12.3892-3898.1997; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sara M, 1996, J BACTERIOL, V178, P2108, DOI 10.1128/jb.178.7.2108-2117.1996; Sara M, 2000, J BACTERIOL, V182, P859, DOI 10.1128/JB.182.4.859-868.2000; Sara M, 1998, J BACTERIOL, V180, P4146; Scott KA, 2002, J MOL BIOL, V315, P819, DOI 10.1006/jmbi.2001.5260; Sleytr U B, 1997, Adv Biophys, V34, P71, DOI 10.1016/S0065-227X(97)89632-3; SLEYTR UB, 1993, MOL MICROBIOL, V10, P911, DOI 10.1111/j.1365-2958.1993.tb00962.x; Sleytr UB, 1999, ANGEW CHEM INT EDIT, V38, P1035, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1034::AID-ANIE1034>3.0.CO;2-#; Sleytr UB, 1999, TRENDS MICROBIOL, V7, P253, DOI 10.1016/S0966-842X(99)01513-9; Sleytr UB, 1997, FEMS MICROBIOL REV, V20, P151, DOI 10.1016/S0168-6445(97)00044-2; THOMAS S, 1992, J MOL BIOL, V228, P652, DOI 10.1016/0022-2836(92)90847-D; TSUBOI A, 1988, J BACTERIOL, V170, P935, DOI 10.1128/jb.170.2.935-945.1988	44	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5207	5215		10.1074/jbc.M308819200	http://dx.doi.org/10.1074/jbc.M308819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625307	hybrid			2022-12-25	WOS:000188776500022
J	Fan, YJ; Rayet, B; Gelinas, C				Fan, YJ; Rayet, B; Gelinas, C			Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes	ONCOGENE			English	Article						NF-kappa B; Rel; cancer; transformation; transcription	HODGKIN/REED-STERNBERG CELLS; CHICKEN SPLEEN-CELLS; DISEASE TUMOR-CELLS; V-REL; DNA-BINDING; TRANSCRIPTION FACTORS; BREAST-CANCER; CYTOPLASMIC RETENTION; TRANSFORMING ACTIVITY; SELECTIVE ACTIVATION	rel/nf-kappaB genes are amplified, overexpressed, or constitutively activated in many human hematopoietic tumors; however, the molecular mechanisms by which they contribute to tumorigenesis remain to be determined. Here, we explored the oncogenic potential of cellular Rel/NF-kappaB proteins in vitro and in vivo. We show that overexpression of wild-type mouse and human c-rel genes suffices to malignantly transform primary spleen cells in stringent soft agar assays and produce fatal tumors in vivo. In contrast relA and a constitutively active form of IKKbeta did not. Importantly, a hybrid RelA protein with its C-terminal transactivation domain substituted by that of v-Rel was potently oncogenic in vitro and in vivo. The transactivation domain of v-Rel selectively conferred an oncogenic phenotype upon the Rel homology domain (RHD) of RelA, but not to the more divergent RHDs of p50/NF-kappaB1, p52/NF-kappaB2, or RelB. Collectively, our results highlight important differences in the intrinsic oncogenic activity of mammalian c-Rel and RelA proteins, and indicate that critical determinants of their differential oncogenicity reside in their divergent transactivation domains. These findings provide experimental evidence for a role of mammalian Rel/NF-kappaB factors in leukemia/lymphomagenesis in an in vivo animal model, and are consistent with the implication of c-rel in many human lymphomas.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gelinas, C (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu			NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; Fujii M, 1996, ONCOGENE, V12, P2193; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; HOFFMANN A, 2003, IN PRESS EMBO J, V22; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KUCHARCZAK J, IN PRESS ONCOGENE; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LU D, 1991, ONCOGENE, V6, P1235; MCDONNELL PC, 1992, ONCOGENE, V7, P163; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Ricca A, 2001, BRIT J CANCER, V85, P1914, DOI 10.1054/bjoc.2001.2174; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297; White DW, 1996, ONCOGENE, V13, P891; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	84	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1030	1042		10.1038/sj.onc.1207221	http://dx.doi.org/10.1038/sj.onc.1207221			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647412				2022-12-25	WOS:000188749900002
J	Coombes, MM; Briggs, KL; Bone, JR; Clayman, GL; El-Naggar, AK; Dent, SYR				Coombes, MM; Briggs, KL; Bone, JR; Clayman, GL; El-Naggar, AK; Dent, SYR			Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation	ONCOGENE			English	Article						squamous cell carcinoma; head and neck; chromatin; acetylation	DEACETYLASE INHIBITORS; LYSINE-9 METHYLATION; X-CHROMOSOME; CANCER-CELLS; GENE; H3; CHROMATIN; HETEROCHROMATIN; REPRESSOR; BINDING	Head and neck squamous cell carcinoma (HNSCC) is the fifth most frequent cancer in the US. Several genetic and epigenetic alterations are associated with HNSCC tumorigenesis, including inactivation of CDKN2A, which encodes the p16 tumor suppressor, in cell lines and primary tumors by DNA methylation. Reactivation of tumor suppressor genes by DNA-demethylating agents and histone deacetylase (HDAC) inhibitors shows therapeutic promise for other cancers. Therefore, we investigated the ability of these agents to reactivate p16 in Tu159 HNSCC cells. Treatment of cells with 5-aza-2' deoxycytidine (5-aza-dC) increases CDKN2A expression and slightly increases histone H3 acetylation at this gene. No reactivation of CDKN2A is observed upon treatment with the HDAC inhibitor trichostatin A (TSA), but synergistic reactivation of CDKN2A is observed upon sequential treatment of Tu159 cells with both 5-aza-dC and TSA. Silencing of CDKN2A in Tu159 cells is correlated with increased methylation of histone H3 at lysine 9 and decreased methylation at lysine 4 relative to the upstream p15 gene promoter. Interestingly, global levels of H3-K9 methylation are decreased upon treatment with 5-aza-dC. Together these data indicate that DNA methylation is a dominant epigenetic mark for silencing of CDKN2A in Tu159 tumor cells. Moreover, changes in DNA methylation can reset the histone code by impacting multiple H3 modifications.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Dent, SYR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	syr@mdacc.tmc.edu	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269				Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Enders GH, 1996, ONCOGENE, V12, P1239; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goldman Michael A., 2002, Trends in Genetics, V18, P390, DOI 10.1016/S0168-9525(02)02735-X; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2002, CURR BIOL, V12, pR434, DOI 10.1016/S0960-9822(02)00919-3; Lai S, 1999, LAB INVEST, V79, P255; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Reed AL, 1996, CANCER RES, V56, P3630; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Schutte M, 1997, CANCER RES, V57, P3126; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Wolffe A. P., 1999, CHROMATIN STRUCTURE; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	79	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8902	8911		10.1038/sj.onc.1207050	http://dx.doi.org/10.1038/sj.onc.1207050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654786				2022-12-25	WOS:000186982200011
J	Trauzold, A; Schmiedel, S; Sipos, B; Wermann, H; Westphal, S; Roder, C; Klapper, W; Arlt, A; Lehnert, L; Ungefroren, H; Johannes, FJ; Kalthoff, H				Trauzold, A; Schmiedel, S; Sipos, B; Wermann, H; Westphal, S; Roder, C; Klapper, W; Arlt, A; Lehnert, L; Ungefroren, H; Johannes, FJ; Kalthoff, H			PKC mu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells	ONCOGENE			English	Article						pancreatic cancer; apoptosis resistance; protein kinase C; death receptor	PROTEIN-KINASE-C; TELOMERASE ACTIVITY; CANCER-CELLS; ADENOCARCINOMA CELLS; PROTEOLYTIC CLEAVAGE; MEDIATED APOPTOSIS; MOLECULAR-CLONING; PHORBOL ESTERS; DNA-SYNTHESIS; ACTIVATION	Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumour progression. Protein kinases C (PKC) have been shown to be important in the regulation of proliferation and apoptosis. In this report, we investigated the role of the PKC-like kinase PKCmu in the control of these processes in pancreatic adenocarcinoma cells. We demonstrate that in these cells, PKCmu expression strongly correlates with resistance to CD95-induced apoptosis. Inhibition of PKCmu with Goe6983 sensitized resistant cells to CD95-induced apoptosis. In CD95-sensitive Colo357 cells, forced overexpression of PKCmu strongly reduced CD95-mediated apoptosis, an effect that could be reversed by pretreatment with Goe6983. In addition, PKCmu overexpression led to a strongly enhanced cell growth and to a significant increase of telomerase activity. In an attempt to identify the signalling pathways affected by PKCmu, we identified the antiapoptotic proteins c-FLIPL and survivin to be strongly upregulated in PKCmu over-expressing cells. Immunohistochemical analysis of pancreatic tumour tissue of 48 patients and 10 normal pancreatic tissues revealed marked overexpression of PKCmu in tumours. In conclusion, we showed that PKCmu controls proliferative, as well as anti-apoptotic, signalling pathways and therefore plays an important role in acquiring the malignant phenotype of pancreatic tumours.	Univ Kiel, Clin Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Univ Kiel, Inst Pathol, D-24105 Kiel, Germany; Univ Kiel, Inst Hematopathol, D-24105 Kiel, Germany; Univ Kiel, Lymph Node Registry, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany	University of Kiel; University of Kiel; University of Kiel; University of Kiel; University of Kiel; Fraunhofer Gesellschaft	Kalthoff, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Klapper, Wolfram/S-6314-2016; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010; Klapper, Wolfram/D-2516-2010; Arlt, Alexander/G-7308-2019; Trauzold, Anna/P-4398-2014	Roeder, Christian/0000-0001-7881-9110; Arlt, Alexander/0000-0002-6160-1059; 				Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Elnemr A, 2001, INT J ONCOL, V18, P311; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Guha S, 2002, CANCER RES, V62, P1632; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Hamilton HB, 1996, J NEUROSURG, V85, P329, DOI 10.3171/jns.1996.85.2.0329; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Hayano RS, 1999, EUR PHYS J A, V6, P99, DOI 10.1007/s100500050322; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hiyama E, 1997, CANCER RES, V57, P326; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kim YW, 2001, EXP MOL MED, V33, P156, DOI 10.1038/emm.2001.27; KLAPPER W, 1998, BIOCHIM BIOPHYS ACTA, V8, P2; Krammer P H, 1999, Adv Immunol, V71, P163; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Palmantier R, 2001, CANCER RES, V61, P2445; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ryder NM, 2001, J CELL PHYSIOL, V186, P53, DOI 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Satoh K, 2001, CANCER, V92, P271, DOI 10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Ungefroren H, 1998, CANCER RES, V58, P1741; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	48	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8939	8947		10.1038/sj.onc.1207001	http://dx.doi.org/10.1038/sj.onc.1207001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654790				2022-12-25	WOS:000186982200015
J	Oksvold, MP; Thien, CBF; Widerberg, J; Chantry, A; Huitfeldt, HS; Langdon, WY				Oksvold, MP; Thien, CBF; Widerberg, J; Chantry, A; Huitfeldt, HS; Langdon, WY			Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor	ONCOGENE			English	Article						receptor tyrosine kinase; endocytosis; down-regulation; ubiquitination	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; DOWN-REGULATION; THREONINE PHOSPHORYLATION; RING FINGER; TRAFFICKING; PATHWAY; GRB2; SITE; DESENSITIZATION	In the present study, we examined EGF-induced internalization, degradation and trafficking of the epidermal growth factor receptor (EGFR) mutated at serines 1046, 1047, 1057 and 1142 located in its cytoplasmic carboxyterminal region. We found the serine-mutated EGFR to be inhibited in EGF-induced internalization and degradation in NIH3T3 cells. We therefore tested the hypothesis that these mutations affect ligand-induced c-Cbl association with the receptor, leading to inhibited receptor ubiquitination. EGF was unable to induce ubiquitination of the serine-mutated EGFR, yet EGF-induced phosphorylation of the c-Cbl-binding site at tyrosine 1045, and c-Cbl-EGFR association, was unaffected. To compare the relevance of these serine residues with tyrosine 1045 in their regulation of c-Cbl binding and receptor ubiquitination, we analysed an EGFR mutated at tyrosine 1045 (Y1045F). EGF-induced c-Cbl-EGFR binding was partially inhibited, and receptor ubiquitination was abrogated in cells expressing Y1045F-EGFR. In contrast, ligand-induced internalization and degradation of the Y1045F mutant was similar to that of wild-type EGFR. Together, our data indicate that the serine residues and tyrosine 1045 are essential for EGF-induced receptor ubiquitination, but only the serine residues are critical for EGFR internalization and degradation.	Univ Oslo, Rikshosp, Inst Pathol, Lab Toxicopathol, N-0027 Oslo, Norway; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Pathol, Nedlands, WA 6009, Australia	University of Oslo; National Hospital Norway; University of East Anglia; University of Western Australia	Oksvold, MP (corresponding author), Univ Oslo, Rikshosp, Inst Pathol, Lab Toxicopathol, N-0027 Oslo, Norway.		Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clague MJ, 2001, J CELL SCI, V114, P3075; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; COVERS R, 1998, J BIOL CHEM, V273, P16426; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; ECCLES SA, 1994, INVAS METAST, V14, P337; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HELIN K, 1991, J BIOL CHEM, V266, P8363; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUND KA, 1990, J BIOL CHEM, V265, P20517; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SORKIN A, 1992, J BIOL CHEM, V267, P8672; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	41	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8509	8518		10.1038/sj.onc.1207117	http://dx.doi.org/10.1038/sj.onc.1207117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627991				2022-12-25	WOS:000186650300014
J	Oliveira, C; de Bruin, J; Nabais, S; Ligtenberg, M; Moutinho, C; Nagengast, FM; Seruca, R; van Krieken, H; Carneiro, F				Oliveira, C; de Bruin, J; Nabais, S; Ligtenberg, M; Moutinho, C; Nagengast, FM; Seruca, R; van Krieken, H; Carneiro, F			Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour	ONCOGENE			English	Article						E-cadherin; hereditary diffuse gastric cancer; HDGC; mutation; intragenic deletion; second hit	FAMILIAL GASTRIC-CANCER; E-CADHERIN GENE; GERMLINE MUTATIONS; BETA-CATENIN; CARCINOMA; METHYLATION; EXPRESSION; PATTERNS; CELLS	Mutations in CDH1, encoding E- cadherin, are the underlying genetic defect in approximately one- third of the hereditary diffuse gastric cancer ( HDGC) families described so far. Tumours arising in these families show abnormal or absence of E- cadherin expression, following the model of tumour suppressor gene inactivation. A single study has been reported showing inactivation of the CDH1 wild- type allele in tumour cells from HDGC families either by promoter methylation or by somatic mutation. In order to find the genetic alteration responsible for the presence of diffuse gastric cancers in four members of a Caucasian family, we have screened the coding sequence of CDH1 for germline mutations and searched for the second inactivating hit in the tumour samples. In this family, we have found a germline splice- site mutation in all members affected by gastric cancer and, in one tumour, a somatic deletion affecting at least exon 8 of CDH1. Our results show that a CDH1 intragenic deletion is the second hit inactivating the wild- type allele, in one of the tumours in this family.	Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal; Univ Med Ctr Nijmegen, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands; Univ Porto, Fac Med, P-4200465 Oporto, Portugal	Universidade do Porto; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Universidade do Porto	Oliveira, C (corresponding author), Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal.	carlaol@ipatimup.pt	seruca, raquel/F-8187-2011; Ligtenberg, Marjolijn/N-9666-2013; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/J-6432-2013; Nabais, Sérgio/AAQ-5859-2020; van Krieken, Joannes H J M/D-4138-2009; Carneiro, Fatima/AAV-8677-2021	Ligtenberg, Marjolijn/0000-0003-1290-1474; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; van Krieken, Joannes H J M/0000-0001-6544-1040; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166				Avizienyte E, 2001, J MED GENET, V38, P49, DOI 10.1136/jmg.38.1.49; Caldas C, 1999, J MED GENET, V36, P873; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dussaulx-Garin L, 2001, EUR J GASTROEN HEPAT, V13, P711, DOI 10.1097/00042737-200106000-00016; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Humar B, 2002, HUM MUTAT, V19, P518, DOI 10.1002/humu.10067; Iida S, 1999, CLIN CANCER RES, V5, P1445; Jonsson BA, 2002, INT J CANCER, V98, P838, DOI 10.1002/ijc.10258; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Machado JC, 2000, J PATHOL, V190, P437; Machado JC, 1998, INT J SURG PATHOL, V6, P135, DOI 10.1177/106689699800600302; Nabais S, 2003, INT J SURG PATHOL, V11, P1, DOI 10.1177/106689690301100102; Oliveira C, 2003, EXPERT REV MOL DIAGN, V3, P201; Oliveira C, 2002, HUM MUTAT, V19, P510, DOI 10.1002/humu.10068; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Shinmura K, 1999, CARCINOGENESIS, V20, P1127, DOI 10.1093/carcin/20.6.1127; Wang Y, 2003, JPN J CLIN ONCOL, V33, P17, DOI 10.1093/jjco/hyg002; Yabuta T, 2002, INT J CANCER, V101, P434, DOI 10.1002/ijc.10633; Yoon KA, 1999, J HUM GENET, V44, P177, DOI 10.1007/s100380050137	25	70	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2236	2240		10.1038/sj.onc.1207335	http://dx.doi.org/10.1038/sj.onc.1207335			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14661064				2022-12-25	WOS:000220280900014
J	Ahvazi, B; Boeshans, KM; Idler, W; Baxa, U; Steinert, PM; Rastinejad, F				Ahvazi, B; Boeshans, KM; Idler, W; Baxa, U; Steinert, PM; Rastinejad, F			Structural basis for the coordinated regulation of transglutaminase 3 by guanine nucleotides and calcium/magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; PROTRANSGLUTAMINASE-E; CORNIFIED ENVELOPE; PHOSPHOLIPASE-C; BINDING PROTEIN; CALCIUM-IONS; GTP-BINDING; ACTIVATION; RECONSTITUTION; PURIFICATION	Transglutaminase 3 (TGase 3) is a member of a family of Ca2+-dependent enzymes that catalyze covalent cross-linking reactions between proteins or peptides. TGase 3 isoform is widely expressed and is important for effective epithelial barrier formation in the assembly of the cell envelope. Among the nine TGase enzyme isoforms known in the human genome, only TGase 2 is known to bind and hydrolyze GTP to GDP; binding GTP inhibits its transamidation activity but allows it to function in signal transduction. Here we present biochemical and crystallographic evidence for the direct binding of GTP/GDP to the active TGase 3 enzyme, and we show that the TGase 3 enzyme undergoes a GTPase cycle. The crystal structures of active TGase 3 with guanosine 5% O-(thiotriphosphate) (GTPgammaS) and GDP were determined to 2.1 and 1.9 Angstrom resolution, respectively. These studies reveal for the first time the reciprocal actions of Ca2+ and GTP with respect to TGase 3 activity. GTPgammaS binding is coordinated with the replacement of a bound Ca2+ with Mg2+ and conformational rearrangements that together close a central channel to the active site. Hydrolysis of GTP to GDP results in two stable conformations, resembling both the GTP state and the nonnucleotide bound state, the latter of which allows substrate access to the active site.	NIAMS, Xray Crystallog Facil, NIH, Bethesda, MD 20892 USA; NIAMS, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA; Univ Virginia Hlth Syst, Dept Pharmacol & Biochem & Mol Genet, Charlottesville, VA 22908 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Virginia	Ahvazi, B (corresponding author), NIAMS, Xray Crystallog Facil, NIH, Bldg 50,Rm 1345,50 South Dr, Bethesda, MD 20892 USA.	ahvazib@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041142, Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1989, MOL CELL BIOCHEM, V85, P57; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAS T, 1993, J BIOL CHEM, V268, P27398; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1992, J BIOL CHEM, V267, P8887; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HC, 2001, J STRUCT BIOL, V135, P73, DOI 10.1006/jsbi.2001.4384; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM IG, 1993, J BIOL CHEM, V268, P12682; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Melino G, 1998, Results Probl Cell Differ, V24, P175; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nemes Z, 2000, J BIOL CHEM, V275, P2636, DOI 10.1074/jbc.275.4.2636; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702	47	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7180	7192		10.1074/jbc.M312310200	http://dx.doi.org/10.1074/jbc.M312310200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645372	hybrid			2022-12-25	WOS:000188969200117
J	Elm, C; Braathen, R; Bergmann, S; Frank, R; Vaerman, JP; Kaetzel, CS; Chhatwal, GS; Johansen, FE; Hammerschmidt, S				Elm, C; Braathen, R; Bergmann, S; Frank, R; Vaerman, JP; Kaetzel, CS; Chhatwal, GS; Johansen, FE; Hammerschmidt, S			Ectodomains 3 and 4 of human polymeric immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS INFECTION; SECRETORY COMPONENT; IG RECEPTOR; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDE; INFLUENZA-VIRUS; CELLS; PROTEIN; TRANSPORT; BINDING	Streptococcus pneumoniae binds to the ectodomain of the human polymeric Ig receptor (plgR), also known as secretory component (SC), via a hexapeptide motif in the choline-binding protein SpsA. The SpsA-pIgR interaction mediates adherence and internalization of the human pathogen into epithelial cells. In this study the results of SpsA binding to human, mouse, and chimeric SC strongly supported the human specificity of this unique interaction and suggested that binding sites in the third and fourth Ig-like domain of human SC (D3 and D4, respectively) are involved in SpsA-pIgR complex formation. Binding of SpsA to SC-derived synthetic peptides indicated surface-located potential binding motifs in D3 and D4. Adherence and uptake of pneumococci or SpsA-coated latex beads depended on the SpsA hexapeptide motif as well as SpsA-binding sites in D3 and D4 of human pIgR. The involvement of D3 and D4 in adherence and invasion was demonstrated by the lack of binding of SpsA-coated latex beads to transfected epithelial cells expressing mutated pIgR. Finally, blocking experiments with chimeric human-mouse SC as well as synthetic peptides indicated the participation of D3 and a key role of D4 in pneumococcal invasion.	Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; GBF, German Res Ctr Biotechnol, D-38124 Braunschweig, Germany; Univ Oslo, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Catholic Univ Louvain, ICP, Expt Med Unit, B-1200 Brussels, Belgium; Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY 40536 USA	University of Wurzburg; Helmholtz Association; Helmholtz-Center for Infection Research; University of Oslo; Universite Catholique Louvain; University of Kentucky	Hammerschmidt, S (corresponding author), Univ Wurzburg, Res Ctr Infect Dis, Rontgenring 11, D-97070 Wurzburg, Germany.	s.hammerschmidt@mail.uni-wuerzburg.de	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681; Kaetzel, Charlotte/0000-0001-7546-0085				BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; Bergmann S, 2001, MOL MICROBIOL, V40, P1273, DOI 10.1046/j.1365-2958.2001.02448.x; Blanch VJ, 1999, J IMMUNOL, V162, P1232; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Brock SC, 2002, INFECT IMMUN, V70, P5091, DOI 10.1128/IAI.70.9.5091-5095.2002; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; de Oliveira IR, 2001, FEMS MICROBIOL LETT, V203, P29, DOI 10.1016/S0378-1097(01)00332-9; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Enriquez FJ, 1998, INFECT IMMUN, V66, P4469; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; FUBARA ES, 1973, J IMMUNOL, V111, P395; Gan YJ, 1997, J VIROL, V71, P519, DOI 10.1128/JVI.71.1.519-526.1997; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Godding V, 1998, EUR RESPIR J, V11, P1043, DOI 10.1183/09031936.98.11051043; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Heremans J F, 1974, Adv Exp Med Biol, V45, P3; Iannelli F, 2002, GENE, V284, P63, DOI 10.1016/S0378-1119(01)00896-4; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; Johansen FE, 1999, EUR J IMMUNOL, V29, P1701, DOI 10.1002/(SICI)1521-4141(199905)29:05<1701::AID-IMMU1701>3.0.CO;2-Z; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Kaetzel CS, 2001, CURR BIOL, V11, pR35, DOI 10.1016/S0960-9822(00)00041-5; KRAMER DR, 1995, J IMMUNOL, V154, P2051; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lin CT, 1997, AM J PATHOL, V150, P1745; Lin CT, 2000, LAB INVEST, V80, P1149, DOI 10.1038/labinvest.3780123; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; Nice EC, 1996, MOL IMMUNOL, V33, P659, DOI 10.1016/0161-5890(96)00016-8; OUTLAW MC, 1990, J GEN VIROL, V71, P69, DOI 10.1099/0022-1317-71-1-69; Phalipon A, 2003, TRENDS IMMUNOL, V24, P55, DOI 10.1016/S1471-4906(02)00031-5; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; PISKURICH JF, 1993, MOL IMMUNOL, V30, P413, DOI 10.1016/0161-5890(93)90071-I; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Shimada S, 1999, J IMMUNOL, V163, P5367; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SOLLID LM, 1987, J IMMUNOL, V138, P4303; TAMER CM, 1995, J IMMUNOL, V155, P707; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WILLIAMS RC, 1972, SCIENCE, V177, P697, DOI 10.1126/science.177.4050.697; YOUNGMAN KR, 1994, J IMMUNOL, V153, P675; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	53	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6296	6304		10.1074/jbc.M310528200	http://dx.doi.org/10.1074/jbc.M310528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660617	hybrid			2022-12-25	WOS:000188969200014
J	Yuan, BZ; Jefferson, AM; Baldwin, KT; Thorgeirsson, SS; Popescu, NC; Reynolds, SH				Yuan, BZ; Jefferson, AM; Baldwin, KT; Thorgeirsson, SS; Popescu, NC; Reynolds, SH			DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas	ONCOGENE			English	Article						DLC-1; tumor suppressor gene; non-small cell lung carcinoma; aberrant DNA methylation; tumorigenicity	ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CLINICAL IMPLICATIONS; RAS TRANSFORMATION; UNITED-STATES; RHOGAP; PATHOGENESIS; IMBALANCES; EXPRESSION	The deleted in liver cancer (DLC-1) gene at chromosome 8p21-22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth. Given the high frequency of deletion involving region 8p21-22 in human non-small cell lung carcinoma (NSCLC), we examined alterations of DLC-1 in a series of primary tumors and tumor cell lines and tested effects of DLC-1 on tumor cell growth. A significant decrease or absence of the DLC-1 mRNA expression was found in 95% of primary NSCLC (20/21) and 58% of NSCLC cell lines (11/19). Transcriptional silencing of DLC-1 was primarily associated with aberrant DNA methylation, rather than genomic deletion as 5-aza-2'-deoxycytidine induced reactivation of DLC-1 expression in 82% (9/11) NSCLC cell lines showing downregulated DLC-1. It was further evidenced by an aberrant DLC-1 promoter methylation pattern, which was detected by Southern blotting in 73% (8/11) of NSCLC cell lines with downregulation of the gene. The transfer of DLC-1 into three DLC-1 negative cell lines caused a significant inhibition in cell proliferation and/or a decrease in colony formation. Furthermore, stable transfer of DLC-1 abolished tumorigenicity in nude mice of two cell lines, suggesting that DLC-1 plays a role in NSCLC by acting as a bona. de new tumor suppressor gene.	NIOSH, Lab Genet Susceptibil, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuan, BZ (corresponding author), 1095 Willowdale Rd,Mailstop L-3014, Morgantown, WV 26505 USA.	bby1@cdc.gov			NATIONAL CANCER INSTITUTE [Z01BC010038, ZIABC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Belinsky SA, 2002, CANCER RES, V62, P2370; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Girard L, 2000, CANCER RES, V60, P4894; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P277, DOI 10.1093/jnci/93.4.277; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kurimoto F, 2001, INT J MOL MED, V8, P89; Minna JD, 2002, CANCER J, V8, pS41; Ng IOL, 2000, CANCER RES, V60, P6581; Niklinski J, 2001, EUR J CANCER PREV, V10, P213, DOI 10.1097/00008469-200106000-00004; Park SW, 2003, INT J ONCOL, V23, P133; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Soria JC, 2002, CANCER RES, V62, P351; Steenland K, 1996, AM J IND MED, V29, P474, DOI 10.1002/(SICI)1097-0274(199605)29:5<474::AID-AJIM6>3.0.CO;2-M; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Vecchione A, 2001, CLIN CANCER RES, V7, P1546; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wistuba II, 1999, CANCER RES, V59, P1973; Yin XL, 2002, CANCER GENET CYTOGEN, V134, P71, DOI 10.1016/S0165-4608(01)00611-2; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zheng SQL, 2003, MUTAT RES-FUND MOL M, V528, P45, DOI 10.1016/S0027-5107(03)00081-2; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	34	126	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1405	1411		10.1038/sj.onc.1207291	http://dx.doi.org/10.1038/sj.onc.1207291			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14661059				2022-12-25	WOS:000189035800007
J	Bleuit, JS; Ma, YJ; Munro, J; Morrical, SW				Bleuit, JS; Ma, YJ; Munro, J; Morrical, SW			Mutations in a conserved motif inhibit single-stranded DNA binding and recombination mediator activities of bacteriophage T4 UvsY protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE 32 PROTEIN; PRESYNAPTIC FILAMENT; NUCLEIC-ACIDS; REPAIR GENE; AFFINITY; SEQUENCE; REPLICATION; PARAMETERS; MUTANTS; PURIFICATION	The UvsY recombination mediator protein is critical for homologous recombination in bacteriophage T4. UvsY uses both protein-protein and protein-DNA interactions to mediate the assembly of the T4 UvsX recombinase onto single-stranded (ss) DNA, forming presynaptic filaments that initiate DNA strand exchange. UvsY helps UvsX compete with Gp32, the T4 ssDNA-binding protein, for binding sites on ssDNA, in part by destabilizing Gp32-ssDNA interactions, and in part by stabilizing UvsX-ssDNA interactions. The relative contributions of UvsY-ssDNA, UvsY-Gp32, UvsY-UvsX, and UvsY-UvsY interactions to these processes are only partially understood. The goal of this study was to isolate mutant forms of UvsY protein that are specifically defective in UvsY-ssDNA interactions, so that the contribution of this activity to recombination processes could be assessed independent of other factors. A conserved motif of UvsY found in other DNA-binding proteins was targeted for mutagenesis. Two missense mutants of UvsY were isolated in which ssDNA binding activity is compromised. These mutants retain self-association activity, and form stable associations with UvsX and Gp32 proteins in patterns similar to wild-type UvsY. Both mutants are partially, but not totally, defective in stimulating UvsX-catalyzed recombination functions including ssDNA-dependent ATP hydrolysis and DNA strand exchange. The data are consistent with a model in which UvsY plays bipartite roles in presynaptic filament assembly. Its protein-ssDNA interactions are suggested to moderate the destabilization of Gp32-ssDNA, whereas its protein-protein contacts induce a conformational change of the UvsX protein, giving UvsX a higher affinity for the ssDNA and allowing it to compete more effectively with Gp32 for binding sites.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Vermont Canc Ctr, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.	smorrica@zoo.uvm.edu			NIGMS NIH HHS [GM48847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048847, R56GM048847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; Ando RA, 1999, BIOCHEMISTRY-US, V38, P16589, DOI 10.1021/bi991917h; Beernink HTH, 1998, BIOCHEMISTRY-US, V37, P5673, DOI 10.1021/bi9800956; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; FREDERICK GD, 1994, HUM MOL GENET, V3, P1783, DOI 10.1093/hmg/3.10.1783; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HARRIS LD, 1988, BIOCHEMISTRY-US, V27, P6954, DOI 10.1021/bi00418a042; HINTON DM, 1986, J BIOL CHEM, V261, P5663; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jiang H, 1997, BIOCHEM BIOPH RES CO, V231, P600, DOI 10.1006/bbrc.1997.6160; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Lamerdin JE, 1996, GENOMICS, V34, P399, DOI 10.1006/geno.1996.0303; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; MELAMEDE RJ, 1977, J VIROL, V24, P28, DOI 10.1128/JVI.24.1.28-40.1977; MELAMEDE RJ, 1978, FEBS LETT, V87, P12, DOI 10.1016/0014-5793(78)80122-7; MELAMEDE RJ, 1980, MOL GEN GENET, V177, P501, DOI 10.1007/BF00271490; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; MORRICAL SW, 1991, J BIOL CHEM, V266, P14031; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; Rivera E, 1996, J BACTERIOL, V178, P5550, DOI 10.1128/jb.178.18.5550-5554.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; Sweezy MA, 1999, BIOCHEMISTRY-US, V38, P936, DOI 10.1021/bi9817055; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WALTER RB, 1991, GENOMICS, V10, P1083, DOI 10.1016/0888-7543(91)90204-R; WEBER CA, 1994, MUTAT RES LETT, V324, P147, DOI 10.1016/0165-7992(94)90012-4; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; Yassa DS, 1997, BIOCHIMIE, V79, P275, DOI 10.1016/S0300-9084(97)83515-8; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	49	17	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6077	6086		10.1074/jbc.M311557200	http://dx.doi.org/10.1074/jbc.M311557200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634008	hybrid			2022-12-25	WOS:000188776500123
J	Jiang, D; Franceschi, RT; Boules, H; Xiao, GZ				Jiang, D; Franceschi, RT; Boules, H; Xiao, GZ			Parathyroid hormone induction of the osteocalcin gene - Requirement for an osteoblast-specific element 1 sequence in the promoter and involvement of multiple signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT COLLAGENASE-3 PROMOTER; TRANSCRIPTION FACTOR CBFA1; FORMATION IN-VIVO; PROTEIN-KINASE; BONE-FORMATION; MC3T3-E1 CELLS; ACTIVATOR PROTEIN-1; CYCLIC-AMP; GLUCOCORTICOID REPRESSION; CLEIDOCRANIAL DYSPLASIA	Parathyroid hormone (PTH) is an important peptide hormone regulator of bone formation and osteoblast activity. However, its mechanism of action in bone cells is largely unknown. This study examined the effect of PTH on mouse osteocalcin gene expression in MC3T3-E1 preosteoblastic cells and primary cultures of bone marrow stromal cells. PTH increased the levels of osteocalcin mRNA 4-5-fold in both cell types. PTH also stimulated transcriptional activity of a 1.3-kb fragment of the mouse osteocalcin gene 2 (mOG2) promoter. Inhibitor studies revealed a requirement for protein kinase A, protein kinase C, and mitogen-activated protein kinase pathways in the PTH response. Deletion of the mOG2 promoter sequence from -1316 to -116 caused no loss in PTH responsiveness whereas deletion from -116 to -34 completely prevented PTH stimulation. Interestingly, this promoter region does not contain the RUNX2 binding site shown to be necessary for PTH responsiveness in other systems. Nuclear extracts from PTH-treated MC3T3-E1 cells exhibited increased binding to OSE1, a previously described osteoblast-specific enhancer in the mOG2 promoter. Furthermore, mutation of OSE1 in DNA transfection assays established the requirement for this element in the PTH response. Collectively, these studies establish that actions of PTH on the osteocalcin gene are mediated by multiple signaling pathways and require OSE1 and associated nuclear proteins.	Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Xiao, GZ (corresponding author), Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	xiaogz@umich.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013386, R03DE014454, R01DE012211, R56DE011723] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE14454, DE13386, DE12211, DE 11723] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aslam F, 1999, ENDOCRINOLOGY, V140, P63, DOI 10.1210/en.140.1.63; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Carpio L, 2001, AM J PHYSIOL-ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; D'Alonzo RC, 2002, J BIOL CHEM, V277, P24788, DOI 10.1074/jbc.M202604200; Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002-220221; Doggett TA, 2002, ENDOCRINOLOGY, V143, P1880, DOI 10.1210/en.143.5.1880; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gopalakrishnan R, 2001, ENDOCRINOLOGY, V142, P4379, DOI 10.1210/en.142.10.4379; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; KESTERSON RA, 1993, MOL ENDOCRINOL, V7, P462, DOI 10.1210/me.7.3.462; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002-0225; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097-4644(19960616)61:4<638::AID-JCB18>3.0.CO;2-B; MCCAULEY LK, 1995, J BONE MINER RES, V10, P1243, DOI 10.1002/jbmr.5650100815; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Miles RR, 2002, J CELL BIOCHEM, V85, P229, DOI 10.1002/jcb.10129; MORRISON N, 1993, J BONE MINER RES, V8, P969; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; Murray EJB, 1997, METABOLISM, V46, P1090, DOI 10.1016/S0026-0495(97)90284-5; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Ogata Y, 2000, MATRIX BIOL, V19, P395, DOI 10.1016/S0945-053X(00)00085-8; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Ouyang HJ, 2000, ENDOCRINOLOGY, V141, P4671, DOI 10.1210/en.141.12.4671; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; RENKAWITZ R, 1979, MOL GEN GENET, V173, P1, DOI 10.1007/BF00267685; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Staal A, 1998, J BONE MINER RES, V13, P36, DOI 10.1359/jbmr.1998.13.1.36; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Yang X, 2002, J BONE MINER RES, V17, pS126; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085	65	38	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5329	5337		10.1074/jbc.M311547200	http://dx.doi.org/10.1074/jbc.M311547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634012	hybrid			2022-12-25	WOS:000188776500037
J	Anger, T; Zhang, W; Mende, U				Anger, T; Zhang, W; Mende, U			Differential contribution of GTPase activation and effector antagonism to the inhibitory effect of RGS proteins on G(q)-mediated signaling in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-BETA; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNITS; KINASE ACTIVATION; ADENYLYL-CYCLASE; MEMBRANE ASSOCIATION; MESSENGER-RNA; MAP KINASE; REGULATOR; EXPRESSION	RGS proteins act as negative regulators of G protein signaling by serving as GTPase-activating proteins (GAP) for a subunits of heterotrimeric G proteins (Galpha), thereby accelerating G protein inactivation. RGS proteins can also block Galpha-mediated signal production by competing with downstream effectors for Ga binding. Little is known about the relative contribution of GAP and effector antagonism to the inhibitory effect of RGS proteins on G protein-mediated signaling. By comparing the inhibitory effect of RGS2, RGS3, RGS5, and RGS16 on Galpha(q)mediated phospholipase Cbeta (PLCbeta) activation under conditions where GTPase activation is possible versus nonexistent, we demonstrate that members of the R4 RGS subfamily differ significantly in their dependence on GTPase acceleration. COS-7 cells were transiently transfected with either muscarinic M-3 receptors, which couple to endogenous G(q) protein and mediate a stimulatory effect of carbachol on PLCbeta, or constitutively active Galpha(q), which is inert to GTP hydrolysis and activates PLCbeta independent of receptor activation. In M-3-expressing cells, all of the RGS proteins significantly blunted the efficacy and potency of carbachol. In contrast, Galpha(q)*-induced PLCbeta activation was inhibited by RGS2 and RGS3 but not RGS5 and RGS16. The observed differential effects were not due to changes in M-3, Galpha(q)/ Galpha(q)*, PLCbeta, or RGS expression, as shown by receptor binding assays and Western blots. We conclude that closely related R4 RGS family members differ in their mechanism of action. RGS5 and RGS16 appear to depend on G protein inactivation, whereas GAP-independent mechanisms (such as effector antagonism) are sufficient to mediate the inhibitory effect of RGS2 and RGS3.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Mende, U (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Thorn Bldg 1228A,75 Francis St, Boston, MA 02115 USA.	umende@rics.bwh.harvard.edu		Anger, Thomas/0000-0001-9071-6405	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052320] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hoffman GA, 2000, J BIOL CHEM, V275, P37533, DOI 10.1074/jbc.M005751200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Kardestuncer T, 1998, FEBS LETT, V438, P285, DOI 10.1016/S0014-5793(98)01319-2; Kehrl JH, 2002, GENOMICS, V79, P860, DOI 10.1006/geno.2002.6773; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Litosch I, 2002, IUBMB LIFE, V54, P253, DOI 10.1080/15216540215673; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Niu JX, 2002, BIOCHEM J, V365, P677, DOI 10.1042/BJ20020390; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Shi CS, 2001, J BIOL CHEM, V276, P24293, DOI 10.1074/jbc.M100089200; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zhang W, 2001, J BIOL CHEM, V276, P2503, DOI 10.1074/jbc.M003562200; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0; Zmijewski JW, 2001, BBA-MOL CELL RES, V1541, P201, DOI 10.1016/S0167-4889(01)00144-6	54	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3906	3915		10.1074/jbc.M309496200	http://dx.doi.org/10.1074/jbc.M309496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14630933	hybrid			2022-12-25	WOS:000188554300003
J	Yoon, HS; Yang, VW				Yoon, HS; Yang, VW			Requirement of Kruppel-like factor 4 in preventing entry into mitosis following DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; MATURATION-PROMOTING FACTOR; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; S-PHASE; TRANSCRIPTIONAL REGULATION; CYTOPLASMIC FACTOR; G2/M TRANSITION; P53 NETWORK; GENE	Previous studies indicate that Kruppel-like factor 4 (KLF4 or GKLF) controls the G(1)/S cell cycle checkpoint upon DNA damage. We present evidence for an equally important role of KLF4 in maintaining the integrity of the G(2)/M checkpoint following DNA damage. HCT116, a colon cancer cell line with wild type p53 alleles, underwent sustained G(2) arrest up to 4 days after gamma-irradiation. In contrast, HCT116 cells null for p53 were able to enter mitosis following irradiation. Western blot analyses of irradiated HCT116 cells showed increased levels of p53, KLF4, and p21(WAF1/CIP1) and decreased levels of cyclin B1 when compared with unirradiated controls. In contrast, the levels of cyclin B1 increased in irradiated HCT116 p53-/- cells, in which KLF4 failed to increase due to the absence of p53. When KLF4 was inhibited by small interfering RNA, irradiated HCT116 cells exhibited increased mitotic indices and a rise in cyclin B1 levels. Conversely, irradiated HCT116 p53-/- cells that were infected with KLF4-expressing adenoviruses demonstrated a concurrent reduction in mitotic indices and cyclin B1 levels. In each case, Cdc2 kinase measurements showed an inverse correlation between Cdc2 kinase activities and KLF4 levels. Co-transfection experiments showed that KLF4 repressed the cyclin B1 promoter through a specific GC-rich element. Moreover, chromatin immunoprecipitation experiments demonstrated that both KLF4 and HDAC were associated with the cyclin B1 promoter in irradiated HCT116 cells. We conclude that KLF4 is essential in preventing mitotic entry following gamma-irradiation and does so by inhibiting cyclin B1 expression.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu			NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399, R01 DK052230, DK52230, DK64399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johns DC, 1999, J NEUROSCI, V19, P1691; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Li A, 2001, NAT CELL BIOL, V3, pE182, DOI 10.1038/35087119; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Samuel T, 2002, CELL CYCLE, V1, P162, DOI 10.4161/cc.1.3.118; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Smith APL, 2002, CELL CYCLE, V1, P16, DOI 10.4161/cc.1.1.96; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; WASSERMAN WJ, 1978, J CELL BIOL, V78, pR15, DOI 10.1083/jcb.78.1.R15; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	66	102	111	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5035	5041		10.1074/jbc.M307631200	http://dx.doi.org/10.1074/jbc.M307631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627709	Green Accepted, hybrid			2022-12-25	WOS:000188554300130
J	Liu, WM; Powles, T; Shamash, J; Propper, D; Oliver, T; Joel, S				Liu, WM; Powles, T; Shamash, J; Propper, D; Oliver, T; Joel, S			Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity	ONCOGENE			English	Article						GM-CSF; Epo; apoptosis; chemosensitivity; receptors	COLONY-STIMULATING FACTOR; GM-CSF; IN-VITRO; RECEPTOR EXPRESSION; BCL-2 EXPRESSION; LEUKEMIA CELLS; DOUBLE-BLIND; BONE-MARROW; C-KIT; ERYTHROPOIETIN	The recombinant growth factors (GFs) erythropoietin (Epo) and granulocyte-macrophage colony stimulating factor (GM-CSF) have important roles in the management of cancer patients. However, the effects of these GFs at a cellular level are not well understood. We examined the effect of GFs alone, and in combination with cytotoxic chemotherapy, in a panel of seven cell lines. Flow cytometric analysis showed varying levels of receptor expression, which correlated with phosphorylated MAPK expression. Additionally, there were also concomitant increases in BCL-2 protein levels in those cells with high levels of MAPK activation. Although culturing cells with Epo or GM-CSF did not alter cell viability by themselves, GF pretreatment in cell lines expressing higher receptor levels resulted in a reduced magnitude of cell kill following exposure to cytotoxic IC50 concentrations of cisplatin. Subsequent co-culture with either the MEK inhibitor U0126 or the GM-CSF antagonist E21R negated this induced resistance to cytotoxic chemotherapy, confirming the importance of the GF receptor as well as MAPK in mediating these effects. These results suggest that the use of GFs during chemotherapy may be detrimental in those cancers expressing higher levels of the specific receptor. Conversely, our results also suggest that GFs are safe to use in chemotherapeutic regimens if the cancer cells do not overexpress the particular receptor.	St Bartholomews Hosp, Barry Reed Oncol Lab, New Drug Study Grp, London, England	University of London; Queen Mary University London	Liu, WM (corresponding author), Inst Canc Res, Haddow Labs, Med Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	wai.liu@icr.ac.uk	Liu, Wai/B-7877-2008	Liu, Wai/0000-0001-7099-7510; Oliver, Tim/0000-0002-7879-8943				ABELS R, 1993, EUR J CANC S, V2, P2; Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BERDEL WE, 1989, BLOOD, V73, P80; BI SC, 1992, LEUKEMIA, V6, P839; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; BRADBURY D, 1994, LEUKEMIA, V8, P786; Bratthauer G L, 1999, Methods Mol Biol, V115, P203; CHERVENICK PA, 1971, BLOOD-J HEMATOL, V37, P131, DOI 10.1182/blood.V37.2.131.131; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Clark O, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-23; CLARKE BJ, 1977, P NATL ACAD SCI USA, V74, P1105, DOI 10.1073/pnas.74.3.1105; DASILVA JL, 1990, BLOOD, V75, P577; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; DEL PL, 1997, SCIENCE, V278, P687; Dempke W, 2000, ANTICANCER RES, V20, P5155; EVERSON MP, 1989, BLOOD, V74, P1472; Fallowfield L, 2002, BRIT J CANCER, V87, P1341, DOI 10.1038/sj.bjc.6600657; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukumi S, 2000, MOL CELL BIOCHEM, V206, P43, DOI 10.1023/A:1007056727876; Galea HR, 2002, CLIN EXP IMMUNOL, V129, P247, DOI 10.1046/j.1365-2249.2002.01929.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerharz CD, 2001, UROLOGY, V58, P821, DOI 10.1016/S0090-4295(01)01371-1; Hisakawa H, 2001, BLOOD, V98, P3618, DOI 10.1182/blood.V98.13.3618; Iversen PO, 1996, BLOOD, V88, P2634, DOI 10.1182/blood.V88.7.2634.bloodjournal8872634; Iversen PO, 1996, P NATL ACAD SCI USA, V93, P2785, DOI 10.1073/pnas.93.7.2785; Iversen PO, 1997, J BIOL CHEM, V272, P9877; Kapur R, 2001, J BIOL CHEM, V276, P1099, DOI 10.1074/jbc.M007442200; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KURZROCK R, 1991, LEUKEMIA, V5, P985; LAUGHLIN MJ, 1993, ANN HEMATOL, V67, P267, DOI 10.1007/BF01696346; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Liu WM, 1998, CANCER CHEMOTH PHARM, V41, P343, DOI 10.1007/s002800050749; Liu WM, 2002, EUR J CANCER, V38, P842, DOI 10.1016/S0959-8049(02)00016-3; Liu WM, 2002, BRIT J CANCER, V86, P1472, DOI 10.1038/sj.bjc.6600288; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCCREDIE KB, 1971, SCIENCE, V171, P293, DOI 10.1126/science.171.3968.293; MCGUCKIN CP, 1995, EXP HEMATOL, V23, P14; ORAZI A, 1992, BLOOD, V79, P2610; Park SA, 2001, MOL BRAIN RES, V93, P18, DOI 10.1016/S0169-328X(01)00176-0; Pless M, 1997, BLOOD, V89, P3175, DOI 10.1182/blood.V89.9.3175; Ramshaw HS, 2002, EXP HEMATOL, V30, P1124, DOI 10.1016/S0301-472X(02)00903-7; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHABO Y, 1990, LEUKEMIA, V4, P797; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; Vansteenkiste J, 2002, J NATL CANCER I, V94, P1211; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Westphal G, 2002, TUMORI, V88, P150, DOI 10.1177/030089160208800214; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	57	48	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					981	990		10.1038/sj.onc.1207294	http://dx.doi.org/10.1038/sj.onc.1207294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647427				2022-12-25	WOS:000188486600014
J	Miyagawa, S; Katsu, Y; Watanabe, H; Iguchi, T				Miyagawa, S; Katsu, Y; Watanabe, H; Iguchi, T			Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol	ONCOGENE			English	Article						mouse; diethylstilbestrol; vagina; erbBs signaling; estrogen receptor	AUTOCRINE GROWTH-FACTOR; GENITAL-TRACT; CROSS-TALK; IN-VITRO; MOLECULAR-MECHANISM; EPITHELIAL-CELLS; AMPHIREGULIN; REQUIREMENT; EXPRESSION; TAMOXIFEN	Growth factors and estrogen receptor (ER) signaling cooperate to play essential roles in cell proliferation, differentiation and tumor progression in mouse reproductive organs. Treatment of neonatal mice with diethylstilbestrol (DES) induces an estrogen-independent persistent proliferation and cornification of the vaginal epithelium, which results in cancerous lesions later in life. However, the mechanisms of the estrogen-dependent and -independent pathways essentially remain unknown. We characterized the expression of epidermal growth factor (EGF)-like growth factors (EGF, transforming growth factor alpha (TGF-alpha), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), amphiregulin (APR), epiregulin (EPR) and neuregulin (NRG) 1) and erbB receptors (EGF receptor (EGFR), erbB/neu, erbB3 and erbB4) in the vaginae of mice treated either neonatally (0-4 day) or as adults (55-59 day) with estrogens. EGFR and erbB2 were activated in the vaginal epithelium of mice by estrogen treatment. This activation was also encountered in vaginae from neonatally DES-exposed mice, along with the expression of EGF, TGF-alpha, HB-EGF, BTC, APR, EPR and NRG1. Immunohistochemical analysis indicated that erbB2 was primarily expressed in vaginal epithelium. Finally, we found that serine 118 and 167 located in the AF-1 domain of ERalpha were phosphorylated in these vaginae. AG825, AG1478 or ICI 182,780 administration blocked proliferation of vaginal epithelium induced by neonatal DES exposure. Thus, signal transduction via EGFR and erbB2 could be related to the estrogen-induced vaginal changes and persistent erbBs phosphorylation and sustained expression of EGF-like growth factors, leading to ERalpha activation that may result in cancerous lesions in vaginae from neonatally DES-exposed mice later in life.	Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST)	Iguchi, T (corresponding author), Okazaki Natl Res Inst, Ctr Integrat Biosci, 5-1 Higashiyama, Aichi 4448585, Japan.	taisen@nibb.ac.jp	Katsu, Yoshinao/F-9122-2012; WATANABE, Hajime/AAJ-8904-2021; Watanabe, Hajime/S-8957-2019; Iguchi, Taisen/AAL-4225-2021	Katsu, Yoshinao/0000-0003-2625-4626; Watanabe, Hajime/0000-0001-9657-6554				Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Buckanan DL, 1998, ENDOCRINOLOGY, V139, P4345, DOI 10.1210/en.139.10.4345; CUNHA GR, 1977, DEV BIOL, V56, P52, DOI 10.1016/0012-1606(77)90154-3; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DUNN TB, 1963, J NATL CANCER I, V31, P425; Falck L, 1996, ANAT REC, V245, P459; Forsberg J G, 1979, Natl Cancer Inst Monogr, P41; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Herbst AL, 2000, GYNECOL ONCOL, V76, P147, DOI 10.1006/gyno.1999.5471; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGUCHI T, 1993, P SOC EXP BIOL MED, V204, P110, DOI 10.3181/00379727-204-43642; IGUCHI T, 1986, ACTA ANAT, V127, P110; IGUCHI T, 1992, INT REV CYTOL, V139, P1, DOI 10.1016/S0074-7696(08)61409-6; IGUCHI T, 1983, P NATL ACAD SCI-BIOL, V80, P3743, DOI 10.1073/pnas.80.12.3743; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; Kurokawa H, 2000, CANCER RES, V60, P5887; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; MARSELOS M, 1993, EUR J CANCER, V29A, P149, DOI 10.1016/0959-8049(93)90597-9; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; PASTAN I, 1983, TRENDS BIOCHEM SCI, V8, P250, DOI 10.1016/0968-0004(83)90351-1; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; Sato T, 1996, ANAT REC, V244, P374; Sato T, 2003, REPROD TOXICOL, V17, P289, DOI 10.1016/S0890-6238(03)00011-X; SATO T, 1996, P 10 INT C END SAN F, P1; TAKASUGI N, 1962, SCIENCE, V138, P438, DOI 10.1126/science.138.3538.438; TAKASUGI N, 1976, INT REV CYTOL, V44, P193, DOI 10.1016/S0074-7696(08)61650-2; TSAI PS, 1991, IN VITRO CELL DEV B, V27, P461; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	47	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					340	349		10.1038/sj.onc.1207207	http://dx.doi.org/10.1038/sj.onc.1207207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647453				2022-12-25	WOS:000188098300003
J	BLANCO, JG; EDICK, MJ; Relling, MV				BLANCO, JG; EDICK, MJ; Relling, MV			Etoposide induces chimeric Mll gene fusions	FASEB JOURNAL			English	Article						translocations; secondary leukemia; topoisomerase II inhibitors; DNA	ACUTE MYELOID-LEUKEMIA; BREAKPOINT CLUSTER REGION; DNA TOPOISOMERASE-II; ACUTE LYMPHOBLASTIC-LEUKEMIA; HOMOLOGOUS RECOMBINATION; INFANT LEUKEMIA; CHROMOSOME-ABERRATIONS; TANDEM DUPLICATION; NORMAL KARYOTYPE; LEUCINE-ZIPPER	MLL gene fusions are the hallmark of more than 70% of therapy-related leukemias (t-ML) associated with topoisomerase II inhibitors (e.g., etoposide) and cause leukemia in murine transgenic models. To determine whether Mll genomic fusions can occur after exposure to topoisomerase II inhibitors, we developed a long-distance inverse PCR DNA-based assay for chimeric MY fusions in mouse embryonic stem cells. We detected Mll fusions at a higher frequency following 100 muM etoposide for 8 h (16x 10(-6) cell(-1))) than in no-drug controls (1.0 x 10(-6) cell (-1), P=0.0002) or after treatment with a comparably cytotoxic exposure to the antimicrotubule drug vincristine (1.0 x 10(-6) cell(-1), P=0.0047). The fusion points in Mll chimeric products induced by etoposide were localized to a 1.5 kb region between exons 9 and 11, analogous to the MLL breakpoint cluster region in human leukemia. All 49 Mll fusion partners analyzed matched known genomic murine sequences, with 40 (82%) matching annotated genes covering eighteen murine autosomes. One partner was Runx1, the murine homologue of the transcription factor AML-1, a target of human translocations in therapy-related leukemia. These findings indicate that etoposide triggers the formation of MY gene fusions, a critical step for the development of treatment-induced leukemic transformation.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Knoxville, TN 37996 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Knoxville	Relling, MV (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale, Memphis, TN 38105 USA.	mary.relling@stjude.org			National Institutes of Health [CA51001, CA36401, CA21765]; Center of Excellence grant from the State of Tennessee; American Lebanese Syrian Associated Charities (ALSAC)	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center of Excellence grant from the State of Tennessee; American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC))	We acknowledge the assistance of Ozden Artinaz, Jean Cai, Perdeep Mehta, Miriam Tamano, Mark Wilkinson, and Wenjian Yang. This work was supported by grants CA51001, CA36401, and CA21765 from the National Institutes of Health; by a Center of Excellence grant from the State of Tennessee; and by American Lebanese Syrian Associated Charities (ALSAC).	Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; Blanco JG, 2001, P NATL ACAD SCI USA, V98, P10338, DOI 10.1073/pnas.181199898; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Christiansen DH, 2001, LEUKEMIA, V15, P1848, DOI 10.1038/sj.leu.2402246; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P6812, DOI 10.1073/pnas.81.21.6812; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DOMER PH, 1995, LEUKEMIA, V9, P1305; Downing J R, 1996, Cancer Treat Res, V84, P73; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Echlin-Bell DR, 2003, HUM GENET, V113, P80, DOI 10.1007/s00439-003-0936-2; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; FISHER JP, 1989, EXP CELL RES, V182, P403, DOI 10.1016/0014-4827(89)90245-0; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GU Y, 1994, CANCER RES, V54, P2327; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Lambert S, 1999, MUTAT RES-DNA REPAIR, V433, P159, DOI 10.1016/S0921-8777(99)00004-X; Lorsbach RB, 2001, INT J HEMATOL, V74, P258, DOI 10.1007/BF02982058; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; RATAIN MJ, 1992, ANN ONCOL, V3, P107, DOI 10.1093/oxfordjournals.annonc.a058121; RATAIN MJ, 1987, BLOOD, V70, P1412; Relling MV, 1998, LEUKEMIA, V12, P346, DOI 10.1038/sj.leu.2400928; Relling MV, 2003, BLOOD, V101, P3862, DOI 10.1182/blood-2002-08-2405; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; Rudin CM, 2001, GENE CHROMOSOME CANC, V30, P64, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1066>3.0.CO;2-F; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; Severson Richard K., 1999, Current Opinion in Oncology, V11, P20, DOI 10.1097/00001622-199901000-00005; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stine KC, 1997, J CLIN ONCOL, V15, P1583, DOI 10.1200/JCO.1997.15.4.1583; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Strissel PL, 1998, GENOMICS, V47, P217, DOI 10.1006/geno.1997.5103; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; Thomsen JB, 1999, CANCER-AM CANCER SOC, V86, P1080, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Webb JC, 1999, BLOOD, V94, P283, DOI 10.1182/blood.V94.1.283.413k23_283_290; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899	47	33	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					173	175		10.1096/fj.03-0638fje	http://dx.doi.org/10.1096/fj.03-0638fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630694				2022-12-25	WOS:000188829300065
J	Straub, RH; Besedovsky, HO				Straub, RH; Besedovsky, HO			Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases	FASEB JOURNAL			English	Article						chronic inflammatory disease; immune system; endocrine system; nervous system; reproductive system	TUMOR-NECROSIS-FACTOR; NONSTEROIDAL ANTIESTROGENS INHIBIT; RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; IMMUNE-SYSTEM; SUBSTANCE-P; SYNOVIAL MACROPHAGES; BETA(1) INTEGRINS; HUMAN ENDOMETRIUM; HUMAN-MONOCYTES	The pathogenesis of chronic disabling inflammatory diseases (CDIDs) is poorly understood. Current concepts that focus on abnormalities of the immune system are, in our view, incomplete. Here we propose that chronic disruption of homeostasis through abnormal neuronal and endocrine host responses to transient inflammatory reactions contributes to the appearance of CDIDs. Coordinated reactions of the supersystems (immune, nervous, endocrine, and reproductive) that maintain homeostasis have been evolutionarily conserved to respond to and eliminate foreign agents over a period of days to a few weeks. If the responses of these supersystems fail to return to normal after elimination of the pathogen, a continuous aggressive immune response is created; this situation can trigger development of CDIDs. Maladaptation of the supersystems during CDIDs has not been evolutionarily conserved but is nevertheless still prevalent because a large proportion of these diseases tend to appear after the reproductive phase. We propose that this integrated systems hypothesis may permit better identification of a patient at risk or in the early stages of developing a CDID such as rheumatoid arthritis and enable more coordinated intervention than is presently attempted.	Univ Hosp Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; Univ Marburg, Inst Normal & Pathol Physiol, D-35033 Marburg, Germany	University of Regensburg; Philipps University Marburg	Straub, RH (corresponding author), Univ Hosp Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany.	rainer.straub@klinik.uni-regensburg.de		Straub, Rainer H/0000-0003-1165-4555				Abbas A K, 2003, CELL MOL IMMUNOL, P115; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; AGRAWAL B, 1991, J IMMUNOL, V147, P383; BAUR M, 2001, ODYSSE MENSCHEN ESBE; BELL DA, 1984, J RHEUMATOL, V11, P475; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Blass S, 1999, ARTHRITIS RHEUM, V42, P2499, DOI 10.1002/1529-0131(199912)42:12<2499::AID-ANR1>3.0.CO;2-R; BLUTHE RM, 1994, PSYCHONEUROENDOCRINO, V19, P197, DOI 10.1016/0306-4530(94)90009-4; Braun J, 2002, CLIN EXP RHEUMATOL, V20, pS1; Burkhardt H, 2002, ARTHRITIS RHEUM, V46, P2339, DOI 10.1002/art.10472; Burnett F. M., 1959, CONAL SELECTION THEO; CASTAGNETTA L, 2003, IN PRESS J RHEUMATOL; CHRISTEFF N, 1987, J STEROID BIOCHEM, V26, P67, DOI 10.1016/0022-4731(87)90032-X; CID MC, 1994, J CLIN INVEST, V93, P17, DOI 10.1172/JCI116941; Crofford LJ, 1997, J CLIN ENDOCR METAB, V82, P1279, DOI 10.1210/jc.82.4.1279; CROKER BP, 1983, LAB INVEST, V48, P19; Cutolo M, 2000, RHEUM DIS CLIN N AM, V26, P825, DOI 10.1016/S0889-857X(05)70171-X; CUTOLO M, 1988, ARTHRITIS RHEUM, V31, P1314, DOI 10.1002/art.1780311015; de Jong EC, 1999, J LEUKOCYTE BIOL, V66, P201, DOI 10.1002/jlb.66.2.201; del Rey A, 2002, J NEUROIMMUNOL, V127, P44, DOI 10.1016/S0165-5728(02)00096-6; Delneste Y, 1999, J IMMUNOL, V163, P3071; DHABHAR FS, 1995, J IMMUNOL, V154, P5511; FAN PT, 1993, TXB RHEUMATOLOGY, P961; FELDMAN C, 1989, S AFR MED J, V76, P593; Galasso F, 1996, J DERMATOL SCI, V13, P76, DOI 10.1016/0923-1811(95)00501-3; Herrmann M, 2000, RHEUM DIS CLIN N AM, V26, P737, DOI 10.1016/S0889-857X(05)70167-8; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JONES SB, 1984, CIRC SHOCK, V14, P189; JORGENSEN C, 1995, J RHEUMATOL, V22, P1829; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kohm AP, 2000, IMMUNOL TODAY, V21, P539, DOI 10.1016/S0167-5699(00)01747-3; Komi J, 2001, RHEUMATOLOGY, V40, P185, DOI 10.1093/rheumatology/40.2.185; Komi J, 2000, BLOOD, V95, P2875, DOI 10.1182/blood.V95.9.2875.009k12_2875_2882; KURTZKE JF, 1992, NEUROEPIDEMIOLOGY, V11, P226, DOI 10.1159/000110935; Lambrecht BN, 1999, EUR J IMMUNOL, V29, P3815, DOI 10.1002/(SICI)1521-4141(199912)29:12<3815::AID-IMMU3815>3.0.CO;2-#; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; MADDEN K S, 1989, Brain Behavior and Immunity, V3, P72, DOI 10.1016/0889-1591(89)90007-X; Marchalonis JJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0953hyp; MASI AT, 1984, SEMIN ARTHRITIS RHEU, V14, P1, DOI 10.1016/0049-0172(84)90005-2; MATERA L, 1992, BRAIN BEHAV IMMUN, V6, P409, DOI 10.1016/0889-1591(92)90039-Q; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99-1082com; MONEKOSSO GL, 1966, LANCET, V1, P1347; Murray JS, 1998, IMMUNOL TODAY, V19, P157, DOI 10.1016/S0167-5699(97)01237-1; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Ostensen M, 2000, J RHEUMATOL, V27, P1783; PEREIRA DSJ, 1990, J RHEUMATOL, V17, P1592; PEREZ E, 1987, INVEST OPHTH VIS SCI, V28, P221; Reichenberg A, 2001, ARCH GEN PSYCHIAT, V58, P445, DOI 10.1001/archpsyc.58.5.445; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; ROCHARVEILLER M, 1986, PHARMACOLOGY, V33, P266, DOI 10.1159/000138225; RUFF MR, 1985, PEPTIDES, V6, P107, DOI 10.1016/0196-9781(85)90142-1; SCHAIBLE HG, 1993, PAIN, V55, P5, DOI 10.1016/0304-3959(93)90183-P; Seiffert K, 2002, J IMMUNOL, V168, P6128, DOI 10.4049/jimmunol.168.12.6128; Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jc.81.8.3112; Shiokawa S, 1996, J CLIN ENDOCR METAB, V81, P1533, DOI 10.1210/jc.81.4.1533; SIMMONS D, 1990, DIABETIC MED, V7, P238, DOI 10.1111/j.1464-5491.1990.tb01377.x; SKLAR CA, 1986, AM J DIS CHILD, V140, P877, DOI 10.1001/archpedi.1986.02140230047026; SMITH JB, 1992, ARCH DERMATOL, V128, P1608, DOI 10.1001/archderm.128.12.1608; SPANGELO BL, 1987, IMMUNOPHARMACOLOGY, V14, P11, DOI 10.1016/0162-3109(87)90004-X; Straub RH, 2002, FASEB J, V16, P993, DOI 10.1096/fj.02-0085com; Straub RH, 2002, J ENDOCRINOL, V175, P467, DOI 10.1677/joe.0.1750467; Straub RH, 2002, ARTHRITIS RHEUM, V46, P654, DOI 10.1002/art.10177; SUZUKI S, 1986, AM J PHYSIOL, V250, pE470, DOI 10.1152/ajpendo.1986.250.4.E470; Thomas L, 1998, CLIN LAB DIAGNOSTICS; TOFT P, 1994, ACTA ANAESTH SCAND, V38, P254, DOI 10.1111/j.1399-6576.1994.tb03884.x; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Torii H, 1999, J DERMATOL SCI, V20, P21, DOI 10.1016/S0923-1811(99)00004-3; Westerman R A, 1993, Clin Exp Neurol, V30, P39; WUCHERPFENNIG AL, 1990, ARCH ORAL BIOL, V35, P443, DOI 10.1016/0003-9969(90)90207-Q; Yoshimura Y, 1998, HORM RES, V50, P46, DOI 10.1159/000053123	73	67	72	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2176	2183		10.1096/fj.03-0433hyp	http://dx.doi.org/10.1096/fj.03-0433hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656978				2022-12-25	WOS:000188067500037
J	Cheng, SH; Hsia, CY; Leone, G; Liou, HC				Cheng, SH; Hsia, CY; Leone, G; Liou, HC			Cyclin E and Bcl-x(L) cooperatively induce cell cycle progression in c-Rel(-/-) B cells	ONCOGENE			English	Article						B cell; lymphoma; leukemia; Rel; cyclin E; Bcl-x(L)	NF-KAPPA-B; C-REL; RETINOBLASTOMA PROTEIN; ANTIGEN RECEPTOR; S-PHASE; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION DOMAIN; REGULATED EXPRESSION; MECHANISMS CONTROL; INDUCED APOPTOSIS	Aberrant overexpression of the c-rel protooncogene is associated with lymphoid malignancy, while c-rel deletion produces severe lymphoproliferative defects and immunodeficiency. To investigate the mechanism of c-rel-induced proliferation and cell cycle progression in B lymphocytes, we have compared signaling events elicited through the BCR in c-rel(-/-) and wild-type B cells. BCR stimulation of c-rel(-/-) B cells fails to induce proper cyclin expression, resulting in G(1) phase arrest, but it is unclear whether these defects are in fact secondary events of decreased B-cell survival, since c-rel deletion also affects the expression of antiapoptotic genes such as bcl-x(L). Here, we use the bcl-x(L) transgene to correct the viability of c-rel-deficient B cells, and show that the inhibition of apoptosis does not necessarily confer hyperproliferation of B cells activated through the BCR. c-rel(-/-) B cells still fail to enter the S phase despite improved survival by bcl-x(L) overexpression, suggesting that c-Rel-associated cell cycle progression is dependent on more than just enhanced cell viability. Overexpression of cyclin E protein, however, can cooperate with Bcl-x(L) to restore cell cycle progression to c-rel(-/-) B cells via induction of the cyclin-CDK/Rb-E2F pathway. Furthermore, we show that c-Rel can directly regulate transcription of the e2f3a promoter/enhancer, which is then likely to lead to transcriptional activation of the cyclin E promoter by E2F3a. Hence, these studies provide clear evidence that control of lymphocyte proliferation via c-Rel is linked to a cyclin-dependent process, and suggest that c-Rel not only activates antiapoptotic signaling but also the induction of cell cycle progression.	Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Cornell University; University System of Ohio; Ohio State University	Liou, HC (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, 515 E 71st St,Room S-210, New York, NY 10021 USA.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300	NATIONAL CANCER INSTITUTE [R55CA068155, R01CA090405, R01CA068155] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90405, CA 68155] Funding Source: Medline; PHS HHS [1 T32 A1 07621] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Aronica MA, 1999, J IMMUNOL, V163, P5116; BARTH TF, 2003, BLOOD, V2, P2; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Botz J, 1996, MOL CELL BIOL, V16, P3401; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Carman JA, 1996, J IMMUNOL, V156, P4562; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Donovan CE, 1999, J IMMUNOL, V163, P6827; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Geng Y, 1996, ONCOGENE, V12, P1173; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hilliard BA, 2002, J CLIN INVEST, V110, P843, DOI 10.1172/JCI200215254; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Houldsworth J, 1996, BLOOD, V87, P25; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lavia P, 1999, BIOESSAYS, V21, P221; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Liou HC, 2002, J BIOCHEM MOL BIOL, V35, P537; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mason N, 2002, J IMMUNOL, V168, P2590, DOI 10.4049/jimmunol.168.6.2590; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang H, 2002, TRANSPLANTATION, V74, P291, DOI 10.1097/00007890-200208150-00002; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	79	41	43	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8472	8486		10.1038/sj.onc.1206917	http://dx.doi.org/10.1038/sj.onc.1206917			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627988				2022-12-25	WOS:000186650300011
J	Anderson, HDI; Wang, F; Gardner, DG				Anderson, HDI; Wang, F; Gardner, DG			Role of the epidermal growth factor receptor in signaling strain-dependent activation of the brain natriuretic peptide gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; CANCER CELL-LINES; EGF-RECEPTOR; NAD(P)H OXIDASE; ANGIOTENSIN-II; MECHANICAL STRETCH; PROTEIN-KINASE; VENTRICULAR MYOCYTES; REGULATED KINASE; HEART-FAILURE	The epidermal growth factor receptor ( EGFR) and ectoshedding of heparin-binding epidermal growth factor (HBEGF), an EGFR ligand, have been linked to the development of cardiac myocyte hypertrophy. However, the precise role that the liganded EGFR plays in the transcriptional activation of the gene program that accompanies hypertrophy remains undefined. Utilizing the human (h) BNP gene as a model of hypertrophy-dependent gene activation, we show that activation of the EGFR plays an important role in mediating mechanical strain-dependent stimulation of the hBNP promoter. Strain promotes endothelin ( ET) generation through NAD(P) H oxidase-dependent production of reactive oxygen species. ET in turn induces metalloproteinase-mediated cleavage of pro-HBEGF and ectoshedding of HBEGF, which activates the EGFR and stimulates hBNP promoter activity. HBEGF also stimulates other phenotypic markers of hypertrophy including protein synthesis and sarcomeric assembly. The antioxidant N-acetylcysteine or the NAD( P) H oxidase inhibitor, apocynin, inhibited strain-dependent activation of the ET-1 promoter, HBEGF shedding, and hBNP promoter activation. The metalloproteinase inhibitor, GM-6001, prevented the induction of HBEGF ectoshedding and the hBNP promoter response to strain, suggesting a critical role for the metalloproteinase-dependent cleavage event in signaling the strain response. These findings suggest that metalloproteinase activity as an essential step in this pathway may prove to be a relevant therapeutic target in the management of cardiac hypertrophy.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	gardner@itsa.ucsf.edu		Anderson, Hope/0000-0001-6570-6678	NHLBI NIH HHS [HL35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BENES AJ, 1985, J CELL SCI, V75, P35; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cordero JB, 2002, J BIOL CHEM, V277, P38965, DOI 10.1074/jbc.M203736200; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P100, DOI 10.1053/joca.2001.0485; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; FALETTE N, 1989, MOL CELL ENDOCRINOL, V63, P189, DOI 10.1016/0303-7207(89)90095-6; Fink C, 2000, FASEB J, V14, P669, DOI 10.1096/fasebj.14.5.669; Fujino T, 1998, CARDIOVASC RES, V38, P365, DOI 10.1016/S0008-6363(98)00010-8; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Gonzalez EA, 2002, KIDNEY INT, V61, P1627, DOI 10.1046/j.1523-1755.2002.00327.x; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Hamilton CA, 2002, HYPERTENSION, V40, P755, DOI 10.1161/01.HYP.0000037063.90643.0B; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; Hashimoto K, 2002, J GASTROINTEST CANC, V32, P7, DOI 10.1385/IJGC:32:1:7; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Kagiyama S, 2003, HYPERTENSION, V41, P824, DOI 10.1161/01.HYP.0000047104.42047.9B; Kent RL, 1996, CIRC RES, V78, P829, DOI 10.1161/01.RES.78.5.829; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; Lee EA, 2001, BIOCHEM BIOPH RES CO, V284, P419, DOI 10.1006/bbrc.2001.4943; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Liang FQ, 2003, ENDOCRINOLOGY, V144, P4187, DOI 10.1210/en.2002-0217; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; Liao JK, 2002, NAT MED, V8, P20, DOI 10.1038/nm0102-20; Marx N, 2003, ARTERIOSCL THROM VAS, V23, P283, DOI 10.1161/01.ATV.0000054195.35121.5E; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; Miyata S, 1996, EUR J PHARMACOL, V307, P81, DOI 10.1016/0014-2999(96)00152-5; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; Nakagami H, 2003, J MOL CELL CARDIOL, V35, P851, DOI 10.1016/S0022-2828(03)00145-7; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PAUL M, 1995, HYPERTENSION, V25, P683, DOI 10.1161/01.HYP.25.4.683; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sabatini M, 2002, OSTEOARTHR CARTILAGE, V10, P673, DOI 10.1053/joca.2002.0827; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Shiomi T, 2002, CIRCULATION, V106, P3126, DOI 10.1161/01.CIR.0000039346.31538.2C; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Song JI, 2001, CANCER RES, V61, P5919; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sunami E, 2002, SURG TODAY, V32, P343, DOI 10.1007/s005950200049; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Tong WM, 1998, EUR J CANCER, V34, P2119, DOI 10.1016/S0959-8049(98)00267-6; Troughton RW, 2000, LANCET, V355, P1126, DOI 10.1016/S0140-6736(00)02060-2; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; WU JP, 1989, J BIOL CHEM, V264, P6472; Xiao L, 2002, AM J PHYSIOL-CELL PH, V282, pC926, DOI 10.1152/ajpcell.00254.2001	68	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9287	9297		10.1074/jbc.M309227200	http://dx.doi.org/10.1074/jbc.M309227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14645255	hybrid			2022-12-25	WOS:000189265900091
J	Mitri, C; Parmentier, ML; Pin, JP; Bockaert, J; Grau, Y				Mitri, C; Parmentier, ML; Pin, JP; Bockaert, J; Grau, Y			Divergent evolution in metabotropic glutamate receptors - A new receptor activated by an endogenous ligand different from glutamate in insects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-BINDING; FUNCTIONAL EXPRESSION; DOMAIN; IDENTIFICATION; SPECIFICITY; RECOGNITION; DATABASE; SUBUNIT; SITE	The metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors involved in the regulation of glutamatergic synapses. Surprisingly, the evolutionarily distant Drosophila mGluR shares a very similar pharmacological profile with its mammalian orthologues (mGlu2R and mGlu3R). Such a conservation in ligand recognition indicates a strong selective pressure during evolution to maintain the ligand recognition selectivity of mGluRs and suggests that structural constraints within the ligand binding pocket (LBP) would hinder divergent evolution. Here we report the identification of a new receptor homologous to mGluRs found in Anopheles gambiae, Apis mellifera, and Drosophila melanogaster genomes and called AmXR, HBmXR, and DmXR, respectively ( the mXRs group). Sequence comparison associated with three-dimensional modeling of the LBP revealed that the residues contacting the amino acid moiety of glutamate (the alpha-COO- and NH3+ groups) were conserved in mXRs, whereas the residues interacting with the gamma-carboxylic group were not. This suggested that the mXRs evolved to recognize an amino acid different from glutamate. The Drosophila cDNA encoding DmXR was isolated and found to be insensitive to glutamate or any other standard amino acid. However, a chimeric receptor with the heptahelical and intracellular domains of DmXR coupled to G-protein. We found that the DmX receptor was activated by a ligand containing an amino group, which was extracted from Drosophila head and from other insects ( Anopheles and Schistocerca). No orthologue of mXR could be detected in Caenorhabditis elegans or human genomes. These data indicate that the LBP of the mGluRs has diverged in insects to recognize a new ligand.	Lab Genom Fonct, CNRS, UPR2580, F-34094 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS)	Grau, Y (corresponding author), Lab Genom Fonct, CNRS, UPR2580, 141 Rue Cardonille, F-34094 Montpellier 05, France.	Yves.Grau@ccipe.cnrs.fr	Parmentier, Marie-Laure/N-9915-2017; Pin, Jean-Philippe/Y-6668-2019	Parmentier, Marie-Laure/0000-0001-6133-3413; Pin, Jean-Philippe/0000-0002-1423-345X; Mitri, Christian/0000-0003-3882-2029				Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Aurelio L, 2002, ORG LETT, V4, P3767, DOI 10.1021/ol026799w; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Broeck JV, 2001, ARCH INSECT BIOCHEM, V48, P1, DOI 10.1002/arch.1054; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Gelbart WM, 2002, NUCLEIC ACIDS RES, V30, P106; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; MIKS B, 1975, FOL HISTOCH CYTOCHEM, V13, P77; Mouillac B, 1995, ADV EXP MED BIOL, V395, P301; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Parmentier ML, 1996, J NEUROSCI, V16, P6687; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; ROSELLIREHFUSS L, 1992, MOL GEN GENET, V235, P213, DOI 10.1007/BF00279363; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	32	36	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9313	9320		10.1074/jbc.M310878200	http://dx.doi.org/10.1074/jbc.M310878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660580	Green Published, hybrid			2022-12-25	WOS:000189265900094
J	Nymalm, Y; Puranen, JS; Nyholm, TKM; Kapyla, J; Kidron, H; Pentikainen, OT; Airenne, TT; Heino, J; Slotte, JP; Johnson, MS; Salminen, TA				Nymalm, Y; Puranen, JS; Nyholm, TKM; Kapyla, J; Kidron, H; Pentikainen, OT; Airenne, TT; Heino, J; Slotte, JP; Johnson, MS; Salminen, TA			Jararhagin-derived RKKH peptides induce structural changes in alpha I-1 domain of human integrin alpha(1)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASE; INTEGRIN I-DOMAIN; PARTICLE MESH EWALD; CRYSTAL-STRUCTURE; CELL-ADHESION; EXTRACELLULAR SEGMENT; MOLECULAR-DYNAMICS; COLLAGEN-BINDING; LIGAND-BINDING; PROTEIN	Integrin alpha(1)beta(1) is one of four collagen-binding integrins in humans. Collagens bind to the alphaI domain and in the case of alpha(2)I collagen binding is competitively inhibited by peptides containing the RKKH sequence and derived from the metalloproteinase jararhagin of snake venom from Bothrops jararaca. In alpha(2)I, these peptides bind near the metal ion-dependent adhesion site (MIDAS), where a collagen ( I)-like peptide is known to bind; magnesium is required for binding. Published structures of the ligand-bound "open" conformation of alpha(2)I differs significantly from the "closed" conformation seen in the structure of apo-alpha(2)I near MIDAS. Here we show that two peptides, CTRKKHDC and CARKKHDC, derived from jararhagin also bind to alpha(1)I and competitively inhibit collagen I binding. Furthermore, calorimetric and fluorimetric measurements show that the structure of the complex of alpha(1)I with Mg2+ and CTRKKHDC differs from structure in the absence of peptide. A comparison of the x-ray structure of apo-alpha(1)I ("closed" conformation) and a model structure of the alpha(1)I ("open" conformation) based on the closely related structure of alpha(2)I reveals that the binding site is partially blocked to ligands by Glu(255) and Tyr(285) in the "closed" structure, whereas in the "open" structure helix C is unwound and these residues are shifted, and the "RKKH" peptides fit well when docked. The "open" conformation of alpha(2)I resulting from binding a collagen ( I)-like peptide leads to exposure of hydrophobic surface, also seen in the model of alpha(1)I and shown experimentally for alpha(1)I using a fluorescent hydrophobic probe.	Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland	Abo Akademi University; University of Jyvaskyla; University of Turku	Salminen, TA (corresponding author), Abo Akad Univ, Dept Biochem & Pharm, POB 66, FIN-20521 Turku, Finland.	tiina.salminen@abo.fi	Kidron, Heidi/A-5826-2015; Salminen, Tiina A./AAM-5443-2021; Pentikäinen, Olli T/E-1980-2012; Salminen, Tiina A/G-7492-2019	Kidron, Heidi/0000-0001-6427-8042; Salminen, Tiina A./0000-0002-4135-8020; Pentikäinen, Olli T/0000-0001-7188-4016; Salminen, Tiina A/0000-0002-4135-8020; Kapyla, Jarmo/0000-0003-3036-713X				Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FREIRE E, 1995, ANNU REV BIOPH BIOM, V24, P141, DOI 10.1146/annurev.bb.24.060195.001041; Ghose AK, 1998, J PHYS CHEM A, V102, P3762, DOI 10.1021/jp980230o; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; Gong WM, 1998, J MOL BIOL, V283, P657, DOI 10.1006/jmbi.1998.2110; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Gullberg D, 2003, MOL B INT U, P67; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; Heino J, 2003, MOL B INT U, P143; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HOCKNEY RW, 1974, J COMPUT PHYS, V14, P148, DOI 10.1016/0021-9991(74)90010-2; Humphries MJ, 2002, ARTHRITIS RES THER, V4, pS69, DOI 10.1186/ar563; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Johnson MS, 2003, MOL B INT U, P1; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kamiguti AS, 2003, FEBS LETT, V549, P129, DOI 10.1016/S0014-5793(03)00799-3; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Karpusas M, 2003, J MOL BIOL, V327, P1031, DOI 10.1016/S0022-2836(03)00203-1; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mendelson JK, 2000, J CUTAN PATHOL, V27, P61, DOI 10.1034/j.1600-0560.2000.027002061.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; PIGOTT R, 1993, ADHESION MOL FACTS; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEITZMAN JB, 1995, J CELL SCI, V108, P3635; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	70	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7962	7970		10.1074/jbc.M312912200	http://dx.doi.org/10.1074/jbc.M312912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660600	hybrid			2022-12-25	WOS:000189103300074
J	Barzilay, E; Ben-Califa, N; Supino-Rosin, L; Kashman, Y; Hirschberg, K; Elazar, Z; Neumann, D				Barzilay, E; Ben-Califa, N; Supino-Rosin, L; Kashman, Y; Hirschberg, K; Elazar, Z; Neumann, D			Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; BENZOQUINONE ANSAMYCINS; SIGNAL-TRANSDUCTION; IN-VIVO; DEGRADATION; HSP90; COMPLEX; ERYTHROPOIETIN; BINDS	Geldanamycin, an ansamycin antibiotic that specifically inhibits heat-shock protein-90 (HSP90) and its endoplasmic reticulum homologue, glucose-regulated protein-94 (GRP94), accelerates the degradation of selected cellular proteins. We showed previously that geldanamycin inhibits maturation and transport of the epidermal growth factor receptor in addition to accelerating its degradation (Supino-Rosin, L., Yoshimura, A., Yarden, Y., Elazar, Z., and Neumann, D. (2000) J. Biol. Chem. 275, 21850-21855). Here we demonstrate that the additional activities of geldanamycin on intracellular transport and protein maturation are related to its supply source. By combining chemical separation of Streptomyces hygroscopicus var. geldanus extracts and biological screens, we show that the geldanamycin-associated effects on intracellular transport and protein maturation are not mediated by geldanamycin itself but are due to the presence of an additional component(s). Chromatography of S. hygroscopicus var. geldanus extracts on a silica-gel column allowed separation between the inhibition of intracellular trafficking and geldanamycin-mediated degradation. One fraction that was devoid of geldanamycin blocked secretion of a soluble form of the erythropoietin receptor, retarded maturation of the epidermal growth factor receptor without enhancing its degradation, and blocked anterograde transport of a temperature-sensitive mutant of the vesicular stomatitis virus G protein (VSVGtsO45) from the early Golgi cisternae. This fraction was enriched (> 95%) in 17-demethylgeldanamycin. However, as synthetically derived 17-demethylgeldanamycin did not inhibit intracellular trafficking, we concluded that 17-demethylgeldanamycin is not the active component. We thus propose that a compound(s) that co-purifies with benzoquinone ansamycins inhibits intracellular transport. Taken together, our data demonstrate that the inhibitory effects on protein maturation and intracellular trafficking, previously attributed to geldanamycin, are mediated by another distinct moiety.	Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Pathol, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Sch Chem, IL-69978 Ramat Aviv, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Weizmann Institute of Science	Neumann, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Ramat Aviv, Israel.	Histo6@post.tau.ac.il	Hirschberg, Koret/AAF-4566-2019	Barzilay, Eran/0000-0001-5496-4866; Neumann, Drorit/0000-0002-4805-7511				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Chavany C, 1996, J BIOL CHEM, V271, P4974; Cohen J, 1997, BIOCHEM J, V327, P391, DOI 10.1042/bj3270391; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MILLER P, 1994, CANCER RES, V54, P2724; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neumann D, 1996, BIOCHEM J, V313, P391, DOI 10.1042/bj3130391; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	27	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6847	6852		10.1074/jbc.M312799200	http://dx.doi.org/10.1074/jbc.M312799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660597	hybrid			2022-12-25	WOS:000188969200079
J	Nishita, M; Wang, Y; Tomizawa, C; Suzuki, A; Niwa, R; Uemura, T; Mizuno, K				Nishita, M; Wang, Y; Tomizawa, C; Suzuki, A; Niwa, R; Uemura, T; Mizuno, K			Phosphoinositide 3-kinase-mediated activation of cofilin phosphatase slingshot and its role for insulin-induced membrane protrusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIN REORGANIZATION; TUMOR-SUPPRESSOR; PROTEIN-KINASE; CELL POLARITY; LIM-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEUTROPHIL CHEMOTAXIS; SIGNALING PATHWAYS; PHOSPHORYLATION; ADF/COFILIN	Cofilin plays an essential role in actin filament dynamics and membrane protrusion in motile cells. Cofilin is inactivated by phosphorylation at Ser-3 by LIM kinase and reactivated by dephosphorylation by cofilin-phosphatase Slingshot (SSH). Although cofilin is dephosphorylated in response to various extracellular stimuli, signaling pathways regulating SSH activation and cofilin dephosphorylation have remained to be elucidated. Here we show that insulin stimulates the phosphatase activity of Slingshot-1L (SSH1L) and cofilin dephosphorylation in cultured cells, in a manner dependent on phosphoinositide 3-kinase (PI3K) activity. Consistent with this, the level of Ser-3-phosphorylated cofilin is increased in PTEN (phosphatase and tensin homolog deleted in chromosome 10)-overexpressing cells and decreased in PTEN-deficient cells. Insulin induced the accumulation of SSH1L and active Akt (a downstream effector of PI3K), together with a PI3K product phosphatidylinositol 3,4,5-trisphosphate, onto membrane protrusions. Cofilin, but not Ser-3-phosphorylated cofilin, accumulated in membrane protrusions in insulin-stimulated cells, indicating that cofilin is dephosphorylated in these areas. Finally, suppression of SSH1L expression by RNA interference abolished insulin-induced cofilin dephosphorylation and the membrane protrusion. These findings suggest that SSH1L is activated downstream of PI3K and plays a critical role in insulin-induced membrane protrusion by dephosphorylating and activating cofilin.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan; Akita Univ, Sch Med, Dept Mol Biol, Akita 0108543, Japan; Kyoto Univ, Inst Virus Res, Dept Mol Genet, Kyoto 6068507, Japan; Japan Sci & Technol Corp, CREST, Kyoto 6068507, Japan	Tohoku University; Akita University; Kyoto University; Japan Science & Technology Agency (JST)	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015; Suzuki, Akira/GYD-6697-2022	Suzuki, Akira/0000-0002-5950-8808; UEMURA, Tadashi/0000-0001-7204-3606				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bailly M, 2003, CURR BIOL, V13, pR128, DOI 10.1016/S0960-9822(03)00072-1; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; Endo M, 2003, J NEUROSCI, V23, P2527; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Kaji N, 2003, J BIOL CHEM, V278, P33450, DOI 10.1074/jbc.M305802200; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosenblatt J, 1998, NATURE, V393, P739, DOI 10.1038/31597; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tobe K, 2003, GENES CELLS, V8, P29, DOI 10.1046/j.1365-2443.2003.00611.x; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	34	89	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7193	7198		10.1074/jbc.M312591200	http://dx.doi.org/10.1074/jbc.M312591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645219	hybrid			2022-12-25	WOS:000188969200118
J	Tan, W; Zheng, L; Lee, WH; Boyer, TG				Tan, W; Zheng, L; Lee, WH; Boyer, TG			Functional dissection of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-binding and BRCA1-dependent transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE RESPONSE; BREAST-CANCER; CELL-CYCLE; ATAXIA-TELANGIECTASIA; GENETIC INSTABILITY; CRYSTAL-STRUCTURE; OVARIAN-CANCER; FACTOR-IIIA; BRCA1; KRAB	The breast- and ovarian-specific tumor suppressor BRCA1 has been implicated in both activation and repression of gene transcription by virtue of its direct interaction with sequence-specific DNA-binding transcription factors. However, the mechanistic basis by which BRCA1 mediates the transcriptional activity of these regulatory proteins remains largely unknown. To clarify this issue, we have examined the functional interaction between BRCA1 and ZBRK1, a BRCAl-dependent KRAB eight zinc finger transcriptional repressor. We report here the identification and molecular characterization of a portable BRCAl-dependent transcriptional repression domain within ZBRK1 composed of zinc fingers 5-8 along with sequences in the unique ZBRK1 C terminus. This C-terminal repression domain functions in a BRCAl-, histone deacetylase-, and promoter-specific manner and is thus functionally distinguishable from the N-terminal KRAB repression domain in ZBRK1, which exhibits no BRCA1 dependence and broad promoter specificity. Significantly, we also find that the BRCAl-dependent transcriptional repression domain on ZBRK1 includes elements that modulate its sequence-specific DNA binding activity. These findings thus reveal the presence within ZBRK1 of functionally bipartite zinc fingers with dual roles in sequence-specific DNA-binding and BRCAl-dependent transcriptional repression. We discuss the implications of these findings for the role of BRCA1 as ZBRK1 co-repressor.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Boyer, TG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	boyer@uthscsa.edu			NCI NIH HHS [CA098301-01, CA81020, CA94170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098301, R01CA094170, P01CA081020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1993, P NATL ACAD SCI USA, V90, P168, DOI 10.1073/pnas.90.1.168; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Park JJ, 2000, CANCER RES, V60, P5946; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peng HZ, 2002, CANCER RES, V62, P3773; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Tirkkonen M, 1997, CANCER RES, V57, P1222; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	64	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6576	6587		10.1074/jbc.M312270200	http://dx.doi.org/10.1074/jbc.M312270200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660588	hybrid			2022-12-25	WOS:000188969200046
J	Batonnet, S; Leibovitch, MP; Tintignac, L; Leibovitch, SA				Batonnet, S; Leibovitch, MP; Tintignac, L; Leibovitch, SA			Critical role for lysine 133 in the nuclear ubiquitin-mediated degradation of MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; SKELETAL-MUSCLE; MYOBLASTS; PROTEIN; PHOSPHORYLATION; EXPRESSION; ACTIVATION; BINDING; SYSTEM; ACETYLATION	The ubiquitin-proteasome system is responsible for the regulation and turnover of the nuclear transcription factor MyoD. The degradation of MyoD can occur via an NH2 terminus-dependent pathway or a lysine-dependent pathway, suggesting that MyoD ubiquitination may be driven by different mechanisms. To understand this process, deletion analysis was used to identify the region of MyoD that is required for rapid proteolysis in the lysine-dependent pathway. Here we report that the basic helix-loop-helix domain is required for ubiquitination and lysine-dependent degradation of MyoD in the nucleus. Site-directed mutagenesis in MyoD revealed that lysine 133 is the major internal lysine of ubiquitination. The half-life of the MyoD K133R mutant protein was longer than that of wild type MyoD, substantiating the implication of lysine 133 in the turnover of MyoD in myoblasts. In addition, the MyoD K133R mutant displayed activity 2-3-fold higher than the wild type in transactivation muscle-specific gene and myogenic conversion of 10T1/2 cells. Taken together, our data demonstrate that lysine 133 is targeted for ubiquitination and rapid degradation of MyoD in the lysine-dependent pathway and plays an integral role in compromising MyoD activity in the nucleus.	CNRS, UMR 8125, Lab Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Leibovitch, SA (corresponding author), CNRS, UMR 8125, Lab Genet Oncol, F-94805 Villejuif, France.	leibovit@igr.fr		Tintignac, Lionel/0000-0001-5902-1138				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Benayoun B, 1998, FEBS LETT, V437, P39, DOI 10.1016/S0014-5793(98)01192-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huijbregts J, 2001, ACTA HISTOCHEM, V103, P379, DOI 10.1078/0065-1281-00607; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5413	5420		10.1074/jbc.M310315200	http://dx.doi.org/10.1074/jbc.M310315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660660	hybrid			2022-12-25	WOS:000188776500047
J	Baudouin-Cornu, P; Schuerer, K; Marliere, P; Thomas, D				Baudouin-Cornu, P; Schuerer, K; Marliere, P; Thomas, D			Intimate evolution of proteins - Proteome atomic content correlates with genome base composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; BACTERIAL EVOLUTION; GENETIC-CODE; DNA; USAGE; YEAST; BIAS	Discerning the significant relations that exist within and among genome sequences is a major step toward the modeling of biopolymer evolution. Here we report the systematic analysis of the atomic composition of proteins encoded by organisms representative of each kingdoms. Protein atomic contents are shown to vary largely among species, the larger variations being observed for the main architectural component of proteins, the carbon atom. These variations apply to the bulk proteins as well as to subsets of ortholog proteins. A pronounced correlation between proteome carbon content and genome base composition is further evidenced, with high G + C genome content being related to low protein carbon content. The generation of random proteomes and the examination of the canonical genetic code provide arguments for the hypothesis that natural selection might have driven genome base composition.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Inst Pasteur, F-75015 Paris, France; Evolg SA, F-91000 Evry, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thomas, D (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.	thomas@cgm.cnrs-gif.fr		Baudouin-Cornu, Peggy/0000-0001-7296-099X				Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; Baudouin-Cornu P, 2001, SCIENCE, V293, P297, DOI 10.1126/science.1061052; BERNARDI G, 1985, J MOL EVOL, V22, P363, DOI 10.1007/BF02115693; BROCK D, 1991, BIOL MICROORGANISMS, P634; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; HAIG D, 1991, J MOL EVOL, V33, P412, DOI 10.1007/BF02103132; KARLIN S, 1992, PROTEIN ENG, V5, P729, DOI 10.1093/protein/5.8.729; KARLIN S, 1992, SCIENCE, V257, P39, DOI 10.1126/science.1621093; Kimura MA, 1985, NEUTRAL THEORY MOL E; Koonin EV, 2000, CELL, V101, P573, DOI 10.1016/S0092-8674(00)80867-3; Lobry JR, 1997, GENE, V205, P309, DOI 10.1016/S0378-1119(97)00403-4; MAZEL D, 1989, NATURE, V341, P245, DOI 10.1038/341245a0; MUTO A, 1987, P NATL ACAD SCI USA, V84, P166, DOI 10.1073/pnas.84.1.166; Nei M., 1987, MOL EVOLUTIONARY GEN; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Rocha EPC, 2002, TRENDS GENET, V18, P291, DOI 10.1016/S0168-9525(02)02690-2; Singer GAC, 2000, MOL BIOL EVOL, V17, P1581, DOI 10.1093/oxfordjournals.molbev.a026257; SUEKOA N, 1961, COLD SPRING HARB SYM, V26, P35; SUEOKA N, 1962, P NATL ACAD SCI USA, V48, P582, DOI 10.1073/pnas.48.4.582; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thorne JL, 2000, CURR OPIN GENET DEV, V10, P602, DOI 10.1016/S0959-437X(00)00142-8; Tourasse NJ, 2000, MOL BIOL EVOL, V17, P656, DOI 10.1093/oxfordjournals.molbev.a026344; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1965, P NATL ACAD SCI USA, V54, P71, DOI 10.1073/pnas.54.1.71	26	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5421	5428		10.1074/jbc.M306415200	http://dx.doi.org/10.1074/jbc.M306415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645368	hybrid			2022-12-25	WOS:000188776500048
J	Bharti, AC; Takada, Y; Shishodia, S; Aggarwal, BB				Bharti, AC; Takada, Y; Shishodia, S; Aggarwal, BB			Evidence that receptor activator of nuclear factor (NF)-kappa B ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappa B-independent and TRAF6-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; LYMPH-NODE ORGANOGENESIS; TNF FAMILY-MEMBER; TERMINAL KINASE; FAS LIGAND; OSTEOPROTEGERIN-LIGAND; MEDIATED APOPTOSIS; T-CELLS; C-MYC	The receptor activator of NF-kappaB ligand (RANKL), a recently identified member of the tumor necrosis factor (TNF) superfamily, has been shown to induce osteoclastogenesis and dendritic cell survival. Most members of the TNF superfamily suppress cell proliferation and induce apoptosis, but whether RANKL does so is not known. We demonstrate that treatment of monocyte RAW 264.7 cells with RANKL induces dose-dependent growth inhibition (IC50 = 10 ng/ml) as determined by dye uptake and [H-3]thymidine incorporation methods. Suppression of RANKL-induced NF-kappaB activation by dominant-negative IkappaBalpha or by the NEMO-peptide had no effect on RANKL-induced cell growth inhibition. Inhibition of RANKL-induced JNK activation, however, abolished the RANKL-induced apoptosis. Suppression of interaction of RANK with TRAF6 by TRAF6-binding peptide abrogated the anti-proliferative effects of RANKL, suggesting the critical role of TRAF6. Flow cytometric analysis of cells treated with RANKL showed accumulation of cells in G(0)/G(1) phase of the cell cycle, and this accumulation correlated with a decline in the levels of cyclin D1, cyclin D3, and cyclin E and an increase in cyclin-dependent kinase inhibitor p27 (Kip). Flow cytometric analysis showed the presence of annexin V-positive cells in cultures treated with RANKL. RANKL-induced apoptosis was further confirmed using calcein AM/ethidium homodimer-1 dye and cleavage of poly(ADP-ribose) polymerase (PARP), procaspase 3, and procaspase 9; benzyloxycarbonyl-VAD, the pancaspase inhibitor, suppressed the PARP cleavage. Thus, overall, our studies indicate that RANKL can inhibit cell proliferation and induce apoptosis through a TRAF-6-dependent but NF-kappaB-independent mechanism.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Sect, Dept Bioimmunol,Unit 143, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Sect, Dept Bioimmunol,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Bharti, Prof. AC/AGL-5994-2022; Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01 CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bergman MC, 1996, J IMMUNOL, V156, P3118; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756-3282(99)00105-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dormond O, 2002, ANTICANCER RES, V22, P3159; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Dunger A, 1996, J AUTOIMMUN, V9, P309, DOI 10.1006/jaut.1996.0042; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fiumara P, 2001, BLOOD, V98, P2784, DOI 10.1182/blood.V98.9.2784; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Josien R, 1999, J IMMUNOL, V162, P2562; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Koo MS, 2002, MOL CELLS, V13, P194; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lecoeur H, 2002, EXP CELL RES, V277, P1, DOI 10.1006/excr.2002.5537; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Lunemann JD, 2002, J IMMUNOL, V168, P4881, DOI 10.4049/jimmunol.168.10.4881; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Matsui K, 1998, J IMMUNOL, V161, P3469; Muller I, 2003, CANCER RES, V63, P1772; N'cho M, 2001, HUM IMMUNOL, V62, P310, DOI 10.1016/S0198-8859(01)00214-2; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NORIMATSU M, 1995, INFECT IMMUN, V63, P1122, DOI 10.1128/IAI.63.3.1122-1126.1995; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Okahashi N, 2001, J CELL BIOCHEM, V80, P339, DOI 10.1002/1097-4644(20010301)80:3<339::AID-JCB60>3.0.CO;2-#; Olashaw Nancy, 2002, Sci STKE, V2002, pre7; PeguetNavarro J, 1997, J IMMUNOL, V158, P144; Qin ZH, 1999, J NEUROSCI, V19, P4023; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	76	91	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6065	6076		10.1074/jbc.M308062200	http://dx.doi.org/10.1074/jbc.M308062200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645259	hybrid			2022-12-25	WOS:000188776500122
J	Liang, XH; Ochaion, A; Xu, YX; Liu, Q; Michaeli, S				Liang, XH; Ochaion, A; Xu, YX; Liu, Q; Michaeli, S			Small nucleolar RNA clusters in trypanosomatid Leptomonas collosoma - Genome organization, expression studies, and the potential role of sequences present upstream from the first repeated cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER-ASSOCIATED RNA; SNORNA GENE CLUSTERS; PRE-MESSENGER-RNA; RIBOSOMAL-RNA; PSEUDOURIDINE FORMATION; PRERIBOSOMAL RNA; BINDING-PROTEIN; SMALL NUCLEAR; SL RNA; BRUCEI	Trypanosomatid small nucleolar RNA (snoRNA) genes are clustered in the genome. snoRNAs are transcribed polycistronically and processed into mature RNAs. In this study, we characterized four snoRNA clusters in Leptomonas collosoma. All of the clusters analyzed carry both C/D and H/ACA RNAs. The H/ACA RNAs are composed of a single hairpin, a structure typical to trypanosome and archaea guide RNAs. Using deletion and mutational analysis of a tagged C/D snoRNA situated within the snoRNA cluster, we identified 10-nucleotide flanking sequences that are essential for processing snoRNA from its precursor. Chromosome walk was performed on a snoRNA cluster, and a sequence of 700 bp was identified between the first repeat and the upstream open reading frame. Cloning of this sequence in an episome vector enhanced the expression of a tagged snoRNA gene in an orientation-dependent manner. However, continuous transcript spanning of this region was detected in steady-state RNA, suggesting that snoRNA transcription also originates from an upstream-long polycistronic transcriptional unit. The 700-bp fragment may therefore represent an example of many more elements to be discovered that enhance transcription along the chromosome, especially when transcription from the upstream gene is reduced or when enhanced transcription is needed.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Michaeli, Shulamit/AAC-8255-2022; Xu, Yu-Xin/G-4041-2010	Xu, Yu-Xin/0000-0002-0200-4633				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; Brown JWS, 2003, TRENDS PLANT SCI, V8, P42, DOI 10.1016/S1360-1385(02)00007-9; Brown JWS, 2001, RNA, V7, P1817; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; Campbell DA, 2000, PARASITOL TODAY, V16, P78, DOI 10.1016/S0169-4758(99)01545-8; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; Downey N, 1999, MOL BIOCHEM PARASIT, V104, P25, DOI 10.1016/S0166-6851(99)00135-8; Dunbar DA, 2000, NUCLEIC ACIDS RES, V28, P2855, DOI 10.1093/nar/28.15.2855; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Estevez AM, 2001, EMBO J, V20, P3831, DOI 10.1093/emboj/20.14.3831; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lee MGS, 1997, ANNU REV MICROBIOL, V51, P463, DOI 10.1146/annurev.micro.51.1.463; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Liang D, 2002, NUCLEIC ACIDS RES, V30, P3262, DOI 10.1093/nar/gkf426; Liang XH, 2003, P NATL ACAD SCI USA, V100, P7521, DOI 10.1073/pnas.1332001100; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Liang XH, 2001, J BIOL CHEM, V276, P40313, DOI 10.1074/jbc.M104488200; McAndrew M, 1998, EXP PARASITOL, V90, P65, DOI 10.1006/expr.1998.4317; Myler PJ, 2000, BIOCHEM SOC T, V28, P527, DOI 10.1042/bst0280527; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Rozhdestvensky TS, 2003, NUCLEIC ACIDS RES, V31, P869, DOI 10.1093/nar/gkg175; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Terns MP, 2002, GENE EXPRESSION, V10, P17; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VALCARCEL J, 1997, CURR BIOL, V7, P705; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2001, J BIOL CHEM, V276, P14289, DOI 10.1074/jbc.M007007200	49	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5100	5109		10.1074/jbc.M308264200	http://dx.doi.org/10.1074/jbc.M308264200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645367	hybrid			2022-12-25	WOS:000188776500009
J	Lorenz, M; Wessler, S; Follmann, E; Michaelis, W; Dusterhoft, T; Baumann, G; Stangl, K; Stangl, V				Lorenz, M; Wessler, S; Follmann, E; Michaelis, W; Dusterhoft, T; Baumann, G; Stangl, K; Stangl, V			A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT THORACIC AORTA; HEART-DISEASE; PHOSPHORYLATION; CONSUMPTION; FLAVONOIDS; CATECHINS; HEALTH; MECHANISMS; MORTALITY; DRINKING	Epidemiological studies suggest that tea catechins may reduce the risk of cardiovascular disease, but the mechanisms of benefit have not been determined. The objective of the present study was to investigate the effects of epigallocatechin-3-gallate (EGCG), the major constituent of green tea, on vasorelaxation and on eNOS expression and activity in endothelial cells. EGCG (1-50 muM) induced dose-dependent vasodilation in rat aortic rings. Vasodilation was abolished by pretreatment with N-G-nitro L-arginine methyl ester. In bovine aortic endothelial cells, EGCG increased endothelial nitric oxide (eNOS) activity dose-dependently after 15 min. Treatment with EGCG induced a sustained activation of Akt, ERK1/2, and eNOS Ser(1179) phosphorylation. Inhibition of extracellular signal-regulated kinase (ERK)1/2 had no influence on eNOS activity or Ser(1179) phosphorylation. Simultaneous treatment of cells with selective inhibitors for cAMP-dependent protein kinase (PKA) and Akt completely prevented the increase in eNOS activity by EGCG after 15 min, indicating that both kinases act in concert. Specific phosphatidylinositol-3-OH-kinase inhibitors yielded identical results. Akt inhibition prevented eNOS Ser(1179) phosphorylation, whereas inhibition of PKA did not influence Akt and eNOS Ser(1179) phosphorylation. Pretreatment of endothelial cells with EGCG for 4 h markedly enhanced the increase in eNOS activity stimulated by Ca-ionomycin, suggesting that Akt accounts for prolonged eNOS activation. Treatment of cells for 72 h with EGCG did not change eNOS protein levels. Our results indicate that EGCG-induced endothelium-dependent vasodilation is primarily based on rapid activation of eNOS by a phosphatidylinositol 3-kinase-, PKA-, and Akt-dependent increase in eNOS activity, independently of an altered eNOS protein content.	Humboldt Univ, Charite, Med Klin Schwerpunkt Kardiol Angiol Pneumol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stangl, V (corresponding author), Humboldt Univ, Charite, Med Klin Schwerpunkt Kardiol Angiol Pneumol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	verena.stangl@charite.de	Wessler, Silja/C-6309-2015	Wessler, Silja/0000-0001-7011-6162; Lorenz, Mario/0000-0001-5267-4101				Andriambeloson E, 1998, J NUTR, V128, P2324, DOI 10.1093/jn/128.12.2324; Arts ICW, 2001, AM J CLIN NUTR, V74, P227; Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Geleijnse JM, 1999, ARCH INTERN MED, V159, P2170, DOI 10.1001/archinte.159.18.2170; Hong J, 2002, CANCER RES, V62, P7241; Huang Y, 1999, BBA-GEN SUBJECTS, V1427, P322, DOI 10.1016/S0304-4165(99)00034-3; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kris-Etherton PM, 2002, CURR OPIN LIPIDOL, V13, P41, DOI 10.1097/00041433-200202000-00007; Landsverk HB, 2001, J CELL SCI, V114, P3255; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Mukamal KJ, 2002, CIRCULATION, V105, P2476, DOI 10.1161/01.CIR.0000017201.88994.F7; Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; Sanae F, 2002, LIFE SCI, V71, P2553, DOI 10.1016/S0024-3205(02)02080-5; Shen JZ, 2003, CLIN EXP PHARMACOL P, V30, P88, DOI 10.1046/j.1440-1681.2003.03796.x; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Umegaki K, 2001, J NUTR SCI VITAMINOL, V47, P402, DOI 10.3177/jnsv.47.402; Vinson JA, 1998, FEBS LETT, V433, P44, DOI 10.1016/S0014-5793(98)00880-1; Woodward M, 1999, J EPIDEMIOL COMMUN H, V53, P481, DOI 10.1136/jech.53.8.481; Yang CS, 1998, CANCER EPIDEM BIOMAR, V7, P351	25	273	295	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6190	6195		10.1074/jbc.M309114200	http://dx.doi.org/10.1074/jbc.M309114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645258	hybrid			2022-12-25	WOS:000188776500135
J	Wang, X; Zhou, YS; Kim, HP; Song, RP; Zarnegar, R; Ryter, SW; Choi, AMK				Wang, X; Zhou, YS; Kim, HP; Song, RP; Zarnegar, R; Ryter, SW; Choi, AMK			Hepatocyte growth factor protects against hypoxia/reoxygenation-induced apoptosis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYTOCHROME-C; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; ISCHEMIA-REPERFUSION; BAX TRANSLOCATION; DEATH; EXPRESSION; SURVIVAL; HYPOXIA; MITOGEN	Hypoxia/reoxygenation causes cellular injury and death associated with a number of pathophysiological conditions, including myocardial ischemia/reperfusion injury and stroke. The cell death pathways induced by hypoxia/reoxygenation and their underlying regulatory mechanisms remain poorly understood. Recent studies have shown that hypoxia/reoxygenation can induce Bax translocation and cytochrome c release. Using murine lung endothelial cells as a model, we found that the induction of apoptosis by hypoxia/reoxygenation involved the activation of both Bax-dependent and death receptor-mediated pathways. We demonstrated the activation of the death-inducing signal complex and Bid pathway after hypoxia/reoxygenation. Hepatocyte growth factor markedly inhibited hypoxia/reoxygenation-induced endothelial cell apoptosis. The cytoprotection afforded by hepatocyte growth factor was mediated in part by the stimulation of FLICE-like inhibiting protein expression, the attenuation of death-inducing signal complex formation, and the inhibition of Bid and Bax activation. Hepatocyte growth factor also prevented cell injury and death by increasing the expression of the antiapoptotic Bcl-X-L protein. The inhibition of Bid/Bax-induced cell death by hepatocyte growth factor primarily involved p38 MAPK and in part Akt-dependent pathways but not ERK1/ERK2.	Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Ctr Biotechnol & Bioengn, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, AMK (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, 3459 5th Ave,MUH NW628, Pittsburgh, PA 15213 USA.	choiam@msx.upmc.edu			NHLBI NIH HHS [R01-HL60234, R01-HL55330] Funding Source: Medline; NIAID NIH HHS [R01-AI42365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cartwright JE, 2002, EXP CELL RES, V279, P219, DOI 10.1006/excr.2002.5616; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Haddad JJE, 2000, BIOCHEM BIOPH RES CO, V271, P257, DOI 10.1006/bbrc.2000.2607; HANSEN TN, 1985, J APPL PHYSIOL, V58, P812, DOI 10.1152/jappl.1985.58.3.812; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeremias I, 2000, CIRCULATION, V102, P915; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; Ma H, 2002, ATHEROSCLEROSIS, V164, P79, DOI 10.1016/S0021-9150(02)00062-X; Mason RJ, 1996, AM J PHYSIOL-LUNG C, V271, pL46, DOI 10.1152/ajplung.1996.271.1.L46; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Nakagami H, 2002, DIABETES, V51, P2604, DOI 10.2337/diabetes.51.8.2604; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SUNNERGREN KP, 1987, AM J PHYSIOL, V252, pH1211, DOI 10.1152/ajpheart.1987.252.6.H1211; Tang ZL, 2002, MOL CELL BIOCHEM, V234, P211, DOI 10.1023/A:1015930927407; Vasir B, 2000, DIABETOLOGIA, V43, P763, DOI 10.1007/s001250051374; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yamada T, 2000, AM J RESP CRIT CARE, V162, P707, DOI 10.1164/ajrccm.162.2.9908064; Yamamoto K, 2001, HYPERTENSION, V37, P1341, DOI 10.1161/01.HYP.37.5.1341; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200	34	65	82	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5237	5243		10.1074/jbc.M309271200	http://dx.doi.org/10.1074/jbc.M309271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625309	hybrid			2022-12-25	WOS:000188776500025
J	Wiechens, N; Heinle, K; Englmeier, L; Schohl, A; Fagotto, F				Wiechens, N; Heinle, K; Englmeier, L; Schohl, A; Fagotto, F			Nucleo-cytoplasmic shuttling of axin, a negative regulator of the Wnt-beta-catenin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN PHOSPHATASE 2A; APC TUMOR-SUPPRESSOR; NUCLEAR EXPORT; SIGNALING PATHWAY; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; DOWN-REGULATION; GENE-PRODUCT; DOMAINS	Axin is a negative regulator of the Wnt pathway essential for down-regulation of beta-catenin. Axin has been considered so far as a cytoplasmic protein. Here we show that, although cytoplasmic at steady state, Axin shuttles in fact in and out of the nucleus; Axin accumulates in the nucleus of cells treated with leptomycin B, a specific inhibitor of the CRM1-mediated nuclear export pathway and is efficiently exported from Xenopus oocyte nuclei in a RanGTP- and CRM1-dependent manner. We have characterized the sequence requirement for export and identified two export domains, which do not contain classical nuclear export consensus sequences, and we show that Axin binds directly to the export factor CRM1 in the presence of RanGTP.	Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; European Mol Biol Lab, D-69117 Heidelberg, Germany	Max Planck Society; McGill University; European Molecular Biology Laboratory (EMBL)	Fagotto, F (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.	francois.fagotto@mcgill.ca	Fagotto, Francois/AAA-9983-2021; Englmeier, Ludwig/AAU-8430-2020	Fagotto, Francois/0000-0002-1495-2112; 				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Englmeier L, 2001, EMBO REP, V2, P926, DOI 10.1093/embo-reports/kve200; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Julius MA, 2000, BIOCHEM BIOPH RES CO, V276, P1162, DOI 10.1006/bbrc.2000.3607; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	42	71	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5263	5267		10.1074/jbc.M307253200	http://dx.doi.org/10.1074/jbc.M307253200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630927	hybrid			2022-12-25	WOS:000188776500029
J	Kamatchi, GL; Franke, R; Lynch, C; Sando, JJ				Kamatchi, GL; Franke, R; Lynch, C; Sando, JJ			Identification of sites responsible for potentiation of type 2.3 calcium currents by acetyl-beta-methylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CA2+ CHANNELS; N-TYPE; XENOPUS-OOCYTES; SYNAPTIC-TRANSMISSION; VOLATILE ANESTHETICS; ALPHA(1C) SUBUNIT; MODULATION; PHOSPHORYLATION; RECEPTORS	To address mechanisms for the differential sensitivity of voltage-gated Ca2+ channels (Ca-v) to agonists, channel activity was compared in Xenopus oocytes coexpressing muscarinic M-1 receptors and different Ca-v alpha1 subunits, all with beta1B,alpha2/delta subunits. Acetyl-beta-methylcholine (MCh) decreased Ca-v 1.2c currents, did not affect 2.1 or 2.2 currents, but potentiated Ca-v 2.3 currents. Phorbol 12-myristate 13-acetate (PMA) did not affect Ca-v 1.2c or 2.1 currents but potentiated 2.2 and 2.3 currents. Comparison of the amino acid sequences of the alpha(1) subunits revealed a set of potential protein kinase C phosphorylation sites in common between the 2.2 and 2.3 channels that respond to PMA and a set of potential sites unique to the alpha(1) 2.3 subunits that respond to MCh. Quadruple Ser ---> Ala mutation of the predicted MCh sites in the alpha(1) 2.3 subunit (Ser-888, Ser-892, and Ser-894 in the II-III linker and Ser-1987 in the C terminus) caused loss of the MCh response but not the PMA response. Triple Ser --> Ala mutation of just the II-III linker sites gave similar results. Ser-888 or Ser-892 was sufficient for the MCh responsiveness, whereas Ser-894 required the presence of Ser-1987. Ser --> Asp substitution of Ser-888, Ser-892, Ser-1987, and Ser-892/Ser-1987 increased the basal current and decreased the MCh response but did not alter the PMA response. These results reveal that sites unique to the II-III linker of alpha(1) 2.3 subunits mediate the responsiveness of Ca-v 2.3 channels to MCh. Because Ca-v 2.3 channels contribute to action potential-induced Ca2+ influx, these sites may account for M-1 receptor-mediated regulation of neurotransmission at some synapses.	Univ Virginia Hlth Sci Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia	Kamatchi, GL (corresponding author), Univ Virginia Hlth Sci Syst, Dept Anesthesiol, POB 800710,1766 Lane Rd, Charlottesville, VA 22908 USA.	gk3p@virginia.edu			NIGMS NIH HHS [GM31184, GM65214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065214, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Jones SW, 1998, J BIOENERG BIOMEMBR, V30, P299, DOI 10.1023/A:1021977304001; Kamatchi GL, 2000, J PHARMACOL EXP THER, V293, P360; Kamatchi GL, 2003, BRAIN RES, V968, P227, DOI 10.1016/S0006-8993(03)02245-5; Kamatchi GL, 2001, J PHARMACOL EXP THER, V297, P981; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; Melliti K, 2000, J NEUROSCI, V20, P7167; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Vinton BB, 1998, BIOCHEM J, V330, P1433, DOI 10.1042/bj3301433; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wu LG, 1998, P NATL ACAD SCI USA, V95, P4720, DOI 10.1073/pnas.95.8.4720; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	24	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4102	4109		10.1074/jbc.M308606200	http://dx.doi.org/10.1074/jbc.M308606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625305	hybrid			2022-12-25	WOS:000188554300024
J	Jiang, K; Delarue, FL; Sebti, SM				Jiang, K; Delarue, FL; Sebti, SM			EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation	ONCOGENE			English	Article						RhoB; Ras; EGFR; ErbB2; transformation; apoptosis	EPIDERMAL-GROWTH-FACTOR; GTP-BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLATED RHOB; CELL-GROWTH; GTPASES; FAMILY; KINASE; ONCOPROTEIN; PHENOTYPE	While some low molecular weight GTPases such as Ras and RhoA contribute to malignant transformation, a closely related family member, RhoB, has tumor-suppressive activity, but little is known about its regulation by oncogenes. In this study, we show that H-Ras, N-Ras, K-Ras, EGFR and ErbB2 but not v-Src suppress RhoB promoter transcriptional activity in NIH3T3 cells and human cancer cell lines derived from lung (A-549), pancreatic (Panc-1) and cervical (C33A) tumors. The EGFR and ErbB2 suppression of RhoB promoter activity is mediated by Ras. Furthermore, Ras suppresses basal as well as 5-fluorouracil (5-FU)-induced RhoB promoter activity and RhoB protein levels. Ectopic expression of RhoB, but not the closely related family member RhoA, antagonizes the ability of EGFR, ErbB2, H-Ras, N-Ras and K-Ras but not v-Src to transform NIH3T3 cells. Furthermore, RhoB, but not RhoA, inhibits colony formation and proliferation and induces anoikis in A-549 cells and Ras-transformed NIH3T3 cells. Finally, Ras-mediated resistance to 5-FU-induced apoptosis is reversed by RhoB. These results demonstrate that RhoB expression is negatively regulated by oncogenes that are prevalent in human cancers, and that ectopic expression of RhoB antagonizes the ability of these oncogenes to induce transformation. Taken together the data suggest that certain oncogenes suppress RhoB as one of the critical steps leading to malignant transformation.	Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Sebti@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 2002, CLIN CANCER RES, V8, P2225; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, MOL CELL BIOL, V19, P1831; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VAN AL, 1997, GENE DEV, V11, P2295; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	25	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1136	1145		10.1038/sj.onc.1207236	http://dx.doi.org/10.1038/sj.onc.1207236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647415				2022-12-25	WOS:000188749900012
J	Daniel, JA; Torok, MS; Sun, ZW; Schieltz, D; Allis, CD; Yates, JR; Grant, PA				Daniel, JA; Torok, MS; Sun, ZW; Schieltz, D; Allis, CD; Yates, JR; Grant, PA			Deubiquitination of histone H2B by a yeast acetyltransferase complex regulates transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SACCHAROMYCES-CEREVISIAE; SAGA COMPLEX; FUNCTIONAL-ORGANIZATION; NUCLEOSOME ACETYLATION; BINDING PROTEIN; COMPONENTS; UBIQUITINATION; IDENTIFICATION; COACTIVATOR	Post-translational modifications of the histone protein components of eukaryotic chromatin play an important role in the regulation of chromatin structure and gene expression ( 1). Given the requirement of Rad6/Bre1-dependent ubiquitination of histone H2B for H3 dimethylation (at lysines 4 and 79) and gene silencing (2 - 7), removal of ubiquitin from H2B may have a significant regulatory effect on transcription. Here we show that a putative deubiquitinating enzyme, Ubp8, is a structurally nonessential component of both the Spt-Ada-Gcn5-acetyltransferase ( SAGA) and SAGA-like (SLIK) histone acetyltransferase ( HAT) complexes in yeast. Disruption of this gene dramatically increases the cellular level of ubiquitinated-H2B, and SAGA and SLIK are shown to have H2B deubiquitinase activity. These findings demonstrate, for the first time, how the ubiquitin moiety can be removed from histone H2B in a regulated fashion. Ubp8 is required for full expression of the SAGA- and SLIK-dependent gene GAL10 and is recruited to the upstream activation sequence (UAS) of this gene under activating conditions, while Rad6 dissociates. Furthermore, trimethylation of H3 at lysine 4 within the UAS increases significantly under activating conditions, and remarkably, Ubp8 is shown to have a role in regulating the methylation status of this residue. Collectively, these data suggest that the SAGA and SLIK HAT complexes can regulate an integrated set of multiple histone modifications, counteracting repressive effects that alter chromatin and regulate gene expression.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Diversa Corp, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Virginia; Scripps Research Institute	Grant, PA (corresponding author), Univ Virginia Hlth Syst, Box 800733, Charlottesville, VA 22908 USA.	pag9n@virginia.edu	Daniel, Jeremy/S-4729-2016	Daniel, Jeremy/0000-0002-1981-5571	NCRR NIH HHS [RR 11823-03] Funding Source: Medline; NIDDK NIH HHS [DK 58646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grant PA, 2001, GENOME BIOL, V2; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kao CF, 2003, METHODS, V31, P59, DOI 10.1016/S1046-2023(03)00088-4; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002	33	220	227	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1867	1871		10.1074/jbc.C300494200	http://dx.doi.org/10.1074/jbc.C300494200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14660634	hybrid			2022-12-25	WOS:000188005700038
J	Ader, I; Delmas, C; Bonnet, J; Rochaix, P; Favre, G; Toulas, C; Cohen-Jonathan-Moyal, E				Ader, I; Delmas, C; Bonnet, J; Rochaix, P; Favre, G; Toulas, C; Cohen-Jonathan-Moyal, E			Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts	ONCOGENE			English	Article						Rho; glioma; hypoxia; MMP; angiogenesis	FARNESYLTRANSFERASE INHIBITOR; H-RAS; TUMOR-GROWTH; CELL-LINES; NUDE-MICE; IN-VIVO; TRANSGENIC MICE; HELA-CELLS; ANGIOGENESIS; REGRESSION	We previously demonstrated in vitro that inhibiting the biological pathways of the small GTPase Rho radio-sensitizes the human glioma U87 cell line. The aim of this study was to determine if Rho might be involved in the control of in vivo radiosensitivity altogether by controlling cellular radioresistance and by modifying tumor micro-environment. We demonstrate here that the in vivo induction of the dominant negative of Rho, RhoBN19, in U87 xenografts induces a significant decrease of tumor cell survival after irradiation more important than the one we previously observed in vitro. This in vivo increased effect of RhoBN19 expression is due to the improvement of the tumor oxygenation associated with a significant decrease of the vessel density and of the metalloproteinase 2 (MMP2) expression. Moreover, in vitro RhoBN19 expression in U87 cells leads to the inhibition of MMP2 activity. Our results demonstrate for the first time that inhibiting Rho pathways modifies the in vivo radiosensitivity of human glioma cells by controlling intrinsic radioresistance, hypoxia and angiogenesis. These data strongly suggest that Rho should be a major determinant of cellular resistance to ionizing radiation.	Inst Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France; Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; Inst Claudius Regaud, Anat Pathol Lab, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Cohen-Jonathan-Moyal, E (corresponding author), Inst Claudius Regaud, Dept Radiotherapie, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Moyal, Elizabeth/A-9802-2015; Rochaix, Philippe/O-4710-2014; delmas, caroline/O-9241-2014; Toulas, Christine/P-3838-2014; Ader-Perarnau, Isabelle/F-7160-2017; FAVRE, Gilles/K-9189-2014	Moyal, Elizabeth/0000-0002-6593-9276; Rochaix, Philippe/0000-0001-6238-1599; Toulas, Christine/0000-0003-1261-1725; FAVRE, Gilles/0000-0002-2344-1883; ADER, isabelle/0000-0001-5103-8509				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Ader I, 2002, ONCOGENE, V21, P5998, DOI 10.1038/sj.onc.1205746; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bernsen HJJA, 1999, J NEURO-ONCOL, V44, P129, DOI 10.1023/A:1006363215260; Bernsen HJJA, 1998, J NEURO-ONCOL, V38, P51, DOI 10.1023/A:1005957201431; Brizel DM, 1996, CANCER RES, V56, P941; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Cohen-Jonathan E, 1999, RADIAT RES, V152, P404, DOI 10.2307/3580225; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; Cohen-Jonathan E, 2001, CANCER RES, V61, P2289; Deb S, 1999, J NEUROSCI RES, V55, P44, DOI 10.1002/(SICI)1097-4547(19990101)55:1<44::AID-JNR6>3.0.CO;2-G; Delmas C, 2002, INT J CANCER, V100, P43, DOI 10.1002/ijc.10439; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Fenton BM, 1999, BRIT J CANCER, V79, P464, DOI 10.1038/sj.bjc.6690072; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; HOCKEL M, 1994, ADV EXP MED BIOL, V345, P445; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Itoh T, 1998, CANCER RES, V58, P1048; Kakeji Y, 1997, INVEST NEW DRUG, V15, P39, DOI 10.1023/A:1005718628223; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Koike T, 2000, BIOCHEM BIOPH RES CO, V277, P43, DOI 10.1006/bbrc.2000.3630; Kunkel P, 2001, CANCER RES, V61, P6624; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; Nozue M, 1997, J SURG ONCOL, V66, P30, DOI 10.1002/(SICI)1096-9098(199709)66:1<30::AID-JSO7>3.0.CO;2-O; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; SUN JZ, 1995, CANCER RES, V55, P4243; TEICHER BA, 1995, INT J CANCER, V61, P732, DOI 10.1002/ijc.2910610523; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Uchida S, 2000, BIOCHEM BIOPH RES CO, V269, P633, DOI 10.1006/bbrc.2000.2315; VAN AL, 1997, GENE DEV, V11, P2295; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wolff JEA, 1997, KLIN PADIATR, V209, P275, DOI 10.1055/s-2008-1043962; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	41	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8861	8869		10.1038/sj.onc.1207095	http://dx.doi.org/10.1038/sj.onc.1207095			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654782				2022-12-25	WOS:000186982200007
J	Iha, H; Kibler, KV; Yedavalli, VRK; Peloponese, JM; Haller, K; Miyazato, A; Kasai, T; Jeang, KT				Iha, H; Kibler, KV; Yedavalli, VRK; Peloponese, JM; Haller, K; Miyazato, A; Kasai, T; Jeang, KT			Segregation of NF-kappa B activation through NEMO/IKK gamma by Tax and TNF alpha: implications for stimulus-specific interruption of oncogenic signaling	ONCOGENE			English	Article						Tax; HTLV-I; adult T-cell leukemia; NEMO/IKK gamma; TNF alpha; NF-kappa B; oncogenic transformation	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; SEVERE LIVER DEGENERATION; IKK-GAMMA; KINASE COMPLEX; DEFICIENT MICE; INCONTINENTIA PIGMENTI; MEDIATED ACTIVATION; SPINDLE CHECKPOINT; REGULATORY SUBUNIT	Nuclear factor-kappaB essential modulator (NEMO), also called IKKgamma, has been proposed as a 'universal' adaptor of the I-kappaB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-kappaB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-kappaB inhibition profiles segregating TNFalpha from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFalpha, IL-1beta, or Tax activation of NF-kappaB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-kappaB activation, but did not serve TNFalpha- or IL-1beta signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-kappaB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.	NIAID, Mol Microbiol Lab, Mol Virol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008	Peloponese, Jean-Marie/0000-0002-9677-9703; Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Bai JR, 2003, J BIOL CHEM, V278, P1433, DOI 10.1074/jbc.M208297200; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Iha H, 2000, AIDS RES HUM RETROV, V16, P1633, DOI 10.1089/08892220050193074; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; MORI N, 1994, BLOOD, V84, P2904; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Ranson M, 2002, ONCOLOGY-BASEL, V63, P17, DOI 10.1159/000066203; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTHWARF DM, 1999, SCI STKE, V26, pRE1; Rudolph D, 2000, GENE DEV, V14, P854; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	67	57	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8912	8923		10.1038/sj.onc.1207058	http://dx.doi.org/10.1038/sj.onc.1207058			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654787	Bronze			2022-12-25	WOS:000186982200012
J	Schild, L; Reinheckel, T; Reiser, M; Horn, TFW; Wolf, G; Augustin, W				Schild, L; Reinheckel, T; Reiser, M; Horn, TFW; Wolf, G; Augustin, W			Nitric oxide produced in rat liver mitochondria causes oxidative stress and impairment of respiration after transient hypoxia	FASEB JOURNAL			English	Article						oxidative phosphorylation; protein carbonyls; glutathione	CYTOCHROME-C RELEASE; SYNTHASE; OXYGEN; PROTEIN; PEROXYNITRITE; SUPEROXIDE; ISCHEMIA; INJURY; HYPOXIA/REOXYGENATION; REOXYGENATION	Nitric oxide (NO) is produced in mammals by different isoforms of NO synthase (NOS), including the constitutive mitochondrial enzyme (mtNOS). Here we demonstrate that the concentration of NO resulting from a mitochondrial NOS activity increases under hypoxic conditions in isolated rat liver mitochondria. We show that mitochondrially derived NO mediates the impairment of active (state 3) respiration as measured in the presence of the substrates glutamate and malate after reoxygenation. Simultaneously, NO induces oxidative stress in mitochondria, characterized by an increase in the amount of protein carbonyls and a decrease in glutathione (GSH). Both the accumulation of oxidative stress markers during and the impaired respiration after reoxygenation were prevented by blocking NO production with the NOS inhibitor L-NAME. These observations suggest that mitochondria are exposed to high amounts of NO generated by a mitochondrial NOS upon hypoxia/reoxygenation. Such increased NO levels, in turn, inhibit mitochondrial respiration and may cause oxidative stress that leads to irreversible impairment of mitochondria.	Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Med Neurobiol, Fac Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	lorenz.schild@medizin.uni-magdeburg.de	Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105				AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Alonso D, 2002, NEUROSCIENCE, V111, P47, DOI 10.1016/S0306-4522(01)00571-1; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Barker JE, 2001, J PATHOL, V194, P109, DOI 10.1002/path.845; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; Bauer G, 2000, ANTICANCER RES, V20, P4115; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bolanos JP, 1998, BRAIN RES, V787, P117, DOI 10.1016/S0006-8993(97)01530-8; Boveris A, 1999, METHOD ENZYMOL, V301, P188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Grattagliano I, 1999, J SURG RES, V86, P2, DOI 10.1006/jsre.1999.5620; Henrich M, 2002, MOL CELL NEUROSCI, V20, P307, DOI 10.1006/mcne.2002.1111; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; Ikemoto H, 2000, CELL DEATH DIFFER, V7, P511, DOI 10.1038/sj.cdd.4400682; Jaeschke Hartmut, 2002, Hepatology, V36, P243; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Madesh M, 2000, BBA-MOL BASIS DIS, V1500, P204, DOI 10.1016/S0925-4439(99)00107-6; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; MCCORMACK JG, 1989, METHOD ENZYMOL, V174, P95; Ockaili R, 1999, AM J PHYSIOL-HEART C, V277, pH2425, DOI 10.1152/ajpheart.1999.277.6.H2425; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; POU S, 1995, BBA-GEN SUBJECTS, V1244, P62, DOI 10.1016/0304-4165(94)00197-6; Rakhit RD, 2001, CIRCULATION, V103, P2617; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V376, P59, DOI 10.1006/abbi.1999.1680; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schild L, 1997, BIOCHEM J, V328, P205, DOI 10.1042/bj3280205; Schild L, 1997, BIOCHEM MOL BIOL INT, V43, P35; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; TOVEY ER, 1987, J BIOCHEM BIOPH METH, V14, P1, DOI 10.1016/0165-022X(87)90002-9; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Wu B, 2002, FREE RADICAL BIO MED, V33, P649, DOI 10.1016/S0891-5849(02)00917-6; Xie YW, 1996, CIRCULATION, V94, P2580, DOI 10.1161/01.CIR.94.10.2580; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	50	61	63	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2194	2201		10.1096/fj.02-1170com	http://dx.doi.org/10.1096/fj.02-1170com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656981				2022-12-25	WOS:000188067500040
J	Sugioka, R; Shimizu, S; Funatsu, T; Tamagawa, H; Sawa, Y; Kawakami, T; Tsujimoto, Y				Sugioka, R; Shimizu, S; Funatsu, T; Tamagawa, H; Sawa, Y; Kawakami, T; Tsujimoto, Y			BH4-domain peptide from Bcl-x(L) exerts anti-apoptotic activity in vivo	ONCOGENE			English	Article						Bcl-x(L); BH4 domain; apoptosis; mitochondria; TAT	DEPENDENT ANION CHANNEL; BCL-2 PROTEIN FAMILY; CYTOCHROME-C; CELL-DEATH; BH4 DOMAIN; CASPASE ACTIVATION; GENE TRANSFECTION; CONSERVED DOMAINS; BAX; MITOCHONDRIA	The Bcl-2 family of proteins regulates apoptosis chiefly by controlling mitochondrial membrane permeability. It has previously been shown that the BH4 domain of Bcl-2/Bcl-x(L) is essential for the prevention of apoptotic mitochondrial changes, including the release of cytochrome c and apoptotic cell death. We have previously reported that BH4 peptide fused to the protein transduction domain of HIV-1 TAT protein (TAT-BH4) significantly inhibits etoposide-induced apoptosis in a cell line. This time, we investigated whether TAT-BH4 peptide was cytoprotective in ex vivo and in vivo rodent models. Intraperitoneal injection of TAT-BH4 peptide greatly inhibited X-ray-induced apoptosis in the small intestine of mice and partially suppressed Fas-induced fulminant hepatitis. In addition, this peptide markedly suppressed heart failure after ischemia-reperfusion injury in isolated rat heart, probably by preventing mitochondrial dysfunction. These findings demonstrate that TAT-BH4 peptide exerts antiapoptotic activity both in vivo and ex vivo, and imply that it may be a useful therapeutic agent for diseases involving mitochondrial dysfunction and apoptosis.	Osaka Univ, Lab Prot Architecton, Res Ctr Struct Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, SORST, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Mol Genet Lab, Dept Postgenomics & Dis, 2-2 Yamadaoka,Room B8, Suita, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Hockenbery D M, 1992, Semin Immunol, V4, P413; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SHIMIZU S, 1994, TRANSPLANTATION, V57, P144, DOI 10.1097/00007890-199401000-00022; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; SOLEM LE, 1993, TOXICOL APPL PHARM, V121, P50, DOI 10.1006/taap.1993.1128; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2000, GENE DEV, V14, P2060; Yamabe K, 1998, BIOCHEM BIOPH RES CO, V243, P217, DOI 10.1006/bbrc.1997.7925; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	41	85	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8432	8440		10.1038/sj.onc.1207180	http://dx.doi.org/10.1038/sj.onc.1207180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627984				2022-12-25	WOS:000186650300007
J	Berndt, C; Lillig, CH; Wollenberg, M; Bill, E; Mansilla, MC; de Mendoza, D; Seidler, A; Schwenn, JD				Berndt, C; Lillig, CH; Wollenberg, M; Bill, E; Mansilla, MC; de Mendoza, D; Seidler, A; Schwenn, JD			Characterization and reconstitution of a 4Fe-4S adenylyl sulfate/phosphoadenylyl sulfate reductase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE REDUCTASE; IRON-SULFUR PROTEINS; ESCHERICHIA-COLI; PAPS-REDUCTASE; 3'-PHOSPHOADENYLYLSULFATE REDUCTASE; CYSTEINE BIOSYNTHESIS; CLUSTER; THIOREDOXIN; FAMILY; SULFOTRANSFERASE	CysH1 from Bacillus subtilis encodes a 3'-phospho/ adenosine-phosphosulfate-sulfonucleotide reductase (SNR) of 27 kDa. Recombinant B. subtilis SNR is a homodimer, which is bispecific and reduces adenylylsulfate (APS) and 3'-phosphoadenylylsulfate ( PAPS) alike with thioredoxin 1 or with glutaredoxin 1 as reductants. The enzyme has a higher affinity for PAPS (K(m)PAPS 6.4 muM Trx-saturating, 10.7 muM Grx-saturating) than for APS (K-m APS 28.7 muM Trx-saturating, 105 muM Grx-saturating) at a V-max ranging from 280 to 780 nmol sulfite mg(-1) min(-1). The catalytic efficiency with PAPS as substrate is higher by a factor of 10 (K-cat/K-m 2.7 x 10(4)- 3.6 x 10(4) liter mol(-1) s(.)(-1) B. subtilis SNR contains one 4Fe-4S cluster per polypeptide chain. SNR activity and color were lost rapidly upon exposure to air or upon dilution. Mossbauer and absorption spectroscopy revealed that the enzyme contained a 4Fe-4S cluster when isolated, but degradation of the 4Fe-4S cluster produced an inactive intermediate with spectral properties of a 2Fe-2S cluster. Activity and spectral properties of the 4Fe-4S cluster were restored by preincubation of SNR with the iron-sulfur cluster-assembling proteins IscA1 and IscS. Reconstitution of the 4Fe-4S cluster of SNR did not affect the reductive capacity for PAPS or APS. The interconversion of the clusters is thought to serve as oxygen-sensitive switch that suppresses SO3 formation under aerobiosis.	Ruhr Univ Bochum, Fak Biol, Lehrstuhl Biochem Pflanzen, D-44780 Bochum, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, Stockholm, Sweden; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbil, RA-2000 Rosario, Santa Fe, Argentina; Inst Mol & Cellular Biol, Rosario, Santa Fe, Argentina; Max Planck Inst Bioorgan Chem, Mulheim, Germany	Ruhr University Bochum; Karolinska Institutet; National University of Rosario; Max Planck Society	Schwenn, JD (corresponding author), Ruhr Univ Bochum, Fak Biol, Lehrstuhl Biochem Pflanzen, ND2-149,Postfach 102148, D-44780 Bochum, Germany.	jens.schwenn@ruhr-uni-bochum.de	Mansilla, María/R-8500-2019; Lillig, Christopher Horst/AAD-7098-2019; Berndt, Carsten/X-6260-2018	Mansilla, María/0000-0002-1444-8661; Lillig, Christopher Horst/0000-0003-2509-5117; Berndt, Carsten/0000-0001-8583-7966				Abola AP, 1999, J BACTERIOL, V181, P5280, DOI 10.1128/JB.181.17.5280-5287.1999; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BERENDT U, 1995, EUR J BIOCHEM, V233, P347, DOI 10.1111/j.1432-1033.1995.347_1.x; Bick JA, 2000, J BACTERIOL, V182, P135, DOI 10.1128/JB.182.1.135-142.2000; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; FEE JA, 1984, J BIOL CHEM, V259, P124; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Grundy F, 2002, BACILLUS SUBTILIS IT, DOI [10.1128/9781555817992.ch18, DOI 10.1128/9781555817992.CH18]; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kopriva S, 2002, J BIOL CHEM, V277, P21786, DOI 10.1074/jbc.M202152200; Kopriva S, 2001, J BIOL CHEM, V276, P42881, DOI 10.1074/jbc.M107424200; LILIG CH, 2000, THIOREDOXINS RELATED; Lillig CH, 2003, J BIOL CHEM, V278, P22325, DOI 10.1074/jbc.M302304200; Lillig CH, 2001, ARCH BIOCHEM BIOPHYS, V392, P303, DOI 10.1006/abbi.2001.2453; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Mansilla MC, 1997, J BACTERIOL, V179, P976, DOI 10.1128/jb.179.3.976-981.1997; Prior A, 1999, BBA-PROTEIN STRUCT M, V1430, P25, DOI 10.1016/S0167-4838(98)00266-0; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; SCHRIEK U, 1986, ARCH MICROBIOL, V145, P32, DOI 10.1007/BF00413024; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; Setya A, 1996, P NATL ACAD SCI USA, V93, P13383, DOI 10.1073/pnas.93.23.13383; Suter M, 2000, J BIOL CHEM, V275, P930, DOI 10.1074/jbc.275.2.930; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Williams SJ, 2002, J BIOL CHEM, V277, P32606, DOI 10.1074/jbc.M204613200; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; 1989, CATALOGUE STRAINS ME, P280	33	51	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7850	7855		10.1074/jbc.M309332200	http://dx.doi.org/10.1074/jbc.M309332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14627706	hybrid			2022-12-25	WOS:000189103300061
J	Denis, M; Haidar, B; Marcil, M; Bouvier, M; Krimbou, L; Genest, J				Denis, M; Haidar, B; Marcil, M; Bouvier, M; Krimbou, L; Genest, J			Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE MICROSOLUBILIZATION; REVERSE CHOLESTEROL TRANSPORT; FAMILIAL HDL DEFICIENCY; PRE-BETA; APOA-I; FUNCTIONAL-PROPERTIES; TANGIER-DISEASE; EFFLUX; PARTICLES	The dynamics of ABCA1-mediated apoA-I lipidation were investigated in intact human fibroblasts induced with 22(R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Specific binding parameters of I-125-apoA-I to ABCA1 at 37degreesC were determined: K-d=0.65 mug/ml, B-max=0.10 ng/mug cell protein. Lipid-free apoA-I inhibited the binding of I-125-apoA-I to ABCA1 more efficiently than pre-beta(1)-LpA-I, reconstituted HDL particles r(LpA-I), or HDL3 (IC50=0.35+/-1.14, apoA-I; 1.69+/-1.07, pre-beta(1)-LpA-I; 17.91+/-1.39, r(LpA-I); and 48.15+/-1.72 mug/ml, HDL3). Treatment of intact cells with either phosphatidylcholine-specific phospholipase C or sphingomyelinase affected neither I-125-apoA-I binding nor I-125-apoA-I/ABCA1 cross-linking. We next investigated the dynamics of apoA-I lipidation by monitoring the kinetic of apoA-I dissociation from ABCA1. The dissociation of I-125-apoA-I from normal cells at 37degreesC was rapid (t(1/2)=1.4+/-0.66 h; n=3) but almost completely inhibited at either 15 or 4degreesC. A time course analysis of apoA-I-containing particles released during the dissociation period showed nascent apoA-I-phospholipid complexes that exhibited alpha-electrophoretic mobility with a particle size ranging from 9 to 20 nm (designated alpha-LpA-I-like particles), whereas lipid-free apoA-I incubated with ABCA1 mutant (Q597R) cells was unable to form such particles. These results demonstrate that: 1) the physical interaction of apoA-I with ABCA1 does not depend on membrane phosphatidylcholine or sphingomyelin; 2) the association of apoA-I with lipids reduces its ability to interact with ABCA1; and 3) the lipid translocase activity of ABCA1 generates alpha-LpA-I-like particles. This process plays in vivo a key role in HDL biogenesis.	McGill Univ, Ctr Hlth, Royal Victoria Hosp, Cardiol Div,Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	McGill University; Royal Victoria Hospital; Universite de Montreal	Genest, J (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Cardiol Div,Cardiovasc Genet Lab, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	jacques.genest@muhc.mcgill.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				Asztalos B, 1997, ARTERIOSCL THROM VAS, V17, P1630, DOI 10.1161/01.ATV.17.9.1630; ASZTALOS BF, 1995, ARTERIOSCL THROM VAS, V15, P1419, DOI 10.1161/01.ATV.15.9.1419; BARRANS A, 1994, J BIOL CHEM, V269, P11572; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; BEDOSSA P, 1989, ARCH PATHOL LAB MED, V113, P777; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8959; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FORTE TM, 1993, J LIPID RES, V34, P317; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; HARA H, 1991, J BIOL CHEM, V266, P3080; JONAS A, 1993, J BIOL CHEM, V268, P1596; Kee P, 2002, ARTERIOSCL THROM VAS, V22, P1912, DOI 10.1161/01.ATV.0000038485.94020.7F; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krimbou L, 1998, J LIPID RES, V39, P861; Krimbou L, 2003, J LIPID RES, V44, P884, DOI 10.1194/jlr.M200273-JLR200; Krimbou L, 1998, J LIPID RES, V39, P2373; Krimbou L, 2001, J BIOL CHEM, V276, P33241, DOI 10.1074/jbc.M100326200; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; Lambert G, 1999, J LIPID RES, V40, P1294; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Paradis V, 1996, CELL MOL BIOL, V42, P525; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200	47	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7384	7394		10.1074/jbc.M306963200	http://dx.doi.org/10.1074/jbc.M306963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660648	hybrid			2022-12-25	WOS:000189103300004
J	Park, SY; Chang, I; Kim, JY; Kang, SW; Park, SH; Singh, K; Lee, MS				Park, SY; Chang, I; Kim, JY; Kang, SW; Park, SH; Singh, K; Lee, MS			Resistance of mitochondrial DNA-depleted cells against cell death - Role of mitochondrial superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; COMPLEX-I DEFICIENCY; INDUCED APOPTOSIS; CYTOCHROME-C; OXIDATIVE STRESS; GENE-EXPRESSION; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS	We have shown that mitochondrial DNA-depleted (rho(0)) SK-Hep1 hepatoma cells are resistant to apoptosis, contrary to previous papers reporting normal apoptotic susceptibility of rho(0) cells. We studied the changes of gene expression in SK-Hep1 rho(0) cells. DNA chip analysis showed that MnSOD expression was profoundly increased in rho(0) cells. O-2(radical anion). contents increased during rho(0) cell derivation but became normalized after establishment of rho(0) phenotypes, suggesting that MnSOD induction is an adaptive process to increased O-2(radical anion). rho(0) cells were resistant to menadione, paraquat, or doxorubicin, and O-2(radical anion) contents after treatment with them were lower in rho(0) cells compared with parental cells because of MnSOD overexpression. Expression levels and activity of glutathione peroxidases were also increased in rho(0) cells, rendering them resistant to exogenous H2O2. rho(0) cells were resistant to p53, and intracellular ROS contents after p53 expression were lower compared with parental cells. Other types of rho(0) cells also showed increased MnSOD expression and resistance against ROS. Heme oxygenase-1 expression was increased in rho(0) cells, and a heme oxygenase-1 inhibitor decreased the induction of MnSOD in rho(0) cells and their resistance against ROS donors. These results indicate that rho(0) cells are resistant to cell death contrary to previous reports and suggest that an adaptive increase in the expression of antioxidant enzymes renders cancer cells or aged cells with frequent mitochondrial DNA mutations to resist against oxidative stress, host anti-cancer surveillance, or chemotherapeutic agents, conferring survival advantage on them.	Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea; Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Korea University; Ewha Womans University; Ewha Womans University; Roswell Park Cancer Institute	Lee, MS (corresponding author), Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Dept Med, 50 Irwon Dong Kangnam Ku, Seoul 135710, South Korea.	mslee@smc.samsung.co.kr	Lee, Myung Shik/C-9606-2011	Lee, Myung-Shik/0000-0003-3292-1720	PHS HHS [R01-097714] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APPLEGATE LA, 1991, CANCER RES, V51, P974; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Delsite R, 2002, MOL CANCER, V1, P1; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Hollensworth SB, 2000, FREE RADICAL BIO MED, V28, P1161, DOI 10.1016/S0891-5849(00)00214-8; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Hwang ES, 1998, INT J GYNECOL CANCER, V8, P27; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Izutani R, 1998, J GASTROENTEROL, V33, P816, DOI 10.1007/s005350050181; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Janssen AML, 1998, BRIT J CANCER, V78, P1051, DOI 10.1038/bjc.1998.626; JI LL, 1990, AM J PHYSIOL, V258, P918; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KADIISKA MB, 1993, TOXICOL APPL PHARM, V123, P187, DOI 10.1006/taap.1993.1236; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Li SJ, 2000, CANCER RES, V60, P3927; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; MANGANARO F, 1995, FREE RADICAL BIO MED, V19, P823, DOI 10.1016/0891-5849(95)02008-X; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marchetti P, 1996, CANCER RES, V56, P2033; MATHAI JC, 1994, J BIOL CHEM, V269, P17784; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MIMNAUGH EG, 1981, BIOCHEM PHARMACOL, V30, P2797, DOI 10.1016/0006-2952(81)90417-2; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERLEY LW, 1979, CANCER RES, V39, P1141; Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Suh Y, 2002, NAT MED, V8, P3, DOI 10.1038/nm0102-3; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; THOR H, 1982, J BIOL CHEM, V257, P2419; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wei YH, 2001, ANN NY ACAD SCI, V928, P97; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; YAGI N, 1995, DIABETES, V44, P744, DOI 10.2337/diabetes.44.7.744	58	155	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7512	7520		10.1074/jbc.M307677200	http://dx.doi.org/10.1074/jbc.M307677200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660625	hybrid			2022-12-25	WOS:000189103300019
J	Rousseau, F; Schymkowitz, JWH; Wilkinson, HR; Itzhaki, LS				Rousseau, F; Schymkowitz, JWH; Wilkinson, HR; Itzhaki, LS			Intermediates control domain swapping during folding of p13(suc1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATORY PROTEIN; CRYSTAL-STRUCTURE; TRANSITION-STATE; CONTACT ORDER; P13SUC1; STABILITY; MECHANISM; PATHWAY; RATES	The 13-kDa protein p13(suc1) has two folded states, a monomer and a structurally similar domain-swapped dimer formed by exchange of a beta-strand. The refolding reaction of p13(suc1) is multiphasic, and in this paper we analyze the kinetics as a function of denaturant and protein concentration and compare the behavior of wild type and a set of mutants previously designed with dimerization propensities that span 9 orders of magnitude. We show that the folding reactions of wild type and all mutants produce the monomer predominantly despite their very different equilibrium behavior. However, the addition of low concentrations of denaturant in the refolding buffer leads to thermodynamic control of the folding reaction with products that correspond to the wild type and mutant equilibrium dimerization propensities. We present evidence that the kinetic control in the absence of urea arises because of the population of the folding intermediates. Intermediates are usually considered to be detrimental to folding because they slow down the reaction; however, our work shows that intermediates buffer the monomeric folding pathway against the effect of mutations that favor the nonfunctional, dimeric state at equilibrium.	Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England; Free Univ Brussels VIB, SWITCH Lab, B-1050 Brussels, Belgium	University of Cambridge; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Itzhaki, LS (corresponding author), Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Lensfield Rd, Cambridge CB2 1EW, England.	isi10@cam.ac.uk	Rousseau, Frederic/J-9044-2016; Schymkowitz, Joost/AAV-3680-2021; Schymkowitz, Joost/K-7764-2016	Rousseau, Frederic/0000-0002-9189-7399; Schymkowitz, Joost/0000-0003-2020-0168				Alonso DOV, 2000, STRUCTURE, V8, P101, DOI 10.1016/S0969-2126(00)00083-6; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BOURNE Y, 1995, P NATL ACAD SCI USA, V92, P10232, DOI 10.1073/pnas.92.22.10232; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P1525, DOI 10.1073/pnas.97.4.1525; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; Khazanovich N, 1996, STRUCTURE, V4, P299, DOI 10.1016/S0969-2126(96)00034-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9; O'Neill JW, 2001, STRUCTURE, V9, P1017, DOI 10.1016/S0969-2126(01)00667-0; Oliveberg M, 2001, CURR OPIN STRUC BIOL, V11, P94, DOI 10.1016/S0959-440X(00)00171-8; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Rousseau F, 2002, STRUCTURE, V10, P649, DOI 10.1016/S0969-2126(02)00762-1; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Schymkowitz JWH, 2000, J MOL BIOL, V301, P199, DOI 10.1006/jmbi.2000.3958; Schymkowitz JWH, 2000, STRUCTURE, V8, P89, DOI 10.1016/S0969-2126(00)00084-8; Silow M, 1999, BIOCHEMISTRY-US, V38, P13006, DOI 10.1021/bi9909997; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p	28	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8368	8377		10.1074/jbc.M310640200	http://dx.doi.org/10.1074/jbc.M310640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662764	hybrid			2022-12-25	WOS:000189103300119
J	Samanta, AK; Huang, HJ; Bast, RC; Liao, WSL				Samanta, AK; Huang, HJ; Bast, RC; Liao, WSL			Overexpression of MEKK3 confers resistance to apoptosis through activation of NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MAP KINASE; PROSTATE-CANCER; UP-REGULATION; PROTEIN; CELLS; TARGET; ERK; EXPRESSION; RECEPTOR	Many cancers have constitutively activated NFkappaB, the elevation of which contributes to cancer cell resistance to chemotherapeutic agent-induced apoptosis. Although mitogen-activated protein kinase/extracellular-regulated kinase kinase kinase-3 (MEKK3) has been shown to participate in the activation of NFkappaB, its relations to apoptosis and cancer are unclear. In this study, we established cell model systems to examine whether stable expression of MEKK3 could lead to increased NFkappaB activity and confer resistance to apoptosis. In addition, we investigated in breast and ovarian cancers whether MEKK3 expression may be altered and correlated with aberrant NFkappaB activity. We show that stable cell lines overexpressing MEKK3 not only had elevated levels of NFkappaB binding activity but also were more responsive to cytokine stimulation. These stable cells showed 2-4-fold higher basal expression of Bcl-2 and xIAP than the parental cells. Consistent with this increased expression of cell survival genes, MEKK3 stable cells showed reduced activation of caspases 3 and 8 and poly(ADPribose) polymerase cleavage and dramatically increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, doxorubicin, daunorubicin, camptothecin, and paclitaxel. Intriguingly, analysis of human breast and ovarian cancers showed that a significant fraction of these samples have elevated MEKK3 protein levels with corresponding increases in NFkappaB binding activities. Thus, our results established that elevated expression of MEKK3 appears to be a frequent occurrence in breast and ovarian cancers and that overexpression of MEKK3 in cells leads to increased NFkappaB activity and increased expression of cell survival factors and ultimately contributes to their resistance to apoptosis. As such, MEKK3 may serve as a therapeutic target to control cancer cell resistance to cytokine- or drug-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev,Unit 117, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liao, WSL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev,Unit 117, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wsliao@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Boone DL, 2002, INFLAMM BOWEL DIS, V8, P201, DOI 10.1097/00054725-200205000-00008; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dugourd C, 2003, HYPERTENSION, V41, P882, DOI 10.1161/01.HYP.0000060821.62417.35; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Fidler IJ, 2000, NAT MED, V6, P500, DOI 10.1038/74969; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Huang S, 2000, CANCER RES, V60, P5334; Huang S, 2000, CLIN CANCER RES, V6, P2573; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Manna SK, 1998, J IMMUNOL, V161, P2863; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mukhopadhyay A, 2002, J BIOL CHEM, V277, P30622, DOI 10.1074/jbc.M204748200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Rabbani SA, 2000, INT J CANCER, V87, P276, DOI 10.1002/1097-0215(20000715)87:2<276::AID-IJC20>3.0.CO;2-L; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reed RC, 2003, J BIOL CHEM, V278, P31853, DOI 10.1074/jbc.M305480200; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Scovassi AI, 1998, EUR J HISTOCHEM, V42, P251; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shibata A, 2002, BREAST CANCER RES TR, V73, P237, DOI 10.1023/A:1015872531675; Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382-200208000-00001; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	48	70	77	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7576	7583		10.1074/jbc.M311659200	http://dx.doi.org/10.1074/jbc.M311659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662759				2022-12-25	WOS:000189103300026
J	Bertelsen, LS; Barrett, KE; Keely, SJ				Bertelsen, LS; Barrett, KE; Keely, SJ			G(s) protein-coupled receptor agonists induce transactivation of the epidermal growth factor receptor in T-84 cells - Implications for epithelial secretory responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; DEPENDENT CHLORIDE SECRETION; SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ARACHIDONIC-ACID; EGF-RECEPTOR; MAP KINASE; CFTR TRAFFICKING; K+ CHANNELS; T84 CELLS	We have previously shown that G(q) protein-coupled receptor (G(q)PCR) agonists stimulate epidermal growth factor receptor (EGFr) transactivation and activation of mitogen-activated protein kinases (MAPK) in colonic epithelial cells. This constitutes a mechanism by which Cl- secretory responses to G(q)PCR agonists are limited. In the present study we examined a possible role for the EGFr in regulating Cl- secretion stimulated by agonists that act through G(s)PCRs. All experiments were performed using monolayers of T-84 colonic epithelial cells grown on permeable supports. Protein phosphorylation and protein-protein interactions were analyzed by immunoprecipitation and Western blotting. Cl- secretion was measured as changes in short-circuit current (DeltaI(sc)) across voltage-clamped T-84 cells. The G(s)PCR agonist, vasoactive intestinal polypeptide (VIP; 100 nm), rapidly stimulated EGFr phosphorylation in T-84 cells. This effect was mimicked by a cell-permeant analog of cAMP, Bt(2)cAMP/AM (3 muM), and was attenuated by the protein kinase A (PKA) inhibitor, H-89 (20 muM). The EGFr inhibitor, tyrphostin AG1478 (1 muM), inhibited both Bt(2)cAMP/ AM-stimulated EGFr phosphorylation and I., responses. VIP and Bt(2)cAMP/AM both stimulated ERK MAPK phosphorylation and recruitment of the p85 subunit of phosphatidylinositol 3-kinase (PI3K) to the EGFr in a tyrphostin AG1478-sensitive manner. The PI3K inhibitor, wortmannin (50 nm), but not the ERK inhibitor, PD 98059 (20 muM), attenuated Bt(2)cAMP/AM-stimulated secretory responses. We conclude that G(s)PCR agonists rapidly transactivate the EGFr in T-84 cells by a signaling pathway involving cAMP and PKA. Through a mechanism that likely involves PI3K, transactivation of the EGFr is required for the full expression of cAMP-dependent Cl- secretory responses.	Univ Calif San Diego, Med Ctr, Div Gastroenterol, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Keely, SJ (corresponding author), Univ Calif San Diego, Med Ctr, Div Gastroenterol, Dept Med, 200 W Arbor Dr, San Diego, CA 92103 USA.	skeely@ucsd.edu		Keely, Stephen/0000-0002-6315-3587	NIDDK NIH HHS [DK28305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alleaume C, 2003, NEUROPEPTIDES, V37, P98, DOI 10.1016/S0143-4179(03)00020-9; Ameen NA, 2000, HISTOCHEM CELL BIOL, V114, P219; Ameen NA, 2003, AM J PHYSIOL-CELL PH, V284, pC429, DOI 10.1152/ajpcell.00261.2002; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Bertelsen LS, 2002, GASTROENTEROLOGY, V122, pA88; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Chang N, 2001, AM J PHYSIOL-GASTR L, V281, pG129, DOI 10.1152/ajpgi.2001.281.1.G129; Charney AN, 2002, GASTROENTEROLOGY, V122, P318, DOI 10.1053/gast.2002.31101; Chow JYC, 2000, J BIOL CHEM, V275, P21169, DOI 10.1074/jbc.M002160200; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC149, DOI 10.1152/ajpcell.1998.274.1.C149; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; Dickson JL, 2000, AM J PHYSIOL-CELL PH, V278, pC865, DOI 10.1152/ajpcell.2000.278.5.C865; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; Ecay TW, 2000, BBA-BIOMEMBRANES, V1467, P54, DOI 10.1016/S0005-2736(00)00204-2; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gallet C, 2003, BIOCHEM J, V371, P733, DOI 10.1042/BJ20021030; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Gekle M, 2002, STEROIDS, V67, P499, DOI 10.1016/S0039-128X(01)00183-0; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HARVEY J, 2000, J PHYSL, V15, P95; Hayama M, 2002, AM J PHYSIOL-RENAL, V282, pF485, DOI 10.1152/ajprenal.00210.2001; He H, 2001, J BIOL CHEM, V276, P26741, DOI 10.1074/jbc.C100229200; Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kjeken R, 2001, BIOCHEM J, V357, P497, DOI 10.1042/0264-6021:3570497; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Lee JY, 2001, ARCH PHARM, V334, P357, DOI 10.1002/1521-4184(200112)334:11<357::AID-ARDP357>3.0.CO;2-Q; Lee-Kwon W, 2001, J BIOL CHEM, V276, P31296, DOI 10.1074/jbc.M103900200; Lehrich RW, 1998, J CLIN INVEST, V101, P737, DOI 10.1172/JCI803; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Piiper A, 2003, BIOCHEM BIOPH RES CO, V301, P848, DOI 10.1016/S0006-291X(03)00055-X; Piiper A, 2002, J BIOL CHEM, V277, P43623, DOI 10.1074/jbc.M203926200; POWELL DW, 1999, TXB GASTROENTEROLOGY, P858; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SCHULTZ C, 1994, MOL PHARMACOL, V46, P702; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Shiraha H, 1999, J CELL BIOL, V146, P243; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Xing MZ, 1997, AM J PHYSIOL-CELL PH, V272, pC1380, DOI 10.1152/ajpcell.1997.272.4.C1380; Xu JF, 2002, J NEUROCHEM, V83, P259, DOI 10.1046/j.1471-4159.2002.01145.x; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yoon JH, 2002, GASTROENTEROLOGY, V122, P985, DOI 10.1053/gast.2002.32410	61	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6271	6279		10.1074/jbc.M311612200	http://dx.doi.org/10.1074/jbc.M311612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660604	hybrid			2022-12-25	WOS:000188969200011
J	Dvorsky, R; Blumenstein, L; Vetter, IR; Ahmadian, MR				Dvorsky, R; Blumenstein, L; Vetter, IR; Ahmadian, MR			Structural insights into the interaction of ROCKI with the switch regions of RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-BINDING DOMAIN; SMALL G-PROTEIN; NUCLEOTIDE EXCHANGE FACTORS; KINASE ROK-ALPHA; CRYSTAL-STRUCTURE; COILED-COIL; IN-VIVO; ACTIVATION; FAMILY; PHOSPHORYLATION	The Rho-ROCK pathway modulates the phosphorylation level of a variety of important signaling proteins and is thereby involved in miscellaneous cellular processes including cell migration, neurite outgrowth, and smooth muscle contraction. The observation of the involvement of the Rho-ROCK pathway in tumor invasion and in diseases such as hypertension and bronchial asthma makes it an interesting target for drug development. We herein present the crystal structure of the complex between active RhoA and the Rho-binding domain of ROCKI. The Rho-binding domain structure forms a parallel a-helical coiled-coil dimer and, in contrast to the published Rho-protein kinase N structure, binds exclusively to the switch I and II regions of the guanosine 5'-(beta,gamma-imido)triphosphate-bound RhoA. The switch regions of two different RhoA molecules form a predominantly hydrophobic patch, which is complementarily bound by two identical short helices of 13 residues (amino acids 9981010). The identified ROCK-binding site of RhoA strikingly supports the assumption of a common consensus-binding site for effector recognition.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Max Planck Society	Ahmadian, MR (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	reza.ahmadian@mpi-dortmund.mpg.de	Dvorsky, Radovan/ABE-3042-2020					Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Fiegen D, 2002, FEBS LETT, V525, P100, DOI 10.1016/S0014-5793(02)03094-6; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Garavini H, 2002, BIOCHEMISTRY-US, V41, P6303, DOI 10.1021/bi025651h; Gruber M, 2003, TRENDS BIOCHEM SCI, V28, P679, DOI 10.1016/j.tibs.2003.10.008; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Nakajima M, 2003, EUR J PHARMACOL, V459, P113, DOI 10.1016/S0014-2999(02)02869-8; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Naud N, 2003, BIOCHEM J, V372, P105, DOI 10.1042/BJ20021652; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ridley AJ, 1997, INT J BIOCHEM CELL B, V29, P1225, DOI 10.1016/S1357-2725(97)00052-6; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Shimizu T, 2003, J BIOL CHEM, V278, P46046, DOI 10.1074/jbc.M306458200; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	63	103	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7098	7104		10.1074/jbc.M311911200	http://dx.doi.org/10.1074/jbc.M311911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660612	Green Published, hybrid			2022-12-25	WOS:000188969200108
J	Hedvat, CV; Yao, JJ; Sokolic, RA; Nimer, SD				Hedvat, CV; Yao, JJ; Sokolic, RA; Nimer, SD			Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; PU.1 SPI-1; MEF; PROMOTER; LEUKEMIA; PROTEIN; TARGET; GROWTH	Myeloid ELF1-like factor (MEF), also known as ELF4, is a member of the ETS family of transcription factors which is expressed in hematopoietic cells. MEF-deficient mice have defects in natural killer cell and natural killer T cell development, suggesting a role for MEF in regulating innate immunity. MEF also functions in myeloid cells, where it can transactivate target genes. To identify MEF target genes in a "myeloid" environment, we created an inducible expression system and used oligonucleotide microarrays to examine the transcript profile of HEL cells after induction of MEF expression. Sixteen genes were reproducibly turned on or off more than 2-fold, 8 h after induction of MEF expression, and we examined one of the genes, interleukin-8 (IL-8), in greater detail. IL-8 is a CXC chemokine involved in neutrophil chemoattraction, angiogenesis, and stem cell mobilization. It is expressed by several tumor types, and its expression is regulated primarily transcriptionally. The IL-8 promoter contains three ETS binding sites, and we identified the specific site that binds MEF and is required for MEF responsiveness. MEF, but not the closely related ETS factors PEA3, ETS1, ETS2, ELF1, or PU.1, strongly activates the IL-8 promoter. MEF overexpression is sufficient to induce IL-8 protein expression, and reduction in MEF expression (using RNA interference) results in decreased IL-8 levels. These data demonstrates that MEF is an important regulator of IL-8 expression.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Hedvat, CV (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.	hedvatc@mskcc.org; s-nimer@mskcc.org	Sokolic, Robert/E-6224-2017; Sokolic, Robert/I-6072-2012	Sokolic, Robert/0000-0002-3399-7893; Yao, JinJuan/0000-0003-4692-9969; HEDVAT, CYRUS/0000-0003-0045-3491	NHLBI NIH HHS [K08-HL04478] Funding Source: Medline; NIDDK NIH HHS [R01-DK52208] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguayo A, 2003, LEUKEMIA LYMPHOMA, V44, P213, DOI 10.1080/1042819021000029777; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; Cammenga J, 2003, BLOOD, V101, P2206, DOI 10.1182/blood-2002-05-1546; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fibbe WE, 1999, ANN NY ACAD SCI, V872, P71, DOI 10.1111/j.1749-6632.1999.tb08454.x; Fukushima T, 2003, LEUKEMIA RES, V27, P387, DOI 10.1016/S0145-2126(02)00214-X; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Iguchi A, 2000, BIOCHEM BIOPH RES CO, V279, P166, DOI 10.1006/bbrc.2000.3925; Kai H, 1999, J BIOL CHEM, V274, P20098, DOI 10.1074/jbc.274.29.20098; King AG, 2000, J IMMUNOL, V164, P3774, DOI 10.4049/jimmunol.164.7.3774; King AG, 2001, BLOOD, V97, P1534, DOI 10.1182/blood.V97.6.1534; Lacorazza HD, 2002, IMMUNITY, V17, P437, DOI 10.1016/S1074-7613(02)00422-3; Laterveer L, 1996, BLOOD, V87, P781, DOI 10.1182/blood.V87.2.781.bloodjournal872781; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; Miyazaki Y, 2001, J BIOL CHEM, V276, P40528, DOI 10.1074/jbc.M103051200; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; Mullan PB, 2001, BIOCHEM SOC T, V29, P678, DOI 10.1042/BST0290678; Padro T, 2002, LEUKEMIA, V16, P1302, DOI 10.1038/sj.leu.2402534; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Seki Y, 2002, CANCER RES, V62, P6579; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Steube KG, 2000, CYTOKINE, V12, P1236, DOI 10.1006/cyto.2000.0702; Steube Klaus G., 2000, Molecular Cell Biology Research Communications, V3, P60, DOI 10.1006/mcbr.2000.0190; Suico MA, 2002, BBA-GENE STRUCT EXPR, V1577, P113, DOI 10.1016/S0167-4781(02)00370-6; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Wilkinson NC, 1999, J BIOL CHEM, V274, P438, DOI 10.1074/jbc.274.1.438; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	34	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6395	6400		10.1074/jbc.M307524200	http://dx.doi.org/10.1074/jbc.M307524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625302	hybrid			2022-12-25	WOS:000188969200025
J	Kim, SM; Kwon, MS; Park, CS; Choi, KR; Chun, JS; Ahn, J; Song, WK				Kim, SM; Kwon, MS; Park, CS; Choi, KR; Chun, JS; Ahn, J; Song, WK			Modulation of Thr phosphorylation of integrin beta(1) during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; BETA-1-INTEGRIN CYTOPLASMIC DOMAIN; FOCAL ADHESION KINASE; CELL-ADHESION; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; EXTRACELLULAR-MATRIX; MUTATIONAL ANALYSIS	By using transient elevations of cytosolic free calcium levels triggered by integrin antibody or laminin (Kwon, M. S., Park, C. S., Choi, K., Park, C.-S., Ahnn, J., Kim, J. I., Eom, S. H., Kaufman, S. J., and Song, W. K. (2000) Mol. Biol. Cell 11, 1433-1443), we have demonstrated that protein phosphatase 2A (PP2A) is implicated in the regulation of reversible phosphorylation of integrin. In E63 skeletal myoblasts, the treatment of PP2A inhibitors such as okadaic acid and endothall induces an increase of phosphorylation of integrin beta(1A) and thereby inhibits integrin-induced elevation of cytosolic calcium level and formation of focal adhesions. None of these effects were in differentiated myotubes expressing the alternate beta(1D) isoform. In the presence of okadaic acid, PP2A in association with integrin beta(1A) was reduced on myoblasts, whereas beta(1D) on myotubes remained bound with PP2A. Both coimmunoprecipitation and in vitro phosphatase assays revealed that dephosphorylation of residues Thr(788)-Thr(789) in the integrin beta(1A) cytoplasmic domain is dependent upon PP2A activity. Mutational analysis of the cytoplasmic domain and confocal microscopy experiments indicated that substitution of Thr(788)- Thr(789) with Asn(788)-Asn(789) is of critical importance for regulating the function of integrin beta(1),. These results suggest that PP2A may be a primary regulator of threonine phosphorylation of integrin beta(1A) and subsequent activation of downstream signaling molecules. Taken together, we propose that dephosphorylation of residues Thr(788)-Thr(789) in the cytoplasmic domain of integrin beta(1A) may contribute to the linkage of integrins to focal adhesion sites and induce the association with cytoskeleton proteins. The switch of integrin beta(1A) to beta(1D) isoform in myotubes therefore may be a mechanism to escape from phospho-regulation by PP2A and promotes a more stable association of the cytoskeleton with the extracellular matrix.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	wksong@kjist.ac.kr		Park, Chun Shik/0000-0002-4329-3953				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Barreuther MF, 1996, EXP CELL RES, V222, P10, DOI 10.1006/excr.1996.0002; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Baudoin C, 1998, GENE DEV, V12, P1202, DOI 10.1101/gad.12.8.1202; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bouvard D, 1998, J CELL SCI, V111, P657; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Green LJ, 1998, INT J BIOCHEM CELL B, V30, P179, DOI 10.1016/S1357-2725(97)00107-6; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HELMER ME, 1990, ANNU REV IMMUNOL, V8, P365; Hendey B, 1996, BLOOD, V87, P2038; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Hiraga A, 2000, BIOCHEM J, V346, P433, DOI 10.1042/0264-6021:3460433; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KAUFMAN SJ, 1977, P NATL ACAD SCI USA, V74, P3888, DOI 10.1073/pnas.74.9.3888; Kim YY, 1999, CELL ADHES COMMUN, V7, P85, DOI 10.3109/15419069909034393; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Liu SC, 2000, J CELL SCI, V113, P3563; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; SONG WK, 1993, J CELL SCI, V106, P1139; Wennerberg K, 1998, J CELL SCI, V111, P1117; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Wrenn RW, 1996, BIOCHEM BIOPH RES CO, V226, P876, DOI 10.1006/bbrc.1996.1443; Wu CY, 1999, J CELL SCI, V112, P4485	60	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7082	7090		10.1074/jbc.M311581200	http://dx.doi.org/10.1074/jbc.M311581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660602	hybrid			2022-12-25	WOS:000188969200106
J	Pellegrino, M; Furmaniak-Kazmierczak, E; LeBlanc, JC; Cho, TW; Cao, K; Marcovina, SM; Boffa, MB; Cote, GP; Koschinsky, ML				Pellegrino, M; Furmaniak-Kazmierczak, E; LeBlanc, JC; Cho, TW; Cao, K; Marcovina, SM; Boffa, MB; Cote, GP; Koschinsky, ML			The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; KINASE RHO-KINASE; MYOSIN PHOSPHATASE; FOCAL ADHESIONS; SMOOTH-MUSCLE; GAP FORMATION; PHOSPHORYLATION; PERMEABILITY; PLASMINOGEN; EXPRESSION	Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a risk factor for a variety of atherosclerotic disorders including coronary heart disease. In the current study, we report that incubation of cultured human umbilical vein or coronary artery endothelial cells with Lp(a) elicits a dramatic rearrangement of the actin cytoskeleton characterized by increased central stress fiber formation and redistribution of focal adhesions. These effects are mediated by the apolipoprotein(a) (apo(a)) component of Lp(a) since incubation of apo(a) with the cells evoked similar cytoskeletal rearrangements, while incubation with low density lipoprotein had no effect. Apo(a) also produced a time-dependent increase in transendothelial permeability. The cytoskeletal rearrangements evoked by apo(a) were abolished by C3 transferase, which inhibits Rho, and by Y-27632, an inhibitor of Rho kinase. In addition to actin cytoskeleton remodeling, apo(a) was found to cause VE-cadherin disruption and focal adhesion molecule reorganization in a Rho- and Rho kinase-dependent manner. Cell-cell contacts were found to be regulated by Rho and Rae but not Cdc42. Apo(a) caused a transient increase in the extent of myosin light chain phosphorylation. Finally apo(a) did not evoke increases in intracellular calcium levels, although the effects of apo(a) on the cytoskeleton were found to be calcium-dependent. We conclude that the apo(a) component of Lp(a) activates aRho/Rho kinase-dependent intracellular signaling cascade that results in increased myosin light chain phosphorylation with attendant rearrangements of the actin cytoskeleton. We propose that the resultant increase in endothelial permeability caused by Lp(a) may help explain the atherosclerotic risk posed by elevated concentrations of this lipoprotein.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Washington, NW Lipid Res Labs, Seattle, WA 98103 USA	Queens University - Canada; University of Washington; University of Washington Seattle	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Rm A208 Botterell Hall, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca	Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Edelstein C, 2001, ANAL BIOCHEM, V288, P201, DOI 10.1006/abio.2000.4904; Essler M, 1999, J BIOL CHEM, V274, P30361, DOI 10.1074/jbc.274.43.30361; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gabel BR, 1998, ARTERIOSCL THROM VAS, V18, P1738, DOI 10.1161/01.ATV.18.11.1738; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GOTLIEB AI, 1991, LAB INVEST, V65, P123; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Hippenstiel S, 2002, AM J PHYSIOL-LUNG C, V283, pL830, DOI 10.1152/ajplung.00467.2001; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LUM H, 1992, AM J PHYSIOL, V263, pL219, DOI 10.1152/ajplung.1992.263.2.L219; LUM H, 1994, AM J PHYSIOL, V267, P223; Marcovina S M, 1999, Curr Cardiol Rep, V1, P105, DOI 10.1007/s11886-999-0067-z; Marcovina Santica M, 2002, Semin Vasc Med, V2, P335, DOI 10.1055/s-2002-35404; Marcovina SM, 1996, J LIPID RES, V37, P2569; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1995, THROMB HAEMOSTASIS, V73, P458; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Norwood N, 2000, AM J PHYSIOL-LUNG C, V279, pL815, DOI 10.1152/ajplung.2000.279.5.L815; Poredos P, 2001, CLIN APPL THROMB-HEM, V7, P276, DOI 10.1177/107602960100700404; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; Scanu Angelo M, 2003, Curr Atheroscler Rep, V5, P106, DOI 10.1007/s11883-003-0081-3; Schachinger V, 1997, J AM COLL CARDIOL, V30, P927, DOI 10.1016/S0735-1097(97)00237-4; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; TSURUMI Y, 1995, J AM COLL CARDIOL, V26, P1242, DOI 10.1016/0735-1097(95)00321-5; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; VERIN AD, 1995, AM J PHYSIOL-LUNG C, V269, pL99, DOI 10.1152/ajplung.1995.269.1.L99; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B	48	37	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6526	6533		10.1074/jbc.M309705200	http://dx.doi.org/10.1074/jbc.M309705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660654	hybrid			2022-12-25	WOS:000188969200039
J	Shiba, Y; Katoh, Y; Shiba, T; Yoshino, K; Takatsu, H; Kobayashi, H; Shin, HW; Wakatsuki, S; Nakayama, K				Shiba, Y; Katoh, Y; Shiba, T; Yoshino, K; Takatsu, H; Kobayashi, H; Shin, HW; Wakatsuki, S; Nakayama, K			GAT (GGA and Tom1) domain responsible for ubiquitin binding and ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUE DOMAIN; PROTEINS; GOLGI; COMPLEX; MOTIF; RECRUITMENT; RECEPTORS; TRANSPORT; ARF; TRAFFICKING	GGAs (Golgi-localizing, gamma-adaptin ear domain homology, ADP-ribosylation factor (ARF)-binding proteins) are a family of monomeric adaptor proteins involved in membrane trafficking from the trans-Golgi network to endosomes. The GAT (GGA and Tom1) domains of GGAs have previously been shown to interact with GTP-bound ARF and to be crucial for membrane recruitment of GGAs. Here we show that the C-terminal subdomain of the GAT domain, which is distinct from the N-terminal GAT subdomain responsible for ARF binding, can bind ubiquitin. The binding is mediated by interactions between residues on one side of the alpha3 helix of the GAT domain and those on the so-called Ile-44 surface patch of ubiquitin. The binding of the GAT domain to ubiquitin can be enhanced by the presence of a GTP-bound form of ARF. Furthermore, GGA itself is ubiquitinated in a manner dependent on the GAT-ubiquitin interaction. These results delineate the molecular basis for the interaction between ubiquitin and GAT and suggest that GGA-mediated trafficking is regulated by the ubiquitin system as endosomal trafficking mediated by other ubiquitin-binding proteins.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 9200934, Japan; KEK, High Energy Accelerator Res Org, Inst Mat Struct Sci, Tsukuba, Ibaraki 3050801, Japan; RIKEN, Res Ctr Allergy & Immunol, Kanagawa 2300045, Japan	University of Tsukuba; Kanazawa University; Kanazawa University; High Energy Accelerator Research Organization (KEK); RIKEN	Nakayama, K (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.	kazunaka@pharm.kyoto-u.ac.jp	Nakayama, Kazuhisa/ABF-2924-2020; Shin, Hye-Won/P-5398-2018; Katoh, Yohei/AAA-3378-2020; Shiba, Yoko/AAX-3885-2020	Shin, Hye-Won/0000-0002-9138-9554; Shiba, Yoko/0000-0001-8229-541X; Nakayama, Kazuhisa/0000-0001-7701-7183; Wakatsuki, Soichi/0000-0001-5896-7968; Katoh, Yohei/0000-0003-1649-4917				Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hinners I, 2003, J CELL SCI, V116, P763, DOI 10.1242/jcs.00270; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; TAKADA K, 1995, EUR J BIOCHEM, V233, P42, DOI 10.1111/j.1432-1033.1995.042_1.x; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; TAKATSU H, 2000, BIOCHEM BIOPH RES CO, V271, P917; TRELER M, 1994, CELL, V78, P787; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Zhu GY, 2003, BIOCHEMISTRY-US, V42, P6392, DOI 10.1021/bi034334n; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	44	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7105	7111		10.1074/jbc.M311702200	http://dx.doi.org/10.1074/jbc.M311702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660606	hybrid			2022-12-25	WOS:000188969200109
J	Grimsley, CM; Kinchen, JM; Tosello-Trampont, AC; Brugnera, E; Haney, LB; Lu, MJ; Chen, Q; Klingele, D; Hengartner, MO; Ravichandran, KS				Grimsley, CM; Kinchen, JM; Tosello-Trampont, AC; Brugnera, E; Haney, LB; Lu, MJ; Chen, Q; Klingele, D; Hengartner, MO; Ravichandran, KS			Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO FAMILY GTPASES; C-ELEGANS; CAENORHABDITIS-ELEGANS; MYOBLAST CITY; CRKII/DOCK180/RAC PATHWAY; SIGNALING PATHWAY; MOLECULAR SWITCH; BINDING PROTEIN; APOPTOTIC CELLS; LIVING CELLS	Cell migration is essential throughout embryonic and adult life. In numerous cell systems, the small GTPase Rac is required for lamellipodia formation at the leading edge and movement ability. However, the molecular mechanisms leading to Rac activation during migration are still unclear. Recently, a mammalian superfamily of proteins related to the prototype member Dock180 has been identified with homologues in Drosophila and Caenorhabditis elegans. Here, we addressed the role of Dock180 and ELMO1 proteins, which function as a complex to mediate Rac activation, in mammalian cell migration. Using mutants of Dock180 and ELMO1 in a Transwell assay as well as transgenic rescue of a C. elegans mutant lacking CED-5 (Dock180 homologue), we identified specific regions of Dock180 and ELMO1 required for migration in vitro and in a whole animal model. In both systems, the Dock180.ELMO1 complex formation and the ability to activate Rac were required. We also found that ELMO1 regulated multiple Dock180 superfamily members to promote migration. Interestingly, deletion mutants of ELMO1 missing their first 531 or first 330 amino acids that can still bind and cooperate with Dock180 in Rac activation failed to promote migration, which correlated with the inability to localize to lamellipodia. This finding suggests that Rac activation by the ELMO.Dock180 complex at discrete intracellular locations mediated by the N-terminal 330 amino acids of ELMO1 rather than generalized Rac activation plays a role in cell migration.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11743 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA	University of Virginia; University of Virginia; University of Virginia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Zurich; Salk Institute	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, MR4,Rm 4072D,Box 801386,Lane Rd, Charlottesville, VA 22908 USA.	Ravi@virginia.edu	Hengartner, Michael O/E-6235-2011; Kinchen, Jason/ABC-5663-2021; Lu, Mingjian/AAO-6179-2021; Hengartner, Michael O/A-7058-2008; Lu, Mingjian/AGK-0751-2022	Lu, Mingjian/0000-0001-9328-4935; Kinchen, Jason/0000-0001-8430-2265; Hengartner, Michael/0000-0002-7584-596X				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; BRENNER S, 1974, GENETICS, V77, P71; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Hubbard EJA, 2000, DEV DYNAM, V218, P2, DOI 10.1002/(SICI)1097-0177(200005)218:1<2::AID-DVDY2>3.0.CO;2-W; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reif K, 2002, TRENDS CELL BIOL, V12, P368, DOI 10.1016/S0962-8924(02)02330-9; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wittmann T, 2001, J CELL SCI, V114, P3795; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	53	172	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6087	6097		10.1074/jbc.M307087200	http://dx.doi.org/10.1074/jbc.M307087200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638695	Green Accepted, hybrid			2022-12-25	WOS:000188776500124
J	Ryan, C; Stokes, DL; Chen, MG; Zhang, ZM; Hardwicke, PMD				Ryan, C; Stokes, DL; Chen, MG; Zhang, ZM; Hardwicke, PMD			Effect of orthophosphate, nucleotide analogues, ADP, and phosphorylation on the cytoplasmic domains of Ca2+-ATPase from scallop sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-FREE CA-ATPASE; PROTEIN-KINASE-A; CALCIUM-PUMP; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; STRUCTURAL-CHANGES; TRYPTIC CLEAVAGE; SKELETAL-MUSCLE; CONFORMATIONAL TRANSITIONS; PHOSPHOENZYME INTERMEDIATE	The effects of orthophosphate, nucleotide analogues, ADP, and covalent phosphorylation on the tryptic fragmentation patterns of the E-1 and E-2 forms of scallop Ca-ATPase were examined. Sites preferentially cleaved by trypsin in the E1 form of the Ca-ATPase were detected in the nucleotide (N) and phosphorylation (P) domains, as well as the actuator (A) domain. These sites were occluded in the E-2 (Ca2+-free) form of the enzyme, consistent with mutual protection of the A, N, and P domains through their association into a clustered structure. Similar protection of cytoplasmic Ca2+-dependent tryptic cleavage sites was observed when the catalytic binding site for substrate on the E1 form of scallop Ca-ATPase was occupied by P-i, AMP-PNP, AMP-PCP, or ADP despite the presence of saturating levels of Ca2+. These results suggest that occupation of the catalytic site on E-1 can induce condensation of the cytoplasmic domains to yield a unique structural intermediate that may be related to the form of the enzyme in which the active site is prepared for phosphoryl transfer. The effect of P-i on the E-2 form of the scallop Ca-ATPase was also investigated, when it was found that formation of E-2-P led to extreme resistance toward secondary cleavage by trypsin and stabilization of enzymatic activity for long periods of time.	So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Hardwicke, PMD (corresponding author), So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.	phardwicke@siumed.edu			NIGMS NIH HHS [R01 GM56960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CASTELLANI L, 1983, J CELL BIOL, V97, P557, DOI 10.1083/jcb.97.2.557; CASTELLANI L, 1989, J CELL BIOL, V108, P511, DOI 10.1083/jcb.108.2.511; Chen MG, 2000, J BIOL CHEM, V275, P22961, DOI 10.1074/jbc.M001743200; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1973, J BIOL CHEM, V248, P3696; DEMEIS L, 1981, SARCOPLASMIC RETICUL, P69; Dode L, 2001, J BIOL CHEM, V276, P3911, DOI 10.1074/jbc.M007719200; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; Farley RA, 2001, BIOCHEMISTRY-US, V40, P6361, DOI 10.1021/bi010270+; FROUD RJ, 1986, BIOCHEM J, V237, P207, DOI 10.1042/bj2370207; Hardwicke PMD, 1999, BBA-BIOMEMBRANES, V1417, P1, DOI 10.1016/S0005-2736(98)00241-7; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P229, DOI 10.1007/BF01739813; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; Hua SM, 2000, J BIOL CHEM, V275, P30546, DOI 10.1074/jbc.M003218200; INESI G, 1967, J BIOL CHEM, V242, P4637; Jorgensen PL, 2001, J BIOENERG BIOMEMBR, V33, P367, DOI 10.1023/A:1010611322024; KALABOKIS V, 1988, J BIOL CHEM, V263, P15184; KALABOKIS VN, 1993, BIOCHEMISTRY-US, V32, P4389, DOI 10.1021/bi00067a031; KALABOKIS VN, 1993, BIOCHIM BIOPHYS ACTA, V1147, P35, DOI 10.1016/0005-2736(93)90313-O; KALABOKIS VN, 1991, J BIOL CHEM, V266, P22044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; Mignaco JA, 1996, BIOCHEMISTRY-US, V35, P3886, DOI 10.1021/bi9518353; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NEET KE, 1977, ARCH BIOCHEM BIOPHYS, V178, P588, DOI 10.1016/0003-9861(77)90230-2; PICKART CM, 1984, J BIOL CHEM, V259, P1629; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1991, J BIOL CHEM, V266, P4613; Saino T, 1997, J BIOL CHEM, V272, P21142, DOI 10.1074/jbc.272.34.21142; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwarz FP, 1997, BIOPHYS J, V73, P2179, DOI 10.1016/S0006-3495(97)78249-3; Shi X, 1998, COMP BIOCHEM PHYS B, V120, P359, DOI 10.1016/S0305-0491(98)10025-1; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; TAYLOR JS, 1981, J BIOL CHEM, V256, P9793; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; THE R, 1972, EUR J BIOCHEM, V28, P357, DOI 10.1111/j.1432-1033.1972.tb01921.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; von Germar F, 2000, BIOPHYS J, V78, P1531, DOI 10.1016/S0006-3495(00)76705-1; WU C, 2002, J MOL BIOL, V316, P201	62	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5380	5386		10.1074/jbc.M310085200	http://dx.doi.org/10.1074/jbc.M310085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645252	hybrid			2022-12-25	WOS:000188776500043
J	Taverna, E; Saba, E; Rowe, J; Francolini, M; Clementi, F; Rosa, P				Taverna, E; Saba, E; Rowe, J; Francolini, M; Clementi, F; Rosa, P			Role of lipid microdomains in P/Q-type calcium channel (Ca(v)2.1) clustering and function in presynaptic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; PLASMA-MEMBRANE; SNARE PROTEINS; RAFTS; CELLS; IDENTIFICATION; LOCALIZATION; ASSOCIATION; DOMAINS; COMPLEX	Lipid microdomains can selectively include or exclude proteins and may be important in a variety of functions such as protein sorting, cell signaling, and synaptic transmission. The present study demonstrates that two different voltage-gated calcium channels, which both interact with soluble N-ethyl-maleimide-sensitive fusion protein attachment protein receptor (SNARE) proteins but have distinct subcellular distributions and roles in synaptic transmission, are differently distributed in lipid microdomains; presynaptic P/Q (Ca(v)2.1) but not Lc (Ca(v)1.2) calcium channel subtypes are mainly accumulated in detergent-insoluble complexes. The immunoisolation of multiprotein complexes from detergent-insoluble or detergent-soluble fractions shows that the alpha1A subunits of Ca(v)2.1 colocalize and interact with SNARE complexes in lipid microdomains. The altered organization of these microdomains caused by saponin and methyl-beta-cyclodextrin treatment largely impairs the buoyancy and distribution of Ca(v)2.1 channels and SNAREs in flotation gradients. On the other hand, cholesterol reloading partially reverses the drug effects. Methyl-beta-cyclodextrin treatment alters the colocalization of Ca(v)2.1 with the proteins of the exocytic machinery and also impairs calcium influx in nerve terminals. These results show that lipid microdomains in presynaptic terminals are important in organizing membrane sites specialized for synaptic vesicle exocytosis. The cholesterol-enriched microdomains contribute to optimizing the compartmentalization of exocytic machinery and the calcium influx that triggers synaptic vesicle exocytosis.	Univ Milan, Ctr Excellence Neurodegenerat Dis, Inst Neurosci Cellular & Mol Pharmacol, CNR,Dept Med Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan	Rosa, P (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Inst Neurosci Cellular & Mol Pharmacol, CNR,Dept Med Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	p.rosa@in.cnr.it	Saba, Elena/ABH-9313-2020; Taverna, Elena/AFW-4935-2022; taverna, elena/O-8180-2014	Saba, Elena/0000-0002-8217-5968; taverna, elena/0000-0002-2430-4725; FRANCOLINI, MAURA/0000-0002-3126-1575; Rosa, Patrizia/0000-0002-2590-6955				Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Christian AE, 1997, J LIPID RES, V38, P2264; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hering H, 2003, J NEUROSCI, V23, P3262; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Mochida S, 2003, P NATL ACAD SCI USA, V100, P2819, DOI 10.1073/pnas.262787699; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rowe J, 2001, J CELL SCI, V114, P3323; SAKURAI T, 1995, J BIOL CHEM, V270, P21234, DOI 10.1074/jbc.270.36.21234; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Taverna E, 2002, J CELL SCI, V115, P3909, DOI 10.1242/jcs.00072; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; Weiss JL, 2001, J BIOL CHEM, V276, P44804, DOI 10.1074/jbc.M103262200	43	102	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5127	5134		10.1074/jbc.M308798200	http://dx.doi.org/10.1074/jbc.M308798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660672	hybrid			2022-12-25	WOS:000188776500012
J	Tombline, G; Bartholomew, L; Gimi, K; Tyndall, GA; Senior, AE				Tombline, G; Bartholomew, L; Gimi, K; Tyndall, GA; Senior, AE			Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITES; MYOSIN MOTOR DOMAIN; ATPASE ACTIVITY; MULTIDRUG-RESISTANCE; LSGGQ MOTIF; TRANSPORTER; MECHANISM; MUTATIONS; WALKER; CELLS	Functional roles of the two ABC signature sequences ("LSGGQ") in the N- and C-terminal nucleotide binding domains of P-glycoprotein were studied by mutating the conserved Ser residues to Ala. The two single mutants (S528A; S1173A) each impaired ATPase activity mildly, and showed generally symmetrical effects on function, consistent with equivalent mechanistic roles of the two nucleotide sites. Synergy between the two mutations when combined was remarkable and resulted in strong catalytic impairment. The Ser residues are not involved significantly in MgATP- or MgADP-binding or in inter-domain communication between catalytic sites and drug binding sites. Retention of product MgADP is not the cause of reduced turnover. Mutation of Ser to Ala reduced the strength of interaction with the chemical transition state specifically, as shown by vanadate-ADP and beryllium fluoride-ADP trapping experiments. Therefore, the two conserved ABC signature motif Ser residues of P-glycoprotein cooperatively accelerate ATP hydrolysis via chemical transition state interaction. Because the transition state complex is currently believed to form in the dimerized state of the nucleotide binding domains, one may also conclude that both Ser-OH are necessary for correct formation of the dimer state.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NCI NIH HHS [T32 CA09363] Funding Source: Medline; NIGMS NIH HHS [GM50156] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Browne BL, 1996, J BACTERIOL, V178, P1712, DOI 10.1128/jb.178.6.1712-1719.1996; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Proff C, 2001, MOL GEN GENET, V264, P883, DOI 10.1007/s004380000378; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, METHOD ENZYMOL, V292, P514; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X	43	54	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5363	5373		10.1074/jbc.M311964200	http://dx.doi.org/10.1074/jbc.M311964200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638679	hybrid			2022-12-25	WOS:000188776500041
J	Okada, M; Hatakeyama, T; Itoh, H; Tokuta, N; Tokumitsu, H; Kobayashi, R				Okada, M; Hatakeyama, T; Itoh, H; Tokuta, N; Tokumitsu, H; Kobayashi, R			S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CALCIUM-BINDING PROTEINS; CITRATE SYNTHASE; NONNATIVE PROTEIN; ESCHERICHIA-COLI; TARGET PROTEIN; IN-VITRO; HSP90; CALMODULIN; HSP70	Although calmodulin is known to be a component of the Hsp70/Hsp90 multichaperone complex, the functional role of the protein remains uncertain. In this study, we have identified S100A1, but not calmodulin or other S100 proteins, as a potent molecular chaperone and a new member of the multichaperone complex. Glutathione S-transferase pull-down assays and co-immunoprecipitation experiments indicated the formation of stable complexes between S100A1 and Hsp90, Hsp70, FKBP52, and CyP40 both in vitro and in mammalian cells. S100A1 potently protected citrate synthase, aldolase, glyceraldehyde-3-phosphate dehydrogenase, and rhodanese from heat-induced aggregation and suppressed the aggregation of chemically denatured rhodanese and citrate synthase during the refolding pathway. In addition, S100A1 suppressed the heat-induced inactivation of citrate synthase activity, similar to that for Hsp90 and p23. The chaperone activity of S100A1 was antagonized by calmodulin antagonists, such as fluphenazine and prenylamine, that is, indeed an intrinsic function of the protein. The overexpression of S100A1 in COS-7 cells protected transiently expressed firefly luciferase and Escherichia coli beta-galactosidase from inactivation during heat shock. The results demonstrate a novel physiological function for S100A1 and bring us closer to a comprehensive understanding of the molecular mechanisms of the Hsp70/Hsp90 multichaperone complex.	Kagawa Univ, Fac Med, Dept Signal Transduct Sci, Miki, Kagawa 7610793, Japan; Akita Univ, Fac Engn & Resource Sci, Dept Mat Proc Engn & Appl Chem Environm, Akita 0108502, Japan	Kagawa University; Akita University	Kobayashi, R (corresponding author), Kagawa Univ, Fac Med, Dept Signal Transduct Sci, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	ryoji@kms.ac.jp	; Tokumitsu, Hiroshi/M-3978-2015	Takashi, Hatakeyama/0000-0001-6325-0814; Tokumitsu, Hiroshi/0000-0002-2193-6794				Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csermely P, 1997, LIFE SCI, V61, P411, DOI 10.1016/S0024-3205(97)00398-6; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FILIPEK A, 1995, INT J BIOCHEM CELL B, V27, P1123, DOI 10.1016/1357-2725(95)00096-8; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Graumann K, 2000, BIOCHEM J, V345, P627, DOI 10.1042/0264-6021:3450627; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; ITOH H, 1990, ARCH BIOCHEM BIOPHYS, V282, P290, DOI 10.1016/0003-9861(90)90119-J; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Landar A, 1996, CELL CALCIUM, V20, P279, DOI 10.1016/S0143-4160(96)90033-0; Landar A, 1998, BIOCHEMISTRY-US, V37, P17429, DOI 10.1021/bi9817921; MARSHAK DR, 1985, BIOCHEMISTRY-US, V24, P144, DOI 10.1021/bi00322a020; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Okada M, 2002, BIOCHEM BIOPH RES CO, V292, P1023, DOI 10.1006/bbrc.2002.6761; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Yamashita K, 1999, PROTEIN EXPRES PURIF, V16, P47, DOI 10.1006/prep.1998.1026; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZIMMER DB, 1993, CELL CALCIUM, V14, P323, DOI 10.1016/0143-4160(93)90053-9; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424; ZIMMER M, 1987, EUR J BIOCHEM, V164, P411, DOI 10.1111/j.1432-1033.1987.tb11073.x	50	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4221	4233		10.1074/jbc.M309014200	http://dx.doi.org/10.1074/jbc.M309014200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638689	hybrid			2022-12-25	WOS:000188554300039
J	Marsit, CJ; Liu, M; Nelson, HH; Posner, M; Suzuki, M; Kelsey, KT				Marsit, CJ; Liu, M; Nelson, HH; Posner, M; Suzuki, M; Kelsey, KT			Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival	ONCOGENE			English	Article						methylation; NSCLC; HNSCC; Fanconi anemia; BRCA	PROMOTER HYPERMETHYLATION; DNA METHYLATION; OVARIAN-TUMORS; BRCA1 PROMOTER; CPG ISLANDS; GENE; SUSCEPTIBILITY; EXPOSURE; BREAST; ASSOCIATION	Inactivation of the FANC-BRCA pathway via promoter methylation of the FANCF gene renders cells sensitive to DNA crosslinking agents, and has been identified in ovarian cancer cell lines and sporadic primary tumor tissues. We investigated epigenetic alterations in the FANC-BRCA pathway in head and neck squamous cell carcinomas (HNSCC) and non-small-cell lung cancers (NSCLC) using methylation-specific PCR. Promoter methylation of FANCF occurred in 15% (13/89) of HNSCCs and 14% (22/158) of NSCLCs. Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. No methylation of BRCA2 was detected. FANCF methylation was associated with a shorter duration of tobacco use (P=0.03) and a younger age of starting smoking (P = 0.06) in NSCLC, and with a greater number of years of alcohol drinking (P=0.02) in HNSCC. In adenocarcinomas of the lung, FANCF promoter methylation was a significant predictor of poor survival with a hazard ratio of 3.1 (95% Cl 1.2-7.9). This study demonstrates that inactivation of the FANC-BRCA pathway is relatively common in solid tumors and may be related to tobacco and alcohol exposure and survival of these patients.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	kelsey@hsph.harvard.edu	Kelsey, Karl T/I-1252-2014	Marsit, Carmen/0000-0003-4566-150X; Nelson, Heather/0000-0003-1901-9513	NCI NIH HHS [T32CA09078, CA78609] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078609, T32CA009078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; Baldwin RL, 2000, CANCER RES, V60, P5329; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2001, CANCER RES, V61, P3225; Fang JY, 2001, J GASTROEN HEPATOL, V16, P960, DOI 10.1046/j.1440-1746.2001.02554.x; Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4; Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; ISHIDA R, 1982, CANCER RES, V42, P4000; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020; Nelson HH, 1999, J NATL CANCER I, V91, P2032, DOI 10.1093/jnci/91.23.2032; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; Phelps RM, 1996, J CELL BIOCHEM, P32; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; SASAKI MS, 1973, CANCER RES, V33, P1829; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543	26	181	197	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1000	1004		10.1038/sj.onc.1207256	http://dx.doi.org/10.1038/sj.onc.1207256			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647419				2022-12-25	WOS:000188486600016
J	Hu, N; Wang, CY; Han, XY; He, LJ; Tang, ZZ; Giffen, C; Emmert-Buck, MR; Goldstein, AM; Taylor, PR				Hu, N; Wang, CY; Han, XY; He, LJ; Tang, ZZ; Giffen, C; Emmert-Buck, MR; Goldstein, AM; Taylor, PR			Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer	ONCOGENE			English	Article						familial; mutation; LOH; high risk; DNA sequencing	SQUAMOUS-CELL CARCINOMA; ALLELIC LOSS; SHANXI-PROVINCE; BREAST	Previous studies of esophageal squamous cell carcinoma (ESCC) have shown a high frequency of allelic loss on chromosome 13q, infrequent somatic mutations in BRCA2, and a suggested association between a positive family history (FH+) of upper gastrointestinal cancer and germline BRCA2 mutations. In all, 70 ESCC patients ( 44 FH+ and 26 FH-) were examined by direct full sequencing of germline DNA for BRCA2 mutations. In addition, 28 family members of three of these patients and 232 unrelated healthy blood bank donor controls were examined for the mutations identified in the 70 ESCC patients. Five BRCA2 germline mutations, including three not previously reported (N1600del, A2054P, and V2109I), were identified in six of 44 FH+ patients, but none of 26 FH- patients ( 14 vs 0%, P = 0.078), consistent with our previous findings (3/34 or 9% FH+ vs 0/22 or 0% FH-, P = 0.27). The cumulative frequency of BRCA2 germline mutations in ESCC patients in this and our previous study combined is 12%, with all mutations found in FH+ as opposed to FH- cases (9/78 or 12% FH+ vs 0/48 or 0% FH-, P = 0.013). We conclude that germline mutations in BRCA2 in ESCC patients from this high-risk area of China are more frequent in FH+ than FH- cases, suggesting that BRCA2 may play a role in genetic susceptibility to familial ESCC.	NCI, Canc Prevent Studies Branch, Bethesda, MD 20892 USA; Shanxi Canc Hosp, Taiyuan 030013, Shanxi, Peoples R China; Yangcheng Canc Hosp, Yangcheng 048100, Shanxi, Peoples R China; Informat Management Serv Inc, Silver Spring, MD 20904 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.	Taylor, PR (corresponding author), NCI, Canc Prevent Studies Branch, 6116 Execut Plaza,Suite 705, Bethesda, MD 20892 USA.	ptaylor@mail.nih.gov			DIVISION OF CANCER PREVENTION AND CONTROL [Z01CN000150] Funding Source: NIH RePORTER	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; CARTER CL, 1992, J NATL CANCER I, V84, P771, DOI 10.1093/jnci/84.10.771; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Harada H, 1999, CANCER RES, V59, P3724; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2001, CLIN CANCER RES, V7, P883; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; HU N, 1991, EUR J CANCER, V27, P1336, DOI 10.1016/0277-5379(91)90116-U; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; LI G, 1986, P 1 SIN AM HUM GEN W, P43; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Li M H, 1980, Adv Cancer Res, V33, P173; Liede A, 2002, HUM MUTAT, V20, P413, DOI 10.1002/humu.10154; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; *NAT CANC CONTR OF, 1980, INV CANC MORT CHIN; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Pyne MT, 2000, J HUM GENET, V45, P351, DOI 10.1007/s100380070007; WANG YP, 1992, CANCER CAUSE CONTROL, V3, P107, DOI 10.1007/BF00051650; WU M, 1989, FAM CANC 1 INT RES C, P187; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Zhi XC, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9083	22	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					852	858		10.1038/sj.onc.1207150	http://dx.doi.org/10.1038/sj.onc.1207150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647438	Bronze			2022-12-25	WOS:000188304900025
J	Huc, L; Sparfel, L; Rissel, M; Dimanche-Boitrel, MT; Guillouzo, A; Fardel, O; Lagadic-Gossmann, D				Huc, L; Sparfel, L; Rissel, M; Dimanche-Boitrel, MT; Guillouzo, A; Fardel, O; Lagadic-Gossmann, D			Identification of Na+/H+ exchange as a new target for toxic polycyclic aromatic hydrocarbons in liver cells	FASEB JOURNAL			English	Article						intracellular pH; benzo(a)pyrene; apoptosis; metabolism	INTRACELLULAR PH; DEPENDENT APOPTOSIS; HYDROGEN-PEROXIDE; DENDRITIC CELLS; IN-VIVO; ACTIVATION; EXPRESSION; INDUCTION; PATHWAY; PHOSPHORYLATION	The ubiquitous environmental pollutants polycyclic aromatic hydrocarbons are responsible for important carcinogenic and apoptotic effects, whose mechanisms are still poorly understood, owing to the multiplicity of possible cellular targets. Among these mechanisms, alterations of ionic homeostasis have been suggested. In this work, the effects of benzo(a)pyrene [B(a)P] on pH(i) were tested in the rat liver F258 epithelial cell line, using the fluoroprobe carboxy-SNARF-1. After a 48-h treatment, B(a)P (50 nM) induced an alkalinization, followed by an acidification after 72 h and the development of apoptosis. Determinations of pHi recovery following an acid load showed an increased acid efflux at 48 h. Cariporide inhibited both the early alkalinization and the increased acid efflux, thus suggesting the involvement of Na+/H+ exchanger 1 (NHE1). Besides, alpha-naphtoflavone (alpha-NF), an inhibitor of CYP1A1-mediated B(a)P metabolism, prevented all pH(i) changes, and NBE1 activation was blocked by the antioxidant thiourea, which inhibited CYP1A1 metabolism-dependent H2O2 production. Regarding B(a)P-induced apoptosis, this was prevented by alpha-NF and bongkrekic acid, an inhibitor of mitochondria-dependent apoptosis. Interestingly, apoptosis was significantly reduced by cariporide. Taken together, our results indicate that B(a)P, via H2O2 produced by CYP1A1-dependent metabolism, induces an early activation of NBE1, resulting in alkalinization; this appears to play a significant role in mitochondria-dependent B(a)P-induced apoptosis.	Univ Rennes 1, Fac Pharm, INSERM, U456, F-35043 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Lagadic-Gossmann, D (corresponding author), Univ Rennes 1, Fac Pharm, INSERM, U456, 2 Ave Professeur Leon Bernard, F-35043 Rennes, France.	Dominique.Lagadic@rennes.inserm.fr	LAGADIC-GOSSMANN, Dominique/I-5079-2015; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; GUILLOUZO, Andre/Z-2373-2019; Fardel, Olivier/J-8560-2015; Huc, Laurence/J-1888-2014; SPARFEL, Lydie/K-1319-2015	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Huc, Laurence/0000-0002-0336-7559; SPARFEL, Lydie/0000-0002-4877-7017; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Benedetti A, 2001, GASTROENTEROLOGY, V120, P545, DOI 10.1053/gast.2001.21203; BLACK KA, 1989, TOXICOL APPL PHARM, V97, P463, DOI 10.1016/0041-008X(89)90251-2; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; Burchiel SW, 1999, CLIN IMMUNOL, V90, P285, DOI 10.1006/clim.1998.4692; Chin BY, 1998, AM J PHYSIOL-LUNG C, V275, pL942, DOI 10.1152/ajplung.1998.275.5.L942; Delescluse C, 2000, TOXICOLOGY, V153, P73, DOI 10.1016/S0300-483X(00)00305-X; Dertinger SD, 2000, BIOCHEM PHARMACOL, V60, P189, DOI 10.1016/S0006-2952(00)00314-2; Dertinger SD, 2001, CARCINOGENESIS, V22, P171, DOI 10.1093/carcin/22.1.171; ETHIER SP, 1982, J NATL CANCER I, V69, P1199; Flowers L, 1996, BIOCHEMISTRY-US, V35, P13664, DOI 10.1021/bi961077w; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; GRINSTEIN S, 1988, J BIOL CHEM, V263, P8658; HENDERSON PJ, 1970, J BIOL CHEM, V245, P1319; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Khaled AR, 2001, MOL CELL BIOL, V21, P7545, DOI 10.1128/MCB.21.22.7545-7557.2001; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lagadic-Gossmann D, 1999, BRIT J PHARMACOL, V128, P1673, DOI 10.1038/sj.bjp.0702972; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; Laupeze W, 2002, J IMMUNOL, V168, P2652, DOI 10.4049/jimmunol.168.6.2652; Lei W, 1998, CANCER RES, V58, P2102; LEWIS DFV, 1995, MUTAT RES-FUND MOL M, V328, P207, DOI 10.1016/0027-5107(95)00009-8; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MENNEAR JH, 1993, REGUL TOXICOL PHARM, V17, P77, DOI 10.1006/rtph.1993.1008; Mounho BJ, 1998, TOXICOL APPL PHARM, V149, P80, DOI 10.1006/taap.1997.8345; Page TJ, 2002, MOL PHARMACOL, V62, P313, DOI 10.1124/mol.62.2.313; Payen L, 2001, TOXICOLOGY, V156, P109, DOI 10.1016/S0300-483X(00)00348-6; PELKONEN O, 1982, PHARMACOL REV, V34, P189; Pessah IN, 2001, MOL PHARMACOL, V59, P506, DOI 10.1124/mol.59.3.506; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Revel A, 2001, REPROD TOXICOL, V15, P479, DOI 10.1016/S0890-6238(01)00149-6; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; Rieder CV, 2002, AM J PHYSIOL-HEART C, V283, pH273, DOI 10.1152/ajpheart.00042.2002; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Rothstein EC, 2002, AM J PHYSIOL-HEART C, V283, pH598, DOI 10.1152/ajpheart.00198.2002; Santodonato J, 1997, CHEMOSPHERE, V34, P835, DOI 10.1016/S0045-6535(97)00012-X; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; Snabaitis AK, 2002, CARDIOVASC RES, V53, P470, DOI 10.1016/S0008-6363(01)00464-3; Sparfel L, 2002, TOXICOL LETT, V129, P245, DOI 10.1016/S0378-4274(02)00015-2; Tannheimer SL, 1999, MOL CARCINOGEN, V25, P48, DOI 10.1002/(SICI)1098-2744(199905)25:1<48::AID-MC6>3.0.CO;2-6; van Grevenynghe J, 2003, J IMMUNOL, V170, P2374, DOI 10.4049/jimmunol.170.5.2374; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V428, P441, DOI 10.1113/jphysiol.1990.sp018221; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; Wei S, 2001, AM J PHYSIOL-CELL PH, V281, pC1542, DOI 10.1152/ajpcell.2001.281.5.C1542; Wilson CL, 1998, TOXICOL PATHOL, V26, P657, DOI 10.1177/019262339802600510; Woods GM, 2000, IMMUNOLOGY, V99, P16, DOI 10.1046/j.1365-2567.2000.00928.x; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; ZEDECK MS, 1980, J ENVIRON PATHOL TOX, V3, P537	57	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					344	+		10.1096/fj.03-0316fje	http://dx.doi.org/10.1096/fj.03-0316fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656999	Green Submitted			2022-12-25	WOS:000188067500025
J	Sumrejkanchanakij, P; Tamamori-Adachi, M; Matsunaga, Y; Eto, K; Ikeda, MA				Sumrejkanchanakij, P; Tamamori-Adachi, M; Matsunaga, Y; Eto, K; Ikeda, MA			Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons	ONCOGENE			English	Article						cyclin D1; cyclin-dependent kinase; neuron; apoptosis; nuclear localization; terminal differentiation	DEPENDENT KINASE-ACTIVITY; PROGRAMMED CELL-DEATH; CDK INHIBITORS; NUCLEAR EXPORT; IN-VIVO; PHOSPHORYLATION; EXPRESSION; PROTEIN; DIFFERENTIATION; LOCALIZATION	Cyclin D-dependent kinases phosphorylate the retinoblastoma (Rb) protein and play a critical role in neuronal cell cycle control and apoptosis. Here we show that cyclin D1 became predominantly cytoplasmic as primary cortical progenitor cells underwent cell cycle withdrawal and terminal differentiation. Furthermore, ectopically expressed cyclin D1 sequestered in the cytoplasm of postmitotic neurons, whereas it efficiently entered the nucleus of proliferating progenitor cells. Cytoplasmic cyclin D1 were complexed with cyclin-dependent kinase 4 (CDK4), and also with CDK inhibitors, p27(KipI) or p21(CipI), which positively regulate assembly and nuclear accumulation of the cyclin D1-CDK4 complex. Although overexpression of p21CipI promoted cyclin D1 nuclear localization, inhibition of either glycogen synthase kinase 3beta- or CRM1-mediated cyclin D1 nuclear export did not, suggesting that the inhibition of its nuclear import, rather than the acceleration of nuclear export, contributes to cytoplasmic sequestration of cyclin D1 in postmitotic neurons. In differentiated progenitor cells, nuclear localization of ectopic cyclin D1 induced apoptosis, and the DNA-damaging compound camptothecin caused nuclear accumulation of endogenous cyclin D1, accompanied by Rb phosphorylation. These results indicate that nuclear accumulation of cyclin D1 is inhibited in postmitotic neurons and suggest a role of its subcellular localization in neuronal death and survival.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Internal Med 2, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ino H, 2001, J NEUROSCI, V21, P6086, DOI 10.1523/JNEUROSCI.21-16-06086.2001; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Takiguchi-Hayashi K, 1998, BRAIN RES, V801, P9, DOI 10.1016/S0006-8993(98)00496-X; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; Tamamori M, 1998, AM J PHYSIOL-HEART C, V275, pH2036, DOI 10.1152/ajpheart.1998.275.6.H2036; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	104	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8723	8730		10.1038/sj.onc.1206870	http://dx.doi.org/10.1038/sj.onc.1206870			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647467				2022-12-25	WOS:000186844900010
J	Chen, SH; Bubb, MR; Yarmola, EG; Zuo, J; Jiang, J; Lee, BS; Lu, M; Gluck, SL; Hurst, IR; Holliday, LS				Chen, SH; Bubb, MR; Yarmola, EG; Zuo, J; Jiang, J; Lee, BS; Lu, M; Gluck, SL; Hurst, IR; Holliday, LS			Vacuolar H+-ATPase binding to microfilaments - Regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actin-binding site in subunit B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; CELL POLARITY; INTERSTITIAL COLLAGENASE; PROFILIN INTERACTS; INTERCALATED CELLS; LIPID PRODUCTS; V-ATPASE; F-ACTIN; OSTEOCLASTS; ASSOCIATION	Vacuolar H+-ATPase (V-ATPase) binds microfilaments, and that interaction may be mediated by an actin binding domain in subunit B of the enzyme. To test for possible physiologic functions of the actin binding activity of V-ATPase, early responses of resorbing osteoclasts to inhibition of phosphatidylinositol 3-kinase activity by wortmannin and LY294002 were examined. Rapid co-localization between V-ATPase and F-actin was demonstrated by immunocytochemistry, and corresponding association between V-ATPase and F-actin in immunoprecipitations and pelleting assays was detected. This response was reversed as osteoclasts recovered resorptive activity after inhibitors were removed. By expressing and characterizing fusion proteins containing segments of the actin-binding amino-terminal regions of the B subunits of V-ATPase, we mapped the actin-binding site to a 44-amino acid domain. An 11-amino acid segment with a sequence similar to the actin-binding site of human profilin I was detected within this region. 13-Mers containing these profilin-like segments bound actin in fluorescent anisotropy studies and competed with profilin for binding to actin. Using site-directed mutagenesis, the 11-amino acid profilin-like actin-binding motifs ( amino acids 49 - 59 of B1 and 55 - 65 of B2) were replaced with an 11-amino acid spacer with a sequence based on the homologous sequence from subunit B of Pyrococcus horikoshii, an organism that lacks an actin cytoskeleton. These substitutions eliminated the actin-binding activity of the B subunit fusion proteins. In summary, binding between V-ATPase and F-actin in osteoclasts occurs in response to blocking phosphatidylinositol 3-kinase activity. This response was fully reversible. The actin binding activities of the B subunits of V-ATPase required 11-amino acid actin-binding motifs that are similar in sequence to the actin-binding site of mammalian profilin I.	Univ Florida, Coll Dent, Dept Orthodont, J Hillis Miller Hlth Ctr, Gainesville, FL 32610 USA; Univ Florida, Coll Dent, Dept Endodont, Gainesville, FL 32610 USA; Malcolm Randall Vet Affairs Med Ctr, Gainesville, FL 32608 USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University System of Ohio; Ohio State University	Holliday, LS (corresponding author), Univ Florida, Coll Dent, Dept Orthodont, J Hillis Miller Hlth Ctr, D7-18,Campus Box 100444, Gainesville, FL 32610 USA.	sholliday@dental.ufl.edu	Holliday, Lexie/GYQ-4972-2022; Lee, Beth S/E-9578-2010	Lee, Beth S/0000-0002-1468-6387; Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [R01 AR047959, R01 AR47959] Funding Source: Medline; NIDDK NIH HHS [R01 DK38848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRATA T, 2003, J BIOL CHEM; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; Holliday LS, 2003, CALCIFIED TISSUE INT, V72, P206, DOI 10.1007/s00223-002-1008-7; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Lelievre SA, 1998, J CELL BIOCHEM, P250; Machen T E, 2001, JOP, V2, P229; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Pilkington MF, 2001, J BONE MINER RES, V16, P1237, DOI 10.1359/jbmr.2001.16.7.1237; Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; Schluter K, 1998, J CELL SCI, V111, P3261; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Skinner MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1247, DOI 10.1177/002215549904701004; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wax MB, 1997, P NATL ACAD SCI USA, V94, P6752, DOI 10.1073/pnas.94.13.6752; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; YOKOYAMA K, 2003, J BIOL CHEM	58	95	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7988	7998		10.1074/jbc.M305351200	http://dx.doi.org/10.1074/jbc.M305351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662773	hybrid			2022-12-25	WOS:000189103300077
J	Leventhal, AR; Leslie, CC; Tabas, I				Leventhal, AR; Leslie, CC; Tabas, I			Suppression of macrophage eicosanoid synthesis by atherogenic lipoproteins is profoundly affected by cholesterol-fatty acyl esterification and the Niemann-Pick C pathway of lipid trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; DISEASE TYPE-C; COENZYME-A; ARACHIDONIC-ACID; LYSOPHOSPHOLIPASE ACTIVITY; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE A(2); J774 MACROPHAGES	Atheroma macrophages internalize large quantities of lipoprotein-derived lipids. While most emphasis has been placed on cholesterol, lipoprotein-derived fatty acids may also play important roles in lesional macrophage biology. Little is known, however, about the trafficking or metabolism of these fatty acids. In this study, we first show that the cholesterol-fatty acyl esterification reaction, catalyzed by acyl-CoA: cholesterol acyltransferase (ACAT), competes for the incorporation of lipoprotein-derived fatty acids into cellular phospholipids. Furthermore, conditions that inhibit trafficking of cholesterol from late endosomes/lysosomes to the endoplasmic reticulum (ER), such as the amphipathic amine U18666A and the Npc1+/- mutation, also inhibit incorporation of lipoprotein-derived fatty acids into phospholipids. The biological relevance of these findings was investigated by studying the suppression of agonist-induced prostaglandin E-2 (PGE(2)) and leukotriene C-4/D-4/E-4 production during lipoprotein uptake by macrophages, which has been postulated to involve enrichment of cellular phospholipids with non-arachidonic fatty acids (NAAFAs). We found that eicosanoid suppression was markedly enhanced when ACAT was inhibited and prevented when late endosomal/lysosomal lipid trafficking was blocked. Moreover, PGE2 suppression depended entirely on acetyl-LDL-derived NAAFAs, not on acetyl-LDL-cholesterol, and was not due to decreased cPLA(2) activity per se. These data support the following model: lipoprotein-derived NAAFAs traffic via the NPC1 pathway from late endosomes/lysosomes to a critical pool of phospholipids. In competing reactions, these NAAFAs can be either esterified to cholesterol or incorporated into phospholipids, resulting in suppression of eicosanoid biosynthesis. In view of recent evidence suggesting dysfunctional cholesterol esterification in late lesional macrophages, these data predict that such cells would have highly suppressed eicosanoid synthesis, thus affecting eicosanoid-mediated cell signaling in advanced atherosclerosis.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA	Columbia University; Columbia University; National Jewish Health	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061378, R01HL057560, P50HL056984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61378, HL-57560, HL-56984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1992, J BIOCHEM-TOKYO, V112, P482, DOI 10.1093/oxfordjournals.jbchem.a123925; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; DIEZ E, 1992, J BIOL CHEM, V267, P18342; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; Groener JEM, 1996, J LIPID RES, V37, P2271; Harzer K, 2003, FEBS LETT, V537, P177, DOI 10.1016/S0014-5793(03)00100-5; Harzer K, 2001, CLIN CHIM ACTA, V305, P65, DOI 10.1016/S0009-8981(00)00421-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; KRIEGER M, 1986, METHOD ENZYMOL, V128, P608; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LI QM, 1995, ISRAEL J MED SCI, V31, P474; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHUR SN, 1989, J LIPID RES, V30, P1385; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Pollaud C, 1995, BBA-LIPID LIPID MET, V1259, P211, DOI 10.1016/0005-2760(95)00164-6; POMERANTZ KB, 1984, CIRC RES, V54, P554, DOI 10.1161/01.RES.54.5.554; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SALBACH PB, 1992, P NATL ACAD SCI USA, V89, P2439, DOI 10.1073/pnas.89.6.2439; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; Starodub O, 2000, AM J PHYSIOL-CELL PH, V279, pC1259, DOI 10.1152/ajpcell.2000.279.4.C1259; Sugii S, 2003, J BIOL CHEM, V278, P27180, DOI 10.1074/jbc.M300542200; Sugimoto Y, 2001, P NATL ACAD SCI USA, V98, P12391, DOI 10.1073/pnas.221181998; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; TABAS I, 1986, J BIOL CHEM, V261, P3147; TABAS I, 2002, BIOCH LIPIDS LIPOPRO, P573; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; TERUYA J, 1995, J LIPID RES, V36, P266; Vanier MT, 1999, NEUROCHEM RES, V24, P481, DOI 10.1023/A:1022575511354; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200	57	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8084	8092		10.1074/jbc.M310672200	http://dx.doi.org/10.1074/jbc.M310672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14638686	hybrid			2022-12-25	WOS:000189103300088
J	Cayouette, S; Lussier, MP; Mathieu, EL; Bousquet, SM; Boulay, G				Cayouette, S; Lussier, MP; Mathieu, EL; Bousquet, SM; Boulay, G			Exocytotic insertion of TRPC6 channel into the plasma membrane upon G(q) protein-coupled receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CALCIUM-ENTRY; CA2+-PERMEABLE CATION CHANNEL; INTRACELLULAR CA2+ STORES; OPERATED HTRP3 CHANNELS; GTP-BINDING PROTEINS; TRANSIENT RECEPTOR; SIGNAL-TRANSDUCTION; MAST-CELLS; FUNCTIONAL EXPRESSION	TRPC proteins are the mammalian homologues of the Drosophila transient receptor potential channel and are involved in calcium entry after agonist stimulation of non-excitable cells. Seven mammalian TRPCs have been cloned, and their mechanisms of activation and regulation are still the subject of intense research. TRPC proteins interact with the inositol 1,4,5-trisphosphate receptor, and the conformational coupling plays a critical role in the activation of calcium entry. Some evidence also supports an exocytotic mechanism as part of the activation of calcium entry. To investigate the possible involvement of exocytosis in TRPC6 activation, we evaluated the location of TRPC6 at the plasma membrane by biotinylation labeling of cell surface proteins and by indirect immunofluorescence marking of TRPC6 in stably transfected HEK 293 cells. We showed that when the muscarinic receptor was stimulated or the thapsigargin-induced intracellular calcium pool was depleted the level of TRPC6 at the plasma membrane increased. The carbachol concentration at which TRPC6 externalization occurred was lower than the concentration required to activate TRPC6. Externalization occurred within the first 30 s of stimulation, and TRPC6 remained at the plasma membrane as long as the stimulus was present. These results indicate that an exocytotic mechanism is involved in the activation of TRPC6.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Boulay, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001,12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Guylain.Boulay@USherbrooke.ca	Boulay, Guylain/D-9773-2010	Lussier, Marc/0000-0001-5568-0072				Alderton JM, 2000, CELL CALCIUM, V28, P161, DOI 10.1054/ceca.2000.0144; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Basora N, 2003, J BIOL CHEM, V278, P31709, DOI 10.1074/jbc.M304437200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fierro L, 1999, J PHYSIOL-LONDON, V520, P407, DOI 10.1111/j.1469-7793.1999.00407.x; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; SUI AL, 1994, NEUROCHEM RES, V19, P753, DOI 10.1007/BF00967716; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Trevino CL, 2001, FEBS LETT, V509, P119, DOI 10.1016/S0014-5793(01)03134-9; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vogler O, 1999, J PHARMACOL EXP THER, V288, P36; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; WenzelSeifert K, 1996, BIOCHEM J, V314, P679, DOI 10.1042/bj3140679; Xu XZS, 2003, CELL, V114, P285, DOI 10.1016/S0092-8674(03)00565-8; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	61	147	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7241	7246		10.1074/jbc.M312042200	http://dx.doi.org/10.1074/jbc.M312042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662757	hybrid			2022-12-25	WOS:000188969200125
J	Dodier, Y; Banderali, U; Klein, H; Topalak, O; Dafi, O; Simoes, M; Bernatchez, G; Sauve, R; Parent, L				Dodier, Y; Banderali, U; Klein, H; Topalak, O; Dafi, O; Simoes, M; Bernatchez, G; Sauve, R; Parent, L			Outer pore topology of the ECaC-TRPV5 channel by cysteine scan mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR M2-M3 LOOP; CA2+ CHANNEL; POTASSIUM CHANNEL; SELECTIVITY FILTER; MOLECULAR DETERMINANTS; SUBSTITUTED CYSTEINES; CRYSTAL-STRUCTURE; CALCIUM-CHANNEL; K+ CHANNEL; M2 SEGMENT	The substituted cysteine accessibility method (SCAM) was used to map the external vestibule and the pore region of the ECaC-TRPV5 calcium-selective channel. Cysteine residues were introduced at 44 positions from the end of S5 (Glu(515)) to the beginning of S6 (Ala(560)). Covalent modification by positively charged MTSET applied from the external medium significantly inhibited whole cell currents at 15/44 positions. Strongest inhibition was observed in the S5-linker to pore region (L520C, G521C, and E522C) with either MTSET or MTSES suggesting that these residues were accessible from the external medium. In contrast, the pattern of covalent modification by MTSET for residues between Pro(527) and Ile(541) was compatible with the presence of a alpha-helix. The absence of modification by the negatively charged MTSES in that region suggests that the pore region has been optimized to favor the entrance of positively charged ions. Cysteine mutants at positions - 1, 0, + 1, +2 around Asp(542) (high Ca2+ affinity site) were non-functional. Whole cell currents of cysteine mutants at +4 and +5 positions were however covalently inhibited by external MTSET and MTSES. Altogether, the pattern of covalent modification by MTS reagents globally supports a KcsA homology-based three-dimensional model whereby the external vestibule in ECaC-TRPV5 encompasses three structural domains consisting of a coiled structure (Glu(515) to Tyr(526)) connected to a small helical segment of 15 amino acids ((527)PTALFSTFELFLT(539)) followed by two distinct coiled structures Ile(540)-Pro(544) (selectivity filter) and Ala(545) -Ile(557) before the beginning of S6.	Univ Montreal, Fac Med, Dept Physiol, Membrane Prot Study Grp GEPROM, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Parent, L (corresponding author), Univ Montreal, Fac Med, Dept Physiol, Membrane Prot Study Grp GEPROM, Montreal, PQ H3C 3J7, Canada.	lucie.parent@umontreal.ca	Banderali, Umberto/AAW-2463-2021					Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Jean K, 2002, AM J PHYSIOL-CELL PH, V282, pC665, DOI 10.1152/ajpcell.00443.2001; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; KALUZ S, 1992, NUCLEIC ACIDS RES, V20, P4369, DOI 10.1093/nar/20.16.4369; Koch SE, 2000, J BIOL CHEM, V275, P34493, DOI 10.1074/jbc.M005569200; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Kuner T, 2001, J NEUROSCI, V21, P4162, DOI 10.1523/JNEUROSCI.21-12-04162.2001; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Neale EJ, 2003, J BIOL CHEM, V278, P29079, DOI 10.1074/jbc.M301991200/6493; Nilius B, 2003, PFLUG ARCH EUR J PHY, V445, P584, DOI 10.1007/s00424-002-0923-9; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; Parent L, 1997, J MEMBRANE BIOL, V160, P127, DOI 10.1007/s002329900302; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Peng JB, 2000, J BIOL CHEM, V275, P28186; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Simoes M, 2002, J GEN PHYSIOL, V120, P99, DOI 10.1085/jgp.20028586; SINGH R, 1995, METHOD ENZYMOL, V251, P167, DOI 10.1016/0076-6879(95)51119-9; Vedantham V, 2000, BIOPHYS J, V78, P2943, DOI 10.1016/S0006-3495(00)76834-2; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Wu XS, 2000, J BIOL CHEM, V275, P31778, DOI 10.1074/jbc.M004829200; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6853	6862		10.1074/jbc.M310534200	http://dx.doi.org/10.1074/jbc.M310534200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14630907	hybrid			2022-12-25	WOS:000188969200080
J	Metz, B; Kersten, GFA; Hoogerhout, P; Brugghe, HF; Timmermans, HAM; de Jong, A; Meiring, H; ten Hove, J; Hennink, WE; Crommelin, DJA; Jiskoot, W				Metz, B; Kersten, GFA; Hoogerhout, P; Brugghe, HF; Timmermans, HAM; de Jong, A; Meiring, H; ten Hove, J; Hennink, WE; Crommelin, DJA; Jiskoot, W			Identification of formaldehyde-induced modifications in proteins - Reactions with model peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIVE ALKYLATION; HYDROGEN-FLUORIDE; ACETALDEHYDE; BIOPROSTHESES; MECHANISM; CYSTEINE; ADDUCTS; VACCINE; FORMOL; LYSINE	Formaldehyde is a well known cross-linking agent that can inactivate, stabilize, or immobilize proteins. The purpose of this study was to map the chemical modifications occurring on each natural amino acid residue caused by formaldehyde. Therefore, model peptides were treated with excess formaldehyde, and the reaction products were analyzed by liquid chromatography-mass spectrometry. Formaldehyde was shown to react with the amino group of the N-terminal amino acid residue and the side-chains of arginine, cysteine, histidine, and lysine residues. Depending on the peptide sequence, methylol groups, Schiff-bases, and methylene bridges were formed. To study intermolecular cross-linking in more detail, cyanoborohydride or glycine was added to the reaction solution. The use of cyanoborohydride could easily distinguish between peptides containing a Schiff-base or a methylene bridge. Formaldehyde and glycine formed a Schiff-base adduct, which was rapidly attached to primary N-terminal amino groups, arginine and tyrosine residues, and, to a lesser degree, asparagine, glutamine, histidine, and tryptophan residues. Unexpected modifications were found in peptides containing a free N-terminal amino group or an arginine residue. Formaldehyde-glycine adducts reacted with the N terminus by means of two steps: the N terminus formed an imidazolidinone, and then the glycine was attached via a methylene bridge. Two covalent modifications occurred on an arginine-containing peptide: (i) the attachment of one glycine molecule to the arginine residue via two methylene bridges, and (a) the coupling of two glycine molecules via four methylene bridges. Remarkably, formaldehyde did not generate intermolecular cross-links between two primary amino groups. In conclusion, the use of model peptides enabled us to determine the reactivity of each particular cross-link reaction as a function of the reaction conditions and to identify new reaction products after incubation with formaldehyde.	Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Fac Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands; Netherlands Vaccine Inst, Unit Res & Dev, NL-3720 AL Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Analyt Chem Lab, NL-3720 BA Bilthoven, Netherlands	Utrecht University; Netherlands National Institute for Public Health & the Environment	Jiskoot, W (corresponding author), Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Fac Pharmaceut Sci, Sorbonnelaan 16,POB 80082, NL-3508 TB Utrecht, Netherlands.	W.Jiskoot@pharm.uu.nl	Jiskoot, Wim/A-6877-2016; Hennink, Wim/O-8632-2016	Jiskoot, Wim/0000-0002-1012-3456; 				BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BLASS J, 1968, ANN I PASTEUR PARIS, V115, P881; BLASS J, 1966, B SOC CHIM FR, P3120; BLASS J, 1965, CR HEBD ACAD SCI, V261, P1448; BRAUN KP, 1995, J BIOL CHEM, V270, P11263, DOI 10.1074/jbc.270.19.11263; CABRAL JMS, 1991, PROTEIN IMMOBILIZATI, P123; FELDMAN MY, 1973, PROG NUCL ACID RES M, V13, P131; Fowles LF, 1996, BIOCHEM PHARMACOL, V51, P1259, DOI 10.1016/0006-2952(95)02408-5; FOX CH, 1985, J HISTOCHEM CYTOCHEM, V33, P845, DOI 10.1177/33.8.3894502; FRAENKELCONRAT H, 1948, J AM CHEM SOC, V70, P2673, DOI 10.1021/ja01188a018; FRAENKELCONRAT H, 1948, J BIOL CHEM, V174, P827; GESQUIERE JC, 1990, J CHEM SOC CHEM COMM, P1402, DOI 10.1039/c39900001402; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; Heck AJR, 2001, CHEM-EUR J, V7, P910, DOI 10.1002/1521-3765(20010216)7:4<910::AID-CHEM910>3.0.CO;2-U; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Jiang WL, 2000, BIOTECHNOL BIOENG, V70, P507, DOI 10.1002/1097-0290(20001205)70:5<507::AID-BIT5>3.3.CO;2-3; KALLEN RG, 1971, J AM CHEM SOC, V93, P6236, DOI 10.1021/ja00752a040; Kelly D P, 1977, Adv Exp Med Biol, V86A, P641; Khor E, 1997, BIOMATERIALS, V18, P95, DOI 10.1016/S0142-9612(96)00106-8; KUNKEL GR, 1981, MOL CELL BIOCHEM, V34, P3, DOI 10.1007/BF02354846; Leppla SH, 2002, J CLIN INVEST, V110, P141, DOI [10.1172/JCI200216204, 10.1172/JCI0216204]; MEANS GE, 1995, ANAL BIOCHEM, V224, P1, DOI 10.1006/abio.1995.1001; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Metz B, 2003, VACCINE, V22, P156, DOI 10.1016/j.vaccine.2003.08.003; MITCHELL MA, 1990, INT J PEPT PROT RES, V36, P350; Murdin AD, 1996, VACCINE, V14, P735, DOI 10.1016/0264-410X(95)00211-I; NENCIONI L, 1991, INFECT IMMUN, V59, P625, DOI 10.1128/IAI.59.2.625-630.1991; Rappuoli R., 1997, NEW GENERATION VACCI, P417; STAPLETON JT, 1997, NEW GENERATION VACCI, P417; VARLET PM, 2001, OSTEOARTHR CARTILAGE, V9, pS6; Walker J. F., 1964, FORMALDEHYDE	33	417	466	2	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6235	6243		10.1074/jbc.M310752200	http://dx.doi.org/10.1074/jbc.M310752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638685	hybrid			2022-12-25	WOS:000188969200007
J	Varadan, R; Assfalg, M; Haririnia, A; Raasi, S; Pickart, C; Fushman, D				Varadan, R; Assfalg, M; Haririnia, A; Raasi, S; Pickart, C; Fushman, D			Solution conformation of Lys(63)-linked di-ubiquitin chain provides clues to functional diversity of polyubiquitin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; MULTIUBIQUITIN CHAIN; MEMBRANE-PROTEIN; BINDING; DOMAIN; PROTEOLYSIS; INHIBITION; VALIDATION; PROTEASOME; RELAXATION	Diverse cellular events are regulated by post-translational modification of substrate proteins via covalent attachment of one or a chain of ubiquitin molecules. The outcome of (poly)ubiquitination depends upon the specific lysine residues involved in the formation of polyubiquitin chains. Lys(48)-linked chains act as a universal signal for proteasomal degradation, whereas Lys(63)-linked chains act as a specific signal in several nondegradative processes. Although it has been anticipated that functional diversity between alternatively linked polyubiquitin chains relies on linkage-dependent differences in chain conformation/topology, direct structural evidence in support of this model has been lacking. Here we use NMR methods to determine the structure of a Lys(63)-linked di-ubiquitin chain. The structure is characterized by an extended conformation, with no direct contact between the hydrophobic residues Leu(8), Ile(44), and Val(70) on the ubiquitin units. This structure contrasts with the closed conformation observed for Lys(48)- linked di-ubiquitin wherein these residues form the interdomain interface (Cook, W. J., Jeffrey, L. C., Carson, M., Zhijian, C., and Pickart, C. M. (1992) J. Biol. Chem. 267, 16467-16471; Varadan, R., Walker, O., Pickart, C., and Fushman, D. (2002) J. Mol. Biol. 324, 637-647). Consistent with the open conformation of the Lys(63)-linked di-ubiquitin, our binding studies show that both ubiquitin domains in this chain can bind a ubiquitin-associated domain from HHR23A independently and in a mode similar to that for mono-ubiquitin. In contrast, Lys(48)- linked di-ubiquitin binds in a different, higher affinity mode that has yet to be determined. This is the first experimental evidence that alternatively linked polyubiquitin chains adopt distinct conformations.	Univ Maryland, Dept Chem & Biochem, Ctr Biomol Struct & Org, College Pk, MD 20742 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland College Park; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Fushman, D (corresponding author), Univ Maryland, Dept Chem & Biochem, Ctr Biomol Struct & Org, 1115 Agr Life Sci Surge Bldg, College Pk, MD 20742 USA.	fushman@wam.umd.edu		Assfalg, Michael/0000-0001-9331-3169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065334, R01GM060372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60372, GM65334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P850; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOSE R, 2001, J MAGN RESON, V149, P214; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fushman D, 1999, BIOCHEMISTRY-US, V38, P10225, DOI 10.1021/bi990897g; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hall JB, 2003, J BIOMOL NMR, V27, P261, DOI 10.1023/A:1025467918856; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	39	264	271	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7055	7063		10.1074/jbc.M309184200	http://dx.doi.org/10.1074/jbc.M309184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645257	hybrid			2022-12-25	WOS:000188969200103
J	Bates, IR; Feix, JB; Boggs, JM; Harauz, G				Bates, IR; Feix, JB; Boggs, JM; Harauz, G			An immunodominant epitope of myelin basic protein is an amphipathic alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-SCLEROSIS PATIENTS; MOLECULAR-DYNAMICS; LIPID-BILAYERS; 3-DIMENSIONAL STRUCTURE; SECONDARY-STRUCTURE; SELF-ASSOCIATION; T4 LYSOZYME; B-CELL; PEPTIDE; CONFORMATION	Myelin basic protein is a candidate autoantigen in multiple sclerosis. One of its dominant antigenic epitopes is segment Pro(85) to Pro(96) (human sequence numbering, corresponding to Pro(82) to Pro(93) in the mouse). There have been several, contradictory predictions of secondary structure in this region; either beta-sheet, alpha-helix, random coil, or combinations thereof have all been proposed. In this paper, molecular dynamics and site-directed spin labeling in aqueous solution indicate that this segment forms a transient alpha-helix, which is stabilized in 30% trifluoroethanol. When bound to a myelin-like membrane surface, this antigenic segment exhibits a depth profile that is characteristic of an amphipathic alpha-helix, penetrating up to 12 Angstrom into the bilayer. The alpha-helix is tilted similar to9degrees, and the central lysine is in an ideal snorkeling position for side-chain interaction with the negatively charged phospholipid head groups.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Univ Guelph, Biophys Interdept Grp, Guelph, ON N1G 2W1, Canada; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Hosp Sick Children, Dept Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Guelph; University of Guelph; Medical College of Wisconsin; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Harauz, G (corresponding author), Univ Guelph, Dept Mol Biol & Genet, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada.	gharauz@uoguelph.ca		Harauz, George/0000-0002-6114-9947	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB001980] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Bates IR, 2003, J MOL MODEL, V9, P290, DOI 10.1007/s00894-003-0145-x; Bates IR, 2003, J BIOL CHEM, V278, P29041, DOI 10.1074/jbc.M302766200; Bates IR, 2000, PROTEIN EXPRES PURIF, V20, P285, DOI 10.1006/prep.2000.1307; Beniac DR, 1997, J BIOL CHEM, V272, P4261, DOI 10.1074/jbc.272.7.4261; Boggs J.M., 1982, LIPID PROTEIN INTERA, P1; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; Cajal Y, 1997, BIOCHEMISTRY-US, V36, P2566, DOI 10.1021/bi962232+; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Hill CM, 2002, J STRUCT BIOL, V139, P13, DOI 10.1016/S1047-8477(02)00513-0; Hill CMD, 2003, MICRON, V34, P25, DOI 10.1016/S0968-4328(02)00058-6; KENIRY MA, 1979, BIOCHIM BIOPHYS ACTA, V578, P381, DOI 10.1016/0005-2795(79)90169-7; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P9264, DOI 10.1021/bi025934+; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; LIEBES LF, 1975, BIOCHIM BIOPHYS ACTA, V405, P27, DOI 10.1016/0005-2795(75)90311-6; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; MARTENSON RE, 1986, J NEUROCHEM, V46, P1612, DOI 10.1111/j.1471-4159.1986.tb01784.x; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; Matsoukas J, 2001, MINI-REV MED CHEM, V1, P273, DOI 10.2174/1389557013406873; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MENDZ GL, 1990, BIOCHEMISTRY-US, V29, P2304, DOI 10.1021/bi00461a014; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; Riccio P, 2000, J NEUROSCI RES, V59, P513, DOI 10.1002/(SICI)1097-4547(20000215)59:4<513::AID-JNR6>3.0.CO;2-M; Ridsdale RA, 1997, J BIOL CHEM, V272, P4269, DOI 10.1074/jbc.272.7.4269; Roccatano D, 2002, P NATL ACAD SCI USA, V99, P12179, DOI 10.1073/pnas.182199699; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; SMITH LS, 1976, BIOCHEM BIOPH RES CO, V71, P459, DOI 10.1016/0006-291X(76)90809-3; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; WARREN KG, 1987, ANN NEUROL, V21, P183, DOI 10.1002/ana.410210211; WARREN KG, 1994, ANN NEUROL, V35, P280, DOI 10.1002/ana.410350307; WHITAKER JN, 1990, J NEUROCHEM, V55, P568, DOI 10.1111/j.1471-4159.1990.tb04171.x; Wucherpfennig KW, 1997, J CLIN INVEST, V100, P1114, DOI 10.1172/JCI119622	38	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5757	5764		10.1074/jbc.M311504200	http://dx.doi.org/10.1074/jbc.M311504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630913	hybrid, Green Published			2022-12-25	WOS:000188776500089
J	Biasio, W; Chang, T; McIntosh, CJ; McDonald, FJ				Biasio, W; Chang, T; McIntosh, CJ; McDonald, FJ			Identification of Murr1 as a regulator of the human delta epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; LIDDLES-SYNDROME; COPPER TOXICOSIS; BETA-SUBUNIT; GAMMA-SUBUNIT; SYNTAXIN 1A; HYPERTENSION; PROTEIN; GENE; EXPRESSION	The human delta epithelial sodium channel (deltaENaC) subunit is related to the alpha-, beta-, and gammaENaC subunits that control salt homeostasis. deltaENaC forms an amiloride-sensitive Na+ channel with the beta and gamma subunits. However, the in vivo function of deltaENaC is not known. To gain insight into the function of deltaENaC, a yeast two-hybrid screen of a human brain cDNA library was carried out using the C- and N-terminal domains of deltaENaC. A novel deltaENaC-interacting protein called Murr1 (mouse U2af1-rs1 region) was isolated in the C- terminal domain screen. Murr1 is a 21-kDa protein mutated in Bedlington terriers suffering from copper toxicosis. The interaction of Murr1 and deltaENaC was confirmed by glutathione S-transferase pulldown assay and coimmunoprecipitation. To test the functional significance of the interaction, Murr1 was coexpressed with deltabetagammaENaC in Xenopus oocytes. Murr1 inhibited amiloride-sensitive sodium current in a dose-dependent manner. In addition, deletion of the last 59 amino acids of deltaENaC abolished the inhibition. Murr1 also bound to the beta- and gammaENaC subunits and inhibited alphabetagammaENaC sodium current. Therefore, these results suggest that Murr1 is a novel regulator of ENaC.	Univ Otago, Dept Physiol, Dunedin 9001, New Zealand; Univ Victoria, Sch Biol Sci, Wellington 6004, New Zealand	University of Otago; Victoria University Wellington	McDonald, FJ (corresponding author), Univ Otago, Dept Physiol, POB 913, Dunedin 9001, New Zealand.	fiona.mcdonald@stonebow.otago.ac.nz						Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Brockway LM, 2002, AM J PHYSIOL-CELL PH, V283, pC126, DOI 10.1152/ajpcell.00457.2001; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Handy RD, 2002, BBA-BIOMEMBRANES, V1566, P104, DOI 10.1016/S0005-2736(02)00590-4; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; JOHNSON GF, 1981, HEPATOLOGY, V1, P243, DOI 10.1002/hep.1840010309; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Muller T, 2003, J HEPATOL, V38, P164, DOI 10.1016/S0168-8278(02)00356-2; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	32	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5429	5434		10.1074/jbc.M311155200	http://dx.doi.org/10.1074/jbc.M311155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645214	hybrid			2022-12-25	WOS:000188776500049
J	Ward, CW; Feng, W; Tu, JC; Pessah, IN; Worley, PK; Schneider, MF				Ward, CW; Feng, W; Tu, JC; Pessah, IN; Worley, PK; Schneider, MF			Homer protein increases activation of Ca2+ sparks in permeabilized skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; IP3 RECEPTORS; COMPLEX; MODULATION; CALMODULIN; BINDING; FROG	Members of the Homer family of proteins are known to form multimeric complexes capable of cross-linking plasma membrane channels (e.g. metabotropic glutamate receptor) and intracellular Ca2+ release channels (e.g. inositol trisphosphate receptor) in neurons, which potentiates Ca2+ release. Recent work has demonstrated direct interaction of Homer proteins with type 1 and type 2 ryanodine receptor (RyR) isoforms. Moreover, Homer proteins have been shown to modulate RyR-dependent Ca2+ release in isolated channels as well as in whole cell preparations. We now show that long and short forms of Homer H1 (H1c and H1-EVH1) are potent activators of Ca2+ release via RyR in skeletal muscle fibers (e.g. Ca-2_ sparks) and potent modulators of ryanodine binding to membranes enriched with RyR, with H1c being significantly more potent than H1-EVH1. Homer did not significantly alter the spatio-temporal properties of the sparks, demonstrating that Homer increases the rate of opening of RyRs, with no change in the overall RyR channel open time and amount of Ca2+ released during a spark. No changes in Ca2+ spark frequency or properties were observed using a full-length H1c with mutation in the EVH1 binding domain (H1c-G89N). One novel finding with each Homer agonist (H1c and H1-EVH1) was that in combination their actions on [3H]ryanodine binding was additive, an effect also observed for these Homer agonists in the Ca2+ spark studies. Finally, in Ca2+ spark studies, excess H1c-G89N prevented the effects of H1c in a dominant negative manner. Taken together our results suggest that the EVH1 domain is critical for the agonist behavior on Ca2+ sparks and ryanodine binding, and that the coiled-coil domain, present in long but not short form Homer, confers an increase in agonist potential apparently through the multimeric association of Homer ligand.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Nursing, Dept Syst & Adult Hlth, Baltimore, MD 21201 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Davis; Johns Hopkins University	Schneider, MF (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St Rm 229, Baltimore, MD 21201 USA.	mschneid@umaryland.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Hwang SY, 2003, CELL CALCIUM, V34, P177, DOI 10.1016/S0143-4160(03)00082-4; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kammermeier PJ, 2000, J NEUROSCI, V20, P7238; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, BIOCHEM BIOPH RES CO, V139, P235, DOI 10.1016/S0006-291X(86)80104-8; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sandona D, 2000, BIOCHEM BIOPH RES CO, V279, P348, DOI 10.1006/bbrc.2000.3948; Schneider MF, 1999, J GEN PHYSIOL, V113, P365, DOI 10.1085/jgp.113.3.365; Schneider MF, 2002, FRONT BIOSCI-LANDMRK, V7, pD1212, DOI 10.2741/schneide; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Tang W, 2002, FRONT BIOSCI, V7, pD1583, DOI 10.2741/tang; Thomas U, 2002, J NEUROCHEM, V81, P407, DOI 10.1046/j.1471-4159.2002.00869.x; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TSUCHIYA T, 1988, BIOPHYS J, V53, P415, DOI 10.1016/S0006-3495(88)83118-7; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Wagenknecht T, 2002, FRONT BIOSCI, V7, pD1464, DOI 10.2741/wagen; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	38	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5781	5787		10.1074/jbc.M311422200	http://dx.doi.org/10.1074/jbc.M311422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660561	hybrid			2022-12-25	WOS:000188776500092
J	Liu, LP; Hachey, DL; Valadez, G; Williams, KM; Guengerich, FP; Loktionova, NA; Kanugula, S; Pegg, AE				Liu, LP; Hachey, DL; Valadez, G; Williams, KM; Guengerich, FP; Loktionova, NA; Kanugula, S; Pegg, AE			Characterization of a mutagenic DNA adduct formed from 1,2-dibromoethane by O-6-alkylguanine-DNA alkyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN O(6)-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MAMMALIAN GLUTATHIONE TRANSFERASES; ESCHERICHIA-COLI; ETHYLENE DIBROMIDE; ALKYLATING-AGENTS; EXCISION-REPAIR; CONJUGATION; BINDING; DIBROMOALKANES; BACTERIAL	It has been proposed that the DNA repair protein O-6-alkylguanine-DNA alkyltransferase increases the mutagenicity of 1,2-dibromoethane by reacting with it at its cysteine acceptor site to form a highly reactive half-mustard, which can then react with DNA (Liu, L., Pegg, A. E., Williams, K. M., and Guengerich, F. P. (2002) J. Biol. Chem. 277, 37920-37928). Incubation of Escherichia coli-expressed human alkyltransferase with 1,2-dibromoethane and single-stranded oligodeoxyribonucleotides led to the formation of covalent transferaseoligo complexes. The order of reaction determined was Gua>Thy>Cyt>Ade. Mass spectrometry analysis of the tryptic digest of the reaction product indicated that some of the adducts led to depurination with the release of the Gly(136)-Arg(147) peptide cross-linked to a Gua at the N-7 position, with the site of reaction being the active site Cys(145) as established by chromatographic retention time and the fragmentation pattern determined by tandem mass spectrometry of a synthetic peptide adduct. The alkyltransferase-mediated mutations produced by 1,2-dibromoethane were predominantly Gua to Ade transitions but, in the spectrum of such rifampicin-resistant mutations in the RpoB gene, 20% were Gua to Thy transversions. The latter are likely to have arisen from the apurinic site generated from the Gua-N-7 adduct. Support exists for an additional adduct/mutagenic pathway because evidence was obtained for DNA adducts other than at the Gua N-7 atom and for mutations other than those attributable to depurination. Thus, chemical and biological evidence supports the existence of at least two alkyltransferase-dependent pathways for 1,2-dibromoethane-induced mutagenicity, one involving Gua N-7-alkylation by alkyltransferase-S-CH2CH2Br and depurination, plus another as yet uncharacterized system(s).	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Vanderbilt University; Vanderbilt University	Pegg, AE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	apegg@psu.edu	Williams, Kevin/C-3804-2011	Williams, Kevin/0000-0003-4019-8528	NCI NIH HHS [R01 CA18137] Funding Source: Medline; NIEHS NIH HHS [R01 ES10546, T32 ES07028, P30 ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, R01ES010546, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abril N, 1997, CARCINOGENESIS, V18, P1883, DOI 10.1093/carcin/18.10.1883; Abril N, 2001, MUTAT RES-GEN TOX EN, V497, P111, DOI 10.1016/S1383-5718(01)00235-2; ABRIL N, 1995, MOL CARCINOGEN, V12, P110, DOI 10.1002/mc.2940120208; Abril N, 1999, CARCINOGENESIS, V20, P2089, DOI 10.1093/carcin/20.11.2089; Abril N, 1999, CHEM RES TOXICOL, V12, P544, DOI 10.1021/tx980250h; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; Bridges BA, 1999, CURR BIOL, V9, pR475, DOI 10.1016/S0960-9822(99)80299-1; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; Crone TM, 1996, MUTAT RES-DNA REPAIR, V363, P15, DOI 10.1016/0921-8777(95)00058-5; Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Garibyan L, 2003, DNA REPAIR, V2, P593, DOI 10.1016/S1568-7864(03)00024-7; Goodtzova K, 1998, BIOCHEMISTRY-US, V37, P12489, DOI 10.1021/bi9811718; GORDON AJE, 1990, MUTAT RES, V233, P95, DOI 10.1016/0027-5107(90)90154-V; Guengerich FP, 2003, BIOCHEMISTRY-US, V42, P10965, DOI 10.1021/bi034937z; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; KOGA N, 1986, BIOCHEMISTRY-US, V25, P2192, DOI 10.1021/bi00356a051; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LETZ GA, 1984, JAMA-J AM MED ASSOC, V252, P2428, DOI 10.1001/jama.252.17.2428; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Liu H, 2000, MUTAT RES-FUND MOL M, V452, P1, DOI 10.1016/S0027-5107(00)00062-2; Liu LP, 2002, CANCER RES, V62, P3037; Liu LP, 2002, J BIOL CHEM, V277, P37920, DOI 10.1074/jbc.M205548200; MANIATIS T, 1982, MOL CLONING LABORATO, P440; MATTES WB, 1986, NUCLEIC ACIDS RES, V14, P2971, DOI 10.1093/nar/14.7.2971; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; OLSON WA, 1973, JNCI-J NATL CANCER I, V51, P1993, DOI 10.1093/jnci/51.6.1993; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; Pieper RO, 1997, PHARMACOL THERAPEUT, V74, P285, DOI 10.1016/S0163-7258(97)00003-X; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; Rasimas JJ, 2003, J BIOL CHEM, V278, P7973, DOI 10.1074/jbc.M211854200; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; Spratt TE, 1999, BIOCHEMISTRY-US, V38, P6801, DOI 10.1021/bi982908w; VANBLADEREN PJ, 1980, BIOCHEM PHARMACOL, V29, P2975, DOI 10.1016/0006-2952(80)90047-7; VANBLADEREN PJ, 1980, MUTAT RES, V74, P341, DOI 10.1016/0165-1161(80)90192-2; VANBLADEREN PJ, 1981, CARCINOGENESIS, V2, P499; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1107, DOI 10.1021/tx0100183; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1118, DOI 10.1021/tx010019v; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Xu-Welliver M, 1998, CANCER RES, V58, P1936; YAMADA M, 1995, J BACTERIOL, V177, P1511, DOI 10.1128/jb.177.6.1511-1519.1995	48	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4250	4259		10.1074/jbc.M311105200	http://dx.doi.org/10.1074/jbc.M311105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645247	hybrid			2022-12-25	WOS:000188554300042
J	Ruefli-Brasse, AA; Lee, WP; Hurst, S; Dixit, VM				Ruefli-Brasse, AA; Lee, WP; Hurst, S; Dixit, VM			Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; IMMUNE-RESPONSES; LYMPHOCYTE-ACTIVATION; MALT LYMPHOMA; CARMA1; KINASE; REGULATOR; CARD11; PHOSPHORYLATION; IDENTIFICATION	Engagement of the T-cell receptor (TCR) initiates a signaling cascade that ultimately results in activation of the transcription factor NF-kappaB, which regulates many T-cell functions including proliferation, differentiation and cytokine production. Herein we demonstrate that Rip2, a caspase recruitment domain (CARD)-containing serine/threonine kinase, plays an important role in this cascade and is required for optimal TCR signaling and NF-kappaB activation. Following TCR engagement, Rip2 associated with Bcl10, a CARD-containing signaling component of the TCR-induced NF-kappaB pathway, and induced its phosphorylation. Rip2-deficient mice were defective in TCR-induced NF-kappaB activation, interleukin-2 production, and proliferation in vitro and exhibited defective T-cell-dependent responses in vivo. The defect in Rip2(-/-) T-cells correlated with a lack of TCR-induced Bcl10 phosphorylation. Furthermore, deficiency in Bcl10-dependent NF-kappaB activation could be rescued in Rip2(-/-) embryonic fibroblasts by exogenous wild-type Rip2 but not a kinase-dead mutant. Together these data define an important role for Rip2 in TCR-induced NF-kappaB activation and T-cell function and highlight the significance of post-translational modification of Bcl10 by Rip2 in T-cell signaling.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Mail Stop 40, San Francisco, CA 94080 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Mak TW, 2002, NATURE, V418, P835, DOI 10.1038/418835a; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thome M, 2001, J CELL BIOL, V152, P1115, DOI 10.1083/jcb.152.5.1115; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287	24	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1570	1574		10.1074/jbc.C300460200	http://dx.doi.org/10.1074/jbc.C300460200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14638696	hybrid			2022-12-25	WOS:000187722800090
J	Johnson, NA; Sengupta, S; Saidi, SA; Lessan, K; Charnock-Jones, SD; Scott, L; Stephens, R; Freeman, TC; Tom, BDM; Harris, M; Denyer, G; Sundaram, M; Sasisekharan, R; Smith, SK; Print, CG				Johnson, NA; Sengupta, S; Saidi, SA; Lessan, K; Charnock-Jones, SD; Scott, L; Stephens, R; Freeman, TC; Tom, BDM; Harris, M; Denyer, G; Sundaram, M; Sasisekharan, R; Smith, SK; Print, CG			Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation	FASEB JOURNAL			English	Article						gene array; survival factor deprivation; cell surface glycosaminoglycans; independent component analysis; cluster analysis	CASPASE-MEDIATED CLEAVAGE; GROWTH-FACTOR VEGF; GENE-EXPRESSION; KAPPA-B; ANGIOGENESIS; ACTIVATION; REGRESSION; SURVIVAL; HEPARIN; PROTEIN	The protein-based changes that underlie the cell biology of apoptosis have been extensively studied. In contrast, mRNA- and polysaccharide-based changes have received relatively little attention. We have combined transcriptome and glycome analyses to show that apoptotic endothelial cell cultures undergo programmed changes to RNA transcript abundance and cell surface polysaccharide profiles. Although a few of the transcriptome changes were protective, most appeared to prepare cells for apoptosis by decreasing the reception and transduction of prosurvival signals, increasing pro-death signals, increasing abundance of apoptotic machinery, inhibiting cellular proliferation, recruiting phagocytes to regions of cell death, and promoting phagocytosis. Additional transcriptornal changes appeared to alter the synthesis and modification of cell surface glycosaminoglycans. The resultant reduced abundance of sulphated cell surface glycosaminoglycans may further promote cell death by inhibiting the presentation of extracellular matrix-tethered survival factors to their receptors on dying cells. We propose that the transcriptome and glycome regulation presented here synergize with previously described protein-based changes to guide the apoptotic program.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; MIT, Biol Engn Div, Cambridge, MA 02139 USA; UK MRC HGMP Resource Ctr, Cambridge, England; MRC, Biostat Unit, Cambridge CB2 2BW, England; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Cambridge; Massachusetts Institute of Technology (MIT); MRC Biostatistics Unit; University of Sydney	Print, CG (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	cgp22@cam.ac.uk	denyer, gareth/E-3437-2010; Denyer, Gareth/M-5417-2016; Charnock-Jones, D. Stephen/B-3743-2009; Charnock-Jones, D. Stephen/AAE-3391-2020	Denyer, Gareth/0000-0003-1551-3936; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Smith, Stephen/0000-0003-1912-3935; Saidi, Samir/0000-0001-5165-2461; Tom, Brian/0000-0002-3335-9322; Freeman, Thomas/0000-0001-5235-8483; Print, Cristin/0000-0001-8345-7812	Pfizer/BBSRC studentship; Wellcome Trust Fellowship	Pfizer/BBSRC studentship; Wellcome Trust Fellowship(Wellcome Trust)	We wish to thank Andrew Sharkey, Amanda Evans, and Reija Valtola for assistance with gene array analysis; Richard Clarkson and Jeremy Skepper for assistance with time-lapse fluorescent microscopy, and Andrew Wyllie for advice on the manuscript. N. J. was funded by a Pfizer/BBSRC studentship, and C. P. was funded by a Wellcome Trust Fellowship.	Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Allen RL., 2001, GENOME BIOL, V2; AMPOFO SA, 1991, ANAL BIOCHEM, V199, P249, DOI 10.1016/0003-2697(91)90098-E; AZMI TI, 1984, LAB INVEST, V51, P206; Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; Bach UC, 2001, EXP CELL RES, V265, P11, DOI 10.1006/excr.2001.5159; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Djonov V, 2001, MICROSC RES TECHNIQ, V52, P182, DOI 10.1002/1097-0029(20010115)52:2<182::AID-JEMT1004>3.3.CO;2-D; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Kabir J, 2002, BIOCHEM J, V367, P145, DOI 10.1042/BJ20020665; Karsan A, 1996, J Atheroscler Thromb, V3, P75; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; Martoglio AM, 2002, BIOINFORMATICS, V18, P1617, DOI 10.1093/bioinformatics/18.12.1617; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Plendl J, 2000, ANAT HISTOL EMBRYOL, V29, P257, DOI 10.1046/j.1439-0264.2000.00265.x; Pober JS, 1998, PATHOL BIOL, V46, P159; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5; Shriver Z, 2000, P NATL ACAD SCI USA, V97, P10359, DOI 10.1073/pnas.97.19.10359; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang NP, 2001, CIRC RES, V88, P1223, DOI 10.1161/hh1201.093162; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Zoellner H, 1996, J CELL SCI, V109, P2571	46	29	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					188	190		10.1096/fj.03-0097fje	http://dx.doi.org/10.1096/fj.03-0097fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630703				2022-12-25	WOS:000188829300069
J	Prokop, A; Wrasidlo, W; Lode, H; Herold, R; Lang, F; Henze, G; Dorken, B; Wieder, T; Daniel, PT				Prokop, A; Wrasidlo, W; Lode, H; Herold, R; Lang, F; Henze, G; Dorken, B; Wieder, T; Daniel, PT			Induction of apoptosis by enediyne antibiotic calicheamicin theta II proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner	ONCOGENE			English	Article						calicheamicin; apoptosis; caspase-3; Bax; Bcl-2; cytochrome c; mitochondria; BJAB; Jurkat; HCT116	DRUG-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; SQUAMOUS-CELL CARCINOMA; HUMAN-MELANOMA CELLS; GEMTUZUMAB OZOGAMICIN; DEATH RECEPTOR; IDENTIFIES PATIENTS; OCCURS DOWNSTREAM; BAX/BCL-2 RATIO	Calicheamicin thetaII is a member of the enediyne class of antitumor antibiotics that bind to DNA and induce apoptosis. These compounds differ, however, from conventional anticancer drugs as they bind in a sequence-specific manner noncovalently to DNA and cause sequence-selective oxidation of deoxyriboses and bending of the DNA helix. Calicheamicin is clinically employed as immunoconjugate to antibodies directed against, for example, CD33 in the case of gemtuzumab ozogamicin. Here, we show by the use of the unconjugated drug that calicheamicin-induced apoptosis is independent from death-receptor/FADD-mediated signals. Moreover, calicheamicin triggers apoptosis in a p53-independent manner as shown by the use of p53 knockout cells. Cell death proceeds via activation of mitochondrial permeability transition, cytochrome c release and activation of caspase-9 and -3. The overexpression of Bcl-x(L) or Bcl-2 strongly inhibited calicheamicin-induced apoptosis. Knockout of Bax abrogated cell death after calicheamicin treatment. Thus, the activation of mitochondria and execution of cell death occur through a fully Bax-dependent mechanism. Interestingly, caspase inhibition by the pancaspase-inhibitor zVAD-fmk interfered with mitochondrial activation by calicheamicin. This places caspase activation upstream of the mitochondria and indicates that calicheamicin-triggered apoptosis is enhanced through death receptor-independent activation of the caspase cascade, that is, an amplification loop that is required for full activation of the mitochondrial pathway.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Humboldt Univ, Univ Med Ctr Charite, Dept Gen pediat, D-13353 Berlin, Germany; Humboldt Univ, Univ Med Ctr Charite, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch, D-13125 Berlin, Germany.			Herold, Ralf/0000-0002-8148-6748				Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cortazzo M, 1996, CANCER RES, V56, P1199; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; DANIEL PT, 2003, IN PRESS ESSAYS BIOC, V39; de Vetten MP, 2000, BRIT J HAEMATOL, V111, P277, DOI 10.1046/j.1365-2141.2000.02402.x; DHEIN J, 1992, J IMMUNOL, V149, P3166; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hiatt A, 1994, Bioorg Med Chem, V2, P315, DOI 10.1016/S0968-0896(00)82187-2; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linenberger ML, 2001, BLOOD, V98, P988, DOI 10.1182/blood.V98.4.988; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAIESE WM, 1989, J ANTIBIOT, V42, P558, DOI 10.7164/antibiotics.42.558; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Nabhan C, 2002, CLIN LYMPHOMA, V2, pS19, DOI 10.3816/CLM.2002.s.004; Nicolaou KC, 1994, CHEM BIOL, V1, P57, DOI 10.1016/1074-5521(94)90041-8; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P183, DOI 10.1002/anie.199401831; NICOLAOU KC, 1993, P NATL ACAD SCI USA, V90, P3142, DOI 10.1073/pnas.90.8.3142; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roucou X, 2001, CELL DEATH DIFFER, V8, P875, DOI 10.1038/sj.cdd.4400910; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Salzberg AA, 2000, BIOCHEMISTRY-US, V39, P7605, DOI 10.1021/bi992227g; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Thorson JS, 2000, CURR PHARM DESIGN, V6, P1841, DOI 10.2174/1381612003398564; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; van der Velden VHJ, 2001, BLOOD, V97, P3197, DOI 10.1182/blood.V97.10.3197; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	71	47	51	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9107	9120		10.1038/sj.onc.1207196	http://dx.doi.org/10.1038/sj.onc.1207196			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14647446				2022-12-25	WOS:000187149100001
J	Baumann, R; Casaulta, C; Simon, D; Conus, S; Yousefi, S; Simon, HU				Baumann, R; Casaulta, C; Simon, D; Conus, S; Yousefi, S; Simon, HU			Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway	FASEB JOURNAL			English	Article						inflammation; MIF; mitochondria	CYTOCHROME-C RELEASE; COLONY-STIMULATING FACTOR; PERMEABILITY TRANSITION PORE; REGULATORY ROLE; FAS RECEPTOR; TYROSINE PHOSPHORYLATION; CELL-DEATH; CYTOKINE; ACTIVATION; PROTEIN	Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine known to activate macrophages and T cells. In this study, we demonstrate that recombinant MIF delays apoptosis of neutrophils in vitro. MIF action is dose and time dependent as well as specific since it was abolished with a neutralizing anti-MIF antibody. MIF, like G-CSF, delayed cleavage of the proapoptotic members of the Bcl-2 family Bid and Bax in neutrophils, suggesting that MIF inhibits apoptosis pathways proximal to mitochondria activation. Indeed, MIF also prevented release of cytochrome c and Smac from the mitochondria and subsequent activation of the critical effector caspase-3 in these cells. Moreover, we observed increased MIF plasma levels in patients with cystic fibrosis, a heterogeneous recessive genetic disorder associated with bacterial infections and delayed neutrophil apoptosis. In conclusion, MIF is a survival cytokine for human neutrophils, a finding with potential pathologic relevance in infectious diseases.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Pediat, CH-3010 Bern, Switzerland; Univ Bern, Dept Dermatol, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BRACH MA, 1992, BLOOD, V80, P2920; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CLARK JM, 1980, J CELL BIOL, V84, P102, DOI 10.1083/jcb.84.1.102; COLOTTA F, 1992, BLOOD, V80, P2012; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Daigle I, 2001, INT ARCH ALLERGY IMM, V126, P147, DOI 10.1159/000049506; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Gao G, 2000, J CELL BIOCHEM, V80, P53; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Hebestreit H, 1996, EUR J IMMUNOL, V26, P1775, DOI 10.1002/eji.1830260817; Heinisch IVWM, 2000, EUR J IMMUNOL, V30, P3441, DOI 10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; IWAI K, 1994, BLOOD, V84, P1201; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Simon D, 2002, ALLERGY, V57, P431, DOI 10.1034/j.1398-9995.2002.13506.x; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; Simon HU, 1997, J IMMUNOL, V158, P3902; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Watson RWG, 1999, FEBS LETT, V453, P67, DOI 10.1016/S0014-5793(99)00688-2; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yousefi S, 2002, CELL DEATH DIFFER, V9, P595, DOI 10.1038/sj.cdd.4401037; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	53	106	108	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2221	2230		10.1096/fj.03-0110com	http://dx.doi.org/10.1096/fj.03-0110com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656984				2022-12-25	WOS:000188067500043
J	Ueda, J; Kajita, M; Suenaga, N; Fujii, K; Seiki, M				Ueda, J; Kajita, M; Suenaga, N; Fujii, K; Seiki, M			Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors	ONCOGENE			English	Article						MT1-MMP; MMP-2; CD44; tumor invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; CD44 CLEAVAGE; SURFACE; CANCER; ACTIVATION; PROGELATINASE; METASTASIS; CARCINOMA; ADHESION	Membrane-type 1 matrix metalloproteinase (MT1-MMP/MMP-14) has been believed a key enzyme in tumor invasion, because it is expressed in a variety of malignant human tumors, and overexpression of the enzyme enhances the ability of cellular invasiveness. However, it has not necessarily been clarified whether the endogenously expressed MT1-MMP in human tumors plays a critical role in their invasiveness. We used RNA silencing technology to downregulate the endogenous MT1-MMP expression in human tumor cells (fibrosarcoma HT1080 and gastric carcinoma MKN-28 cell lines), and evaluated the effect on the invasion of a reconstituted basement membrane (Matrigel). Transfection of a double-stranded RNA targeted to the MT1-MMP gene decreased the level of the enzyme to less than 10-20% without affecting production of other MMPs. According to the degree of silencing, activation of proMMP-2 was inhibited. CD44 shedding was also inhibited, but only in part. Decreased MT1-MMP levels were also reflected in reduced cell motility on hyaluronan (HA) and invasion in Matrigel. Thus, specific downregulation of MT1-MMP expression was sufficient to cause significant inhibition of the migration and invasion of tumor cells, even though other MMPs continued to be expressed.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Jikei Univ, Sch Med, Dept Orthopaed Surg, Minato Ku, Tokyo, Japan	University of Tokyo; Jikei University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015					Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Goebeler M, 1996, J CELL SCI, V109, P1957; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; McCarthy M, 2001, J RENAL NUTR, V11, P115; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAOT D, 1997, ADV CANCER RES, V71, P241; NOMURA H, 1995, CANCER RES, V55, P3263; Okada Y, 2000, VERH DEUT G, V84, P33; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	36	116	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8716	8722		10.1038/sj.onc.1206962	http://dx.doi.org/10.1038/sj.onc.1206962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647466				2022-12-25	WOS:000186844900009
J	Barnhart, BC; Lee, JC; Alappat, EC; Peter, ME				Barnhart, BC; Lee, JC; Alappat, EC; Peter, ME			The death effector domain protein family	ONCOGENE			English	Review						apoptosis; DD fold; cancer	TRAIL-INDUCED APOPTOSIS; NF-KAPPA-B; FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; CHRONIC LYMPHOCYTIC-LEUKEMIA; DOMINANT INTERFERING MUTANT; NECROSIS-FACTOR RECEPTOR-1; INDUCED-PROXIMITY MODEL	Apoptosis signaling is regulated and executed by specialized proteins that often carry protein/protein interaction domains. One of these domains is the death effector domain (DED) that is predominantly found in components of the death-inducing signaling complex, which forms at the members of the death receptor family following their ligation. Both proapoptotic- and antiapoptotic-DED-containing proteins have been identified, which makes these proteins exquisitely suited to the regulation of apoptosis. Aside from their pivotal role in the control of the apoptotic program, DED-containing proteins have recently been demonstrated to exert their influence on other cellular processes as well, including cell proliferation. These data highlight the multiple roles for the members of this family, suggesting that they are suited to control both life and death decisions of cells. Additionally, because they can act proapoptotically, antiapoptotically, or in the regulation of the cell cycle, this family of proteins may be excellent candidates for cancer therapy targets.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	MPeter@uchicago.edu		Peter, Marcus Ernst/0000-0003-3216-036X; Lee, Justine C./0000-0002-8943-0837				Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Alcivar A, 2003, ONCOGENE, V22, P291, DOI 10.1038/sj.onc.1206099; Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; ALGECIRASSCHIMN.A, 2003, IN PRESS P NATL SCI; ALGECIRASSCHIMN.A, 2002, CASPASES LANDES BIOS, P123; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chatterjee D, 2001, CANCER RES, V61, P7148; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Derfuss T, 2002, CURR TOP MICROBIOL, V269, P257; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Dong G, 2001, CANCER RES, V61, P4797; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Eggert A, 2001, CANCER RES, V61, P1314; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao CH, 2001, CANCER RES, V61, P1162; Harada K, 2002, CANCER RES, V62, P5897; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kim PKM, 1996, J IMMUNOL, V157, P5461; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Koga S, 2001, ANTICANCER RES, V21, P1937; Komata T, 2001, INT J ONCOL, V19, P1015; Kondo S, 1998, HUM GENE THER, V9, P1599, DOI 10.1089/hum.1998.9.11-1599; Koonin EV, 1999, NATURE, V401, P662, DOI 10.1038/44317; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kubes M, 1998, J NEUROCHEM, V71, P1307; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Leo CP, 1998, ENDOCRINOLOGY, V139, P4839, DOI 10.1210/en.139.12.4839; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Roth W, 2002, J BIOL CHEM, V277, P7501, DOI 10.1074/jbc.M110749200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Stegh Alexander H., 2001, Cardiology Clinics, V19, P13, DOI 10.1016/S0733-8651(05)70192-2; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Telliez JB, 2000, J MOL BIOL, V300, P1323, DOI 10.1006/jmbi.2000.3899; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Uzzo RG, 2001, CLIN CANCER RES, V7, P3276; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhan Y, 2002, CELL DEATH DIFFER, V9, P439, DOI 10.1038/sj.cdd.4401038; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	163	82	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8634	8644		10.1038/sj.onc.1207103	http://dx.doi.org/10.1038/sj.onc.1207103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634625				2022-12-25	WOS:000186720000009
J	Spurgers, KB; Coombes, KR; Meyn, RE; Gold, DL; Logothetis, CJ; Johnson, TJ; McDonnell, TJ				Spurgers, KB; Coombes, KR; Meyn, RE; Gold, DL; Logothetis, CJ; Johnson, TJ; McDonnell, TJ			A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells	ONCOGENE			English	Article						p53; bcl-2; apoptosis; cell cycle; transcriptome; genomics; adenovirus	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REPRESSION; P53-DEPENDENT APOPTOSIS; SUPEROXIDE-DISMUTASE; DEATH INDUCTION; DOWN-REGULATION; 26S PROTEASOME; BREAST-CANCER; BCL-2 FAMILY	The p53 protein can induce cell cycle arrest or apoptosis following activation in response to DNA damage. The function of p53 is largely mediated by regulating the expression of downstream target genes. Adenoviral- p53 gene transfer (Ad-p53) is currently being evaluated in clinical trials as a therapeutic intervention. Tumor response is likely to be influenced by context-dependent variables, such as expression of bcl-2. Bcl-2 is upregulated in a variety of neoplasms, and can inhibit p53-dependent apoptosis. It was therefore of interest to use a global genomic strategy to assess gene expression following Ad-p53 gene transfer and to determine if the expression of specific Ad-p53-responsive genes could be modulated in the context of bcl-2 gene deregulation. cDNA arrays were used to identify p53-responsive genes following Ad-p53 gene transfer in control and bcl-2-overexpressing PC3 prostate cancer cells. A total of 40 transcripts were significantly upregulated by Ad-p53 in both control and bcl-2-transfectant PC3 cells. Conversely, 19 transcripts were significantly repressed in both cell lines. These Adp53-responsive transcripts included previously identified p53 targets, known genes representing candidate p53 targets, and transcripts identified as expressed sequence tags. A subset of 15 transcripts was differentially modulated by Ad-p53 in the context of bcl-2. Some of these genes were also differentially modulated in LNCaP (wt p53) cells following DNA damage. These results document a number of potential p53 targets and mediators of therapeutically relevant genotoxic stress. The findings further suggest that bcl-2 may inhibit cell death at multiple points downstream of p53 activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tmcdonne@mdanderson.org		Coombes, Kevin/0000-0002-7630-2123	NATIONAL CANCER INSTITUTE [T32CA060440, P01CA078778, P50CA090270] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90270, P01 CA78778, CA60440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; [Anonymous], 2003, BIODRUGS, V17, P216; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Beham AW, 1998, INT J MOL MED, V1, P953; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruckheimer EM, 2000, ONCOGENE, V19, P5251, DOI 10.1038/sj.onc.1203881; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen SR, 2003, FREE RADICAL BIO MED, V34, P1315, DOI 10.1016/S0891-5849(03)00146-1; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dummer R, 2000, CANCER GENE THER, V7, P1069, DOI 10.1038/sj.cgt.7700214; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; HAINAUT P, 1993, CANCER RES, V53, P4469; HALL PA, 1993, ONCOGENE, V8, P203; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda T, 2002, CANCER BIOL THER, V1, P163, DOI 10.4161/cbt.63; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; ISAACS WB, 1991, CANCER RES, V51, P4716; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; KAIGHN ME, 1979, INVEST UROL, V17, P16; KASTAN MB, 1991, CANCER RES, V51, P6304; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lowe SW, 1999, CANC DRUG DISC DEV, V5, P21; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moul JV, 1999, EUR UROL, V35, P399, DOI 10.1159/000019916; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2000, CANCER RES, V60, P2805; Pagliaro LC, 2000, WORLD J UROL, V18, P148, DOI 10.1007/s003450050188; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Pollack A, 2003, CANCER-AM CANCER SOC, V97, P1630, DOI 10.1002/cncr.11230; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Robles AI, 2001, CANCER RES, V61, P6660; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schumacher G, 2001, INT J CANCER, V91, P159, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Swisher Stephen G, 2002, Surg Oncol Clin N Am, V11, P521, DOI 10.1016/S1055-3207(02)00028-5; Tanaka K, 1997, MOL BIOL REP, V24, P3, DOI 10.1023/A:1006876904158; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2003, CANCER GENE THER, V10, P224, DOI 10.1038/sj.cgt.7700562; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1994, CANCER GENE THER, V1, P5; Zhao RB, 2000, GENE DEV, V14, P981	97	12	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1712	1723		10.1038/sj.onc.1207293	http://dx.doi.org/10.1038/sj.onc.1207293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14647426				2022-12-25	WOS:000220029300007
J	Bhella, D; Goodfellow, IG; Roversi, P; Pettigrew, D; Chaudhry, Y; Evans, DJ; Lea, SM				Bhella, D; Goodfellow, IG; Roversi, P; Pettigrew, D; Chaudhry, Y; Evans, DJ; Lea, SM			The structure of echovirus type 12 bound to a two-domain fragment of its cellular attachment protein decay-accelerating factor (CD 55)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; COMMON COLD VIRUS; FACTOR CD55; 3-DIMENSIONAL STRUCTURE; COXSACKIEVIRUS A21; BINDING DOMAINS; RECEPTOR; POLIOVIRUS; RESOLUTION; CELLS	Echovirus type 12 (EV12), an Enterovirus of the Picornaviridae family, uses the complement regulator decay-accelerating factor (DAF, CD55) as a cellular receptor. We have calculated a three-dimensional reconstruction of EV12 bound to a fragment of DAF consisting of short consensus repeat domains 3 and 4 from cryo-negative stain electron microscopy data (EMD code 1057). This shows that, as for an earlier reconstruction of the related echovirus type 7 bound to DAF, attachment is not within the viral canyon but occurs close to the 2-fold symmetry axes. Despite this general similarity our reconstruction reveals a receptor interaction that is quite different from that observed for EV7. Fitting of the crystallographic co-ordinates for DAF(34) and EV11 into the reconstruction shows a close agreement between the crystal structure of the receptor fragment and the density for the virus-bound receptor, allowing unambiguous positioning of the receptor with respect to the virion (PDB code 1UPN). Our finding that the mode of virus-receptor interaction in EV12 is distinct from that seen for EV7 raises interesting questions regarding the evolution and biological significance of the DAF binding phenotype in these viruses.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	University of Glasgow; University of Oxford	Bhella, D (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	d.bhella@vir.gla.ac.uk	Bhella, David/J-8514-2012; Evans, David/C-7553-2012; Roversi, Pietro/F-8925-2011; Roversi, Pietro/AAK-4241-2021; Lea, Susan M/B-7678-2009	Bhella, David/0000-0003-2096-8310; Roversi, Pietro/0000-0001-9280-9437; Roversi, Pietro/0000-0001-9280-9437; Lea, Susan M/0000-0001-9287-8053; Evans, David J./0000-0002-1315-4258; Goodfellow, Ian/0000-0002-9483-510X	Medical Research Council [MC_U130115834] Funding Source: Medline; MRC [MC_U130115834] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Adrian M, 1998, MICRON, V29, P145, DOI 10.1016/S0968-4328(97)00068-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DOUGHERTY M, 2000, MICROSC MICROANAL, V6, P282; FENWICK ML, 1962, VIROLOGY, V18, P212, DOI 10.1016/0042-6822(62)90007-7; Filman DJ, 1998, ACTA CRYSTALLOGR D, V54, P1261, DOI 10.1107/S0907444998002790; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; Goodfellow IG, 2000, J GEN VIROL, V81, P1393, DOI 10.1099/0022-1317-81-5-1393; Goodfellow IG, 2001, J VIROL, V75, P4918, DOI 10.1128/JVI.75.10.4918-4921.2001; GUTTMAN N, 1977, VIROLOGY, V82, P25, DOI 10.1016/0042-6822(77)90029-0; He YN, 2003, J VIROL, V77, P4827, DOI 10.1128/JVI.77.8.4827-4835.2003; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; Hewat EA, 2000, EMBO J, V19, P6317, DOI 10.1093/emboj/19.23.6317; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Karnauchow TM, 1996, J VIROL, V70, P5143, DOI 10.1128/JVI.70.8.5143-5152.1996; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; LUKACIK P, 2003, IN PRESS P NATL ACAD; McDermott BM, 2000, J BIOL CHEM, V275, P23089, DOI 10.1074/jbc.M002146200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; PHAM T, 1995, INFECT IMMUN, V63, P1663, DOI 10.1128/IAI.63.5.1663-1668.1995; Powell RM, 1999, J GEN VIROL, V80, P3145, DOI 10.1099/0022-1317-80-12-3145; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Powell RM, 1998, J GEN VIROL, V79, P1707, DOI 10.1099/0022-1317-79-7-1707; Reischl A, 2001, J VIROL, V75, P9312, DOI 10.1128/JVI.75.19.9312-9319.2001; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SaCarvalho D, 1997, J VIROL, V71, P5115, DOI 10.1128/JVI.71.7.5115-5123.1997; SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; Spiller OB, 2002, J GEN VIROL, V83, P45, DOI 10.1099/0022-1317-83-1-45; Stuart AD, 2002, J VIROL, V76, P7694, DOI 10.1128/JVI.76.15.7694-7704.2002; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; WILLIAMS DT, 2003, IN PRESS J GEN VIROL; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200; Xiao C, 2001, J VIROL, V75, P2444, DOI 10.1128/JVI.75.5.2444-2451.2001; Xing L, 2000, EMBO J, V19, P1207, DOI 10.1093/emboj/19.6.1207	53	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8325	8332		10.1074/jbc.M311334200	http://dx.doi.org/10.1074/jbc.M311334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14634014	hybrid			2022-12-25	WOS:000189103300114
J	Foukas, LC; Panayotou, G; Shepherd, PR				Foukas, LC; Panayotou, G; Shepherd, PR			Direct interaction of major histocompatibility complex class II-derived peptides with class Ia phosphoinositide 3-kinase results in dose-dependent stimulatory effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; SH2 DOMAINS; REGULATORY SUBUNIT; PI 3-KINASE; INHIBITION; ACTIVATION; KINASE; SITE; RAPAMYCIN; ANTIGENS	Peptides corresponding to residues 65-79 of human lymphocyte antigen class II sequence (DQA*03011) are cell-permeable and at high concentrations block activation of protein kinase B/Akt and p70-S6 kinase in T-cells, effects attributed to inhibition of phosphoinositide (PI) 3-kinase activity. To understand the molecular basis of this, we analyzed the effect this peptide had on activity of class I PI 3-kinases. Although there was no effect on the activity of class Ib PI 3-kinase or on the protein kinase activity of class I PI 3-kinases, there was a biphasic effect on lipid kinase activity of the class Ia enzymes. There was an inhibition of activity at higher peptide concentrations because of a formation of insoluble complexes between peptide and enzyme. Conversely, at lower peptide concentrations there was a profound activation of PI 3-kinase activity of class Ia PI 3-kinases. Studies of peptide variants revealed that all active peptides conform to heptad repeat motifs characteristic of coiled-coil helices. Surface plasmon resonance studies confirmed direct sequence-specific binding of active peptide to the p85alpha adapter subunit of class Ia PI 3-kinase. Active peptides also activated protein kinase B and extracellular signal-regulated kinase (ERK) in vivo in a wortmannin-sensitive manner while reducing recoverable cellular p85 levels. These results indicate that the human lymphocyte antigen class II-derived peptides regulate PI 3-kinase by direct interaction, probably via the coiled-coil domain. These peptides define a novel mechanism of regulating PI 3-kinase and will provide a useful tool for specifically dissecting the function of class Ia PI 3-kinase in cells and for probing structure-function relationships in the class Ia PI 3-kinase heterodimers.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Greece	University of London; University College London; Alexander Fleming Biomedical Sciences Research Center	Shepherd, PR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	p.shepherd@ucl.ac.uk						BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Beeton C A, 1999, Mol Cell Biol Res Commun, V1, P153, DOI 10.1006/mcbr.1999.0124; Boytim ML, 2000, J CLIN INVEST, V105, P1447, DOI 10.1172/JCI8139; Boytim ML, 1998, J IMMUNOL, V160, P2215; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CLAUS R, 1990, IMMUNOL LETT, V26, P203, DOI 10.1016/0165-2478(90)90147-I; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; KRANGEL MS, 1986, J EXP MED, V163, P1173, DOI 10.1084/jem.163.5.1173; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PUPPO F, 1995, IMMUNOL TODAY, V16, P124, DOI 10.1016/0167-5699(95)80127-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	25	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7505	7511		10.1074/jbc.M303999200	http://dx.doi.org/10.1074/jbc.M303999200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660637	hybrid			2022-12-25	WOS:000189103300018
J	Liang, XQ; Lu, Y; Wilkes, M; Neubert, TA; Resh, MD				Liang, XQ; Lu, Y; Wilkes, M; Neubert, TA; Resh, MD			The N-terminal SH4 region of the Src family kinase Fyn is modified by methylation and heterogeneous fatty acylation - Role in membrane targeting, cell adhesion, and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 METHYLATION; ARGININE METHYLATION; LYSINE 9; IN-VIVO; METHYLTRANSFERASE; BINDING; PROTEINS; P59(FYN); ASSOCIATION; HP1	The N-terminal SH4 domain of Src family kinases is responsible for promoting membrane binding and plasma membrane targeting. Most Src family kinases contain an N-terminal Met-Gly-Cys consensus sequence that undergoes dual acylation with myristate and palmitate after removal of methionine. Previous studies of Src family kinase fatty acylation have relied on radiolabeling of cells with radioactive fatty acids. Although this method is useful for verifying that a given fatty acid is attached to a protein, it does not reveal whether other fatty acids or other modifying groups are attached to the protein. Here we use matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry to identify fatty acylated species of the Src family kinase Fyn. Our results reveal that Fyn is efficiently myristoylated and that some of the myristoylated proteins are also heterogeneously S-acylated with palmitate, palmitoleate, stearate, or oleate. Furthermore, we show for the first time that Fyn is trimethylated at lysine residues 7 and/or 9 within its N-terminal region. Both myristoylation and palmitoylation were required for methylation of Fyn. However, a general methylation inhibitor had no inhibitory effect on myristoylation and palmitoylation of Fyn, suggesting that methylation occurs after myristoylation and palmitoylation. Lysine mutants of Fyn that could not be methylated failed to promote cell adhesion and spreading, suggesting that methylation is important for Fyn function.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Columbia Univ, New York, NY 10027 USA	Memorial Sloan Kettering Cancer Center; New York University; New York University; Columbia University	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	m-resh@ski.mskcc.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR14662-01] Funding Source: Medline; NIGMS NIH HHS [GM 57966] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; DURBAN E, 1978, J BIOL CHEM, V253, P1427; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MAHER PA, 1993, J BIOL CHEM, V268, P4244; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; ROWE PM, 1986, J BIOL CHEM, V261, P7060; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159	26	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8133	8139		10.1074/jbc.M311180200	http://dx.doi.org/10.1074/jbc.M311180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660555	hybrid			2022-12-25	WOS:000189103300094
J	Kataoka, N; Dreyfuss, G				Kataoka, N; Dreyfuss, G			A simple whole cell lysate system for in vitro splicing reveals a stepwise assembly of the exon-exon junction complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; NONSENSE-MEDIATED DECAY; BINDING PROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; YEAST HOMOLOG; MAGO NASHI; SURVEILLANCE; DROSOPHILA; TRANSLATION	Pre-mRNA splicing removes introns and leaves in its wake a multiprotein complex near the exon-exon junctions of mRNAs. This complex, termed the exon-exon junction complex (EJC), contains at least seven proteins and provides a link between pre-mRNA splicing and downstream events, including transport, localization, and nonsense-mediated mRNA decay. Using a simple whole cell lysate system we developed for in vitro splicing, we prepared lysates from cells transfected with tagged EJC proteins and studied the association of these proteins with pre-mRNA, splicing intermediates, and mRNA, as well as formation of the EJC during splicing. Three of the EJC components, Aly/REF, RNPS1, and SRm160, are found on pre-mRNA by the time the spliceosome is formed, whereas Upf3b associates with splicing intermediates during or immediately after the first catalytic step of the splicing reaction (cleavage of exon 1 and intron-lariat formation). In contrast, Y14 and magoh, which remain stably associated with mRNA after export to the cytoplasm, join the EJC during or after completion of exon-exon ligation. These findings indicate that EJC formation is an ordered pathway that involves stepwise association of components and is coupled to specific intermediates of the splicing reaction.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Kyoto University; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Kataoka, Naoyuki/H-6298-2019; Dreyfuss, Gideon/D-1218-2013	Kataoka, Naoyuki/0000-0002-4498-7420; Dreyfuss, Gideon/0000-0001-8129-8774				Aoufouchi S, 1996, CELL, V85, P415, DOI 10.1016/S0092-8674(00)81119-8; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Brogna S, 1999, RNA, V5, P562, DOI 10.1017/S1355838299981359; Buhler M, 2002, EMBO REP, V3, P646, DOI 10.1093/embo-reports/kvf129; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Hachet O, 2001, CURR BIOL, V11, P1666, DOI 10.1016/S0960-9822(01)00508-5; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Liu ZR, 1997, RNA, V3, P1207; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Mohr SE, 2001, GENE DEV, V15, P2886; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Reichert VL, 2002, GENE DEV, V16, P2778, DOI 10.1101/gad.1030602; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Serin G, 2001, MOL CELL BIOL, V21, P209, DOI 10.1128/MCB.21.1.209-223.2001; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Wagner E, 2002, J CELL SCI, V115, P3033; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	50	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7009	7013		10.1074/jbc.M307692200	http://dx.doi.org/10.1074/jbc.M307692200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625303	hybrid			2022-12-25	WOS:000188969200097
J	Kolski-Andreaco, A; Tomita, H; Shakkottai, VG; Gutman, GA; Cahalan, MD; Gargus, JJ; Chandy, KG				Kolski-Andreaco, A; Tomita, H; Shakkottai, VG; Gutman, GA; Cahalan, MD; Gargus, JJ; Chandy, KG			SK3-1C, a dominant-negative suppressor of SKCa and IKCa channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; ACTIVATED POTASSIUM CHANNELS; POLYMORPHIC CAG REPEAT; SMALL-CONDUCTANCE; KCNN3 GENE; DIFFERENTIAL EXPRESSION; FUNCTIONAL EXPRESSION; SYMPTOM DIMENSIONS; TRUNCATED ISOFORM; HSKCA3 GENE	Small conductance Ca2+-activated K+ channels, products of the SK1-SK3 genes, regulate membrane excitability both within and outside the nervous system. We report the characterization of a SK3 variant (SK3-1C) that differs from SK3 by utilizing an alternative first exon (exon 1C) in place of exon 1A used by SK3, but is otherwise identical to SK3. Quantitative RT-PCR detected abundant expression of SK3-1C transcripts in human lymphoid tissues, skeletal muscle, trachea, and salivary gland but not the nervous system. SK3-1C did not produce functional channels when expressed alone in mammalian cells, but suppressed SK1, SK2, SK3, and IKCa1 channels, but not BKCa. or K-v channels. Confocal microscopy revealed that SK3-1C sequestered SK3 protein intracellularly. Dominant-inhibitory activity of SK3-1C was not due to a nonspecific calmodulin sponge effect since overexpression of calmodulin did not reverse SK3-1C-mediated intracellular trapping of SK3 protein, and calmodulin-Ca2+-dependent inactivation of Ca-v channels was not affected by SK3-1C overexpression. Deletion analysis identified a dominant-inhibitory segment in the SK3-1C C terminus that resembles tetramerization-coiled-coiled domains reported to enhance tetramer stability and selectivity of multimerization of many K+ channels. SK3-1C may therefore suppress calmodulin-gated SKCa/IKCa. channels by trapping these channel proteins intracellularly via subunit interactions mediated by the dominant-inhibitory segment and thereby reduce functional channel expression on the cell surface. Such family-wide dominant-negative suppression by SK3-1C provides a powerful mechanism to titrate membrane excitability and is a useful approach to define the functional in vivo role of these channels in diverse tissues by their targeted silencing.	Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Chandy, KG (corresponding author), Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Room 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.	gchandy@uci.edu		Tomita, Hiroaki/0000-0003-2628-880X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NIMH NIH HHS [MH59222] Funding Source: Medline; PHS HHS [1T32 N507444] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; Andelfinger G, 2002, AM J HUM GENET, V71, P663, DOI 10.1086/342360; Antonarakis SE, 1999, AM J MED GENET, V88, P348, DOI 10.1002/(SICI)1096-8628(19990820)88:4<348::AID-AJMG11>3.3.CO;2-E; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; Bond CT, 2000, SCIENCE, V289, P1942, DOI 10.1126/science.289.5486.1942; Bonnet-Brilhault F, 1999, EUR J HUM GENET, V7, P247, DOI 10.1038/sj.ejhg.5200278; Bowen T, 1998, MOL PSYCHIATR, V3, P266, DOI 10.1038/sj.mp.4000400; Bowen T, 2001, MOL PSYCHIATR, V6, P259, DOI 10.1038/sj.mp.4000128; Cardno AG, 1999, BIOL PSYCHIAT, V45, P1592, DOI 10.1016/S0006-3223(99)00033-5; CATERRALL WA, IUPHAR COMPENDIUM VO, P141; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Chowdari KV, 2000, MOL PSYCHIATR, V5, P237, DOI 10.1038/sj.mp.4000694; Crociani O, 2003, J BIOL CHEM, V278, P2947, DOI 10.1074/jbc.M210789200; Demolombe S, 1998, J BIOL CHEM, V273, P6837, DOI 10.1074/jbc.273.12.6837; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Eichler I, 2003, BRIT J PHARMACOL, V138, P594, DOI 10.1038/sj.bjp.0705075; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Figueroa KP, 2001, ARCH NEUROL-CHICAGO, V58, P1649, DOI 10.1001/archneur.58.10.1649; Gage MJ, 2002, MOL PHARMACOL, V61, P936, DOI 10.1124/mol.61.4.936; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Hawi Z, 1999, MOL PSYCHIATR, V4, P488, DOI 10.1038/sj.mp.4000560; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hohaus A, 2000, BIOCHEM J, V348, P657, DOI 10.1042/0264-6021:3480657; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jacobson D, 2002, MUSCLE NERVE, V26, P817, DOI 10.1002/mus.10280; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Jiang M, 1997, J BIOL CHEM, V272, P24109, DOI 10.1074/jbc.272.39.24109; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joober R, 1999, AM J MED GENET, V88, P154, DOI 10.1002/(SICI)1096-8628(19990416)88:2<154::AID-AJMG11>3.3.CO;2-1; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Koronyo-Hamaoui M, 2002, MOL PSYCHIATR, V7, P82, DOI 10.1038/sj/mp/4000931; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Miller MJ, 2001, J BIOL CHEM, V276, P27753, DOI 10.1074/jbc.C100221200; Mohammad-Panah R, 1999, AM J HUM GENET, V64, P1015, DOI 10.1086/302346; Monaghan AS, 2004, J BIOL CHEM, V279, P1003, DOI 10.1074/jbc.M308070200; Neelands TR, 2001, J PHYSIOL-LONDON, V536, P397, DOI 10.1111/j.1469-7793.2001.0397c.xd; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; Obermair GJ, 2003, EUR J NEUROSCI, V17, P721, DOI 10.1046/j.1460-9568.2003.02488.x; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Pereon Y, 2000, AM J PHYSIOL-HEART C, V278, pH1908, DOI 10.1152/ajpheart.2000.278.6.H1908; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Raghib A, 2001, J NEUROSCI, V21, P8495, DOI 10.1523/JNEUROSCI.21-21-08495.2001; RANE SG, 1994, J NEUROSCI RES, V38, P590, DOI 10.1002/jnr.490380511; Ritsner M, 2002, BIOL PSYCHIAT, V51, P788, DOI 10.1016/S0006-3223(01)01348-8; Sailer CA, 2002, J NEUROSCI, V22, P9698; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SHEPARD PD, 1988, BRAIN RES, V463, P380, DOI 10.1016/0006-8993(88)90414-3; Shmukler BE, 2001, BBA-GENE STRUCT EXPR, V1518, P36, DOI 10.1016/S0167-4781(01)00166-X; Smith JS, 2001, J NEUROSCI, V21, P1096; STEKETEE JD, 1990, J PHARMACOL EXP THER, V254, P711; Stober G, 2000, EUR ARCH PSY CLIN N, V250, P163, DOI 10.1007/s004060070020; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Tomita H, 2003, MOL PSYCHIATR, V8, P524, DOI 10.1038/sj.mp.4001271; Tsai MT, 1999, MOL PSYCHIATR, V4, P271, DOI 10.1038/sj.mp.4000482; Ujike H, 2001, PSYCHIAT RES, V101, P203, DOI 10.1016/S0165-1781(01)00229-3; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zarei MM, 2001, J BIOL CHEM, V276, P16232, DOI 10.1074/jbc.M008852200; Zerr P, 1998, J NEUROSCI, V18, P2842; Zhang BM, 2001, BIOCHEMISTRY-US, V40, P3189, DOI 10.1021/bi001675h	65	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6893	6904		10.1074/jbc.M311725200	http://dx.doi.org/10.1074/jbc.M311725200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638680	hybrid			2022-12-25	WOS:000188969200084
J	Saito, S; Liu, XF; Kamijo, K; Raziuddin, R; Tatsumoto, T; Okamoto, I; Chen, XY; Lee, CC; Lorenzi, MV; Ohara, N; Miki, T				Saito, S; Liu, XF; Kamijo, K; Raziuddin, R; Tatsumoto, T; Okamoto, I; Chen, XY; Lee, CC; Lorenzi, MV; Ohara, N; Miki, T			Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CDNA CLONING; EXCHANGE FACTOR ECT2; FISSION YEAST; DBL FAMILY; GTPASES; RAC; ONCOGENE; REPLICATION; PROTEINS; DAMAGE	The human ECT2 protooncogene encodes a guanine nucleotide exchange factor for the Rho GTPases and regulates cytokinesis. Although the oncogenic form of ECT2 contains an N-terminal truncation, it is not clear how the structural abnormality of ECT2 causes malignant transformation. Here we show that both the removal of the negative regulatory domain and alteration of subcellular localization are required to induce the oncogenic activity of ECT2. The transforming activity of oncogenic ECT2 was strongly inhibited by dominant negative Rho GTPases, suggesting the involvement of Rho GTPases in ECT2 transformation. Although deletion of the N-terminal cell cycle regulator-related domain (N) of ECT2 did not activate its transforming activity, removal of the small central domain (S), which contains two nuclear localization signals (NLSs), significantly induced the activity. The ECT2 N domain interacted with the catalytic domain and significantly inhibited the focus formation by oncogenic ECT2. Interestingly, the introduction of the NLS mutations in the S domain of N-terminally truncated ECT2 dramatically induced the transforming activity of this otherwise nononcogenic derivative. Among the known Rho GTPases expressed in NIH 3T3 cells, RhoA was predominantly activated by oncogenic ECT2 in vivo. Therefore, the mislocalization of structurally altered ECT2 might cause the untimely activation of cytoplasmic Rho GTPases leading to the malignant transformation.	NCI, Mol Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Basic Res Lab, NIH, 37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	toru@helix.nih.gov	OHARA, Naoya/B-2481-2011		NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, ONCOGENE, V9, P1057; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739	31	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7169	7179		10.1074/jbc.M306725200	http://dx.doi.org/10.1074/jbc.M306725200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645260	hybrid			2022-12-25	WOS:000188969200116
J	Tripp, BC; Bell, CB; Cruz, F; Krebs, C; Ferry, JG				Tripp, BC; Bell, CB; Cruz, F; Krebs, C; Ferry, JG			A role for iron in an ancient carbonic anhydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEINS	Since 1933, carbonic anhydrase research has focused on enzymes from mammals (alpha class) and plants (beta class); however, two additional classes (gamma and delta) were discovered recently. Cam, from the procaryote Methanosarcina thermophila, is the prototype of the gamma class and the first carbonic anhydrase to be characterized from either an anaerobic organism or the Archaea domain. All of the enzymes characterized from the four classes have been purified aerobically and are reported to contain a catalytic zinc. Herein, we report the anaerobic reconstitution of apo-Cam with Fe2+, which yielded Cam with an effective k(cat) that exceeded that for the Zn2+-reconstituted enzyme. Mossbauer spectroscopy showed that the Fe2+-reconstituted enzyme contained high spin Fe2+ that, when oxidized to Fe3+, inactivated the enzyme. Reconstitution with Fe3+ was unsuccessful. Reconstitution with Cu2+, Mn2+, Ni2+, or Cd2+ yielded enzymes with effective k(cat), values that were 10% or less than the value for the Zn2+-reconstituted Cam. Cam produced in Escherichia coli and purified anaerobically contained iron with effective k(cat) and k(cat)/K-m values exceeding the values for Zn2+-reconstituted Cam. The results identify a previously unrecognized biological function for iron.	Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA; Western Michigan Univ, Dept Chem, Kalamazoo, MI 49008 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Western Michigan University; Western Michigan University	Ferry, JG (corresponding author), Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jgf3@psu.edu	Krebs, Carsten/D-4773-2009	Krebs, Carsten/0000-0002-3302-7053	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber BE, 1999, BIOCHEMISTRY-US, V38, P13119, DOI 10.1021/bi9828876; ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; Alber BE, 1996, J BACTERIOL, V178, P3270, DOI 10.1128/jb.178.11.3270-3274.1996; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Da Silva J. F., 2001, BIOL CHEM ELEMENTS I; DAILEY HA, 1977, J BACTERIOL, V129, P815, DOI 10.1128/JB.129.2.815-820.1977; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; Hewett-Emmett D, 2000, EXS, V90, P29; Hunt JA, 1999, BIOCHEMISTRY-US, V38, P9054, DOI 10.1021/bi9900166; Iverson TM, 2000, BIOCHEMISTRY-US, V39, P9222, DOI 10.1021/bi000204s; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Lane TW, 2000, P NATL ACAD SCI USA, V97, P4627, DOI 10.1073/pnas.090091397; LINDSKOG S, 1966, BIOCHEMISTRY-US, V5, P2641, DOI 10.1021/bi00872a023; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; Milligan AJ, 2002, SCIENCE, V297, P1848, DOI 10.1126/science.1074958; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Potter CPS, 2003, BRIT J CANCER, V89, P2, DOI 10.1038/sj.bjc.6600936; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Rajagopalan PTR, 1998, J BIOL CHEM, V273, P22305, DOI 10.1074/jbc.273.35.22305; ROWLETT RS, 1994, BIOCHEMISTRY-US, V33, P13967, DOI 10.1021/bi00251a003; SCHERER P, 1983, BIOL TRACE ELEM RES, V5, P149, DOI 10.1007/BF02916619; SIGEL H, 1970, ACCOUNTS CHEM RES, V3, P201, DOI 10.1021/ar50030a004; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Smith KS, 2000, FEMS MICROBIOL REV, V24, P335, DOI 10.1016/S0168-6445(00)00030-9; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; Tripp BC, 2000, BIOCHEMISTRY-US, V39, P9232, DOI 10.1021/bi0001877; Tripp BC, 2002, BIOCHEMISTRY-US, V41, P669, DOI 10.1021/bi010768b; Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200; WACHTERSHAUSER G, 1990, ORIGINS LIFE EVOL B, V20, P173, DOI 10.1007/BF01808279	32	112	120	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6683	6687		10.1074/jbc.M311648200	http://dx.doi.org/10.1074/jbc.M311648200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662760	hybrid			2022-12-25	WOS:000188969200059
J	Abraham, EG; Islam, S; Srinivasan, P; Ghosh, AK; Valenzuela, JG; Ribeiro, JMC; Kafatos, FC; Dimopoulos, G; Jacobs-Lorena, M				Abraham, EG; Islam, S; Srinivasan, P; Ghosh, AK; Valenzuela, JG; Ribeiro, JMC; Kafatos, FC; Dimopoulos, G; Jacobs-Lorena, M			Analysis of the Plasmodium and Anopheles transcriptional repertoire during ookinete development and midgut invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; IN-VITRO; IMMUNE-RESPONSE; MOSQUITO; EXPRESSION; GAMBIAE; FALCIPARUM; BERGHEI; CELLS; INFECTION	Plasmodium, the causative agent of malaria, has to undergo sexual differentiation and development in anopheline mosquitoes for transmission to occur. To isolate genes specifically induced in both organisms during the early stages of Plasmodium differentiation in the mosquito, two cDNA libraries were constructed, one enriched for sequences expressed in differentiating Plasmodium berghei ookinetes and another enriched for sequences expressed in Anopheles stephensi guts containing invading ookinetes and early oocysts. Sequencing of 457 ookinete library clones and 652 early oocyst clones represented 175 and 346 unique expressed sequence tags, respectively. Nine of 13 Plasmodium and four of the five Anopheles novel expressed sequence tags analyzed on Northern blots were induced during ookinete differentiation and mosquito gut invasion. Ancaspase-7, an Anopheles effector caspase, is proteolytically activated during Plasmodium invasion of the midgut. WARP, a gene encoding a Plasmodium surface protein with a von Willebrand factor A- like adhesive domain, is expressed only in ookinetes and early oocysts. An anti- WARP polyclonal antibody strongly inhibits ( 70 - 92%) Plasmodium development in the mosquito, making it a candidate antigen for transmission blocking vaccines. The present results and those of an accompanying report ( Srinivasan, P., Abraham, E. G., Ghosh, A. K., Valenzuela, J., Ribeiro, J. M. C., Dimopoulos G., Kafatos, F. C., Adams, J. H., and Jacobs- Lorena, M. ( 2004) J. Biol. Chem. 279, 5581 - 5587) provide the foundation for further analysis of Plasmodium differentiation in the mosquito and of mosquito responses to the parasite.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; NIAID, Med Entomol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); European Molecular Biology Laboratory (EMBL)	Jacobs-Lorena, M (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.	mlorena@jhsph.edu		Dimopoulos, George/0000-0001-6755-8111; Ribeiro, Jose/0000-0002-9107-0818	NIAID NIH HHS [R01 AI031478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031478, Z01AI000932, Z01AI000810] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Olayan EM, 2002, SCIENCE, V295, P677, DOI 10.1126/science.1067159; ARRIGHI RB, 2000, INT J PARASITOL, V32, P91; Barr SD, 2001, J BIOL CHEM, V276, P34279, DOI 10.1074/jbc.M104406200; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Edwards MJ, 1997, INSECT BIOCHEM MOLEC, V27, P1063, DOI 10.1016/S0965-1748(97)00093-3; Fidyk NJ, 2002, BIOCHEMISTRY-US, V41, P15644, DOI 10.1021/bi026413p; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Ghosh A, 2000, PARASITOL TODAY, V16, P196, DOI 10.1016/S0169-4758(99)01626-9; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Li JL, 2000, BBA-GENE STRUCT EXPR, V1491, P341, DOI 10.1016/S0167-4781(00)00032-4; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; Oduol F, 2000, P NATL ACAD SCI USA, V97, P11397, DOI 10.1073/pnas.180060997; PARKES TL, 1993, GENOME, V36, P1007, DOI 10.1139/g93-134; Siden-Kiamos I, 2000, J CELL SCI, V113, P3419; SINDEN RE, 1987, PROC R SOC SER B-BIO, V230, P443, DOI 10.1098/rspb.1987.0028; Sinden Robert E., 1998, P25; Srinivasan P, 2004, J BIOL CHEM, V279, P5581, DOI 10.1074/jbc.M307587200; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Tahar R, 2002, EMBO J, V21, P6673, DOI 10.1093/emboj/cdf664; VERVENNE RAW, 1994, MOL BIOCHEM PARASIT, V68, P259, DOI 10.1016/0166-6851(94)90170-8; von Mering M, 2001, BRAIN PATHOL, V11, P282; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yuda M, 2001, MOL BIOCHEM PARASIT, V116, P65, DOI 10.1016/S0166-6851(01)00304-8; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zieler H, 2000, P NATL ACAD SCI USA, V97, P11516, DOI 10.1073/pnas.97.21.11516	36	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5573	5580		10.1074/jbc.M307582200	http://dx.doi.org/10.1074/jbc.M307582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14627712	hybrid			2022-12-25	WOS:000188776500066
J	Fang, XD; Han, HM; Stamatoyannopoulos, G; Li, QL				Fang, XD; Han, HM; Stamatoyannopoulos, G; Li, QL			Developmentally specific role of the CCAAT box in regulation of human gamma-globin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN FACTORS; NF-Y; PROMOTER ELEMENTS; IN-VIVO; HEREDITARY PERSISTENCE; FETAL HEMOGLOBIN; BINDING; TRANSCRIPTION; REGION; RECRUITMENT	The CCAAT box is a widespread motif in eukaryotic promoters. In this study we demonstrate that the effects of the CCAAT box on gamma-globin gene activation are developmentally distinct. Although this promoter element is essential for high level gamma gene expression in adult erythropoiesis, it plays little role in embryonic erythroid cells. The CCAAT mutation in the human gamma-globin gene promoter impairs recruitment of TATA-binding protein (TBP), TFIIB, and RNA polymerase II in adult splenic erythroblasts but not in embryonic erythroid cells. We also show that the efficiency of gamma gene transcription is correlated with recruitment of TBP on the TATA box but that the level of TBP recruitment is not nuclear factor Y (NF-Y)-dependent. Our data also suggest that it is unlikely that transcriptional stimulation by the CCAAT box is exerted through direct protein-protein interaction between NF-Y and TBP.	Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Li, QL (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet, I-164 Hlth Sci Bldg,Box 357720, Seattle, WA 98195 USA.	li111640@u.washington.edu			NHLBI NIH HHS [HL73439, R01 HL073439] Funding Source: Medline; NIDDK NIH HHS [DK61805, R56 DK045365, R01 DK045365-06S1, R01 DK045365, DK45365, R37 DK045365-07S1, R37 DK045365, R01 DK061805] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045365, R56DK045365, R37DK045365, R01DK061805] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANAGNOU NP, 1986, EMBO J, V5, P121, DOI 10.1002/j.1460-2075.1986.tb04185.x; ANTONIOU M, 1995, NUCLEIC ACIDS RES, V23, P3473, DOI 10.1093/nar/23.17.3473; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; Duan ZJ, 2002, P NATL ACAD SCI USA, V99, P5509, DOI 10.1073/pnas.072084499; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; HARA H, 1976, AM J HEMATOL, V1, P453, DOI 10.1002/ajh.2830010410; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Langdon SD, 1998, BLOOD, V91, P309, DOI 10.1182/blood.V91.1.309.309_309_318; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Ottolenghi S, 1989, Prog Clin Biol Res, V316A, P229; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; ULRICH MJ, 1990, BLOOD, V75, P990	35	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5444	5449		10.1074/jbc.M306241200	http://dx.doi.org/10.1074/jbc.M306241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645237	Green Accepted, hybrid			2022-12-25	WOS:000188776500051
J	Sampaio, MM; Chevance, F; Dippel, R; Eppler, T; Schlegel, A; Boos, W; Lu, YJ; Rock, CO				Sampaio, MM; Chevance, F; Dippel, R; Eppler, T; Schlegel, A; Boos, W; Lu, YJ; Rock, CO			Phosphotransferase-mediated transport of the osmolyte 2-O-alpha-mannosyl-D-glycerate in Escherichia coli occurs by the product of the mngA (hrsA) gene and is regulated by the mngR (farR) gene product acting as repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; TREHALOSE SYNTHESIS; MANNOSYLGLYCERATE; MUTAGENESIS; POLYMERASE; EXPRESSION; PROTEINS; SEQUENCE; SOLUTES; ENZYMES	2-O-alpha- Mannosyl- D- glycerate ( MGs) has been recognized as an osmolyte in hyperthermophilic but not mesophilic prokaryotes. We report that MG is taken up and utilized as sole carbon source by Escherichia coli K12, strainMC4100. Uptake is mediated by the P- enolpyruvate-dependent phosphotransferase system with the MG-inducible HrsA ( now called MngA) protein as its specific EIIABC complex. The apparent K-m of MG uptake in induced cells was 10 muM, and the V-max was 0.65 nmol/ min/ 10(9) cells. Inverted membrane vesicles harboring plasmid-encoded MngA phosphorylated MG in a P- enolpyruvate-dependent manner. A deletion mutant in mngA was devoid of MG transport but is complemented by a plasmid harboring mngA. Uptake of MG in MC4100 also caused induction of a regulon specifying the uptake and the metabolism of galactarate and glucarate controlled by the CdaR activator. The ybgG gene ( now called mngB) the gene immediately downstream of mngA encodes a protein with alpha- mannosidase activity. farR, the gene upstream of mngA ( now called mngR) had previously been characterized as a fatty acyl- responsive regulator; however, deletion of mngR resulted in the up- regulation of only two genes, mngA and mngB. The mngR deletion caused constitutive MG transport that became MG- inducible after transformation with plasmid expressed mngR. Thus, MngR is the regulator ( repressor) of the MG transport/ metabolism system. Thus, the mngR mngA mngB gene cluster encodes an MG utilizing system.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Stab Vida, P-2781601 Oeiras, Portugal; St Jude Childrens Res Hosp, Dept Infect Dis, Div Prot Sci, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	University of Konstanz; Universidade Nova de Lisboa; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Boos, W (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Winfried.Boos@Uni-Konstanz.de		Sampaio, Maria Manuel/0000-0003-3019-3694	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Borges N, 2002, EXTREMOPHILES, V6, P209, DOI 10.1007/s007920100236; BOUVENG H, 1955, ACTA CHEM SCAND, V9, P807, DOI 10.3891/acta.chem.scand.09-0807; BURSTEIN C, 1965, BIOCHIM BIOPHYS ACTA, V95, P634, DOI 10.1016/0005-2787(65)90517-4; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COZZAREL.NR, 1965, J BACTERIOL, V90, P1325, DOI 10.1128/JB.90.5.1325-1329.1965; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Empadinhas N, 2001, J BIOL CHEM, V276, P43580, DOI 10.1074/jbc.M108054200; ERNI B, 1987, J BIOL CHEM, V262, P5238; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; LI YT, 1967, J BIOL CHEM, V242, P5474; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; Miller JH, 1972, EXPT MOL GENETICS, P354; Monterrubio R, 2000, J BACTERIOL, V182, P2672, DOI 10.1128/JB.182.9.2672-2674.2000; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; OCHMAN H, 1988, GENETICS, V120, P621; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; QUAIL MA, 1994, FEBS LETT, V356, P183, DOI 10.1016/0014-5793(94)01264-4; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; SAMPAIO MM, 2003, J BACTERIOL, V69, P233; Santos H, 2001, METHOD ENZYMOL, V334, P302; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TCHIEU JH, 2002, JMMB SYMP S, V5, P9; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; Utsumi R, 1996, BIOSCI BIOTECH BIOCH, V60, P309, DOI 10.1271/bbb.60.309; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; YARMOLINSKY MB, 1959, P NATL ACAD SCI USA, V45, P1786, DOI 10.1073/pnas.45.12.1786; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang YM, 2002, J BIOL CHEM, V277, P15558, DOI 10.1074/jbc.M201399200	35	32	36	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5537	5548		10.1074/jbc.M310980200	http://dx.doi.org/10.1074/jbc.M310980200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645248	hybrid			2022-12-25	WOS:000188776500062
J	Uno, T; Ryu, D; Tsutsumi, H; Tomisugi, Y; Ishikawa, Y; Wilkinson, AJ; Sato, H; Hayashi, T				Uno, T; Ryu, D; Tsutsumi, H; Tomisugi, Y; Ishikawa, Y; Wilkinson, AJ; Sato, H; Hayashi, T			Residues in the distal heme pocket of neuroglobin - Implications for the multiple ligand binding steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION-ASSOCIATED PROTEIN; SPERM WHALE MYOGLOBIN; RESONANCE RAMAN; HEXACOORDINATE HEMOGLOBIN; AXIAL COORDINATION; GENE SYNTHESIS; NITRIC-OXIDE; GLOBIN; EXPRESSION; HISTIDINE	Amino acid residues in the ligand binding pocket of human neuroglobin have been identified by site-directed mutagenesis and their properties investigated by resonance Raman and flash photolysis methods. Wildtype neuroglobin has been shown to have six-coordinate heme in both ferric and ferrous states. Substitution of His(96) by alanine leads to complete loss of heme, indicating that His(96) is the proximal ligand. The resonance Raman spectra of M69L and K67T mutants were similar to those of wild-type (WT) neuroglobin in both ferric and ferrous states. By contrast, H64V was six-coordinate high-spin and five-coordinate high-spin in the ferric and ferrous states, respectively, at acidic pH. The spectra were pH-dependent and six-coordinate with the low-spin component dominating at alkaline pH. In a double mutant H64V/K67T, the high-spin component alone was detected in the both ferric and the ferrous states. This implies that His(64) is the endogenous ligand and that Lys(67) is situated nearby in the distal pocket. In the ferrous H64V and H64V/K67T mutants, the v(Fe-His) stretching frequency appears at 221 cm(-1), which is similar to that of deoxymyoglobin. In the ferrous CO-bound state, the v(Fe-CO) stretching frequency was detected at 521 and 494 cm(-1) in WT, M69L, and K67T, while only the 494 cm(-1) component was detected in the H64V and H64V/K67T mutants. Thus, the 521 cm(-1) component is attributed to the presence of polar His(64). The CO binding kinetics were biphasic for WT, H64V, and K67T and monophasic for H64V/K67T. Thus, His(64) and Lys(67) comprise a unique distal heme pocket in neuroglobin.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan; Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Kyushu Univ, Grad Sch Engn, Dept Chem & Biochem, Fukuoka 8128581, Japan	Kumamoto University; University of York - UK; Kyushu University	Uno, T (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan.	unot@gpo.kumamoto-u.ac.jp	Uno, Tadayuki/E-1622-2013	Uno, Tadayuki/0000-0003-2056-5781; Hayashi, Takashi/0000-0002-2215-935X; Wilkinson, Anthony/0000-0003-4577-9479				Asahina K, 2002, BBA-GENE STRUCT EXPR, V1577, P471, DOI 10.1016/S0167-4781(02)00477-3; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CASIMIRO DR, 1995, BIOCHEMISTRY-US, V34, P6640, DOI 10.1021/bi00020a009; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; HANSON JC, 1981, J MOL BIOL, V153, P117, DOI 10.1016/0022-2836(81)90530-1; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Iizuka T, 1970, Adv Biophys, V1, P157; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kincaid J.R., 2000, PORPHYRIN HDB, V7, P227; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Merx Marc W., 2001, FASEB Journal, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Nistor SV, 2002, CHEM PHYS LETT, V361, P355, DOI 10.1016/S0009-2614(02)00961-2; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; OLDFIELD TJ, 1992, BIOCHEMISTRY-US, V31, P8732, DOI 10.1021/bi00152a008; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Uno T, 2003, BIOCHEMISTRY-US, V42, P10191, DOI 10.1021/bi034569z; UNO T, 1987, J BIOL CHEM, V262, P4549; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028; Zhang CG, 2002, BIOCHEM BIOPH RES CO, V290, P1411, DOI 10.1006/bbrc.2002.6360	48	64	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5886	5893		10.1074/jbc.M311748200	http://dx.doi.org/10.1074/jbc.M311748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645216	hybrid			2022-12-25	WOS:000188776500104
J	Chen, RC; Yang, ZY; Zhou, Q				Chen, RC; Yang, ZY; Zhou, Q			Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IMMUNODEFICIENCY-VIRUS TYPE-1; LONG-TERMINAL REPEAT; TAT TRANSACTIVATION; HIGH-AFFINITY; CYCLIN T1; HIV-1 TAT; KINASE; PROTEIN; CELLS	The positive transcription elongation factor b (P-TEFb), comprising CDK9 and cyclin T, stimulates transcription of cellular and viral genes by phosphorylating RNA polymerase II. A major portion of nuclear P-TEFb is sequestered and inactivated by the coordinated actions of the 7SK snRNA and the HEXIM1 protein, whose induced dissociation from P-TEFb is crucial for stress-induced transcription and pathogenesis of cardiac hypertrophy. The 7SK-P-TEFb interaction, which can occur independently of HEXIM1 and does not by itself inhibit P-TEFb, recruits HEXIM1 for P-TEFb inactivation. To study the control of this interaction, we established an in vitro system that reconstituted the specific interaction of P-TEFb with 7SK but not other snRNAs. Using this system, together with an in vivo binding assay, we show that the phosphorylation of CDK9, on possibly the conserved Thr-186 in the T-loop, was crucial for the 7SK-P-TEFb interaction. This phosphorylation was not caused by CDK9 autophosphorylation or the general CDK-activating kinase CAK, but rather by a novel HeLa nuclear kinase. Furthermore, the stress-induced disruption of the 7SK-P-TEFb interaction was not caused by any prohibitive changes in 7SK but by the dephosphorylation of P-TEFb, leading to the loss of the key phosphorylation important for 7SK binding. Thus, the phosphorylated P-TEFb is tagged for inhibition through association with 7SK. We discuss the implications of this mechanism in controlling P-TEFb activity during normal and stress-induced transcription.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Zhou, Q (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	qzhou@uclink4.berkeley.edu	Chen, Ruichuan/G-4618-2010; Yang, Zhiyuan/C-9543-2012	Yang, Zhiyuan/0000-0002-1175-4188	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041757] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-41757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammosova T, 2003, J BIOL CHEM, V278, P32189, DOI 10.1074/jbc.M300521200; Bharucha DC, 2002, VIROLOGY, V296, P6, DOI 10.1006/viro.2002.1438; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; HUMPHRIES P, 1987, Biochemical Journal, V24, P281; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Liou LY, 2002, J VIROL, V76, P10579, DOI 10.1128/JVI.76.21.10579-10587.2002; Marks PA, 1996, INT J HEMATOL, V63, P1; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURPHY S, 1984, J MOL BIOL, V177, P575, DOI 10.1016/0022-2836(84)90038-X; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; REDDY R, 1984, J BIOL CHEM, V259, P2265; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sano M, 2003, CELL CYCLE, V2, P99, DOI 10.4161/cc.2.2.332; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; ULLU E, 1982, NUCLEIC ACIDS RES, V10, P2209, DOI 10.1093/nar/10.7.2209; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; ZIEVE G, 1977, BIOCHEMISTRY-US, V16, P4520, DOI 10.1021/bi00639a029	40	122	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4153	4160		10.1074/jbc.M310044200	http://dx.doi.org/10.1074/jbc.M310044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627702	hybrid			2022-12-25	WOS:000188554300030
J	Pasyk, EA; Kang, YH; Huang, XH; Cui, NR; Sheu, L; Gaisano, HY				Pasyk, EA; Kang, YH; Huang, XH; Cui, NR; Sheu, L; Gaisano, HY			Syntaxin-1A binds the nucleotide-binding folds of sulphonylurea receptor 1 to regulate the K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; GK RAT; 1A; PROTEINS; SNAP-25; CA2+; EXPRESSION; INTERACTS; CLEAVES; MGADP	ATP-sensitive potassium (K-ATP) channels in neuron and neuroendocrine cells consist of a pore-forming Kir6.2 and regulatory sulfonylurea receptor (SUR1) subunits, which are regulated by ATP and ADP. SNARE protein syntaxin 1A (Syn-1A) is known to mediate exocytic fusion, and more recently, to also bind and modulate membrane-repolarizing voltage-gated K+ channels. Here we show that Syn-1A acts as an endogenous regulator of K-ATP channels capable of closing these channels when cytosolic ATP concentrations were lowered. Botulinum neurotoxin C1 cleavage of endogenous Syn-1A in insulinoma HIT-T15 cells resulted in the increase in K-ATP currents, which could be subsequently inhibited by recombinant Syn-1A. Whereas Syn-1A binds both nucleotide-binding folds (NBF-1 and NBF-2) of SUR1, the functional inhibition of K-ATP channels in rat islet beta-cells by Syn-1A seems to be mediated primarily by its interactions with NBF-1. These inhibitory actions of Syn-1A can be reversed by physiologic concentrations of ADP and by diazoxide. Syn-1A therefore acts to fine-tune the regulation of K-ATP channels during dynamic changes in cytosolic ATP and ADP concentrations. These actions of Syn-1A on K-ATP channels contribute to the role of Syn-1A in coordinating the sequence of ionic and exocytic events leading to secretion.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada.	gaisano@utoronto.ca			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055160] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55160] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1992, INSULIN MOL BIOL PAT; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Gaisano HY, 2002, ENDOCRINOLOGY, V143, P4218, DOI 10.1210/en.2002-220237; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Honer WG, 2002, CEREB CORTEX, V12, P349, DOI 10.1093/cercor/12.4.349; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; MATSUO M, 1999, J BIOL CHEM, V274, P41184; Nagamatsu S, 1999, DIABETES, V48, P2367, DOI 10.2337/diabetes.48.12.2367; Nakayama T, 1998, CYTOGENET CELL GENET, V82, P49, DOI 10.1159/000015063; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSUURA Y, 1993, DIABETES, V42, P1446, DOI 10.2337/diabetes.42.10.1446; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Vanoye CG, 2002, J BIOL CHEM, V277, P23260, DOI 10.1074/jbc.M112004200; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164	33	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4234	4240		10.1074/jbc.M309667200	http://dx.doi.org/10.1074/jbc.M309667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645230	hybrid			2022-12-25	WOS:000188554300040
J	Xu, QJ; Yan, B; Li, SH; Duan, CM				Xu, QJ; Yan, B; Li, SH; Duan, CM			Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes its ligand-dependent action on cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-5; IGF-I; EXTRACELLULAR-MATRIX; AMINO-ACIDS; HUMAN FIBROBLASTS; TERMINAL DOMAINS; HEPARIN-BINDING; IGFBP-5; SURVIVAL; SUBSTITUTIONS	Insulin-like growth factor-binding protein 5 (IGFBP-5) is a secreted protein that binds to insulin-like growth factors (IGFs) and modulates IGF actions on cell proliferation, differentiation, survival, and motility. IGFBP-5 also regulates these cellular events through IGF-independent mechanisms. To elucidate the molecular mechanisms governing these diverse actions of IGFBP-5, we screened a human cDNA library by a yeast two-hybrid system using IGFBP-5 as bait and identified fibronectin (FN) as a potential IGFBP-5-interacting partner. The complex formation of IGFBP-5 and FN was established by glutathione S-transferase pull-down, solution, and solid phase binding assays using glutathione S-transferase-IGFBP-5 and native IGFBP-5 in vitro and by co-immunoprecipitation in vivo. Binding assay using deletion mutants indicated that the IGFBP-5 C domain binds to the 10(th) and 11(th) type I repeats of FN. IGFBP-5 potentiated IGF-I-induced cell migration in FN-null, but not in wildtype, mouse embryonic cells. When FN was reintroduced either as an adhesive substrate or in solution to the FN-null cells, the potentiating effect of IGFBP-5 on IGF-I-induced cell migration was abolished. Binding of IGFBP-5 to FN had no effect on the ability of IGFBP-5 to bind IGF-I, but it increased the proteolytic degradation of IGFBP-5. Inhibition of IGFBP-5 proteolysis restored the potentiating effect of IGFBP-5. These results suggest that FN and IGFBP-5 bind to each other, and this binding negatively regulates the ligand-dependent action of IGFBP-5 by triggering IGFBP-5 proteolysis.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu	Xu, Qijin/B-2680-2009	Xu, Qijin/0000-0003-0521-9039	NHLBI NIH HHS [R01HL60679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; Busby WH, 2000, J BIOL CHEM, V275, P37638, DOI 10.1074/jbc.M006107200; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Duan Cunming, 2003, Acta Zoologica Sinica, V49, P421; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Globus RK, 1998, J CELL SCI, V111, P1385; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Martin JA, 2002, OSTEOARTHR CARTILAGE, V10, P556, DOI 10.1053/joca.2002.0791; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nam T, 2002, ENDOCRINOLOGY, V143, P30, DOI 10.1210/en.143.1.30; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Sottile J, 1998, J CELL SCI, V111, P2933; Sottile J, 2000, J CELL SCI, V113, P4287; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	43	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4269	4277		10.1074/jbc.M311586200	http://dx.doi.org/10.1074/jbc.M311586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645245	hybrid			2022-12-25	WOS:000188554300044
J	Pirko, I; Johnson, A; Ciric, B; Gamez, J; Macura, SI; Pease, LR; Rodriguez, M				Pirko, I; Johnson, A; Ciric, B; Gamez, J; Macura, SI; Pease, LR; Rodriguez, M			In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies	FASEB JOURNAL			English	Article						cell-specific MRI; targeted contrast materials; experimental MRI imaging	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IRON-OXIDE PARTICLES; CONTRAST AGENTS; T-CELLS; MONOCLONAL-ANTIBODY; RAT; BRAIN; INFLAMMATION; ENHANCEMENT; MENINGITIS	We developed a novel MRI technique to image immune cell location and homing in vivo to the central nervous system (CNS). Superparamagnetic antibodies specific for cell surface markers allowed imaging of CD4+ T cells, CD8+ T cells, and Mac1+ cells in the CNS of mice infected with Theiler's murine encephalomyelitis virus (TMEV) and in mice with experimental autoimmune encephalomyelitis (EAE). Superparamagnetic antibodies have excellent T2, T2*, and good T1 relaxation properties, which makes them ideal MRI contrast materials. Immunohistochemistry of corresponding sections confirmed the specificity of the technique to detect immune cell types in the CNS. This powerful technique has potential to image any cell with unique surface antigens. Because superparamagnetic antibodies similar to those used in the study are approved for human use, the in vivo MRI technique we have described could be developed for human use.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MI 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MI 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MI 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MI 55905 USA.	Rodriguez@mayo.edu		Rodriguez, Moses/0000-0001-6328-6497	NIH [NS32129, NS24180, NS38468]; National Multiple Sclerosis Society	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society)	This work was supported by NIH grants NS32129, NS24180 and NS38468. We would also like to thank the National Multiple Sclerosis Society for additional funding.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; Allkemper T, 2002, RADIOLOGY, V223, P432, DOI 10.1148/radiol.2232010241; ANDERSONBERG WT, 1986, J NUCL MED, V27, P829; Bjornerud A, 2002, MAGNET RESON MED, V47, P461, DOI 10.1002/mrm.10066; Brugger W, 2002, SEMIN ONCOL, V29, P23, DOI 10.1053/sonc.2002.32751; CERDAN S, 1989, MAGN RESON MED, V12, P151, DOI 10.1002/mrm.1910120202; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Dardzinski BJ, 2001, MAGN RESON IMAGING, V19, P1209, DOI 10.1016/S0730-725X(01)00448-9; DEWYNTER EA, 1995, STEM CELLS, V13, P524, DOI 10.1002/stem.5530130510; Dousset V, 1999, MAGNET RESON MED, V41, P329, DOI 10.1002/(SICI)1522-2594(199902)41:2<329::AID-MRM17>3.0.CO;2-Z; Dousset V, 1999, MAGN RESON MATER PHY, V8, P185; Enochs WS, 1999, JMRI-J MAGN RESON IM, V9, P228, DOI 10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.3.CO;2-B; Fleige G, 2001, NEOPLASIA, V3, P489, DOI 10.1038/sj.neo.7900176; Franklin RJM, 1999, NEUROREPORT, V10, P3961, DOI 10.1097/00001756-199912160-00043; GOHRROSENTHAL S, 1993, INVEST RADIOL, V28, P789; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Hudgins PA, 2002, AM J NEURORADIOL, V23, P649; Johansson LO, 2001, J MAGN RESON IMAGING, V13, P615, DOI 10.1002/jmri.1086; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; Johnson AJ, 2001, FASEB J, V15, P2760, DOI 10.1096/fj.01-0373fje; Kerr DA, 2002, CURR OPIN NEUROL, V15, P339, DOI 10.1097/00019052-200206000-00019; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; Meli DN, 2002, CURR OPIN INFECT DIS, V15, P253, DOI 10.1097/00001432-200206000-00007; Miller DJ, 1997, J NEUROIMMUNOL, V75, P204, DOI 10.1016/S0165-5728(97)00027-1; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Owens T, 2001, NAT MED, V7, P161, DOI 10.1038/84603; Piehl F, 2001, IMMUNOL REV, V184, P212, DOI 10.1034/j.1600-065x.2001.1840119.x; RENSHAW PF, 1986, MAGNET RESON MED, V3, P217, DOI 10.1002/mrm.1910030205; Stohlman SA, 2001, BRAIN PATHOL, V11, P92; SU XM, 1991, J NEUROIMMUNOL, V34, P181; Suwa T, 1998, INT J CANCER, V75, P626, DOI 10.1002/(SICI)1097-0215(19980209)75:4<626::AID-IJC22>3.0.CO;2-5; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; UNGER EC, 1985, INVEST RADIOL, V20, P693, DOI 10.1097/00004424-198510000-00008; Weissleder R, 1997, J MAGN RESON IMAGING, V7, P258, DOI 10.1002/jmri.1880070140; Wingerchuk DM, 2001, LAB INVEST, V81, P263, DOI 10.1038/labinvest.3780235; Ye Q, 2002, KIDNEY INT, V61, P1124, DOI 10.1046/j.1523-1755.2002.00195.x; YEH TC, 1993, MAGN RESON MED, V30, P617, DOI 10.1002/mrm.1910300513; YEH TC, 1995, MAGN RESON MED, V33, P200, DOI 10.1002/mrm.1910330209; Zhang YQ, 2000, KIDNEY INT, V58, P1300, DOI 10.1046/j.1523-1755.2000.00286.x	40	66	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					179	182		10.1096/fj.02-1124fje	http://dx.doi.org/10.1096/fj.02-1124fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630708				2022-12-25	WOS:000188829300066
J	Balachandran, R; Welsh, MJ; Day, BW				Balachandran, R; Welsh, MJ; Day, BW			Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells	ONCOGENE			English	Article						stathmin; p21(WAF1); microtubules; p53	HUMAN BREAST-CANCER; MICROTUBULE DYNAMICS; DOWN-REGULATION; IN-VIVO; PROTEIN; EXPRESSION; PHOSPHORYLATION; TUBULIN; P53; ONCOPROTEIN-18	Two paclitaxel(Ptx)-resistant ovarian cancer cell lines, 1A9/Ptx-10 and 1A9/Ptx-22, isolated from the 1A9 cell line (a clone of the A2780 line) by continuous exposure to Ptx and verapamil, have point mutations in their major beta-tubulin gene and in one or both alleles of their TP53 gene. These cells were examined for alterations in cell cycle regulators and the tubulin-binding protein stathmin. Unlike parental cells, neither 1A9/Ptx-10 nor 1A9/Ptx-22 expressed detectable levels of p21(WAF1/Cip1), a putative transcriptional regulator of stathmin, but did overexpress stathmin and Bcl2. No differences were noted in the expression levels of proliferative cell nuclear antigen or tyrosine-phosphorylated p34(Cdc2). Ptx treatment altered little the expression of stathmin in the parental cell line, although it increased p21(WAF1/Cip1) levels several-fold. Infection of Ptx-resistant lines with a wild-type TP53-bearing adenovirus (AdWTp53) changed cell cycle distribution and increased the levels of p21(WAF1/Cip1), but caused no changes in stathmin levels. Microtubule drug resistance in ovarian carcinoma may be associated with altered p53/21(WAF1/Cip1) regulatory pathways for stathmin expression and function.	Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Day, BW (corresponding author), 721 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.			Day, Billy/0000-0001-6208-9950	NCI NIH HHS [CA 78039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alli E, 2002, CANCER RES, V62, P6864; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Cheon MS, 2001, J NEURAL TRANSM-SUPP, P281; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; EUSTACE W, 1995, FEBS LETT, V364, P309, DOI 10.1016/0014-5793(95)00416-7; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Gavet O, 1998, J CELL SCI, V111, P3333; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; Hummert TW, 2000, J CELL BIOCHEM, V79, P150, DOI 10.1002/1097-4644(2000)79:1<150::AID-JCB140>3.3.CO;2-2; Iancu C, 2000, CANCER RES, V60, P3537; JI H, 1993, J BIOL CHEM, V268, P13396; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420; Katayose D, 1995, CLIN CANCER RES, V1, P889; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Liedtke W, 2002, AM J PATHOL, V160, P469, DOI 10.1016/S0002-9440(10)64866-3; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; Moreno FJ, 1998, MOL CELL BIOCHEM, V183, P201, DOI 10.1023/A:1006807814580; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Price DK, 2000, CANCER INVEST, V18, P722, DOI 10.3109/07357900009012204; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; ROWLANDS DC, 1995, LAB INVEST, V72, P100; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Vancompernolle K, 2000, J BIOL CHEM, V275, P33876, DOI 10.1074/jbc.M004785200; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	45	53	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8924	8930		10.1038/sj.onc.1207060	http://dx.doi.org/10.1038/sj.onc.1207060			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654788				2022-12-25	WOS:000186982200013
J	Vit, JP; Rosselli, F				Vit, JP; Rosselli, F			Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis	ONCOGENE			English	Article						ionizing radiations; apoptosis; ceramide; DNA damage	ATAXIA-TELANGIECTASIA; CELL-DEATH; PROTEIN; ATM; P53; GROWTH; INHIBITION; CHECKPOINT; RESISTANCE; GENES	Ionizing radiations (IR) exposure leads to damage on several cellular targets. How signals from different targets are integrated to determine the cell fate remains a controversial issue. Understanding the pathway(s) responsible(s) for the cell killing effect of the IR exposure is of prime importance in light of using radiations as anticancer agent or as diagnostic tool. In this study, we have established that IR-induced cell damage initiates two independent signaling pathways that lead to a biphasic intracellular ceramide increase. A transitory increase of ceramide is observed within minutes after IR exposure as a consequence of DNA damage-independent acid sphingomyelinase activation. Several hours after irradiation, a second wave of ceramide accumulation is observed depending on the DNA damage-dependent activation of ceramide synthase, which requires a signaling pathway involving ATM. Importantly, we have demonstrated that the late ceramide accumulation is also dependent on the first one and is rate limiting for the apoptotic process induced by IR. In conclusion, our observations suggest that ceramide is a major determinant of the IR-induced apoptotic process at the cross-point of different signal transduction pathways.	Inst Gustave Roussy, IFR 54, CNRS, UPR 2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rosselli, F (corresponding author), Inst Gustave Roussy, IFR 54, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	rosselli@vjf.cnrs.fr	vit, jean-philippe/Q-7286-2019; Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745; Vit, Jean-Philippe/0000-0001-5057-8554				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chmura SJ, 1997, CANCER RES, V57, P1270; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Duchaud E, 1996, CANCER RES, V56, P1400; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAREL R, 1993, J BIOL CHEM, V268, P14476; HARPER JW, 1993, CELL, V75, P805; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANNA KK, 1993, ONCOGENE, V8, P3307; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Meijer AE, 1999, INT J RADIAT BIOL, V75, P709, DOI 10.1080/095530099140041; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takagi M, 1998, CANCER RES, V58, P4923; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	42	58	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8645	8652		10.1038/sj.onc.1207087	http://dx.doi.org/10.1038/sj.onc.1207087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647458	Bronze			2022-12-25	WOS:000186844900001
J	Corazza, A; Pettirossi, F; Viglino, P; Verdone, G; Garcia, J; Dumy, P; Giorgetti, S; Mangione, P; Raimondi, S; Stoppini, M; Bellotti, V; Esposito, G				Corazza, A; Pettirossi, F; Viglino, P; Verdone, G; Garcia, J; Dumy, P; Giorgetti, S; Mangione, P; Raimondi, S; Stoppini, M; Bellotti, V; Esposito, G			Properties of some variants of human beta(2)-microglobulin and amyloidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN REVEALS; AMYLOID FIBRIL FORMATION; DISULFIDE BOND; PH; SPECTROSCOPY; MECHANISMS; EXCITATION; ENERGY; COPPER; STATES	Three variants of human beta(2)-microglobulin (beta(2)-m) were compared with wild-type protein. For two variants, namely the mutant R3Abeta(2)-m and the form devoid of the N-terminal tripeptide (DeltaN3beta(2)-m), a reduced unfolding free energy was measured compared with wild-type beta(2)-m, whereas an increased stability was observed for the mutant H31Ybeta(2)-m. The solution structure could be determined by H-1 NMR spectroscopy and restrained modeling only for R3Abeta(2)-m that showed the same conformation as the parent species, except for deviations at the interstrand loops. Analogous conclusions were reached for H31Ybeta(2)-m and DeltaN3beta(2)-m. Precipitation and unfolding were observed over time periods shorter than 4 - 6 weeks with all the variants and, sometimes, with wild-type protein. The rate of structured protein loss from solution as a result of precipitation and unfolding always showed pseudo-zeroth order kinetics. This and the failure to observe an unfolded species without precipitation suggest that a nucleated conformational conversion scheme should apply for beta(2)-m fibrillogenesis. The mechanism is consistent with the previous and present results on beta(2)-m amyloid transition, provided a nucleated oligomeric species be considered the stable intermediate of fibrillogenesis, the monomeric intermediate being the necessary transition step along the pathway from the native protein to the nucleated oligomer.	Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Udine, Micrograv Aging Training & Immobil Ctr Excellence, I-33100 Udine, Italy; Univ Grenoble 1, Etud Dynam & Struct Select Lab, F-38041 Grenoble 9, France; Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy; Policlin San Matteo, Ist Recovero & Cura Carattere Sci, Lab Biotecnol, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Udine; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Pavia; IRCCS Fondazione San Matteo	Esposito, G (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Piazzale Kolbe 4, I-33100 Udine, Italy.	gesposito@mail.dstb.uniud.it	Corazza, Alessandra/AGB-1457-2022; dumy, pascal/C-4863-2008; Giorgetti, Sofia/AAD-4341-2019; Bellotti, Vittorio/A-6201-2014	Corazza, Alessandra/0000-0003-2272-1928; dumy, pascal/0000-0002-7660-763X; Giorgetti, Sofia/0000-0001-9438-6511; Bellotti, Vittorio/0000-0001-8678-662X; Mangione, Palma/0000-0003-0260-1400				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; De Lorenzi E, 2002, ELECTROPHORESIS, V23, P918, DOI 10.1002/1522-2683(200203)23:6<918::AID-ELPS918>3.0.CO;2-F; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Eakin CM, 2002, BIOCHEMISTRY-US, V41, P10646, DOI 10.1021/bi025944a; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Fogolari F, 2000, PROTEINS, V39, P317, DOI 10.1002/(SICI)1097-0134(20000601)39:4<317::AID-PROT50>3.0.CO;2-W; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KEELER J, 1994, METHOD ENZYMOL, V239, P145; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Monti M, 2002, PROTEIN SCI, V11, P2362, DOI 10.1110/ps.0206902; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; OKON M, 1992, BIOCHEMISTRY-US, V31, P8906, DOI 10.1021/bi00152a030; Pace C N, 1986, Methods Enzymol, V131, P266; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rosano C, 2004, J MOL BIOL, V335, P1051, DOI 10.1016/j.jmb.2003.11.040; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015; Uchanska-Ziegler B, 2003, TRENDS IMMUNOL, V24, P73, DOI 10.1016/S1471-4906(02)00028-5; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1986, NMR SPECTROSCOPY PRO; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	53	61	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9176	9189		10.1074/jbc.M310779200	http://dx.doi.org/10.1074/jbc.M310779200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660575	hybrid			2022-12-25	WOS:000189265900079
J	Park, JS; Svetkauskaite, D; He, QB; Kim, JY; Strassheim, D; Ishizaka, A; Abraham, E				Park, JS; Svetkauskaite, D; He, QB; Kim, JY; Strassheim, D; Ishizaka, A; Abraham, E			Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; I-KAPPA-B; TUMOR-NECROSIS-FACTOR; NEURITE OUTGROWTH; MULTILIGAND RECEPTOR; CUTTING EDGE; MOLECULAR-MECHANISMS; CHROMATIN PROTEIN; HUMAN NEUTROPHILS; GENE-EXPRESSION	High mobility group box 1 (HMGB1) protein, originally described as a DNA-binding protein that stabilizes nucleosomes and facilitates transcription, can also be released extracellularly during acute inflammatory responses. Exposure of neutrophils, monocytes, or macrophages to HMGB1 results in increased nuclear translocation of NF-kappaB and enhanced expression of proinflammatory cytokines. Although the receptor for advanced glycation end products (RAGE) has been shown to interact with HMGB1, other putative HMGB1 receptors are known to exist but have not been characterized. In the present experiments, we explored the role of RAGE, Toll-like receptor (TLR) 2, and TLR 4, as well as associated kinases, in HMGB1-induced cellular activation. Culture of neutrophils or macrophages with HMGB1 produced activation of NF-kappaB through TLR 4-independent mechanisms. Unlike lipopolysaccharide (LPS), which primarily increased the activity of IKKbeta, HMGB1 exposure resulted in activation of both IKKalpha and IKKbeta. Kinases and scaffolding proteins downstream of TLR 2 and TLR 4, but not TLR/interleukin- 1 receptor (IL-1R)-independent kinases such as tumor necrosis factor receptor-associated factor 2, were involved in the enhancement of NF-kappaB-dependent transcription by HMGB1. Transfections with dominant negative constructs demonstrated that TLR 2 and TLR 4 were both involved in HMGB1-induced activation of NF-kappaB. In contrast, RAGE played only a minor role in macrophage activation by HMGB1. Interactions of HMGB1 with TLR 2 and TLR 4 may provide an explanation for the ability of HMGB1 to generate inflammatory responses that are similar to those initiated by LPS.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Keio Univ, Sch Med, Dept Med, Tokyo 160, Japan	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Keio University	Abraham, E (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Box C272,4200 E 9th Ave, Denver, CO 80262 USA.	Edward.Abraham@uchsc.edu	STRASSHEIM, DEREK/AHB-1158-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068743, R01HL062221] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P01HL068743, HL62221] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham E, 2003, J IMMUNOL, V170, P5644, DOI 10.4049/jimmunol.170.11.5644; Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Andersson U, 2002, J LEUKOCYTE BIOL, V72, P1084; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Arcaroli J, 2002, J LEUKOCYTE BIOL, V72, P571; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Chung JY, 2002, J CELL SCI, V115, P679; Czura CJ, 2003, CRIT CARE MED, V31, pS46, DOI 10.1097/00003246-200301001-00007; Czura CJ, 2001, J ENDOTOXIN RES, V7, P315, DOI 10.1177/09680519010070041401; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dintilhac A, 2002, J BIOL CHEM, V277, P7021, DOI 10.1074/jbc.M108417200; DUNNE A, 2003, SCI STKE; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hori O, 1996, NEPHROL DIAL TRANSPL, V11, P13; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2002, CANCER RES, V62, P4805; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Imler J L, 2000, Rev Immunogenet, V2, P294; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nick JA, 1996, J IMMUNOL, V156, P4867; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200; SANDERS C, 1977, BIOCHEM BIOPH RES CO, V78, P1034, DOI 10.1016/0006-291X(77)90525-3; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Schmidt AM, 1996, DIABETES, V45, pS77, DOI 10.2337/diab.45.3.S77; SCHWARTZ MC, 1995, AM J RESP CELL MOL, V12, P434, DOI 10.1165/ajrcmb.12.4.7695923; Sparatore B, 2002, BIOCHEM J, V363, P529, DOI 10.1042/0264-6021:3630529; Stern D, 2002, ADV DRUG DELIVER REV, V54, P1615, DOI 10.1016/S0169-409X(02)00160-6; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yang H, 2001, SHOCK, V15, P247, DOI 10.1097/00024382-200115040-00001; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Yoshinari D, 2001, CRIT CARE MED, V29, P628, DOI 10.1097/00003246-200103000-00029; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414	66	1252	1340	3	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7370	7377		10.1074/jbc.M306793200	http://dx.doi.org/10.1074/jbc.M306793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660645	hybrid			2022-12-25	WOS:000189103300002
J	Shibasaki, T; Sunaga, Y; Fujimoto, K; Kashima, Y; Seino, S				Shibasaki, T; Sunaga, Y; Fujimoto, K; Kashima, Y; Seino, S			Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE ZONE; SYNAPTOTAGMIN-I; BINDING DOMAINS; RAB3 EFFECTOR; PROTEIN; COMPLEX; FAMILY; SECRETION; PICCOLO; SUBUNIT	ATP, cAMP, and Ca2+ are the major signals in the regulation of insulin granule exocytosis in pancreatic beta cells. The sensors and regulators of these signals have been characterized individually. The ATP-sensitive K+ channel, acting as the ATP sensor, couples cell metabolism to membrane potential. cAMP-GEFII, acting as a cAMP sensor, mediates cAMP-dependent, protein kinase A-independent exocytosis, which requires interaction with both Piccolo as a Ca2+ sensor and Rim2 as a Rab3 effector. L-type voltage-dependent Ca2+ channels (VDCCs) regulate Ca2+ influx. In the present study, we demonstrate interactions of these molecules. Sulfonylurea receptor 1, a subunit of ATP-sensitive K+ channels, interacts specifically with cAMP-GEFII through nucleotide-binding fold 1, and the interaction is decreased by a high concentration of cAMP. Localization of cAMP-GEFII overlaps with that of Rim2 in plasma membrane of insulin-secreting MIN6 cells. Localization of Rab3 coincides with that of Rim2. Rim2 mutant lacking the Rab3 binding region, when overexpressed in MIN6 cells, is localized exclusively in cytoplasm, and impairs cAMP-dependent exocytosis in MIN6 cells. In addition, Rim2 and Piccolo bind directly to the alpha(1) 1.2- subunit of VDCC. These results indicate that ATP sensor, cAMP sensor, Ca2+ sensor, and VDCC interact with each other, which further suggests that ATP, cAMP, and Ca2+ signals in insulin granule exocytosis are integrated in a specialized domain of pancreatic beta cells to facilitate stimulus-secretion coupling.	Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba 2608670, Japan	Kobe University; Chiba University	Seino, S (corresponding author), Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan.	seino@med.kobe-u.ac.jp						Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brown J C, 1975, Recent Prog Horm Res, V31, P487; Calakos N, 1996, PHYSIOL REV, V76, P1; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; Harris BZ, 2001, J CELL SCI, V114, P3219; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LANDIS DMD, 1988, J ELECTRON MICR TECH, V10, P129, DOI 10.1002/jemt.1060100203; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; YORIFUJI H, 1989, J ELECTRON MICR TECH, V12, P160, DOI 10.1002/jemt.1060120210; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	131	141	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7956	7961		10.1074/jbc.M309068200	http://dx.doi.org/10.1074/jbc.M309068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660679	hybrid			2022-12-25	WOS:000189103300073
J	Watabe, H; Valencia, JC; Yasumoto, K; Kushimoto, T; Ando, H; Muller, J; Vieira, WD; Mizoguchi, M; Appella, E; Hearing, VJ				Watabe, H; Valencia, JC; Yasumoto, K; Kushimoto, T; Ando, H; Muller, J; Vieira, WD; Mizoguchi, M; Appella, E; Hearing, VJ			Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; MOUSE MELANOMA-CELLS; B-16 MURINE MELANOMA; VACUOLAR H+-ATPASE; ENDOPLASMIC-RETICULUM; OCULOCUTANEOUS ALBINISM; MAMMALIAN TYROSINASE; GENE-PRODUCT; HUMAN-SKIN; INTRACELLULAR TRAFFICKING	Pigmentation of the hair, skin, and eyes of mammals results from a number of melanocyte-specific proteins that are required for the biosynthesis of melanin. Those proteins comprise the structural and enzymatic components of melanosomes, the membrane-bound organelles in which melanin is synthesized and deposited. Tyrosinase (TYR) is absolutely required for melanogenesis, but other melanosomal proteins, such as TYRP1, DCT, and gp100, also play important roles in regulating mammalian pigmentation. However, pigmentation does not always correlate with the expression of TYR mRNA/protein, and thus its function is also regulated at the post-translational level. Thus, TYR does not necessarily exist in a catalytically active state, and its post-translational activation could be an important control point for regulating melanin synthesis. In this study, we used a multidisciplinary approach to examine the processing and sorting of TYR through the endoplasmic reticulum ( ER), Golgi apparatus, coated vesicles, endosomes and early melanosomes because those organelles hold the key to understanding the trafficking of TYR to melanosomes and thus the regulation of melanogenesis. In pigmented cells, TYR is trafficked through those organelles rapidly, but in amelanotic cells, TYR is retained within the ER and is eventually degraded by proteasomes. We now show that TYR can be released from the ER in the presence of protonophore or proton pump inhibitors which increase the pH of intracellular organelles, after which TYR is transported correctly to the Golgi, and then to melanosomes via the endosomal sorting system. The expression of TYRP1, which facilitates TYR processing in the ER, is down-regulated in the amelanotic cells; this is analogous to a hypopigmentary disease known as oculocutaneous albinism type 3 and further impairs melanin production. The sum of these results shows that organellar pH, proteasome activity, and down-regulation of TYRP1 expression all contribute to the lack of pigmentation in TYR-positive amelanotic melanoma cells.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Rockville, MD 20852 USA; St Marianna Univ, Sch Med, Dept Dermatol, Kawasaki, Kanagawa 2168511, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Saint Marianna University	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov		Yasumoto, Ken-ichi/0000-0002-8090-1161	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ancans J, 2000, FEBS LETT, V478, P57, DOI 10.1016/S0014-5793(00)01795-6; Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Bhatnagar V, 1998, MOL CELL BIOCHEM, V189, P99, DOI 10.1023/A:1006876411202; BHATNAGAR V, 1993, ARCH BIOCHEM BIOPHYS, V307, P183, DOI 10.1006/abbi.1993.1577; Boissy RE, 1996, AM J HUM GENET, V58, P1145; Boissy RE, 1998, LAB INVEST, V78, P1037; Borovansky J, 1997, ARCH DERMATOL RES, V289, P145, DOI 10.1007/s004030050170; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; BURCHILL SA, 1991, PATHOBIOLOGY, V59, P335, DOI 10.1159/000163673; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHAPMAN PB, 1996, IMMUNOL HUM MELANOMA, V12, P195; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Costin GE, 2003, J CELL SCI, V116, P3203, DOI 10.1242/jcs.00598; DEVI CC, 1987, EUR J BIOCHEM, V166, P705, DOI 10.1111/j.1432-1033.1987.tb13569.x; DEVI CC, 1989, PIGM CELL RES, V2, P117; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Francis E, 2003, J BIOL CHEM, V278, P25607, DOI 10.1074/jbc.M303411200; FULLER BB, 1988, J CELL PHYSIOL, V134, P149, DOI 10.1002/jcp.1041340119; Fuller BB, 2001, EXP CELL RES, V262, P197, DOI 10.1006/excr.2000.5092; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; Hirosaki K, 2002, J INVEST DERMATOL, V119, P475, DOI 10.1046/j.1523-1747.2002.01832.x; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Huizing M, 2002, PIGM CELL RES, V15, P405, DOI 10.1034/j.1600-0749.2002.02074.x; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; Jimbow K, 2000, PIGM CELL RES, V13, P110, DOI 10.1034/j.1600-0749.13.s8.20.x; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Kushimoto T, 2003, PIGM CELL RES, V16, P237, DOI 10.1034/j.1600-0749.2003.00034.x; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; Manga P, 2001, PIGM CELL RES, V14, P362, DOI 10.1034/j.1600-0749.2001.140508.x; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mendiratta SK, 2001, CANCER RES, V61, P859; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Negroiu G, 2003, J BIOL CHEM, V278, P27035, DOI 10.1074/jbc.M303167200; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; Olivares C, 2003, J BIOL CHEM, V278, P15735, DOI 10.1074/jbc.M300658200; Orlow SJ, 1998, CANCER RES, V58, P1521; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; Puri N, 2000, J INVEST DERMATOL, V115, P607, DOI 10.1046/j.1523-1747.2000.00108.x; Raposo G, 2002, TRAFFIC, V3, P237, DOI 10.1034/j.1600-0854.2002.030401.x; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; SAEKI H, 1985, J INVEST DERMATOL, V85, P423, DOI 10.1111/1523-1747.ep12277091; Shen B, 2001, TRAFFIC, V2, P202, DOI 10.1034/j.1600-0854.2001.020306.x; Spritz RA, 2000, PIGM CELL RES, V13, P15, DOI 10.1034/j.1600-0749.2000.130104.x; Spritz RA, 2003, CURR OPIN GENET DEV, V13, P284, DOI 10.1016/S0959-437X(03)00059-5; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Takeuchi H, 2003, CANCER RES, V63, P441; TOWNSEND D, 1984, ANAL BIOCHEM, V139, P345, DOI 10.1016/0003-2697(84)90015-0; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; TRIPATHI RK, 1988, BIOCHEM J, V252, P481, DOI 10.1042/bj2520481; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Virador V, 2001, PIGM CELL RES, V14, P289, DOI 10.1034/j.1600-0749.2001.140410.x; YAVUZER U, 1995, ONCOGENE, V10, P123; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; ZHAO HQ, 1994, LAB INVEST, V71, P25	81	95	104	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7971	7981		10.1074/jbc.M309714200	http://dx.doi.org/10.1074/jbc.M309714200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14634018	hybrid			2022-12-25	WOS:000189103300075
J	Zylberman, V; Craig, PO; Klinke, S; Braden, BC; Cauerhff, A; Goldbaum, FA				Zylberman, V; Craig, PO; Klinke, S; Braden, BC; Cauerhff, A; Goldbaum, FA			High order quaternary arrangement confers increased structural stability to Brucella sp lumazine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; HEAVY RIBOFLAVIN SYNTHASE; RAY STRUCTURE-ANALYSIS; BETA-SUBUNIT CAPSIDS; BACILLUS-SUBTILIS; ANGSTROM RESOLUTION; B-SUBUNIT; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; CYTOPLASMIC PROTEIN; LABILE ENTEROTOXIN	The penultimate step in the pathway of riboflavin biosynthesis is catalyzed by the enzyme lumazine synthase (LS). One of the most distinctive characteristics of this enzyme is the structural quaternary divergence found in different species. The protein exists as pentameric and icosahedral forms, built from practically the same structural monomeric unit. The pentameric structure is formed by five 18-kDa monomers, each extensively contacting neighboring monomers. The icosahedrical structure consists of 60 LS monomers arranged as 12 pentamers giving rise to a capsid exhibiting icosahedral 532 symmetry. In all lumazine synthases studied, the topologically equivalent active sites are located at the interfaces between adjacent subunits in the pentameric modules. The Brucella sp. lumazine synthase (BLS) sequence clearly diverges from pentameric and icosahedric enzymes. This unusual divergence prompted us to further investigate its quaternary arrangement. In the present work, we demonstrate by means of solution light scattering and x-ray structural analyses that BLS assembles as a very stable dimer of pentamers, representing a third category of quaternary assembly for lumazine synthases. We also describe by spectroscopic studies the thermodynamic stability of this oligomeric protein and postulate a mechanism for dissociation/unfolding of this macromolecular assembly. The higher molecular order of BLS increases its stability 20degreesC compared with pentameric lumazine synthases. The decameric arrangement described in this work highlights the importance of quaternary interactions in the stabilization of proteins.	Consejo Nacl Invest Cient & Tecn, Inst Leloir, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; Bowie State Univ, Dept Nat Sci, Bowie, MD 20715 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires; University System of Maryland; Bowie State University	Goldbaum, FA (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Leloir, Patricias Argentinas 435,C1405BWE, Buenos Aires, DF, Argentina.	fgoldbaum@leloir.org.ar	Klinke, Sebastián/N-6174-2018	Klinke, Sebastián/0000-0002-8777-0870; Goldbaum, Fernando/0000-0001-6235-3002; Cauerhff, Ana/0000-0001-9686-9883				BACHER A, 1986, METHOD ENZYMOL, V122, P192; BHAKUNI V, 1991, BIOCHEMISTRY-US, V30, P5055, DOI 10.1021/bi00234a031; Botelho MG, 2003, J BIOL CHEM, V278, P34259, DOI 10.1074/jbc.M303189200; Boudker O, 1997, J MOL BIOL, V272, P770, DOI 10.1006/jmbi.1997.1263; Braden BC, 2000, J MOL BIOL, V297, P1031, DOI 10.1006/jmbi.2000.3640; D'Alfonso L, 1999, BBA-PROTEIN STRUCT M, V1432, P194, DOI 10.1016/S0167-4838(99)00105-3; Dams T, 1999, BIOCHEMISTRY-US, V38, P9169, DOI 10.1021/bi990635e; DANIEL E, 1966, BIOCHEMISTRY-US, V5, P1893, DOI 10.1021/bi00870a016; FORNASARI MS, 2003, MOL BIOL EVOL; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; Goldbaum FA, 1998, J STRUCT BIOL, V123, P175, DOI 10.1006/jsbi.1998.4022; Goldbaum FA, 1999, J MED MICROBIOL, V48, P833, DOI 10.1099/00222615-48-9-833; GOLDBAUM FA, 1993, J CLIN MICROBIOL, V31, P2141, DOI 10.1128/JCM.31.8.2141-2145.1993; GREENE RF, 1974, J BIOL CHEM, V249, P5388; Guidry JJ, 2000, PROTEIN SCI, V9, P2109, DOI 10.1110/ps.9.11.2109; Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; Kohler S, 2003, TRENDS MICROBIOL, V11, P215, DOI 10.1016/S0966-842X(03)00078-7; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LADENSTEIN R, 1994, EUR J BIOCHEM, V223, P1007, DOI 10.1111/j.1432-1033.1994.tb19079.x; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Mok YK, 1996, PROTEIN SCI, V5, P310; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2362, DOI 10.1021/bi992484l; Polikarpov I, 1998, NUCL INSTRUM METH A, V405, P159, DOI 10.1016/S0168-9002(97)01202-3; Reddy GB, 1999, BIOCHEMISTRY-US, V38, P4464, DOI 10.1021/bi982828s; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; Ruddock LW, 1996, BIOCHEMISTRY-US, V35, P16069, DOI 10.1021/bi961865l; Ruddock LW, 1996, J BIOL CHEM, V271, P19118, DOI 10.1074/jbc.271.32.19118; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Velikovsky CA, 2002, INFECT IMMUN, V70, P2507, DOI 10.1128/IAI.70.5.2507-2511.2002; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435	38	64	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8093	8101		10.1074/jbc.M312035200	http://dx.doi.org/10.1074/jbc.M312035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660615	hybrid			2022-12-25	WOS:000189103300089
J	Gelling, CL; Piper, MDW; Hong, SP; Kornfeld, GD; Dawes, IW				Gelling, CL; Piper, MDW; Hong, SP; Kornfeld, GD; Dawes, IW			Identification of a novel one-carbon metabolism regulon in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE HYDROXYMETHYLTRANSFERASE; MOLECULAR CHARACTERIZATION; PURINE BIOSYNTHESIS; TRYPTOPHAN SYNTHASE; MASTER REGULATOR; FOLATE COENZYMES; GENE-EXPRESSION; FOLIC-ACID; IN-VIVO; YEAST	Glycine specifically induces genes encoding subunits of the glycine decarboxylase complex (GCV1, GCV2, and GCV3), and this is mediated by a fall in cytoplasmic levels of 5,10-methylenetetrahydrofolate caused by inhibition of cytoplasmic serine hydroxymethyltransferase. Here it is shown that this control system extends to genes for other enzymes of one-carbon metabolism and de novo purine biosynthesis. Northern analysis of the response to glycine demonstrated that the induction of the GCV genes and the induction of other amino acid metabolism genes are temporally distinct. The genomewide response to glycine revealed that several other genes are rapidly co-induced with the GCV genes, including SHM2, which encodes cytoplasmic serine hydroxymethyltransferase. These results were refined by examining transcript levels in an shm2Delta strain (in which cytoplasmic 5,10-methylenetetrahydrofolate levels are reduced) and a met13Delta strain, which lacks the main methylenetetrahydrofolate reductase activity of yeast and is effectively blocked at consumption of 5,10-methylene tetrahydrofolate for methionine synthesis. Glycine addition also caused a substantial transient disturbance to metabolism, including a sequence of changes in induction of amino acid biosynthesis and respiratory chain genes. Analysis of the glycine response in the shm2Delta strain demonstrated that apart from the one-carbon regulon, most of these transient responses were not contingent on a disturbance to one-carbon metabolism. The one-carbon response is distinct from the Bas1p purine biosynthesis regulon and thus represents the first example of transcriptional regulation in response to activated one-carbon status.	Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia.	i.dawes@unsw.edu.au	Piper, Matthew/C-1714-2008	Piper, Matthew/0000-0003-3245-7219				ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; Bailey LB, 2003, J NUTR, V133, p1961S, DOI 10.1093/jn/133.6.1961S; BARLOWE C K, 1988, Biofactors, V1, P171; BLANCHETTE M, 2001, BIOINFORMATICS, V1, P1; BOTSFORD JL, 1969, J BACTERIOL, V97, P1176, DOI 10.1128/JB.97.3.1176-1183.1969; CAPERELLI CA, 1980, J BIOL CHEM, V255, P1885; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Dax SL, 1997, ANTIBACTERIAL CHEMOT, P38; Denis V, 1998, MOL GEN GENET, V259, P246, DOI 10.1007/s004380050810; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Halsted CH, 2002, ALCOHOL, V27, P169, DOI 10.1016/S0741-8329(02)00225-2; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hong SP, 1999, J BIOL CHEM, V274, P10523, DOI 10.1074/jbc.274.15.10523; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; HOUBEN KF, 1989, BIOCHEMISTRY-US, V28, P4140, DOI 10.1021/bi00436a003; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; MCKENZIE KQ, 1977, GENETICS, V86, P85; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; McNeil JB, 1996, GENETICS, V142, P371; MORGAN SL, 1995, FOLATE HLTH DIS, P405; Morris Martha Savaria, 2002, Nutr Clin Care, V5, P124, DOI 10.1046/j.1523-5408.2002.t01-1-00006.x; Nagarajan L, 1997, J BIOL CHEM, V272, P4444, DOI 10.1074/jbc.272.7.4444; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Pinson B, 2000, MOL MICROBIOL, V36, P1460, DOI 10.1046/j.1365-2958.2000.01966.x; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; Ro HS, 1999, J BIOL CHEM, V274, P31189, DOI 10.1074/jbc.274.44.31189; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sinclair DA, 1996, MOL MICROBIOL, V19, P611, DOI 10.1046/j.1365-2958.1996.419947.x; Sinha S, 2002, NUCLEIC ACIDS RES, V30, P5549, DOI 10.1093/nar/gkf669; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1991, J BIOL CHEM, V266, P1543; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; Tibbetts AS, 2000, J BIOL CHEM, V275, P20920, DOI 10.1074/jbc.M909851199; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906	54	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7072	7081		10.1074/jbc.M309178200	http://dx.doi.org/10.1074/jbc.M309178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645232	hybrid			2022-12-25	WOS:000188969200105
J	Clifford, DM; Marinco, SM; Brush, GS				Clifford, DM; Marinco, SM; Brush, GS			The meiosis-specific protein kinase Ime2 directs phosphorylation of replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; SPORULATION-SPECIFIC GENES; MITOTIC CHECKPOINT GENES; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; S-PHASE; YEAST MEIOSIS; TRANSCRIPTIONAL ACTIVATION; ATAXIA-TELANGIECTASIA; SIGNALING PATHWAY	In Saccharomyces cerevisiae, the cellular single-stranded DNA-binding protein replication protein A (RPA) becomes phosphorylated during meiosis in two discrete reactions. The primary reaction is first observed shortly after cells enter the meiotic program and leads to phosphorylation of nearly all the detectable RPA. The secondary reaction, which requires the ATM/ATR homologue Mec1, is induced upon initiation of recombination and only modifies a fraction of the total RPA. We now report that correct timing of both RPA phosphorylation reactions requires Ime2, a meiosis-specific protein kinase that is critical for proper initiation of meiotic progression. Expression of Ime2 in vegetative cells leads to an unscheduled RPA phosphorylation reaction that does not require other tested meiosis-specific kinases and is distinct from the RPA phosphorylation reaction that normally occurs during mitotic growth. In addition, immunoprecipitated Ime2 catalyzes phosphorylation of purified RPA. Our data strongly suggest that Ime2 is an RPA kinase in vivo. We propose that Ime2 directly catalyzes RPA phosphorylation in the primary reaction and indirectly promotes the Mec1-dependent secondary reaction by advancing cells through meiotic progression. Our studies have identified a novel meiosis-specific reaction that targets a key protein required for DNA replication, repair, and recombination. This pathway could be important in differentiating mitotic and meiotic DNA metabolism.	Wayne State Univ, Karmanos Canc Inst, Program Mol Biol & Genet, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Brush, GS (corresponding author), Wayne State Univ, Karmanos Canc Inst, Program Mol Biol & Genet, 110 E Warren Ave, Detroit, MI 48201 USA.	brushg@karmanos.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061860] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61860] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1998, METHODS YEAST GENETI, P145; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benjamin KR, 2003, GENE DEV, V17, P1524, DOI 10.1101/gad.1101503; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Bolte M, 2002, P NATL ACAD SCI USA, V99, P4385, DOI 10.1073/pnas.072385099; Borde V, 2000, SCIENCE, V290, P806, DOI 10.1126/science.290.5492.806; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Brush GS, 2001, NUCLEIC ACIDS RES, V29, P4808, DOI 10.1093/nar/29.23.4808; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cha RS, 2000, GENE DEV, V14, P493; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; Dirick L, 1998, SCIENCE, V281, P1854, DOI 10.1126/science.281.5384.1854; Foiani M, 1996, MOL GEN GENET, V253, P278, DOI 10.1007/s004380050323; Guttmann-Raviv N, 2002, MOL CELL BIOL, V22, P2047, DOI 10.1128/MCB.22.7.2047-2056.2002; Hepworth SR, 1998, MOL CELL BIOL, V18, P5750, DOI 10.1128/MCB.18.10.5750; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Hui CM, 2002, PROTEIN EXPRES PURIF, V26, P416, DOI 10.1016/S1046-5928(02)00548-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KADYK LC, 1992, GENETICS, V132, P387; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KASSIR Y, 1988, CELL, V52, P853, DOI 10.1016/0092-8674(88)90427-8; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KOMINAMI K, 1993, BIOSCI BIOTECH BIOCH, V57, P1731, DOI 10.1271/bbb.57.1731; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MITCHELL AP, 1990, MOL CELL BIOL, V10, P2104, DOI 10.1128/MCB.10.5.2104; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Paciotti V, 2000, GENE DEV, V14, P2046; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schramke V, 2001, GENE DEV, V15, P1845, DOI 10.1101/gad.193901; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; SMITH HE, 1993, GENETICS, V133, P775; SMITH HE, 1989, MOL CELL BIOL, V9, P2142, DOI 10.1128/MCB.9.5.2142; Smith KN, 2001, CURR BIOL, V11, P88, DOI 10.1016/S0960-9822(01)00026-4; Sopko R, 2002, MOL CELL BIOL, V22, P7024, DOI 10.1128/MCB.22.20.7024-7040.2002; Stuart D, 1998, GENE DEV, V12, P2698, DOI 10.1101/gad.12.17.2698; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; XU LZ, 1995, MOL CELL BIOL, V15, P6572; YOSHIDA M, 1990, MOL GEN GENET, V221, P176, DOI 10.1007/BF00261718; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6163	6170		10.1074/jbc.M306943200	http://dx.doi.org/10.1074/jbc.M306943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634024	hybrid			2022-12-25	WOS:000188776500132
J	Hatano, N; Ohya, S; Muraki, K; Clark, RB; Giles, WR; Imaizumi, Y				Hatano, N; Ohya, S; Muraki, K; Clark, RB; Giles, WR; Imaizumi, Y			Two arginines in the cytoplasmic C-terminal domain are essential for voltage-dependent regulation of A-type K+ current in the Kv4 channel subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; CLOSED-STATE INACTIVATION; ACTIVATION GATE; INTERACTING PROTEIN-2; MOLECULAR-CLONING; PYRAMIDAL NEURONS; BINDING PROTEIN; SPLICE VARIANTS; T1 DOMAIN; EXPRESSION	Contributions of the C-terminal domain of Kv4.3 to the voltage-dependent gating of A-type K+ current (I-A) were examined by (i) making mutations in this region, (ii) heterologous expression in HEK293 cells, and (iii) detailed voltage clamp analyses. Progressive deletions of the C terminus of rat Kv4.3M ( to amino acid 429 from the N terminus) did not markedly change the inactivation time course of IA but shifted the voltage dependence of steady state inactivation in the negative direction to a maximum of -17 mV. Further deletions ( to amino acid 420) shifted this parameter in the positive direction, suggesting a critical role for the domain 429-420 in the voltage-dependent regulation of IA. There are four positively charged amino acids in this domain: Lys(423), Lys(424), Arg(426), and Arg(429). The replacement of the two arginines with alanines (R2A) resulted in -23 and -13 mV shifts of inactivation and activation, respectively. Additional replacement of the two lysines with alanines did not result in further shifts. Single replacements of R426A or R429A induced -15 and -10 mV shifts of inactivation, respectively. R2A did not significantly change the inactivation rate but did markedly change the voltage dependence of recovery from inactivation. These two arginines are conserved in Kv4 subfamily, and alanine replacement of Arg(429) and Arg(432) in Kv4.2 gave essentially the same results. These effects of R2A were not modulated by co-expression of the K+ channel beta subunit, KChIPs. In conclusion, the two arginines in the cytosolic C-terminal domain of alpha-subunits of Kv4 subfamily strongly regulate the voltage dependence of channel activation, inactivation, and recovery.	Nagoya City Univ, Dept Mol & Cellular Pharmacol, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Univ Calgary, Fac Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	Nagoya City University; University of Calgary	Imaizumi, Y (corresponding author), Nagoya City Univ, Dept Mol & Cellular Pharmacol, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabedori, Nagoya, Aichi 4678603, Japan.	yimaizum@phar.nagoya-cu.ac.jp	Ohya, Susumu/AAB-3618-2020; Imaizumi, Yuji/AAF-6585-2020	Ohya, Susumu/0000-0002-5765-0667; 				An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bahring R, 2001, J PHYSIOL-LONDON, V535, P65, DOI 10.1111/j.1469-7793.2001.00065.x; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Beck EJ, 2001, BIOPHYS J, V81, P867, DOI 10.1016/S0006-3495(01)75747-5; Castro PA, 2001, J NEUROSCI, V21, P6626, DOI 10.1523/JNEUROSCI.21-17-06626.2001; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Decher N, 2001, CARDIOVASC RES, V52, P255, DOI 10.1016/S0008-6363(01)00374-1; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Hatano N, 2002, PFLUG ARCH EUR J PHY, V444, P80, DOI 10.1007/s00424-002-0798-9; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IMAIZUMI Y, 1990, J PHYSIOL-LONDON, V427, P301, DOI 10.1113/jphysiol.1990.sp018173; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LIPKIND GM, 1995, P NATL ACAD SCI USA, V92, P9215, DOI 10.1073/pnas.92.20.9215; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; Martina M, 1998, J NEUROSCI, V18, P8111; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Nakamura TY, 2001, FEBS LETT, V499, P205, DOI 10.1016/S0014-5793(01)02560-1; Ohya S, 2001, LIFE SCI, V68, P1703, DOI 10.1016/S0024-3205(01)00958-4; Ohya S, 2001, BIOCHEM BIOPH RES CO, V282, P96, DOI 10.1006/bbrc.2001.4558; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Patel SP, 2002, J PHYSIOL-LONDON, V539, P649, DOI 10.1113/jphysiol.2001.015156; Petrecca K, 2000, J NEUROSCI, V20, P8736; Rasmusson RL, 1995, J PHYSIOL-LONDON, V489, P709, DOI 10.1113/jphysiol.1995.sp021085; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Song M, 2001, J BIOL CHEM, V276, P31883, DOI 10.1074/jbc.M101058200; Takimoto K, 1997, CIRC RES, V81, P533, DOI 10.1161/01.RES.81.4.533; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; Wang SM, 2002, BIOCHEM BIOPH RES CO, V295, P223, DOI 10.1016/S0006-291X(02)00658-7; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	48	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5450	5459		10.1074/jbc.M302034200	http://dx.doi.org/10.1074/jbc.M302034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645239	hybrid			2022-12-25	WOS:000188776500052
J	Moon, JJ; Rubio, ED; Martino, A; Krumm, A; Nelson, BH				Moon, JJ; Rubio, ED; Martino, A; Krumm, A; Nelson, BH			A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; IL-2 RECEPTOR; BETA-CHAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; NUCLEAR SPECKLES; BREAST-CANCER; C-MYC; STAT5; INDUCTION	The interleukin- 2 ( IL- 2) receptor promotes T cell proliferation in part by inducing the expression of D- type cyclins, which enable cells to progress from the G(1) to S phase of the cell cycle. We previously showed that the IL- 2 receptor induces expression of cyclin D2 by activating the transcription factor Stat5, which binds directly and immediately to a site upstream of the cyclin D2 promoter. We show here that subsequent transcription of the cyclin D2 gene occurs by a delayed, cycloheximide-sensitive mechanism, which implies the involvement of additional regulatory mechanisms. The transcription factor c- Myc is induced by Stat5 and is reported to bind to two E box motifs in the cyclin D2 promoter. However, in IL- 2- stimulated T cells, c- Myc does not appear to be involved in cyclin D2 induction, since we found that these two E boxes are preferentially bound by USF- 1 and USF- 2 and, moreover, are dispensable for cyclin D2 promoter activity. Instead, we found that Stat5 activates the phosphatidylinositol 3- kinase ( PI3 kinase) pathway by a delayed, cycloheximide- sensitive mechanism and that PI3 kinase activity is essential for the induction of cyclin D2 by Stat5. Chromatin immunoprecipitation experiments revealed that PI3 kinase is required for the optimal binding of RNA polymerase II to the promoters of cyclin D2 as well as other genes. Our results reveal a novel link between PI3 kinase and RNA polymerase II promoter binding activity and demonstrate discrete, coordinated roles for the PI3 kinase and Stat5 pathways in cyclin D2 transcription.	Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA; Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Benaroya Research Institute; Virginia Mason Medical Center; Fred Hutchinson Cancer Center	Nelson, BH (corresponding author), BC Canc Agcy, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada.	bnelson@bccancer.bc.ca	Nelson, Brad H/K-2622-2014	Nelson, Brad/0000-0002-4445-5539	NATIONAL CANCER INSTITUTE [T32CA009537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057931] Funding Source: NIH RePORTER; NCI NIH HHS [CA09537] Funding Source: Medline; NIGMS NIH HHS [GM57931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Friedrichsen BN, 2001, MOL ENDOCRINOL, V15, P136, DOI 10.1210/me.15.1.136; Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002-0356; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lord JD, 1998, J IMMUNOL, V161, P4627; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Moon JJ, 2001, J IMMUNOL, V167, P2714, DOI 10.4049/jimmunol.167.5.2714; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; TURNER JM, 1993, INT IMMUNOL, V5, P1199, DOI 10.1093/intimm/5.10.1199; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1	53	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5520	5527		10.1074/jbc.M308998200	http://dx.doi.org/10.1074/jbc.M308998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660677	hybrid			2022-12-25	WOS:000188776500060
J	Snyder, PM; Steines, JC; Olson, DR				Snyder, PM; Steines, JC; Olson, DR			Relative contribution of Nedd4 and Nedd4-2 to ENaC regulation in epithelia determined by RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL ENAC; LIDDLES-SYNDROME; SODIUM-CHANNEL; CELL-SURFACE; WW DOMAINS; PY MOTIF; ALDOSTERONE; EXPRESSION; INHIBITION; SGK	Epithelial Na+ transport is regulated in large part by mechanisms that control expression of the epithelial Na+ channel (ENaC) at the cell surface. Nedd4 and Nedd4-2 are candidates to control ENaC surface expression, but it is not known which of these proteins contributes to ENaC regulation in epithelia. To address this question, we used RNA interference to selectively reduce expression of Nedd4 or Nedd4-2. We found that endogenous Nedd4-2, but not Nedd4, negatively regulates ENaC in two epithelial cell lines (Fischer rat thyroid and H441); small interfering RNA (siRNA) against Nedd4-2 increased amiloride-sensitive Na+ current (compared with control siRNA), but Nedd4 siRNA did not. A mutation associated with Liddle's syndrome (beta(R566X)) abolished the effect of Nedd4-2 siRNA, suggesting that a defect in ENaC regulation by Nedd4-2 contributes to the pathogenesis of this inherited form of hypertension. Previous work found that Nedd4-2 is phosphorylated by serum and glucocorticoid-regulated kinase, a Ser/Thr kinase induced by steroid hormones. Here we found that Nedd4-2 phosphorylation contributes to ENaC regulation by steroid hormones. Consistent with this model, ENaC stimulation by dexamethasone was reduced by Nedd4-2 siRNA and by overexpression of a mutant Nedd4-2 lacking serum and glucocorticoid-regulated kinase phosphorylation sites. Thus, endogenous Nedd4-2 negatively regulates ENaC in epithelia and is a component of a signaling pathway by which steroid hormones regulate ENaC. Defects in this regulation may contribute to the pathogenesis of hypertension.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 371 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NHLBI NIH HHS [HL03575, HL61781, HL58812, HL55006] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061781, P50HL055006, R29HL058812, R01HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; Benos DJ, 1997, NEWS PHYSIOL SCI, V12, P55; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Dahlmann A, 2003, AM J PHYSIOL-RENAL, V285, pF310, DOI 10.1152/ajprenal.00016.2003; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Helms MN, 2003, AM J PHYSIOL-RENAL, V284, pF480, DOI 10.1152/ajprenal.00299.2002; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699	33	123	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5042	5046		10.1074/jbc.M312477200	http://dx.doi.org/10.1074/jbc.M312477200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645220	hybrid			2022-12-25	WOS:000188554300131
J	Chen, Y; Ke, QG; Yang, YK; Rana, JMS; Tang, J; Morgan, JP; Xiao, YF				Chen, Y; Ke, QG; Yang, YK; Rana, JMS; Tang, J; Morgan, JP; Xiao, YF			Cardiomyocytes overexpressing TNF-alpha attract migration of embryonic stem cells via activation of p38 and c-Jun amino-terminal kinase	FASEB JOURNAL			English	Article						myocardial infarction; transfection; Transwell assay	NECROSIS-FACTOR-ALPHA; ACUTE MYOCARDIAL-INFARCTION; IMPROVES CARDIAC-FUNCTION; NF-KAPPA-B; GROWTH-FACTOR; FETAL CARDIOMYOCYTES; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ACTIN REORGANIZATION; VIRAL MYOCARDITIS	Tumor necrosis factor-alpha (TNF-alpha) plays an important role in the pathogenesis of myocardial infarction. Stem cells are able to regenerate infarcted myocardium. This study investigated whether TNF-alpha was able to induce migration of embryonic stem cells (ESCs) in vitro. We used a Transwell assay in which neonatal rat cardiomyocytes, with or without transfection of TNF-alpha cDNA, were plated in the lower compartments and mouse ESCs tagged with green fluorescent protein were added to the upper compartments. TNF-alpha level was significantly increased in the medium of the lower compartments seeded with TNF-alpha-transfected cardiomyocytes. Compared with the controls, overexpression of TNF-alpha significantly enhanced migration of ESCs to the lower compartments. This enhancement was attenuated by preincubation of ESCs with the antibody against the type II TNF-alpha receptor (TNF-RII), but not by the antibody against the type I TNF-alpha receptor (TNF-RI). Western blot analysis showed that the phosphorylated protein levels of p38 and c-Jun amino-terminal kinase (JNK) were significantly increased in TNF-alpha-treated ESCs. Inhibition of the activity of p38 or JNK significantlyattenuated TNF-alpha-induced ESC migration. Our data demonstrate that excessive TNF-alpha stimulates TNF-RII and enhances migration of ESCs in vitro. Activation of p38 and JNK is required for TNF-alpha-enhanced ESC migration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc,Dept Med,Harvard Thorndike Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Charles A Dana Res Inst,Stem Cells Rees Lab, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Xiao, YF (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc,Dept Med,Harvard Thorndike Lab, 330 Brookline Ave, Boston, MA 02215 USA.	yxiao@caregroup.harvard.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012774, R01DA011762] Funding Source: NIH RePORTER; NIDA NIH HHS [DA12774, DA11762] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Bahra P, 1998, CELL ADHES COMMUN, V6, P491, DOI 10.3109/15419069809010797; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Condorelli G, 2002, FASEB J, V16, P1732, DOI 10.1096/fj.02-0419com; Cumberbatch M, 1999, BRIT J DERMATOL, V141, P192; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Dekaris I, 1999, J IMMUNOL, V162, P4235; Ebert EC, 1998, GUT, V42, P650, DOI 10.1136/gut.42.5.650; Fiers W, 1996, J INFLAMM, V47, P67; Gee K, 2002, J IMMUNOL, V169, P5660, DOI 10.4049/jimmunol.169.10.5660; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; Halawa B, 1999, Pol Arch Med Wewn, V101, P197; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Jacobs M, 1999, J MOL CELL CARDIOL, V31, P1949, DOI 10.1006/jmcc.1999.1007; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; KIMBER I, 1992, J INVEST DERMATOL, V99, pS48, DOI 10.1111/1523-1747.ep12668986; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; Li RK, 1996, CIRC RES, V78, P283, DOI 10.1161/01.RES.78.2.283; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MAURY CPJ, 1989, J INTERN MED, V225, P333, DOI 10.1111/j.1365-2796.1989.tb00090.x; Min JY, 2002, ANN THORAC SURG, V74, P1568, DOI 10.1016/S0003-4975(02)03952-8; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Min JY, 2002, CIRCULATION, V106, P419; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peschon JJ, 1998, J IMMUNOL, V160, P943; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; Seko Y, 2002, CARDIOVASC PATHOL, V11, P166, DOI 10.1016/S1054-8807(02)00101-1; SMART SJ, 1994, AM J PHYSIOL, V266, pL238, DOI 10.1152/ajplung.1994.266.3.L238; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sundstrom M, 2001, EXP CELL RES, V267, P144, DOI 10.1006/excr.2001.5239; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wada H, 2001, CIRCULATION, V103, P743; Wang BH, 1997, J IMMUNOL, V159, P6148; Wang JF, 2002, CELL TRANSPLANT, V11, P753; Wang ZB, 2001, FEBS LETT, V508, P360, DOI 10.1016/S0014-5793(01)03109-X; Wong CK, 2002, CLIN EXP IMMUNOL, V128, P483, DOI 10.1046/j.1365-2249.2002.01880.x; Wuu YD, 1998, BIOL REPROD, V58, P1416, DOI 10.1095/biolreprod58.6.1416; Yang YK, 2002, J APPL PHYSIOL, V93, P1140, DOI 10.1152/japplphysiol.00307.2002	50	33	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2231	2239		10.1096/fj.03-0030com	http://dx.doi.org/10.1096/fj.03-0030com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656985				2022-12-25	WOS:000188067500044
J	Choi, SI; Vidal, R; Frangione, B; Levy, E				Choi, SI; Vidal, R; Frangione, B; Levy, E			Axonal transport of British and Danish amyloid peptides via secretory vesicles	FASEB JOURNAL			English	Article						amyloid; axonal transport; familial British and Danish dementia; BRI2 processing; neurite outgrowth	DISULFIDE-BONDED LOOP; CEREBELLAR-ATAXIA; CHROMOGRANIN-B; DEMENTIA; FURIN; EXPRESSION; ACTIVATION; PROTEINS; CELLS; GOLGI	The ABri and ADan amyloid peptides deposited in familial British and Danish neurodegenerative disorders are generated by processing mutant forms of the precursor protein BRI2. Although the pathogenic process that leads to deposition of amyloid in the brains of patients has been studied extensively, the cellular processes and normal function of the precursor protein did not receive much attention. We observed in a variety of transfected cell lines the presence of two independent proteolytic processing events. In addition to the previously described cleavage, which results in the production of carb oxyl-terminal similar to3 kDa wild-type peptide or similar to4 kDa ABri or ADan peptides, we describe a novel amino-terminal cleavage site within BRI2. Both cleavages occur within the cis- or medial-Golgi. Following cleavage, the BRI2-derived carb oxyl-terminal peptides are transported via a regulated secretory pathway into secretory vesicles in neuronal cells. Worth noting is that expression of wild-type British or Danish mutants of BRI2, in mouse neuroblastoma N2a cells that do not express endogenous BRI2, induces elongation of neurites, which suggests a role for this protein in differentiation of neuronal cells.	NYU, Sch Med, Dept Pathol, New York, NY USA; NYU, Sch Med, Dept Psychiat, New York, NY USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Indiana Univ, Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN USA; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	New York University; New York University; New York University; Indiana University System; Indiana University-Purdue University Indianapolis; Nathan Kline Institute for Psychiatric Research; New York University	Levy, E (corresponding author), NYU, Sch Med, Nathan S Kline Inst Psychiat Res, 140 Old Orangeburg Rd, Orangeburg, NY 10962 USA.	elevy@nki.rfmh.org		choi, seung-il/0000-0001-7168-8795				BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; De Strooper B, 2000, J CELL SCI, V113, P1857; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; El-Agnaf OMA, 2001, BIOCHEMISTRY-US, V40, P3449, DOI 10.1021/bi002287i; Ghiso JA, 2001, J BIOL CHEM, V276, P43909, DOI 10.1074/jbc.M105956200; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GRIFFITHS RA, 1982, J NEUROL NEUROSUR PS, V45, P396, DOI 10.1136/jnnp.45.5.396; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kim SH, 2002, J BIOL CHEM, V277, P1872, DOI 10.1074/jbc.M108739200; Kim SH, 2000, ANN NY ACAD SCI, V920, P93; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; LOVE S, 1982, J NEUROL NEUROSUR PS, V45, P271, DOI 10.1136/jnnp.45.3.271; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; Rostagno A, 2002, J BIOL CHEM, V277, P49782, DOI 10.1074/jbc.M206448200; STROMGREN E, 1970, ACTA NEUROL SCAND, V46, P261; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Vidal R, 2001, GENE, V266, P95, DOI 10.1016/S0378-1119(01)00374-2; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27	32	45	47	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					373	+		10.1096/fj.03-0730fje	http://dx.doi.org/10.1096/fj.03-0730fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656991				2022-12-25	WOS:000188067500032
J	Rodriguez, JA; Schuchner, S; Au, WWY; Fabbro, M; Henderson, BR				Rodriguez, JA; Schuchner, S; Au, WWY; Fabbro, M; Henderson, BR			Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1	ONCOGENE			English	Article						BARD1; BRCA1; nuclear export; cancer; apoptosis	CANCER-PREDISPOSING MUTATIONS; RING DOMAIN; TUMOR-SUPPRESSOR; CELL-CYCLE; IN-VIVO; GENE; PROTEIN; BREAST; IDENTIFICATION; BRCA1-BARD1	The breast cancer-associated protein, BARD1, colocalizes with BRCA1 in nuclear foci in the S phase and after DNA damage, and the two proteins form a stable heterodimer implicated in DNA repair, protein ubiquitination, and control of mRNA processing. BARD1 has a BRCA1-independent proapoptotic activity; however, little is known about its regulation. Here, we show that BARD1 localization and apoptotic activity are regulated by nuclear-cytoplasmic shuttling. We identified a functional CRM1-dependent nuclear export sequence (NES) near the N-terminal RING domain of BARD1. The NES forms part of the BRCA1 dimerization domain, and coexpression of BRCA1 resulted in masking of the NES and nuclear retention of BARD1. In transient expression assays, BARD1 apoptotic activity was stimulated by nuclear export, and both apoptotic function and nuclear export were markedly reduced by BRCA1. Similar findings were obtained for endogenous BARD1. Silencing BRCA1 expression by siRNA, or disrupting the endogenous BARD1/BRCA1 interaction by peptide competition caused a reduction in BARD1 nuclear localization and foci formation, and increased the level of cytoplasmic BARD1 correlating with increased apoptosis. Our findings suggest that BRCA1/BARD1 heterodimer formation is important for optimal nuclear targeting of BARD1 and its role in DNA repair and cell survival.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au	Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Spahn L, 2002, CANCER RES, V62, P4583; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108	28	62	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1809	1820		10.1038/sj.onc.1207302	http://dx.doi.org/10.1038/sj.onc.1207302			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647430				2022-12-25	WOS:000220129500002
J	Lalonde, JP; Lim, R; Ingley, E; Tilbrook, PA; Thompson, MJ; McCulloch, R; Beaumont, JG; Wicking, C; Eyre, HJ; Sutherland, GR; Howe, K; Solomon, E; Williams, JH; Klinken, SP				Lalonde, JP; Lim, R; Ingley, E; Tilbrook, PA; Thompson, MJ; McCulloch, R; Beaumont, JG; Wicking, C; Eyre, HJ; Sutherland, GR; Howe, K; Solomon, E; Williams, JH; Klinken, SP			HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; RETINOIC ACID RECEPTOR; J2E ERYTHROID-CELLS; AUG INITIATOR CODON; TRANSCRIPTION FACTOR; COLORECTAL-CANCER; RAR-ALPHA; MYELODYSPLASTIC SYNDROME; NUCLEAR RECEPTORS	Hemopoietic cells, apparently committed to one lineage, can be reprogrammed to display the phenotype of another lineage. The J2E erythroleukemic cell line has on rare occasions developed the features of monocytic cells. Subtractive hybridization was used in an attempt to identify genes that were up-regulated during this erythroid to myeloid transition. We report here on the isolation of hemopoietic lineage switch 5 (Hls5), a gene expressed by the monocytoid variant cells, but not the parental J2E cells. Hls5 is a novel member of the RBCC (Ring finger, B box, coiled-coil) family of genes, which includes Pml, Herf1, Tif-1alpha, and Rfp. Hls5 was expressed in a wide range of adult tissues; however, at different stages during embryogenesis, Hls5 was detected in the branchial arches, spinal cord, dorsal root ganglia, limb buds, and brain. The protein was present in cytoplasmic granules and punctate nuclear bodies. Isolation of the human cDNA and genomic DNA revealed that the gene was located on chromosome 8p21, a region implicated in numerous leukemias and solid tumors. Enforced expression of Hls5 in HeLa cells inhibited cell growth, clonogenicity, and tumorigenicity. It is conceivable that HLS5 is one of the tumor suppressor genes thought to reside at the 8p21 locus.	Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia; Curtin Univ Technol, Sch Biomed Sci, Bentley, WA 6102, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Womens Hosp Med Ctr, Dept Cytogenet & Mol Genet, Ctr Med Genet, Adelaide, SA 5006, Australia; Canc Res UK, Lymphocyte Activat Lab, London WC2A 3PX, England; Guys Sch Med, Div Med & Mol Genet, London SE1 9RT, England; Kings Sch Med, Div Med & Mol Genet, London SE1 9RT, England; St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England	Royal Perth Hospital; University of Western Australia; University of Western Australia; Curtin University; University of Queensland; Cancer Research UK; University of London; King's College London; University of London; King's College London; University of London; King's College London	Klinken, SP (corresponding author), Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Level 6,Med Res Fdn Bldg Rear,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Sutherland, Grant Robert/D-2606-2012; Endersby, Raelene/A-2969-2013; Wicking, Carol/J-1814-2014	Ingley, Evan/0000-0002-8112-9134; Endersby, Raelene/0000-0003-3554-2769; Wicking, Carol/0000-0002-7225-3803				BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BOYD AW, 1982, NATURE, V297, P691, DOI 10.1038/297691a0; BUSFIELD SJ, 1992, BLOOD, V80, P412; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Cao TY, 1997, J CELL SCI, V110, P1563; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ELEFANTY AG, 1992, BLOOD, V79, P1271; ElRifai W, 1996, GENE CHROMOSOME CANC, V15, P34, DOI 10.1002/(SICI)1098-2264(199601)15:1<34::AID-GCC5>3.0.CO;2-5; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gingras R, 1999, J BIOL CHEM, V274, P11742, DOI 10.1074/jbc.274.17.11742; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Grimwade D, 2000, BLOOD, V96, P1297; Gustafson CE, 1996, CANCER RES, V56, P5238; Harada H, 1999, MOL CELL BIOL, V19, P3808; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kimura F, 2003, J BIOL CHEM, V278, P25046, DOI 10.1074/jbc.M303438200; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; LINDEMAN GJ, 1994, IMMUNITY, V1, P517, DOI 10.1016/1074-7613(94)90094-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; METCALF D, 1988, MED J AUSTRALIA, V148, P516, DOI 10.5694/j.1326-5377.1988.tb99462.x; MIURA I, 1994, CANCER GENET CYTOGEN, V72, P75, DOI 10.1016/0165-4608(94)90115-5; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Sayer MS, 2000, J BIOL CHEM, V275, P25292, DOI 10.1074/jbc.M908695199; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SONODA Y, 1985, CANCER GENET CYTOGEN, V17, P61, DOI 10.1016/0165-4608(85)90102-5; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vocke CD, 1996, CANCER RES, V56, P2411; Wang ZG, 1998, SCIENCE, V279, P1547; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; YonedaKato N, 1996, ONCOGENE, V12, P265; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	75	27	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8181	8189		10.1074/jbc.M306751200	http://dx.doi.org/10.1074/jbc.M306751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662771	Green Published, hybrid			2022-12-25	WOS:000189103300099
J	Nakayama, K; Okugawa, S; Yanagimoto, S; Kitazawa, T; Tsukada, K; Kawada, M; Kimura, S; Hirai, K; Takagaki, Y; Ota, Y				Nakayama, K; Okugawa, S; Yanagimoto, S; Kitazawa, T; Tsukada, K; Kawada, M; Kimura, S; Hirai, K; Takagaki, Y; Ota, Y			Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; EARLY ENDOTOXIN TOLERANCE; MONOPHOSPHORYL LIPID-A; CROSS-TOLERANCE; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; LIPOTEICHOIC ACID; DOWN-REGULATION; LIPOPOLYSACCHARIDE; CYTOKINE	The molecular mechanisms by which pathogen-associated molecular patterns recognized by TLR2, such as peptidoglycan (PGN), induce homotolerance are largely unknown. It was recently reported that IRAK-M negatively regulates TLR signaling. In this study, we elucidate the molecular mechanisms of tolerance induced by PGN, with a focus on the role of IRAK-M. We demonstrate that pretreatment of macrophage RAW264.7 cells with a high concentration (30 mug/ml) of PGN for 16 h effectively induces tolerance against following stimulation with 30 mug/ml of PGN; while pretreatment with a low concentration (1 mug/ml) of PGN does not. IRAK-M is induced in cells treated with the high concentration of PGN 4-24 h after PGN stimulation, but not in cells treated with the low concentration of PGN up to 24 h after stimulation. Phosphorylation of MAPKs and IkappaBalpha is inhibited after the second PGN stimulation in tolerant cells. Kinase activity of IRAK-1 and association between IRAK-1 and MyD88 are also suppressed in PGN-induced tolerant cells. Furthermore, down-regulation of IRAK-M expression by small interfering RNAs specific for IRAK-M reinstates the production of TNF-alpha after PGN restimulation. These results suggest that induction of IRAK-M and inhibition of kinase activity of IRAK-1 are crucial to PGN-induced tolerance in macrophages.	Univ Tokyo, Grad Sch Med, Dept Infect Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Tokyo 1138655, Japan; Kitasato Univ, Grad Sch Med, Dept Mol Med, Kanagawa 2288555, Japan	University of Tokyo; University of Tokyo; Kitasato University	Ota, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Infect Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yasuota-tky@umin.ac.jp		Okugawa, Shu/0000-0003-3455-8291				Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Bhat N, 1999, J IMMUNOL, V162, P7335; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; Ertel W, 1997, BLOOD, V89, P1612, DOI 10.1182/blood.V89.5.1612.1612_1612_1620; Gustafson G L, 1995, Prog Clin Biol Res, V392, P567; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HENRICSON BE, 1991, INFECT IMMUN, V59, P1188, DOI 10.1128/IAI.59.3.1188-1191.1991; HENRICSON BE, 1990, INFECT IMMUN, V58, P2429, DOI 10.1128/IAI.58.8.2429-2437.1990; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kraatz J, 1999, SHOCK, V11, P58, DOI 10.1097/00024382-199901000-00009; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Okugawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC399, DOI 10.1152/ajpcell.00026.2003; Salkowski CA, 1998, INFECT IMMUN, V66, P3569, DOI 10.1128/IAI.66.8.3569-3578.1998; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; VANDEUREN M, 1994, J INFECT DIS, V169, P157, DOI 10.1093/infdis/169.1.157; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Zeisberger E, 1998, ANN NY ACAD SCI, V856, P116, DOI 10.1111/j.1749-6632.1998.tb08320.x; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	37	92	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6629	6634		10.1074/jbc.M308620200	http://dx.doi.org/10.1074/jbc.M308620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660668	hybrid			2022-12-25	WOS:000188969200052
J	Barac, A; Basile, J; Vazquez-Prado, J; Gao, YA; Zheng, Y; Gutkind, JS				Barac, A; Basile, J; Vazquez-Prado, J; Gao, YA; Zheng, Y; Gutkind, JS			Direct interaction of p21-activated kinase 4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; LEUKEMIA-ASSOCIATED RHOGEF; HETEROTRIMERIC G-PROTEINS; SERINE/THREONINE KINASE; ACTIN CYTOSKELETON; SIGNALING PATHWAY; COUPLED RECEPTORS; FAMILY GTPASES; CDC42 GTPASES; PAK4	Rho GTPases regulate a wide variety of cellular processes, ranging from actin cytoskeleton remodeling to cell cycle progression and gene expression. Cell surface receptors act through a complex regulatory molecular network that includes guanine exchange factors (GEFs), GTPase activating proteins, and guanine dissociation inhibitors to achieve the coordinated activation and deactivation of Rho proteins, thereby controlling cell motility and ultimately cell fate. Here we found that a member of the RGL-containing family of Rho guanine exchange factors, PDZ RhoGEF, which, together with LARG and p115RhoGEF, links the G(12/13) family of heterotrimeric G proteins to Rho activation, binds through its C-terminal region to the serine-threonine kinase p21-activated kinase 4 (PAK4), an effector for Cdc42. This interaction results in the phosphorylation of PDZ RhoGEF and abolishes its ability to mediate the accumulation of Rho-GTP by Galpha(13). Moreover, when overexpressed, active PAK4 was able to dramatically decrease Rho-GTP loading in vivo and the formation of actin stress fibers in response to serum or LPA stimulation. Together, these results provide evidence that PAK4 can negatively regulate the activation of Rho through a direct protein-protein interaction with G protein-linked Rho GEFs, thus providing a novel potential mechanism for cross-talk among Rho GTPases.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; IPN, Ctr Invest & Estudios Avanzados, Dept Pharmacol, Mexico City 07360, DF, Mexico; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 212, Bethesda, MD 20892 USA.	sg39v@nih.gov	Zheng, Yi/J-7235-2015; VAZQUEZ-PRADO, JOSE/C-1630-2017; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Zheng, Yi/0000-0001-7089-6074; VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Gutkind, J. Silvio/0000-0002-5150-4482; Barac, Ana/0000-0002-9935-8904	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; An SZ, 1998, J CELL BIOCHEM, P147; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895	33	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6182	6189		10.1074/jbc.M309579200	http://dx.doi.org/10.1074/jbc.M309579200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625312	hybrid			2022-12-25	WOS:000188776500134
J	Luo, AP; Kong, JP; Hu, GX; Liew, CC; Xiong, MM; Wang, XQ; Ji, JF; Wang, T; Zhi, HY; Wu, M; Liu, ZH				Luo, AP; Kong, JP; Hu, GX; Liew, CC; Xiong, MM; Wang, XQ; Ji, JF; Wang, T; Zhi, HY; Wu, M; Liu, ZH			Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray	ONCOGENE			English	Article						differentiation; calcium; cell envelope; esophageal squamous cell carcinoma; cDNA microarray	PROLINE-RICH PROTEINS; ANNEXIN-I; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS; CORNIFIED ENVELOPE; BARRIER FUNCTION; KERATIN 4; EXPRESSION; CANCER; OVEREXPRESSION	To identify genes that are differentially expressed in human esophageal squamous cell carcinoma (ESCC), we have developed a cDNA microarray representing 34 176 clones to analyse gene expression profiles in ESCC. A total of 77 genes ( including 31 novel genes) were downregulated, and 15 genes ( including one novel gene) were upregulated in cancer tissues compared with their normal counterparts. Immunohistochemistry and Northern blot analysis were carried out to verify the cDNA microarray results. It was revealed that genes involved in squamous cell differentiation were coordinately downregulated, including annexin I, small proline-rich proteins (SPRRs), calcium-binding S100 proteins (S100A8, S100A9), transglutaminase (TGM3), cytokeratins (KRT4, KRT13), gut-enriched Krupple-like factor ( GKLF) and cystatin A. Interestingly, most of the downregulated genes encoded Ca2+-binding or - modulating proteins that constitute the cell envelope (CE). Moreover, genes associated with invasion or proliferation were upregulated, including genes such as fibronectin, secreted protein acidic and rich in cystein ( SPARC), cathepsin B and KRT17. Functional analysis of the alteration in the expression of GKLF suggested that GKLF might be able to regulate the expression of SPRR1A, SPRR2A and KRT4 in ESCC. This study provides new insights into the role of squamous cell differentiation-associated genes in ESCC initiation and progression.	Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Texas, Ctr Human Genet, Houston, TX 77030 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Texas System	Liu, ZH (corresponding author), Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China.	liuzh@pubem.cicams.ac.cn						Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Busatto G, 1998, J CLIN PATHOL-MOL PA, V51, P80, DOI 10.1136/mp.51.2.80; Chang S, 1999, Wei Sheng Yan Jiu, V28, P364; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Frey BM, 1999, FASEB J, V13, P2235, DOI 10.1096/fasebj.13.15.2235; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Geboes K, 1978, Front Gastrointest Res, V3, P1; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Ishizuka T, 2002, BIOCHEM BIOPH RES CO, V296, P152, DOI 10.1016/S0006-291X(02)00836-7; JANKOWSKI J, 1993, EUR J GASTROEN HEPAT, V5, P235, DOI 10.1097/00042737-199304000-00008; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Lam KY, 1997, INT J CANCER, V74, P212, DOI 10.1002/(SICI)1097-0215(19970422)74:2<212::AID-IJC13>3.0.CO;2-F; Li W, 1998, Wei Sheng Yan Jiu, V27, P69; Liew CC, 1997, MOL CELL BIOCHEM, V172, P81, DOI 10.1023/A:1006811403996; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Ma SH, 1997, GENE EXPRESSION, V6, P361; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Nagasawa S, 2001, J SURG ONCOL, V78, P208, DOI 10.1002/jso.1152; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEVEN AC, 1994, J CELL SCI, V107, P693; Suzuki H, 1997, CANCER INVEST, V15, P411, DOI 10.3109/07357909709047579; THIEL C, 1992, J CELL SCI, V103, P733; Turksen K, 2002, DEVELOPMENT, V129, P1775; van Dorst EBL, 1998, J CLIN PATHOL, V51, P679, DOI 10.1136/jcp.51.9.679; Wang Q, 2002, CANCER LETT, V179, P71, DOI 10.1016/S0304-3835(01)00846-1; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Xu L, 2001, CANCER RES, V61, P3176; Xu Y, 2002, CANCER RES, V62, P3493; Yamazaki M, 1997, DNA SEQUENCE, V8, P71, DOI 10.3109/10425179709020888; Zhang WH, 2000, AM J HUM GENET, V67, P110, DOI 10.1086/302970	49	178	204	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1291	1299		10.1038/sj.onc.1207218	http://dx.doi.org/10.1038/sj.onc.1207218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647409				2022-12-25	WOS:000188892200014
J	Takeuchi, K; Takahashi, H; Sugai, M; Iwai, H; Kohno, T; Sekimizu, K; Natori, S; Shimada, I				Takeuchi, K; Takahashi, H; Sugai, M; Iwai, H; Kohno, T; Sekimizu, K; Natori, S; Shimada, I			Channel-forming membrane permeabilization by an antibacterial protein, sapecin - Determination of membrane-buried and oligomerization surfaces by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA FLESH FLY; SARCOPHAGA-PEREGRINA; INSECT DEFENSIN; PURIFICATION; COMPLEXES; PEPTIDES; MELITTIN; MODE	The action mechanism of sapecin, an antibacterial peptide with membrane permeabilization activity, was investigated. The dose dependence of the membrane permeabilization caused by sapecin was sigmoidal, suggesting that sapecin oligomerization leads to the membrane permeabilization. Solution nuclear magnetic resonance analysis of the sapecin-phospholipid vesicle complex revealed the surface buried in the membrane and oligomerization surface on the sapecin molecule. The membrane-buried surface of sapecin was determined by observing the transferred cross-saturation phenomena from the alkyl chains of the phospholipid vesicle to the amide protons of sapecin. The membrane-buried surface contains basic and highly exposed hydrophobic residues, which are suitable for interacting with the acidic bacterial membrane. The oligomerization surface was also identified by comparisons between the results from hydrogen-deuterium exchange experiments and transferred cross-saturation experiments. On the basis of the results from the NMR experiments we built a putative model of sapecin oligomers, which provides insights into the membrane permeabilization caused by insect defensins.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biomed Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Mitsubishi Kagaku Inst Lifer Sci, Tokyo 1948511, Japan; RIKEN, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Saskatchewan, Dept Chem, Saskatoon, SK S7N 5C9, Canada; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Mitsubishi Kagaku Institute of Life Sciences (MITILS); RIKEN; University of Saskatchewan; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp	Iwaï, Hideo/A-6416-2009; Takeuchi, Koh/B-4971-2010	Iwaï, Hideo/0000-0001-7376-5264; Takeuchi, Koh/0000-0002-6227-4627				Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DEMPSEY CE, 1992, BIOCHEMISTRY-US, V31, P11973, DOI 10.1021/bi00163a003; Dempsey CE, 2003, BIOCHEMISTRY-US, V42, P402, DOI 10.1021/bi026328h; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; Halsall A, 1999, J MOL BIOL, V293, P901, DOI 10.1006/jmbi.1999.3194; HANZAWA H, 1990, FEBS LETT, V269, P413, DOI 10.1016/0014-5793(90)81206-4; Jayalakshmi V, 2002, J MAGN RESON, V155, P106, DOI 10.1006/jmre.2001.2499; KIM JI, 1994, FEBS LETT, V342, P189, DOI 10.1016/0014-5793(94)80498-2; Kohno T, 1998, J BIOMOL NMR, V12, P109, DOI 10.1023/A:1008254603368; KUZUHARA T, 1990, J BIOCHEM-TOKYO, V107, P514, DOI 10.1093/oxfordjournals.jbchem.a123077; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEE SY, 1995, BIOL PHARM BULL, V18, P457, DOI 10.1248/bpb.18.457; MagetDana R, 1997, BIOPHYS J, V73, P2527, DOI 10.1016/S0006-3495(97)78281-X; MATSUYAMA K, 1990, J BIOCHEM-TOKYO, V108, P128, DOI 10.1093/oxfordjournals.jbchem.a123151; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; Nakanishi T, 2002, J MOL BIOL, V318, P245, DOI 10.1016/S0022-2836(02)00018-9; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; Rex S, 1998, BIOCHEMISTRY-US, V37, P2336, DOI 10.1021/bi971009p; SCHWARZ G, 1995, BBA-BIOMEMBRANES, V1239, P51, DOI 10.1016/0005-2736(95)00134-O; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220	23	61	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4981	4987		10.1074/jbc.M307815200	http://dx.doi.org/10.1074/jbc.M307815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14630928	hybrid			2022-12-25	WOS:000188554300124
J	Tomida, M; Saito, T				Tomida, M; Saito, T			The human hepatocyte growth factor (HGF) gene is transcriptionally activated by leukemia inhibitory factor through the Stat binding element	ONCOGENE			English	Article						human HGF promoter; LIF; Stat3	DNA-BINDING; CELL-LINES; DIFFERENTIATION; EXPRESSION; RECEPTOR; INDUCIBILITY; FIBROBLASTS; PROTEINS; CLONING; FAMILY	We found that human melanoma SEKI and neuroepithelioma NAGAI cells, which are known to secrete high concentrations of leukemia inhibitory factor (LIF), also secrete high levels of hepatocyte growth factor (HGF). We therefore examined the role of LIF in HGF expression and examined the human HGF promoter. The expression of both LIF and HGF mRNA is very low in HEK293 cells. Treatment of these cells with LIF stimulated the expression of HGF mRNA. The cis-acting regulatory element of the HGF promoter in SEKI and 293 cells was analysed by means of a transient expression assay. By deletion analysis, we showed that the region comprising the -181 to -73 bp was required for full activity of the HGF promoter in SEKI cells and for LIF responsiveness of 293 cells. This region contains putative consensus sequences for the Stat and NF-IL6 (C/EBP beta) transcription factors. The activity of the HGF promoter was abolished by mutation of the Stat site at -99/-91, while the activity only slightly decreased on mutation of the NF-IL6 site. Treatment with anti-LIF antibodies or interruption of Stat3 signaling by dominant-negative Stat3 also reduced the HGF promoter activity. Stat3 activation was constitutive in SEKI cells and induced on treatment of 293 cells with LIF. These results suggest that cytokines, growth factors and oncogenes (v-Src, etc.) that activate Stat3 are important regulators of HGF expression.	Saitama Canc Ctr, Div Res, Ina, Saitama 3620806, Japan; Saitama Small Enterprise Promot Corp, REDS Grp, Saitama Prefecture Collaborat Reg Entities Adv Te, Kawaguchi 3330844, Japan		Tomida, M (corresponding author), Saitama Canc Ctr, Div Res, 818 Komuro, Ina, Saitama 3620806, Japan.	tomida@cancer-c.pref.saitama.jp						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; ISEKI H, 1995, JPN J CANCER RES, V86, P562, DOI 10.1111/j.1349-7006.1995.tb02435.x; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIU YH, 1994, J BIOL CHEM, V269, P4152; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; Nakamura T, 1997, CANCER RES, V57, P3305; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484, DOI 10.1006/abbi.1993.1243; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TOMIDA M, 1990, FEBS LETT, V268, P261, DOI 10.1016/0014-5793(90)81023-H; TOMIDA M, 1984, FEBS LETT, V178, P291, DOI 10.1016/0014-5793(84)80619-5; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	37	26	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					679	686		10.1038/sj.onc.1207190	http://dx.doi.org/10.1038/sj.onc.1207190			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647442				2022-12-25	WOS:000188304900006
J	Liu, ZM; Chen, GG; Ng, EKW; Leung, WK; Sung, JJY; Chung, SCS				Liu, ZM; Chen, GG; Ng, EKW; Leung, WK; Sung, JJY; Chung, SCS			Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells	ONCOGENE			English	Article						gastric cancer; heme oxygenase-1; p21; p53; apoptosis	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INHIBITS APOPTOSIS; GENE-EXPRESSION; TNF-ALPHA; CARCINOMA; PATHWAY; DEATH; HEAT-SHOCK-PROTEIN-70; OVEREXPRESSION	Both heme oxygenase-1 (HO-1) and p21(WAF1/Cip1) (p21) are involved in the pathogenesis of human cancer and their functions are closely associated with apoptosis. However, how these two molecules regulate apoptosis in human gastric cancer is unknown. In this study, we studied how HO-1 and p21 were regulated in two gastric cancer cell lines, MKN-45 with wild p53 and MKN-28 with mutant p53. The cells were treated with hemin and cadmium to induce HO-1. The result showed that HO-1 protein was significantly induced by hemin and cadmium in both cells tested. Following the HO-1 expression, p21 level was also markedly induced. The cells with increased HO-1 and p21 showed obviously resistantance to apoptotic stimuli. The levels of HO-1 and p21 induced were significantly inhibited by p38 mitogen-activated protein kinase (p38 MAPK) inhibitor (SB203580) and extracellular-regulated kinase (ERK) inhibitor (PD098059). Parallel to decreased HO-1 and p21 expression, the kinase inhibitors also significantly attenuated the resistance of the cells to apoptosis. The elevated HO-1 and p21 was further found to be associated with increase activity of the nuclear NF-kappaB and the inhibition of NF-kappaB led to the block of their induction. The elevated HO-1 and p21 were also demonstrated to be related to increased cellular inhibitor of caspase inbitory protein-2 (c-IAP2) and decreased caspapse-3 activity. It was noted that the above changes observed were not different between MKN-45 and MKN-28 cells, suggesting the functions of HO-1 and p21 were irrespective of the status of p53. In conclusion, we demonstrate that the resistance to apoptosis in gastric cancer cells with elevated HO-1 and p21 is independent of p53 status in a p38 MAPK- and ERK-mediated pathway with elevated c-IAP2 and decreased caspase-3 activity and that this pathway is sensitive to the inhibition of NF-kappaB.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Sichuan Univ, W China Hosp, Inst Gasterointestinal Surg, Chengdu 610041, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Sichuan University	Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.	gchen@cuhk.edu.hk	Leung, Wai Keung/B-8140-2011; Chen, George Gong/I-2757-2016; Sung, Joseph J. Y./R-3203-2018; Lin, Hualiang/E-6622-2010; Ng, Enders Kwok-wai/E-8276-2016	Leung, Wai Keung/0000-0002-5993-1059; Sung, Joseph J. Y./0000-0003-3125-5199; Lin, Hualiang/0000-0002-2462-5158; Ng, Enders Kwok-wai/0000-0001-7219-5810				Baas IO, 1998, J CLIN PATHOL, V51, P662, DOI 10.1136/jcp.51.9.662; Baldus SE, 2001, SCAND J GASTROENTERO, V36, P975, DOI 10.1080/003655201750305512; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; Chen GG, 2002, LIFE SCI, V70, P2631, DOI 10.1016/S0024-3205(02)01510-2; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Craanen ME, 1999, J PATHOL, V189, P481, DOI 10.1002/(SICI)1096-9896(199912)189:4<481::AID-PATH482>3.0.CO;2-U; Davis JN, 2001, FREE RADICAL BIO MED, V30, P1293, DOI 10.1016/S0891-5849(01)00535-4; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; ELLEDGE RM, 1994, CANCER RES, V54, P3752; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; Helt CE, 2001, TOXICOL SCI, V63, P214, DOI 10.1093/toxsci/63.2.214; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Inguaggiato P, 2001, KIDNEY INT, V60, P2181, DOI 10.1046/j.1523-1755.2001.00046.x; Jobin C, 1998, J IMMUNOL, V160, P410; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 1999, J PHARMACOL EXP THER, V291, P911; Maines MD, 1996, UROLOGY, V47, P727, DOI 10.1016/S0090-4295(96)00010-6; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MURPHY BJ, 1993, CANCER RES, V53, P2700; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; TAKAHASHI S, 1994, AM J CLIN PATHOL, V101, P519; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Wakana Y, 2002, ONCOL REP, V9, P1213; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	43	147	158	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					503	513		10.1038/sj.onc.1207173	http://dx.doi.org/10.1038/sj.onc.1207173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647439				2022-12-25	WOS:000188098300021
J	Bak-Jensen, KS; Andre, G; Gottschalk, TE; Paes, G; Tran, V; Svensson, B				Bak-Jensen, KS; Andre, G; Gottschalk, TE; Paes, G; Tran, V; Svensson, B			Tyrosine 105 and threonine 212 at outermost substrate binding subsites -6 and +4 control substrate specificity, oligosaccharide cleavage patterns, and multiple binding modes of barley alpha-amylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-AMYLASE FAMILY; AMYLOSE CHAIN BEHAVIOR; CATALYTIC (BETA/ALPHA)(8)-BARREL DOMAIN; X-RAY-STRUCTURE; CYCLODEXTRIN-GLYCOSYLTRANSFERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; INTERACTING CONTEXT; STARCH-BINDING	The role in activity of outer regions in the substrate binding cleft in alpha-amylases is illustrated by mutational analysis of Tyr(105) and Thr(212) localized at subsites - 6 and +4 ( substrate cleavage occurs between subsites -1 and +1) in barley alpha-amylase 1 (AMY1). Tyr(105) is conserved in plant alpha-amylases whereas Thr(212) varies in these and related enzymes. Compared with wild-type AMY1, the subsite -6 mutant Y105A has 140, 15, and < 1% activity (k(cat)/K-m) on starch, amylose DP17, and 2-chloro-4-nitrophenyl beta-D-maltoheptaoside, whereas T212Y at subsite +4 has 32, 370, and 90% activity, respectively. Thus engineering of aromatic stacking interactions at the ends of the 10-subsite long binding cleft affects activity very differently, dependent on the substrate. Y105A dominates in dual subsite -6/+4 [Y105A/T212(Y/W)] AMY1 mutants having almost retained and low activity on starch and oligosaccharides, respectively. Bond cleavage analysis of oligosaccharide degradation by wild-type and mutant AMY1 supports that Tyr105 is critical for binding at subsite -6. Substrate binding is improved by T212(Y/W) introduced at subsite +4 and the [Y105A/ T212(Y/W)] AMY1 double mutants synergistically enhanced productive binding of the substrate aglycone. The enzymatic properties of the series of AMY1 mutants suggest that longer substrates adopt several binding modes. This is in excellent agreement with computed distinct multiple docking solutions observed for maltododecaose at outer binding areas of AMY1 beyond subsites -3 and +3.	Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; INRA, Lab Physicochim Macromol, F-44316 Nantes 03, France	INRAE	Svensson, B (corresponding author), Tech Univ Denmark, Biocentrum, Biochem & Nutr Grp, DK-2800 Lyngby, Denmark.	bis@biocentrum.dtu.dk	PAES, Gabriel/F-2568-2010; Paës, Gabriel/AAT-8796-2021	PAES, Gabriel/0000-0003-0239-9716; Paës, Gabriel/0000-0003-0239-9716; Svensson, Birte/0000-0002-2993-8196				Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; ANDERSEN JS, 1994, BIOL MASS SPECTROM, V23, P547, DOI 10.1002/bms.1200230904; Andre G, 1999, BIOPOLYMERS, V50, P751, DOI 10.1002/(SICI)1097-0282(199912)50:7<751::AID-BIP8>3.3.CO;2-X; Andre G, 1999, BIOPOLYMERS, V49, P107, DOI 10.1002/(SICI)1097-0282(199901)49:1<107::AID-BIP10>3.0.CO;2-S; Andre G, 1996, BIOPOLYMERS, V39, P737, DOI 10.1002/(SICI)1097-0282(199611)39:5<737::AID-BIP12>3.0.CO;2-2; Andre G, 1999, ROY SOC CH, P165; ANDRE G, 2003, RECENT ADV ENZYMES G, P9; Armand S, 2001, BIOCHEMISTRY-US, V40, P7404, DOI 10.1021/bi002704r; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERTOFT E, 1984, J I BREWING, V90, P298, DOI 10.1002/j.2050-0416.1984.tb04278.x; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; Frandsen TP, 1996, J MOL BIOL, V263, P79, DOI 10.1006/jmbi.1996.0557; Fujimoto Z, 1998, J MOL BIOL, V277, P393, DOI 10.1006/jmbi.1997.1599; Gottschalk TE, 2001, BIOCHEMISTRY-US, V40, P12844, DOI 10.1021/bi0108608; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; Janecek S, 2003, EUR J BIOCHEM, V270, P635, DOI 10.1046/j.1432-1033.2003.03404.x; Janecek S, 2002, BIOLOGIA, V57, P29; Jensen MT, 2003, J CEREAL SCI, V38, P289, DOI 10.1016/S0733-5210(03)00032-8; JONES RL, 1991, INT REV CYTOL, V126, P49; Juge N, 1996, PROTEIN EXPRES PURIF, V8, P204, DOI 10.1006/prep.1996.0093; Kadziola A, 1998, J MOL BIOL, V278, P205, DOI 10.1006/jmbi.1998.1683; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Koivula A, 1998, FEBS LETT, V429, P341, DOI 10.1016/S0014-5793(98)00596-1; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Leemhuis H, 2002, J BIOL CHEM, V277, P1113, DOI 10.1074/jbc.M106667200; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MacGregor EA, 2001, BBA-PROTEIN STRUCT M, V1546, P1, DOI 10.1016/S0167-4838(00)00302-2; MACGREGOR EA, 1994, CARBOHYD RES, V257, P249, DOI 10.1016/0008-6215(94)80039-1; Machius M, 1996, J MOL BIOL, V260, P409, DOI 10.1006/jmbi.1996.0410; Machius M, 1998, STRUCTURE, V6, P281, DOI 10.1016/S0969-2126(98)00032-X; Matsui I, 1997, J BIOL CHEM, V272, P22456, DOI 10.1074/jbc.272.36.22456; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; Mori H, 2002, EUR J BIOCHEM, V269, P5377, DOI 10.1046/j.1432-1033.2002.03185.x; Mori H, 2001, EUR J BIOCHEM, V268, P6545, DOI 10.1046/j.0014-2956.2001.02609.x; Nielsen JE, 2000, BBA-PROTEIN STRUCT M, V1543, P253, DOI 10.1016/S0167-4838(00)00240-5; NITTA Y, 1971, J BIOCHEM, V69, P567; Parsiegla G, 1998, EUR J BIOCHEM, V255, P710, DOI 10.1046/j.1432-1327.1998.2550710.x; Przylas I, 2000, EUR J BIOCHEM, V267, P6903, DOI 10.1046/j.1432-1033.2000.01790.x; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; RAPPENECKER G, 1981, CARBOHYD RES, V89, P11, DOI 10.1016/S0008-6215(00)85225-8; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; ROBYT JF, 1970, J BIOL CHEM, V245, P3917; RODENBURG KW, 1994, EUR J BIOCHEM, V221, P277, DOI 10.1111/j.1432-1033.1994.tb18739.x; Rodenburg KW, 2000, EUR J BIOCHEM, V267, P1019, DOI 10.1046/j.1432-1327.2000.01094.x; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; ROGERS JC, 1985, J BIOL CHEM, V260, P3731; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sierks MR, 2000, BIOCHEMISTRY-US, V39, P8585, DOI 10.1021/bi9925219; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1993, BIO-TECHNOL, V11, P1162, DOI 10.1038/nbt1093-1162; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; STONE BA, 2001, GLYCOSCIENCE CHEM CH, P1907; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Svensson B., 1999, Journal of Applied Glycoscience, V46, P49; SVENSSON B, 1985, CARLSBERG RES COMMUN, V50, P15, DOI 10.1007/BF02910534; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Uitdehaag JCM, 2001, PROTEINS, V43, P327, DOI 10.1002/prot.1044; Uitdehaag JCM, 2000, BIOCHEMISTRY-US, V39, P7772, DOI 10.1021/bi000340x; van der Veen BA, 2001, J BIOL CHEM, V276, P44557, DOI 10.1074/jbc.M107533200; Varrot A, 1999, BIOCHEM J, V337, P297, DOI 10.1042/0264-6021:3370297; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; YAMAMOTO T, 1995, ENZYME CHEM MOL BIOL; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3	77	34	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10093	10102		10.1074/jbc.M312825200	http://dx.doi.org/10.1074/jbc.M312825200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660599	hybrid, Green Published			2022-12-25	WOS:000220050400054
J	Duverger, O; Paslaru, L; Morange, M				Duverger, O; Paslaru, L; Morange, M			HSP25 is involved in two steps of the differentiation of PAM212 keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; P38 MAP KINASE; CENTRAL-NERVOUS-SYSTEM; ACTIN POLYMERIZATION; HL-60 CELLS; GENE-EXPRESSION; RETINOIC ACID; CYTOCHROME-C; PHOSPHORYLATION	HSP25 is a member of the small heat shock protein family. This 25-kDa protein exhibits a highly specific distribution during mouse embryonic development. Although multiple functions have been proposed for HSP25, the role it plays during differentiation is still unknown. High levels of HSP25 can be detected in embryonic and adult skin. During epidermis differentiation, the concentration of HSP25 increases with the distance of keratinocytes from the basal layer, in parallel with the extent of keratinization. We used an ex vivo cellular system, PAM212 cells, to analyze quantitatively and qualitatively the dynamics of HSP25 production and phosphorylation during the differentiation of keratinocytes. Our observations suggest that HSP25 is involved in two steps of PAM212 keratinocyte differentiation. Shortly after the induction of differentiation, a transient hyperphosphorylation of HSP25 seems to be essential for the expression of differentiation markers. Later, the chaperone-active form of HSP25 is organized progressively into characteristic aggregates involved in the dynamics of keratin filament networks.	Ecole Normale Super, Dept Biol, Mol Genet Unit, F-75230 Paris, France; Univ Med & Pharm Carol Davila, Postgrad Dept Biochem, Fundeni Hosp, Bucharest 2, Romania	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Carol Davila University of Medicine & Pharmacy; Institutul Clinic Fundeni	Morange, M (corresponding author), Ecole Normale Super, Dept Biol, Mol Genet Unit, 46 Rue Ulm, F-75230 Paris, France.	morange@wotan.ens.fr						Armstrong CL, 2001, J COMP NEUROL, V434, P262, DOI 10.1002/cne.1176; Arrigo AP, 2002, EXP GERONTOL, V37, P1247, DOI 10.1016/S0531-5565(02)00131-6; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Cuesta R, 2000, GENE DEV, V14, P1460; Davidson Sean M, 2002, Prog Mol Subcell Biol, V28, P103; Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Ehrnsperger M, 2000, METH MOL B, V99, P421; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Favet N, 2001, CELL DEATH DIFFER, V8, P603, DOI 10.1038/sj.cdd.4400847; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; GOEBEL HH, 1993, VIRCHOWS ARCH B, V64, P127, DOI 10.1007/BF02915105; Guay J, 1997, J CELL SCI, V110, P357; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jantschitsch C, 1998, BRIT J DERMATOL, V139, P247; Jonak C, 2002, BRIT J DERMATOL, V147, P13, DOI 10.1046/j.1365-2133.2002.04667.x; KATO S, 1992, ACTA NEUROPATHOL, V84, P443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; Loones MT, 1997, CELL MOL LIFE SCI, V53, P179, DOI 10.1007/PL00000590; LOWE J, 1992, NEUROPATH APPL NEURO, V18, P341, DOI 10.1111/j.1365-2990.1992.tb00796.x; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1999, CELL DEATH DIFFER, V6, P227, DOI 10.1038/sj.cdd.4400483; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Morange M, 1998, ANN NY ACAD SCI, V851, P117, DOI 10.1111/j.1749-6632.1998.tb08984.x; MORANGE M, 1999, MOL CHAPERONES FOLDI, P163; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Perng MD, 1999, J CELL SCI, V112, P2099; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROOP DR, 1983, J INVEST DERMATOL, V81, pS144, DOI 10.1111/1523-1747.ep12540939; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Schultz H, 1997, CELL STRESS CHAPERON, V2, P41, DOI 10.1379/1466-1268(1997)002<0041:TPKISU>2.3.CO;2; SPECTOR NL, 1994, FEBS LETT, V337, P184, DOI 10.1016/0014-5793(94)80270-X; SPECTOR NL, 1993, J CELL PHYSIOL, V156, P619, DOI 10.1002/jcp.1041560322; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YUSPA SH, 1980, CANCER RES, V40, P4694	57	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10252	10260		10.1074/jbc.M309906200	http://dx.doi.org/10.1074/jbc.M309906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14662766	hybrid			2022-12-25	WOS:000220050400073
J	Ibarra, C; Estrada, M; Carrasco, L; Chiong, M; Liberona, JL; Cardenas, C; Diaz-Araya, G; Jaimovich, E; Lavandero, S				Ibarra, C; Estrada, M; Carrasco, L; Chiong, M; Liberona, JL; Cardenas, C; Diaz-Araya, G; Jaimovich, E; Lavandero, S			Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; SKELETAL-MUSCLE; G(BETA-GAMMA) SUBUNITS; VENTRICULAR MYOCYTES; SENSITIVE MECHANISM; RELEASE CHANNELS; CA2+ CHANNELS; RECEPTOR	In the heart, insulin-like growth factor-1 (IGF-1) is a pro-hypertrophic and anti-apoptotic peptide. In cultured rat cardiomyocytes, IGF-1 induced a fast and transient increase in Ca-i(2+) levels apparent both in the nucleus and cytosol, releasing this ion from intracellular stores through an inositol 1,4,5-trisphosphate (IP3)-dependent signaling pathway. Intracellular IP3 levels increased after IGF-1 stimulation in both the presence and absence of extracellular Ca2+. A different spatial distribution of IP3 receptor isoforms in cardiomyocytes was found. Ryanodine did not prevent the IGF-1-induced increase of Ca-i(2+) levels but inhibited the basal and spontaneous Ca-i(2+) oscillations observed when cardiac myocytes were incubated in Ca2+-containing resting media. Spatial analysis of fluorescence images of IGF-1-stimulated cardiomyocytes incubated in Ca2+/--containing resting media showed an early increase in Ca-i(2+), initially localized in the nucleus. Calcium imaging suggested that part of the Ca2+ released by stimulation with IGF-1 was initially contained in the perinuclear region. The IGF-1-induced increase on Ca-i(2+) levels was prevented by 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-AM, thapsigargin, xestospongin C, 2-aminoethoxy diphenyl borate, U-73122, pertussis toxin, and betaARKct (a peptide inhibitor of Gbetagamma signaling). Pertussis toxin also prevented the IGF-1-dependent IP3 mass increase. Genistein treatment largely decreased the IGF-1-induced changes in both Ca-i(2+) and IP3. LY29402 (but not PD98059) also prevented the IGF-1-dependent Ca-i(2+) increase. Both pertussis toxin and U73122 prevented the IGF-1-dependent induction of both ERKs and protein kinase B. We conclude that IGF-1 increases Ca-i(2+) levels in cultured cardiac myocytes through a Gbetagamma subunit of a pertussis toxin-sensitive G protein-PI3K-phospholipase C signaling pathway that involves participation of IP3.	Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 6640750, Chile; Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Bioquim & Biol Mol, Santiago 6640750, Chile; Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Quim Farmacol & Toxicol, Santiago 6640750, Chile; Univ Chile, Ctr FONDAP Estudios Mol Celula, Santiago 6640750, Chile	Universidad de Chile; Universidad de Chile; Universidad de Chile; Universidad de Chile	Jaimovich, E (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Independencia 1027, Santiago 6640750, Chile.	ejaimovi@machi.med.uchile.cl; slavander@uchile.cl	Estrada, Manuel/AAS-5605-2020; Chiong, Mario/I-1043-2013; Estrada, Manuel/C-1269-2014; Lavandero, Sergio/B-6001-2013; Ibarra, Cristian/D-9386-2013; Chiong, M./ABH-5784-2020; Jaimovich, Enrique/AAY-7632-2020	Estrada, Manuel/0000-0001-7877-8160; Chiong, Mario/0000-0002-5174-6545; Estrada, Manuel/0000-0001-7877-8160; Lavandero, Sergio/0000-0003-4258-1483; Chiong, M./0000-0002-5174-6545; 				Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; BROWN J H, 1986, P245; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; CASTLEMAN KR, 1989, DIGITAL IMAGE PROCES; Chik CL, 1997, ENDOCRINOLOGY, V138, P2033, DOI 10.1210/en.138.5.2033; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Cittadini A, 1998, CIRC RES, V83, P50, DOI 10.1161/01.RES.83.1.50; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; ENGELMANN GL, 1989, MOL CELL ENDOCRINOL, V63, P1, DOI 10.1016/0303-7207(89)90076-2; Estrada M, 2001, J BIOL CHEM, V276, P22868, DOI 10.1074/jbc.M100118200; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Foncea R, 2000, BIOCHEM BIOPH RES CO, V273, P736, DOI 10.1006/bbrc.2000.3008; Freestone NS, 1996, MOL CELL BIOCHEM, V164, P223, DOI 10.1007/BF00408662; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Geertz R, 1997, MOL CELL BIOCHEM, V177, P33, DOI 10.1023/A:1006836631673; Goutsouliak V, 1997, CELL SIGNAL, V9, P505, DOI 10.1016/S0898-6568(97)00008-9; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HILENSKI LL, 1991, CELL TISSUE RES, V264, P577, DOI 10.1007/BF00319047; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; Hong F, 2001, BIOCHEM BIOPH RES CO, V282, P816, DOI 10.1006/bbrc.2001.4644; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; KLEPPISCH T, 1992, BRAIN RES, V591, P283, DOI 10.1016/0006-8993(92)91709-N; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Lee WK, 1999, BIOCHEM BIOPH RES CO, V261, P393, DOI 10.1006/bbrc.1999.1035; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Liberona JL, 1998, MUSCLE NERVE, V21, P902, DOI 10.1002/(SICI)1097-4598(199807)21:7<902::AID-MUS8>3.0.CO;2-A; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; Liu JL, 2000, ENDOCRINOLOGY, V141, P4436, DOI 10.1210/en.141.12.4436; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; MINTA A, 1989, J BIOL CHEM, V264, P8171; Otani H, 2000, J CARDIOVASC PHARM, V35, P275, DOI 10.1097/00005344-200002000-00015; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Poiraudeau S, 1997, J CELL BIOCHEM, V64, P414; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Renganathan M, 1997, BIOCHEM BIOPH RES CO, V235, P784, DOI 10.1006/bbrc.1997.6881; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6413; SELINFREUND RH, 1994, MOL PHARMACOL, V45, P1215; Shah AS, 2001, CIRCULATION, V103, P1311; Solem ML, 1998, BIOCHEM BIOPH RES CO, V252, P151, DOI 10.1006/bbrc.1998.9626; Takahashi T, 1999, CIRC RES, V85, P884; *US NIH, 1985, NIH PUBL, V8523; Vlcek S, 2001, CELL MOL LIFE SCI, V58, P1758, DOI 10.1007/PL00000815; Ward CW, 2001, J CLIN PATHOL-MOL PA, V54, P125; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961	70	70	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7554	7565		10.1074/jbc.M311604200	http://dx.doi.org/10.1074/jbc.M311604200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660553	hybrid			2022-12-25	WOS:000189103300024
J	Das, S; Ward, SV; Markle, D; Samuel, CE				Das, S; Ward, SV; Markle, D; Samuel, CE			DNA damage-binding proteins and heterogeneous nuclear ribonucleoprotein A1 function as constitutive KCS element components of the interferon-inducible RNA-dependent protein kinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PKR GENE; CHROMATIN-STRUCTURE; MAMMALIAN-CELLS; REPAIR PROTEIN; MESSENGER-RNA; HELA-CELLS; V-PROTEIN; X-PROTEIN	Protein kinase regulated by RNA (PKR) plays important roles in many cellular processes including virus multiplication and cell growth, differentiation, and apoptosis. The promoter of the PKR gene possesses a novel 15-bp element designated KCS, positioned upstream of a consensus interferon (IFN)-stimulated response element, that is required for both basal and interferon-inducible transcription. Protein binding to the KCS element is not dependent upon IFN treatment and correlates with transcriptional activity of the PKR promoter. The identity of KCS-binding proteins (KBP) that selectively bind at the KCS element is largely unknown, except for the transcription factor Sp1. We now have purified KBP from HeLa cell nuclear extracts by ion-exchange and DNA-affinity chromatography steps and then identified four constituent proteins of the KBP complex by mass spectrometry and immunochemistry: KBP120 and KBP45 are the damaged DNA-binding protein subunits, p127 DDB1 and p48 DDB2, respectively; KBP100 is the transcription factor Sp1; and KBP35 is the heterogeneous nuclear ribonucleoprotein A1. The steady-state levels of these four KCS-binding proteins in human cells are not altered by IFN treatment. Components of the KBP complex bind selectively and constitutively to the KCS element in the absence of IFN treatment, both in vitro as measured by competition electrophoretic mobility shift assay (EMSA) and DNA pull-down assays and in vivo as measured by chromatin immunoprecipitation assays. Depletion of DDB2 by antisense strategy reduces KBP complex formation by EMSA. These results provide new insight into the biochemical identity and activity of proteins involved in PKR promoter function.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu			NIAID NIH HHS [AI-20611, AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI020611, R01AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; ABRAMIC M, 1991, J BIOL CHEM, V266, P22439; Ayora S, 1996, J MOL BIOL, V256, P301, DOI 10.1006/jmbi.1996.0087; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DeLuca JG, 2001, J BIOL CHEM, V276, P28014, DOI 10.1074/jbc.M102801200; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hall P, 2001, J PALLIATIVE CARE, V17, P220; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; Kuhen KL, 1997, VIROLOGY, V227, P119, DOI 10.1006/viro.1996.8306; Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536; Kuhen KL, 1998, J VIROL, V72, P9934, DOI 10.1128/JVI.72.12.9934-9939.1998; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Martel LS, 2002, MOL CELL BIOL, V22, P2788, DOI 10.1128/MCB.22.8.2788-2798.2002; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Otrin VR, 1997, J CELL SCI, V110, P1159; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Reith W, 1999, MICROBES INFECT, V1, P839; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1993, VIROLOGY, V130, P474; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Shtrichman R, 2002, INFECT IMMUN, V70, P5579, DOI 10.1128/IAI.70.10.5579-5588.2002; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sun NK, 2002, FEBS LETT, V512, P168, DOI 10.1016/S0014-5793(02)02250-0; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; TOTH J, 2000, NUCLEIC ACIDS RES, V28, pR1; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; van't Wout AB, 2003, J VIROL, V77, P1392, DOI 10.1128/JVI.77.2.1392-1402.2003; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Ward SV, 2003, VIROLOGY, V313, P553, DOI 10.1016/S0042-6822(03)00347-7; Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; Wieland SF, 2003, J VIROL, V77, P1227, DOI 10.1128/JVI.77.2.1227-1236.2003; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291	58	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7313	7321		10.1074/jbc.M312585200	http://dx.doi.org/10.1074/jbc.M312585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645369	hybrid			2022-12-25	WOS:000188969200133
J	Goo, YH; Na, SY; Zhang, H; Xu, JM; Hong, SH; Cheong, JH; Lee, SK; Lee, JW				Goo, YH; Na, SY; Zhang, H; Xu, JM; Hong, SH; Cheong, JH; Lee, SK; Lee, JW			Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; NUCLEAR-RECEPTOR; DEPENDENT TRANSACTIVATION; HORMONE-RECEPTORS; COACTIVATOR; CANCER; MICE; TRANSCRIPTION; MOTIF; COREGULATORS	Activating signal cointegrator-2 (ASC-2), a cancer-amplified transcription coactivator of nuclear receptors and numerous other transcription factors, was previously shown to contain two LXXLL motifs, each of which interacts with a distinct set of nuclear receptors. In this work, we showed that ASC-2 has an indirect, separate binding site for androgen receptor (AR). Interestingly, this region overlapped with the direct interaction interfaces with the tumor suppressor retinoblastoma (Rb). Although ASC-2 alone stimulated AR transactivation in cotransfections of HeLa cells, ectopic expression of Rb effected ASC-2 to act as a transcription coactivator of AR in Rb-null Saos2 cells. These results, along with the previous report in which AR was shown to directly interact with Rb (Yeh, S., Miyamoto, H., Nishimura, K., Kang, H., Ludlow, J., Hsiao, P., Wang, C., Su, C., and Chang C. (1998) Biochem. Biophys. Res. Commun. 248, 361-367), suggest that the AR-ASC-2 interactions in vivo may involve Rb. Thus, ASC-2 appears to contain at least three distinct nuclear receptor interaction domains.	Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Salk Inst Biol Studies, Gene Express Lab, San Diego, CA 92185 USA	Baylor College of Medicine; Baylor College of Medicine; Pohang University of Science & Technology (POSTECH); Harvard University; Massachusetts General Hospital; Pusan National University; Salk Institute	Lee, JW (corresponding author), Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA.	jwlee@bcm.tmc.edu						Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kim SW, 2003, MOL CELL BIOL, V23, P3583, DOI 10.1128/MCB.23.10.3583-3592.2003; Kim SW, 2002, MOL CELL BIOL, V22, P8409, DOI 10.1128/MCB.22.24.8409-8414.2002; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lee SK, 2001, MOL ENDOCRINOL, V15, P241, DOI 10.1210/me.15.2.241; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; SAIJO M, 1995, GENOMICS, V27, P511, DOI 10.1006/geno.1995.1084; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Tanner MM, 1996, CANCER RES, V56, P3441; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Zhang H, 2003, ENDOCRINOLOGY, V144, P1435, DOI 10.1210/en.2002-0018; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200	27	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7131	7135		10.1074/jbc.M312563200	http://dx.doi.org/10.1074/jbc.M312563200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645241	hybrid			2022-12-25	WOS:000188969200112
J	Hirata, A; Adachi, M; Sekine, A; Kang, YN; Utsumi, S; Mikami, B				Hirata, A; Adachi, M; Sekine, A; Kang, YN; Utsumi, S; Mikami, B			Structural and enzymatic analysis of soybean beta-amylase mutants with increased pH optimum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; ASPERGILLUS-AWAMORI; CRYSTAL-STRUCTURE; RAW STARCH; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; GLYCOSYL HYDROLASES; ESCHERICHIA-COLI; GLUCOAMYLASE; CLONING	Comparison of the architecture around the active site of soybean beta-amylase and Bacillus cereus beta-amylase showed that the hydrogen bond networks (Glu(380)- (Lys(295)-Met(51)) and Glu(380)-Asn(340)-Glu(178)) in soybean beta-amylase around the base catalytic residue, Glu(380), seem to contribute to the lower pH optimum of soybean beta-amylase. To convert the pH optimum of soybean beta-amylase (pH 5.4) to that of the bacterial type enzyme (pH 6.7), three mutants of soybean beta-amylase, M51T, E178Y, and N340T, were constructed such that the hydrogen bond networks were removed by site-directed mutagenesis. The kinetic analysis showed that the pH optimum of all mutants shifted dramatically to a neutral pH (range, from 5.4 to 6.0 - 6.6). The K-m values of the mutants were almost the same as that of soybean beta-amylase except in the case of M51T, while the V-max values of all mutants were low compared with that of soybean beta-amylase. The crystal structure analysis of the wild type-maltose and mutant-maltose complexes showed that the direct hydrogen bond between Glu(380) and Asn(340) was completely disrupted in the mutants M51T, E178Y, and N340T. In the case of M51T, the hydrogen bond between Glu(380) and Lys(295) was also disrupted. These results indicated that the reduced pK(a) value of Glu(380) is stabilized by the hydrogen bond network and is responsible for the lower pH optimum of soybean beta-amylase compared with that of the bacterial beta-amylase.	Kyoto Univ, Grad Sch Agr, Lab Food Qual Design & Dev, Kyoto 6110011, Japan	Kyoto University	Mikami, B (corresponding author), Kyoto Univ, Grad Sch Agr, Lab Food Qual Design & Dev, Kyoto 6110011, Japan.	mikami@kais.kyoto-u.ac.jp						Adachi M, 1998, J BIOL CHEM, V273, P19859, DOI 10.1074/jbc.273.31.19859; Becker D, 2001, BIOCHEM J, V356, P19, DOI 10.1042/0264-6021:3560019; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fang TY, 1998, PROTEIN ENG, V11, P383, DOI 10.1093/protein/11.5.383; FRANDSEN TP, 1994, BIOCHEMISTRY-US, V33, P13808, DOI 10.1021/bi00250a035; GERTLER A, 1966, BIOCHIM BIOPHYS ACTA, V118, P98, DOI 10.1016/S0926-6593(66)80148-0; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; HENRISSAT B, 1995, BIOCHEM J, V311, P350, DOI 10.1042/bj3110350; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGASHIHARA M, 1974, AGR BIOL CHEM TOKYO, V38, P1023, DOI 10.1080/00021369.1974.10861268; HIROMI K, 1966, J BIOCHEM, V59, P469, DOI 10.1093/oxfordjournals.jbchem.a128329; HIROMI K, 1983, MOL CELL BIOCHEM, V51, P79, DOI 10.1007/BF00215589; HOSHINO M, 1975, AGR BIOL CHEM TOKYO, V39, P2415, DOI 10.1080/00021369.1975.10861974; HYE JY, 1999, J MICROBIOL BIOTECHN, V9, P619; Joshi MD, 2000, J MOL BIOL, V299, P255, DOI 10.1006/jmbi.2000.3722; Joshi MD, 2001, BIOCHEMISTRY-US, V40, P10115, DOI 10.1021/bi0105429; KAWAZU T, 1987, J BACTERIOL, V169, P1564, DOI 10.1128/jb.169.4.1564-1570.1987; KITAMOTO N, 1988, J BACTERIOL, V170, P5848, DOI 10.1128/jb.170.12.5848-5854.1988; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREIS M, 1987, EUR J BIOCHEM, V169, P517, DOI 10.1111/j.1432-1033.1987.tb13640.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JS, 2001, APPL MICROBIOL BIOT, V56, P205, DOI 10.1007/s002530100645; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; Mikami B, 1999, J MOL BIOL, V285, P1235, DOI 10.1006/jmbi.1998.2379; Mikami B, 1999, BIOCHEMISTRY-US, V38, P7050, DOI 10.1021/bi9829377; MIKAMI B, 1993, BIOCHEMISTRY-US, V32, P6836, DOI 10.1021/bi00078a006; MIKAMI B, 1994, BIOCHEMISTRY-US, V33, P7779, DOI 10.1021/bi00191a005; MIKAMI B, 2000, STRUCTURE BETA AMYLA, P55; MONROE JD, 1991, PLANT PHYSIOL, V97, P1599, DOI 10.1104/pp.97.4.1599; MORITA Y, 1975, J BIOCHEM-TOKYO, V77, P343, DOI 10.1093/oxfordjournals.jbchem.a130731; NANMORI T, 1993, APPL ENVIRON MICROB, V59, P623, DOI 10.1128/AEM.59.2.623-627.1993; Nanmori T., 1988, HDB AMYLASES RELATED, P94; NITTA Y, 1979, J BIOCHEM-TOKYO, V85, P41, DOI 10.1093/oxfordjournals.jbchem.a132328; NITTA Y, 1989, J BIOCHEM-TOKYO, V100, P1175; NOMURA K, 1995, J BIOCHEM-TOKYO, V118, P1124, DOI 10.1093/oxfordjournals.jbchem.a124997; OHNISHI H, 1994, J BIOL CHEM, V269, P3503; Oyama T, 1999, J BIOCHEM-TOKYO, V125, P1120, DOI 10.1093/oxfordjournals.jbchem.a022394; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RHODES C, 1987, NUCLEIC ACIDS RES, V15, P3934, DOI 10.1093/nar/15.9.3934; RORAT T, 1991, THEOR APPL GENET, V83, P257, DOI 10.1007/BF00226260; SAHA BC, 1987, ENZYME MICROB TECH, V9, P598, DOI 10.1016/0141-0229(87)90112-8; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; THOMA AJ, 1965, BIOCHEMISTRY-US, V4, P714; THOMA JA, 1971, ENZYMES, V5, P115; Totsuka A, 1996, EUR J BIOCHEM, V240, P655, DOI 10.1111/j.1432-1033.1996.0655h.x; TOTSUKA A, 1993, EUR J BIOCHEM, V214, P787, DOI 10.1111/j.1432-1033.1993.tb17981.x; UEDA S, 1980, STARKE, V32, P122, DOI 10.1002/star.19800320406; YOSHIDA N, 1991, J BIOCHEM-TOKYO, V110, P196, DOI 10.1093/oxfordjournals.jbchem.a123556; ZHEREBTSOV N. A., 1968, BIOKHIMIYA, V33, P435	55	35	37	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7287	7295		10.1074/jbc.M309411200	http://dx.doi.org/10.1074/jbc.M309411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638688	hybrid			2022-12-25	WOS:000188969200130
J	Just, H; Sitte, HH; Schmid, JA; Freissmuth, M; Kudlacek, O				Just, H; Sitte, HH; Schmid, JA; Freissmuth, M; Kudlacek, O			Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HUMAN DOPAMINE TRANSPORTER; RAT GABA TRANSPORTER-1; PROTEIN-KINASE-C; ESCHERICHIA-COLI; SYNTAXIN 1A; FUNCTIONAL CONSEQUENCES; TRANSFER MICROSCOPY; PLASMA-MEMBRANE; CROSS-LINKING	Na+/Cl--dependent neurotransmitter transporters form constitutive oligomers. The topological arrangement is not known, but a leucine heptad repeat in transmembrane domain (TM) 2 and a glycophorin-like motif in TM6 have been proposed to stabilize the oligomer. To determine the topology, we generated versions of the human serotonin transporter (hSERT) that carried cyan or yellow fluorescent proteins at their amino and/or carboxyl terminus. Appropriate pairs were coexpressed to measure fluorescence resonance energy transfer (FRET). Donor photobleaching FRET microscopy was employed to deduce the following arrangement: within the monomer, the amino and carboxyl termini are in close vicinity. In addition, in the oligomer, the carboxyl termini are closer to each other than the amino termini. Hence, a separate interaction domain (i.e. distinct from TM2 and TM6) must reside in the carboxyl-terminal half of hSERT. This was confirmed by expressing the amino- and carboxyl-terminal halves of hSERT. These were retained intracellularly; they also retained the coexpressed full-length transporter by forming export-deficient oligomers and, when cotransfected in all possible combinations, supported FRET. Hence, both the carboxyl and amino termini contain elements that drive oligomerization. By employing fragments comprising two neighboring TM helices, we unequivocally identified TM11/12 as a new contact site by donor photobleaching FRET and beta-lactamase protein fragment complementation assay. TM1/2 was also found to self-associate. Thus, oligomerization of hSERT involves at least two discontinuous interfaces. The currently identified interaction sites drive homophilic interactions. This is consistent with assembly of SERT oligomers in an array-like structure containing multimers of dimers.	Univ Vienna, Sch Med, Inst Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Sch Med, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria	University of Vienna; University of Vienna	Freissmuth, M (corresponding author), Univ Vienna, Sch Med, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@univie.ac.at	Sitte, Harald/N-2681-2013; Schmid, Johannes A./C-7659-2009; Sitte, Harald/O-7025-2019	Sitte, Harald/0000-0002-1339-7444; Schmid, Johannes A./0000-0002-6586-3507; Sitte, Harald/0000-0002-1339-7444; Freissmuth, Michael/0000-0001-9398-1765; Kudlacek, Oliver/0000-0002-3086-8551				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Beckman ML, 1998, J NEUROSCI, V18, P6103; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Kocabas AM, 2003, J NEUROCHEM, V85, P1513, DOI 10.1046/j.1471-4159.2003.01793.x; Li HM, 2001, BIOCHEMISTRY-US, V40, P6636, DOI 10.1021/bi0026573; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Scholze P, 2000, J PHARMACOL EXP THER, V293, P870; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Sung U, 2003, J NEUROSCI, V23, P1697; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	33	85	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6650	6657		10.1074/jbc.M306092200	http://dx.doi.org/10.1074/jbc.M306092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660642	hybrid			2022-12-25	WOS:000188969200055
J	Almagro, S; Riveline, D; Hirano, T; Houchmandzadeh, B; Dimitrov, S				Almagro, S; Riveline, D; Hirano, T; Houchmandzadeh, B; Dimitrov, S			The mitotic chromosome is an assembly of rigid elastic axes organized by structural maintenance of chromosomes (SMC) proteins and surrounded by a soft chromatin envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; TOPOISOMERASE-II; CONDENSATION; XENOPUS; SCAFFOLD; COMPONENT; COMPLEXES; PLAY; DNA	The structure of mitotic chromosomes is still poorly understood. Here we describe the use of a novel approach based on elasticity measurements of a single chromosome for studying the organization of these objects. The data reveal that mitotic chromosomes exhibit a non-homogenous structure consisting of rigid elastic axes surrounded by a soft chromatin envelope. The chemical continuity of DNA, but not RNA, was required for the maintenance of these axes. The axes show a modular structure, and the structural maintenance of chromosomes (SMC) proteins participate in their organization. Topoisomerase II was not involved in either the organization of the axes or the maintenance of the mitotic chromosomes. A model for the assembly and the structure of the mitotic chromosome is proposed. According this model, the chromosome axes are dynamic structures that assemble at the onset and disassemble the end of mitosis, respectively. The SMC proteins, in addition to maintaining axis elasticity, are essential for the determination of the rod-like chromosome shape. The extreme compaction of mitotic chromosomes is determined mainly by the high amount of bivalent ions bound to DNA at mitosis.	Inst Albert Bonniot, INSERM, U309, Lab Biol Mol & Cellulaire Differenciat, F-38706 La Tronche, France; Univ Grenoble 1, UMR 5588, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Cold Spring Harbor Laboratory	Dimitrov, S (corresponding author), Inst Albert Bonniot, INSERM, U309, Lab Biol Mol & Cellulaire Differenciat, Domaine Merci, F-38706 La Tronche, France.	stefan.dimitrov@ujf-grenoble.fr	Houchmandzadeh, Bahram/F-9199-2012; Hirano, Tatsuya/F-6008-2011; Riveline, Daniel/GXV-6609-2022; dimitrov, stefan/M-7697-2013	Houchmandzadeh, Bahram/0000-0001-8104-2576; Hirano, Tatsuya/0000-0002-4219-6473; dimitrov, stefan/0000-0002-1326-3630				ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; Clerc P, 2003, SEMIN CELL DEV BIOL, V14, P85, DOI 10.1016/S1084-9521(02)00140-4; de la Barre AE, 1999, METH MOL B, V119, P219; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; DUPRAW EJ, 1966, NATURE, V209, P577, DOI 10.1038/209577a0; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Houchmandzadeh B, 1999, J CELL BIOL, V145, P215, DOI 10.1083/jcb.145.2.215; HOUCHMANDZADEH B, 1997, J CELL BIOL, V138, P1; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; LAEMMLI UK, 1978, COLD SPRING HARB SYM, V42, P351; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Poirier M, 2000, MOL BIOL CELL, V11, P269, DOI 10.1091/mbc.11.1.269; Poirier MG, 2002, P NATL ACAD SCI USA, V99, P15393, DOI 10.1073/pnas.232442599; Poirier MG, 2002, MOL BIOL CELL, V13, P2170, DOI 10.1091/mbc.01-08-0401; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SMIRNOV IV, 1988, J BIOMOL STRUCT DYN, V5, P1149, DOI 10.1080/07391102.1988.10506455; Strick R, 2001, J CELL BIOL, V155, P899, DOI 10.1083/jcb.200105026; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6	29	38	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5118	5126		10.1074/jbc.M307221200	http://dx.doi.org/10.1074/jbc.M307221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660618	hybrid			2022-12-25	WOS:000188776500011
J	Averous, J; Bruhat, A; Jousse, C; Carraro, V; Thiel, G; Fafournoux, P				Averous, J; Bruhat, A; Jousse, C; Carraro, V; Thiel, G; Fafournoux, P			Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE SYNTHETASE GENE; ACTIVATING TRANSCRIPTION FACTOR-2; SENSING RESPONSE PATHWAY; RNA INTERFERENCE; PROTEIN; C/EBP; DEPRIVATION; NUTRIENT; GADD153; DEFICIENCY	The CHOP gene is transcriptionally induced by amino acid starvation. We have previously identified a genomic cis-acting element (amino acid response element (AARE)) involved in the transcriptional activation of the human CHOP gene by leucine starvation and shown that it binds the activating transcription factor 2 (ATF2). The present study was designed to identify other transcription factors capable of binding to the CHOP AARE and to establish their role with regard to induction of the gene by amino acid deprivation. Electrophoretic mobility shift assay and transient transfection experiments show that several transcription factors that belong to the C/EBP or ATF families bind the AARE sequence and activate transcription. Among all these transcription factors, only ATF4 and ATF2 are involved in the amino acid control of CHOP expression. We show that inhibition of ATF2 or ATF4 expression impairs the transcriptional activation of CHOP by amino acid starvation. The transacting capacity of ATF4 depends on its expression level and that of ATF2 on its phosphorylation state. In response to leucine starvation, ATF4 expression and ATF2 phosphorylation are increased. However, induction of ATF4 expression by the endoplasmic reticulum stress pathway does not fully activate the AARE-dependent transcription. Taken together our results demonstrate that at least two pathways, one leading to ATF4 induction and one leading to ATF2 phosphorylation, are necessary to induce CHOP expression by amino acid starvation. This work was extended to the regulation of other amino acid regulated genes and suggests that ATF4 and ATF2 are key components of the amino acid control of gene expression.	INRA, Unite Nutr & Metab Prot, F-63122 St Genes Champanelle, France; Univ Saarland, Med Ctr, Dept Med Biochem & Mol Biol, D-66421 Homburg, Germany	INRAE; Saarland University	Fafournoux, P (corresponding author), INRA, Unite Nutr & Metab Prot, F-63122 St Genes Champanelle, France.	fpierre@clermont.inra.fr						Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; Aubel C, 2001, CELL SIGNAL, V13, P417, DOI 10.1016/S0898-6568(01)00159-0; BAERTL JM, 1974, AM J CLIN NUTR, V27, P733, DOI 10.1093/ajcn/27.7.733; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fontanier-Razzaq N, 2002, J NUTR, V132, P2137, DOI 10.1093/jn/132.8.2137; GIETZEN DW, 1986, TIME COURSE FOOD INT, P415; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LUETHY JD, 1992, CANCER RES, V52, P5; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MORDIER S, 2002, CELL MELRCULAR RESPO, P189; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Steinmuller L, 2003, BIOL CHEM, V384, P667, DOI 10.1515/BC.2003.074; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Young V. R., 1994, Nestle Nutrition Workshop Series, V33, P1	47	215	219	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5288	5297		10.1074/jbc.M311862200	http://dx.doi.org/10.1074/jbc.M311862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630918	hybrid, Green Published			2022-12-25	WOS:000188776500032
J	Chapman-Smith, A; Lutwyche, JK; Whitelaw, ML				Chapman-Smith, A; Lutwyche, JK; Whitelaw, ML			Contribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; DIOXIN RECEPTOR; ESCHERICHIA-COLI; AH RECEPTOR; PROTEIN; ARNT; HYPOXIA; LIGAND; RECOGNITION; DEFINITION	The basic helix-loop-helix (bHLH) PAS transcriptional regulators control critical developmental and metabolic processes, including transcriptional responses to stimuli such as hypoxia and environmental pollutants, mediated respectively by hypoxia inducible factors (HIF-alpha) and the dioxin (aryl hydrocarbon) receptor (DR). The bHLH proteins contain a basic DNA binding sequence adjacent to a helix-loop-helix dimerization domain. Dimerization among bHLH. PAS proteins is additionally regulated by the PAS region, which controls the specificity of partner choice such that HIF-alpha and DR must dimerize with the aryl hydrocarbon nuclear translocator (Arnt) to form functional DNA binding complexes. Here, we have analyzed purified bacterially expressed proteins encompassing the N-terminal bHLH and bHLH. PAS regions of Arnt, DR, and HIF-1alpha and evaluated the contribution of the PAS domains to DNA binding in vitro. Recovery of functional DNA binding proteins from bacteria was dramatically enhanced by coexpression of the bHLH. PAS regions of DR or HIF-1alpha with the corresponding region of Arnt. Formation of stable protein-DNA complexes by DR/Arnt and HIF-1alpha/Arnt heterodimers with their cognate DNA sequences required the PAS A domains and exhibited K-D values of 0.4 nM and similar to50 nM, respectively. In contrast, the presence of the PAS domains of Arnt had little effect on DNA binding by Arnt homodimers, and these bound DNA with a K-D of 45 nM. In the case of the DR, both high affinity DNA binding and dimer stability were specific to its native PAS domain, since a chimera in which the PAS A domain was substituted with the equivalent domain of Arnt generated a destabilized protein that bound DNA poorly.	Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Chapman-Smith, A (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia.	anne.chapmansmith@adelaide.edu.au						Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; Chapman-Smith A, 2001, PROTEIN SCI, V10, P2608, DOI 10.1110/ps.ps.22401; ChapmanSmith A, 1997, J BIOL CHEM, V272, P26017, DOI 10.1074/jbc.272.41.26017; Ciarapica R, 2003, J BIOL CHEM, V278, P12182, DOI 10.1074/jbc.M211991200; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Ema M, 1996, MOL CELL BIOL, V16, P5865; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Y, 2000, J NEUROSCI, V20, P4596, DOI 10.1523/JNEUROSCI.20-12-04596.2000; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x	42	60	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5353	5362		10.1074/jbc.M310041200	http://dx.doi.org/10.1074/jbc.M310041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638687	hybrid			2022-12-25	WOS:000188776500040
J	Schafer, B; Gschwind, A; Ullrich, A				Schafer, B; Gschwind, A; Ullrich, A			Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion	ONCOGENE			English	Article						EGFR; GPCR; transactivation; LPA; invasion; metalloprotemase	CELL-CARCINOMA-CELLS; EGF RECEPTOR; HB-EGF; TRANSFORMING GROWTH; AUTOCRINE GROWTH; BLADDER-CANCER; FACTOR-ALPHA; TRANSACTIVATION; CLEAVAGE; EXPRESSION	Signalling through G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTK) is involved in the regulation of essential cellular processes and its deregulation is associated with tumorigenesis in vitro and in vivo. We investigated pathophysiological processes that are regulated by GPCR pathways in human kidney and bladder cancer cell lines. Our results show that GPCR ligands induce tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as well as downstream signalling events such as recruitment of the adapter protein Shc and activation of the mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. Moreover, we report that the EGFR transactivation signal involves the EGFR ligands amphiregulin, HB-EGF and TGFalpha as well as the metalloproteinases ADAM 10, 15 and 17, depending on the cellular system. Finally, we demonstrate that EGFR transactivation is part of a regulatory system that modulates the migratory and invasive behaviour of kidney and bladder cancer cells. In conclusion, our findings demonstrate that metalloproteinase-mediated transactivation of the EGFR is a key mechanism of the cellular signalling network that promotes MAPK activation as well as tumour cell migration and invasion in response to a variety of physiologically relevant GPCR ligands, and therefore represents a novel target for cancer intervention strategies.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de						Bue P, 1998, INT J CANCER, V76, P189, DOI 10.1002/(SICI)1097-0215(19980413)76:2<189::AID-IJC4>3.0.CO;2-T; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Ghanem MA, 2001, CANCER-AM CANCER SOC, V92, P3120, DOI 10.1002/1097-0142(20011215)92:12<3120::AID-CNCR10173>3.0.CO;2-2; Gildea JJ, 2002, CANCER RES, V62, P982; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; Gschwind A, 2002, CANCER RES, V62, P6329; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; ISHIKAWA J, 1989, INT J CANCER, V44, P1000, DOI 10.1002/ijc.2910440610; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Ruck A, 1997, ANTICANCER RES, V17, P1925; Ruck A, 1998, ANTICANCER RES, V18, P1447; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; Van Brussel JP, 1999, BJU INT, V83, P902; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	34	214	220	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					991	999		10.1038/sj.onc.1207278	http://dx.doi.org/10.1038/sj.onc.1207278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647423				2022-12-25	WOS:000188486600015
J	Mizuno, M; Tonozuka, T; Suzuki, S; Uotsu-Tomita, R; Kamitori, S; Nishikawa, A; Sakano, Y				Mizuno, M; Tonozuka, T; Suzuki, S; Uotsu-Tomita, R; Kamitori, S; Nishikawa, A; Sakano, Y			Structural insights into substrate specificity and function of glucodextranase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROBACTER-GLOBIFORMIS I42; ACID-SEQUENCE SIMILARITIES; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; THERMOANAEROBACTERIUM-THERMOSACCHAROLYTICUM; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; GLUCOAMYLASE GENE; ESCHERICHIA-COLI; BINDING DOMAIN	A glucodextranase (iGDase) from Arthrobacter globiformis I42 hydrolyzes alpha-1,6-glucosidic linkages of dextran from the non-reducing end to produce beta-D-glucose via an inverting reaction mechanism and classified into the glycoside hydrolase family 15 (GH15). Here we cloned the iGDase gene and determined the crystal structures of iGDase of the unliganded form and the complex with acarbose at 2.42-Angstrom resolution. The structure of iGDase is composed of four domains N, A, B, and C. Domain A forms an (alpha/alpha)(6)-barrel structure and domain N consists of 17 antiparallel beta-strands, and both domains are conserved in bacterial glucoamylases (GAs) and appear to be mainly concerned with catalytic activity. The structure of iGDase complexed with acarbose revealed that the positions and orientations of the residues at subsites - 1 and + 1 are nearly identical between iGDase and GA; however, the residues corresponding to subsite 3, which form the entrance of the substrate binding pocket, and the position of the open space and constriction of iGDase are different from those of GAs. On the other hand, domains B and C are not found in the bacterial GAs. The primary structure of domain C is homologous with a surface layer homology domain of pullulanases, and the three-dimensional structure of domain C resembles the carbohydrate-binding domain of some glycohydrolases.	Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo 1838509, Japan; Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology	Sakano, Y (corresponding author), Tokyo Univ Agr & Technol, Dept Appl Biol Sci, 3-5-8 Saiwai Cho, Tokyo 1838509, Japan.	sakano@cc.tuat.ac.jp	Tonozuka, Takashi/D-2268-2013; Nishikawa, Atsushi/E-6766-2013	Tonozuka, Takashi/0000-0002-5422-7548; Nishikawa, Atsushi/0000-0003-4325-1160; Kamitori, Shigehiro/0000-0002-3950-3372				ALESHIN AE, 1994, J BIOL CHEM, V269, P15631; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; ASHIKARI T, 1986, AGR BIOL CHEM TOKYO, V50, P957; Brechtel E, 1999, J BACTERIOL, V181, P5017, DOI 10.1128/JB.181.16.5017-5023.1999; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COUTINHO PM, 1994, PROTEIN ENG, V7, P393, DOI 10.1093/protein/7.3.393; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducki A, 1998, J GEN APPL MICROBIOL, V44, P327, DOI 10.2323/jgam.44.327; Erra-Pujada M, 1999, J BACTERIOL, V181, P3284, DOI 10.1128/JB.181.10.3284-3287.1999; Ganghofner D, 1998, BIOSCI BIOTECH BIOCH, V62, P302, DOI 10.1271/bbb.62.302; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITOH T, 1987, J BACTERIOL, V169, P4171, DOI 10.1128/jb.169.9.4171-4176.1987; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Janecek S, 1999, FEBS LETT, V456, P119, DOI 10.1016/S0014-5793(99)00919-9; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laskowski RA, 1992, PROCHECK V 2 PROGRAM; LEE SP, 1994, APPL ENVIRON MICROB, V60, P3764, DOI 10.1128/AEM.60.10.3764-3773.1994; LEE YE, 1993, APPL ENVIRON MICROB, V59, P3134, DOI 10.1128/AEM.59.9.3134-3137.1993; LUPAS A, 1994, J BACTERIOL, V176, P1224, DOI 10.1128/jb.176.5.1224-1233.1994; MATUSCHEK M, 1994, J BACTERIOL, V176, P3295, DOI 10.1128/jb.176.11.3295-3302.1994; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSNER P, 1992, ADV MICROB PHYSIOL, V33, P213, DOI 10.1016/S0065-2911(08)60218-0; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Oguma T., 1996, Journal of Applied Glycoscience, V43, P73; Oguma T, 1999, BIOSCI BIOTECH BIOCH, V63, P2174, DOI 10.1271/bbb.63.2174; OHNISHI H, 1992, EUR J BIOCHEM, V207, P413, DOI 10.1111/j.1432-1033.1992.tb17064.x; OKADA G, 1988, AGR BIOL CHEM TOKYO, V52, P2169; OKADA G, 1989, AGR BIOL CHEM TOKYO, V53, P223, DOI 10.1080/00021369.1989.10869251; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZAKI K, 1990, J GEN MICROBIOL, V136, P1327, DOI 10.1099/00221287-136-7-1327; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWAI T, 1974, J BIOCHEM-TOKYO, V75, P105, DOI 10.1093/oxfordjournals.jbchem.a130363; SAWAI T, 1976, AGR BIOL CHEM TOKYO, V40, P1293, DOI 10.1080/00021369.1976.10862217; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SIERKS MR, 1989, PROTEIN ENG, V2, P621, DOI 10.1093/protein/2.8.621; Sleytr UB, 1997, FEMS MICROBIOL REV, V20, P5, DOI 10.1016/S0168-6445(97)00039-9; Uotsu-Tomita R, 2001, APPL MICROBIOL BIOT, V56, P465, DOI 10.1007/s002530100609; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; YAMAGUCH.T, 1973, AGR BIOL CHEM TOKYO, V37, P2527, DOI 10.1080/00021369.1973.10861047	50	35	37	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10575	10583		10.1074/jbc.M310771200	http://dx.doi.org/10.1074/jbc.M310771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660574	hybrid			2022-12-25	WOS:000220050400111
J	Ji, H; Yeh, SR; Rousseau, DL				Ji, H; Yeh, SR; Rousseau, DL			Modulation of the electron redistribution in mixed valence cytochrome c oxidase by protein conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC RESONANCE SIGNAL; ESCHERICHIA-COLI; CARBON-MONOXIDE; 2.8 ANGSTROM; PHOTOLYSIS; PHOTODISSOCIATION; SPECTROSCOPY; EQUILIBRIUM; ACTIVATION; TURNOVER	The redistribution of two electrons in the four redox centers of cytochrome c oxidase following photodissociation of CO from the CO-bound mixed valence species has been examined by resonance Raman spectroscopy. To account for both the kinetic data, obtained from 5 mus to 2 ms, and the equilibrium results, a model is proposed in which the electron redistribution is modulated by a protein conformation transition from a nascent P-1 state to a relaxed P-2 state in a time window longer than 2 ms. In this model, all six possible two-electron reduced species are considered. The high population of species with a one-electron reduced binuclear center, in which the spectrum of heme a(3) is perturbed by the redox state of Cu-B, accounts for the significant residuals in the fitting of the kinetic data with four standard spectra derived from redox species with either zero or two electrons in the binuclear center. Under equilibrium conditions, the conformational change to the P-2 state destabilizes the redox states with only one electron in the binuclear center with respect to those with either zero or two electrons. As a result, the redox equilibrium is perturbed, and the electrons are redistributed. A simulation based on the new kinetics scheme, in which the electron redistribution is modulated by the protein conformation, gives reasonable agreement with both the equilibrium and the kinetic data, demonstrating the validity of this model.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu		Yeh, Syun-Ru/0000-0002-9858-386X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P2844; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BEINERT H, 1977, BIOCHIM BIOPHYS ACTA, V462, P121, DOI 10.1016/0005-2728(77)90194-3; BOELENS R, 1979, BIOCHIM BIOPHYS ACTA, V547, P296, DOI 10.1016/0005-2728(79)90012-4; BOELENS R, 1982, BIOCHIM BIOPHYS ACTA, V682, P264, DOI 10.1016/0005-2728(82)90107-4; Brzezinski P, 1996, BIOCHEMISTRY-US, V35, P5611, DOI 10.1021/bi960260m; BRZEZINSKI P, 1987, BIOCHIM BIOPHYS ACTA, V894, P29, DOI 10.1016/0005-2728(87)90209-X; Ching E, 2003, BIOPHYS J, V84, P2728, DOI 10.1016/S0006-3495(03)75078-4; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; EINARSDOTTIR O, 1995, BIOCHEMISTRY-US, V34, P496, DOI 10.1021/bi00002a014; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FINDSEN EW, 1987, J AM CHEM SOC, V109, P5367, DOI 10.1021/ja00252a011; GEORGIADIS KE, 1994, BIOCHEMISTRY-US, V33, P9245, DOI 10.1021/bi00197a028; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; JENSEN P, 1981, FEBS LETT, V125, P161, DOI 10.1016/0014-5793(81)80709-0; KARLSSON B, 1981, BIOCHIM BIOPHYS ACTA, V635, P73, DOI 10.1016/0005-2728(81)90008-6; LOU BS, 1993, J AM CHEM SOC, V115, P403, DOI 10.1021/ja00055a006; MALATESTA F, 1995, BIOPHYS CHEM, V54, P1, DOI 10.1016/0301-4622(94)00117-3; MORGAN JE, 1993, BIOCHEMISTRY-US, V32, P11413, DOI 10.1021/bi00093a019; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; Namslauer A, 2002, BIOCHEMISTRY-US, V41, P10369, DOI 10.1021/bi025976y; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; REINHAMMAR B, 1980, J BIOL CHEM, V255, P5000; Rousseau DL, 2002, METHOD ENZYMOL, V354, P351; ROUSSEAU DL, 1981, J RAMAN SPECTROSC, V10, P94, DOI 10.1002/jrs.1250100116; SHAW RW, 1978, J BIOL CHEM, V253, P6637; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERKHOVSKY MI, 1992, BIOCHEMISTRY-US, V31, P11860, DOI 10.1021/bi00162a026; Verkhovsky MI, 2001, BBA-BIOENERGETICS, V1506, P143, DOI 10.1016/S0005-2728(01)00220-1; WITT SN, 1986, J BIOL CHEM, V261, P8104; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; Yoshikawa S, 1998, J BIOENERG BIOMEMBR, V30, P7, DOI 10.1023/A:1020595108560; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498	34	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9392	9399		10.1074/jbc.M310729200	http://dx.doi.org/10.1074/jbc.M310729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660573	hybrid			2022-12-25	WOS:000189265900104
J	Prasad, A; Fernandis, AZ; Rao, Y; Ganju, RK				Prasad, A; Fernandis, AZ; Rao, Y; Ganju, RK			Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; REPULSIVE AXON GUIDANCE; OLFACTORY-BULB AXONS; TYROSINE PHOSPHATASE; MATRIX METALLOPROTEINASES; CHEMOKINE RECEPTORS; ROUNDABOUT RECEPTOR; NIH3T3 FIBROBLASTS; NEURONAL MIGRATION	Slit, which mediates its function by binding to the Roundabout ( Robo) receptor, has been shown to regulate neuronal and CXCR4-mediated leukocyte migration. Slit-2 was shown to be frequently inactivated in lung and breast cancers because of hypermethylation of its promoter region. Furthermore, the CXCR4/CXCL12 axis has been reported recently to be actively involved in breast cancer metastasis to target organs such as lymph nodes, lung, and bone. In this study, we sought to characterize the effect of Slit ( = Slit-2) on the CXCL12/ CXCR4-mediated metastatic properties of breast cancer cells. We demonstrate here that breast cancer cells and tissues derived from breast cancer patients express Robo 1 and 2 receptors. We also show that Slit treatment inhibits CXCL12/ CXCR4-induced breast cancer cell chemotaxis, chemoinvasion, and adhesion, the fundamental components that promote metastasis. Slit had no significant effect on the CXCL12-induced internalization process of CXCR4. In addition, characterization of signaling events revealed that Slit inhibits CXCL12-induced tyrosine phosphorylation of focal adhesion components such as RAFTK/Pyk2 at residues 580 and 881, focal adhesion kinase at residue 576, and paxillin. We found that Slit also inhibits CXCL12-induced phosphatidylinositol 3-kinase, p44/42 MAP kinase, and metalloproteinase 2 and 9 activities. However, it showed no effect on JNK and p38 MAP kinase activities. To our knowledge, this is the first report to analyze in detail the effect of Slit on breast cancer cell motility as well as its effect on the critical components of the cancer cell chemotactic machinery. Studies of the Slit-Robo complex may foster new anti-chemotactic approaches to block cancer cell metastasis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Washington University (WUSTL)	Ganju, RK (corresponding author), Harvard Inst Med, BIDMC, 4 Blackfan Circle,Room 343, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu	Fernandis, Aaron/C-3718-2012					Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Chen JH, 2001, J NEUROSCI, V21, P1548, DOI 10.1523/JNEUROSCI.21-05-01548.2001; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Dallol A, 2002, CANCER RES, V62, P5874; Fernandis A. Z., 2001, SCI STKE, V2001, ppe1; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Ghose A, 2002, BIOESSAYS, V24, P401, DOI 10.1002/bies.10080; Gold MR, 2000, IMMUNOL REV, V176, P47; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Manes S, 1999, MOL CELL BIOL, V19, P3125; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Scotton CJ, 2002, CANCER RES, V62, P5930; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Taichman RS, 2002, CANCER RES, V62, P1832; TAYLOR P, 1990, P1; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Verbeek BS, 1999, EXP CELL RES, V248, P531, DOI 10.1006/excr.1999.4416; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	66	96	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9115	9124		10.1074/jbc.M308083200	http://dx.doi.org/10.1074/jbc.M308083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14645233	hybrid			2022-12-25	WOS:000189265900073
J	Jiang, H; Ross, AE; Desiderio, S				Jiang, H; Ross, AE; Desiderio, S			Cell cycle-dependent accumulation in vivo of transposition-competent complexes between recombination signal ends and full-length RAG proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; TERMINAL REGION; B-CELL; DNA; REARRANGEMENT; DEGRADATION; THYMOCYTES; RESOLUTION; DELETION; PORTION	V(D) J recombination is initiated by a specialized transposase consisting of RAG-1 and RAG-2. Because full-length RAG proteins are insoluble under physiologic conditions, most previous analyses of RAG activity in vitro have used truncated core RAG-1 and RAG-2 fragments. These studies identified an intermediate in V(D) J recombination, the signal end complex (SEC), in which core RAG proteins remain associated with recombination signal sequences at the cleaved signal ends. From transfected cells expressing affinity-tagged RAG proteins, we have isolated in vivo assembled SECs containing full-length RAG proteins and cleaved recombination substrates. SEC formation in vivo did not require the repair proteins DNA-dependent protein kinase, Ku80, or XRCC4. In the presence of full-length RAG-2, SEC formation in vivo was cell cycle-regulated and restricted to the G(0)/G(1) phases. In contrast, complexes accumulated throughout cell cycle in cells expressing a RAG-2 CDK2 phosphorylation site mutant. Both core and full-length SECs supported transposition in vitro with similar efficiencies. Intracellular SECs, which are likely to persist in the absence of coding ends, represent potential donors whose transposition is not suppressed by the non-core regions of the RAG proteins.	Johns Hopkins Univ, Sch Med, Inst Cell Engn, Program Immunol,Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Desiderio, S (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Program Immunol,Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	sdesider@jhmi.edu			NCI NIH HHS [CA16519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; Clatworthy AE, 2003, MOL CELL, V12, P489, DOI 10.1016/S1097-2765(03)00305-8; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; Desiderio S, 1996, CURR TOP MICROBIOL, V217, P45; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Lee GS, 2002, MOL CELL BIOL, V22, P2068, DOI 10.1128/MCB.22.7.2068-2077.2002; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; Li WH, 2001, MOL CELL BIOL, V21, P3935, DOI 10.1128/MCB.21.12.3935-3946.2001; Li Z, 1996, IMMUNITY, V5, P575, DOI 10.1016/S1074-7613(00)80272-1; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Livak F, 1996, MOL CELL BIOL, V16, P609; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, MOL CELL BIOL, V17, P4544, DOI 10.1128/MCB.17.8.4544; Melek M, 2000, CELL, V101, P625, DOI 10.1016/S0092-8674(00)80874-0; Messier TL, 2003, EMBO J, V22, P1381, DOI 10.1093/emboj/cdg137; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Ross AE, 2003, MOL CELL BIOL, V23, P5308, DOI 10.1128/MCB.23.15.5308-5319.2003; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Steen SB, 1999, MOL CELL BIOL, V19, P3010; Tsai CL, 2003, NUCLEIC ACIDS RES, V31, P6180, DOI 10.1093/nar/gkg819; Tsai CL, 2003, EMBO J, V22, P1922, DOI 10.1093/emboj/cdg185; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8478	8486		10.1074/jbc.M311219200	http://dx.doi.org/10.1074/jbc.M311219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660558	hybrid			2022-12-25	WOS:000189103300131
J	Reader, JS; Metzgar, D; Schimmel, P; de Crecy-Lagard, V				Reader, JS; Metzgar, D; Schimmel, P; de Crecy-Lagard, V			Identification of four genes necessary for biosynthesis of the modified nucleoside queuosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE I; TRANSFER-RNA; QUEUINE; TRANSFORMATION; REPLACEMENT; DROSOPHILA; INSERTION; PROCEEDS; POSITION; PATHWAY	Queuosine (Q) is a hypermodified 7-deazaguanosine nucleoside located in the anticodon wobble position of four amino acid-specific tRNAs. In bacteria, Q is produced de novo from GTP via the 7-deazaguanosine precursor preQ, (7-aminoethyl 7-deazaguanine) by an uncharacterized pathway. PreQ(1) is subsequently transferred to its specific tRNA by a tRNA-guanine transglycosylase (TGT) and then further modified in situ to produce Q. Here we use comparative genomics to implicate four gene families (best exemplified by the B. subtilis operon ykvJKLM) as candidates in the preQ(1) biosynthetic pathway. Deletions were constructed in genes for each of the four orthologs in Acinetobacter. High pressure liquid chromatography analysis showed the Q nucleoside was absent from the tRNAs of each of four deletion strains. Electrospray ionization mass spectrometry confirmed the absence of Q in each mutant strain. Finally, introduction of the Bacillus subtilis ykvJKLM operon in trans complemented the Q deficiency of the two deletion mutants that were tested. Thus, the products of these four genes (named queC, -D, -E, and -F) are essential for the Q biosynthetic pathway.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-379,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu; vcrecy@scripps.edu	de Crecy-Lagard, Valerie/AAN-8995-2020		NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auerbach G, 1997, BIOL CHEM, V378, P185; Bishop AC, 2002, J BIOL CHEM, V277, P25090, DOI 10.1074/jbc.M203208200; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; Bracher A, 1999, J BIOL CHEM, V274, P16727, DOI 10.1074/jbc.274.24.16727; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Garcia G.R., 1998, MODIFICATION EDITING; Graupner M, 2002, J BACTERIOL, V184, P1952, DOI 10.1128/JB.184.7.1952-1957.2002; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; JUNI E, 1969, J BACTERIOL, V98, P281, DOI 10.1128/JB.98.1.281-288.1969; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KERSTEN H, 1988, Biofactors, V1, P27; KERSTEN H, 1990, CHROMATOGRAPHY MODIF, P69; Kok RG, 1997, J BACTERIOL, V179, P4270, DOI 10.1128/jb.179.13.4270-4276.1997; KUCHINO Y, 1976, NUCLEIC ACIDS RES, V3, P393, DOI 10.1093/nar/3.2.393; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Marks T, 1997, BIOCHEM BIOPH RES CO, V230, P233, DOI 10.1006/bbrc.1996.5768; Morris RC, 2001, MOL GENET METAB, V74, P147, DOI 10.1006/mgme.2001.3216; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; OWENBY RK, 1979, MECH AGEING DEV, V11, P91, DOI 10.1016/0047-6374(79)90027-7; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; WHITE BN, 1973, J MOL BIOL, V74, P635, DOI 10.1016/0022-2836(73)90054-5; Woo HJ, 2002, FEBS LETT, V523, P234, DOI 10.1016/S0014-5793(02)02997-6; YOKOYAMA S, 1979, NATURE, V282, P107, DOI 10.1038/282107a0; Young David M, 2002, Methods Mol Biol, V182, P103	35	107	119	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6280	6285		10.1074/jbc.M310858200	http://dx.doi.org/10.1074/jbc.M310858200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660578	hybrid			2022-12-25	WOS:000188969200012
J	Zhang, LY; Lee, JK; John, SA; Uozumi, N; Kodama, I				Zhang, LY; Lee, JK; John, SA; Uozumi, N; Kodama, I			Mechanosensitivity of GIRK channels is mediated by protein kinase C-dependent channel-phosphatidylinositol 4,5-bisphosphate interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; POTASSIUM CHANNELS; XENOPUS-OOCYTES; CA2+ MOBILIZATION; BETA-GAMMA; HEART; PIP2; ACTIVATION; MECHANISM; MEMBRANE	Gprotein-activated inwardly rectifying K+ channel (GIRK or Kir3) currents are inhibited by mechanical stretch of the cell membrane, but the underlying mechanisms are not understood. In Xenopus oocytes heterologously expressing GIRK channels, membrane stretch induced by 50% reduction of osmotic pressure caused a prompt reduction of GIRK1/4, GIRK1, and GIRK4 currents by 16.6-42.6%. Comparable GIRK current reduction was produced by protein kinase C (PKC) activation (phorbol 12-myristate 13-acetate). The mechanosensitivity of the GIRK4 current was abolished by pretreatment with PKC inhibitors (staurosporine or calphostin C). Neither hypo-osmotic challenge nor PKC activation affected IRK1 currents. GIRK4 chimera (GIRK4-IRK1(Lys(207)-Leu(245))) and single point mutant (GIRK4(I229L)), in which the phosphatidylinositol 4,5-bisphosphate (PIP2) binding domain or residue was replaced by the corresponding region of IRK1 to strengthen the channel-PIP2 interaction, showed no mechanosensitivity and minimal PKC sensitivity. IRK1 gained mechanosensitivity and PKC sensitivity by reverse double point mutation of the PIP2 binding domain (L222I/R213Q). Overexpression of Gbetagamma, which is known to strengthen the channel-PIP2 interaction, attenuated the mechanosensitivity of GIRK4 channels. In oocytes expressing a pleckstrin homology domain of PLC-delta tagged with green fluorescent protein, hypo-osmotic challenge or PKC activation caused a translocation of the fluorescence signal from the cell membrane to the cytosol, reflecting PIP2 hydrolysis. The translocation was prevented by pretreatment with PKC inhibitors. Involvement of PKC activation in the mechanosensitivity of muscarinic K+ channels was confirmed in native rabbit atrial myocytes. These results suggest that the mechanosensitivity of GIRK channels is mediated primarily by channel-PIP2 interaction, with PKC playing an important role in modulating the interaction probably through PIP2 hydrolysis.	Nagoya Univ, Environm Med Res Inst, Dept Circulat, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA	Nagoya University; Nagoya University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lee, JK (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Circulat, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	jlee@riem.nagoya-u.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019	John, Scott/0000-0002-1232-9140; Uozumi, Nobuyuki/0000-0003-4268-1126				Arai A, 1996, AM J PHYSIOL-HEART C, V270, pH1726, DOI 10.1152/ajpheart.1996.270.5.H1726; Bolter CP, 1999, AM J PHYSIOL-REG I, V276, pR1112, DOI 10.1152/ajpregu.1999.276.4.R1112; BOON AM, 1985, BIOCHEM BIOPH RES CO, V129, P431, DOI 10.1016/0006-291X(85)90169-X; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Ghuran AV, 2001, BRIT MED BULL, V59, P193, DOI 10.1093/bmb/59.1.193; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ivanina T, 2000, FEBS LETT, V466, P327, DOI 10.1016/S0014-5793(99)01738-X; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LAB MJ, 1982, CIRC RES, V50, P757, DOI 10.1161/01.RES.50.6.757; Lab MJ, 1996, CARDIOVASC RES, V32, P3, DOI 10.1016/S0008-6363(96)00088-0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Lu ZB, 2001, CIRCULATION, V104, P951, DOI 10.1161/hc3401.093151; Mason HS, 2002, MOL PHARMACOL, V61, P285, DOI 10.1124/mol.61.2.285; Nasuhoglu C, 2002, AM J PHYSIOL-CELL PH, V283, pC223, DOI 10.1152/ajpcell.00486.2001; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1999, ADV SEC MESS PHOSPH, V33, P179; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; VanDenBerg MP, 1997, HEART, V77, P309, DOI 10.1136/hrt.77.4.309; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhou W, 2001, P NATL ACAD SCI USA, V98, P6482, DOI 10.1073/pnas.111447798	37	29	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7037	7047		10.1074/jbc.M307323200	http://dx.doi.org/10.1074/jbc.M307323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660621	hybrid			2022-12-25	WOS:000188969200101
J	Gupta, S; Natarajan, R; Payne, SG; Studer, EJ; Spiegel, S; Dent, P; Hylemon, PB				Gupta, S; Natarajan, R; Payne, SG; Studer, EJ; Spiegel, S; Dent, P; Hylemon, PB			Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes - Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-REGULATED KINASE; T-CELL-RECEPTOR; BILE-ACIDS; FEEDBACK-REGULATION; INDUCED APOPTOSIS; PROTEIN-KINASES; RAT-HEPATOCYTES; MEMBRANE RAFTS; IN-VIVO	We have shown previously that bile acids can activate the JNK pathway and down-regulate cholesterol 7alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in the neutral pathway of bile acid biosynthesis. In this study, the mechanism(s) by which deoxycholic acid (DCA) activates the JNK pathway were examined. FAS receptor (FAS-R) and acidic sphingomyelinase (ASM)-deficient hepatocytes were resistant to DCA-induced activation of the JNK pathway. Activation of the JNK pathway (2-3-fold) in response to tumor necrosis factor-alpha was similar in both wild-type and FAS-R-/- hepatocytes. In wildtype and FAS-R-/- hepatocytes, ceramide elevation was detected as early as 2 min and peaked at 10 min after DCA treatment. In contrast, ASM(-/-) hepatocytes were defective in DCA-induced ceramide generation. Treatment with DCA resulted in movement of FAS-R to the cell surface, which was blocked upon treatment with brefeldin A. However, brefeldin A failed to block DCA-mediated JNK activation in wild-type hepatocytes. DCA-induced JNK activation was independent of either the epidermal growth factor receptor activation or free radical generation. Addition of ASM to rat hepatocytes activated JNK and down-regulated CYP7A1 mRNA levels. In conclusion, these results show that DCA activates JNK and represses CYP7A1 mRNA levels in primary hepatocytes via an ASM/FAS-R-dependent mechanism that is independent of either the epidermal growth factor receptor or free radical generation.	Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Hylemon, PB (corresponding author), Virginia Commonwealth Univ, Dept Microbiol & Immunol, POB 980678, Richmond, VA 23298 USA.	hylemon@hsc.vcu.edu		Natarajan, Ramesh/0000-0002-3431-9971	NIDDK NIH HHS [F32 DK59770-01, P01-DK38030, R01-DK52825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030, R01DK052825, F32DK059770] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN RN, 1976, GUT, V17, P413, DOI 10.1136/gut.17.6.413; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brenner D, 1998, J GASTROEN HEPATOL, V13, pS93; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CRAWFORD JM, 1994, LAB INVEST, V71, P42; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Guicciardi ME, 2002, DIGEST LIVER DIS, V34, P387, DOI 10.1016/S1590-8658(02)80033-0; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; Gulbins Erich, 2002, Subcell Biochem, V36, P229; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Higuchi H, 2003, AM J PHYSIOL-GASTR L, V284, pG734, DOI 10.1152/ajpgi.00491.2002; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Junge S, 1999, CELL SIGNAL, V11, P301, DOI 10.1016/S0898-6568(98)00068-0; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KITAMURA T, 1990, HEPATOLOGY, V12, P1358, DOI 10.1002/hep.1840120617; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Liedtke C, 2002, HEPATOLOGY, V36, P315, DOI 10.1053/jhep.2002.34615; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P110; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rao YP, 2002, HEPATOLOGY, V35, P307, DOI 10.1053/jhep.2002.31104; RATCLIFFE MJH, 1992, J IMMUNOL, V148, P1643; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schliess F, 1997, GASTROENTEROLOGY, V113, P1306, DOI 10.1053/gast.1997.v113.pm9322526; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; SUCHY FJ, 1983, AM J PHYSIOL, V245, pG681, DOI 10.1152/ajpgi.1983.245.5.G681; Takikawa Y, 2001, GASTROENTEROLOGY, V120, P1810, DOI 10.1053/gast.2001.24835; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Vlahcevic ZR, 1996, HEPATOLOGY TXB LIVER, V1, P376; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	73	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5821	5828		10.1074/jbc.M310979200	http://dx.doi.org/10.1074/jbc.M310979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660582	hybrid			2022-12-25	WOS:000188776500096
J	Hearn, AS; Fan, L; Lepock, JR; Luba, JP; Greenleaf, WB; Cabelli, DE; Tainer, JA; Nick, HS; Silverman, DN				Hearn, AS; Fan, L; Lepock, JR; Luba, JP; Greenleaf, WB; Cabelli, DE; Tainer, JA; Nick, HS; Silverman, DN			Amino acid substitution at the dimeric interface of human manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; HYDROGEN-BOND; RADIOLYSIS; PROGRAM; SYSTEM	The side chains of His(30) and Tyr(166) from adjacent subunits in the homotetramer human manganese superoxide dismutase (Mn-SOD) form a hydrogen bond across the dimer interface and participate in a hydrogen-bonded network that extends to the active site. Compared with wild-type Mn-SOD, the site-specific mutants H30N, Y166F, and the corresponding double mutant showed 10-fold decreases in steady-state constants for catalysis measured by pulse radiolysis. The observation of no additional effect upon the second mutation is an example of cooperatively interacting residues. A similar effect was observed in the thermal stability of these enzymes; the double mutant did not reduce the major unfolding transition to an extent greater than either single mutant. The crystal structures of these site-specific mutants each have unique conformational changes, but each has lost the hydrogen bond across the dimer interface, which results in a decrease in catalysis. These same mutations caused an enhancement of the dissociation of the product-inhibited complex. That is, His(30) and Tyr(166) in wild-type Mn-SOD act to prolong the lifetime of the inhibited complex. This would have a selective advantage in blocking a cellular overproduction of toxic H2O2.	Univ Florida, Ctr Hlth, Dept Pharmacol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Scripps Research Institute; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Toronto	Silverman, DN (corresponding author), Univ Florida, Ctr Hlth, Dept Pharmacol, Box 100267, Gainesville, FL 32610 USA.	silvermn@college.med.ufl.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054903, P01GM048495] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48495, GM54903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; Cabelli DE, 2000, BIOMIMETIC OXIDATIONS CATALYZED BY TRANSITION METAL COMPLEXES, P461, DOI 10.1142/9781848160699_0010; Edwards RA, 2001, BIOCHEMISTRY-US, V40, P4622, DOI 10.1021/bi002403h; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; Guan Y, 1998, BIOCHEMISTRY-US, V37, P4722, DOI 10.1021/bi972394l; Hearn AS, 2003, BIOCHEMISTRY-US, V42, P2781, DOI 10.1021/bi0266481; Hearn AS, 2001, BIOCHEMISTRY-US, V40, P12051, DOI 10.1021/bi011047f; Hsieh YS, 1998, BIOCHEMISTRY-US, V37, P4731, DOI 10.1021/bi972395d; Lee JW, 2002, METHOD ENZYMOL, V349, P90, DOI 10.1016/S0076-6879(02)49324-X; Leveque VJP, 2001, BIOCHEMISTRY-US, V40, P10586, DOI 10.1021/bi010792p; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MCCLUNE GJ, 1978, BIOPHYS J, V24, P65, DOI 10.1016/S0006-3495(78)85340-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Miller A.-F., 1997, COMMENTS MOL CELL BI, V9, P1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; Ramilo CA, 1999, J BIOL CHEM, V274, P27711, DOI 10.1074/jbc.274.39.27711; SCHWARZ HA, 1981, J CHEM EDUC, V58, P101, DOI 10.1021/ed058p101; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Silverman DN, 2002, METHOD ENZYMOL, V349, P61, DOI 10.1016/S0076-6879(02)49321-4; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vance CK, 2001, BIOCHEMISTRY-US, V40, P13079, DOI 10.1021/bi0113317	29	27	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5861	5866		10.1074/jbc.M311310200	http://dx.doi.org/10.1074/jbc.M311310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638684	hybrid			2022-12-25	WOS:000188776500101
J	Kramps, C; Strieder, V; Sapetschnig, A; Suske, G; Lutz, W				Kramps, C; Strieder, V; Sapetschnig, A; Suske, G; Lutz, W			E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-MYC; TRANSCRIPTIONAL ACTIVATION; HISTONE DEACETYLASE; C-MYC; REPRESS TRANSCRIPTION; CYTOSINE METHYLATION; ORDERED RECRUITMENT; MYC/MAX/MAD NETWORK; IN-VIVO; EXPRESSION	Amplification of the MYCN gene, resulting in overexpression of MYCN, distinguishes a subset of neuroblastomas with poor prognosis. We recently identified MYCN as a target gene of the E2F transcription factors. Here we show that Sp1 and Sp3 cooperate with E2F-1 to activate the MYCN promoter. However, in a neuroblastoma cell line that does not express MYCN, overexpression of E2F-1 was not sufficient to activate the MYCN promoter even in the presence of trichostatin A and 5-aza-cytidine. This was because of a failure of E2F-1 to bind to the MYCN promoter in these cells, although access of E2F-1 to the inactive MYCN promoter was not blocked by a nucleosome. Differences in nucleosomal organization of the MYCN promoter in different cell lines did not correlate with gene activation per se but with the switch from basal to activated transcription. Binding of E2F and Sp1/Sp3 to the MYCN promoter in vivo correlated with acetylation of histones H3 and H4 and recruitment of RNA polymerase II and the protein acetyltransferase Tip60 but not with nucleosome remodeling. Our results define distinct chromatin states of the MYCN promoter, indicate that factors in addition to E2F and Sp1/Sp3 are required to activate MYCN in neuroblastomas, and provide evidence for a novel mechanism of controlling access of E2F to selected target genes.	Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany		Lutz, W (corresponding author), Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany.	lutz@imt.uni-marburg.de		Suske, Guntram/0000-0002-4807-0513				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Blau J, 1996, MOL CELL BIOL, V16, P2044; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lutz W, 1997, ONCOGENE, V15, P303, DOI 10.1038/sj.onc.1201195; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; ROSS RA, 1983, J NATL CANCER I, V71, P741; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SADEE W, 1987, CANCER RES, V47, P5207; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; Suske G, 2000, Methods Mol Biol, V130, P175; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Takahashi Y, 2000, GENE DEV, V14, P804; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	56	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5110	5117		10.1074/jbc.M304758200	http://dx.doi.org/10.1074/jbc.M304758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645238	hybrid			2022-12-25	WOS:000188776500010
J	Lucca, C; Vanoli, F; Cotta-Ramusino, C; Pellicioli, A; Liberi, G; Haber, J; Foiani, M				Lucca, C; Vanoli, F; Cotta-Ramusino, C; Pellicioli, A; Liberi, G; Haber, J; Foiani, M			Checkpoint-mediated control of replisome-fork association and signalling in response to replication pausing	ONCOGENE			English	Article						checkpoint; genome instability; chromosome replication; ATM pathway; Rad53	DOUBLE-STRAND BREAKS; DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-A; HOMOLOG MEC1; G2/M ARREST; DAMAGE; PROGRESSION; PHOSPHORYLATION	The replication checkpoint controls the integrity of replicating chromosomes by stabilizing stalled forks, thus preventing the accumulation of abnormal replication and recombination intermediates that contribute to genome instability. Checkpoint-defective cells are susceptible to rearrangements at chromosome fragile sites when replication pauses, and certain human cancer prone diseases suffer checkpoint abnormalities. It is unclear as to how the checkpoint stabilizes stalled forks and how cells sense replication blocks. We have analysed the checkpoint contribution in controlling replisome-fork association when replication pauses. We show that in yeast wild-type cells, stalled forks exhibit stable replisome complexes and the checkpoint sensors Ddc1 and Ddc2, thus activating Rad53 checkpoint kinase. Ddc1/Ddc2 recruitment on stalled forks and Rad53 activation are influenced by the single-strand-binding protein replication factor A (RFA). rad53 forks exhibit a defective association with DNA polymerases alpha, epsilon and delta. Further, in rad53 mutants, stalled forks progressively generate abnormal structures that turn into checkpoint signals by accumulating RFA, Ddc1 and Ddc2. We suggest that, following replication blocks, checkpoint activation mediated by RFA-ssDNA. laments stabilizes stalled forks by controlling replisome - fork association, thus preventing unscheduled recruitment of recombination enzymes that could otherwise cause the pathological processing of the forks.	Ist FIRC Oncol Mol, I-20141 Milan, Italy; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	IFOM - FIRC Institute of Molecular Oncology; University of Milan; Brandeis University	Foiani, M (corresponding author), Ist FIRC Oncol Mol, Via Adamello 16, I-20141 Milan, Italy.	foiani@ifom-firc.it	LIBERI, GIORDANO/AAY-7273-2020; Foiani, Marco/M-8234-2014; Pellicioli, Achille/B-8765-2017	LIBERI, GIORDANO/0000-0003-3160-2242; Foiani, Marco/0000-0003-4795-834X; Pellicioli, Achille/0000-0002-1528-9009; Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020056, R01GM061766, R01GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20056, GM61766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cimprich KA, 2003, CURR BIOL, V13, pR231, DOI 10.1016/S0960-9822(03)00158-1; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kornberg A., 1992, DNA REPLICATION; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee SE, 2001, CURR BIOL, V11, P1053, DOI 10.1016/S0960-9822(01)00296-2; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marini F, 1997, EMBO J, V16, P639, DOI 10.1093/emboj/16.3.639; Melo JA, 2001, GENE DEV, V15, P2809; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Paciotti V, 2000, GENE DEV, V14, P2046; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Umezu K, 1998, GENETICS, V148, P989; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	128	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1206	1213		10.1038/sj.onc.1207199	http://dx.doi.org/10.1038/sj.onc.1207199			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647447				2022-12-25	WOS:000188892200004
J	Zheng, YH; Shi, Y; Tian, CH; Jiang, CS; Jin, HJ; Chen, JJ; Almasan, A; Tang, H; Chen, Q				Zheng, YH; Shi, Y; Tian, CH; Jiang, CS; Jin, HJ; Chen, JJ; Almasan, A; Tang, H; Chen, Q			Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide	ONCOGENE			English	Article						apoptosis; arsenic trioxide; Bcl-2 proteins; cytochrome c; VDAC	ACUTE PROMYELOCYTIC LEUKEMIA; BCL-2 FAMILY; CASPASE ACTIVATION; CELL APOPTOSIS; BAX; MODULATION; MEMBRANE; PROTEIN; MEGACHANNEL; YEAST	The precise molecular mechanism underlying arsenic trioxide (As2O3)-induced apoptosis is a subject of extensive study. Here, we show that clinically relevant doses of As2O3 can induce typical apoptosis in IM-9, a multiple myeloma cell line, in a Bcl-2 inhibitable manner. We confirmed that As2O3 directly induced cytochrome c (cyto c) release from isolated mouse liver mitochondria via the mitochondrial permeability transition pore, and we further identified the voltage-dependent anion channel (VDAC) as a biological target of As2O3 responsible for eliciting cyto c release in apoptosis. First, pretreatment of the isolated mitochondria with an anti-VDAC antibody specifically prevented As2O3-induced cyto c release. Second, in proteoliposome experiments, VDAC by itself was sufficient to mediate As2O3-induced cyto c release, which could be specifically inhibited by Bcl-X-L. Third, As2O3 induced mitochondria membrane potential (DeltaPsim) reduction and cyto c release only in the VDAC-expressing, but not in the VDAC-deficient yeast strain. Finally, we found that As2O3 induced the increased expression and homodimerization of VDAC in IM-9 cells, but not in Bcl-2 overexpressing cells, suggesting that VDAC homodimerization could potentially determine its gating capacity to cyto c, and Bcl-2 blockage of VDAC homodimerization represents a novel mechanism for its inhibition of apoptosis.	Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, State Key lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing 100080, Peoples R China; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS; Cleveland Clinic Foundation	Chen, Q (corresponding author), Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, State Key lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China.	chenq@panda.ioz.ac.cn	Almasan, Alex/C-2715-2008; Tian, Changhai/AAD-4856-2019; yang, zheng/HGC-7753-2022	Almasan, Alex/0000-0002-8916-6650; Chen, Quan/0000-0001-7539-8728	NCI NIH HHS [R01 CA081504, R01 CA081504-05, CA82858, CA81504, R01 CA082858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; BERNARDI P, 1984, BIOCHIM BIOPHYS ACTA, V766, P277, DOI 10.1016/0005-2728(84)90242-1; Chen GQ, 1996, BLOOD, V88, P1052; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KRAUSE J, 1986, BIOCHIM BIOPHYS ACTA, V860, P690, DOI 10.1016/0005-2736(86)90568-7; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Matsuyama S, 1999, CURR OPIN MICROBIOL, V2, P618, DOI 10.1016/S1369-5274(99)00031-4; Miller WH, 2002, CANCER RES, V62, P3893; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Rousselot P, 1999, CANCER RES, V59, P1041; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shi Y, 2003, BIOCHEM BIOPH RES CO, V303, P475, DOI 10.1016/S0006-291X(03)00359-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Takagi-Morishita Y, 2003, BIOL REPROD, V68, P1178, DOI 10.1095/biolreprod.102.007997; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang XD, 2001, GENE DEV, V15, P2922; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Xia T, 2002, CHINESE SCI BULL, V47, P553, DOI 10.1360/02tb9127; Xia T, 2002, FEBS LETT, V510, P62, DOI 10.1016/S0014-5793(01)03228-8; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762	69	150	163	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1239	1247		10.1038/sj.onc.1207205	http://dx.doi.org/10.1038/sj.onc.1207205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647451	Green Accepted			2022-12-25	WOS:000188892200008
J	Chidambaram, S; Mullers, N; Wiederhold, K; Haucke, V; von Mollard, GF				Chidambaram, S; Mullers, N; Wiederhold, K; Haucke, V; von Mollard, GF			Specific interaction between SNARES and epsin N-terminal homology (ENTH) domains of epsin-related proteins in trans-Golgi network to endosome transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; SACCHAROMYCES-CEREVISIAE; MEMBRANE-TRANSPORT; ENTH/ANTH DOMAINS; SYNAPTIC VESICLES; LYSOSOME FUSION; SYNTAXIN 7; T-SNARE; YEAST; COMPLEX	SNARE proteins on transport vesicles and target membranes have important roles in vesicle targeting and fusion. Therefore, localization and activity of SNARES have to be tightly controlled. Regulatory proteins bind to N-terminal domains of some SNARES. vti1b is a mammalian SNARE that functions in late endosomal fusion. To investigate the role of the N terminus of vti1b we performed a yeast two-hybrid screen. The N terminus of vti1b interacted specifically with the epsin N-terminal homology (ENTH) domain of enthoprotin/GLINT/epsinR. The interaction was confirmed using in vitro binding assays. This complex formation between a SNARE and an ENTH domain was conserved between mammals and yeast. Yeast Vti1p interacted with the ENTH domain of Ent3p. ENTH proteins are involved in the formation of clathrin-coated vesicles. Both epsinR and Ent3p bind adaptor proteins at the traps-Golgi network. Vti1p is required for multiple transport steps in the endosomal system. Genetic interactions between VTI1 and ENT3 were investigated. Synthetic defects suggested that Vti1p and Ent3p cooperate in transport from the traps-Golgi network to the prevacuolar endosome. Our experiments identified the first cytoplasmic protein binding to specific ENTH domains. These results point toward a novel function of the ENTH domain and a connection between proteins that function either in vesicle formation or in vesicle fusion.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	von Mollard, GF (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	gfische1@gwdg.de	von Mollard, Gabriele Fischer/O-9778-2019; von Mollard, Gabriele Fischer/A-3935-2012	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Chidambaram, Subbulakshmi/0000-0002-3180-4429; Haucke, Volker/0000-0003-3119-6993				Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; Antonin W, 2002, J BIOL CHEM, V277, P36449, DOI 10.1074/jbc.M204369200; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Betz A, 1997, J BIOL CHEM, V272, P2520; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brickner JH, 2001, J CELL BIOL, V155, P969, DOI 10.1083/jcb.200104093; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; De Matteis MA, 2002, CURR OPIN CELL BIOL, V14, P434, DOI 10.1016/S0955-0674(02)00357-5; Duncan MC, 2003, TRENDS CELL BIOL, V13, P211, DOI 10.1016/S0962-8924(03)00076-X; Duncan MC, 2003, NAT CELL BIOL, V5, P77, DOI 10.1038/ncb901; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Hinners I, 2003, J CELL SCI, V116, P763, DOI 10.1242/jcs.00270; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Hussain NK, 2003, J BIOL CHEM, V278, P28823, DOI 10.1074/jbc.M300995200; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kreykenbohm V, 2002, EUR J CELL BIOL, V81, P273, DOI 10.1078/0171-9335-00247; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Peden AA, 2001, J BIOL CHEM, V276, P49183, DOI 10.1074/jbc.M106646200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; von Mollard GF, 1998, J BIOL CHEM, V273, P2624, DOI 10.1074/jbc.273.5.2624; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	47	71	71	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4175	4179		10.1074/jbc.M308667200	http://dx.doi.org/10.1074/jbc.M308667200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14630930	hybrid			2022-12-25	WOS:000188554300033
J	Coupier, I; Baldeyron, U; Rousseau, A; Mosseri, V; Pages-Berhouet, S; Caux-Moncoutier, V; Papadopoulo, D; Stoppa-Lyonnet, D				Coupier, I; Baldeyron, U; Rousseau, A; Mosseri, V; Pages-Berhouet, S; Caux-Moncoutier, V; Papadopoulo, D; Stoppa-Lyonnet, D			Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations	ONCOGENE			English	Article						BRCA1 heterozygous carriers; missense mutation; DNA end-joining; double-strand break repair	OVARIAN-CANCER FAMILIES; DAMAGE RESPONSE; GENE; SUSCEPTIBILITY; REARRANGEMENTS; ASSOCIATION; RAD51; RISK	Germ-line mutations of the BRCA1 and BRCA2 genes, when they lead to a truncated protein, confer a high risk of breast and ovarian cancer. However, the role of BRCA1 missense mutations in cancer predisposition is unclear. Functional assays may be very helpful to more clearly define the biological effect of these mutations, and could therefore be useful in clinical practice. A recent study using a Host Cell End-Joining assay showed that a truncating mutation results in impaired fidelity of DSB repair by DNA end-joining. In the present study, we examined the fidelity of DSB repair in four lymphoblastoid cell lines with BRCA1 missense mutations. The fidelity of DNA end-joining was impaired in the four cell lines studied compared to the normal control cell line. The fidelity of end-joining was similar to that of a truncated mutation control cell line for one cell line and slightly higher for the other cell lines.	Inst Curie, Serv Genet Oncol, Med Sect, F-75248 Paris 05, France; Inst Curie, INSERM, U509, Sect Rech, Paris, France; Inst Curie, CNRS, UMR 218, Sect Rech, F-75231 Paris, France; Inst Curie, Serv Biostat, Med Sect, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Stoppa-Lyonnet, D (corresponding author), Inst Curie, Serv Genet Oncol, Med Sect, 26 Rue Ulm, F-75248 Paris 05, France.	dominique.stoppa-lyonnet@curie.net	Baldeyron, Céline/F-6990-2019	Baldeyron, Céline/0000-0003-2311-1523				Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Casilli F, 2002, HUM MUTAT, V20, P218, DOI 10.1002/humu.10108; Chen JJ, 1999, CANCER RES, V59, p1752S; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Gad S, 2002, ONCOGENE, V21, P6841, DOI 10.1038/sj.onc.1205685; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Rothfuss A, 2000, CANCER RES, V60, P390; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	26	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					914	919		10.1038/sj.onc.1207191	http://dx.doi.org/10.1038/sj.onc.1207191			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647443				2022-12-25	WOS:000188486600006
J	Hobbs, SS; Cameron, EM; Hammer, RP; Le, ATD; Gallo, RM; Blommell, EN; Coffing, SL; Chang, H; Riese, DJ				Hobbs, SS; Cameron, EM; Hammer, RP; Le, ATD; Gallo, RM; Blommell, EN; Coffing, SL; Chang, H; Riese, DJ			Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase	ONCOGENE			English	Article						heregulins; neuregulins; ErbB4; HER4	EPIDERMAL-GROWTH-FACTOR; CONSTITUTIVELY ACTIVE ERBB4; FACTOR-ALPHA; DIFFERENTIATION FACTOR; EXTRACELLULAR DOMAIN; CELLULAR-RESPONSE; CRYSTAL-STRUCTURE; HIGH-AFFINITY; EGF RECEPTOR; FAMILY	The neuregulins (NRGs) are members of the epidermal growth factor (EGF) family of peptide growth factors. These hormones are agonists for the ErbB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ErbB1), ErbB2/ Neu/HER2, ErbB3/HER3, and ErbB4/HER4. We recently observed that the EGF family hormone NRG2beta is a potent agonist for ErbB4. In contrast, NRG2alpha, a splicing isoform of the same gene that encodes NRG2beta, is a poor ErbB4 agonist. We hypothesized that carboxyl-terminal residues of NRG2beta are critical for stimulation of ErbB4 tyrosine phosphorylation and coupling to downstream signaling events. Here, we demonstrate that the substitution of a lysine residue for Phe45 in NRG2beta results in reduced ligand potency. We also demonstrate that substitution of a phenylalanine for Lys45 in NRG2alpha: results in increased ligand potency. Finally, analyses of the gain-of-function NRG2alpha Chg5 mutant demonstrate that Gln43, Met47, Asn49, and Phe50 regulate ligand efficacy. Thus, these data indicate that carboxyl-terminal residues of NRG2beta are critical for activation of ErbB4 signaling. Moreover, these NRG2alpha: and NRG2beta mutants reveal new insights into models for ligand-induced ErbB family receptor tyrosine phosphorylation and coupling to downstream signaling events.	Purdue Univ, Dept Med Chem & Mol Pharmacol, Sch Pharm, W Lafayette, IN 47907 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Louisiana State University System; Louisiana State University; Bristol-Myers Squibb	Riese, DJ (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Sch Pharm, 201 S Univ St,HANS 114, W Lafayette, IN 47907 USA.	driese@purdue.edu	Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [F33CA085049, R21CA089274, R21CA080770] Funding Source: Medline; NIGMS NIH HHS [T32GM008737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F33CA085049, R21CA089274, R21CA080770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Halgren TA, 1999, J COMPUT CHEM, V20, P720, DOI 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P11928; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Miura K, 2002, BIOCHEM BIOPH RES CO, V294, P1040, DOI 10.1016/S0006-291X(02)00585-5; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Sherrill JM, 1997, BIOCHEMISTRY-US, V36, P12890, DOI 10.1021/bi971418l; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	36	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					883	893		10.1038/sj.onc.1207250	http://dx.doi.org/10.1038/sj.onc.1207250			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661053				2022-12-25	WOS:000188486600003
J	Morale, MC; Serra, PA; Delogu, MR; Migheli, R; Rocchitta, G; Tirolo, C; Caniglia, S; Testa, N; L'Episcopo, F; Gennuso, F; Scoto, GM; Barden, N; Miele, E; Desole, MS; Marchetti, B				Morale, MC; Serra, PA; Delogu, MR; Migheli, R; Rocchitta, G; Tirolo, C; Caniglia, S; Testa, N; L'Episcopo, F; Gennuso, F; Scoto, GM; Barden, N; Miele, E; Desole, MS; Marchetti, B			Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide	FASEB JOURNAL			English	Article						Parkinson's disease (PD); inflammation; hypothalamic-pituitary-adrenocortical (UPA) axis; astroglial inducible nitric oxide synthase (iNOS); neuroprotection	CENTRAL-NERVOUS-SYSTEM; KAPPA-B-ALPHA; GENE-EXPRESSION; PARKINSONS-DISEASE; IMMUNE FUNCTION; AUTOIMMUNE ENCEPHALOMYELITIS; SELECTIVE-INHIBITION; INDUCED APOPTOSIS; LHRH NEURONS; MPTP MODEL	Glucocorticoids (GCs) exert via glucocorticoid receptors (GRs) potent anti-inflammatory and immunosuppressive effects. Emerging evidence indicates that an inflammatory process is involved in dopaminergic nigro-striatal neuronal loss in Parkinson's disease. We here report that the GR deficiency of transgenic (Tg) mice expressing GR antisense RNA from early embryonic life has a dramatic impact in "programming" the vulnerability of doparninergic neurons to 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). The GR deficiency of Tg mice exacerbates MPTP-induced toxicity to doparninergic neurons, as revealed by both severe loss of tyrosine hydroxylase positive nigral neurons and sharp decreases in striatal levels of dopamine and its metabolites. In addition, the late increase in dopamine oxidative metabolism and ascorbic acid oxidative status in GR-deficient mice was far greater than in wild-type (Wt) mice. Inducible nitric oxide synthase (iNOS) was sharply increased in activated astrocytes, macrophages/microglia of GR-deficient as compared with Wt mice. Moreover, GR-deficient microglia produced three- to fourfold higher nitrite levels than Wt mice; these increases preceded the loss of doparninergic function and were resistant to GR the inhibitory effect of GC, pointing to peroxynitrites as candidate neurotoxic effectors. The NOS inhibitor N-6-(1-iminoethyl)-L-lysine normalized vulnerability of Tg mice, thus establishing a novel link between genetic impairment of GR function and vulnerability to MPTP.	IRCCS, OASI Inst Res & Care Mental Retardat & Brain Aging, I-94018 Troina, EN, Italy; Univ Sassari, Fac Med, Dept Pharmacol, I-07100 Sassari, Italy; Univ Catania, Fac Pharm, Dept Pharmacol, Catania, Italy; Univ Laval, Dept Anat & Physiol, Quebec City, PQ, Canada; Univ Laval, CHUL, Res Ctr, Quebec City, PQ, Canada	IRCCS Oasi Maria SS; University of Sassari; University of Catania; Laval University; Laval University	Marchetti, B (corresponding author), IRCCS, OASI Inst Res & Care Mental Retardat & Brain Aging, Via Conte Ruggero 73, I-94018 Troina, EN, Italy.	bianca.marchetti@oasi.en.it	Rocchitta, Gaia/HHM-8002-2022; Caniglia, Salvatore/D-1001-2017; L'Episcopo, Francesca/K-4602-2016; Morale, Maria Concetta/D-5847-2017; Tirolo, Cataldo/C-9929-2017; Nunzio, Testa/D-8023-2017; Marchetti, Bianca Maria/K-4623-2016; Caniglia, Salvatore/D-1001-2017	Caniglia, Salvatore/0000-0002-9416-8458; L'Episcopo, Francesca/0000-0003-3292-9677; Morale, Maria Concetta/0000-0003-0624-7234; Tirolo, Cataldo/0000-0003-1747-8134; Nunzio, Testa/0000-0002-4024-2325; Marchetti, Bianca Maria/0000-0002-9287-8448; Gennuso, Florinda/0000-0001-5635-4973; MIGHELI, Rossana/0000-0001-5520-5511; SERRA, Pier Andrea/0000-0003-2401-5146; ROCCHITTA, Gaia Giovanna Maria/0000-0002-4319-4197; Caniglia, Salvatore/0000-0003-1238-6193	Italian Ministry of Health; Italian Ministry of Research (MURST); OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy; Medical Research Council of Canada;  [RF-2002]	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of Research (MURST)(Ministry of Education, Universities and Research (MIUR)); OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy; Medical Research Council of Canada(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); 	The authors wish to thank the Italian Ministry of Health (Strategic Research Project RF-2002, conv. n. 189), Italian Ministry of Research (MURST), OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy, and The Medical Research Council of Canada for support of this project. M.C.M. and P.A.S. share the first authorship.	AHBON E, 2000, P NATL ACAD SCI USA, V97, P14726; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Avola R, 2000, INT J DEV NEUROSCI, V18, P743, DOI 10.1016/S0736-5748(00)00052-6; Bakker JM, 2000, J IMMUNOL, V165, P5932, DOI 10.4049/jimmunol.165.10.5932; Barden N, 1997, NEUROENDOCRINOLOGY, V66, P212, DOI 10.1159/000127240; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Barthwal MK, 2001, REDOX REP, V6, P297, DOI 10.1179/135100001101536436; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; Bye N, 1998, NEUROREPORT, V9, P1179, DOI 10.1097/00001756-199804200-00040; Bye N, 2001, NEUROSCIENCE, V105, P853, DOI 10.1016/S0306-4522(01)00236-6; Chrousos GP, 2000, ANN NY ACAD SCI, V917, P38, DOI 10.1111/j.1749-6632.2000.tb05371.x; COHEN J, 1991, LANCET, V338, P736, DOI 10.1016/0140-6736(91)91453-2; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; De Groot CJA, 2001, MICROSC RES TECHNIQ, V54, P34, DOI 10.1002/jemt.1118; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; DEGROOT CJA, 1989, IMMUNOBIOLOGY, V179, P314, DOI 10.1016/S0171-2985(89)80038-5; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; DEKLOET ER, 1987, PSYCHONEUROENDOCRINO, V12, P83, DOI 10.1016/0306-4530(87)90040-0; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Drew PD, 2000, BRAIN RES BULL, V52, P391, DOI 10.1016/S0361-9230(00)00275-6; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; Gallo F, 2000, SYNAPSE, V36, P233, DOI 10.1002/(SICI)1098-2396(20000615)36:4<233::AID-SYN1>3.0.CO;2-I; Gallo F, 2000, J NEUROENDOCRINOL, V12, P941, DOI 10.1046/j.1365-2826.2000.00554.x; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Ho A, 1998, J NEUROSCI, V18, P5614; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Ito K, 2001, FASEB J, V15, pA473; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Karanth S, 1997, ENDOCRINOLOGY, V138, P3476, DOI 10.1210/en.138.8.3476; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Kitraki E, 1996, NEUROENDOCRINOLOGY, V63, P305, DOI 10.1159/000126971; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Laflamme N, 1997, J MOL NEUROSCI, V8, P165, DOI 10.1007/BF02736831; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lapchak PA, 1998, MOVEMENT DISORD, V13, P49; Levecque C, 2003, HUM MOL GENET, V12, P79, DOI 10.1093/hmg/ddg009; Liberatore GT, 1999, NAT MED, V5, P1403; Linthorst ACE, 1999, EUR J NEUROSCI, V11, P178, DOI 10.1046/j.1460-9568.1999.00425.x; Linthorst ACE, 2000, EUR J NEUROSCI, V12, P283, DOI 10.1046/j.1460-9568.2000.00878.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marchetti B, 2001, BRAIN RES REV, V37, P259, DOI 10.1016/S0165-0173(01)00130-8; Marchetti B, 2002, J IMMUNOL, V168, P5848, DOI 10.4049/jimmunol.168.11.5848; Marchetti B, 2000, ANN NY ACAD SCI, V917, P678; MARCHETTI B, 1994, ANN NY ACAD SCI, V719, P308, DOI 10.1111/j.1749-6632.1994.tb56839.x; MARCHETTI B, 1932, 32 ANN M SOC NEUR MI; McCann SM, 2003, CURR PHARM DESIGN, V9, P381, DOI 10.2174/1381612033391766; McCann SM, 1998, ANN NY ACAD SCI, V840, P174, DOI 10.1111/j.1749-6632.1998.tb09561.x; McCann SM, 1997, NEUROIMMUNOMODULAT, V4, P98, DOI 10.1159/000097327; McCartney-Francis NL, 2001, J IMMUNOL, V166, P2734, DOI 10.4049/jimmunol.166.4.2734; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MCGEER EG, 1995, NEURODEGENER DIS, P277; Meaney MJ, 1996, DEV NEUROSCI-BASEL, V18, P49, DOI 10.1159/000111395; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; Morale MC, 2001, IMMUNOL CELL BIOL, V79, P400, DOI 10.1046/j.1440-1711.2001.01030.x; Nichols NR, 2001, BRAIN RES REV, V37, P273, DOI 10.1016/S0165-0173(01)00131-X; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; Sacedon R, 1999, J NEUROIMMUNOL, V98, P157, DOI 10.1016/S0165-5728(99)00091-0; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Serra PA, 2002, J BIOL CHEM, V277, P34451, DOI 10.1074/jbc.M202099200; Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; Snyder SH, 1996, NAT MED, V2, P965, DOI 10.1038/nm0996-965; STEC I, 1994, J PSYCHIAT RES, V28, P1, DOI 10.1016/0022-3956(94)90031-0; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.3.CO;2-U; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Tolwani RJ, 1999, LAB ANIM SCI, V49, P363; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRIARHOU LC, 1988, J NEUROCYTOL, V17, P221, DOI 10.1007/BF01674209; UHL GR, 1985, LANCET, V1, P956; WESTERINK BHC, 1982, J NEUROCHEM, V38, P680, DOI 10.1111/j.1471-4159.1982.tb08685.x; Willenborg DO, 1999, J IMMUNOL, V163, P5278; Wu CH, 2001, NEUROSCI RES, V40, P235, DOI 10.1016/S0168-0102(01)00231-0; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Zhou XL, 2000, J BIOL CHEM, V275, P21241, DOI 10.1074/jbc.M904498199	90	56	56	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					164	166		10.1096/fj.03-0501fje	http://dx.doi.org/10.1096/fj.03-0501fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630699				2022-12-25	WOS:000188829300062
J	Moller, A; Sirma, H; Hofmann, TG; Staege, H; Gresko, E; Ludi, KS; Klimczak, E; Droge, W; Will, H; Schmitz, ML				Moller, A; Sirma, H; Hofmann, TG; Staege, H; Gresko, E; Ludi, KS; Klimczak, E; Droge, W; Will, H; Schmitz, ML			Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression	ONCOGENE			English	Article						HIPK2; Sp100; p53; PML nuclear body	PRIMARY BILIARY-CIRRHOSIS; NUCLEAR-BODIES; TRANSCRIPTIONAL ACTIVITY; P53; PML; LOCALIZATION; CELLS; DOMAINS; PHOSPHORYLATION; COMPONENTS	HIPK2 shows overlapping localization with p53 in promyelocytic leukemia (PML) nuclear bodies (PML-NBs) and functionally interacts with p53 to increase gene expression. Here we demonstrate that HIPK2 and the PML-NB resident protein Sp100 synergize for the activation of p53-dependent gene expression. Sp100 and HIPK2 interact and partially colocalize in PML-NBs. The cooperation of HIPK2 and Sp100 for the induction of p21(Waf1) is completely dependent on the presence of p53 and the kinase function of HIPK2. Downregulation of Sp100 levels by expression of siRNA does not interfere with p53-mediated transcription, but obviates the enhancing effect of HIPK2. In summary, these experiments reveal a novel function for Sp100 as a coactivator for HIPK2-mediated p53 activation.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; German Canc Res Ctr, Div Immunochem G0200, D-69120 Heidelberg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany	University of Bern; Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Pette Institute	Schmitz, ML (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.		Schmitz, M. Lienhard/D-9328-2017; Möller, Andreas/O-1063-2015	Schmitz, M. Lienhard/0000-0002-6984-7192; Möller, Andreas/0000-0002-8618-6998				Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; EL DW, 1993, CELL, V75, P817; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; Greenwood E, 2002, NAT REV CANCER, V2, P5, DOI 10.1038/nrc715; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Moller A, 2003, CANCER RES, V63, P4310; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Negorev D, 2001, J CELL SCI, V114, P59; Rogalla P, 2000, GENOMICS, V63, P117, DOI 10.1006/geno.1999.6008; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Sourvinos G, 2002, EMBO J, V21, P4989, DOI 10.1093/emboj/cdf458; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Vogel A, 2002, J MOL MED, V80, P201, DOI 10.1007/s00109-001-0306-2; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	30	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8731	8737		10.1038/sj.onc.1207079	http://dx.doi.org/10.1038/sj.onc.1207079			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647468				2022-12-25	WOS:000186844900011
J	Allen, RJW; Kirk, K				Allen, RJW; Kirk, K			The membrane potential of the intraerythrocytic malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; VACUOLAR H+-ATPASE; TRYPANOSOMA-BRUCEI; ERYTHROCYTIC STAGES; CYTOPLASMIC PH; CELLS; TETRAPHENYLPHOSPHONIUM; MITOCHONDRION; PROMASTIGOTES; CHANNELS	The membrane potential (Deltapsi) of the mature asexual form of the human malaria parasite, Plasmodium falciparum, isolated from its host erythrocyte using a saponin permeabilization technique, was investigated using both the radiolabeled Deltapsi indicator tetraphenylphosphonium ([H-3]TPP+) and the fluorescent Deltapsi indicator DiBAC(4)(3) (bis-oxonol). For isolated parasites suspended in a high Na+, low K+ solution, Deltapsi was estimated from the measured distribution of [H-3]TPP+ to be -95 +/- 2 mV. Deltapsi was reduced by the specific V-type H+ pump inhibitor bafilomycin A(1), by the H+ ionophore CCCP, and by glucose deprivation. Acidification of the parasite cytosol ( induced by the addition of lactate) resulted in a transient hyperpolarization, whereas a cytosolic alkalinization (induced by the addition of NH4+) resulted in a transient depolarization. A decrease in the extracellular pH resulted in a membrane depolarization, whereas an increase in the extracellular pH resulted in a membrane hyperpolarization. The parasite plasma membrane depolarized in response to an increase in the extracellular K+ concentration and hyperpolarized in response to a decrease in the extracellular K+ concentration and to the addition of the K+ channel blockers Ba2+ or Cs+ to the suspending medium. The data are consistent with Deltapsi of the intraerythrocytic P. falciparum trophozoite being due to the electrogenic extrusion of H+ via the V-type H+ pump at the parasite surface. The current associated with the efflux of H+ is countered, in part, by the influx of K+ via Ba2+- and Cs+ -sensitive K+ channels in the parasite plasma membrane.	Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University	Kirk, K (corresponding author), Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.	kiaran.kirk@anu.edu.au	Allen, Richard/B-4752-2008; Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622				Alleva LM, 2001, MOL BIOCHEM PARASIT, V117, P121, DOI 10.1016/S0166-6851(01)00338-3; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BENNEKOU P, 1990, BIOCHIM BIOPHYS ACTA, V1030, P183, DOI 10.1016/0005-2736(90)90255-M; Biagini GA, 2000, FEMS MICROBIOL LETT, V192, P153, DOI 10.1111/j.1574-6968.2000.tb09374.x; Chang HK, 2003, J BIOL CHEM, V278, P908, DOI 10.1074/jbc.M208839200; DefriseQuertain F, 1996, BIOCHEM J, V314, P595, DOI 10.1042/bj3140595; DIVO AA, 1985, J PROTOZOOL, V32, P442, DOI 10.1111/j.1550-7408.1985.tb04041.x; GLASER TA, 1992, MOL BIOCHEM PARASIT, V51, P9, DOI 10.1016/0166-6851(92)90195-P; Hayashi M, 2000, J BIOL CHEM, V275, P34353, DOI 10.1074/jbc.M003323200; Hockings PD, 1996, BBA-BIOMEMBRANES, V1282, P101, DOI 10.1016/0005-2736(96)00045-4; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KITASATO H, 1968, J GEN PHYSIOL, V52, P60, DOI 10.1085/jgp.52.1.60; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEE P, 1988, AM J TROP MED HYG, V39, P157, DOI 10.4269/ajtmh.1988.39.157; LOLKEMA JS, 1983, EUR J BIOCHEM, V130, P287, DOI 10.1111/j.1432-1033.1983.tb07149.x; Marchesini N, 2002, MOL BIOCHEM PARASIT, V119, P225, DOI 10.1016/S0166-6851(01)00419-4; McIntosh MT, 2002, INT J PARASITOL, V32, P1, DOI 10.1016/S0020-7519(01)00325-3; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; Moreno SNJ, 1998, BIOCHEM J, V330, P853; Nolan DP, 2000, EUR J BIOCHEM, V267, P4615, DOI 10.1046/j.1432-1327.2000.01477.x; PRASAD R, 1986, BIOCHIM BIOPHYS ACTA, V861, P377, DOI 10.1016/0005-2736(86)90442-6; RICHARDS JL, 1974, J MEMBRANE BIOL, V16, P121, DOI 10.1007/BF01872410; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; Sato S, 2003, MOL BIOCHEM PARASIT, V130, P155, DOI 10.1016/S0166-6851(03)00166-X; SLAYMAN CL, 1970, AM ZOOL, V10, P377; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; Van der Heyden N, 2002, J EUKARYOT MICROBIOL, V49, P407, DOI 10.1111/j.1550-7408.2002.tb00220.x; Van Der Heyden N, 2002, MOL BIOCHEM PARASIT, V120, P127, DOI 10.1016/S0166-6851(01)00444-3; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; VIEIRA L, 1995, J BIOL CHEM, V270, P5299, DOI 10.1074/jbc.270.10.5299; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794	32	92	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11264	11272		10.1074/jbc.M311110200	http://dx.doi.org/10.1074/jbc.M311110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14630911	hybrid			2022-12-25	WOS:000220157600054
J	Kashiwagi, M; Enghild, JJ; Gendron, C; Hughes, C; Caterson, B; Itoh, Y; Nagase, H				Kashiwagi, M; Enghild, JJ; Gendron, C; Hughes, C; Caterson, B; Itoh, Y; Nagase, H			Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE DEGRADATION; INTERGLOBULAR DOMAIN; IN-VITRO; MATRIX METALLOPROTEINASES; AGGRECANASE-1 ADAM-TS4; MONOCLONAL-ANTIBODIES; ARTICULAR-CARTILAGE; ESCHERICHIA-COLI; CLEAVAGE; CATABOLISM	ADAMTS-4 ( a disintegrin and metalloprotease with thrombospondin motifs) is a multidomain metalloproteinase belonging to the reprolysin family. The enzyme cleaves aggrecan core protein at several sites. Here we report that the non-catalytic ancillary domains of the enzyme play a major role in regulating aggrecanase activity, with the C-terminal spacer domain masking the general proteolytic activity. Expressing a series of domain deletion mutants in mammalian cells and examining their aggrecan-degrading and general proteolytic activities, we found that full-length ADAMTS-4 of 70 kDa was the most effective aggrecanase, but it exhibited little activity against the Glu(373)-Ala(374) bond, the site originally characterized as a signature of aggrecanase activity. Little activity was detected against reduced and carboxymethylated transferrin (Cm-Tf), a general proteinase substrate. However, it readily cleaved the Glu(1480)-Gly(1481) bond in the chondroitin sulfate-rich region of aggrecan. Of the constructed mutants, the C-terminal spacer domain deletion mutant more effectively hydrolyzed both the Glu(373)-Ala(374) and Glu(1480)-Gly(1481) bonds. It also revealed new activities against Cm-Tf, fibromodulin, and decorin. Further deletion of the cysteine-rich domain reduced the aggrecanase activity by 80% but did not alter the activity against Cm-Tf or fibromodulin. Further removal of the thrombospondin type I domain drastically reduced all tested proteolytic activities, and very limited enzymatic activity was detected with the catalytic domain. Full-length ADAMTS-4 binds to pericellular and extracellular matrix, but deletion of the spacer domain releases the enzyme. ADAMTS-4 lacking the spacer domain has promiscuous substrate specificity considerably different from that previously reported for aggrecan core protein. Finding of ADAMTS-4 in the interleukin-1alpha-treated porcine articular cartilage primarily as a 46-kDa form suggests that it exhibits a broader substrate spectrum in the tissue than originally considered.	Univ London Imperial Coll Sci & Technol, Div Rheumatol, Kennedy Inst, London W6 8LH, England; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Cardiff, Cardiff Sch Biosci, Connect Tissue Labs, Cardiff CF1 3US, S Glam, Wales	Imperial College London; University of Oxford; Aarhus University; Cardiff University	Nagase, H (corresponding author), Univ London Imperial Coll Sci & Technol, Div Rheumatol, Kennedy Inst, 1 Aspenlea Rd, London W6 8LH, England.	h.nagase@imperial.ac.uk	Caterson, Bruce/A-8085-2010; Hughes, Clare E/A-4526-2010	Enghild, Jan Johannes/0000-0001-9292-9172; Itoh, Yoshifumi/0000-0002-2128-2823; Hughes, Clare/0000-0003-4726-5877; Caterson, Bruce/0000-0001-6016-0661	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arner EC, 2002, CURR OPIN PHARMACOL, V2, P322, DOI 10.1016/S1471-4892(02)00148-0; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CATERSON B, 1985, FED PROC, V44, P386; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Komorowicz E, 1998, BIOCHEMISTRY-US, V37, P9112, DOI 10.1021/bi980180d; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; Little CB, 2002, ARTHRITIS RHEUM-US, V46, P124, DOI 10.1002/1529-0131(200201)46:1<124::AID-ART10121>3.0.CO;2-X; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Miller JA, 2003, ANAL BIOCHEM, V314, P260, DOI 10.1016/S0003-2697(02)00638-3; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1995, METHOD ENZYMOL, V248, P449; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	45	174	184	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10109	10119		10.1074/jbc.M312123200	http://dx.doi.org/10.1074/jbc.M312123200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14662755	hybrid			2022-12-25	WOS:000220050400056
J	Ji, HL; Bishop, LTR; Anderson, SJ; Fuller, CM; Benos, DJ				Ji, HL; Bishop, LTR; Anderson, SJ; Fuller, CM; Benos, DJ			The role of pre-H2 domains of alpha- and delta-epithelial Na+ channels in ion permeation, conductance, and amiloride sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; XENOPUS OOCYTES; SELECTIVITY FILTER; CATION SELECTIVITY; PORE REGION; SUBUNIT; MUTATIONS; RESIDUES; BLOCK; NEURODEGENERATION	Epithelial Na+ channels (ENaC) regulate salt and water re-absorption across the apical membrane of absorptive epithelia such as the kidney, colon, and lung. Structure-function studies have suggested that the second transmembrane domain (M2) and the adjacent pre- and post-M2 regions are involved in channel pore formation, cation selectivity, and amiloride sensitivity. Because Na+ selectivity, unitary Na+ conductance (gamma(Na)), and amiloride sensitivity of delta-ENaC are strikingly different from those of alpha-ENaC, the hypothesis that the pre-H2 domain may contribute to these characterizations has been examined by swapping the pre-H2, H2, and both (pre-H2 + H2) domains of delta- and alpha-ENaCs. Whole-cell and single channel results showed that the permeation ratio of Li+ and Na+ (P-Li/P-Na) for the swap alpha chimeras co-expressed with betagamma-ENaC in Xenopus oocytes decreased significantly. In contrast, the ratio of P-Li/P-Na for the swap delta constructs was not significantly altered. Single channel studies confirmed that swapping of the H2 and the pre-H2 + H2 domains increased the gamma(Na) of alpha-ENaC but decreased the gamma(Na) of delta-ENaC. A significant increment in the apparent inhibitory dissociation constant for amiloride (K-i(amil)) was observed in the alpha chimeras by swapping the pre- H2, H2, and pre-H2 + H2 domains. In contrast, a striking decline of K-i(amil) was obtained in the chimeric delta constructs with substitution of the H2 and pre-H2 + H2 domains. Our results demonstrate that the pre- H2 domain, combined with the H2 domain, contributes to the P-Li/P-Na ratio, single channel Na+ conductance, and amiloride sensitivity of alpha- and delta-ENaCs.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ji, HL (corresponding author), Univ Alabama, Dept Physiol & Biophys, UAb Stn, Birmingham, AL 35294 USA.	ji@physiology.uab.edu	Fuller, Cathy/B-4046-2011; JI, HONGLONG/N-7822-2014	JI, HONGLONG/0000-0002-3228-7144	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK056095, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206, DK56095] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 2001, BIOPHYS J, V80, P2176, DOI 10.1016/S0006-3495(01)76190-5; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Choe H, 2000, J GEN PHYSIOL, V115, P391, DOI 10.1085/jgp.115.4.391; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; LI XJ, 1995, MOL PHARMACOL, V47, P1133; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Mense M, 2002, BIOCHEMISTRY-US, V41, P9803, DOI 10.1021/bi025819z; PALMER LG, 1985, J MEMBRANE BIOL, V87, P191, DOI 10.1007/BF01871218; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Segal A, 2002, PFLUG ARCH EUR J PHY, V443, P882, DOI 10.1007/s00424-001-0773-x; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	39	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8428	8440		10.1074/jbc.M312012200	http://dx.doi.org/10.1074/jbc.M312012200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660613	hybrid			2022-12-25	WOS:000189103300126
J	Chiu, VK; Silletti, J; Dinsell, V; Wiener, H; Loukeris, K; Ou, GM; Philips, MR; Pillinger, MH				Chiu, VK; Silletti, J; Dinsell, V; Wiener, H; Loukeris, K; Ou, GM; Philips, MR; Pillinger, MH			Carboxyl methylation of Ras regulates membrane targeting and effector engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; CAAX MOTIF; K-RAS; H-RAS; PROTEIN; METHYLTRANSFERASE; ACTIVATION	Post-translational modification of Ras proteins includes prenylcysteine-directed carboxyl methylation. Because Ras participates in Erk activation by epidermal growth factor (EGF), we tested whether Ras methylation regulates Erk activation. EGF stimulation of Erk was inhibited by AFC (N-acetyl-S-farnesyl-L-cysteine), an inhibitor of methylation, but not AGC (N-acetyl-S-geranyl-L-cysteine), an inactive analog of AFC. AFC inhibited Ras methylation as well as the activation of pathway enzymes between Ras and Erk but did not inhibit EGF receptor phosphorylation, confirming action at the level of Ras. Transient transfection of human prenylcysteine-directed carboxyl methyltransferase increased EGF-stimulated Erk activation. AFC but not AGC inhibited movement of transiently transfected green fluorescent protein-Ras from the cytosol to the plasma membrane of COS-1 cells and depleted green fluorescent protein-Ras from the plasma membrane in stably transfected Madin-Darby canine kidney cells, suggesting that methylation regulates Erk by ensuring proper membrane localization of Ras. However, when COS-1 cells were transfected with Ras complexed to CD8, plasma membrane localization of Ras was unaffected by AFC, yet EGF-stimulated Erk activation was inhibited by AFC. Thus, Ras methylation appears to regulate Erk activation both through the localization of Ras as well as the propagation of Ras-dependent signals.	New York Harbor Healthcare Syst Vet Affairs, Dept Med, New York, NY 10010 USA; Hosp Joint Dis & Med Ctr, New York, NY 10003 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; New York University; New York University	Pillinger, MH (corresponding author), New York Harbor Healthcare Syst, Dept Med 630 111J, Div Rheumatol, 423 E 23rd St, New York, NY 10010 USA.	michael.pillinger@med.nyu.edu		Mark, Philips/0000-0002-1179-8156; Dinsell, Victoria/0000-0002-5067-3698	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036224, R01AI036224] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00096] Funding Source: Medline; NIAID NIH HHS [AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Hart KC, 2000, EXP CELL RES, V257, P89, DOI 10.1006/excr.2000.4874; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LACAL PM, 1988, ONCOGENE, V2, P533; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MAGEE AI, 1989, J CELL SCI, P149; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; TAN EW, 1991, J BIOL CHEM, V266, P10719; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	37	42	43	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7346	7352		10.1074/jbc.M311602200	http://dx.doi.org/10.1074/jbc.M311602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660603	hybrid			2022-12-25	WOS:000188969200137
J	Stegman, MA; Goetz, JA; Ascano, M; Ogden, SK; Nybakken, KE; Robbins, DJ				Stegman, MA; Goetz, JA; Ascano, M; Ogden, SK; Nybakken, KE; Robbins, DJ			The kinesin-related protein Costal2 associates with membranes in a Hedgehog-sensitive, smoothened-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMA; DROSOPHILA CUBITUS INTERRUPTUS; SIGNAL-TRANSDUCTION PATHWAYS; TARGET GENE-EXPRESSION; SONIC HEDGEHOG; HUMAN HOMOLOG; PATCHED GENE; SUBCELLULAR-LOCALIZATION; MOTOR DOMAIN; TRANSCRIPTIONAL ACTIVATOR	In Drosophila, Hedgehog (Hh) signal transduction has been shown to require a multiprotein complex (Hedgehog signaling complex (HSC)), which includes the Kinesin-related protein Costal2 (Cos2), the serine/threonine protein kinase Fused (Fu), and the transcription factor Cubitus interruptus (Ci). We present evidence that a biologically relevant fraction of the HSC is found in association with cellular membranes. We demonstrate that Cos2 is capable of tethering an exogenous protein to vesicular membranes and that Cos2 association with membranes is Hh-sensitive. In addition, we demonstrate that Cos2 associates with membranes in cells that lack the transmembrane protein Smoothened (Smo) through a domain of Cos2 distinct from its recently characterized Smo binding domain. We suggest that an Hh-regulated membrane binding activity of Cos2 is part of the mechanism by which Cos2 contributes to Hh signaling. We propose a model in which there are two distinct HSCs with discrete subcellular localizations and activities: one is endosome-associated and facilitates production of a repressor form of Ci (HSC-R), and one is Smo-associated and promotes Ci activation (HSC-A). In response to Hh and through interaction with Cos2, Smo mediates both inhibition of the endosome-associated HSC-R and activation of HSC-A at the plasma membrane.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Grad Program, Cincinnati, OH 45267 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Dartmouth College; University System of Ohio; University of Cincinnati; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Robbins, DJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen Hall, Hanover, NH 03755 USA.	david.j.robbins@dartmouth.edu	Ascano, Manuel/ABA-3586-2020; Ogden, Stacey K/N-2528-2018; Ogden, Stacey K/P-9585-2019	Ascano, Manuel/0000-0002-9370-5493; Ogden, Stacey K/0000-0001-8991-3065	NCI NIH HHS [CA82628, R01 CA082628] Funding Source: Medline; NIEHS NIH HHS [5-T32 ES07250, T32 ES007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Ascano M, 2002, MOL CELL BIOL, V22, P1555, DOI 10.1128/MCB.22.5.1555-1566.2002; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1999, DEVELOPMENT, V126, P3607; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chidambaram A, 1996, CANCER RES, V56, P4599; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Dollar G, 2002, DEVELOPMENT, V129, P517; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FORBES AJ, 1993, DEVELOPMENT, P115; Fukumoto T, 2001, J BIOL CHEM, V276, P38441, DOI 10.1074/jbc.M105871200; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gallet A, 2000, DEVELOPMENT, V127, P5509; Gilman A.G., 2001, GOODMAN GILMANS PHAR; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HO K, 2002, REGULATION HH TARGET; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Hooper JE, 2003, DEVELOPMENT, V130, P3951, DOI 10.1242/dev.00594; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lefers MA, 2001, DEV BIOL, V236, P411, DOI 10.1006/dbio.2001.0345; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MARIOL MC, 1987, MOL CELL BIOL, V7, P3244, DOI 10.1128/MCB.7.9.3244; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Methot N, 2000, DEVELOPMENT, V127, P4001; Mok H, 2002, J NEUROSCI, V22, P5253; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Monnier Veronique, 2002, BMC Dev Biol, V2, P4, DOI 10.1186/1471-213X-2-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nybakken KE, 2002, J BIOL CHEM, V277, P24638, DOI 10.1074/jbc.M110730200; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Reifenberger J, 1998, CANCER RES, V58, P1798; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SIMPSON P, 1987, DEV BIOL, V122, P201, DOI 10.1016/0012-1606(87)90345-9; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Unden AB, 1996, CANCER RES, V56, P4562; Unden AB, 1997, CANCER RES, V57, P2336; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wang QT, 1999, DEVELOPMENT, V126, P5097; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zhu AJ, 2003, GENE DEV, V17, P1240, DOI 10.1101/gad.1080803	87	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7064	7071		10.1074/jbc.M311794200	http://dx.doi.org/10.1074/jbc.M311794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645371	Green Accepted, hybrid			2022-12-25	WOS:000188969200104
J	Vasseur, S; Folch-Puy, E; Hlouschek, V; Garcia, S; Fiedler, F; Lerch, MM; Dagorn, JC; Closa, D; Iovanna, JL				Vasseur, S; Folch-Puy, E; Hlouschek, V; Garcia, S; Fiedler, F; Lerch, MM; Dagorn, JC; Closa, D; Iovanna, JL			p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HORMONE-RELEASING HORMONE; KAPPA-B ACTIVATION; PROMOTES CELLULAR GROWTH; ALPHA GENE-EXPRESSION; BREAST-CANCER CELLS; MESSENGER-RNA; ACINAR-CELLS; ACUTE-PHASE; TRYPSINOGEN ACTIVATION	p8 is a transcription cofactor whose expression is strongly and rapidly activated in pancreatic acinar cells during the acute phase of pancreatitis. A p8-deficient mouse strain was generated as a tool to investigate its function. Upon induction of acute pancreatitis, myeloperoxidase activity in pancreas and serum concentrations of amylase and lipase were much higher and pancreatic lesions more severe in p8-deficient mice than in wild-type, indicating that p8 expression decreased pancreatic sensitivity to pancreatitis induction. The protective mechanism might involve the pancreatitis-associated protein (PAP 1), whose strong induction during pancreatitis is p8-dependent, because administration of anti-PAP I antibodies to rats increased pancreatic inflammation during pancreatitis. In addition, 100 ng/ml PAP I in the culture medium of macrophages prevented their activation by tumor necrosis factor a, strongly suggesting that PAP I was an anti-inflammatory factor. Finally, PAP I was able to inhibit NFkappaB activation by tumor necrosis factor a, in macrophages and in the AR42J pancreatic acinar cell line. In conclusion, p8 improves pancreatic resistance to inducers of acute pancreatitis by a mechanism implicating the expression of the anti-inflammatory protein PAP I.	CSIC, IIBB, Dept Expt Pathol, Barcelona 08036, Spain; INSERM, Ctr Rech, F-13009 Marseille, France; Univ Munster, Med Klin B, D-48129 Munster, Germany; Hop Nord Marseille, F-13915 Marseille, France; Univ Heidelberg, Klinikum Mannheim, Inst Anasthesie, D-68167 Mannheim, Germany; Univ Greifswald, Dept Med A, Div Gastroenterol & Endocrinol, D-17487 Greifswald, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Munster; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Ruprecht Karls University Heidelberg; Ernst Moritz Arndt Universitat Greifswald	Iovanna, JL (corresponding author), CSIC, IIBB, Dept Expt Pathol, C Rossello 161,7, Barcelona 08036, Spain.	iovanna@marseille.inserm.fr	vasseur, sophie/O-9803-2017; Folch Puy, Emma/Q-3157-2017; Iovanna, Juan/M-9805-2017; Lerch, Markus M./E-2206-2016; Puy, Emma Folch/AAX-5558-2020; Closa, Daniel/Y-3848-2019	vasseur, sophie/0000-0002-2339-8854; Folch Puy, Emma/0000-0002-6277-9027; Iovanna, Juan/0000-0003-1822-2237; Lerch, Markus M./0000-0002-9643-8263; Puy, Emma Folch/0000-0002-6277-9027; Closa Autet, Daniel/0000-0003-3797-3095				Aggarwal S, 2001, J INTERF CYTOK RES, V21, P1047, DOI 10.1089/107999001317205178; Bartoli C, 1998, J CLIN ENDOCR METAB, V83, P4041, DOI 10.1210/jc.83.11.4041; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bratland A, 2000, CANCER RES, V60, P5578; Broekaert D, 2002, EUR CYTOKINE NETW, V13, P78; CHAKRABORTY C, 1995, MOL CELL ENDOCRINOL, V108, P149, DOI 10.1016/0303-7207(94)03470-E; CHAKRABORTY C, 1995, ENDOCRINOLOGY, V136, P1843, DOI 10.1210/en.136.5.1843; Christa L, 1996, AM J PHYSIOL-GASTR L, V271, pG993, DOI 10.1152/ajpgi.1996.271.6.G993; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; Denham W, 1997, AM SURGEON, V63, P1045; Denham W, 1997, GASTROENTEROLOGY, V113, P1741, DOI 10.1053/gast.1997.v113.pm9352880; Deviere J, 2001, GASTROENTEROLOGY, V120, P498, DOI 10.1053/gast.2001.21172; Dieckgraefe BK, 2002, J INVEST MED, V50, P421, DOI 10.1136/jim-50-06-02; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; Dunn JA, 1997, AM SURGEON, V63, P1036; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; Ethridge RT, 2002, J AM COLL SURGEONS, V195, P497, DOI 10.1016/S1072-7515(02)01222-X; Folch E, 1998, INFLAMMATION, V22, P83, DOI 10.1023/A:1022399824880; Garcia-Montero AC, 2001, BIOCHEM J, V357, P249, DOI 10.1042/0264-6021:3570249; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Grady T, 1996, AM J PHYSIOL-GASTR L, V271, pG20, DOI 10.1152/ajpgi.1996.271.1.G20; Grisham MB, 1999, GASTROENTEROLOGY, V116, P489, DOI 10.1016/S0016-5085(99)70148-4; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Heller A, 1999, ANESTHESIOLOGY, V91, P1408, DOI 10.1097/00000542-199911000-00034; Hoffmeister A, 2002, J BIOL CHEM, V277, P22314, DOI 10.1074/jbc.M201657200; Hughes CB, 1996, AM J SURG, V171, P274, DOI 10.1016/S0002-9610(97)89568-2; Hughes CB, 1996, AM SURGEON, V62, P8; HUTTUNEN R, 1975, SCAND J GASTROENTERO, V10, P177; Igarashi T, 2001, DEV GROWTH DIFFER, V43, P693; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA J, 1991, AM J PHYSIOL, V261, pG418; IOVANNA JL, 1993, AM J PHYSIOL, V265, pG611, DOI 10.1152/ajpgi.1993.265.4.G611; Jaffray C, 2000, J GASTROINTEST SURG, V4, P370, DOI 10.1016/S1091-255X(00)80015-3; Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953; KATSUMATA N, 1995, ENDOCRINOLOGY, V136, P1332, DOI 10.1210/en.136.4.1332; KEIM V, 1991, GASTROENTEROLOGY, V100, P775, DOI 10.1016/0016-5085(91)80025-5; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; LASSERRE C, 1992, CANCER RES, V52, P5089; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; MASCIOTRA L, 1995, DIGEST DIS SCI, V40, P519, DOI 10.1007/BF02064359; Morisset J, 1997, GASTROENTEROLOGY, V112, P543, DOI 10.1053/gast.1997.v112.pm9024308; Motoo Y, 1998, INT J PANCREATOL, V23, P11; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Norman JG, 1996, SURGERY, V120, P515, DOI 10.1016/S0039-6060(96)80072-9; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Quirk CC, 2003, J BIOL CHEM, V278, P1680, DOI 10.1074/jbc.M209906200; Rechreche H, 1999, INT J CANCER, V81, P688, DOI 10.1002/(SICI)1097-0215(19990531)81:5<688::AID-IJC3>3.0.CO;2-R; Ree AH, 1999, CANCER RES, V59, P4675; Rongione A J, 1997, J Gastrointest Surg, V1, P159, DOI 10.1016/S1091-255X(97)80104-7; Rongione AJ, 1997, GASTROENTEROLOGY, V112, P960, DOI 10.1053/gast.1997.v112.pm9041259; Satoh A, 1999, GUT, V44, P253, DOI 10.1136/gut.44.2.253; Sparmann G, 2001, DIGEST DIS SCI, V46, P1647, DOI 10.1023/A:1010689117772; Spielman J, 1998, J IMMUNOL, V161, P7063; STEER ML, 1987, NEW ENGL J MED, V316, P144; STEER ML, 1992, ARCH SURG-CHICAGO, V127, P1350; TACHIBANA K, 1988, MOL ENDOCRINOL, V2, P973, DOI 10.1210/mend-2-10-973; Vaccaro MI, 2000, BIOCHEM BIOPH RES CO, V268, P485, DOI 10.1006/bbrc.2000.2151; Van Laethem JL, 1998, GUT, V43, P408, DOI 10.1136/gut.43.3.408; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1917, DOI 10.1016/0016-5085(95)90158-2; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-25; Vasseur S, 2002, ONCOGENE, V21, P1685, DOI 10.1038/sj.onc.1205222; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vasseur S, 1999, BIOCHEM J, V343, P377, DOI 10.1042/0264-6021:3430377; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; WILLEMER S, 1992, EUR SURG RES, V24, P29, DOI 10.1159/000129237; Yang J, 1998, SHOCK, V10, P169, DOI 10.1097/00024382-199809000-00004; Yasuda H, 1999, J INTERF CYTOK RES, V19, P637, DOI 10.1089/107999099313785; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600; Zou WG, 2002, J SURG RES, V103, P121, DOI 10.1006/jsre.2001.6327	78	100	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7199	7207		10.1074/jbc.M309152200	http://dx.doi.org/10.1074/jbc.M309152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660681	hybrid			2022-12-25	WOS:000188969200119
J	Hanakawa, Y; Schechter, NM; Lin, CY; Nishifuji, K; Amagai, M; Stanley, JR				Hanakawa, Y; Schechter, NM; Lin, CY; Nishifuji, K; Amagai, M; Stanley, JR			Enzymatic and molecular characteristics of the efficiency and specificity of exfoliative toxin cleavage of desmoglein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCALDED-SKIN SYNDROME; BULLOUS IMPETIGO; SERINE-PROTEASE; ADHESION; SUPERANTIGEN; MECHANISMS; THROMBIN; DOMAINS; BINDING; DSG1	Exfoliative toxins (ETs) from Staphylococcus aureus blister the superficial epidermis by hydrolyzing a single peptide bond, Glu(381)-Gly(382), located between extracellular domains 3 and 4 of desmoglein 1 (Dsg1). Enzyme activity is dependent on the calcium-stabilized structure of Dsg1. Here we further define the characteristics of this cleavage. Kinetic studies monitoring the cleavage of Dsg1 by ETA, ETB, and ETD demonstrated k(cat)/K-m values of 2-6 x 10(4) M-1 s(-1), suggesting very efficient proteolysis. Proteolysis by ETA was not efficiently inhibited by broad spectrum serine protease inhibitors, suggesting that the enzyme cleavage site may be inactive or inaccessible before specific binding to its substrate. Using truncated mutants of human Dsg1 and chimeric molecules between human Dsg1 and either human Dsg3 or canine Dsg1, we show that for cleavage, human-specific amino acids from Dsg1 are necessary in extracellular domain 3 upstream of the scissile bond. If these residues are canine rather than human, ETA binds, but does not cleave, canine Dsg1. These data suggest that the exquisite specificity and efficiency of ETA may depend on the enzyme's binding upstream of the cleavage site with a very specific fit, like a key in a lock.	Univ Penn, Dept Dermatol, Sch Med, Philadelphia, PA 19104 USA; Keio Univ, Sch Med, Dept Dermatol, Tokyo 1608582, Japan	University of Pennsylvania; Keio University	Stanley, JR (corresponding author), Univ Penn, Dept Dermatol, Sch Med, 211 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	jrstan@mail.med.upenn.edu	Nishifuji, Koji/C-8457-2013; Amagai, Masayuki/K-5325-2013	Nishifuji, Koji/0000-0003-4583-5485; Amagai, Masayuki/0000-0003-3314-7052				Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; AMAGAI M, 1994, J INVEST DERMATOL, V102, P402, DOI 10.1111/1523-1747.ep12372164; Amagai M, 2002, J INVEST DERMATOL, V118, P845, DOI 10.1046/j.1523-1747.2002.01751.x; Angst BD, 2001, J CELL SCI, V114, P625; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Cavarelli J, 1997, STRUCTURE, V5, P813, DOI 10.1016/S0969-2126(97)00235-9; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hanakawa Y, 2003, J INVEST DERMATOL, V121, P383, DOI 10.1046/j.1523-1747.2003.12362.x; Hanakawa Y, 2002, J CLIN INVEST, V110, P53, DOI 10.1172/JCI200215766; Ishii K, 1997, J IMMUNOL, V159, P2010; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; Janin J, 2000, PROTEIN PROTEIN RECO, P1; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Ladhani S, 2001, CLIN MICROBIOL INFEC, V7, P301, DOI 10.1046/j.1198-743x.2001.00258.x; Ladhani S, 1999, CLIN MICROBIOL REV, V12, P224, DOI 10.1128/CMR.12.2.224; MELISH ME, 1972, J INFECT DIS, V125, P129, DOI 10.1093/infdis/125.2.129; MELISH ME, 1971, J PEDIATR-US, V78, P958, DOI 10.1016/S0022-3476(71)80425-0; MELISH ME, 1970, NEW ENGL J MED, V282, P1114, DOI 10.1056/NEJM197005142822002; Muller E, 2000, J INVEST DERMATOL, V114, P1211; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGATA K, 1991, J BIOCHEM, V110, P859, DOI 10.1093/oxfordjournals.jbchem.a123679; Nishifuji K, 2003, VET IMMUNOL IMMUNOP, V95, P177, DOI 10.1016/S0165-2427(03)00107-7; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Papageorgiou AC, 2000, PROTEIN SCI, V9, P610; PRIOSOERYANTO BP, 1995, RES VET SCI, V58, P101, DOI 10.1016/0034-5288(95)90099-3; SATO H, 1991, VET MICROBIOL, V28, P157, DOI 10.1016/0378-1135(91)90090-3; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Syed SEH, 2002, BIOCHEM J, V362, P317, DOI 10.1042/0264-6021:3620317; van Holde KE, 2002, BIOPHYS CHEM, V101, P249, DOI 10.1016/S0301-4622(02)00176-X; Vath GM, 1999, BIOCHEMISTRY-US, V38, P10239, DOI 10.1021/bi990721e; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; Yamaguchi T, 2002, INFECT IMMUN, V70, P5835, DOI 10.1128/IAI.70.10.5835-5845.2002; [No title captured]; [No title captured]	38	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5268	5277		10.1074/jbc.M311087200	http://dx.doi.org/10.1074/jbc.M311087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630910	hybrid			2022-12-25	WOS:000188776500030
J	Hu, L; Lau, SH; Tzang, CH; Wen, JM; Wang, WS; Xie, D; Huang, MH; Wang, Y; Wu, MC; Huang, JF; Zeng, WF; Sham, JST; Yang, MS; Guan, XY				Hu, L; Lau, SH; Tzang, CH; Wen, JM; Wang, WS; Xie, D; Huang, MH; Wang, Y; Wu, MC; Huang, JF; Zeng, WF; Sham, JST; Yang, MS; Guan, XY			Association of Vimentin overexpression and hepatocellular carcinoma metastasis	ONCOGENE			English	Article						Vimentin; hepatocellular carcinoma; metastasis; microarray	TISSUE MICROARRAY; BREAST-CARCINOMA; EXPRESSION; PROTEIN; CELLS; CLUSTERIN; CANCER; RNA	The poor prognosis of hepatocellular carcinoma (HCC) has been associated with recurrence and metastasis. Recently, we established a pair of HCC cell lines from a primary (H2-P) and its matched metastatic (H2-M) HCC tumors. A high density of cDNA microarray with 9184 human cDNA was used to identify the differentially expressed genes between H2-P and H2-M. Comparing with H2-P, eight upregulated and six downregulated genes were detected in H2-M. One interesting finding is the overexpression of Vimentin (VIM), a well-defined intermediate filament, which has been linked to a more aggressive status in various tumors. The correlation of overexpression of VIM and HCC metastasis was studied by immunohistochemistry using a tissue microarray with 200 primary HCCs and 60 pairs of primary and matched metastatic HCC samples. Tissue microarray demonstrated that the overexpression of VIM was significantly associated with HCC metastasis (P<0.01). This finding strongly suggests that the overexpression of VIM may play an important role in the metastasis of HCC.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobilliary Surg, Guangzhou, Peoples R China; Second Mil Med Univ, Eastern Hepatobilliary Surg Hosp, Shanghai, Peoples R China	University of Hong Kong; City University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University; Naval Medical University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,1-F,Sch Chinese Med Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Yang, Mengsu/I-5750-2015; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Yang, Mengsu/0000-0003-2083-2296; Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Aguayo A, 2001, SEMIN ONCOL, V28, P503, DOI 10.1053/sonc.2001.26953; Aldamassi M., 2001, PRACTICAL GUIDE MICR; BENZEEV A, 1985, CANCER RES, V45, P2632; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DOMAGALA W, 1994, EUR J CANCER, V30A, P1527, DOI 10.1016/0959-8049(94)00288-G; FAN C, 1995, ONCOLOGY, V52, P498; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Guan XY, 1996, NAT GENET, V12, P10, DOI 10.1038/ng0196-10; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Iwatsuki H, 1999, ACTA HISTOCHEM, V101, P369, DOI 10.1016/S0065-1281(99)80038-5; Lang SH, 2002, PROSTATE, V52, P253, DOI 10.1002/pros.10088; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lelievre V, 2001, J BIOL CHEM, V276, P43668, DOI 10.1074/jbc.M107341200; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Qin LX, 1999, CANCER RES, V59, P5662; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; THOMASSALGAR S, 1994, J BIOL CHEM, V269, P17879; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wang Y, 2002, J PATHOL, V197, P610, DOI 10.1002/path.1150; Wen JM, 2002, CANCER GENET CYTOGEN, V135, P91, DOI 10.1016/S0165-4608(01)00636-7	24	180	201	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					298	302		10.1038/sj.onc.1206483	http://dx.doi.org/10.1038/sj.onc.1206483			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14647434				2022-12-25	WOS:000187895300031
J	Bertholon, J; Wang, Q; Falette, N; Verny, C; Auclair, J; Chassot, C; Navarro, C; Saurin, JC; Puisieux, A				Bertholon, J; Wang, Q; Falette, N; Verny, C; Auclair, J; Chassot, C; Navarro, C; Saurin, JC; Puisieux, A			Chfr inactivation is not associated to chromosomal instability in colon cancers	ONCOGENE			English	Article						Chfr; hypermethylation; chromosome instability; breast cancer; colon cancer	COMPARATIVE GENOMIC HYBRIDIZATION; MITOTIC STRESS CHECKPOINT; CELL-LINES; BREAST-CANCER; COLORECTAL-CANCER; CPG ISLAND; CENTROSOME AMPLIFICATION; MULTIPLE MUTATIONS; LUNG-CANCER; GENES	Numerous observations suggest that chromosome instability is caused by mitotic abnormalities such as errors in the partitioning of chromosomes. Chfr was recently defined as a central component of a new mitotic checkpoint that delays chromosome condensation in response to mitotic stress. Chfr was shown to be frequently inactivated in several human neoplasms, including colon, lung and esophageal cancers. To test whether Chfr inactivation may lead or participate to chromosomal instability (CIN), we analysed the genetic and epigenetic status of the gene in a large panel of primary colon and breast cancers, as well as in colon and breast cancer cell lines displaying either a microsatellite instability or a CIN. Our results confirm that Chfr is frequently inactivated in colon cancers, through a mechanism of hypermethylation of the promoter sequences. In contrast, the loss of Chfr expression appears to be a rare event in breast cancers. Furthermore, our data demonstrate that Chfr inactivation is not associated with CIN in these frequent types of human cancers.	Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, F-69373 Lyon 08, France; Fac Pharm Lyon, F-69373 Lyon, France; Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Puisieux, A (corresponding author), Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, 28 Rue Laennec, F-69373 Lyon 08, France.			PUISIEUX, Alain/0000-0002-9938-3798				Ahuja N, 1997, CANCER RES, V57, P3370; Bunz F, 2002, CANCER RES, V62, P1129; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2; Forozan F, 2000, CANCER RES, V60, P4519; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Jackson AL, 1998, SEMIN CANCER BIOL, V8, P421, DOI 10.1006/scbi.1998.0113; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kytola S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; Luker KE, 2001, CANCER RES, V61, P6540; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	32	30	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8956	8960		10.1038/sj.onc.1207078	http://dx.doi.org/10.1038/sj.onc.1207078			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654793				2022-12-25	WOS:000186982200018
J	Shinozaki, T; Nota, A; Taya, Y; Okamoto, K				Shinozaki, T; Nota, A; Taya, Y; Okamoto, K			Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export	ONCOGENE			English	Article						p53; Mdm2; ATR	RING-FINGER DOMAIN; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; DNA; ACTIVATION; CHECKPOINT; AKT; REPLICATION; DEGRADATION; UBIQUITINATION	Mdm2 oncoprotein plays a major role in inhibiting the p53 tumor suppressor protein. Here, we investigate phosphorylation of Mdm2 at serine 407 (S407). S407 is phosphorylated in cells after treatment with camptothecin (CPT) or hydroxyurea, inhibitors of DNA replication. S407 phosphorylation after CPT treatment is induced upon cell cycle arrest during S phase and prevented if entry into S phase of cell cycle is blocked. We found that a major kinase responsible for S407 phosphorylation is ATR, a DNA damage checkpoint protein that induces cell cycle arrest and promotes DNA repair in response to impaired DNA replication; induction of S407 phosphorylation is enhanced after expression of wild-type ATR, while it is inhibited by a dominant-negative form of ATR. Further, S407 is specifically phosphorylated by ATR in vitro. Substitution of S407 with aspartate (S407D), but not with alanine (S407A), promotes nuclear localization of p53. Taken together, our data indicate that S407 phosphorylation of Mdm2 by ATR reduces Mdm2-dependent export of p53 from nuclei to cytoplasm.	Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki, Japan	National Cancer Center - Japan; Japan Science & Technology Agency (JST)	Okamoto, K (corresponding author), Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	kojokamo@gan2.res.ncc.go.jp						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brown EJ, 2000, GENE DEV, V14, P397; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Taya Yoichi, 2003, Methods Mol Biol, V223, P17; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang HY, 2002, CANCER RES, V62, P2483; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	63	59	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8870	8880		10.1038/sj.onc.1207176	http://dx.doi.org/10.1038/sj.onc.1207176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654783				2022-12-25	WOS:000186982200008
J	Erber, R; Thurnher, A; Katsen, AD; Groth, G; Kerger, H; Hammes, HP; Menger, MD; Ullrich, A; Vajkoczy, P				Erber, R; Thurnher, A; Katsen, AD; Groth, G; Kerger, H; Hammes, HP; Menger, MD; Ullrich, A; Vajkoczy, P			Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms	FASEB JOURNAL			English	Article						angiogenesis; glioma; resistance; tyrosine kinase inhibitors; vessel maturation	GROWTH-FACTOR RECEPTOR; ANGIOGENESIS IN-VIVO; SMOOTH-MUSCLE-CELLS; TRANSDUCTION PATHWAY; TYROSINE KINASES; BLOOD-VESSELS; TIE2 RECEPTOR; PHASE-I; ANGIOPOIETIN-1; EXPRESSION	Destruction of existing tumor blood vessels may be achieved by targeting vascular endothelial growth factor (VEGF) signaling, which mediates not only endothelial cell proliferation but also endothelial cell survival. In this study, however, intravital microscopy failed to demonstrate that targeting of VEGFR-2 (by the tyrosine kinase inhibitor SU5416) induces significant regression of experimental tumor blood vessels. Immunohistochemistry, electron microscopy, expression analyses, and in situ hybridization provide evidence that this resistance of tumor blood vessels to VEGFR-2 targeting is conferred by pericytes that stabilize blood vessels and provide endothelial cell survival signals via the Ang-1/Tie2 pathway. In contrast, targeting VEGFR-2 plus the platelet-derived growth factor receptor (PDGFR)-beta system (PDGFR-beta) signaling (by SU6668) rapidly forced 40% of tumor blood vessels into regression, rendering these tumors hypoxic as shown by phosphorescence quenching. TUNEL staining, electron microscopy, and apoptosis blocking experiments suggest that VEGFR-2 plus PDGFR-beta targeting enforced tumor blood vessel regression by inducing endothelial cell apoptosis. We further show that this is achieved by an interference with pericyte-endothelial cell interaction. This study provides novel insights into the mechanisms of how 1) pericytes may provide escape strategies to anti-angiogenic therapies and 2) novel concepts that target not only endothelial cells but also pericyte-associated pathways involved in vascular stabilization and maturation exert potent anti-vascular effects.	Heidelberg Univ, Fac Med, Dept Neurosurg, D-6800 Mannheim, Germany; Univ Saarland, Inst Clin & Expt Surg, D-6650 Homburg, Germany; Heidelberg Univ, Fac Med, Vth Med Clin, Dept Anesthesiol & Intens Care Med, D-6800 Mannheim, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Ruprecht Karls University Heidelberg; Saarland University; Ruprecht Karls University Heidelberg; Max Planck Society	Vajkoczy, P (corresponding author), Heidelberg Univ, Klinikum Mannheim, Dept Neurosurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	peter.vajkoczy@nch.ma.uni-heidelberg.de	Hammes, Hans-Peter/S-3719-2019; Erber, Ralf/AAF-3002-2020; Erber, Ralf/B-6790-2008					Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chekenya M, 2002, NEUROPATH APPL NEURO, V28, P367, DOI 10.1046/j.1365-2990.2002.00412.x; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; Drevs J, 2000, CANCER RES, V60, P4819; Fong TAT, 1999, CANCER RES, V59, P99; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Hawighorst T, 2002, AM J PATHOL, V160, P1381, DOI 10.1016/S0002-9440(10)62565-5; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Jayson GC, 2002, J NATL CANCER I, V94, P1484, DOI 10.1093/jnci/94.19.1484; Katsen AD, 1998, VIRCHOWS ARCH, V433, P75, DOI 10.1007/s004280050219; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerger H, 1996, AM J PHYSIOL-HEART C, V270, pH827, DOI 10.1152/ajpheart.1996.270.3.H827; Kerger H, 2003, MICROVASC RES, V65, P32, DOI 10.1016/S0026-2862(02)00027-4; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Laird AD, 2000, CANCER RES, V60, P4152; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Mendel DB, 2000, CLIN CANCER RES, V6, P4848; Menter DG, 2002, EXPERT OPIN INV DRUG, V11, P1749, DOI 10.1517/13543784.11.12.1749; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NICOSIA RF, 1995, LAB INVEST, V73, P658; Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026-2862(02)00035-3; Prewett M, 1999, CANCER RES, V59, P5209; Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; Schramm R, 2003, TRANSPLANTATION, V75, P239, DOI 10.1097/01.TP.0000040869.19883.4A; St Croix B, 2000, SCIENCE, V289, P1197; STEWART PA, 1991, INT J RADIAT BIOL, V60, P125, DOI 10.1080/09553009114551701; STEWART PA, 1985, ACTA NEUROPATHOL, V67, P96, DOI 10.1007/BF00688129; Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vajkoczy P, 1999, INT J DEV NEUROSCI, V17, P557, DOI 10.1016/S0736-5748(99)00021-0; Vajkoczy P, 1998, J CEREBR BLOOD F MET, V18, P510, DOI 10.1097/00004647-199805000-00006; Vajkoczy P, 2000, NEOPLASIA, V2, P53, DOI 10.1038/sj.neo.7900062; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Vajkoczy Peter, 1999, Neoplasia (New York), V1, P31, DOI 10.1038/sj.neo.7900006; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; WESSELING P, 1995, J NEUROPATH EXP NEUR, V54, P304, DOI 10.1097/00005072-199505000-00003	54	492	530	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					338	340		10.1096/fj.03-0271fje	http://dx.doi.org/10.1096/fj.03-0271fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657001				2022-12-25	WOS:000188067500023
J	Mettus, RV; Rane, SG				Mettus, RV; Rane, SG			Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice	ONCOGENE			English	Article						cyclin-dependent kinase 4; pancreas; fertility	CELL; DEFICIENT; DYSFUNCTION	Cyclin-dependent kinase 4 (Cdk4) and Cdk6, and later Cdk2, in association with their specific cyclin partners, regulate the G1 to S phase cell cycle transition of mammalian cells by phosphorylation of retinoblastoma (Rb) family proteins. Phosphorylation of Rb results in the release of S-phase specific transcription factors; cell cycle-promoting gene expression, and advancement of the cell cycle. Loss of Cdk4 by homologous-targeted disruption leads to a delay in S-phase entry in serum-stimulated mouse embryo fibroblast (MEF) cultures. Homozygous Cdk4-deficient mice display defects in weight gain, fertility and hypoproliferation of specific endocrine cells of the pituitary and pancreas, the latter of which results in a diabetes-like phenotype. In contrast, inheritance of the p16(Ink4a)-insensitive Cdk4(R24C) mutation leads to spontaneous transformation of MEF cultures in vitro and, in vivo, hyperproliferative disorders that progress to cancer. In this manuscript, we report characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. We observe that, whereas Cdk4 is dispensable for early pancreatic development, normal Cdk4 expression is critical for optimal growth of the organism. Also, we observe that loss of Cdk4 may result in insulin insensitivity, implicating an additional role of Cdk4 in beta-cell function, in addition to its role in beta-cell proliferation. Further, we demonstrate that loss of Cdk4 leads to an age-dependent defect in spermatogenesis and disruption in the timing of the estrus cycle. Taken together, our results indicate that the overall defects in growth, fertility and pancreatic development in Cdk4-deficient mice may be a combination of cell-type specific defects and altered glucose metabolism, as a result of defects in postnatal pancreatic development.	NCI, Cell Cycle & Human Dis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Rane, SG (corresponding author), NCI, Cell Cycle & Human Dis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.	sushil_rane@nih.gov			NCI NIH HHS [K22CA90790-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN RP, 1976, BIOL REPROD, V15, P586, DOI 10.1095/biolreprod15.5.586; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BENTON L, 1995, J STEROID BIOCHEM, V53, P61, DOI 10.1016/0960-0760(95)00022-R; Bouwens L, 1996, VIRCHOWS ARCH, V427, P553; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Mauvais-Jarvis F, 2002, CLIN ENDOCRINOL, V57, P1, DOI 10.1046/j.1365-2265.2002.01563.x; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MURRAY FT, 1985, HORM METAB RES, V17, P495, DOI 10.1055/s-2007-1013588; Murray J, 2001, COMB CHEM HIGH T SCR, V4, P265; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Rane SG, 2000, FRONT BIOSCI, V5, pD1, DOI 10.2741/Rane; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sherr CJ, 2000, CANCER RES, V60, P3689; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	24	74	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8413	8421		10.1038/sj.onc.1206888	http://dx.doi.org/10.1038/sj.onc.1206888			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627982				2022-12-25	WOS:000186650300005
J	Ohno, H; Hirabayashi, S; Kansaku, A; Yao, I; Tajima, M; Nishimura, W; Ohnishi, H; Mashima, H; Fujita, T; Omata, M; Hata, Y				Ohno, H; Hirabayashi, S; Kansaku, A; Yao, I; Tajima, M; Nishimura, W; Ohnishi, H; Mashima, H; Fujita, T; Omata, M; Hata, Y			Carom: a novel membrane-associated guanylate kinase-interacting protein with two SH3 domains	ONCOGENE			English	Article						epithelial junctions; MAGI-1; CASK; SH3; PDZ	TIGHT JUNCTION PROTEIN; CELL-ADHESION; PDZ DOMAIN; BASOLATERAL MEMBRANE; EPITHELIAL-CELLS; KIDNEY-CELLS; MAGI-1; CASK/LIN-2; BINDS; LOCALIZATION	MAGI-1 and CASK are membrane-associated guanylate kinases of epithelial junctions. MAGI-1 is localized at tight junctions in polarized epithelial cells, whereas CASK is localized along the lateral membranes. We obtained the KIAA0769 gene product through the yeast two-hybrid screening using MAGI-1 as a bait and named it Carom. Carom has a coiled-coil domain in the middle region, and two src homology 3 domains and a PSD-95/Dlg-A/ZO-1 (PDZ)-binding motif in the C-terminal region. Carom binds to the fifth PDZ domain of MAGI-1 and the calmodulin kinase domain of CASK in vitro. MAGI-1 and CASK bind to the distinct sequences in the C-terminal region of Carom, but still compete with each other for Carom binding. The study using a stable transformant of Madine Darby canine kidney (MDCK) cells expressing GFP-Carom revealed that Carom was partially overlapped by MAGI-1 in MDCK cells, which have not yet established mature cell junctions, but became separated from MAGI-1 and colocalized with CASK in polarized cells. Carom was highly resistant to Triton X-100 extractions and recruited CASK to the Triton X-100-insoluble structures. Carom is a binding partner of CASK, which interacts with CASK in polarized epithelial cells and may link it to the cytoskeleton.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo, Japan; Jichi Med Sch, Dept Gastroenterol, Minami Kawachi, Tochigi 32904, Japan; Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); University of Tokyo; Jichi Medical University; University of Tokyo	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.		Nishimura, Wataru/R-9215-2019	Nishimura, Wataru/0000-0002-8068-1277				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BIERDERER T, 2001, J BIOL CHEM, V276, P47869; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARINEZESTRADA OM, 2001, J BIOL CHEM, V276, P9291; Maximov A, 2002, J NEUROSCI, V22, P6939; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002	35	19	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8422	8431		10.1038/sj.onc.1206996	http://dx.doi.org/10.1038/sj.onc.1206996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627983				2022-12-25	WOS:000186650300006
J	Daran-Lapujade, P; Jansen, MLA; Daran, JM; van Gulik, W; de Winde, JH; Pronk, JT				Daran-Lapujade, P; Jansen, MLA; Daran, JM; van Gulik, W; de Winde, JH; Pronk, JT			Role of transcriptional regulation in controlling fluxes in central carbon metabolism of Saccharomyces cerevisiae - A chemostat culture study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYASE GENE ICL1; ACETYL-COA; GLUCONEOGENIC ENZYMES; CATABOLITE REPRESSION; FUNCTIONAL-ANALYSIS; GLUCOSE REGULATION; PROMOTER ELEMENTS; ACTIVATOR CAT8P; YEAST-CELLS; EXPRESSION	In contrast to batch cultivation, chemostat cultivation allows the identification of carbon source responses without interference by carbon-catabolite repression, accumulation of toxic products, and differences in specific growth rate. This study focuses on the yeast Saccharomyces cerevisiae, grown in aerobic, carbon-limited chemostat cultures. Genome-wide transcript levels and in vivo fluxes were compared for growth on two sugars, glucose and maltose, and for two C2-compounds, ethanol and acetate. In contrast to previous reports on batch cultures, few genes ( 180 genes) responded to changes of the carbon source by a changed transcript level. Very few transcript levels were changed when glucose as the growth-limiting nutrient was compared with maltose ( 33 transcripts), or when acetate was compared with ethanol ( 16 transcripts). Although metabolic flux analysis using a stoichiometric model revealed major changes in the central carbon metabolism, only 117 genes exhibited a significantly different transcript level when sugars and C2-compounds were provided as the growth-limiting nutrient. Despite the extensive knowledge on carbon source regulation in yeast, many of the carbon source-responsive genes encoded proteins with unknown or incompletely characterized biological functions. In silico promoter analysis of carbon source-responsive genes confirmed the involvement of several known transcriptional regulators and suggested the involvement of additional regulators. Transcripts involved in the glyoxylate cycle and gluconeogenesis showed a good correlation with in vivo fluxes. This correlation was, however, not observed for other important pathways, including the pentose-phosphate pathway, tricarboxylic acid cycle, and, in particular, glycolysis. These results indicate that in vivo fluxes in the central carbon metabolism of S. cerevisiae grown in steadystate, carbon-limited chemostat cultures are controlled to a large extent via post-transcriptional mechanisms.	Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands; DSM GIST Delft, Beijerinck Lab, NL-2600 MA Delft, Netherlands	Delft University of Technology; DSM NV	Daran-Lapujade, P (corresponding author), Delft Univ Technol, Kluyver Lab Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.	p.lapujade@tnw.tudelft.nl	Daran, Jean-Marc/X-8787-2019; de Winde, J.H./AAC-5520-2021	de Winde, J.H./0000-0002-7999-9317; Daran, Jean-Marc/0000-0003-3136-8193; Pronk, Jack/0000-0002-5617-4611; Daran-Lapujade, Pascale/0000-0002-4097-7831				Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; Andrade RP, 2001, FUNGAL GENET BIOL, V32, P105, DOI 10.1006/fgbi.2001.1254; Aranda A, 2003, YEAST, V20, P747, DOI 10.1002/yea.991; Ball CA, 2001, NUCLEIC ACIDS RES, V29, P80, DOI 10.1093/nar/29.1.80; Barnett J A, 1976, Adv Carbohydr Chem Biochem, V32, P125, DOI 10.1016/S0065-2318(08)60337-6; Barnett J. A., 1983, YEASTS CHARACTERISTI; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Bojunga N, 1998, MOL GEN GENET, V260, P453, DOI 10.1007/s004380050916; Bojunga N, 1999, MOL GEN GENET, V262, P869, DOI 10.1007/s004380051152; Boles E, 1996, MOL MICROBIOL, V20, P65, DOI 10.1111/j.1365-2958.1996.tb02489.x; Bro C, 2003, J BIOL CHEM, V278, P32141, DOI 10.1074/jbc.M304478200; BRUINENBERG PM, 1983, J GEN MICROBIOL, V129, P953; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Casal M, 1996, MICROBIOL-UK, V142, P1385, DOI 10.1099/13500872-142-6-1385; Caspary F, 1997, MOL GEN GENET, V255, P619, DOI 10.1007/s004380050536; Cereghino GP, 1996, EMBO J, V15, P363, DOI 10.1002/j.1460-2075.1996.tb00366.x; Chen SP, 1997, J BIOL CHEM, V272, P10839; Colby G, 1998, YEAST, V14, P1001, DOI 10.1002/(SICI)1097-0061(199808)14:11<1001::AID-YEA304>3.0.CO;2-K; Daran-Lapujade P, 2003, FEMS YEAST RES, V4, P259, DOI 10.1016/S1567-1356(03)00156-9; Day RE, 2002, YEAST, V19, P1015, DOI 10.1002/yea.894; DEJONGGUBBELS P, 1995, YEAST, V11, P407, DOI 10.1002/yea.320110503; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Even S, 2003, MICROBIOL-SGM, V149, P1935, DOI 10.1099/mic.0.26146-0; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; FEUERMANN M, 1995, YEAST, V11, P667, DOI 10.1002/yea.320110707; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Frolova E, 1999, NUCLEIC ACIDS RES, V27, P1350, DOI 10.1093/nar/27.5.1350; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Glanemann C, 2003, APPL MICROBIOL BIOT, V61, P61, DOI 10.1007/s00253-002-1191-5; GRIGGS DW, 1993, MOL CELL BIOL, V13, P4999, DOI 10.1128/MCB.13.8.4999; Hammerle M, 1998, J BIOL CHEM, V273, P25000, DOI 10.1074/jbc.273.39.25000; HARDER W, 1977, J APPL BACTERIOL, V43, P1, DOI 10.1111/j.1365-2672.1977.tb00717.x; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; HU Z, 1995, CURR GENET, V28, P258, DOI 10.1007/BF00309785; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; JONES RP, 1988, FEMS MICROBIOL LETT, V54, P239, DOI 10.1016/0378-1097(88)90004-3; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Kurita O, 1999, FEMS MICROBIOL LETT, V181, P281, DOI 10.1111/j.1574-6968.1999.tb08856.x; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; LANGE HC, 2002, THESIS TU DELFT NETH; LEE FJS, 1990, J BIOL CHEM, V265, P7413; LEVINE J, 1992, CURR GENET, V22, P181, DOI 10.1007/BF00351724; Lutfiyya LL, 1998, GENETICS, V150, P1377; Makuc J, 2001, YEAST, V18, P1131, DOI 10.1002/yea.763; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mashego MR, 2003, BIOTECHNOL BIOENG, V83, P395, DOI 10.1002/bit.10683; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; MERCADO JJ, 1991, FEBS LETT, V291, P97, DOI 10.1016/0014-5793(91)81112-L; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Muller S, 1997, MICROBIOL-UK, V143, P3055, DOI 10.1099/00221287-143-9-3055; Narendranath NV, 2001, J IND MICROBIOL BIOT, V26, P171, DOI 10.1038/sj.jim.7000090; NEEDLEMAN RB, 1984, P NATL ACAD SCI-BIOL, V81, P2811, DOI 10.1073/pnas.81.9.2811; NI B, 1990, MOL CELL BIOL, V10, P3797, DOI 10.1128/MCB.10.7.3797; Nissen TL, 1997, MICROBIOL-UK, V143, P203, DOI 10.1099/00221287-143-1-203; Overkamp KM, 2002, YEAST, V19, P509, DOI 10.1002/yea.856; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; Planta RJ, 1999, YEAST, V15, P329, DOI 10.1002/(SICI)1097-0061(19990315)15:4<329::AID-YEA360>3.0.CO;2-C; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P468, DOI 10.1128/AEM.55.2.468-477.1989; PRONK JT, 1994, MICROBIOL-SGM, V140, P601, DOI 10.1099/00221287-140-3-601; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; RATLEDGE C, 1989, YEASTS, V3, P367; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Sass E, 2003, J BIOL CHEM, V278, P45109, DOI 10.1074/jbc.M302344200; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; SCHMALIX W, 1993, J BIOL CHEM, V268, P27428; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; SCHOLER A, 1993, CURR GENET, V23, P375, DOI 10.1007/BF00312621; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; Stuckrath I, 2002, BIOTECHNOL BIOENG, V77, P61, DOI 10.1002/bit.10123; Swiegers JH, 2001, YEAST, V18, P585, DOI 10.1002/yea.712; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vallino J.J., 1990, FRONTIERS BIOPRARSSI, P205; van den Berg MA, 1998, YEAST, V14, P1089, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1089::AID-YEA312>3.3.CO;2-B; van Gulik WM, 2000, BIOTECHNOL BIOENG, V68, P602, DOI 10.1002/(SICI)1097-0290(20000620)68:6<602::AID-BIT3>3.0.CO;2-2; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; van Maris AJA, 2003, APPL ENVIRON MICROB, V69, P2094, DOI 10.1128/AEM.69.4.2094-2099.2003; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; VANDERHEIJDEN RTJM, 1994, BIOTECHNOL BIOENG, V43, P11, DOI 10.1002/bit.260430104; VANGULIK WM, 1995, BIOTECHNOL BIOENG, V48, P681, DOI 10.1002/bit.260480617; vanGulik WM, 2001, BIOTECHNOL BIOENG, V72, P185, DOI 10.1002/1097-0290(20000120)72:2<185::AID-BIT7>3.0.CO;2-M; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; VERDUYN C, 1991, ANTON LEEUW INT J G, V59, P49, DOI 10.1007/BF00582119; Wang XP, 1998, J BACTERIOL, V180, P822, DOI 10.1128/JB.180.4.822-830.1998; Yang C, 2002, APPL MICROBIOL BIOT, V58, P813, DOI 10.1007/s00253-002-0949-0; Zaragoza O, 2001, BIOCHEM J, V359, P193, DOI 10.1042/0264-6021:3590193	96	196	200	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9125	9138		10.1074/jbc.M309578200	http://dx.doi.org/10.1074/jbc.M309578200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14630934	hybrid, Green Published			2022-12-25	WOS:000189265900074
J	Dur n, RV; Herv s, M; De la Rosa, MA; Navarro, JA				Dur n, RV; Herv s, M; De la Rosa, MA; Navarro, JA			The efficient functioning of photosynthesis and respiration in Synechocystis sp PCC 6803 strictly requires the presence of either cytochrome c(6) or plastocyanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLASH KINETIC-ANALYSIS; PHOTOSYSTEM-I; ELECTRON-TRANSFER; CYANOBACTERIUM; C(6); MUTAGENESIS; REDUCTION; PROTEINS; FEATURES; MEMBRANE	In cyanobacteria, cytochrome c(6) and plastocyanin are able to replace each other as redox carriers in the photosynthetic and respiratory electron transport chains with the synthesis of one or another protein being regulated by the copper concentration in the culture medium. However, the presence of a third unidentified electron carrier has been suggested. To address this point, we have constructed two deletion mutants of the cyanobacterium Synechocystis sp. PCC 6803, each variant lacking either the petE or petJ gene, which respectively codes for the copper or heme protein. The photoautotrophic and heterotrophic growth rate of the two mutants in copper-free and copper-supplemented medium as well as their photosystem I reduction kinetics in vivo were compared with those of wild-type cells. The two mutant strains grow at equivalent rates and show similar in vivo photosystem I reduction kinetics as wildtype cells when cultured in media that allow the expression of just one of the two electron donor proteins, but their ability to grow and reduce photosystem I is much lower when neither cytochrome c(6) nor plastocyanin is expressed. These findings indicate that the normal functioning of the cyanobacterial photosynthetic and respiratory chains obligatorily depends on the presence of either cytochrome c(6) or plastocyanin.	Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	De la Rosa, MA (corresponding author), Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.	marosa@us.es	Duran, Raul V./E-4764-2011; Hervas, Manuel/K-9279-2014; De la Rosa, Miguel/B-2545-2014; navarro, jose a/B-6354-2015	Duran, Raul V./0000-0002-2249-9215; Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; navarro, jose a/0000-0002-0536-6074				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Ardelean I, 2002, FEMS MICROBIOL LETT, V213, P113, DOI 10.1016/S0378-1097(02)00801-7; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Baymann F, 2001, BIOCHEMISTRY-US, V40, P10570, DOI 10.1021/bi010194a; BINDER A, 1984, BIOCHIM BIOPHYS ACTA, V765, P241, DOI 10.1016/0005-2728(84)90161-0; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; De la Rosa MA, 2002, BIOELECTROCHEMISTRY, V55, P41, DOI 10.1016/S1567-5394(01)00136-0; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 2003, ACCOUNTS CHEM RES, V36, P798, DOI 10.1021/ar020084b; Hervas M, 2003, J BIOL CHEM, V278, P8179, DOI 10.1074/jbc.M211913200; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Kaneko T, 1996, DNA Res, V3, P109; Malakhov MP, 1999, FEBS LETT, V444, P281, DOI 10.1016/S0014-5793(99)00074-5; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Metzger SU, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P823; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Peschek, 1999, PHOTOTROPHIC PROKARY, P201, DOI DOI 10.1007/978-1-4615-4827-0_24; Pils D, 1997, FEMS MICROBIOL LETT, V152, P83, DOI 10.1111/j.1574-6968.1997.tb10412.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; ZHANG L, 1992, J BIOL CHEM, V267, P19054; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	29	58	69	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7229	7233		10.1074/jbc.M311565200	http://dx.doi.org/10.1074/jbc.M311565200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660567	hybrid, Green Published			2022-12-25	WOS:000188969200123
J	Han, DC; Lee, MY; Shin, KD; Jeon, SB; Kim, JM; Son, KH; Kim, HC; Kim, HM; Kwon, BM				Han, DC; Lee, MY; Shin, KD; Jeon, SB; Kim, JM; Son, KH; Kim, HC; Kim, HM; Kwon, BM			2 '-benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; OXIDATIVE STRESS; GENE-EXPRESSION; CANCER; KINASE; CINNAMALDEHYDES; INHIBITION; RADIATION; MECHANISM	2'-Hydroxycinnamaldehyde (HCA) has been shown to have inhibitory effects on farnesyl protein transferase in vitro, angiogenesis, and tumor cell growth. However, mechanism for these inhibitions remains unknown. As a derivative of HCA, BCA (2'-benzoyl-oxycinnamaldehyde) was synthesized by replacing hydroxyl group with benzoyl-oxyl group. When p53-mutated cancer cell lines (MDA-MB-231 breast cancer cell and SW620 colon cancer cell) were treated with 10 muM HCA or BCA, it induced growth arrest and apoptosis of tumor cells. Markers of apoptosis such as degradations of chromosomal DNA and poly(ADP-ribose) polymerase and activation of caspase-3 were detected after HCA or BCA treatment. BCA-induced apoptosis was blocked by pretreatment of cells with anti-oxidants, glutathione, or N-acetyl-cysteine. In addition, BCA-induced activation of caspase-3 and degradation of poly(ADP-ribose) polymerase were abolished by pretreatment of cells with the anti-oxidants. These results suggest that reactive oxygen species are major regulator of BCA-induced apoptosis. HCA or BCA-induced accumulation of reactive oxygen species was detected by using DCF-DA, an intracellular probe of oxidative stress. Furthermore, when BCA (100 mg/kg) was administrated intraperitoneally or orally into a nude mouse, it inhibited >88 or 41% of tumor growth, respectively, without any detectable weight change. These results suggest that BCA is a good drug candidate for cancer therapy.	Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kwon, BM (corresponding author), Korea Res Inst Biosci & Biotechnol, 52 Uendong Yoosunggu, Taejon 305600, South Korea.	kwonbm@kribb.re.kr		Kim, Jung Min/0000-0001-6319-0217				ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; ENNIS BW, 1991, CANCER INVEST, V9, P553, DOI 10.3109/07357909109018953; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Henkels KM, 1999, CANCER RES, V59, P3077; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Koh WS, 1998, INT J IMMUNOPHARMACO, V20, P643, DOI 10.1016/S0192-0561(98)00064-2; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Kwon BM, 1996, PLANTA MED, V62, P183, DOI 10.1055/s-2006-957851; Kwon BM, 1997, BIOORG MED CHEM LETT, V7, P2473, DOI 10.1016/S0960-894X(97)10008-7; Lee CW, 1999, PLANTA MED, V65, P263, DOI 10.1055/s-2006-960772; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rao GN, 1996, ONCOGENE, V13, P713; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	38	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6911	6920		10.1074/jbc.M309708200	http://dx.doi.org/10.1074/jbc.M309708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660655	hybrid			2022-12-25	WOS:000188969200086
J	Ohashi, T; Erickson, HP				Ohashi, T; Erickson, HP			The disulfide bonding pattern in ficolin multimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-D; MANNOSE-BINDING PROTEIN; HELICAL COILED-COIL; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; INNATE IMMUNITY; FIBRINOGEN-LIKE; HAKATA ANTIGEN	Ficolin is a plasma lectin, consisting of a short N-terminal multimerization domain, a middle collagen domain, and a C-terminal fibrinogen-like domain. The collagen domains assemble the subunits into trimers, and the N-terminal domain assembles four trimers into 12-mers. Two cysteine residues in the N-terminal domain are thought to mediate multimerization by disulfide bonding. We have generated three mutants of ficolin a in which the N-terminal cysteines were substituted by serines (Cys(4), Cys(24) , and Cys(4)/Cys(24)). The N-terminal cysteine mutants were produced in a mammalian cell expression system, purified by affinity chromatography, and analyzed under nondenaturing conditions to resolve the multimer structure of the native protein and under denaturing conditions to resolve the disulfide-linked structure. Glycerol gradient sedimentation and electron microscopy in nondenaturing conditions showed that plasma and recombinant wild-type protein formed 12-mers. The Cys(4) mutant also formed 12-mers, but CyS24 and CyS4/CyS24 mutants formed only trimers. This means that protein interfaces containing Cys(4) are stable as noncovalent protein-protein interactions and do not require disulfides, whereas those containing Cys(24)-Cys(24) require the disulfides for stability. Proteins were also analyzed by nonreducing SDS-PAGE to show the covalent structure under denaturing conditions. Wild-type ficolin was covalently linked into 12-mers, whereas elimination of either Cys(4) or Cys(24) gave dimers and monomers. We present a model in which symmetric Cys(24)-Cys(24) disulfide bonds between trimers are the basis for multimerization. The model may also be relevant to collectin multimers.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	H.Erickson@cellbio.duke.edu			NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NCI NIH HHS [CA47056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Endo Y, 1996, GENOMICS, V36, P515, DOI 10.1006/geno.1996.0497; ERICKSON H P, 1974, Journal of Supramolecular Structure, V2, P393, DOI 10.1002/jss.400020228; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Fujimori Y, 1998, BIOCHEM BIOPH RES CO, V244, P796, DOI 10.1006/bbrc.1998.8344; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; HAAS C, 1991, EUR J BIOCHEM, V197, P799; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Harumiya S, 1996, J BIOCHEM-TOKYO, V120, P745; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; Holmskov UL, 2000, APMIS, V108, P7; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kakinuma Y, 2003, IMMUNOGENETICS, V55, P29, DOI 10.1007/s00251-003-0552-2; Kenjo A, 2001, J BIOL CHEM, V276, P19959, DOI 10.1074/jbc.M011723200; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lu J, 1996, IMMUNOLOGY, V89, P289, DOI 10.1046/j.1365-2567.1996.d01-732.x; LU J, 1990, J IMMUNOL, V144, P2287; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; Ohashi T, 1998, ARCH BIOCHEM BIOPHYS, V360, P223, DOI 10.1006/abbi.1998.0957; Olsen DR, 2001, J BIOL CHEM, V276, P24038, DOI 10.1074/jbc.M101613200; Rothmann AB, 1997, EUR J BIOCHEM, V243, P630, DOI 10.1111/j.1432-1033.1997.t01-1-00630.x; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Storgaard P, 1996, SCAND J IMMUNOL, V43, P289, DOI 10.1046/j.1365-3083.1996.d01-39.x; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Teh C, 2000, IMMUNOLOGY, V101, P225, DOI 10.1046/j.1365-2567.2000.00099.x; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	47	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6534	6539		10.1074/jbc.M310555200	http://dx.doi.org/10.1074/jbc.M310555200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660572	hybrid			2022-12-25	WOS:000188969200040
J	Sayasith, K; Bouchard, N; Sawadogo, M; Lussier, JG; Sirois, J				Sayasith, K; Bouchard, N; Sawadogo, M; Lussier, JG; Sirois, J			Molecular characterization and role of bovine upstream stimulatory factor 1 and 2 in the regulation of the prostaglandin G/H synthase-2 promoter in granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; HUMAN CHORIONIC-GONADOTROPIN; MESSENGER-RIBONUCLEIC-ACID; ELEMENT-BINDING PROTEIN; ENDOPEROXIDE SYNTHASE-2; PREOVULATORY FOLLICLES; OVARIAN-FOLLICLES; GENE-EXPRESSION; DNA-BINDING; INDUCTION	The transcriptional activation of the prostaglandin G/H synthase-2 (PGHS-2) gene in granulosa cells is required for ovulation. To directly study the ability of upstream stimulatory factor 1 (USF1) and USF2 to trans-activate the bovine PGHS-2 promoter in granulosa cells, USF1 or USF2 expression vectors were cotransfected with the PGHS-2/luciferase (LUC) chimeric construct, -149/-2PGHS-2.LUC. Results revealed that overexpression of USF1 or USF2 caused a marked and significant increase in basal and forskolin-inducible promoter activities (p < 0.05), and these effects were dependent on the presence of a consensus E-box cis-element within the promoter fragment. Co-transfections with different N- and C-terminal truncated USF mutants led to significant reductions in promoter activation, as compared with full-length constructs (p < 0.05), thus allowing identification of putative bovine USF functional domains. Overexpression of a USF2 truncated mutant lacking the first 220 residues (U2Delta1-220) acted as a dominant negative mutant and blocked endogenous and USF-stimulated PGHS-2 promoter activation. Interestingly, transfections with U2Delta1-220 blocked the forskolin-dependent induction of PGHS-2 mRNA in granulosa cells, whereas transfections with full-length USF2 increased PGHS-2 transcript levels. Immunoblot analyses confirmed overexpression of full-length and truncated USF proteins, and electrophoretic mobility shift assays (EMSAs) and supershift EMSAs established that the observed effects were dependent on specific interactions between USF proteins and the consensus E-box cis-element. Stimulation of cells with forskolin increased, whereas treatment of extracts with phosphatase decreased USF binding activities to the E-box. Thus, this study presents for the first time direct evidence for a role of USF proteins in the regulation of the PGHS-2 promoter in preovulatory granulosa cells.	Univ Montreal, Fac Med Vet, CRRA, St Hyacinthe, PQ J2S 7C6, Canada; Univ Montreal, Fac Med Vet, Dept Biomed Vet, St Hyacinthe, PQ J2S 7C6, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Universite de Montreal; Universite de Montreal; University of Texas System; UTMD Anderson Cancer Center	Sirois, J (corresponding author), Univ Montreal, Fac Med Vet, CRRA, CP 5000, St Hyacinthe, PQ J2S 7C6, Canada.	jean.sirois@umontreal.ca						ARMSTRONG DT, 1981, J REPROD FERTIL, V62, P283; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Boerboom D, 1998, ENDOCRINOLOGY, V139, P1662, DOI 10.1210/en.139.4.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breen GAM, 1997, J BIOL CHEM, V272, P10538; Breen GAM, 2000, BBA-GENE STRUCT EXPR, V1517, P119, DOI 10.1016/S0167-4781(00)00269-4; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chen WG, 2003, J NEUROSCI, V23, P2572; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; Conti M, 2002, BIOL REPROD, V67, P1653, DOI 10.1095/biolreprod.102.004952; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Galibert MD, 1997, J IMMUNOL, V159, P6176; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Goueli BS, 2003, ONCOGENE, V22, P8042, DOI 10.1038/sj.onc.1206847; Gourdon L, 1997, Genes Funct, V1, P87; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Han SY, 2001, FEBS LETT, V505, P57, DOI 10.1016/S0014-5793(01)02777-6; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; Kingsley-Kallesen ML, 1999, J BIOL CHEM, V274, P34020, DOI 10.1074/jbc.274.48.34020; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; Lajoie S, 2002, J HISTOCHEM CYTOCHEM, V50, P923, DOI 10.1177/002215540205000706; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1999, J BIOL CHEM, V274, P35037, DOI 10.1074/jbc.274.49.35037; Liu JM, 2001, BIOL REPROD, V64, P983, DOI 10.1095/biolreprod64.3.983; Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200; Luo X, 1996, MOL CELL BIOL, V16, P1367; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Mikuni M, 1998, BIOL REPROD, V59, P1077, DOI 10.1095/biolreprod59.5.1077; Moore ML, 2003, J BIOL CHEM, V278, P17263, DOI 10.1074/jbc.M210486200; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; PRIDDY AR, 1993, PROSTAG LEUKOTR ESS, V49, P827, DOI 10.1016/0952-3278(93)90204-A; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Saito T, 2003, INT J MOL MED, V12, P161; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SIROIS J, 1992, J BIOL CHEM, V267, P6382; Sirois J, 2000, SERONO SYMP, P208; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tsai SJ, 1996, ENDOCRINOLOGY, V137, P3348, DOI 10.1210/en.137.8.3348; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; Wu YL, 2002, BIOL REPROD, V66, P1505, DOI 10.1095/biolreprod66.5.1505; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; Yamada K, 2001, BIOL REPROD, V64, P1315, DOI 10.1095/biolreprod64.5.1315	61	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6327	6336		10.1074/jbc.M311222200	http://dx.doi.org/10.1074/jbc.M311222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660559	hybrid			2022-12-25	WOS:000188969200017
J	Wang, MC; Collins, RF; Ford, RC; Berrow, NS; Dolphin, AC; Kitmitto, A				Wang, MC; Collins, RF; Ford, RC; Berrow, NS; Dolphin, AC; Kitmitto, A			The three-dimensional structure of the cardiac L-type voltage-gated calcium channel - Comparison with the skeletal muscle form reveals a common architectural motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON CRYOMICROSCOPY; CA2+ CHANNELS; 1,4-DIHYDROPYRIDINE RECEPTOR; BETA-SUBUNITS; DIHYDROPYRIDINE RECEPTOR; ANGULAR RECONSTITUTION; GAMMA-SUBUNIT; PORCINE HEART; K+ CHANNEL; EXPRESSION	We describe here the first three-dimensional structure of the cardiac L-type voltage-gated calcium channel (VGCC) purified from bovine heart. The structure was determined by electron microscopy and single particle analysis of negatively stained complexes, using the angular reconstitution method. The cardiac VGCC can be isolated as a stable dimer, as reported previously for the skeletal muscle VGCC, with a central aqueous chamber formed by the two halves of the complex. Moreover, we demonstrate that the dimeric cardiac VGCC binds the dihydropyridine [H-3]azidopine with a K-d similar to310 pm. We have compared the cardiac VGCC structure with the skeletal muscle form, determined using the same reconstructive methodology, allowing us to identify common and distinct features of the complexes. By using antibody and lectin-gold labeling, we have localized the intracellular beta polypeptides and the extracellular glycosylation sites of the skeletal muscle VGCC, which can be correlated to the cardiac three-dimensional structure. From the data presented here the assignment of the orientation of the VGCC complexes with respect to the lipid bilayer is now possible. A difference between the cardiac and skeletal muscle ion channels is apparent in the putative transmembrane region, which would be consistent with the absence of the gamma subunit in the cardiac VGCC assembly.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; UCL, Dept Pharmacol, London WC1E 6BT, England	University of Manchester; University of London; University College London	Kitmitto, A (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.	a.kitmitto@umist.ac.uk	Dolphin, Annette C/F-7416-2010	Dolphin, Annette C/0000-0003-4626-4856; Berrow, Nick/0000-0002-6104-4117; Ford, Robert/0000-0002-0958-1505				Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; BERROW N, 1995, J PHYSIOL-LONDON, V489P, pP52; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; CHANG CF, 1990, BIOCHEM BIOPH RES CO, V172, P751, DOI 10.1016/0006-291X(90)90738-9; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FERRY DR, 1984, FEBS LETT, V169, P112, DOI 10.1016/0014-5793(84)80299-9; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gandhi CS, 2003, NEURON, V40, P515, DOI 10.1016/S0896-6273(03)00646-9; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Gurnett CA, 1997, J BIOL CHEM, V272, P18508, DOI 10.1074/jbc.272.29.18508; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; Harris JR, 2001, MICRON, V32, P599, DOI 10.1016/S0968-4328(00)00051-2; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KUNIYASU A, 1992, J BIOCHEM, V112, P235, DOI 10.1093/oxfordjournals.jbchem.a123883; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LEUNG AT, 1988, J BIOL CHEM, V263, P994; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Murata K, 2001, BIOCHEM BIOPH RES CO, V282, P284, DOI 10.1006/bbrc.2001.4529; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Serysheva II, 2002, P NATL ACAD SCI USA, V99, P10370, DOI 10.1073/pnas.162363499; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; Taylor AM, 2001, BRIT J PHARMACOL, V134, P1609, DOI 10.1038/sj.bjp.0704400; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; Wang MC, 2002, J MOL BIOL, V323, P85, DOI 10.1016/S0022-2836(02)00890-2; Wolf M, 2003, J MOL BIOL, V332, P171, DOI 10.1016/S0022-2836(03)00899-4	49	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7159	7168		10.1074/jbc.M308057200	http://dx.doi.org/10.1074/jbc.M308057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14634003	hybrid			2022-12-25	WOS:000188969200115
J	He, Q; Huang, Y; Sheikh, MS				He, Q; Huang, Y; Sheikh, MS			Bax deficiency affects caspase-2 activation during ultraviolet radiation-induced apoptosis	ONCOGENE			English	Article						caspase-2; ultraviolet radiation; Bax deficiency; colon cancer cells	FAMILY-MEMBERS; CELL-DEATH; MITOCHONDRIA; REQUIREMENT; FAS/APO-1; RECEPTORS; SULINDAC; PATHWAY	There has been a considerable debate as to whether caspase-2 is an initiator or effector caspase. Recently, a new model of intrinsic pathway of apoptosis has been proposed, which suggests caspase-2 to be an initiator caspase. For example, ultraviolet radiation (UV) and other DNA damage-inducing agents were shown to first activate caspase-2 and then regulate the mitochondrial and postmitochondrial events. Active caspase-2 was found to engage mitochondria by promoting Bax translocation to the mitochondria. Consequently, Bax was proposed to play a central role in bridging the active caspase-2 with mitochondria by affecting mitochondrial permeability, cytochrome c release into the cytosol and caspase- 9 activation. In the present study, we investigated the role of Bax in UV-induced apoptosis and caspase- 2 activation. Our results indicate that UV-induced apoptosis and caspase- 2 activation were diminished in Bax-deficient cells, suggesting that Bax appears to play an important role in UV-induced apoptosis as well as caspase- 2 activation, and that it also appears to reside upstream of caspase-2. Bax deficiency also affected the activation of caspase- 3 and - 8 and abolished caspase- 9 activation during UV-induced apoptosis, suggesting that the absence of caspase- 9 activation may affect caspase- 2, - 3 and - 8 activation in Bax-deficient cells. Based on our results, we propose that activation of caspases is not a linear cascade of events, but is rather connected via complex feedback loops.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA86945, CA89043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043, R01CA086945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang Y, 2001, CANCER RES, V61, P6918; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 2001, GENE DEV, V15, P2922; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	25	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1321	1325		10.1038/sj.onc.1207212	http://dx.doi.org/10.1038/sj.onc.1207212			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647455				2022-12-25	WOS:000188892200018
J	Maeda, O; Usami, N; Kondo, M; Takahashi, M; Goto, H; Shimokata, K; Kusugami, K; Sekido, Y				Maeda, O; Usami, N; Kondo, M; Takahashi, M; Goto, H; Shimokata, K; Kusugami, K; Sekido, Y			Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line	ONCOGENE			English	Article						plakoglobin; beta-catenin; malignant mesothelioma; transcriptional activity; Wnt signaling cascade	3P21.3 HOMOZYGOUS DELETION; HUMAN LUNG-CANCER; MALIGNANT MESOTHELIOMA; CYCLIN D1; MUTATIONS; PATHWAY; TARGET; APC; GROWTH; GENE	beta-Catenin is an essential element for the transcriptional activation of target genes in the Wnt signaling cascade and is also a cell adhesion molecule that couples with cadherins. Although plakoglobin (gamma-catenin), a closely related homologue of beta-catenin, is also known to be a cell adhesion molecule, its function as a transcriptional factor has not been revealed in detail. Using a human malignant mesothelioma cell line, NCI-H28, in which we have identified a homozygous deletion of the beta-catenin gene, we studied whether plakoglobin has a T-cell factor/ lymphocyte enhancer factor (TCF/LEF) family-dependent transcriptional activity. Transfection with the wildtype plakoglobin expression vector induced accumulation of plakoglobin in the nucleus. Immunoprecipitation assay with cotransfection of plakoglobin and either TCF-4 or LEF-1 detected binding of plakoglobin to TCF-4 or LEF-1. Luciferase reporter assay demonstrated transcriptional activity of the wild-type plakoglobin when transfected with TCF/LEF, although plakoglobin showed less activity than beta-catenin. Exogenous plakoglobin was also shown to promote entrance of exogenous beta-catenin into the nuclei. Furthermore, small interfering RNA directed against plakoglobin suppressed expression of endogenous plakoglobin and its transcriptional activity, suggesting that endogenous plakoglobin has a weak transcriptional activity. These results suggest that plakoglobin can activate the Wnt signaling cascade directly without interaction of beta-catenin, and that plakoglobin has multiple functions as a transcriptional activator and a cell adhesion molecule like beta-catenin.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668560, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668560, Japan.	ysekido@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; Kondo, Masashi/I-7378-2014; TAKAHASHI, Masahide/I-7244-2014; Sekido, Yoshitaka/P-9756-2015	Takahashi, Masahide/0000-0002-2803-2683; Sekido, Yoshitaka/0000-0002-2428-3848				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Clements WM, 2002, CANCER RES, V62, P3503; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Kolligs FT, 2000, GENE DEV, V14, P1319; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SEKIDO Y, 1994, CANCER RES, V54, P4988; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sparks AB, 1998, CANCER RES, V58, P1130; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	33	124	126	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					964	972		10.1038/sj.onc.1207254	http://dx.doi.org/10.1038/sj.onc.1207254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661054				2022-12-25	WOS:000188486600012
J	Sato, K; Nakano, A				Sato, K; Nakano, A			Reconstitution of coat protein complex II (COPII) vesicle formation from cargo-reconstituted proteoliposomes reveals the potential role of GTP hydrolysis by Sar1p in protein sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI-APPARATUS; ER; EXPORT; GLYCOPROTEIN; LIPOSOMES; YEAST	Secretory proteins are transported from the endoplasmic reticulum ( ER) in vesicles coated with coat protein complex II ( COPII). To investigate the molecular mechanism of protein sorting into COPII vesicles, we have developed an in vitro budding reaction comprising purified coat proteins and cargo reconstituted proteolipsomes. Emp47p, a type-I membrane protein, is specifically required for the transport of an integral membrane protein, Emp46p, from the ER. Recombinant Emp46/47p proteins and the ER resident protein Ufe1p were reconstituted into liposomes whose composition resembles yeast ER membranes. When the proteoliposomes were mixed with COPII proteins and GMP-PNP, Emp46/47p, but not Ufe1p, were concentrated into COPII vesicles. We also show here that reconstituted Emp47p accelerates the GTP hydrolysis by Sar1p as stimulated by its GTPase-activating protein, Sec23/24p, both of which are components of the COPII coat. Furthermore, this GTP hydrolysis decreases the error of cargo sorting. We suggest that GTP hydrolysis by Sar1p promotes exclusion of improper proteins from COPII vesicles.	RIKEN, Mol Membrane Biol Lab, Discovery Res Inst, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, PRESTO, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; Japan Science & Technology Agency (JST); University of Tokyo	Sato, K (corresponding author), RIKEN, Mol Membrane Biol Lab, Discovery Res Inst, Wako, Saitama 3510198, Japan.		Nakano, Akihiko/C-6185-2009; Nakano, Akihiko/G-4942-2014; Nakano, Akihiko/A-6420-2016	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X				Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; Emery G, 2000, J CELL SCI, V113, P2507; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lanoix J, 2001, J CELL BIOL, V155, P1199, DOI 10.1083/jcb.200108017; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; Matsuoka K, 2000, METHODS, V20, P417, DOI 10.1006/meth.2000.0955; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	26	41	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1330	1335		10.1074/jbc.C300457200	http://dx.doi.org/10.1074/jbc.C300457200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14627716	hybrid			2022-12-25	WOS:000187722800060
J	Erol, E; Kumar, LS; Cline, GW; Shulman, GI; Kelly, DP; Binas, B				Erol, E; Kumar, LS; Cline, GW; Shulman, GI; Kelly, DP; Binas, B			Liver fatty acid-binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPAR-alpha in fasting mice	FASEB JOURNAL			English	Article						lipid metabolism; gene expression	PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOME PROLIFERATORS; EXPRESSION; GENE; MITOCHONDRIAL; CHOLESTEROL; TRANSPORT; LACKING; MURINE; ALTER	Liver fatty acid binding protein (L-FABP) has been proposed to limit the availability of long-chain fatty acids (LCFA) for oxidation and for peroxisome proliferator-activated receptor alpha (PPAR-alpha), a fatty acid binding transcription factor that determines the capacity of hepatic fatty acid oxidation. Here, we used L-FABP null mice to test this hypothesis. Under fasting conditions, this mutation reduced beta-hydroxybutyrate (BHB) plasma levels as well as BHB release and palmitic acid oxidation by isolated hepatocytes. However, the capacity for ketogenesis was not reduced: BHB plasma levels were restored by octanoate injection; BHB production and palmitic acid oxidation were normal in liver homogenates; and hepatic expression of key PPAR-alpha. target (MCAD, mitochondrial HMG CoA synthase, ACO, CYP4A3) and other (CPTI, LCAD) genes of mitochondrial and extramitochondrial LCFA oxidation and ketogenesis remained at wild-type levels. During standard diet, mitochondrial HMG CoA synthase mRNA was selectively reduced in L-FABP null liver. These results suggest that under fasting conditions, hepatic L-FABP contributes to hepatic LCFA oxidation and ketogenesis by a nontranscriptional mechanism, whereas L-FABP can activate ketogenic gene expression in fed mice. Thus, the mechanisms whereby L-FABP affects fatty acid oxidation may vary with physiological condition.	Texas A&M Univ, Coll Vet Med, Dept Pathobiol, College Stn, TX 77843 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO USA	Texas A&M University System; Texas A&M University College Station; Howard Hughes Medical Institute; Yale University; Washington University (WUSTL)	Binas, B (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Pathobiol, Raymond Stotzer Pkwy, College Stn, TX 77843 USA.	bbinas@cvm.tamu.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NIDDK NIH HHS [R01 DK040936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; Chao H, 2003, J LIPID RES, V44, P72, DOI 10.1194/jlr.M200191-JLR200; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; HAINLINE BE, 1993, BIOCHIM BIOPHYS ACTA, V1216, P460, DOI 10.1016/0167-4781(93)90015-6; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Hung DY, 2003, AM J PHYSIOL-GASTR L, V284, pG423, DOI 10.1152/ajpgi.00328.2002; KAIKAUS RM, 1993, MOL CELL BIOCHEM, V123, P93, DOI 10.1007/BF01076479; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Luxon BA, 1996, AM J PHYSIOL-GASTR L, V271, pG113, DOI 10.1152/ajpgi.1996.271.1.G113; Luxon BA, 1997, AM J PHYSIOL-CELL PH, V273, pC859, DOI 10.1152/ajpcell.1997.273.3.C859; Madden CR, 2000, J VIROL, V74, P5266, DOI 10.1128/JVI.74.11.5266-5272.2000; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; McArthur MJ, 1999, J LIPID RES, V40, P1371; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; OCKNER RK, 1979, J CLIN INVEST, V64, P172, DOI 10.1172/JCI109437; Sambrook J, 2001, MOL CLONING LAB MANU; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; VEERKAMP JH, 1986, BIOCHIM BIOPHYS ACTA, V875, P301, DOI 10.1016/0005-2760(86)90180-3; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u; Wolfrum C, 1999, J LIPID RES, V40, P708; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898	38	84	85	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					347	+		10.1096/fj.03-0330fje	http://dx.doi.org/10.1096/fj.03-0330fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656998				2022-12-25	WOS:000188067500019
J	Philp, D; Nguyen, M; Scheremeta, B; St-Surin, S; Villa, AM; Orgel, A; Kleinman, HK; Elkin, M				Philp, D; Nguyen, M; Scheremeta, B; St-Surin, S; Villa, AM; Orgel, A; Kleinman, HK; Elkin, M			Thymosin beta(4) increases hair growth by activation of hair follicle stem cells	FASEB JOURNAL			English	Article						matrix metalloproteinase-2; clonogenic keratinocytes	VEIN ENDOTHELIAL-CELLS; FACTOR HGF ACTIVATOR; RAT VIBRISSA; IN-VIVO; BETA-4; BULGE; SKIN; COLLAGEN; ANAGEN; MATRIX	Thymosin beta(4), a 43-amino acid polypeptide that is an important mediator of cell migration and differentiation, also promotes angiogenesis and wound healing. Here, we report that thymosin beta(4) stimulates hair growth in normal rats and mice. A specific subset of hair follicular keratinocytes in mouse skin expresses thymosin beta(4) in a highly coordinated manner during the hair growth cycle. These keratinocytes originate in the hair follicle bulge region, a niche for skin stem cells. Rat vibrissa follicle clonogenic keratinocytes, closely related, if not identical, to the bulge-residing stem cells, were isolated and their migration and differentiation increased in the presence of nanomolar concentrations of thymosin beta(4). Expression and secretion of the extracellular matrix-degrading enzyme matrix metalloproteinase-2 were increased by thymosin beta(4). Thus, thymosin beta(4) accelerates hair growth, in part, due to its effect on critical events in the active phase of the hair follicle cycle, including promoting the migration of stem cells and their immediate progeny to the base of the follicle, differentiation, and extracellular matrix remodeling.	NICHHD, Cell Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kleinman, HK (corresponding author), NIDCR, Cell Biol Sect, NIH, Bldg 30,Room 433,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.	hkleinman@dir.nidcr.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bao L, 1998, CLIN EXP METASTAS, V16, P227, DOI 10.1023/A:1006540824969; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cotsarelis G, 1997, AM J PATHOL, V151, P1505; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; GRANT DS, 1995, J CELL SCI, V108, P3685; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; JAHODA CAB, 1992, J ANAT, V181, P47; Janes SM, 2002, J PATHOL, V197, P479, DOI 10.1002/path.1156; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Karelina TV, 2000, J INVEST DERMATOL, V114, P371, DOI 10.1046/j.1523-1747.2000.00886.x; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Lee YR, 2001, J DERMATOL SCI, V25, P156, DOI 10.1016/S0923-1811(00)00124-9; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; LINK RE, 1990, J INVEST DERMATOL, V95, P202, DOI 10.1111/1523-1747.ep12478002; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Lyle S, 1998, J CELL SCI, V111, P3179; Lyle S, 1999, J INVEST DERM SYMP P, V4, P296, DOI 10.1038/sj.jidsp.5640233; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Oh IS, 2002, BIOCHEM BIOPH RES CO, V296, P401, DOI 10.1016/S0006-291X(02)00888-4; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; PAUS R, 1989, LAB INVEST, V60, P365; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Roy P, 2001, J CELL BIOL, V153, P1035, DOI 10.1083/jcb.153.5.1035; SCANDURRO AB, 1995, J INVEST DERMATOL, V105, P177, DOI 10.1111/1523-1747.ep12317089; Shapiro J, 1998, DERMATOL CLIN, V16, P341, DOI 10.1016/S0733-8635(05)70017-6; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2002, CURR EYE RES, V24, P268, DOI 10.1076/ceyr.24.4.268.8414; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; SUN TT, 1991, J INVEST DERMATOL, V96, pS77, DOI 10.1111/1523-1747.ep12471959; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WILSON CL, 1994, SKIN PHARMACOL, V7, P8; Yamazaki M, 1999, J INVEST DERM SYMP P, V4, P312, DOI 10.1038/sj.jidsp.5640236; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Young JD, 1999, NAT MED, V5, P1424; YUSPA SH, 1993, J INVEST DERMATOL, V101, pS27, DOI 10.1111/1523-1747.ep12362567	46	90	93	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					385	+		10.1096/fj.03-0244fje	http://dx.doi.org/10.1096/fj.03-0244fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657002				2022-12-25	WOS:000188067500024
J	Radtke, C; Akiyama, Y; Brokaw, J; Lankford, KL; Wewetzer, K; Fodor, WL; Kocsis, JD				Radtke, C; Akiyama, Y; Brokaw, J; Lankford, KL; Wewetzer, K; Fodor, WL; Kocsis, JD			Remyelination of the nonhuman primate spinal cord by transplantation of H-transferase transgenic adult pig olfactory ensheathing cells	FASEB JOURNAL			English	Article						OEC; HT; transplantation	SCHWANN-CELLS; AXONAL REGENERATION; GLIA; EXPRESSION; CONDUCTION; RECOVERY; BULB	Olfactory ensheathing cells (OECs) have been shown to mediate remyelination and to stimulate axonal regeneration in a number of in vivo rodent spinal cord studies. However, whether OECs display similar properties in the primate model has not been tested so far. In the present study, we thus transplanted highly-purified OECs isolated from transgenic pigs expressing the alpha1,2 fucosyltransferase gene (H-transferase or HT) gene into a demyelinated lesion of the African green monkey spinal cord. Four weeks posttransplantation, robust remyelination was found in 62.5% of the lesion sites, whereas there was virtually no remyelination in the nontransplanted controls. This together with the immunohistochemical demonstration of the grafted cells within the lesioned area confirmed that remyelination was indeed achieved by OECs. Additional in vitro assays demonstrated 1) that the applied cell suspension consisted of >98% OECs, 2) that the majority of the cells expressed the transgene, and 3) that expression of the HT gene reduced complement activation more than twofold compared with the nontransgenic control. This is the first demonstration that xenotransplantation of characterized OECs into the primate spinal cord results in remyelination.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06516 USA; Vet Affairs Med Ctr, Neurosci Res Ctr, West Haven, CT 06516 USA; Alex Pharmaceut Inc, Cheshire, CT 06410 USA; Hannover Med Sch, CTR Anat, D-3000 Hannover, Germany	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Hannover Medical School	Kocsis, JD (corresponding author), Yale Univ, Sch Med, Neurosci Res Ctr 127A, VAMC, West Haven, CT 06516 USA.	william.fodor@uconn.edu	Messier, Claude/A-2322-2008; Radtke, Christine/M-2927-2013; Radtke, Christine/B-8491-2018	Messier, Claude/0000-0002-4791-1763; Radtke, Christine/0000-0001-6877-5038	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043432, P50NS010174, F05NS010174] Funding Source: NIH RePORTER; NICHD NIH HHS [R44 HD095784] Funding Source: Medline; NINDS NIH HHS [R01 NS043432-05, P50 NS010174-290027, R01 NS043432, F05 NS010174] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; BERTHOLD CH, PHYSL PATHOBIOLOGY A, P3; Chen SC, 1997, ANN NY ACAD SCI, V831, P350; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; CICCHETTI F, 2002, XENOTRANSPLANTATION, V9, P1; Costa C, 2002, XENOTRANSPLANTATION, V9, P45, DOI 10.1034/j.1399-3089.2002.0o142.x; Costa C, 1999, FASEB J, V13, P1762, DOI 10.1096/fasebj.13.13.1762; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; Imaizumi T, 2000, BRAIN RES, V854, P70, DOI 10.1016/S0006-8993(99)02285-4; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Imaizumi T, 2000, NAT BIOTECHNOL, V18, P949, DOI 10.1038/79432; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 1998, J NEUROSCI, V18, P10514; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; McCurry KR, 1997, HUM IMMUNOL, V58, P91, DOI 10.1016/S0198-8859(97)00229-2; PIXLEY SK, 1992, GLIA, V5, P269, DOI 10.1002/glia.440050405; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; Smith PM, 2002, EXP NEUROL, V176, P402, DOI 10.1006/exnr.2002.7936; Takami T, 2002, J NEUROSCI, V22, P6670; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Wewetzer K, 2002, CELL TISSUE RES, V309, P337, DOI 10.1007/s00441-002-0607-y	29	72	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					335	+		10.1096/fj.03-0214fje	http://dx.doi.org/10.1096/fj.03-0214fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657003	Green Accepted			2022-12-25	WOS:000188067500034
J	Balakrishnan, L; Venter, H; Shilling, RA; van Veen, HW				Balakrishnan, L; Venter, H; Shilling, RA; van Veen, HW			Reversible transport by the ATP-binding cassette multidrug export pump LmrA - ATP synthesis at the expense of downhill ethidium uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; TERTIARY STRUCTURE CHANGES; REFLECTION INFRARED-SPECTROSCOPY; DISULFIDE CROSS-LINKING; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGES; ABC TRANSPORTERS; TRANSITION-STATE; DRUG-BINDING; TRANSMEMBRANE DOMAINS	The ATP dependence of ATP-binding cassette (ABC) transporters has led to the widespread acceptance that these systems are unidirectional. Interestingly, in the presence of an inwardly directed ethidium concentration gradient in ATP-depleted cells of Lactococcus lactis, the ABC multidrug transporter LmrA mediated the reverse transport <LF>(or uptake) of ethidium with an apparent K-t of 2.0 muM. This uptake reaction was competitively inhibited by the LmrA substrate vinblastine and was significantly reduced by an E314A substitution in the membrane domain of the transporter. Similar to efflux, LmrA-mediated ethidium uptake was inhibited by the E512Q replacement in the Walker B region of the nucleotide-binding domain of the protein, which strongly reduced its drug-stimulated ATPase activity, consistent with published observations for other ABC transporters. The notion that ethidium uptake is coupled to the catalytic cycle in LmrA was further corroborated by studies in LmrA-containing cells and proteoliposomes in which reverse transport of ethidium was associated with the net synthesis of ATP. Taken together, these data demonstrate that the conformational changes required for drug transport by LmrA are (i) not too far from equilibrium under ATP-depleted conditions to be reversed by appropriate changes in ligand concentrations and (ii) not necessarily coupled to ATP hydrolysis, but associated with a reversible catalytic cycle. These findings and their thermodynamic implications shed new light on the mechanism of energy coupling in ABC transporters and have implications for the development of new modulators that could enable reverse transport-associated drug delivery in cells through their ability to uncouple ATP binding/hydrolysis from multidrug efflux.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	van Veen, Hendrik W./A-4162-2008; Venter, Rietie/E-4795-2013	van Veen, Hendrik W./0000-0002-9658-8077; Venter, Rietie/0000-0001-5569-7755				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P237, DOI 10.1113/jphysiol.1967.sp008298; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; KO YH, 1994, J BIOL CHEM, V269, P14584; Lew V L, 1970, Nature, V225, P865, DOI 10.1038/225865a0; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1345, DOI 10.1021/bi0267745; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharom FJ, 1999, BBA-BIOMEMBRANES, V1461, P327, DOI 10.1016/S0005-2736(99)00166-2; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, BBA-BIOENERGETICS, V1365, P31, DOI 10.1016/S0005-2728(98)00039-5; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; van Veen HW, 2001, SEMIN CELL DEV BIOL, V12, P239, DOI 10.1006/scdb.2000.0249; van Veen HW, 2003, ABC PROTEINS BACTERI, P81; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; Vigano C, 2000, J BIOL CHEM, V275, P10962, DOI 10.1074/jbc.275.15.10962; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x	48	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11273	11280		10.1074/jbc.M308494200	http://dx.doi.org/10.1074/jbc.M308494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14660649	hybrid			2022-12-25	WOS:000220157600055
J	Zhang, F; Cheng, J; Hackett, NR; Lam, G; Shido, K; Pergolizzi, R; Jin, DK; Crystal, RG; Rafii, S				Zhang, F; Cheng, J; Hackett, NR; Lam, G; Shido, K; Pergolizzi, R; Jin, DK; Crystal, RG; Rafii, S			Adenovirus E4 gene promotes selective endothelial cell survival and angiogenesis via activation of the vascular endothelial-cadherin/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; VE-CADHERIN; GROWTH-FACTOR; BETA-CATENIN; EXPRESSION; VECTORS; AKT; TRANSDUCTION; TRANSCRIPTION; E1(-)E4(+)	The early 4 region (E4) of the adenoviral vectors (AdE4(+)) prolongs human endothelial cell (EC) survival and alters the angiogenic response, although the mechanisms for the EC-specific, AdE4(+)-mediated effects remain unknown. We hypothesized that AdE4(+) modulates EC survival through activation of the vascular endothelial (VE)-cadherin/Akt pathway. Here, we showed that AdE4(+), but not AdE4(-) vectors, selectively stimulated phosphorylation of both Akt at Ser(473) and Src kinase in ECs. The phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and wortmannin abrogated AdE4(+) induction of both phospho-Akt expression and prolonged EC survival. Regulation of phospho-Akt was found to be under the control of various factors, namely VE-cadherin activation, Src kinase, tyrosine kinase, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). Downstream targets of Akt signaling resulted in glycogen synthase kinase-3alpha/beta phosphorylation, beta-catenin up-regulation, and caspase-3 suppression, all of which led to AdE4(+)-mediated EC survival. Furthermore, infection with AdE4(+) vectors increased the angiogenic potential of ECs by promoting EC migration and capillary tube formation in Matrigel plugs. This selective AdE4(+)-mediated enhanced motility of ECs was also blocked by PI3K inhibitors. Taken together, these results suggest that activation of the VE-cadherin/ Akt pathway is critical for AdE4(+)-mediated survival of ECs and angiogenic potential.	Cornell Univ, Weill Med Coll, Dept Med Genet, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Hematol & Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Belfer Gene Therapy Core Facil, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, Div Hematol Oncol, 1300 York Ave,Rm D601, New York, NY 10021 USA.	srafii@med.cornell.edu	Zhang, Feng/B-6691-2012		NHLBI NIH HHS [R01 HL61849, P01 HL59312, HL67839, HL66592, HL59312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL059312, P01HL059312, P01HL067839, R01HL061849] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Amalfitano A, 1998, J VIROL, V72, P926, DOI 10.1128/JVI.72.2.926-933.1998; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gorziglia MI, 1996, J VIROL, V70, P4173, DOI 10.1128/JVI.70.6.4173-4178.1996; Harris JD, 2002, HUM MOL GENET, V11, P43, DOI 10.1093/hmg/11.1.43; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HERSH J, 1995, GENE THER, V2, P124; Jornot L, 2001, ENDOTHELIUM-NEW YORK, V8, P167; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Leppard KN, 1997, J GEN VIROL, V78, P2131, DOI 10.1099/0022-1317-78-9-2131; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; Ma H, 2002, ATHEROSCLEROSIS, V164, P79, DOI 10.1016/S0021-9150(02)00062-X; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; Rafii S, 2001, CIRC RES, V88, P903, DOI 10.1161/hh0901.089884; Ramalingam R, 1999, BLOOD, V93, P2936; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhang F, 2003, BLOOD, V102, P2115, DOI 10.1182/blood-2003-01-0049	33	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11760	11766		10.1074/jbc.M312221200	http://dx.doi.org/10.1074/jbc.M312221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14660586	hybrid			2022-12-25	WOS:000220157600113
J	Koike, T; Liang, JY; Wang, XF; Ichikawa, T; Shiomi, M; Liu, G; Sun, HJ; Kitajima, S; Morimoto, M; Watanabe, T; Yamada, N; Fan, JL				Koike, T; Liang, JY; Wang, XF; Ichikawa, T; Shiomi, M; Liu, G; Sun, HJ; Kitajima, S; Morimoto, M; Watanabe, T; Yamada, N; Fan, JL			Overexpression of lipoprotein lipase in transgenic watanabe heritable hyperlipidemic rabbits improves hyperlipidemia and obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-FED RABBITS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; LDL RECEPTOR; APOLIPOPROTEIN-E; SKELETAL-MUSCLE; KNOCKOUT MICE; ATHEROSCLEROSIS; METABOLISM	Lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis of the triglyceride-rich lipoproteins and plays a critical role in lipoprotein and free fatty acid metabolism. Genetic manipulation of LPL may be beneficial in the treatment of hypertriglyceridemias, but it is unknown whether increased LPL activity may be effective in lowering plasma cholesterol and improving insulin resistance in familial hypercholesterolemic patients. To test the hypothesis that stimulation of LPL expression may be used as an adjunctive therapy for treatment of homozygous familial hypercholesterolemia, we have generated transgenic (Tg) Watanabe heritable hyperlipidemic (WHHL) rabbits that overexpress the human LPL transgene and compared their plasma lipid levels, glucose metabolism, and body fat accumulation with those of non-Tg WHHL rabbits. Overexpression of LPL dramatically ameliorated hypertriglyceridemia in Tg WHHL rabbits. Furthermore, increased LPL activity in male Tg WHHL rabbits also corrected hypercholesterolemia (544+/-52 in non-Tg versus 227+/-29 mg/dl in Tg, p<0.01) and reduced body fat accumulation by 61% (323 +/- 27 in non-Tg versus 125 +/- 21 g in Tg, p<0.01), suggesting that LPL plays an important role in mediating plasma cholesterol homeostasis and adipose accumulation. In addition, overexpression of LPL significantly suppressed high fat diet-induced obesity and insulin resistance in Tg WHHL rabbits. These results imply that systemic elevation of LPL expression may be potentially useful for the treatment of hyperlipidemias, obesity, and insulin resistance.	Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Cardiovasc Dis Lab, Tsukuba, Ibaraki 3058575, Japan; Kobe Univ, Sch Med, Inst Expt Anim, Kobe, Hyogo 6500017, Japan; Peking Univ, Inst Cardiovasc Sci, Beijing 100083, Peoples R China; Dalian Med Univ, Dept Pharmacol, Dalian 116027, Peoples R China; Saga Univ, Sch Med, Saga 8498502, Japan; Univ Tsukuba, Inst Clin Med, Div Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; Kobe University; Peking University; Dalian Medical University; Saga University; University of Tsukuba	Fan, JL (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Cardiovasc Dis Lab, Tsukuba, Ibaraki 3058575, Japan.	j-lfan@md.tsukuba.ac.jp	Liang, Jingyan/F-6630-2014	Fan, Jianglin/0000-0002-1737-6130; Kitajima, Shuji/0000-0002-6239-2682				AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; Brousseau ME, 1998, J LIPID RES, V39, P1558; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; Excoffon KJDA, 1997, ARTERIOSCL THROM VAS, V17, P2532, DOI 10.1161/01.ATV.17.11.2532; Fan JL, 2000, J LIPID RES, V41, P1004; Fan JL, 2001, ARTERIOSCL THROM VAS, V21, P88, DOI 10.1161/01.ATV.21.1.88; Fan JL, 2001, J BIOL CHEM, V276, P40071, DOI 10.1074/jbc.M105456200; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Ginzinger DG, 1999, EUR J CLIN INVEST, V29, P17, DOI 10.1046/j.1365-2362.1999.00435.x; Goldberg IJ, 1996, J LIPID RES, V37, P693; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; Huang YD, 1997, J BIOL CHEM, V272, P22685, DOI 10.1074/jbc.272.36.22685; IKEDA Y, 1990, J LIPID RES, V31, P1911; IVERIUS PH, 1988, J CLIN INVEST, V82, P1106, DOI 10.1172/JCI113667; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; Kastelein JJP, 2000, CIRCULATION, V102, P1629, DOI 10.1161/01.CIR.102.14.1629; KAWAMURA M, 1994, ARTERIOSCLER THROMB, V14, P235, DOI 10.1161/01.ATV.14.2.235; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kusunoki M, 2000, DIABETOLOGIA, V43, P875, DOI 10.1007/s001250051464; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; Mingrone G, 1999, DIABETES, V48, P1258, DOI 10.2337/diabetes.48.6.1258; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHIMADA M, 1995, BIOCHEM BIOPH RES CO, V211, P761, DOI 10.1006/bbrc.1995.1878; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; Shiomi M, 2003, ARTERIOSCL THROM VAS, V23, P1239, DOI 10.1161/01.ATV.0000075947.28567.50; Sugihara H, 2001, Nihon Rinsho, V59 Suppl 2, P477; TSUTSUMI K, 1993, J CLIN INVEST, V92, P411, DOI 10.1172/JCI116582; Voshol PJ, 2001, DIABETES, V50, P2585, DOI 10.2337/diabetes.50.11.2585; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Wittekoek ME, 1998, CIRCULATION, V97, P729, DOI 10.1161/01.CIR.97.8.729; Yagyu H, 1999, J LIPID RES, V40, P1677; Yin Weidong, 2003, Int J Exp Diabesity Res, V4, P27; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005; Zechner R, 2000, INT J OBESITY, V24, pS53, DOI 10.1038/sj.ijo.0801506; Zhang B, 2001, BRIT J BIOMED SCI, V58, P217; ZHANG B, 1991, ATHEROSCLEROSIS, V91, P277, DOI 10.1016/0021-9150(91)90175-3; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	46	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7521	7529		10.1074/jbc.M311514200	http://dx.doi.org/10.1074/jbc.M311514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660566	hybrid			2022-12-25	WOS:000189103300020
J	Rodriguez, D; Quiros, LM; Salas, JA				Rodriguez, D; Quiros, LM; Salas, JA			MtmMII-mediated C-methylation during biosynthesis of the antitumor drug mithramycin is essential for biological activity and DNA-drug interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREOLIC ACID GROUP; STREPTOMYCES-ARGILLACEUS; POLYKETIDE MITHRAMYCIN; FOLD RECOGNITION; BINDING; METHYLTRANSFERASES; PURIFICATION; GENES; OLEANDOMYCIN; ANTIBIOTICUS	The antitumor drug mithramycin consists of a polyketide chromophore glycosylated with a trisaccharide and a disaccharide. Two post-polyketide methylations take place during mithramycin biosynthesis. One of these methylations has been shown to be very relevant for biological activity, that is the introduction of a methyl group at aromatic C-7. We have purified to 282-fold the MtmMII methyltransferase involved in this reaction. The protein is a monomer, and results from kinetic studies were consistent with a model for the enzyme acting via a compulsory order mechanism. The enzyme showed high substrate specificity and was unable to operate on structurally closely related molecules. Structural predictions suggest that the molecule is integrated by two domains, an essentially all alpha-amino domain and an alpha/beta-carboxyl domain displaying a variation of a Rossmann-fold containing the cofactor binding site. Although 7-demethyl-mithramycin did not show any biological activity, it was able to reach the nucleus of eukaryotic cells, with subsequent binding to DNA. Mithramycin and 7-demethylmithramycin were able to form similar complexes with Mg2+, although their respective DNA binding isotherms were very different. The dinucleotide binding model fit well the isotherms recorded for both compounds, predicting that the C-7 methyl group was essential for high affinity binding to specific GC and CG sequences. Considering previous structural studies, we propose that this effect is performed by positioning the group in the floor of the minor groove, allowing the interaction with the third sugar moiety of the trisaccharide, D-mycarose, which is involved in sequence selectivity.	Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, IUOPA, E-33006 Oviedo, Spain	University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Salas, JA (corresponding author), Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain.	jasalas@correo.uniovi.es	Rodríguez, David/K-3872-2017; Quirós, Luis/T-3822-2017	Rodríguez, David/0000-0002-7530-2770; Quirós, Luis/0000-0003-3505-3762				AICH P, 1990, BIOCHEM BIOPH RES CO, V173, P689, DOI 10.1016/S0006-291X(05)80090-7; AICH P, 1995, BIOCHEMISTRY-US, V34, P1376, DOI 10.1021/bi00004a032; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; Blanco G, 1996, CHEM BIOL, V3, P193, DOI 10.1016/S1074-5521(96)90262-8; Blanco G, 2000, MOL GEN GENET, V262, P991, DOI 10.1007/PL00008667; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaires JB, 2001, METHOD ENZYMOL, V340, P3; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3933, DOI 10.1021/bi00260a005; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DEWICK PM, 1997, MED NATURAL PRODUCTS, P85; Fernandez E, 1998, J BACTERIOL, V180, P4929; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNINGER AL, 1972, BIOCHEMISTRY-US, P711; Lombo F, 1996, GENE, V172, P87, DOI 10.1016/0378-1119(96)00029-7; Lozano MJF, 2000, J BIOL CHEM, V275, P3065, DOI 10.1074/jbc.275.5.3065; Malygin EG, 2003, J BIOL CHEM, V278, P15713, DOI 10.1074/jbc.M213213200; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mendez C, 2001, TRENDS BIOTECHNOL, V19, P449, DOI 10.1016/S0167-7799(01)01765-6; Mir MA, 2001, BIOCHEM BIOPH RES CO, V280, P68, DOI 10.1006/bbrc.2000.4075; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; Prado L, 1999, MOL GEN GENET, V261, P216, DOI 10.1007/s004380050960; Prado L, 1999, CHEM BIOL, V6, P19, DOI 10.1016/S1074-5521(99)80017-9; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; QUIROS LM, 1995, J BIOL CHEM, V270, P18234, DOI 10.1074/jbc.270.31.18234; Reither S, 2003, J MOL BIOL, V329, P675, DOI 10.1016/S0022-2836(03)00509-6; Rodriguez D, 2003, J BACTERIOL, V185, P3962, DOI 10.1128/JB.185.13.3962-3965.2003; Rohr J, 1998, CHEM COMMUN, P437, DOI 10.1039/a707446h; Rohr J, 1999, BIOORG CHEM, V27, P41, DOI 10.1006/bioo.1998.1110; ROHR J, 2002, Patent No. P200032; Rudolph F B, 1979, Methods Enzymol, V63, P138; SASTRY M, 1993, BIOCHEMISTRY-US, V32, P6588, DOI 10.1021/bi00077a012; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; VILCHES C, 1990, J GEN MICROBIOL, V136, P1447, DOI 10.1099/00221287-136-8-1447; VILTAIKIS G, 2001, J BIOL CHEM, V276, P20924; ZHOU ZS, 2001, FRONT BIOTECH PHARM, V2, P199; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	42	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8149	8158		10.1074/jbc.M312351200	http://dx.doi.org/10.1074/jbc.M312351200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660589	hybrid			2022-12-25	WOS:000189103300096
J	Sheahan, S; Bellamy, COC; Treanor, L; Harrison, DJ; Prost, S				Sheahan, S; Bellamy, COC; Treanor, L; Harrison, DJ; Prost, S			Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes	ONCOGENE			English	Article						polyploidy; proliferation; liver; carcinogenesis; regeneration	KINASE INHIBITOR P21; CELL-CYCLE; INDUCED APOPTOSIS; GENE-EXPRESSION; INDUCTION; GROWTH; POLYPLOIDY; PATHWAY; ROLES; MICE	Using Cre-Lox technology to inducibly delete Rb from wild-type, p21- and/or p53-deficient primary hepatocytes, we investigated the role of p53, p21 and pRb in the regulation of liver cell proliferation, polyploidization and death. These cellular decisions are critical to maintaining liver cell replacement in disease, and in determining the likelihood of carcinogenesis in chronic liver injury. Clearly, the present study shows a complex interplay between p53, p21 and pRb, which regulates the likelihood of hepatocytes stimulated from quiescence, to proliferate, undergo polyploidy or die. It reveals that these proteins act both in concert and independently, demonstrating that a small set of key cellular players is common to diverse cell decisions of fundamental importance to disease.	Univ Edinburgh, Sch Mol & Clin Med, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.prost@ed.ac.uk		harrison, david/0000-0001-9041-9988; prost, sandrine/0000-0002-0140-7115				Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NURSE P, 1991, NATURE, V354, P356, DOI 10.1038/354356a0; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; PURDIE CA, 1994, ONCOGENE, V9, P603; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vooijs M, 2002, CANCER RES, V62, P1862; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	56	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1489	1497		10.1038/sj.onc.1207280	http://dx.doi.org/10.1038/sj.onc.1207280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647424				2022-12-25	WOS:000189219500001
J	Hashmi, S; Zhang, J; Oksov, Y; Lustigman, S				Hashmi, S; Zhang, J; Oksov, Y; Lustigman, S			The Caenorhabditis elegans cathepsin Z-like cysteine protease, Ce-CPZ-1, has a multifunctional role during the worms' development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; C-ELEGANS; ONCHOCERCA-VOLVULUS; GENE-EXPRESSION; MOLECULAR-CLONING; ROLLER MUTANTS; STAGE LARVAE; CUTICLE; ECDYSIS; INTERFERENCE	We have analyzed the expression and function of Ce-cpz-1, a Caenorhabditis elegans cathepsin Z-like cysteine protease gene, during development of the worm. The cpz-1 gene is expressed in various hypodermal cells of all developmental stages and is specifically expressed in the gonads and the pharynx of adult worms. Disruption of cpz-1 function by RNA interference or cpz-1(ok497) deletion mutant suggests that cpz-1 has a role in the molting pathways. The presence of the native CPZ-1 protein in the hypodermis/cuticle of larval and adult stages and along the length of the pharynx of adult worms, as well as the cyclic expression of the transcript during larval development, supports such function. We hypothesize that the CPZ-1 enzyme functions directly as a proteolytic enzyme degrading cuticular proteins before ecdysis and/or indirectly by processing other proteins such as proenzymes and/or other proteins that have an essential role during molting. Notably, an impressive level of the CPZ-1 native protein is present in both the new and the old cuticles during larval molting, in particular in the regions that are degraded prior to shedding and ecdysis. The similar localization of the related Onchocerca volvulus cathepsin Z protein suggests that the function of CPZ-1 during molting might be conserved in other nematodes. Based on the cpz-1 RNA interference and cpz-1 (ok497) deletion mutant phenotypes, it appears that cpz-1 have additional roles during morphogenesis. Deletion of cpz-1 coding sequence or inhibition of cpz-1 function by RNA interference also caused morphological defects in the head or tail region of larvae, improperly developed gonad in adult worms and embryonic lethality. The CPZ-1 native protein in these affected regions may have a role in the cuticular and the basement membrane extracellular matrix assembly process. The present findings have defined a critical role for cathepsin Z in nematode biology.	New York Blood Ctr, Mol Parasitol Lab, Lindsley F Kimball Res Inst, New York, NY 10021 USA; New York Blood Ctr, Electron Microscopy Lab, Lindsley F Kimball Res Inst, New York, NY 10021 USA	New York Blood Center; New York Blood Center	Hashmi, S (corresponding author), New York Blood Ctr, Mol Parasitol Lab, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	shashmi@nybloodcenter.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048057, R01AI048057] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48057] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asahina M, 2000, GENES CELLS, V5, P711, DOI 10.1046/j.1365-2443.2000.00361.x; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; Blelloch R, 1999, DEV BIOL, V216, P382, DOI 10.1006/dbio.1999.9491; BURLING RT, 1998, INT J PARASITOL, V28, P395; Bynum J, 1999, HYBRIDOMA, V18, P407, DOI 10.1089/hyb.1999.18.407; COLE SCJ, 1993, FEMS MICROBIOL LETT, V113, P189, DOI 10.1016/0378-1097(93)90267-6; COX GN, 1980, GENETICS, V95, P317; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; Dalton JP, 1996, INFECT IMMUN, V64, P5066, DOI 10.1128/IAI.64.12.5066-5074.1996; DAVEY KG, 1968, CAN J ZOOLOG, V46, P893, DOI 10.1139/z68-125; Falcone FH, 2000, EXP PARASITOL, V94, P201, DOI 10.1006/expr.2000.4489; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GAMBLE HR, 1989, J PARASITOL, V75, P303, DOI 10.2307/3282779; GAMBLE HR, 1989, MOL BIOCHEM PARASIT, V33, P49, DOI 10.1016/0166-6851(89)90041-8; Gissendanner CR, 2000, DEV BIOL, V221, P259, DOI 10.1006/dbio.2000.9679; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Guncar G, 2000, STRUCTURE, V8, P305, DOI 10.1016/S0969-2126(00)00108-8; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Hashmi S, 2001, TRENDS PARASITOL, V17, P387, DOI 10.1016/S1471-4922(01)01986-9; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; HONG XQ, 1993, EXP PARASITOL, V76, P127, DOI 10.1006/expr.1993.1015; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KEMPHUES KJ, 1986, DEV BIOL, V113, P449, DOI 10.1016/0012-1606(86)90180-6; Kilpatrick KE, 1997, HYBRIDOMA, V16, P381, DOI 10.1089/hyb.1997.16.381; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kostrouchova M, 1998, DEVELOPMENT, V125, P1617; Kostrouchova M, 2001, P NATL ACAD SCI USA, V98, P7360, DOI 10.1073/pnas.131171898; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KRAMER JM, 1997, C ELEGANS, V2, P471; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; Lee Donald L., 2002, P171; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Lustigman S, 1996, J BIOL CHEM, V271, P30181, DOI 10.1074/jbc.271.47.30181; LUSTIGMAN S, 1993, PARASITOL TODAY, V9, P294, DOI 10.1016/0169-4758(93)90128-3; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nagler DK, 1998, FEBS LETT, V434, P135, DOI 10.1016/S0014-5793(98)00964-8; Nagler DK, 1999, BIOCHEMISTRY-US, V38, P12648, DOI 10.1021/bi991371z; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; Radice AD, 1996, MOL BIOCHEM PARASIT, V80, P41, DOI 10.1016/0166-6851(96)02667-9; RICHER JK, 1992, EXP PARASITOL, V75, P213, DOI 10.1016/0014-4894(92)90181-9; SAMUELS RI, 1995, COMP BIOCHEM PHYS B, V110, P661, DOI 10.1016/0305-0491(94)00205-9; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Wood W. B., 1988, NEMATODE C ELEGANS, P215; Yang J, 1999, J BIOL CHEM, V274, P32744, DOI 10.1074/jbc.274.46.32744; Yochem J, 1999, DEVELOPMENT, V126, P597	60	49	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6035	6045		10.1074/jbc.M312346200	http://dx.doi.org/10.1074/jbc.M312346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630920	hybrid			2022-12-25	WOS:000188776500119
J	Hosking, BM; Wang, SCM; Downes, M; Koopman, P; Muscat, GEO				Hosking, BM; Wang, SCM; Downes, M; Koopman, P; Muscat, GEO			The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sry-related high mobility group box gene, Sox18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE-INDUCED VCAM-1; LEUKOCYTE ADHESION; INTEGRIN VLA-4; E-SELECTIN; LYMPHATIC ENDOTHELIUM; TRANSCRIPTION FACTOR; FUNCTIONAL-ANALYSIS; MESSENGER-RNA; TNF-ALPHA; IN-VIVO	VCAM-1 (vascular cell adhesion molecule-1) and Sox18 are involved in vascular development. VCAM-1 is an important adhesion molecule that is expressed on endothelial cells and has a critical role in endothelial activation, inflammation, lymphatic pathophysiology, and atherogenesis. The Sry-related high mobility group box factor Sox18 has previously been implicated in endothelial pathologies. Mutations in human and mouse Sox18 leads to hypotrichosis and lymphedema. Furthermore, both Sox18 and VCAM-1 have very similar spatio-temporal patterns of expression, which is suggestive of crosstalk. We use biochemical techniques, cell culture systems, and the ragged opossum (RaOP) mouse model with a naturally occurring mutation in Sox18 to demonstrate that VCAM-1 is an important target of Sox18. Transfection, site-specific mutagenesis, and gel shift analyses demonstrated that Sox18 directly targeted and trans-activated VCAM-1 expression. Importantly, the naturally occurring Sox18 mutant attenuates the expression and activation of VCAM-1 in vitro. Furthermore, in vivo quantitation of VCAM-1 mRNA levels in wild type and RaOP mice demonstrates that RaOP animals show a dramatic and significant reduction in VCAM-1 mRNA expression in lung, skin, and skeletal muscle. Our observation that the VCAM-1 gene is an important target of SOX18 provides the first molecular insights into the vascular abnormalities in the mouse mutant ragged and the human hypotrichosis-lymphedematelangiectasia disorder.	Univ Queensland, Inst Mol Biosci, Queensland Biosci Project, Brisbane, Qld 4072, Australia	University of Queensland	Muscat, GEO (corresponding author), Univ Queensland, Inst Mol Biosci, Queensland Biosci Project, Brisbane, Qld 4072, Australia.	g.muscat@imb.uq.edu.au	Downes, Meredith/B-7370-2013; Koopman, Peter A/C-9416-2009; Downes, Meredith/P-8203-2018; Muscat, George/A-6401-2017; Wang, Shu-Ching/C-6082-2017	Koopman, Peter A/0000-0001-6939-0914; Downes, Meredith/0000-0002-6517-1834; Muscat, George/0000-0002-5829-5695; Wang, Shu-Ching/0000-0002-7871-3735				Abe Y, 1996, J LEUKOCYTE BIOL, V60, P692, DOI 10.1002/jlb.60.6.692; Barks JL, 1997, J IMMUNOL, V159, P4532; Beck-Schimmer B, 2001, AM J RESP CELL MOL, V25, P780, DOI 10.1165/ajrcmb.25.6.4433; BRISCOE DM, 1992, J IMMUNOL, V149, P2954; CARTER TC, 1954, J HERED, V45, P150; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; Chen SL, 2000, GENE DEV, V14, P1209; COFFIN JD, 1991, ANAT REC, V231, P383; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Davies D, 1999, IMMUNOLOGY, V97, P150; DeGraba Thomas J, 2003, Adv Neurol, V92, P29; Dyer CM, 2003, VACCINE, V21, P2115, DOI 10.1016/S0264-410X(02)00742-9; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Feeley BT, 1999, J HEART LUNG TRANSPL, V18, P1088, DOI 10.1016/S1053-2498(99)00078-9; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; GREEN EL, 1961, J HERED, V52, P223, DOI 10.1093/oxfordjournals.jhered.a107077; GROVES RW, 1993, J AM ACAD DERMATOL, V29, P67, DOI 10.1016/0190-9622(93)70154-L; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; Harrison AA, 1997, J IMMUNOL, V159, P4546; Henninger DD, 1997, J IMMUNOL, V158, P1825; HERBERTSON B M, 1964, J Med Genet, V1, P10, DOI 10.1136/jmg.1.1.10; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Hosking BM, 2001, BIOCHEM BIOPH RES CO, V287, P493, DOI 10.1006/bbrc.2001.5589; Hosking BM, 2001, GENE, V262, P239, DOI 10.1016/S0378-1119(00)00525-4; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Irrthum A, 2003, AM J HUM GENET, V72, P1470, DOI 10.1086/375614; James K, 2003, GENESIS, V36, P1, DOI 10.1002/gene.10190; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Klimiuk PA, 2002, ANN RHEUM DIS, V61, P804, DOI 10.1136/ard.61.9.804; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KORENAGA R, 1997, AM J PHYSIOL, V273, pC1506; Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; KWEE L, 1995, DEVELOPMENT, V121, P489; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; MANN SJ, 1963, GENET RES, V4, P1, DOI 10.1017/S0016672300003372; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; Park SK, 2000, NEPHROL DIAL TRANSPL, V15, P596, DOI 10.1093/ndt/15.5.596; Pennisi D, 2000, NAT GENET, V24, P434, DOI 10.1038/74301; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Sawa Y, 1999, MICROVASC RES, V57, P100, DOI 10.1006/mvre.1998.2132; Schieffer B, 2003, AM J CARDIOL, V91, p12H, DOI 10.1016/S0002-9149(03)00429-6; SHEPPARD AM, 1994, CELL ADHES COMMUN, V2, P27, DOI 10.3109/15419069409014200; SLEE JOHN, 1957, JOUR GENETICS, V55, P570, DOI 10.1007/BF02984073; SLEE JOHN, 1957, JOUR GENETICS, V55, P100, DOI 10.1007/BF02981618; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; Steinman L, 2003, NAT REV IMMUNOL, V3, P483, DOI 10.1038/nri1108; STEPP MA, 1994, CELL ADHES COMMUN, V2, P359, DOI 10.3109/15419069409014210; WALLACE ME, 1979, HEREDITY, V43, P9, DOI 10.1038/hdy.1979.54; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Willuweit A, 2001, J IMMUNOL, V167, P3944, DOI 10.4049/jimmunol.167.7.3944; Yamazaki R, 2000, EUR J PHARMACOL, V404, P375, DOI 10.1016/S0014-2999(00)00620-8; Young AJ, 2000, EUR J IMMUNOL, V30, P327, DOI 10.1002/1521-4141(200001)30:1<327::AID-IMMU327>3.3.CO;2-K	64	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5314	5322		10.1074/jbc.M308512200	http://dx.doi.org/10.1074/jbc.M308512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634005	hybrid			2022-12-25	WOS:000188776500035
J	Krengel, U; Olsson, LL; Martinez, C; Talavera, A; Rojas, G; Mier, E; Angstrom, J; Moreno, E				Krengel, U; Olsson, LL; Martinez, C; Talavera, A; Rojas, G; Mier, E; Angstrom, J; Moreno, E			Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GLYCOLYLNEURAMINIC ACID; DYNAMICS CALCULATIONS; MONOCLONAL-ANTIBODY; DIFFRACTION DATA; FAB FRAGMENT; DATA-BANK; GANGLIOSIDES; RECOGNITION; ANTIGEN	N- Glycolyl GM3 ganglioside is an attractive target antigen for cancer immunotherapy, because this epitope is a molecular marker of certain tumor cells and not expressed in normal human tissues. The murine monoclonal antibody 14F7 specifically recognizes N- glycolyl GM3 and shows no cross- reactivity with the abundant N- acetyl GM3 ganglioside, a close structural homologue of N- glycolyl GM3. Here, we report the crystal structure of the 14F7 Fab fragment at 2.5 Angstrom resolution and its molecular model with the saccharide moiety of N- glycolyl GM3, NeuGcalpha3Galbeta4Glcbeta. Fab 14F7 contains a very long CDR H3 loop, which divides the antigen- binding site of this antibody into two subsites. In the docking model, the saccharide ligand is bound to one of these subsites, formed solely by heavy chain residues. The discriminative feature of N- glycolyl GM3 versus N- acetyl GM3, its hydroxymethyl group, is positioned in a hydrophilic cavity, forming hydrogen bonds with the carboxyl group of Asp H52, the indole NH of Trp H33 and the hydroxyl group of Tyr H50. For the hydrophobic methyl group of N- acetyl GM3, this environment would not be favorable, explaining why the antibody specifically recognizes N- glycolyl GM3, but not N- acetyl GM3. Mutation of Asp H52 to hydrophobic residues of similar size completely abolished binding. Our model of the antibody-carbohydrate complex is consistent with binding data for several tested glycolipids as well as for a variety of 14F7 mutants with replaced VL domains.	Chalmers Univ Technol, Dept Chem & Biosci, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Ctr Genet Engn & Biotechnol, Havana 10600, Cuba; Ctr Mol Immunol, Havana 11600, Cuba	Chalmers University of Technology; University of Gothenburg; Centro de Ingenieria Genetica y Biotecnologia	Moreno, E (corresponding author), Chalmers Univ Technol, Dept Chem & Biosci, POB 462, SE-40530 Gothenburg, Sweden.	emoreno@ict.cim.sld.cu	Talavera, Ariel/AAG-9932-2019; Moreno, Ernesto/D-2128-2012; Gray, Elin/V-6707-2019	Gray, Elin/0000-0002-8613-3570; Moreno, Ernesto/0000-0002-2309-4826; Rojas, Gertrudis/0000-0001-6335-6264; Krengel, Ute/0000-0001-6688-8151				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5183, DOI 10.1021/bi00183a023; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Carr A, 2002, HYBRIDOMA HYBRIDOM, V21, P463, DOI 10.1089/153685902321043990; Carr A, 2000, HYBRIDOMA, V19, P241, DOI 10.1089/02724570050109639; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; CYGLER M, 1993, BIOCHEM SOC T, V21, P437, DOI 10.1042/bst0210437; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Gschwend DA, 1996, J COMPUT AID MOL DES, V10, P123, DOI 10.1007/BF00402820; IMBERTY A, 1991, GLYCOCONJUGATE J, V8, P456, DOI 10.1007/BF00769847; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; Johnson G, 2001, NUCLEIC ACIDS RES, V29, P205, DOI 10.1093/nar/29.1.205; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Malykh YN, 2001, BIOCHIMIE, V83, P623, DOI 10.1016/S0300-9084(01)01303-7; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Marquina G, 1996, CANCER RES, V56, P5165; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Moreno E, 1998, GLYCOBIOLOGY, V8, P695, DOI 10.1093/glycob/8.7.695; Moreno E, 2002, PROTEINS, V47, P1, DOI 10.1002/prot.10026; MUTHING J, 1994, J BIOCHEM, V116, P64; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NYHOLM PG, 1993, BIOCHEMISTRY-US, V32, P1225, DOI 10.1021/bi00056a005; Pichla SL, 1997, J STRUCT BIOL, V119, P6, DOI 10.1006/jsbi.1997.3857; Portoukalian J, 2000, CLIN REV ALLERG IMMU, V19, P73, DOI 10.1385/CRIAI:19:1:73; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; SIEBERT HC, 1992, BIOCHEMISTRY-US, V31, P6962, DOI 10.1021/bi00145a014; Varki A, 2001, BIOCHIMIE, V83, P615, DOI 10.1016/S0300-9084(01)01309-8; Villeneuve S, 2000, P NATL ACAD SCI USA, V97, P8433, DOI 10.1073/pnas.060022997; Vyas NK, 2002, BIOCHEMISTRY-US, V41, P13575, DOI 10.1021/bi0261387; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	40	32	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5597	5603		10.1074/jbc.M311693200	http://dx.doi.org/10.1074/jbc.M311693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14627696	hybrid			2022-12-25	WOS:000188776500069
J	Li, XR; Chen, HQ; Oo, TH; Daly, TM; Bergman, LW; Liu, SC; Chishti, AH; Oh, SS				Li, XR; Chen, HQ; Oo, TH; Daly, TM; Bergman, LW; Liu, SC; Chishti, AH; Oh, SS			A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIC REPEAT ANTIGEN; SURFACE PROTEIN-1 COMPLEX; MALARIA PARASITES; ESCHERICHIA-COLI; BINDING ANTIGEN; GLYCOPHORIN-A; S-ANTIGEN; MEMBRANE; HETEROGENEITY; GLYCOPROTEIN	In Plasmodium falciparum malaria, erythrocyte invasion by circulating merozoites may occur via two distinct pathways involving either a sialic acid-dependent or -independent mechanism. Earlier, we identified two nonglycosylated exofacial regions of erythrocyte band 3 termed 5ABC and 6A as an important host receptor in the sialic acid-independent invasion pathway. 5ABC, a major segment of this receptor, interacts with the 42-kDa processing product of merozoite surface protein 1 (MSP1(42)) through its 19-kDa C-terminal domain. Here, we show that two regions of merozoite surface protein 9 (MSP9), also known as acidic basic repeat antigen, interact directly with 5ABC during erythrocyte invasion by P. falciparum. Native MSP9 as well as recombinant polypeptides derived from two regions of MSP9 (MSP9/Delta1 and MSP9/Delta2) interacted with both 5ABC and intact erythrocytes. Soluble 5ABC added to the assay mixture drastically diminished the binding of MSP9 to erythrocytes. Recombinant MSP9/Delta1 and MSP9/Delta2 present in the culture medium blocked P. falciparum reinvasion into erythrocytes in vitro. Native MSP9 and MSP1(42), the two ligands binding to the 5ABC receptor, existed as a stable complex. Our results establish a novel concept wherein the merozoite exploits a specific complex of co-ligands on its surface to target a single erythrocyte receptor during invasion. This new paradigm poses a new challenge in the development of a vaccine for blood stage malaria.	Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Div Cell Biol, Boston, MA 02135 USA; Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19129 USA	St. Elizabeth's Medical Center; Tufts University; Drexel University	Oh, SS (corresponding author), Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Div Cell Biol, 736 Cambridge St, Boston, MA 02135 USA.	steven.oh@tufts.edu	Oo, Thein/P-1539-2019	Oo, Thein/0000-0002-5201-731X	NHLBI NIH HHS [HL60961, HL51445] Funding Source: Medline; NIAID NIH HHS [AI054532] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060961, R56HL051445, R01HL051445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI054532] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; BUSHELL GR, 1988, MOL BIOCHEM PARASIT, V28, P105, DOI 10.1016/0166-6851(88)90057-6; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CHULAY JD, 1987, J IMMUNOL, V139, P2768; Colfen H, 1998, EUR BIOPHYS J BIOPHY, V27, P651, DOI 10.1007/s002490050177; CULVENOR JG, 1990, J PROTOZOOL, V37, P59, DOI 10.1111/j.1550-7408.1990.tb01117.x; Curtidor H, 2001, VACCINE, V19, P4496, DOI 10.1016/S0264-410X(01)00202-X; Daly TM, 2001, MOL BIOCHEM PARASIT, V117, P27, DOI 10.1016/S0166-6851(01)00329-2; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; Duraisingh MT, 2003, P NATL ACAD SCI USA, V100, P4796, DOI 10.1073/pnas.0730883100; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200; Goel VK, 2003, P NATL ACAD SCI USA, V100, P5164, DOI 10.1073/pnas.0834959100; Kaneko O, 2000, MOL BIOCHEM PARASIT, V110, P135, DOI 10.1016/S0166-6851(00)00263-2; Kushwaha A, 2000, MOL BIOCHEM PARASIT, V106, P213, DOI 10.1016/S0166-6851(99)00212-1; Kushwaha A, 2002, MOL BIOCHEM PARASIT, V122, P45, DOI 10.1016/S0166-6851(02)00077-4; Lobo CA, 2003, BLOOD, V101, P4628, DOI 10.1182/blood-2002-10-3076; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; MCCOLL DJ, 1994, MOL BIOCHEM PARASIT, V68, P53, DOI 10.1016/0166-6851(94)00149-9; Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x; MITCHELL GH, 1986, BLOOD, V67, P1519; NWAGWU M, 1992, EXP PARASITOL, V75, P399, DOI 10.1016/0014-4894(92)90253-7; OEUVRAY C, 1994, BLOOD, V84, P1594; Okoyeh JN, 1999, INFECT IMMUN, V67, P5784, DOI 10.1128/IAI.67.11.5784-5791.1999; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; PERKINS ME, 1990, EXP PARASITOL, V70, P207, DOI 10.1016/0014-4894(90)90101-H; Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; Stafford WHL, 1996, MOL BIOCHEM PARASIT, V80, P159, DOI 10.1016/0166-6851(96)02696-5; STAHL HD, 1986, MOL BIOL MED, V3, P351; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; Vargas-Serrato E, 2002, MOL BIOCHEM PARASIT, V120, P41, DOI 10.1016/S0166-6851(01)00433-9; Vince JW, 1997, BBA-BIOMEMBRANES, V1326, P295, DOI 10.1016/S0005-2736(97)00033-3; WEBER JL, 1988, J BIOL CHEM, V263, P11421; YU J, 1975, J BIOL CHEM, V250, P9170; Zhang DC, 2000, BLOOD, V96, P2925	42	82	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5765	5771		10.1074/jbc.M308716200	http://dx.doi.org/10.1074/jbc.M308716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630931	hybrid			2022-12-25	WOS:000188776500090
J	Weskamp, G; Schlondorff, J; Lum, L; Becherer, JD; Kim, TW; Saftig, P; Hartmann, D; Murphy, G; Blobel, CP				Weskamp, G; Schlondorff, J; Lum, L; Becherer, JD; Kim, TW; Saftig, P; Hartmann, D; Murphy, G; Blobel, CP			Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75(NTR))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; REGULATED INTRAMEMBRANE PROTEOLYSIS; METALLOPROTEASE-DISINTEGRIN MDC9; PROTEIN-COUPLED RECEPTORS; INTRACELLULAR MATURATION; CELL-SURFACE; HB-EGF; TRANSMEMBRANE PROTEINS; JUXTAMEMBRANE STALK; SIGNALING PATHWAYS	Protein ectodomain shedding, the proteolytic release of the extracellullar domain of membrane-tethered proteins, can dramatically affect the function of cell surface receptors, growth factors, cytokines, and other proteins. In this study, we evaluated the activities involved in ectodomain shedding of p75(NTR), a neurotrophin receptor with critical roles in neuronal differentiation and survival. p75(NTR) is shed in a variety of cell types, including dorsal root ganglia cells and PC12 cells. In Chinese hamster ovary cells, inhibitors of the MEK/ERK and p38 MAP kinase pathways uncovered distinct signaling pathways required for the constitutive and stimulated shedding of p75(NTR). Stimulated p75(NTR) shedding is abrogated in M2 mutant Chinese hamster ovary cells that lack functional tumor necrosis factor-alpha converting enzyme (TALE, also referred to as ADAM17) and in cells isolated from adam17-/- mice, but not in cells from adam9/12/15-/- or adam10-/- mice. Stimulated p75(NTR) shedding is strongly reduced by deletion of 15 amino acid residues in its extracellular membrane-proximal stalk domain. However, similar to other shed proteins, point mutations and overlapping shorter deletions within this region have little or no effect on shedding. Because ectodomain shedding of p75(NTR) releases a soluble ectodomain and could also be a prerequisite for its regulated intramembrane proteolysis, these findings may have important implications for the functional regulation of p75(NTR).	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, New York, NY 10021 USA; Triinst Cornell Univ Rockefeller Univ Sloan Kette, New York, NY 10021 USA; GlaxoSmithKline Inc, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA; Columbia Univ, Ctr Neurobiol & Behav, Dept Pathol, New York, NY 10032 USA; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Katholieke Univ Leuven, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB4, B-3000 Louvain, Belgium; Cambridge Inst Med Res, Cambridge CB2 2XY, England	Memorial Sloan Kettering Cancer Center; GlaxoSmithKline; Columbia University; University of Kiel; KU Leuven; University of Cambridge	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Saftig, Paul/A-7966-2010	Schlondorff, Johannes/0000-0002-9973-9731	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750, T32GM007739] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [5T32GM07739-17, R01 GM64750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfalah M, 2001, J BIOL CHEM, V276, P21105, DOI 10.1074/jbc.M100339200; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Codony-Servat J, 1999, CANCER RES, V59, P1196; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mischel PS, 2001, J BIOL CHEM, V276, P11294, DOI 10.1074/jbc.M005132200; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342	78	129	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4241	4249		10.1074/jbc.M307974200	http://dx.doi.org/10.1074/jbc.M307974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638693	hybrid			2022-12-25	WOS:000188554300041
J	Wang, SH; Mezosi, E; Wolf, JM; Cao, ZY; Utsugi, S; Gauger, PG; Doherty, GM; Baker, JR				Wang, SH; Mezosi, E; Wolf, JM; Cao, ZY; Utsugi, S; Gauger, PG; Doherty, GM; Baker, JR			IFN gamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression	ONCOGENE			English	Article						Bak; thyroid cancer; apoptosis; IFN gamma; TRAIL	FAS-MEDIATED APOPTOSIS; INTERFERON-GAMMA; FOLLICULAR CELLS; CYTOCHROME-C; BCL-2 FAMILY; CANCER-CELLS; DEATH; LIGAND; PATHWAY; RELEASE	TRAIL preferentially induces apoptosis in tumor cells and virus-infected cells. Unlike other tumor necrosis factor family members, TRAIL does not kill cells from most normal tissues and has thus been proposed as a promising new cancer treatment. Our study demonstrated that IFNgamma combined with TRAIL can trigger apoptosis in vitro in several resistant thyroid tumor cell lines, such as thyroid anaplastic carcinoma cells (ARO cells), while either agent alone exerts only a minimal effect. We further tested this effect on a mouse thyroid tumor model, when in vivo tumor growth was also significantly inhibited by this combination. The mechanism of how IFNgamma sensitized thyroid carcinoma cells to TRAIL-induced apoptosis was investigated by screening global gene alterations in ARO cells treated with IFNgamma. Microarray data revealed that a proapoptotic gene, Bak, is markedly upregulated by IFNgamma, and this was confirmed by RNase protection assay. Western blot analysis also showed a significant increase in Bak at the protein level. Upregulation of Bak and sensitization for apoptosis by IFNgamma was blocked by overexpression of antisense Bak in ARO cells. Furthermore, overexpression of Bak sensitized ARO cell to TRAIL-induced apoptosis without the need for IFNgamma pretreatment. This suggests that Bak is a regulatory molecule involved in IFNgamma-facilitated TRAIL-mediated apoptosis in thyroid cancer cells.	Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ctr Biol Nanotechnol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu	Gauger, Paul/W-8176-2019	Doherty, Gerard/0000-0002-1685-9552	NIDDK NIH HHS [P60DK20572, DK58771] Funding Source: Medline; PHS HHS [R01 A137141] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ain KB, 1998, THYROID, V8, P715, DOI 10.1089/thy.1998.8.715; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Beatty GL, 2001, IMMUNOL RES, V24, P201, DOI 10.1385/IR:24:2:201; Bonavida B, 1999, INT J ONCOL, V15, P793; Braga-Basaria M, 2003, J CLIN ENDOCR METAB, V88, P1947, DOI 10.1210/jc.2002-021863; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; Caturegli P, 2000, P NATL ACAD SCI USA, V97, P1719, DOI 10.1073/pnas.020522597; de Metz J, 2000, THYROID, V10, P87, DOI 10.1089/thy.2000.10.87; Egle A, 1996, EUR J IMMUNOL, V26, P3119, DOI 10.1002/eji.1830261244; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; Kandasamy K, 2003, CANCER RES, V63, P1712; Kayagaki N, 1999, J IMMUNOL, V162, P2639; KILLINGER WA, 1992, ANN THORAC SURG, V53, P472, DOI 10.1016/0003-4975(92)90271-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2001, B ACAD NAT MED PARIS, V185, P1135, DOI 10.1016/S0001-4079(19)34476-0; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Langaas V, 2001, ANTICANCER RES, V21, P3733; LEE YS, 1988, CANCER RES, V48, P559; Mitsiades N, 2000, CANCER RES, V60, P4122; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Poulaki V, 2002, AM J PATHOL, V161, P643, DOI 10.1016/S0002-9440(10)64220-4; Ruiz-Ruiz C, 2002, BIOCHEM J, V365, P825, DOI 10.1042/BJ20020184; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin EC, 2001, CANCER IMMUNOL IMMUN, V50, P23, DOI 10.1007/s002620000166; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Voigt W, 2000, CLIN CANCER RES, V6, P2087; Wang SH, 1999, ENDOCRINOLOGY, V140, P1649, DOI 10.1210/en.140.4.1649; Wang SH, 2002, J IMMUNOL, V168, P2470, DOI 10.4049/jimmunol.168.5.2470; Wang SH, 2001, THYROID, V11, P725, DOI 10.1089/10507250152484556; Yano H, 1996, J HEPATOL, V25, P454, DOI 10.1016/S0168-8278(96)80204-2; Yeung SCJ, 2000, CANCER RES, V60, P650	39	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					928	935		10.1038/sj.onc.1207213	http://dx.doi.org/10.1038/sj.onc.1207213			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647456				2022-12-25	WOS:000188486600008
J	Sredni, B; Gal, R; Cohen, IJ; Dazard, JE; Givol, D; Gafter, U; Motro, B; Eliyahu, S; Albeck, M; Lander, HM; Kalechman, Y				Sredni, B; Gal, R; Cohen, IJ; Dazard, JE; Givol, D; Gafter, U; Motro, B; Eliyahu, S; Albeck, M; Lander, HM; Kalechman, Y			Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression	FASEB JOURNAL			English	Article						KGF; hair; P21(waf); P21(ras); AS101	PROTECTIVE ROLE; MURINE MODEL; TNF-ALPHA; MICE; MOUSE; NUDE; SKIN; COMBINATION; ALOPECIA; PROTEIN	The synthetic immunomodulator AS101 {ammonium trichloro(dioxoethylene-o,o')tellurate} was previously found to protect cancer patients from chemotherapy-induced bone marrow toxicity and alopecia. Here we show that AS101 induces hair growth in nude and normal mice. AS101 possesses the dual ability to both induce anagen and retard spontaneous catagen in the C57BL/6 mouse model. Anagen induced by AS101 is mediated by keratinocyte growth factor (KGF), as it is abrogated both in nude mice co-treated with AS101 plus neutralizing anti KGF antibodies and in AS101-treated transgenic mice expressing a dominant-negative KGF receptor transgene in basal keratinocytes. AS101 up-regulates KGF expression by activating the ras signaling pathway in cultured fibroblasts. AS101-induced delayed catagen is associated with inhibition of terminal differentiation marker expression both in nude and C57BL/6 mice epidermal follicular keratinocytes and in cultures of primary mouse follicular keratinocytes induced to differentiate. This activity is associated with relatively sustained elevation of p21(waf). Delayed expression of terminal differentiation markers was not induced by AS101 in follicular keratinocytes from p21(waf) knockout mice. Because similar results were obtained with cultures of primary human keratinocytes and fibroblasts, preliminary case report studies revealed substantial hair growth when AS101 was topically applied on three adolescents who had remained alopeciac 1-2 years after chemotherapy. The results emphasize the unique mode of action of AS101 and highlight its potential clinical use for treating certain types of alopecia.	Bar Ilan Univ, Fac Life Sci, CAIR Inst, IL-52900 Ramat Gan, Israel; Rabin Med Ctr, Dept Pathol, IL-49372 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Nephrol, IL-49372 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Rabin Med Ctr, Schneider Childrens Med Ctr Israel, Inst Pediat Hematol Oncol, IL-49372 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Cornell Univ, Coll Med, Dept Biochem, New York, NY USA	Bar Ilan University; Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Cornell University	Sredni, B (corresponding author), Bar Ilan Univ, Fac Life Sci, CAIR Inst, IL-52900 Ramat Gan, Israel.	srednib@mail.biu.ac.il	Cohen, Ian/H-3358-2013; /ABF-8487-2022					ANDERSON TD, 1993, INT REV EXP PATHOL, V34, P9; Andreadis ST, 2001, FASEB J, V15, P898, DOI 10.1096/fj.00-0324com; Botchkareva NV, 2000, AM J PATHOL, V156, P1041, DOI 10.1016/S0002-9440(10)64972-3; BRISSETT JL, 1966, GENE DEV, V10, P2212; CAIRNS JI, 1989, J INVEST DERMATOL, V92, P410; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; DANILENKO DM, 1995, AM J PATHOL, V147, P145; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DUCROS DL, 1993, J INVEST DERMATOL, V101, pS106, DOI 10.1111/1523-1747.ep12363020; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; FUCHS E, 1993, J CELL SCI, P197; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; JINDO T, 1994, J INVEST DERMATOL, V103, P306, DOI 10.1111/1523-1747.ep12394731; Kalechman Y, 1997, J IMMUNOL, V159, P2658; KALECHMAN Y, 1995, BLOOD, V85, P1555, DOI 10.1182/blood.V85.6.1555.bloodjournal8561555; Kalechman Y, 1996, J IMMUNOL, V156, P1101; KALECHMAN Y, 1993, CANCER RES, V53, P5962; Kalechman Y, 2000, INT J CANCER, V86, P281, DOI 10.1002/(SICI)1097-0215(20000415)86:2<281::AID-IJC20>3.0.CO;2-X; Kalechman Y, 2002, J IMMUNOL, V169, P384, DOI 10.4049/jimmunol.169.1.384; KALECHMAN Y, 1991, CANCER RES, V51, P1499; KALECHMAN Y, 1990, J IMMUNOL, V145, P1512; KOPFMAIER P, 1990, ACTA ANAT, V139, P178; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lindner G, 1997, AM J PATHOL, V151, P1601; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Pantelouris E M, 1973, Differentiation, V1, P437, DOI 10.1111/j.1432-0436.1973.tb00143.x; Paus R, 1996, ARCH DERMATOL RES, V288, P408, DOI 10.1007/s004030050072; Paus R, 1999, J INVEST DERM SYMP P, V4, P338, DOI 10.1038/sj.jidsp.5640241; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Paus Ralf, 1998, Journal of Dermatology (Tokyo), V25, P793; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; SREDNI B, 1987, NATURE, V330, P173, DOI 10.1038/330173a0; Sredni B, 1996, J NATL CANCER I, V88, P1276, DOI 10.1093/jnci/88.18.1276; SREDNI B, 1995, J CLIN ONCOL, V13, P2342, DOI 10.1200/JCO.1995.13.9.2342; Sredni B, 1996, INT J CANCER, V65, P97, DOI 10.1002/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; Strassmann G, 1997, CELL IMMUNOL, V176, P180, DOI 10.1006/cimm.1997.1087; TANIGAKI N, 1990, ARCH DERMATOL RES, V282, P402, DOI 10.1007/BF00372092; TERRELL TG, 1993, INT REV EXP PATHOL, V34, P43; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	45	42	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					400	+		10.1096/fj.03-0552fje	http://dx.doi.org/10.1096/fj.03-0552fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656992				2022-12-25	WOS:000188067500031
J	Paronetto, MP; Venables, JP; Elliott, DJ; Geremia, R; Rossi, P; Sette, C				Paronetto, MP; Venables, JP; Elliott, DJ; Geremia, R; Rossi, P; Sette, C			tr-kit promotes the formation of a multimolecular complex composed by Fyn, PLC gamma 1 and Sam68	ONCOGENE			English	Article						tyrosine kinase; SH3; RNA; adaptor proteins; signal transduction	RNA-BINDING PROTEIN; FAMILY TYROSINE KINASES; C-KIT; SIGNAL-TRANSDUCTION; EGG ACTIVATION; TRUNCATED FORM; SH3 DOMAINS; MOUSE EGGS; SRC; PHOSPHORYLATION	tr-kit is a truncated form of the tyrosine kinase receptor c-kit expressed in the haploid phase of spermatogenesis. Upon microinjection, tr-kit triggers metaphase-to-anaphase transition in mouse eggs by the sequential activation of Fyn and PLCgamma1. Here, we show that tr-kit promotes the interaction of several tyrosine-phosphorylated proteins with the SH3 domain of PLCgamma1. Western blot analysis indicates that one of these proteins is Sam68, an RNA-binding protein that is known to interact with and be phosphorylated by Src-like kinases in mitosis. tr-kit promotes the association of Sam68 with PLCgamma1 and Fyn in a multimolecular complex, as demonstrated by co-immunoprecipitation of the phosphorylated forms of these proteins using antibodies directed to anyone of the partners of the complex. Expression of tr-kit potentiates the interaction of endogenous Sam68 also with the SH3 domain of Fyn. Further more, the subcellular localization of Sam68 is affected by tr-kit through activation of Fyn in live cells. Lastly, we show that interaction with the SH3 domain of Fyn triggers the release of Sam68 from bound RNA. Thus, our data suggest that tr-kit promotes the formation of a multimolecular complex composed of Fyn, PLCgamma1 and Sam68, which allows phosphorylation of PLCgamma1 by Fyn, and may modulate RNA metabolism.	Univ Roma Tor Vergata, Sect Anat, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy; Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Rome Tor Vergata; Newcastle University - UK	Sette, C (corresponding author), Univ Roma Tor Vergata, Sect Anat, Dipartimento Sanita Pubbl & Biol Cellulare, Via Montpellier 1, I-00133 Rome, Italy.		Rossi, Pellegrino/AAA-7072-2019; Sette, Claudio/S-4307-2019; Paronetto, Maria Paola/A-9578-2012	Sette, Claudio/0000-0003-2864-8266; Paronetto, Maria Paola/0000-0001-5324-0903; ROSSI, PELLEGRINO/0000-0003-4796-327X; GEREMIA, Raffaele/0000-0001-9056-6603; Elliott, David/0000-0002-6930-0699				Albanesi C, 1996, DEVELOPMENT, V122, P1291; BESMER P, 1993, DEVELOPMENT, P125; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Lang V, 1999, J IMMUNOL, V162, P7224; Lee MH, 2001, GENE DEV, V15, P2408, DOI 10.1101/gad.915901; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Li JL, 2002, J VIROL, V76, P8374, DOI 10.1128/JVI.76.16.8374-8382.2002; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Oh B, 2000, DEVELOPMENT, V127, P3795; Oneyama C, 2002, ONCOGENE, V21, P2037, DOI 10.1038/sj.onc.1205271; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Sette C, 1997, DEVELOPMENT, V124, P2267; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SORRENTINO V, 1991, ONCOGENE, V6, P149; Takaoka A, 1997, CANCER LETT, V115, P257, DOI 10.1016/S0304-3835(97)04746-0; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOYOTA M, 1994, CANCER RES, V54, P272; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171	33	46	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8707	8715		10.1038/sj.onc.1207016	http://dx.doi.org/10.1038/sj.onc.1207016			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647465	Bronze			2022-12-25	WOS:000186844900008
J	Febbraio, F; Andolfo, A; Tanfani, F; Briante, R; Gentile, F; Formisano, S; Vaccaro, C; Scire, A; Bertoli, E; Pucci, P; Nucci, R				Febbraio, F; Andolfo, A; Tanfani, F; Briante, R; Gentile, F; Formisano, S; Vaccaro, C; Scire, A; Bertoli, E; Pucci, P; Nucci, R			Thermal stability and aggregation of Sulfolobus solfataricus beta-glycosidase are dependent upon the n-epsilon-methylation of specific lysyl residues - Critical role of in vivo post-translational modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; CRYSTAL-STRUCTURE; HISTONE H3; THERMOACIDOPHILIC ARCHAEBACTERIUM; SALT BRIDGES; ASPARTATE-AMINOTRANSFERASE; PROTEIN THERMOSTABILITY; ALCOHOL-DEHYDROGENASE; ESCHERICHIA-COLI; HP1 PROTEINS	Methylation in vivo is a post-translational modification observed in several organisms belonging to eucarya, bacteria, and archaea. Although important implications of this modification have been demonstrated in several eucaryotes, its biological role in hyperthermophilic archaea is far from being understood. The aim of this work is to clarify some effects of methylation on the properties of beta-glycosidase from Sulfolobus solfataricus, by a structural comparison between the native, methylated protein and its unmethylated counterpart, recombinantly expressed in Escherichia coli. Analysis by Fourier transform infrared spectroscopy indicated similar secondary structure contents for the two forms of the protein. However, the study of temperature perturbation by Fourier transform infrared spectroscopy and turbidimetry evidenced denaturation and aggregation events more pronounced in recombinant than in native beta-glycosidase. Red Nile fluorescence analysis revealed significant differences of surface hydrophobicity between the two forms of the protein. Unlike the native enzyme, which dissociated into SDS-resistant dimers upon exposure to the detergent, the recombinant enzyme partially dissociated into monomers. By electrospray mapping, the methylation sites of the native protein were identified. A computational analysis of beta-glycosidase three-dimensional structure and comparisons with other proteins from S. solfataricus revealed analogies in the localization of methylation sites in terms of secondary structural elements and overall topology. These observations suggest a role for the methylation of lysyl residues, located in selected domains, in the thermal stabilization of beta-glycosidase from S. solfataricus.	CNR, Inst Prot Biochem, I-80125 Naples, Italy; CEINGE Adv Biotechnol Scarl, I-80131 Naples, Italy; Polytech Univ Marche, Inst Biochem, I-60131 Ancona, Italy; Polytech Univ Marche, Fac Med & Surg, I-60131 Ancona, Italy; Polytech Univ Marche, Fac Sci, I-60131 Ancona, Italy; Univ Molise, Dept SAVA, I-86100 Campobasso, Italy; Univ Naples Federico II, Dept Cell & Mol Biol & Pathol, I-80131 Naples, Italy; CNR, Inst Expt Endocrinol & Oncol, I-80131 Naples, Italy; Univ Naples Federico II, Dept Organ & Biol Chem, I-80126 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); CEINGE Biotecnologie Avanzate; Marche Polytechnic University; Marche Polytechnic University; Marche Polytechnic University; University of Molise; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Febbraio, F (corresponding author), CNR, Inst Prot Biochem, Via Marconi 10, I-80125 Naples, Italy.	f.febbraio@ibp.cnr.it	Gentile, Fabrizio/K-2475-2012; Scirè, Andrea/A-2961-2010; Tanfani, Fabio/F-1441-2010; Andolfo, Annapaola/B-2532-2013; Febbraio, Ferdinando/AAX-8255-2020	Gentile, Fabrizio/0000-0002-6704-3115; Scirè, Andrea/0000-0002-8288-6989; Andolfo, Annapaola/0000-0002-0566-2391; Febbraio, Ferdinando/0000-0002-3653-9847; PUCCI, Pietro/0000-0002-5885-1495; Tanfani, Fabio/0000-0001-7685-4692				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; AMMENDOLA S, 1992, BIOCHEMISTRY-US, V31, P12514, DOI 10.1021/bi00164a031; BANECKI B, 1992, J BIOL CHEM, V267, P25051; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; *BIOS MSI, 1995, INS US GUID; Bismuto E, 2003, PROTEINS, V51, P10, DOI 10.1002/prot.10317; CACACE MG, 1976, BIOCHEMISTRY-US, V15, P1692, DOI 10.1021/bi00653a016; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; CUBELLIS MV, 1990, GENE, V94, P89, DOI 10.1016/0378-1119(90)90472-4; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; DEROSA M, 1980, BIOTECHNOL LETT, V2, P29, DOI 10.1007/BF00136880; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; Esposito L, 2002, J MOL BIOL, V318, P463, DOI 10.1016/S0022-2836(02)00088-8; FERNANDEZBALLESTER G, 1992, BIOCHEM J, V288, P421, DOI 10.1042/bj2880421; FONTANA A, 1991, LIFE EXTREME CONDITI, P89; Gentile F, 2002, J BIOL CHEM, V277, P44050, DOI 10.1074/jbc.M206761200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haseltine C, 1999, J BACTERIOL, V181, P3920, DOI 10.1128/JB.181.13.3920-3927.1999; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hughes E, 2000, J BIOL CHEM, V275, P25109, DOI 10.1074/jbc.M003554200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Katz ML, 1997, BBA-MOL BASIS DIS, V1361, P66, DOI 10.1016/S0925-4439(97)00017-3; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; MARAS B, 1992, EUR J BIOCHEM, V203, P81, DOI 10.1111/j.1432-1033.1992.tb19831.x; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MORACCI M, 1995, ENZYME MICROB TECH, V17, P992, DOI 10.1016/0141-0229(95)00012-7; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; NUCCI R, 1993, BIOTECHNOL APPL BIOC, V17, P239; OSBORNE HB, 1982, METHOD ENZYMOL, V88, P676; Paik W K, 1986, Yonsei Med J, V27, P159; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SACKETT DL, 1987, ANAL BIOCHEM, V167, P228, DOI 10.1016/0003-2697(87)90157-6; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; SkorkoGlonek J, 1997, J BIOL CHEM, V272, P8974; SPASSOV VZ, 1995, PROTEIN SCI, V4, P1516, DOI 10.1002/pro.5560040809; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TANFANI F, 1993, EUR J BIOCHEM, V218, P499, DOI 10.1111/j.1432-1033.1993.tb18402.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMSCHY A, 1994, PROTEIN ENG, V7, P1471, DOI 10.1093/protein/7.12.1471; TORCHILIN VP, 1979, BIOCHIM BIOPHYS ACTA, V567, P1, DOI 10.1016/0005-2744(79)90165-7; UMEMURA J, 1980, BIOCHIM BIOPHYS ACTA, V602, P32, DOI 10.1016/0005-2736(80)90287-4; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; Westhead DR, 1999, PROTEIN SCI, V8, P897; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; ZAPPACOSTA F, 1994, EUR J BIOCHEM, V222, P761, DOI 10.1111/j.1432-1033.1994.tb18922.x	54	35	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10185	10194		10.1074/jbc.M308520200	http://dx.doi.org/10.1074/jbc.M308520200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660666	hybrid			2022-12-25	WOS:000220050400065
J	Li, YM; Syvitski, RT; Auclair, K; de Montellano, PRO; La Mar, GN				Li, YM; Syvitski, RT; Auclair, K; de Montellano, PRO; La Mar, GN			H-1 NMR investigation of the solution structure of substrate-free human heme oxygenase - Comparison to the cyanide-inhibited, substrate-bound complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; CHEMICAL-SHIFTS; ELECTRONIC-STRUCTURE; RESONANCE RAMAN; CATALYTIC SITE; RAT HEME; MECHANISM; PROTEIN; IDENTIFICATION	H-1 NMR was used to investigate the molecular structure, and dynamic properties of soluble, recombinant, substrate-free human heme oxygenase (apohHO) on a comparative basis with similar studies on the substrate complex. Limited but crucial sequence-specific assignments identify five conserved secondary structural elements, and the detection of highly characteristic dipolar or H-bond interactions among these elements together with insignificant chemical shift differences confirm a strongly conserved folding topology of helices C - H relative to that of substrate complexes in either solution or the crystal. The correction of the chemical shifts for paramagnetic and porphyrin ring current influences in the paramagnetic substrate complex reveals that the strength of all but one of the numerous relatively robust H-bonds are conserved in apohHO, and similar ordered water molecules are located near these H-bond donors as observed in the substrate complexes. The unique and significant weakening of the Tyr(58) OH hydrogen bond to the catalytically critical Asp(140) carboxylate in apohHO is suggested to arise from the removal of the axial H-bond acceptor ligand rather than the loss of substrate. The interhelical positions of the conserved strong H-bonds argue for a structural role in maintaining a conserved structure for helices C - H upon loss of substrate. While the structure and H-bond network are largely conserved upon loss of substrate, the variably increased rate of NH lability dictates a significant loss of dynamic stability in the conserved structure, particularly near the distal helix F.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California San Francisco	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, Davis, CA 95616 USA.	lamar@indigo.ucdavis.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062830] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM62830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asokan A, 2001, J AM CHEM SOC, V123, P4243, DOI 10.1021/ja003687w; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Beale S. I., 1994, MOL BIOL CYANOBACTER, P519; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; Clark K, 1996, J AM CHEM SOC, V118, P4654, DOI 10.1021/ja953719t; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; DEMONTELLANO PRO, 2003, PORPHRYIN HDB, P175; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Frey PA, 2001, MAGN RESON CHEM, V39, pS190, DOI 10.1002/mrc.953; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Harris TK, 1999, PROTEINS, V35, P275, DOI 10.1002/(SICI)1097-0134(19990515)35:3<275::AID-PROT1>3.0.CO;2-V; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jeffrey G. A., 1997, INTRO HYDROGEN BONDI, P11, DOI DOI 10.1246/CL.2012.65; JOHNSTON PD, 1979, P NATL ACAD SCI USA, V76, P3130, DOI 10.1073/pnas.76.7.3130; KUNTZ ID, 1991, J AM CHEM SOC, V113, P1406, DOI 10.1021/ja00004a050; La Mar G.N., 2000, PORPHYRIN HDB, V5, P185; La Mar GN, 2001, J BIOL CHEM, V276, P15676, DOI 10.1074/jbc.M009974200; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; Li YM, 2002, J BIOL CHEM, V277, P33018, DOI 10.1074/jbc.M204216200; Li YM, 2003, J AM CHEM SOC, V125, P13392, DOI 10.1021/ja036176t; Li YM, 2003, J BIOL CHEM, V278, P6651, DOI 10.1074/jbc.M211249200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McDermott A., 1996, ENCY NMR, P3820; Mildvan AS, 1999, METHOD ENZYMOL, V308, P219; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Otting G, 1999, BIOL MAGN RESON, V17, P485; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Yoshida T, 2000, J INORG BIOCHEM, V82, P33, DOI 10.1016/S0162-0134(00)00156-2; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	55	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10195	10205		10.1074/jbc.M308379200	http://dx.doi.org/10.1074/jbc.M308379200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660632	hybrid			2022-12-25	WOS:000220050400066
J	Hildesheim, J; Belova, GI; Tyner, SD; Zhou, XW; Vardanian, L; Fornace, AJ				Hildesheim, J; Belova, GI; Tyner, SD; Zhou, XW; Vardanian, L; Fornace, AJ			Gadd45a regulates matrix metalloproteinases by suppressing Delta Np63 alpha and beta-catenin via p38 MAP kinase and APC complex activation	ONCOGENE			English	Article						Gadd45a; beta-catenin; Delta Np63 alpha; keratinocyte; UV	P63 EXPRESSION; P53 HOMOLOG; CYCLIN D1; SKIN; CANCER; MATRILYSIN; APOPTOSIS; PHOSPHORYLATION; PROTEIN; TARGET	The p53-regulated growth arrest and DNA damage-inducible gene product Gadd45a has been recently identified as a key factor protecting the epidermis against ultraviolet radiation (UVR)-induced skin tumors by activating p53 via the stress mitogen-activated protein kinase ( MAPK) signaling pathway. Herein we identify Gadd45a as an important negative regulator of two oncogenes commonly over-expressed in epithelial tumors: the p53 homologue DeltaNp63alpha and beta-catenin. DeltaNp63alpha is one of the several p63 isoforms and is the predominant species expressed in basal epidermal keratinocytes. DeltaNp63alpha lacks the N-terminal transactivation domain and behaves as a dominant-negative factor blocking expression of several p53-effector genes. DeltaNp63alpha also associates with and blocks activation of the adenomatous polyposis coli (APC) destruction complex that targets free cytoplasmic beta-catenin for degradation. While most beta-catenin protein is localized to the cell membrane and is involved in cell-cell adhesion, accumulation of free cytoplasmic beta-catenin will translocate into the nucleus where it functions in a bipartite transcription factor complex, whose targets include invasion and metastasis promoting endopeptidases, matrix metalloproteinases (MMP). We show that Gadd45a not only directly associates with two components of the APC complex, namely protein phosphatase 2A (PP2A) and glycogen synthase kinase 3beta (GSK3beta) but also promotes GSK3b dephosphorylation at Ser9, which is essential for GSK3b activation, and resultant activation of the APC destruction complex. We demonstrate that lack of Gadd45a not only prevents DeltaNp63alpha suppression and GSK3b dephosphorylation but also prevents free cytoplasmic beta-catenin degradation after UV irradiation. The inability of Gadd45a-null keratinocytes to suppress beta-catenin may contribute to the resulting observation of increased MMP expression and activity along with significantly faster keratinocyte migration in Matrigel in vitro and accelerated wound closure in vivo. Furthermore, epidermal keratinocytes treated with p38 MAPK inhibitors, both in vivo and in vitro, behave very similarly to Gadd45a-null keratinocytes after UVR. Similarly, Trp53-null mice are unable to attenuate DeltaNp63alpha expression in epidermal keratinocytes after such stress. These findings demonstrate a dependence on Gadd45a-mediated p38 MAPK and p53 activation for proper modulation of DeltaNp63alpha, GSK3beta, and beta-catenin after irradiation. Taken together, our results indicate that Gadd45a is able to repress DeltaNp63alpha, beta-catenin, and consequently MMP expression by two means: by maintaining UVR-induced p38 MAPK and p53 activation and also by associating with the APC complex. This implicates Gadd45a in the negative regulation of cell migration, and invasion.	NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fornace, AJ (corresponding author), NCI, Gene Response Sect, Ctr Canc Res, NIH, Bldg 37,Rm 6144,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	af6z@nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hildesheim J, 2002, CANCER RES, V62, P7305; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KARELINA TV, 1994, J INVEST DERMATOL, V103, P482, DOI 10.1111/1523-1747.ep12395596; Kusukawa J, 1996, ORAL ONCOL, V32B, P217, DOI 10.1016/0964-1955(96)00016-4; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li G, 1996, AM J PATHOL, V148, P1113; Liefer KM, 2000, CANCER RES, V60, P4016; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Polakis P, 2000, GENE DEV, V14, P1837; POWELL WC, 1993, CANCER RES, V53, P417; PYKE C, 1992, CANCER RES, V52, P1336; Quinn AG, 1997, BRIT J HOSP MED, V58, P261; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; YAMAMOTO H, 1995, INT J CANCER, V61, P218, DOI 10.1002/ijc.2910610213; Yamasawa K, 2002, CLIN CANCER RES, V8, P2563; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	50	54	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1829	1837		10.1038/sj.onc.1207301	http://dx.doi.org/10.1038/sj.onc.1207301			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647429				2022-12-25	WOS:000220129500004
J	Smith, FM; Vearing, C; Lackmann, M; Treutlein, H; Himanen, J; Chen, K; Saul, A; Nikolov, D; Boyd, AW				Smith, FM; Vearing, C; Lackmann, M; Treutlein, H; Himanen, J; Chen, K; Saul, A; Nikolov, D; Boyd, AW			Dissecting the EphA3/ephrin-A5 interactions using a novel functional mutagenesis screen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EPH RECEPTORS; LIGAND-BINDING; CRYSTAL-STRUCTURE; HEK; DIMERIZATION; ATTACHMENT; EPHRINS; DOMAIN	The EphA3 receptor tyrosine kinase preferentially binds ephrin-A5, a member of the corresponding subfamily of membrane-associated ligands. Their interaction regulates critical cell communication functions in normal development and may play a role in neoplasia. Here we describe a random mutagenesis approach, which we employed to study the molecular determinants of the EphA3/ephrin-A5 recognition. Selection and functional characterization of EphA3 point mutants with impaired ephrin-A5 binding from a yeast expression library defined three EphA3 surface areas that are essential for the EphA3/ephrin-A5 interaction. Two of these map to regions identified previously in the crystal structure of the homologous EphB2-ephrin-B2 complex as potential ligand/receptor interfaces. In addition, we identify a third EphA3/ephrin-A5 interface that falls outside the structurally characterized interaction domains. Functional analysis of EphA3 mutants reveals that all three Eph/ephrin contact areas are essential for the assembly of signaling-competent, oligomeric receptor-ligand complexes.	PO Royal Brisbane Hosp, Leukaemia Fdn Queensland Lab, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; PO Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Melbourne, Vic 3050, Australia; Cytopia, Melbourne, Vic 3004, Australia; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, Upton, NY 11973 USA; Univ Queensland, PO Royal Brisbane Hosp, Dept Med, St Lucia, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Memorial Sloan Kettering Cancer Center; University of Queensland	Lackmann, M (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.	Martin.Lackmann@med.monash.edu.au	Saul, Allan J/I-6968-2013; Boyd, Andrew/G-2083-2010; Treutlein, Herbert Rudolf/AAC-7648-2021; Saul, Allan/ABH-2091-2020	Saul, Allan J/0000-0003-0665-4091; Treutlein, Herbert Rudolf/0000-0001-5553-5553; Saul, Allan/0000-0003-0665-4091	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000727] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYD AW, 2001, SCI STKE; Coulthard MG, 2001, GROWTH FACTORS, V18, P303, DOI 10.3109/08977190109029118; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Drescher U, 2002, CURR OPIN GENET DEV, V12, P397, DOI 10.1016/S0959-437X(02)00316-7; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Holmberg J, 2002, TRENDS NEUROSCI, V25, P239, DOI 10.1016/S0166-2236(02)02149-5; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lemke G, 1997, MOL CELL NEUROSCI, V9, P331, DOI 10.1006/mcne.1997.0630; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Smith DK, 1998, PROTEIN SCI, V7, P886; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515	24	73	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9522	9531		10.1074/jbc.M309326200	http://dx.doi.org/10.1074/jbc.M309326200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660665	hybrid			2022-12-25	WOS:000189265900119
J	De Rosa, MF; Sillence, D; Ackerley, C; Lingwood, C				De Rosa, MF; Sillence, D; Ackerley, C; Lingwood, C			Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MDR1 P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; GLUCOSYLCERAMIDE SYNTHASE; GOLGI-APPARATUS; IMPROVED INHIBITORS; EXPRESSION CLONING; BROAD-SPECIFICITY; PLASMA-MEMBRANE; CYCLOSPORINE-A	Transfection studies have implicated the multiple drug resistance pump, MDR1, as a glucosyl ceramide translocase within the Golgi complex (Lala, P., Ito, S., and Lingwood, C. A. ( 2000) J. Biol. Chem. 275, 6246 6251). We now show that MDR1 inhibitors, cyclosporin A or ketoconazole, inhibit neutral glycosphingolipid biosynthesis in 11 of 12 cell lines tested. The exception, HeLa cells, do not express MDR1. Microsomal lactosyl ceramide and globotriaosyl ceramide synthesis from endogenous or exogenously added liposomal glucosyl ceramide was inhibited by cyclosporin A, consistent with a direct role for MDR1/glucosyl ceramide translocase activity in their synthesis. In contrast, cellular ganglioside synthesis in the same cells, was unaffected by MDR1 inhibition, suggesting neutral and acid glycosphingolipids are synthesized from distinct precursor glycosphingolipid pools. Metabolic labeling in wild type and knockout (MDR1a, 1b, MRP1) mouse fibroblasts showed the same loss of neutral glycosphingolipid ( glucosyl ceramide, lactosyl ceramide) but not ganglioside (GM3) synthesis, confirming the proposed role for MDR1 translocase activity. Cryo-immunoelectron microscopy showed MDR1 was predominantly intracellular, largely in rab6-containing Golgi vesicles and Golgi cisternae, the site of glycosphingolipid synthesis. These studies identify MDR1 as the major glucosyl ceramide flippase required for neutral glycosphingolipid anabolism and demonstrate a previously unappreciated dichotomy between neutral and acid glycosphingolipid synthesis.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Oxford	Lingwood, C (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cling@sickkids.on.ca	Sillence, Dan J/J-9513-2019	Sillence, Dan J/0000-0003-4747-5655				ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; Allende ML, 2000, GLYCOBIOLOGY, V10, P1025, DOI 10.1093/glycob/10.10.1025; Arab S, 1999, ONCOL RES, V11, P33; Arab S, 1998, J CELL PHYSIOL, V177, P646, DOI 10.1002/(SICI)1097-4652(199812)177:4<646::AID-JCP15>3.0.CO;2-B; Arab S, 1996, GLYCOCONJUGATE J, V13, P159, DOI 10.1007/BF00731490; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Binnington B, 2002, NEUROCHEM RES, V27, P807, DOI 10.1023/A:1020261125008; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; BOULANGER J, 1990, J CLIN MICROBIOL, V28, P2830, DOI 10.1128/JCM.28.12.2830-2833.1990; BRADLEY G, 1989, CANCER RES, V49, P2790; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; Chark D., 2004, EUR J BIOCHEM, V271, P1; COHEN A, 1990, INT IMMUNOL, V2, P1, DOI 10.1093/intimm/2.1.1; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; Demeule M, 2000, FEBS LETT, V466, P219, DOI 10.1016/S0014-5793(00)01087-5; ENGELHARDT D, 1994, J STEROID BIOCHEM, V49, P261, DOI 10.1016/0960-0760(94)90267-4; FORSYTH GW, 1993, CLIN CHIM ACTA, V216, P11, DOI 10.1016/0009-8981(93)90135-Q; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; Futscher BW, 1996, INT J CANCER, V66, P520, DOI 10.1002/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B; Gariepy J, 2001, CRIT REV ONCOL HEMAT, V39, P99, DOI 10.1016/S1040-8428(01)00126-3; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HEATHENGEL H, 2004, IN PRESS ANGIOGENESI; HILL BT, 1994, CANCER, V73, P2990, DOI 10.1002/1097-0142(19940615)73:12<2990::AID-CNCR2820731217>3.0.CO;2-L; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Johnson DR, 2001, CANCER RES, V61, P1469; KIARASH A, 1994, J BIOL CHEM, V269, P11138; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 1997, J BIOL CHEM, V272, P1349, DOI 10.1074/jbc.272.2.1349; Lingwood CA, 1999, BIOSCIENCE REP, V19, P345, DOI 10.1023/A:1020299819637; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Lucci A, 1998, ANTICANCER RES, V18, P475; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; Luker GD, 2001, J LIPID RES, V42, P1389; LUM BL, 1995, HEMATOL ONCOL CLIN N, V9, P319, DOI 10.1016/S0889-8588(18)30097-2; MacLeod RAF, 1999, INT J CANCER, V83, P555; Majoul I, 2002, J CELL SCI, V115, P817; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; Nutikka Anita, 2003, Methods Mol Med, V73, P187; Nutikka Anita, 2003, Methods Mol Med, V73, P197; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; Plo I, 2002, MOL PHARMACOL, V62, P304, DOI 10.1124/mol.62.2.304; PUDYMAITIS A, 1991, ARCH BIOCHEM BIOPHYS, V286, P448, DOI 10.1016/0003-9861(91)90064-P; Raggers RJ, 2001, BIOCHEM J, V357, P859, DOI 10.1042/0264-6021:3570859; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; SAEKI T, 1993, J BIOL CHEM, V268, P6077; Salhia B, 2002, NEOPLASIA, V4, P304, DOI 10.1038/sj.neo.7900243; SANDVIG K, 1987, INFECT IMMUN, V55, P298, DOI 10.1128/IAI.55.2.298-303.1987; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Shabbits JA, 2002, MOL CANCER THER, V1, P205; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Smith AJ, 1998, HEPATOLOGY, V28, P530, DOI 10.1002/hep.510280234; Stern CA, 2000, GLYCOBIOLOGY, V10, P365, DOI 10.1093/glycob/10.4.365; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; Takano M, 1998, EUR J PHARMACOL, V358, P289, DOI 10.1016/S0014-2999(98)00607-4; Touhey S, 2002, EUR J CANCER, V38, P1661, DOI 10.1016/S0959-8049(02)00128-4; Tsuboi N, 2001, KIDNEY INT, V60, P1378, DOI 10.1046/j.1523-1755.2001.00967.x; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; van Meer G, 2001, P NATL ACAD SCI USA, V98, P1321, DOI 10.1073/pnas.98.4.1321; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VELDMAN J, 2002, FASEB J, V10, P1096; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; YOGEESWARAN G, 1975, BIOCHEMISTRY-US, V14, P2151, DOI 10.1021/bi00681a017; ZACHARIAS C, 1994, J BIOL CHEM, V269, P13313; Zager RA, 2001, KIDNEY INT, V60, P944, DOI 10.1046/j.1523-1755.2001.060003944.x; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	81	81	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7867	7876		10.1074/jbc.M305645200	http://dx.doi.org/10.1074/jbc.M305645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662772	hybrid			2022-12-25	WOS:000189103300063
J	Kim, OJ; Gardner, BR; Williams, DB; Marinec, PS; Cabrera, DM; Peters, JD; Mak, CC; Kim, KM				Kim, OJ; Gardner, BR; Williams, DB; Marinec, PS; Cabrera, DM; Peters, JD; Mak, CC; Kim, KM			The role of phosphorylation in D-1 dopamine receptor desensitization - Evidence for a novel mechanism of arrestin association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; PROTEIN-COUPLED RECEPTORS; CYTOPLASMIC TAIL; DEPENDENT PHOSPHORYLATION; DIFFERENTIAL REGULATION; BETA-ARRESTINS; ACTIVATION; BINDING; KINASE; IDENTIFICATION	Homologous desensitization of D-1 dopamine receptors is thought to occur through their phosphorylation leading to arrestin association which interdicts G protein coupling. In order to identify the relevant domains of receptor phosphorylation, and to determine how this leads to arrestin association, we created a series of mutated D-1 receptor constructs. In one mutant, all of the serine/threonine residues within the 3rd cytoplasmic domain were altered (3rdTOT). A second construct was created in which only three of these serines (serines 256, 258, and 259) were mutated (3rd234). We also created four truncation mutants of the carboxyl terminus (T347, T369, T394, and T404). All of these constructs were comparable with the wild-type receptor with respect to expression and adenylyl cyclase activation. In contrast, both of the 3rd loop mutants exhibited attenuated agonist-induced receptor phosphorylation that was correlated with an impaired desensitization response. Sequential truncation of the carboxyl terminus of the receptor resulted in a sequential loss of agonist-induced phosphorylation. No phosphorylation was observed with the most severely truncated T347 mutant. Surprisingly, all of the truncated receptors exhibited normal desensitization. The ability of the receptor constructs to promote arrestin association was evaluated using arrestin-green fluorescent protein translocation assays and confocal fluorescence microscopy. The 3rd234 mutant receptor was impaired in its ability to induce arrrestin translocation, whereas the T347 mutant was comparable with wild type. Our data suggest a model in which arrestin directly associates with the activated 3rd cytoplasmic domain in an agonist-dependent fashion; however, under basal conditions, this is sterically prevented by the carboxyl terminus of the receptor. Receptor activation promotes the sequential phosphorylation of residues, first within the carboxyl terminus and then the 3rd cytoplasmic loop, thereby dissociating these domains and allowing arrestin to bind to the activated 3rd loop. Thus, the role of receptor phosphorylation is to allow access of arrestin to its receptor binding domain rather than to create an arrestin binding site per se.	NINDS, Mol Neuropharmacol Sect, NIH, Bethesda, MD 20892 USA; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Chonnam National University	Kim, KM (corresponding author), NINDS, Mol Neuropharmacol Sect, NIH, Bldg 10,Rm 5C108,10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.	sibley@helix.nih.gov	Cabrera, David/I-1013-2014		Intramural NIH HHS [Z01 NS002263-31] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002263] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1999, METHOD ENZYMOL, V302, P153, DOI 10.1016/S0076-6879(99)02016-9; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Chaar ZY, 2001, J NEUROCHEM, V79, P1047, DOI 10.1046/j.1471-4159.2001.00648.x; Felder RA, 2002, P NATL ACAD SCI USA, V99, P3872, DOI 10.1073/pnas.062694599; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Jackson A, 2000, FEBS LETT, V470, P183, DOI 10.1016/S0014-5793(00)01315-6; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Jiang D, 1999, MOL PHARMACOL, V56, P675; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kishi H, 2002, J BIOL CHEM, V277, P21939, DOI 10.1074/jbc.M110894200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lewis MM, 1998, J PHARMACOL EXP THER, V286, P345; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mason JN, 2002, MOL PHARMACOL, V61, P806, DOI 10.1124/mol.61.4.806; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Richardson MD, 2003, J NEUROCHEM, V84, P854, DOI 10.1046/j.1471-4159.2003.01577.x; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; SIBLEY DR, 1996, DOPAMINE RECEPTORS, P383; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tumova K, 2003, J BIOL CHEM, V278, P8146, DOI 10.1074/jbc.M208059200; Ventura ALM, 2000, J PHARMACOL EXP THER, V293, P426; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	38	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7999	8010		10.1074/jbc.M308281200	http://dx.doi.org/10.1074/jbc.M308281200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660631	hybrid, Green Accepted			2022-12-25	WOS:000189103300078
J	Wang, Y; Pennock, SD; Chen, XM; Kazlauskas, A; Wang, ZX				Wang, Y; Pennock, SD; Chen, XM; Kazlauskas, A; Wang, ZX			Platelet-derived growth factor receptor-mediated signal transduction from endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; 2 DISTINCT PHASES; PDGF RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; BETA(2)-ADRENERGIC RECEPTOR; KINASE COMPLEXES; PROTEIN-KINASE; BETA-RECEPTOR; BINDING-SITE	Although accumulated evidence supports the concept of endosomal signaling of receptor tyrosine kinases, most results are generated from studies of epidermal growth factor receptor (EGFR). It is not clear whether the concept of endosomal signaling could be generally applied to the other receptor tyrosine kinases. For example, platelet-derived growth factor receptor (PDGFR) is very similar to EGFR in terms of both signaling and trafficking; however, little is known about the endosomal signaling of PDGFR. In this research, we applied the same approaches from our recent studies regarding EGFR endosomal signaling to investigate the endosomal signaling of PDGFR. We showed in this communication that we are able to establish a system that allows the specific activation of endosome-associated PDGFR without the activation of the plasma membrane-associated PDGFR and without disrupting the overall endocytosis pathway. By using this system, we showed that endosomal activation of PDGFR recruits various signaling proteins including Grb2, SHC, phospholipase C-gamma1, and the p85alpha subunit of phosphatidylinositol 3-kinase into endosomes and forms signaling complexes with PDGFR. We also showed that endosomal PDGFR signaling is sufficient to activate the major signaling pathways implicated in cell proliferation and survival. Moreover, we demonstrate that endosomal PDGFR signaling is sufficient to generate physiological output including cell proliferation and cell survival.	Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Fac Med & Dent, Signal Transduct Res Grp, Edmonton, AB T6G 2H7, Canada; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	University of Alberta; University of Alberta; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Wang, ZX (corresponding author), Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.	zwang@cellbnt.ualberta.ca						Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Clague MJ, 2001, J CELL SCI, V114, P3075; COHEN S, 1985, J BIOL CHEM, V260, P2351; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAY DG, 1986, J BIOL CHEM, V261, P8473; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS RJ, 1993, TRENDS BIOTECHNOL, V11, P439, DOI 10.1016/0167-7799(93)90075-K; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Kong M, 2003, MOL ENDOCRINOL, V17, P935, DOI 10.1210/me.2002-0391; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WAHL MI, 1990, J BIOL CHEM, V265, P3944; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wang Y., 2002, SCI STKE, V161, pl17; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	54	104	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8038	8046		10.1074/jbc.M311494200	http://dx.doi.org/10.1074/jbc.M311494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660565	hybrid			2022-12-25	WOS:000189103300082
J	Jung, JY; Shin, JS; Lee, SY; Hwang, SW; Koo, J; Cho, HW; Oh, U				Jung, JY; Shin, JS; Lee, SY; Hwang, SW; Koo, J; Cho, HW; Oh, U			Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its vanilloid binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; NONSELECTIVE CATION CHANNEL; CAPSAICIN RECEPTOR; THERMAL HYPERALGESIA; POTASSIUM CHANNELS; TOPICAL CAPSAICIN; PROTEIN-KINASES; ION-CHANNEL; RAT; DESENSITIZATION	Vanilloid receptor 1 (VR1), a capsaicin receptor, is known to play a major role in mediating inflammatory thermal nociception. Although the physiological role and biophysical properties of VR1 are known, the mechanism of its activation by ligands is poorly understood. Here we show that VR1 must be phosphorylated by Ca2+-calmodulin dependent kinase II (CaMKII) before its activation by capsaicin. In contrast, the dephosphorylation of VR1 by calcineurin leads to a desensitization of the receptor. Moreover, point mutations in VR1 at two putative consensus sites for CaMKII failed to elicit capsaicin-sensitive currents and caused a concomitant reduction in VR1 phosphorylation in vivo. Such mutants also lost their high affinity binding with [H-3]resiniferatoxin, a potent capsaicin receptor agonist. We conclude that the dynamic balance between the phosphorylation and dephosphorylation of the VR1 channel by CaMKII and calcineurin, respectively, controls the activation/ desensitization states by regulating VR1 binding. Furthermore, because sensitization by protein kinase A and C converge at these sites, phosphorylation stress in the cell appears to control a wide range of excitabilities in response to various adverse stimuli.	Seoul Natl Univ, Coll Pharm, Sensory Res Ctr, Seoul 151742, South Korea; Hankyong Natl Univ, Dept Gen Engn, Ansung 456749, South Korea	Seoul National University (SNU); Hankyong National University	Oh, U (corresponding author), Seoul Natl Univ, Coll Pharm, Sensory Res Ctr, Shinlim 9 Dong, Seoul 151742, South Korea.	utoh@plaza.snu.ac.kr		Hwang, Sun Wook/0000-0001-8460-7480				BERNSTEIN JE, 1989, J AM ACAD DERMATOL, V21, P265, DOI 10.1016/S0190-9622(89)70171-7; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHOLEWINSKI A, 1993, NEUROSCIENCE, V55, P1015, DOI 10.1016/0306-4522(93)90315-7; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; ESPINO PC, 1990, ONCOGENE, V5, P283; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; Koplas PA, 1997, J NEUROSCI, V17, P3525; Lopshire JC, 1998, J NEUROSCI, V18, P6081; NAGEL G, 1992, NATURE, V360, P81, DOI 10.1038/360081a0; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Oh U, 1996, J NEUROSCI, V16, P1659; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Rathee PK, 2002, J NEUROSCI, V22, P4740, DOI 10.1523/JNEUROSCI.22-11-04740.2002; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; SPRUCE AE, 1985, NATURE, V316, P736, DOI 10.1038/316736a0; SZALLASI A, 1992, J PHARMACOL EXP THER, V262, P883; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; SZALLASI A, 1993, J PHARMACOL EXP THER, V267, P728; Szolcsanyi J., 1993, CAPSAICIN STUDY PAIN, P1; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; WATSON CPN, 1988, PAIN, V33, P333, DOI 10.1016/0304-3959(88)90292-8; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929; ZHANG B, 1991, J BIOL CHEM, V266, P990; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	50	196	207	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7048	7054		10.1074/jbc.M311448200	http://dx.doi.org/10.1074/jbc.M311448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14630912	hybrid			2022-12-25	WOS:000188969200102
J	Lee, JM; Rho, SH; Shin, DW; Cho, CH; Park, WJ; Eom, SH; Ma, JJ; Kim, DH				Lee, JM; Rho, SH; Shin, DW; Cho, CH; Park, WJ; Eom, SH; Ma, JJ; Kim, DH			Negatively charged amino acids within the intraluminal loop of ryanodine receptor are involved in the interaction with triadin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; CA2+ RELEASE CHANNEL; PORE-FORMING SEGMENT; SKELETAL-MUSCLE; MOLECULAR-CLONING; CALCIUM-RELEASE; CALSEQUESTRIN; PROTEIN; DOMAIN; IDENTIFICATION	In mammalian striated muscles, ryanodine receptor (RyR), triadin, junctin, and calsequestrin form a quaternary complex in the lumen of sarcoplasmic reticulum. Such intermolecular interactions contribute not only to the passive buffering of sarcoplasmic reticulum luminal Ca2+, but also to the active Ca2+ release process during excitation-contraction coupling. Here we tested the hypothesis that specific charged amino acids within the luminal portion of RyR mediate its direct interaction with triadin. Using in vitro binding assay and site-directed mutagenesis, we found that the second intraluminal loop of the skeletal muscle RyR1 (amino acids 4860-4917), but not the first intraluminal loop of RyR1 (amino acids 4581-4640) could bind triadin. Specifically, three negatively charged residues Asp(4878), Asp(4907), and Glu(4908) appear to be critical for the association with triadin. Using deletional approaches, we showed that a KEKE motif of triadin (amino acids 200-232) is essential for the binding to RyR1. Because the second intraluminal loop of RyR has been previously shown to contain the ion-conducting pore as well as the selectivity filter of the Ca2+ release channel, and Asp(4878) Asp(4907), and Glu(4908) residues are predicted to locate at the periphery of the pore assembly of the channel, our data suggest that a physical interaction between RyR1 and triadin could play an active role in the overall Ca2+ release process of excitation-contraction coupling in muscle cells.	Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Hanwha Chem Co, R&D Ctr, Dept Genet, Taejon 305345, South Korea; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Gwangju Institute of Science & Technology (GIST); Rutgers State University New Brunswick; Rutgers State University Medical Center	Kim, DH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea.	dhkim@kjist.ac.kr		Rho, Seong-Hwan/0000-0002-8650-8205	NHLBI NIH HHS [R01-HL69000] Funding Source: Medline; NIA NIH HHS [R01-AG15556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balshaw D, 1999, P NATL ACAD SCI USA, V96, P3345, DOI 10.1073/pnas.96.7.3345; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; GUO W, 1994, J BIOL CHEM, V269, P28359; HE ZP, 1993, J BIOL CHEM, V268, P24635; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; JOHNSON EA, 1967, J CELL BIOL, V33, P103, DOI 10.1083/jcb.33.1.103; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KIM DH, 1984, BIOCHIM BIOPHYS ACTA, V775, P320, DOI 10.1016/0005-2736(84)90187-1; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kobayashi YM, 2000, J BIOL CHEM, V275, P17639, DOI 10.1074/jbc.M002091200; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HG, 2001, J BIOL CHEM, V276, P39533, DOI 10.1074/jbc.M010664200; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; Maguire PB, 1997, BIOCHEM BIOPH RES CO, V240, P721, DOI 10.1006/bbrc.1997.7729; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TU Q, 1994, BIOPHYS J, V67, P2280, DOI 10.1016/S0006-3495(94)80713-1; Wang SR, 1998, NAT STRUCT BIOL, V5, P476, DOI 10.1038/nsb0698-476; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	40	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6994	7000		10.1074/jbc.M312446200	http://dx.doi.org/10.1074/jbc.M312446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638677	hybrid			2022-12-25	WOS:000188969200095
J	Kuberan, B; Lech, M; Borjigin, J; Rosenberg, RD				Kuberan, B; Lech, M; Borjigin, J; Rosenberg, RD			Light-induced 3-O-sulfotransferase expression alters pineal heparan sulfate fine structure - A surprising link to circadian rhythm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HUMAN CDNAS; PROTEOGLYCANS; ISOFORMS	Proteoglycans are dominant glycoconjugates located on the cell surface and in extracellular spaces and consist of a core protein with one or more glycosaminoglycan side chains linked covalently. Heparan sulfate (HS) belongs to the family of glycosaminoglycans. HS has been assigned a variety of physiological and pathological functions, such as cell-cell adhesion, cell-matrix adhesion, cell proliferation, motility and differentiation, lipoprotein metabolism, blood coagulation, inflammation, tissue regeneration, tumor progression and invasion, pathogenic infection by bacteria, protozoa, and viruses, through specific interaction with a wide array of proteins, ligands, receptors, and pathogens (Bernfield, M., Gotte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) Annu. Rev. Biochem. 68, 729 777). We have shown here for the first time that light induces changes in pineal HS fine structure and that occurrence of the rare 3-O sulfation catalyzed by HS 3-O-sulfotransferase (3-OST2) is predominantly restricted to daytime pineal glands.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, Boston, MA 02215 USA	University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 1137 Catherine St, Ann Arbor, MI 48109 USA.	borjigin@umich.edu; rdrrosen@mit.edu	Borjigin, Jimo/GXA-3484-2022	Balagurunathan, Kuberan/0000-0001-9203-8118				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borjigin J, 2003, J BIOL CHEM, V278, P16315, DOI 10.1074/jbc.M300828200; Kuberan B, 2003, J BIOL CHEM, V278, P52613, DOI 10.1074/jbc.M305029200; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Kuberan B, 2003, J AM CHEM SOC, V125, P12424, DOI 10.1021/ja036737g; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200	13	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5053	5054		10.1074/jbc.C300492200	http://dx.doi.org/10.1074/jbc.C300492200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630922	hybrid			2022-12-25	WOS:000188776500002
J	Staniforth, V; Wang, SY; Shyur, LF; Yang, NS				Staniforth, V; Wang, SY; Shyur, LF; Yang, NS			Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHEUMATOID-ARTHRITIS; TNF-ALPHA; PARTICLE BOMBARDMENT; MECHANICAL-STRESS; ANTIBODY CDP571; C-JUN; EXPRESSION; PROTEIN; DISEASE	Tumor necrosis factor alpha (TNF-alpha) contributes to the pathogenesis of both acute and chronic inflammatory diseases and has been a target for the development of new anti-inflammatory drugs. Shikonins, the naphthoquinone pigments present in the root tissues of Lithospermum erythrorhizon Sieb. et Zucc. (Boraginaceae), have been reported to exert anti-inflammatory effects both in vitro and in vivo. In this study, we evaluated the effects of shikonin and its derivatives on the transcriptional activation of human TNF-alpha promoter in a gene gun-transfected mouse skin system by using a luciferase reporter gene assay. The crude plant extract of L. erythrorhizon as well as derived individual compounds shikonin, isobutyryl shikonin, acetyl shikonin, dimethylacryl shikonin and isovaleryl shikonin showed significant dose-dependent inhibition of TNF-alpha promoter activation. Among the tested compounds, shikonin and isobutyryl shikonin exhibited the highest inhibition of TNF-alpha promoter activation and also showed significant suppression of transgenic human TNF-alpha mRNA expression and protein production. We demonstrated that shikonin-inhibitory response was retained in the core TNF-alpha promoter region containing the TATA box and a 48-bp downstream sequence relative to the transcription start site. Further our results indicated that shikonin suppressed the basal transcription and activator-regulated transcription of TNF-alpha by inhibiting the binding of transcription factor IID protein complex (TATA box-binding protein) to TATA box. These in vivo results suggest that shikonins inhibit the transcriptional activation of the human TNF-alpha promoter through interference with the basal transcription machinery. Thus, shikonins may have clinical potential as anti-inflammatory therapeutics.	Acad Sinica, Inst Bioagr Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Yang, NS (corresponding author), Acad Sinica, Inst Bioagr Sci, 128,Sec 2, Taipei 11529, Taiwan.	nsyang@gate.sinica.edu.tw						Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Becker C, 1999, GENE EXPRESSION, V8, P115; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; Bos JD, 1997, CLIN EXP IMMUNOL, V107, P3; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen X, 2002, PHYTOTHER RES, V16, P199, DOI 10.1002/ptr.1100; Chen X, 2001, INT IMMUNOPHARMACOL, V1, P229, DOI 10.1016/S1567-5769(00)00033-3; CHENG L, 1993, P NATL ACAD SCI USA, V90, P4455, DOI 10.1073/pnas.90.10.4455; CHIH HW, 1995, AM J CHINESE MED, V23, P273, DOI 10.1142/S0192415X95000328; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Evans RC, 1997, ALIMENT PHARM THERAP, V11, P1031, DOI 10.1046/j.1365-2036.1997.00251.x; FELDMANN M, 1994, CIRC SHOCK, V43, P179; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; KUO CF, 2002, GENE THERAPY PROTOCO, P137; LaDuca JR, 2001, DERMATOL CLIN, V19, P617, DOI 10.1016/S0733-8635(05)70304-1; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Palmieri EA, 2002, AM J PHYSIOL-HEART C, V282, pH926, DOI 10.1152/ajpheart.00436.2001; Papageorgiou VP, 1999, ANGEW CHEM INT EDIT, V38, P270, DOI 10.1002/(SICI)1521-3773(19990201)38:3<270::AID-ANIE270>3.0.CO;2-0; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Pozzi L, 2003, J NEUROCHEM, V86, P451, DOI 10.1046/j.1471-4159.2003.01851.x; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; RIECKMANN P, 1995, ANN NEUROL, V37, P82, DOI 10.1002/ana.410370115; SETO Y, 1992, YAKUGAKU ZASSHI, V112, P259, DOI 10.1248/yakushi1947.112.4_259; Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Subbaramaiah K, 2001, J BIOMOL SCREEN, V6, P101; TANAKA S, 1986, J NAT PROD, V49, P466, DOI 10.1021/np50045a014; THOMPSON TA, 1993, IN VITRO CELL DEV-AN, V29, P165, DOI 10.1007/BF02630949; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WANG JP, 1995, EUR J PHARMACOL, V272, P87, DOI 10.1016/0014-2999(94)00627-J; Wang JP, 1997, BIOCHEM PHARMACOL, V53, P1173, DOI 10.1016/S0006-2952(97)00098-1; Wang JP, 1997, BRIT J PHARMACOL, V121, P409, DOI 10.1038/sj.bjp.0701147; WANG QW, 1994, WARME STOFFUBERTRAG, V29, P161, DOI 10.1007/BF01548600; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Yokoyama T, 1999, AM J PHYSIOL-HEART C, V276, pH1968, DOI 10.1152/ajpheart.1999.276.6.H1968	45	119	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5877	5885		10.1074/jbc.M309185200	http://dx.doi.org/10.1074/jbc.M309185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645256	hybrid			2022-12-25	WOS:000188776500103
J	Lee, SF; Shah, S; Yu, C; Wigley, WC; Li, H; Lim, M; Pedersen, K; Han, WP; Thomas, P; Lundkvist, J; Hao, YH; Yu, G				Lee, SF; Shah, S; Yu, C; Wigley, WC; Li, H; Lim, M; Pedersen, K; Han, WP; Thomas, P; Lundkvist, J; Hao, YH; Yu, G			A conserved GXXXG motif in APH-1 is critical for assembly and activity of the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; BETA-APP; PRESENILIN; NICASTRIN; MEMBRANE; PROTEIN; PEN-2; NOTCH; ASSOCIATION; SUBCOMPLEX	The multipass membrane protein APH-1, found in the gamma-secretase complex together with presenilin, nicastrin, and PEN-2, is essential for Notch signaling in Caenorhabditis elegans embryos and is required for intramembrane proteolysis of Notch and beta-amyloid precursor protein in mammalian and Drosophila cells. In C. elegans, a mutation of the conserved transmembrane Gly(123) in APH-1 (mutant or28) leads to a notch/glp-1 loss-of-function phenotype. In this study, we show that the corresponding mutation in mammalian APH-1a(L) (G122D) disrupts the physical interaction of APH-1a(L) with hypoglycosylated immature nicastrin and the presenilin holoprotein as well as with mature nicastrin, presenilin, and PEN-2. The G122D mutation also reduced gamma-secretase activity in intramembrane proteolysis of membrane-tethered Notch. Moreover, we found that the conserved transmembrane Gly(122), Gly(126), and Gly(130) in the fourth transmembrane region of mammalian APH-1a(L) are part of the membrane helix-helix interaction GXXXG motif and are essential for the stable association of APH-1a(L) with presenilin, nicastrin, and PEN-2. These findings suggest that APH-1 plays a GXXXG-dependent scaffolding role in both the initial assembly and subsequent maturation and maintenance of the active gamma-secretase complex.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Karolinska Institutet	Yu, G (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Gang.Yu@UTSouthwestern.edu						Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gerber D, 2001, J BIOL CHEM, V276, P31229, DOI 10.1074/jbc.M101889200; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Ubarretxena-Belandia I, 2001, CURR OPIN STRUC BIOL, V11, P370, DOI 10.1016/S0959-440X(00)00217-7; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	38	92	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4144	4152		10.1074/jbc.M309745200	http://dx.doi.org/10.1074/jbc.M309745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627705	hybrid			2022-12-25	WOS:000188554300029
J	Sugars, KL; Brown, R; Cook, LJ; Swartz, J; Rubinsztein, DC				Sugars, KL; Brown, R; Cook, LJ; Swartz, J; Rubinsztein, DC			Decreased cAMP response element-mediated transcription - An early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; GENE-EXPRESSION CHANGES; EXPANDED POLYGLUTAMINE; MUTANT HUNTINGTIN; HEAT-SHOCK; REPRESSES TRANSCRIPTION; KAPPA-B; TOXICITY; LOCALIZATION; AGGREGATION	Huntington's disease (HD) is one of nine neurodegenerative diseases caused by an expanded polyglutamine (polyQ) tract within the disease protein. To characterize pathways induced early in HD, we have developed stable inducible PC12 cell lines expressing wild-type or mutant forms of huntingtin exon 1 fragments or the full-length huntingtin protein. Three cAMP response element-binding protein (CREB)-binding protein-dependent transcriptional pathways, regulated by cAMP response element (CRE), retinoic acid response element, and nuclear factor kappaB, show abnormalities in our exon 1 cell model. Of these, the CRE pathway shows the earliest disruption and is significantly down-regulated as early as 12 h following mutant htt transgene induction. This pathway is also the only one of the three that is similarly perturbed in our full-length HD model, where it is also down-regulated at an early time point, compatible with observations in HD brains. Reduced CRE-dependent transcription may contribute to polyQ disease pathogenesis because overexpression of transcriptionally active CREB, but not an inactive form of the protein, is able to protect against polyQ-induced cell death and reduce aggregation.	Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Wellcome Trust, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Wellcome Trust, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	dcr1000@cus.cam.ac.uk	Rubinsztein, David C/C-3472-2011					Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Augood SJ, 1996, NEUROSCIENCE, V72, P1023, DOI 10.1016/0306-4522(95)00595-1; Boone DL, 2002, INFLAMM BOWEL DIS, V8, P201, DOI 10.1097/00054725-200205000-00008; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan EYW, 2002, HUM MOL GENET, V11, P1939, DOI 10.1093/hmg/11.17.1939; Coles R, 1998, HUM MOL GENET, V7, P791, DOI 10.1093/hmg/7.5.791; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DESOUZA EB, 1987, BRAIN RES, V437, P355, DOI 10.1016/0006-8993(87)91651-9; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Ho LW, 2001, PSYCHOL MED, V31, P3, DOI 10.1017/S0033291799002871; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; KHOSHNAN A, 2002, PROGRAM 388 2 2002 A; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LATCHMAN DS, 1998, EUKARYOTIC TRANSCRIP; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1911, DOI 10.1093/hmg/11.17.1911; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; SAPP E, 1995, NEUROSCIENCE, V67, P397; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Song C, 2002, J BIOL CHEM, V277, P6703, DOI 10.1074/jbc.M110338200; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Taylor JP, 2003, GENE DEV, V17, P1463, DOI 10.1101/gad.1087503; The Huntington's Disease Collaborative Research Group, 1983, CELL, V72, P971; Timmers HJLM, 1996, BRAIN RES, V728, P141, DOI 10.1016/0006-8993(96)00080-7; Toneff T, 2002, J NEUROCHEM, V82, P84, DOI 10.1046/j.1471-4159.2002.00940.x; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yohrling GJ, 2003, MOL CELL NEUROSCI, V23, P28, DOI 10.1016/S1044-7431(03)00032-0; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038	49	116	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4988	4999		10.1074/jbc.M310226200	http://dx.doi.org/10.1074/jbc.M310226200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627700	hybrid			2022-12-25	WOS:000188554300125
J	Kauraniemi, P; Hautaniemi, S; Autio, R; Astola, J; Monni, O; Elkahloun, A; Kallioniemi, A				Kauraniemi, P; Hautaniemi, S; Autio, R; Astola, J; Monni, O; Elkahloun, A; Kallioniemi, A			Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines	ONCOGENE			English	Article						HER2; herceptin; amplification; breast cancer; cDNA microarray	MONOCLONAL-ANTIBODY; C-FOS; MUTATIONS; KIT; CHEMOTHERAPY; TRASTUZUMAB; ACTIVATION; ESTROGEN; EFFICACY; AMPLICON	Herceptin is a humanized monoclonal antibody targeted against the extracellular domain of the HER2 oncogene, which is amplified and overexpressed in 10-34% of breast cancers. Herceptin therapy provides effective treatment in HER2-positive metastatic breast cancer, although a favorable treatment response is not achieved in all cases. Here, we show that Herceptin treatment induces a dose-dependent growth reduction in breast cancer cell lines with HER2 amplification, whereas nonamplified cell lines are practically resistant. Time-course analysis of global gene expression patterns in amplified and nonamplified cell tines indicated a major change in transcript levels between 24 and 48 h of Herceptin treatment. A step-wise gene selection algorithm revealed a set of 439 genes whose temporal expression profiles differed most between the amplified and nonamplified cell lines. The discriminatory power of these genes was confirmed by both hierarchical clustering and self-organizing map analyses. In the amplified cell lines, the Herceptin treatment induced the expression of several genes involved in RNA processing and DNA repair, while cell adhesion mediators and known oncogenes, such as e-FOS and c-KIT, were downregulated. These results provide additional clues to the downstream effects of blocking the HER2 pathway in breast cancer and may provide new targets for more effective treatment.	Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33520 Tampere, Finland; Tampere Univ Hosp, FIN-33520 Tampere, Finland; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; Univ Helsinki, Biomedicum Helsinki, Biomedicum Biochip Ctr, FIN-00290 Helsinki, Finland; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	Tampere University; Tampere University; Tampere University Hospital; Tampere University; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kallioniemi, A (corresponding author), Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33520 Tampere, Finland.	anne.kallioniemi@uta.fi	Astola, Jaakko T/G-4297-2014; Autio, Reija/D-2037-2014; Hautaniemi, Sampsa/CAG-0362-2022; Hautaniemi, Sampsa/A-3122-2009	Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Astola, Jaakko/0000-0002-2750-5311; Autio, Reija/0000-0002-6519-2715				Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Duan RQ, 2002, BIOCHEM BIOPH RES CO, V294, P384, DOI 10.1016/S0006-291X(02)00499-0; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hautaniemi S, 2003, MACH LEARN, V52, P45, DOI 10.1023/A:1023941307670; HAUTANIEMI S, 2003, STRATEGY IDENTIFYING; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kohonen T., 2001, SELF ORG MAPS, DOI [DOI 10.1007/978-3-642-56927-2, 10.1007/978-3-642-56927-2, DOI 10.1007/978-3-642-56927-2_1]; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Molina MA, 2001, CANCER RES, V61, P4744; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Mousses S, 2000, PRACT APPROACH SER, P113; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Vesanto J., 2000, SOM TOOLBOX MATLAB 5; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WILDING G, 1988, CANCER RES, V48, P802; Yakes FM, 2002, CANCER RES, V62, P4132; Yang YH, 2001, PROC SPIE, V4266, P141, DOI 10.1117/12.427982	27	53	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1010	1013		10.1038/sj.onc.1207200	http://dx.doi.org/10.1038/sj.onc.1207200			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647448				2022-12-25	WOS:000188486600018
J	Baudhuin, LM; Jiang, Y; Zaslavsky, A; Ishii, I; Chun, J; Xu, Y				Baudhuin, LM; Jiang, Y; Zaslavsky, A; Ishii, I; Chun, J; Xu, Y			S1P(3)-mediated Akt activation and crosstalk with platelet-derived growth factor receptor (PDGFR)	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; mouse embryonic fibroblasts; GPCR	PROTEIN-COUPLED RECEPTOR; NITRIC-OXIDE PRODUCTION; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; PHOSPHOLIPASE-D; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE	Akt plays a pivotal role in cell survival and tumorigenesis. We investigated the potential interaction between sphingosine-1-phosphate (S1P) and platelet-derived growth factor (PDGF) in the Akt signaling pathway. Using mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P3 was required for S473 phosphorylation of Akt by S1P. In addition, S1P-stimulated activation of Akt, but not ERK, was blocked by a PDGF receptor (PDGFR)-specific inhibitor, AG1296, suggesting a S1P3-mediated specific crosstalk between the Akt signaling pathways of SIP and PDGFR in MEFs. We investigated this crosstalk under different conditions and found that both Akt and ERK activation induced by S1P, but not lysophosphatidic acid (LPA), in BEY ovarian cancer cells required PDGFR but not epidermal growth factor receptor (EGFR) or insulin-like growth factor-I receptor (IGFR). Importantly, S1P induced a G(i)-dependent tyrosine phosphorylation of PDGFR in BEY cells. This dependence on PDGFR in SIP-induced Akt activation was also observed in A2780, T47D, and HMEC-1 cells (which express S1P(3)), but not in PC-3 or GI-101A cells (which do not express S1P(3)), further supporting that S1P(3) mediates the crosstalk between S1P and PDGFR. This is the first report demonstrating a unique interaction between S1P(3) and PDGFR, in addition to demonstrating a specific role for S1P(3) in SIP-induced Akt activation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Natl Inst Neurosci, Dept Mol Genet, Tokyo 1878502, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Cleveland Clin Fdn, Dept Obstet & Gynecol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; National Center for Neurology & Psychiatry - Japan; Scripps Research Institute; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	xuy@ccf.org	Chun, Jerold/Y-4670-2019	Ishii, Isao/0000-0002-5367-205X				Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; Banno Y, 2003, BIOCHEM J, V369, P363, DOI 10.1042/BJ20021368; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Im DS, 2000, BIOCHEM BIOPH RES CO, V279, P139, DOI 10.1006/bbrc.2000.3933; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kluk MJ, 2003, FEBS LETT, V533, P25, DOI 10.1016/S0014-5793(02)03742-0; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; Kou RQ, 2002, BIOCHEMISTRY-US, V41, P4982, DOI 10.1021/bi016017r; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu AX, 1998, CANCER RES, V58, P2973; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	40	67	74	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					341	+		10.1096/fj.03-0302fje	http://dx.doi.org/10.1096/fj.03-0302fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657000				2022-12-25	WOS:000188067500028
J	Lou, YR; Laaksi, I; Syvala, H; Blauer, M; Tammela, TLJ; Ylikomi, T; Tuohimaa, P				Lou, YR; Laaksi, I; Syvala, H; Blauer, M; Tammela, TLJ; Ylikomi, T; Tuohimaa, P			25-hydroxyvitamin D-3 is an active hormone in human primary prostatic stromal cells	FASEB JOURNAL			English	Article						fibroblast; prostate cancer; cell proliferation; 25-hydroxyvitamin D-3 24-hydroxylase; 25-hydroxyvitamin D-3 1 alpha-hydroxylase	1-ALPHA-HYDROXYLASE GENE-EXPRESSION; VITAMIN-D; 1,25-DIHYDROXYVITAMIN D-3; ALPHA-HYDROXYLASE; IN-VITRO; CANCER; CALCITRIOL; INHIBITION; CLONING; GROWTH	According to the present paradigm, 1alpha,25-dihydroxyvitamin D-3 [1alpha,25-(OH)(2)D-3] is a biologically active hormone; whereas 25-hydroxyvitamin D-3 (25OHD(3)) is regarded as a prohormone activated through the action of 25-hydroxyvitamin D-3 1alpha-hydroxylase (1alpha-hydroxylase). Although the role of vitamin D-3 in the regulation of growth and differentiation of prostatic epithelial cells has been well studied, its action and metabolism in prostatic stroma are still largely unknown. We investigated the effects of 25OHD(3) and 1alpha,25-(OH)(2)D-3 on two human stromal primary cultures termed P29SN and P32S. In a cell proliferation assay, 25OHD(3) was found at physiological concentrations of 100-250 nM to inhibit the growth of both primary cultures, whereas 1alpha,25-(OH)(2)D-3 at a pharmacological concentration of 10 nM exhibited the growth-inhibitory effects on P29SN cells but not on P32S cells. Quantitative real-time RT-PCR analysis revealed that both 25OHD(3) and 1alpha,25-(OH)(2)D-3 induced 25-hydroxyvitamin D-3 24-hydroxylase (24-hydroxylase) mRNA in a dose- and time-dependent manner. By inhibiting 1alpha-hydroxylase and/or 24-hydroxylase enzyme activities, the induction of 24-hydroxylase mRNA by 250 nM 25OHD(3) was clearly enhanced, suggesting that 1alpha-hydroxylation is not a prerequisite for the hormonal activity of 25OHD(3). Altogether our results suggest that 25OHD(3) at a high but physiological concentration acts as an active hormone with respect to vitamin D-3 responsive gene regulation and suppression of cell proliferation.	Univ Tampere, Sch Med, Dept Anat, FIN-33014 Tampere, Finland; Univ Tampere, Sch Med, Dept Cell Biol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland; Tampere Univ Hosp, Dept Urol, Tampere, Finland	Tampere University; Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital	Lou, YR (corresponding author), Univ Tampere, Sch Med, Dept Anat, FIN-33014 Tampere, Finland.	loyalo@uta.fi	Lou, Yan-Ru/K-4348-2012; Lou, Yan-Ru/AAX-4008-2020	Lou, Yan-Ru/0000-0001-7717-6010; Lou, Yan-Ru/0000-0001-7717-6010				Ahonen MH, 2000, CANCER CAUSE CONTROL, V11, P847, DOI 10.1023/A:1008923802001; Barreto AM, 2000, CANCER EPIDEM BIOMAR, V9, P265; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; Bland R, 2001, KIDNEY INT, V60, P1277, DOI 10.1046/j.1523-1755.2001.00966.x; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Brenza HL, 2000, ARCH BIOCHEM BIOPHYS, V381, P143, DOI 10.1006/abbi.2000.1970; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DOKOH S, 1983, ENDOCRINOLOGY, V112, P200, DOI 10.1210/endo-112-1-200; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Harant H, 2000, J CELL BIOCHEM, V78, P112, DOI 10.1002/(SICI)1097-4644(20000701)78:1<112::AID-JCB10>3.0.CO;2-7; Hawkins GA, 2002, PROSTATE, V53, P175, DOI 10.1002/pros.10144; HINE TJ, 1994, ANN CLIN BIOCHEM, V31, P31, DOI 10.1177/000456329403100105; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsu JY, 2001, CANCER RES, V61, P2852; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kivineva M, 1998, J STEROID BIOCHEM, V66, P121, DOI 10.1016/S0960-0760(98)00054-5; Konety BR, 2000, J UROLOGY, V164, P1812, DOI 10.1016/S0022-5347(05)67112-1; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krill D, 1999, UROLOGY, V54, P171, DOI 10.1016/S0090-4295(99)00103-X; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lokeshwar BL, 1999, CANCER EPIDEM BIOMAR, V8, P241; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Monkawa T, 2000, KIDNEY INT, V58, P559, DOI 10.1046/j.1523-1755.2000.00202.x; Monkawa T, 1997, BIOCHEM BIOPH RES CO, V239, P527, DOI 10.1006/bbrc.1997.7508; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; Olumi AF, 1998, CANCER RES, V58, P4525; Olumi AF, 1999, CANCER RES, V59, P5002; Osborn J L, 1995, Urol Oncol, V1, P195, DOI 10.1016/1078-1439(95)00061-5; Peehl DM, 1997, EXP CELL RES, V232, P208, DOI 10.1006/excr.1997.3525; PEEHL DM, 1994, CANCER RES, V54, P805; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; Schuster I, 2001, STEROIDS, V66, P409, DOI 10.1016/S0039-128X(00)00159-8; Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727; SIMPSON RU, 1980, P NATL ACAD SCI-BIOL, V77, P5822, DOI 10.1073/pnas.77.10.5822; SKOWRONSKI RJ, 1995, ENDOCRINOLOGY, V136, P20, DOI 10.1210/en.136.1.20; Smith DC, 1999, CLIN CANCER RES, V5, P1339; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TURNBULL H, 1982, CLIN CHIM ACTA, V120, P65, DOI 10.1016/0009-8981(82)90078-X; Vieth R, 1999, AM J CLIN NUTR, V69, P842; Ylikomi T, 2002, VITAM HORM, V64, P357, DOI 10.1016/S0083-6729(02)64010-5; Zehnder D, 1999, J AM SOC NEPHROL, V10, P2465; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888; Zierold C, 2003, J CELL BIOCHEM, V88, P234, DOI 10.1002/jcb.10341	51	71	73	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					332	+		10.1096/fj.03-0140fje	http://dx.doi.org/10.1096/fj.03-0140fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657005				2022-12-25	WOS:000188067500033
J	Gryz, EA; Meakin, SO				Gryz, EA; Meakin, SO			Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-dependent, but not nerve growth factor-independent, differentiation and cell cycle arrest in the human neuroblastoma cell line, SY5Y	ONCOGENE			English	Article						nerve growth factor; TrkA; tyrosine kinase receptor; kinase activation; activation loop; neurotrophins; mutagenesis; neuroblastomas; neuronal tumors; signalling	PC12 CELLS; NEURONAL DIFFERENTIATION; FACTOR RECEPTOR; N-MYC; SIGNALING ENDOSOMES; NEURITE OUTGROWTH; KINASE ACTIVATION; PROTEIN-KINASE; MESSENGER-RNA; EXPRESSION	TrkA is the receptor tyrosine kinase (RTK) for nerve growth factor (NGF) and stimulates NGF-dependent cell survival and differentiation in primary neurons and also differentiation of neuroblastomas and apoptosis of medulloblastomas. We have previously shown that aspartic acid and glutamic acid substitution (AspGlu and GluAsp) of the activation loop tyrosines in TrkA (Tyr(683) and Tyr(684)) supports NGF-independent neuritogenesis and cell survival in PC12 cell-derived nnr5 cells. In this study, the AspGlu and GluAsp mutant Trks have been analysed for their ability to support NGF-independent and NGF-dependent neuritogenesis, proliferation and cell signalling in the human neuroblastoma cell line, SY5Y. We find that the AspGlu and GluAsp mutant Trks support NGF-dependent, but not NGF-independent, autophosphorylation, neuritogenic responses and/or inhibit cell cycle progression. The NGF-dependent neuritogenic responses are lower for the mutant Trks (approximately 30-60% for AspGlu and 50-60% for GluAsp), relative to wild-type TrkA. While both the AspGlu and GluAsp mutant Trks support NGF-dependent transient phosphorylation of Shc, PLCgamma-1, AKT, FRS2, SH2B as well as prolonged MAP kinase activation, the GluAsp mutant induces stronger NGF-dependent tyrosine phosphorylation of FRS2 and SH2B, as well as a stronger reduction in bromodeoxyuridine (BrdU) incorporation. Collectively, these data suggest that neither absolute levels of receptor autophosphorylation, high levels of TrkA expression nor the activation of a specific signalling pathway is dominant and absolutely essential for neuritogenesis and cell cycle arrest of SY5Y cells.	John P Robarts Res Inst, Cell Biol Grp, Lab Neural Signalling, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Cell Biol Grp, Lab Neural Signalling, 100 Perth Dr, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	41	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8774	8785		10.1038/sj.onc.1206890	http://dx.doi.org/10.1038/sj.onc.1206890			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647472				2022-12-25	WOS:000186844900015
J	Hideshima, T; Hayashi, T; Chauhan, D; Akiyama, M; Richardson, P; Anderson, K				Hideshima, T; Hayashi, T; Chauhan, D; Akiyama, M; Richardson, P; Anderson, K			Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines	ONCOGENE			English	Article						multiple myeloma; JNK; growth arrest; p21; NF-kappa B	N-TERMINAL KINASE; PROTEASOME INHIBITOR PS-341; MARROW STROMAL CELLS; KAPPA-B; THERAPEUTIC APPLICATIONS; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; DRUG-RESISTANCE; PLASMA-CELLS; INTERLEUKIN-6	Although c-Jun NH2-terminal kinase (JNK) is activated by treatment with therapeutic agents, the biologic sequelae of inhibiting constitutive activation of JNK has not yet been clarified. In this study, we examine the biologic effect of JNK inhibition in multiple myeloma (MM) cell lines. JNK-specific inhibitor SP600125 induces growth inhibition via induction of G1 or G2/M arrest in U266 and MM.1S multiple myeloma cell lines, respectively. Neither exogenous IL-6 nor insulin-like growth factor-1 (IGF-1) overcome SP600125-induced growth inhibition, and IL-6 enhances SP600125-induced G2/M phase in MM.1S cells. Induction of growth arrest is mediated by upregulation of p27(Kip1), without alteration of p53 and JNK protein expression. Importantly, SP600125 inhibits growth of MM cells adherent to bone marrow stromal cells (BMSCs). SP600125 induces NF-kappaB activation in a dose-dependent fashion, associated with phosphorylation of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha. In contrast, SP600125 does not affect phosphorylation of STAT3, Akt, and/or ERK. IKK-specific inhibitor PS-1145 inhibits SP600125-induced NF-kappaB activation and blocks the protective effect of SP600125 against apoptosis. Our data therefore demonstrate for the first time that inhibiting JNK activity induces growth arrest and activates NF-kappaB in MM cells.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, K (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA050947, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [P0-1 CA78378, R0-1 CA50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; FREUND GG, 1993, J IMMUNOL, V151, P1811; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; HIDESHIMA T, 2003, UNPUB CANC RES; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Mitsiades CS, 2002, BLOOD, V100, p170A; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Ogata A, 1997, J IMMUNOL, V159, P2212; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1	29	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8797	8801		10.1038/sj.onc.1206919	http://dx.doi.org/10.1038/sj.onc.1206919			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647474				2022-12-25	WOS:000186844900017
J	Lebedeva, IV; Sarkar, D; Su, ZZ; Kitada, S; Dent, P; Stein, CA; Reed, JC; Fisher, PB				Lebedeva, IV; Sarkar, D; Su, ZZ; Kitada, S; Dent, P; Stein, CA; Reed, JC; Fisher, PB			Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24	ONCOGENE			English	Review						cancer gene therapy; prostate cancer; Bcl-2 protein family; apoptosis; mda-7/IL-24	HUMAN ADENOVIRUS TYPE-5; IN-VIVO; GROWTH ARREST; UP-REGULATION; DNA-DAMAGE; IMMUNOHISTOCHEMICAL ANALYSIS; CLONOGENIC SURVIVAL; ANDROGEN-ABLATION; CARCINOMA-CELLS; OVER-EXPRESSION	Subtraction hybridization identified melanoma differentiation associated gene-7, mda-7, in the context of terminally differentiated human melanoma cells. Based on its structure, cytokine-like properties and proposed mode of action, mda-7 has now been classified as IL-24. When expressed by means of a replication-incompetent adenovirus, Ad. mda-7 induces apoptosis in a broad range of cancer cells, without inducing harmful effects in normal fibroblast or epithelial cells. These unique properties of mda-7/IL-24 suggest that this gene will prove beneficial for cancer gene therapy. We now demonstrate that Ad. mda-7 decreases viability by induction of apoptosis in hormone-responsive (LNCaP) and hormone-independent (DU-145 and PC-3) human prostate carcinomas, without altering growth or survival in early-passage normal human prostate epithelial cells (HuPEC). Ad. mda-7 causes G(2)/M arrest and apoptosis in LNCaP (p53-wildtype), DU-145 (p53 mutant, Bax-negative) and PC-3 (p53-negative) prostate carcinomas, but not in HuPEC. Apoptosis induction correlated with changes in the ratio of pro- to antiapoptotic Bcl-2 protein family members. A potential functional role for changes in bcl-2 family gene expression in Ad. mda-7-induced apoptosis was suggested by the finding that forced overexpression of bcl-xL or bcl-2 differentially diminished the apoptotic effect of Ad. mda-7 in prostate carcinomas. These results confirm that induction of apoptosis by the mda-7/IL-24 gene in prostate cancer cells is Bax- and p53-independent and is mediated by mitochondrial pathways involving bcl-2 family gene members. The mda-7/IL-24 gene represents a new class of cancer-specific apoptosis-inducing genes with obvious potential for the targeted gene-based therapy of human prostate cancer.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA	Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University; Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.		Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA088906, R01CA097318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [BC98-0148, CA97318, CA88906, CA35675] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2002, CELL DEATH DIFFER, V9, P1240, DOI 10.1038/sj.cdd.4401097; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amundson SA, 2000, CANCER RES, V60, P6101; Bai XZ, 1999, INT J ONCOL, V14, P785; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beham AW, 1998, INT J MOL MED, V1, P953; BERCHEM GJ, 1995, CANCER RES, V55, P735; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Cao XX, 2002, MOL MED, V8, P869, DOI 10.1007/BF03402093; Chadbourne DE, 2001, POPTRONICS, V2, P3; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Curiel DT, 2000, CANCER GENE THER, V7, P1197, DOI 10.1038/sj.cgt.7700222; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; Gazdar AF, 2001, P NATL ACAD SCI USA, V98, P10028, DOI 10.1073/pnas.191379998; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; Gopalkrishnan RV, 2001, J CELL PHYSIOL, V189, P245, DOI 10.1002/jcp.10023; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Hall SJ, 1999, CANCER GENE THER, V6, P54, DOI 10.1038/sj.cgt.7700004; Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Hull GW, 2000, CLIN CANCER RES, V6, P4101; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jin RJ, 2000, CANCER GENE THER, V7, P1537, DOI 10.1038/sj.cgt.7700266; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Ko SC, 1996, HUM GENE THER, V7, P1683, DOI 10.1089/hum.1996.7.14-1683; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEON JA, 1994, PHARMACOL THERAPEUT, V61, P237, DOI 10.1016/0163-7258(94)90065-5; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Li XY, 2001, CANCER RES, V61, P1699; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lock RB, 1996, CANCER RES, V56, P4006; Lowe SL, 2001, GENE THER, V8, P1363, DOI 10.1038/sj.gt.3301531; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; Matsubara S, 2001, CANCER RES, V61, P6012; MAY WS, 1994, J BIOL CHEM, V269, P26865; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miyake H, 2001, INT J UROL, V8, P337, DOI 10.1046/j.1442-2042.2001.00311.x; Nasu Y, 1999, GENE THER, V6, P338, DOI 10.1038/sj.gt.3300834; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pataer A, 2002, CANCER RES, V62, P2239; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Pramudji C, 2001, CLIN CANCER RES, V7, P4272; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed J C, 1996, Behring Inst Mitt, P72; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodriguez R, 1997, CANCER RES, V57, P2559; Rots M G, 2000, Cancer Gene Ther, V7, P1507, DOI 10.1038/sj.cgt.7700253; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shalev M, 2000, J UROLOGY, V163, P1747, DOI 10.1016/S0022-5347(05)67534-9; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; Sweeney P, 2000, WORLD J UROL, V18, P121, DOI 10.1007/s003450050183; Tang DG, 1998, CANCER RES, V58, P3466; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; Xie XM, 2001, CANCER RES, V61, P6795; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	108	118	134	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8758	8773		10.1038/sj.onc.1206891	http://dx.doi.org/10.1038/sj.onc.1206891			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647471				2022-12-25	WOS:000186844900014
J	Wu, XH; Reiter, CEN; Antonetti, DA; Kimball, SR; Jefferson, LS; Gardner, TW				Wu, XH; Reiter, CEN; Antonetti, DA; Kimball, SR; Jefferson, LS; Gardner, TW			Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; GROWTH-FACTOR-I; PHOSPHOINOSITIDE 3-KINASE PATHWAY; PROTEIN-KINASE; SIGNALING PATHWAY; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLATIONAL CONTROL; RECEPTOR SUBSTRATE-1; GENE-EXPRESSION	The purpose of this study was to examine the role of the ribosomal protein S6 protein kinase (p70S6K), a protein synthesis regulator, in promoting retinal neuronal cell survival. Differentiated R28 rat retinal neuronal cells were used as an experimental model. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, and during the period of experimentation were exposed either to the absence or presence of 10 nM insulin. Insulin treatment induced p70S6K, mTOR, and Akt phosphorylation, effects that were completely prevented by the PI3K inhibitor, LY294002. Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin. Apoptosis, induced by serum deprivation and evaluated by Hoechst staining, was inhibited by insulin treatment in R28 cells, but not in L6 muscle cells. This effect of insulin was also largely prevented by rapamycin. Inhibition of p70S6K activity by exogenous expression of a dominant negative mutant of p70S6K prevented insulin-induced cell survival, whereas, overexpression of wild type p70S6K or expression of a rapamycin resistant form of the kinase enhanced the effect of insulin on survival. Enhanced cell survival under the latter condition was accompanied by increased p70S6K activity and phosphorylation. Rapamycin did not inhibit insulin induced p70S6K phosphorylation and activity in cells transfected with the rapamycin-resistant mutant. Together, these results suggest that p70S6K plays a key role in insulin stimulated retinal neuronal cell survival.	Penn State Univ, Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA; Penn State Univ, Ulerich Ophthalmol Res Ctr, Hershey, PA 17033 USA; Penn State Univ, JDRF Diabet Retinopathy Ctr, Hershey, PA 17033 USA; Penn State Univ, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Gardner, TW (corresponding author), Penn State Univ, Coll Med, Dept Ophthalmol, 500 Univ Dr, Hershey, PA 17033 USA.	tgardner@psu.edu		Gardner, Thomas/0000-0002-5112-5810; antonetti, david/0000-0003-1130-6577	NEI NIH HHS [EY12021] Funding Source: Medline; NIDDK NIH HHS [DK13499, DK15658] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK013499, R01DK015658] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anthony JC, 2002, AM J PHYSIOL-ENDOC M, V282, pE1092, DOI 10.1152/ajpendo.00208.2001; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Burren CP, 1996, INVEST OPHTH VIS SCI, V37, P1459; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; De Pablo F, 1996, Int J Dev Biol, VSuppl 1, p109S; DELAROSA EJ, 1994, EUR J NEUROSCI, V6, P1801; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Diaz B, 2000, DEVELOPMENT, V127, P1641; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Folli F, 1996, MOL NEUROBIOL, V13, P155, DOI 10.1007/BF02740639; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gardner T W, 2000, Diabetes Technol Ther, V2, P601; Gosbell AD, 2000, CLIN EXP OPHTHALMOL, V28, P212, DOI 10.1046/j.1442-9071.2000.00305.x; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hosoi H, 1999, CANCER RES, V59, P886; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kawada M, 2002, J BIOL CHEM, V277, P27765, DOI 10.1074/jbc.M200318200; Kimball SR, 2002, J APPL PHYSIOL, V93, P1168, DOI 10.1152/japplphysiol.00221.2002; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lieberthal W, 2001, AM J PHYSIOL-RENAL, V281, pF693, DOI 10.1152/ajprenal.2001.281.4.F693; MARTIN DM, 1992, MOL BRAIN RES, V12, P181, DOI 10.1016/0169-328X(92)90082-M; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Reiter CEN, 2003, AM J PHYSIOL-ENDOC M, V285, pE763, DOI 10.1152/ajpendo.00507.2002; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Seigel G, 2000, MOL VIS, V6, P157; SIGAL NH, 1991, TRANSPLANT P, V23, P1; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; TERADA Y, 1994, J BIOL CHEM, V269, P31296; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Woltman AM, 2001, BLOOD, V98, P174, DOI 10.1182/blood.V98.1.174	70	71	75	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9167	9175		10.1074/jbc.M312397200	http://dx.doi.org/10.1074/jbc.M312397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660591	hybrid			2022-12-25	WOS:000189265900078
J	Sarret, P; Esdaile, MJ; McPherson, PS; Schonbrunn, A; Kreienkamp, HJ; Beaudet, A				Sarret, P; Esdaile, MJ; McPherson, PS; Schonbrunn, A; Kreienkamp, HJ; Beaudet, A			Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SYNAPTIC VESICLE ENDOCYTOSIS; SH3 DOMAIN; MEDIATED ENDOCYTOSIS; RAT-BRAIN; ADRENOCORTICOTROPIN SECRETION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA AMPHIPHYSIN; INTERACTING PROTEIN; ACTIN CYTOSKELETON	Amphiphysins are SH3 domain-containing proteins thought to function in clathrin-mediated endocytosis. To investigate the potential role of amphiphysin II in cellular trafficking of G protein-coupled somatostatin (SRIF) receptors, we generated an AtT-20 cell line stably overexpressing amphiphysin IIb, a splice variant that does not bind clathrin. Endocytosis of I-125-[D-Trp(8)]SRIF was not affected by amphiphysin IIb overexpression. However, the maximal binding capacity (B-max) of the ligand on intact cells was significantly lower in amphiphysin IIb overexpressing than in non-transfected cells. This difference was no longer apparent when the experiments were performed on crude cell homogenates, suggesting that amphiphysin IIb overexpression interferes with SRIF receptor targeting to the cell surface and not with receptor synthesis. Accordingly, immunofluorescence experiments demonstrated that, in amphiphysin overexpressing cells, sst(2A) and sst(5) receptors were segregated in a juxtanuclear compartment identified as the trans-Golgi network. Amphiphysin IIb overexpression had no effect on corticotrophin-releasing factor 41-stimulated adrenocorticotropic hormone secretion, suggesting that it is not involved in the regulated secretory pathway. Taken together, these results suggest that amphiphysin II is not necessary for SRIF receptor endocytosis but is critical for its constitutive targeting to the plasma membrane. Therefore, amphiphysin IIb may be an important component of the constitutive secretory pathway.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Texas, Sch Med, Dept Pharmacol, Houston, TX 77225 USA; Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	McGill University; University of Texas System; University of Hamburg	Beaudet, A (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.beaudet@mcgill.ca		Sarret, Philippe/0000-0002-7627-701X				Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bensen ES, 2000, GENETICS, V154, P83; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cervia D, 2003, BRIT J PHARMACOL, V139, P109, DOI 10.1038/sj.bjp.0705235; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dournaud P, 1996, J NEUROSCI, V16, P4468; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Guild SB, 2001, MOL CELL ENDOCRINOL, V184, P51, DOI 10.1016/S0303-7207(01)00645-1; Gully D, 2002, J PHARMACOL EXP THER, V301, P322, DOI 10.1124/jpet.301.1.322; HEISLER S, 1982, P NATL ACAD SCI-BIOL, V79, P6502, DOI 10.1073/pnas.79.21.6502; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kruse MS, 2003, PFLUG ARCH EUR J PHY, V445, P534, DOI 10.1007/s00424-002-0899-5; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Leprince C, 2003, J CELL SCI, V116, P1937, DOI 10.1242/jcs.00403; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; Leventis PA, 2001, TRAFFIC, V2, P839; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; LUINI A, 1986, J NEUROSCI, V6, P3128; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 2002, TRENDS CELL BIOL, V12, P312, DOI 10.1016/S0962-8924(02)02309-7; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Muller AJ, 2003, MOL CELL BIOL, V23, P4295, DOI 10.1128/MCB.23.12.4295-4306.2003; Mundigl O, 1998, J NEUROSCI, V18, P93; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1994, J BIOL CHEM, V269, P1506; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1999, J BIOL CHEM, V274, P19785, DOI 10.1074/jbc.274.28.19785; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; REISINE T, 1988, J PHARMACOL EXP THER, V245, P225; RICHARDSON UI, 1981, ENDOCRINOLOGY, V108, P281, DOI 10.1210/endo-108-1-281; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sarret P, 1998, NEUROENDOCRINOLOGY, V68, P37, DOI 10.1159/000054348; Sarret P, 1999, J BIOL CHEM, V274, P19294, DOI 10.1074/jbc.274.27.19294; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stroh T, 1999, J COMP NEUROL, V412, P69, DOI 10.1002/(SICI)1096-9861(19990913)412:1<69::AID-CNE5>3.0.CO;2-V; Strowski MZ, 2002, NEUROENDOCRINOLOGY, V75, P339, DOI 10.1159/000059430; Szaszak M, 2002, J BIOL CHEM, V277, P21650, DOI 10.1074/jbc.M200778200; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Tannenbaum GS, 1999, HDB PHYSL 7, P221; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Wakeham DE, 2000, TRAFFIC, V1, P393, DOI 10.1034/j.1600-0854.2000.010504.x; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wasiak S, 2001, J BIOL CHEM, V276, P26622, DOI 10.1074/jbc.M100591200; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200; Zelhof AC, 2001, DEVELOPMENT, V128, P5005; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x	99	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8029	8037		10.1074/jbc.M310792200	http://dx.doi.org/10.1074/jbc.M310792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660576	hybrid			2022-12-25	WOS:000189103300081
J	Li, CX; Chi, SM; He, NG; Zhang, XL; Guicherit, O; Wagner, R; Tyring, S; Xie, JW				Li, CX; Chi, SM; He, NG; Zhang, XL; Guicherit, O; Wagner, R; Tyring, S; Xie, JW			IFN alpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling	ONCOGENE			English	Article						hedgehog; smoothened; BCCs; PDGFR alpha; INF alpha; MEK; Fas	PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; MEDIATED APOPTOSIS; HUMAN HOMOLOG; PATCHED GENE; SOMATIC MUTATIONS; NEVUS SYNDROME; ONCOGENIC RAS; CARCINOMA; SKIN	Basal cell carcinoma (BCC), the most common form of human cancer, is understood to be associated with activation of the sonic hedgehog pathway, through loss-of-function mutations of tumor suppressor PTCH1 or gain-of-function mutations of smoothened. Interferon (IFN)-based therapy is quite effective in BCC treatment, but the molecular basis is not well understood. Here we report a novel mechanism by which IFNalpha mediates apoptosis in BCCs. In the presence of IFNalpha, we observed increased apoptosis in a BCC cell line ASZ001, in which PTC is null, and therefore with constitutive activation of the sonic hedgehog pathway. We demonstrate that SMO agonist Ag-1.4 mediates activation of extracellular signal-regulated kinase (Erk) phosphorylation, which is abrogated by IFNalpha in sonic hedgehog responsive C3H10T1/2 cells. In transient transfection experiments, we demonstrate that IFNalpha inhibits Erk phosphorylation and serum response element activation induced by expression of SMO, Gli1, PDGFRalpha and activated Raf, but not activated mitogen-activated Erk-regulating kinase (Mek), suggesting that IFNalpha targets mainly on Mek function. We further show that IFNalpha induces expression of Fas in BCC cells through interfering with Mek function. The role of the Fas-L/Fas signaling axis in IFNalpha-mediated apoptosis is demonstrated by the fact that addition of Fas-L neutralizing antibodies, just as caspase-8 inhibitor Z-IETD-FMK, effectively prevents IFNalpha-mediated apoptosis. Thus, our data indicate that IFNalpha-based BCC therapy induces Fas expression and apoptosis through interfering with Mek function.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Curis Inc, Cambridge, MA 02138 USA; Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77555 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Air Force Military Medical University	Xie, JW (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA.	jinxie@utmb.edu						Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; CHIMENTI S, 1995, DERMATOLOGY, V190, P214, DOI 10.1159/000246688; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; Epstein E, 2001, MED PEDIATR ONCOL, V36, P555, DOI 10.1002/mpo.1129; Fenton RG, 1998, CANCER RES, V58, P3391; Filipowicz E, 2002, CANCER, V94, P814, DOI 10.1002/cncr.10277; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GROB JJ, 1988, LANCET, V1, P878; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hottiger MO, 1999, GENE THER, V6, P1929, DOI 10.1038/sj.gt.3301036; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Larner A, 1996, BIOTHERAPY, V8, P175, DOI 10.1007/BF01877202; Lee SH, 1998, BRIT J DERMATOL, V139, P186; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Reifenberger J, 1998, CANCER RES, V58, P1798; Romerio F, 2002, FASEB J, V16, P1680, DOI 10.1096/fj.02-0120fje; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Vander Straten M, 2000, Adv Dermatol, V16, P299; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xie JW, 1997, GENE CHROMOSOME CANC, V18, P305	34	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1608	1617		10.1038/sj.onc.1207273	http://dx.doi.org/10.1038/sj.onc.1207273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647422				2022-12-25	WOS:000189219500015
J	Argirov, OK; Lin, B; Ortwerth, BJ				Argirov, OK; Lin, B; Ortwerth, BJ			2-ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine) is a newly identified advanced glycation end product in cataractous and aged human lenses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAILLARD REACTION; ASCORBIC-ACID; CROSS-LINKS; YELLOW CHROMOPHORES; PROTEINS; ALPHA; METHYLGLYOXAL; CROSSLINKING; DEGRADATION; FLUOROPHORE	Post-translational modifications of proteins take place during the aging of human lens. The present study describes a newly isolated glycation product of lysine, which was found in the human lens. Cataractous and aged human lenses were hydrolyzed and fractionated using reverse-phase and ion-exchange high performance liquid chromatography (HPLC). One of the nonproteinogenic amino acid components of the hydrolysates was identified as a 3-hydroxypyridinium derivative of lysine, 2-ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine). The compound was synthesized independently from 3-hydroxypyridine and methyl 2-[(tert-butoxycarbonyl)amino]-6-iodohexanoate. The spectral and chromatographic properties of the synthetic OP-lysine and the substance isolated from hydrolyzed lenses were identical. HPLC analysis showed that the amounts of OP-lysine were higher in water-insoluble compared with water-soluble proteins and was higher in a pool of cataractous lenses compared with normal aged lenses, reaching 500 pmol/mg protein. The model incubations showed that an anaerobic reaction mixture of N-alpha-tert-butoxycarbonyllysine, glycolaldehyde, and glyceraldehyde could produce the N-alpha-t-butoxycarbonyl derivative of OP-lysine. The irradiation of OP-lysine with UVA under anaerobic conditions in the presence of ascorbate led to a photochemical bleaching of this compound. Our results argue that OP-lysine is a newly identified glycation product of lysine in the lens. It is a marker of aging and pathology of the lens, and its formation could be considered as a potential cataract risk-factor based on its concentration and its photochemical properties.	Univ Missouri, Mason Eye Inst, Columbia, MO 65201 USA	University of Missouri System; University of Missouri Columbia	Argirov, OK (corresponding author), Univ Missouri, Mason Eye Inst, 404 Portland St, Columbia, MO 65201 USA.	argirovo@health.missouri.edu	Lin, Binshan/A-9772-2009	Lin, Binshan/0000-0002-8481-302X	NEI NIH HHS [EY 07070] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007070] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamczyk M, 1999, TETRAHEDRON, V55, P63, DOI 10.1016/S0040-4020(98)01023-0; Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Argirov OK, 2003, BBA-GEN SUBJECTS, V1620, P235, DOI 10.1016/S0304-4165(03)00002-3; Argirova M, 2002, J BIOCHEM MOL TOXIC, V16, P140, DOI 10.1002/jbt.10031; Bera S, 2002, BIOCHEMISTRY-US, V41, P12421, DOI 10.1021/bi0204140; Biemel KM, 2001, NAHRUNG, V45, P210, DOI 10.1002/1521-3803(20010601)45:3&lt;210::AID-FOOD210&gt;3.0.CO;2-L; CERAMI A, 1979, METABOLISM, V28, P431, DOI 10.1016/0026-0495(79)90051-9; Cheng RZ, 2001, BBA-MOL BASIS DIS, V1537, P14, DOI 10.1016/S0925-4439(01)00051-5; Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657; Dillon J, 1999, EXP EYE RES, V68, P785, DOI 10.1006/exer.1999.0687; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; Frye EB, 1998, J BIOL CHEM, V273, P18714, DOI 10.1074/jbc.273.30.18714; HIRSCH J, 1995, CARBOHYD RES, V273, P171, DOI 10.1016/0008-6215(95)00114-9; Lee KW, 1999, BBA-MOL BASIS DIS, V1453, P141, DOI 10.1016/S0925-4439(98)00097-0; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MASON SF, 1959, J CHEM SOC, P1253, DOI 10.1039/jr9590001253; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/bi00406a016; Nagai R, 2002, J BIOL CHEM, V277, P48905, DOI 10.1074/jbc.M205688200; OGAWA T, 1982, BIOCHEM BIOPH RES CO, V107, P1252, DOI 10.1016/S0006-291X(82)80132-0; ORTWERTH BJ, 1988, EXP EYE RES, V47, P737, DOI 10.1016/0014-4835(88)90041-3; Ortwerth BJ, 2002, EXP EYE RES, V74, P217, DOI 10.1006/exer.2001.1114; Padayatti PS, 2001, INVEST OPHTH VIS SCI, V42, P1299; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; Simpson GLW, 2000, BBA-MOL BASIS DIS, V1501, P12, DOI 10.1016/S0925-4439(00)00009-0; Stevens A, 1995, J Am Optom Assoc, V66, P744; Sugimoto H, 1999, DIABETOLOGIA, V42, P878, DOI 10.1007/s001250051241; TAYLOR A, 1991, CURR EYE RES, V10, P751, DOI 10.3109/02713689109013869; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Tessier FJ, 2003, BIOCHEM J, V369, P705, DOI 10.1042/BJ20020668; Usui T, 2003, BIOSCI BIOTECH BIOCH, V67, P930, DOI 10.1271/bbb.67.930	30	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6487	6495		10.1074/jbc.M309090200	http://dx.doi.org/10.1074/jbc.M309090200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14634019	hybrid			2022-12-25	WOS:000188969200034
J	Nakayama, M; Kimura, M; Wada, A; Yahiro, K; Ogushi, K; Niidome, T; Fujikawa, A; Shirasaka, D; Aoyama, N; Kurazono, H; Noda, M; Moss, J; Hirayama, T				Nakayama, M; Kimura, M; Wada, A; Yahiro, K; Ogushi, K; Niidome, T; Fujikawa, A; Shirasaka, D; Aoyama, N; Kurazono, H; Noda, M; Moss, J; Hirayama, T			Helicobacter pylori VacA activates the p38/activating transcription factor 2-mediated signal pathway in AZ-521 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GASTRIC EPITHELIAL-CELLS; VACUOLATING CYTOTOXIN; MELANOMA-CELLS; CELLULAR VACUOLATION; HUMAN NEUTROPHILS; BINDING PROTEIN; AMINO-ACIDS; CYCLIN D1; P38 MAPK	Persistent Helicobacter pylori colonization in the stomach induces gastritis and peptic ulcer and interferes with ulcer healing. Most strains of H. pylori produce a cytotoxin, VacA, that induces cytoplasmic vacuolation in epithelial cells with structural and functional changes, leading to gastric injury. VacA is known to cause cell death by mitochondrial damage. We hypothesized that VacA might disrupt other signaling pathways; to that end, we examined the effects of VacA on MAPKs to elucidate their role in the abnormalities seen in VacA-treated cells. VacA stimulated phosphorylation of p38 and Erk1/2, but not JNK, in AZ-521 cells. Both phosphorylation and kinase activation of p38 were maximal 10-30 min after addition of VacA and declined thereafter. Treatment with anti-VacA antibody or the p38 inhibitor SB203580 blocked p38 phosphorylation caused by VacA and inhibited VacA-induced phosphorylation of activating transcription factor 2 (ATF-2), which is implicated in transcriptional control of stress-responsive genes. These data indicate that VacA stimulates a p38/ ATF-2-mediated signal pathway. However, 10 muM SB203580, which is sufficient to decrease p38 phosphorylation, did not inhibit VacA-induced cellular vacuolation, decrease in mitochondrial membrane potential, or cytochrome c release from mitochondria. These results suggest that VacA-induced activation of p38/ATF-2-mediated signal pathway is independent of cellular vacuolation, decrease in mitochondrial membrane potential, or cytochrome c release from mitochondria caused by VacA. The cytotoxin may thus act independently on several cellular targets, leading to disruption of signaling, regulatory, and metabolic pathways.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Okayama Univ, Sch Hlth Sci, Dept Med Technol, Okayama 7008558, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan; Kobe Univ, Sch Med, Dept Endoscopy, Kobe, Hyogo 6578501, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Okayama University; Japan Science & Technology Agency (JST); Nagasaki University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kobe University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Fujikawa, Akihiro/K-9805-2015; Niidome, Takuro/F-1508-2010; Noda, Masaharu/D-7146-2016	Fujikawa, Akihiro/0000-0002-3950-0550; Niidome, Takuro/0000-0002-8070-8708; Noda, Masaharu/0000-0002-3796-524X; Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caputo R, 2003, CLIN CANCER RES, V9, P2015; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Correa P, 1998, BRIT MED BULL, V54, P151; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; Cover TL, 2003, CANCER RES, V63, P951; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; Del Giudice G, 2001, ANNU REV IMMUNOL, V19, P523, DOI 10.1146/annurev.immunol.19.1.523; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; Eaton KA, 1997, INFECT IMMUN, V65, P3462, DOI 10.1128/IAI.65.8.3462-3464.1997; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Houghton J, 1999, DIGEST DIS SCI, V44, P465, DOI 10.1023/A:1026628601284; Houghton J, 2000, INFECT IMMUN, V68, P1189, DOI 10.1128/IAI.68.3.1189-1195.2000; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jones NL, 1997, AM J PATHOL, V151, P1695; Keates S, 1999, J IMMUNOL, V163, P5552; Kim JS, 2001, DIGEST DIS SCI, V46, P2277, DOI 10.1023/A:1011939704802; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Nagata H, 1999, MICROB PATHOGENESIS, V26, P103, DOI 10.1006/mpat.1998.0256; Nishioka H, 2003, EUR J IMMUNOL, V33, P840, DOI 10.1002/eji.200323726; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Peek RM, 1999, CANCER RES, V59, P6124; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; Pomorski T, 2001, J BIOL CHEM, V276, P804, DOI 10.1074/jbc.M003819200; Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603; Suzuki J, 2003, J BIOL CHEM, V278, P25585, DOI 10.1074/jbc.M212445200; SUZUKI J, 2001, J CLIN INVEST, V107, P15200; Takahashi S, 2001, J PHARMACOL EXP THER, V296, P48; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; Xia HHX, 2001, AM J GASTROENTEROL, V96, P16, DOI 10.1111/j.1572-0241.2001.03447.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	60	73	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7024	7028		10.1074/jbc.M308898200	http://dx.doi.org/10.1074/jbc.M308898200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14630932	hybrid			2022-12-25	WOS:000188969200099
J	Tronchere, H; Laporte, J; Pendaries, C; Chaussade, C; Liaubet, L; Pirola, L; Mandel, JL; Payrastre, B				Tronchere, H; Laporte, J; Pendaries, C; Chaussade, C; Liaubet, L; Pirola, L; Mandel, JL; Payrastre, B			Production of phosphatidylinositol 5-phosphate by the phosphoinositide 3-phosphatase myotubularin in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE MYOTUBULARIN; LIPID 2ND-MESSENGER; MYOPATHY; GENE; FAMILY; IDENTIFICATION; MUTATIONS; PROTEIN; MTMR2; DEPHOSPHORYLATES	MTM1, the gene encoding myotubularin (MTM1), is mutated in the X-linked myotubular myopathy (XLMTM), a severe genetic muscular disorder. MTM1 is a phosphoinositide phosphatase hydrolyzing phosphatidylinositol 3-phosphate (PtdIns(3)P) in yeast and in vitro. Because this lipid is implicated in the regulation of vesicular trafficking, we used established cell lines from XLMTM patients to evaluate whether the lack of endogenous MTM1 expression could affect PtdIns(3)P labeling patterns. Our results showed that the vesicular trafficking related to early endosomes was not significantly affected in the XLMTM cell lines compared with control cells. However, in addition to PtdIns(3)P, we found that MTM1 can hydrolyze phosphatidylinositol 3,5-bisphosphate both in vitro and in mammalian cells. Using a mass assay, we demonstrated that the product generated is phosphatidylinositol 5-phosphate (PtdIns(5)P), a recently discovered phosphoinositide, the function of which is still unknown. In L6 myotubes overexpressing MTM1, hyperosmotic shock induced an increase in the mass level of PtdIns(5)P that was reduced by 50% upon overexpression of the MTM1 inactive mutant D278A. These data demonstrate for the first time a role for MTM1 in the production of PtdIns(5)P in mammalian cells, suggesting that the lack of transformation of phosphatidylinositol 3,5-bisphosphate into PtdIns(5)P might be an important component in the etiology of myotubular myopathy.	Hop Purpan, INSERM, U563,CPTP, Dept Oncogenese & Signalisat Cellules Hematopoiet, F-31059 Toulouse, France; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Fac Med, INSERM, U145, F-06107 Nice 2, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Tronchere, H (corresponding author), Hop Purpan, INSERM, U563, CPTP Bat C, F-31039 Toulouse, France.	helentro@toulouse.insenn.fr	Pirola, Luciano/I-5250-2018; TRONCHERE, Helene/M-5631-2014; laporte, jocelyn/O-4888-2019; Laporte, Jocelyn/H-6801-2016; laporte, jocelyn/J-7008-2012; Mandel, Jean Louis/Q-2668-2016	Mandel, Jean Louis/0000-0002-0535-6589; , Bernard/0000-0002-8693-0190; Pirola, Luciano/0000-0001-6539-5435; Liaubet, Laurence/0000-0003-0201-0264				Azzedine H, 2003, AM J HUM GENET, V72, P1141, DOI 10.1086/375034; Berger P, 2002, HUM MOL GENET, V11, P1569, DOI 10.1093/hmg/11.13.1569; Biancalana V, 2003, HUM GENET, V112, P135, DOI 10.1007/s00439-002-0869-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Bolino A, 2002, GENE, V283, P17, DOI 10.1016/S0378-1119(01)00876-9; Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399; Buj-Bello A, 2002, HUM MOL GENET, V11, P2297, DOI 10.1093/hmg/11.19.2297; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Firestein R, 2002, J CLIN INVEST, V109, P1165, DOI [10.1172/JCI200212589, 10.1172/JCI0212589]; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Kim SA, 2003, P NATL ACAD SCI USA, V100, P4492, DOI 10.1073/pnas.0431052100; Kim SA, 2002, J BIOL CHEM, V277, P4526, DOI 10.1074/jbc.M111087200; Laporte J, 1998, HUM MOL GENET, V7, P1703, DOI 10.1093/hmg/7.11.1703; Laporte J, 2002, J CELL SCI, V115, P3105; Laporte J, 2002, BIOCHEM BIOPH RES CO, V291, P305, DOI 10.1006/bbrc.2002.6445; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Laporte J, 2001, ANN NEUROL, V50, P42, DOI 10.1002/ana.1033; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Nandurkar HH, 2003, P NATL ACAD SCI USA, V100, P8660, DOI 10.1073/pnas.1033097100; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Senderek J, 2003, HUM MOL GENET, V12, P349, DOI 10.1093/hmg/ddg030; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Taylor GS, 2001, ANAL BIOCHEM, V295, P122, DOI 10.1006/abio.2001.5179; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Tronchere H, 2003, CELL MOL LIFE SCI, V60, P2084, DOI 10.1007/s00018-003-3062-3; Walker DM, 2001, CURR BIOL, V11, P1600, DOI 10.1016/S0960-9822(01)00501-2; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051	40	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7304	7312		10.1074/jbc.M311071200	http://dx.doi.org/10.1074/jbc.M311071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660569	hybrid			2022-12-25	WOS:000188969200132
J	Zheng, XL; Gui, Y; Du, GW; Frohman, MA; Peng, DQ				Zheng, XL; Gui, Y; Du, GW; Frohman, MA; Peng, DQ			Calphostin-C induction of vascular smooth muscle cell apoptosis proceeds through phospholipase D and microtubule inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STRESS FIBER FORMATION; HUMAN NEUTROPHILS; IN-VITRO; ATHEROSCLEROSIS; ACTIVATION; STIMULATION; FIBROBLASTS; CYTOMETRY	Calphostin-C, a protein kinase C inhibitor, induces apoptosis of cultured vascular smooth muscle cells. However, the mechanisms are not completely defined. Because apoptosis of vascular smooth muscle cells is critical in several proliferating vascular diseases such as atherosclerosis and restenosis after angioplasty, we decided to investigate the mechanisms underlying the calphostin-C-induced apoptotic pathway. We show here that apoptosis is inhibited by the addition of exogenous phosphatidic acid, a metabolite of phospholipase D (PLD), and that calphostin-C inhibits completely the activities of both isoforms of PLD, PLD1 and PLD2. Overexpression of either PLD1 or PLD2 prevented the vascular smooth muscle cell apoptosis induced by serum withdrawal but not the calphostin-C-elicited apoptosis. These data suggest that PLDs have anti-apoptotic effects and that complete inhibition of PLD activity by calphostin-C induces smooth muscle cell apoptosis. We also report that calphostin-C induced microtubule disruption and that the addition of exogenous phosphatidic acid inhibits calphostin-C effects on microtubules, suggesting a role for PLD in stabilizing the microtubule network. Overexpressing PLD2 in Chinese hamster ovary cells phenocopies this result, providing strong support for the hypothesis. Finally, taxol, a microtubule stabilizer, not only inhibited the calphostin-C-induced microtubule disruption but also inhibited apoptosis. We therefore conclude that calphostin-C induces apoptosis of cultured vascular smooth muscle cells through inhibiting PLD activity and subsequent microtubule polymerization.	Univ Calgary, Hlth Sci Ctr, Fac Med,Smooth Muscle Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zheng, XL (corresponding author), Univ Calgary, Hlth Sci Ctr, Fac Med,Smooth Muscle Res Grp, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	xlzheng@ucalgary.ca		Zheng, Xi-Long/0000-0002-0889-1827; Du, Guangwei/0000-0003-4193-6975	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064166] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK64166] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; Aoki M, 1997, HEART VESSELS, P71; Axel DI, 1997, CIRCULATION, V96, P636; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; CARNERO A, 1994, ONCOGENE, V9, P1387; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; deBlois D, 1997, HYPERTENSION, V29, P340, DOI 10.1161/01.HYP.29.1.340; Devlin AM, 2000, HYPERTENSION, V36, P110, DOI 10.1161/01.HYP.36.1.110; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gardiner JC, 2001, PLANT CELL, V13, P2143, DOI 10.1105/tpc.13.9.2143; Hamet P, 1995, Curr Opin Nephrol Hypertens, V4, P1, DOI 10.1097/00041552-199501000-00001; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kamentsky LA, 1997, ACTA CYTOL, V41, P123, DOI 10.1159/000332315; KAMENTSKY LA, 1991, CYTOMETRY, V12, P381, DOI 10.1002/cyto.990120502; Kim JH, 1999, IUBMB LIFE, V48, P445; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; LESZCZYNSKI D, 1994, AM J PATHOL, V145, P1265; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Park MA, 2002, FEBS LETT, V519, P45, DOI 10.1016/S0014-5793(02)02705-9; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rossig L, 2001, BASIC RES CARDIOL, V96, P11, DOI 10.1007/s003950170073; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Spinedi A, 1998, BIOCHEM PHARMACOL, V56, P1489, DOI 10.1016/S0006-2952(98)00169-5; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; SVETLOV S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P75, DOI 10.1016/0167-4889(93)90160-Q; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zhu DM, 1998, CLIN CANCER RES, V4, P2967	36	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7112	7118		10.1074/jbc.M310721200	http://dx.doi.org/10.1074/jbc.M310721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660552	hybrid			2022-12-25	WOS:000188969200110
J	Bass, R; Ruddock, LW; Klappa, P; Freedman, RB				Bass, R; Ruddock, LW; Klappa, P; Freedman, RB			A major fraction of endoplasmic reticulum-located glutathione is present as mixed disulfides with protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN-CONTAINING MONOOXYGENASE; BOND FORMATION; REDOX STATE; ISOMERASE; YEAST; PDI; MONOBROMOBIMANE; OXIDATION; CATALYSTS; PATHWAYS	The tripeptide glutathione is the most abundant thiol/disulfide component of the eukaryotic cell and is known to be present in the endoplasmic reticulum lumen. Accordingly, the thiol/ disulfide redox status of the endoplasmic reticulum lumen is defined by the status of glutathione, and it has been assumed that reduced and oxidized glutathione form the principal redox buffer. We have determined the distribution of glutathione between different chemical states in rat liver microsomes by labeling with the thiol-specific label monobromobimane and subsequent separation by reversed phase high performance liquid chromatography. More than half of the microsomal glutathione was found to be present in mixed disulfides with protein, the remainder being distributed between the reduced and oxidized forms of glutathione in the ratio of 3:1. The high proportion of the total population of glutathione that was found to be in mixed disulfides with protein has significant implications for the redox state and buffering capacity of the endoplasmic reticulum and, hence, for the formation of disulfide bonds in vivo.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Kent	Ruddock, LW (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	lloyd.ruddock@oulu.fi	Bass, Rosemary A/A-5328-2009	Bass, Rosemary A/0000-0003-4997-5207; Ruddock, Lloyd/0000-0002-6247-686X				Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; BUKAU B, 1999, MOL CHAPERONES FOLDI; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; GUZMAN NA, 1998, PROLYL HYDROXYLASE P; HARRAP KR, 1973, BIOCHIM BIOPHYS ACTA, V310, P104, DOI 10.1016/0005-2795(73)90012-3; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISAACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192, DOI 10.1016/0304-4165(77)90152-0; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; LILIE H, 1994, J BIOL CHEM, V269, P14290; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; NEWTON GL, 1995, METHOD ENZYMOL, V251, P148, DOI 10.1016/0076-6879(95)51118-0; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; ROTHBLATT J, 1994, GUIDEBOOK SECRETORY; Ruoppolo M, 1996, BIOCHEMISTRY-US, V35, P13636, DOI 10.1021/bi960755b; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Suh JK, 2000, P NATL ACAD SCI USA, V97, P121, DOI 10.1073/pnas.97.1.121; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; TANGEN O, 1973, ANAL BIOCHEM, V54, P597, DOI 10.1016/0003-2697(73)90392-8; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; WETLAUFER DB, 1977, PROTEIN CROSSLINKI A, P43	46	119	124	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5257	5262		10.1074/jbc.M304951200	http://dx.doi.org/10.1074/jbc.M304951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14630926	hybrid			2022-12-25	WOS:000188776500028
J	Okamoto, Y; Morishita, J; Tsuboi, K; Tonai, T; Ueda, N				Okamoto, Y; Morishita, J; Tsuboi, K; Tonai, T; Ueda, N			Molecular characterization of a phospholipase D generating anandamide and its congeners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; N-ACYLETHANOLAMINE PHOSPHOLIPIDS; ACYL-ETHANOLAMINE PHOSPHOLIPIDS; CANNABINOID-RECEPTOR-LIGAND; BETA-LACTAMASE; GENE FAMILY; ENZYME-ACTIVITY; GLYOXALASE II; RAT-BRAIN; PHOSPHODIESTERASE	Anandamide (N-arachidonoylethanolamine) is known to be an endogenous ligand of cannabinoid and vanilloid receptors. Its congeners (collectively referred to as N-acylethanolamines) also show a variety of biological activities. These compounds are principally formed from their corresponding N-acyl-phosphatidylethanolamines by a phosphodiesterase of the phospholipase D-type in animal tissues. We purified the enzyme from rat heart, and by the use of the sequences of its internal peptides cloned its complementary DNAs from mouse, rat, and human. The deduced amino acid sequences were composed of 393-396 residues, and showed that the enzyme has no homology with the known phospholipase D enzymes but is classified as a member of the zinc metallohydrolase family of the beta-lactamase fold. As was overexpressed in COS-7 cells, the recombinant enzyme generated anandamide and other N-acylethanolamines from their corresponding N-acyl-phosphatidylethanolamines at comparable rates. In contrast, the enzyme was inactive with phosphatidylcholine and phosphatidylethanolamine. Assays of the enzyme activity and the messenger RNA and protein levels revealed its wide distribution in murine organs with higher contents in the brain, kidney, and testis. These results confirm that a specific phospholipase D is responsible for the generation of N-acylethanolamines including anandamide, strongly suggesting the physiological importance of lipid molecules of this class.	Kagawa Univ, Dept Biochem, Sch Med, Kagawa 7610793, Japan; Natl Zentsuji Hosp, Dept Orthoped Surg, Kagawa 7650001, Japan; Natl Zentsuji Hosp, Clin Res Inst, Kagawa 7650001, Japan	Kagawa University	Ueda, N (corresponding author), Kagawa Univ, Dept Biochem, Sch Med, 1750-1 Ikenobe, Kagawa 7610793, Japan.	nueda@kms.ac.jp	OKAMOTO, Yasuo/J-8438-2015					Aravind L, 1999, In Silico Biol, V1, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Clement AB, 2003, J NEUROSCI, V23, P3916; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Evans RM, 1998, BIOESSAYS, V20, P79, DOI 10.1002/(SICI)1521-1878(199801)20:1<79::AID-BIES11>3.3.CO;2-I; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; IWASAKI Y, 1994, APPL MICROBIOL BIOT, V42, P290, DOI 10.1007/s002530050252; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Liu Q, 2002, CHEM PHYS LIPIDS, V115, P77, DOI 10.1016/S0009-3084(02)00015-4; Maccarrone M, 2002, BIOCHEM J, V366, P137, DOI 10.1042/BJ20020438; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Moesgaard B, 2000, J LIPID RES, V41, P985; Moesgaard B, 2002, COMP BIOCHEM PHYS B, V131, P475, DOI 10.1016/S1096-4959(02)00003-9; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; Petersen G, 2000, J LIPID RES, V41, P1532; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; Schmid PC, 1997, P NATL ACAD SCI USA, V94, P4188, DOI 10.1073/pnas.94.8.4188; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Ueda N, 2001, BBA-MOL CELL BIOL L, V1532, P121, DOI 10.1016/S1388-1981(01)00120-2; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200	44	617	642	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5298	5305		10.1074/jbc.M306642200	http://dx.doi.org/10.1074/jbc.M306642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634025	hybrid			2022-12-25	WOS:000188776500033
J	Todeschini, AR; Dias, WB; Girard, MF; Wieruszeski, JM; Mendonca-Previato, L; Previato, JO				Todeschini, AR; Dias, WB; Girard, MF; Wieruszeski, JM; Mendonca-Previato, L; Previato, JO			Enzymatically inactive trans-sialidase from Trypanosoma cruzi binds sialyl and beta-galactopyranosyl residues in a sequential ordered mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST T-LYMPHOCYTES; CELL; ACID; INVASION; NEURAMINIDASE; GLYCOSYLATION; HYDROLYSIS; TYROSINE; ENZYME; CD22	Host/parasite interaction mediated by carbohydrate/ lectin recognition results in the attachment to and invasion of host cells and immunoregulation, enabling parasite replication and establishment of infection. Trypanosoma cruzi, the protozoan responsible for Chagas disease, expresses on its surface a family of enzymatically active and inactive trans-sialidases. The parasite uses the active trans-sialidase for glycoprotein sialylation in an unusual trans-glycosylation reaction. Inactive trans-sialidase is a sialic acid-binding lectin that co-stimulates host T cells through leucosialin (CD43) engagement. The co-mitogenic effect of trans-sialidase can be selectively abrogated by N-acetyllactosamine, suggesting the presence of an additional carbohydrate binding domain for galactosides, in addition to that for sialic acid. Here we investigated the interaction of inactive trans-sialidase in the presence of beta-galactosides. By using NMR spectroscopy, we demonstrate that inactive trans-sialidase has a beta-galactoside recognition site formed following a conformational switch induced by sialoside binding. Thus prior positioning of a sialyl residue is required for the beta-galactoside interaction. When an appropriate sialic acid-containing molecule is available, both sialoside and beta-galactoside are simultaneously accommodated in the inactive trans-sialidase binding pocket. This is the first report of a lectin recognizing two distinct ligands by a sequential ordered mechanism. This uncommon binding behavior may play an important role in several biological aspects of T. cruzi/host cell interaction and could shed more light into the catalytic mechanism of the sialic acid transfer reaction of enzymatically active trans-sialidase.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Ctr Ciencias Saude, BR-21944970 Rio De Janeiro, Brazil; Univ Limoges, Inst Epidemiol Neurol & Neurol Trop, F-87025 Limoges, France; Inst Pasteur, Lab RMN Synth Struct & Fonct Biomol, F-59019 Lille, France	Universidade Federal do Rio de Janeiro; Universite de Limoges; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Mendonca-Previato, L (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Ctr Ciencias Saude, CCS Bloco G,Cidade Univ, BR-21944970 Rio De Janeiro, Brazil.	luciamp@biof.ufrj.br	Todeschini, Adriane/AAG-8128-2020; Dias, Wagner/B-1401-2016; Todeschini, Adriane Regina/ABC-9165-2020	Todeschini, Adriane Regina/0000-0002-6049-2751; Mendonca Previato, Lucia/0000-0003-3927-3244; Previato, Jose Osvaldo/0000-0002-9233-9954; Girard, Murielle/0000-0003-1222-0329; Dias, Wagner/0000-0002-8378-8846				BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Burleigh BA, 2002, CELL MICROBIOL, V4, P701, DOI 10.1046/j.1462-5822.2002.00226.x; BURMEISTER WP, 1993, STRUCTURE, V1, P19, DOI 10.1016/0969-2126(93)90005-2; Buschiazzo A, 2002, MOL CELL, V10, P757, DOI 10.1016/S1097-2765(02)00680-9; CIAVAGLIA MD, 1993, BIOCHEM BIOPH RES CO, V193, P718, DOI 10.1006/bbrc.1993.1684; Collins BE, 2002, GLYCOBIOLOGY, V12, P563, DOI 10.1093/glycob/cwf067; CREMONA ML, 1995, GENE, V160, P123, DOI 10.1016/0378-1119(95)00175-6; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; Harrison JA, 2001, BIOORG MED CHEM LETT, V11, P141, DOI 10.1016/S0960-894X(00)00611-9; MING M, 1993, MOL BIOCHEM PARASIT, V59, P243, DOI 10.1016/0166-6851(93)90222-J; Moncayo A, 2003, MEM I OSWALDO CRUZ, V98, P577, DOI 10.1590/S0074-02762003000500001; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; Ribeirao M, 1997, GLYCOBIOLOGY, V7, P1237, DOI 10.1093/glycob/7.8.1237; SCHENKMAN RPF, 1993, INFECT IMMUN, V61, P898, DOI 10.1128/IAI.61.3.898-902.1993; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCUDDER P, 1993, J BIOL CHEM, V268, P9886; Todeschin AR, 2002, J BIOL CHEM, V277, P45962, DOI 10.1074/jbc.M203185200; Todeschini AR, 2002, J IMMUNOL, V168, P5192, DOI 10.4049/jimmunol.168.10.5192; Todeschini AR, 2000, GLYCOBIOLOGY, V10, P213, DOI 10.1093/glycob/10.2.213; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; Yoshida N, 1997, MOL BIOCHEM PARASIT, V84, P57, DOI 10.1016/S0166-6851(96)02783-1	25	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5323	5328		10.1074/jbc.M310663200	http://dx.doi.org/10.1074/jbc.M310663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14634017	hybrid			2022-12-25	WOS:000188776500036
J	Tomomori-Sato, C; Sato, S; Parmely, TJ; Banks, CAS; Sorokina, I; Florens, L; Zybailov, B; Washburn, MP; Brower, CS; Conaway, RC; Conaway, JW				Tomomori-Sato, C; Sato, S; Parmely, TJ; Banks, CAS; Sorokina, I; Florens, L; Zybailov, B; Washburn, MP; Brower, CS; Conaway, RC; Conaway, JW			A mammalian mediator subunit that shares properties with Saccharomyces cerevisiae Mediator subunit Cse2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; COFACTOR COMPLEX; PROTEIN; YEAST; IDENTIFICATION; ACTIVATION	The multiprotein Mediator complex is a coactivator required for activation of RNA polymerase II transcription by DNA bound transcription factors. We previously identified and partially purified a mammalian Mediator complex from rat liver nuclei (Brower, C. S., Sato, S., Tomomori-Sato, C., Kamura, T., Pause, A., Stearman, R., Klausner, R. D., Malik, S., Lane, W. S., Sorokina, I., Roeder, R. G., Conaway, J. W., and Conaway, R. C. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10353-10358). Analysis by tandem mass spectrometry of proteins present in the most highly purified rat Mediator fractions led to the identification of a collection of new mammalian Mediator subunits, as well as several potential Mediator subunits including a previously uncharacterized protein encoded by the FLJ10193 open reading frame. In this study, we present direct biochemical evidence that the FLJ10193 protein, which we designate Med25, is a bona fide subunit of the mammalian Mediator complex. In addition, we present evidence that Med25 shares structural and functional properties with Saccharomyces cerevisiae Mediator subunit Cse2 and may be a mammalian Cse2 ortholog. Taken together, our findings identify a novel mammalian Mediator subunit and shed new light on the architecture of the mammalian Mediator complex.	Stowers Inst Med Res, Kansas City, MO 64110 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; California Institute of Technology; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	jlc@stowers-institute.org		Washburn, Michael/0000-0001-7568-2585; Florens, Laurence/0000-0002-9310-6650; Sorokina, Irina/0000-0003-1531-1832; Conaway, Joan/0000-0002-2786-0663; Tomomori-Sato, Chieri/0000-0002-2543-293X; Zybailov, Boris/0000-0003-2432-9145; Banks, Charles/0000-0002-0404-2940	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sadygov RG, 2002, J PROTEOME RES, V1, P211, DOI 10.1021/pr015514r; Sato S, 2003, J BIOL CHEM, V278, P49671, DOI 10.1074/jbc.C300444200; Sato S, 2003, J BIOL CHEM, V278, P15123, DOI 10.1074/jbc.C300054200; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686	18	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5846	5851		10.1074/jbc.M312523200	http://dx.doi.org/10.1074/jbc.M312523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638676	Green Accepted, hybrid			2022-12-25	WOS:000188776500099
J	Guo, Q; Xie, J				Guo, Q; Xie, J			AATF inhibits aberrant production of amyloid beta peptide 1-42 by interacting directly with par-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE APOPTOSIS RESPONSE-4; DAP-KINASE FAMILY; KAPPA-B ACTIVITY; ALZHEIMERS-DISEASE; DLK/ZIP KINASE; TRANSCRIPTION FACTOR; HIPPOCAMPAL-NEURONS; PRECURSOR PROTEIN; INCREASED VULNERABILITY; PRESENILIN-1	Aggregation of the neurotoxic amyloid beta peptide 1-42 (Abeta-(1-42)) in the brain is considered to be an early event in the pathogenesis of Alzheimer's disease (AD). Par-4 (prostate apoptosis response-4) is a leucine zipper protein that is pro-apoptotic and associated with neuronal degeneration in AD. Overexpression of Par-4 significantly increased production of Abeta-(1-42) after initiation of apoptotic cascades, indicating factors regulating apoptotic pathways may also affect processing of beta-amyloid precursor protein (APP). AATF (apoptosis-antagonizing transcription factor) was recently identified as an interaction partner of DAP-like kinase (Dlk), a member of the DAP (death-associated protein) kinase family. AATF antagonizes apoptosis induced by Par-4, suggesting that AATF might directly or indirectly participate in regulation of Par-4 activity. We now report that AATF colocalizes with Par-4 in both cytoplasmic and nuclear compartments, and it interacts directly and selectively with Par-4 via the leucine zipper domain in neural cells. Par-4 induced an aberrant production and secretion of Abeta in neuroblastoma IMR-32 cells after apoptotic cascades are initiated. Co-expression of AATF completely blocked aberrant production and secretion of Abeta-(1-42) induced by Par-4, and AATF/Par-4 complex formation was essential for the inhibitory effect of AATF on aberrant Abeta secretion. These results indicate that AATF is an endogenous antagonist of Par-4 activity and an effective inhibitor of aberrant Abeta production and secretion under apoptotic conditions.	Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Guo, Q (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.	qing-guo@ouhsc.edu			NINDS NIH HHS [R01NS043296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Bush AI, 2002, P NATL ACAD SCI USA, V99, P7317, DOI 10.1073/pnas.122249699; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; Culmsee C, 2001, J CEREBR BLOOD F MET, V21, P334, DOI 10.1097/00004647-200104000-00002; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; Duan WZ, 1999, ANN NEUROL, V46, P587, DOI 10.1002/1531-8249(199910)46:4<587::AID-ANA6>3.0.CO;2-M; Eberhardt O, 2003, TOXICOL LETT, V139, P135, DOI 10.1016/S0378-4274(02)00428-9; El-Guendy N, 2003, MOL CELL BIOL, V23, P5516, DOI 10.1128/MCB.23.16.5516-5525.2003; El-Guendy N, 2003, EXP CELL RES, V283, P51, DOI 10.1016/S0014-4827(02)00016-2; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Gandy S, 2001, NATURE, V411, P654, DOI 10.1038/35079682; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 2001, BRAIN RES, V903, P13, DOI 10.1016/S0006-8993(01)02304-6; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 2001, J BIOL CHEM, V276, P16040, DOI 10.1074/jbc.M010996200; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Guo Q, 2000, BRAIN RES, V874, P221, DOI 10.1016/S0006-8993(00)02559-2; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Kogel D, 2003, EUR J CANCER, V39, P249, DOI 10.1016/S0959-8049(02)00477-X; Kogel D, 2001, BRIT J CANCER, V85, P1801, DOI 10.1054/bjoc.2001.2158; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; Kosik KS, 1998, SCIENCE, V279, P463; Lindfors K, 2000, BIOCHEM BIOPH RES CO, V276, P660, DOI 10.1006/bbrc.2000.3480; Mattson MP, 1999, J MOL NEUROSCI, V13, P17, DOI 10.1385/JMN:13:1-2:17; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Nishimura M, 1999, CLIN GENET, V55, P219, DOI 10.1034/j.1399-0004.1999.550401.x; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Pedersen WA, 2000, FASEB J, V14, P913, DOI 10.1096/fasebj.14.7.913; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Roussigne M, 2003, ONCOGENE, V22, P2432, DOI 10.1038/sj.onc.1206271; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SELKOE DJ, 1990, SCIENCE, V248, P1058, DOI 10.1126/science.2111582; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; Sisodia SS, 2000, SCIENCE, V289, P2296, DOI 10.1126/science.289.5488.2296; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Weihl CC, 1999, J NEUROSCI, V19, P5360; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xie J, 2001, BRAIN RES, V915, P1, DOI 10.1016/S0006-8993(01)02803-7	59	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4596	4603		10.1074/jbc.M309811200	http://dx.doi.org/10.1074/jbc.M309811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14627703	hybrid			2022-12-25	WOS:000188554300081
J	Swevers, L; Kravariti, L; Ciolfi, S; Xenou-Kokoletsi, M; Ragoussis, N; Smagghe, G; Nakagawa, Y; Mazomenos, B; Iatrou, K				Swevers, L; Kravariti, L; Ciolfi, S; Xenou-Kokoletsi, M; Ragoussis, N; Smagghe, G; Nakagawa, Y; Mazomenos, B; Iatrou, K			A cell-based high-throughput screening system for detecting ecdysteroid agonists and antagonists in plant extracts and libraries of synthetic compounds	FASEB JOURNAL			English	Article						20-hydroxyecdysone; insect cell line; lepidopteran cells; silkworm; Bombyx mori; green fluorescent protein; ecdysone response; chemical libraries	QUANTITATIVE STRUCTURE-ACTIVITY; INSECT GROWTH-REGULATORS; N-ACETYLGLUCOSAMINE INCORPORATION; DROSOPHILA ECDYSONE RECEPTOR; CYTOPLASMIC ACTIN GENE; BOMBYX-MORI; SPODOPTERA-FRUGIPERDA; CULTURED INTEGUMENT; LARVICIDAL ACTIVITY; BIOLOGICAL-ACTIVITY	Screening systems for ecdysteroid mimetic or antiecdysteroid substances in plant extracts or libraries of synthetic compounds are commonly based on the observation of morphological and/or growth responses in insect cell lines. Because these responses are slow and require careful monitoring, existing screening systems are considered limited regarding their applicability to analysis in high-throughput (HT) formats. Here we describe the generation of transformed silkmoth (Bombyx mori) cell lines that respond to the addition of ecdysone-like substances through the expression of the green fluorescent protein (GFP) and the appearance of green fluorescence. Because tests consist of three simple steps, i.e., 1) distribution of transformed cells in microtiter plates; 2) addition of compounds/extracts at different concentrations; and 3) quantification of fluorescence intensity by a fluorescence plate reader, they can be performed quickly and be easily adapted to a HT format. The generated reporter cell lines are used for the screening of extracts from available plant collections for the presence of compounds with ecdysone mimetic or antagonistic activities as well as for monitoring subsequent activity during enrichment and purification steps. The same cell lines are also used here for the determination of structure-activity relationships among available synthetic dibenzoylhydrazine derivatives. Finally, for the identified agonists, we show that their activity as determined by the cell-based screening assays parallels their bioactivity in growth inhibition and toxicity assays carried out on live insects.	Natl Ctr Sci Res Demokritos, Inst Biol, Athens 15310, Greece; Vioryl SA, Athens 14564, Greece; Univ Ghent, Lab Agrozool, B-9000 Ghent, Belgium; Kyoto Univ, Grad Sch Agr, Kyoto 6068502, Japan	National Centre of Scientific Research "Demokritos"; Ghent University; Kyoto University	Swevers, L (corresponding author), Natl Ctr Sci Res Demokritos, Inst Biol, POB 60228, Athens 15310, Greece.	swevers@bio.demokritos.gr; iatrou@bio.demokritos.gr	Kravariti, Lara/AAM-6512-2021; Smagghe, Guy/AAE-8914-2019	Smagghe, Guy/0000-0001-8334-3313	General Secretariat of Science and Technology, Greek Ministry of Development [98BI-26]	General Secretariat of Science and Technology, Greek Ministry of Development	We thank Drs. G. R. Carlson and T. Dhadialla for the generous gift of RH-5992, RH-2485, RH-0345, and RH-5849; Dr. M. Koelle (Stanford University) for the gift of the pMK43.2 reporter vector; Dr. P. J. Farrell (University of Calgary) for help and advice during the construction of the Bm5/ERE.gfp cell lines; Grace Wong for help with the determination of promoter strength determinations through CAT assays of transfected cells; and Laurie Robertson (Flow Cytometry Facility, Department of Biochemistry and Molecular Biology, University of Calgary) for the flow cytometry analyses. This work was supported by grant No 98BI-26 of the General Secretariat of Science and Technology, Greek Ministry of Development.	ADLER JH, 1995, LIPIDS, V30, P257, DOI 10.1007/BF02537830; ANTONIEWSKI C, 1993, INSECT BIOCHEM MOLEC, V23, P105, DOI 10.1016/0965-1748(93)90088-A; BERGAMASCO R., 1980, PROGR ECDYSONE RES, P299; Cespedes CL, 2000, J AGR FOOD CHEM, V48, P1903, DOI 10.1021/jf990443q; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS L, 1980, ROUX ARCH DEV BIOL, V189, P1, DOI 10.1007/BF00848562; CLEMENT CY, 1993, INSECT BIOCHEM MOLEC, V23, P187, DOI 10.1016/0965-1748(93)90100-7; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; Dinan L, 1997, BIOCHEM J, V327, P643, DOI 10.1042/bj3270643; Dinan L, 2001, PHYTOCHEMISTRY, V57, P325, DOI 10.1016/S0031-9422(01)00078-4; Dinan L, 2001, CELL MOL LIFE SCI, V58, P321, DOI 10.1007/PL00000859; DREVET JR, 1994, J BIOL CHEM, V269, P10660; Eystathioy T, 2001, MECH DEVELOP, V103, P107, DOI 10.1016/S0925-4773(01)00335-5; Farrell PJ, 1998, BIOTECHNOL BIOENG, V60, P656, DOI 10.1002/(SICI)1097-0290(19981220)60:6<656::AID-BIT2>3.0.CO;2-9; Farrell PJ, 2000, PROTEINS, V41, P144, DOI 10.1002/1097-0134(20001001)41:1<144::AID-PROT160>3.3.CO;2-8; GRACE TDC, 1967, NATURE, V216, P613, DOI 10.1038/216613a0; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Harmatha J, 1997, ARCH INSECT BIOCHEM, V35, P219, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<219::AID-ARCH20>3.3.CO;2-Z; Harmatha J, 2002, INSECT BIOCHEM MOLEC, V32, P181, DOI 10.1016/S0965-1748(01)00099-6; Jayaprakasha GK, 1997, PHYTOCHEMISTRY, V44, P843, DOI 10.1016/S0031-9422(96)00589-4; JOHNSON R, 1992, VIROLOGY, V190, P815, DOI 10.1016/0042-6822(92)90919-G; Keith MBA, 2000, BIOTECHNIQUES, V28, P148, DOI 10.2144/00281rr03; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOOLMAN J, 1989, ECDYSONE CHEMISTRY M; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lu M, 1997, J BIOL CHEM, V272, P30724, DOI 10.1074/jbc.272.49.30724; Mange A, 1997, J MOL BIOL, V265, P266, DOI 10.1006/jmbi.1996.0734; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; Nakagawa Y, 1999, PESTIC SCI, V55, P909, DOI 10.1002/(SICI)1096-9063(199909)55:9&lt;909::AID-PS34&gt;3.0.CO;2-G; NAKAGAWA Y, 1995, STEROIDS, V60, P401, DOI 10.1016/0039-128X(94)00065-K; Nakagawa Y, 1998, PESTIC SCI, V53, P267, DOI 10.1002/(SICI)1096-9063(199808)53:4&lt;267::AID-PS765&gt;3.0.CO;2-U; Nakagawa Y, 2002, PEST MANAG SCI, V58, P131, DOI 10.1002/ps.429; Nakagawa Y, 2001, PEST MANAG SCI, V57, P858, DOI 10.1002/ps.376; Nijhout H.F., 1994, INSECT HORMONES; OIKAWA N, 1994, PESTIC BIOCHEM PHYS, V48, P135, DOI 10.1006/pest.1994.1014; OIKAWA N, 1994, PESTIC SCI, V41, P139, DOI 10.1002/ps.2780410210; OIKAWA N, 1993, PESTIC BIOCHEM PHYS, V47, P165, DOI 10.1006/pest.1993.1075; QUACK S, 1995, EUR J ENTOMOL, V92, P341; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; Ruberto G, 2002, J AGR FOOD CHEM, V50, P6766, DOI 10.1021/jf020607u; Sarker SD, 1997, ARCH INSECT BIOCHEM, V35, P211, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<211::AID-ARCH19>3.3.CO;2-X; Sawada Y, 2003, PEST MANAG SCI, V59, P49, DOI 10.1002/ps.606; Schmelz EA, 2002, ARCH INSECT BIOCHEM, V51, P204, DOI 10.1002/arch.10062; Smagghe G, 1999, ARCH INSECT BIOCHEM, V41, P42, DOI 10.1002/(SICI)1520-6327(1999)41:1&lt;42::AID-ARCH7&gt;3.0.CO;2-H; SMAGGHE G, 1995, EUR J ENTOMOL, V92, P333; Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530; Suresh G, 2002, J AGR FOOD CHEM, V50, P4484, DOI 10.1021/jf025534t; Suzuki S, 1996, GEN COMP ENDOCR, V104, P129, DOI 10.1006/gcen.1996.0155; SWEVERS L, 1995, INSECT BIOCHEM MOLEC, V25, P857, DOI 10.1016/0965-1748(95)00024-P; Swevers L, 1996, INSECT BIOCHEM MOLEC, V26, P217, DOI 10.1016/0965-1748(95)00097-6; Tazima Y, 1978, SILKWORM IMPORTANT L; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; WING KD, 1988, SCIENCE, V241, P470, DOI 10.1126/science.241.4864.470; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YOUNG NJ, 1993, GEN COMP ENDOCR, V90, P183, DOI 10.1006/gcen.1993.1073	56	55	59	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					134	136		10.1096/fj.03-0627fje	http://dx.doi.org/10.1096/fj.03-0627fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630695				2022-12-25	WOS:000188829300051
J	Imai, T; Adachi, S; Nishijo, K; Ohgushi, M; Okada, M; Yasumi, T; Watanabe, K; Nishikomori, R; Nakayama, T; Yonehara, S; Toguchida, J; Nakahata, T				Imai, T; Adachi, S; Nishijo, K; Ohgushi, M; Okada, M; Yasumi, T; Watanabe, K; Nishikomori, R; Nakayama, T; Yonehara, S; Toguchida, J; Nakahata, T			FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells	ONCOGENE			English	Article						histone deacetylase inhibitor; osteosarcoma; apoptosis; Fas ligand; Fas	HISTONE DEACETYLASE INHIBITOR; CHROMOBACTERIUM-VIOLACEUM NO-968; ACUTE PROMYELOCYTIC LEUKEMIA; COLON-CANCER CELLS; MEDIATED APOPTOSIS; DEPSIPEPTIDE FR901228; IN-VITRO; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; OSTEOGENIC-SARCOMA	We investigated the antitumor effects of FR901228, a HDAC inhibitor, on human osteosarcoma cells, in vitro and in vivo to explore its possible utility in the treatment of pediatric bone cancers. FR901228 caused marked growth inhibition with a 50% inhibitory concentration of 1.2-7.3 nM and induction of apoptosis in all eight osteosarcoma cell lines tested. These effects of FR901228 were also observed in vivo xenograft models on BALB/c nude mice, and treatment with 5.6 mg/kg/day resulting in a >70% reduction in the mean final tumor volume compared with the mean initial tumor volume. TUNEL assays demonstrated extensive apoptosis in tumor sections of mice treated with FR901228. Induction of apoptosis was preceded by increased expression of Fas ligand ( FasL) mRNA, resulting in expression of membrane-bound FasL, which was followed by sequential activation of caspase-8 and -3. The level of apoptosis induction was reduced using a neutralizing anti-FasL antibody and overexpression of either the dominant-negative FADD or the viral FLICE inhibitory protein. Furthermore, treatment with a suboptimal dose of FR901228 greatly sensitized osteosarcoma cells to agonistic anti-Fas antibody-mediated apoptosis. These findings suggest that FR901228 is a highly promising antitumor agent against osteosarcoma, inducing apoptosis by the activation of the Fas/FasL system.	Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Kyoto University	Adachi, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.		Nishikomori, Ryuta/AAM-5771-2020; Nishikomori, Ryuta/N-4039-2018	Nishikomori, Ryuta/0000-0002-9407-6158; Nishikomori, Ryuta/0000-0002-9407-6158; Yasumi, Takahiro/0000-0003-3257-5071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; BERON G, 1985, EUR PAEDIATR HAEMAT, V2, P77, DOI 10.3109/08880018509141211; Bonnotte B, 1998, CELL DEATH DIFFER, V5, P480, DOI 10.1038/sj.cdd.4400371; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Debatin KM, 1999, DRUG RESIST UPDATE, V2, P85, DOI 10.1054/drup.1999.0073; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; Fellenberg J, 1997, INT J CANCER, V72, P536, DOI 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, INT J CANCER, V76, P105; Gastman BR, 1999, CANCER RES, V59, P5356; Glick RD, 1999, CANCER RES, V59, P4392; Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamada T, 1999, INT J ONCOL, V15, P1125; Haruyama H, 2002, BIOL PHARM BULL, V25, P1537, DOI 10.1248/bpb.25.1537; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Himelstein Bruce P., 1998, Current Opinion in Oncology, V10, P326, DOI 10.1097/00001622-199807000-00009; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; ISHII S, 1982, INT ORTHOP, V6, P215; Jaboin J, 2002, CANCER RES, V62, P6108; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Kosugi H, 2001, JPN J CANCER RES, V92, P529, DOI 10.1111/j.1349-7006.2001.tb01126.x; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; Lafleur EA, 2001, CANCER RES, V61, P4066; LINK MP, 1991, CLIN ORTHOP RELAT R, P8; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; MARINA NM, 1992, CANCER-AM CANCER SOC, V70, P2722, DOI 10.1002/1097-0142(19921201)70:11<2722::AID-CNCR2820701125>3.0.CO;2-S; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5; Mizutani Y, 1997, CANCER, V79, P1180, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W; Murakami H, 2002, CANCER LETT, V182, P203, DOI 10.1016/S0304-3835(02)00096-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OhYama T, 2000, MICROBIOL IMMUNOL, V44, P289, DOI 10.1111/j.1348-0421.2000.tb02498.x; Ozaki T, 2003, J CLIN ONCOL, V21, P334, DOI 10.1200/JCO.2003.01.142; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Richon VM, 2002, CLIN CANCER RES, V8, P662; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, J ANTIBIOT, V47, P315; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wang LH, 1998, ANTICANCER RES, V18, P321; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wu XX, 2000, CANCER RES, V60, P2912; Yonehara S, 2002, CYTOKINE GROWTH F R, V13, P393, DOI 10.1016/S1359-6101(02)00024-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	76	60	66	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9231	9242		10.1038/sj.onc.1207184	http://dx.doi.org/10.1038/sj.onc.1207184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14647441	Green Submitted			2022-12-25	WOS:000187400400005
J	Dinulescu, DM; Wood, LJ; Shen, L; Loriaux, M; Corless, CL; Gross, AW; Ren, RB; Deininger, MWN; Druker, BJ				Dinulescu, DM; Wood, LJ; Shen, L; Loriaux, M; Corless, CL; Gross, AW; Ren, RB; Deininger, MWN; Druker, BJ			c-CBL is not required for leukemia induction by Bcr-Abl in mice	ONCOGENE			English	Article						c-Cbl; Bcr-Abl; leukemia; CML	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PHILADELPHIA-CHROMOSOME; TYROSINE PHOSPHORYLATION; MYELOPROLIFERATIVE DISEASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR	Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are required for Bcr-Abl to transform cells. The multifunctional protein c-Cbl is one of the most prominently tyrosine-phosphorylated proteins in Bcr-Abl-expressing cells. Using cell lines and mice with homozygous disruption of the c-CBL locus, we investigated the role of this protein for Bcr-Abl-driven transformation. We find that although c-Cbl(-/-) fibroblast cell lines show a deficit in Bcr-Abl transformation compared to wild-type (Wt) cells, this deficit was less pronounced in c-Cbl(-/-) B cells derived from murine bone marrow. Most importantly, in a transplantation model of CML, Bcr-Abl was capable of inducing fatal leukemia in mice in the absence of c-Cbl protein. Our results indicate that c-Cbl is dispensable for Bcr-Abl-induced leukemo-genesis in mice.	Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol & Med Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Inst Canc, Div Hematol Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Sch Nursing, Dept Primary Care, Portland, OR 97239 USA; VA Med Ctr, Dept Pathol, Portland, OR 97239 USA; Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Brandeis University	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol & Med Oncol, L592,3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	drukerb@ohsu.edu		Wood, Lisa/0000-0003-1145-3649; Druker, Brian/0000-0001-8331-8206				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DEKLEIN A, 1986, BLOOD, V68, P1369; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE RP, 1988, LEUKEMIA, V2, P321; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gaston I, 2000, EXP HEMATOL, V28, P77, DOI 10.1016/S0301-472X(99)00130-7; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLDMAN A, 1998, CELLS LAB MANUAL; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEANE MM, 1995, ONCOGENE, V10, P2367; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okuda K, 1996, ONCOGENE, V13, P1147; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Rader AE, 2001, CANCER CYTOPATHOL, V93, P269, DOI 10.1002/cncr.9041; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Sattler M, 1996, ONCOGENE, V12, P839; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	67	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8852	8860		10.1038/sj.onc.1206892	http://dx.doi.org/10.1038/sj.onc.1206892			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654781				2022-12-25	WOS:000186982200006
J	Baust, H; Schoke, A; Brey, A; Gern, U; Los, M; Schmid, RM; Rottinger, EM; Seufferlein, T				Baust, H; Schoke, A; Brey, A; Gern, U; Los, M; Schmid, RM; Rottinger, EM; Seufferlein, T			Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-kappa B independent mechanisms	ONCOGENE			English	Article						gliotoxin and radiosensitizing; NF-kappa B; XIAP; survivin; JNK	PROTEIN-KINASE PATHWAY; IONIZING-RADIATION; PERSISTENT ACTIVATION; 26S PROTEASOME; APOPTOSIS; INHIBITION; GENE; P53; SENSITIVITY; EXPRESSION	Radioresistance markedly impairs the efficacy of tumor radiotherapy and may involve antiapoptotic signal transduction pathways that prevent radiation-induced cell death. A common cellular response to genotoxic stress induced by radiation is the activation of the nuclear factor kappa B (NF-kappaB). NF-kappaB activation in turn can lead to an inhibition of radiation-induced apoptotic cell death. Thus, inhibition of NF-kappaB activation is commonly regarded as an important strategy to abolish radioresistance. Among other compounds, the fungal metabolite gliotoxin (GT) has been reported to be a highly selective inhibitor of NF-kappaB activation. Indeed, low doses of GT were sufficient to significantly enhance radiation-induced apoptosis in HL-60 cells. However, this effect turned out to be largely independent of NF-kappaB activation since radiation of HL-60 cells with clinically relevant doses of radiation induced only a marginal increase in NF-kappaB activity, and selective inhibition of NF-kappaB by SN50 did not result in a marked enhancement of GT-induced apoptosis. GT induced activation of JNKs, cytochrome c release from the mitochondria and potently stimulated the caspase cascade inducing cleavage of caspases -9, -8, -7 and -3. Furthermore, cleavage of the antiapoptotic protein X-linked IAP and downregulation of the G2/M-specific IAP-family member survivin were observed during GT-induced apoptosis. Finally, the radiation-induced G2/M arrest was markedly reduced in GT-treated cells most likely due to the rapid induction of apoptosis. Our data demonstrate that various other pathways apart from the NF-kappaB signaling complex can sensitize tumor cells to radiation and propose a novel mechanism for radio-sensitization by GT, the interference with the G2/M checkpoint that is important for repair of radiation-induced DNA damage in p53-deficient tumor cells.	Univ Ulm, Dept Radiat Oncol, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med, D-89081 Ulm, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany	Ulm University; Ulm University; University of Munster; University of Munich	Baust, H (corresponding author), Univ Ulm, Dept Radiat Oncol, Robert Koch Str 6, D-89070 Ulm, Germany.	heinrich.baust@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018	Los, Marek/0000-0001-9518-1411				Aldridge DR, 1998, CANCER RES, V58, P2817; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bratton DL, 1999, J BIOL CHEM, V274, P28113, DOI 10.1074/jbc.274.40.28113; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; EICHNER RD, 1988, J BIOL CHEM, V263, P3772; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hida A, 2000, IMMUNOLOGY, V99, P553, DOI 10.1046/j.1365-2567.2000.00985.x; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; KERR JFR, 1972, J PATHOL, V107, P217, DOI 10.1002/path.1711070309; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pajonk F, 2001, RADIOTHER ONCOL, V59, P203, DOI 10.1016/S0167-8140(01)00311-5; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; POWELL SN, 1995, CANCER RES, V55, P1643; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Waring P, 1996, GEN PHARMACOL, V27, P1311, DOI 10.1016/S0306-3623(96)00083-3; WARING P, 1990, J BIOL CHEM, V265, P14476; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	50	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8786	8796		10.1038/sj.onc.1206969	http://dx.doi.org/10.1038/sj.onc.1206969			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647473	Green Published			2022-12-25	WOS:000186844900016
J	Kioi, M; Yamamoto, K; Higashi, S; Koshikawa, N; Fujita, K; Miyazaki, K				Kioi, M; Yamamoto, K; Higashi, S; Koshikawa, N; Fujita, K; Miyazaki, K			Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model	ONCOGENE			English	Article						matrilysin; matrix metalloproteinases; metastasis; colon carcinoma; E-cadherin	MATRIX-DEGRADING METALLOPROTEINASE; ANCHORAGE-INDEPENDENT GROWTH; HUMAN COLORECTAL CANCERS; E-CADHERIN; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; TUMOR INVASION; EXPRESSION; CLEAVAGE; INTEGRIN	Matrilysin (MMP-7) is thought to contribute to invasive growth and metastasis of colon carcinoma and many other human cancers. The present study demonstrates that treatment of human colon carcinoma cells with active matrilysin induces cell aggregation in vitro and promotes liver metastasis in nude mice. When two kinds of colon carcinoma cell lines were incubated with active matrilysin, this enzyme efficiently bound to the cell surface and induced loose cell aggregation, which led to E-cadherin-mediated tight cell aggregation. Synthetic MMP inhibitors inhibited both the membrane binding of matrilysin and matrilysin-induced cell aggregation, while TIMP-2 inhibited only the cell aggregation. Two other active MMPs, stromelysin and gelatinase A, neither bound to cell membrane nor induced cell aggregation. Tumor cells in loose cell aggregates could reaggregate even after they were freed from matrilysin and dispersed. When injected into the spleen of nude mice, the tumor cells in the stable aggregates produced much larger metastatic nodules in the livers than control cells and those in the loose aggregates. These results suggest that matrilysin may enhance metastatic potential of tumor cells by processing a cell surface protein(s) and thereby inducing loose and then tight aggregation of tumor cells.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Sch Med, Dept Oral Maxillofacial Surg, Kanazawa Ku, Yokohama, Kanagawa 2360008, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.		Yamamoto, Kazuhiro/AAD-9650-2019; Koshikawa, Naohiko/S-7306-2017	Koshikawa, Naohiko/0000-0002-4539-888X; Kioi, Mitomu/0000-0002-7981-3340				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; Davies G, 2001, CLIN CANCER RES, V7, P3289; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; INCH WR, 1970, GROWTH, V34, P271; Inohara H, 1996, CANCER RES, V56, P4530; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kondo K, 1998, CANCER RES, V58, P2014; Mitsiades N, 2001, CANCER RES, V61, P577; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MONZ B, 1994, ONCOL REP, V1, P1177; Mueller S, 2000, CANCER RES, V60, P156; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Noe V, 2001, J CELL SCI, V114, P111; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; Olive PL, 1997, CANCER RES, V57, P5528; SEMPLE TU, 1978, CANCER RES, V38, P1345; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; YOSHIMOTO M, 1993, INT J CANCER, V54, P614, DOI 10.1002/ijc.2910540415; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	44	84	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8662	8670		10.1038/sj.onc.1207181	http://dx.doi.org/10.1038/sj.onc.1207181			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647460				2022-12-25	WOS:000186844900003
J	Gensler, M; Buschbeck, M; Ullrich, A				Gensler, M; Buschbeck, M; Ullrich, A			Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; EGF-RECEPTOR; NEU ONCOGENE; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; FUNCTIONAL-ANALYSIS; ACTIVATED ERBB2; LIGAND-BINDING; HUMAN-PLACENTA	Signaling by receptor tyrosine kinases (RTK) mediates a variety of complex cellular functions and in case of deregulation can contribute to pathophysiological processes. A tight and finely tuned control of RTK activity is therefore critical for the cell. We investigated the role of the PEST-type protein-tyrosine phosphatase BDP1 in the regulation of HER2, a member of the epidermal growth factor receptor (EGFR) family of RTKs. Here we demonstrate that HER2 signaling is highly sensitive to BDP1 activity. Overexpression of BDP1 inhibited ligand-induced activation of HER2 but not that of the closely related EGFR. On the other hand, suppression of endogenous BDP1 expression increased the phosphorylation state of HER2. In addition, BDP1 was able to interfere with downstream signaling events by inhibiting the phosphorylation of the adaptor protein Gab1 and reducing mitogen-activated protein kinase activation. Supported by the finding that BDP1 is coexpressed with HER2 in breast cancer cells, we suggest that BDP1 is an important regulator of HER2 activity and thus the first protein-tyrosine phosphatase shown to be involved in HER2 signal attenuation.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de	Buschbeck, Marcus/J-8204-2017	Buschbeck, Marcus/0000-0002-3218-4567				Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Azios NG, 2001, ONCOGENE, V20, P5199, DOI 10.1038/sj.onc.1204555; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Baribault H, 1997, TRANSGENIC RES, V6, P359, DOI 10.1023/A:1018427215923; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; de Melker AA, 2001, J CELL SCI, V114, P2167; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Dosil M, 1996, BLOOD, V88, P4510, DOI 10.1182/blood.V88.12.4510.bloodjournal88124510; FENDLY BM, 1990, CANCER RES, V50, P1550; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Huang K, 1996, ONCOGENE, V13, P1567; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Kim YW, 1996, ONCOGENE, V13, P2275; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; LONARDO F, 1990, New Biologist, V2, P992; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SEGATTO O, 1993, ONCOGENE, V8, P2105; Settle M, 2003, ONCOGENE, V22, P1916, DOI 10.1038/sj.onc.1206240; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; YANG Q, 1993, J BIOL CHEM, V268, P6622; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	63	45	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12110	12116		10.1074/jbc.M309527200	http://dx.doi.org/10.1074/jbc.M309527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14660651	hybrid			2022-12-25	WOS:000220334900016
J	Branco, MR; Marinho, HS; Cyrne, L; Antunes, F				Branco, MR; Marinho, HS; Cyrne, L; Antunes, F			Decrease of H2O2 plasma membrane permeability during adaptation to H2O2 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HYDROGEN-PEROXIDE; MOLECULAR EVOLUTION; OXIDATIVE STRESS; YEAST-CELLS; MITOCHONDRIA; EXPRESSION; ERGOSTEROL; APOPTOSIS; CATALASE	Contrary to what is widely believed, recent published results show that H2O2 does not freely diffuse across biomembranes. The fast removal of H2O2 by antioxidant enzymes is able to generate a gradient if H2O2 is produced in a different compartment from that containing the enzymes (Antunes, F., and Cadenas, E. (2000) FEBS Lett. 475, 121-126). In this work, we extended these studies and tested whether an active regulation of biomembranes permeability characteristics is part of the cell response to oxidative stress. Using Saccharomyces cerevisiae as a model, we showed that: (a) H2O2 gradients across the plasma membrane are formed upon exposure to external H2O2; W there is a correlation between the magnitude of the gradients and the resistance to H2O2; (c) there is not a correlation between the intracellular capacity to remove H2O2 and the resistance to H2O2; (d) the plasma membrane permeability to H2O2 decreases by a factor of two upon acquisition of resistance to this agent by pre-exposing cells either to nonlethal doses of H2O2 or to cycloheximide, an inhibitor of protein synthesis; and (e) erg3Delta and erg6Delta mutants, which have impaired ergosterol biosynthesis pathways, show higher plasma membrane permeability to H2O2 and are more sensitive to H2O2. Altogether, the regulation of the plasma membrane permeability to H2O2 emerged as a new mechanism by which cells respond and adapt to H2O2. The consequences of the results to cellular redox compartmentalization and to the origin and evolution of the eukaryotic cell are discussed.	Univ Lisbon, Fac Ciencias, Dept Quim & Bioquim, P-1749016 Lisbon, Portugal; Univ Lisbon, Fac Ciencias, Ctr Quim & Bioquim, Grp Bioquim Oxidantes & Antioxidantes, P-1749016 Lisbon, Portugal; Inst Invest Cient Bento da Rocha Cabral, P-1250047 Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa	Antunes, F (corresponding author), Univ Lisbon, Fac Ciencias, Dept Quim & Bioquim, P-1749016 Lisbon, Portugal.	fantunes@fc.ul.pt	Antunes, Fernando/A-1030-2009; Cyrne, Luisa/A-1358-2009; Branco, Miguel/H-9509-2019; Marinho, H. Susana/A-1357-2009	Antunes, Fernando/0000-0002-4192-2840; Cyrne, Luisa/0000-0002-0183-7713; Branco, Miguel/0000-0001-9447-1548; Marinho, H. Susana/0000-0002-4625-2516				AEBI HE, 1983, METHOD ENZYMAT AN, P273; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Antunes F, 2001, FREE RADICAL BIO MED, V30, P1008, DOI 10.1016/S0891-5849(01)00493-2; Antunes F, 1996, FREE RADICAL BIO MED, V21, P917, DOI 10.1016/S0891-5849(96)00185-2; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CAVALIERSMITH T, 1991, NATURE, V351, P110, DOI 10.1038/351110a0; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; COSTA SL, 2001, J BACTERIOL, V183, P7182; Cyrne L, 2003, FREE RADICAL BIO MED, V34, P385, DOI 10.1016/S0891-5849(02)01300-X; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEDUVE C, 1965, HARVEY LECT SER, V59, P48; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Klotz MG, 2003, MOL BIOL EVOL, V20, P1098, DOI 10.1093/molbev/msg129; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; MA M, 1992, P NATL ACAD SCI USA, V89, P7924, DOI 10.1073/pnas.89.17.7924; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MATHAI JC, 1994, J BIOL CHEM, V269, P17784; Mukhopadhyay K, 2002, ANTIMICROB AGENTS CH, V46, P3695, DOI 10.1128/AAC.46.12.3695-3705.2002; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; NICHOLLS P, 1965, BIOCHIM BIOPHYS ACTA, V99, P286, DOI 10.1016/S0926-6593(65)80125-4; OMKUMAR RV, 1993, BIOCHIM BIOPHYS ACTA, V1156, P267, DOI 10.1016/0304-4165(93)90041-6; Ovalle R, 1998, YEAST, V14, P1159, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1159::AID-YEA317>3.0.CO;2-3; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Schopf J.W., 1983, P361; Smith SJ, 1996, MOL CELL BIOL, V16, P5427; Stone JR, 2002, J BIOL CHEM, V277, P15621, DOI 10.1074/jbc.M112153200; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; YONETANI T, 1965, J BIOL CHEM, V240, P4503	43	122	129	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6501	6506		10.1074/jbc.M311818200	http://dx.doi.org/10.1074/jbc.M311818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645222	hybrid			2022-12-25	WOS:000188969200036
J	Gregory, CW; Fei, XY; Ponguta, LA; He, B; Bill, HM; French, FS; Wilson, EM				Gregory, CW; Fei, XY; Ponguta, LA; He, B; Bill, HM; French, FS; Wilson, EM			Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TYROSINE KINASE INHIBITOR; LIGAND-BINDING DOMAIN; MOLECULAR-BIOLOGY; TRANSCRIPTIONAL ACTIVATION; TERMINAL INTERACTION; GENE AMPLIFICATION; PROTEIN EXPRESSION; COMPLEMENTARY-DNA; RESPONSIVE GENES; THERAPY FAILURE	Growth of normal and neoplastic prostate is mediated by the androgen receptor (AR), a ligand-dependent transcription factor activated by high affinity androgen binding. The AR is highly expressed in recurrent prostate cancer cells that proliferate despite reduced circulating androgen. In this report, we show that epidermal growth factor (EGF) increases androgen-dependent AR transactivation in the recurrent prostate cancer cell line CWR-R1 through a mechanism that involves a posttranscriptional increase in the p160 coactivator transcriptional intermediary factor 2/glucocorticoid receptor interacting protein 1 (TIF2/GRIP1). Site-specific mutagenesis and selective MAPK inhibitors linked the EGF-induced increase in AR transactivation to phosphorylation of TIF2/GRIP1. EGF signaling increased the coimmunoprecipitation of TIF2 and AR. AR transactivation and its stimulation by EGF were reduced by small interfering RNA inhibition of TIF2/GRIP1 expression. The data indicate that EGF signaling through MAPK increases TIF2/GRIP1 coactivation of AR transactivation in recurrent prostate cancer.	Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Labs Reprod Biol, CB 7500,Rm 3340C,Med Biomol Res Bldg,103 Mason Fa, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004466, R01HD004466, R01HD016910, R37HD016910] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77739] Funding Source: Medline; NICHD NIH HHS [HD04466, HD16910] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Agus DB, 1999, CANCER RES, V59, P4761; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Baselga J, 2002, CANCER CELL, V2, P93, DOI 10.1016/S1535-6108(02)00098-3; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Buchanan G, 2001, CLIN CANCER RES, V7, P1273; Calegari F, 2002, P NATL ACAD SCI USA, V99, P14236, DOI 10.1073/pnas.192559699; Calvo BF, 2003, CLIN CANCER RES, V9, P1087; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chang CY, 2001, CANCER RES, V61, P8712; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; CONNOLLY JM, 1990, PROSTATE, V16, P209, DOI 10.1002/pros.2990160304; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; Gregory CW, 2001, J ANDROL, V22, P537; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hakimi JM, 1997, CLIN CANCER RES, V3, P1599; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; ISAACS JT, 1994, VITAM HORM, V49, P433; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang F, 2003, ENDOCRINOLOGY, V144, P1257, DOI 10.1210/en.2002-220718; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kim D, 2002, AM J PATHOL, V160, P219, DOI 10.1016/S0002-9440(10)64365-9; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Koivisto P, 1997, CANCER RES, V57, P314; Koivisto P, 1998, AM J PATHOL, V152, P1; Kung HJ, 2001, CONT CANC RES, P241; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lara PN, 1999, CRIT REV ONCOL HEMAT, V32, P197, DOI 10.1016/S1040-8428(99)00041-4; Leung HY, 1997, BRIT J UROL, V79, P212, DOI 10.1046/j.1464-410X.1997.30412.x; Linja MJ, 2001, CANCER RES, V61, P3550; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Marcelli M, 2000, CANCER RES, V60, P944; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MOHLER JL, 2004, IN PRESS CLIN CANC R, V10; Morris MJ, 2002, CANCER-AM CANCER SOC, V94, P980, DOI 10.1002/cncr.10339; Murphy LC, 2000, CANCER RES, V60, P6266; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Osman I, 2001, CLIN CANCER RES, V7, P2643; Palmberg C, 2000, J UROLOGY, V164, P1992, DOI 10.1016/S0022-5347(05)66935-2; Pang S, 1997, CANCER RES, V57, P495; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERHEENTUPA J, 1984, ACTA ENDOCRINOL-COP, V107, P571, DOI 10.1530/acta.0.1070571; PERHEENTUPA J, 1985, AM J PHYSIOL, V248, pE391, DOI 10.1152/ajpendo.1985.248.4.E391; PETERZIEL H, 1995, INT J CANCER, V63, P544, DOI 10.1002/ijc.2910630415; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reese DM, 2001, AM J CLIN PATHOL, V116, P234; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Roy AK, 1999, VITAM HORM, V55, P309; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Scher HI, 1995, CLIN CANCER RES, V1, P545; Shi XB, 2002, CANCER RES, V62, P1496; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sirotnak FM, 2002, CLIN CANCER RES, V8, P3870; Solit DB, 2002, CLIN CANCER RES, V8, P986; STEINER MS, 1997, PROSTATE BASIC CLIN, P151; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wen Y, 2000, CANCER RES, V60, P6841; White RD, 1997, EUR UROL, V31, P1; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	116	164	183	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7119	7130		10.1074/jbc.M307649200	http://dx.doi.org/10.1074/jbc.M307649200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662770	hybrid, Green Published			2022-12-25	WOS:000188969200111
J	Trisciuoglio, D; Iervolino, A; Candiloro, A; Fibbi, G; Fanciulli, M; Zangemeister-Wittke, U; Zupi, G; Del Bufalo, D				Trisciuoglio, D; Iervolino, A; Candiloro, A; Fibbi, G; Fanciulli, M; Zangemeister-Wittke, U; Zupi, G; Del Bufalo, D			bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation - Involvement of ERK1/ERK2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR SP1; DNA-BINDING ACTIVITY; CARCINOMA-CELLS; UP-REGULATION; PROTEIN-KINASE; TUMOR-GROWTH; HUMAN GLIOBLASTOMA; HYPOXIC INDUCTION; BREAST-CARCINOMA	We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor. In this work we demonstrated, for the first time, that Bcl-2 overexpression in cancer cells exposed to hypoxia modulates urokinase plasminogen activator receptor (uPAR) expression through Sp1 transcription factor and that the extracellular signal-regulated kinase (ERK) pathway plays a role in Sp1 transcriptional activity. In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Up-regulation of uPAR expression was accompanied by increased Sp1 protein expression, stability, serine phosphorylation, and DNA binding activity. Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. The contribution of the ERK pathway in Sp1-increased transcriptional activity was demonstrated by the use of chemical inhibition. In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor U0126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. Using a human breast carcinoma line, we obtained data supporting our findings with melanoma cells and identified a link between the induction of Sp1 and uPAR expression as a common bcl-2-controlled phenomenon in human tumors. In conclusion, our results strongly indicate that up-regulation of uPAR expression by Bcl-2 in hypoxia is modulated by Sp1 DNA binding activity through the ERK signaling pathway.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Lab B, I-00158 Rome, Italy; Univ Florence, Dept Pathol & Oncol, I-50134 Florence, Italy; Univ Zurich Hosp, Dept Oncol, CH-8044 Zurich, Switzerland	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; University of Zurich; University Zurich Hospital	Del Bufalo, D (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro 156, I-00158 Rome, Italy.	delbufalo@ifo.it	fanciulli, maurizio/ABH-6745-2020; trisciuoglio, Daniela/H-2131-2016; Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; trisciuoglio, daniela/AAL-4002-2021	trisciuoglio, Daniela/0000-0002-7007-7914; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; Fibbi, gabriella/0000-0002-0629-851X				Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Del Bufalo D, 2003, ONCOGENE, V22, P8441, DOI 10.1038/sj.onc.1206999; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DELROSSO M, 1992, EXP CELL RES, V203, P427; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; Evans CP, 1997, CANCER RES, V57, P3594; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; FOJAS DB, 2001, EMBO J, V20, P5737; FOLKMAN J, 1986, CANCER RES, V46, P467; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Gualandris A, 1997, MICROVASC RES, V53, P254, DOI 10.1006/mvre.1996.1998; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HARDENBOL P, 1992, BIOCHEM BIOPH RES CO, V185, P553, DOI 10.1016/0006-291X(92)91660-I; Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KIESER A, 1994, ONCOGENE, V9, P963; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kroon ME, 2000, BLOOD, V96, P2775; Kroon ME, 1999, AM J PATHOL, V154, P1731, DOI 10.1016/S0002-9440(10)65429-6; Maity A, 2000, EXP CELL RES, V255, P250, DOI 10.1006/excr.1999.4804; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Min HY, 1996, CANCER RES, V56, P2428; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nor JE, 2001, CANCER RES, V61, P2183; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sandberg T, 2001, J CLIN ENDOCR METAB, V86, P1724, DOI 10.1210/jc.86.4.1724; Schewe DM, 2003, CLIN CANCER RES, V9, P2267; SCOTLANDI K, 1994, INT J CANCER, V58, P95, DOI 10.1002/ijc.2910580116; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simmen RCM, 2000, MOL CELL ENDOCRINOL, V159, P159, DOI 10.1016/S0303-7207(99)00191-4; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Zannetti A, 2000, CANCER RES, V60, P1546; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027	63	60	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6737	6745		10.1074/jbc.M308938200	http://dx.doi.org/10.1074/jbc.M308938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660675	hybrid			2022-12-25	WOS:000188969200066
J	Heske, J; Heller, U; Winklhofer, KF; Tatzelt, J				Heske, J; Heller, U; Winklhofer, KF; Tatzelt, J			The C-terminal globular domain of the prion protein is necessary and sufficient for import into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL SEQUENCE; PROTEASOMAL DEGRADATION; TRANSMEMBRANE DOMAIN; MOLECULAR CHAPERONES; ER MEMBRANE; SCRAPIE; TRANSLOCATION; GLYCOSYLATION; TRANSPORT; RIBOSOME	The mammalian prion protein (PrP) is composed of an unstructured flexible N-terminal region and a C-terminal globular domain. We examined the import of PrP into the endoplasmic reticulum (ER) of neuronal cells and show that information present in the C-terminal globular domain is required for ER import of the N terminus. N-terminal fragments of PrP, devoid of structural domains located in the C terminus, remained in the cytosol with an uncleaved signal peptide and were rapidly degraded by the proteasome. Conversely, the separate C-terminal domain of PrP, comprising the highly ordered helix 2-loop-helix 3 motif, was entirely imported into the ER. As a consequence, two PrP mutants linked to inherited prion disease in humans, PrP-W145Stop and PrP-Q160Stop, were partially retained in the cytosol. The cytosolic fraction was characterized by an uncleaved N-terminal signal peptide and was degraded by the proteasome. Our study identified a new regulatory element in the C-terminal globular domain of PrP necessary and sufficient to promote import of PrP into the ER.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zimmermann R, 1998, BIOL CHEM, V379, P275	54	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5435	5443		10.1074/jbc.M309570200	http://dx.doi.org/10.1074/jbc.M309570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645231	hybrid			2022-12-25	WOS:000188776500050
J	Philipp-Staheli, J; Kim', KH; Liggitt, D; Gurley, KE; Longton, G; Kemp, CJ				Philipp-Staheli, J; Kim', KH; Liggitt, D; Gurley, KE; Longton, G; Kemp, CJ			Distinct roles for p53, p27(Kip1), and p21(Cip1) during tumor development	ONCOGENE			English	Article						tumor suppressor gene; lymphoma; sarcoma haploinsufficiency; epistasis	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; MAMMARY-CANCER MODEL; CDK INHIBITOR; MICE LACKING; P53-DEFICIENT MICE; P27; EXPRESSION; TUMORIGENESIS; DEGRADATION	Mutations in p53 and reduced expression of the Cdk inhibitor P27(Kip1) are frequently observed in a wide variety of human cancers, but it is not known whether alterations in these tumor suppressors interact to influence tumor progression. To address this, we measured tumor latency and spectrum in p53 and p27 single and compound mutant mice. p53-/- (null) mice developed T-cell lymphomas and soft-tissue sarcomas, while p27-/- mice developed adenomas of the pituitary and lung, but with much longer latency. The latency for tumor development in p53-/- p27-/- and p53 -/- p27 +/- compound mutant mice was significantly reduced, by 15-30%, compared to single mutant p53-/- mice. The tumor spectrum in the compound mutants was similar to that of p53-/- mice, and additional tumors of diverse histotypes. In tumors from p53-/- mice, p27 protein levels were reduced to a greater extent than were mRNA levels, indicating that p27 is downregulated in tumors at the transcriptional as well as post-transcriptional levels. In contrast, mice deficient in another Cdk inhibitor p21(Cip1), which is also a transcriptional target and effector of p53, showed only a marginal increase in tumor predisposition in response to ENU treatment. Thus, downregulation of p27 is a common feature in p53-/- tumors. Germline deletion of one or both alleles of p27 accelerates tumor development and associated mortality in p53-/- mice, indicating potent synergy between loss of p27 and p53. Although p21 is functionally similar to both p53 and p27, it plays a lesser role in tumor suppression. These results further highlight the highly cooperative nature of p27 and its central role in tumor suppression.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, C1-015,1100 Fairview Ave N, Seattle, WA 98109 USA.	cjkemp@fhcrc.org			NCI NIH HHS [CA70414] Funding Source: Medline; NIEHS NIH HHS [ES011045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Bearss DJ, 2002, CANCER RES, V62, P2077; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BULLRICH F, 1995, CANCER RES, V55, P1199; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Ciaparrone M, 1998, CANCER RES, V58, P114; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDIERY WS, 2001, NAT CELL BIOL, V3, P71; Erlanson M, 1998, BLOOD, V92, P770; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson RJ, 2003, CANCER RES, V63, P3021; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maronpot R, 1999, PATHOLOGY MOUSE; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Masciullo V, 1999, CANCER RES, V59, P3790; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PIETENPOL JA, 1995, CANCER RES, V55, P1206; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Quintanilla-Martinez L, 1998, AM J PATHOL, V153, P175, DOI 10.1016/S0002-9440(10)65558-7; SanchezBeato M, 1997, AM J PATHOL, V151, P151; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Singh SP, 1998, CANCER RES, V58, P1730; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; TIMME TL, 1994, BIOTECHNIQUES, V17, P462; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Yang WC, 2001, CANCER RES, V61, P565; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	63	53	56	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					905	913		10.1038/sj.onc.1207220	http://dx.doi.org/10.1038/sj.onc.1207220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647411				2022-12-25	WOS:000188486600005
J	Maru, D; Wu, TT; Canada, A; Houlihan, PS; Hamilton, SR; Rashid, A				Maru, D; Wu, TT; Canada, A; Houlihan, PS; Hamilton, SR; Rashid, A			Loss of chromosome 18q and DPC4 (Smad4) mutations in appendiceal adenocarcinomas	ONCOGENE			English	Article						appendix; adenocarcinoma; chromosome 18q loss; beta-catenin; DPC4	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; FREQUENT LOSS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; GASTRIC-CANCER; COLON-CANCER; ALLELIC LOSS; CARCINOMAS; DCC	Appendiceal adenocarcinomas are uncommon, and the genetic alterations present in these tumors are not well characterized. We studied genetic alterations including loss of chromosome 18q ( location of DCC, DPC4, and JV-18 genes), and mutations of the DPC4 (SMAD4) and beta-catenin genes in 28 appendiceal adenocarcinomas, consisting of 17 mucinous and 11 nonmucinous carcinomas. Chromosome 18q loss was present in 57% (12/21) of appendiceal carcinomas including 54% (7/13) of mucinous and 63% (5/8) of nonmucinous carcinomas. Mutation of the DPC4 gene was present in 14% ( three of 22) of the carcinomas occurring in one tumor with chromosome 18q loss and in two with unassessed chromosome 18q status. beta-catenin gene mutation was present in 0%( 0 of 25) of the carcinomas. Chromosome 18q loss status was not associated with any clinicopathological features. The presence of chromosome 18q loss and DPC4 mutations in appendiceal adenocarcinomas suggests involvement of DPC4 and nearby genes on chromosome 18q ( DCC and/or JV-18) in the pathogenesis of appendiceal adenocarcinomas.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Rashid, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	arashid@mdacc.tmc.edu						Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Blons H, 2002, ONCOGENE, V21, P5016, DOI 10.1038/sj.onc.1205626; CARR NJ, 2000, PATHOLOGY GENETICS T, P94; Dai JL, 1998, CANCER RES, V58, P4592; DEVILEE P, 1991, ONCOGENE, V6, P311; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Font A, 2001, DIS COLON RECTUM, V44, P549, DOI 10.1007/BF02234328; Fujii H, 1997, AM J PATHOL, V151, P1447; GAO X, 1993, CANCER RES, V53, P2723; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; HOHNE MW, 1992, CANCER RES, V52, P2616; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kabbani W, 2002, MODERN PATHOL, V15, P599, DOI 10.1038/modpathol.3880572; Kanazawa T, 2002, INT J CANCER, V102, P225, DOI 10.1002/ijc.10690; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281; Kytola S, 2002, GENE CHROMOSOME CANC, V34, P325, DOI 10.1002/gcc.10081; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; Lassus H, 2001, AM J PATHOL, V159, P35, DOI 10.1016/S0002-9440(10)61670-7; Lei JY, 1996, ONCOGENE, V13, P2459; LYSS AP, 1988, SEMIN ONCOL, V15, P129; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McCusker ME, 2002, CANCER, V94, P3307, DOI 10.1002/cncr.10589; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Powell SM, 1997, CANCER RES, V57, P4221; Rashid A, 2001, CANCER RES, V61, P3406; Roth S, 2000, BRIT J CANCER, V83, P1015, DOI 10.1054/bjoc.2000.1387; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sparks AB, 1998, CANCER RES, V58, P1130; Szych C, 1999, AM J PATHOL, V154, P1849, DOI 10.1016/S0002-9440(10)65442-9; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; UCHINO S, 1992, CANCER RES, V52, P3099; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					859	864		10.1038/sj.onc.1207194	http://dx.doi.org/10.1038/sj.onc.1207194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647445				2022-12-25	WOS:000188304900026
J	Alcouffe, J; Therville, N; Segui, B; Nazzal, D; Blaes, N; Salvayre, R; Thomsen, M; Benoist, H				Alcouffe, J; Therville, N; Segui, B; Nazzal, D; Blaes, N; Salvayre, R; Thomsen, M; Benoist, H			Expression of membrane-bound and soluble FasL in Fas- and FADD-dependent T lymphocyte apoptosis induced by mildly oxidized LDL	FASEB JOURNAL			English	Article						lipoproteins; ROS; MAPK; ceramide; atherosclerosis	LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; OXLDL-INDUCED APOPTOSIS; ENDOTHELIAL-CELLS; LIGAND EXPRESSION; ATHEROSCLEROTIC LESIONS; DOWN-REGULATION; DEATH; CERAMIDE	Apoptosis plays an essential role in atherosclerosis. Oxidized low-density lipoproteins (oxLDL) and activated T lymphocytes are present in atherosclerotic lesions, and we have previously reported that oxLDL induce apoptosis of activated T lymphocytes. We now show that this is preceded by an increase of Fas and FasL expression. Fas and FasL overexpression was dependent on reactive oxygen species (ROS) production as well as ERK and JNK activation. In addition, oxLDL triggered an early production of soluble FasL by T lymphocytes. Blocking anti-Fas antibody or Fas-Fc protein, but also antioxidant molecules and inhibitors of ERK and JNK, decreased oxLDL-mediated apoptosis. Moreover, PHA-activated murine lymphocytes lacking a functional Fas receptor were partially resistant to oxLDL. Finally, Jurkat T cells deficient for FADD, an adaptor protein required for Fas signaling, resisted oxLDL-induced apoptosis. OxLDL triggered caspase 8 and 3 activation as well as ceramide production in PHA-activated lymphocytes and in Jurkat cells. Caspase activation was completely impaired in FADD-deficient cells, but ceramide production was not affected. Altogether, our results highlight the putative role of both membrane-bound and soluble FasL in oxLDL-induced Fas and FADD-dependent apoptosis of T lymphocytes and suggest an involvement of ROS, ERK, and JNK in this process.	CHU Rangueil, INSERM U466, F-31059 Toulouse 9, France; Univ Toulouse 3, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Benoist, H (corresponding author), CHU Rangueil, INSERM U466, 1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	hbenoist@toulouse.inserm.fr	Blaes, Nelly/M-1468-2018; Ségui, Bruno/O-8957-2014; Therville, Nicole/P-2371-2014; Thomsen, Mogens/B-7651-2011; Benoist, Hervé/P-2927-2014	Ségui, Bruno/0000-0002-6119-1889; Therville, Nicole/0000-0002-7068-1361; Thomsen, Mogens/0000-0002-4546-0129; 	Universite Paul Sabatier-Toulouse 3; Association pour la Recherche contre le Cancer (ARC)	Universite Paul Sabatier-Toulouse 3; Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR))	We thank Dr. Olivier Cuvillier and Pr. Thierry Levade for helpful discussions; Dr. Sophie Koutouzov for the gift of C3H-MRL-Faslpr mice; and Stephane Carpentier, Patricia Clave, and Sylvain Lagorce for excellent technical assistance. This work was supported by grants from the Universite Paul Sabatier-Toulouse 3 and the Association pour la Recherche contre le Cancer (ARC).	Alcouffe J, 1999, J LIPID RES, V40, P1200; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; Ayroldi E, 1999, BLOOD, V94, P3456, DOI 10.1182/blood.V94.10.3456.422k33_3456_3467; Benoist Herve, 2002, Subcell Biochem, V36, P123; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Caspar-Bauguil S, 1998, BIOCHEM J, V330, P659, DOI 10.1042/bj3300659; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DREW AF, 1995, ARTERIOSCL THROM VAS, V15, P1563, DOI 10.1161/01.ATV.15.10.1563; Esaki T, 2000, NITRIC OXIDE-BIOL CH, V4, P561, DOI 10.1006/niox.2000.0311; Escargueil-Blanc I, 1998, J BIOL CHEM, V273, P27389, DOI 10.1074/jbc.273.42.27389; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; Faris M, 1998, J IMMUNOL, V160, P134; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; Geng YJ, 1998, CIRCULATION, V98, P48; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Huang Y, 2001, ATHEROSCLEROSIS, V156, P119, DOI 10.1016/S0021-9150(00)00638-9; Janssen O, 2000, CELL TISSUE RES, V301, P85, DOI 10.1007/s004419900155; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KLEINDIENST R, 1993, AM J PATHOL, V142, P1927; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Lee TS, 2001, AM J PHYSIOL-CELL PH, V280, pC709, DOI 10.1152/ajpcell.2001.280.3.C709; Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568; Mallat Z, 2000, BRIT J PHARMACOL, V130, P947, DOI 10.1038/sj.bjp.0703407; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; MartinezLorenzo MJ, 1996, IMMUNOLOGY, V89, P511, DOI 10.1046/j.1365-2567.1996.d01-782.x; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 2001, J CELL BIOCHEM, V82, P674, DOI 10.1002/jcb.1198; Negre-Salvayre A, 2002, METHOD ENZYMOL, V352, P62; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; Okura T, 2002, J HYPERTENS, V20, P895, DOI 10.1097/00004872-200205000-00024; RAJAVASHISTH TB, 1995, ARTERIOSCL THROM VAS, V15, P1591, DOI 10.1161/01.ATV.15.10.1591; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Schneider DB, 2000, ARTERIOSCL THROM VAS, V20, P298, DOI 10.1161/01.ATV.20.2.298; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shimizu M, 1999, J IMMUNOL, V162, P7350; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Vindelov L, 1990, Methods Cell Biol, V33, P127; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017; Zhou XH, 1996, AM J PATHOL, V149, P359	62	24	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					122	124		10.1096/fj.02-0808fje	http://dx.doi.org/10.1096/fj.02-0808fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630709				2022-12-25	WOS:000188829300047
J	Chau, CH; Shum, DKY; Li, H; Pei, J; Lui, YY; Wirthlin, L; Chan, YS; Xu, XM				Chau, CH; Shum, DKY; Li, H; Pei, J; Lui, YY; Wirthlin, L; Chan, YS; Xu, XM			Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded guidance channels after spinal cord injury	FASEB JOURNAL			English	Article						chondroitin sulfates; regeneration; transplantation; Schwann cells	ADULT-RAT BRAIN; SULFATE PROTEOGLYCANS; TRANSPLANTS SUPPORT; FUNCTIONAL RECOVERY; SCIATIC-NERVES; CNS AXONS; IN-VIVO; REGENERATION; GROWTH; EXPRESSION	Grafting of Schwann cell-seeded channels into hemisected adult rat thoracic spinal cords has been tested as a strategy to bridge the injured cord. Despite success in guiding axonal growth into the graft, regeneration across the distal graft-host interface into the host spinal cord was limited. We hypothesized that chondroitin sulfate (CS) glycoforms deposited at the gliotic front of the interface constitute a molecular barrier to axonal growth into the host cord. Because CS glycoforms deposited by purified astrocytes in vitro were removable by digestion with chondroitinase ABC, we attempted to achieve likewise by infusion of the enzyme to the host side of the interface. By I month post-treatment, significant numbers of regenerating axons crossed an interface that was subdued in macrophage/microglia reaction and decreased in CS-immunopositivity. The axons extended as far into the caudal cord as 5 mm, in contrast to nil in vehicle-infused controls. Fascicular organizations of axon-Schwann cell units within the regenerated tissue cable were better-preserved in enzyme-treated cords than in vehicle-infused controls. We conclude that CS glycoforms deposited during gliosis at the distal graft-host interface could be cleared by the in vivo action of chondroitinase ABC to improve prospects of axonal regeneration into the host spinal cord.	Univ Hong Kong, Dept Biochem, Fac Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Physiol, Fac Med, Hong Kong, Hong Kong, Peoples R China; St Louis Univ, Sch Med, Dept Anat & Neurobio, St Louis, MO 63104 USA; Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA	University of Hong Kong; University of Hong Kong; Saint Louis University; University of Louisville	Xu, XM (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	shumdkhk@hkucc.hku.hk; xmxu0001@gwise.louisville.edu		Xu, Xiao-ming/0000-0002-7229-0081; Chan, Ying Shing/0000-0002-6228-1595	National Institutes of Health [NS36350]; International Spinal Research Trust; Daniel Heumann Fund for Spinal Cord Research; Hong Kong Research Grants Council [HKU328/93M, HKU7355/00M]; Croucher Foundation Fellowship	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Spinal Research Trust; Daniel Heumann Fund for Spinal Cord Research; Hong Kong Research Grants Council(Hong Kong Research Grants Council); Croucher Foundation Fellowship	We wish to thank Xiaobin Lu for helpful technical assistance. This work was supported by grants from National Institutes of Health NS36350, International Spinal Research Trust, and The Daniel Heumann Fund for Spinal Cord Research (to XMX), Hong Kong Research Grants Council HKU328/93M and HKU7355/00M (to DKYS) and a Croucher Foundation Fellowship (to CHC).	ANDERSON DK, 1995, BRAIN PATHOL, V5, P451, DOI 10.1111/j.1750-3639.1995.tb00624.x; BALENTINE JD, 1978, LAB INVEST, V39, P236; Bamber NI, 2001, EUR J NEUROSCI, V13, P257, DOI 10.1046/j.1460-9568.2001.01387.x; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bregman BS, 2002, PROG BRAIN RES, V137, P257; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Bunge R P, 1997, Adv Neurol, V72, P305; Chau CH, 1999, EUR J NEUROSCI, V11, P1914, DOI 10.1046/j.1460-9568.1999.00615.x; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Cheng HL, 1997, J CELL PHYSIOL, V171, P161; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Diener PS, 1998, J NEUROSCI, V18, P779; Diener PS, 1998, J NEUROSCI, V18, P763; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ECCLESTON PA, 1990, EUR J NEUROSCI, V2, P985, DOI 10.1111/j.1460-9568.1990.tb00011.x; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; Fitch MT, 1999, J NEUROSCI, V19, P8182; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; GHIRNIKAR RS, 1995, GLIA, V14, P145, DOI 10.1002/glia.440140209; GRILLNER S, 1975, PHYSIOL REV, V55, P247, DOI 10.1104/pp.55.2.247; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Haas CA, 1999, J NEUROSCI, V19, P9953; JAKEMAN LB, 1991, J COMP NEUROL, V307, P311, DOI 10.1002/cne.903070211; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; KATO M, 1987, J BIOL CHEM, V262, P7180; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Moon LDF, 2003, J NEUROSCI RES, V71, P23, DOI 10.1002/jnr.10449; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; OUDEGA M, 1994, EXP NEUROL, V129, P194, DOI 10.1006/exnr.1994.1161; Plant GW, 2001, MOL CELL NEUROSCI, V17, P471, DOI 10.1006/mcne.2000.0948; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Shum DKY, 1996, J NEUROSCI RES, V46, P465, DOI 10.1002/(SICI)1097-4547(19961115)46:4<465::AID-JNR8>3.0.CO;2-E; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; TONA A, 1993, J NEUROSCI RES, V36, P191, DOI 10.1002/jnr.490360209; Tuszynski MH, 1999, J NEUROTRAUM, V16, P523, DOI 10.1089/neu.1999.16.523; Ughrin YM, 2003, J NEUROSCI, V23, P175; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004; WILLIAMS LR, 1987, EXP NEUROL, V95, P743, DOI 10.1016/0014-4886(87)90313-X; Xu XM, 1999, EUR J NEUROSCI, V11, P1723, DOI 10.1046/j.1460-9568.1999.00591.x; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; Yan P, 1999, J NEUROSCI, V19, P9355; Yick LW, 2000, NEUROREPORT, V11, P1063, DOI 10.1097/00001756-200004070-00032; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951	59	154	162	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					194	196		10.1096/fj.03-0196fje	http://dx.doi.org/10.1096/fj.03-0196fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630702				2022-12-25	WOS:000188829300071
J	Nakagawachi, T; Soejima, H; Urano, T; Zhao, W; Higashimoto, K; Satoh, Y; Matsukura, S; Kudo, S; Kitajima, Y; Harada, H; Furukawa, K; Matsuzaki, H; Emi, M; Nakabeppu, Y; Miyazaki, K; Sekiguchi, M; Mukai, T				Nakagawachi, T; Soejima, H; Urano, T; Zhao, W; Higashimoto, K; Satoh, Y; Matsukura, S; Kudo, S; Kitajima, Y; Harada, H; Furukawa, K; Matsuzaki, H; Emi, M; Nakabeppu, Y; Miyazaki, K; Sekiguchi, M; Mukai, T			Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer	ONCOGENE			English	Article						MGMT; DNA methylation; histone modification; histone methylation; chromatin; gene silencing	O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; DNA METHYLATION; BINDING-PROTEIN; PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; LYSINE-9 METHYLATION; CHROMATIN-STRUCTURE; H3 LYSINE-9; REPAIR; TRANSCRIPTION	O6-methylguanine-DNA methyltransferase (MGMT) repairs the cytotoxic and mutagenic O6-alkylguanine produced by alkylating agents such as chemotherapeutic agents and mutagens. Recent studies have shown that in a subset of tumors, MGMT expression is inversely linked to hypermethylation of the CpG island in the promoter region; however, how the epigenetic silencing mechanism works, as it relates to hypermethylation, was still unclear. To understand the mechanism, we examined the detailed methylation status of the whole island with bisulfite-sequencing in 19 MGMT non-expressed cancer cell lines. We found two highly methylated regions in the island. One was upstream of exon 1, including minimal promoter, and the other was downstream, including enhancer. Reporter gene assay showed that methylation of both the upstream and downstream regions suppressed luciferase activity drastically. Chromatin immunoprecipitation assay revealed that histone H3 lysine 9 was hypermethylated throughout the island in the MGMT negative line, whereas acetylation on H3 and H4 and methylation on H3 lysine 4 were at significantly high levels outside the minimal promoter in the MGMT-expressed line. Furthermore, MeCP2 preferentially bound to the CpG-methylated island in the MGMT negative line. Given these results, we propose a model for gene silencing of MGMT that is dependent on the epigenetic state in cancer.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Nagoya, Aichi, Japan; Hokkaido Inst Publ Hlth, Sapporo, Hokkaido, Japan; Saga Med Sch, Dept Surg, Saga, Japan; Int Med Ctr Japan Res Inst, Dept Pathol, Div Histol, Tokyo, Japan; RIKEN, Spring 8, Harima Inst, Synchrotron Radiat Res Network,Membrane Dynam Pro, Tokyo, Japan; Nippon Med Coll, Inst Gerontol, Dept Mol Biol, Tokyo, Japan; Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 812, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan	Saga University; Nagoya University; Saga University; National Center for Global Health & Medicine - Japan; RIKEN; Nippon Medical School; Kyushu University; Japan Science & Technology Agency (JST)	Soejima, H (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.	soejimah@post.saga-med.ac.jp	Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; Urano, Takeshi/0000-0003-3383-3554; Soejima, Hidenobu/0000-0001-5076-6563				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Becker K, 1996, CANCER RES, V56, P3244; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Chen FY, 1997, P NATL ACAD SCI USA, V94, P4348, DOI 10.1073/pnas.94.9.4348; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Danam RP, 2001, INT J ONCOL, V18, P1187; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, CANCER RES, V60, P2368; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1994, NUCLEIC ACIDS RES, V22, P4614, DOI 10.1093/nar/22.22.4614; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herfarth KKF, 1999, MOL CARCINOGEN, V24, P90, DOI 10.1002/(SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; OLSSON M, 1980, J BIOL CHEM, V255, P569; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; PEGG AE, 1983, J BIOL CHEM, V258, P2327; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916; Qian XLC, 1997, CANCER RES, V57, P3672; Roder K, 2002, J BIOL CHEM, V277, P30543, DOI 10.1074/jbc.M111891200; Sakumi K, 1997, CANCER RES, V57, P2415; Satoh Y, 2003, J BIOCHEM, V133, P303, DOI 10.1093/jb/mvg041; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; URANO T, 1993, ONCOGENE, V8, P1371; VONWRONSKI MA, 1992, ONCOL RES, V4, P167; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Whitehall VLJ, 2001, CANCER RES, V61, P827; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469	52	138	145	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8835	8844		10.1038/sj.onc.1207183	http://dx.doi.org/10.1038/sj.onc.1207183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14647440				2022-12-25	WOS:000186982200004
J	Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M				Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M			5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking	FASEB JOURNAL			English	Article; Proceedings Paper	8th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases	SEP, 2003	Chicago, IL			eicosanoids; mesothelioma	CANCER-THERAPY; MALIGNANT MESOTHELIOMA; LEUKOTRIENE SYNTHESIS; CELL-SURVIVAL; EXPRESSION; PROTEIN; CYCLOOXYGENASE-2; OVEREXPRESSION; BIOSYNTHESIS; LINES	5-Lipoxygenase (5-LO) promotes cancer cell proliferation and survival by unclear mechanisms. Here, we show that 5-LO expression and activity were induced by genotoxic agents in a p53-independent manner and antagonized p53- or genotoxic drug-induced apoptosis in a variety of cancer cells. 5-LO inhibited p53- governed transactivation of the pro-apoptotic genes bax and pig3 but not of p21(WAF1/CIP1) or mdm2. This may be explained by 5-LO capability to inhibit the binding of p53 to promyelocytic leukemia protein (PML) and p53 subnuclear relocalization into PML-nuclear bodies in response to genotoxic stress. Interestingly, 5-LO activity appears to be involved in nuclear retention and inactivation of wild-type p53 in malignant mesothelioma cells. In these cells, genetic or pharmacological inhibition of 5-LO enabled suppression of in vitro tumorigenicity by low doses of chemotherapeutic drugs. Together, these results uncover novel functions of 5-LO and contribute to the understanding of 5-LO involvement in tumor progression. Moreover, they provide a rationale to the therapeutic use of 5-LO inhibitors to enhance cancer chemosensitivity in selected tumors.	Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, I-60131 Ancona, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Dept Biomed Sci, Chieti, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Aging Res Ctr, Chieti, Italy; NCI, Neural Dev Grp, Mouse Canc Genet Program, Frederick, MD 21701 USA	Marche Polytechnic University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Catalano, A (corresponding author), Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, Via Ranieri, I-60131 Ancona, Italy.	catgfp@yahoo.it	Soddu, Silvia/K-2467-2018; Procopio, Antonio Domenico/AAB-2451-2021; Soddu, Silvia/ABH-6774-2020; Romano, Mario/I-7986-2012	Soddu, Silvia/0000-0001-8526-0044; Procopio, Antonio Domenico/0000-0001-6897-8724; Soddu, Silvia/0000-0001-8526-0044; Romano, Mario/0000-0001-8512-1458				Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Catalano A, 2004, CRIT REV ONCOL HEMAT, V50, P101, DOI 10.1016/j.critrevonc.2003.10.001; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; GIACCIA AJ, 1998, GENE DEV, V14, P2015; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; Hong SH, 1999, CANCER RES, V59, P2223; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Prives C, 1999, J PATHOL, V187, P112; REID GK, 1990, J BIOL CHEM, V265, P19818; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vivo C, 2003, BRIT J CANCER, V88, P388, DOI 10.1038/sj.bjc.6600736; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	35	102	104	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1740	+		10.1096/fj.04-2258fje	http://dx.doi.org/10.1096/fj.04-2258fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15375079	Green Published			2022-12-25	WOS:000224243200022
